PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Jacob, JS; Cistola, DP; Hsu, FF; Muzaffar, S; Mueller, DM; Hazen, SL; Heinecke, JW				Jacob, JS; Cistola, DP; Hsu, FF; Muzaffar, S; Mueller, DM; Hazen, SL; Heinecke, JW			Human phagocytes employ the myeloperoxidase-hydrogen peroxide system to synthesize dityrosine, trityrosine, pulcherosine, and isodityrosine by a tyrosyl radical-dependent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; LINKING AMINO-ACID; ATHEROSCLEROTIC LESIONS; HYPOCHLOROUS ACID; CROSS-LINKING; FERTILIZATION MEMBRANE; LIPID-PEROXIDATION; HUMAN-NEUTROPHILS; OXIDATION; SUPEROXIDE	Myeloperoxidase, a heme protein secreted by activated phagocytes, may be a catalyst for lipoprotein oxidation in vivo. Active myeloperoxidase is a component of human atherosclerotic lesions, and atherosclerotic tissue exhibits selective enrichment of protein dityrosine cross-links, a well characterized product of myeloperoxidase, Tyrosylation of lipoproteins with peroxidase-generated tyrosyl radical generates multiple protein-bound tyrosine oxidation products in addition to dityrosine. The structural characterization of these products would thus serve as an important step in determining the role of myeloperoxidase in lipoprotein oxidation in the artery wall. We now report the identification and characterization of four distinct tyrosyl radical addition products generated by human phagocytes. Activated neutrophils synthesized three major fluorescent products from L-tyrosine; on reverse phase HPLC, each compound coeluted with fluorescent oxidation products formed by myeloperoxidase. We purified the oxidation products to apparent homogeneity by cation and anion exchange chromatographies and identified the compounds as dityrosine (3,3'-dityrosine), trityrosine (3,3',5',3 ''-trityrosine) and pulcherosine (5-[4 ''-(2-carboxy-2-aminoethyl)phenoxy]3,3'-dityrosine) by high resolution NMR spectroscopy and mass spectrometry. Additionally, we have found that dityrosine is a precursor to trityrosine, but not pulcherosine. In a search for a precursor to pulcherosine, we identified isodityrosine (3-[4'-(2-carboxy-2-aminoethyl)phenoxy] tyrosine), a non-fluorescent product of L-tyrosine oxidation by human phagocytes. Our results represent the first identification of this family of tyrosyl radical addition products in a mammalian system. Moreover, these compounds may serve as markers specific for tyrosyl radical-mediated oxidative damage in atherosclerosis and other inflammatory conditions.	WASHINGTON UNIV,SCH MED,DEPT MED,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT BIOCHEM & MOL BIOPHYS,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT MOL BIOL & PHARMACOL,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)			Hazen, Stanley L/ABD-5845-2021	Cistola, David/0000-0002-9586-8720; Hsu, Fong-Fu/0000-0001-5368-0183	NIA NIH HHS [R01 AG12293] Funding Source: Medline; NICHD NIH HHS [R01 HD29920] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD029920] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG012293] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALBRICH JM, 1981, P NATL ACAD SCI-BIOL, V78, P210, DOI 10.1073/pnas.78.1.210; AMADO R, 1984, METHOD ENZYMOL, V107, P377; Andersen S.O, 1966, ACTA PHYSIOL SC S263, V66, P1; BABIOR BM, 1978, NEW ENGL J MED, V298, P659, DOI 10.1056/NEJM197803232981205; BABIOR BM, 1973, J CLIN INVEST, V52, P741, DOI 10.1172/JCI107236; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BAX A, 1990, J MAGN RESON, V86, P304, DOI 10.1016/0022-2364(90)90262-8; Berliner JA, 1996, FREE RADICAL BIO MED, V20, P707, DOI 10.1016/0891-5849(95)02173-6; BRIZA P, 1986, J BIOL CHEM, V261, P4288; BRIZA P, 1990, GENE DEV, V4, P1775, DOI 10.1101/gad.4.10.1775; DAUGHERTY A, 1994, J CLIN INVEST, V94, P437, DOI 10.1172/JCI117342; DAUGHERTY A, 1988, ARTERIOSCLEROSIS, V8, P768, DOI 10.1161/01.ATV.8.6.768; DEITS T, 1984, J BIOL CHEM, V259, P3525; ESTERBAUER H, 1993, BRIT MED BULL, V49, P566, DOI 10.1093/oxfordjournals.bmb.a072631; FOERDER CA, 1977, P NATL ACAD SCI USA, V74, P4214, DOI 10.1073/pnas.74.10.4214; FRANCIS GA, 1993, P NATL ACAD SCI USA, V90, P6631, DOI 10.1073/pnas.90.14.6631; FRY SC, 1982, BIOCHEM J, V204, P449, DOI 10.1042/bj2040449; GROSS AJ, 1959, J BIOL CHEM, V234, P1611; HARRISON JE, 1976, J BIOL CHEM, V251, P1371; HAZELL LJ, 1993, BIOCHEM J, V290, P165, DOI 10.1042/bj2900165; Hazell LJ, 1996, J CLIN INVEST, V97, P1535, DOI 10.1172/JCI118576; Hazen SL, 1996, J BIOL CHEM, V271, P1861, DOI 10.1074/jbc.271.4.1861; HEINECKE JW, 1994, BIOCHEMISTRY-US, V33, P10127, DOI 10.1021/bi00199a041; HEINECKE JW, 1986, J CLIN INVEST, V77, P757, DOI 10.1172/JCI112371; HEINECKE JW, 1993, J CLIN INVEST, V91, P2866, DOI 10.1172/JCI116531; HEINECKE JW, 1993, J BIOL CHEM, V268, P4069; HICKSTEIN DD, 1987, J BIOL CHEM, V262, P5576; HOFF HF, 1992, J BIOL CHEM, V267, P602; HUNTER EPL, 1989, FREE RADICAL BIO MED, V6, P581, DOI 10.1016/0891-5849(89)90064-6; HURST JK, 1989, CRIT REV BIOCHEM MOL, V24, P271, DOI 10.3109/10409238909082555; KETTLE AJ, 1988, BIOCHIM BIOPHYS ACTA, V956, P58, DOI 10.1016/0167-4838(88)90297-X; KLEBANOFF SJ, 1980, ANN INTERN MED, V93, P480, DOI 10.7326/0003-4819-93-3-480; LUSIS AJ, 1993, BIOCHEM PHARMACOL, V46, P2119, DOI 10.1016/0006-2952(93)90599-R; Marquez LA, 1995, J BIOL CHEM, V270, P30434, DOI 10.1074/jbc.270.51.30434; MORITA Y, 1986, J BIOCHEM-TOKYO, V99, P761, DOI 10.1093/oxfordjournals.jbchem.a135535; Musso H., 1963, ANGEW CHEM INT EDIT, V2, P723, DOI DOI 10.1002/ANIE.196307231; NOMURA K, 1990, BIOCHEMISTRY-US, V29, P4525, DOI 10.1021/bi00471a004; PANDEY NK, 1979, J BACTERIOL, V137, P1208, DOI 10.1128/JB.137.3.1208-1218.1979; PRUTZ WA, 1983, INT J RADIAT BIOL, V44, P183, DOI 10.1080/09553008314550981; RAKITA RM, 1990, BIOCHEMISTRY-US, V29, P1075, DOI 10.1021/bi00456a033; RAVEN DJ, 1971, BIOCHIM BIOPHYS ACTA, V251, P96, DOI 10.1016/0005-2795(71)90065-1; ROSENFELD ME, 1990, ARTERIOSCLEROSIS, V10, P336, DOI 10.1161/01.ATV.10.3.336; SAVENKOVA MI, 1994, J BIOL CHEM, V269, P20394; SCOTT AI, 1965, Q REV CHEM SOC, V19, P1, DOI 10.1039/qr9651900001; STATES DJ, 1982, J MAGN RESON, V48, P286, DOI 10.1016/0022-2364(82)90279-7; STEINBRECHER UP, 1992, ARTERIOSCLER THROMB, V12, P608, DOI 10.1161/01.ATV.12.5.608; THOMAS EL, 1982, BIOCHEMISTRY-US, V21, P6299, DOI 10.1021/bi00267a040; VISSERS MCM, 1991, ARCH BIOCHEM BIOPHYS, V285, P53, DOI 10.1016/0003-9861(91)90327-F; WEISS SJ, 1989, NEW ENGL J MED, V320, P365; WEISS SJ, 1986, SCIENCE, V234, P200, DOI 10.1126/science.3018933; WINTERBOURN CC, 1992, ARCH BIOCHEM BIOPHYS, V296, P547, DOI 10.1016/0003-9861(92)90609-Z; WITZTUM JL, 1991, J CLIN INVEST, V88, P1785, DOI 10.1172/JCI115499; YLAHERTTUALA S, 1989, J CLIN INVEST, V84, P1086, DOI 10.1172/JCI114271	53	141	151	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					19950	19956		10.1074/jbc.271.33.19950	http://dx.doi.org/10.1074/jbc.271.33.19950			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702710	hybrid			2022-12-25	WOS:A1996VC66900051
J	Kim, JM; DasSarma, S				Kim, JM; DasSarma, S			Isolation and chromosomal distribution of natural Z-DNA-forming sequences in Halobacterium halobium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HANDED Z-DNA; ESCHERICHIA-COLI; BINDING-PROTEIN; PLASMIDS; NUCLEI	Conditions favoring left-handed Z-DNA such as high salinity (> 4 M), high negative DNA supercoiling, and GC-rich DNA [statistically favoring d(CG)(n) repeat sequences], are all found in the extremely halophilic archaeum (archaebaeterium) Halobacterium halobium. In order to identify and study Z-DNA regions of the H. halobium genome, an affinity chromatography method with high Z-DNA selection efficiency was developed. Supercoiled plasmids were incubated with a Z-DNA-specific antibody (Z22) and passed over a protein A-agarose column, and the bound plasmids were eluted using an ethidium bromide gradient. In control experiments using mixtures of pUC12 (Z-negative) and a d(CG)(5)-containing (Z-positive) pUC12 derivative, up to 4,000-fold enrichment of the Z-DNA-containing plasmid was demonstrated per cycle of the Z-DNA selection procedure. The selection efficiency was determined by transformation of Escherichia coli DH5 alpha with eluted plasmids and blue-white screening on X-gal plates. Twenty recombinant plasmids containing Z-DNA-forming sequences of H. halobium were isolated from a genomic library using affinity chromatography, Z-DNA-forming sequences in selected plasmids were identified by bandshift and antibody footprinting assays using Z22 monoclonal antibody. Alternating purine-pyrimidine sequences ranging from 8 base pairs (bp) to 13 bp with at least a 6-bp alternating d(GC) stretch were found in the Z22 antibody binding regions of isolated plasmids. The distribution of Z-DNA-forming sequences in the Halobacterium salinarum GRB chromosome was analyzed by dot-blot hybridization of an ordered cosmid library using the cloned H. halobium, Z-DNA segments as probe. Among the 11 Z-DNA segments tested, five were found to be clustered in a 100-kilobase pair region of the genome, whereas six others were distributed throughout the rest of the genome.	UNIV MASSACHUSETTS,DEPT MICROBIOL,AMHERST,MA 01003	University of Massachusetts System; University of Massachusetts Amherst				DasSarma, Shiladitya/0000-0003-4162-2810	NIGMS NIH HHS [GM41980] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041980] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARNDTJOVIN DJ, 1993, BIOCHEMISTRY-US, V32, P4862, DOI 10.1021/bi00069a023; BIANCHI A, 1990, J BIOL CHEM, V265, P21789; BLAHO JA, 1987, J BIOL CHEM, V262, P6082; CHRISTIAN JHB, 1962, BIOCHIM BIOPHYS ACTA, V65, P506, DOI 10.1016/0006-3002(62)90453-5; DASSARMA S, 1987, MOL MICROBIOL, V1, P365, DOI 10.1111/j.1365-2958.1987.tb01943.x; FERL RJ, 1992, PLANT MOL BIOL, V18, P1181, DOI 10.1007/BF00047722; FREUND AM, 1989, P NATL ACAD SCI USA, V86, P7465, DOI 10.1073/pnas.86.19.7465; GARNER MM, 1987, J MOL BIOL, V196, P581, DOI 10.1016/0022-2836(87)90034-9; HACKETT NR, 1994, J BACTERIOL, V176, P7711, DOI 10.1128/JB.176.24.7711-7718.1994; HERBERT A, 1995, P NATL ACAD SCI USA, V92, P7550, DOI 10.1073/pnas.92.16.7550; HERBERT AG, 1993, P NATL ACAD SCI USA, V90, P3339, DOI 10.1073/pnas.90.8.3339; HOHEISEL JD, 1987, J MOL BIOL, V193, P447, DOI 10.1016/0022-2836(87)90259-2; JOHNSTON BH, 1992, METHOD ENZYMOL, V211, P127; KILPATRICK MW, 1984, J BIOL CHEM, V259, P7268; Kim J, 1996, J BIOL CHEM, V271, P9340, DOI 10.1074/jbc.271.16.9340; KIM JM, 1995, THESIS U MASSACHUSET; LAFER EM, 1981, P NATL ACAD SCI-BIOL, V78, P3546, DOI 10.1073/pnas.78.6.3546; MIRKIN SM, 1987, NATURE, V330, P495, DOI 10.1038/330495a0; MOORE RL, 1969, J BACTERIOL, V99, P248, DOI 10.1128/JB.99.1.248-254.1969; PALECEK E, 1991, CRIT REV BIOCHEM MOL, V26, P151, DOI 10.3109/10409239109081126; PANAYOTATOS N, 1981, NATURE, V289, P466, DOI 10.1038/289466a0; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PECK LJ, 1985, CELL, V40, P129, DOI 10.1016/0092-8674(85)90316-2; POHL FM, 1972, J MOL BIOL, V67, P375, DOI 10.1016/0022-2836(72)90457-3; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASSARMA S, 1995, ARCHAEA LAB MANUAL H; SEHROTH GP, 1992, J BIOL CHEM, V267, P11846; SEN D, 1988, NATURE, V334, P364, DOI 10.1038/334364a0; SINDEN R. R., 1994, DNA STRUCTURE FUNCTI; STIRDIVANT SM, 1982, J BIOL CHEM, V257, P159; STJEAN A, 1994, NUCLEIC ACIDS RES, V22, P1476; THOMAE R, 1983, P NATL ACAD SCI-BIOL, V80, P5550, DOI 10.1073/pnas.80.18.5550; THOMAS MJ, 1990, MOL CELL BIOL, V53, P78; VLACH J, 1989, BIOCHEM BIOPH RES CO, V158, P737, DOI 10.1016/0006-291X(89)92783-6; WANG AHJ, 1979, NATURE, V282, P680, DOI 10.1038/282680a0; WELLS RD, 1988, FASEB J, V2, P2939, DOI 10.1096/fasebj.2.14.3053307; WITTIG B, 1991, P NATL ACAD SCI USA, V88, P2259, DOI 10.1073/pnas.88.6.2259; Yang CF, 1996, J BACTERIOL, V178, P840, DOI 10.1128/jb.178.3.840-845.1996; ZHANG SG, 1992, EMBO J, V11, P3787, DOI 10.1002/j.1460-2075.1992.tb05464.x	40	6	7	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					19724	19731		10.1074/jbc.271.33.19724	http://dx.doi.org/10.1074/jbc.271.33.19724			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702677	hybrid			2022-12-25	WOS:A1996VC66900018
J	Milstien, S; Jaffe, H; Kowlessur, D; Bonner, TI				Milstien, S; Jaffe, H; Kowlessur, D; Bonner, TI			Purification and cloning of the GTP cyclohydrolase I feedback regulatory protein, GFRP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; MESSENGER-RNA EXPRESSION; TETRAHYDROBIOPTERIN LEVELS; COFACTOR BIOSYNTHESIS; INTERFERON-GAMMA; SMOOTH-MUSCLE; RAT; TRIPHOSPHATE; ENZYME; CELLS	The activity of GTP cyclohydrolase I, the initial enzyme of the de novo pathway for biosynthesis of tetrahydrobiopterin, the cofactor required for aromatic amino acid hydroxylations and nitric oxide synthesis, is sensitive to end-product feedback inhibition by tetrahydrobiopterin. This inhibition by tetrahydrobiopterin is mediated by the GTP cyclohydrolase I feedback regulatory protein GFRP, previously named p35 (Harada, T., Kagamiyama, H., and Hatakeyama, K. (1993) Science 260, 1507-1510), and L-phenylalanine specifically reverses the tetrahydrobiopterin dependent inhibition. As a first step in the investigation of the physiological role of this unique mechanism of regulation, a convenient procedure has been developed to co purify to homogeneity both GTP cyclohydrolase I and GFRP from rat liver, GTP cyclohydrolase I and GFRP exist in a complex which can be bound to a GTP-affinity column from which GTP cyclohydrolase I and GFRP are separately and selectively eluted. GFRP is dissociated from the GTP agarose-bound complex with 0.2 M NaCl, a concentration of salt which also effectively blocks the tetrahydrobiopterin-dependent inhibitory activity of GFRP. GTP cyclohydrolase I is then eluted from the GTP-agarose column with GTP, Both GFRP and GTP cyclohydrolase I were then purified separately to near homogeneity by sequential high performance anion exchange and gel filtration chromatography, GFRP was found to have a native molecular mass of 20 kDa and consist of a homodimer of 9.5-kDa subunits. Based on peptide sequences obtained from purified GFRP, oligonucleotides were synthesized and used to clone a cDNA from a rat liver cDNA library by polymerase chain reaction-based methods. The cDNA contained an open reading frame that encoded a novel protein of 84 amino acids (calculated molecular mass 9665 daltons). This protein when expressed in Escherichia coli as a thioredoxin fusion protein had tetrahydrobiopterin-dependent GTP cyclohydrolase I inhibitory activity. Northern blot analysis indicated the presence of an 0.8-kilobase GFRP mRNA in most rat tissues, the amounts generally correlating with levels of GTP cyclohydrolase I and tetrahydrobiopterin. Thus, mRNA levels were relatively high in liver and kidney and somewhat lower in testis, heart, brain, and lung. These results suggest that GFRP is widely expressed and may play a role in regulating not only phenylalanine metabolism in the liver, but also the production of biogenic amine neurotransmitters as well as nitric oxide synthesis.	NINCDS,LNC NINDS PROT PEPTIDE SEQUENCING FACIL,NIH,BETHESDA,MD 20892; NIMH,NEUROCHEM LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)	Milstien, S (corresponding author), NIMH,CELL BIOL LAB,36 CONVENT DR,BLDG 36,RM 3A-17,BETHESDA,MD 20892, USA.							ABOUDONIA MM, 1983, ENDOCRINOLOGY, V112, P2088, DOI 10.1210/endo-112-6-2088; ABOUDONIA MM, 1981, P NATL ACAD SCI-BIOL, V78, P2703, DOI 10.1073/pnas.78.5.2703; BELLAHSENE Z, 1984, BIOCHEM J, V217, P59, DOI 10.1042/bj2170059; BLAU N, 1986, BIOCHIM BIOPHYS ACTA, V880, P26, DOI 10.1016/0304-4165(86)90115-7; BLAU N, 1985, J CLIN CHEM CLIN BIO, V23, P169; DUCH DS, 1984, LIFE SCI, V35, P1895, DOI 10.1016/0024-3205(84)90541-1; DUCH DS, 1991, J NUTR BIOCHEM, V2, P411, DOI 10.1016/0955-2863(91)90110-Q; DUCH DS, 1986, MOL CELL ENDOCRINOL, V47, P209, DOI 10.1016/0303-7207(86)90114-0; FERNANDEZ J, 1992, ANAL BIOCHEM, V201, P255, DOI 10.1016/0003-2697(92)90336-6; GUTLICH M, 1994, BIOCHEM J, V302, P215, DOI 10.1042/bj3020215; HARADA T, 1993, SCIENCE, V260, P1507, DOI 10.1126/science.8502995; HATAKEYAMA K, 1989, J BIOL CHEM, V264, P21660; HATAKEYAMA K, 1991, J BIOL CHEM, V266, P765; HATTORI Y, 1993, BIOCHEM BIOPH RES CO, V195, P435, DOI 10.1006/bbrc.1993.2062; HIRAYAMA K, 1993, J NEUROCHEM, V61, P1006, DOI 10.1111/j.1471-4159.1993.tb03614.x; ICHINOSE H, 1994, NAT GENET, V8, P236, DOI 10.1038/ng1194-236; Kaufman S., 1974, MOL MECH OXYGEN ACTI, P285; LEEMING RJ, 1976, ARCH DIS CHILD, V51, P771, DOI 10.1136/adc.51.10.771; MILSTIEN S, 1991, PTERINS BIOGENIC AMI, P89; MILSTIEN S, 1983, CHEM BIOL PTERIDINES, P753; MONCADA S, 1991, PHARMACOL REV, V43, P109; NIEDERWIESER A, 1984, EUR J PEDIATR, V141, P208, DOI 10.1007/BF00572762; ROSENKRANZWEISS P, 1994, J CLIN INVEST, V93, P2236, DOI 10.1172/JCI117221; SAKAI N, 1993, MOL PHARMACOL, V43, P6; SCHOTT K, 1993, J CELL PHYSIOL, V156, P12, DOI 10.1002/jcp.1041560103; SCOTTBURDEN T, 1993, BIOCHEM BIOPH RES CO, V196, P1261, DOI 10.1006/bbrc.1993.2388; STONE KL, 1990, LABORATORY METHODOLO, P181; WERNER ER, 1990, J BIOL CHEM, V265, P3189; WERNERFELMAYER G, 1993, FEBS LETT, V322, P223, DOI 10.1016/0014-5793(93)81574-J; ZAGALAK B, 1988, BIOCHEM BIOPH RES CO, V152, P1193, DOI 10.1016/S0006-291X(88)80411-X	30	77	79	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					19743	19751		10.1074/jbc.271.33.19743	http://dx.doi.org/10.1074/jbc.271.33.19743			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702680	hybrid			2022-12-25	WOS:A1996VC66900021
J	Rajagopalan, LE; Malter, JS				Rajagopalan, LE; Malter, JS			Turnover and translation of in vitro synthesized messenger RNAs in transfected, normal cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3' UNTRANSLATED REGION; AU-RICH ELEMENTS; URIDINE BINDING-FACTOR; 3'-UNTRANSLATED REGION; TRANSFERRIN RECEPTOR; C-FOS; AUUUA MOTIFS; DEGRADATION; PROTEIN; STABILITY	We have developed a novel system to examine intracellular mRNA decay pathways in the absence of transcriptional blockade. In vitro transcribed, capped, and adenylated granulocyte macrophage colony stimulating factor (GM-CSF) or globin mRNAs were introduced by particle-mediated gene transfer into primary cultures of normal peripheral blood mononuclear cells. Transfected wild type, human GM-CSF (GM-AUUUA) mRNA decayed rapidly (t(1/2) = 9 min), while a mutated version lacking AUUUA repeats (hGM-AUGUA) was significantly more stable (t(1/2) = 30 min). A truncated GM-CSF mRNA lacking the entire 3'-UTR (hGM-Delta 3' UTR) was still more stable (t(1/2) = 80 min) demonstrating the existence of non-AUUUA, 3'-UTR destabilizing domains. Transfected beta-globin mRNA was very stable, decaying with a half-life of >360 min. Transfected mRNAs were >90% polysome associated with transgenic protein detectable within 15 min of transfection. The most stable GM-CSF mRNAs were not associated with maximal GM-CSF protein production. Agents known or hypothesized to interfere with mRNA decay, including cycloheximide, phorbol ester, or actinomycin D, stabilized both hGM-AUUUA and hGM-AUGUA mRNAs. These data demonstrate the presence of 3'-UTR, destabilizing, and translational regulatory elements outside of the AUUUA repeats and unambiguously show that actinomycin D at concentrations commonly used to inhibit transcription stabilizes cytokine mRNAs.	UNIV WISCONSIN,DEPT PATHOL & LAB MED,MADISON,WI 53792; UNIV WISCONSIN,CTR COMPREHENS CANC,MADISON,WI 53792	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison					NATIONAL INSTITUTE ON AGING [R01AG010675] Funding Source: NIH RePORTER; NIA NIH HHS [AG 10675] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AHARON T, 1993, MOL CELL BIOL, V13, P1971, DOI 10.1128/MCB.13.3.1971; AKASHI M, 1994, BLOOD, V83, P3182; BICKEL M, 1990, J IMMUNOL, V145, P840; BOHJANEN PR, 1991, MOL CELL BIOL, V11, P3288, DOI 10.1128/MCB.11.6.3288; BREWER G, 1991, MOL CELL BIOL, V11, P2460, DOI 10.1128/MCB.11.5.2460; BURKHOLDER JK, 1993, J IMMUNOL METHODS, V165, P149, DOI 10.1016/0022-1759(93)90340-D; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; CHEN CYA, 1995, MOL CELL BIOL, V15, P5777; CURATOLA AM, 1995, MOL CELL BIOL, V15, P6331; ELDREDGE ER, 1995, METHOD ENZYMOL, V254, P481; GILLIS P, 1991, J BIOL CHEM, V266, P3172; GOLDBERG MA, 1991, BLOOD, V77, P271; GRAFI G, 1993, MOL CELL BIOL, V13, P3487, DOI 10.1128/MCB.13.6.3487; IWAI Y, 1993, J IMMUNOL, V150, P4386; IWAI Y, 1991, J BIOL CHEM, V266, P17959; KATZ DA, 1994, NUCLEIC ACIDS RES, V22, P238, DOI 10.1093/nar/22.2.238; KOELLER DM, 1991, P NATL ACAD SCI USA, V88, P7778, DOI 10.1073/pnas.88.17.7778; KRUYS V, 1989, SCIENCE, V245, P852, DOI 10.1126/science.2672333; LAGNADO CA, 1994, MOL CELL BIOL, V14, P7984, DOI 10.1128/MCB.14.12.7984; LINDSTEN T, 1989, SCIENCE, V244, P339, DOI 10.1126/science.2540528; MALONE RW, 1989, P NATL ACAD SCI USA, V86, P6077, DOI 10.1073/pnas.86.16.6077; MALTER JS, 1989, SCIENCE, V246, P664, DOI 10.1126/science.2814487; MULLER WEG, 1992, J MOL BIOL, V226, P721, DOI 10.1016/0022-2836(92)90628-W; MULLNER EW, 1988, CELL, V53, P815, DOI 10.1016/0092-8674(88)90098-0; NAKAGAWA J, 1995, P NATL ACAD SCI USA, V92, P2051, DOI 10.1073/pnas.92.6.2051; PELTZ S W, 1991, Critical Reviews in Eukaryotic Gene Expression, V1, P99; Qiu P, 1996, GENE THER, V3, P262; RAJAGOPALAN LE, 1995, BLOOD, V86, P2551; RAJAGOPALAN LE, 1994, J BIOL CHEM, V269, P23882; SAVANTBHONSALE S, 1992, GENE DEV, V6, P1927, DOI 10.1101/gad.6.10.1927; SCHIAVI SC, 1994, J BIOL CHEM, V269, P3441; SEISER C, 1995, J BIOL CHEM, V270, P29400, DOI 10.1074/jbc.270.49.29400; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHYU AB, 1989, GENE DEV, V3, P60, DOI 10.1101/gad.3.1.60; SONG HJ, 1995, EUR J BIOCHEM, V232, P778, DOI 10.1111/j.1432-1033.1995.tb20873.x; Tanguay RL, 1996, MOL CELL BIOL, V16, P146; VAKALOPOULOU E, 1991, MOL CELL BIOL, V11, P3355, DOI 10.1128/MCB.11.6.3355; WINSTALL E, 1995, MOL CELL BIOL, V15, P3796; WISDOM R, 1991, GENE DEV, V5, P232, DOI 10.1101/gad.5.2.232; WODNARFILIPOWIC.A, 1990, P NATL ACAD SCI USA, V290, P777; ZHANG W, 1993, MOL CELL BIOL, V13, P7652, DOI 10.1128/MCB.13.12.7652; ZUBIAGA AM, 1995, MOL CELL BIOL, V15, P2219	42	52	74	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					19871	19876		10.1074/jbc.271.33.19871	http://dx.doi.org/10.1074/jbc.271.33.19871			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702698	hybrid			2022-12-25	WOS:A1996VC66900039
J	Lagrost, L; Athias, A; Herbeth, B; GuyardDangremont, V; Artur, Y; Paille, F; Gambert, P; Lallemant, C				Lagrost, L; Athias, A; Herbeth, B; GuyardDangremont, V; Artur, Y; Paille, F; Gambert, P; Lallemant, C			Opposite effects of cholesteryl ester transfer protein and phospholipid transfer protein on the size distribution of plasma high density lipoproteins - Physiological relevance in alcoholic patients	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN-A-I; PARTICLE-SIZE; HDL-SUBFRACTIONS; LIPID TRANSFERS; HEPATIC LIPASE; FATTY-ACIDS; CONVERSION; CONSUMPTION; REDUCTION; ETHANOL	The aim of the present study was to investigate the role of the cholesteryl ester transfer protein (CETP) and the phospholipid transfer protein (PLTP) in determining the size distribution of high density lipoproteins (ADL) in human plasma, Whereas both purified CETP and PLTP preparations were able to promote the size redistribution of isolated HDL(3), CETP favored the emergence of small HDL, while PLTP induced the formation of both small and large conversion products. When the total plasma lipoprotein fractions isolated from nine distinct subjects were incubated for 24 h at 37 degrees C with either purified PLTP or purified CETP, significant alterations in the relative proportions of the five distinct plasma HDL subpopulations, i.e., HDL(21) (9.71-12.90 nm), HDL(2a) (8.77-9.71 nm), HDL(3a) (8.17-8.77 nm), HDL(3b) (7.76-8.17 nm), and HDL(3c) (7.21-7.16 nm) were also observed, PLTP induced a significant increase in the relative abundance of HDL(2b) (8.66 +/- 2.34% versus 7.87 +/- 1.83% in controls; p < 0.01) and a significant decrease in the relative abundance of HDL(3a) (32.16 +/- 3.42% versus 37.87 +/- 2.62% in controls; p < 0.05). In contrast, CETP significantly reduced the relative proportion of HDL2a (33.03 +/- 2.53% versus 37.56 +/- 6.43% in controls; p < 0.01) but significantly increased the relative proportion of both HDL(3b) (21.36 +/- 6.97% versus 15.58 +/- 7.75% in controls; p < 0.01) and HDL(3b) (3.21 +/- 4.84% versus 1.13 +/- 0.56% in controls; p < 0.05). Finally, in order to assess further the physiological relevance of in vitro observations, CETP activity, PLTP activity, and HDL size distribution were determined in plasmas from 33 alcoholic patients entering a cessation program. Alcohol withdrawaI was associated with (i) a significant increase in plasma CETP activity (173.5 +/- 70.55 h/ml before versus 223.2 +/- 69.3%/h/ml after alcohol withdrawal, p = 0.0001), (ii) a significant reduction in plasma PLTP activity (473.9 +/- 203.7%/h/ml before versus 312.7 +/- 148.4%/h/ml after alcohol withdrawal, p = 0.0001), and (iii) a significant shift of large HDL(2b) and RDL(2a) toward small HDL(3b)and HDL(3c). On the one hand, changes in plasma CETP activity correlated negatively with changes in the proportion of HDL(2a) (r = -0.597, p = 0.0002) and positively with changes in the proportion of HDL(3b) (r = 0.457, p = 0.0075), On the other hand, changes in plasma PLTP activity correlated positively with changes in the proportion of RDL(2b) (r = 0.482, p = 0.0045) and negatively with changes in the proportion of HDL(3a) (r = -0.418, p = 0.0154), Taken together, data of the present study revealed that plasma PLTP and CETP can exert opposite effects on the size distribution of plasma HDL. PLTP can promote the formation of HDL(2b) particles at the expense of HDL(3a), while CETP can promote the formation of HDL(3b) particles at the expense of HDL(2a).	FAC MED,INSERM CJF 93 10,LAB BIOCHIM LIPOPROT,F-21033 DIJON,FRANCE; LAB CTR MED PREVENT,CNRS URA 597,F-54500 VANDOEUVRE NANCY,FRANCE; FAC MED & PHARM,FORMAT BIOCHIM PHARMACOL,F-21033 DIJON,FRANCE; CHRU,HOP FOURNIER,CTR ALCOOL,F-54000 NANCY,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne; Universite de Bourgogne; CHU de Nancy			ARTUR, Yves E/A-8504-2019					AMARASURIYA RN, 1992, METABOLISM, V41, P827, DOI 10.1016/0026-0495(92)90162-4; BARTER PJ, 1990, BIOCHIM BIOPHYS ACTA, V1045, P81, DOI 10.1016/0005-2760(90)90206-D; BLANCHE PJ, 1981, BIOCHIM BIOPHYS ACTA, V665, P408, DOI 10.1016/0005-2760(81)90253-8; CHEUNG MC, 1984, J BIOL CHEM, V259, P2201; CHEUNG MC, 1991, J LIPID RES, V32, P383; CLAY MA, 1992, BIOCHIM BIOPHYS ACTA, V1124, P52, DOI 10.1016/0005-2760(92)90125-F; DAMEN J, 1982, BIOCHIM BIOPHYS ACTA, V712, P444, DOI 10.1016/0005-2760(82)90271-5; DAMEN J, 1980, BIOCHIM BIOPHYS ACTA, V620, P90, DOI 10.1016/0005-2760(80)90188-5; DANIELSSON B, 1978, SCAND J CLIN LAB INV, V38, P113, DOI 10.1080/00365517809156078; DECKELBAUM RJ, 1979, J BIOL CHEM, V254, P6079; GOLDBERG CS, 1984, J LIPID RES, V25, P714; GUYARDDANGREMONT V, 1994, CLIN CHIM ACTA, V231, P147, DOI 10.1016/0009-8981(94)90199-6; HAGIAGE M, 1992, METABOLISM, V41, P856, DOI 10.1016/0026-0495(92)90167-9; HANNUKSELA M, 1992, J LIPID RES, V33, P737; HANNUKSELA M, 1992, ALCOHOL ALCOHOLISM, V27, P557; HENNESSY LK, 1993, BIOCHEMISTRY-US, V32, P5759, DOI 10.1021/bi00073a006; HIRANO K, 1992, METABOLISM, V41, P1313, DOI 10.1016/0026-0495(92)90101-F; JAUHIAINEN M, 1993, J BIOL CHEM, V268, P4032; JOHANSSON J, 1991, ARTERIOSCLER THROMB, V11, P174, DOI 10.1161/01.ATV.11.1.174; LAGROST L, 1994, J BIOL CHEM, V269, P3189; LAGROST L, 1992, BIOCHIM BIOPHYS ACTA, V1126, P143, DOI 10.1016/0005-2760(92)90284-3; LAGROST L, 1995, ARTERIOSCL THROM VAS, V15, P1388, DOI 10.1161/01.ATV.15.9.1388; LAGROST L, 1994, BBA-LIPID LIPID MET, V1215, P209, DOI 10.1016/0005-2760(94)90047-7; LAGROST L, 1994, J LIPID RES, V35, P825; LAGROST L, 1990, J LIPID RES, V31, P1569; LAGROST L, 1993, ARTERIOSCLER THROMB, V13, P815, DOI 10.1161/01.ATV.13.6.815; LAGROST L, 1994, ARTERIOSCLER THROMB, V14, P1327, DOI 10.1161/01.ATV.14.8.1327; LAMISSE F, 1994, ALCOHOL ALCOHOLISM, V29, P25; LECOMTE E, 1994, AM J CLIN NUTR, V60, P255, DOI 10.1093/ajcn/60.2.255; LEE SP, 1982, EXPERIENTIA, V38, P914; LIANG HQ, 1994, J LIPID RES, V35, P1187; Lusa S, 1996, BIOCHEM J, V313, P275, DOI 10.1042/bj3130275; OKAMOTO Y, 1988, J LAB CLIN MED, V111, P482; PERIER C, 1983, CLIN CHEM, V29, P874; PULCINI T, 1995, BBA-LIPID LIPID MET, V1254, P13, DOI 10.1016/0005-2760(94)00156-S; PUSSINEN P, 1995, J LIPID RES, V36, P975; REDGRAVE TG, 1979, J CLIN INVEST, V64, P162, DOI 10.1172/JCI109435; SAVOLAINEN MJ, 1990, EUR J CLIN INVEST, V20, P593, DOI 10.1111/j.1365-2362.1990.tb01906.x; SCHNEIDER J, 1985, ATHEROSCLEROSIS, V57, P281, DOI 10.1016/0021-9150(85)90040-1; SILLANAUKEE P, 1993, EUR J CLIN INVEST, V23, P486, DOI 10.1111/j.1365-2362.1993.tb00795.x; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; TALL A, 1995, ANNU REV BIOCHEM, V64, P235; TALL AR, 1985, J LIPID RES, V26, P842; TALL AR, 1990, J CLIN INVEST, V86, P379, DOI 10.1172/JCI114722; TALL AR, 1983, J LIPID RES, V24, P277; TU AY, 1993, J BIOL CHEM, V268, P23098; VALIMAKI M, 1988, EUR J CLIN INVEST, V18, P472, DOI 10.1111/j.1365-2362.1988.tb01042.x; VALIMAKI M, 1993, EUR J CLIN INVEST, V23, P406, DOI 10.1111/j.1365-2362.1993.tb00783.x; VALIMAKI M, 1986, ATHEROSCLEROSIS, V59, P147, DOI 10.1016/0021-9150(86)90043-2; WILLIAMS PT, 1993, ARTERIOSCLER THROMB, V13, P1654, DOI 10.1161/01.ATV.13.11.1654	50	71	95	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19058	19065		10.1074/jbc.271.32.19058	http://dx.doi.org/10.1074/jbc.271.32.19058			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702577	hybrid			2022-12-25	WOS:A1996VB68400011
J	Sobel, JH; Gawinowicz, MA				Sobel, JH; Gawinowicz, MA			Identification of the alpha chain lysine donor sites involved in factor XIII(a) fibrin cross-linking	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SEQUENCE; ALPHA-2-PLASMIN INHIBITOR; ELECTROPHORETIC TRANSFER; MONOCLONAL-ANTIBODY; POLYACRYLAMIDE GELS; TRANSGLUTAMINASE; CROSSLINKING; PROTEINS; HETEROGENEITIES; NITROCELLULOSE	Biochemical studies of fibrin cross-linking were conducted to identify the specific A alpha chain lysine residues that potentially serve as Factor XIII(a) amine donor substrates during alpha polymer formation. A previously characterized Factor XIII(a) fibrin lysine labeling system was employed to localize sites of donor activity based on their covalent incorporation of a synthetic peptide acceptor substrate analog modelled after the NH2-terminal cross-linking domain of alpha(2) antiplasmin, Peptide-decorated fibrin was prepared using purified fibrinogen as the starting material, Cyanogen bromide digestion, immunoaffinity chromatography, high pressure liquid chromatography (HPLC), and enzyme-linked immunosorbent assay (anti-peptide) methodologies were employed to isolate purified CNBr fibrin fragments whose structures included the acceptor probe in cross-linked form and, therefore, represented regions of (amine) donor activity, Five alpha chain CNBr fragments (within A alpha 208-610) and one gamma chain CNBr fragment (gamma 385-411) were the only portions of fibrin found associated with the acceptor peptide, based on collective sequencing, mass, and compositional data, Trypsin digestion, HPLC, and enzyme-linked immunosorbent assay (anti-peptide) methodologies were used to isolate smaller derivatives whose structures included an or chain tryptic cleavage product (the donor arm) cross-linked to the trypsin-resistant synthetic peptide (the acceptor arm). Biochemical characterization and quantitative peptide recovery data revealed that 12 of the 23 potential lysine donor residues within alpha 208-610 had incorporated the peptide probe, whereas gamma chain donor activity was due solely to peptide cross-linking at, (gamma) Lys(406); the alpha chain lysines, Lys(556) and Lys(580), accounted for 50% of the total alpha chain donor cross-linking activity observed, with Lys(539), Lys(508), Lys(418), and Lys(448) contributing an additional 25% and Lys(601), Lys(606), Lys(427), Lys(429), Lys(208), Lys(224), and/or Lys(219) responsible for the remaining proportion (25%, each), The collective findings extend current models proposed for the mechanism of alpha polymer formation, raise questions concerning the physiological role of multiple cu chain donor sites, and, most importantly, provide specific information that should facilitate future efforts to identify the respective lysine and glutamine partners involved in native fibrin alpha chain cross-linking.			Sobel, JH (corresponding author), COLUMBIA UNIV,COLL PHYS & SURG,DEPT MED,IRVING CTR CLIN RES,630 W 168TH ST,NEW YORK,NY 10032, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045936] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 45936] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BENDIXEN E, 1993, J BIOL CHEM, V268, P21962; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CHEN R, 1971, BIOCHEMISTRY-US, V10, P4486, DOI 10.1021/bi00800a021; CHUNG DW, 1983, BIOCHEMISTRY-US, V22, P3250, DOI 10.1021/bi00282a033; CORCORAN DH, 1980, THROMB RES, V19, P883, DOI 10.1016/0049-3848(80)90016-X; COTTRELL BA, 1979, BIOCHEMISTRY-US, V18, P5405, DOI 10.1021/bi00591a023; DOOLITTLE RF, 1977, BIOCHEMISTRY-US, V16, P1715, DOI 10.1021/bi00627a030; DOOLITTLE RF, 1971, BIOCHEM BIOPH RES CO, V44, P94, DOI 10.1016/S0006-291X(71)80163-8; EHRLICH PH, 1983, BIOCHEMISTRY-US, V22, P4184, DOI 10.1021/bi00287a004; FATH MJ, 1994, BIOCHEMISTRY-US, V33, P6911, DOI 10.1021/bi00188a021; FINLAYSON J S, 1973, Thrombosis Research, V2, P467, DOI 10.1016/0049-3848(73)90001-7; FOWLER WE, 1979, J MOL BIOL, V134, P241, DOI 10.1016/0022-2836(79)90034-2; FRETTO LJ, 1978, J BIOL CHEM, V253, P6614; GALANAKIS DK, 1983, THROMB RES, V31, P403, DOI 10.1016/0049-3848(83)90405-X; GARDLUND B, 1977, EUR J BIOCHEM, V77, P595, DOI 10.1111/j.1432-1033.1977.tb11704.x; HALL CE, 1959, J BIOPHYS BIOCHEM CY, V5, P11, DOI 10.1083/jcb.5.1.11; HENSCHEN A, 1979, H-S Z PHYSIOL CHEM, V360, P1951; HIROSAWA S, 1988, P NATL ACAD SCI USA, V85, P6836, DOI 10.1073/pnas.85.18.6836; ICHINOSE A, 1983, FEBS LETT, V153, P369, DOI 10.1016/0014-5793(83)80645-0; KIMURA S, 1986, J BIOL CHEM, V261, P5591; KOEHN JA, 1981, ANAL BIOCHEM, V116, P349, DOI 10.1016/0003-2697(81)90370-5; KOOPMAN J, 1992, BLOOD, V80, P1972; KUDRYK B, 1984, MOL IMMUNOL, V21, P89, DOI 10.1016/0161-5890(84)90093-2; LAEMMLI UK, 1973, J MOL BIOL, V80, P575, DOI 10.1016/0022-2836(73)90198-8; LORAND L, 1992, BIOCONJUGATE CHEM, V3, P37, DOI 10.1021/bc00013a006; LORAND L, 1992, P NATL ACAD SCI USA, V89, P11161, DOI 10.1073/pnas.89.23.11161; Lorand L., 1970, METHOD ENZYMOL, V19, P770; LOTTSPEICH F, 1978, H-S Z PHYSIOL CHEM, V359, P1611; LOTTSPEICH F, 1978, H-S Z PHYSIOL CHEM, V359, P1451; MATACIC S, 1968, BIOCHEM BIOPH RES CO, V30, P356, DOI 10.1016/0006-291X(68)90750-X; MCDONAGH RP, 1971, FEBS LETT, V14, P33, DOI 10.1016/0014-5793(71)80268-5; MCKEE PA, 1970, P NATL ACAD SCI USA, V66, P738, DOI 10.1073/pnas.66.3.738; Mitkevich OV, 1996, BLOOD COAGUL FIBRIN, V7, P85, DOI 10.1097/00001721-199601000-00011; MOSESSON MW, 1990, J LAB CLIN MED, V116, P8; MOSESSON MW, 1989, P NATL ACAD SCI USA, V86, P1113, DOI 10.1073/pnas.86.4.1113; MOSESSON MW, 1972, J BIOL CHEM, V247, P5210; PARAMESWARAN KN, 1990, P NATL ACAD SCI USA, V87, P8472, DOI 10.1073/pnas.87.21.8472; RIXON MW, 1983, BIOCHEMISTRY-US, V22, P3237, DOI 10.1021/bi00282a031; SOBEL JH, 1983, BIOCHEMISTRY-US, V22, P4175, DOI 10.1021/bi00287a003; SOBEL JH, 1995, BLOOD, V86, P989, DOI 10.1182/blood.V86.3.989.bloodjournal863989; SOBEL JH, 1988, THROMB HAEMOSTASIS, V60, P160; SOBEL JH, 1994, BLOOD, V84, P535; TAMAKI T, 1982, J BIOL CHEM, V257, P4767; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WATT KWK, 1979, BIOCHEMISTRY-US, V18, P68, DOI 10.1021/bi00568a011; WEISEL JW, 1985, SCIENCE, V230, P1388, DOI 10.1126/science.4071058	46	64	69	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19288	19297		10.1074/jbc.271.32.19288	http://dx.doi.org/10.1074/jbc.271.32.19288			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702612	hybrid			2022-12-25	WOS:A1996VB68400046
J	Thornhill, WB; Wu, MB; Jiang, XQ; Wu, XY; Morgan, PT; Margiotta, JF				Thornhill, WB; Wu, MB; Jiang, XQ; Wu, XY; Morgan, PT; Margiotta, JF			Expression of Kv1.1 delayed rectifier potassium channels in Lec mutant Chinese hamster ovary cell lines reveals a role for sialidation in channel function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENDROTOXIN-BINDING PROTEIN; GOLGI VESICLE MEMBRANES; SHAKER K+-CHANNELS; SQUID GIANT-AXONS; SIALIC-ACID; SODIUM-CHANNELS; XENOPUS-OOCYTES; SURFACE-CHARGE; DIVALENT-CATIONS; CARDIAC MYOCYTES	Kv1.1 potassium (K+) channels contain significant amounts of negatively charged sialic acids, To examine the role of sialidation in K+ channel function. Chinese hamster ovary cell lines deficient in glycosylation (Lee mutants) were transfected with rat brain Kv1.1 cDNA, The K+ channel was functionally expressed in all cell lines, but the voltage dependence of activation (V-1/2) was shifted to more positive voltages and the activation kinetics were slower in the mutant cell lines compared with control, A similar positive shift in VM was recorded in control cells expressing Kv1.1 following treatment with sialidase or by raising extracellular Ca2+, In contrast, these treatments had little or no effect on the Lec mutants, which indicates that channel sialic acids appear to be the negative surface charges sensitive to Ca2+, The data suggest that sialic acid addition modifies Kv1.1 channel function, possibly by influencing the local electric field detected by its voltage sensor, but that these carbohydrates are not required for cell surface expression.			Thornhill, WB (corresponding author), CUNY MT SINAI SCH MED,DEPT PHYSIOL & BIOPHYS,1 GUSTAVE LEVY PL,NEW YORK,NY 10029, USA.		Morgan, Peter/AAD-1891-2022		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024417, R01NS029633] Funding Source: NIH RePORTER; NINDS NIH HHS [NS29633, NS24417] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARMSTRONG CM, 1990, P NATL ACAD SCI USA, V87, P7579, DOI 10.1073/pnas.87.19.7579; ARMSTRONG CM, 1981, PHYSIOL REV, V61, P644, DOI 10.1152/physrev.1981.61.3.644; ARMSTRONG CM, 1986, J GEN PHYSIOL, V87, P817, DOI 10.1085/jgp.87.5.817; ARMSTRONG CM, 1987, SCIENCE, V236, P712, DOI 10.1126/science.2437654; Ausubel F, 1990, CURRENT PROTOCOLS MO, V1; AUSUBEL FM, 1990, CURRENT PROTOCOLS MO, V2; BARCHI RL, 1988, ANNU REV NEUROSCI, V11, P455, DOI 10.1146/annurev.ne.11.030188.002323; BAUMANN A, 1988, EMBO J, V7, P2457, DOI 10.1002/j.1460-2075.1988.tb03092.x; BEGENISICH T, 1988, TRENDS NEUROSCI, V11, P270, DOI 10.1016/0166-2236(88)90109-9; BENNET E, 1995, BIOPHYS J, V68, P152; CATTERALL WA, 1988, SCIENCE, V242, P50, DOI 10.1126/science.2459775; CHRISTIE MJ, 1989, SCIENCE, V244, P221, DOI 10.1126/science.2539643; CUKIERMAN S, 1988, J GEN PHYSIOL, V92, P431, DOI 10.1085/jgp.92.4.431; DEAL KK, 1994, J NEUROSCI, V14, P1666, DOI 10.1523/JNEUROSCI.14-03-01666.1994; DEUTSCHER SL, 1986, J BIOL CHEM, V261, P96; DEUTSCHER SL, 1984, CELL, V39, P295, DOI 10.1016/0092-8674(84)90007-2; FERMINI B, 1991, AM J PHYSIOL, V260, pH735, DOI 10.1152/ajpheart.1991.260.3.H735; FERMINI B, 1990, J MEMBRANE BIOL, V114, P61, DOI 10.1007/BF01869385; FRANKENHAEUSER B, 1976, ACTA PHYSIOL SCAND, V96, P548, DOI 10.1111/j.1748-1716.1976.tb10225.x; FRANKENHAEUSER B, 1957, J PHYSIOL-LONDON, V137, P218, DOI 10.1113/jphysiol.1957.sp005808; GILLY WF, 1982, J GEN PHYSIOL, V79, P965, DOI 10.1085/jgp.79.6.965; HAHIN R, 1983, J GEN PHYSIOL, V82, P785, DOI 10.1085/jgp.82.6.785; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hille B., 1992, IONIC CHANNELS EXCIT; INOUE I, 1981, J GEN PHYSIOL, V78, P43, DOI 10.1085/jgp.78.1.43; ISACOFF EY, 1991, NATURE, V353, P86, DOI 10.1038/353086a0; IVANINA T, 1994, BIOCHEMISTRY-US, V33, P8786, DOI 10.1021/bi00195a021; JAN LY, 1990, TRENDS NEUROSCI, V13, P415, DOI 10.1016/0166-2236(90)90123-R; Kaczmarek LK, 1987, NEUROMODULATION BIOC; KAGAWA Y, 1988, J BIOL CHEM, V263, P17508; LATORRE R, 1989, ANNU REV PHYSIOL, V51, P385, DOI 10.1146/annurev.ph.51.030189.002125; LENNARZ W, 1983, METHOD ENZYMOL, V98, P91; LEVIN G, 1995, J BIOL CHEM, V270, P14611, DOI 10.1074/jbc.270.24.14611; LEVINSON SR, 1986, ION CHANNELS NEURAL, P375; LEVITAN IB, 1988, ANNU REV NEUROSCI, V11, P119, DOI 10.1146/annurev.neuro.11.1.119; LIMAN ER, 1991, NATURE, V353, P752, DOI 10.1038/353752a0; LOGOTHETIS DE, 1992, NEURON, V8, P531, DOI 10.1016/0896-6273(92)90281-H; LOPEZ GA, 1991, NEURON, V7, P327, DOI 10.1016/0896-6273(91)90271-Z; MCCORMACK K, 1991, P NATL ACAD SCI USA, V88, P2931, DOI 10.1073/pnas.88.7.2931; MCDONAGH JC, 1990, J MOL CELL CARDIOL, V22, P1305, DOI 10.1016/0022-2828(90)90066-B; NEGISHI M, 1992, CARBOHYD RES, V236, P209, DOI 10.1016/0008-6215(92)85017-T; NEUMCKE B, 1984, PFLUG ARCH EUR J PHY, V401, P125, DOI 10.1007/BF00583872; PAPAZIAN DM, 1991, NATURE, V349, P305, DOI 10.1038/349305a0; PAULSON JC, 1989, J BIOL CHEM, V264, P10931; PERNEY T M, 1991, Current Opinion in Cell Biology, V3, P663, DOI 10.1016/0955-0674(91)90039-2; Pongs O, 1992, PHYSL REV S, V72, pS69; RECIOPINTO E, 1990, NEURON, V5, P675, DOI 10.1016/0896-6273(90)90221-Z; REHM H, 1989, FEBS LETT, V247, P28, DOI 10.1016/0014-5793(89)81233-5; REHM H, 1989, FEBS LETT, V249, P224, DOI 10.1016/0014-5793(89)80628-3; RETTIG J, 1994, NATURE, V369, P289, DOI 10.1038/369289a0; ROSENBERG RL, 1992, NATURE, V360, P166, DOI 10.1038/360166a0; RUDY B, 1991, Molecular and Cellular Neuroscience, V2, P89, DOI 10.1016/1044-7431(91)90001-5; RUDY B, 1988, NEUROSCIENCE, V25, P729, DOI 10.1016/0306-4522(88)90033-4; SALKOFF L, 1992, TRENDS NEUROSCI, V15, P161, DOI 10.1016/0166-2236(92)90165-5; SANTACRUZTOLOZA L, 1994, BIOCHEMISTRY-US, V33, P5607, DOI 10.1021/bi00184a033; SCOTT VES, 1990, J BIOL CHEM, V265, P20094; STANLEY P, 1977, SOMAT CELL GENET, V3, P391, DOI 10.1007/BF01542968; STANLEY P, 1989, MOL CELL BIOL, V9, P377, DOI 10.1128/MCB.9.2.377; STUHMER W, 1989, NATURE, V339, P597, DOI 10.1038/339597a0; STUHMER W, 1989, EMBO J, V8, P3235, DOI 10.1002/j.1460-2075.1989.tb08483.x; TEMPEL BL, 1988, NATURE, V332, P837, DOI 10.1038/332837a0; TRIMMER JS, 1989, ANNU REV PHYSIOL, V51, P401, DOI 10.1146/annurev.physiol.51.1.401; Uebele VN, 1996, J BIOL CHEM, V271, P2406, DOI 10.1074/jbc.271.5.2406; WANN KT, 1994, EUR J NEUROSCI, V6, P607, DOI 10.1111/j.1460-9568.1994.tb00305.x; YEE HF, 1989, AM J PHYSIOL, V256, pC1267, DOI 10.1152/ajpcell.1989.256.6.C1267; ZAGOTTA WN, 1994, J GEN PHYSIOL, V103, P279, DOI 10.1085/jgp.103.2.279	66	75	76	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19093	19098		10.1074/jbc.271.32.19093	http://dx.doi.org/10.1074/jbc.271.32.19093			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702582	hybrid			2022-12-25	WOS:A1996VB68400016
J	Webb, DL; Islam, MS; Efanov, AM; Brown, G; Kohler, M; Larsson, O; Berggren, PO				Webb, DL; Islam, MS; Efanov, AM; Brown, G; Kohler, M; Larsson, O; Berggren, PO			Insulin exocytosis and glucose-mediated increase in cytoplasmic free Ca2+ concentration in the pancreatic beta-cell are independent of cyclic ADP-ribose	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FREE CA-2+ CONCENTRATION; INOSITOL TRISPHOSPHATE; SECRETING CELLS; RELEASE; CALCIUM; HYDROLYSIS; INHIBITION; RECEPTOR; FURA-2; ISLETS	Stimulation of pancreatic P-cells by glucose gives rise to an increase in the cytoplasmic free calcium concentration ([Ca2+](i)) and exocytosis of insulin. Cyclic adenosine 5'-diphosphate ribose (cADPR), a metabolite of beta-NAD(+), has been reported to increase [Ca2+](i) in pancreatic beta-cells by releasing Ca2+ from inositol 1,4,5-trisphosphate-insensitive intracellular stores. In the present study, we have examined the role of cADPR in glucose-mediated increases in [Ca2+](i) and insulin exocytosis. Dispersed ob/ob mouse beta-cell aggregates were either pressure microinjected with fura-2 salt or loaded with fura-2 acetoxymethyl ester, and [Ca2+](i) was monitored by microfluorimetry. Microinjection of beta-NAD(+) into fura-2-loaded beta-cells did not increase [Ca2+](i) nor did it alter the cells' subsequent [Ca2+](i) response to glucose. Cells microinjected with the cADPR antagonist 8NH(2)-cADPR increased [Ca2+](i) in response to glucose equally well as those injected with cADPR. Finally, the ability of cADPR to promote exocytosis of insulin ill electropermeabilized beta-cells was investigated. cADPR on its own did not increase insulin secretion nor did it potentiate Ca2+-induced insulin secretion. We conclude that cADPR neither plays a significance role in glucose-mediated increases in [Ca2+](i) nor interacts directly with the molecular mechanisms regulating exocytosis of insulin in normal pancreatic beta-cells.	KAROLINSKA INST, KAROLINSKA HOSP, DEPT MOL MED, ROLF LUFT CTR DIABET RES, S-17176 STOCKHOLM, SWEDEN	Karolinska Institutet; Karolinska University Hospital			Islam, Shahidul/K-3295-2019; Efanov, Alexander/R-3630-2019	Islam, Shahidul/0000-0002-9016-1881; Efanov, Alexander/0000-0002-8630-1503; Webb, Dominic-Luc/0000-0002-6979-9194; Berggren, Per-Olof/0000-0001-8991-413X; Kohler, Martin/0000-0001-6487-4303				ARKHAMMAR P, 1987, J BIOL CHEM, V262, P5448; ARKHAMMAR P, 1989, CELL CALCIUM, V10, P17, DOI 10.1016/0143-4160(89)90040-7; BERGGREN PO, 1993, ADV EXP MED BIOL, V334, P24; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; CLAPPER DL, 1987, J BIOL CHEM, V262, P9561; GALIONE A, 1993, SCIENCE, V259, P325, DOI 10.1126/science.8380506; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HOWARD M, 1993, SCIENCE, V262, P1056, DOI 10.1126/science.8235624; ISLAM MS, 1992, FEBS LETT, V296, P287, DOI 10.1016/0014-5793(92)80306-2; ISLAM MS, 1993, SCIENCE, V262, P584, DOI 10.1126/science.8211188; KASS GEN, 1994, BIOCHEM J, V302, P5, DOI 10.1042/bj3020005; KNIGHT DE, 1986, BIOCHEM J, V234, P497, DOI 10.1042/bj2340497; LEE HC, 1989, J BIOL CHEM, V264, P1608; LEE HC, 1993, SCIENCE, V261, P352, DOI 10.1126/science.8392749; LEE HC, 1994, NATURE, V370, P307, DOI 10.1038/370307a0; NILSSON T, 1987, BIOCHEM J, V248, P329, DOI 10.1042/bj2480329; RUTTER GA, 1994, CELL CALCIUM, V16, P71, DOI 10.1016/0143-4160(94)90002-7; STREB H, 1983, NATURE, V306, P67, DOI 10.1038/306067a0; TAKASAWA S, 1993, J BIOL CHEM, V268, P26052; TAKASAWA S, 1993, SCIENCE, V259, P370, DOI 10.1126/science.8420005; TAKASAWA S, 1993, SCIENCE, V262, P585, DOI 10.1126/science.262.5133.585-a; TSIEN RY, 1980, BIOCHIM BIOPHYS ACTA, V599, P623, DOI 10.1016/0005-2736(80)90205-9; WALSETH TF, 1993, BIOCHIM BIOPHYS ACTA, V1178, P235, DOI 10.1016/0167-4889(93)90199-Y; ZHANG A, 1991, J BIOL CHEM, V266, P21649; ZHOU YP, 1995, ENDOCRINOLOGY, V136, P3546, DOI 10.1210/en.136.8.3546	25	38	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19074	19079		10.1074/jbc.271.32.19074	http://dx.doi.org/10.1074/jbc.271.32.19074			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702579	hybrid			2022-12-25	WOS:A1996VB68400013
J	HammondsOdie, LP; Jackson, TR; Profit, AA; Blader, IJ; Turck, CW; Prestwich, GD; Theibert, AB				HammondsOdie, LP; Jackson, TR; Profit, AA; Blader, IJ; Turck, CW; Prestwich, GD; Theibert, AB			Identification and cloning of centaurin-alpha - A novel phosphatidylinositol 3,4,5-trisphosphate-binding protein from rat brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION FACTOR; KINASE-C; PHOSPHOINOSITIDE 3-KINASE; INOSITOL 1,3,4,5-TETRAKISPHOSPHATE; SACCHAROMYCES-CEREVISIAE; ACTIVATED NEUTROPHILS; SIGNAL-TRANSDUCTION; GLUCOSE-TRANSPORT; RECEPTOR; BINDING	Using an affinity resin and photoaffinity label based on phospholipid analogs of inositol 1,3,4,5-tetrakisphosphate (InsP(4)), we have isolated, characterized, and cloned a 46-kDa protein from rat brain, which we have named centaurin-alpha. Binding specificity was determined using displacement of 1-O-[H-3](3-[4-benzoyldihydrocinnamidyl]propyl)-InsP(4) photoaffinity labeling. Centaurin-alpha displayed highest affinity for phosphatidylinositol 3,4,5-trisphosphate (PtdInsP(3)) (IC50 = 120 nm), whereas InsP(4), PtdInsP(2), and InsP(3) bound with 5-, 12-, and >50-fold lower affinity, respectively. Screening a rat brain cDNA library with a polymerase chain reaction product, generated using partial amino acid sequence from tryptic peptides, yielded a full-length clone. The 2,450-base pair cDNA contained an open reading frame (ORF) encoding a novel protein of 419 amino acids. Northern analysis revealed a 2.5-kilobase transcript that is highly expressed in brain. The deduced sequence contains a novel putative zinc finger motif, 10 ankyrin-like repeats, and shows homology to recently identified yeast and mammalian Arf GTPase-activating proteins. Given the specificity of binding and enrichment in brain, centaurin-alpha is a candidate PtdInsP(3) receptor that may link the activation of phosphoinositide 3-kinase to downstream responses in the brain.	UNIV ALABAMA,NEUROBIOL RES CTR,BIRMINGHAM,AL 35294; UNIV ALABAMA,DEPT CELL BIOL,BIRMINGHAM,AL 35294; BABRAHAM INST,MOL SIGNALLING LAB,DEPT ZOOL,CAMBRIDGE CB2 3ES,ENGLAND; SUNY STONY BROOK,DEPT CHEM & BIOCHEM,STONY BROOK,NY 11794; SUNY STONY BROOK,DEPT CELL BIOL,STONY BROOK,NY 11794; UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,SAN FRANCISCO,CA 94143	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Howard Hughes Medical Institute; University of California System; University of California San Francisco				Hammonds-Odie, Latanya/0000-0001-7482-8239	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P50HD032901] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R29MH050102, R01MH050102] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS029632] Funding Source: NIH RePORTER; NICHD NIH HHS [DDRC P50HD32901] Funding Source: Medline; NIMH NIH HHS [R01 MH050102, R29 MH050102, R29MH50102] Funding Source: Medline; NINDS NIH HHS [NS29632] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARPIN M, 1994, CURR OPIN CELL BIOL, V6, P136, DOI 10.1016/0955-0674(94)90127-9; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BOGERD HP, 1995, CELL, V82, P485, DOI 10.1016/0092-8674(95)90437-9; BORK P, 1993, PROTEINS, V17, P363, DOI 10.1002/prot.340170405; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CHAUDHARY A, 1995, TETRAHEDRON LETT, V6, P395; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; COE JGS, 1994, MOL GEN GENET, V244, P661, DOI 10.1007/BF00282757; CUKIERMAN E, 1995, SCIENCE, V270, P1999, DOI 10.1126/science.270.5244.1999; CULLEN PJ, 1995, NATURE, V376, P527, DOI 10.1038/376527a0; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; DORMAN G, 1994, BIOCHEMISTRY-US, V33, P5661, DOI 10.1021/bi00185a001; ESTEVEZ VA, 1991, J AM CHEM SOC, V113, P9885, DOI 10.1021/ja00026a043; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FERRIS CD, 1992, ANNU REV PHYSIOL, V54, P469, DOI 10.1146/annurev.physiol.54.1.469; FLEISCHER B, 1994, J BIOL CHEM, V269, P17826; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; FRITZ CC, 1995, NATURE, V376, P530, DOI 10.1038/376530a0; Fukami K, 1996, J BIOL CHEM, V271, P2646, DOI 10.1074/jbc.271.5.2646; FUKUDA M, 1994, J BIOL CHEM, V269, P29206; HAMMOND SM, 1995, J BIOL CHEM, V270, P29640; HARA K, 1994, P NATL ACAD SCI USA, V91, P7415, DOI 10.1073/pnas.91.16.7415; HAWKINS PT, 1992, NATURE, V358, P157, DOI 10.1038/358157a0; HAWKINS PT, 1995, CURR BIOL, V5, P393, DOI 10.1016/S0960-9822(95)00080-7; IRELAND LS, 1994, EMBO J, V13, P3812, DOI 10.1002/j.1460-2075.1994.tb06692.x; Jackson TR, 1996, J CELL SCI, V109, P289; JANMEY PA, 1994, ANNU REV PHYSIOL, V56, P169, DOI 10.1146/annurev.ph.56.030194.001125; JOLY M, 1995, J BIOL CHEM, V270, P13225, DOI 10.1074/jbc.270.22.13225; KIMURA K, 1994, J BIOL CHEM, V269, P18961; KOHN AD, 1995, EMBO J, V14, P4288, DOI 10.1002/j.1460-2075.1995.tb00103.x; KOTANI K, 1994, EMBO J, V13, P2313, DOI 10.1002/j.1460-2075.1994.tb06515.x; LAMBERT S, 1990, P NATL ACAD SCI USA, V87, P1730, DOI 10.1073/pnas.87.5.1730; LISCOVITCH M, 1994, CELL, V77, P329, DOI 10.1016/0092-8674(94)90148-1; LISCOVITCH M, 1995, CELL, V81, P659, DOI 10.1016/0092-8674(95)90525-1; MENNITI FS, 1993, TRENDS BIOCHEM SCI, V18, P53, DOI 10.1016/0968-0004(93)90053-P; MICHELL RH, 1992, TRENDS BIOCHEM SCI, V17, P274, DOI 10.1016/0968-0004(92)90433-A; MITSUI K, 1994, MOL CELL BIOL, V14, P5569, DOI 10.1128/MCB.14.8.5569; MOUREY RJ, 1993, BIOCHEMISTRY-US, V32, P1719, DOI 10.1021/bi00058a004; NAKAMURA S, 1994, J BIOCHEM, V115, P1029, DOI 10.1093/oxfordjournals.jbchem.a124451; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; OGAWA W, 1994, BBA-MOL CELL RES, V1224, P533, DOI 10.1016/0167-4889(94)90291-7; OKADA T, 1994, J BIOL CHEM, V269, P3568; PALMER RH, 1995, J BIOL CHEM, V270, P22412, DOI 10.1074/jbc.270.38.22412; PRESTWICH GD, 1996, IN PRESS PHOTOCHEM P; RAMEH LE, 1995, CELL, V83, P821, DOI 10.1016/0092-8674(95)90195-7; REISER G, 1995, BIOCHEM BIOPH RES CO, V214, P20, DOI 10.1006/bbrc.1995.2251; SERUNIAN LA, 1989, J BIOL CHEM, V264, P17809; SINGH SS, 1993, BIOCHEM BIOPH RES CO, V195, P104, DOI 10.1006/bbrc.1993.2016; Standaert ML, 1996, BIOCHEM J, V313, P1039, DOI 10.1042/bj3131039; STEPHENS LR, 1993, BIOCHIM BIOPHYS ACTA, V1179, P27, DOI 10.1016/0167-4889(93)90072-W; STEPHENS LR, 1991, NATURE, V351, P33, DOI 10.1038/351033a0; STRICKER R, 1995, FEBS LETT, V370, P236, DOI 10.1016/0014-5793(95)00822-Q; THEIBERT AB, 1991, P NATL ACAD SCI USA, V88, P3165, DOI 10.1073/pnas.88.8.3165; THEIBERT AB, 1992, J BIOL CHEM, V267, P9071; TIMERMAN AP, 1992, P NATL ACAD SCI USA, V89, P12655; TOKER A, 1994, J BIOL CHEM, V269, P32358; TRAYNORKAPLAN AE, 1988, NATURE, V334, P353, DOI 10.1038/334353a0; VOGLMAIER SM, 1992, BIOCHEM BIOPH RES CO, V187, P158, DOI 10.1016/S0006-291X(05)81473-1; WENNSTROM S, 1994, CURR BIOL, V4, P385, DOI 10.1016/S0960-9822(00)00087-7; WHITNEY JA, 1995, CELL, V83, P703; WYMANN M, 1994, BIOCHEM J, V298, P517, DOI 10.1042/bj2980517; YE WL, 1995, J BIOL CHEM, V270, P1564, DOI 10.1074/jbc.270.4.1564; YONEZAWA N, 1991, J BIOL CHEM, V266, P17218; ZHANG GG, 1995, CELL, V81, P917, DOI 10.1016/0092-8674(95)90011-X; ZHANG J, 1995, J BIOL CHEM, V270, P22807, DOI 10.1074/jbc.270.39.22807	67	138	139	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18859	18868		10.1074/jbc.271.31.18859	http://dx.doi.org/10.1074/jbc.271.31.18859			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702546	hybrid, Green Accepted			2022-12-25	WOS:A1996VB68300084
J	Pluta, AF; Earnshaw, WC				Pluta, AF; Earnshaw, WC			Specific interaction between human kinetochore protein CENP-C and a nucleolar transcriptional regulator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CENTROMERE; FACTOR HUBF; CELL-CYCLE; MOLECULAR-CLONING; BINDING PROTEIN; S-PHASE; CHROMOSOME; METAPHASE; MITOSIS; YEAST	CENP-C is a human kinetochore protein that was originally identified as a chromosomal autoantigen in patients with scleroderma spectrum disease. To bean to establish a comprehensive protein map of the human centromere, affinity chromatography was used to identify nuclear proteins that specifically interact with CENP-C. Whereas a number of polypeptides appeared to interact with the full-length CENP-C protein, only a pair of similarly sized proteins of similar to 100 kDa specifically interacted with the isolated carboxyl-terminal third of the CENP-C protein. Neither protein of the doublet bound to control affinity columns. Affinity purification and microsequence analysis of the proteins in the doublet identified them as the two highly related nucleolar transcription factors, UBF1 and UBF2 (also known as the nucleolar autoantigen NOR-90). Immunoblot analysis confirmed that both proteins also interacted with the full-length CENP-C polypeptide with similar affinities. Double indirect immunofluorescence using monospecific antibodies demonstrated that a subset of CENP-C and UBF/NOR-90 is colocalized at nucleoli of interphase HeLa cells, suggesting that the in vitro interaction detected by affinity chromatography may reflect an interaction that occurs in vivo. We discuss the implications of these findings in terms of the properties of interphase centromeres and the role of the nucleolus in scleroderma autoimmunity.	JOHNS HOPKINS UNIV,SCH MED,DEPT ANAT & CELL BIOL,BALTIMORE,MD 21205	Johns Hopkins University			Earnshaw, William/AAY-7438-2020	Earnshaw, William/0000-0002-7191-0621				ADOLPH KW, 1977, CELL, V12, P805, DOI 10.1016/0092-8674(77)90279-3; BELL SP, 1988, SCIENCE, V241, P1192, DOI 10.1126/science.3413483; BERNAT RL, 1991, HUMAN CENTROMERE PRO; BRAM RJ, 1987, MOL CELL BIOL, V7, P403, DOI 10.1128/MCB.7.1.403; BRENNER S, 1981, J CELL BIOL, V91, P95, DOI 10.1083/jcb.91.1.95; BROWN MT, 1995, GENE, V160, P111, DOI 10.1016/0378-1119(95)00163-Z; CAI MJ, 1990, CELL, V61, P437, DOI 10.1016/0092-8674(90)90525-J; CASIANO CA, 1993, J CELL SCI, V106, P1045; CAVANAUGH AH, 1995, NATURE, V374, P177, DOI 10.1038/374177a0; CHAN EKL, 1991, J EXP MED, V174, P1239, DOI 10.1084/jem.174.5.1239; COOKE CA, 1990, J CELL BIOL, V110, P1475, DOI 10.1083/jcb.110.5.1475; COOKE CA, 1987, J CELL BIOL, V105, P2053, DOI 10.1083/jcb.105.5.2053; CYERT MS, 1988, DEV BIOL, V129, P209, DOI 10.1016/0012-1606(88)90175-3; EARNSHAW WC, 1984, J CELL BIOL, V98, P352, DOI 10.1083/jcb.98.1.352; EARNSHAW WC, 1991, J CELL SCI, V98, P443; EARNSHAW WC, 1987, J CELL BIOL, V104, P817, DOI 10.1083/jcb.104.4.817; EARNSHAW WC, 1989, CHROMOSOMA, V98, P1, DOI 10.1007/BF00293329; EARNSHAW WC, 1987, J CELL BIOL, V105, P1479, DOI 10.1083/jcb.105.4.1479; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FORMOSA T, 1983, P NATL ACAD SCI-BIOL, V80, P2442, DOI 10.1073/pnas.80.9.2442; FORMOSA T, 1991, METHOD ENZYMOL, V208, P24; GORBSKY GJ, 1993, J CELL BIOL, V122, P1311, DOI 10.1083/jcb.122.6.1311; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; JANTZEN HM, 1992, GENE DEV, V6, P1950, DOI 10.1101/gad.6.10.1950; JANTZEN HM, 1990, NATURE, V344, P830, DOI 10.1038/344830a0; JIANG WD, 1993, MOL CELL BIOL, V13, P4884, DOI 10.1128/MCB.13.8.4884; MATSUMOTO H, 1989, J CELL BIOL, V109, P1963; MATSUMOTO H, 1989, EXP CELL RES, V181, P181; MEIER UT, 1994, J CELL BIOL, V127, P1505, DOI 10.1083/jcb.127.6.1505; MELLOR J, 1990, EMBO J, V9, P4017, DOI 10.1002/j.1460-2075.1990.tb07623.x; MELUH PB, 1995, MOL BIOL CELL, V6, P793, DOI 10.1091/mbc.6.7.793; MITCHISON TJ, 1985, J CELL BIOL, V101, P755, DOI 10.1083/jcb.101.3.755; MOROI Y, 1981, J CELL BIOL, V90, P254, DOI 10.1083/jcb.90.1.254; MURO Y, 1991, J INVEST DERMATOL, V97, P378, DOI 10.1111/1523-1747.ep12480836; OCHS RL, 1992, EXP CELL RES, V200, P339, DOI 10.1016/0014-4827(92)90181-7; PAULSON JR, 1977, CELL, V12, P817, DOI 10.1016/0092-8674(77)90280-X; PLUTA AF, 1992, J CELL BIOL, V116, P1081, DOI 10.1083/jcb.116.5.1081; Pollard KM, 1989, CLIN EXP RHEUMATO S3, V7, P57; RATTNER JB, 1993, CELL MOTIL CYTOSKEL, V26, P214, DOI 10.1002/cm.970260305; RODRIGUEZSANCHEZ JL, 1987, J IMMUNOL, V139, P2579; ROUSSEL P, 1993, J CELL SCI, V104, P327; SAITOH H, 1992, CELL, V70, P115, DOI 10.1016/0092-8674(92)90538-N; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; SULLIVAN KF, 1994, J CELL BIOL, V127, P581, DOI 10.1083/jcb.127.3.581; TAN EM, 1988, CLIN IMMUNOL IMMUNOP, V47, P121, DOI 10.1016/0090-1229(88)90066-9; TOMKIEL J, 1994, J CELL BIOL, V125, P531, DOI 10.1083/jcb.125.3.531; WORDEMAN L, 1991, J CELL BIOL, V114, P285, DOI 10.1083/jcb.114.2.285; Yang CH, 1996, MOL CELL BIOL, V16, P3576; YEN TJ, 1991, EMBO J, V10, P1245, DOI 10.1002/j.1460-2075.1991.tb08066.x; YEN TJ, 1992, NATURE, V359, P536, DOI 10.1038/359536a0; ZHU XL, 1995, MOL CELL BIOL, V15, P5017	51	30	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18767	18774		10.1074/jbc.271.31.18767	http://dx.doi.org/10.1074/jbc.271.31.18767			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702533	hybrid			2022-12-25	WOS:A1996VB68300071
J	Solomon, MS; Morgenthaler, PML; Turesky, RJ; Essigmann, JM				Solomon, MS; Morgenthaler, PML; Turesky, RJ; Essigmann, JM			Mutational and DNA binding specificity of the carcinogen 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROCYCLIC AROMATIC-AMINES; ESCHERICHIA-COLI; MUTAGENIC SPECIFICITY; ADDUCT FORMATION; FRIED BEEF; N-2 ATOMS; 2-AMINO-3-METHYLIMIDAZO<4,5-F>QUINOLINE; GENE; TUMORS; GUANINE	The mutagenic specificity of 2-amino3,8-dimethylimidazo[4,5-f]quinoxaline (MeIQx), a food-borne mutagen and carcinogen, was studied, Plasmid pK19 was modified by photolysis with the 2-azido form of the carcinogen, High pressure liquid chromatography confirmed that the photoactivated azide formed primarily C8 and N-2 guanyl adducts. Transformation of modified pK19 into excision repair competent Escherichia coli resulted in dose-dependent increases in genotoxicity and in mu tagenesis within the lacZ alpha target sequence. Upon induction of the SOS response, a 20-fold increase in mutation frequency over background was observed, A mutational spectrum for MeIQx, generated by sequencing 125 independent mutants, revealed base substitutions (41%), frameshifts (54%), and complex mutations (5.6%); >90% of the mutations occurred at G-C base pairs, Two hotspots were evident at runs of three or five G-C base pairs; similar to 60% of the mutations occurred at the hotspot sites, The hotspot at position 2532 produced mainly base substitutions, while that at position 2576 gave exclusively frameshift mutations, A polymerase inhibition assay mapped the sites of MeIQx adducts, Arrest sites were primarily at or one base 3' to a guanine residue, which correlated well with the distribution of mutations. No direct correlation was seen, however, between intensity of modification and hotspots for mutation.	MIT,WHITAKER COLL HLTH SCI & TECHNOL,DEPT CHEM,CAMBRIDGE,MA 02139; MIT,WHITAKER COLL HLTH SCI & TECHNOL,DIV TOXICOL,CAMBRIDGE,MA 02139; NESTEC LTD,NESTLE RES CTR,CH-1000 LAUSANNE 26,SWITZERLAND	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Nestle SA					NCI NIH HHS [R32-CA52127] Funding Source: Medline; NIEHS NIH HHS [F32-ES05582] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA052127] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [F32ES005582] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ADAMSON RH, 1990, JPN J CANCER RES, V81, P10, DOI 10.1111/j.1349-7006.1990.tb02500.x; AESCHBACHER HU, 1991, MUTAT RES, V259, P235, DOI 10.1016/0165-1218(91)90120-B; ENDO H, 1994, CANCER RES, V54, P3745; EVANS FE, 1980, CARCINOGENESIS, V1, P955, DOI 10.1093/carcin/1.11.955; FRANTZ CE, 1995, CARCINOGENESIS, V16, P367, DOI 10.1093/carcin/16.2.367; GARCIA A, 1993, P NATL ACAD SCI USA, V90, P5989, DOI 10.1073/pnas.90.13.5989; GUPTA PK, 1991, CARCINOGENESIS, V12, P819, DOI 10.1093/carcin/12.5.819; HUMPHREYS WG, 1992, P NATL ACAD SCI USA, V89, P8278, DOI 10.1073/pnas.89.17.8278; KAKIUCHI H, 1995, P NATL ACAD SCI USA, V92, P910, DOI 10.1073/pnas.92.3.910; KASAI H, 1980, P JPN ACAD B-PHYS, V56, P278, DOI 10.2183/pjab.56.278; KASAI H, 1981, CHEM LETT, P485, DOI 10.1246/cl.1981.485; KATO T, 1988, CARCINOGENESIS, V9, P71, DOI 10.1093/carcin/9.1.71; KOFFELSCHWARTZ N, 1984, J MOL BIOL, V177, P33, DOI 10.1016/0022-2836(84)90056-1; KOSAKARN P, 1993, CARCINOGENESIS, V14, P511, DOI 10.1093/carcin/14.3.511; KRISHNAMURTHY G, 1990, BIOCHEMISTRY-US, V29, P981, DOI 10.1021/bi00456a021; KUNKEL TA, 1984, P NATL ACAD SCI-BIOL, V81, P1494, DOI 10.1073/pnas.81.5.1494; KUNKEL TA, 1990, BIOCHEMISTRY-US, V29, P8003, DOI 10.1021/bi00487a001; LASKO DD, 1988, J BIOL CHEM, V263, P15429; MAKINO H, 1992, P NATL ACAD SCI USA, V89, P4850, DOI 10.1073/pnas.89.11.4850; MAKINO H, 1992, CANCER LETT, V62, P115, DOI 10.1016/0304-3835(92)90181-T; MALIA SA, 1995, BIOCHEMISTRY-US, V34, P96, DOI 10.1021/bi00001a012; Maniatis T, 1989, DECONTAMINATION DILU; MILLER EC, 1978, CANCER RES, V38, P1479; MOORE PD, 1981, P NATL ACAD SCI-BIOL, V78, P110, DOI 10.1073/pnas.78.1.110; OHANDLEY SF, 1993, BIOCHEMISTRY-US, V32, P2481, DOI 10.1021/bi00061a005; PRIDMORE RD, 1987, GENE, V56, P309, DOI 10.1016/0378-1119(87)90149-1; ROSS H, 1993, CANCER RES, V53, P1273; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAAPER RM, 1983, P NATL ACAD SCI-BIOL, V80, P487, DOI 10.1073/pnas.80.2.487; SNYDERWINE EG, 1993, CARCINOGENESIS, V14, P1389, DOI 10.1093/carcin/14.7.1389; TAKAYAMA S, 1984, GANN, V75, P467; TURESKY RJ, 1992, CHEM RES TOXICOL, V5, P479, DOI 10.1021/tx00028a005; TURESKY RJ, 1994, CHEM RES TOXICOL, V7, P752, DOI 10.1021/tx00042a007; TURESKY RJ, 1991, CARCINOGENESIS, V12, P1839, DOI 10.1093/carcin/12.10.1839; TURESKY RJ, 1990, CHEM RES TOXICOL, V3, P524, DOI 10.1021/tx00018a006; WAKABAYASHI K, 1992, CANCER RES, V52, pS2092; WATANABE M, 1993, CARCINOGENESIS, V14, P1149, DOI 10.1093/carcin/14.6.1149; WILD D, 1989, CARCINOGENESIS, V10, P335, DOI 10.1093/carcin/10.2.335; YAREMA KJ, 1994, J MOL BIOL, V236, P1034, DOI 10.1016/0022-2836(94)90010-8	39	19	19	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18368	18374		10.1074/jbc.271.31.18368	http://dx.doi.org/10.1074/jbc.271.31.18368			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702479	hybrid			2022-12-25	WOS:A1996VB68300017
J	Kirstein, M; Sanz, L; Quinones, S; Moscat, J; DiazMeco, MT; Saus, J				Kirstein, M; Sanz, L; Quinones, S; Moscat, J; DiazMeco, MT; Saus, J			Cross-talk between different enhancer elements during mitogenic induction of the human stromelysin-1 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; EPIDERMAL GROWTH-FACTOR; MESSENGER-RNA; TRANSCRIPTIONAL ACTIVATION; PHOSPHOLIPASE-C; RAT FIBROBLASTS; EXPRESSION; ONCOGENE; PROMOTER; FOS	Platelet-derived growth factor (PDGF) induces the expression of human stromelysin-1, a matrix metalloproteinase involved in tumor invasion and metastasis. Here it is shown that stromelysin-1 gene induction by PDGF depends on Ras and involves three previously identified promoter elements (the stromelysin-1 PDGF-responsive element (SPRE) site, the two head to-head polyomavirus enhancer A-binding protein 3 (PEA3) sites, and the activator protein-1 (AP-1) binding site). During mitogenic induction, these responsive elements appear to be organized in two independent transcriptional units, SPRE-AP-1 and PEA3-AP-1, which result from specific element cross talking. Interestingly, expression of a dominant negative mutant of Raf-1 significantly interfered with the induction through PEA3-AP-1 but not with that operating through SPRE-AP-1. Conversely, only the induction operating through SPRE-AP-1 was affected significantly by the expression of a dominant negative mutant of the atypical lambda/iota protein kinase C (lambda/iota PKC). These data strongly suggest that the signal triggered by PDGF flows through Ras and bifurcates toward two distinct pathways, one operating through Raf and involving PEA3-AP-1 and the other one Raf-independent, operating through lambda/iota PKC and SPRE-AP-1. Furthermore, we present evidence suggesting that the novel SPRE-binding transcription factor SPBP cross-couples with c-Jun to transactivate the SPRE site.	INST INVEST CITOLOG,FUNDAC VALENCIANA INVEST BIOMED,E-46010 VALENCIA,SPAIN; CTR BIOL MOL SEVERO OCHOA,E-28049 MADRID,SPAIN; UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT ENVIRONM & COMMUNITY MED,PISCATAWAY,NJ 08854; UNIV VALENCIA,FAC FARM,DEPT BIOQUIM & BIOL MOLEC,E-46100 VALENCIA,SPAIN	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM); Rutgers State University New Brunswick; Rutgers State University Medical Center; University of Valencia			Moscat, Jorge/A-7011-2009; Kirstein, Martina/L-9247-2014	Kirstein, Martina/0000-0001-8716-2309; Diaz-Meco, Maria/0000-0003-0147-0998; Saus, Juan/0000-0003-2082-1597				ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BASSUK AG, 1995, IMMUNITY, V3, P223, DOI 10.1016/1074-7613(95)90092-6; BJORKOY G, 1995, J BIOL CHEM, V270, P21299; BORDEN P, 1994, GENE, V151, P315, DOI 10.1016/0378-1119(94)90677-7; BREATHNACH R, 1987, NUCLEIC ACIDS RES, V15, P1139, DOI 10.1093/nar/15.3.1139; BUTTICE G, 1993, J BIOL CHEM, V268, P7196; BUTTICE G, 1991, NUCLEIC ACIDS RES, V19, P3723, DOI 10.1093/nar/19.13.3723; CAI H, 1990, MOL CELL BIOL, V10, P5314, DOI 10.1128/MCB.10.10.5314; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DIAZMECO MT, 1991, J BIOL CHEM, V266, P22597; DiazMeco MT, 1996, MOL CELL BIOL, V16, P105; DIAZMECO MT, 1993, MOL CELL BIOL, V13, P4770, DOI 10.1128/MCB.13.8.4770; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; IMLER JL, 1988, NATURE, V332, P275, DOI 10.1038/332275a0; KERR LD, 1988, SCIENCE, V242, P1424, DOI 10.1126/science.2462278; KERR LD, 1990, CELL, V61, P267, DOI 10.1016/0092-8674(90)90807-Q; LARRODERA P, 1990, CELL, V61, P1113, DOI 10.1016/0092-8674(90)90074-O; LOPEZBARAHONA M, 1990, J BIOL CHEM, V265, P9022; MATRISIAN LM, 1986, P NATL ACAD SCI USA, V83, P9413, DOI 10.1073/pnas.83.24.9413; MATRISIAN LM, 1985, EMBO J, V4, P1435, DOI 10.1002/j.1460-2075.1985.tb03799.x; MCDONNELL SE, 1990, MOL CELL BIOL, V10, P4284, DOI 10.1128/MCB.10.8.4284; NICHOLSON R, 1989, BIOCHEMISTRY-US, V28, P5195, DOI 10.1021/bi00438a042; OTANI Y, 1990, EUR J BIOCHEM, V192, P75, DOI 10.1111/j.1432-1033.1990.tb19197.x; QUINONES S, 1994, BIOCHEM J, V302, P471, DOI 10.1042/bj3020471; QUINONES S, 1989, J BIOL CHEM, V264, P8339; SANZ L, 1994, J BIOL CHEM, V269, P10044; SANZ L, 1995, MOL CELL BIOL, V15, P3164; SREENATH T, 1992, CANCER RES, V52, P4942; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WASYLYK C, 1989, EMBO J, V8, P3371, DOI 10.1002/j.1460-2075.1989.tb08500.x; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x	32	57	61	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					18231	18236		10.1074/jbc.271.30.18231	http://dx.doi.org/10.1074/jbc.271.30.18231			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663478	hybrid			2022-12-25	WOS:A1996UY93500096
J	Trofimova, M; Sprenkle, AB; Green, M; Sturgill, TW; Goebl, MG; Harrington, MA				Trofimova, M; Sprenkle, AB; Green, M; Sturgill, TW; Goebl, MG; Harrington, MA			Developmental and tissue-specific expression of mouse Pelle-like protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; SIGNAL-TRANSDUCTION PATHWAY; TRANSCRIPTION FACTOR; DROSOPHILA EMBRYO; DNA-BINDING; ACTIVATION; INHIBITION; SEQUENCES; CYTOKINES; SUBUNITS	The NF-kappa B/c-Rel proteins are a family of evolutionarily conserved transcription factors activated during development that in the adult, mediate many processes including the immune response, A high degree of sequence similarity is shared between the NF-kappa B/c-Rel family of transcription factors and the Drosophila Dorsal protein as well as between its cytoplasmic inhibitor, I kappa B alpha and the Drosophila Cactus protein, Genetic analyses of Dorsal have defined components of a signaling pathway for Dorsal activation, including a serine/threonine kinase, Pelle, placed upstream of Dorsal and Cactus, We demonstrate that this pathway is likely to be conserved in mammals by the isolation of a cDNA that encodes a novel mouse protein highly related to Pelle, mPLK (mouse Pelle-like protein kinase), Expression of mPLK mRNA is developmentally regulated in the mouse and in adult tissue mPLK expression is greatest in the liver, a tissue that expresses a high level of NF-kappa B, Recombinant mPLK produced in bacteria is a protein kinase capable of autophosphorylating and phosphorylating I kappa B alpha.	INDIANA UNIV, SCH MED, DEPT BIOCHEM & MOLEC BIOL, INDIANAPOLIS, IN 46202 USA; INDIANA UNIV, DEPT MED, INDIANAPOLIS, IN 46202 USA; INDIANA UNIV, WALTHER ONCOL CTR, INDIANAPOLIS, IN 46202 USA; UNIV VIRGINIA, HOWARD HUGHES MED INST, CHARLOTTESVILLE, VA 22908 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; Howard Hughes Medical Institute; University of Virginia					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM043972, R01GM043972, R29GM045460] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM43972, GM45460] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALKALAY I, 1995, P NATL ACAD SCI USA, V92, P10599, DOI 10.1073/pnas.92.23.10599; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BAEUERLE PA, 1989, GENE DEV, V3, P1689, DOI 10.1101/gad.3.11.1689; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; Baldi L, 1996, J BIOL CHEM, V271, P376, DOI 10.1074/jbc.271.1.376; BAUMANN H, 1994, IMMUNOL TODAY, V15, P74, DOI 10.1016/0167-5699(94)90137-6; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; BRESSLER P, 1993, J VIROL, V67, P288, DOI 10.1128/JVI.67.1.288-293.1993; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Cao ZD, 1996, SCIENCE, V271, P1128, DOI 10.1126/science.271.5252.1128; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; FEINSTEIN E, 1995, TRENDS BIOCHEM SCI, V20, P342, DOI 10.1016/S0968-0004(00)89070-2; GANCHI PA, 1992, MOL BIOL CELL, V3, P1339, DOI 10.1091/mbc.3.12.1339; GRIMM S, 1993, BIOCHEM J, V290, P297, DOI 10.1042/bj2900297; GROSSHANS J, 1994, NATURE, V372, P563, DOI 10.1038/372563a0; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; ISRAEL A, 1995, TRENDS GENET, V11, P203, DOI 10.1016/S0168-9525(00)89045-9; KOHCHI C, 1994, INT J BIOCHEM, V26, P111, DOI 10.1016/0020-711X(94)90203-8; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KUNO K, 1995, J BIOL CHEM, V270, P27914, DOI 10.1074/jbc.270.46.27914; LOGEAT F, 1991, EMBO J, V10, P1827, DOI 10.1002/j.1460-2075.1991.tb07708.x; LOH YT, 1995, P NATL ACAD SCI USA, V92, P4181, DOI 10.1073/pnas.92.10.4181; McElhinny JA, 1996, MOL CELL BIOL, V16, P899; MUKAIDA N, 1990, J BIOL CHEM, V265, P21128; SANCEAU J, 1995, J BIOL CHEM, V270, P27920, DOI 10.1074/jbc.270.46.27920; SCHNEIDER DS, 1991, GENE DEV, V5, P797, DOI 10.1101/gad.5.5.797; SHELTON CA, 1993, CELL, V72, P515, DOI 10.1016/0092-8674(93)90071-W; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; TAVASSOLI M, 1988, ONTOGENY HEMOPOIESIS, P101; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; WASSERMAN SA, 1993, MOL BIOL CELL, V4, P767, DOI 10.1091/mbc.4.8.767; ZABEL U, 1993, EMBO J, V12, P201, DOI 10.1002/j.1460-2075.1993.tb05646.x; ZHOU JM, 1995, CELL, V83, P925, DOI 10.1016/0092-8674(95)90208-2	36	30	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					17609	17612		10.1074/jbc.271.30.17609	http://dx.doi.org/10.1074/jbc.271.30.17609			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663605	hybrid			2022-12-25	WOS:A1996UY93500005
J	Crouch, DH; Fincham, VJ; Frame, MC				Crouch, DH; Fincham, VJ; Frame, MC			Targeted proteolysis of the focal adhesion kinase pp125(FAK) during c-myc-induced apoptosis is suppressed by integrin signalling	ONCOGENE			English	Article						focal adhesion kinase; c-myc; apoptosis	PROTEIN-TYROSINE KINASE; CELL-ADHESION; EXTRACELLULAR-MATRIX; PHOSPHORYLATION; TRANSFORMATION; PP125FAK; DOMAIN	The product of the c-myc proto-oncogene has a central role in induction of apoptosis, a physiological form of cell death characterised in vitro by morphological rounding, detachment and nuclear disintegration. Induction of apoptosis by serum withdrawal from c-Myc-transformed chicken embryo fibroblasts (CEF) results in early proteolysis of focal adhesion kinase (pp125(FAK)), a tyrosine kinase implicated in the conversion of integrin signals into their biological responses. Proteolysis of pp125(FAK) occurs in adherent cells prior to commitment to death, suggesting that it contributes to c-Myc-induced apoptosis, rather than being a consequence of it. Furthermore, c-Myc-induced detachment, cell death and cleavage of pp125(FAK) are coordinately suppressed by treating with insulin or plating on the extracellular matrix components collagen and fibronectin. In addition, proteolysis of pp125(FAK) is suppressed by a beta 1-specific integrin antibody, which promotes cell survival in the face of the oncoprotein-induced signal for apoptosis. These results provide compelling evidence that the c-Myc-induced cell death programme in CEF requires disruption of the integrin signalling pathways which normally function when cells are spread on ECM, and that maintaining cellular pp125(FAK), which couples integrins to their downstream effecters, is closely linked to cell survival.	BEATSON INST CANC RES, CRC, BEATSON LABS, GLASGOW G61 1BD, LANARK, SCOTLAND	Beatson Institute								AKASAKA T, 1995, J INVEST DERMATOL, V105, P104, DOI 10.1111/1523-1747.ep12313396; BECKERLE MC, 1987, CELL, V51, P569, DOI 10.1016/0092-8674(87)90126-7; BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; CHEN HC, 1994, P NATL ACAD SCI USA, V91, P10148, DOI 10.1073/pnas.91.21.10148; CROUCH DH, 1990, ONCOGENE, V5, P683; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FINCHAM VJ, 1995, ONCOGENE, V10, P2247; Freshney RI, 1994, CULTURE ANIMAL CELLS; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; GIBSON AW, 1995, EXP CELL RES, V218, P351, DOI 10.1006/excr.1995.1166; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; HALL CL, 1994, J CELL BIOL, V126, P575, DOI 10.1083/jcb.126.2.575; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; LLIC D, 1995, NATURE, V377, P539; MARTIN SJ, 1995, J BIOL CHEM, V270, P6425, DOI 10.1074/jbc.270.12.6425; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; MOGI A, 1995, FEBS LETT, V373, P135, DOI 10.1016/0014-5793(95)01014-6; OWENS LV, 1995, CANCER RES, V55, P2752; ROZENGURT E, 1995, CANCER SURV, V24, P81; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; SARIN A, 1993, J EXP MED, V178, P1693, DOI 10.1084/jem.178.5.1693; SCHALLER MD, 1993, MOL CELL BIOL, V13, P785, DOI 10.1128/MCB.13.2.785; SCHALLER MD, 1995, MOL CELL BIOL, V15, P2635; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; Schaller Michael D., 1993, Trends in Cell Biology, V3, P258, DOI 10.1016/0962-8924(93)90053-4; SCHLAEPFER DD, 1994, NATURE, V372, P786; VUORI K, 1994, SCIENCE, V266, P1576, DOI 10.1126/science.7527156; ZACHARY I, 1992, J BIOL CHEM, V267, P19031	34	122	122	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 20	1996	12	12					2689	2696						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UW487	8700528				2022-12-25	WOS:A1996UW48700023
J	Beamish, H; Williams, R; Chen, P; Lavin, MF				Beamish, H; Williams, R; Chen, P; Lavin, MF			Defect in multiple cell cycle checkpoints in ataxia-telangiectasia postirradiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAPAMYCIN-INDUCED INHIBITION; IONIZING-RADIATION; PHOSPHATIDYLINOSITOL 3-KINASE; DEPENDENT KINASES; DNA-SYNTHESIS; SCHIZOSACCHAROMYCES-POMBE; MAMMALIAN PROTEIN; CATALYTIC SUBUNIT; X-IRRADIATION; P53 PROTEIN	The recent description of a novel gene (ATM) mutated in ataxia-telangiectasia (A-T), with homologies to genes encoding proteins involved in both G(1)/S and G(2)/M checkpoint control, points to a common defect in cell cycle control in A-T operating through the cyclin-dependent kinases. In this report we demonstrate that cyclin-dependent kinases are resistant to inhibition by ionizing radiation exposure in A-T cells, and this appears to be due to insufficient induction of WAF1. Exposure of control lymphoblastoid cells to radiation during S phase and in G(2) phase causes a rapid inhibition of cyclin A-Cdk2 and cyclin B-Cdc2 activities, respectively, Irradiation led to a 5-20-fold increase in Cdk-associated WAF1 in these cells, which accounts at least in part for the decrease in cyclin-dependent kinase activity. In contrast, radiation did not inhibit any of the cyclin-dependent kinase activities in S phase or G(2) phase in A-T cells at short times after irradiation nor was there any significant change in the level of Cdk-associated WAF1 compared to unirradiated cells. These results are similar to those reported previously for the G(1) checkpoint and provide additional evidence for the involvement of ATM at multiple points in cell cycle regulation.	QUEENSLAND INST MED RES,BANCROFT CTR,QUEENSLAND CANC FUND RES UNIT,BRISBANE,QLD 4029,AUSTRALIA; UNIV QUEENSLAND,ROYAL BRISBANE HOSP,DEPT SURG,HERSTON,QLD 4029,AUSTRALIA	QIMR Berghofer Medical Research Institute; Royal Brisbane & Women's Hospital; University of Queensland			Lavin, Martin F/F-5961-2014	Lavin, Martin F/0000-0002-5940-4769				AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8492; ALBERS MW, 1993, J BIOL CHEM, V268, P22825; ALKHODAIRY F, 1992, EMBO J, V11, P1343, DOI 10.1002/j.1460-2075.1992.tb05179.x; ALONIGRINSTEIN R, 1995, EMBO J, V14, P1392, DOI 10.1002/j.1460-2075.1995.tb07125.x; BATES PR, 1989, MUTAT RES, V218, P165, DOI 10.1016/0921-8777(89)90023-2; BEAMISH H, 1994, INT J RADIAT BIOL, V65, P175, DOI 10.1080/09553009414550211; BODEY B, 1994, MODERN PATHOL, V7, P846; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; CANMAN CE, 1994, CANCER RES, V54, P5054; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; CHEN P, 1983, THESIS U QUEENSLAND; DEWEY WC, 1976, RADIAT RES, V65, P511, DOI 10.2307/3574383; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FORD MD, 1984, MUTAT RES, V125, P115, DOI 10.1016/0027-5107(84)90038-1; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HARL KL, 1996, CELL, V82, P815; HARPER JW, 1993, CELL, V75, P805; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; HOFFMANN I, 1993, EMBO J, V12, P53, DOI 10.1002/j.1460-2075.1993.tb05631.x; HONG JH, 1994, RADIAT RES, V140, P17, DOI 10.2307/3578563; HOULDSWORTH J, 1980, NUCLEIC ACIDS RES, V8, P3709, DOI 10.1093/nar/8.16.3709; HU P, 1994, MOL CELL BIOL, V14, P2577, DOI 10.1128/MCB.14.4.2577; JIMENEZ G, 1992, P NATL ACAD SCI USA, V89, P4952, DOI 10.1073/pnas.89.11.4952; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KHANNA KK, 1995, ONCOGENE, V11, P609; KHANNA KK, 1993, ONCOGENE, V8, P3307; KLIPPEL A, 1993, MOL CELL BIOL, V13, P5560, DOI 10.1128/MCB.13.9.5560; KUNZ J, 1993, CELL, V73, P585, DOI 10.1016/0092-8674(93)90144-F; LAVIN MF, 1988, MUTAT RES, V193, P193, DOI 10.1016/0167-8817(88)90030-2; LAVIN MF, 1994, INT J RADIAT BIOL, V66, P5151; LEEPER DB, 1972, RADIAT RES, V50, P410; LEVEDAKOU EN, 1995, CANCER RES, V55, P2500; LI Y, 1994, ONCOGENE, V9, P2261; LINDMO T, 1979, CELL TISSUE KINET, V12, P43, DOI 10.1111/j.1365-2184.1979.tb00112.x; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MEYN MS, 1994, INT J RADIAT BIOL, V66, P5141; MORICE WG, 1993, J BIOL CHEM, V268, P3734; MUSCHEL RJ, 1991, CANCER RES, V51, P5113; NAGASAWA H, 1983, MUTAT RES, V109, P2987; PAINTER RB, 1980, P NATL ACAD SCI-BIOL, V77, P7315, DOI 10.1073/pnas.77.12.7315; PAINTER RB, 1986, INT J RADIAT BIOL, V49, P771; PRICE BD, 1994, CANCER RES, V54, P896; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; ROWLEY R, 1992, NATURE, V356, P353, DOI 10.1038/356353a0; RUDOLPH NS, 1989, MUTAT RES, V211, P31, DOI 10.1016/0027-5107(89)90104-8; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SCHNEIDERMAN MH, 1977, RADIAT RES, V70, P130, DOI 10.2307/3574737; SCHREIBER SL, 1991, TRANSPLANT P, V23, P2839; SEDGWICK RP, 1991, HEREDITARY NEUROPATH, P347; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZAKIAN VA, 1995, CELL, V82, P685, DOI 10.1016/0092-8674(95)90463-8; ZAMPETTIBOSSELER F, 1981, INT J RADIAT BIOL, V39, P547, DOI 10.1080/09553008114550651	59	126	129	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20486	20493		10.1074/jbc.271.34.20486	http://dx.doi.org/10.1074/jbc.271.34.20486			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702789	hybrid			2022-12-25	WOS:A1996VD33700041
J	Szabo, I; Gulbins, E; Apfel, H; Zhang, XF; Barth, P; Busch, AE; Schlottmann, K; Pongs, O; Lang, F				Szabo, I; Gulbins, E; Apfel, H; Zhang, XF; Barth, P; Busch, AE; Schlottmann, K; Pongs, O; Lang, F			Tyrosine phosphorylation-dependent suppression of a voltage-gated K+ channel in T lymphocytes upon Fas stimulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POTASSIUM CHANNELS; VOLUME REGULATION; PATCH-CLAMP; KINASE; CHARYBDOTOXIN; PURIFICATION; TEMPERATURE; ACTIVATION; MARGATOXIN; APOPTOSIS	Selective cell death plays a critical role in the development of the immune system and in the elimination of target cells expressing foreign antigens. Most of programmed cell death occurs by apoptosis, Apoptotic cell death of lymphocytes can be triggered by ligation of APO-1/Fas (CD95) antigen (Suda, T., and Nagata, S. (1994) J. Exp. Med. 179, 873-879; Nagata, S., and Golstein, P. (1995) Science 267, 1449-1456). We find that activation of Fas leads to the inhibition of the voltage-dependent n-type K+ channels (Kv1.3) studied by patch clamp technique in Jurkat T lymphocytes, Tyrosine kinases have been shown to be crucial in Fas-induced cell death (Eischen, C. M., Dick, C. J,, and Leibson, P. J. (1994) J. Immunol. 153, 1947-1954), The inhibition of the current is correlated with the tyrosine phosphorylation of immunoprecipitated and blotted K+ channel protein. We show, that the Src-like protein-tyrosine kinase inhibitor herbimycin A and the deficiency of the p56(lck) tyrosine kinase in mutant Jurkat cells abolished the channel inhibition and phosphorylation by anti-Fas antibody, while reconstitution of the p56(lck) kinase partly restored these effects of Fas receptor triggering. These results suggest a regulation of n-type K+ channels by tyrosine kinases upon Fas receptor triggering, which might be important for apoptosis.	OHIO STATE UNIV, DEPT MICROBIOL, COLUMBUS, OH 43210 USA; UNIV HAMBURG, CTR MOL NEUROBIOL, D-20246 HAMBURG, GERMANY	University System of Ohio; Ohio State University; University of Hamburg	Szabo, I (corresponding author), UNIV TUBINGEN, INST PHYSIOL 1, D-72076 TUBINGEN, GERMANY.		Szabo, Ildiko/AAW-5972-2021; Gulbins, Erich/L-6989-2014; Padova, Ildiko/K-5344-2016	Szabo, Ildiko/0000-0002-3637-3947; Gulbins, Erich/0000-0002-3117-1342; 				BEDNAREK MA, 1994, BIOCHEM BIOPH RES CO, V198, P619, DOI 10.1006/bbrc.1994.1090; CAHALAN MD, 1985, J PHYSIOL-LONDON, V358, P197, DOI 10.1113/jphysiol.1985.sp015548; DECOURSEY TE, 1984, NATURE, V307, P465, DOI 10.1038/307465a0; DECOURSEY TE, 1985, J NEUROIMMUNOL, V10, P71, DOI 10.1016/0165-5728(85)90035-9; DEUTSCH C, 1986, J PHYSIOL-LONDON, V372, P405, DOI 10.1113/jphysiol.1986.sp016016; DEUTSCH C, 1993, P NATL ACAD SCI USA, V90, P10036, DOI 10.1073/pnas.90.21.10036; EISCHEN CM, 1994, J IMMUNOL, V153, P1947; GARCIACALVO M, 1993, J BIOL CHEM, V268, P18866; GRINSTEIN S, 1990, J GEN PHYSIOL, V95, P97, DOI 10.1085/jgp.95.1.97; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HUANG XY, 1993, CELL, V75, P1145, DOI 10.1016/0092-8674(93)90324-J; LEE SC, 1990, BIOPHYS J, V57, P49, DOI 10.1016/S0006-3495(90)82506-6; LEONARD RJ, 1992, P NATL ACAD SCI USA, V89, P10094, DOI 10.1073/pnas.89.21.10094; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; LIN CS, 1993, J EXP MED, V177, P637, DOI 10.1084/jem.177.3.637; MATTESON DR, 1984, NATURE, V307, P468, DOI 10.1038/307468a0; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; PAHAPILL PA, 1990, J PHYSIOL-LONDON, V422, P103, DOI 10.1113/jphysiol.1990.sp017975; PAYET MD, 1992, J BIOL CHEM, V267, P18270; PONGS O, 1992, PHYSIOL REV, V72, pS69, DOI 10.1152/physrev.1992.72.suppl_4.S69; SANDS SB, 1989, J GEN PHYSIOL, V93, P1061, DOI 10.1085/jgp.93.6.1061; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; SUDA T, 1994, J EXP MED, V179, P873, DOI 10.1084/jem.179.3.873; TSIEN RY, 1982, NATURE, V295, P68, DOI 10.1038/295068a0; VEH RW, 1995, IN PRESS EUR J NEURO, V7	25	192	197	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20465	20469		10.1074/jbc.271.34.20465	http://dx.doi.org/10.1074/jbc.271.34.20465			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702786	hybrid			2022-12-25	WOS:A1996VD33700038
J	Wiborg, O; Andersen, C; Knudsen, CR; Clark, BFC; Nyborg, J				Wiborg, O; Andersen, C; Knudsen, CR; Clark, BFC; Nyborg, J			Mapping Escherichia coli elongation factor Tu residues involved in binding of aminoacyl-tRNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-EF-TU; CRYSTAL-STRUCTURE; TRANSFER-RNA; NUCLEOTIDE-SEQUENCE; HISTIDINE-RESIDUES; STEP PURIFICATION; TERNARY COMPLEX; GTP HYDROLYSIS; MECHANISM; CONFORMATION	Two residues of Escherichia coli elongation factor Tu involved in binding of aminoacyl-tRNA were identified and subjected to mutational analysis, Lys-89 and Asn-90 were each replaced by either Ala or Glu. The four single mutants were denoted K89A, K89E, N90A, and N90E, respectively. The mutants were characterized with respect to thermal and chemical stability, GTPase activity, tRNA affinity, and activity in an in vitro translation assay, Most conspicuously tRNA affinities were reduced for all mutants. The results verify our structural analysis of elongation factor Tu in complex with aminoacyl-tRNA, which suggested an important role of Lys-89 and Asn-90 in tRNA binding, Furthermore, our results indicate helix B to be an important target site for nucleotide exchange factor EF-Ts. Also the mutants His-66 to Ala and His-118 to either Ala or Glu were characterized in an in vitro translation assay. Their functional roles are discusses in relation to the structure of elongation factor Tu in complex with aminoacyl-tRNA.	AARHUS UNIV, DEPT CHEM, DK-8000 AARHUS C, DENMARK	Aarhus University	Wiborg, O (corresponding author), HOSP PSYCHIAT, CYTOGENET LAB, SKOVAGERVEJ 2, DK-8240 RISSKOV, DENMARK.			Knudsen, Charlotte/0000-0003-2356-4821				AEVARSSON A, 1994, EMBO J, V13, P3669, DOI 10.1002/j.1460-2075.1994.tb06676.x; AN G, 1980, GENE, V12, P33, DOI 10.1016/0378-1119(80)90013-X; ANDERSEN C, 1994, EUR J BIOCHEM, V220, P739, DOI 10.1111/j.1432-1033.1994.tb18674.x; BERCHTOLD H, 1993, NATURE, V365, P126, DOI 10.1038/365126a0; Bodley J W, 1974, Methods Enzymol, V30, P235; BOGESTRAND S, 1995, FEBS LETT, V368, P49, DOI 10.1016/0014-5793(95)00597-3; BOSCH L, 1983, PROG NUCLEIC ACID RE, V30, P91; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; Clark Brian F. C., 1995, P423; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; CZWORKOWSKI J, 1994, EMBO J, V13, P3661, DOI 10.1002/j.1460-2075.1994.tb06675.x; DUFFY LK, 1981, BIOCHEMISTRY-US, V20, P4663, DOI 10.1021/bi00519a022; EHRENBERG M, 1988, RIBOSOMES PROTEIN SY, P101; GUMUSEL F, 1990, BIOCHIM BIOPHYS ACTA, V1050, P215, DOI 10.1016/0167-4781(90)90169-3; HARMARK K, 1990, EUR J BIOCHEM, V194, P731, DOI 10.1111/j.1432-1033.1990.tb19463.x; JONAK J, 1987, BIOCHIM BIOPHYS ACTA, V908, P97, DOI 10.1016/0167-4781(87)90026-1; JONAK J, 1984, EUR J BIOCHEM, V144, P295, DOI 10.1111/j.1432-1033.1984.tb08463.x; JONES MD, 1980, EUR J BIOCHEM, V108, P507, DOI 10.1111/j.1432-1033.1980.tb04748.x; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; KENNELL D, 1977, J MOL BIOL, V114, P1, DOI 10.1016/0022-2836(77)90279-0; KJAERSGARD IVH, 1995, EUR J BIOCHEM, V228, P184; KJELDGAARD M, 1992, J MOL BIOL, V223, P721, DOI 10.1016/0022-2836(92)90986-T; KJELDGAARD M, 1993, STRUCTURE, V1, P35, DOI 10.1016/0969-2126(93)90007-4; KNUDSEN CR, 1995, EUR J BIOCHEM, V228, P176; KNUDSEN CR, 1992, BIOCHEM INT, V28, P353; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; LEDER P, 1971, METHOD ENZYMOL, V20, P302; LOUIE A, 1985, BIOCHEMISTRY-US, V24, P6433, DOI 10.1021/bi00344a019; METZBOUTIGUE MH, 1989, FEBS LETT, V245, P194, DOI 10.1016/0014-5793(89)80220-0; Miller D L, 1974, Methods Enzymol, V30, P219; Miller DL, 1977, MOL MECH PROTEIN BIO, P323; MURRAY V, 1989, NUCLEIC ACIDS RES, V17, P8889, DOI 10.1093/nar/17.21.8889; NISSEN P, 1995, SCIENCE, V270, P1464, DOI 10.1126/science.270.5241.1464; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; PARMEGGIANI A, 1981, MOL CELL BIOCHEM, V35, P129, DOI 10.1007/BF02357085; PINGOUD A, 1979, ANAL BIOCHEM, V92, P123, DOI 10.1016/0003-2697(79)90632-8; RHEINBERGER HJ, 1988, METHOD ENZYMOL, V164, P658; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SEDMAK JJ, 1977, ANAL BIOCHEM, V79, P544, DOI 10.1016/0003-2697(77)90428-6; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8765; von der Haar F, 1979, Methods Enzymol, V59, P257; WIBORG O, 1994, BIOTECHNOL APPL BIOC, V19, P3; WOOLLEY P, 1989, BIO-TECHNOL, V7, P913, DOI 10.1038/nbt0989-913; YOKOTA T, 1980, GENE, V12, P25	48	13	13	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20406	20411		10.1074/jbc.271.34.20406	http://dx.doi.org/10.1074/jbc.271.34.20406			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702777	hybrid			2022-12-25	WOS:A1996VD33700029
J	Yu, Q; Toole, BP				Yu, Q; Toole, BP			A new alternatively spliced exon between v9 and v10 provides a molecular basis for synthesis of soluble CD44	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYALURONATE RECEPTOR; ADHESION MOLECULE; HOMING RECEPTOR; MONOCLONAL-ANTIBODY; PERICELLULAR MATRIX; LUNG DEVELOPMENT; SERUM CD44; EXPRESSION; DIFFERENTIATION; VARIANTS	The numerous isoforms of murine CD44 contain a common peptide region that is encoded by exons 1-5, 16-18, and 20 and variant regions derived from exons 6-15, usually referred to as v1-v10, We have obtained evidence for expression of an additional exon between v9 (or exon 14) and the exon previously termed v10 (or exon 15), Thus, we now number the variant exons as follows: v1-v9 (exons 6-14), v10 (exon 15), and v11 (exon 16); the remaining 3'-exons become exons 17-21 (newly numbered exons are underlined), The new exon, now termed exon v10, contains 93 base pairs and can be internally spliced; the 5'-region is termed v10a, and the 3'-region, v10b, Stop codons are positioned in v10a such that translated protein would be truncated prior to the transmembrane domain and secreted as a soluble protein, We have also found that the previously described v9 exon (now termed v9a), which is 90 base pairs in length, is actually the 5'-region of a longer exon of 142 base pairs (the 3'-region is termed v9b) and thus arises by internal splicing of the longer exon, Using reverse transcription-polymerase chain reaction, four different cDNAs for CD44 isoforms that use different combinations of the new exonic sequences have been found, The mRNAs containing the new exonic sequences are restricted in their expression; to date, we have demonstrated their presence in murine G8 myoblasts in culture and in embryonic muscle and cartilage tissues in vivo, Of these new isoforms, the predominant, full-length amplified product is encoded by exons 1-5, exon 13 (v8), the 5'-part of exon 14 (v9a), exon 15 (v10), exon 16 (v11), exons 17-19, and exon 21, When COS-7 cells were transfected with v10-containing cDNA constructs, the cells secreted low molecular weight soluble CD44 into their medium, Thus, the stop codons within the new exon v10 provide a molecular basis for de novo synthesis of soluble CD44 isoforms.	TUFTS UNIV,SCH MED,DEPT ANAT & CELLULAR BIOL,BOSTON,MA 02111	Tufts University					NICHD NIH HHS [HD23681] Funding Source: Medline; NIDCR NIH HHS [DE05838] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD023681] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE005838] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ARCH R, 1992, SCIENCE, V257, P682, DOI 10.1126/science.1496383; ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; BARTOLAZZI A, 1994, J EXP MED, V180, P53, DOI 10.1084/jem.180.1.53; BAZIL V, 1992, J IMMUNOL, V149, P747; CAMPANERO MR, 1991, EUR J IMMUNOL, V21, P3045, DOI 10.1002/eji.1830211222; CULTY M, 1990, J CELL BIOL, V111, P2765, DOI 10.1083/jcb.111.6.2765; CULTY M, 1992, J CELL BIOL, V116, P1055, DOI 10.1083/jcb.116.4.1055; GREEN SJ, 1988, EXP CELL RES, V178, P224, DOI 10.1016/0014-4827(88)90393-X; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; GUO YJ, 1994, CANCER RES, V54, P422; HAYNES BF, 1991, ARTHRITIS RHEUM, V34, P1434; HUA Q, 1993, J CELL SCI, V106, P365; JACKSON DG, 1995, J CELL BIOL, V128, P673, DOI 10.1083/jcb.128.4.673; KAINZ C, 1995, CANCER LETT, V90, P231, DOI 10.1016/0304-3835(95)03708-5; KASPER M, 1995, AM J RESP CELL MOL, V13, P648, DOI 10.1165/ajrcmb.13.6.7576702; KATOH S, 1994, J IMMUNOL, V153, P3440; KNUDSON CB, 1993, J CELL BIOL, V120, P825, DOI 10.1083/jcb.120.3.825; KNUDSON CB, 1985, DEV BIOL, V112, P308, DOI 10.1016/0012-1606(85)90401-4; KNUDSON CB, 1987, DEV BIOL, V124, P82, DOI 10.1016/0012-1606(87)90462-3; KNUDSON W, 1993, P NATL ACAD SCI USA, V90, P4003, DOI 10.1073/pnas.90.9.4003; LESLEY J, 1993, ADV IMMUNOL, V54, P271, DOI 10.1016/S0065-2776(08)60537-4; LUCAS MG, 1989, BLOOD, V73, P596; MACKAY CR, 1994, J CELL BIOL, V124, P71, DOI 10.1083/jcb.124.1.71; MIYAKE K, 1990, J EXP MED, V172, P69, DOI 10.1084/jem.172.1.69; ORKIN RW, 1985, DEV BIOL, V107, P527, DOI 10.1016/0012-1606(85)90333-1; RISTAMAKI R, 1994, BLOOD, V84, P238; RUDY W, 1993, CANCER RES, V53, P1262; RUIZ P, 1995, BIOESSAYS, V17, P17, DOI 10.1002/bies.950170106; SCREATON GR, 1993, J BIOL CHEM, V268, P12235; STAMENKOVIC I, 1991, EMBO J, V10, P343, DOI 10.1002/j.1460-2075.1991.tb07955.x; THOMAS L, 1992, J CELL BIOL, V118, P971, DOI 10.1083/jcb.118.4.971; Toole B. P., 1991, CELL BIOL EXTRACELLU, P305; UNDERHILL CB, 1993, DEV BIOL, V155, P324, DOI 10.1006/dbio.1993.1032; YANG H, 1993, IMMUNOLOGY, V78, P547	34	49	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20603	20607		10.1074/jbc.271.34.20603	http://dx.doi.org/10.1074/jbc.271.34.20603			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702806	hybrid			2022-12-25	WOS:A1996VD33700058
J	Takeuchi, M; Rothe, M; Goeddel, DV				Takeuchi, M; Rothe, M; Goeddel, DV			Anatomy of TRAF2 - Distinct domains for nuclear factor-kappa B activation and association with tumor necrosis factor signaling proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RING FINGER PROTEIN; CYTOPLASMIC DOMAIN; FACTOR RECEPTOR; DEATH DOMAIN; TNF RECEPTOR; FACTOR-ALPHA; CELL-DEATH; CD40; INTERACTS; FAMILY	The tumor necrosis factor (TNF) receptor-associated factor (TRAF) family of proteins interact with and transduce signals for members of the TNF receptor superfamily. TRAF1, TRAF2, and TRAF3 share a conserved C-terminal TRAF domain. TRAF2 plays a key role in transducing signals for activation of the transcription factor nuclear factor-kappa B (NF-kappa B). We have performed extensive mutational analysis on TRAF2, examining the requirements for NF-kappa B activation, self-association, and interaction with other molecules involved in TNF signaling. Examination of point mutants and TRAF2-TRAF3 chimeric proteins indicates that the N-terminal RING finger and two adjacent zinc fingers of TRAF2 are required for NF-kappa B activation. The two distinct TRAF-N and TRAF-C subdomains of the TRAF domain appear to independently mediate self-association and interaction with TRAF1. Interaction of TRAF2 with TNF-R2 and TRADD requires sequences at the C terminus of the TRAF-C domain, whereas interaction with the protein kinase receptor-interacting protein V(RIP) occurs via sequences at the N terminus of the TRAF-C domain. Thus, distinct domains of TRAF2 are involved in recruitment and signaling functions.	TULARIK INC, San Francisco, CA 94080 USA; YAMANOUCHI PHARMACEUT CO LTD, TSUKUBA, IBARAKI 305, JAPAN	Astellas Pharmaceuticals								BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BERBERICH I, 1994, J IMMUNOL, V153, P4357; BEUTLER BE, 1992, TUMOR NECROSIS FACTO; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; BORDEN KLB, 1995, EMBO J, V14, P1532, DOI 10.1002/j.1460-2075.1995.tb07139.x; CHENG GH, 1995, SCIENCE, V267, P1494, DOI 10.1126/science.7533327; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; FREEMONT PS, 1993, ANN NY ACAD SCI, V684, P174, DOI 10.1111/j.1749-6632.1993.tb32280.x; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; HU HM, 1994, J BIOL CHEM, V269, P30069; ITOH N, 1993, J BIOL CHEM, V268, P10932; KLUG A, 1995, FASEB J, V9, P597, DOI 10.1096/fasebj.9.8.7768350; KRUPPA G, 1992, J IMMUNOL, V148, P3152; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; ROTHE J, 1992, IMMUNOL RES, V11, P81, DOI 10.1007/BF02918612; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; SATO T, 1995, FEBS LETT, V358, P113, DOI 10.1016/0014-5793(94)01406-Q; SCHINDLER U, 1994, MOL CELL BIOL, V14, P5820, DOI 10.1128/MCB.14.9.5820; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; SONG HY, 1995, BIOCHEM J, V309, P825, DOI 10.1042/bj3090825; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; TAKEUCHI M, 1995, P NATL ACAD SCI USA, V92, P3561, DOI 10.1073/pnas.92.8.3561; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; VANDENABEELE P, 1995, TRENDS CELL BIOL, V5, P392, DOI 10.1016/S0962-8924(00)89088-1	30	274	283	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					19935	19942		10.1074/jbc.271.33.19935	http://dx.doi.org/10.1074/jbc.271.33.19935			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702708	hybrid			2022-12-25	WOS:A1996VC66900049
J	Wardenburg, JB; Fu, C; Jackman, JK; Flotow, H; Wilkinson, SE; Williams, DH; Johnson, R; Kong, GH; Chan, AC; Findell, PR				Wardenburg, JB; Fu, C; Jackman, JK; Flotow, H; Wilkinson, SE; Williams, DH; Johnson, R; Kong, GH; Chan, AC; Findell, PR			Phosphorylation of SLP-76 by the ZAP-70 protein-tyrosine kinase is required for T-cell receptor function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEVERE COMBINED IMMUNODEFICIENCY; ANTIGEN-RECEPTOR; MAJOR SUBSTRATE; MICE LACKING; HS1 PROTEIN; ACTIVATION; GRB2; SYK; PHOSPHOPROTEIN; IDENTIFICATION	Two families of tyrosine kinases, the Src and Syk families, are required for T-cell receptor activation. While the Src kinases are responsible for phosphorylation of receptor-encoded signaling motifs and for up-regulation of ZAP-70 activity, the downstream substrates of ZAP-70 are unknown. Evidence is presented herein that the Src homology 2 (SH2) domain-containing leukocyte protein of 76 kDa (SLP-76) is a substrate of ZAP-70. Phosphorylation of SLP-76 is diminished in T cells that express a catalytically inactive ZAP-70. Moreover, SLP-76 is preferentially phosphorylated by ZAP-70 in vitro and in heterologous cellular systems. In T cells, overexpression of wild-type SLP-76 results in a hyperactive receptor, while expression of a SLP-76 molecule that is unable to be tyrosine-phosphorylated attenuates receptor function. In addition, the SH2 domain of SLP-76 is required for T-cell receptor function, although its role is independent of the ability of SLP-76 to undergo tyrosine phosphorylation. As SLP-76 interacts with both Grb2 and phospholipase C-gamma 1, these data indicate that phosphorylation of SLP-76 by ZAP-70 provides an important functional link between the T-cell receptor and activation of ras and calcium pathways.	WASHINGTON UNIV,SCH MED,CTR IMMUNOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,HOWARD HUGHES MED INST,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT MED,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT PATHOL,ST LOUIS,MO 63110; ROCHE BIOSCI,PALO ALTO,CA 94304; ROCHE RES CTR,WELWYN GARDEN CIT AL7 3AY,HERTS,ENGLAND	Washington University (WUSTL); Howard Hughes Medical Institute; Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Roche Holding; Roche Holding			Orchard, Sandra/ABC-1609-2020	Orchard, Sandra/0000-0002-8878-3972	NIGMS NIH HHS [5T32GM07200] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007200] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARPAIA E, 1994, CELL, V76, P947, DOI 10.1016/0092-8674(94)90368-9; BUDAY L, 1994, J BIOL CHEM, V269, P9019; CHAN A, 1994, ANNU REV IMMUNOL, V14, P555; CHAN AC, 1994, SCIENCE, V264, P1599, DOI 10.1126/science.8202713; CHAN AC, 1995, EMBO J, V14, P2499, DOI 10.1002/j.1460-2075.1995.tb07247.x; CHAN AC, 1991, P NATL ACAD SCI USA, V88, P9166, DOI 10.1073/pnas.88.20.9166; CHAN AC, 1996, IN PRESS CURR OPINIO; CHENG AM, 1995, NATURE, V378, P303, DOI 10.1038/378303a0; COLIGAN JE, 1995, CURRENT PROTOCOLS IM, V2; COUTURE C, 1994, P NATL ACAD SCI USA, V91, P5301, DOI 10.1073/pnas.91.12.5301; ELDER ME, 1994, SCIENCE, V264, P1596, DOI 10.1126/science.8202712; FLOTOW H, 1991, J BIOL CHEM, V266, P3724; FUKAMACHI H, 1994, J IMMUNOL, V152, P642; IWASHIMA M, 1994, SCIENCE, V263, P1163; JACKMAN JK, 1995, J BIOL CHEM, V270, P7029, DOI 10.1074/jbc.270.13.7029; KATZAV S, 1994, J BIOL CHEM, V269, P32579; KITAMURA D, 1989, NUCLEIC ACIDS RES, V17, P9367; KONG GH, 1995, IMMUNITY, V2, P485, DOI 10.1016/1074-7613(95)90029-2; LAHESMAA R, 1995, J IMMUNOL, V155, P3815; MOTTO DG, 1994, J BIOL CHEM, V269, P21608; NEGISHI I, 1995, NATURE, V376, P435, DOI 10.1038/376435a0; PASTOR MI, 1995, IMMUNOL TODAY, V16, P159, DOI 10.1016/0167-5699(95)80134-0; PERLMUTTER RM, 1993, ANNU REV IMMUNOL, V11, P451, DOI 10.1146/annurev.iy.11.040193.002315; RAMOSMORALES F, 1994, ONCOGENE, V9, P1917; REIF K, 1994, J BIOL CHEM, V269, P14081; ROWLEY RB, 1995, J BIOL CHEM, V270, P11590, DOI 10.1074/jbc.270.19.11590; RUBY RDJ, 1995, J BIOL CHEM, V270, P30241; SHIUE L, 1995, J BIOL CHEM, V270, P10498, DOI 10.1074/jbc.270.18.10498; SIEH M, 1994, MOL CELL BIOL, V14, P4435, DOI 10.1128/MCB.14.7.4435; SZABO SJ, 1993, MOL CELL BIOL, V13, P4793, DOI 10.1128/MCB.13.8.4793; TANIUCHI I, 1995, EMBO J, V14, P3664, DOI 10.1002/j.1460-2075.1995.tb00036.x; TURNER M, 1995, NATURE, V378, P298, DOI 10.1038/378298a0; VANOERS NSC, 1994, IMMUNITY, V1, P675, DOI 10.1016/1074-7613(94)90038-8; WANGE RL, 1995, J BIOL CHEM, V270, P18730, DOI 10.1074/jbc.270.32.18730; WEISS A, 1984, J EXP MED, V160, P1284, DOI 10.1084/jem.160.5.1284; Wiest DL, 1996, IMMUNITY, V4, P495, DOI 10.1016/S1074-7613(00)80415-X; YAMANASHI Y, 1993, P NATL ACAD SCI USA, V90, P3631, DOI 10.1073/pnas.90.8.3631; YE ZS, 1994, P NATL ACAD SCI USA, V91, P12629, DOI 10.1073/pnas.91.26.12629	38	265	270	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					19641	19644		10.1074/jbc.271.33.19641	http://dx.doi.org/10.1074/jbc.271.33.19641			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702662	hybrid			2022-12-25	WOS:A1996VC66900003
J	Auge, N; Andrieu, N; NegreSalvayre, A; Thiers, JC; Levade, T; Salvayre, R				Auge, N; Andrieu, N; NegreSalvayre, A; Thiers, JC; Levade, T; Salvayre, R			The sphingomyelin-ceramide signaling pathway is involved in oxidized low density lipoprotein-induced cell proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; SMOOTH-MUSCLE CELLS; FACTOR-KAPPA-B; ACIDIC SPHINGOMYELINASE; ATHEROSCLEROTIC LESIONS; OXIDATIVE MODIFICATION; LIPID PEROXIDES; HL-60 CELLS; FREE SYSTEM; ACTIVATION	Development of atherosclerosis is believed to involve proliferation of smooth muscle cells (SMC). Our laboratory previously demonstrated that the growth of bovine aortic SMC was stimulated by mildly oxidized low density lipoproteins (oxLDL) and that the mitogenic effect of oxLDL was greater than that induced by native LDL (AugB, N., Pieraggi, M. T., Thiers, J. C., Negre-Salvayre, A., and Salvayre R. (1995) Biochem. J. 309, 1015-1020). Since the lipid mediator ceramide has been described to be proliferative, the present work aimed at studying the potential involvement of the so-called sphingomyelin ceramide pathway in the Signal transduction cascade induced by oxLDL. Incubation of SMC with UV-oxidized LDL induced sphingomyelin hydrolysis (32%), which peaked at 60 min and was accompanied by a concomitant increase of intracellular ceramide level. The effect of oxidized LDL on sphingomyelin turnover exhibited the same LDL dose dependence as their mitogenic effect, Exogenous bacterial sphingomyelinase induced sphingomyelin hydrolysis and ceramide generation and also stimulated cell growth, in contrast to exogenous phospholipases A2, C, or D. This mitogenic effect was reproduced by incubating the cells with the cell-permeant ceramides, N-acetyl- and N-hexanoylsphingosines. Altogether, these data strongly suggest for the first time that activation of the sphingomyelin-ceramide pathway may play a pivotal role in the oxLDL-induced SMC proliferation and atherogenesis.	UNIV TOULOUSE 3,RANGUEIL FAC MED,INSERM CJF9206,METAB DIS SECT,LAB BIOCHEM,F-31054 TOULOUSE,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier			Levade, Thierry/O-8948-2014; Andrieu-Abadie, Nathalie/N-6793-2013	Andrieu-Abadie, Nathalie/0000-0003-2698-1970; Auge, Nathalie/0000-0003-2088-7211; Negre-Salvayre, Anne/0000-0003-2136-5706				ANDRIEU N, 1994, BIOCHEM J, V303, P341, DOI 10.1042/bj3030341; ANDRIEU N, 1995, J BIOL CHEM, V270, P24518, DOI 10.1074/jbc.270.41.24518; AUGE N, 1995, BIOCHEM J, V309, P1015, DOI 10.1042/bj3091015; BALLOU LR, 1992, J BIOL CHEM, V267, P20044; BOUCHER LM, 1995, J EXP MED, V181, P2059, DOI 10.1084/jem.181.6.2059; CHAN G, 1995, EUR J IMMUNOL, V25, P1999, DOI 10.1002/eji.1830250730; CHATTERJEE S, 1992, MOL CELL BIOCHEM, V111, P143; CIFONE MG, 1994, J EXP MED, V180, P1547, DOI 10.1084/jem.180.4.1547; DBAIBO GS, 1993, J BIOL CHEM, V268, P17762; DOBROWSKY RT, 1994, SCIENCE, V265, P1596, DOI 10.1126/science.8079174; DRESSLER KA, 1992, SCIENCE, V255, P1715, DOI 10.1126/science.1313189; ESTERBAUER H, 1992, FREE RADICAL BIO MED, V13, P341, DOI 10.1016/0891-5849(92)90181-F; FOLCH J, 1957, J BIOL CHEM, V226, P497; HABERLAND ME, 1988, SCIENCE, V241, P215, DOI 10.1126/science.2455346; HAKOMORI SI, 1981, ANNU REV BIOCHEM, V50, P733, DOI 10.1146/annurev.bi.50.070181.003505; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HANNUN YA, 1993, BIOCHIM BIOPHYS ACTA, V1154, P223, DOI 10.1016/0304-4157(93)90001-5; HAUSER JML, 1994, J BIOL CHEM, V269, P6803; HAVEL RI, 1955, J CLIN INVEST, V39, P1345; JARVIS WD, 1994, P NATL ACAD SCI USA, V91, P73, DOI 10.1073/pnas.91.1.73; KIM MY, 1991, J BIOL CHEM, V266, P484; KOLESNICK R, 1995, J EXP MED, V181, P1949, DOI 10.1084/jem.181.6.1949; Kolesnick Richard, 1992, Trends in Cell Biology, V2, P232, DOI 10.1016/0962-8924(92)90310-J; KOLESNICK RN, 1991, PROG LIPID RES, V30, P1, DOI 10.1016/0163-7827(91)90005-P; MATHIAS S, 1993, SCIENCE, V259, P519, DOI 10.1126/science.8424175; MERRILL AH, 1991, J BIOENERG BIOMEMBR, V23, P83; NATARAJAN V, 1995, J LIPID RES, V36, P2005; NEGRESALVAYRE A, 1990, BIOCHIM BIOPHYS ACTA, V1045, P224, DOI 10.1016/0005-2760(90)90124-G; NEGRESALVAYRE A, 1992, PHOTOCHEM PHOTOBIOL, V55, P197, DOI 10.1111/j.1751-1097.1992.tb04228.x; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; OBEID LM, 1995, J CELL BIOCHEM, V58, P191, DOI 10.1002/jcb.240580208; OKAZAKI T, 1989, J BIOL CHEM, V264, P19076; OLIVERA A, 1992, J BIOL CHEM, V267, P26121; OLIVERA A, 1992, GLYCOCONJUGATE J, V9, P109; PARTHASARATHY S, 1989, P NATL ACAD SCI USA, V86, P1046, DOI 10.1073/pnas.86.3.1046; PRICE P, 1990, CANCER RES, V50, P1392; RAINES MA, 1993, J BIOL CHEM, V268, P14572; ROSS R, 1973, SCIENCE, V180, P1332, DOI 10.1126/science.180.4093.1332; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SASAKI T, 1995, BIOCHEM J, V311, P829, DOI 10.1042/bj3110829; SCHUTTE B, 1987, J HISTOCHEM CYTOCHEM, V35, P1343, DOI 10.1177/35.11.3116075; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STARY HC, 1990, EUR HEART J, V11, P3, DOI 10.1093/eurheartj/11.suppl_E.3; TEPPER CG, 1995, P NATL ACAD SCI USA, V92, P8443, DOI 10.1073/pnas.92.18.8443; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; WITZTUM JL, 1991, J CLIN INVEST, V88, P1785, DOI 10.1172/JCI115499; YAGI K, 1987, CHEM PHYS LIPIDS, V45, P337, DOI 10.1016/0009-3084(87)90071-5; YLAHERTTUALA S, 1989, J CLIN INVEST, V84, P1086, DOI 10.1172/JCI114271	49	112	116	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19251	19255		10.1074/jbc.271.32.19251	http://dx.doi.org/10.1074/jbc.271.32.19251			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702606	hybrid			2022-12-25	WOS:A1996VB68400040
J	Kim, S; Kim, HD; Park, IW; Lee, YH				Kim, S; Kim, HD; Park, IW; Lee, YH			Mutational analysis of RNA structures and sequences postulated to affect 3' processing of M1 RNA, the RNA component of Escherichia coli RNase P	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBONUCLEASE-P; SECONDARY STRUCTURE; MESSENGER-RNA; E-CLEAVAGE; SUBUNIT; ENZYME; GENE; PRECURSOR; TRANSCRIPTION; SPECIFICITY	When the rnpB gene encoding M1 RNA, the RNA component of Escherichia coli RNase P, is transcribed, the primary M1 RNA transcript (pM1 RNA) is produced and subsequently processed at the 3' end to generate the mature M1 RNA, To study features of pM1 RNA thought to be involved in RNA processing, systematic mutations were introduced, in sequence elements and secondary structures surrounding the processing site using p23 RNA, a truncated pM1 RNA transcribed from the internally deleted, rnpB gene, as a model substrate and the processing of its mutant derivatives was analyzed in vivo and in vitro. Neither the alteration of two bases forming the processing site nor the disruption of secondary structures surrounding the site significantly affected the processing efficiency although the secondary structures were required for maintaining RNA stability. In contrast, mutations at the rne-dependent site, GAUUU, immediately 3' to the processing site inhibited the processing and the extent of the inhibition varied with the altered sequences. Furthermore, the processing of the mutants of the rne-dependent site as well as wild-type p23 RNA was inhibited in an E. coli rne(ts) strain at the nonpermissive temperature.	KOREA ADV INST SCI & TECHNOL, DEPT CHEM, TAEJON 305701, SOUTH KOREA; SEOUL NATL UNIV, DEPT CHEM, SEOUL 151742, SOUTH KOREA	Korea Advanced Institute of Science & Technology (KAIST); Seoul National University (SNU)			Lee, Younghoon/C-1991-2011	Lee, Younghoon/0000-0002-3841-719X; Kim, Semi/0000-0001-8043-1465				ALTMAN S, 1989, ADV ENZYMOL RAMB, V62, P1; Bechhofer D., 1993, CONTROL MESSENGER RN, P31; CARPOUSIS AJ, 1994, CELL, V76, P889, DOI 10.1016/0092-8674(94)90363-8; EHRETSMANN CP, 1992, GENE DEV, V6, P149, DOI 10.1101/gad.6.1.149; GUERRIERTAKADA C, 1984, BIOCHEMISTRY-US, V23, P6327, DOI 10.1021/bi00321a006; GUREVITZ M, 1983, P NATL ACAD SCI-BIOL, V80, P4450, DOI 10.1073/pnas.80.14.4450; HAAS ES, 1994, P NATL ACAD SCI USA, V91, P2527, DOI 10.1073/pnas.91.7.2527; Higgins C.F., 1993, CONTROL MESSENGER RN, P13; JAIN SK, 1982, J MOL BIOL, V162, P515, DOI 10.1016/0022-2836(82)90386-2; JAMES BD, 1988, CELL, V52, P19, DOI 10.1016/0092-8674(88)90527-2; KOLE R, 1981, BIOCHEMISTRY-US, V20, P1902, DOI 10.1021/bi00510a028; LAWRENCE NP, 1987, P NATL ACAD SCI USA, V84, P6825, DOI 10.1073/pnas.84.19.6825; LEE SJ, 1991, MOL CELLS, V1, P415; LEE Y, 1989, J BIOL CHEM, V264, P5098; LEE Y M, 1989, Korean Biochemical Journal, V22, P276; LEE YH, 1985, J BACTERIOL, V164, P556, DOI 10.1128/JB.164.2.556-562.1985; LUNDBERG U, 1995, RNA, V1, P327; MACKIE GA, 1992, J BIOL CHEM, V267, P1054; Maxam A M, 1980, Methods Enzymol, V65, P499; MCDOWALL KJ, 1995, NATURE, V374, P287, DOI 10.1038/374287a0; MCDOWALL KJ, 1994, J BIOL CHEM, V269, P10790; MOTAMEDI H, 1984, P NATL ACAD SCI-BIOL, V81, P3959, DOI 10.1073/pnas.81.13.3959; REED RE, 1982, CELL, V30, P627, DOI 10.1016/0092-8674(82)90259-8; REED RE, 1983, P NATL ACAD SCI-BIOL, V80, P5359, DOI 10.1073/pnas.80.17.5359; ROBERTSON HD, 1972, J BIOL CHEM, V247, P5243; ROSENBERG M, 1979, ANNU REV GENET, V13, P319, DOI 10.1146/annurev.ge.13.120179.001535; SAKAMOTO H, 1983, P NATL ACAD SCI-BIOL, V80, P6187, DOI 10.1073/pnas.80.20.6187; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STARK BC, 1978, P NATL ACAD SCI USA, V75, P3717, DOI 10.1073/pnas.75.8.3717; TUERK C, 1988, P NATL ACAD SCI USA, V85, P1364, DOI 10.1073/pnas.85.5.1364; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZUKER M, 1989, SCIENCE, V244, P48, DOI 10.1126/science.2468181	33	51	52	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19330	19337		10.1074/jbc.271.32.19330	http://dx.doi.org/10.1074/jbc.271.32.19330			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702618	hybrid			2022-12-25	WOS:A1996VB68400052
J	Reinhardt, DP; Sasaki, T; Dzamba, BJ; Keene, DR; Chu, ML; Gohring, W; Timpl, R; Sakai, LY				Reinhardt, DP; Sasaki, T; Dzamba, BJ; Keene, DR; Chu, ML; Gohring, W; Timpl, R; Sakai, LY			Fibrillin-1 and fibulin-2 interact and are colocalized in some tissues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR-MATRIX PROTEIN; BETA-BINDING-PROTEIN; EGF-LIKE REPEATS; MARFAN-SYNDROME; ELASTIC FIBERS; STRUCTURAL CHARACTERIZATION; NIDOGEN AFFINITY; CALCIUM-BINDING; GENE-PRODUCT; MICROFIBRILS	Microfibrils 10-12 nm in diameter are found in elastic and non-elastic tissues with fibrillin as a major component. Little is known about the supramolecular structure of these microfibrils and the protein interactions it is based on. To identify protein binding ligands of fibrillin-1, we tested binding of recombinant fibrillin-1 peptides to different extracellular matrix proteins in solid phase assays. Among the proteins tested, only fibulin-2 showed significant binding to rF11, the N-terminal half of fibrillin-1, in a calcium-dependent manner. Surface plasmon resonance demonstrated high affinity binding with a K-d=56 nM. With overlapping recombinant fibrillin-1 peptides, the binding site for fibulin-2 was narrowed down to the N terminus of fibrillin-1 (amino acid positions 45-450). Immunofluorescence in tissues demonstrated colocalization of fibrillin and fibulin-2 in skin, perichondrium, elastic intima of blood vessels, and kidney glomerulus. Fibulin-2 was not present in ocular ciliary zonules, tendon, and the connective tissue around kidney tubules and lung alveoli, which all contain fibrillin. Immunogold labeling of fibulin-2 on microfibrils in skin was found preferentially at the interface between microfibrils and the amorphous elastin core, suggesting that in vivo the interaction between fibrillin-1 and fibulin-2 is regulated by cellular expression and deposition as well as by protein-protein interactions.	SHRINERS HOSP CRIPPLED CHILDREN,PORTLAND,OR 97201; MAX PLANCK INST BIOCHEM,D-82152 MARTINSRIED,GERMANY; THOMAS JEFFERSON UNIV,DEPT BIOCHEM & MOL BIOL,PHILADELPHIA,PA 19107; THOMAS JEFFERSON UNIV,DEPT DERMATOL & CUTANEOUS BIOL,PHILADELPHIA,PA 19107; OREGON HLTH SCI UNIV,DEPT BIOCHEM & MOL BIOL,PORTLAND,OR 97201	Max Planck Society; Jefferson University; Jefferson University; Oregon Health & Science University			Reinhardt, Dieter P/A-3102-2008	Reinhardt, Dieter P/0000-0001-6535-9872	NIAMS NIH HHS [AR38923] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR038923] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BALBONA K, 1992, J BIOL CHEM, V267, P20120; BRESSAN GM, 1993, J CELL BIOL, V121, P201, DOI 10.1083/jcb.121.1.201; BROWN JC, 1994, J CELL SCI, V107, P329; CLEARY EG, 1983, INT REV CONNECT TISS, V10, P97; CORSON GM, 1993, GENOMICS, V17, P476, DOI 10.1006/geno.1993.1350; DAHLBACK B, 1990, J BIOL CHEM, V265, P16082; DIETZ HC, 1994, ADV HUM GENET, V22, P153; DIETZ HC, 1995, HUM MOL GENET, V4, P1799, DOI 10.1093/hmg/4.suppl_1.1799; FAGERSTAM LG, 1992, J CHROMATOGR, V597, P397, DOI 10.1016/0021-9673(92)80137-J; FARQUHAR MG, 1961, J EXP MED, V113, P47, DOI 10.1084/jem.113.1.47; HOSAKA M, 1991, J BIOL CHEM, V266, P12127; HURLE JM, 1994, DEV DYNAM, V200, P321, DOI 10.1002/aja.1002000407; KANZAKI T, 1990, CELL, V61, P1051, DOI 10.1016/0092-8674(90)90069-Q; KEENE DR, 1991, J HISTOCHEM CYTOCHEM, V39, P441, DOI 10.1177/39.4.2005373; LEE B, 1991, NATURE, V352, P330, DOI 10.1038/352330a0; LITTLE CD, 1995, EXPERIENTIA, V51, P873, DOI 10.1007/BF01921738; LOW FN, 1962, ANAT REC, V142, P131, DOI 10.1002/ar.1091420205; LOW FN, 1961, ANAT RECORD, V139, P105, DOI 10.1002/ar.1091390203; MADDOX BK, 1989, J BIOL CHEM, V264, P21381; MASLEN CL, 1991, NATURE, V352, P334, DOI 10.1038/352334a0; MAYER U, 1995, FEBS LETT, V365, P129, DOI 10.1016/0014-5793(95)00438-F; MILLER EJ, 1982, METHOD ENZYMOL, V82, P33; MOREN A, 1994, J BIOL CHEM, V269, P32469; NISCHT R, 1991, EUR J BIOCHEM, V200, P529, DOI 10.1111/j.1432-1033.1991.tb16214.x; PAN TC, 1993, J CELL BIOL, V123, P1269, DOI 10.1083/jcb.123.5.1269; PAULSSON M, 1987, EUR J BIOCHEM, V166, P11, DOI 10.1111/j.1432-1033.1987.tb13476.x; PEREIRA L, 1993, HUM MOL GENET, V2, P961, DOI 10.1093/hmg/2.7.961; PUTNAM EA, 1995, NAT GENET, V11, P456, DOI 10.1038/ng1295-456; RAVIOLA G, 1971, INVEST OPHTH VISUAL, V10, P851; REBAY I, 1991, CELL, V67, P687, DOI 10.1016/0092-8674(91)90064-6; REES DJG, 1988, EMBO J, V7, P2053, DOI 10.1002/j.1460-2075.1988.tb03045.x; Reinhardt DP, 1996, J MOL BIOL, V258, P104, DOI 10.1006/jmbi.1996.0237; ROARK EF, 1995, J HISTOCHEM CYTOCHEM, V43, P401, DOI 10.1177/43.4.7534784; SAKAI LY, 1994, METHOD ENZYMOL, V245, P29; SAKAI LY, 1986, J CELL BIOL, V103, P2499, DOI 10.1083/jcb.103.6.2499; SASAKI T, 1995, J MOL BIOL, V254, P892, DOI 10.1006/jmbi.1995.0664; SASAKI T, 1995, J MOL BIOL, V245, P241, DOI 10.1006/jmbi.1994.0020; TSIPOURAS P, 1992, NEW ENGL J MED, V326, P905, DOI 10.1056/NEJM199204023261401; TSUJI T, 1980, BRIT J DERMATOL, V102, P413, DOI 10.1111/j.1365-2133.1980.tb06554.x; WHARTON KA, 1985, CELL, V43, P567, DOI 10.1016/0092-8674(85)90229-6; YIN WS, 1995, J BIOL CHEM, V270, P1798, DOI 10.1074/jbc.270.4.1798; YIN WS, 1995, J BIOL CHEM, V270, P10147, DOI 10.1074/jbc.270.17.10147; ZHANG H, 1995, J CELL BIOL, V129, P1165, DOI 10.1083/jcb.129.4.1165; ZHANG H, 1994, J CELL BIOL, V124, P855, DOI 10.1083/jcb.124.5.855; ZHANG HY, 1995, DEV BIOL, V167, P18, DOI 10.1006/dbio.1995.1003; ZHANG RZ, 1994, GENOMICS, V22, P425, DOI 10.1006/geno.1994.1404	46	170	176	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19489	19496		10.1074/jbc.271.32.19489	http://dx.doi.org/10.1074/jbc.271.32.19489			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702639	Green Published, hybrid			2022-12-25	WOS:A1996VB68400073
J	Sekiguchi, J; Shuman, S				Sekiguchi, J; Shuman, S			Covalent DNA binding by vaccinia topoisomerase results in unpairing of the thymine base 5' of the scissile bond	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVE-SITE TYROSINE; DUPLEX DNA; ESCHERICHIA-COLI; STRAND CLEAVAGE; MUTANT ALLELES; I CLEAVAGE; SV40 DNA; SEQUENCE; RECOMBINATION; CATALYSIS	We have used potassium permanganate to probe contacts between vaccinia DNA topoisomerase and thymine residues in its 5'-CCCTT down arrow DNA target site. Two major conclusions emerge from the experiments presented: (i) permanganate oxidation of the +2T base of the scissile strand interferes with topoisomerase binding to DNA, and (ii) the +1T base of the scissile strand becomes unpaired upon formation of the covalent topoisomerase-DNA intermediate. Disruption of T:A base pairing is confined to the +1-position. Covalently bound DNAs that have experienced this structural distortion (such DNAs being marked by oxidation at +1T) are fully capable of being religated. We suggest that a protein-induced DNA conformational change is a component of the strand passage step of the topoisomerase reaction.			Sekiguchi, J (corresponding author), MEM SLOAN KETTERING CANC CTR,PROGRAM MOL BIOL,NEW YORK,NY 10021, USA.			Sekiguchi, JoAnn/0000-0002-7178-4258	NIGMS NIH HHS [GM46330] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM046330, R01GM046330] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEEN MD, 1984, NUCLEIC ACIDS RES, V12, P3097, DOI 10.1093/nar/12.7.3097; BOROWIEC JA, 1988, EMBO J, V7, P3149, DOI 10.1002/j.1460-2075.1988.tb03182.x; Champoux JJ, 1990, DNA TOPOLOGY ITS BIO, P217; CHRISTIANSEN K, 1993, J BIOL CHEM, V268, P9690; CHRISTIANSEN K, 1994, J BIOL CHEM, V269, P721; EDWARDS KA, 1982, NUCLEIC ACIDS RES, V10, P2565, DOI 10.1093/nar/10.8.2565; ENG WK, 1989, J BIOL CHEM, V264, P13373; HAYATSU H, 1967, BIOCHEM BIOPH RES CO, V29, P556, DOI 10.1016/0006-291X(67)90521-9; JAXEL C, 1991, J BIOL CHEM, V266, P20418; KLEMPERER N, 1993, J BIOL CHEM, V268, P15887; KLIMASAUSKAS S, 1994, CELL, V76, P357, DOI 10.1016/0092-8674(94)90342-5; LIMA CD, 1994, NATURE, V367, P138, DOI 10.1038/367138a0; LYNN RM, 1989, P NATL ACAD SCI USA, V86, P3559, DOI 10.1073/pnas.86.10.3559; MORHAM SG, 1992, J BIOL CHEM, V267, P15984; MORHAM SG, 1990, GENE DEV, V4, P515, DOI 10.1101/gad.4.4.515; PANIGRAHI GB, 1992, NUCLEIC ACIDS RES, V20, P5827; SASSEDWIGHT S, 1989, J BIOL CHEM, V264, P8074; SEKIGUCHI J, 1994, NUCLEIC ACIDS RES, V22, P5360, DOI 10.1093/nar/22.24.5360; SEKIGUCHI J, 1995, J BIOL CHEM, V270, P11636, DOI 10.1074/jbc.270.19.11636; SEKIGUCHI J, 1994, J BIOL CHEM, V269, P31731; SEKIGUCHI J, 1996, IN PRESS EMBO J; Sekiguchi JA, 1996, P NATL ACAD SCI USA, V93, P785, DOI 10.1073/pnas.93.2.785; SHUMAN S, 1991, J BIOL CHEM, V266, P1796; SHUMAN S, 1991, J BIOL CHEM, V266, P11372; SHUMAN S, 1988, J BIOL CHEM, V263, P16401; SHUMAN S, 1992, J BIOL CHEM, V267, P16755; SHUMAN S, 1992, J BIOL CHEM, V267, P8620; SHUMAN S, 1990, J BIOL CHEM, V265, P17826; SHUMAN S, 1993, J BIOL CHEM, V268, P18943; SHUMAN S, 1991, P NATL ACAD SCI USA, V88, P10104, DOI 10.1073/pnas.88.22.10104; SHUMAN S, 1989, P NATL ACAD SCI USA, V86, P9793, DOI 10.1073/pnas.86.24.9793; STEVNSNER T, 1989, J BIOL CHEM, V264, P10110; STIVERS JT, 1994, BIOCHEMISTRY-US, V33, P15449, DOI 10.1021/bi00255a027; STIVERS JT, 1994, BIOCHEMISTRY-US, V33, P327, DOI 10.1021/bi00167a043; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; WITTSCHIEBEN J, 1994, J BIOL CHEM, V269, P29978	36	21	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19436	19442		10.1074/jbc.271.32.19436	http://dx.doi.org/10.1074/jbc.271.32.19436			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702632	hybrid			2022-12-25	WOS:A1996VB68400066
J	Lindorfer, MA; Sherman, NE; Woodfork, KA; Fletcher, JE; Hunt, DF; Garrison, JC				Lindorfer, MA; Sherman, NE; Woodfork, KA; Fletcher, JE; Hunt, DF; Garrison, JC			G protein gamma subunits with altered prenylation sequences are properly modified when expressed in Sf9 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING REGULATORY PROTEINS; ALPHA-SUBUNIT; MASS-SPECTROMETRY; PHOSPHOLIPASE-C; BOVINE BRAIN; ISOPRENYLATION; DIMERS; SYSTEM; GERANYLGERANYLTRANSFERASE; FARNESYLTRANSFERASE	The gamma subunits of heterotrimeric G proteins undergo post-translational prenylation and carboxylmethylation after formation of the beta gamma dimer, modifications that are essential for alpha-beta gamma, beta gamma-receptor, and beta gamma-effector interactions, We have determined the specific prenyl group present on the beta(1) gamma(1), beta(1) gamma(2), and beta(1) gamma(3) dimers purified from baculovirus-infected Sf9 cells by specific binding to G protein cu subunits immobilized on agarose, These recombinant dimers undergo the same post-translational modifications determined for gamma(1) and gamma(2) isolated from mammalian tissues, Furthermore, infection of Sf9 cells with a recombinant baculovirus encoding an alteration of the gamma(1), CaaX sequence (gamma(1)-S74L) resulted in geranylgeranylation of the resulting gamma(1) subunit, and alteration of the gamma(2) CaaX sequence to CAIS (gamma(2)-L71S) resulted in farnesylation, Both of these altered gamma subunits were able to associate stably with beta(1), and the resulting beta gamma dimer bound tightly to alpha-agarose and eluted specifically with aluminum fluoride, These results indicate that Sf9 insect cells properly process the CaaX motif in G protein gamma subunits and are a useful model system to study the role of prenylation in the protein-protein interactions in which the beta gamma subunits participate.	UNIV VIRGINIA,HLTH SCI CTR,DEPT PATHOL,CHARLOTTESVILLE,VA 22908; UNIV VIRGINIA,HLTH SCI CTR,DEPT CHEM,CHARLOTTESVILLE,VA 22908	University of Virginia; University of Virginia	Lindorfer, MA (corresponding author), UNIV VIRGINIA,HLTH SCI CTR,DEPT PHARMACOL,BOX 448,CHARLOTTESVILLE,VA 22908, USA.		Hunt, Donald F/I-6936-2012	Hunt, Donald F/0000-0003-2815-6368; Sherman, Nicholas/0000-0003-3206-3113	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019952] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037537] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01-DK-19952] Funding Source: Medline; NIGMS NIH HHS [R01-GM-37537] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASANO T, 1993, J BIOL CHEM, V268, P20512; BOYER JL, 1994, J BIOL CHEM, V269, P2814; BUSS JE, 1991, MOL CELL BIOL, V11, P1523, DOI 10.1128/MCB.11.3.1523; CALDWELL GA, 1994, P NATL ACAD SCI USA, V91, P1275, DOI 10.1073/pnas.91.4.1275; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; CASEY PJ, 1992, J LIPID RES, V33, P1731; Cox Adrienne D., 1992, Current Opinion in Cell Biology, V4, P1008, DOI 10.1016/0955-0674(92)90133-W; DIETRICH A, 1994, EUR J BIOCHEM, V219, P171, DOI 10.1111/j.1432-1033.1994.tb19927.x; FUKADA Y, 1995, METHOD ENZYMOL, V250, P91; FUKADA Y, 1990, NATURE, V346, P658, DOI 10.1038/346658a0; GRABER SG, 1992, J BIOL CHEM, V267, P13123; GRABER SG, 1996, METH NEUROSCI, V29, P207; HIGGINS JB, 1994, J BIOL CHEM, V269, P9067; HUNT DF, 1991, TECHNIQUES PROTEIN C, V2, P441; INIGUEZLLUHI JA, 1992, J BIOL CHEM, V267, P23409; KALMAN VK, 1995, J BIOL CHEM, V270, P14835, DOI 10.1074/jbc.270.24.14835; KALYANARAMAN S, 1995, BIOCHEM BIOPH RES CO, V216, P126, DOI 10.1006/bbrc.1995.2600; KISSELEV O, 1993, J BIOL CHEM, V268, P24519; LOWE PN, 1992, BIOCHEM SOC T, V20, P484, DOI 10.1042/bst0200484; MARSHALL CJ, 1993, SCIENCE, V259, P1865, DOI 10.1126/science.8456312; MATSUDA T, 1994, J BIOL CHEM, V269, P30358; MOORES SL, 1991, J BIOL CHEM, V266, P14603; MORISHITA R, 1992, EUR J BIOCHEM, V210, P1061, DOI 10.1111/j.1432-1033.1992.tb17512.x; MORISHITA R, 1995, J BIOL CHEM, V270, P29469, DOI 10.1074/jbc.270.49.29469; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P5873, DOI 10.1073/pnas.87.15.5873; MUNTZ KH, 1992, MOL BIOL CELL, V3, P49, DOI 10.1091/mbc.3.1.49; OHGURO H, 1991, EMBO J, V10, P3669, DOI 10.1002/j.1460-2075.1991.tb04934.x; PAGE M J, 1990, Methods (Orlando), V1, P221, DOI 10.1016/S1046-2023(05)80321-4; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; RAY K, 1995, J BIOL CHEM, V270, P21765, DOI 10.1074/jbc.270.37.21765; REISS Y, 1991, P NATL ACAD SCI USA, V88, P732, DOI 10.1073/pnas.88.3.732; ROBISHAW JD, 1989, J BIOL CHEM, V264, P15758; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SEABRA MC, 1991, CELL, V65, P429, DOI 10.1016/0092-8674(91)90460-G; SIMONDS WF, 1991, J BIOL CHEM, V266, P5363; SUMMERS MD, 1987, TEXAS AGR EXPT STATI, V1555, P1; TUINMAN AA, 1991, ANAL BIOCHEM, V193, P173, DOI 10.1016/0003-2697(91)90004-D; UEDA N, 1994, J BIOL CHEM, V269, P4388; WEDEGAERTNER PB, 1995, J BIOL CHEM, V270, P503, DOI 10.1074/jbc.270.2.503; WILCOX MD, 1994, J BIOL CHEM, V269, P12508; WILCOX MD, 1995, BIOCHEM BIOPH RES CO, V212, P367, DOI 10.1006/bbrc.1995.1979; WILDMAN DE, 1993, P NATL ACAD SCI USA, V90, P794, DOI 10.1073/pnas.90.3.794; XUE CB, 1990, INT J PEPT PROT RES, V36, P362; YAMANE HK, 1990, P NATL ACAD SCI USA, V87, P5868, DOI 10.1073/pnas.87.15.5868; Yasuda H, 1996, J BIOL CHEM, V271, P18588, DOI 10.1074/jbc.271.31.18588; YOKOYAMA K, 1991, P NATL ACAD SCI USA, V88, P5302, DOI 10.1073/pnas.88.12.5302	48	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18582	18587		10.1074/jbc.271.31.18582	http://dx.doi.org/10.1074/jbc.271.31.18582			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702508	hybrid			2022-12-25	WOS:A1996VB68300046
J	Yan, K; Gautam, N				Yan, K; Gautam, N			A domain on the G protein beta subunit interacts with both adenylyl cyclase 2 and the muscarinic atrial potassium channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADRENERGIC-RECEPTOR KINASE; HETEROTRIMERIC G-PROTEINS; GAMMA-SUBUNITS; K+ CHANNEL; PHOSPHOLIPASE-C; BINDING; STIMULATION; ACTIVATION; G(BETA-GAMMA); REGION	The G protein beta gamma complex modulates the function of a variety of effecters in biological signaling. However, the individual roles of the beta and gamma subunits in this interaction are unknown. Unlike in the case of the alpha subunit, domains on the beta gamma complex that contact effecters have not yet been identified. We show here using the yeast two-hybrid system that the beta subunit and not the gamma subunit interacts with domains specific to adenylyl cyclase type 2 (AC2) and the muscarinic receptor-gated atrial inwardly rectifying potassium channel, GIRK1. Different beta subunit types interact with these effector domains with different efficacies. Furthermore, an N-terminal fragment of 100 residues interacts with both these effector domains as effectively as the whole beta subunit. This domain includes the region where the beta subunit contacts with the alpha subunit in the crystal structure and may therefore explain the ability of the alpha subunit to shut off the activity of the beta gamma complex.	WASHINGTON UNIV,SCH MED,DEPT ANESTHESIOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT GENET,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL)								CAMPS M, 1992, NATURE, V360, P684, DOI 10.1038/360684a0; CAMPS M, 1992, EUR J BIOCHEM, V206, P821, DOI 10.1111/j.1432-1033.1992.tb16990.x; CHEN JQ, 1995, SCIENCE, V268, P1166, DOI 10.1126/science.7761832; DIETRICH A, 1994, EUR J BIOCHEM, V219, P171, DOI 10.1111/j.1432-1033.1994.tb19927.x; HAGA K, 1992, J BIOL CHEM, V267, P2222; HUANG CL, 1995, NEURON, V15, P1133, DOI 10.1016/0896-6273(95)90101-9; INANOBE A, 1995, BIOCHEM BIOPH RES CO, V212, P1022, DOI 10.1006/bbrc.1995.2072; INIGUEZLLUHI JA, 1992, J BIOL CHEM, V267, P23409; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; KISSELEV O, 1995, P NATL ACAD SCI USA, V92, P9102, DOI 10.1073/pnas.92.20.9102; KISSELEV OG, 1994, J BIOL CHEM, V269, P21399; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; KRAPIVINSKY G, 1995, J BIOL CHEM, V270, P29059, DOI 10.1074/jbc.270.49.29059; Kuang YN, 1996, P NATL ACAD SCI USA, V93, P2964, DOI 10.1073/pnas.93.7.2964; KUNKEL MT, 1995, CELL, V83, P443, DOI 10.1016/0092-8674(95)90122-1; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; LEBERER E, 1992, EMBO J, V11, P4805, DOI 10.1002/j.1460-2075.1992.tb05586.x; LOGOTHETIS DE, 1987, NATURE, V325, P321, DOI 10.1038/325321a0; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; PRONIN AN, 1992, P NATL ACAD SCI USA, V89, P6220, DOI 10.1073/pnas.89.13.6220; SCHMIDT CJ, 1992, J BIOL CHEM, V267, P13807; TAKAO K, 1994, NEURON, V13, P747, DOI 10.1016/0896-6273(94)90041-8; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; TAUSSIG R, 1993, J BIOL CHEM, V268, P9; Taylor JM, 1996, J BIOL CHEM, V271, P3336; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; WICKMAN KD, 1994, NATURE, V368, P255, DOI 10.1038/368255a0; Yan K, 1996, J BIOL CHEM, V271, P7141, DOI 10.1074/jbc.271.12.7141	29	57	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					17597	17600		10.1074/jbc.271.30.17597	http://dx.doi.org/10.1074/jbc.271.30.17597			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663592	hybrid			2022-12-25	WOS:A1996UY93500002
J	Lindahl, B; Eriksson, L; Spillmann, D; Caterson, B; Lindahl, U				Lindahl, B; Eriksson, L; Spillmann, D; Caterson, B; Lindahl, U			Selective loss of cerebral keratan sulfate in Alzheimer's disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCLONAL-ANTIBODIES; SYNAPTIC VESICLES; PROTEOGLYCAN; OLIGOSACCHARIDES; BRAIN	Proteoglycans, especially heparan sulfate-substituted species, are known to be associated with the deposition of amyloid in Alzheimer's disease, We previously found that heparan sulfate from afflicted brains, and from control subjects, differed minimally in quantity and structure (Lindahl, B., Eriksson, L., and Lindahl, U. (1995) Biochem, J, 306, 177-184), In the present study, a glyco saminoglycan fraction, shown to contain heparan sulfate and keratan sulfate, was radiolabeled by partial N-deacetylation (hydrazinolysis) followed by re-N-acetylation using [H-3]acetic anhydride, Quantitation of the H-3-labeled polysaccharides, based on digestion with heparitinase I from Flavobacterium heparinum and keratanase from Pseudomonas sp., revealed that the amounts of keratan sulfate in Alzheimer cerebral cortex are reduced to less than half of control values. Moreover, a monoclonal antibody against a highly sulfated keratan sulfate epitope bound to the majority of the neurons in normal cortex but not in the diseased tissue. The lack of highly sulfated keratan sulfate structures may reflect a specific functional defect of the cells.	UNIV UPPSALA, DEPT MED & PHYSIOL CHEM, CTR BIOMED, S-75123 UPPSALA, SWEDEN; UNIV UPPSALA, DEPT PATHOL, S-75123 UPPSALA, SWEDEN; UNIV WALES COLL CARDIFF, SCH MOL & MED BIOSCI, CARDIFF CF1 3US, S GLAM, WALES	Uppsala University; Uppsala University; Cardiff University			Caterson, Bruce/A-8085-2010	Caterson, Bruce/0000-0001-6016-0661				BAHR BA, 1992, BIOCHEMISTRY-US, V31, P5778, DOI 10.1021/bi00140a013; Bertolotto A, 1995, Brain Res Dev Brain Res, V86, P233; BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; FEIZI T, 1985, NATURE, V314, P53, DOI 10.1038/314053a0; FUNDERBURGH JL, 1991, BIOCHEM SOC T, V19, P871, DOI 10.1042/bst0190871; Greiling H, 1994, EXS, V70, P101; KHACHATURIAN ZS, 1985, ARCH NEUROL-CHICAGO, V42, P1097, DOI 10.1001/archneur.1985.04060100083029; KRUSIUS T, 1986, J BIOL CHEM, V261, P8237; LINDAHL B, 1995, BIOCHEM J, V306, P177, DOI 10.1042/bj3060177; LINDAHL U, 1994, THROMB RES, V75, P1, DOI 10.1016/0049-3848(94)90136-8; LIU HM, 1987, J NEUROIMMUNOL, V14, P49, DOI 10.1016/0165-5728(87)90100-7; MARGOLIS RK, 1993, EXPERIENTIA, V49, P429, DOI 10.1007/BF01923587; MEHMET H, 1986, EUR J BIOCHEM, V157, P385, DOI 10.1111/j.1432-1033.1986.tb09680.x; SCRANTON TW, 1993, J NEUROCHEM, V61, P29, DOI 10.1111/j.1471-4159.1993.tb03535.x; SNOW AD, 1988, AM J PATHOL, V133, P456; SORRELL JM, 1990, HISTOCHEMISTRY, V94, P269	16	52	53	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					16991	16994		10.1074/jbc.271.29.16991	http://dx.doi.org/10.1074/jbc.271.29.16991			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663590	hybrid			2022-12-25	WOS:A1996UX94300003
J	Orth, K; Chinnaiyan, AM; Garg, M; Froelich, CJ; Dixit, VM				Orth, K; Chinnaiyan, AM; Garg, M; Froelich, CJ; Dixit, VM			The CED-3/ICE-like protease Mch2 is activated during apoptosis and cleaves the death substrate lamin A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-DEATH; GENE CED-3; IL-1-BETA-CONVERTING ENZYME; INDUCTION; ENCODES	Phylogenetic analysis of the CED-3/ICE family of cysteine proteases suggests the existence of a subfamily most related to the Caenorhabditis elegans death gene ced-3 and includes Yama (CPP32, apopain), LAPS (Mch3, CMH1), and Mch2. Here, we show that Mch2 is processed from its zymogen form to a proteolytically active dimeric species during execution of the apoptotic program and by the cytotoxic T cell death protease granzyme B. Additionally, like Yama and LAP3, Mch2 functions downstream of the death inhibitors Bcl-2, Bcl-(xL), and CrmA. Importantly, Mch2, but not Yama or LAPS, is capable of cleaving lamin A to its signature apoptotic fragment, indicating that Mch2 is an apoptotic laminase.	UNIV MICHIGAN,SCH MED,DEPT PATHOL,ANN ARBOR,MI 48109; EVANSTON HOSP CORP,DEPT MED,EVANSTON,IL 60201; NORTHWESTERN UNIV,SCH MED,EVANSTON,IL 60201	University of Michigan System; University of Michigan; NorthShore University Health System; Northwestern University			dixit, vishva m/A-4496-2012; Orth, Kim/AAV-4421-2021	dixit, vishva m/0000-0001-6983-0326; Orth, Kim/0000-0002-0678-7620	NATIONAL CANCER INSTITUTE [R01CA064803, F32CA068769] Funding Source: NIH RePORTER; NCI NIH HHS [CA68769, CA64803] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BRANCOLINI C, 1995, EMBO J, V14, P5179, DOI 10.1002/j.1460-2075.1995.tb00202.x; CASCIOLAROSEN LA, 1994, J BIOL CHEM, V269, P30757; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; CHINNAIYAN AM, 1996, IN PRESS CURR BIOL, V6; DUAN H, 1996, J BIOL CHEM, V271, P35013; FAUCHEU C, 1995, EMBO J, V14, P1914, DOI 10.1002/j.1460-2075.1995.tb07183.x; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P6045; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P2737; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; HORVITZ HR, 1994, COLD SPRING HARB SYM, V59, P377, DOI 10.1101/SQB.1994.059.01.042; KAMENS J, 1995, J BIOL CHEM, V270, P15250, DOI 10.1074/jbc.270.25.15250; KAUFMANN SH, 1993, CANCER RES, V53, P3976; KAYLAR C, 1996, P NATL ACAD SCI USA, V93, P2234; KERR JF, 1978, BRIT J CANCER, V26, P239; KERR JFR, 1994, CANCER-AM CANCER SOC, V73, P2013, DOI 10.1002/1097-0142(19940415)73:8<2013::AID-CNCR2820730802>3.0.CO;2-J; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; LAZEBNIK YA, 1993, J CELL BIOL, V123, P7, DOI 10.1083/jcb.123.1.7; LAZEBNIK YA, 1995, P NATL ACAD SCI USA, V92, P9042, DOI 10.1073/pnas.92.20.9042; Lippke JA, 1996, J BIOL CHEM, V271, P1825, DOI 10.1074/jbc.271.4.1825; MARTIN SJ, 1995, EMBO J, V14, P5191, DOI 10.1002/j.1460-2075.1995.tb00203.x; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MUNDAY NA, 1995, J BIOL CHEM, V270, P15870, DOI 10.1074/jbc.270.26.15870; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Nicholson DW, 1996, NAT BIOTECHNOL, V14, P297, DOI 10.1038/nbt0396-297; Quan LT, 1996, P NATL ACAD SCI USA, V93, P1972, DOI 10.1073/pnas.93.5.1972; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; Wang XD, 1996, EMBO J, V15, P1012, DOI 10.1002/j.1460-2075.1996.tb00438.x; Wyllie A H, 1980, Int Rev Cytol, V68, P251; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	33	364	371	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16443	16446		10.1074/jbc.271.28.16443	http://dx.doi.org/10.1074/jbc.271.28.16443			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663580	hybrid			2022-12-25	WOS:A1996UX12600004
J	Nickel, W; Helms, JB; Kneusel, RE; Wieland, FT				Nickel, W; Helms, JB; Kneusel, RE; Wieland, FT			Forskolin stimulates detoxification of Brefeldin A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE; ADENYLATE-CYCLASE; GOLGI MEMBRANES; CELLS; PROTEIN; ACTIVATION; TRANSPORT; CAMP; ARF; RAT	Forskolin has been shown to prevent the effects brefeldin A (BFA) exerts on many mammalian cells with respect to the disassembly of the Golgi apparatus as well as an increase of sphingomyelin synthesis (Lippincott, S, J,, Glickman, J,, Donaldson, J, G,, Robbins, J., Kreis, T, E., Seamen, K. B,, Sheetz, M, P,, and Klausner, R, D, (1991) J, Cell Biol, 112, 567-577), It has been speculated that forskolin interferes with the action of BFA by competition for the binding of BFA to its target protein, which is most likely the Golgi-localized nucleotide exchange factor specific for ADP-ribosylation factor 1, Here we show that in vitro forskolin does not prevent inhibition of Golgi-catalyzed nucleotide exchange by BFA. Therefore it appears unlikely that forskolin and BFA bind to the same target protein, Using [H-3]BFA we have measured detoxification of BFA by Chinese hamster ovary (CHO) cells, BFA is secreted from CHO cells as cysteine and glutathione conjugates (Bruning, A, Ishikawa, T., Kneusel, R, FF., Matern, U,, Lottspeich, F,, and Wieland, F, T, (1992) J, Biol. Chem. 267, 7726-7732), We present evidence that forskolin treatment of CHO cells results in increased levels of Cys-EFA, the major FFA conjugate secreted by CHO cells, in the medium, Elevated levels of Cys-BFA are also found intracellularly, The effect of forskolin is shown to be independent of its ability to raise the intracellular concentration of cyclic AMP, Therefore, we suggest that the effect of forskolin on BFA-induced disassembly of the Golgi apparatus might be due to an enhanced detoxification of the drug.	UNIV FREIBURG, INST BIOL 2, D-79104 FREIBURG, GERMANY	University of Freiburg	Nickel, W (corresponding author), UNIV HEIDELBERG, INST BIOCHEM 1, NEUENHEIMER FELD 328, D-69120 HEIDELBERG, GERMANY.							BALCH WE, 1984, CELL, V39, P405, DOI 10.1016/0092-8674(84)90019-9; BRUNING A, 1992, J BIOL CHEM, V267, P7726; BRUNING A, 1992, J BIOL CHEM, V267, P5052; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; DONALDSON JG, 1990, J CELL BIOL, V111, P2295, DOI 10.1083/jcb.111.6.2295; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; HELMS JB, 1993, J CELL BIOL, V121, P751, DOI 10.1083/jcb.121.4.751; HEUSCHNEIDER G, 1989, P NATL ACAD SCI USA, V86, P2938, DOI 10.1073/pnas.86.8.2938; HOSHI T, 1988, SCIENCE, V240, P1652, DOI 10.1126/science.2454506; KASHIWAGI A, 1983, J BIOL CHEM, V258, P3685; LAURENZA A, 1991, METHOD ENZYMOL, V195, P52; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; LIPPINCOTTSCHWARTZ J, 1991, J CELL BIOL, V112, P567, DOI 10.1083/jcb.112.4.567; MCHUGH EM, 1986, J BIOL CHEM, V261, P3103; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; MORRIS DI, 1991, BIOCHEMISTRY-US, V30, P8371, DOI 10.1021/bi00098a014; RANDAZZO PA, 1993, J BIOL CHEM, V268, P9555; RANDERATH K, 1970, ANAL BIOCHEM, V34, P188, DOI 10.1016/0003-2697(70)90100-4; SEAMON K, 1981, J BIOL CHEM, V256, P9799; SEAMON KB, 1981, P NATL ACAD SCI-BIOL, V78, P3363, DOI 10.1073/pnas.78.6.3363; TIETJEN KG, 1985, PHYSIOL PLANT PATHOL, V26, P241, DOI 10.1016/0048-4059(85)90024-4; WADLER S, 1988, CANCER RES, V48, P539	22	5	5	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	1996	271	27					15870	15873		10.1074/jbc.271.27.15870	http://dx.doi.org/10.1074/jbc.271.27.15870			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UW352	8663452	hybrid			2022-12-25	WOS:A1996UW35200007
J	Noguchi, K; Naito, M; Kugoh, H; Oshimura, M; Mashima, T; Fujita, N; Yonehara, S; Tsuruo, T				Noguchi, K; Naito, M; Kugoh, H; Oshimura, M; Mashima, T; Fujita, N; Yonehara, S; Tsuruo, T			Chromosome 22 complements apoptosis in Fas- and TNF-resistant mutant UK110 cells	ONCOGENE			English	Article						microcell-fusion; chromosome 22; Fas; TNF; apoptosis	TUMOR-NECROSIS-FACTOR; DEATH GENE CED-3; INSITU HYBRIDIZATION; RECEPTOR; ANTIGEN; INDUCTION; HYBRIDS; HT1080; DOMAIN; ENZYME	Fas and p55 tumor necrosis factor receptor (TNFR) transfer an apoptosis signal when they are crosslinked with their ligands or agonistic antibodies, However, the signal transduction mechanism of apoptosis via Fas and p55 TNFR has not yet been elucidated, We previously described a recessive mutant UK110 from the human monocytic leukemia U937 cell line, that showed resistance against Fas- and p55 TNFR-mediated apoptosis. By cytogenetic analysis and microcell-fusion method, we demonstrate here that introduction of chromosome 22 can specifically restore the sensitivity to Fas- and TNF-mediated apoptosis in UK110 cells, Moreover, introduction of chromosome 22 into UK110 can complement the processing of interleukin-1 beta converting enzyme (ICE)-like proteases, such as CPP32/Yama/Apopain and ICH-1L, after treatment with anti-Pas and anti-p55 TNFR antibodies, These results suggest that the product of a gene located on chromosome 22 participates in the Fas-and p55 TNFR-mediated apoptosis at a point upstream of ICE-like proteases.	UNIV TOKYO,INST MOLEC & CELLULAR BIOSCI,LAB BIOMED RES,BUNKYO KU,TOKYO 113,JAPAN; TOTTORI UNIV,DEPT MOLEC & CELL GENET,TOTTORI 683,JAPAN; KYOTO UNIV,INST VIRUS RES,KYOTO 60601,JAPAN; JAPANESE FDN CANC RES,CTR CANC CHEMOTHERAPY,TOKYO 170,JAPAN	University of Tokyo; Tottori University; Kyoto University; Japanese Foundation for Cancer Research								BEHRMANN I, 1994, EUR J IMMUNOL, V24, P3057, DOI 10.1002/eji.1830241221; BENEDICT WF, 1984, CANCER RES, V44, P3471; CERRETTI DP, 1994, GENOMICS, V20, P468, DOI 10.1006/geno.1994.1202; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; DONG JT, 1995, SCIENCE, V268, P884, DOI 10.1126/science.7754374; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; FUCHS P, 1992, GENOMICS, V13, P219, DOI 10.1016/0888-7543(92)90226-I; GOLSTEIN P, 1995, CELL, V81, P185, DOI 10.1016/0092-8674(95)90327-5; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; ITOH N, 1993, J BIOL CHEM, V268, P10932; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; KATAOKA S, 1994, EXP CELL RES, V215, P199, DOI 10.1006/excr.1994.1332; KOI M, 1989, JPN J CANCER RES, V80, P413, DOI 10.1111/j.1349-7006.1989.tb02329.x; KUGOH HM, 1990, ONCOGENE, V5, P1637; KUMAR S, 1995, HUM GENET, V95, P641; KURAHASHI H, 1994, HUM GENET, V93, P248, DOI 10.1007/BF00212017; KURIMASA A, 1994, HUM GENET, V93, P21; LICHTER P, 1990, P NATL ACAD SCI USA, V87, P6634, DOI 10.1073/pnas.87.17.6634; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MASHIMA T, 1995, BIOCHEM BIOPH RES CO, V209, P907, DOI 10.1006/bbrc.1995.1584; Mashima T, 1995, BIOCHEM BIOPH RES CO, V217, P1185, DOI 10.1006/bbrc.1995.2894; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; NOGUCHI K, 1995, CELL GROWTH DIFFER, V6, P1271; PEREIRA LD, 1991, GENOMICS, V9, P229, DOI 10.1016/0888-7543(91)90246-B; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; SUGAWARA O, 1990, SCIENCE, V247, P707, DOI 10.1126/science.2300822; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; UEJIMA H, 1995, GENE CHROMOSOME CANC, V14, P120, DOI 10.1002/gcc.2870140206; WALKER NPC, 1994, CELL, V78, P343, DOI 10.1016/0092-8674(94)90303-4; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; WHITE K, 1994, SCIENCE, V264, P677, DOI 10.1126/science.8171319; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	43	18	18	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 4	1996	13	1					39	46						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UX319	8700552				2022-12-25	WOS:A1996UX31900005
J	Suzuki, A; Matsuzawa, A; Iguchi, T				Suzuki, A; Matsuzawa, A; Iguchi, T			Down regulation of Bcl-2 is the first step on Fas-mediated apoptosis of male reproductive tract	ONCOGENE			English	Article						Bcl-2; Fas; 1pr mutant mouse; apoptosis; in vivo apoptosis-model	CELL-DEATH; EXPRESSION; ANTIGEN; RECEPTOR; LIGAND; APO-1; MICE; CLONING; MEMBER; GENE	Suppression of apoptosis by Bcl-2, an oncogene product, has been previously reported, Although the down regulation of Bcl-2 has been encountered in various types of apoptosis, the time course of changes in the expression of Bcl-2 has yet to be determined, In the present study, we established and analysed an in vivo model of apoptosis, The mouse male reproductive tract, specifically the prostate and epididymis, which is regulated by sex steroid hormones, especially testosterone, showed regression induced by chromosomal DNA fragmentation, apoptotic cell death, after gonadectomy, Following this apoptosis, down regulation of Bcl-2 and the new expression of Fas were seen, Using functional Fas-lacking mice, we demonstrated that this regression of the male reproductive tract is triggered by Fas-mediated apoptosis, In addition, time course experiments revealed that down regulation of Bcl-2 when apoptosis occurs heralds Fas expression, We propose here that apoptotic death signal transduction in total involve, a number of steps, the first and most important of which is down regulation of Bcl-2.	UNIV TOKYO,INST MED SCI,LAB ANIM RES CTR,MINATO KU,TOKYO 108,JAPAN; YOKOHAMA CITY UNIV,DEPT BIOL,KANAZAWA KU,YOKOHAMA,KANAGAWA 236,JAPAN	University of Tokyo; Yokohama City University	Suzuki, A (corresponding author), DAIICHI PHARMACEUT CO LTD,DRUG SAFETY RES LAB,TOKYO R&D CTR,EDOGAWA KU,16-13 KITAKASAI 1,TOKYO 134,JAPAN.		Iguchi, Taisen/AAL-4225-2021; Matsuzawa, Atsushi/GLU-1387-2022					AKAO Y, 1994, CANCER RES, V54, P2468; BUTTYAN R, 1989, MOL CELL BIOL, V9, P3473, DOI 10.1128/MCB.9.8.3473; ENARI M, 1995, EMBO J, V14, P5201, DOI 10.1002/j.1460-2075.1995.tb00204.x; HILL HD, 1988, ANAL BIOCHEM, V170, P203, DOI 10.1016/0003-2697(88)90109-1; IGUCHI T, 1992, INT REV CYTOL, V139, P1, DOI 10.1016/S0074-7696(08)61409-6; ITOH N, 1993, J IMMUNOL, V151, P621; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; JACOBSON MD, 1994, EMBO J, V13, P1899, DOI 10.1002/j.1460-2075.1994.tb06459.x; JACOBSON MD, 1995, NATURE, V374, P814, DOI 10.1038/374814a0; KAMADA S, 1995, CANCER RES, V55, P354; KONDO S, 1994, BRIT J CANCER, V70, P421, DOI 10.1038/bjc.1994.321; LEITHAUSER F, 1993, LAB INVEST, V69, P415; LICHTER P, 1992, GENOMICS, V14, P179, DOI 10.1016/S0888-7543(05)80302-7; MAPARA MY, 1993, EUR J IMMUNOL, V23, P702, DOI 10.1002/eji.1830230320; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; NAGATA S, 1994, PHILOS T ROY SOC B, V345, P281, DOI 10.1098/rstb.1994.0107; OGASAWARA J, 1995, J EXP MED, V181, P485, DOI 10.1084/jem.181.2.485; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; OTANI H, 1993, J BIOL CHEM, V268, P22733; SHIMIZU S, 1995, NATURE, V374, P811, DOI 10.1038/374811a0; SMITH CA, 1989, NATURE, V337, P181, DOI 10.1038/337181a0; SMITH PK, 1985, ANAL BIOCHEM, V170, P203; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; Suzuki A, 1996, EMBO J, V15, P211, DOI 10.1002/j.1460-2075.1996.tb00351.x; TAKAHASHI T, 1994, CELL, V76, P969, DOI 10.1016/0092-8674(94)90375-1; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; TSUJIMOTO Y, 1989, ONCOGENE, V4, P1331; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; WILSON DL, 1977, ANAL BIOCHEM, V83, P33, DOI 10.1016/0003-2697(77)90506-1; Wyllie A H, 1980, Int Rev Cytol, V68, P251	30	106	112	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 4	1996	13	1					31	37						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UX319	8700551				2022-12-25	WOS:A1996UX31900004
J	Cosgaya, JM; Aranda, A				Cosgaya, JM; Aranda, A			Ras- and Raf-mediated regulation of transforming growth factor beta 1 gene expression by ligands of tyrosine kinase receptors in PC12 cells	ONCOGENE			English	Article						PC12 cells; TGF-beta 1; Egr-1; Ras; Raf; growth factors	PHEOCHROMOCYTOMA CELLS; SIGNAL-TRANSDUCTION; PROTEIN-KINASE; B-RAF; NERVE; DIFFERENTIATION; ONCOGENE; INHIBITION; ACTIVATION; LINE	Different ligands of tyrosine kinase receptors have neurotrophic or mitogenic effects in PC12 cells, NFG and FGF, which-cause morphological differentiation, as well as EGF, that induces cell growth, produce a significant increase of TGF-beta 1 transcripts in PC12 cells. Sequences responsible for the transcriptional effects of the growth factors are located in the 5'-flanking region of the TGF-beta 1 gene, The TGF-beta 1 gene has two promoters and the growth factors significantly enhance the activity of constructs containing either the first or the second promoter, A functional p21(ras) is required for the regulation of TGF-beta 1 by ligands of tyrosine kinase receptors since expression of oncogenic I as in PC12 cells also increases TGF-beta 1 transcripts, and a dominant inhibitory ras mutant blocks activation of TGF-beta 1 gene expression by NGF, Oncogenic raf stimulates the activity of both promoters and a dominant negative raf also significantly inhibits growth factor activation. As determined by Mv1Lu cell proliferation inhibition assay, PC12 cells release a significant amount of TGF-beta 1 in a latent form and incubation with growth factors or expression of oncogenic ras further increase TGF-beta 1 production. These results suggest that during proliferation or growth factor-induced differentiation of sympathetic neurons there is an increase in TGF-beta 1 that could be an important mediator of neural cells function.	CSIC, INST INVEST BIOMED, E-28029 MADRID, SPAIN	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM)			Aranda, Ana/ABG-8820-2020; Cosgaya, Jose M/B-4936-2008	Aranda, Ana/0000-0002-8338-9589; Cosgaya, Jose Miguel/0000-0002-6005-2916				BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; CHALAZONITIS A, 1992, DEV BIOL, V152, P121, DOI 10.1016/0012-1606(92)90162-A; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COSGAYA JM, 1995, J NEUROCHEM, V65, P2484; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DACUNHA A, 1993, J NEUROIMMUNOL, V42, P71, DOI 10.1016/0165-5728(93)90214-J; DARCANGELO G, 1993, MOL CELL BIOL, V13, P3146, DOI 10.1128/MCB.13.6.3146; DERYNK R, 1996, J BIOL CHEM, V261, P4377; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FLANDERS KC, 1991, DEVELOPMENT, V113, P183; GEISER AG, 1991, MOL CELL BIOL, V11, P84, DOI 10.1128/MCB.11.1.84; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; GUERRERO I, 1988, BIOCHEM BIOPH RES CO, V150, P1185, DOI 10.1016/0006-291X(88)90754-1; HAGAG N, 1986, NATURE, V319, P680, DOI 10.1038/319680a0; HALEGOUA S, 1991, CURR TOP MICROBIOL, V165, P119; HEASLEY LE, 1992, MOL BIOL CELL, V3, P545, DOI 10.1091/mbc.3.5.545; HUFF K, 1981, J CELL BIOL, V88, P189, DOI 10.1083/jcb.88.1.189; JAISWAL RK, 1994, MOL CELL BIOL, V14, P6944, DOI 10.1128/MCB.14.10.6944; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KAZLAUSKAS A, 1994, CURR OPIN GENET DEV, V4, P5, DOI 10.1016/0959-437X(94)90085-X; KIM SJ, 1989, J BIOL CHEM, V264, P19373; KIM SJ, 1994, J BIOL CHEM, V269, P3739; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KREMER NE, 1991, J CELL BIOL, V115, P809, DOI 10.1083/jcb.115.3.809; LEVIMONTALCINI R, 1987, EMBO J, V6, P1145, DOI 10.1002/j.1460-2075.1987.tb02347.x; LI BQ, 1992, SCIENCE, V256, P1456, DOI 10.1126/science.1604323; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MCKINNON RD, 1993, J CELL BIOL, V121, P1397, DOI 10.1083/jcb.121.6.1397; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; MUROYA K, 1992, ONCOGENE, V7, P277; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; OSHIMA M, 1991, J BIOL CHEM, V266, P23753; QIU MS, 1992, NEURON, V9, P705, DOI 10.1016/0896-6273(92)90033-A; Qui MS, 1991, NEURON, V7, P937, DOI [DOI 10.1016/0896-6273(91)90339-2, 10.1016/0896-6273(91)90339-2]; RABIN SJ, 1993, MOL CELL BIOL, V13, P2203, DOI 10.1128/MCB.13.4.2203; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P419; ROGERS SL, 1992, DEV BIOL, V151, P192, DOI 10.1016/0012-1606(92)90226-7; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; SPORN MB, 1992, J CELL BIOL, V119, P1017, DOI 10.1083/jcb.119.5.1017; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; THOMSON TM, 1990, MOL CELL BIOL, V10, P1556, DOI 10.1128/MCB.10.4.1556; TOGARI A, 1983, BIOCHEM BIOPH RES CO, V114, P1189, DOI 10.1016/0006-291X(83)90688-5; TROPPMAIR J, 1992, ONCOGENE, V7, P1867; WOOD KW, 1993, P NATL ACAD SCI USA, V90, P5016, DOI 10.1073/pnas.90.11.5016; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O	50	15	15	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 20	1996	12	12					2651	2660						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UW487	8700524				2022-12-25	WOS:A1996UW48700019
J	Damaj, BB; McColl, SR; Neote, K; Hebert, CA; Naccache, PH				Damaj, BB; McColl, SR; Neote, K; Hebert, CA; Naccache, PH			Diverging signal transduction pathways activated by interleukin 8 (IL-8) and related chemokines in human neutrophils - IL-8 and Gro-alpha differentially stimulate calcium influx through IL-8 receptors A and B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHEMOTACTIC CYTOKINES; A RECEPTOR; BINDING; LEUKOCYTES; EXPRESSION; MEMBRANES; RESIDUES; DOMAIN; NAP-2; CELLS	Interleukin 8 (IL-8) and Gro-alpha are members of the CXC branch of a family of cytokines recently designated the ''chemokine'' superfamily. Recent evidence indicates that, contrary to previously held beliefs, IL-8 and Gro-alpha may not be perceived equivalently by neutrophils. In this study, we have evaluated the effects of IL-8 and Gro-alpha on the rate of calcium influx in human neutrophils and in 293 cells transfected with type A or type B IL-8 receptors, Of these two chemokines, only Gro-alpha induced an influx of calcium in neutrophils as judged by the sensitivity of the mobilization of calcium to the extracellular calcium chelator EGTA and to the nonselective divalent cation channel inhibitor SK&F 96365, as well as by manganese quenching experiments, IL-8 was similarly without effect on the rate of Mn2+ influx in 293 cells transfected with IL-8 receptor A (IL-8RA) or IL-8RB. On the other hand, Gro-alpha induced an SK&F 96365-sensitive increase of the rate of Mn+2 influx in IL-8RB-, but not in IL-8RA-transfected 293 cells. These results indicate not only that neutrophils respond differently to IL-8 than they do to Gro-alpha but, furthermore, that the consequences of the binding of IL-8 and Gro-alpha to IL-8RB are distinct.	CHUL,CTR RECH RHUMATOL & IMMUNOL,CTR RECH,ST FOY,PQ G1V 4G2,CANADA; UNIV LAVAL,FAC MED,DEPT MED,ST FOY,PQ G1V 4G2,CANADA; UNIV ADELAIDE,DEPT MICROBIOL & IMMUNOL,ADELAIDE,SA 5001,AUSTRALIA; PFIZER INC,DIV CENT RES,GROTON,CT 06340; GENENTECH INC,DEPT IMMUNOL,S SAN FRANCISCO,CA 94080	Laval University; Laval University; University of Adelaide; Pfizer; Roche Holding; Genentech								Ahuja SK, 1996, J BIOL CHEM, V271, P225, DOI 10.1074/jbc.271.1.225; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; BAGGIOLINI M, 1993, CLIN INVESTIGATOR, V71, P812; BARNETT ML, 1993, BIOCHIM BIOPHYS ACTA, V1177, P275, DOI 10.1016/0167-4889(93)90123-7; BIGNOLD LP, 1992, INT ARCH ALLERGY IMM, V97, P350, DOI 10.1159/000236144; BOOTMAN MD, 1995, CELL, V83, P675, DOI 10.1016/0092-8674(95)90179-5; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P23128; Damaj BB, 1996, J BIOL CHEM, V271, P12783, DOI 10.1074/jbc.271.22.12783; FAUCHER N, 1987, J CELL PHYSIOL, V132, P483, DOI 10.1002/jcp.1041320310; GEISER T, 1993, J BIOL CHEM, V268, P15419; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HEBERT CA, 1993, CANCER INVEST, V11, P743, DOI 10.3109/07357909309046949; HEBERT CA, 1993, J BIOL CHEM, V268, P18549; HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701; KELVIN DJ, 1993, J LEUKOCYTE BIOL, V54, P604, DOI 10.1002/jlb.54.6.604; LEE J, 1992, J BIOL CHEM, V267, P16283; LEONG SR, 1994, J BIOL CHEM, V269, P19343; LHEUREUX G, 1994, BLOOD, V85, P522; LOETSCHER P, 1994, FEBS LETT, V341, P187, DOI 10.1016/0014-5793(94)80454-0; MERRITT JE, 1989, J BIOL CHEM, V264, P1522; MICHEL G, 1992, FEBS LETT, V305, P241, DOI 10.1016/0014-5793(92)80677-9; MOLSKI TFP, 1983, CELL CALCIUM, V4, P57, DOI 10.1016/0143-4160(83)90049-0; MURPHY PM, 1991, SCIENCE, V253, P1280, DOI 10.1126/science.1891716; PETERSEN F, 1994, J IMMUNOL, V152, P2467; PIEPER SC, 1996, CHEMOATTRACTANT LIGA; RICHMOND A, 1988, J CELL BIOCHEM, V36, P185, DOI 10.1002/jcb.240360209; STRIETER RM, 1994, J LAB CLIN MED, V123, P183; TSIEN RY, 1982, J CELL BIOL, V94, P3325; UNEMORI EN, 1993, J BIOL CHEM, V268, P1338; WU DQ, 1993, SCIENCE, V261, P101, DOI 10.1126/science.8316840	30	52	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20540	20544		10.1074/jbc.271.34.20540	http://dx.doi.org/10.1074/jbc.271.34.20540			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702797	hybrid			2022-12-25	WOS:A1996VD33700049
J	Hisano, T; Hata, Y; Fujii, T; Liu, JQ; Kurihara, T; Esaki, N; Soda, K				Hisano, T; Hata, Y; Fujii, T; Liu, JQ; Kurihara, T; Esaki, N; Soda, K			Crystal structure of L-2-haloacid dehalogenase from Pseudomonas sp YL - An alpha/beta hydrolase structure that is different from the alpha/beta hydrolase fold	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SP STRAIN-YL; ACID DEHALOGENASE; HALOALKANE DEHALOGENASE; REACTION-MECHANISM; SERINE CARBOXYPEPTIDASE; TRIACYLGLYCEROL LIPASE; TRIAD FORMS; PURIFICATION; PROTEINS; RESOLUTION	L-2-Haloacid dehalogenase catalyzes the hydrolytic dehalogenation of L-2-haloalkanoic acids to yield the corresponding D-2-hydroxyalkanoic acids. The crystal structure of the homodimeric enzyme from Pseudomonas sp. YL has been determined by a multiple isomorphous replacement method and refined at 2.5 Angstrom resolution to a crystallographic R-factor of 19.5%. The subunit consists of two structurally distinct domains: the core domain and the subdomain. The core domain has an alpha/beta structure formed by a six-stranded parallel beta-sheet flanked by five alpha-helices. The subdomain inserted into the core domain has a four helix bundle structure providing the greater part of the interface for dimer formation. There is an active site cavity between the domains. An experimentally identified nucleophilic residue, Asp-10, is located on a loop following the amino-terminal beta-strand in the core domain, and other functional residues, Thr-14, Arg-41, Ser-118, Lys-151, Tyr-157, Ser-175, Asn-177, and Asp-180, detected by a site-directed mutagenesis experiment, are arranged around the nucleophile in the active site. Although the enzyme is an alpha/beta-type hydrolase, it does not belong to the alpha/beta hydrolase fold family, from the viewpoint of the topological feature and the position of the nucleophile.	KYOTO UNIV,INST CHEM RES,UJI,KYOTO 611,JAPAN	Kyoto University								BRADY L, 1990, NATURE, V343, P767, DOI 10.1038/343767a0; BRANDEN CI, 1980, Q REV BIOPHYS, V13, P317, DOI 10.1017/S0033583500001712; BRUNGER AT, 1992, XPLOR MANUAL VERSION; DEREWENDA U, 1992, BIOCHEMISTRY-US, V31, P1532, DOI 10.1021/bi00120a034; DEREWENDA U, 1994, NAT STRUCT BIOL, V1, P36, DOI 10.1038/nsb0194-36; EKLUND H, 1976, J MOL BIOL, V102, P27, DOI 10.1016/0022-2836(76)90072-3; ENDRIZZI JA, 1994, BIOCHEMISTRY-US, V33, P11106, DOI 10.1021/bi00203a007; FRANKEN SM, 1991, EMBO J, V10, P1297, DOI 10.1002/j.1460-2075.1991.tb07647.x; FUREY W, 1990, AM CRYSTALLOGR ASS 2, V18, P73; GROCHULSKI P, 1993, J BIOL CHEM, V268, P12843; HASAN AKMQ, 1994, BIOSCI BIOTECH BIOCH, V58, P1599, DOI 10.1271/bbb.58.1599; Hisano T, 1996, PROTEINS, V24, P520, DOI 10.1002/(SICI)1097-0134(199604)24:4<520::AID-PROT12>3.0.CO;2-N; JANIN J, 1988, J MOL BIOL, V204, P155, DOI 10.1016/0022-2836(88)90606-7; JONES TA, 1985, METHOD ENZYMOL, V115, P157; KAWASAKI H, 1981, AGR BIOL CHEM TOKYO, V45, P35, DOI 10.1080/00021369.1981.10864494; KLAGES U, 1983, H-S Z PHYSIOL CHEM, V364, P529, DOI 10.1515/bchm2.1983.364.1.529; KOONIN EV, 1994, J MOL BIOL, V244, P125, DOI 10.1006/jmbi.1994.1711; KURIHARA T, 1995, J BIOCHEM, V117, P1317, DOI 10.1093/oxfordjournals.jbchem.a124861; LAWSON DM, 1994, BIOCHEMISTRY-US, V33, P9382, DOI 10.1021/bi00198a003; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LIAO DI, 1992, BIOCHEMISTRY-US, V31, P9796, DOI 10.1021/bi00155a037; LIU JQ, 1995, J BIOL CHEM, V270, P18309, DOI 10.1074/jbc.270.31.18309; LIU JQ, 1994, APPL ENVIRON MICROB, V60, P2389, DOI 10.1128/AEM.60.7.2389-2393.1994; LIU JQ, 1995, BIODEGRADATION, V6, P223, DOI 10.1007/BF00700461; LIU JQ, 1994, J BIOCHEM-TOKYO, V116, P248, DOI 10.1093/oxfordjournals.jbchem.a124514; LUZZATI V, 1953, ACTA CRYSTALLOGR, V6, P142, DOI 10.1107/S0365110X53000508; MARTINEZ C, 1992, NATURE, V356, P615, DOI 10.1038/356615a0; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; MILLER S, 1987, J MOL BIOL, V196, P641, DOI 10.1016/0022-2836(87)90038-6; MOTOSUGI K, 1982, J BACTERIOL, V150, P522, DOI 10.1128/JB.150.2.522-527.1982; MOTOSUGI K, 1982, AGR BIOL CHEM TOKYO, V46, P837, DOI 10.1080/00021369.1982.10865158; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; NARDIDEI V, 1994, APPL ENVIRON MICROB, V60, P3375, DOI 10.1128/AEM.60.9.3375-3380.1994; NOBLE MEM, 1993, FEBS LETT, V331, P123, DOI 10.1016/0014-5793(93)80310-Q; OLLIS DL, 1992, PROTEIN ENG, V5, P197, DOI 10.1093/protein/5.3.197; PATHAK D, 1990, J MOL BIOL, V214, P497, DOI 10.1016/0022-2836(90)90196-S; Ramachandran G N, 1968, Adv Protein Chem, V23, P283, DOI 10.1016/S0065-3233(08)60402-7; REID KSC, 1985, FEBS LETT, V190, P209, DOI 10.1016/0014-5793(85)81285-0; ROMAO MJ, 1992, J MOL BIOL, V226, P1111, DOI 10.1016/0022-2836(92)91056-U; SCHRAG JD, 1991, NATURE, V351, P761, DOI 10.1038/351761a0; SMITH JM, 1990, J GEN MICROBIOL, V136, P881, DOI 10.1099/00221287-136-5-881; SUSSMAN JL, 1991, SCIENCE, V253, P872, DOI 10.1126/science.1678899; THOMAS KA, 1982, P NATL ACAD SCI-BIOL, V79, P4843, DOI 10.1073/pnas.79.16.4843; VANDERPLOEG J, 1991, J BACTERIOL, V173, P7925, DOI 10.1128/jb.173.24.7925-7933.1991; VERSCHUEREN KHG, 1993, J MOL BIOL, V232, P856, DOI 10.1006/jmbi.1993.1436; VERSCHUEREN KHG, 1993, NATURE, V363, P693, DOI 10.1038/363693a0; WEIGHTMAN AJ, 1982, J GEN MICROBIOL, V128, P1755; WINKLER FK, 1990, NATURE, V343, P771, DOI 10.1038/343771a0	48	129	132	2	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20322	20330		10.1074/jbc.271.34.20322	http://dx.doi.org/10.1074/jbc.271.34.20322			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702766	hybrid			2022-12-25	WOS:A1996VD33700018
J	Johnson, NP; Mazarguil, H; Lopez, A				Johnson, NP; Mazarguil, H; Lopez, A			Strandedness discrimination in peptide-polynucleotide complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI RECA PROTEIN; DNA-BINDING; NUCLEIC-ACIDS; RECOMBINATION; TRYPTOPHAN; OLIGOLYSINES; BACTERIOPHAGE-T4; THERMODYNAMICS; DOMAIN; YEAST	Preferential binding to single- or double-stranded nucleic acids is important for the activity of many proteins that process RNA and DNA. We have investigated the mechanism of strandedness discrimination with peptides derived from the putative DNA-binding domain of the RecA protein, a bacterial recombinase that modulates its affinity for single-stranded DNA by means of ATP binding and hydrolysis. Contributions of electrostatic and non-electrostatic interactions to binding of these peptides with polynucleotides were evaluated by fluorescence spectroscopy as a function of salt concentration and peptide charge. Binding of these peptides to single- and double-stranded nucleic acids was dominated by non-electrostatic interactions. Small electrostatic contributions selectively enhanced peptide complexation with single-stranded nucleic acids. Similar results were observed in control experiments carried out with tripeptides containing charged and aromatic amino acid residues, It was possible to modify the strandedness preference of peptide-polynucleotide complexes by changing electrostatic contributions to the binding free energy. These observations suggest a mechanism whereby some proteins that interact with DNA or RNA might determine and regulate their relative affinity for single- and double-stranded nucleic acids.			Johnson, NP (corresponding author), CNRS,INST PHARMACOL & BIOL STRUCT,205 ROUTE NARBONNE,F-31077 TOULOUSE,FRANCE.							BRUN F, 1975, BIOCHEMISTRY-US, V14, P558, DOI 10.1021/bi00674a015; CASASFINET JR, 1992, P NATL ACAD SCI USA, V89, P1050, DOI 10.1073/pnas.89.3.1050; CAZAUX C, 1991, BIOCHIMIE, V73, P281, DOI 10.1016/0300-9084(91)90214-L; CAZAUX C, 1994, J BIOL CHEM, V269, P8246; CAZAUX C, 1992, J MOL BIOL, V223, P823, DOI 10.1016/0022-2836(92)90243-D; CHASE JW, 1986, ANNU REV BIOCHEM, V55, P103, DOI 10.1146/annurev.biochem.55.1.103; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; GARDNER RV, 1995, EUR J BIOCHEM, V233, P419, DOI 10.1111/j.1432-1033.1995.419_2.x; Kornberg A., 1992, DNA REPLICATION; KOWALCZYKOWSKI SC, 1986, BIOCHEMISTRY-US, V25, P1226, DOI 10.1021/bi00354a006; KOWALCZYKOWSKI SC, 1991, ANNU REV BIOPHYS BIO, V20, P539, DOI 10.1146/annurev.bb.20.060191.002543; Lakowicz J.R., 2010, PRINCIPLE FLUORESCEN, DOI 10.1007/978-0-387-46312-4/COVER; LATT SA, 1967, BIOCHEMISTRY-US, V6, P3293, DOI 10.1021/bi00862a040; LOHMAN TM, 1994, ANNU REV BIOCHEM, V63, P527, DOI 10.1146/annurev.biochem.63.1.527; LOHMAN TM, 1991, METHOD ENZYMOL, V208, P258; MASCOTTI DP, 1990, P NATL ACAD SCI USA, V87, P3142, DOI 10.1073/pnas.87.8.3142; MASCOTTI DP, 1993, BIOCHEMISTRY-US, V32, P10568, DOI 10.1021/bi00091a006; MASCOTTI DP, 1992, BIOCHEMISTRY-US, V31, P8932, DOI 10.1021/bi00152a033; MCGEE JD, 1974, J MOL BIOL, V86, P469; MENETSKI JP, 1990, J MOL BIOL, V211, P845, DOI 10.1016/0022-2836(90)90078-Z; MORAND P, 1977, J BACTERIOL, V131, P572, DOI 10.1128/JB.131.2.572-582.1977; RAJESWARI MR, 1987, BIOCHEMISTRY-US, V26, P6825, DOI 10.1021/bi00395a036; RECORD MT, 1976, J MOL BIOL, V107, P145, DOI 10.1016/S0022-2836(76)80023-X; SHINOHARA A, 1993, NAT GENET, V4, P239, DOI 10.1038/ng0793-239; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; SKINNER MM, 1994, P NATL ACAD SCI USA, V91, P2071, DOI 10.1073/pnas.91.6.2071; STORY RM, 1993, SCIENCE, V259, P1892, DOI 10.1126/science.8456313; STORY RM, 1992, NATURE, V355, P318, DOI 10.1038/355318a0; TOULME JJ, 1974, P NATL ACAD SCI USA, V71, P3185, DOI 10.1073/pnas.71.8.3185; WONG I, 1992, SCIENCE, V256, P350, DOI 10.1126/science.256.5055.350	30	7	7	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					19675	19679		10.1074/jbc.271.33.19675	http://dx.doi.org/10.1074/jbc.271.33.19675			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702670	hybrid			2022-12-25	WOS:A1996VC66900011
J	Keck, JL; Marqusee, S				Keck, JL; Marqusee, S			The putative substrate recognition loop of Escherichia coli ribonuclease H is not essential for activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIV-1 REVERSE-TRANSCRIPTASE; AMINO-ACID-RESIDUES; DOMAIN; MUTAGENESIS; SITE	The RNase H family of enzymes catalyzes the hydrolysis of RNA from RNA . DNA hybrids in a divalent metal-dependent fashion. To date, structure/function studies have focused on two members of this family: Escherichia coli RNase HI, a small monomeric protein; and human immunodeficiency virus, type I (HIV) RNase H, a domain of HIV reverse transcriptase. The isolated RNase H domain from HIV reverse transcriptase can be expressed independently and shares significant structural homology with its E. coli homologue; however, unlike the bacterial protein, it is inactive. The most notable difference between the inactive domain from HIV and the active E. coli protein is a basic helix/loop sequence, present in E. coli but absent from the HIV homologue. Substitution of this basic region into the HIV domain partially restores its activity and increases its thermodynamic stability, By deleting the basic helix/loop region, we have modeled the structural difference between these two polypeptides onto the E. coli homologue. Surprisingly, the resulting mutant protein is active in Mn2+-dependent fashion. Therefore, the basic helix/loop is not required for RNase H activity.	UNIV CALIF BERKELEY,DIV BIOCHEM & MOL BIOL,BERKELEY,CA 94720	University of California System; University of California Berkeley				Keck, James/0000-0002-5961-0220				BERKOWER I, 1973, J BIOL CHEM, V248, P5914; Blain SW, 1996, J BIOL CHEM, V271, P1448, DOI 10.1074/jbc.271.3.1448; Cantor C.R., 1980, BIOPHYS CHEM; CIRINO NM, 1995, BIOCHEMISTRY-US, V34, P9936, DOI 10.1021/bi00031a016; DABORA JM, 1994, PROTEIN SCI, V3, P1401, DOI 10.1002/pro.5560030906; DAVIES JF, 1991, SCIENCE, V252, P88, DOI 10.1126/science.1707186; EVANS DB, 1991, J BIOL CHEM, V266, P20583; HARUKI M, 1994, EUR J BIOCHEM, V220, P623, DOI 10.1111/j.1432-1033.1994.tb18664.x; HARUKI M, 1994, J BIOL CHEM, V269, P26904; Hostomsky Z., 1993, NUCLEASES, V2nd, P341; JOHNSON MS, 1986, P NATL ACAD SCI USA, V83, P7648, DOI 10.1073/pnas.83.20.7648; KANAYA E, 1995, J BIOL CHEM, V270, P19853, DOI 10.1074/jbc.270.34.19853; KANAYA S, 1990, J BIOL CHEM, V265, P4615; KANAYA S, 1991, J BIOL CHEM, V266, P11621; KANE CM, 1988, BIOCHEMISTRY-US, V27, P3187, DOI 10.1021/bi00409a010; KATAYANAGI K, 1990, NATURE, V347, P306, DOI 10.1038/347306a0; KECH JL, 1995, P NATL ACAD SCI USA, V29, P2740; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; ODA Y, 1993, J BIOL CHEM, V268, P88; POWERS R, 1991, J MOL BIOL, V221, P1081, DOI 10.1016/0022-2836(91)80113-9; POWERS R, 1992, BIOCHEMISTRY-US, V31, P9150, DOI 10.1021/bi00153a006; Sambrook J., 2002, MOL CLONING LAB MANU; SANTORO MM, 1988, BIOCHEMISTRY-US, V27, P8063, DOI 10.1021/bi00421a014; SCHATZ O, 1989, FEBS LETT, V257, P311, DOI 10.1016/0014-5793(89)81559-5; SKALKA A, 1993, REVERSE TRANSCRIPTAS; SMITH JS, 1993, J VIROL, V67, P4037, DOI 10.1128/JVI.67.7.4037-4049.1993; STAHL SJ, 1994, PROTEIN ENG, V7, P1103, DOI 10.1093/protein/7.9.1103; YANG W, 1990, SCIENCE, V249, P1398, DOI 10.1126/science.2169648; ZHAN XY, 1994, BIOCHEMISTRY-US, V33, P1366, DOI 10.1021/bi00172a012	29	31	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					19883	19887		10.1074/jbc.271.33.19883	http://dx.doi.org/10.1074/jbc.271.33.19883			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702700	hybrid			2022-12-25	WOS:A1996VC66900041
J	Martinez, A; Haavik, J; Flatmark, T; Arrondo, JLR; Muga, A				Martinez, A; Haavik, J; Flatmark, T; Arrondo, JLR; Muga, A			Conformational properties and stability of tyrosine hydroxylase studied by infrared spectroscopy - Effect of iron/catecholamine binding and phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THERMAL-DENATURATION; PROTEIN-KINASE; CLONED ENZYME; CHOLERA-TOXIN; METAL-IONS; PURIFICATION; 3-MONOOXYGENASE; EXPRESSION; ISOZYMES; RECEPTOR	The conformation and stability of recombinant tetrameric human tyrosine hydroxylase isoenzyme 1 (hTH1) was studied by infrared spectroscopy and by limited tryptic proteolysis, Its secondary structure was estimated to be 42% alpha-helix, 35% beta-extended structures (including beta-sheet), 14% beta-turns, and 10% nonstructured conformations. Addition of Fe(II) or Fe(II) plus dopamine to the apoenzyme did not significantly modify its secondary structure. However, an increased thermal stability and resistance to proteolysis, as well as a decreased cooperativity in the thermal denaturation transition, was observed for the ligand-bound forms. Thus, as compared with the apoenzyme, the ligand-bound subunits of hTH1 showed a more compact tertiary structure but weaker intersubunit contacts within the protein tetramer. Phosphorylation of the apoenzyme by cyclic AMP-dependent protein kinase did not change its overall conformation but allowed on iron binding a conformational change characterized by an increase (about 10%) in alpha-helix and protein stability. Our results suggest that the conformational events involved in TH inhibition by catecholamines are mainly related to modifications of tertiary and quaternary structural features. However, the combined effect of iron binding and phosphorylation. which activates the enzyme, also involves modifications of the protein secondary structure.	UNIV BASQUE COUNTRY, FAC SCI, DEPT BIOCHEM & MOL BIOL, E-48080 BILBAO, SPAIN; UNIV BERGEN, DEPT BIOCHEM & MOL BIOL, N-5009 BERGEN, NORWAY	University of Basque Country; University of Bergen			Haavik, Jan/AAI-3974-2020; Muga, Arturo/N-1174-2014; Haavik, Jan/ABE-1535-2020; Martinez, Aurora/M-3088-2019	Haavik, Jan/0000-0001-7865-2808; Muga, Arturo/0000-0003-0345-6882; Martinez, Aurora/0000-0003-1643-6506				ABATE C, 1988, BIOCHEM BIOPH RES CO, V151, P1446, DOI 10.1016/S0006-291X(88)80524-2; ALMAS B, 1992, EUR J BIOCHEM, V209, P249, DOI 10.1111/j.1432-1033.1992.tb17283.x; ANDERSSON KK, 1992, BIOCHEM J, V284, P687, DOI 10.1042/bj2840687; ANDERSSON KK, 1988, J BIOL CHEM, V263, P18621; ARRONDO JLR, 1994, BIOCHEMISTRY-US, V33, P11650, DOI 10.1021/bi00204a029; ARRONDO JLR, 1993, PROG BIOPHYS MOL BIO, V59, P23, DOI 10.1016/0079-6107(93)90006-6; ARRONDO JLR, 1988, BIOCHIM BIOPHYS ACTA, V952, P261, DOI 10.1016/0167-4838(88)90125-2; BANUELOS S, 1995, J BIOL CHEM, V270, P29910, DOI 10.1074/jbc.270.50.29910; ECHABE I, 1995, BIOCHEMISTRY-US, V34, P13565, DOI 10.1021/bi00041a036; FITZPATRICK PF, 1990, J BIOL CHEM, V265, P2042; FUJISAWA H, 1987, AMINO ACIDS HLTH DIS, P245; GAHN LG, 1995, BIOCHEMISTRY-US, V34, P252, DOI 10.1021/bi00001a030; GRIMA B, 1987, NATURE, V326, P707, DOI 10.1038/326707a0; HAAVIK J, 1988, BIOCHIM BIOPHYS ACTA, V953, P142, DOI 10.1016/0167-4838(88)90019-2; HAAVIK J, 1990, FEBS LETT, V262, P363, DOI 10.1016/0014-5793(90)80230-G; HAAVIK J, 1992, EUR J BIOCHEM, V210, P23, DOI 10.1111/j.1432-1033.1992.tb17386.x; HAAVIK J, 1991, EUR J BIOCHEM, V199, P371, DOI 10.1111/j.1432-1033.1991.tb16133.x; HADDEN JM, 1994, BBA-PROTEIN STRUCT M, V1205, P59, DOI 10.1016/0167-4838(94)90092-2; HUFTON SE, 1995, BIOCHEM J, V311, P353, DOI 10.1042/bj3110353; KAUFMAN S, 1985, FOLATES PTERINS, V2, P251; KRIMM S, 1986, ADV PROTEIN CHEM, V38, P181, DOI 10.1016/S0065-3233(08)60528-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAZAR MA, 1981, J NEUROCHEM, V36, P677, DOI 10.1111/j.1471-4159.1981.tb01641.x; LEBOURDELLES B, 1988, J NEUROCHEM, V50, P988; LEBOURDELLES B, 1991, J BIOL CHEM, V266, P17124; MANN SP, 1979, J NEUROCHEM, V33, P133, DOI 10.1111/j.1471-4159.1979.tb11715.x; MUGA A, 1993, ARCH BIOCHEM BIOPHYS, V300, P451, DOI 10.1006/abbi.1993.1061; PULLEN K, 1995, PROTEIN SCI, V4, P2478, DOI 10.1002/pro.5560041204; REIMANN EM, 1983, METHOD ENZYMOL, V99, P51; REINHARD JF, 1986, LIFE SCI, V39, P2185, DOI 10.1016/0024-3205(86)90395-4; ROSKOSKI R, 1983, METHOD ENZYMOL, V99, P3; SCHON A, 1989, BIOCHEMISTRY-US, V28, P5019, DOI 10.1021/bi00438a017; SPRANG SR, 1988, NATURE, V336, P215, DOI 10.1038/336215a0; SUREWICZ WK, 1990, BIOCHEMISTRY-US, V29, P8106, DOI 10.1021/bi00487a017; WANG YH, 1991, P NATL ACAD SCI USA, V88, P8779, DOI 10.1073/pnas.88.19.8779	35	72	72	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					19737	19742		10.1074/jbc.271.33.19737	http://dx.doi.org/10.1074/jbc.271.33.19737			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702679	hybrid			2022-12-25	WOS:A1996VC66900020
J	Beck, CA; Zhang, YX; Altmann, M; Weigel, NL; Edwards, DP				Beck, CA; Zhang, YX; Altmann, M; Weigel, NL; Edwards, DP			Stoichiometry and site-specific phosphorylation of human progesterone receptor in native target cells and in the baculovirus expression system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ESTROGEN-RECEPTOR; ACTIVATED PROTEIN-KINASE; HUMAN ANDROGEN RECEPTOR; DNA-BINDING; GLUCOCORTICOID RECEPTOR; BREAST-CANCER; A-FORM; 1,25-DIHYDROXYVITAMIN-D3 RECEPTOR; TRANSCRIPTIONAL ACTIVATION; DEPENDENT PHOSPHORYLATION	Human progesterone receptor (PR) in T47D breast cancer cells is phosphorylated on nine different serine residues; three are hormone-inducible (Ser(102), Ser(294), and Ser(345)), while others are basal but hormone-stimulated. In the present, study, we have compared the phosphorylation state of native and recombinant PR expressed in a baculovirus insect cell system, Stoichiometric measurements showed that unliganded native PR in T47D cells was approximately 50% phosphorylated (approximate to 4 phosphates/PR) and became essentially 100% phosphorylated (approximate to 9 phosphates/PR) when bound to hormone. Unliganded PR expressed in Sf9 insect cells was phosphorylated with a similar stoichiometry (approximate to 3 phosphates/PR), but the phosphate content did not change with hormone addition. Site-specific phosphorylation analyzed by tryptic phosphopeptide mapping and manual peptide sequencing revealed that expressed PR bound to hormone in the Sf9 insect cells was phosphorylated on all the same sites as hormone-treated PR in T47D cells. Only minor differences were detected in the relative proportion of three sites (two basal sites and Ser(345)) and phosphorylation did not occur on alternate sites, Interestingly unliganded baculovirus-expressed PR was constitutively phosphorylated on hormone inducible sites and was phosphorylated on basal sites to the same extent as hormone treated PR. Thus, in the absence of hormone, the phosphorylation state of baculovirus-expressed PR resembled that of the hyperphosphorylated native PR, In contrast to native PR, the expressed receptor in cytosols of Sf9 cells did not form a large oligomeric complex suggesting that hyperphosphorylation may be due to dissociation of the complex in the absence of hormone. This study demonstrating phosphorylation on correct sites with a stoichiometry similar to that of native PR indicates that overexpressed PR in the baculovirus system is suitable for in vitro structure/function studies.	UNIV COLORADO, HLTH SCI CTR, DEPT PATHOL, DENVER, CO 80262 USA; UNIV COLORADO, HLTH SCI CTR, PROGRAM MOL BIOL, DENVER, CO 80262 USA; BAYLOR COLL MED, DEPT CELL BIOL, HOUSTON, TX 77030 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Baylor College of Medicine				Zhang, Yixian/0000-0002-6429-3127	NATIONAL CANCER INSTITUTE [R01CA057539, P30CA046934, R55CA057539] Funding Source: NIH RePORTER; NCI NIH HHS [P30-CA46934, CA57539] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALI S, 1993, EMBO J, V12, P1153, DOI 10.1002/j.1460-2075.1993.tb05756.x; ALNEMRI ES, 1993, BIOCHEMISTRY-US, V32, P5387, DOI 10.1021/bi00071a014; ALNEMRI ES, 1991, J BIOL CHEM, V266, P3925; ARNOLD SF, 1995, J STEROID BIOCHEM, V55, P163, DOI 10.1016/0960-0760(95)00177-2; ARNOLD SF, 1994, MOL ENDOCRINOL, V8, P1208, DOI 10.1210/me.8.9.1208; BAI WL, 1994, MOL ENDOCRINOL, V8, P1465, DOI 10.1210/me.8.11.1465; BECK CA, 1993, ENDOCRINOLOGY, V133, P728, DOI 10.1210/en.133.2.728; Beck CA, 1996, J BIOL CHEM, V271, P1209, DOI 10.1074/jbc.271.2.1209; BECK CA, 1992, MOL ENDOCRINOL, V6, P607, DOI 10.1210/me.6.4.607; BINART N, 1991, P NATL ACAD SCI USA, V88, P10681, DOI 10.1073/pnas.88.23.10681; BODWELL JE, 1991, J BIOL CHEM, V266, P7549; BROWN M, 1990, J BIOL CHEM, V265, P11238; CASHEL M, 1969, J CHROMATOGR, V40, P103, DOI 10.1016/S0021-9673(01)96624-5; CHANG CS, 1992, P NATL ACAD SCI USA, V89, P5946, DOI 10.1073/pnas.89.13.5946; CHRISTENSEN K, 1991, MOL ENDOCRINOL, V5, P1755, DOI 10.1210/mend-5-11-1755; DEMARZO AM, 1991, P NATL ACAD SCI USA, V88, P72, DOI 10.1073/pnas.88.1.72; EDWARDS DP, 1992, BIOCHEMISTRY-US, V31, P2482, DOI 10.1021/bi00124a007; ELASHRYSTOWERS D, 1988, CANCER RES, V48, P6462; ELLISTON JF, 1992, J BIOL CHEM, V267, P5193; ELLISTON JF, 1990, MOL CELL BIOL, V10, P6607, DOI 10.1128/MCB.10.12.6607; ESTES PA, 1987, BIOCHEMISTRY-US, V26, P6250, DOI 10.1021/bi00393a045; HILLIARD GM, 1994, BIOCHEMISTRY-US, V33, P4300, DOI 10.1021/bi00180a026; HORWITZ KB, 1992, ENDOCR REV, V13, P146, DOI 10.1210/er.13.2.146; JOHNSON JL, 1994, J BIOL CHEM, V269, P24989; JURUTKA PW, 1993, BIOCHEM BIOPH RES CO, V191, P1089, DOI 10.1006/bbrc.1993.1328; KALLIO PJ, 1993, ANN NY ACAD SCI, V684, P233, DOI 10.1111/j.1749-6632.1993.tb32295.x; KASTNER P, 1990, EMBO J, V9, P1603, DOI 10.1002/j.1460-2075.1990.tb08280.x; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; KUIPER GGJM, 1994, MOL CELL ENDOCRINOL, V100, P103, DOI 10.1016/0303-7207(94)90287-9; LEGOFF P, 1994, J BIOL CHEM, V269, P4458; MCDONNELL DP, 1994, J BIOL CHEM, V269, P11945; MCDONNELL DP, 1994, J STEROID BIOCHEM, V48, P425, DOI 10.1016/0960-0760(94)90190-2; OBOURN JD, 1993, BIOCHEMISTRY-US, V32, P6229, DOI 10.1021/bi00075a016; OFIATE SA, 1994, MOL CELL BIOL, V14, P3376; ONATE SA, 1991, MOL ENDOCRINOL, V5, P1993, DOI 10.1210/mend-5-12-1993; ORTI E, 1992, ENDOCR REV, V13, P105, DOI 10.1210/er.13.1.105; ORTI E, 1989, J BIOL CHEM, V264, P9728; ROSS TK, 1991, P NATL ACAD SCI USA, V88, P6555, DOI 10.1073/pnas.88.15.6555; SHERIDAN PL, 1989, J BIOL CHEM, V264, P6520; SMITH DF, 1993, MOL ENDOCRINOL, V7, P4, DOI 10.1210/me.7.1.4; SMITH DF, 1993, J BIOL CHEM, V268, P24270; SRINIVASAN G, 1990, MOL ENDOCRINOL, V4, P209, DOI 10.1210/mend-4-2-209; SRINIVASAN G, 1992, MOL ENDOCRINOL, V6, P857, DOI 10.1210/me.6.6.857; SULLIVAN S, 1991, ANAL BIOCHEM, V197, P65, DOI 10.1016/0003-2697(91)90356-X; TAKIMOTO GS, 1992, P NATL ACAD SCI USA, V89, P3050, DOI 10.1073/pnas.89.7.3050; TUNG L, 1993, MOL ENDOCRINOL, V7, P1256, DOI 10.1210/me.7.10.1256; VEGETO E, 1993, MOL ENDOCRINOL, V7, P1244, DOI 10.1210/me.7.10.1244; WEN DX, 1994, MOL CELL BIOL, V14, P8356, DOI 10.1128/MCB.14.12.8356; XIE YB, 1992, J BIOL CHEM, V267, P4939; ZHANG YX, 1994, J BIOL CHEM, V269, P31034; ZHANG YX, 1995, MOL ENDOCRINOL, V9, P1029, DOI 10.1210/me.9.8.1029; ZHOU ZX, 1995, MOL ENDOCRINOL, V9, P605, DOI 10.1210/me.9.5.605	52	25	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19546	19555		10.1074/jbc.271.32.19546	http://dx.doi.org/10.1074/jbc.271.32.19546			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702648	hybrid			2022-12-25	WOS:A1996VB68400082
J	Akbar, GKM; Dasari, VR; Webb, TE; Ayyanathan, K; Pillarisetti, K; Sandhu, AK; Athwal, RS; Daniel, JL; Ashby, B; Barnard, EA; Kunapuli, SP				Akbar, GKM; Dasari, VR; Webb, TE; Ayyanathan, K; Pillarisetti, K; Sandhu, AK; Athwal, RS; Daniel, JL; Ashby, B; Barnard, EA; Kunapuli, SP			Molecular cloning of a novel P2 purinoceptor from human erythroleukemia cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE RECEPTOR; ATP RECEPTOR; EXPRESSION; INCREASE; COUPLES	Screening of a human erythroleukemia cell cDNA library with radiolabeled chicken P2Y(3) cDNA at low stringency revealed a cDNA clone encoding a novel G protein-coupled receptor with homology to P2 purinoceptors, This receptor, designated P2Y(7), has 352 amino acids and shares 23-30% amino acid identity with the P2Y(1)-P2Y(6) purinoceptors. The P2Y(7) cDNA was transiently expressed in COS-7 cells: binding studies thereon showed a very high affinity for ATP (37 +/- 6 nM), much less for UTP and ADP (similar to 1300 nM), and a novel rank order of affinities in the binding series studied of 8 nucleotides and suramin, The P2Y(7) receptor sequence appears to denote a different subfamily from that of all the other known P2Y purinoceptors, with only a few of their characteristic sequence motifs shared, The P2Y(7) receptor mRNA is abundantly present in the human heart and the skeletal muscle, moderately in the brain and liver, but not in the other tissues tested, The P2Y(7) receptor mRNA was also abundantly present in the rat heart and cultured neonatal rat cardiomyocytes, The P2Y(7) receptor is functionally coupled to phospholipase C in COS-7 cells transiently expressing this receptor, The P2Y(7) gene was shown to be localized to human chromosome 14. We have thus cloned a unique member of the P2Y purinoceptor family which probably plays a role in the regulation of cardiac muscle contraction.	TEMPLE UNIV,SCH MED,DEPT PHYSIOL,PHILADELPHIA,PA 19140; TEMPLE UNIV,SCH MED,DEPT PHARMACOL,PHILADELPHIA,PA 19140; TEMPLE UNIV,SCH MED,SOL SHERRY THROMBOSIS RES CTR,PHILADELPHIA,PA 19140; TEMPLE UNIV,SCH MED,FELS INST CANC RES & MOL BIOL,PHILADELPHIA,PA 19140; ROYAL FREE HOSP,SCH MED,MOL NEUROBIOL UNIT,LONDON NW3 2PF,ENGLAND	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School			Webb, Tania/AAT-9554-2020	Dasari, Venkat/0000-0001-9795-6567				AKBAR GKM, 1995, FASEB J, V9, P684; Ayyanathan K, 1996, BIOCHEM BIOPH RES CO, V218, P783, DOI 10.1006/bbrc.1996.0139; Burnstock G., 1978, CELL MEMBRANE RECEPT, Vpp, P107; CHANG KG, 1995, J BIOL CHEM, V270, P26152, DOI 10.1074/jbc.270.44.26152; Communi D, 1995, J BIOL CHEM, V270, P30849, DOI 10.1074/jbc.270.52.30849; DASARI VR, 1996, SOMAT CELL MOLEC GEN, V21, P75; FILTZ TM, 1994, MOL PHARMACOL, V46, P8; FREDHOLM BB, 1994, PHARMACOL REV, V46, P143; HEILBRONN E, 1989, NEUROMUSCULAR JUNCTI, P395; HENDERSON DJ, 1995, BIOCHEM BIOPH RES CO, V212, P648, DOI 10.1006/bbrc.1995.2018; KOZAK M, 1992, ANNU REV CELL BIOL, V8, P197, DOI 10.1146/annurev.cb.08.110192.001213; KUNAPULI SP, 1994, BIOCHEM J, V298, P263, DOI 10.1042/bj2980263; LEGSSYER A, 1988, J PHYSIOL-LONDON, V401, P185, DOI 10.1113/jphysiol.1988.sp017157; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; LU Z, 1991, J PHYSIOL-LONDON, V436, P45, DOI 10.1113/jphysiol.1991.sp018538; LUSTIG KD, 1993, P NATL ACAD SCI USA, V90, P5113, DOI 10.1073/pnas.90.11.5113; MANTELLI L, 1993, BRIT J PHARMACOL, V109, P1268, DOI 10.1111/j.1476-5381.1993.tb13759.x; NAKAHATA N, 1987, BIOCHEM J, V241, P337, DOI 10.1042/bj2410337; Nguyen T, 1995, J BIOL CHEM, V270, P30845, DOI 10.1074/jbc.270.52.30845; PARR CE, 1994, P NATL ACAD SCI USA, V91, P3275, DOI 10.1073/pnas.91.8.3275; SCAMPS F, 1992, J GEN PHYSIOL, V100, P675, DOI 10.1085/jgp.100.4.675; SCAMPS F, 1994, BRIT J PHARMACOL, V113, P982, DOI 10.1111/j.1476-5381.1994.tb17089.x; Simon J, 1995, EUR J PHARM-MOLEC PH, V291, P281, DOI 10.1016/0922-4106(95)90068-3; WANG DS, 1993, CIRCULATION, V88, P431; Webb TE, 1996, BIOCHEM BIOPH RES CO, V219, P105, DOI 10.1006/bbrc.1996.0189; WEBB TE, 1993, FEBS LETT, V324, P219, DOI 10.1016/0014-5793(93)81397-I; WEBB TE, 1996, IN PRESS MOL PHARM; ZHENG JS, 1993, AM J PHYSIOL, V264, pC1411, DOI 10.1152/ajpcell.1993.264.6.C1411	28	106	116	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18363	18367		10.1074/jbc.271.31.18363	http://dx.doi.org/10.1074/jbc.271.31.18363			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702478	hybrid			2022-12-25	WOS:A1996VB68300016
J	Blazquez, M; Fominaya, JM; Hofsteenge, J				Blazquez, M; Fominaya, JM; Hofsteenge, J			Oxidation of sulfhydryl groups of ribonuclease inhibitor in epithelial cells is sufficient for its intracellular degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TIGHT-BINDING INHIBITION; LEUCINE-RICH REPEATS; AMINO-ACID SEQUENCE; KAPPA-B; EXTINCTION COEFFICIENTS; ANGIOGENIN INHIBITOR; TRANSCRIPTION FACTOR; PORCINE LIVER; PROTEIN; STRESS	Ribonuclease inhibitor (RI) is a cytoplasmic protein (50 kDa) that inhibits a variety of pancreatic type RNases. The porcine inhibitor contains 30 cysteine residues, all of which occur in the reduced state. It is well known that in vitro modification of the thiol groups inactivates the protein and greatly increases its susceptibility to proteolysis. Here we show that oxidation of thiol groups in RI can also occur within the cell. Induction of an oxidative insult in cultured LLC-PK1 cells, either with a general oxidant, H2O2, or with a thiol-specific oxidant, diamide, led to the loss of RI activity. By using specific antibodies it was demonstrated that the decrease correlated with a decline in the amount of RI protein in the cells. Furthermore, analysis of RI mRNA levels and half life of the protein excluded inhibition of the synthesis of RI as the cause of its depletion. The results indicate that oxidation of thiol groups in RI is sufficient to cause its rapid inactivation and disappearance from the cell. Most likely this results from intracellular degradation of the protein.	FRIEDRICH MIESCHER INST,CH-4002 BASEL,SWITZERLAND	Friedrich Miescher Institute for Biomedical Research								ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; AOKI Y, 1981, BIOCHEM J, V196, P699, DOI 10.1042/bj1960699; BEUTLER E, 1963, J LAB CLIN MED, V61, P882; BHUYAN DK, 1994, METHOD ENZYMOL, V233, P630; BLACKBURN P, 1977, J BIOL CHEM, V252, P5904; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUTTKE TM, 1994, IMMUNOL TODAY, V15, P7, DOI 10.1016/0167-5699(94)90018-3; CAVALLI L, 1979, OPHTHALMIC RES, V11, P416, DOI 10.1159/000265044; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAS DK, 1994, METHOD ENZYMOL, V233, P601; FOMINAYA JM, 1988, BIOCHEM J, V253, P517, DOI 10.1042/bj2530517; FOMINAYA JM, 1992, J BIOL CHEM, V267, P24655; FOMINAYA JM, 1988, BIOCHIM BIOPHYS ACTA, V954, P216, DOI 10.1016/0167-4838(88)90074-X; GILBERT HF, 1990, ADV ENZYMOL, V63, P169; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GIRIJA NS, 1966, BIOCHEM J, V98, P562, DOI 10.1042/bj0980562; GRIBNAU AAM, 1969, ARCH BIOCHEM BIOPHYS, V130, P48, DOI 10.1016/0003-9861(69)90007-1; Harlow E., 1988, ANTIBODIES LAB MANUA; HOFSTEENGE J, 1988, BIOCHEMISTRY-US, V27, P8537, DOI 10.1021/bi00423a006; HOFSTEENGE J, 1989, BIOCHEMISTRY-US, V28, P9806, DOI 10.1021/bi00451a040; HULL RN, 1976, IN VITRO CELL DEV B, V12, P670, DOI 10.1007/BF02797469; JAHNGENHODGE J, 1994, METHOD ENZYMOL, V233, P512; KAWANOMOTO M, 1992, BIOCHIM BIOPHYS ACTA, V1129, P335, DOI 10.1016/0167-4781(92)90513-Y; KOBE B, 1993, NATURE, V366, P751, DOI 10.1038/366751a0; KOSOWER NS, 1987, METHOD ENZYMOL, V143, P264; KOSOWER NS, 1995, METHOD ENZYMOL, V251, P123, DOI 10.1016/0076-6879(95)51116-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE FS, 1988, BIOCHEMISTRY-US, V27, P8545, DOI 10.1021/bi00423a007; LEE FS, 1989, BIOCHEMISTRY-US, V28, P225, DOI 10.1021/bi00427a031; LEE FS, 1993, PROG NUCLEIC ACID RE, V44, P1, DOI 10.1016/S0079-6603(08)60215-9; LEE FS, 1989, BIOCHEMISTRY-US, V28, P219, DOI 10.1021/bi00427a030; MACH H, 1992, ANAL BIOCHEM, V200, P74, DOI 10.1016/0003-2697(92)90279-G; McConkey David J., 1994, Trends in Cell Biology, V4, P370, DOI 10.1016/0962-8924(94)90087-6; MEISTER A, 1995, METHOD ENZYMOL, V252, P26; MEISTER A, 1994, CANCER RES, V54, pS1969; ORTWERTH BJ, 1971, EXP EYE RES, V12, P120, DOI 10.1016/0014-4835(71)90136-9; ORTWERTH BJ, 1972, EXP EYE RES, V14, P114, DOI 10.1016/0014-4835(72)90056-5; PACIFICI RE, 1990, METHOD ENZYMOL, V186, P485; ROTH JS, 1956, BIOCHIM BIOPHYS ACTA, V21, P34, DOI 10.1016/0006-3002(56)90091-9; ROTH JS, 1958, J BIOL CHEM, V231, P1085; SCHNEIDER R, 1988, EMBO J, V7, P4151, DOI 10.1002/j.1460-2075.1988.tb03310.x; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SHORTMAN K, 1962, BIOCHIM BIOPHYS ACTA, V55, P88; SPECTOR A, 1995, FASEB J, V9, P1173, DOI 10.1096/fasebj.9.12.7672510; STAAL FJT, 1990, P NATL ACAD SCI USA, V87, P9943, DOI 10.1073/pnas.87.24.9943; STADTMAN ER, 1992, SCIENCE, V257, P1220, DOI 10.1126/science.1355616; STADTMAN ER, 1995, METHOD ENZYMOL, V258, P379; STORRIE B, 1990, METHOD ENZYMOL, V182, P220; TOLEDANO MB, 1991, P NATL ACAD SCI USA, V88, P4328, DOI 10.1073/pnas.88.10.4328; VICENTINI AM, 1990, BIOCHEMISTRY-US, V29, P8827, DOI 10.1021/bi00489a046; ZIEGLER DM, 1985, ANNU REV BIOCHEM, V54, P305, DOI 10.1146/annurev.bi.54.070185.001513	51	53	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18638	18642		10.1074/jbc.271.31.18638	http://dx.doi.org/10.1074/jbc.271.31.18638			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702516	hybrid			2022-12-25	WOS:A1996VB68300054
J	Hernandez, VJ; Hsu, LM; Cashel, M				Hernandez, VJ; Hsu, LM; Cashel, M			Conserved region 3 of Escherichia coli sigma(70) is implicated in the process of abortive transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LAC UV5 PROMOTER; RNA-POLYMERASE; INITIATION; DNA; PURIFICATION; BINDING; SUBUNIT; COMPLEXES; INVITRO	Multiple-round in vitro transcription assays were performed using purified Escherichia coli RNA polymerase reconstituted with either wild-type or mutant sigma(70) proteins, These mutants, sigma(70)(P504L) and sigma(70)(S506F), bear single amino acid changes in conserved protein region 3, Behavior of the mutant enzymes on three test templates, bearing either the T7 Al, T5 N25, or T5 N25(antiDSR) promoter, were characterized, Transcription of all three promoter templates produced a pattern of specific abortive RNA species, which was qualitatively different for the mutants compared to the wild-type sigma(70) enzyme. Short abortive RNAs were produced at similar levels for mutant and wild-type enzymes, The production of longer abortive species was either reduced or increased by the mutant enzymes in a systematic manner that appears promoter specific, and could be RNA length- or promoter distance-dependent. The process of abortive RNA transcription is thought to be tightly associated with that of promoter clearance, However, promoter clearance from these templates appears only slightly affected by the mutant enzymes, These mutants implicated region 3 of sigma(70) in the process of abortive transcription and suggest that the sequence of enzymatic events leading to the production of abortive or full-length RNA may be separable.	MT HOLYOKE COLL, PROGRAM BIOCHEM, S HADLEY, MA 01075 USA	Mount Holyoke College	Hernandez, VJ (corresponding author), NICHHD, NIH,LMG,9000 ROCKVILLE PIKE,BLDG 6B, RM 316, BETHESDA, MD 20892 USA.							BORUKHOV S, 1993, CELL, V72, P459, DOI 10.1016/0092-8674(93)90121-6; CARPOUSIS AJ, 1985, J MOL BIOL, V183, P165, DOI 10.1016/0022-2836(85)90210-4; CARPOUSIS AJ, 1980, BIOCHEMISTRY-US, V19, P3245, DOI 10.1021/bi00555a023; CHAMBERLIN MJ, 1979, J BIOL CHEM, V254, P61; DOMBROSKI AJ, 1993, GENE DEV, V7, P2446, DOI 10.1101/gad.7.12a.2446; DOMBROSKI AJ, 1992, CELL, V70, P501, DOI 10.1016/0092-8674(92)90174-B; GILL SC, 1991, J MOL BIOL, V220, P307, DOI 10.1016/0022-2836(91)90015-X; GOODRICH JA, 1994, CELL, V77, P145, DOI 10.1016/0092-8674(94)90242-9; GRIBSKOV M, 1983, GENE, V26, P109, DOI 10.1016/0378-1119(83)90180-4; GROSS CA, 1992, TRANSCRIPTIONAL REGU, P129; HANSEN UM, 1980, J BIOL CHEM, V254, P5713; HERNANDEZ VJ, 1995, J MOL BIOL, V252, P536; JOHNSTON DE, 1976, RNA POLYM, P101; KAMMERER W, 1986, EMBO J, V5, P2995, DOI 10.1002/j.1460-2075.1986.tb04597.x; KRUMMEL B, 1989, BIOCHEMISTRY-US, V28, P7829, DOI 10.1021/bi00445a045; MCCLURE WR, 1985, ANNU REV BIOCHEM, V54, P171, DOI 10.1146/annurev.bi.54.070185.001131; MUNSON LM, 1981, BIOCHEMISTRY-US, V20, P2081, DOI 10.1021/bi00511a003; NGUYEN LH, 1993, PROTEIN EXPRES PURIF, V4, P425, DOI 10.1006/prep.1993.1056; Sambrook J., 2002, MOL CLONING LAB MANU; SEVERINOV K, 1994, J BIOL CHEM, V269, P20826; STEFANO JE, 1979, BIOCHEMISTRY-US, V18, P1063, DOI 10.1021/bi00573a020; STRANEY DC, 1987, J MOL BIOL, V193, P267, DOI 10.1016/0022-2836(87)90218-X; STRICKLAND MS, 1988, BIOCHEMISTRY-US, V27, P5755, DOI 10.1021/bi00415a054; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUH WC, 1993, SCIENCE, V259, P358, DOI 10.1126/science.8420002; SUMIMOTO H, 1991, NATURE, V354, P401, DOI 10.1038/354401a0; THOMPSON NE, 1992, BIOCHEMISTRY-US, V31, P7003, DOI 10.1021/bi00145a019	27	35	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18775	18779		10.1074/jbc.271.31.18775	http://dx.doi.org/10.1074/jbc.271.31.18775			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702534	hybrid			2022-12-25	WOS:A1996VB68300072
J	Marszalek, J; Zhang, WG; Hupp, TR; Margulies, C; Carr, KM; Cherry, S; Kaguni, JM				Marszalek, J; Zhang, WG; Hupp, TR; Margulies, C; Carr, KM; Cherry, S; Kaguni, JM			Domains of DnaA protein involved in interaction with DnaB protein, and in unwinding the Escherichia coli chromosomal origin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATP BINDING-SITE; P-LOOP MOTIF; RECA PROTEIN; REPLICATION ORIGIN; ADENYLATE KINASE; AMINO-ACIDS; INITIATION; RESOLUTION; ANTIBODY; COMPLEX	DnaA protein of Escherichia coli is a sequence-specific DNA-binding protein required for the initiation of DNA replication from the chromosomal origin, oriC, It is also required for replication of several plasmids including pSC101, F, P-1, and R6K. A collection of monoclonal antibodies to DnaA protein has been produced and the primary epitopes recognized by them have been determined, These antibodies have also been examined for the ability to inhibit activities of DNA binding, ATP binding, unwinding of oriC, and replication of both an oriC plasmid, and an M13 single-stranded DNA with a proposed hairpin structure containing a DnaA protein-binding site, Replication of the latter DNA is dependent on DnaA protein by a mechanism termed ABC priming, These studies suggest regions of DnaA protein involved in interaction with DnaB protein, and in unwinding of oriC, or low-affinity binding of ATP.	MICHIGAN STATE UNIV, DEPT BIOCHEM, E LANSING, MI 48824 USA; UNIV GDANSK, DEPT MOL BIOL, PL-80822 GDANSK, POLAND; UNIV DUNDEE, NINEWELLS MED SCH, DEPT PATHOL, DUNDEE DD1 4HN, SCOTLAND	Michigan State University; Fahrenheit Universities; University of Gdansk; University of Dundee			Marszalek, Jaroslaw/F-5824-2011	Marszalek, Jaroslaw/0000-0002-6978-1189; Kaguni, Jon/0000-0002-3096-4447	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033992] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM33992, R01 GM033992] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		APPEL JR, 1990, J IMMUNOL, V144, P976; BAKER TA, 1986, CELL, V45, P53, DOI 10.1016/0092-8674(86)90537-4; BRAMHILL D, 1988, CELL, V52, P743, DOI 10.1016/0092-8674(88)90412-6; COLMAN PM, 1987, NATURE, V326, P358, DOI 10.1038/326358a0; DREUSICKE D, 1988, J MOL BIOL, V199, P359, DOI 10.1016/0022-2836(88)90319-1; FLOWER AM, 1986, NUCLEIC ACIDS RES, V14, P8091, DOI 10.1093/nar/14.20.8091; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; FULLER RS, 1983, P NATL ACAD SCI-BIOL, V80, P5817, DOI 10.1073/pnas.80.19.5817; GARNER MM, 1981, BIOCHEMISTRY-US, V20, P306, DOI 10.1021/bi00505a012; GEYSEN HM, 1984, P NATL ACAD SCI-BIOL, V81, P3998, DOI 10.1073/pnas.81.13.3998; GINES CE, 1995, J BACTERIOL, V177, P705; HANSEN FG, 1992, MOL GEN GENET, V234, P14, DOI 10.1007/BF00272340; Harlow E., 1988, ANTIBODIES LAB MANUA; HIROTA Y, 1968, COLD SPRING HARB SYM, V33, P677, DOI 10.1101/SQB.1968.033.01.077; HODGESGARCIA Y, 1989, J BIOL CHEM, V264, P14621; HOUGHTEN RA, 1985, P NATL ACAD SCI USA, V82, P5131, DOI 10.1073/pnas.82.15.5131; HUPP TR, 1993, J BIOL CHEM, V268, P13128; HWANG DS, 1988, J BIOL CHEM, V263, P10633; HWANG DS, 1992, J BIOL CHEM, V267, P23088; JURNAK F, 1985, SCIENCE, V230, P32, DOI 10.1126/science.3898365; KODAIRA M, 1983, MOL GEN GENET, V192, P80, DOI 10.1007/BF00327650; KOHIYAMA M, 1968, COLD SPRING HARB SYM, V33, P317, DOI 10.1101/SQB.1968.033.01.036; KONOLA JT, 1994, J MOL BIOL, V237, P20, DOI 10.1006/jmbi.1994.1206; LOGAN KM, 1993, J MOL BIOL, V232, P1048, DOI 10.1006/jmbi.1993.1459; MARSZALEK J, 1994, J BIOL CHEM, V269, P4883; MASAI H, 1990, J BIOL CHEM, V265, P15134; MESSER W, 1996, ESCHERICHIA COLI SAL, V2; MULLER CW, 1992, J MOL BIOL, V224, P159, DOI 10.1016/0022-2836(92)90582-5; MULLIN DA, 1983, MOL GEN GENET, V192, P73, DOI 10.1007/BF00327649; OKA A, 1980, MOL GEN GENET, V178, P9, DOI 10.1007/BF00267207; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; PINILLA C, 1993, MOL IMMUNOL, V30, P577, DOI 10.1016/0161-5890(93)90032-7; ROTH A, 1995, EMBO J, V14, P2106, DOI 10.1002/j.1460-2075.1995.tb07202.x; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SEKIMIZU K, 1987, CELL, V50, P259, DOI 10.1016/0092-8674(87)90221-2; SMITH AD, 1992, ARCH BIOCHEM BIOPHYS, V292, P165, DOI 10.1016/0003-9861(92)90065-5; STANFIELD RL, 1990, SCIENCE, V248, P712, DOI 10.1126/science.2333521; STENZEL TT, 1987, CELL, V49, P709, DOI 10.1016/0092-8674(87)90547-2; STEPHEN CW, 1995, J MOL BIOL, V248, P58, DOI 10.1006/jmbi.1995.0202; STORY RM, 1992, NATURE, V355, P374, DOI 10.1038/355374a0; TOUGU K, 1994, J BIOL CHEM, V269, P4675; WALKER JR, 1982, P NATL ACAD SCI-BIOL, V79, P3340, DOI 10.1073/pnas.79.10.3340; YUNG BYM, 1988, P NATL ACAD SCI USA, V85, P7202, DOI 10.1073/pnas.85.19.7202; YUNG BYM, 1989, J BIOL CHEM, V264, P6146	44	59	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18535	18542		10.1074/jbc.271.31.18535	http://dx.doi.org/10.1074/jbc.271.31.18535			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702501	hybrid			2022-12-25	WOS:A1996VB68300039
J	Phelps, RG; Turner, AN; Rees, AJ				Phelps, RG; Turner, AN; Rees, AJ			Direct identification of naturally processed autoantigen-derived peptides bound to HLA-DR15	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLASS-II MOLECULES; ALPHA-3 CHAIN; IV COLLAGEN; HLA-DR; GOODPASTURE ANTIGEN; MHC; IMMUNODOMINANT; DETERMINANTS; RECOGNITION; TOLERANCE	Biochemical analysis of HLA class II-associated peptides from antigen pulsed cells is a potentially useful approach to the analysis of antigen processing and presentation because it examines directly which antigen-derived peptides are presented. This is especially advantageous in the analysis of self-antigen presentation where conventional approaches utilizing antigen-specific T cells may be biased by the presence of self-tolerance, However, successful biochemical analysis has been reported for only one exogenous antigen and no autoantigens. We have used a novel analytical approach coupling biochemical data with the reported properties of class II-associated peptides to characterize the peptides derived from a clinically relevant autoantigen presented on the disease-associated class II type. Incubating the target of autoimmune attack in patients with Goodpasture's disease, the 230-amino acid NC1 domain of the alpha 3 chain of type IV collagen (Goodpasture antigen, alpha 3(IV)NC1), with human B cells homozygous for HLA-DR15, the allele carried by 80% of patients, we find that alpha 3(IV)NC1 is presented as at least two sets of three to five peptides centered on common core sequences (nested sets). Synthetic peptides containing these core sequences bind to HLA-DR15 with intermediate affinity (IC50, 1.1-6 mu m).			Phelps, RG (corresponding author), UNIV ABERDEEN,DEPT MED & THERAPEUT,POLWARTH BLDG,ABERDEEN AB9 2ZD,SCOTLAND.			Turner, Neil/0000-0003-4547-873X				APPLE RJ, 1988, J IMMUNOL, V140, P3290; BROWN JH, 1993, NATURE, V364, P33, DOI 10.1038/364033a0; BURNS AP, 1995, QJM-MON J ASSOC PHYS, V88, P93; BUUS S, 1987, SCIENCE, V235, P1353, DOI 10.1126/science.2435001; BUUS S, 1986, CELL, V47, P1071, DOI 10.1016/0092-8674(86)90822-6; CABANIOLS JP, 1994, EUR J IMMUNOL, V24, P1743, DOI 10.1002/eji.1830240804; CHICZ RM, 1993, J EXP MED, V178, P27, DOI 10.1084/jem.178.1.27; CHICZ RM, 1992, NATURE, V358, P764, DOI 10.1038/358764a0; CIBOTTI R, 1992, P NATL ACAD SCI USA, V89, P416, DOI 10.1073/pnas.89.1.416; DEMOTZ S, 1990, SCIENCE, V249, P1028, DOI 10.1126/science.2118680; FAIRCHILD PJ, 1993, INT IMMUNOL, V5, P1151, DOI 10.1093/intimm/5.9.1151; FALK K, 1994, IMMUNOGENETICS, V39, P230; GUO DC, 1986, J CHROMATOGR, V359, P499, DOI 10.1016/0021-9673(86)80102-9; HAMMER J, 1995, J EXP MED, V181, P1847, DOI 10.1084/jem.181.5.1847; HAMMER J, 1994, J EXP MED, V180, P2353, DOI 10.1084/jem.180.6.2353; HUEY B, 1993, KIDNEY INT, V44, P307, DOI 10.1038/ki.1993.245; HUNT DF, 1992, SCIENCE, V256, P1817, DOI 10.1126/science.1319610; JENSEN PE, 1991, J EXP MED, V174, P1111, DOI 10.1084/jem.174.5.1111; KALLURI R, 1995, J AM SOC NEPHROL, V6, P1178; LEHMANN PV, 1992, NATURE, V358, P155, DOI 10.1038/358155a0; MARRACK P, 1993, J EXP MED, V178, P2173, DOI 10.1084/jem.178.6.2173; Marshall K W, 1995, Biomed Pept Proteins Nucleic Acids, V1, P157; MOORE SEH, 1995, IMMUNOLOGY, V85, P523; MORRISON KE, 1991, AM J HUM GENET, V49, P545; NELSON CA, 1992, P NATL ACAD SCI USA, V89, P7380, DOI 10.1073/pnas.89.16.7380; PUSEY CD, 1987, LAB INVEST, V56, P23; RUDENSKY AY, 1991, NATURE, V353, P622, DOI 10.1038/353622a0; SAUS J, 1988, J BIOL CHEM, V263, P13374; SERCARZ EE, 1993, ANNU REV IMMUNOL, V11, P729, DOI 10.1146/annurev.immunol.11.1.729; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; THEOFILOPOULOS AN, 1995, IMMUNOL TODAY, V16, P90, DOI 10.1016/0167-5699(95)80095-6; TURNER N, 1992, J CLIN INVEST, V89, P592, DOI 10.1172/JCI115625; VIGNALI DAA, 1993, EUR J IMMUNOL, V23, P1602, DOI 10.1002/eji.1830230731; VINER NJ, 1995, P NATL ACAD SCI USA, V92, P2214, DOI 10.1073/pnas.92.6.2214; VOGT AB, 1994, J IMMUNOL, V153, P1665; WUCHERPFENNIG KW, 1994, J EXP MED, V179, P279, DOI 10.1084/jem.179.1.279	36	32	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18549	18553		10.1074/jbc.271.31.18549	http://dx.doi.org/10.1074/jbc.271.31.18549			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702503	hybrid			2022-12-25	WOS:A1996VB68300041
J	Graichen, R; Losch, A; Appel, D; KochBrandt, C				Graichen, R; Losch, A; Appel, D; KochBrandt, C			Glycolipid-independent sorting of a secretory glycoprotein to the apical surface of polarized epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANCHORED PROTEINS; MEMBRANE ANCHOR; MDCK CELLS; COMPLEX; LINE; BIOSYNTHESIS; TRANSPORT; CAVEOLAE	Proteins attached to the membrane by a glycosylphosphatidylinositol (GPI)-anchor cluster together with glycolipids in detergent-insoluble complexes at the site of sorting in the trans-Golgi network. This process has been shown to be critical for the targeting of these proteins to the apical cell surface in polarized epithelial cells, We show in this study that gp80 (clusterin), an apically secreted glycoprotein, is not included in detergent-insoluble complexes in Madin-Darby canine kidney cells, Furthermore in Fisher rat thyroid cells, which target GPI-anchored proteins preferentially to the basolateral cell surface, gp80 is secreted apically, Together these results suggest that this secretory glycoprotein and GPI-linked proteins use different mechanisms to reach the apical membrane.	UNIV MAINZ, INST BIOCHEM, D-55099 MAINZ, GERMANY	Johannes Gutenberg University of Mainz								APPEL D, 1994, J CELL SCI, V107, P553; BOLL W, 1991, P NATL ACAD SCI USA, V88, P8592, DOI 10.1073/pnas.88.19.8592; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Brown Deborah A., 1992, Trends in Cell Biology, V2, P338; COLLARD MW, 1987, BIOCHEMISTRY-US, V26, P3297, DOI 10.1021/bi00386a008; DANIELSEN EM, 1995, BIOCHEMISTRY-US, V34, P1596, DOI 10.1021/bi00005a016; DUPREE P, 1993, EMBO J, V12, P1597, DOI 10.1002/j.1460-2075.1993.tb05804.x; FIEDLER K, 1993, BIOCHEMISTRY-US, V32, P6365, DOI 10.1021/bi00076a009; FIEDLER K, 1995, CELL, V81, P309, DOI 10.1016/0092-8674(95)90380-1; HANNAN LA, 1993, J CELL BIOL, V120, P353, DOI 10.1083/jcb.120.2.353; HOOPER NM, 1988, BIOCHEM J, V250, P865, DOI 10.1042/bj2500865; JENNE DE, 1992, TRENDS BIOCHEM SCI, V17, P154, DOI 10.1016/0968-0004(92)90325-4; KITAGAWA Y, 1994, EXP CELL RES, V213, P449, DOI 10.1006/excr.1994.1222; LISANTI MP, 1990, TRENDS BIOCHEM SCI, V15, P113, DOI 10.1016/0968-0004(90)90195-H; LISANTI MP, 1989, J CELL BIOL, V109, P2145, DOI 10.1083/jcb.109.5.2145; LISANTI MP, 1993, J CELL BIOL, V123, P595, DOI 10.1083/jcb.123.3.595; LISANTI MP, 1988, P NATL ACAD SCI USA, V85, P9557, DOI 10.1073/pnas.85.24.9557; MATLIN K S, 1992, Current Opinion in Cell Biology, V4, P623; MATLIN KS, 1983, CELL, V34, P233, DOI 10.1016/0092-8674(83)90154-X; MAYS RW, 1995, J CELL BIOL, V130, P1105, DOI 10.1083/jcb.130.5.1105; MEISS HK, 1982, MOL CELL BIOL, V2, P1287, DOI 10.1128/MCB.2.10.1287; MOSTOV K, 1992, J CELL BIOL, V116, P577, DOI 10.1083/jcb.116.3.577; MUSTO NA, 1993, EXP CELL RES, V209, P271, DOI 10.1006/excr.1993.1311; PARCZYK K, 1991, FEBS LETT, V278, P267, DOI 10.1016/0014-5793(91)80132-M; PICCIONI R, 1982, METHODS CHLOROPLAST, P985; PILARSKY C, 1993, BIOCHIM BIOPHYS ACTA, V1179, P306, DOI 10.1016/0167-4889(93)90086-5; SCHEIFFELE P, 1995, NATURE, V378, P96, DOI 10.1038/378096a0; SIMONS K, 1990, CELL, V62, P207, DOI 10.1016/0092-8674(90)90357-K; SKIBBENS JE, 1989, J CELL BIOL, V108, P821, DOI 10.1083/jcb.108.3.821; ULLRICH O, 1991, J BIOL CHEM, V266, P3518; URBAN J, 1987, J CELL BIOL, V105, P2735, DOI 10.1083/jcb.105.6.2735; VAN MEER G, 1988, J CELL BIOCHEM, V36, P51, DOI 10.1002/jcb.240360106; WAGNER M, 1995, EUR J CELL BIOL, V67, P84; ZURZOLO C, 1993, J CELL BIOL, V121, P1031, DOI 10.1083/jcb.121.5.1031; ZURZOLO C, 1994, EMBO J, V13, P42, DOI 10.1002/j.1460-2075.1994.tb06233.x	37	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	1996	271	27					15854	15857		10.1074/jbc.271.27.15854	http://dx.doi.org/10.1074/jbc.271.27.15854			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UW352	8663455	hybrid			2022-12-25	WOS:A1996UW35200003
J	Lander, HM; Jacovina, AT; Davis, RJ; Tauras, JM				Lander, HM; Jacovina, AT; Davis, RJ; Tauras, JM			Differential activation of mitogen-activated protein kinases by nitric oxide-related species	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-JUN; SIGNAL-TRANSDUCTION; MAMMALIAN-CELLS; STRESS; RAS; PHOSPHORYLATION; CASCADE; PATHWAY; GTPASES; CDC42	Many studies have identified nitric oxide (NO) and related chemical species (NOx) as having critical roles in neurotransmission, vasoregulation, and cellular signaling, Previous work in this laboratory has focused on elucidating the mechanism of NOx signaling in cells. We have demonstrated that NOx-induced activation of the guanine nucleotide-binding protein p21(ras) leads to nuclear translocation of the transcription factor NF kappa B. Here, we investigated whether intermediary signaling elements, namely the mitogen-activated protein (MAP) kinases, are involved in mediating NOx signaling. We found that NOx activates the extracellular signal regulated kinase (ERK), p38, and c-Jun NH2-terminal kinase (JNK) subgroups of MAP kinases in human Jurkat T cells. JNK was found to be 100-fold more sensitive to NOx stimulation than p38 and ERK. In addition, the activation of JNK and p38 by NOx was more rapid than ERK activation. Depletion of intracellular glutathione augmented the NOx-induced increase in kinase activity. Furthermore, endogenous NOx generated from NO synthase, activated ERK, and NOx-induced MAP kinase activation was effectively blocked by the farnesyl transferase inhibitor alpha-hydroxyfarnesylphosphonic acid. These data support the hypothesis that critical signaling kinases, such as ERK, p38, and JNK, are activated by NO-related species and thus participate in NO signal. transduction. These findings establish a role for multi pie MAP kinase signaling pathways in the cellular response to NOx.	UNIV MASSACHUSETTS,SCH MED,HOWARD HUGHES MED INST,PROGRAM MOL MED,DEPT BIOCHEM & MOL BIOL,WORCESTER,MA 01605	Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester	Lander, HM (corresponding author), CORNELL UNIV,MED CTR,DEPT BIOCHEM,NEW YORK,NY 10021, USA.				NCI NIH HHS [CA58396] Funding Source: Medline; NHLBI NIH HHS [HL46403] Funding Source: Medline; NIAID NIH HHS [AI37637] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058396] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL046403] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI037637] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ahn Natalie G., 1992, Current Opinion in Cell Biology, V4, P992, DOI 10.1016/0955-0674(92)90131-U; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; FIELD L, 1978, J CHEM SOC CHEM COMM, P249, DOI 10.1039/c39780000249; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; GIBBS JB, 1994, CELL, V77, P175, DOI 10.1016/0092-8674(94)90308-5; GRIFFITH OW, 1979, J BIOL CHEM, V254, P7558; GROSS SS, 1995, ANNU REV PHYSIOL, V57, P737, DOI 10.1146/annurev.ph.57.030195.003513; Halliwell B, 1989, FREE RADICALS BIOL M, VUK; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; KOHL NE, 1993, SCIENCE, V260, P1934, DOI 10.1126/science.8316833; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LANDER HM, 1995, J BIOL CHEM, V270, P7017, DOI 10.1074/jbc.270.13.7017; LANDER HM, 1993, J IMMUNOL, V151, P7182; LANDER HM, 1993, J IMMUNOL, V150, P1509; LANDER HM, 1995, J BIOL CHEM, V270, P21195, DOI 10.1074/jbc.270.36.21195; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; ROSENKRANZWEISS P, 1994, J CLIN INVEST, V93, P2236, DOI 10.1172/JCI117221; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SATOH T, 1992, J BIOL CHEM, V267, P24149; STAMLER JS, 1992, SCIENCE, V258, P1898, DOI 10.1126/science.1281928; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934; ZHOU GC, 1995, J BIOL CHEM, V270, P12665, DOI 10.1074/jbc.270.21.12665	36	281	290	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					19705	19709		10.1074/jbc.271.33.19705	http://dx.doi.org/10.1074/jbc.271.33.19705			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702674	hybrid			2022-12-25	WOS:A1996VC66900015
J	Ward, LD; Hammacher, A; Howlett, GJ; Matthews, JM; Fabri, L; Moritz, RL; Nice, EC; Weinstock, J; Simpson, RJ				Ward, LD; Hammacher, A; Howlett, GJ; Matthews, JM; Fabri, L; Moritz, RL; Nice, EC; Weinstock, J; Simpson, RJ			Influence of interleukin-6 (IL-6) dimerization on formation of the high affinity hexameric IL-6 receptor complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SURFACE-PLASMON RESONANCE; SIGNAL TRANSDUCER; MOLECULAR-CLONING; BINDING CONSTANTS; TYROSINE KINASE; 2 DISTINCT; GP130; ASSOCIATION; ACTIVATION; EXPRESSION	The high affinity interleukin-6 (IL-6) signaling complex consists of IL-6 and two membrane-associated receptor components: a low affinity but specific IL-6 receptor and the affinity converter/signal transducing protein gp130. Monomeric (IL-6(M)) and dimeric (IL-6(D)) forms of Escherichia coli-derived human IL-6 and the extracellular (''soluble'') portions of the IL-6 receptor (sIL-6R) and gp130 have been purified in order to investigate the effect of IL-6 dimerization on binding to the receptor complex. Although IL-6(D) has a higher binding affinity for immobilized sIL-6R, as determined by biosensor analysis employing surface plasmon resonance detection, IL-6(M) is more potent than IL-6(D) in a STAT3 phosphorylation assay. The difference in potency is significantly less pronounced when measured in the murine 7TD1 hybridoma growth factor assay and the human hepatoma HepG2 bioassay due to time-dependent dissociation of 37 degrees C of IL-6 dimers into active monomers. The increased binding affinity of IL-6(D) appears to be due to its ability to cross-link two sIL-6R molecules on the biosensor surface. Studies of the IL-6 ternary complex formation demonstrated that the reduced biological potency of IL-6(D) resulted from a decreased ability of the IL-6(D) .(sIL-6R)(2) complex to couple with the soluble portion of gp130. These data imply that the IL-6-induced dimerization of sIL-6R is not the driving force in promoting formation of the hexameric (IL-6 . IL-6R . gp130)(2) complex. A model is presented whereby the trimeric complex of IL-6R, pg130, and IL-6(M) forms before the functional hexamer. Due to its increased affinity for the IL-6R but its decreased ability to couple with gp130, we suggest that a stable IL-6 dimer may be an efficient IL-6 antagonist.	UNIV MELBOURNE,LUDWIG INST CANC RES,WALTER & ELIZA HALL INST MED RES,JOINT PROT STRUCT LAB,PARKVILLE,VIC 3050,AUSTRALIA; UNIV MELBOURNE,DEPT BIOCHEM,PARKVILLE,VIC 3050,AUSTRALIA; LUDWIG INST CANC RES,PARKVILLE,VIC 3050,AUSTRALIA	Ludwig Institute for Cancer Research; University of Melbourne; Walter & Eliza Hall Institute; University of Melbourne; Ludwig Institute for Cancer Research			Nice, Edouard C/B-1026-2011; Matthews, Jacqueline/A-7322-2013; Moritz, Robert L/B-9222-2011	Matthews, Jacqueline/0000-0001-8518-3472; Simpson, Richard/0000-0002-9834-0796; fabri, louis/0000-0003-4033-3304				AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; DALESSANDRO F, 1993, J BIOL CHEM, V268, P2149; DAVIS S, 1993, SCIENCE, V260, P1805, DOI 10.1126/science.8390097; EHLERS M, 1995, J BIOL CHEM, V270, P8158, DOI 10.1074/jbc.270.14.8158; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; Hammacher A, 1996, J BIOL CHEM, V271, P5464, DOI 10.1074/jbc.271.10.5464; HAMMACHER A, 1994, PROTEIN SCI, V3, P2280, DOI 10.1002/pro.5560031213; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; HILTON DJ, 1994, EMBO J, V13, P4765, DOI 10.1002/j.1460-2075.1994.tb06802.x; HIRANO T, 1994, CYTOKINE HDB, P145; IP NY, 1992, CELL, V69, P1121, DOI 10.1016/0092-8674(92)90634-O; JILKA RL, 1992, SCIENCE, V257, P88, DOI 10.1126/science.1621100; JONSSON U, 1991, BIOTECHNIQUES, V11, P620; KALININ NL, 1995, ANAL BIOCHEM, V228, P238, DOI 10.1006/abio.1995.1345; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; KLEIN B, 1995, BLOOD, V85, P863, DOI 10.1182/blood.V85.4.863.bloodjournal854863; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; MATSUDA T, 1995, J BIOL CHEM, V270, P11037, DOI 10.1074/jbc.270.19.11037; MATSUDA T, 1995, BLOOD, V85, P627, DOI 10.1182/blood.V85.3.627.bloodjournal853627; MAY LT, 1991, J BIOL CHEM, V266, P9950; MURAKAMI M, 1993, SCIENCE, V260, P1808, DOI 10.1126/science.8511589; Narazaki M., 1994, GUIDEBOOK CYTOKINES, P56; OSHANNESSY DJ, 1993, ANAL BIOCHEM, V212, P457, DOI 10.1006/abio.1993.1355; PAONESSA G, 1995, EMBO J, V14, P1942, DOI 10.1002/j.1460-2075.1995.tb07186.x; PENNICA D, 1995, J BIOL CHEM, V270, P10915, DOI 10.1074/jbc.270.18.10915; ROSEJOHN S, 1991, J BIOL CHEM, V266, P3841; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; STENBERG E, 1991, J COLLOID INTERF SCI, V143, P513, DOI 10.1016/0021-9797(91)90284-F; STOYAN T, 1993, EUR J BIOCHEM, V216, P239, DOI 10.1111/j.1432-1033.1993.tb18138.x; TAGA T, 1992, CRIT REV IMMUNOL, V11, P265; VANSNICK J, 1990, ANNU REV IMMUNOL, V8, P253, DOI 10.1146/annurev.immunol.8.1.253; WARD LD, 1995, TECH PROT CHEM, V6, P417, DOI 10.1016/S1080-8914(06)80051-7; WARD LD, 1994, J BIOL CHEM, V269, P23286; WARD LD, 1995, BIOCHEMISTRY-US, V34, P2931; YAMASAKI K, 1988, SCIENCE, V241, P825, DOI 10.1126/science.3136546; YASUKAWA K, 1992, IMMUNOL LETT, V31, P123, DOI 10.1016/0165-2478(92)90138-E; YASUKAWA K, 1990, J BIOCHEM-TOKYO, V108, P673, DOI 10.1093/oxfordjournals.jbchem.a123261; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	38	46	52	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					20138	20144		10.1074/jbc.271.33.20138	http://dx.doi.org/10.1074/jbc.271.33.20138			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702737	hybrid			2022-12-25	WOS:A1996VC66900078
J	Bolin, DJ; Jonas, A				Bolin, DJ; Jonas, A			Sphingomyelin inhibits the lecithin-cholesterol acyltransferase reaction with reconstituted high density lipoproteins by decreasing enzyme binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN-A-I; HUMAN-PLASMA LECITHIN; DISCOIDAL COMPLEXES; MICELLAR COMPLEXES; PHOSPHATIDYLCHOLINE; MEMBRANES; BILAYERS; ESTERIFICATION; LIPIDS; SIZE	Lecithin-cholesterol acyltransferase (LCAT) catalyzes the formation of cholesterol esters on high density lipoproteins (HDL) and plays a critical role in reverse cholesterol transport, Sphingomyelin, an important constituent of HDL, may regulate the activity of LCAT at any of the key steps of the enzymatic reaction: binding of LCAT to the interface, activation by apo A-I, or inhibition at the catalytic site, In order to clarify the Pole of sphingomyelin in the regulation of the LCAT reaction and its effects on the structure of apolipoprotein A-I, we prepared reconstituted HDL (rHDL) containing egg phosphatidylcholine, cholesterol, apolipoprotein A-I, and up to 22 mol % sphingomyelin, Because the interfacial properties of substrate particles can dramatically affect LCAT binding and kinetics, we also prepared and analyzed proteoliposome substrates having the same components as the rHDL, except for a 4-fold higher ratio of phospholipid to apolipoprotein A-I. The reaction kinetics of LCAT with the rHDL particles revealed no significant, change in the apparent V-max but showed a concentration-dependent increase in slope of the reciprocal plots and in the apparent K-m values with sphingomyelin content, The dissociation constant (K-d) for LCAT with these particles increased linearly with sphingomyelin content. up to 22 mol %, changing in parallel with the apparent K-m values. No structural changes of apolipoprotein A-I were detected in the particles with increasing content of sphingomyelin, but fluorescence results with lipophilic probes revealed that significant changes in the acyl chain, backbone, and head group regions of the Lipid bilayer of the particles are introduced by the addition of sphingomyelin. On the other-hand, the proteoliposome substrates also had increased K-d values for LCAT at high sphingomyelin contents but compared with the rHDL particles had a 6-10-fold lower affinity for LCAT binding and exhibited kinetics consistent with competitive inhibition by sphingomyelin at the active site, These results show conclusively that the dominant mechanism for the inhibition of LCAT activity with rHDL particles by sphingomyelin is the impaired binding of the enzyme to the interface. The results also underscore the significant differences in the enzyme reaction kinetics with different substrate particles.	UNIV ILLINOIS,COLL MED,DEPT BIOCHEM,URBANA,IL 61801	University of Illinois System; University of Illinois Urbana-Champaign					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL029939, R01HL016059] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 29939, HL 16059] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABRAHAMSSON S, 1977, STRUCTURE BIOL MEMBR, P1; BARENHOLZ Y, 1980, BIOCHIM BIOPHYS ACTA, V604, P129, DOI 10.1016/0005-2736(80)90572-6; BARENHOLZ Y, 1984, PHYSL MEMBRANE FLUID, P131; BARENHOLZ Y, 1982, PHOSPHOLIPIDS, P129; BARTER PJ, 1985, ATHEROSCLEROSIS, V58, P97, DOI 10.1016/0021-9150(85)90058-9; BOLIN DJ, 1994, J BIOL CHEM, V269, P7429; BONOMO EA, 1990, BIOCHEMISTRY-US, V29, P5094, DOI 10.1021/bi00473a014; CALHOUN WI, 1979, BIOCHEMISTRY-US, V18, P1717, DOI 10.1021/bi00576a013; CHEN PS, 1956, ANAL CHEM, V28, P1756, DOI 10.1021/ac60119a033; CHEN YH, 1972, BIOCHEMISTRY-US, V11, P4120, DOI 10.1021/bi00772a015; DORY L, 1983, P NATL ACAD SCI-BIOL, V80, P3489, DOI 10.1073/pnas.80.11.3489; FIELDING CJ, 1972, BIOCHEM BIOPH RES CO, V46, P1493, DOI 10.1016/0006-291X(72)90776-0; GLOMSET JA, 1972, BLOOD LIPIDS LIPOPRO, P745; GWYNNE J, 1974, J BIOL CHEM, V249, P2411; JONAS A, 1985, J BIOL CHEM, V260, P2757; JONAS A, 1991, BIOCHIM BIOPHYS ACTA, V1084, P205, DOI 10.1016/0005-2760(91)90062-M; JONAS A, 1993, BIOCHIM BIOPHYS ACTA, V1166, P202, DOI 10.1016/0005-2760(93)90098-T; JONAS A, 1983, J BIOL CHEM, V258, P335; JONAS A, 1989, J BIOL CHEM, V264, P4818; JONAS A, 1984, J BIOL CHEM, V259, P6369; JONAS A, 1982, BIOCHEMISTRY-US, V21, P6867, DOI 10.1021/bi00269a037; LEROY A, 1993, J BIOL CHEM, V268, P4798; LICHTENBERG D, 1981, BIOCHEMISTRY-US, V20, P3462, DOI 10.1021/bi00515a024; LIU M, 1992, J BIOL CHEM, V267, P5139; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUNDKATZ S, 1988, BIOCHEMISTRY-US, V27, P3416, DOI 10.1021/bi00409a044; MASSEY JB, 1985, J BIOL CHEM, V260, P1719; MASSEY JB, 1985, BIOCHEMISTRY-US, V24, P6973, DOI 10.1021/bi00345a033; MATZ CE, 1982, J BIOL CHEM, V257, P4541; NICHOLS AV, 1976, BIOCHIM BIOPHYS ACTA, V446, P226, DOI 10.1016/0005-2795(76)90113-6; POWNALL HJ, 1985, J BIOL CHEM, V260, P2146; REICHL D, 1992, BIOCHIM BIOPHYS ACTA, V1127, P28, DOI 10.1016/0005-2760(92)90197-4; Rye KA, 1996, J BIOL CHEM, V271, P4243; SCHMIDT CF, 1977, BIOCHEMISTRY-US, V16, P2649, DOI 10.1021/bi00631a011; SHEETZ MP, 1972, BIOCHEMISTRY-US, V11, P4573, DOI 10.1021/bi00774a024; SKIPSKI V, 1992, BLOOD LIPIDS LIPOPRO, P471; SLOTTE JP, 1988, BIOCHEM J, V250, P653, DOI 10.1042/bj2500653; SMALL DM, 1986, PHYSICAL CHEM LIPIDS, P382; SUBBAIAH PV, 1993, J BIOL CHEM, V268, P20156; SWANEY JB, 1983, J BIOL CHEM, V258, P1254; VERGER R, 1973, J BIOL CHEM, V248, P4023; WALD JH, 1990, J BIOL CHEM, V265, P20044; WEBER G, 1979, BIOCHEMISTRY-US, V18, P3075, DOI 10.1021/bi00581a025; WONG L, 1992, J CLIN INVEST, V90, P2370, DOI 10.1172/JCI116127; ZORICH NL, 1987, BIOCHIM BIOPHYS ACTA, V919, P181, DOI 10.1016/0005-2760(87)90206-2	45	102	109	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19152	19158		10.1074/jbc.271.32.19152	http://dx.doi.org/10.1074/jbc.271.32.19152			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702592	hybrid			2022-12-25	WOS:A1996VB68400026
J	Hocking, AM; Strugnell, RA; Ramamurthy, P; McQuillan, DJ				Hocking, AM; Strugnell, RA; Ramamurthy, P; McQuillan, DJ			Eukaryotic expression of recombinant biglycan - Post-translational processing and the importance of secondary structure for biological activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUCINE-RICH REPEATS; GROWTH-FACTOR-BETA; LINE UMR 106-01; ARTICULAR-CARTILAGE; SMALL PROTEOGLYCAN; VACCINIA VIRUS; CORE PROTEIN; I COLLAGEN; DECORIN; BINDING	Biglycan is a small chondroitin sulfate proteoglycan found in many tissues and is structurally related to decorin, fibromodulin, and lumican. The biological function of biglycan is poorly understood, although several studies have indicated interaction with other extracellular matrix components, We have initiated studies of structural and functional domains of biglycan by transient eukaryotic expression using the vaccinia virus/T7 bacteriophage expression system, A recombinant vaccinia virus, vBGN4 encoding the mature biglycan core protein as a polyhistidine fusion protein under control of the T7 phage promoter was expressed in HT-1080 cells and UMR106 cells, The structure of the recombinant biglycan secreted by these cells was defined by analyzing molecules labeled in the presence of [S-35]sulfate, [H-3]glucosamine, and [S-35]methionine. Glycoforms of biglycan were separated by imidazole gradient elution, under non-denaturing conditions, and comprised: a large proteoglycan form substituted with two chondroitin sulfate chains of molecular mass similar to 34 kDa (HT-1080 cells) or similar to 40 kDa (UMR106 cells); a small proteoglycan form substituted with two chondroitin sulfate chains with a median molecular mass similar to 28 kDa; and a core protein form secreted devoid of glycosaminoglycan chains, All the glycoforms were substituted with two N-linked oligosaccharides, and the disaccharide composition of the two glycosaminoglycan populations were identical, Approximately 70% of the recombinant biglycan secreted by HT-1080 cells was substituted with chondroitin sulfate chains, whereas about 50% of the biglycan expressed by UMR106 cells was substituted with chondroitin sulfate chains, Infection with vBGN4 in both HT-1080 and UMR106 cells resulted in the production of approximately 10 mg of biglycan/10(9) cells per 24 h, The native recombinant biglycan was shown to bind to collagen type V and the complement protein, Clq, However, when the secondary structure of recombinant biglycan was disrupted by exposure to 4 hi guanidine hydrochloride, the affinity for collagen type V was dramatically reduced. These data demonstrate the importance of secondary structure to the function of this small proteoglycan.	TEXAS A&M UNIV,INST BIOSCI & TECHNOL,CTR EXTRACELLULAR MATRIX BIOL,HOUSTON,TX 77030	Texas A&M University System				Hocking, Anne/0000-0003-2130-3732; Strugnell, Richard/0000-0003-0614-5641	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR042826] Funding Source: NIH RePORTER; NIAMS NIH HHS [R01 AR 42826] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BIDANSET DJ, 1992, J BIOL CHEM, V267, P5250; BIDANSET DJ, 1992, J CELL BIOL, V118, P1523, DOI 10.1083/jcb.118.6.1523; CARLSON DM, 1968, J BIOL CHEM, V243, P616; ELROYSTEIN O, 1989, P NATL ACAD SCI USA, V86, P6126, DOI 10.1073/pnas.86.16.6126; FONT B, 1993, J BIOL CHEM, V268, P25015; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; HILDEBRAND A, 1994, BIOCHEM J, V302, P527, DOI 10.1042/bj3020527; HOFFMANN A, 1991, NUCLEIC ACIDS RES, V19, P6337, DOI 10.1093/nar/19.22.6337; JOHNSTONE B, 1993, BIOCHEM J, V292, P661, DOI 10.1042/bj2920661; KOBE B, 1995, NATURE, V374, P183, DOI 10.1038/374183a0; KOBE B, 1994, TRENDS BIOCHEM SCI, V19, P415, DOI 10.1016/0968-0004(94)90090-6; KOBE B, 1993, NATURE, V366, P751, DOI 10.1038/366751a0; KRUMDIECK R, 1992, J IMMUNOL, V149, P3965; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU J, 1994, J BIOL CHEM, V269, P28366; MACKETT M, 1985, DNA CLONING PRACTICA, P191; MCQUILLAN DJ, 1991, BIOCHEM J, V277, P199, DOI 10.1042/bj2770199; MCQUILLAN DJ, 1992, BIOCHEM J, V285, P25, DOI 10.1042/bj2850025; PARTRIDGE NC, 1983, CANCER RES, V43, P4308; POGANY G, 1994, ARCH BIOCHEM BIOPHYS, V313, P102, DOI 10.1006/abbi.1994.1365; Ramamurthy P, 1996, J BIOL CHEM, V271, P19578, DOI 10.1074/jbc.271.32.19578; ROBINSON HC, 1975, BIOCHEM J, V148, P25, DOI 10.1042/bj1480025; ROUGHLEY PJ, 1993, BIOCHEM J, V295, P421, DOI 10.1042/bj2950421; SCHONHERR E, 1995, J BIOL CHEM, V270, P2776, DOI 10.1074/jbc.270.6.2776; SCHONHERR E, 1995, J BIOL CHEM, V270, P8877, DOI 10.1074/jbc.270.15.8877; SPRING J, 1994, P NATL ACAD SCI USA, V91, P3334, DOI 10.1073/pnas.91.8.3334; TAKEUCHI Y, 1994, J BIOL CHEM, V269, P32634; VOGEL KG, 1987, BIOCHEM BIOPH RES CO, V148, P658, DOI 10.1016/0006-291X(87)90927-2; VOGEL KG, 1984, BIOCHEM J, V223, P587, DOI 10.1042/bj2230587; WASTESON A, 1971, J CHROMATOGR, V59, P87, DOI 10.1016/S0021-9673(01)80009-1; WHINNA HC, 1993, J BIOL CHEM, V268, P3920; YAMAGUCHI Y, 1990, NATURE, V346, P281, DOI 10.1038/346281a0; ZEBROWER ME, 1986, ANAL BIOCHEM, V157, P93, DOI 10.1016/0003-2697(86)90201-0	33	58	60	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19571	19577		10.1074/jbc.271.32.19571	http://dx.doi.org/10.1074/jbc.271.32.19571			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702651	hybrid			2022-12-25	WOS:A1996VB68400085
J	Kalchman, MA; Graham, RK; Xia, G; Koide, HB; Hodgson, JG; Graham, KC; Goldberg, YP; Gietz, RD; Pickart, CM; Hayden, MR				Kalchman, MA; Graham, RK; Xia, G; Koide, HB; Hodgson, JG; Graham, KC; Goldberg, YP; Gietz, RD; Pickart, CM; Hayden, MR			Huntingtin is ubiquitinated and interacts with a specific ubiquitin-conjugating enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPINOCEREBELLAR ATAXIA TYPE-1; PALLIDOLUYSIAN ATROPHY DRPLA; PROTEIN-PROTEIN INTERACTIONS; FAMILIAL ALZHEIMERS-DISEASE; CAG REPEAT; INSITU HYBRIDIZATION; ERYTHROID-DIFFERENTIATION; PROTEOLYTIC PATHWAY; PROTEASOME PATHWAY; MISSENSE MUTATIONS	Using the yeast two-hybrid system, we have identified a human ubiquitin-conjugating enzyme (hE2-25K) as a protein that interacts with the gene product for Huntington disease (HD) (Huntingtin). This protein has complete amino acid identity with the bovine E2-25K protein and has striking similarity to the UBC-1, -4 and -5 enzymes of Saccharomyces cerevisiae. This protein is highly expressed in brain and a slightly larger protein recognized by an anti-E2-25K polyclonal antibody is selectively expressed in brain regions affected in HD. The huntingtin-E2-25K interaction is not obviously modulated by CAG length. We also demonstrate that huntingtin is ubiquitinated. These findings have implications for the regulated catabolism of the gene product for HD.	UNIV BRITISH COLUMBIA,DEPT MED GENET,VANCOUVER,BC V6T 1Z4,CANADA; JOHNS HOPKINS UNIV,SCH PUBL HLTH,DEPT BIOCHEM,BALTIMORE,MD 21205; UNIV MANITOBA,DEPT HUMAN GENET,WINNIPEG,MB R3E 0W3,CANADA	University of British Columbia; Johns Hopkins University; University of Manitoba			Graham, Rona K/R-7358-2018; Hayden, Michael R/D-8581-2011	Graham, Rona K/0000-0003-3722-6241; Hayden, Michael R/0000-0001-5159-1419				ARONIN N, 1995, NEURON, V15, P1193, DOI 10.1016/0896-6273(95)90106-X; BOYLE AL, 1992, GENOMICS, V12, P106, DOI 10.1016/0888-7543(92)90412-L; CAMMARATA S, 1993, NEUROSCI LETT, V156, P96, DOI 10.1016/0304-3940(93)90448-T; CHEN ZJ, 1990, J BIOL CHEM, V265, P21835; CHEN ZJ, 1991, J BIOL CHEM, V266, P15698; CHONG SS, 1995, NAT GENET, V10, P344, DOI 10.1038/ng0795-344; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; DESHAIES RJ, 1995, TRENDS CELL BIOL, V5, P428, DOI 10.1016/S0962-8924(00)89102-3; DIFIGLIA M, 1995, NEURON, V14, P1075, DOI 10.1016/0896-6273(95)90346-1; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FIELDS S, 1994, TRENDS GENET, V10, P286, DOI 10.1016/0168-9525(90)90012-U; Goldberg YP, 1996, HUM MOL GENET, V5, P177, DOI 10.1093/hmg/5.2.177; GUSELLA JF, 1994, NEW ENGL J MED, V330, P1400; GUTEKUNST CA, 1995, P NATL ACAD SCI USA, V92, P8710, DOI 10.1073/pnas.92.19.8710; HAAS AL, 1985, J BIOL CHEM, V260, P2464; HAAS AL, 1995, J BIOL CHEM, V270, P9407, DOI 10.1074/jbc.270.16.9407; HALDEMAN MT, 1995, J BIOL CHEM, V270, P9507, DOI 10.1074/jbc.270.16.9507; HARPER JW, 1993, CELL, V75, P805; Hayden MR., 1981, HUNTINGTONS CHOREA, P45; HENG HHQ, 1993, CHROMOSOMA, V102, P325, DOI 10.1007/BF00661275; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P4918, DOI 10.1128/MCB.13.8.4918; JENTSCH S, 1995, CELL, V82, P881, DOI 10.1016/0092-8674(95)90021-7; JENTSCH S, 1992, ANNU REV GENET, V26, P179, DOI 10.1146/annurev.ge.26.120192.001143; JOU YS, 1995, HUM MOL GENET, V4, P465, DOI 10.1093/hmg/4.3.465; KOEMER TJ, 1990, METHOD ENZYMOL, V194, P477; LI XJ, 1995, NATURE, V378, P398, DOI 10.1038/378398a0; LICHTER P, 1990, SCIENCE, V247, P64, DOI 10.1126/science.2294592; MACDONALD RJ, 1987, METHOD ENZYMOL, V152, P219; Miller J.H., 1972, EXPT MOL GENETICS; NASIR J, 1995, CELL, V81, P811, DOI 10.1016/0092-8674(95)90542-1; ORIAN A, 1995, J BIOL CHEM, V270, P21707, DOI 10.1074/jbc.270.37.21707; PAETKAU DW, 1994, GENE DEV, V8, P2035, DOI 10.1101/gad.8.17.2035; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PICKART CM, 1992, J BIOL CHEM, V267, P14418; PICKART CM, 1989, ARCH BIOCHEM BIOPHYS, V272, P114, DOI 10.1016/0003-9861(89)90201-4; RILEY DA, 1988, J HISTOCHEM CYTOCHEM, V36, P621, DOI 10.1177/36.6.2835410; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; ROSS CA, 1995, NEURON, V15, P493, DOI 10.1016/0896-6273(95)90138-8; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1995, NATURE, V373, P81, DOI 10.1038/373081a0; Schiestl Robert H., 1993, Methods (Orlando), V5, P79, DOI 10.1006/meth.1993.1011; SCHIFFER D, 1994, NEUROSCI LETT, V180, P21, DOI 10.1016/0304-3940(94)90904-0; SCHILLING G, 1995, HUM MOL GENET, V4, P1365, DOI 10.1093/hmg/4.8.1365; SERVADIO A, 1995, NAT GENET, V10, P94, DOI 10.1038/ng0595-94; SEUFERT W, 1990, EMBO J, V9, P543, DOI 10.1002/j.1460-2075.1990.tb08141.x; SEUFERT W, 1990, EMBO J, V9, P4535, DOI 10.1002/j.1460-2075.1990.tb07905.x; SHARP AH, 1995, NEURON, V14, P1065, DOI 10.1016/0896-6273(95)90345-3; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; SUGIYAMA H, 1994, CLIN NEUROPATHOL, V13, P55; TADDEI N, 1993, NEUROSCI LETT, V151, P158, DOI 10.1016/0304-3940(93)90010-I; TELENIUS H, 1994, NAT GENET, V6, P409, DOI 10.1038/ng0494-409; TROTTIER Y, 1995, NAT GENET, V10, P104, DOI 10.1038/ng0595-104; UENO S, 1995, HUM MOL GENET, V4, P663, DOI 10.1093/hmg/4.4.663; VARSHAVSKY A, 1992, CELL, V69, P725, DOI 10.1016/0092-8674(92)90285-K; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; WEFES I, 1995, P NATL ACAD SCI USA, V92, P4982, DOI 10.1073/pnas.92.11.4982; WILLEMS PJ, 1994, NAT GENET, V8, P213, DOI 10.1038/ng1194-213; WING SS, 1995, BIOCHEM J, V305, P125, DOI 10.1042/bj3050125; YAZAWA I, 1995, NAT GENET, V10, P99, DOI 10.1038/ng0595-99; 1993, CELL, V72, P971	62	285	305	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19385	19394		10.1074/jbc.271.32.19385	http://dx.doi.org/10.1074/jbc.271.32.19385			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702625	hybrid			2022-12-25	WOS:A1996VB68400059
J	Lugemwa, FN; Sarkar, AK; Esko, JD				Lugemwa, FN; Sarkar, AK; Esko, JD			Unusual beta-D-xylosides that prime glycosaminoglycans in animal cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-ACETYLGLUCOSAMINYLTRANSFERASE-V; HEPARAN-SULFATE BIOSYNTHESIS; GENE-SPECIFIED GLYCOSYLTRANSFERASES; HUMAN SKIN FIBROBLASTS; BLOOD-GROUP-A; CHONDROITIN SULFATE; ACCEPTOR ALPHA-L-FUCP-(1->2)-BETA-D-GALP-OR; PROTEIN INTERACTIONS; RECOGNITION; OLIGOSACCHARIDE	The biosynthesis of glycosaminoglycans (GAG) takes place while the polysaccharide chains are usually attached to a proteoglycan core protein, Cells also will assemble GAG chains on beta-D-xylosides containing hydrophobic aglycones, In order to evaluate the relationship of the structure of the sugar to priming activity of the glycoside, we synthesized beta-D-xyloside analogs in which the hydroxyls were substituted with hydrogen, fluorine, -O-methyl, amino, -O-isopropyl, and -O-benzyl groups, Epimers at the 2-, 3-, and 8-position of xylose also were made, Their ability to prime GAGs was tested in Chinese hamster ovary cells by measuring (SO4)-S-35 incorporation into polysaccharide chains and by assaying the transfer of galactose to the xylosides by galactosyltransferase I (UDP-D-galactose:xylose beta 1-4-galactosyltransferase) in vitro, All of the analogs failed to act as primers of GAGs in vivo and as substrates in vitro with the following exceptions, Substitution of 2-OH and 3-OH with -OCH3 were active at high concentration (1 mM), but the deoxygenated derivatives were inactive, Efficient priming also occurred on a derivative with fluorine instead of the 3-OH group, suggesting that the oxygen atoms at C-2 and C-3 were involved as hydrogen bond accepters, Methylated and deoxy analogs at C-4 were inactive, due to the loss of the acceptor hydroxyl group, Interestingly, benzyl-beta-D-threo-pentopyranos-4-uloside (4-keto derivative) and benzyl-4-methyl-beta-D-xyloside, with a methyl group in place of an axial hydrogen at C-4, primed GAG chains, Priming by these unusual xylosides suggests the possibility of designing inhibitors of GAG synthesis based on xyloside analogs with reactive groups in key positions.	UNIV ALABAMA,SCH MED,DEPT BIOCHEM & MOL GENET,BIRMINGHAM,AL 35294; UNIV ALABAMA,SCH DENT,BIRMINGHAM,AL 35294	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham					NCI NIH HHS [CA46462] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA046462] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAME KJ, 1989, J BIOL CHEM, V264, P8059; DEBRUYN A, 1975, CARBOHYD RES, V41, P290, DOI 10.1016/S0008-6215(00)87027-5; DULBECCO R, 1954, J EXP MED, V99, P167, DOI 10.1084/jem.99.2.167; ESKO JD, 1987, J BIOL CHEM, V262, P12189; ESKO JD, 1985, P NATL ACAD SCI USA, V82, P3197, DOI 10.1073/pnas.82.10.3197; FREEZE HH, 1993, J BIOL CHEM, V268, P1618; FRITZ TA, 1994, J BIOL CHEM, V269, P28809; FRITZ TA, 1994, J BIOL CHEM, V269, P300; GAHKOKIDZE AM, 1946, CHEM ABSTR, V40, P4673; GAHKOKIDZE AM, 1945, ZH OBSHCH KHIM, V15, P530; GAREGG PJ, 1960, ACTA CHEM SCAND, V14, P12; HAM RG, 1965, P NATL ACAD SCI USA, V53, P288, DOI 10.1073/pnas.53.2.288; HELTING T, 1969, J BIOL CHEM, V244, P2790; HINDSGAUL O, 1991, J BIOL CHEM, V266, P17858; INOUE S, 1993, J BIOL CHEM, V268, P5894; IZUMI J, 1994, J BIOCHEM-TOKYO, V116, P524, DOI 10.1093/oxfordjournals.jbchem.a124556; JACKSON RL, 1991, PHYSIOL REV, V71, P481, DOI 10.1152/physrev.1991.71.2.481; JEANLOZ R, 1948, J AM CHEM SOC, V70, P4055, DOI 10.1021/ja01192a026; KANIE O, 1993, CARBOHYD RES, V243, P139, DOI 10.1016/0008-6215(93)84087-M; KHAN SH, 1993, J BIOL CHEM, V268, P2468; KINGSLEY DM, 1986, CELL, V44, P749, DOI 10.1016/0092-8674(86)90841-X; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; KOLSET SO, 1990, BIOCHEM J, V265, P637, DOI 10.1042/bj2650637; Levene PA, 1929, J BIOL CHEM, V83, P803; LINKER T, 1993, CARBOHYD RES, V245, P323, DOI 10.1016/0008-6215(93)80081-O; LOWARY TL, 1993, CARBOHYD RES, V249, P163, DOI 10.1016/0008-6215(93)84068-H; LOWARY TL, 1994, CARBOHYD RES, V251, P33, DOI 10.1016/0008-6215(94)84275-2; LOWARY TL, 1994, CARBOHYD RES, V256, P257, DOI 10.1016/0008-6215(94)84212-4; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUGEMWA FN, 1991, J BIOL CHEM, V266, P6674; MANZI A, 1995, J BIOL CHEM, V270, P9154, DOI 10.1074/jbc.270.16.9154; NAKAMURA T, 1994, BIOCHEM J, V304, P731, DOI 10.1042/bj3040731; OGAWA S, 1995, CARBOHYD RES, V271, P197, DOI 10.1016/0008-6215(95)00083-6; OKAYAMA M, 1973, J BIOCHEM-TOKYO, V74, P1069; OVEREND WG, 1950, J CHEM SOC, P671, DOI 10.1039/jr9500000671; PALCIC MM, 1989, J BIOL CHEM, V264, P17174; RIO S, 1991, CARBOHYD RES, V219, P71, DOI 10.1016/0008-6215(91)89043-F; ROBINSON HC, 1975, BIOCHEM J, V148, P25, DOI 10.1042/bj1480025; Roden L., 1980, BIOCH GLYCOPROTEINS, P267; ROHRMANN K, 1985, EUR J BIOCHEM, V148, P463, DOI 10.1111/j.1432-1033.1985.tb08862.x; ROSENFELD L, 1976, CARBOHYD RES, V46, P155, DOI 10.1016/S0008-6215(00)83542-9; SANANTONIO JD, 1993, BIOCHEMISTRY-US, V32, P4746, DOI 10.1021/bi00069a008; SARKAR AK, 1995, P NATL ACAD SCI USA, V92, P3323, DOI 10.1073/pnas.92.8.3323; SCHWARTZ NB, 1974, P NATL ACAD SCI USA, V71, P4047, DOI 10.1073/pnas.71.10.4047; SHIBATA S, 1995, J BIOL CHEM, V270, P13794, DOI 10.1074/jbc.270.23.13794; SPILLMANN D, 1994, CURR OPIN STRUC BIOL, V4, P677, DOI 10.1016/S0959-440X(94)90165-1; WERMUTH B, 1982, EUR J BIOCHEM, V127, P279, DOI 10.1111/j.1432-1033.1982.tb06867.x; ZHANG L, 1995, J BIOL CHEM, V270, P12557, DOI 10.1074/jbc.270.21.12557; ZHANG LJ, 1994, J BIOL CHEM, V269, P19295; ZHANG LJ, 1995, J BIOL CHEM, V270, P27127, DOI 10.1074/jbc.270.45.27127	50	43	43	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19159	19165		10.1074/jbc.271.32.19159	http://dx.doi.org/10.1074/jbc.271.32.19159			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702593	hybrid			2022-12-25	WOS:A1996VB68400027
J	Magnuson, P; Lehnherr, H; Mukhopadhyay, G; Yarmolinsky, MB				Magnuson, P; Lehnherr, H; Mukhopadhyay, G; Yarmolinsky, MB			Autoregulation of the plasmid addiction operon of bacteriophage P1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPRESSOR-OPERATOR COMPLEX; AMINO-ACID-SEQUENCE; ESCHERICHIA-COLI; ARC REPRESSOR; F-PLASMID; SECONDARY-STRUCTURE; CRYSTAL-STRUCTURE; CLONING VECTORS; GEL RETARDATION; DNA RECOGNITION	The P1 plasmid addiction operon increases the apparent stability of a plasmid that carries it by killing plasmid-free (cured) segregants. The operon consists of a gene encoding an endotoxin responsible for death on curing (dec), preceded by a gene encoding a relatively unstable antidote that can prevent host death (phd). When the copy number of the operon was increased, expression of a lacZ reporter fused to the promoter of the operon decreased, indicating that expression of the operon was stabilized by an autoregulatory circuit. Transcription of the lacZ reporter was repressed about 10-fold when phd, without dec, was expressed from an exogenous promoter, DNase I footprinting showed that Phd binds a perfect 10-base pair palindromic DNA sequence and, at higher concentrations, an adjacent, imperfect palindrome. The palindromic sites are located between the -10 region of the putative promoter and the start codon of phd. Electrophoretic mobility of DNA containing the promoter region was retarded in the presence of Phd and further retarded in the presence of Phd and Dec. When doc was co-expressed with phd, repression of the lacZ fusion was enhanced more than 100-fold. Thus, both products of the addiction operon participate in its autoregulation.	NCI,BIOCHEM LAB,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								Arber W., 1983, LAMBDA, P433; BERNARD P, 1991, MOL GEN GENET, V226, P297, DOI 10.1007/BF00273616; BOWIE JU, 1990, J MOL BIOL, V211, P5, DOI 10.1016/0022-2836(90)90004-6; BREG JN, 1990, NATURE, V346, P586, DOI 10.1038/346586a0; BROSIUS J, 1984, P NATL ACAD SCI-BIOL, V81, P6929, DOI 10.1073/pnas.81.22.6929; BROWN BM, 1993, BIOCHEMISTRY-US, V32, P1354, DOI 10.1021/bi00056a022; CAREY J, 1991, METHOD ENZYMOL, V208, P103; CASADABAN MJ, 1980, J MOL BIOL, V138, P179, DOI 10.1016/0022-2836(80)90283-1; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; CLERGET M, 1991, NEW BIOL, V3, P780; DAVIS TL, 1992, MOL MICROBIOL, V6, P1981, DOI 10.1111/j.1365-2958.1992.tb01371.x; DEFEYTER R, 1989, MOL GEN GENET, V218, P481, DOI 10.1007/BF00332413; EBERL L, 1994, MOL MICROBIOL, V12, P131, DOI 10.1111/j.1365-2958.1994.tb01002.x; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; HASUNUMA K, 1977, MOL GEN GENET, V154, P225, DOI 10.1007/BF00571277; HOCHSCHILD A, 1991, METHOD ENZYMOL, V208, P343; IIDA S, 1980, MOL GEN GENET, V177, P261, DOI 10.1007/BF00267437; JENSEN RB, 1995, MOL MICROBIOL, V17, P205, DOI 10.1111/j.1365-2958.1995.mmi_17020205.x; Johnson EP, 1996, J BACTERIOL, V178, P1420, DOI 10.1128/jb.178.5.1420-1429.1996; LANE D, 1992, MICROBIOL REV, V56, P509, DOI 10.1128/MMBR.56.4.509-528.1992; LEHNHERR H, 1995, P NATL ACAD SCI USA, V92, P3274, DOI 10.1073/pnas.92.8.3274; LEHNHERR H, 1993, J MOL BIOL, V233, P414, DOI 10.1006/jmbi.1993.1521; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; Miller J.H., 1992, SHORT COURSE BACTERI, P150; NEEDLEMAN SB, 1970, J MOL BIOL, V48, P443, DOI 10.1016/0022-2836(70)90057-4; NORDSTROM K, 1989, ANNU REV GENET, V23, P37, DOI 10.1146/annurev.genet.23.1.37; PHILLIPS SEV, 1989, NATURE, V341, P711, DOI 10.1038/341711a0; PRENTKI P, 1977, MOL GEN GENET, V152, P71, DOI 10.1007/BF00264942; RAUMANN BE, 1994, NATURE, V367, P754, DOI 10.1038/367754a0; ROBERTS RC, 1993, J BIOL CHEM, V268, P27109; ROSNER JL, 1972, VIROLOGY, V48, P679, DOI 10.1016/0042-6822(72)90152-3; RUIZECHEVARRIA MJ, 1991, MOL MICROBIOL, V5, P2685, DOI 10.1111/j.1365-2958.1991.tb01977.x; RUIZECHEVARRIA MJ, 1991, MOL GEN GENET, V225, P355, DOI 10.1007/BF00261674; SALMON MA, 1994, MOL GEN GENET, V244, P530, DOI 10.1007/BF00583904; Sambrook J., 2002, MOL CLONING LAB MANU; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Silhavy T.J., 1984, EXPT GENE FUSIONS; SIMONS RW, 1987, GENE, V53, P85, DOI 10.1016/0378-1119(87)90095-3; SOMERS WS, 1992, NATURE, V359, P387, DOI 10.1038/359387a0; TAM JE, 1989, J BACTERIOL, V171, P2353, DOI 10.1128/jb.171.5.2353-2360.1989; TAM JE, 1989, MOL GEN GENET, V219, P26, DOI 10.1007/BF00261153; TSUCHIMOTO S, 1993, MOL GEN GENET, V237, P81, DOI 10.1007/BF00282787; WILLIAMS DR, 1992, J GEN MICROBIOL, V138, P1; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	44	60	64	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18705	18710		10.1074/jbc.271.31.18705	http://dx.doi.org/10.1074/jbc.271.31.18705			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702525	hybrid			2022-12-25	WOS:A1996VB68300063
J	Schissel, SL; Schuchman, EH; Williams, KJ; Tabas, I				Schissel, SL; Schuchman, EH; Williams, KJ; Tabas, I			Zn2+-stimulated sphingomyelinase is secreted by many cell types and is a product of the acid sphingomyelinase gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; NIEMANN-PICK DISEASE; MOUSE PERITONEAL-MACROPHAGES; NEUTRAL SPHINGOMYELINASE; NUCLEOTIDE-SEQUENCE; MISSENSE MUTATION; LYSOSOMAL-ENZYMES; RAT-BRAIN; CHOLESTEROL; ACCUMULATION	Mammalian sphingomyelinases have been implicated in many important physiological and pathophysiological processes. Although several mammalian sphingomyelinases have been identified and studied, one of these, an acidic Zn2+-stimulated sphingomyelinase (Zn-SMase) originally found in fetal bovine serum, has received little attention since its first and only report 7 years ago. We now show that Zn-SMase activity is secreted by human and murine macrophages, human skin fibroblasts, microglial cells, and several other cells in culture and is markedly up-regulated during differentiation of human monocytes to macrophages. Remarkably, peritoneal macrophages from mice in which the acid SMase gene had been disrupted by homologous recombination secreted no Zn-SMase activity, indicating that this enzyme and the intracellular lysosomal SMase, which is Zn-independent, arise from the same gene, Furthermore, skin fibroblasts from patients with types A and B Niemann-Pick disease, which are known to lack lysosomal SMase activity, also lack Zn-SMase activity in their conditioned media. Chinese hamster ovary cells stably transfected with a cDNA encoding lysosomal SMase massively overexpress both cellular lysosomal SMase and secreted Zn-SMase activities. Thus, Zn-SMase arises independently of alternative splicing, suggesting a post-translational process. In summary, a wide variety of cell types secrete Zn-SMase activity, which arises from the same gene as lysosomal SMase. This secreted enzyme may play roles in physiological and pathophysiological processes involving extracellular sphingomyelin hydrolysis.	COLUMBIA UNIV, DEPT MED, NEW YORK, NY 10032 USA; COLUMBIA UNIV, DEPT ANAT & CELL BIOL, NEW YORK, NY 10032 USA; CUNY MT SINAI SCH MED, DEPT HUMAN GENET, NEW YORK, NY 10029 USA; THOMAS JEFFERSON UNIV, DIV ENDOCRINOL DIABET & METAB DIS, DORRANCE H HAMILTON RES LABS, PHILADELPHIA, PA 19107 USA	Columbia University; Columbia University; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Jefferson University				Williams, Kevin Jon/0000-0002-0000-2159	NHLBI NIH HHS [HL39703, HL21006] Funding Source: Medline; NICHD NIH HHS [HD28607] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R37HD028607] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD028607] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL039703, P50HL021006] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AHMAD TY, 1985, J LIPID RES, V26, P1160; ASSAF SY, 1984, NATURE, V308, P734, DOI 10.1038/308734a0; BAUER J, 1994, J NEUROSCI RES, V38, P365, DOI 10.1002/jnr.490380402; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOND JS, 1995, PROTEIN SCI, V4, P1247, DOI 10.1002/pro.5560040701; BOTTALICO LA, 1993, J BIOL CHEM, V268, P8569; Brady R. O., 1983, METABOLIC BASIS INHE, P831; CHATTERJEE S, 1991, METHOD ENZYMOL, V197, P540; CIFONE MG, 1995, EMBO J, V14, P5859, DOI 10.1002/j.1460-2075.1995.tb00274.x; DONANGELO CM, 1981, CLIN CHIM ACTA, V113, P201, DOI 10.1016/0009-8981(81)90154-6; FOGELMAN AM, 1981, J LIPID RES, V22, P1131; Frederickson C. J., 1994, Biological Signals, V3, P127; GATT S, 1978, J NEUROCHEM, V31, P547, DOI 10.1111/j.1471-4159.1978.tb02671.x; GUYTON JR, 1996, J LIPID RES, V16, P4; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; HARTUNG HP, 1992, J NEUROIMMUNOL, V40, P197, DOI 10.1016/0165-5728(92)90134-7; HASILIK A, 1992, EXPERIENTIA, V48, P130, DOI 10.1007/BF01923507; HEINEMANN T, 1994, J LIPID RES, V35, P2200; HOFF HF, 1985, ANN NY ACAD SCI, V454, P183, DOI 10.1111/j.1749-6632.1985.tb11857.x; HORINOUCHI K, 1995, NAT GENET, V10, P288, DOI 10.1038/ng0795-288; HURWITZ R, 1994, J BIOL CHEM, V269, P5440; IOANNOU YA, 1992, J CELL BIOL, V119, P1137, DOI 10.1083/jcb.119.5.1137; KAKAJIMA K, 1989, BIOMED RES, V10, P411; KHOO JC, 1989, BIOCHIM BIOPHYS ACTA, V1012, P215, DOI 10.1016/0167-4889(89)90099-2; KOLESNICK RN, 1991, PROG LIPID RES, V30, P1, DOI 10.1016/0163-7827(91)90005-P; KORNFELD S, 1987, FASEB J, V1, P462, DOI 10.1096/fasebj.1.6.3315809; LEVADE T, 1986, J CLIN CHEM CLIN BIO, V24, P205; LEVRAN O, 1991, P NATL ACAD SCI USA, V88, P3748, DOI 10.1073/pnas.88.9.3748; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAROUDAS A, 1988, BIOPHYS CHEM, V32, P257, DOI 10.1016/0301-4622(88)87012-1; MARUYAMA EN, 1989, J NEUROCHEM, V52, P611, DOI 10.1111/j.1471-4159.1989.tb09163.x; MENDIS S, 1989, BIOL TRACE ELEM RES, V22, P251, DOI 10.1007/BF02916613; Menkin V, 1934, AM J PATHOL, V10, P193; MYERS JN, 1993, J CELL BIOL, V123, P1389, DOI 10.1083/jcb.123.6.1389; NIEVELSTEIN PFEM, 1991, ARTERIOSCLER THROMB, V11, P1795, DOI 10.1161/01.ATV.11.6.1795; Nolan C M, 1987, Adv Exp Med Biol, V225, P199; OKAZAKI T, 1994, J BIOL CHEM, V269, P4070; OKWU AK, 1994, J LIPID RES, V35, P644; OTTERBACH B, 1995, CELL, V81, P1053, DOI 10.1016/S0092-8674(05)80010-8; PORN MI, 1995, BIOCHEM J, V308, P269; SCHISSEL SL, 1994, CIRCULATION, V90, P403; SCHUCHMAN EH, 1992, GENOMICS, V12, P197, DOI 10.1016/0888-7543(92)90366-Z; SCHUCHMAN EH, 1991, J BIOL CHEM, V266, P8531; SILVER IA, 1988, EXP CELL RES, V175, P266, DOI 10.1016/0014-4827(88)90191-7; Skiba PJ, 1996, J BIOL CHEM, V271, P13392, DOI 10.1074/jbc.271.23.13392; SLOTTE JP, 1988, BIOCHEM J, V250, P653, DOI 10.1042/bj2500653; SMITH EB, 1979, ADV EXP MED BIOL, V115, P245; Smith H C, 1993, Semin Cell Biol, V4, P267, DOI 10.1006/scel.1993.1032; SPENCE MW, 1993, ADV LIPID RES, V26, P3; SPENCE MW, 1989, J BIOL CHEM, V264, P5358; SRIPADA PK, 1987, J LIPID RES, V28, P710; SVENSSON M, 1993, BRAIN RES BULL, V30, P499, DOI 10.1016/0361-9230(93)90284-I; TABAS I, 1993, J BIOL CHEM, V268, P20419; TABAS I, 1987, J CLIN INVEST, V79, P418, DOI 10.1172/JCI112828; Takahashi Tsutomu, 1992, Human Mutation, V1, P70, DOI 10.1002/humu.1380010111; TAKEDA A, 1994, BRAIN RES, V658, P252, DOI 10.1016/S0006-8993(09)90032-4; TAPPER H, 1992, BIOCHEM J, V281, P245, DOI 10.1042/bj2810245; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; WILLIAMS KJ, 1995, ARTERIOSCL THROM VAS, V15, P551, DOI 10.1161/01.ATV.15.5.551; XU XX, 1991, J BIOL CHEM, V266, P24849	60	246	266	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18431	18436		10.1074/jbc.271.31.18431	http://dx.doi.org/10.1074/jbc.271.31.18431			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702487	hybrid			2022-12-25	WOS:A1996VB68300025
J	Valiquette, M; Vu, HK; Yue, SY; Wahlestedt, C; Walker, P				Valiquette, M; Vu, HK; Yue, SY; Wahlestedt, C; Walker, P			Involvement of trp-284, val-296, and val-297 of the human delta-opioid receptor in binding of delta-selective ligands	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTINOCICEPTION; PLASMID; CDNA; RATS	Given the high homology in amino acid sequence between the delta-opioid receptor and the two other types (mu and kappa), distinct residues in this receptor may confer its selectivity to some ligands, In order to identify molecular determinants in the human delta receptor responsible for the selectivity of delta-selective ligands, two different delta/mu chimeras were constructed, In the first one, the delta sequence from the top of transmembrane 5 to the C terminus was replaced by the equivalent Ir sequence, and in the second one, 13 consecutive residues in the third extracellular loop region of the delta receptor were replaced by the mu counterpart, These two chimeras retained the ability to bind the nonselective bremazocine but completely lost the ability to bind different delta-selective ligands, These results suggested that the region of the third extracellular loop of the delta receptor is crucial for the type selectivity, Furthermore, an alanine scan was performed by site-directed mutagenesis of 20 amino acids located in or proximal to the third extracellular loop, Among all the point mutations, only mutations of Trp-284, Val-296, or Val-297 significantly decreased the binding of delta-selective ligands tested, Moreover, combined mutation of Trp-284, Val-296, and Val-297 considerably decreased the affinities of the receptor for delta-selective ligands compared with the single point mutations, These findings suggest that Trp-284, Val-296, and Val-297 are crucial residues involved in the delta receptor type selectivity.	ASTRA PAIN RES UNIT,MONTREAL,PQ H4P 2R2,CANADA				Wahlestedt, Claes/A-7039-2009					Ballesteros J. A., 1995, RECEPTOR MOL BIOL, V25, P366, DOI [10.1016/S1043-9471(05)80049-7, DOI 10.1016/S1043-9471(05)80049-7]; Befort K, 1996, J BIOL CHEM, V271, P10161, DOI 10.1074/jbc.271.17.10161; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COWAN A, 1988, J PHARMACOL EXP THER, V246, P950; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; Ellison Neil M., 1993, P185; FUKUDA K, 1995, J BIOL CHEM, V270, P6702, DOI 10.1074/jbc.270.12.6702; Heyman J S, 1986, NIDA Res Monogr, V75, P442; HEYMAN JS, 1987, BRAIN RES, V420, P100, DOI 10.1016/0006-8993(87)90244-7; HEYMAN JS, 1988, TRENDS PHARMACOL SCI, V9, P134, DOI 10.1016/0165-6147(88)90195-2; HJORTH SA, 1995, MOL PHARMACOL, V47, P1089; Jaffe JH, 1990, PHARMACOL BASIS THER, P485; Kieffer BL, 1995, CELL MOL NEUROBIOL, V15, P615, DOI 10.1007/BF02071128; KNAPP RJ, 1994, LIFE SCI, V54, pPL463, DOI 10.1016/0024-3205(94)90138-4; KONG HY, 1993, J BIOL CHEM, V268, P23055; LUTZ RA, 1992, J RECEPTOR RES, V12, P267, DOI 10.3109/10799899209074796; MALDONADO R, 1992, NEUROPHARMACOLOGY, V31, P1231, DOI 10.1016/0028-3908(92)90051-P; MANSSON E, 1994, BIOCHEM BIOPH RES CO, V202, P1431, DOI 10.1006/bbrc.1994.2091; MENG F, 1995, J BIOL CHEM, V270, P12730, DOI 10.1074/jbc.270.21.12730; PERSSON B, 1994, J MOL BIOL, V237, P182, DOI 10.1006/jmbi.1994.1220; PFEIFFER A, 1986, SCIENCE, V233, P774, DOI 10.1126/science.3016896; PORTOGHESE PS, 1993, HDB EXP PHARM, V104, P276; PROBST WC, 1992, DNA CELL BIOL, V11, P1, DOI 10.1089/dna.1992.11.1; SCHERTLER GFX, 1993, NATURE, V362, P770, DOI 10.1038/362770a0; SIMON EJ, 1991, MED RES REV, V11, P357, DOI 10.1002/med.2610110402; UNTERWALD E, 1987, EUR J PHARMACOL, V133, P275, DOI 10.1016/0014-2999(87)90023-9; WANG JB, 1994, FEBS LETT, V338, P217, DOI 10.1016/0014-5793(94)80368-4; Wang WW, 1995, P NATL ACAD SCI USA, V92, P12436, DOI 10.1073/pnas.92.26.12436	29	98	98	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18789	18796		10.1074/jbc.271.31.18789	http://dx.doi.org/10.1074/jbc.271.31.18789			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702536	hybrid			2022-12-25	WOS:A1996VB68300074
J	Wang, ZY; Wang, XL; Rana, TM				Wang, ZY; Wang, XL; Rana, TM			Protein orientation in the Tat-TAR complex determined by psoralen photocross-linking	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; TRANS-ACTIVATOR GENE; LONG TERMINAL REPEAT; HIV-1 TAT; MESSENGER-RNA; TYPE-1; ELEMENT; LOOP; TRANSCRIPTION; SEQUENCE	Replication of human immunodeficiency virus type 1 (HIV-1) requires specific interactions of Tat protein with the trans-activation responsive region (TAR) RNA, a 59-base stem-loop structure located at the 5'-end of all HIV mRNAs. We have used a new method based on psoralen photochemistry to identify a specific contact between a fragment of Tat protein (residues 38-72) and TAR RNA. We synthesized a 35 amino acid fragment containing arginine-rich RNA-binding domain of Tat (38-72), and replaced Arg(57) With Cys to introduce a unique thiol group (SH) in our model peptide, A psoralen derivative, which can react with thiol groups, was synthesized and used for specific chemical modification of Cys(57)-Tat-(38-72). We used this psoralen-Tat conjugate (psoralen-Cys(57)-Tat-(38-72)) to form a specific complex with TAR RNA, Upon near-ultraviolet irradiation (360 nm), this synthetic psoralen-peptide cross-linked to a single site in the TAR RNA sequence. The RNA-protein complex was purified and the cross-link site on TAR RNA was determined by RNA sequencing, which revealed that Cys(57) Of Tat is close to U31 of TAR RNA, Our results provide high-resolution proximity and orientation information about Tat-TAR complex, Such psoralen-peptide conjugates provide a new class of probes for sequence-specific protein-nucleic acid interactions and could be used to selectively control gene expression or to induce site-directed mutations.	UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT PHARMACOL,PISCATAWAY,NJ 08854; RUTGERS STATE UNIV,MOL BIOL & BIOCHEM GRAD PROGRAM,PISCATAWAY,NJ 08854	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick					NIAID NIH HHS [AI 34785] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI034785] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABOULELA F, 1995, J MOL BIOL, V253, P313, DOI 10.1006/jmbi.1995.0555; ACHARIAS M, 1995, P NATL AC SCI US, V92, P6052; BAYER P, 1995, J MOL BIOL, V247, P529, DOI 10.1016/S0022-2836(05)80133-0; BERKHOUT B, 1989, CELL, V59, P273, DOI 10.1016/0092-8674(89)90289-4; BERKHOUT B, 1989, J VIROL, V63, P5501, DOI 10.1128/JVI.63.12.5501-5504.1989; CALNAN BJ, 1991, SCIENCE, V252, P1167, DOI 10.1126/science.252.5009.1167; CHURCHER MJ, 1993, J MOL BIOL, V230, P90, DOI 10.1006/jmbi.1993.1128; CIMINO GD, 1985, ANNU REV BIOCHEM, V54, P1151, DOI 10.1146/annurev.bi.54.070185.005443; CORDINGLEY MG, 1990, P NATL ACAD SCI USA, V87, P8985, DOI 10.1073/pnas.87.22.8985; CULLEN BR, 1993, CELL, V73, P417, DOI 10.1016/0092-8674(93)90126-B; CULLEN BR, 1986, CELL, V46, P973, DOI 10.1016/0092-8674(86)90696-3; DAYTON AI, 1986, CELL, V44, P941, DOI 10.1016/0092-8674(86)90017-6; DELLING U, 1991, P NATL ACAD SCI USA, V88, P6234, DOI 10.1073/pnas.88.14.6234; DINGWALL C, 1989, P NATL ACAD SCI USA, V86, P6925, DOI 10.1073/pnas.86.18.6925; FENG S, 1988, NATURE, V334, P165, DOI 10.1038/334165a0; FISHER AG, 1986, NATURE, V320, P367, DOI 10.1038/320367a0; GATIGNOL A, 1989, P NATL ACAD SCI USA, V86, P7828, DOI 10.1073/pnas.86.20.7828; JAKOBOVITS A, 1988, MOL CELL BIOL, V8, P2555, DOI 10.1128/MCB.8.6.2555; KAO SY, 1987, NATURE, V330, P489, DOI 10.1038/330489a0; MARCINIAK RA, 1990, P NATL ACAD SCI USA, V87, P3624, DOI 10.1073/pnas.87.9.3624; NEENHOLD HR, 1995, BIOCHEMISTRY-US, V34, P6303, DOI 10.1021/bi00019a007; PETERLIN BM, 1986, P NATL ACAD SCI USA, V83, P9734, DOI 10.1073/pnas.83.24.9734; PUGLISI JD, 1992, SCIENCE, V257, P76, DOI 10.1126/science.1621097; RICE AP, 1988, NATURE, V332, P551, DOI 10.1038/332551a0; ROSEN CA, 1985, CELL, V41, P813, DOI 10.1016/S0092-8674(85)80062-3; SHELINE CT, 1991, GENE DEV, V5, P2508, DOI 10.1101/gad.5.12b.2508; SIDEROVSKI DP, 1992, NUCLEIC ACIDS RES, V20, P5311, DOI 10.1093/nar/20.20.5311; TAN RY, 1992, BIOCHEMISTRY-US, V31, P10288, DOI 10.1021/bi00157a016; WANG ZY, 1995, J AM CHEM SOC, V117, P5438, DOI 10.1021/ja00125a002; WEEKS KM, 1990, SCIENCE, V249, P1281, DOI 10.1126/science.2205002; WU F, 1991, GENE DEV, V5, P2128, DOI 10.1101/gad.5.11.2128	31	24	26	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					16995	16998		10.1074/jbc.271.29.16995	http://dx.doi.org/10.1074/jbc.271.29.16995			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663586	hybrid			2022-12-25	WOS:A1996UX94300004
J	Kanazawa, S; Ilic, D; Hashiyama, M; Okada, M; Noumura, T; Aizawa, S; Suda, T				Kanazawa, S; Ilic, D; Hashiyama, M; Okada, M; Noumura, T; Aizawa, S; Suda, T			Impaired development of CD4(+) CD8(+) thymocytes by csk-(knock-in) into fyn locus	ONCOGENE			English	Article						p59(fyn); p50(csk); p56(lck); knock-in; thymocytes; T cell development	PROTEIN-TYROSINE KINASE; CELL ANTIGEN RECEPTOR; SRC FAMILY KINASES; CROSS-LINKING; MICE LACKING; MUTANT MICE; ACTIVATION; ASSOCIATION; P56(LCK); ZAP-70	p59(fyn) is one of the Src-family kinases thought to play an important role in signaling through T cell receptor, However, Fyn deficiency has caused no overt defects in vivo on T cell development, nor has it caused any changes in the phosphorylation status of molecules such as ZAP-70 which have been proposed as p59(fyn) substrates, This could be explained as being due to compensation of Fyn deficiency by other Src-family kinases, Here, we have 'knocked-in' the csk gene, a negative regulator of Src-family kinases, into fyn locus to challenge the problem of redundant functions among Src-family kinases, The csk-'knock-in' mice displayed atrophy of the thymic cortex and impaired development of CD4(+) CD8(+) thymocytes, This was concomitant with decrease in tyrosine phosphorylation of ZAP-70 and p120(cbl).	KUMAMOTO UNIV,SCH MED,INST MOLEC EMBRYOL & GENET,DEPT MORPHOGENESIS,KUMAMOTO 860,JAPAN; KUMAMOTO UNIV,SCH MED,INST MOLEC EMBRYOL & GENET,DEPT CELL DIFFERENTIAT,KUMAMOTO 860,JAPAN; SAITAMA UNIV,GRAD SCH ENGN SCI,URAWA,SAITAMA 338,JAPAN; OSAKA UNIV,INST PROT RES,DIV PROT METAB,SUITA,OSAKA 565,JAPAN	Kumamoto University; Kumamoto University; Saitama University; Osaka University			Suda, Toshio/H-6761-2013	Suda, Toshio/0000-0001-7540-1771; ILIC, DUSKO/0000-0003-1647-0026				ALLAND L, 1994, J BIOL CHEM, V269, P16701; APPLEBY MW, 1992, CELL, V70, P751, DOI 10.1016/0092-8674(92)90309-Z; BLACK TJ, 1993, EMBO J, V12, P2017; BOLEN JB, 1993, ONCOGENE, V8, P2025; CHAN AC, 1994, ANNU REV IMMUNOL, V12, P555, DOI 10.1146/annurev.iy.12.040194.003011; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; CHOW LML, 1993, NATURE, V365, P156, DOI 10.1038/365156a0; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; ELDER ME, 1994, SCIENCE, V264, P1596, DOI 10.1126/science.8202712; FUSAKI N, 1994, INT IMMUNOL, V6, P1245, DOI 10.1093/intimm/6.8.1245; GAUEN LKT, 1992, MOL CELL BIOL, V12, P5438, DOI 10.1128/MCB.12.12.5438; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; GROSS JA, 1995, J EXP MED, V181, P463, DOI 10.1084/jem.181.2.463; ILIC D, 1995, BIOCHEM BIOPH RES CO, V209, P300, DOI 10.1006/bbrc.1995.1503; IMAMOTO A, 1993, CELL, V73, P117; KELLER G, 1993, MOL CELL BIOL, V13, P473, DOI 10.1128/MCB.13.1.473; KOLANUS W, 1993, CELL, V74, P171, DOI 10.1016/0092-8674(93)90304-9; LEDBETTER JA, 1993, CURR OPIN IMMUNOL, V5, P334, DOI 10.1016/0952-7915(93)90050-3; LEVIN SD, 1993, J EXP MED, V178, P245, DOI 10.1084/jem.178.1.245; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; NADA S, 1993, CELL, V73, P1125, DOI 10.1016/0092-8674(93)90642-4; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; NEGISHI I, 1995, NATURE, V376, P435, DOI 10.1038/376435a0; OKADA M, 1989, J BIOL CHEM, V264, P20886; OKADA M, 1991, J BIOL CHEM, V266, P24249; OKADA S, 1993, BLOOD, V81, P1720; OLSZOWY MW, 1995, J IMMUNOL, V155, P4236; PERLMUTTER RM, 1993, ANNU REV IMMUNOL, V11, P451, DOI 10.1146/annurev.iy.11.040193.002315; RUDD CE, 1994, IMMUNOL TODAY, V15, P225, DOI 10.1016/0167-5699(94)90248-8; SAMELSON LE, 1992, J BIOL CHEM, V267, P24913; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SAROSI GA, 1992, INT IMMUNOL, V4, P1211, DOI 10.1093/intimm/4.11.1211; STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y; STRAUS DB, 1993, J EXP MED, V178, P1523, DOI 10.1084/jem.178.5.1523; TAMURA T, 1993, J IMMUNOL, V151, P6051; TSYGANKOV AY, 1992, J BIOL CHEM, V267, P18259; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; WEIL R, 1995, J BIOL CHEM, V270, P2791, DOI 10.1074/jbc.270.6.2791; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; YAGI T, 1993, ONCOGENE, V8, P3343; YAGI T, 1993, ANAL BIOCHEM, V214, P77, DOI 10.1006/abio.1993.1459; YAGI T, 1993, ANAL BIOCHEM, V214, P70, DOI 10.1006/abio.1993.1458; YAGI T, 1994, ONCOGENE, V9, P2433	43	6	6	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 4	1996	13	1					199	204						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UX319	8700547				2022-12-25	WOS:A1996UX31900023
J	Antolin, I; Rodriguez, C; Sainz, RM; Mayo, JC; Uria, H; Kotler, MI; RodriguezColunga, MJ; Tolivia, D; MenendezPelaez, A				Antolin, I; Rodriguez, C; Sainz, RM; Mayo, JC; Uria, H; Kotler, MI; RodriguezColunga, MJ; Tolivia, D; MenendezPelaez, A			Neurohormone melatonin prevents cell damage: Effect on gene expression for antioxidant enzymes	FASEB JOURNAL			English	Article						antioxidative protection; melatonin; Harderian glands; porphyrin synthesis	CONTAINING SUPEROXIDE-DISMUTASE; HAMSTER HARDERIAN-GLAND; SYNTHASE MESSENGER-RNA; MAMMALIAN-TISSUES; SYRIAN-HAMSTERS; GOLDEN-HAMSTER; RAT-LIVER; PORPHYRINS; ACID; PROTOPORPHYRIN	It is well known that porphyrins cause a toxic light-mediated effect due to their capability to generate free radicals. Several reports have proved that melatonin is a potent free radical scavenger. The aim of this work has been to study the ability of melatonin to prevent the cell damage caused by porphyrins in the Harderian gland of female Syrian hamsters. Cell injury was evaluated estimating the percentage of damaged cells found in the gland and analyzing the degree of this damage at ultrastructural level. To explain the mechanism by which this hormone could prevent the cell damage caused by porphyrins, its capability to both decrease porphyrin synthesis and increase the mRNA levels for antioxidant enzymes was evaluated. Our results demonstrate that melatonin administration decreases the percentage of damaged cells, porphyrin synthesis, and aminolevulinate synthase (ALA-S) mRNA levels and increases the mRNA levels for manganese superoxide-dismutase and copper-zinc superoxide dismutase. When observed under an electron microscope, the lesions in the clear cells of the treated females were much less severe than in the corresponding cells of the control animals. Melatonin exerts a cytoprotective effect by inhibiting the ALA-S gene expression (and so porphyrin synthesis) and by raising the mRNA levels for several antioxidant enzymes.			Antolin, I (corresponding author), UNIV OVIEDO, DEPT MORFOL & BIOL CELULAR, E-33006 OVIEDO, ASTURIAS, SPAIN.		Mayo, Juan Carlos/H-3435-2011; Sainz, Rosa M./N-5885-2014; Antolin, Isaac/L-6210-2014	Mayo, Juan Carlos/0000-0002-0882-2047; Sainz, Rosa M./0000-0003-3048-5582; Antolin, Isaac/0000-0002-4232-9248; Kotler, Monica Lidia/0000-0002-3555-7621; Rodriguez, Carmen/0000-0002-3203-4753				ACUNACASTROVIEJO D, 1993, RES COMMUN CHEM PATH, V82, P253; ANTOLIN I, 1994, ANAT REC, V239, P349, DOI 10.1002/ar.1092390402; ANTOLIN I, 1996, IN PRESS J STRUCT BI; AVNER DL, 1983, GASTROENTEROLOGY, V85, P700; AVRAHAM KB, 1988, CELL, V54, P823, DOI 10.1016/S0092-8674(88)91153-1; BARLOWWALDEN LR, 1995, NEUROCHEM INT, V26, P497, DOI 10.1016/0197-0186(94)00154-M; BECKERANDRE M, 1994, J BIOL CHEM, V269, P28531; BLOOMER JR, 1988, HEPATOLOGY, V8, P402, DOI 10.1002/hep.1840080235; BUETTNER GR, 1979, FEBS LETT, V98, P18, DOI 10.1016/0014-5793(79)80141-6; BUZZELL GR, 1989, J EXP ZOOL, V249, P172, DOI 10.1002/jez.1402490209; CALBERG C, 1995, J PINEAL RES, V18, P171; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DIVARIS DXG, 1990, AM J PATHOL, V136, P891; EMILIANI C, 1983, PHOTOCHEM PHOTOBIOL, V37, P487, DOI 10.1111/j.1751-1097.1983.tb04505.x; FREEMAN BA, 1983, J BIOL CHEM, V258, P2534; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HALLIWELL B, 1987, FASEB J, V1, P358, DOI 10.1096/fasebj.1.5.2824268; HARDELAND R, 1993, NEUROSCI BIOBEHAV R, V17, P347, DOI 10.1016/S0149-7634(05)80016-8; Hardeland R., 1993, CHRONOBIOLOGY CHRONO, P113; HIROSE K, 1993, FASEB J, V7, P361, DOI 10.1096/fasebj.7.2.8440412; HO YS, 1987, NUCLEIC ACIDS RES, V15, P10070, DOI 10.1093/nar/15.23.10070; HO YS, 1987, NUCLEIC ACIDS RES, V15, P6746, DOI 10.1093/nar/15.16.6746; HOFFMAN RA, 1971, AM J ANAT, V132, P463, DOI 10.1002/aja.1001320405; HURT J, 1992, NUCLEIC ACIDS RES, V20, P2985, DOI 10.1093/nar/20.12.2985; JONAS SK, 1989, BIOCHEM J, V264, P651, DOI 10.1042/bj2640651; KRALL J, 1988, J BIOL CHEM, V263, P1910; MAGNUS IA, 1969, J INVEST DERMATOL, V53, P400, DOI 10.1038/jid.1969.167; MENENDEZPELAEZ A, 1993, J PINEAL RES, V15, P59, DOI 10.1111/j.1600-079X.1993.tb00511.x; MENENDEZPELAEZ A, 1993, J CELL BIOCHEM, V53, P373, DOI 10.1002/jcb.240530415; MENENDEZPELAEZ A, 1991, MOL CELL ENDOCRINOL, V80, P177, DOI 10.1016/0303-7207(91)90154-K; MENENDEZPELAEZ A, 1993, J PINEAL RES, V14, P34, DOI 10.1111/j.1600-079X.1993.tb00482.x; MOAN J, 1984, PHOTOCHEM PHOTOBIOL, V39, P445; PAYNE AP, 1977, J ENDOCRINOL, V75, P73, DOI 10.1677/joe.0.0750073; PAYNE AP, 1994, J ANAT, V185, P1; PIERI C, 1994, LIFE SCI, V55, pPL271, DOI 10.1016/0024-3205(94)00666-0; POEGGELER B, 1993, J PINEAL RES, V14, P151, DOI 10.1111/j.1600-079X.1993.tb00498.x; POHFITZPATRICK MB, 1986, PHOTODERMATOLOGY, V3, P148; REITER RJ, 1993, NEUROENDOCRINOL LETT, V15, P103; RIMINGTON C, 1967, Q J MED, V36, P29; RODRIGUEZ C, 1994, ENDOCRINE, V2, P863; RODRIGUEZCOLUNGA MJ, 1991, J PINEAL RES, V11, P42, DOI 10.1111/j.1600-079X.1991.tb00825.x; RODRIGUEZCOLUNGA MJ, 1992, ANAT REC, V232, P293, DOI 10.1002/ar.1092320214; SANDBERG S, 1982, ACTA DERM-VENEREOL, P75; SLATER TF, 1984, BIOCHEM J, V222, P1; SPIKE RC, 1985, J ANAT, V142, P59; SPIKES JD, 1975, ANN NY ACAD SCI, V244, P496, DOI 10.1111/j.1749-6632.1975.tb41550.x; SRIVASTAVA G, 1988, J BIOL CHEM, V263, P5202; STANKOV B, 1992, J PINEAL RES, V13, P20, DOI 10.1111/j.1600-079X.1992.tb00050.x; STEINHILBER D, 1995, J BIOL CHEM, V270, P7037, DOI 10.1074/jbc.270.13.7037; STRAKA JG, 1990, ANNU REV MED, V41, P457; STRUM JM, 1982, TISSUE CELL, V14, P149, DOI 10.1016/0040-8166(82)90014-3; URIA H, 1994, CELL BIOL PROBLEMS C, P89; VANSTEVENINCK J, 1986, PHOTOCHEM PHOTOBIOL, V44, P711; WARNER B, 1993, AM J PHYSIOL, V264, pL598, DOI 10.1152/ajplung.1993.264.6.L598; YOSHIMURA S, 1988, BIOCHEM BIOPH RES CO, V154, P1024, DOI 10.1016/0006-291X(88)90242-2; ZEEVI M, 1982, MOL CELL BIOL, V2, P517, DOI 10.1128/MCB.2.5.517	56	421	431	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	1996	10	8					882	890		10.1096/fasebj.10.8.8666165	http://dx.doi.org/10.1096/fasebj.10.8.8666165			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	UQ456	8666165				2022-12-25	WOS:A1996UQ45600010
J	Ames, RS; Li, Y; Sarau, HM; Nuthulaganti, P; Foley, JJ; Ellis, C; Zeng, ZZ; Su, K; Jurewicz, AJ; Hertzberg, RP; Bergsma, DJ; Kumar, C				Ames, RS; Li, Y; Sarau, HM; Nuthulaganti, P; Foley, JJ; Ellis, C; Zeng, ZZ; Su, K; Jurewicz, AJ; Hertzberg, RP; Bergsma, DJ; Kumar, C			Molecular cloning and characterization of the human anaphylatoxin C3a receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPRESSION CLONING; C5A ANAPHYLATOXIN; CELL-LINE; SEQUENCE; RESPONSES; BINDING	In a human neutrophil cDNA library, an orphan G-protein-coupled receptor, HNFAG09, with 37% nucleotide identity to the C5a receptor (C5a-R, CD88) was identified. A novel feature of this gene, unlike C5a-R and other G-protein-coupled receptors, is the presence of an extraordinarily large predicted extracellular loop comprised of in excess of 160 amino acid residues between transmembrane domains 4 and 5. Northern blot analysis revealed that expression of mRNA for this receptor in human tissues, while similar, was distinct from C5a-R expression. Although there were differences in expression, transcripts for both receptors were detected in tissues throughout the body and the central nervous system. Mammalian cells stably expressing HNFAG09 specifically bound I-125-C3a and responded to a C3a carboxyl-terminal analogue synthetic peptide and to human C3a but not to rC5a with a robust calcium mobilization response. HNFAG09 encodes the human anaphylatoxin C3a receptor.	SMITHKLINE BEECHAM PHARMACEUT,DEPT MOL GENET,KING OF PRUSSIA,PA 19406; SMITHKLINE BEECHAM PHARMACEUT,DEPT BIOMOL DISCOVERY,KING OF PRUSSIA,PA 19406; SMITHKLINE BEECHAM PHARMACEUT,DEPT PULMONOL PHARMACOL,KING OF PRUSSIA,PA 19406	GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline	Ames, RS (corresponding author), SMITHKLINE BEECHAM PHARMACEUT,DEPT MOL IMMUNOL UE0548,709 SWEDELAND RD,POB 1539,KING OF PRUSSIA,PA 19406, USA.							ADAMS MD, 1992, NATURE, V355, P632, DOI 10.1038/355632a0; ADAMS MD, 1995, NATURE, V377, P3; ADAMS MD, 1991, SCIENCE, V252, P1651, DOI 10.1126/science.2047873; AIYAR N, 1994, MOL CELL BIOCHEM, V131, P75, DOI 10.1007/BF01075727; BOULAY F, 1991, BIOCHEMISTRY-US, V30, P2993, DOI 10.1021/bi00226a002; DEMARTINO JA, 1994, J BIOL CHEM, V269, P14446; EMBER JA, 1991, BIOCHEMISTRY-US, V30, P3603, DOI 10.1021/bi00229a003; GERARD C, 1994, ANNU REV IMMUNOL, V12, P775, DOI 10.1146/annurev.iy.12.040194.004015; GERARD NP, 1991, NATURE, V349, P614, DOI 10.1038/349614a0; HUGLI TE, 1984, SPRINGER SEMIN IMMUN, V7, P193; JELINEK LJ, 1993, SCIENCE, V259, P1614, DOI 10.1126/science.8384375; KLOS A, 1992, BIOCHEMISTRY-US, V31, P11274, DOI 10.1021/bi00161a003; MORGAN BP, 1994, EUR J CLIN INVEST, V24, P219, DOI 10.1111/j.1365-2362.1994.tb01078.x; MURAKAMI Y, 1993, IMMUNOL LETT, V36, P301, DOI 10.1016/0165-2478(93)90104-A; NEEDLEMAN SB, 1970, J MOL BIOL, V48, P443, DOI 10.1016/0022-2836(70)90057-4; RITTERSUERMANN D, 1988, COMPLEMENT SYSTEM, P367; Roglic A, 1996, BBA-GENE STRUCT EXPR, V1305, P39, DOI 10.1016/0167-4781(95)00209-X; SAUSSY DL, 1989, J BIOL CHEM, V264, P19845; SIRAGANIAN RP, 1982, FED PROC, V41, P30; VOGT W, 1986, Complement, V3, P177; WETSEL RA, 1995, CURR OPIN IMMUNOL, V7, P48, DOI 10.1016/0952-7915(95)80028-X	21	201	214	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20231	20234		10.1074/jbc.271.34.20231	http://dx.doi.org/10.1074/jbc.271.34.20231			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702752	hybrid			2022-12-25	WOS:A1996VD33700004
J	Caplan, S; Baniyash, M				Caplan, S; Baniyash, M			Normal T cells express two T cell antigen receptor populations, one of which is linked to the cytoskeleton via zeta chain and displays a unique activation-dependent phosphorylation pattern	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYMPHOCYTE MEMBRANE-PROTEINS; LIGAND-INDUCED ASSOCIATION; TYROSINE KINASE-ACTIVITY; CROSS-LINKING; SIGNAL-TRANSDUCTION; PLASMA-MEMBRANE; CD3-ZETA CHAIN; ZAP-70; TCR; ANTIBODY	The TCR couples antigen recognition and the transmission of activation signals, We report the expression of two TCR populations on the surface of T lymphocytes, one of which is linked to the cytoskeleton via the zeta chain, We also demonstrate that assembly of the CD3 subunits with cytoskeleton associated zeta is necessary for their maximal localization to the cytoskeleton, The potential significance of these two receptor forms is underscored by differences observed in non-activated T cells; while detergent-soluble phosphorylated zeta appears as a 21-kDa protein, phosphorylated cytoskeleton-associated zeta appears as a 16-kDa form, This dichotomous phosphorylation pattern is rigidly maintained following activation, although each of the receptor populations undergoes different activation-dependent modifications: 1) levels of soluble phosphorylated 21-kDa zeta are enhanced, while phosphorylated 16-kDa cytoskeleton-associated zeta exhibits little change; 2) soluble non-phosphorylated 16-kDa zeta translocates to the cytoskeleton; 3) activation dependent ubiquitinated zeta forms localize to both fractions, albeit with different kinetics, We also show that the protein tyrosine kinase Lck undergoes activation-dependent modifications and translocates to the cytoskeleton, The phosphorylation profiles of the dichotomous TCR populations in both non-activated and activated lymphocytes suggest that each population could regulate distinct cellular functions, possibly by select intermolecular associations.	HEBREW UNIV JERUSALEM,HADASSAH MED SCH,LAUTENBERG CTR GEN & TUMOR IMMUNOL,IL-91120 JERUSALEM,ISRAEL	Hebrew University of Jerusalem								ALBRECHT DL, 1988, J IMMUNOL, V141, P3915; APGAR JR, 1990, J IMMUNOL, V145, P3814; AVNUR Z, 1983, J CELL BIOL, V96, P1622, DOI 10.1083/jcb.96.6.1622; BANIYASH M, 1988, J BIOL CHEM, V263, P18225; BRAUN J, 1982, J IMMUNOL, V128, P1198; CAPLAN S, 1995, IMMUNOL RES, V14, P98, DOI 10.1007/BF02918171; CAPLAN S, 1995, P NATL ACAD SCI USA, V92, P4768, DOI 10.1073/pnas.92.11.4768; CENCIARELLI C, 1992, SCIENCE, V257, P795, DOI 10.1126/science.1323144; CLARK EA, 1994, TRENDS BIOCHEM SCI, V19, P464, DOI 10.1016/0968-0004(94)90131-7; DEBELL KE, 1992, J IMMUNOL, V149, P2271; DENHARTIGH JC, 1992, J CELL BIOL, V119, P349, DOI 10.1083/jcb.119.2.349; FRANK SJ, 1990, SCIENCE, V249, P174, DOI 10.1126/science.2371564; GAUEN LKT, 1992, MOL CELL BIOL, V12, P5438, DOI 10.1128/MCB.12.12.5438; GEPPERT TD, 1991, J IMMUNOL, V146, P3298; GRONOWSKI AM, 1993, ENDOCRINOLOGY, V133, P2838, DOI 10.1210/en.133.6.2838; GRONOWSKI AM, 1995, ENDOCRINOLOGY, V136, P2198, DOI 10.1210/en.136.5.2198; HAMEL E, 1984, BIOCHEMISTRY-US, V23, P4173, DOI 10.1021/bi00313a026; HEDRICK SM, 1982, CELL, V30, P141, DOI 10.1016/0092-8674(82)90020-4; HOU D, 1994, J BIOL CHEM, V269, P14244; ISAKOV N, 1995, J EXP MED, V181, P375, DOI 10.1084/jem.181.1.375; LELKES PI, 1986, FEBS LETT, V208, P357, DOI 10.1016/0014-5793(86)81049-3; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; LETOURNEUR F, 1991, P NATL ACAD SCI USA, V88, P8905, DOI 10.1073/pnas.88.20.8905; LOKESHWAR VB, 1992, J BIOL CHEM, V267, P21551; LUNA EJ, 1992, SCIENCE, V258, P955, DOI 10.1126/science.1439807; MADRENAS J, 1995, SCIENCE, V267, P515, DOI 10.1126/science.7824949; MANOLIOS N, 1994, EUR J IMMUNOL, V24, P84, DOI 10.1002/eji.1830240114; MAO SY, 1992, P NATL ACAD SCI USA, V89, P222, DOI 10.1073/pnas.89.1.222; MARANO N, 1989, J IMMUNOL, V143, P931; NAKAYAMA T, 1989, NATURE, V341, P651, DOI 10.1038/341651a0; NEL AE, 1995, J BIOL CHEM, V270, P18428, DOI 10.1074/jbc.270.31.18428; OFFRINGA R, 1993, J BIOL CHEM, V268, P4979; ONO S, 1995, IMMUNITY, V2, P639, DOI 10.1016/1074-7613(95)90008-X; ORLOFF DG, 1989, J BIOL CHEM, V264, P14812; OSMAN N, 1995, EUR J IMMUNOL, V25, P2863, DOI 10.1002/eji.1830251023; OSMAN N, 1995, J BIOL CHEM, V270, P13981, DOI 10.1074/jbc.270.23.13981; PARSEY MV, 1993, J IMMUNOL, V151, P1881; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; ROBERTSON D, 1986, J IMMUNOL, V136, P4565; ROZDZIAL MM, 1995, IMMUNITY, V3, P323; RUDD CE, 1994, IMMUNOL TODAY, V15, P225, DOI 10.1016/0167-5699(94)90248-8; SALMERON A, 1995, J IMMUNOL, V154, P1675; SAMELSON LE, 1992, J BIOL CHEM, V267, P24913; SAMELSON LE, 1986, J IMMUNOL, V137, P3254; SAMELSON LE, 1986, CELL, V46, P1083, DOI 10.1016/0092-8674(86)90708-7; SAROSI GA, 1992, INT IMMUNOL, V4, P1211, DOI 10.1093/intimm/4.11.1211; SLOANLANCASTER J, 1994, CELL, V79, P913, DOI 10.1016/0092-8674(94)90080-9; SUSSMAN JJ, 1988, CELL, V52, P85, DOI 10.1016/0092-8674(88)90533-8; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; VALITUTTI S, 1995, J EXP MED, V181, P577, DOI 10.1084/jem.181.2.577; VANOERS NSC, 1994, IMMUNITY, V1, P675, DOI 10.1016/1074-7613(94)90038-8; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WEISS A, 1993, CELL, V73, P209, DOI 10.1016/0092-8674(93)90221-B; WODA BA, 1983, J IMMUNOL, V131, P1917; WODA BA, 1984, J IMMUNOL, V133, P2767	55	50	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20705	20712		10.1074/jbc.271.34.20705	http://dx.doi.org/10.1074/jbc.271.34.20705			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702821	hybrid			2022-12-25	WOS:A1996VD33700073
J	Chandran, UR; Attardi, B; Friedman, R; Zheng, ZW; Roberts, JL; DeFranco, DB				Chandran, UR; Attardi, B; Friedman, R; Zheng, ZW; Roberts, JL; DeFranco, DB			Glucocorticoid repression of the mouse gonadotropin-releasing hormone gene is mediated by promoter elements that are recognized by heteromeric complexes containing glucocorticoid receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL HYPOTHALAMIC-AMENORRHEA; PROTEIN-PROTEIN-INTERACTION; OCTAMER-BINDING PROTEINS; NEURON-SPECIFIC ENHANCER; TRANSCRIPTION FACTOR; CELL-LINES; POU DOMAIN; KINASE-C; LUTEINIZING-HORMONE; NEGATIVE REGULATION	We have identified two regions of the mouse gonadotropin-releasing hormone (GnRH) promoter, one between -237 and -201 (distal element) and the other between -184 and -150 (proximal element), which are required for glucocorticoid repression in transiently transfected GT1-7 cells. These sequences show no similarity to known positive or negative glucocorticoid response elements (nGREs) and do not function when placed upstream of heterologous viral promoters. The glucocorticoid receptor (GR) does not bind directly to the distal or proximal promoter elements but may participate in glucocorticoid repression of GdRH gene transcription by virtue of its association within multiprotein complexes at these nGREs. Electrophoretic mobility shift assays with GT1-7 nuclear extract demonstrate the presence of GR-containing protein complexes on GnRH nGREs. One protein that co-occupies the distal nGRE fn vitro along with GR is the POU domain transcription factor Oct-1. Thus, the tethering of Oh to the GnRH distal nGRE, by virtue of a direct or indirect association with DNA-bound Oct-1, could play a role in hormone-dependent transcriptional repression of the GnRH gene. In contrast, Oct-1 does not appear to be a component of the GR-containing protein complex that is bound to the proximal nGRE.	UNIV PITTSBURGH, DEPT BIOL SCI, PITTSBURGH, PA 15260 USA; UNIV PITTSBURGH, SCH MED, DEPT MED, PITTSBURGH, PA 15261 USA; MT SINAI SCH MED, ARTHUR M FISHBERG RES CTR NEUROBIOL, NEW YORK, NY 10029 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Icahn School of Medicine at Mount Sinai					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047938] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK47938] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHIMA RS, 1992, NEUROENDOCRINOLOGY, V56, P845, DOI 10.1159/000126315; ATTARDI B, 1991, FOCUS, V13, P84; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BENDALL AJ, 1993, EUR J BIOCHEM, V217, P799, DOI 10.1111/j.1432-1033.1993.tb18308.x; BERGA SL, 1989, J CLIN ENDOCR METAB, V68, P301, DOI 10.1210/jcem-68-2-301; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRANN DW, 1991, BIOL REPROD, V44, P1005, DOI 10.1095/biolreprod44.6.1005; BRUDER JM, 1992, ENDOCRINOLOGY, V131, P2552, DOI 10.1210/en.131.6.2552; BRUGGEMEIER U, 1991, CELL, V64, P565, DOI 10.1016/0092-8674(91)90240-Y; CHANDRAN UR, 1994, ENDOCRINOLOGY, V134, P1467, DOI 10.1210/en.134.3.1467; CLARK ME, 1995, MOL CELL BIOL, V15, P6169; COLLUM RG, 1992, NUCLEIC ACIDS RES, V20, P4919, DOI 10.1093/nar/20.18.4919; DELAESCALERA G, 1995, NEUROENDOCRINOLOGY, V61, P310, DOI 10.1159/000126853; DELAESCALERA GM, 1994, NEUROENDOCRINOLOGY, V59, P420, DOI 10.1159/000126687; DELAESCALERA GM, 1992, ENDOCRINOLOGY, V131, P1397; DELAESCALERA GM, 1992, ENDOCRINOLOGY, V131, P2965; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DROUIN J, 1993, EMBO J, V12, P145, DOI 10.1002/j.1460-2075.1993.tb05640.x; DUBEY AK, 1985, BIOL REPROD, V33, P423, DOI 10.1095/biolreprod33.2.423; ERALY SA, 1995, MOL ENDOCRINOL, V9, P848, DOI 10.1210/me.9.7.848; EUSTICE DC, 1991, BIOTECHNIQUES, V11, P739; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GAMETCHU B, 1984, ENDOCRINOLOGY, V114, P274, DOI 10.1210/endo-114-1-274; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; HARA Y, 1992, P NATL ACAD SCI USA, V89, P3280, DOI 10.1073/pnas.89.8.3280; HERR W, 1995, GENE DEV, V9, P1679, DOI 10.1101/gad.9.14.1679; HOLLOWAY JM, 1995, GENE DEV, V9, P1992, DOI 10.1101/gad.9.16.1992; JANTZEN HM, 1987, CELL, V49, P29, DOI 10.1016/0092-8674(87)90752-5; KEPA JK, 1992, NUCLEIC ACIDS RES, V20, P1393, DOI 10.1093/nar/20.6.1393; KEPA JK, 1994, ENDOCRINE, V2, P947; KONIG H, 1992, EMBO J, V11, P2241, DOI 10.1002/j.1460-2075.1992.tb05283.x; KRISTIE TM, 1990, GENE DEV, V4, P2383, DOI 10.1101/gad.4.12b.2383; KUTOH E, 1992, MOL CELL BIOL, V12, P4960, DOI 10.1128/MCB.12.11.4960; LUO Y, 1992, CELL, V71, P231, DOI 10.1016/0092-8674(92)90352-D; MATHIS JM, 1992, EMBO J, V11, P2551, DOI 10.1002/j.1460-2075.1992.tb05320.x; MELLON PL, 1990, NEURON, V5, P1, DOI 10.1016/0896-6273(90)90028-E; MORDACQ JC, 1989, GENE DEV, V3, P760, DOI 10.1101/gad.3.6.760; MORETTO M, 1993, ENDOCRINOLOGY, V133, P2399, DOI 10.1210/en.133.5.2399; Nakai S, 1995, GENE DEV, V9, P3109, DOI 10.1101/gad.9.24.3109; PADMANABHAN V, 1983, ENDOCRINOLOGY, V112, P1782, DOI 10.1210/endo-112-5-1782; PAYVAR F, 1983, CELL, V35, P381, DOI 10.1016/0092-8674(83)90171-X; POMERANTZ JL, 1995, P NATL ACAD SCI USA, V92, P9752, DOI 10.1073/pnas.92.21.9752; REAME NE, 1985, J CLIN ENDOCR METAB, V61, P851, DOI 10.1210/jcem-61-5-851; SAKAI DD, 1988, GENE DEV, V2, P1144, DOI 10.1101/gad.2.9.1144; SAMBROOK J, 1982, MOL CLONING LAB MANU, P1; SCHEINMAN RI, 1995, MOL CELL BIOL, V15, P943; Schonemann MD, 1995, GENE DEV, V9, P3122, DOI 10.1101/gad.9.24.3122; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; STROMSTEDT PE, 1991, MOL CELL BIOL, V11, P3379, DOI 10.1128/MCB.11.6.3379; STRUBIN M, 1995, CELL, V80, P497, DOI 10.1016/0092-8674(95)90500-6; STURM R, 1987, GENE DEV, V1, P1147, DOI 10.1101/gad.1.10.1147; SUH BY, 1988, J CLIN ENDOCR METAB, V66, P733, DOI 10.1210/jcem-66-4-733; SULLIVAN WP, 1986, ENDOCRINOLOGY, V119, P1549, DOI 10.1210/endo-119-4-1549; Wegner M, 1993, CURR OPIN CELL BIOL, V5, P488, DOI 10.1016/0955-0674(93)90015-I; WETSEL WC, 1993, ENDOCRINOLOGY, V132, P2360, DOI 10.1210/en.132.6.2360; WHYTE DB, 1995, MOL ENDOCRINOL, V9, P467, DOI 10.1210/me.9.4.467; XI H, 1989, NATURE, V340, P35, DOI 10.1038/340035a0; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; YU KL, 1994, MOL CELL ENDOCRINOL, V102, P85, DOI 10.1016/0303-7207(94)90101-5	62	62	62	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20412	20420		10.1074/jbc.271.34.20412	http://dx.doi.org/10.1074/jbc.271.34.20412			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702778	hybrid			2022-12-25	WOS:A1996VD33700030
J	Liapakis, G; Fitzpatrick, D; Hoeger, C; Rivier, J; Vandlen, R; Reisine, T				Liapakis, G; Fitzpatrick, D; Hoeger, C; Rivier, J; Vandlen, R; Reisine, T			Identification of ligand binding determinants in the somatostatin receptor subtypes 1 and 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KAPPA-OPIOID RECEPTOR; TYROSINE PHOSPHATASE; CELL-PROLIFERATION; MOLECULAR-BIOLOGY; GASTRIC-ACID; ANALOGS; INHIBITION; CLONING; SSTR2; AFFINITY	The somatostatin (SRIF) receptors (SSTRs) 1 and 2 bind SRIF and SRIF 28 with high affinity, although a number of synthetic hexapeptide and octapeptide analogs of SRIF bind selectively to SSTR2. Extracellular loop three and its adjoining trans-membrane-spanning regions contain elements essential for the binding of such analogs to murine SSTR2. In particular, a stretch of amino acids from residues 294-297 (FDFV) in murine SSTR2 in trans membrane domain seven can determine affinity for the SSTR2-selective analogs. Within this region, Phe(294) has previously been predicted to be essential for the binding of octapeptides (Kaupmann, K., Bruns, C., Raulf, F., Weber, H., Mattes, H., and Lubbert, H. (1995) EMBO J. 14, 727-735) based on the observation that SSTR1 can bind the octapeptide SMS-201-995 with reasonable affinity after a Ser to-Phe conversion in the analogous region of this receptor (SSTR(1S305F)). We find that SSTR1(S305F) has low affinity for a number of SSTR2-selective hexapeptides, suggesting that these analogs have different binding requirements than SMS-201-995. A correlation is seen between the ability of SSTR1(S305F) to bind hexapeptide analogs and the presence of a phenylalanine, but not tyrosine, at position two in these small cyclic molecules. Thus, a single hydroxyl group in hexapeptides can play a critical role in determining re ceptor binding to these receptor mutants. We also find that the second extracellular loop of SSTR1 is important for the selectivity of certain SRIF agonists for binding to SSTR1. Taken together, our data indicate that there are multiple elements in the somatostatin receptors that can determine the binding affinity and selectivity of peptide analogs.	UNIV PENN,SCH MED,DEPT PHARMACOL,PHILADELPHIA,PA 19104; GENENTECH INC,DEPT PROT CHEM,SAN FRANCISCO,CA 94080; SALK INST BIOL STUDIES,PEPTIDE BIOL LAB,LA JOLLA,CA 92037	University of Pennsylvania; Roche Holding; Genentech; Salk Institute					NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH048518] Funding Source: NIH RePORTER; NIMH NIH HHS [MH45533, MH48518] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BELL GI, 1993, TRENDS NEUROSCI, V16, P34, DOI 10.1016/0166-2236(93)90050-V; BLOOM SR, 1975, GUT, V16, P834; BRAZEAU P, 1972, SCIENCE, V129, P77; BROWN M, 1977, SCIENCE, V196, P1467, DOI 10.1126/science.867045; BROWN NJ, 1990, AM J MED SCI, V300, P267, DOI 10.1097/00000441-199010000-00011; BRUNO JF, 1992, P NATL ACAD SCI USA, V89, P11151, DOI 10.1073/pnas.89.23.11151; BUSCAIL L, 1995, P NATL ACAD SCI USA, V92, P1580, DOI 10.1073/pnas.92.5.1580; BUSCAIL L, 1994, P NATL ACAD SCI USA, V91, P2315, DOI 10.1073/pnas.91.6.2315; FITZPATRICK VD, 1994, J BIOL CHEM, V269, P24621; FONG TM, 1992, MOL PHARMACOL, V41, P24; GOMEZPAN A, 1975, LANCET, V1, P888; HELLMAN B, 1969, ENDOCRINOLOGY, V84, P1484, DOI 10.1210/endo-84-6-1484; HUANG ZW, 1992, J AM CHEM SOC, V114, P9390, DOI 10.1021/ja00050a019; IMAI Y, 1991, NUCLEIC ACIDS RES, V19, P2785, DOI 10.1093/nar/19.10.2785; KAUPMANN K, 1995, EMBO J, V14, P727, DOI 10.1002/j.1460-2075.1995.tb07051.x; KONG HY, 1994, P NATL ACAD SCI USA, V91, P8042, DOI 10.1073/pnas.91.17.8042; KUBOTA A, 1994, J CLIN INVEST, V93, P1321, DOI 10.1172/JCI117090; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAMBERTS SWJ, 1991, ENDOCR REV, V12, P450, DOI 10.1210/edrv-12-4-450; Liapakis G, 1996, J PHARMACOL EXP THER, V276, P1089; LIEBOW C, 1989, P NATL ACAD SCI USA, V86, P2003, DOI 10.1073/pnas.86.6.2003; MANDARINO L, 1981, NATURE, V291, P76, DOI 10.1038/291076a0; OCARROLL AM, 1994, MOL PHARMACOL, V46, P291; OCARROLL AM, 1992, MOL PHARMACOL, V42, P939; RAYNOR K, 1993, MOL PHARMACOL, V44, P385; RAYNOR K, 1993, MOL PHARMACOL, V43, P838; RAYNOR K, 1992, CRIT REV NEUROBIOL, V16, P273; REICHLIN S, 1983, NEW ENGL J MED, V309, P1495, DOI 10.1056/NEJM198312153092406; REISINE T, 1995, ENDOCR REV, V16, P427, DOI 10.1210/er.16.4.427; RENSDOMIANO S, 1992, MOL PHARMACOL, V42, P28; ROSSOWSKI WJ, 1994, BIOCHEM BIOPH RES CO, V205, P341, DOI 10.1006/bbrc.1994.2670; ROSSOWSKI WJ, 1994, PEPTIDES, V15, P1421, DOI 10.1016/0196-9781(94)90118-X; TAYLOR JE, 1994, PEPTIDES, V15, P1229, DOI 10.1016/0196-9781(94)90146-5; WANG JB, 1994, J BIOL CHEM, V269, P25966; XUE JC, 1994, J BIOL CHEM, V269, P30195; YAMADA Y, 1992, P NATL ACAD SCI USA, V89, P251, DOI 10.1073/pnas.89.1.251; YAMADA Y, 1992, MOL ENDOCRINOL, V6, P2136, DOI 10.1210/me.6.12.2136; YASUDA K, 1992, J BIOL CHEM, V267, P20422	38	42	44	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20331	20339		10.1074/jbc.271.34.20331	http://dx.doi.org/10.1074/jbc.271.34.20331			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702767	hybrid			2022-12-25	WOS:A1996VD33700019
J	Pellizzari, R; Rossetto, O; Lozzi, L; Giovedi, S; Johnson, E; Shone, CC; Montecucco, C				Pellizzari, R; Rossetto, O; Lozzi, L; Giovedi, S; Johnson, E; Shone, CC; Montecucco, C			Structural determinants of the specificity for synaptic vesicle-associated membrane protein/synaptobrevin of tetanus and botulinum type B and G neurotoxins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUROTRANSMITTER RELEASE; CLOSTRIDIAL NEUROTOXINS; PROTEOLYTIC CLEAVAGE; SEROTYPE-A; IN-VITRO; PROTEIN; TOXIN; TRANSPORT; FUSION; VAMP/SYNAPTOBREVIN	Tetanus and botulinum neurotoxins type B and G are zinc-endopeptidases of remarkable specificity. They recognize and cleave a synaptic vesicle-associated membrane protein (VAMP)/synaptobrevin, an essential protein component of the vesicle docking and fusion apparatus. VAMP contains two copies of a nine-residue motif, also present in SNAP-25 (synaptosomal-associated protein of 25 kDa) and syntaxin, the two other substrates of clostridial neurotoxins. This motif was suggested to be a determinant of the target specificity of neurotoxins. Antibodies raised against this motif cross-react among VAMP, SNAP-25, and syntaxin and inhibit the proteolytic activity of the neurotoxins. Moreover; the various neurotoxins cross-inhibit each other's proteolytic action. The role of the three negatively charged residues of the motif in neurotoxin recognition was probed by site-directed mutagenesis. Substitution of acidic residues in both copies of the VAMP motif indicate that the first one is involved in tetanus neurotoxin recognition, whereas the second one is implicated in binding botulinum B and G neurotoxins. These results suggest that the two copies of the motif have a tandem association in the VAMP molecule.	UNIV PADUA,CTR CONSIGLIO NAZL RIC BIOMEMBRANE,I-35100 PADUA,ITALY; UNIV SIENA,DIPARTIMENTO BIOL MOL,SIENA,ITALY; UNIV WISCONSIN,FOOD RES INST,MADISON,WI 53706; PUBL HLTH LAB SERV,CTR APPL MICROBIOL & RES,SALISBURY SP4 0JG,WILTS,ENGLAND	University of Padua; University of Siena; University of Wisconsin System; University of Wisconsin Madison	Pellizzari, R (corresponding author), UNIV PADUA,DIPARTIMENTO SCI BIOMED,VIA TRIESTE 75,I-35100 PADUA,ITALY.		Lozzi, Luisa/Q-8542-2018; rossetto, ornella/AAC-3866-2022; Giovedì, Silvia/AAB-7614-2019	Lozzi, Luisa/0000-0002-1603-8770; rossetto, ornella/0000-0002-6113-3857; GIOVEDI', SILVIA/0000-0001-7949-4274	Telethon [763] Funding Source: Medline	Telethon(Fondazione Telethon)		BINZ T, 1994, J BIOL CHEM, V269, P1617; BLASI J, 1993, EMBO J, V12, P4821, DOI 10.1002/j.1460-2075.1993.tb06171.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAPMAN ER, 1995, J BIOL CHEM, V270, P23667, DOI 10.1074/jbc.270.40.23667; CORNILLE F, 1994, EUR J BIOCHEM, V222, P173, DOI 10.1111/j.1432-1033.1994.tb18855.x; DasGupta B. R., 1994, THERAPY BOTULINUM TO, P15; DENTE L, 1987, METHOD ENZYMOL, V155, P111; DESNOS C, 1995, J CELL BIOL, V130, P1041, DOI 10.1083/jcb.130.5.1041; EFFERINK LA, 1989, J BIOL CHEM, V264, P11061; FERRONOVICK S, 1994, NATURE, V370, P191, DOI 10.1038/370191a0; Foran P, 1996, BIOCHEMISTRY-US, V35, P2630, DOI 10.1021/bi9519009; FORAN P, 1994, BIOCHEMISTRY-US, V33, P15365, DOI 10.1021/bi00255a017; GROTE E, 1995, CELL, V81, P581, DOI 10.1016/0092-8674(95)90079-9; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Halpern JL, 1995, CURR TOP MICROBIOL, V195, P221; HAYASHI T, 1994, EMBO J, V13, P5051, DOI 10.1002/j.1460-2075.1994.tb06834.x; KREIS TE, 1986, EMBO J, V5, P931, DOI 10.1002/j.1460-2075.1986.tb04306.x; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEBEDA FJ, 1994, PROTEINS, V20, P293, DOI 10.1002/prot.340200402; MONTECUCCO C, 1994, FEBS LETT, V346, P92, DOI 10.1016/0014-5793(94)00449-8; Montecucco C, 1995, Q REV BIOPHYS, V28, P423, DOI 10.1017/S0033583500003292; OsenSand A, 1996, J COMP NEUROL, V367, P222, DOI 10.1002/(SICI)1096-9861(19960401)367:2<222::AID-CNE5>3.0.CO;2-7; PELLEGRINI LL, 1995, EMBO J, V14, P4705, DOI 10.1002/j.1460-2075.1995.tb00152.x; ROSSETTO O, 1994, NATURE, V372, P415, DOI 10.1038/372415a0; ROSSETTO O, 1992, BIOCHEM J, V285, P9, DOI 10.1042/bj2850009; ROSSETTO O, 1995, J PHYSIOLOGY-PARIS, V89, P43, DOI 10.1016/0928-4257(96)80550-X; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SCHIAVO G, 1995, J BIOL CHEM, V270, P10566, DOI 10.1074/jbc.270.18.10566; SCHIAVO G, 1992, NATURE, V359, P832, DOI 10.1038/359832a0; SCHIAVO G, 1995, METHOD ENZYMOL, V248, P643; SCHIAVO G, 1993, J BIOL CHEM, V268, P23784; SCHIAVO G, 1993, J BIOL CHEM, V268, P11516; SCHIAVO G, 1993, FEBS LETT, V335, P99, DOI 10.1016/0014-5793(93)80448-4; SCHIAVO G, 1991, EUR J BIOCHEM, V199, P705, DOI 10.1111/j.1432-1033.1991.tb16174.x; SCHIAVO G, 1994, J BIOL CHEM, V269, P20213; SHONE CC, 1994, EUR J BIOCHEM, V225, P263, DOI 10.1111/j.1432-1033.1994.00263.x; SHONE CC, 1993, EUR J BIOCHEM, V217, P965, DOI 10.1111/j.1432-1033.1993.tb18327.x; Shone CC, 1995, CURR TOP MICROBIOL, V195, P143; Simpson L.L., 1989, BOTULINUM NEUROTOXIN; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; SWEENEY ST, 1995, NEURON, V14, P341, DOI 10.1016/0896-6273(95)90290-2; Williamson LC, 1996, J BIOL CHEM, V271, P7694, DOI 10.1074/jbc.271.13.7694; YAMASAKI S, 1994, J BIOL CHEM, V269, P12764; [No title captured]	44	92	98	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20353	20358		10.1074/jbc.271.34.20353	http://dx.doi.org/10.1074/jbc.271.34.20353			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702770	hybrid, Green Published			2022-12-25	WOS:A1996VD33700022
J	Saint, N; Lou, KL; Widmer, C; Luckey, M; Schirmer, T; Rosenbusch, JP				Saint, N; Lou, KL; Widmer, C; Luckey, M; Schirmer, T; Rosenbusch, JP			Structural and functional characterization of OmpF porin mutants selected for larger pore size .2. Functional characterization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI OUTER-MEMBRANE; ESCHERICHIA-COLI; CHANNELS; PROTEIN; SELECTIVITY; DIFFUSION; BACTERIA	The effects on the channel characteristics of four single amino acid substitutions in OmpF porin and of a deletion mutant in the constriction loop L3 have been studied. These mutations are all located in the narrow section of the channel of the protein that forms pores across the outer membrane of Escherichia coli, The single channel conductance of the deletion mutant (Delta 109-114) is decreased by one third, whereas the point mutations do not exhibit significant deviations from that of the wild-type protein. The mutants exhibit drastic changes in ion selectivities. In the wild-type protein, the critical threshold potential (V-c), above which channels close reversibly, exhibits a strong pH dependence, with a titration point of similar to pH 7.7, which is abolished in all mutants studied here. Diffusion of six monosaccharides is little affected in the point mutants, while four disaccharides are taken up at highly increased rates by the deletion mutant. The functional results, presented here, are correlated to the x-ray structures of the mutants (Leu, K.-L., Saint, N., Prilipov, A, Rummel, G., Benson, S.A., Rosenbusch, J.P., and Schirmer, T. (1998) J. Biol. Chem. 271, 20669-20675). in most, but not all, cases, the structural changes explain the functional alterations observed.	UNIV BASEL, BIOZENTRUM, DEPT MICROBIOL, CH-4056 BASEL, SWITZERLAND; UNIV BASEL, BIOZENTRUM, DEPT BIOL STRUCT, CH-4056 BASEL, SWITZERLAND; SAN FRANCISCO STATE UNIV, DEPT CHEM & BIOCHEM, SAN FRANCISCO, CA 94132 USA	University of Basel; University of Basel; California State University System; San Francisco State University			Saint, Nathalie/S-5286-2016	Saint, Nathalie/0000-0001-5219-9486				BENSON SA, 1988, J MOL BIOL, V203, P961, DOI 10.1016/0022-2836(88)90121-0; BENZ R, 1988, ANNU REV MICROBIOL, V42, P359, DOI 10.1146/annurev.mi.42.100188.002043; BENZ R, 1985, J BACTERIOL, V162, P722, DOI 10.1128/JB.162.2.722-727.1985; BUEHLER LK, 1991, J BIOL CHEM, V266, P24446; COWAN SW, 1992, NATURE, V358, P727, DOI 10.1038/358727a0; DARGENT B, 1987, FEBS LETT, V220, P136, DOI 10.1016/0014-5793(87)80891-8; Dutzler R, 1996, STRUCTURE, V4, P127, DOI 10.1016/S0969-2126(96)00016-0; EISENBERG RS, 1995, J CHEM PHYS, V102, P1767, DOI 10.1063/1.468704; HODGKIN AL, 1949, J PHYSIOL-LONDON, V108, P37, DOI 10.1113/jphysiol.1949.sp004310; JEANTEUR D, 1994, P NATL ACAD SCI USA, V91, P10675, DOI 10.1073/pnas.91.22.10675; KARSHIKOFF A, 1994, J MOL BIOL, V240, P372, DOI 10.1006/jmbi.1994.1451; Lou KL, 1996, J BIOL CHEM, V271, P20669, DOI 10.1074/jbc.271.34.20669; LUCKEY M, 1980, P NATL ACAD SCI-BIOL, V77, P167, DOI 10.1073/pnas.77.1.167; MCDERMOTT G, 1995, NATURE, V374, P517, DOI 10.1038/374517a0; MIZUNO T, 1983, J BIOL CHEM, V258, P6932; NIKAIDO H, 1985, MICROBIOL REV, V49, P1; PARDEE AB, 1959, J MOL BIOL, V1, P165, DOI 10.1016/S0022-2836(59)80045-0; PAUPTIT RA, 1991, J MOL BIOL, V218, P505, DOI 10.1016/0022-2836(91)90696-4; Saint N, 1996, BIOCHEM BIOPH RES CO, V223, P118, DOI 10.1006/bbrc.1996.0855; SCHINDLER H, 1978, P NATL ACAD SCI USA, V75, P3751, DOI 10.1073/pnas.75.8.3751; SCHINDLER H, 1981, P NATL ACAD SCI-BIOL, V78, P2302, DOI 10.1073/pnas.78.4.2302; SCHINDLER H, 1989, METHOD ENZYMOL, V171, P225; SCHIRMER T, 1995, SCIENCE, V264, P914; STEIERT M, 1993, THESIS U BASEL BASEL; TODT JC, 1992, BIOCHEMISTRY-US, V31, P10479, DOI 10.1021/bi00158a010	25	169	175	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20676	20680		10.1074/jbc.271.34.20676	http://dx.doi.org/10.1074/jbc.271.34.20676			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702817	hybrid			2022-12-25	WOS:A1996VD33700069
J	Li, QS; DasGupta, J; Hunt, AG				Li, QS; DasGupta, J; Hunt, AG			A plant poly(A) polymerase requires a novel RNA-binding protein for activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; SACCHAROMYCES-CEREVISIAE; POLYADENYLATION SIGNAL; GENE; PURIFICATION; EXPRESSION; ELEMENT	We have purified a novel factor (PAP-III) that is a component of a multisubunit poly(A) polymerase from pea seedlings. This factor consists of one or more polypeptides with molecular masses of about 105 kDa and of a population of associated RNAs that can serve as substrates for polyadenylation. When these RNAs are separated from the 105-kDa polypeptides, polyadenylation becomes dependent upon exogenously added RNA. This RNA-dependent activity does not require the presence of a polyadenylation signal in the substrate, indicating that the activity under study is a nonspecific polyadenylation activity. One or more of the 108-kDa polypeptides could be cross-linked to the products of polyadenylation labeled with [alpha-P-32]ATP and to exogenously added labeled RNAs. Cross-linking of the 105-kDa polypeptides to the products of polyadenylation was not affected by the presence of exogenously added competitors, whereas cross-linking to exogenous RNAs was diminished by excesses of RNA homopolymers. Exogenous RNAs could be polyadenylated by the combination of PAP-I + PAP-III, and this activity was diminished if the binding of the exogenous RNAs to PAP-III was prevented. We conclude from these studies that PAP-III is an RNA binding protein, that polyadenylation by the poly(A) polymerase occurs while the substrate RNAs are associated with this protein, and that the pea poly(A) polymerase can only polyadenylate those RNAs that are associated with PAP-III.	UNIV KENTUCKY,DEPT AGRON,PLANT PHYSIOL BIOCHEM MOLEC BIOL PROGRAM,LEXINGTON,KY 40546	University of Kentucky			Li, Qingshun/C-5603-2009; Hunt, Arthur/A-8040-2009	Li, Qingshun/0000-0003-4105-1480; Hunt, Arthur/0000-0002-0008-4158				ANDERSON JT, 1993, MOL CELL BIOL, V13, P2730, DOI 10.1128/MCB.13.5.2730; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; CAO GJ, 1992, P NATL ACAD SCI USA, V89, P10380, DOI 10.1073/pnas.89.21.10380; CHEN J, 1992, MOL CELL BIOL, V12, P3470, DOI 10.1128/MCB.12.8.3470; CORRUZZI G, 1994, EMBO J, V3, P1671; DASGUPTA J, 1995, PLANT SCI, V110, P215; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; GERSHON PD, 1991, CELL, V66, P1269, DOI 10.1016/0092-8674(91)90048-4; LI QS, 1995, PLANT MOL BIOL, V28, P927, DOI 10.1007/BF00042076; LINGNER J, 1991, NATURE, V354, P496, DOI 10.1038/354496a0; LINGNER J, 1991, J BIOL CHEM, V266, P8741; MANLEY JL, 1995, P NATL ACAD SCI USA, V92, P1800, DOI 10.1073/pnas.92.6.1800; MOGEN BD, 1992, MOL CELL BIOL, V12, P5406, DOI 10.1128/MCB.12.12.5406; PULLMAN JM, 1983, J CELL BIOL, V97, P99, DOI 10.1083/jcb.97.1.99; RAABE T, 1991, NATURE, V353, P229, DOI 10.1038/353229a0; WAHLE E, 1991, J BIOL CHEM, V266, P3131; WAHLE E, 1993, J BIOL CHEM, V268, P2937; WAHLE E, 1991, CELL, V66, P759, DOI 10.1016/0092-8674(91)90119-J; WAHLE E, 1995, J BIOL CHEM, V270, P2800, DOI 10.1074/jbc.270.6.2800; WAHLE E, 1995, BBA-GENE STRUCT EXPR, V1261, P183, DOI 10.1016/0167-4781(94)00248-2; WILSON SM, 1994, J CELL BIOL, V127, P1173, DOI 10.1083/jcb.127.5.1173; WILUSZ J, 1990, MOL CELL BIOL, V10, P6397, DOI 10.1128/MCB.10.12.6397	22	14	14	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					19831	19835		10.1074/jbc.271.33.19831	http://dx.doi.org/10.1074/jbc.271.33.19831			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702692	hybrid			2022-12-25	WOS:A1996VC66900033
J	Messmer, UK; Reed, JC; Brune, B				Messmer, UK; Reed, JC; Brune, B			Bcl-2 protects macrophages from nitric oxide-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN FOLLICULAR LYMPHOMA; PROGRAMMED CELL-DEATH; TUMOR-SUPPRESSOR P53; MAMMALIAN-CELLS; BAX GENE; IN-VIVO; THYMOCYTES; EXPRESSION	Endogenously generated or exogenously supplied nitric oxide (NO)-induced apoptotic cell death in the mouse macrophage cell line RAW 264.7. Apoptotic signaling caused an early accumulation of the tumor suppressor p53 prior to DNA fragmentation. Contrary to the notion of specific activating signals, inhibitory transduction mechanisms largely remain unknown. Therefore, RAW 264.7 macrophages were stably transfected with human Bcl-2, an anti-apoptotic protein. Bcl-2 transfectants showed substantial protection from cell death induced following the exposure to NO donors such as S-nitrosoglutathione (GSNO) and spermine-NO. In contrast, RAW 264.7 parent or in neomycin control-transformed cells, these NO donors induced internucleosomal DNA cleavage in a dose-dependent manner. Similarly, expression of the inducible NO synthase in response to lipopolysaccharide and interferon-gamma also caused apoptosis in RAW macrophages and neo controls within 24 h. In contrast, Bcl-2 transfectants appeared highly resistant, although inducible NO synthase levels increased along with concomitant and Bcl-2 transfectants after GSNO addition. GSNO induced p53 expression in Bcl-2 transfectants at levels comparable with nontransfected RAW macrophages. Moreover, GSNO induced increases in the steady-state levels of Bax protein in parental and Bcl-2-transfected cells. We conclude therefore, that Bcl-2 acts downstream of p53, presumably nullifying the NO-mediated increased in Bax protein in RAW 264.7 cells.	UNIV ERLANGEN NURNBERG,FAC MED,DEPT MED 4,EXPT DIV,D-91054 ERLANGEN,GERMANY; BURNHAM INST,CTR CANC RES,LA JOLLA,CA 92037	University of Erlangen Nuremberg; Sanford Burnham Prebys Medical Discovery Institute					NATIONAL CANCER INSTITUTE [R01CA060181] Funding Source: NIH RePORTER; NCI NIH HHS [CA60181] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBINA JE, 1993, J IMMUNOL, V150, P5080; BAFFY G, 1993, J BIOL CHEM, V268, P6511; BLANCO FJ, 1995, AM J PATHOL, V146, P75; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREDT DS, 1992, NEURON, V8, P3, DOI 10.1016/0896-6273(92)90104-L; BURTON K, 1956, BIOCHEM J, V62, P315, DOI 10.1042/bj0620315; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; CHIOU CK, 1994, MOL CELL BIOL, V14, P2558; FEHSEL K, 1995, J IMMUNOL, V155, P2858; Forrester K, 1996, P NATL ACAD SCI USA, V93, P2442, DOI 10.1073/pnas.93.6.2442; HART TW, 1985, TETRAHEDRON LETT, V26, P2013, DOI 10.1016/S0040-4039(00)98368-0; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; HRABIE JA, 1993, J ORG CHEM, V58, P1472, DOI 10.1021/jo00058a030; JOHNSTON RF, 1990, ELECTROPHORESIS, V11, P355, DOI 10.1002/elps.1150110503; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; KANETO H, 1995, DIABETES, V44, P733, DOI 10.2337/diabetes.44.7.733; MCCONKEY DJ, 1989, ARCH BIOCHEM BIOPHYS, V269, P365, DOI 10.1016/0003-9861(89)90119-7; MEIKRANTZ W, 1994, P NATL ACAD SCI USA, V91, P3754, DOI 10.1073/pnas.91.9.3754; MESSMER UK, 1995, MOL PHARMACOL, V47, P757; Messmer UK, 1996, FEBS LETT, V384, P162; MESSMER UK, 1994, FEBS LETT, V355, P23; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MONCADA S, 1991, PHARMACOL REV, V43, P109; Muhl H, 1996, FEBS LETT, V382, P271, DOI 10.1016/0014-5793(96)00179-2; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; SARIH M, 1993, BIOCHEM BIOPH RES CO, V191, P503, DOI 10.1006/bbrc.1993.1246; SATO T, 1994, P NATL ACAD SCI USA, V91, P9238, DOI 10.1073/pnas.91.20.9238; Smith ML, 1996, AM J PATHOL, V148, P1019; STEINMAN HM, 1995, J BIOL CHEM, V270, P3487; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373	35	199	203	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					20192	20197		10.1074/jbc.271.33.20192	http://dx.doi.org/10.1074/jbc.271.33.20192			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702745	hybrid			2022-12-25	WOS:A1996VC66900087
J	Murthy, YVSN; Massey, V				Murthy, YVSN; Massey, V			F-19 NMR studies with 2'-F-2'-deoxyarabinoflavoproteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OLD YELLOW ENZYME; NUCLEAR MAGNETIC-RESONANCE; FLAVIN MONONUCLEOTIDES; FLAVOPROTEINS; RESOLUTION; BINDING; LIGAND; SITE; FORM	Apoproteins of several flavoproteins were reconstituted with 2'-F-2'-deoxyarabinoflavins and studied by F-19 NMR and absorption spectroscopy. Extensive protein-fluorine interactions were observed by large chemical shift changes on binding to the apoprotein of Old Yellow Enzyme (apoOYE) and apoflavodoxin, whereas binding to apoglucose oxidase and apo D-amino acid oxidase (apoDAAO) resulted in minimal interactions. Modification at the flavin 2'-position in OYE resulted in a substantial decrease in the binding affinity of the flavin, possibly from the disruption of two important hydrogen bonds to Pro-35 and Arg-243. F-19 NMR studies of complexes of OYE with testosterone, cyclohexenone, and beta-estradiol suggest that phenols and alpha,beta-unsaturated ketones orient differently at the active site on binding. The two separate one-electron potentials for the EFl(ox)/EFl(sq) and EFl(sq)/EFl(red) couples were different for the reconstituted OYE. With native enzyme, there is 15-20% thermodynamic stabilization of the anionic flavin semiquinone, while no detectable amount of semiquinone was observed with modified OYE. This change in potential was further substantiated by blue shifts for the maxima of the modified protein-phenol charge transfer complexes. In accordance with the crystal structure of the OYE-p-OH-benzaldehyde complex (Fox, K.M. & Karplus, P.A. (1994) Structure 2, 1089-1105), F-19 NMR studies with the modified OYE-2,4-F-2-phenol suggest strong interaction between the para-fluorine of the phenol and Tyr-375.	UNIV MICHIGAN,SCH MED,DEPT BIOL CHEM,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan					NIGMS NIH HHS [GM-11106] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM011106, R01GM011106] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAMOVITZ AS, 1976, J BIOL CHEM, V251, P5321; ABRAMOVITZ AS, 1976, J BIOL CHEM, V251, P5327; BEINERT WD, 1985, EUR J BIOCHEM, V152, P573, DOI 10.1111/j.1432-1033.1985.tb09234.x; BEINERT WD, 1985, EUR J BIOCHEM, V152, P581, DOI 10.1111/j.1432-1033.1985.tb09235.x; BURNETT RM, 1974, J BIOL CHEM, V249, P4383; FOX KM, 1994, STRUCTURE, V2, P1089, DOI 10.1016/S0969-2126(94)00111-1; Fox KM, 1994, FLAVINS AND FLAVOPROTEINS 1993, P381; GHISLA S, 1986, BIOCHEM J, V239, P1; GIBSON QH, 1964, J BIOL CHEM, V239, P3927; GREIG JP, 1978, BIOL MAGN RESON, V1, P139; JARDETZKY O, 1981, NMR MOL BIOL, P52; LINDON JC, 1980, PROG NUCL MAG RES SP, V14, P27, DOI 10.1016/0079-6565(80)80002-1; LUDWIG ML, 1992, CHEM BIOCH FLAVOENZY, V3, P427; MACHEROUX P, 1990, BIOCHEMISTRY-US, V29, P2670, DOI 10.1021/bi00463a008; MASSEY V, 1966, J BIOL CHEM, V241, P3417; MASSEY V, 1991, FLAVINS AND FLAVOPROTEINS 1990, P59; Massey V, 1994, FLAVINS AND FLAVOPROTEINS 1993, P371; MATTHEWS RG, 1969, J BIOL CHEM, V244, P1779; MATTHEWS RG, 1975, J BIOL CHEM, V250, P9294; MAYER EJ, 1981, ANAL BIOCHEM, V116, P227, DOI 10.1016/0003-2697(81)90348-1; MAYHEW SG, 1971, BIOCHIM BIOPHYS ACTA, V235, P289, DOI 10.1016/0005-2744(71)90207-5; MAYHEW SG, 1969, J BIOL CHEM, V244, P794; MILLER SM, 1995, BIOCHEMISTRY-US, V34, P13066, DOI 10.1021/bi00040a018; MURTHY YVSN, 1995, J BIOL CHEM, V270, P28586, DOI 10.1074/jbc.270.48.28586; QUAY S, 1977, BIOCHEMISTRY-US, V16, P3348, DOI 10.1021/bi00634a010; SCHOPFER LM, 1990, STUDY ENZYMES, P247; STEWART RC, 1985, J BIOL CHEM, V260, P3639; STOTT K, 1993, J BIOL CHEM, V268, P6097; SWOBODA BEP, 1965, J BIOL CHEM, V240, P2209; Sykes B D, 1978, Methods Enzymol, V49, P270; SYKES BD, 1980, MAGNETIC RESONANCE B, V1, P171; VAZ ADN, 1995, BIOCHEMISTRY-US, V34, P4246, DOI 10.1021/bi00013a014; YAGI K, 1992, BIOCHIM BIOPHYS ACTA, V56, P413; [No title captured]	34	9	10	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					19915	19921		10.1074/jbc.271.33.19915	http://dx.doi.org/10.1074/jbc.271.33.19915			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702705	hybrid			2022-12-25	WOS:A1996VC66900046
J	Walker, WH; Girardet, C; Habener, JF				Walker, WH; Girardet, C; Habener, JF			Alternative exon splicing controls a translational switch from activator to repressor isoforms of transcription factor CREB during spermatogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING PROTEIN CREB; MESSENGER-RNAS; GENE; ADENOSINE-3',5'-MONOPHOSPHATE; EXPRESSION; CELLS; INITIATION; CONTAINS; ELEMENTS; ENHANCER	The cAMP/protein kinase A signaling pathway activates the cAMP-responsive transcription factor CREB. Here we describe a unique alternative RNA splicing event that occurs during the development of germ cells in the testis, resulting in a translational switch from an mRNA encoding activator CREB to an mRNA encoding novel inhibitor CREB isoforms (I-CREBs). Alternative splicing of an additional exon into the CREB mRNA in mid to late pachytene spermatocytes results in the premature termination of translation and consequent downstream reinitiation of translation producing I-CREBs, The I-CREBs down-regulate cAMP activated gene expression by inhibiting activator CREB from binding to cAMP response elements. Further, the developmental stage-specific expression of I-CREBs in germ cells of the seminiferous tubules correlates with the cyclical down-regulation of activator CREB, suggesting that I-CREBs repress expression of the cAMP-inducible CREB gene as well as other genes transiently induced by cAMP during the 12-day cycle of spermatogenesis.	HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,HOWARD HUGHES MED INST,LAB MOL ENDOCRINOL,BOSTON,MA 02114; CTR MED UNIV GENEVA,DEPT PATHOL,CH-1211 GENEVA 4,SWITZERLAND	Harvard University; Harvard Medical School; Massachusetts General Hospital; Howard Hughes Medical Institute; University of Geneva					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK025532] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK25532] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BELLVE AR, 1977, J HISTOCHEM CYTOCHEM, V25, P480, DOI 10.1177/25.7.893996; CHEN WJ, 1991, CELL, V66, P327, DOI 10.1016/0092-8674(91)90622-6; DELMAS V, 1993, MOL ENDOCRINOL, V7, P1502, DOI 10.1210/me.7.11.1502; DEUTSCH PJ, 1988, J BIOL CHEM, V263, P18466; Girardet C, 1996, MOL ENDOCRINOL, V10, P879, DOI 10.1210/me.10.7.879; HOEFFLER JP, 1989, MOL ENDOCRINOL, V3, P868, DOI 10.1210/mend-3-5-868; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P3873, DOI 10.1093/nar/12.9.3873; KOZAK M, 1987, MOL CELL BIOL, V7, P3438, DOI 10.1128/MCB.7.10.3438; KOZAK M, 1989, MOL CELL BIOL, V9, P5134, DOI 10.1128/MCB.9.11.5134; LIU CC, 1984, NATURE, V309, P82, DOI 10.1038/309082a0; MACEJAK DG, 1991, NATURE, V353, P90, DOI 10.1038/353090a0; MAURER RA, 1989, J BIOL CHEM, V264, P6870; MEYER TE, 1993, ENDOCRINOLOGY, V132, P770, DOI 10.1210/en.132.2.770; MEYER TE, 1993, ENDOCR REV, V14, P269, DOI 10.1210/er.14.3.269; MONOCO L, 1995, P NATL ACAD SCI USA, V92, P10673; RUPPERT S, 1992, EMBO J, V11, P1503, DOI 10.1002/j.1460-2075.1992.tb05195.x; VALLEJO M, 1992, J BIOL CHEM, V267, P12876; WAEBER G, 1992, ENDOCRINOLOGY, V131, P2010, DOI 10.1210/en.131.4.2010; WAEBER G, 1991, MOL ENDOCRINOL, V5, P1418, DOI 10.1210/mend-5-10-1418; WALKER WH, 1995, ENDOCRINOLOGY, V136, P3534, DOI 10.1210/en.136.8.3534; WALKER WH, 1992, J VIROL, V66, P5018, DOI 10.1128/JVI.66.8.5018-5029.1992; WALKER WH, 1990, J BIOL CHEM, V265, P12940; WALKER WH, 1994, P NATL ACAD SCI USA, V91, P12423, DOI 10.1073/pnas.91.26.12423	24	67	68	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					20145	20150						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702738	hybrid			2022-12-25	WOS:A1996VC66900079
J	Fu, GK; Markovitz, DM				Fu, GK; Markovitz, DM			Purification of the pets factor - A nuclear protein that binds to the inducible TG-rich element of the human immunodeficiency virus type 2 enhancer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MURINE LEUKEMIA-VIRUS; NF-KAPPA-B; DIFFERENTIAL REGULATION; POLYACRYLAMIDE GELS; RNA-POLYMERASE; ACTIVATION; TRANSCRIPTION; RECEPTOR; ELF-1; SPECIFICITY	The peri-ets (pets) site is a TG-rich element found immediately adjacent to two binding sites for the ets family member Elf-1 in the human immunodeficiency virus type 2 (HIV-2) enhancer, Enhancer activation in response to T cell stimulation by phorbol myristate acetate, phytohemagglutinin, soluble or cross-linked anti bodies to the T cell receptor, or antigen is mediated through this site in conjunction with its two adjacent Elf-1 binding sites, PuB1 and PuB2, and a KB site, Site-specific mutation of the pets element significantly reduces inducible activation of this enhancer but does not affect its transactivation by HIV-2 tat or other viral transactivators, Similar TG-rich sequences adjacent to ets-binding sites have also been found to be functionally important in the human T-cell leukemia virus type I and murine Moloney leukemia virus enhancers, As the cellular factor binding to the pets site plays a significant role in regulating the HIV-2 enhancer in both T cells and monocytes, we have purified this protein from bovine spleens and demonstrate that it is 43 kDa in size, In addition, using glycerol gradient centrifugation, Southwestern blotting, electrophoretic mobility shift assays employing purified protein eluted from a gel, and a new in solution UV cross-linking competitive assay, we show that the dominant protein binding to the pets site is 43 kDa in size, These results indicate that a nuclear protein of 43 kDa binds specifically to the pets site of the HIV-2 enhancer and may mediate transcriptional activation of this important human pathogen in response to T cell stimulation, As retroviruses generally expropriate important human regulatory proteins for their own use, the 43-kDa pets factor is also likely to play a significant role in signal transduction in T cells and in other cellular processes.	UNIV MICHIGAN,MED CTR,DEPT INTERNAL MED,DIV INFECT DIS,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH PUBL HLTH,DEPT EPIDEMIOL,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan					NATIONAL CANCER INSTITUTE [T32CA009676] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI030924, R01AI036685] Funding Source: NIH RePORTER; NCI NIH HHS [T32 CA09676] Funding Source: Medline; NIAID NIH HHS [AI36685, AI30924] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		CLARK NM, 1995, J VIROL, V69, P4854, DOI 10.1128/JVI.69.8.4854-4862.1995; CLARK NM, 1993, J VIROL, V67, P5522, DOI 10.1128/JVI.67.9.5522-5528.1993; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DYAN WS, 1983, CELL, V35, P79; GALAS DJ, 1978, NUCLEIC ACIDS RES, V5, P3157, DOI 10.1093/nar/5.9.3157; GOTTSCHALK LR, 1993, J EXP MED, V178, P1681, DOI 10.1084/jem.178.5.1681; GUYADER M, 1987, NATURE, V326, P662, DOI 10.1038/326662a0; HAGER DA, 1980, ANAL BIOCHEM, V109, P76, DOI 10.1016/0003-2697(80)90013-5; HANNIBAL MC, 1993, J VIROL, V67, P5035, DOI 10.1128/JVI.67.8.5035-5040.1993; HANNIBAL MC, 1994, BLOOD, V83, P1839; HILFINGER JM, 1993, J VIROL, V67, P4448, DOI 10.1128/JVI.67.7.4448-4453.1993; JOHN S, 1995, MOL CELL BIOL, V15, P1786; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEIDEN JM, 1992, J VIROL, V66, P5890, DOI 10.1128/JVI.66.10.5890-5897.1992; MARKOVITZ DM, 1993, ANN INTERN MED, V118, P211, DOI 10.7326/0003-4819-118-3-199302010-00010; MARKOVITZ DM, 1990, P NATL ACAD SCI USA, V87, P9098, DOI 10.1073/pnas.87.23.9098; MARKOVITZ DM, 1992, J VIROL, V66, P5479, DOI 10.1128/JVI.66.9.5479-5484.1992; MARKOVITZ DM, 1992, J VIROL, V66, P3961, DOI 10.1128/JVI.66.6.3961-3965.1992; MARTIN RG, 1961, J BIOL CHEM, V236, P1372; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; PERKINS ND, 1993, EMBO J, V12, P3551, DOI 10.1002/j.1460-2075.1993.tb06029.x; SPECK NA, 1990, GENE DEV, V4, P233, DOI 10.1101/gad.4.2.233; SUN WW, 1995, J VIROL, V69, P4941, DOI 10.1128/JVI.69.8.4941-4949.1995; TANIMURA A, 1993, J VIROL, V67, P5375, DOI 10.1128/JVI.67.9.5375-5382.1993; TRAVIS A, 1993, MOL CELL BIOL, V13, P3392, DOI 10.1128/MCB.13.6.3392; WANG CY, 1994, MOL CELL BIOL, V14, P1153, DOI 10.1128/MCB.14.2.1153; WANG SW, 1993, MOL CELL BIOL, V13, P3324, DOI 10.1128/MCB.13.6.3324; WANG SW, 1992, MOL CELL BIOL, V12, P89, DOI 10.1128/MCB.12.1.89; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2	30	17	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19599	19605		10.1074/jbc.271.32.19599	http://dx.doi.org/10.1074/jbc.271.32.19599			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702655	hybrid			2022-12-25	WOS:A1996VB68400089
J	Ramamurthy, P; Hocking, AM; McQuillan, DJ				Ramamurthy, P; Hocking, AM; McQuillan, DJ			Recombinant decorin glycoforms - Purification and structure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUCINE-RICH REPEATS; DERMATAN SULFATE PROTEOGLYCANS; GROWTH-FACTOR-BETA; PROTEODERMATAN SULFATE; HUMAN-FIBROBLASTS; PROTEIN; BINDING; CDNA; BIGLYCAN; SEQUENCE	The vaccinia virus/T7 bacteriophage expression system was used to express human decorin in HT-1080 cells by co-infection with vTF7-3, encoding T7 RNA polymerase, and vDCN1, encoding the decorin core protein fused to a polyhistidine-insulin signal sequence fusion-protein cassette. Overexpression using the vaccinia virus/T7 phage system resulted in secretion of approximately 30 mg of decorin/10(9) cells per 24 h which enabled purification and separation of multiple glycoforms under native conditions. Cells were cultured in the presence of [S-35]methionine or a mixture of [H-3]glucosamine and [S-35]sulfate, and recombinant glycoprotein purified by metal affinity chromatography which resolved the secreted decorin into two classes, a proteoglycan form and a core protein form, About 25% of the recombinant protein was secreted into the culture medium as core protein devoid of glycosaminoglycan chains. The decorin core protein was resolved into two forms (similar to 49 and similar to 53 kDa) that differed in the extent of N-linked oligosaccharide substitution (2 and 3 N-linked oligosaccharides, respectively), Deglycosylation of the recombinant proteoglycans and core proteins resulted in a single band migrating with an apparent molecular mass similar to 43 kDa when analyzed by SDS-polyacrylamide gel electrophoresis. Far-UV circular dichroism spectra of native decorin proteoglycan showed a minima at 218 nm, consistent with a secondary structure that is predominantly beta-sheet. Circular dichroism spectra of bovine decorin extracted from articular cartilage and recombinant decorin similarly treated revealed a minima of 205 nm indicating a loss of secondary structure, The affinity of decorin proteoglycan and core protein for collagen-like molecules was demonstrated, with the complement component C1q exhibiting the most striking affinity for decorin, although adherence to collagen types I and V was also observed, The extensive secondary structure maintained in the purified recombinant protein is likely to be important for the biological function of decorin.	TEXAS A&M UNIV, INST BIOSCI & TECHNOL, CTR EXTRACELLULAR MATRIX BIOL, HOUSTON, TX 77030 USA	Texas A&M University System				Hocking, Anne/0000-0003-2130-3732	NIAMS NIH HHS [R01 AR42826] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR042826] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BIANCO P, 1990, J HISTOCHEM CYTOCHEM, V38, P1549, DOI 10.1177/38.11.2212616; BIDANSET DJ, 1992, J BIOL CHEM, V267, P5250; BLOCHBERGER TC, 1992, J BIOL CHEM, V267, P347; BROWN DC, 1990, MATRIX, V9, P468, DOI 10.1016/S0934-8832(11)80016-8; CHOI HU, 1989, J BIOL CHEM, V264, P2876; CHOPRA RK, 1985, BIOCHEM J, V232, P277, DOI 10.1042/bj2320277; COOPER NR, 1985, ADV IMMUNOL, V37, P151, DOI 10.1016/S0065-2776(08)60340-5; DAY AA, 1987, BIOCHEM J, V248, P801, DOI 10.1042/bj2480801; DAY AA, 1986, NUCLEIC ACIDS RES, V14, P9861, DOI 10.1093/nar/14.24.9861; FISHER LW, 1989, J BIOL CHEM, V264, P4571; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GLOSSL J, 1983, BIOCHEM J, V215, P295; GLOSSL J, 1984, J BIOL CHEM, V259, P4144; HEINEGARD D, 1981, BIOCHEM J, V197, P355, DOI 10.1042/bj1970355; HILDEBRAND A, 1994, BIOCHEM J, V302, P527, DOI 10.1042/bj3020527; Hocking AM, 1996, J BIOL CHEM, V271, P19571, DOI 10.1074/jbc.271.32.19571; HUNTER B, 1978, HDB EXPT IMMUNOLOGY; KOBE B, 1995, NATURE, V374, P183, DOI 10.1038/374183a0; KOBE B, 1994, TRENDS BIOCHEM SCI, V19, P415, DOI 10.1016/0968-0004(94)90090-6; KOBE B, 1993, NATURE, V366, P751, DOI 10.1038/366751a0; KRUMDIECK R, 1992, J IMMUNOL, V149, P3695; KRUSIUS T, 1986, P NATL ACAD SCI USA, V83, P7683, DOI 10.1073/pnas.83.20.7683; Mackett M., 1985, DNA CLONING PRACTICA, P191; OLDBERG A, 1989, EMBO J, V8, P2601, DOI 10.1002/j.1460-2075.1989.tb08399.x; REINKE R, 1988, CELL, V52, P291, DOI 10.1016/0092-8674(88)90518-1; ROSENBERG LC, 1985, J BIOL CHEM, V260, P6304; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHMIDT G, 1987, J CELL BIOL, V104, P1683, DOI 10.1083/jcb.104.6.1683; SREERAMA N, 1993, ANAL BIOCHEM, V209, P32, DOI 10.1006/abio.1993.1079; SUZUKI N, 1990, P NATL ACAD SCI USA, V87, P8711, DOI 10.1073/pnas.87.22.8711; SVENSSON L, 1995, J BIOL CHEM, V270, P20712, DOI 10.1074/jbc.270.35.20712; VOGEL KG, 1984, BIOCHEM J, V223, P587, DOI 10.1042/bj2230587; VOSS B, 1986, J HISTOCHEM CYTOCHEM, V34, P1013, DOI 10.1177/34.8.2426331; YAMAGUCHI Y, 1990, NATURE, V346, P281, DOI 10.1038/346281a0	34	86	87	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19578	19584		10.1074/jbc.271.32.19578	http://dx.doi.org/10.1074/jbc.271.32.19578			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702652	hybrid			2022-12-25	WOS:A1996VB68400086
J	Sechi, S; Roller, PP; WilletteBrown, J; Kinet, JP				Sechi, S; Roller, PP; WilletteBrown, J; Kinet, JP			A conformational rearrangement upon binding of IgE to its high affinity receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FC-EPSILON-RI; BOUND IMMUNOGLOBULIN-E; ALPHA-CHAIN; MAST-CELLS; CIRCULAR-DICHROISM; MEMBRANE-SURFACE; SITE; PROTEIN; COMPLEX; DOMAIN	One of the critical steps in the allergic reaction is the binding of immunoglobulin E (IgE) to its high affinity receptor (Fc epsilon RI), Fc epsilon RI is a tetrameric complex composed of an a chain, a beta-chain, and a dimeric gamma-chain. The extracellular paction of the alpha-chain (alpha-t) is sufficient for the binding of IgE. The Fe portion of IgE contains two copies of the Fc epsilon RI binding sites, In contrast, the binding stoichiometry is 1:1, Previously, it was hypothesized that the binding of Fc epsilon EI to IgE results in a conformational change ill IgE that precludes the binding of a second molecule (Presta, L., Shields, R., O'Connel, L., Lahr, S., Porter, J., German, C., and Jardieu, P. (1994) J. Biol. Chem. 269, 26568-26313), Here we characterize the secondary structure of IgE and alpha-t and analyze their interaction by circular dichroism spectroscopy, Binding experiments show that when IgE interacts with alpha-t there is a 15-26% decrease of the negative ellipticity at 217 nm, Together, the absence of all alpha-helix element in alpha-t and the small contribution of alpha-t to the spectra of the complex indicate that upon binding, a major conformational rearrangement must occur oil IgE, In addition, we analyze the thermal unfolding of alpha-t, IgE, and their complex. Despite the several domains that constitute IgE and alpha-t. these molecules unfold cooperatively with two-state kinetics.	NIAID,MOL ALLERGY & IMMUNOL SECT,NIH,ROCKVILLE,MD 20852; NCI,DIV BASIC SCI,MED CHEM LAB,NIH,BETHESDA,MD 20892; HARVARD UNIV,BETH ISRAEL HOSP,SCH MED,BOSTON,MA 02215	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School								ARGOS P, 1989, PROTEIN STRUCTURE PR, P169; ATTANASIO R, 1994, J BIOL CHEM, V269, P1834; BAIRD B, 1985, BIOCHEMISTRY-US, V24, P6252, DOI 10.1021/bi00343a032; BASU M, 1993, J BIOL CHEM, V268, P13118; BLANK U, 1991, J BIOL CHEM, V266, P2639; BORK P, 1994, J MOL BIOL, V242, P309, DOI 10.1006/jmbi.1994.1582; CASSIM JY, 1969, BIOCHEMISTRY-US, V8, P1947, DOI 10.1021/bi00833a026; DEISENHOFER J, 1981, BIOCHEMISTRY-US, V20, P2361, DOI 10.1021/bi00512a001; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DORRINGTON KJ, 1978, IMMUNOL REV, V41, P3, DOI 10.1111/j.1600-065X.1978.tb01458.x; DORRINGTON KJ, 1973, J BIOL CHEM, V248, P8378; GREENFIELD C, 1989, EMBO J, V8, P4115, DOI 10.1002/j.1460-2075.1989.tb08596.x; HAKIMI J, 1990, J BIOL CHEM, V265, P22079; HELM B, 1989, P NATL ACAD SCI USA, V86, P9465, DOI 10.1073/pnas.86.23.9465; HELM B, 1988, NATURE, V331, P180, DOI 10.1038/331180a0; HOLOWKA D, 1985, BIOCHEMISTRY-US, V24, P6260, DOI 10.1021/bi00343a033; HOLOWKA D, 1983, BIOCHEMISTRY-US, V22, P3475, DOI 10.1021/bi00283a026; HUBER AH, 1993, J MOL BIOL, V230, P1077, DOI 10.1006/jmbi.1993.1220; HULLET MD, 1994, ADV IMMUNOLOGY; ISHIZAKA K, 1970, IMMUNOCHEMISTRY, V7, P687, DOI 10.1016/0019-2791(70)90175-8; KANELLOPOULOS JM, 1980, J BIOL CHEM, V255, P9060; KEOWN MB, 1995, P NATL ACAD SCI USA, V92, P1841, DOI 10.1073/pnas.92.6.1841; KOCHWA S, 1971, ANN NY ACAD SCI, V190, P49, DOI 10.1111/j.1749-6632.1971.tb13523.x; LETOURNEUR O, 1995, J BIOL CHEM, V270, P8249, DOI 10.1074/jbc.270.14.8249; MENDOZA G, 1976, NATURE, V264, P548, DOI 10.1038/264548a0; NISSIM A, 1991, EMBO J, V10, P101, DOI 10.1002/j.1460-2075.1991.tb07925.x; NISSIM A, 1992, MOL IMMUNOL, V29, P1065, DOI 10.1016/0161-5890(92)90038-Y; OGRADY JH, 1986, J IMMUNOL, V137, P2307; ORTEGA E, 1991, BIOCHEMISTRY-US, V30, P3473, DOI 10.1021/bi00228a018; PADLAN EA, 1986, MOL IMMUNOL, V23, P1063, DOI 10.1016/0161-5890(86)90005-2; PERKINS SJ, 1986, EUR J BIOCHEM, V157, P169, DOI 10.1111/j.1432-1033.1986.tb09653.x; PRESTA L, 1994, J BIOL CHEM, V269, P26368; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; ROBERTSON MW, 1993, J BIOL CHEM, V268, P12736; SCHAEFER EM, 1992, J BIOL CHEM, V267, P23393; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schmid FX., 1989, SPECTRAL METHODS CHA, P251; SCHWARZBAUM S, 1989, EUR J IMMUNOL, V19, P1015, DOI 10.1002/eji.1830190610; WANG B, 1992, J EXP MED, V175, P1353, DOI 10.1084/jem.175.5.1353; WOODY RW, 1994, EUR BIOPHYS J BIOPHY, V23, P253, DOI 10.1007/BF00213575; WOODY WR, 1995, METHOD ENZYMOL, V260, P34; ZHENG Y, 1992, BIOCHEMISTRY-US, V31, P7446, DOI 10.1021/bi00148a004; ZHENG Y, 1991, BIOCHEMISTRY-US, V30, P9125, DOI 10.1021/bi00102a002	43	30	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19256	19263		10.1074/jbc.271.32.19256	http://dx.doi.org/10.1074/jbc.271.32.19256			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702607	hybrid			2022-12-25	WOS:A1996VB68400041
J	Smart, CC; Fleming, AJ				Smart, CC; Fleming, AJ			Hormonal and environmental regulation of a plant PDR5-like ABC transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-CASSETTE TRANSPORTER; CYSTIC-FIBROSIS MUTATIONS; ATP-DEPENDENT PERMEASES; BREFELDIN-A RESISTANCE; SPIRODELA-POLYRRHIZA L; SACCHAROMYCES-CEREVISIAE; MULTIDRUG-RESISTANCE; ABSCISIC-ACID; DROSOPHILA-MELANOGASTER; SCHIZOSACCHAROMYCES-POMBE	The PDR5 gene from yeast encodes an ABC (ATP-binding cassette) transporter involved in the ATP-dependent efflux of a variety of structurally unrelated cytotoxic compounds. We report here on the cDNA cloning and characterization of a PDR5 homolog (TUR2) from a higher eukaryote, the aquatic plant Spirodela polyrrhiza. We show that TUR2 transcripts accumulate throughout the plant following treatment with the steroid-like hormone, abscisic acid, and that this induction can be repressed by the adenine-derived hormone, kinetin. Furthermore, TUR2 gene expression is induced by environmental stress treatments such as low temperature and high salt. These data indicate that PDR5 homologs are present in plants, that they may function during stress conditions in an analogous fashion to that described in yeast, and that the expression of such ABC transporters is subject to a complex hormonal and environmental regulation.	UNIV BERN,INST PLANT PHYSIOL,CH-3013 BERN,SWITZERLAND	University of Bern	Smart, CC (corresponding author), ETH ZURICH,INST PLANT SCI PLANT BIOCHEM & PHYSIOL,UNIV STR 2,CH-8092 ZURICH,SWITZERLAND.							AHMED M, 1994, J BIOL CHEM, V269, P28506; BALZI E, 1994, J BIOL CHEM, V269, P2206; BALZI E, 1994, BBA-BIOENERGETICS, V1187, P152, DOI 10.1016/0005-2728(94)90102-3; BERKOWER C, 1991, EMBO J, V10, P3777, DOI 10.1002/j.1460-2075.1991.tb04947.x; BISSINGER PH, 1994, J BIOL CHEM, V269, P4180; CAVENER DR, 1991, NUCLEIC ACIDS RES, V19, P3185, DOI 10.1093/nar/19.12.3185; CHALOUPKOVA K, 1994, PLANT PHYSIOL, V105, P497, DOI 10.1104/pp.105.2.497; CUTTING GR, 1990, NATURE, V346, P366, DOI 10.1038/346366a0; DECOTTIGNIES A, 1994, J BIOL CHEM, V269, P12797; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DREESEN TD, 1988, MOL CELL BIOL, V8, P5206, DOI 10.1128/MCB.8.12.5206; DUDLER R, 1992, J BIOL CHEM, V267, P5882; EGNER R, 1995, MOL CELL BIOL, V15, P5879; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; EWART GD, 1994, J BIOL CHEM, V269, P10370; FATH MJ, 1993, MICROBIOL REV, V57, P995, DOI 10.1128/MMBR.57.4.995-1017.1993; Fleming A. J., 1995, P273; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; HAN JH, 1987, BIOCHEMISTRY-US, V26, P1617, DOI 10.1021/bi00380a020; HERRIN DL, 1988, BIOTECHNIQUES, V6, P196; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HIRATA D, 1994, CURR GENET, V26, P285, DOI 10.1007/BF00310491; HOOF T, 1994, J BIOL CHEM, V269, P20575; KOZAK M, 1991, J BIOL CHEM, V266, P19867; KRALLI A, 1995, P NATL ACAD SCI USA, V92, P4701, DOI 10.1073/pnas.92.10.4701; KUCHLER K, 1993, EMBO J, V13, P3973; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LOGEMANN J, 1987, ANAL BIOCHEM, V163, P16, DOI 10.1016/0003-2697(87)90086-8; NAGAO K, 1995, J BACTERIOL, V177, P1536, DOI 10.1128/jb.177.6.1536-1543.1995; OHARE K, 1984, J MOL BIOL, V180, P437, DOI 10.1016/0022-2836(84)90021-4; PRASAD R, 1995, CURR GENET, V27, P320, DOI 10.1007/BF00352101; PURNELLE B, 1991, YEAST, V7, P867, DOI 10.1002/yea.320070813; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROGERS SO, 1988, PLANT MOL BIOL MANUA, P1; SERVOS J, 1993, MOL GEN GENET, V236, P214, DOI 10.1007/BF00277115; SHYAMALA V, 1991, J BIOL CHEM, V266, P18714; SIPOS L, 1993, EUR J BIOCHEM, V213, P1333, DOI 10.1111/j.1432-1033.1993.tb17885.x; SMART C, 1987, MOL BIOL PLANT GROWT, P345; SMART CC, 1983, PLANT CELL ENVIRON, V6, P507, DOI 10.1111/1365-3040.ep11588135; SMART CC, 1993, PLANT J, V4, P279, DOI 10.1046/j.1365-313X.1993.04020279.x; SMART CC, 1995, PLANT PHYSIOL, V108, P623, DOI 10.1104/pp.108.2.623; TURI TG, 1995, BIOCHEM BIOPH RES CO, V213, P410, DOI 10.1006/bbrc.1995.2147; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x	44	89	101	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19351	19357		10.1074/jbc.271.32.19351	http://dx.doi.org/10.1074/jbc.271.32.19351			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702621	hybrid			2022-12-25	WOS:A1996VB68400055
J	Chandel, NS; Budinger, GRS; Schumacker, PT				Chandel, NS; Budinger, GRS; Schumacker, PT			Molecular oxygen modulates cytochrome c oxidase functions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEADY-STATE KINETICS; ELECTRON-TRANSFER; HEPATOCYTES; OXIDATION; TURNOVER	This study sought to determine whether molecular oxygen interacts with cytochrome c oxidase to modify its catalytic activity, Such an interaction could explain the observation that mitochondria incubated under low O-2 concentrations exhibit a reversible suppression of State 3 respiration, Oxidized bovine heart cytochrome c oxidase was incubated in oxygen concentrations of < 50 mu M for 4 h, The enzyme exhibited a reversible decrease in V-max after incubation, compared with control enzyme incubated at higher oxygen concentrations, This change was accompanied by a small increase in the apparent K-m of the enzyme for both cytochrome c and oxygen, although the optical absorption spectra of oxidized, cycling, or reduced enzyme were not affected, Spectroscopy studies after 4 h of incubation revealed that heme a(3) was 33% reduced during cycling at [O-2] = 25 mu M whereas enzyme at [O-2] = 135 mu M was only 18% reduced, suggesting that the site of inhibition occurred at the electron transfer step between heme a(2) and O-2. These results provide a mechanistic explanation for the observation that intact cells or mitochondria exhibit a reversible inhibition of respiration during prolonged exposure to [O-2] < 25 mM, by demonstrating that the catalytic activity of cytochrome c oxidase function is similarly inhibited, possibly through an allosteric effect of molecular O-2 on the enzyme.	UNIV CHICAGO,DEPT MED,CHICAGO,IL 60637	University of Chicago				Schumacker, Paul T/0000-0001-9591-2034	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL032646, R01HL035440, R55HL032646] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL32646, HL35440] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BRUNORI M, 1995, BIOCHIMIE, V77, P668, DOI 10.1016/0300-9084(96)88182-X; BUDINGER GRS, 1996, AM J PHYSIOL, V14, pL37; CHANDEL N, 1995, AM J PHYSIOL-LUNG C, V268, pL918, DOI 10.1152/ajplung.1995.268.6.L918; COOPER CE, 1990, BIOCHIM BIOPHYS ACTA, V1017, P187, DOI 10.1016/0005-2728(90)90184-6; COPELAND RA, 1991, P NATL ACAD SCI USA, V88, P7281, DOI 10.1073/pnas.88.16.7281; CORNISHBOWDEN A, 1976, PRINCIPLES ENZYME KI; DIPAOLO ML, 1994, J BIOCHEM BIOPH METH, V28, P205, DOI 10.1016/0165-022X(94)90017-5; EINARSDOTTIR O, 1995, BBA-BIOENERGETICS, V1229, P129, DOI 10.1016/0005-2728(94)00196-C; ERREDE B, 1976, P NATL ACAD SCI USA, V73, P113, DOI 10.1073/pnas.73.1.113; FERGUSONMILLER S, 1976, J BIOL CHEM, V251, P1104; FLEMING JE, 1983, INT J PEPT PROT RES, V22, P565; HARTZELL CR, 1974, BIOCHIM BIOPHYS ACTA, V368, P318, DOI 10.1016/0005-2728(74)90178-9; HILL BC, 1991, J BIOL CHEM, V266, P2219; HILL BC, 1994, J BIOL CHEM, V269, P2419; JONES DP, 1978, J BIOL CHEM, V253, P4874; LONGMUIR IS, 1957, BIOCHEM J, V65, P378, DOI 10.1042/bj0650378; MINNAERT K, 1961, BIOCHIM BIOPHYS ACTA, V50, P23, DOI 10.1016/0006-3002(61)91055-1; SCHUMACKER PT, 1993, AM J PHYSIOL, V265, pL395, DOI 10.1152/ajplung.1993.265.4.L395; SHERMAN D, 1991, P NATL ACAD SCI USA, V88, P4265, DOI 10.1073/pnas.88.10.4265; SINJORGO KMC, 1986, BIOCHIM BIOPHYS ACTA, V850, P108, DOI 10.1016/0005-2728(86)90014-9; SMITH L, 1956, ARCH BIOCHEM BIOPHYS, V63, P403, DOI 10.1016/0003-9861(56)90055-8; Wikstrom M., 1981, CYTOCHROME OXIDASE S; WILSON DF, 1988, J BIOL CHEM, V263, P2712; YONETANI T, 1965, J BIOL CHEM, V240, P3392	25	113	113	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18672	18677		10.1074/jbc.271.31.18672	http://dx.doi.org/10.1074/jbc.271.31.18672			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702521	hybrid			2022-12-25	WOS:A1996VB68300059
J	Patel, SB; Grundy, SM				Patel, SB; Grundy, SM			Interactions between microsomal triglyceride transfer protein and apolipoprotein B within the endoplasmic reticulum in a heterologous expression system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEP G2 CELLS; CARBOXYL-TERMINAL TRUNCATION; PRE-GOLGI COMPARTMENT; CONTAINING LIPOPROTEINS; QUALITY-CONTROL; GENE DEFECTS; LIVER-CELL; SECRETION; MEMBRANE; CALNEXIN	When apolipoprotein B (apoB) is expressed in heterologous cells, it is not secreted but retained and de graded within the endoplasmic reticulum (ER), We have previously characterized carboxyl-terminal truncated forms of apoB expressed in COS cells and have shown that these proteins were readily synthesized but retained within the ER and degraded, if the size of the truncated protein was larger than apoB 29, Below this size, the smaller the size of the apoB truncates, the greater the extent of secretion, although > 50% of these smaller proteins were also degraded within the ER, In the present study, we demonstrate that this secretory defect can be overcome by coexpression with microsomal triglyceride transfer protein (MTP); moreover, this complementation is inversely related to the size of apoB, Secretion of apoBs larger than B29 required the coexpression of MTP and, in the presence of MTP, was oleate-responsive, MTP, in the presence or absence of oleate supplementation, had little or no effect on the secretion of the shorter truncates, We discovered, however, that MTP was physically associated with all forms of apoB intracellularly (B13-B41), The association of MTP with apoB 41 was stable to high salt washing, as well as to low pH, suggesting that these interactions may be hydrophobic in nature, In addition to the interaction with MTP, apoB was also found to be associated with calnexin, confirming previous studies, and with proteins bearing the KDEL retention signal, However, studies on overexpression of human calnexin and tunicamycin inhibition of glycosylation showed that interaction with calnexin was not necessary for the formation or secretion of apoB 41-containing lipoproteins; moreover, in the presence of MTP, the association of calnexin with apoB 41 was transient or absent, These data suggest that for apoB to attain a folded state sufficient to escape the quality control of the ER, it needs to obtain neutral lipid (supplied by MTP), as well as its ability to keep it packaged as a rudimentary lipoprotein, dependent on its size being larger than B29.	UNIV TEXAS,SW MED CTR,CTR HUMAN NUTR,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT CLIN NUTR,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Patel, SB (corresponding author), UNIV TEXAS,SW MED CTR,DEPT INTERNAL MED,Y3 208,5323 HARRY HINES BLVD,DALLAS,TX 75235, USA.			Patel, Shailendra/0000-0003-0046-5513	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL029252, R37HL029252] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-29252] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BOREN J, 1990, J BIOL CHEM, V265, P10556; BOREN J, 1992, J BIOL CHEM, V267, P9858; BOSTROM K, 1986, J BIOL CHEM, V261, P3800; BU GJ, 1995, EMBO J, V14, P2269, DOI 10.1002/j.1460-2075.1995.tb07221.x; DAVID V, 1993, J BIOL CHEM, V268, P9585; DAVIS RA, 1990, J BIOL CHEM, V265, P10005; DIXON JL, 1993, J LIPID RES, V34, P167; DIXON JL, 1991, J BIOL CHEM, V266, P5080; ELBEIN AD, 1987, ANNU REV BIOCHEM, V56, P497, DOI 10.1146/annurev.biochem.56.1.497; FOLCH J, 1957, J BIOL CHEM, V226, P497; FOURIE AM, 1994, J BIOL CHEM, V269, P30470; GORDON DA, 1994, P NATL ACAD SCI USA, V91, P7628, DOI 10.1073/pnas.91.16.7628; GRAHAM DL, 1991, BIOCHEMISTRY-US, V30, P5616, DOI 10.1021/bi00236a040; HAMMOND C, 1994, P NATL ACAD SCI USA, V91, P913, DOI 10.1073/pnas.91.3.913; HAMMOND C, 1994, J CELL BIOL, V126, P41, DOI 10.1083/jcb.126.1.41; HERSCOVITZ H, 1991, P NATL ACAD SCI USA, V88, P7313, DOI 10.1073/pnas.88.16.7313; HOCHSTENBACH F, 1992, P NATL ACAD SCI USA, V89, P4734, DOI 10.1073/pnas.89.10.4734; HUOVILA APJ, 1992, J CELL BIOL, V118, P1305, DOI 10.1083/jcb.118.6.1305; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; Kane J.B., 1989, METABOLIC BASIS INHE, P1139; KANE JP, 1980, P NATL ACAD SCI-BIOL, V77, P2465, DOI 10.1073/pnas.77.5.2465; KLAUSNER R D, 1989, New Biologist, V1, P3; KRUL ES, 1988, J LIPID RES, V29, P937; LABELLE M, 1990, BIOCHIM BIOPHYS ACTA, V1046, P288, DOI 10.1016/0005-2760(90)90243-Q; LEIPER JM, 1994, J BIOL CHEM, V269, P21951; LODISH HF, 1988, J BIOL CHEM, V263, P2107; MARGOLESE L, 1993, J BIOL CHEM, V268, P17959; MCLEOD RS, 1994, J BIOL CHEM, V269, P2852; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; OU WJ, 1993, NATURE, V364, P771, DOI 10.1038/364771a0; PATEL S, 1994, ATHEROSCLEROSIS, V108, P201, DOI 10.1016/0021-9150(94)90115-5; PATEL SB, 1995, J LIPID RES, V36, P2090; PELHAM HRB, 1990, TRENDS BIOCHEM SCI, V15, P483, DOI 10.1016/0968-0004(90)90303-S; PESSAH M, 1991, J CLIN INVEST, V87, P367, DOI 10.1172/JCI114996; RAJAGOPALAN S, 1994, SCIENCE, V263, P387, DOI 10.1126/science.8278814; ROSE JK, 1988, ANNU REV CELL BIOL, V4, P257, DOI 10.1146/annurev.cellbio.4.1.257; SAKATA N, 1993, J BIOL CHEM, V268, P22967; SATO R, 1990, J BIOL CHEM, V265, P11880; SCHUMAKER VN, 1994, ADV PROTEIN CHEM, V45, P205; SHARP D, 1993, NATURE, V365, P65, DOI 10.1038/365065a0; SIUTAMANGANO P, 1982, J BIOL CHEM, V257, P4292; SOUSA MC, 1992, BIOCHEMISTRY-US, V31, P97, DOI 10.1021/bi00116a015; SPRING DJ, 1992, J BIOL CHEM, V267, P14839; THRIFT RN, 1992, P NATL ACAD SCI USA, V89, P9161, DOI 10.1073/pnas.89.19.9161; TROMBETTA SE, 1989, BIOCHEMISTRY-US, V28, P8108, DOI 10.1021/bi00446a022; WETTERAU JR, 1992, SCIENCE, V258, P999; WHITE AL, 1992, J BIOL CHEM, V267, P15657; YAO ZM, 1991, J BIOL CHEM, V266, P3300	48	93	93	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18686	18694		10.1074/jbc.271.31.18686	http://dx.doi.org/10.1074/jbc.271.31.18686			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702523	hybrid			2022-12-25	WOS:A1996VB68300061
J	Seykora, JT; Myat, MM; Allen, LAH; Ravetch, JV; Aderem, A				Seykora, JT; Myat, MM; Allen, LAH; Ravetch, JV; Aderem, A			Molecular determinants of the myristoyl-electrostatic switch of MARCKS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; SUBSTRATE MARCKS; BACTERIAL LIPOPOLYSACCHARIDE; MEMBRANE ASSOCIATION; CELLULAR SUBSTRATE; PLASMA-MEMBRANE; 87-KDA PROTEIN; BOVINE BRAIN; CLONING; PHOSPHORYLATION	MARCKS is a protein kinase C (PKC) substrate which binds calcium/calmodulin and actin, and which has been implicated in cell motility, phagocytosis, membrane traffic, and mitogenesis, MARCKS cycles on and off the membrane via a myristoyl electrostatic switch (McLaughlin, S., and Aderem, A. (1995) Trends Biochem, Sci, 20, 272-276), Here we define the molecular determinants of the myristoyl-electrostatic switch. Mutation of the N-terminal glycine results in a nonmyristoylated form of MARCKS which does not bind membranes and is poorly phosphorylated, This indicates that myristic acid targets MARCKS to the membrane, where it is efficiently phosphorylated by PKC, A chimeric protein in which the N terminus of MARCKS is replaced by a sequence, which is doubly palmitoylated, is phosphorylated by PKC but not released from the membrane, Thus two palmitic acid moieties confer sufficient membrane binding energy to render the second, electrostatic membrane binding site superfluous, Mutation of the PKC phosphorylation sites results in a mutant which does not translocate from the membrane to the cytosol, A mutant in which the intervening sequence between the myristoyl moiety and the basic effector domain is deleted, is not displaced from the membrane by PKC dependent phosphorylation, fulfilling a theoretical prediction of the model, In addition to the nonspecific membrane binding interactions conferred by the myristoyl-electrostatic switch, indirect immunofluorescence microscopy demonstrates that specific protein-protein interactions also specify the intracellular localization of MARCKS.	ROCKEFELLER UNIV,LAB SIGNAL TRANSDUCT,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,PROGRAM MOL BIOL,DEWITT WALLACE RES LAB,NEW YORK,NY 10021	Rockefeller University; Memorial Sloan Kettering Cancer Center			Ravetch, Jeffrey/Z-1596-2019	Ravetch, Jeffrey/0000-0003-2024-9041	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI025032, R37AI025032] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 25032] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADEREM A, 1992, CELL, V71, P713, DOI 10.1016/0092-8674(92)90546-O; ALBERT KA, 1987, P NATL ACAD SCI USA, V84, P7046, DOI 10.1073/pnas.84.20.7046; ALLEN LAH, 1995, EMBO J, V14, P1109, DOI 10.1002/j.1460-2075.1995.tb07094.x; ALLEN LAH, 1995, J EXP MED, V182, P829, DOI 10.1084/jem.182.3.829; AMES JB, 1994, BIOCHEMISTRY-US, V33, P10743, DOI 10.1021/bi00201a023; BLACKSHEAR PJ, 1993, J BIOL CHEM, V268, P1501; BOMAN AL, 1995, TRENDS BIOCHEM SCI, V20, P147, DOI 10.1016/S0968-0004(00)88991-4; BUSER CA, 1994, BIOCHEMISTRY-US, V33, P13093, DOI 10.1021/bi00248a019; Chang S, 1996, J BIOL CHEM, V271, P1174, DOI 10.1074/jbc.271.2.1174; DIZHOOR AM, 1993, SCIENCE, V259, P829, DOI 10.1126/science.8430337; ERUSALIMSKY JD, 1991, J BIOL CHEM, V266, P7073; FLAHERTY KM, 1993, CELL, V75, P709, DOI 10.1016/0092-8674(93)90491-8; GEORGE DJ, 1992, J BIOL CHEM, V267, P24879; GRAFF JM, 1989, SCIENCE, V246, P503, DOI 10.1126/science.2814478; GRAFF JM, 1989, MOL ENDOCRINOL, V3, P1903, DOI 10.1210/mend-3-11-1903; GRAFF JM, 1989, J BIOL CHEM, V264, P21818; HARLAN DM, 1991, J BIOL CHEM, V266, P14399; HARTWIG JH, 1992, NATURE, V356, P618, DOI 10.1038/356618a0; KARNS LR, 1987, SCIENCE, V236, P597, DOI 10.1126/science.2437653; KIM JY, 1994, J BIOL CHEM, V269, P28214; KIM JY, 1994, BIOPHYS J, V67, P227, DOI 10.1016/S0006-3495(94)80473-4; MANENTI S, 1992, J BIOL CHEM, V267, P22310; MCLAUGHLIN S, 1995, TRENDS BIOCHEM SCI, V20, P272, DOI 10.1016/S0968-0004(00)89042-8; Myat M. M., 1994, Molecular Biology of the Cell, V5, p295A; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; PIETZSCH RM, 1993, BIOCHEMISTRY-US, V32, P10436; ROSEN A, 1989, J BIOL CHEM, V264, P9118; ROSEN A, 1990, J EXP MED, V172, P1211, DOI 10.1084/jem.172.4.1211; Sambrook J., 2002, MOL CLONING LAB MANU; SEYKORA JT, 1991, P NATL ACAD SCI USA, V88, P2505, DOI 10.1073/pnas.88.6.2505; SHAHINIAN S, 1995, BIOCHEMISTRY-US, V34, P3813, DOI 10.1021/bi00011a039; SIGAL CT, 1994, P NATL ACAD SCI USA, V91, P12253, DOI 10.1073/pnas.91.25.12253; SILVIUS JR, 1994, BIOCHEMISTRY-US, V33, P3014, DOI 10.1021/bi00176a034; STUMPO DJ, 1989, P NATL ACAD SCI USA, V86, P4012, DOI 10.1073/pnas.86.11.4012; SWIERCZYNSKI SL, 1995, J BIOL CHEM, V270, P13436, DOI 10.1074/jbc.270.22.13436; TANIGUCHI H, 1993, J BIOL CHEM, V268, P9960; THELEN M, 1991, NATURE, V351, P320, DOI 10.1038/351320a0; WANG JKT, 1989, P NATL ACAD SCI USA, V86, P2253, DOI 10.1073/pnas.86.7.2253; ZOZULYA S, 1992, P NATL ACAD SCI USA, V89, P11569, DOI 10.1073/pnas.89.23.11569	39	97	99	2	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18797	18802		10.1074/jbc.271.31.18797	http://dx.doi.org/10.1074/jbc.271.31.18797			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702537	hybrid			2022-12-25	WOS:A1996VB68300075
J	Wiemer, EAC; Luers, GH; Faber, KN; Wenzel, T; Veenhuis, M; Subramani, S				Wiemer, EAC; Luers, GH; Faber, KN; Wenzel, T; Veenhuis, M; Subramani, S			Isolation and characterization of Pas2p, a peroxisomal membrane protein essential for peroxisome biogenesis in the methylotrophic yeast Pichia pastoris	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POSITIVE SELECTION PROCEDURE; HAMSTER OVARY CELLS; SACCHAROMYCES-CEREVISIAE; TARGETING SIGNAL; HANSENULA-POLYMORPHA; 3-KETOACYL-COA THIOLASE; IMPORT DEFICIENCIES; ASSEMBLY MUTANTS; 3-OXOACYL-COA THIOLASE; ZELLWEGER SYNDROME	The pas2 mutant of the methylotrophic yeast Pichia pastoris is characterized by a deficiency in peroxisome biogenesis. We have cloned the PpPAS2 gene by functional complementation and show that it encodes a protein of 455 amino acids with a molecular mass of 52 kDa. In a Pppas2 null mutant, import of both peroxisomal targeting signal 1 (PTS1)- and PTS2-containing proteins is impaired as shown by biochemical fractionation and fluorescence microscopy. No morphologically distinguishable peroxisomal structures could be detected by electron microscopy in Pppas2 null cells induced on methanol and oleate, suggesting that PpPas2p is involved in the early stages of peroxisome biogenesis. PpPas2p is a peroxisomal membrane protein (PMP) and is resistant to extraction by 1 M NaCl or alkaline sodium carbonate, suggesting that it is a peroxisomal integral membrane protein. Two hydrophobic domains can be distinguished which may be involved in anchoring PpPas2p to the peroxisomal membrane. PpPas2p is homologous to the Saccharomyces cerevisiae Pas3p. The first 40 amino acids of PpPas2p, devoid of the hydrophobic domains, are sufficient to target a soluble fluorescent reporter protein to the peroxisomal membrane, with which it associates tightly, A comparison with the membrane peroxisomal targeting signal of PMP47 of Candida boidinii revealed a stretch of positively charged amino acids common to both sequences. The role of peroxisomal membrane targeting signals and transmembrane domains in anchoring PMPs to the peroxisomal membrane is discussed.	UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093; UNIV GRONINGEN,CTR BIOL,LAB ELECTRON MICROSCOPY,NL-9751 NN HAREN,NETHERLANDS	University of California System; University of California San Diego; University of Groningen				Wiemer, Erik/0000-0002-0673-7236	NICHD NIH HHS [NIHDK41737] Funding Source: Medline	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BAUDHUIN P, 1964, BIOCHEM J, V92, P179, DOI 10.1042/bj0920179; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CREGG JM, 1985, MOL CELL BIOL, V5, P3376, DOI 10.1128/MCB.5.12.3376; CREGG JM, 1990, YEAST, V6, P87, DOI 10.1002/yea.320060202; DIESTELKOTTER P, 1993, J CELL BIOL, V123, P1717, DOI 10.1083/jcb.123.6.1717; ELGERSMA Y, 1993, GENETICS, V135, P731; ERDMANN R, 1994, YEAST, V10, P935, DOI 10.1002/yea.320100708; ERDMANN R, 1995, J CELL BIOL, V128, P509, DOI 10.1083/jcb.128.4.509; ERDMANN R, 1989, P NATL ACAD SCI USA, V86, P519; FABER KN, 1995, FEBS LETT, V357, P115, DOI 10.1016/0014-5793(94)01317-T; GLOVER JR, 1994, J BIOL CHEM, V269, P7558; GOULD SJ, 1992, YEAST, V8, P613, DOI 10.1002/yea.320080805; GOULD SJ, 1989, J CELL BIOL, V108, P1657, DOI 10.1083/jcb.108.5.1657; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HARLOW E, 1988, ANTIBODIES LAB MANUA, P92; HEIM R, 1995, NATURE, V373, P663, DOI 10.1038/373663b0; HEYMAN JA, 1994, J CELL BIOL, V127, P1259, DOI 10.1083/jcb.127.5.1259; HOHFELD J, 1991, J CELL BIOL, V114, P1167, DOI 10.1083/jcb.114.6.1167; HOHFELD J, 1992, MEMBRANE BIOGENESIS, P185; Imanaka T, 1996, J BIOL CHEM, V271, P3706; KALISH JE, 1995, MOL CELL BIOL, V15, P6406; KELLER GA, 1991, J CELL BIOL, V114, P893, DOI 10.1083/jcb.114.5.893; KUAN J, 1993, RES MICROBIOL, V144, P671, DOI 10.1016/0923-2508(93)90073-B; Kunau W.-H., 1987, PEROXISOMES BIOL MED, P128; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lazarow P. B., 1989, METABOLIC BASIS INHE, P1479; LIU H, 1992, J BACTERIOL, V174, P4943, DOI 10.1128/JB.174.15.4943-4951.1992; LIU H, 1995, J BIOL CHEM, V270, P10940, DOI 10.1074/jbc.270.18.10940; MADDEN EA, 1987, ANAL BIOCHEM, V163, P350, DOI 10.1016/0003-2697(87)90235-1; MARZIOCH M, 1994, EMBO J, V13, P4908, DOI 10.1002/j.1460-2075.1994.tb06818.x; MCCAMMON MT, 1994, J CELL BIOL, V124, P915, DOI 10.1083/jcb.124.6.915; MCCOLLUM D, 1993, J CELL BIOL, V121, P761, DOI 10.1083/jcb.121.4.761; McNew JA, 1996, TRENDS BIOCHEM SCI, V21, P54, DOI 10.1016/S0968-0004(96)80181-2; Monosov EZ, 1996, J HISTOCHEM CYTOCHEM, V44, P581, DOI 10.1177/44.6.8666743; MOTLEY A, 1994, J CELL BIOL, V125, P755, DOI 10.1083/jcb.125.4.755; NUTTLEY WM, 1993, YEAST, V9, P507, DOI 10.1002/yea.320090506; OSUMI T, 1991, BIOCHEM BIOPH RES CO, V181, P947, DOI 10.1016/0006-291X(91)92028-I; RAPP S, 1993, EXP CELL RES, V205, P59, DOI 10.1006/excr.1993.1058; RICKEY C, 1990, MOL BIOL REP, V9, P2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SLAWECKI ML, 1995, J CELL SCI, V108, P1817; SLOT JW, 1984, IMMUNOLABELLING ELEC, P129; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SPONG AP, 1993, J CELL BIOL, V123, P535, DOI 10.1083/jcb.123.3.535; SUBRAMANI S, 1993, ANNU REV CELL BIOL, V9, P445, DOI 10.1146/annurev.cb.09.110193.002305; SWINKELS BW, 1991, EMBO J, V10, P3255, DOI 10.1002/j.1460-2075.1991.tb04889.x; TAN XQ, 1995, J CELL BIOL, V128, P307, DOI 10.1083/jcb.128.3.307; TERLECKY SR, 1995, EMBO J, V14, P3627, DOI 10.1002/j.1460-2075.1995.tb00032.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANDENBOSCH H, 1992, ANNU REV BIOCHEM, V61, P157, DOI 10.1146/annurev.bi.61.070192.001105; VANDERLEIJ I, 1992, J CELL BIOL, V119, P153, DOI 10.1083/jcb.119.1.153; VANDERLEIJ I, 1993, P NATL ACAD SCI USA, V90, P11782, DOI 10.1073/pnas.90.24.11782; VEENHUIS M, 1992, CELL BIOCHEM FUNCT, V10, P175, DOI 10.1002/cbf.290100307; WENDLAND M, 1993, J CELL BIOL, V120, P675, DOI 10.1083/jcb.120.3.675; Wiemer E A, 1994, Mol Genet Med, V4, P119; WIEMER EAC, 1989, EUR J CELL BIOL, V50, P407; ZHANG JW, 1993, J CELL BIOL, V123, P1133, DOI 10.1083/jcb.123.5.1133; ZHANG JW, 1995, J CELL BIOL, V129, P65, DOI 10.1083/jcb.129.1.65; Zhang JW, 1996, J CELL BIOL, V132, P325, DOI 10.1083/jcb.132.3.325	61	106	108	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18973	18980		10.1074/jbc.271.31.18973	http://dx.doi.org/10.1074/jbc.271.31.18973			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702562	hybrid, Green Published			2022-12-25	WOS:A1996VB68300100
J	Cooper, JT; Stroka, DM; Brostjan, C; Palmetshofer, A; Bach, FH; Ferran, C				Cooper, JT; Stroka, DM; Brostjan, C; Palmetshofer, A; Bach, FH; Ferran, C			A20 blocks endothelial cell activation through a NF-kappa B-dependent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZINC FINGER PROTEIN; LEUKOCYTE ADHESION MOLECULE-1; E-SELECTIN PROMOTER; TRANSCRIPTION FACTOR; GENE-TRANSCRIPTION; REGULATORY SYSTEM; ALPHA; EXPRESSION; ANTIOXIDANT; INDUCTION	The A20 gene product is a novel zinc finger protein originally described as a tumor necrosis factor alpha (TNF)-inducible early response gene in human umbilical vein endothelial cells (HUVEC), Its described function is to block TNF-induced apoptosis in fibroblasts and B lymphocytes, but more recently it has also been shown to play a role in lymphoid cell maturation. The mechanism of action of A20 is unknown, The aim of our study was to assess the effect of A20 upon endothelial cell activation, By transfecting bovine aortic endothelial cells (BAEC) with A20 as well as reporter constructs consisting of the promoters of genes known to be up-regulated during endothelial cell activation, i.e. E selectin, interleukin (IL)-8, tissue factor (TF), and inhibitor of nuclear factor kappa B alpha (I kappa B alpha), we demonstrate that A20 expression inhibits gene up-regulation associated with TNF, lipopolysaccharide (LPS), phorbol 12-myristate 13 acetate (PMA), and hydrogen peroxide (H2O2)-induced endothelial cell (EC) activation. The mechanism of action of A20 is in part, or totally, due to the blockade of nuclear factor kappa B (NF-kappa B), as shown by its ability to suppress the activity of a NF-KB reporter, This effect is specific, as A20 does not block a noninducible, constitutively expressed reporter, Rous sarcoma virus-luciferase (RSV-LUC); nor does it block the c-Tat-inducible, NF-kappa B-independent reporter, human immunodeficiency virus-chloramphenicol acetyltransferase (HIV-CAT). How A20 blocks NF-kappa B is unclear, although we demonstrate that it does not affect p65 (RelA)-mediated gene transactivation, The inhibition of endothelial cell activation by A20 is a novel function for A20.	HARVARD UNIV, NEW ENGLAND DEACONESS HOSP, SCH MED, SANDOZ CTR IMMUNOBIOL, BOSTON, MA 02215 USA	Harvard University; Harvard Medical School; Novartis; Sandoz			Stroka, Deborah M/F-1806-2013	Brostjan, Christine/0000-0003-1462-5397; Stroka, Deborah/0000-0002-3517-3871; COOPER, JEFFREY/0000-0002-5732-5143				BACH FH, 1994, IMMUNOL REV, V141, P5, DOI 10.1111/j.1600-065X.1994.tb00870.x; BACH FH, 1995, NAT MED, V1, P869, DOI 10.1038/nm0995-869; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; Berg JM, 1996, SCIENCE, V271, P1081, DOI 10.1126/science.271.5252.1081; BERG JM, 1990, ANNU REV BIOPHYS BIO, V19, P405; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; BRAY TM, 1990, FREE RADICAL BIO MED, V8, P281, DOI 10.1016/0891-5849(90)90076-U; CHENG Q, 1994, J BIOL CHEM, V269, P13551; COLLINS T, 1993, TRENDS CARDIOVAS MED, V3, P92, DOI 10.1016/1050-1738(93)90030-A; CROSSMAN DC, 1990, J BIOL CHEM, V265, P9782; DELUCA LG, 1994, J BIOL CHEM, V269, P19193; DEMARTIN R, 1993, EMBO J, V12, P2773, DOI 10.1002/j.1460-2075.1993.tb05938.x; DIXIT VM, 1990, J BIOL CHEM, V265, P2973; FERRAN C, 1995, BIOCHEM BIOPH RES CO, V214, P212, DOI 10.1006/bbrc.1995.2277; GERRITSEN ME, 1993, FASEB J, V7, P523, DOI 10.1096/fasebj.7.6.8472891; GRILLI M, 1993, INT REV CYTOL, V143, P1; HENNIG B, 1993, ANN NY ACAD SCI, V686, P99, DOI 10.1111/j.1749-6632.1993.tb39161.x; Jaattela M, 1996, J IMMUNOL, V156, P1166; KASZUBSKA W, 1993, MOL CELL BIOL, V13, P7180, DOI 10.1128/MCB.13.11.7180; KRIKOS A, 1992, J BIOL CHEM, V267, P17971; LAHERTY CD, 1992, J BIOL CHEM, V267, P24157; LARUE KEA, 1994, J EXP MED, V180, P2269, DOI 10.1084/jem.180.6.2269; MARUI N, 1993, J CLIN INVEST, V92, P1866, DOI 10.1172/JCI116778; MOLL T, 1995, J BIOL CHEM, V270, P3849, DOI 10.1074/jbc.270.8.3849; OPIPARI AW, 1990, J BIOL CHEM, V265, P14705; OPIPARI AW, 1992, J BIOL CHEM, V267, P12424; POBER JS, 1990, TRANSPLANTATION, V50, P537, DOI 10.1097/00007890-199010000-00001; POBER JS, 1990, PHYSIOL REV, V70, P427, DOI 10.1152/physrev.1990.70.2.427; READ MA, 1994, J EXP MED, V179, P503, DOI 10.1084/jem.179.2.503; SARMA V, 1995, J BIOL CHEM, V270, P12343, DOI 10.1074/jbc.270.21.12343; SCHRECK R, 1992, FREE RADICAL RES COM, V17, P221, DOI 10.3109/10715769209079515; SICA A, 1990, IMMUNOLOGY, V69, P548; STEIN B, 1993, MOL CELL BIOL, V13, P7191, DOI 10.1128/MCB.13.11.7191; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; TEWARI M, 1995, J IMMUNOL, V154, P1699; WHELAN J, 1991, NUCLEIC ACIDS RES, V19, P2645, DOI 10.1093/nar/19.10.2645; Winer BJ., 1971, STAT PRINCIPLES EXPT, V2nd ed; ZIMMERMANN K, 1991, VIROLOGY, V182, P874, DOI 10.1016/0042-6822(91)90633-M	38	224	233	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					18068	18073		10.1074/jbc.271.30.18068	http://dx.doi.org/10.1074/jbc.271.30.18068			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663499	hybrid			2022-12-25	WOS:A1996UY93500072
J	Hoffmann, A; Roeder, RG				Hoffmann, A; Roeder, RG			Cloning and characterization of human TAF20/15 - Multiple interactions suggest a central role in TFIID complex formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-II; TATA-BINDING PROTEIN; TRANSCRIPTION FACTOR ATF; IMMEDIATE EARLY PROTEIN; CONSERVED CORE DOMAIN; PROMOTER INTERACTIONS; MOLECULAR-CLONING; PREINITIATION COMPLEX; ACCURATE INITIATION; BASAL TRANSCRIPTION	TFIID is a multiprotein complex that plays a central role in the initiation and regulation of class II transcription. Transcription factor IID (TFIID) nucleates transcription initiation complex formation by direct core promoter binding and mediates the action of transcriptional activators, in part via direct interactions with them. Molecular studies of the TFIID complex have identified multiple subunits whose potential interactions can be recapitulated in vitro with recombinant polypeptides, Here we report the cloning of human TATA box binding protein (TBP)-associated factor 20 (TAF20) and the consequent identification of an additional, related TFIID subunit, human TAF15 (hTAF15), Multiple TAF20/15 interactions have been detected within native TFIID preparations and further analyzed with recombinant subunits. Along with the demonstration of a high affinity association between TAF20/15 and TBP, the present results suggest that hTAF20/15 may complement hTAF250 in directing the association of TAFs with TBP to form a TFIID complex. Finally, we present detailed mutagenesis studies that reveal multiple, distinct interaction surfaces on the presumed globular domain of hTAF20/15 and may be used, in conjunction with structural data, to model the architecture of the TFIID multiprotein complex.	ROCKEFELLER UNIV, BIOCHEM & MOLEC BIOL LAB, NEW YORK, NY 10021 USA	Rockefeller University								ABMAYR SM, 1988, GENE DEV, V2, P542, DOI 10.1101/gad.2.5.542; ARENTS G, 1991, P NATL ACAD SCI USA, V88, P10148, DOI 10.1073/pnas.88.22.10148; Burley SK, 1996, ANNU REV BIOCHEM, V65, P769, DOI 10.1146/annurev.bi.65.070196.004005; CHEN JL, 1994, CELL, V79, P93, DOI 10.1016/0092-8674(94)90403-0; CHIANG CM, 1993, EMBO J, V12, P2749, DOI 10.1002/j.1460-2075.1993.tb05936.x; CHIANG CM, 1995, SCIENCE, V267, P531, DOI 10.1126/science.7824954; DAVISON BL, 1983, NATURE, V301, P680, DOI 10.1038/301680a0; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; GOODRICH LA, 1994, CURR OPIN CELL BIOL, V6, P403, DOI 10.1016/0955-0674(94)90033-7; HAI T, 1988, CELL, V54, P1043, DOI 10.1016/0092-8674(88)90119-5; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; HISATAKE K, 1995, P NATL ACAD SCI USA, V92, P8195, DOI 10.1073/pnas.92.18.8195; HOFFMANN A, 1990, NATURE, V346, P387, DOI 10.1038/346387a0; HOFFMANN A, 1991, NUCLEIC ACIDS RES, V19, P6337, DOI 10.1093/nar/19.22.6337; Hoffmann A, 1996, NATURE, V380, P356, DOI 10.1038/380356a0; HOFFMANN A, 1994, MOL CHARACTERIZATION; HORIKOSHI M, 1988, CELL, V54, P665, DOI 10.1016/S0092-8674(88)80011-4; HORIKOSHI M, 1988, CELL, V54, P1033, DOI 10.1016/0092-8674(88)90118-3; JACQ X, 1994, CELL, V79, P107, DOI 10.1016/0092-8674(94)90404-9; KLEMM RD, 1995, P NATL ACAD SCI USA, V92, P5788, DOI 10.1073/pnas.92.13.5788; KOKUBO T, 1993, GENE DEV, V7, P1033, DOI 10.1101/gad.7.6.1033; KOKUBO T, 1994, NATURE, V367, P484, DOI 10.1038/367484a0; KOKUBO T, 1993, MOL CELL BIOL, V13, P7859, DOI 10.1128/MCB.13.12.7859; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LIEBERMAN PM, 1994, GENE DEV, V8, P995, DOI 10.1101/gad.8.9.995; MARTINEZ E, 1994, EMBO J, V13, P3115, DOI 10.1002/j.1460-2075.1994.tb06610.x; MATSUI T, 1980, J BIOL CHEM, V255, P1992; MENGUS G, 1995, EMBO J, V14, P1520, DOI 10.1002/j.1460-2075.1995.tb07138.x; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; PRUSS D, 1995, BIOESSAYS, V17, P161, DOI 10.1002/bies.950170211; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; SAUER F, 1995, SCIENCE, V270, P1783, DOI 10.1126/science.270.5243.1783; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TAKADA R, 1992, P NATL ACAD SCI USA, V89, P11809, DOI 10.1073/pnas.89.24.11809; TANESE N, 1991, GENE DEV, V5, P2212, DOI 10.1101/gad.5.12a.2212; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; WEIL PA, 1979, CELL, V18, P469; WEINZIERL ROJ, 1993, NATURE, V362, P511, DOI 10.1038/362511a0; WORKMAN JL, 1988, CELL, V55, P211, DOI 10.1016/0092-8674(88)90044-X; Xie XL, 1996, NATURE, V380, P316, DOI 10.1038/380316a0; YOKOMORI K, 1993, GENE DEV, V7, P2587, DOI 10.1101/gad.7.12b.2587; ZAWEL Z, 1993, PROG NUCL ACIDS RES, V44, P67; ZHOU Q, 1993, GENE DEV, V7, P180, DOI 10.1101/gad.7.2.180	47	47	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					18194	18202		10.1074/jbc.271.30.18194	http://dx.doi.org/10.1074/jbc.271.30.18194			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663456	hybrid			2022-12-25	WOS:A1996UY93500091
J	Jiang, BH; Rue, E; Wang, GL; Roe, R; Semenza, GL				Jiang, BH; Rue, E; Wang, GL; Roe, R; Semenza, GL			Dimerization, DNA binding, and transactivation properties of hypoxia-inducible factor 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR NUCLEAR TRANSLOCATOR; ENDOTHELIAL GROWTH-FACTOR; ERYTHROPOIETIN GENE-EXPRESSION; LACTATE-DEHYDROGENASE-A; TRANSCRIPTIONAL ACTIVATION; DIOXIN RECEPTOR; FACTOR-I; MESSENGER-RNA; PROTEIN ARNT; C-JUN	Hypoxia-inducible factor 1 (HIF-1) is a heterodimeric basic helix-loop-helix transcription factor that regulates hypoxia-inducible genes including the human erythropoietin (EPO) gene, In this study, we report structural features of the HIF-1 alpha subunit that are required for heterodimerization, DNA binding, and transactivation. The HIF-1 alpha and HIF-1 beta (ARNT; aryl hydrocarbon receptor nuclear translocator) subunits were coimmunoprecipitated from nuclear extracts, indicating that these proteins heterodimerize in the absence of DNA, In vitro-translated HIF-1 alpha and HIF-1 beta generated a HIF-1/DNA complex with similar electrophoretic mobility and sequence specificity as HIF-1 present in nuclear extracts from hypoxic cells, Compared to 826-amino acid, full-length HIF-1 alpha, amino acids 1-166 mediated heterodimerization with HIF-1 beta (ARNT), but amino acids 1-390 were required for optimal DNA binding, A deletion involving the basic domain of HIF-1 alpha eliminated DNA binding without affecting heterodimerization, In cotransfection assays, forced expression of recombinant HIF-1 alpha and HIF-1 beta (ARNT) activated transcription of reporter genes containing EPO enhancer sequences with intact, but not mutant, HIF-1 binding sites, Deletion of the car boxy terminus of HIF-1 alpha (amino acids 391-826) markedly decreased the ability of recombinant HIF-1 to activate transcription, Overexpression of a HIF-1 alpha construct with deletions of the basic domain and carboxy terminus blocked reporter gene activation by endogenous HIF-1 in hypoxic cells.	JOHNS HOPKINS UNIV HOSP, SCH MED, DEPT PEDIAT, CTR GENET MED, BALTIMORE, MD 21287 USA; JOHNS HOPKINS UNIV HOSP, SCH MED, DEPT MED, CTR GENET MED, BALTIMORE, MD 21287 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine				Jiang, Bing-Hua/0000-0003-4526-2031	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039869] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01-DK39869] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANTONSSON C, 1995, J BIOL CHEM, V270, P13968, DOI 10.1074/jbc.270.23.13968; BECK I, 1993, BLOOD, V82, P704; BURBACH KM, 1992, P NATL ACAD SCI USA, V89, P8185, DOI 10.1073/pnas.89.17.8185; CITRI Y, 1987, NATURE, V326, P42, DOI 10.1038/326042a0; FANDREY J, 1993, BLOOD, V81, P617; FIRTH JD, 1995, J BIOL CHEM, V270, P21021, DOI 10.1074/jbc.270.36.21021; FIRTH JD, 1994, P NATL ACAD SCI USA, V91, P6496, DOI 10.1073/pnas.91.14.6496; GALSON DL, 1995, MOL CELL BIOL, V15, P2135; GOLDBERG MA, 1994, J BIOL CHEM, V269, P4355; GOLDBERG MA, 1991, BLOOD, V77, P271; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; JELKMANN W, 1992, PHYSIOL REV, V72, P449, DOI 10.1152/physrev.1992.72.2.449; KADESCH T, 1993, CELL GROWTH DIFFER, V4, P49; KRANTZ SB, 1991, BLOOD, V77, P419; LEVY AP, 1995, J BIOL CHEM, V270, P13333, DOI 10.1074/jbc.270.22.13333; LI H, 1994, J BIOL CHEM, V269, P28098; LINDEBRO MC, 1995, EMBO J, V14, P3528, DOI 10.1002/j.1460-2075.1995.tb07359.x; MA Q, 1995, J BIOL CHEM, V270, P12697, DOI 10.1074/jbc.270.21.12697; MAXWELL PH, 1993, P NATL ACAD SCI USA, V90, P2423, DOI 10.1073/pnas.90.6.2423; Murre  C., 1992, TRANSCRIPTIONAL REGU, P861; NAMBU JR, 1991, CELL, V67, P1157, DOI 10.1016/0092-8674(91)90292-7; PAPAVASSILIOU AG, 1992, SCIENCE, V258, P1941, DOI 10.1126/science.1470918; RATCLIFFE PJ, 1993, KIDNEY INT, V44, P887, DOI 10.1038/ki.1993.327; REISZPORSZASZ S, 1994, MOL CELL BIOL, V14, P6075, DOI 10.1128/MCB.14.9.6075; REYES H, 1992, SCIENCE, V256, P1193, DOI 10.1126/science.256.5060.1193; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; SEMENZA GL, 1994, HEMATOL ONCOL CLIN N, V8, P863, DOI 10.1016/S0889-8588(18)30134-5; SEMENZA GL, 1994, J BIOL CHEM, V269, P23757; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; SOGAWA K, 1995, P NATL ACAD SCI USA, V92, P1936, DOI 10.1073/pnas.92.6.1936; SWANSON HI, 1995, J BIOL CHEM, V270, P26292, DOI 10.1074/jbc.270.44.26292; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; WANG GL, 1993, P NATL ACAD SCI USA, V90, P4304, DOI 10.1073/pnas.90.9.4304; WANG GL, 1993, BLOOD, V82, P3610; WANG GL, 1993, J BIOL CHEM, V268, P21513; WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; WHITELAW ML, 1994, MOL CELL BIOL, V14, P8343, DOI 10.1128/MCB.14.12.8343	39	858	918	4	53	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					17771	17778		10.1074/jbc.271.30.17771	http://dx.doi.org/10.1074/jbc.271.30.17771			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663540	hybrid			2022-12-25	WOS:A1996UY93500030
J	Albury, MS; Dudley, P; Watts, FZ; Moore, AL				Albury, MS; Dudley, P; Watts, FZ; Moore, AL			Targeting the plant alternative oxidase protein to Schizosaccharomyces pombe mitochondria confers cyanide-insensitive respiration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SAUROMATUM-GUTTATUM SCHOTT; RESISTANT RESPIRATION; ELECTRON-TRANSPORT; HANSENULA-ANOMALA; CLONING; CDNA; GENE; PATHWAY; IMPORT; POOL	The Sauromatum guttatum alternative oxidase has been expressed in Schizosaccharomyces pombe under the control of the thiamine repressible nmt1 promoter. Alternative oxidase protein and activity were detected both in spheroplasts and isolated mitochondria, indicating that the enzyme is expressed in a functional form and confers cyanide-resistant respiration to S. pombe, which is sensitive to inhibition by octyl-gallate. Protein import studies revealed that the precursor form of the alternative oxidase protein is efficiently imported into isolated mitochondria and processed to its mature form comparable to that observed with potato mitochondria. Western blot analysis and respiratory studies revealed that the alternative oxidase protein is expressed in the inner mitochondrial membrane in its reduced (active) form, Treatment of mitochondria with diamide and dithiothreitol resulted in interconversion of the reduced and oxidized species and modulation of respiratory activity. The addition of pyruvate did not effect either the respiratory rate or expression of the reduced species of the protein, To our knowledge this is the first time that the alternative oxidase has been effectively targeted to and integrated into the inner mitochondrial membrane of S. pombe, and we conclude that the expression of a single polypeptide is sufficient for alternative oxidase activity.	UNIV SUSSEX,SCH BIOL SCI,DEPT BIOCHEM,BRIGHTON BN1 9QG,E SUSSEX,ENGLAND	University of Sussex								DAY DA, 1995, AUST J PLANT PHYSIOL, V22, P497, DOI 10.1071/PP9950497; DRY IB, 1989, ARCH BIOCHEM BIOPHYS, V273, P148, DOI 10.1016/0003-9861(89)90173-2; ELTHON TE, 1989, PLANT PHYSIOL, V89, P1311, DOI 10.1104/pp.89.4.1311; ELTHON TE, 1989, PLANTA, V180, P82, DOI 10.1007/BF02411413; HOEFNAGEL MHN, 1995, EUR J BIOCHEM, V233, P531, DOI 10.1111/j.1432-1033.1995.531_2.x; HOEFNAGEL MHN, 1995, ARCH BIOCHEM BIOPHYS, V318, P394, DOI 10.1006/abbi.1995.1245; KEARNS A, 1992, PLANT PHYSIOL, V99, P712, DOI 10.1104/pp.99.2.712; KUMAR AM, 1992, P NATL ACAD SCI USA, V89, P10842, DOI 10.1073/pnas.89.22.10842; LAEMMLI UK, 1970, NATURE, V227, P415; Leach GR, 1996, BIOCHEM J, V317, P313, DOI 10.1042/bj3170313; MAUNDRELL K, 1990, J BIOL CHEM, V265, P10857; MCINTOSH L, 1994, PLANT PHYSIOL, V105, P781, DOI 10.1104/pp.105.3.781; MINAGAWA N, 1990, FEBS LETT, V264, P149, DOI 10.1016/0014-5793(90)80787-J; MOORE AL, 1988, FEBS LETT, V235, P76, DOI 10.1016/0014-5793(88)81237-7; MOORE AL, 1992, YEAST, V8, P923, DOI 10.1002/yea.320081103; MOORE AL, 1995, J BIOENERG BIOMEMBR, V27, P367, DOI 10.1007/BF02109999; MOORE AL, 1994, ANNU REV PLANT PHYS, V45, P545, DOI 10.1146/annurev.pp.45.060194.002553; MOORE AL, 1991, BIOCHIM BIOPHYS ACTA, V1059, P121, DOI 10.1016/S0005-2728(05)80197-5; MOORE AL, 1991, PLANT PHYSIOL, V95, P34, DOI 10.1104/pp.95.1.34; MURRAY JM, 1994, MOL CELL BIOL, V14, P4878, DOI 10.1128/MCB.14.7.4878; MURRAY JM, 1991, NUCLEIC ACIDS RES, V19, P3525, DOI 10.1093/nar/19.13.3525; Nordlund P, 1995, CURR OPIN STRUC BIOL, V5, P758, DOI 10.1016/0959-440X(95)80008-5; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OKAZAKI K, 1990, NUCLEIC ACIDS RES, V18, P6485, DOI 10.1093/nar/18.22.6485; RHOADS DM, 1991, P NATL ACAD SCI USA, V88, P2122, DOI 10.1073/pnas.88.6.2122; RIBAS-CARBO M, 1995, ARCH BIOCHEM BIOPHYS, V317, P156, DOI 10.1006/abbi.1995.1148; SAKAJO S, 1991, BIOCHIM BIOPHYS ACTA, V1090, P102; Sambrook J., 2002, MOL CLONING LAB MANU; SIEDOW JN, 1995, FEBS LETT, V362, P10, DOI 10.1016/0014-5793(95)00196-G; SIEDOW JN, 1995, PLANT CELL, V7, P821, DOI 10.1105/tpc.7.7.821; SIEDOW JN, 1993, BIOCHIM BIOPHYS ACTA, V1142, P165, DOI 10.1016/0005-2728(93)90098-Z; STUEBER D, 1984, EMBO J, V3, P3143, DOI 10.1002/j.1460-2075.1984.tb02271.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UMBACH AL, 1993, PLANT PHYSIOL, V103, P845, DOI 10.1104/pp.103.3.845; VANDENBERGEN CWM, 1994, EUR J BIOCHEM, V226, P1071; VANLERBERGHE GC, 1995, PLANT PHYSIOL, V109, P353, DOI 10.1104/pp.109.2.353; WAGNER AM, 1995, PHYSIOL PLANTARUM, V95, P318, DOI 10.1111/j.1399-3054.1995.tb00844.x; WATTS FZ, 1992, PLANT MOL BIOL, V18, P23, DOI 10.1007/BF00018453; WEBER A, 1995, BIOCHEMISTRY-US, V34, P2621, DOI 10.1021/bi00008a028; Whelan J, 1996, PLANTA, V198, P197, DOI 10.1007/BF00206244; WHITEHOUSE DG, 1989, PLANT PHYSIOL, V91, P487, DOI 10.1104/pp.91.2.487	41	36	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					17062	17066		10.1074/jbc.271.29.17062	http://dx.doi.org/10.1074/jbc.271.29.17062			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663588	hybrid			2022-12-25	WOS:A1996UX94300015
J	Sonoda, H; Nishida, K; Yoshioka, T; Ohtani, M; Sugita, K				Sonoda, H; Nishida, K; Yoshioka, T; Ohtani, M; Sugita, K			Oxamflatin: A novel compound which reverses malignant phenotype to normal one via induction of JunD	ONCOGENE			English	Article						transformation; inhibitor; ras; junD; fibronectin	RAS-ONCOGENE; NIH3T3 CELLS; TRANSFORMATION; GENE; EXPRESSION; CANCER; DNA	In the course of screening for inhibitors of tumorigenic phenotype of K-ras-transformed NIH3T3 cells (DT cells), we found a novel compound, oxamflatin, an aromatic sulfonamide hydroxamate derivative, which induces flat phenotype in these cells and suppresses their anchorage-independent growth. In contrast to DT cells, in v-raf-transformed NIH3T3 cells, no change in their morphology and no specific inhibition of their anchorage-independent growth was observed, Interestingly, oxamflatin was effective to NIH3T3 cells transformed by constitutively activated mutant of MEK, indicating the possibility that oncogene-induced morphological change is not necessarily induced by common signaling pathway such as MAP kinase cascade, In oxamflatin-treated DT cells, the expression of transcription factor junD was highly augmented, resulting in trans-activation of fibronectin gene by junD via cyclic AMP responsive element in its promoter, This behavior of junD was confirmed to correlate well with partial blocking of malignant phenotype in DT cells, Thus, oxamflatin can be categorized as the first reagent which induces genes whose products can interfere with oncogene-dependent transformation.			Sonoda, H (corresponding author), SHIONOGI & CO LTD, SHIONOGI RES LABS, FUKUSHIMA KU, SAGISU 5-12-4, OSAKA 553, JAPAN.							ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BOS JL, 1989, CANCER RES, V49, P4682; CASINI A, 1994, ALCOHOL ALCOHOLISM, V29, P303; CHEN JY, 1995, EMBO J, V14, P1187, DOI 10.1002/j.1460-2075.1995.tb07102.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COX AD, 1994, J BIOL CHEM, V269, P19203; CUTLER ML, 1992, MOL CELL BIOL, V12, P3750, DOI 10.1128/MCB.12.9.3750; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; FUJITA T, 1986, CELL, V46, P401, DOI 10.1016/0092-8674(86)90660-4; FUTAMURA M, 1995, ONCOGENE, V10, P1119; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HYNES RO, 1990, FIBRONECTINS, pCH12; JAMES GL, 1993, SCIENCE, V260, P1937, DOI 10.1126/science.8316834; KAMEDA T, 1993, P NATL ACAD SCI USA, V90, P9369, DOI 10.1073/pnas.90.20.9369; KIM JH, 1994, J BIOL CHEM, V269, P13740; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KOHL NE, 1993, SCIENCE, V260, P1934, DOI 10.1126/science.8316833; KREISBERG JI, 1994, KIDNEY INT, V46, P105, DOI 10.1038/ki.1994.249; KUO ML, 1995, BIOCHEM BIOPH RES CO, V212, P767, DOI 10.1006/bbrc.1995.2035; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MCCORMICK F, 1994, CURR OPIN GENET DEV, V4, P71, DOI 10.1016/0959-437X(94)90093-0; MURRAY MJ, 1981, CELL, V25, P355, DOI 10.1016/0092-8674(81)90054-4; NAKAJIMA T, 1992, MOL CELL BIOL, V12, P2837, DOI 10.1128/MCB.12.6.2837; NODA M, 1983, P NATL ACAD SCI-BIOL, V80, P5602, DOI 10.1073/pnas.80.18.5602; OHTANI M, 1993, Patent No. 9312075; PFARR CM, 1994, CELL, V76, P747, DOI 10.1016/0092-8674(94)90513-4; PRASAD GL, 1993, P NATL ACAD SCI USA, V90, P7039, DOI 10.1073/pnas.90.15.7039; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SREBROW A, 1993, FEBS LETT, V327, P25, DOI 10.1016/0014-5793(93)81031-T; SUGITA K, 1992, BIOCHEM BIOPH RES CO, V182, P379, DOI 10.1016/S0006-291X(05)80156-1; SUGITA K, 1992, CANCER RES, V52, P168; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z; YOSHIDA H, 1992, JPN J CANCER RES, V83, P324, DOI 10.1111/j.1349-7006.1992.tb00109.x; ZHAO JF, 1995, ONCOGENE, V11, P161	35	40	45	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 4	1996	13	1					143	149						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UX319	8700540				2022-12-25	WOS:A1996UX31900016
J	Vaillancourt, RR; Gardner, AM; Kazlauskas, A; Johnson, GL				Vaillancourt, RR; Gardner, AM; Kazlauskas, A; Johnson, GL			The kinase-inactive PDGF beta-receptor mediates activation of the MAP kinase cascade via the endogenous PDGF alpha-receptor in HepG2 cells	ONCOGENE			English	Article						PDGF receptor; HepG2 cells; MAP kinase; Raf-1	GROWTH-FACTOR RECEPTOR; PHOSPHOLIPASE-C-GAMMA; SIGNAL TRANSDUCTION; TYROSINE PHOSPHORYLATION; PROTEIN-KINASE; BINDING-SITE; PHOSPHATIDYLINOSITOL-3 KINASE; AUTOPHOSPHORYLATION SITES; INSULIN-RECEPTORS; CDNA CLONING	The PDGF beta-receptor in which the active-site lysine in the kinase domain has been mutated to arginine (K634R) lacks intrinsic kinase activity, When expressed in HepG2 cells, the kinase-inactive PDGF beta-receptor was tyrosine phosphorylated in response to PDGF-BB. Previously, HepG2 cells were thought to be devoid of PDGF alpha-receptor primarily due to lack of specific antibody which precluded detection of the PDGF alpha-receptor. In fact, these cells express low levels of PDGF alpha-receptor. In HepG2 cells that express the kinase-inactive PDGF beta-receptor, PDGF-BB activates the PDGF alpha-receptors to trans phosphorylate the kinase-inactive PDGF beta-receptor in an intermolecular fashion. As a result, stimulation of HepG2 cells that express the kinase-inactive receptor leads to activation of serine-threonine kinases of the MAP kinase cascade which include RAF-1, MEK-1 and p42 MAP kinase. In contrast, the kinase-inactive receptor does not activate any signaling pathways when it is expressed in PC12 cells which do not express the endogenous PDGF alpha-receptor. Thus, the kinase-inactive K634R PDGF beta-receptor is able to enhance PDGF-BB signaling in HepG2 cells that express the PDGF alpha-receptor.	UNIV COLORADO,SCH MED,DEPT PHARMACOL,DENVER,CO 80262	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Vaillancourt, RR (corresponding author), NATL JEWISH CTR IMMUNOL & RESP MED,DIV BASIC SCI,1400 JACKSON ST,DENVER,CO 80206, USA.			Gardner, Anne/0000-0001-7095-772X	NCI NIH HHS [CA58187] Funding Source: Medline; NIDDK NIH HHS [DK37871] Funding Source: Medline; NIGMS NIH HHS [GM30324] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA058187] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037871] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM030324, R01GM030324] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARVIDSSON AK, 1994, MOL CELL BIOL, V14, P6715, DOI 10.1128/MCB.14.10.6715; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BAZENET CE, 1993, ONCOGENE, V9, P517; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAMPOSGONZALEZ R, 1992, J BIOL CHEM, V267, P14535; CHOU CK, 1987, J BIOL CHEM, V262, P1842; CLAESSONWELSH L, 1989, P NATL ACAD SCI USA, V86, P4917, DOI 10.1073/pnas.86.13.4917; CLAESSONWELSH L, 1988, MOL CELL BIOL, V8, P3476, DOI 10.1128/MCB.8.8.3476; CLAESSONWELSH L, 1994, J BIOL CHEM, V269, P32023; COKER KJ, 1994, P NATL ACAD SCI USA, V91, P6967, DOI 10.1073/pnas.91.15.6967; COUGHLIN SR, 1989, SCIENCE, V243, P1191; CREWS CM, 1992, SCIENCE, V25; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; ELDREDGE ER, 1994, MOL CELL BIOL, V14, P7527, DOI 10.1128/MCB.14.11.7527; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FLING SP, 1986, ANAL BIOCHEM, V155, P83, DOI 10.1016/0003-2697(86)90228-9; GARDNER AM, 1993, J BIOL CHEM, V268, P17896; GARDNER AM, 1994, METHOD ENZYMOL, V238, P258; GRONWALD RGK, 1988, P NATL ACAD SCI USA, V85, P3435, DOI 10.1073/pnas.85.10.3435; HEASLEY LE, 1992, MOL BIOL CELL, V3, P545, DOI 10.1091/mbc.3.5.545; HEIDARAN MA, 1993, J BIOL CHEM, V268, P9287; HELDIN CH, 1992, EMBO J, V11, P4251, DOI 10.1002/j.1460-2075.1992.tb05523.x; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HELDIN CH, 1989, J BIOL CHEM, V264, P8905; HONEGGER AM, 1990, MOL CELL BIOL, V10, P4035, DOI 10.1128/MCB.10.8.4035; JOHNSON GL, 1994, CURR OPIN CELL BIOL, V6, P230, DOI 10.1016/0955-0674(94)90141-4; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KASHISHIAN A, 1992, EMBO J, V11, P1373, DOI 10.1002/j.1460-2075.1992.tb05182.x; KASHISHIAN A, 1993, MOL BIOL CELL, V4, P49, DOI 10.1091/mbc.4.1.49; KAZLAUSKAS A, 1990, EMBO J, V9, P3279, DOI 10.1002/j.1460-2075.1990.tb07527.x; KAZLAUSKAS A, 1993, P NATL ACAD SCI USA, V90, P6939, DOI 10.1073/pnas.90.15.6939; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KAZLAUSKAS A, 1991, CELL REGUL, V2, P413, DOI 10.1091/mbc.2.6.413; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KELLY JD, 1991, J BIOL CHEM, V266, P8987; KOHLER N, 1974, EXP CELL RES, V87, P297, DOI 10.1016/0014-4827(74)90484-4; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; LEE KH, 1990, MOL CELL BIOL, V10, P2237, DOI 10.1128/MCB.10.5.2237; LI BQ, 1992, SCIENCE, V256, P1456, DOI 10.1126/science.1604323; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; LINSEMAN DA, 1995, J BIOL CHEM, V270, P12563, DOI 10.1074/jbc.270.21.12563; MAEGAWA H, 1988, J BIOL CHEM, V263, P12629; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; MCCLAIN DA, 1987, J BIOL CHEM, V262, P14663; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; RAY LB, 1988, P NATL ACAD SCI USA, V85, P3753, DOI 10.1073/pnas.85.11.3753; RONNSTRAND L, 1992, EMBO J, V11, P3911, DOI 10.1002/j.1460-2075.1992.tb05484.x; ROSS R, 1974, P NATL ACAD SCI USA, V71, P1207, DOI 10.1073/pnas.71.4.1207; RUSSELL M, 1995, BIOCHEMISTRY-US, V34, P6611, DOI 10.1021/bi00020a005; SCHLESSINGER J, 1988, TRENDS BIOCHEM SCI, V13, P443, DOI 10.1016/0968-0004(88)90219-8; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SEIFERT RA, 1989, J BIOL CHEM, V264, P8771; SELVA E, 1993, J BIOL CHEM, V268, P2250; UENO H, 1991, SCIENCE, V252, P844, DOI 10.1126/science.1851331; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VAILLANCOURT RR, 1995, MOL CELL BIOL, V15, P3644; VALIUS M, 1993, MOL CELL BIOL, V13, P133, DOI 10.1128/MCB.13.1.133; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WESTERMARK B, 1976, EXP CELL RES, V98, P170, DOI 10.1016/0014-4827(76)90476-6; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922; WRIGHT JD, 1995, J BIOL CHEM, V270, P12085, DOI 10.1074/jbc.270.20.12085; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; YOKOTE K, 1994, J BIOL CHEM, V269, P15337; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	73	7	7	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 4	1996	13	1					151	159						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UX319	8700541				2022-12-25	WOS:A1996UX31900017
J	Rickert, P; Seghezzi, W; Shanahan, F; Cho, H; Lees, E				Rickert, P; Seghezzi, W; Shanahan, F; Cho, H; Lees, E			Cyclin C/CDK8 is a novel CTD kinase associated with RNA polymerase II	ONCOGENE			English	Article						cyclin C; CDK8; RNA polymerase II; cell cycle	CARBOXYL-TERMINAL-DOMAIN; HUMAN CELL-CYCLE; PROTEIN-KINASE; CATALYTIC SUBUNIT; SACCHAROMYCES-CEREVISIAE; MAMMALIAN FIBROBLASTS; YEAST; PHOSPHORYLATION; PHASE; G(1)	A number of cyclin/kinase complexes have been identified in mammalian cells that are essential for controlled cell proliferation. Cyclin C was isolated by virtue of its ability to rescue the triple CLN mutation in yeast; however, until now its function has remained unclear. Cyclin C associates with a novel cyclin dependent kinase, CDK8, and we demonstrate that this complex is associated with kinase activity towards the carboxy-terminal domain (CTD) of RNA polymerase II. We have identified at least two distinct cyclin C/CDK8 containing complexes within the cell, a larger complex over 500 kD in size, that also contains the largest subunit of RNA polymerase II, and a smaller 170 kD species. Both of these cyclin C complexes retain potent CTD kinase activity. We further demonstrate that the cyclin C/CDK8 complex associates with the large subunit of RNA polymerase II in vivo, implicating a potential role for cyclin C/CDK8 in regulating its activities.	DNAX RES INST MOLEC & CELLULAR BIOL INC,PALO ALTO,CA 94304; STANFORD UNIV,DEPT CHEM,STANFORD,CA 94305; UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT BIOCHEM,HOWARD HUGHES MED INST,PISCATAWAY,NJ 08854	Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.; Stanford University; Howard Hughes Medical Institute; Rutgers State University New Brunswick; Rutgers State University Medical Center								BAI C, 1994, EMBO J, V13, P6087, DOI 10.1002/j.1460-2075.1994.tb06955.x; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BASKARAN R, 1993, P NATL ACAD SCI USA, V90, P11167, DOI 10.1073/pnas.90.23.11167; BATES S, 1994, ONCOGENE, V9, P71; BROWN AJ, 1994, MOL BIOL CELL, V5, P921, DOI 10.1091/mbc.5.8.921; CISEK LJ, 1989, NATURE, V339, P679, DOI 10.1038/339679a0; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; CORDEN JL, 1993, CURR OPIN GENET DEV, V3, P213, DOI 10.1016/0959-437X(93)90025-K; CORDEN JL, 1990, TRENDS BIOCHEM SCI, V15, P383, DOI 10.1016/0968-0004(90)90236-5; DRAPKIN R, 1994, NATURE, V368, P769, DOI 10.1038/368769a0; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; EMILI A, 1995, CURR OPIN GENET DEV, V5, P204, DOI 10.1016/0959-437X(95)80009-3; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; FEAVER WJ, 1991, CELL, V67, P1223, DOI 10.1016/0092-8674(91)90298-D; FEAVER WJ, 1994, CELL, V79, P1103, DOI 10.1016/0092-8674(94)90040-X; FESQUET D, 1993, EMBO J, V12, P3111, DOI 10.1002/j.1460-2075.1993.tb05980.x; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GRANA X, 1995, ONCOGENE, V11, P211; HARLOW E, 1985, J VIROL, V55, P533, DOI 10.1128/JVI.55.3.533-546.1985; Helin Kristian, 1993, Trends in Cell Biology, V3, P43, DOI 10.1016/0962-8924(93)90150-Y; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; KOLESKE AJ, 1995, TRENDS BIOCHEM SCI, V20, P113, DOI 10.1016/S0968-0004(00)88977-X; KOLESKE AJ, 1994, NATURE, V368, P466, DOI 10.1038/368466a0; KUCHIN A, 1995, P NATL ACAD SCI USA, V92, P4006; LEE JM, 1991, GENE EXPRESSION, V1, P149; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; LEES E, 1995, CURR OPIN CELL BIOL, V7, P773, DOI 10.1016/0955-0674(95)80060-3; LEHNER CF, 1990, CELL, V61, P535, DOI 10.1016/0092-8674(90)90535-M; LEOPOLD P, 1991, CELL, V66, P1207, DOI 10.1016/0092-8674(91)90043-X; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LIAO SM, 1995, NATURE, V374, P193, DOI 10.1038/374193a0; LU H, 1992, NATURE, V358, P641, DOI 10.1038/358641a0; MAKELA TP, 1994, NATURE, V371, P254, DOI 10.1038/371254a0; MALDONADO E, 1996, IN PRESS NATURE; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; NAKAMURA T, 1995, EXP CELL RES, V221, P534, DOI 10.1006/excr.1995.1406; NEVINS JR, 1992, SCIENCE, V258, P424; NONET ML, 1989, GENETICS, V123, P715; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; OSSIPOW V, 1995, CELL, V83, P137, DOI 10.1016/0092-8674(95)90242-2; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PAGANO M, 1993, J CELL BIOL, V121, P101, DOI 10.1083/jcb.121.1.101; PAYNE JM, 1993, J BIOL CHEM, V268, P80; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; Pines Jonathon, 1994, Seminars in Cell Biology, V5, P399, DOI 10.1006/scel.1994.1047; POON RYC, 1993, EMBO J, V12, P3123, DOI 10.1002/j.1460-2075.1993.tb05981.x; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; ROY R, 1994, CELL, V79, P1093, DOI 10.1016/0092-8674(94)90039-6; SERIZAWA H, 1992, P NATL ACAD SCI USA, V89, P7476, DOI 10.1073/pnas.89.16.7476; SERIZAWA H, 1995, NATURE, V374, P280, DOI 10.1038/374280a0; SHAO ZH, 1995, ONCOGENE, V10, P221; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHIEKHATTAR R, 1995, NATURE, V374, P283, DOI 10.1038/374283a0; SOLOMON MJ, 1993, EMBO J, V12, P3133, DOI 10.1002/j.1460-2075.1993.tb05982.x; STERNER DE, 1995, MOL CELL BIOL, V15, P5716; TAMURA K, 1993, ONCOGENE, V8, P2113; TASSAN JP, 1995, P NATL ACAD SCI USA, V92, P8871, DOI 10.1073/pnas.92.19.8871; TASSAN JP, 1994, J CELL BIOL, V127, P467, DOI 10.1083/jcb.127.2.467; THOMPSON CM, 1993, CELL, V73, P1361, DOI 10.1016/0092-8674(93)90362-T; THOMPSON NE, 1989, J BIOL CHEM, V264, P1151; TSAI LH, 1993, ONCOGENE, V8, P1593; WU LT, 1994, ONCOGENE, V9, P2089; XIAO H, 1994, MOL CELL BIOL, V14, P7013, DOI 10.1128/MCB.14.10.7013	72	150	157	0	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 20	1996	12	12					2631	2640						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UW487	8700522				2022-12-25	WOS:A1996UW48700017
J	Rodenhiser, D; Chakraborty, P; Andrews, J; Ainsworth, P; Mancini, D; Lopes, E; Singh, S				Rodenhiser, D; Chakraborty, P; Andrews, J; Ainsworth, P; Mancini, D; Lopes, E; Singh, S			Heterogeneous point mutations in the BRCA1 breast cancer susceptibility gene occur in high frequency at the site of homonucleotide tracts, short repeats and methylatable CpG/CpNpG motifs	ONCOGENE			English	Article						BRCA1; mutation; mutagenesis; homonucleotides; repeats; CpG	NF1 GENE; DNA; DELETIONS; MUTAGENESIS; DISEASE; COLON	Heterogeneous mutations in the BRCA1 tumour suppressor gene are responsible for a large percentage of inherited breast cancers as well as breast/ovarian cancers in families with a high incidence of both cancer types, Over a hundred BRCA1 mutations have been reported, but little is known of the mechanism(s) responsible for BRCA1 mutagenesis, To determine the significance of specific nucleotide sequences at mutational sites within the BRCA1 gene, are assessed how frequently independent BRCA1 mutations occur at the site of short direct repeats, single nucleotide repeats (homonucleotides) and at CpG and CpNpG motifs, We found that homonucleotide and short direct repeats are commonly associated with small deletions and insertions, Substitution mutations are frequently associated with homonucleotide repeats and with methylatable CpG dinucleotides and CpNpG trinucleotides, Our methylation and sequencing experiments show that CpG and certain CpNpG motifs are methylated, supporting the hypothesis that DNA methylation specificity at these sites may be an important contributor to BRCA1 mutagenesis. We suggest that BRCA1 mutations are acquired by replication errors and are retained by cells through an intricate balancing of replication and repair mechanisms, Such mutations may provide a proliferative advantage for a cell, leading to the tumour phenotype.	UNIV WESTERN ONTARIO, DEPT PAEDIAT, LONDON, ON, CANADA; UNIV WESTERN ONTARIO, DEPT ZOOL, LONDON, ON, CANADA; UNIV WESTERN ONTARIO, DEPT BIOCHEM, LONDON, ON, CANADA; VICTORIA HOSP, MOL DIAGNOST LAB, LONDON, ON N6A 4G5, CANADA	Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario); University of Victoria; Western University (University of Western Ontario)	Rodenhiser, D (corresponding author), CHILDRENS HOSP WESTERN ONTARIO, CHILD HLTH RES INST, MOL MED GENET PROGRAM, LONDON, ON N6C 2V5, CANADA.							AINSWORTH PJ, 1993, HUM GENET, V91, P151; Andrews JD, 1996, HUM MOL GENET, V5, P503, DOI 10.1093/hmg/5.4.503; BOTTEMA CDK, 1993, HUM GENET, V91, P496; CANNING S, 1989, P NATL ACAD SCI USA, V86, P5044, DOI 10.1073/pnas.86.13.5044; CASTILLA LH, 1994, NAT GENET, V8, P387, DOI 10.1038/ng1294-387; CLARK SJ, 1995, NAT GENET, V10, P20, DOI 10.1038/ng0595-20; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; CLAUS EB, 1991, AM J HUM GENET, V48, P232; COOPER DN, 1988, HUM GENET, V78, P151, DOI 10.1007/BF00278187; FORD D, 1994, LANCET, V343, P692, DOI 10.1016/S0140-6736(94)91578-4; FRIEDMAN LS, 1995, AM J HUM GENET, V57, P1284; FRIEDMAN LS, 1994, NAT GENET, V8, P399, DOI 10.1038/ng1294-399; FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; HOGERVORST FBL, 1995, NAT GENET, V10, P208, DOI 10.1038/ng0695-208; HOSKING L, 1995, NAT GENET, V9, P343, DOI 10.1038/ng0495-343; INOUE R, 1995, CANCER RES, V55, P3521; JEGO N, 1993, ONCOGENE, V8, P209; KRAWCZAK M, 1991, HUM GENET, V86, P425; KUNKEL TA, 1986, J BIOL CHEM, V261, P3581; KUNKEL TA, 1990, BIOCHEMISTRY-US, V29, P8003, DOI 10.1021/bi00487a001; LINDBLOM A, 1993, NAT GENET, V5, P279, DOI 10.1038/ng1193-279; MAGEWU AN, 1994, MOL CELL BIOL, V14, P4225, DOI 10.1128/MCB.14.6.4225; MATSUSHIMA M, 1995, HUM MOL GENET, V4, P1953, DOI 10.1093/hmg/4.10.1953; MERAJVER SD, 1995, NAT GENET, V9, P439, DOI 10.1038/ng0495-439; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; MIYOSHI Y, 1992, P NATL ACAD SCI USA, V89, P4452, DOI 10.1073/pnas.89.10.4452; NEWMAN B, 1988, P NATL ACAD SCI USA, V85, P3044, DOI 10.1073/pnas.85.9.3044; PLUMMER SJ, 1995, HUM MOL GENET, V4, P1989, DOI 10.1093/hmg/4.10.1989; REDSTON MS, 1994, CANCER RES, V54, P3025; RICHARDS RI, 1994, NAT GENET, V6, P114, DOI 10.1038/ng0294-114; RODENHISER DI, 1993, HUM MOL GENET, V2, P439, DOI 10.1093/hmg/2.4.439; RODENHISER DI, 1995, AM J HUM GENET, V57, P1829; SCHLOTTERER C, 1992, NUCLEIC ACIDS RES, V20, P211, DOI 10.1093/nar/20.2.211; SCHMUTTE C, 1995, CANCER RES, V55, P3742; SHATTUCKEIDENS D, 1995, JAMA-J AM MED ASSOC, V273, P535, DOI 10.1001/jama.273.7.535; SIMARD J, 1994, NAT GENET, V8, P392, DOI 10.1038/ng1294-392; Sinden Richard R., 1992, Current Opinion in Biotechnology, V3, P612, DOI 10.1016/0958-1669(92)90005-4; STRAND M, 1993, NATURE, V365, P274, DOI 10.1038/365274a0; STREISINGER G, 1966, COLD SPRING HARB SYM, V31, P77, DOI 10.1101/SQB.1966.031.01.014; STRUEWING JP, 1995, AM J HUM GENET, V57, P1; SZABO CI, 1995, HUM MOL GENET, V4, P1811, DOI 10.1093/hmg/4.suppl_1.1811; TAKAHASHI H, 1995, CANCER RES, V55, P2998; TASHEVA ES, 1993, SOMAT CELL MOLEC GEN, V19, P275, DOI 10.1007/BF01233075; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; TORNALETTI S, 1995, ONCOGENE, V10, P1493; UPADHYAYA M, 1994, HUM MUTAT, V4, P83, DOI 10.1002/humu.1380040202; WOOSTER R, 1994, NAT GENET, V6, P152, DOI 10.1038/ng0294-152	49	37	37	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 20	1996	12	12					2623	2629						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UW487	8700521				2022-12-25	WOS:A1996UW48700016
J	Sjoblom, T; Lahdetie, J				Sjoblom, T; Lahdetie, J			Expression of p53 in normal and gamma-irradiated rat testis suggests a role for p53 in meiotic recombination and repair	ONCOGENE			English	Article						p53; testis; spermatocytes; meiosis; rat; gamma-irradiation	TUMOR-SUPPRESSOR PROTEIN; DNA-DAMAGING AGENTS; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; GERM-CELLS; X-RAYS; MOUSE; SPERMATOGENESIS; SPERMATOCYTES; CHROMOSOMES	In testis, the expression of tumor suppressor protein p53 is stronger than in other tissues suggesting a role for it in spermatogenesis. We have studied the expression of p53 in both unirradiated and gamma-irradiated rat testis using the stage-specific model of rat seminiferous epithelium, Our results show that p53 is expressed during meiosis in normal rat spermatogenesis and its expression is localized to the preleptotene-early pachytene spermatocytes. The most prominent expression is in zygotene - early pachytene spermatocytes (stages XIII-I of seminiferous epithelium). After irradiation p53 levels increased in a time and a dose-dependent manner being highest with the doses of 6.0 and 12.0 Gy and 4 h after irradiation, This increase occurs in the same cells that normally express elevated levels of p53. These results support the view that p53 is involved in meiosis of the male rat and we suggest that p53 has a role in recombinational processes and/or formation of the synaptonemal complex. We also demonstrate that p53 takes part in the response of primary spermatocytes to gamma-irradiation induced DNA damage.	UNIV TURKU,CTR REPROD & DEV MED,FIN-20520 TURKU,FINLAND	University of Turku	Sjoblom, T (corresponding author), UNIV TURKU,DEPT MED GENET,KIINAMYLLYNKATU 10,FIN-20520 TURKU,FINLAND.							ALMON E, 1993, DEV BIOL, V156, P107, DOI 10.1006/dbio.1993.1062; BACKER LC, 1991, RADIAT RES, V125, P187, DOI 10.2307/3577887; BAE IS, 1995, CANCER RES, V55, P2387; BERNARDS R, 1989, P NATL ACAD SCI USA, V86, P6474, DOI 10.1073/pnas.86.17.6474; COOGAN TP, 1988, MUTAT RES, V194, P183, DOI 10.1016/0167-8817(88)90020-X; COX LS, 1995, EMBO J, V14, P2099, DOI 10.1002/j.1460-2075.1995.tb07201.x; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FRITSCHE M, 1993, ONCOGENE, V8, P307; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; HAAF T, 1995, P NATL ACAD SCI USA, V92, P2298, DOI 10.1073/pnas.92.6.2298; HAAPAJARVI T, 1995, ONCOGENE, V11, P151; HAN KA, 1992, NUCLEIC ACIDS RES, V20, P1979, DOI 10.1093/nar/20.8.1979; HARPER JW, 1993, CELL, V75, P805; JONES DJ, 1995, TRENDS GENET, V11, P165; KASTAN MB, 1991, CANCER RES, V51, P6304; KIERSZENBAUM AL, 1994, ENDOCR REV, V15, P116, DOI 10.1210/er.15.1.116; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEBLOND CP, 1952, ANN NY ACAD SCI, V55, P548, DOI 10.1111/j.1749-6632.1952.tb26576.x; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MEEK DW, 1994, SEMIN CANCER BIOL, V5, P203; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MIDGLEY CA, 1992, J CELL SCI, V101, P183; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MORITA T, 1993, P NATL ACAD SCI USA, V90, P6577, DOI 10.1073/pnas.90.14.6577; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; PADMORE R, 1991, CELL, V66, P1239, DOI 10.1016/0092-8674(91)90046-2; PARVINEN M, 1993, METHODS TOXICOLOGY A, V3, P142; PERRY ME, 1993, CURR OPIN GENET DEV, V3, P50, DOI 10.1016/S0959-437X(05)80340-5; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; RASMUSSEN SW, 1978, CARLSBERG RES COMMUN, V43, P275, DOI 10.1007/BF02906106; ROGEL A, 1985, MOL CELL BIOL, V5, P2851, DOI 10.1128/MCB.5.10.2851; ROTTER V, 1994, SEMIN CANCER BIOL, V5, P229; ROTTER V, 1993, P NATL ACAD SCI USA, V90, P9075, DOI 10.1073/pnas.90.19.9075; SCHMID P, 1991, DEVELOPMENT, V113, P857; SCHWARTZ D, 1993, ONCOGENE, V8, P1487; SHAULSKY G, 1991, P NATL ACAD SCI USA, V88, P8982, DOI 10.1073/pnas.88.20.8982; SHI SR, 1991, J HISTOCHEM CYTOCHEM, V39, P741, DOI 10.1177/39.6.1709656; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; SJOBLOM T, 1995, MUTAT RES-FUND MOL M, V331, P181, DOI 10.1016/0027-5107(95)00067-S; SMITH ML, 1995, ONCOGENE, V10, P1053; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; STEWART N, 1995, ONCOGENE, V10, P109; TATES AD, 1983, MUTAT RES, V121, P131, DOI 10.1016/0165-7992(83)90111-2; TISHLER RB, 1993, CANCER RES, V53, P2212; VANDERMEER Y, 1992, RADIAT RES, V130, P296, DOI 10.2307/3578374; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; WOLFES H, 1989, SCIENCE, V245, P740, DOI 10.1126/science.2475907; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZENVIRTH D, 1992, EMBO J, V11, P3441, DOI 10.1002/j.1460-2075.1992.tb05423.x; ZHAN QM, 1994, ONCOGENE, V9, P3743	56	70	73	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 20	1996	12	12					2499	2505						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UW487	8700508				2022-12-25	WOS:A1996UW48700003
J	Velasco, JA; Zimonjic, DB; Popescu, NC; Cansado, J; DiPaolo, JA; Albor, A; Notario, V				Velasco, JA; Zimonjic, DB; Popescu, NC; Cansado, J; DiPaolo, JA; Albor, A; Notario, V			Tissue-specific expression, evolutionary conservation and localization of the cph proto-oncogene on Syrian hamster chromosome X	ONCOGENE			English	Article						cph oncogene; evolution; FISH; gene expression; gene mapping; Syrian hamster	BANDING PATTERNS; GENES; SEQUENCES; CELLS	Treatment of Syrian hamster embryo fibroblasts with a single dose of 3-methylcholanthrene caused the activation of the transforming potential of cellular sequences (Notario et al,, Oncogene 5: 1425-1430, 1990), which were subsequently isolated by cosmid rescue techniques, and further identified as a novel oncogene, termed cph because of its involvement in the carcinogenic progression of hamster embryo cells (Velasco ed al., Oncogene 9: 2065-2069, 1994), We have analysed the expression of the cph proto-oncogene in adult Syrian hamster tissues by northern hybridization using cph-specific genomic probes, The three cph transcripts expressed in normal and neoplastic Syrian hamster embryo cells in culture (5.0, 3.5 and 2.0 kb) were also present in most adult tissues, although different mRNA species, most likely resulting from alternative splicing events, were expressed in testes, The highest steady-state level of cph mRNA was found in kidney, whereas cph expression was nearly undetectable in skin and skeletal muscle, Southern blot analyses of DNAs from other eucaryotic organisms were performed under moderate stringency conditions with a Syrian hamster-specific cph probe, Discrete cpk-hybridizing sequences were present in genomes from yeast to mammalian species, including humans, thus demonstrating that cph is a highly conserved gene in eucaryotic evolution, Using fluorescence in situ hybridization (FISH), we have determined also the chromosomal Idealization of the cph proto-oncogene in the hamster genome, FISH experiments demonstrated that cph is a single copy gene, localized on the euchromatic short arm of the X chromosome, at region Xpa7, Because chromosome X is frequently involved in structural alterations in neoplastic Syrian hamster cells transformed by chemical carcinogens and oncogenic viruses, the localization of the cph locus on this chromosome supports the notion that the cph oncogene plays a role in the malignant conversion of chemically transformed hamster fibroblasts, The wide range of tissue-specific expression and species-specific distribution of cph strongly suggest that the normal function of the cph protein product(s) may be essential for metabolic processes involved in the regulation of cell proliferation and survival.	GEORGETOWN UNIV,MED CTR,DEPT RADIAT MED,WASHINGTON,DC 20007; NCI,BIOL LAB,NIH,BETHESDA,MD	Georgetown University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			/AFP-0764-2022; Cansado, Jose/ABC-6872-2020; /AAB-6461-2022; Cansado, Jose/K-5212-2014; Zimonjic, Drazen/AAX-7513-2020	Cansado, Jose/0000-0002-2342-8152; 	NCI NIH HHS [CA64472] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA064472] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBOR A, 1994, CANCER RES, V54, P4502; AVILA MA, 1995, ONCOGENE, V10, P963; AVILA MA, 1994, YEAST, V10, P1003, DOI 10.1002/yea.320100803; BARRETT JC, 1984, PHARMACOL REV, V36, P535; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DiPaolo J A, 1979, Prog Exp Tumor Res, V24, P2; DIPAOLO JA, 1973, CANCER RES, V33, P3250; HAMEISTER H, 1986, HUM GENET, V72, P242; HUEBNER K, 1986, P NATL ACAD SCI USA, V83, P3934, DOI 10.1073/pnas.83.11.3934; LI S, 1982, CYTOGENET CELL GENET, V33, P295, DOI 10.1159/000131775; MIYOSHI J, 1984, NUCLEIC ACIDS RES, V12, P1821, DOI 10.1093/nar/12.4.1821; MORTON CC, 1989, GENOMICS, V4, P367, DOI 10.1016/0888-7543(89)90344-3; NOGUCHI T, 1987, EMBO J, V6, P1301, DOI 10.1002/j.1460-2075.1987.tb02368.x; NOTARIO V, 1990, ONCOGENE, V5, P1425; OBRIEN SJ, 1983, NATURE, V302, P839, DOI 10.1038/302839a0; OSHIMURA M, 1985, NATURE, V316, P636, DOI 10.1038/316636a0; PATHAK S, 1974, GENETICS, V78, P703; PATHAK S, 1981, GENES CHROMOSOMES NE, P405; POPESCU NC, 1980, CYTOGENET CELL GENET, V28, P10, DOI 10.1159/000131507; POPESCU NC, 1988, CANCER RES, V48, P7246; POPESCU NC, 1995, CYTOGENET CELL GENET, V68, P71, DOI 10.1159/000133893; POPESCU NC, 1989, ONCOGENE, V4, P517; RAO VN, 1989, SCIENCE, V244, P66, DOI 10.1126/science.2539641; SATOH H, 1994, CYTOGENET CELL GENET, V65, P127, DOI 10.1159/000133617; TARUSCIO D, 1991, CHROMOSOMA, V101, P141, DOI 10.1007/BF00355364; TRONICK SR, 1989, GENOMICS, V5, P546, DOI 10.1016/0888-7543(89)90022-0; VELASCO JA, 1993, GENE, V137, P179, DOI 10.1016/0378-1119(93)90004-M; VELASCO JA, 1994, ONCOGENE, V9, P2065; VELASCO JA, 1995, ONCOGENE, V10, P2253; WAHL GM, 1979, P NATL ACAD SCI USA, V76, P3683, DOI 10.1073/pnas.76.8.3683; ZIMONJIC DB, 1994, CYTOGENET CELL GENET, V65, P184, DOI 10.1159/000133628	31	17	17	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 20	1996	12	12					2713	2717						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UW487	8700531				2022-12-25	WOS:A1996UW48700026
J	Wertheim, I; Tangir, J; Muto, MG; Welch, WR; Berkowitz, RS; Chen, WY; Mok, SC				Wertheim, I; Tangir, J; Muto, MG; Welch, WR; Berkowitz, RS; Chen, WY; Mok, SC			Loss of heterozygosity of chromosome 17 in human borderline and invasive epithelial ovarian tumors	ONCOGENE			English	Article						ovary; borderline; loss of heterozygosity; microsatellite instability	GENE-MUTATIONS; FREQUENT LOSS; CANCER LOCUS; P53 GENE; MALIGNANCY; DELETION	Polymerase chain reaction (PCR) analysis of microsatellite polymorphisms corresponding to four loci which map to chromosome 17p and 11 loci which map to chromosome 17q was performed to screen for loss of heterozygosity (LOH) in paired normal and tumor tissues from 27 cases of borderline epithelial ovarian tumors (BEOT) and 32 cases of invasive epithelial ovarian cancers (IOC), LOH was observed in six of 27 (22%) of the borderline tumors and in 29 of 32 (90%) of the invasive ovarian cancers (P<0.001), At all 15 loci studied, a lower percentage of allelic loss was detected in borderline tumors (0-14%) vs invasive cancer (8-93%), At eight loci this difference was statistically significant, For IOC, one common loss region was identified on chromosome 17p and four distinct common loss regions were on chromosome 17q, which supports the notion that multiple tumor suppressors may reside on chromosome 17 in IOC. These data suggest that LOH on chromosome 17 is an infrequent event in BEOT compared with IOC and therefore may not be important in the distinct pathogenesis of BEOT.	HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DIV GYNECOL ONCOL,LAB GYNECOL ONCOL,BOSTON,MA 02115; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT PATHOL,DIV WOMENS & PERINATAL PATHOL,BOSTON,MA 02115; CHINESE UNIV HONG KONG,DEPT ANAT,SHATIN,HONG KONG	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Chinese University of Hong Kong			Chan, Wood Yee/R-6692-2018	Chan, Wood Yee/0000-0002-7114-1463	NATIONAL CANCER INSTITUTE [R01CA063381] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA63381] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BERCHUCK A, 1994, GYNECOL ONCOL, V52, P232, DOI 10.1006/gyno.1994.1037; CROPP CS, 1994, CANCER RES, V54, P2548; ECCLES DM, 1992, ONCOGENE, V7, P2069; FOULKES WD, 1993, INT J CANCER, V54, P220, DOI 10.1002/ijc.2910540210; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; GODWIN AK, 1994, AM J HUM GENET, V55, P666; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; HORN GT, 1989, NUCLEIC ACIDS RES, V17, P2140, DOI 10.1093/nar/17.5.2140; International Federation of Gynecology and Obstetrics (FIGO), 1987, AM J OBSTET GYNECOL, V56, P263; JACOBS IJ, 1993, CANCER RES, V53, P1218; KAERN J, 1993, CANCER, V71, P1810, DOI 10.1002/1097-0142(19930301)71:5<1810::AID-CNCR2820710516>3.0.CO;2-V; KUPRYJANCZYK J, 1993, P NATL ACAD SCI USA, V90, P4961, DOI 10.1073/pnas.90.11.4961; LEE JH, 1990, CANCER RES, V50, P2724; LI Y, 1992, CELL, V69, P275, DOI 10.1016/0092-8674(92)90408-5; MARKS JR, 1991, CANCER RES, V51, P2979; MOK CH, 1992, CANCER RES, V52, P5119; Mok S. C., 1995, Proceedings of the American Association for Cancer Research Annual Meeting, V36, P571; MOK SCH, 1993, CANCER RES, V53, P1489; NAROD SA, 1991, LANCET, V338, P82; PIERETTI M, 1995, HUM PATHOL, V26, P393, DOI 10.1016/0046-8177(95)90139-6; RICE LW, 1990, GYNECOL ONCOL, V39, P195, DOI 10.1016/0090-8258(90)90431-J; RUSSELL SEH, 1990, ONCOGENE, V5, P1581; Sambrook J., 2002, MOL CLONING LAB MANU; SATO T, 1991, CANCER RES, V51, P5118; Serov S., 1973, INT HISTOLOGICAL CLA, V9; TANGIR J, 1996, IN PRESS ONCOGENE; TENERIELLO MG, 1993, CANCER RES, V53, P3103; TSAO SW, 1991, ANTICANCER RES, V11, P1975; WEITZEL JN, 1994, GYNECOL ONCOL, V55, P245, DOI 10.1006/gyno.1994.1285; WERTHEIM I, 1994, J NATL CANCER I, V86, P1549, DOI 10.1093/jnci/86.20.1549	30	48	48	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 16	1996	12	10					2147	2153						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UP283	8668340				2022-12-25	WOS:A1996UP28300013
J	Banerjee, A; Kowalchyk, JA; DasGupta, BR; Martin, TFJ				Banerjee, A; Kowalchyk, JA; DasGupta, BR; Martin, TFJ			SNAP-25 is required for a late postdocking step in Ca2+-dependent exocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNAPTIC VESICLE FUSION; BOTULINUM NEUROTOXIN-A; AMINO-ACID-COMPOSITION; CLOSTRIDIAL NEUROTOXINS; CA2+-ACTIVATED SECRETION; PC12 CELLS; SEROTYPE-A; COMPLEX; PURIFICATION; DOCKING	The Ca2+-activated fusion of large dense core vesicles (LDCVs) with the plasma membrane is reconstituted in mechanically permeabilized PC12 cells by provision of millimolar MgATP and cytosolic proteins, Ca2+-activated LDCV exocytosis was inhibited completely by the type E but not the type A botulinum neurotoxin (BoNT) even though both BoNTs were equally effective in proteolytically cleaving the synaptosome-associated protein of 25 kDa (SNAP-25). The greater inhibition of exocytosis by BoNT E correlated with a greater destabilization of detergent-extracted complexes consisting of SNAP-25, synaptobrevin, and syntaxin. LDCVs in permeable PC12 cells can be poised at a late postdocking, prefusion state by MgATP dependent priming processes catalyzed by N-ethylmaleimide sensitive factor and priming in exocytosis proteins. BoNT E completely blocked Ca2+-activated LDCV exocytosis in ATP-primed cells, whereas BoNT A was only slightly inhibitory, implying that the C-terminal region of SNAP-25 (Ile(181)-Gln(197)) between the cleavage sites for BoNT E and BoNT A is essential for late postdocking steps. A required role for SNAP-25 at this stage was also indicated by inhibition of Ca2+-activated LDCV fusion in ATP-primed cells by a C-terminal peptide antibody. We conclude that plasma membrane SNAP-25, particularly residues 181-197, is required for Ca2+-regulated membrane fusion at a step beyond LDCV docking and ATP utilization.	UNIV WISCONSIN, DEPT BIOCHEM, MADISON, WI 53706 USA; UNIV WISCONSIN, DEPT FOOD MICROBIOL & TOXICOL, MADISON, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK025861, R01DK040428, R01DK025861] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS017742] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK40428, DK25861] Funding Source: Medline; NINDS NIH HHS [NS17742] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BAJJALIEH SM, 1995, J BIOL CHEM, V270, P1971, DOI 10.1074/jbc.270.5.1971; BINZ T, 1994, J BIOL CHEM, V269, P1617; BLASI J, 1993, NATURE, V365, P160, DOI 10.1038/365160a0; CALAKOS N, 1994, SCIENCE, V263, P1146, DOI 10.1126/science.8108733; CARROLL AG, 1990, J NEUROCHEM, V55, P930, DOI 10.1111/j.1471-4159.1990.tb04580.x; CHAPMAN ER, 1994, J BIOL CHEM, V269, P27427; DASGUPTA BR, 1983, TOXICON, V21, P535, DOI 10.1016/0041-0101(83)90131-9; DASGUPTA BR, 1984, TOXICON, V22, P415, DOI 10.1016/0041-0101(84)90085-0; HAY JC, 1993, NATURE, V366, P572, DOI 10.1038/366572a0; HAY JC, 1992, J CELL BIOL, V119, P139, DOI 10.1083/jcb.119.1.139; HAY JC, 1995, NATURE, V374, P173, DOI 10.1038/374173a0; HAYASHI T, 1994, EMBO J, V13, P5051, DOI 10.1002/j.1460-2075.1994.tb06834.x; HOLZ RW, 1989, J BIOL CHEM, V264, P5412; HUNT JM, 1994, NEURON, V12, P1269, DOI 10.1016/0896-6273(94)90443-X; KEE Y, 1995, NEURON, V14, P991, DOI 10.1016/0896-6273(95)90337-2; LOMNETH R, 1991, J NEUROCHEM, V57, P1413, DOI 10.1111/j.1471-4159.1991.tb08308.x; MARTIN TFJ, 1989, METHOD ENZYMOL, V168, P225; MONTECUCCO C, 1993, TRENDS BIOCHEM SCI, V18, P324, DOI 10.1016/0968-0004(93)90065-U; Niemann Heiner, 1994, Trends in Cell Biology, V4, P179, DOI 10.1016/0962-8924(94)90203-8; OTTO H, 1995, BIOCHEM BIOPH RES CO, V212, P945, DOI 10.1006/bbrc.1995.2061; PELLEGRINI LL, 1995, EMBO J, V14, P4705, DOI 10.1002/j.1460-2075.1995.tb00152.x; PEVSNER J, 1994, NEURON, V13, P353, DOI 10.1016/0896-6273(94)90352-2; SATHYAMOORTHY V, 1985, J BIOL CHEM, V260, P461; SCHIAVO G, 1993, J BIOL CHEM, V268, P23784; SCHIAVO G, 1993, FEBS LETT, V335, P99, DOI 10.1016/0014-5793(93)80448-4; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; WALENT JH, 1992, CELL, V70, P765, DOI 10.1016/0092-8674(92)90310-9	28	133	135	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20227	20230		10.1074/jbc.271.34.20227	http://dx.doi.org/10.1074/jbc.271.34.20227			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702751	hybrid			2022-12-25	WOS:A1996VD33700003
J	Zheng, JA; Mitchell, AE; Jones, AD; Hammock, BD				Zheng, JA; Mitchell, AE; Jones, AD; Hammock, BD			Haloenol lactone is a new isozyme-selective and active site-directed inactivator of glutathione S-transferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLASS-PI; CYSTEINE RESIDUES; IDENTIFICATION; INHIBITION; MECHANISM; PURIFICATION; RAT	A haloenol lactone derivative has been synthesized and found to be an isozyme-selective and active site directed inactivator of glutathione S-transferase (GST). Preincubation of the haloenol lactone (100 mu M) With murine Alpha, Mu, or Pi GST isozyme (1.0 mu M) at pH 6.5, 37 degrees C resulted in time-dependent loss of enzyme activity with highly selective inhibition of the Pi isozyme (t(1/2), similar to 2 min), In a separate experiment, a 10-fold excess of the lactone was incubated with GST-Pi isozyme at 37 degrees C for 3 h, followed by dialysis against Nanopure water. GST activity lost upon incubation with the lactone could not be restored by exhaustive dialysis, and only 8% of enzyme activity for the modified GST remained relative to the control that was treated identically except the lactone was omitted from the incubation, Both control and modified GST were characterized using electrospray ionization mass spectrometry. No native GST (23,478 Da) was observed in the spectrum of modified GST. Instead, protein incubated with the lactone exhibited an increase in molecular mass of 230 Da relative to control GST. The lactone (100 mu M) was incubated with GST Pi isozyme (1.0 mu M) in the presence of the competitive inhibitor S-hexylglutathione (10 mu M), which suppressed time-dependent inhibition of GST by the lactone, The results suggest that this haloenol lactone is an irreversible and active site-directed inhibitor of GST that appears to inhibit the enzyme through two consecutive steps of nucleophilic attack.	UNIV CALIF DAVIS,DEPT ENTOMOL,DAVIS,CA 95616; UNIV CALIF DAVIS,DEPT ENVIRONM TOXICOL,DAVIS,CA 95616; UNIV CALIF DAVIS,FACIL ADV INSTRUMENTAT,DAVIS,CA 95616	University of California System; University of California Davis; University of California System; University of California Davis; University of California System; University of California Davis			Jones, Arthur D/C-2670-2013	Mitchell, Alyson/0000-0003-0286-5238; Jones, A. Daniel/0000-0002-7408-6690	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P42ES004699, P30ES005707] Funding Source: NIH RePORTER; NIEHS NIH HHS [1P30 ES05707, 2P42 ES04699-08] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BORHAN B, 1995, J BIOL CHEM, V270, P26923, DOI 10.1074/jbc.270.45.26923; CACCURI AM, 1994, BIOCHEM BIOPH RES CO, V200, P1428, DOI 10.1006/bbrc.1994.1610; CACCURI AM, 1992, ARCH BIOCHEM BIOPHYS, V297, P119, DOI 10.1016/0003-9861(92)90648-G; CARMICHAEL J, 1985, CANCER RES, V45, P1169; CHEN WL, 1992, BIOCHEM J, V286, P205, DOI 10.1042/bj2860205; DIRR H, 1994, EUR J BIOCHEM, V220, P645, DOI 10.1111/j.1432-1033.1994.tb18666.x; DIRR HW, 1991, EUR J BIOCHEM, V196, P693, DOI 10.1111/j.1432-1033.1991.tb15867.x; GARCIASAEZ I, 1994, J MOL BIOL, V237, P298, DOI 10.1006/jmbi.1994.1232; HABIG WH, 1974, J BIOL CHEM, V249, P7130; HAYES JD, 1989, GLUTATHIONE S TRANSF, P3; JACOBY WB, 1980, ENZYMATIC BASIS DETO, V2, P63; JI XH, 1992, BIOCHEMISTRY-US, V31, P10169, DOI 10.1021/bi00157a004; KARSHIKOFF A, 1993, EUR J BIOCHEM, V215, P663, DOI 10.1111/j.1432-1033.1993.tb18077.x; KETLEY JN, 1975, J BIOL CHEM, V250, P8670; KRAFFT GA, 1981, J AM CHEM SOC, V103, P5459, DOI 10.1021/ja00408a030; LIU S, 1992, J MED CHEM, V35, P1067, DOI 10.1021/jm00084a012; LOBELLO M, 1990, FEBS LETT, V263, P389, DOI 10.1016/0014-5793(90)81421-J; LOBELLO M, 1993, J BIOL CHEM, V268, P19033; MANNERVIK B, 1985, P NATL ACAD SCI USA, V82, P7202, DOI 10.1073/pnas.82.21.7202; MEYER DJ, 1991, BIOCHEM J, V274, P409, DOI 10.1042/bj2740409; MITCHELL AE, 1995, CHEM RES TOXICOL, V8, P1054, DOI 10.1021/tx00050a009; PLOEMEN JHTM, 1994, J BIOL CHEM, V269, P26890; PLOEMEN JHTM, 1993, BIOCHEM PHARMACOL, V45, P633, DOI 10.1016/0006-2952(93)90137-L; SHEN H, 1993, ARCH BIOCHEM BIOPHYS, V300, P137, DOI 10.1006/abbi.1993.1019; TAMAI K, 1990, BIOCHEM BIOPH RES CO, V167, P331, DOI 10.1016/0006-291X(90)91769-O; WINTERSTEN M, 1991, FEBS LETT, V293, P156	26	23	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20421	20425		10.1074/jbc.271.34.20421	http://dx.doi.org/10.1074/jbc.271.34.20421			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702779	hybrid			2022-12-25	WOS:A1996VD33700031
J	Lavigne, AC; Mengus, G; May, M; Dubrovskaya, V; Tora, L; Chambon, P; Davidson, I				Lavigne, AC; Mengus, G; May, M; Dubrovskaya, V; Tora, L; Chambon, P; Davidson, I			Multiple interactions between hTAF(II)55 and other TFIID subunits - Requirements for the formation of stable ternary complexes between hTAF(II)55 and the TATA-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; MEDIATE TRANSCRIPTIONAL ACTIVATION; HUMAN ESTROGEN-RECEPTOR; MOLECULAR-CLONING; SACCHAROMYCES-CEREVISIAE; BASAL TRANSCRIPTION; LESS PROMOTER; IN-VITRO; COACTIVATORS; TBP	We have cloned and characterized the human TATA-binding protein (TBP)-associated factor hTAF(II)55. hTAF(II)55, which has no known Drosophila counterpart, is present in both of the previously described TFIID alpha and TFIID beta subpopulations. We describe the interactions of hTAF(II)55 with other subunits of the transcription factor TFIID. By cotransfection in COS cells, we show that hTAF(II)55 interacts with hTAF(II)250, hTAF(II)100, hTAF(II)28, hTAF(II)20, and hTAF(II)18, but not with hTAF(II)30 or TBP. Analysis of the binding of hTAF(II)55 and TBP to hTAF(II)28 deletion mutants indicates that distinct regions of hTAF(II)28 are required for these interactions. Although hTAF(II)55 does not interact by itself with TBP, stable ternary complexes containing hTAF(II)55 and TBP can be formed in the presence of hTAF(II)250, hTAF(II)100, or hTAF(II)28. These results not only show that hTAF(II)100 and hTAF(II)28 interact with TBP, but also that they can nucleate the formation of partial TFIID complexes.	COLL FRANCE, INST GENET & BIOL MOL & CELLULAIRE,CNRS,INSERM,ULP, F-67404 ILLKIRCH GRAFFENSTADEN, FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg			Tora, Laszlo/E-9999-2018; Lavigne, Anne-Claire/O-8805-2015	Tora, Laszlo/0000-0001-7398-2250; MENGUS, Gabrielle/0000-0002-2844-1778; Davidson, Irwin/0000-0001-5533-1171				ALI S, 1993, HYBRIDOMA, V12, P391, DOI 10.1089/hyb.1993.12.391; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; BROU C, 1993, NUCLEIC ACIDS RES, V21, P5, DOI 10.1093/nar/21.1.5; BROU C, 1993, EMBO J, V12, P489, DOI 10.1002/j.1460-2075.1993.tb05681.x; BURATOWSKI S, 1994, CELL, V77, P1, DOI 10.1016/0092-8674(94)90226-7; BURATOWSKI S, 1993, TRANSCRIPTIONAL REGU, V1, P227; Chambon Pierre, 1994, Seminars in Cell Biology, V5, P115, DOI 10.1006/scel.1994.1015; CHAUDHARY S, 1995, J BIOL CHEM, V270, P3631, DOI 10.1074/jbc.270.8.3631; CHAUDHARY S, 1994, MOL CELL BIOL, V14, P5290, DOI 10.1128/MCB.14.8.5290; CHEN JL, 1994, CELL, V79, P93, DOI 10.1016/0092-8674(94)90403-0; CHIANG CM, 1993, EMBO J, V12, P2749, DOI 10.1002/j.1460-2075.1993.tb05936.x; CHIANG CM, 1995, SCIENCE, V267, P531, DOI 10.1126/science.7824954; COMAI L, 1994, SCIENCE, V266, P1966, DOI 10.1126/science.7801123; CONAWAY RC, 1993, ANNU REV BIOCHEM, V62, P161; CROSS SH, 1994, NAT GENET, V6, P236, DOI 10.1038/ng0394-236; DUBROVSKAYA V, 1996, IN PRESS EMBO J; DYNLACHT BD, 1993, NATURE, V363, P176, DOI 10.1038/363176a0; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; EISENMANN DM, 1992, GENE DEV, V6, P1319, DOI 10.1101/gad.6.7.1319; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; GOODRICH LA, 1994, CURR OPIN CELL BIOL, V6, P403, DOI 10.1016/0955-0674(94)90033-7; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; HISATAKE K, 1993, NATURE, V362, P179, DOI 10.1038/362179a0; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; HOEY T, 1990, CELL, V61, P1179, DOI 10.1016/0092-8674(90)90682-5; Hoffmann A, 1996, NATURE, V380, P356, DOI 10.1038/380356a0; JACQ X, 1994, CELL, V79, P107, DOI 10.1016/0092-8674(94)90404-9; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; Kaufmann J, 1996, GENE DEV, V10, P873, DOI 10.1101/gad.10.7.873; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; KLEMM RD, 1995, P NATL ACAD SCI USA, V92, P5788, DOI 10.1073/pnas.92.13.5788; KOKUBO T, 1994, NATURE, V367, P484, DOI 10.1038/367484a0; KOKUBO T, 1993, MOL CELL BIOL, V13, P7859, DOI 10.1128/MCB.13.12.7859; LU H, 1995, P NATL ACAD SCI USA, V92, P5154, DOI 10.1073/pnas.92.11.5154; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; May M, 1996, EMBO J, V15, P3093, DOI 10.1002/j.1460-2075.1996.tb00672.x; MENGUS G, 1995, EMBO J, V14, P1520, DOI 10.1002/j.1460-2075.1995.tb07138.x; OSSIPOW V, 1995, CELL, V83, P137, DOI 10.1016/0092-8674(95)90242-2; Parker MG, 1993, CURR OPIN CELL BIOL, V5, P499, DOI 10.1016/0955-0674(93)90016-J; PIERRAT B, 1994, GENE, V143, P193, DOI 10.1016/0378-1119(94)90096-5; POON D, 1995, P NATL ACAD SCI USA, V92, P8224, DOI 10.1073/pnas.92.18.8224; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; REESE JC, 1994, NATURE, V371, P523, DOI 10.1038/371523a0; SAUER F, 1995, SCIENCE, V270, P1783, DOI 10.1126/science.270.5243.1783; TANESE N, 1991, GENE DEV, V5, P2212, DOI 10.1101/gad.5.12a.2212; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; TIMMERS HTM, 1992, P NATL ACAD SCI USA, V89, P8140, DOI 10.1073/pnas.89.17.8140; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; VERRIJZER CP, 1994, SCIENCE, V264, P933, DOI 10.1126/science.8178153; VERRIJZER CP, 1995, CELL, V81, P1115, DOI 10.1016/S0092-8674(05)80016-9; WEINZIERL ROJ, 1993, NATURE, V362, P511, DOI 10.1038/362511a0; WHITE J, 1992, EMBO J, V11, P2229, DOI 10.1002/j.1460-2075.1992.tb05282.x; Wilson CJ, 1996, CELL, V84, P235, DOI 10.1016/S0092-8674(00)80978-2; Wurtz JM, 1996, NAT STRUCT BIOL, V3, P87, DOI 10.1038/nsb0196-87; Xie XL, 1996, NATURE, V380, P316, DOI 10.1038/380316a0; YOKOMORI K, 1993, GENE DEV, V7, P2587, DOI 10.1101/gad.7.12b.2587; ZAWEL L, 1995, ANNU REV BIOCHEM, V64, P533; ZHOU Q, 1992, GENE DEV, V6, P1964, DOI 10.1101/gad.6.10.1964	60	41	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					19774	19780		10.1074/jbc.271.33.19774	http://dx.doi.org/10.1074/jbc.271.33.19774			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702684	Green Published, hybrid			2022-12-25	WOS:A1996VC66900025
J	AnandSrivastava, MB; Sehl, PD; Lowe, DG				AnandSrivastava, MB; Sehl, PD; Lowe, DG			Cytoplasmic domain of natriuretic peptide receptor-C inhibits adenylyl cyclase - Involvement of a pertussis toxin-sensitive G protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE REGULATORY PROTEIN; SIGNAL-TRANSDUCTION SYSTEM; GTP-BINDING PROTEIN; GROWTH-FACTOR; GUANYLATE-CYCLASE; PORCINE BRAIN; 2ND MESSENGER; ATRIAL; CELLS; MECHANISMS	Natriuretic peptide receptor C (NPR-C) is a disulfide-linked homodimer with an approximately 440-amino acid extracellular domain and a 37-amino acid cytoplasmic domain; it functions in the internalization and degradation of bound ligand. The use of NPR-C-specific natriuretic peptide analogs has implicated this receptor in mediating the inhibition of adenylyl cyclase or activation of phospholipase C, In the present studies we have investigated the role of the cytoplasmic domain of NPR-C in signaling the inhibition of adenylyl cyclase. Polyclonal rabbit antisera were raised against a 37-amino acid synthetic peptide (R37A) corresponding to the cytoplasmic domain of NPR-C. Incubation of anti-R37A with rat heart particulate fractions blocked atrial natriuretic peptide-dependent inhibition of adenylyl cyclase. The cytoplasmic domain peptides R37A and TMC (10 residues of transmembrane domain appended on R37A) were equipotent in inhibiting adenylyl cyclase (K-i similar to 1 nan) in a GTP-dependent manner, whereas K37E (a scrambled peptide control for R37A) did not inhibit adenylyl cyclase activity, Prior incubation of membranes with pertussis toxin blocked R37A or TMC inhibition of cAMP production. Detergent solubilization of the rat heart particulate fraction destroyed natriuretic peptide inhibition of adenylyl cyclase, but TMC was able to inhibit cAMP production in a dose-dependent manner. Our results provide evidence that the 37-amino acid cytoplasmic domain of NPR-C is sufficient for signaling inhibition of adenylyl cyclase through. a pertussis toxin-sensitive G protein.	GENENTECH INC,DEPT CARDIOVASC RES,S SAN FRANCISCO,CA 94080	Roche Holding; Genentech	AnandSrivastava, MB (corresponding author), UNIV MONTREAL,FAC MED,DEPT PHYSIOL,CP 6128,SUCCURSALE CENTREVILLE,MONTREAL,PQ H3C 3J7,CANADA.							ANANDSRIVASTAVA MB, 1980, J NEUROCHEM, V35, P905, DOI 10.1111/j.1471-4159.1980.tb07089.x; ANANDSRIVASTAVA MB, 1986, AM J PHYSIOL, V251, pF417, DOI 10.1152/ajprenal.1986.251.3.F417; ANANDSRIVASTAVA MB, 1991, BIOCHEM J, V278, P211, DOI 10.1042/bj2780211; ANANDSRIVASTAVA MB, 1990, J BIOL CHEM, V265, P8566; ANANDSRIVASTAVA MB, 1987, J BIOL CHEM, V262, P4931; ANANDSRIVASTAVA MB, 1992, BIOCHEM J, V288, P79, DOI 10.1042/bj2880079; ANANDSRIVASTAVA MB, 1993, PHARMACOL REV, V45, P455; ARAMORI I, 1992, J BIOL CHEM, V267, P12468; BENNETT BD, 1991, J BIOL CHEM, V266, P23060; BERL T, 1991, AM J PHYSIOL, V260, pF590, DOI 10.1152/ajprenal.1991.260.4.F590; BRENNER BM, 1990, PHYSIOL REV, V70, P665, DOI 10.1152/physrev.1990.70.3.665; CHANG M, 1989, NATURE, V341, P68, DOI 10.1038/341068a0; CHINKERS M, 1989, NATURE, V338, P78, DOI 10.1038/338078a0; CLAVELL AL, 1993, AM J PHYSIOL, V264, pR290, DOI 10.1152/ajpregu.1993.264.2.R290; CUNNINGHAM BC, 1994, EMBO J, V13, P2508, DOI 10.1002/j.1460-2075.1994.tb06540.x; FULLER F, 1988, J BIOL CHEM, V263, P9395; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HIGASHIJIMA T, 1988, J BIOL CHEM, V263, P6491; HIRATA M, 1989, BIOCHIM BIOPHYS ACTA, V1010, P346, DOI 10.1016/0167-4889(89)90060-8; HUANG CL, 1986, P NATL ACAD SCI USA, V83, P8015, DOI 10.1073/pnas.83.20.8015; ITAKURA M, 1994, J BIOL CHEM, V269, P8314; JONES DT, 1987, J BIOL CHEM, V262, P14241; KATADA T, 1982, J BIOL CHEM, V257, P3739; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; KOLLER KJ, 1991, SCIENCE, V252, P120, DOI 10.1126/science.1672777; LEFKOWITZ RJ, 1988, J BIOL CHEM, V263, P4993; LEVIN ER, 1993, ENDOCRINOL METAB, V27, pE483; LIGHT DB, 1989, SCIENCE, V243, P383, DOI 10.1126/science.2463673; LINCOLN TM, 1993, FASEB J, V7, P328, DOI 10.1096/fasebj.7.2.7680013; LOWE DG, 1989, EMBO J, V8, P1377, DOI 10.1002/j.1460-2075.1989.tb03518.x; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAACK T, 1987, SCIENCE, V238, P675, DOI 10.1126/science.2823385; NISHIMOTO I, 1989, J BIOL CHEM, V264, P14029; NISHIMOTO I, 1987, J BIOL CHEM, V262, P12120; NUSSENZVEIG DR, 1990, J BIOL CHEM, V265, P20952; OKAMOTO T, 1992, J BIOL CHEM, V267, P8342; RESINK TJ, 1988, EUR J BIOCHEM, V174, P531, DOI 10.1111/j.1432-1033.1988.tb14131.x; ROTHENBERG PL, 1988, J BIOL CHEM, V263, P15546; RUSKOAHO H, 1992, PHARMACOL REV, V44, P479; SCHULZ S, 1989, CELL, V58, P1155, DOI 10.1016/0092-8674(89)90513-8; SOLOMON Y, 1974, ANAL BIOCHEM, V58, P541; STANTON BA, 1991, CAN J PHYSIOL PHARM, V69, P1546, DOI 10.1139/y91-230; STINGO AJ, 1992, AM J PHYSIOL, V262, pH308, DOI 10.1152/ajpheart.1992.262.1.H308; STRITTMATTER SM, 1990, NATURE, V344, P836, DOI 10.1038/344836a0; STULTS JT, 1994, BIOCHEMISTRY-US, V33, P11372, DOI 10.1021/bi00203a036; SUDOH T, 1990, BIOCHEM BIOPH RES CO, V168, P863, DOI 10.1016/0006-291X(90)92401-K; SUDOH T, 1988, NATURE, V332, P78, DOI 10.1038/332078a0; SUGA S, 1992, J CLIN INVEST, V90, P1145, DOI 10.1172/JCI115933; SUGA SI, 1992, ENDOCRINOLOGY, V130, P229, DOI 10.1210/en.130.1.229; TANG WJ, 1992, CELL, V70, P869, DOI 10.1016/0092-8674(92)90236-6; TAUSSIG R, 1995, J BIOL CHEM, V270, P1, DOI 10.1074/jbc.270.1.1; TAUSSIG R, 1994, J BIOL CHEM, V269, P6093; WALDMAN SA, 1987, PHARMACOL REV, V39, P163	53	143	149	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19324	19329		10.1074/jbc.271.32.19324	http://dx.doi.org/10.1074/jbc.271.32.19324			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702617	hybrid			2022-12-25	WOS:A1996VB68400051
J	Brostjan, C; Anrather, J; Csizmadia, V; Stroka, D; Soares, M; Bach, FH; Winkler, H				Brostjan, C; Anrather, J; Csizmadia, V; Stroka, D; Soares, M; Bach, FH; Winkler, H			Glucocorticoid-mediated repression of NF kappa B activity in endothelial cells does not involve induction of I kappa B alpha synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERCELLULAR-ADHESION MOLECULE-1; TUMOR-NECROSIS-FACTOR; TRANSCRIPTIONAL ACTIVATION; FUNCTIONAL ANTAGONISM; DNA-BINDING; C-JUN; RECEPTOR; EXPRESSION; INHIBITION; HORMONE	Repression of NF kappa B-dependent gene expression is one of the major elements of immunosuppression by glucocorticoids. Protein-protein interactions between the glucocorticoid receptor and NF kappa B have been characterized and shown to be a possible mechanism of mutual inhibition of transactivation properties, More recently, glucocorticoid-mediated induction of I kappa B alpha, an inhibitor of NF kappa B, has been described in monocytes and lymphocytes; an increase in I kappa B alpha mRNA and protein resulted in inactivation and cytosolic retention of NF kappa B, Thus, rather than the physical interaction between the glucocorticoid receptor and NF kappa B, the up-regulation of I kappa B alpha was presented as the key element in immunosuppression by glucocorticoids. in contrast, we show that the I kappa B alpha pathway is not involved in glucocorticoid-mediated inhibition of NF kappa B activity in endothelial cells, Although transcriptional activation by NF kappa B was significantly reduced in the presence of glucocorticoids, we did not detect induction of I kappa B alpha protein that could prevent nuclear translocation of NF kappa B upon stimulation with lipopolysaccharide or tumor necrosis factor alpha, Furthermore, treatment with glucocorticoids did not seem to affect the transcription rate or mRNA stability of I kappa B alpha. Ne therefore conclude that, although induction of I kappa B alpha expression by glucocorticoids seems to be of importance in monocytes and lymphocytes, it cannot explain inhibition of NF kappa B-dependent gene expression in endothelial cells. Our results emphasize the relevance of physical interaction between the glucocorticoid receptor and NF kappa B in endothelial cells and thus in suppression of inflammation by glucocorticoids.			Brostjan, C (corresponding author), HARVARD UNIV,SCH MED,DEACONESS HOSP,SANDOZ CTR IMMUNOBIOL,99 BROOKLINE AVE,BOSTON,MA 02215, USA.		Stroka, Deborah M/F-1806-2013	Stroka, Deborah/0000-0002-3517-3871; Brostjan, Christine/0000-0003-1462-5397; Soares, Miguel/0000-0002-9314-4833				ARYA SK, 1984, J IMMUNOL, V133, P273; AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; CALDENHOVEN E, 1995, MOL ENDOCRINOL, V9, P401, DOI 10.1210/me.9.4.401; CHANDLER VL, 1983, CELL, V33, P489, DOI 10.1016/0092-8674(83)90430-0; CRONSTEIN BN, 1992, P NATL ACAD SCI USA, V89, P9991, DOI 10.1073/pnas.89.21.9991; CULPEPPER JA, 1985, J IMMUNOL, V135, P3191; DANIELSEN M, 1987, MOL ENDOCRINOL, V1, P816, DOI 10.1210/mend-1-11-816; DEMARTIN R, 1993, EMBO J, V12, P2773, DOI 10.1002/j.1460-2075.1993.tb05938.x; DEWAAL RMW, 1994, MOL BIOL REP, V19, P81, DOI 10.1007/BF00997151; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DYER RB, 1995, BIOTECHNIQUES, V19, P192; FERRAN C, 1995, BIOCHEM BIOPH RES CO, V214, P212, DOI 10.1006/bbrc.1995.2277; FINCO TS, 1995, IMMUNITY, V3, P263, DOI 10.1016/1074-7613(95)90112-4; HECK S, 1994, EMBO J, V13, P4087, DOI 10.1002/j.1460-2075.1994.tb06726.x; HOLLENBERG SM, 1987, CELL, V49, P39, DOI 10.1016/0092-8674(87)90753-7; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KNUDSEN PJ, 1987, J IMMUNOL, V139, P4129; LEW W, 1988, J IMMUNOL, V140, P1895; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MUKAIDA N, 1994, J BIOL CHEM, V269, P13289; MUKAIDA N, 1992, IMMUNOLOGY, V75, P674; RAY A, 1994, P NATL ACAD SCI USA, V91, P752, DOI 10.1073/pnas.91.2.752; SCHEINMAN RI, 1995, MOL CELL BIOL, V15, P943; SCHEINMAN RI, 1995, SCIENCE, V270, P283, DOI 10.1126/science.270.5234.283; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SUBRAMANIAM M, 1992, J CELL BIOCHEM, V50, P411, DOI 10.1002/jcb.240500410; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; TOBLER A, 1992, BLOOD, V79, P45; VANDESTOLPE A, 1994, J BIOL CHEM, V269, P6185; VANDESTOLPE A, 1993, AM J RESP CELL MOL, V8, P340, DOI 10.1165/ajrcmb/8.3.340; WAAGE A, 1990, EUR J IMMUNOL, V20, P2439, DOI 10.1002/eji.1830201112; WAAGE A, 1988, IMMUNOLOGY, V63, P299; WINKLER H, 1996, IN PRESS GENE; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V	36	185	186	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19612	19616		10.1074/jbc.271.32.19612	http://dx.doi.org/10.1074/jbc.271.32.19612			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702657	hybrid			2022-12-25	WOS:A1996VB68400091
J	Mitchell, AH; West, SC				Mitchell, AH; West, SC			Role of RuvA in branch migration reactions catalyzed by the RuvA and RuvB proteins of Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNTHETIC HOLLIDAY JUNCTIONS; COMPLEX IN-VITRO; DNA-REPAIR; RECOMBINATION REPAIR; HEXAMERIC RINGS; ATPASE ACTIVITY; PURIFICATION; HYDROLYSIS	The RuvA and RuvB proteins of Escherichia coli promote ATP-dependent branch migration of Holliday junctions during homologous genetic recombination and DNA repair, In this process, RuvA acts as a specificity factor that targets RuvB, a hexameric ring motor protein, to the junction, Because elevated concentrations of RuvB can promote branch migration in the absence of RuvA, it has been suggested that RuvA acts as a molecular matchmaker, In the studies presented here, we compared the requirements for RuvAB- and RuvB-mediated branch migration reactions and found that reactions catalyzed by RuvB alone were highly sensitive to inhibition by NaCl, temperature, ADP, and ATP gamma S. Our observations indicate that the two reactions occur by distinct mechanisms and support the notion that RuvAB-mediated branch migration is physiologically more relevant than that catalyzed by RuvB, We also show that ongoing RuvAB-mediated branch migration reactions were blocked by the addition of polyclonal antibodies raised against RuvA, The role of RuvA is therefore unlikely to be restricted to RuvB targeting; instead, it is required continually during branch migration, Competition with excess synthetic Holliday junctions, sufficient to sequester released RuvA, failed to cause an immediate block and leads us to suggest that RuvAB promote branch migration by a processive mechanism.	IMPERIAL CANC RES FUND, CLARE HALL LABS, S MIMMS EN6 3LD, HERTS, ENGLAND					West, Stephen/0000-0001-8848-9418				ADAMS DE, 1995, J MOL BIOL, V247, P404, DOI 10.1006/jmbi.1995.0149; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Harlow E., 1988, ANTIBODIES LAB MANUA; HIOM K, 1995, NUCLEIC ACIDS RES, V23, P3621, DOI 10.1093/nar/23.18.3621; HIOM K, 1995, CELL, V80, P787, DOI 10.1016/0092-8674(95)90357-7; IWASAKI H, 1989, J BACTERIOL, V171, P5276, DOI 10.1128/jb.171.10.5276-5280.1989; IWASAKI H, 1992, GENE DEV, V6, P2214, DOI 10.1101/gad.6.11.2214; KODADEK T, 1988, J BIOL CHEM, V263, P9427; LLOYD RG, 1993, EMBO J, V12, P17, DOI 10.1002/j.1460-2075.1993.tb05627.x; LLOYD RG, 1984, MOL GEN GENET, V194, P303, DOI 10.1007/BF00383532; MARRIONE PE, 1995, BIOCHEMISTRY-US, V34, P9809, DOI 10.1021/bi00030a019; MITCHELL AH, 1994, J MOL BIOL, V243, P208, DOI 10.1006/jmbi.1994.1648; MOREL P, 1993, NUCLEIC ACIDS RES, V21, P3205, DOI 10.1093/nar/21.14.3205; MULLER B, 1993, J BIOL CHEM, V268, P17185; MULLER B, 1993, J BIOL CHEM, V268, P17179; PANYUTIN IG, 1994, P NATL ACAD SCI USA, V91, P2021, DOI 10.1073/pnas.91.6.2021; PANYUTIN IG, 1995, EMBO J, V14, P1819, DOI 10.1002/j.1460-2075.1995.tb07170.x; PARSONS CA, 1995, EMBO J, V14, P5736, DOI 10.1002/j.1460-2075.1995.tb00260.x; PARSONS CA, 1995, NATURE, V374, P375, DOI 10.1038/374375a0; PARSONS CA, 1993, J MOL BIOL, V232, P397, DOI 10.1006/jmbi.1993.1399; PARSONS CA, 1992, P NATL ACAD SCI USA, V89, P5452, DOI 10.1073/pnas.89.12.5452; SANCAR A, 1993, SCIENCE, V259, P1415, DOI 10.1126/science.8451638; SHAH R, 1994, NUCLEIC ACIDS RES, V22, P2490, DOI 10.1093/nar/22.13.2490; SHARPLES GJ, 1990, MOL GEN GENET, V221, P219, DOI 10.1007/BF00261724; SHIBA T, 1993, MOL GEN GENET, V237, P395, DOI 10.1007/BF00279443; SHIBA T, 1991, P NATL ACAD SCI USA, V88, P8445, DOI 10.1073/pnas.88.19.8445; STASIAK A, 1994, P NATL ACAD SCI USA, V91, P7618, DOI 10.1073/pnas.91.16.7618; TSANEVA IR, 1992, MOL GEN GENET, V235, P1, DOI 10.1007/BF00286175; TSANEVA IR, 1992, CELL, V69, P1171, DOI 10.1016/0092-8674(92)90638-S; TSANEVA IR, 1993, P NATL ACAD SCI USA, V90, P1315, DOI 10.1073/pnas.90.4.1315; WEST SC, 1994, CELL, V76, P9, DOI 10.1016/0092-8674(94)90168-6; West SC, 1996, J BACTERIOL, V178, P1237, DOI 10.1128/jb.178.5.1237-1241.1996; Whitby M. C., 1995, NUCLEIC ACIDS MOL BI, V9, P66	33	18	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19497	19502		10.1074/jbc.271.32.19497	http://dx.doi.org/10.1074/jbc.271.32.19497			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702640	hybrid			2022-12-25	WOS:A1996VB68400074
J	Sugano, M; Makino, N				Sugano, M; Makino, N			Changes in plasma lipoprotein cholesterol levels by antisense oligodeoxynucleotides against cholesteryl ester transfer protein in cholesterol-fed rabbits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; TRANSGENIC MICE; FAMILIAL HYPERALPHALIPOPROTEINEMIA; DENSITY LIPOPROTEINS; NUCLEIC-ACIDS; IN-VIVO; GENE; RECEPTOR; OLIGONUCLEOTIDES; DEFICIENCY	Cholesteryl ester transfer protein (CETP) is the enzyme that facilitates the transfer of cholesteryl ester from high density lipoprotein (HDL) to apoB-containing. lipoproteins and also affects the low density lipoprotein metabolism, On the other hand, the liver is the major tissue responsible for the production of CETP (CETP mRNA) in rabbits, To test the hypothesis that a reduction of CETP mRNA in the liver by antisense oligodeoxynucleotides (ODNs) may affect the plasma lipoprotein cholesterol levels, we intravenously injected antisense ODNs against rabbit CETP coupled with asialoglycoprotein carrier molecules, which serve as an important method to regulate liver gene expression, to cholesterol-fed rabbits via their ear veins, All rabbits were fed a standard rabbit chow supplement with 0.1% cholesterol for 10 weeks before and throughout the experiment, After injecting rabbits with antisense ODNs, the plasma total cholesterol concentrations and plasma CETP activities all decreased at 24, 48, and 96 h, whereas the plasma HDL cholesterol concentrations increased at 48 h, A reduction in the hepatic CETP mRNA was also observed at 6, 24, and 48 h after tire injection with antisense ODNs, However, in the rabbits injected with sense ODNs, the plasma total and HDL cholesterol concentrations and the plasma CETP activities did not significantly change, and the hepatic CETP mRNA did not change either throughout: the experimental period. Although the exact role of CETP in the development of atherosclerosis remains to be clarified, these findings showed for the first time that the intravenous injection with antisense ODNs against CETP coupled to asialoglycoprotein carrier molecules targeted to the liver could thus inhibit plasma CETP activity and, as a result, could induce a decrease in the plasma low density lipoprotein and very low density lipoprotein cholesterol and an increase in the plasma HDL cholesterol in cholesterol-fed rabbits.			Sugano, M (corresponding author), KYUSHU UNIV, MED INST BIOREGULAT, DEPT BIOCLIMATOL & MED, 4546 TSURUMIHARA, BEPPU, OITA 874, JAPAN.							BROWN ML, 1989, NATURE, V342, P448, DOI 10.1038/342448a0; CHIOU HC, 1994, NUCLEIC ACIDS RES, V22, P5439, DOI 10.1093/nar/22.24.5439; FIELDING CJ, 1995, J LIPID RES, V36, P211; HA YC, 1982, COMP BIOCHEM PHYS B, V71, P265, DOI 10.1016/0305-0491(82)90252-8; HAYEK T, 1995, J CLIN INVEST, V96, P2071, DOI 10.1172/JCI118255; HAYEK T, 1992, J CLIN INVEST, V90, P505, DOI 10.1172/JCI115887; HELENE C, 1990, BIOCHIM BIOPHYS ACTA, V1049, P99, DOI 10.1016/0167-4781(90)90031-V; HESLER CB, 1987, J BIOL CHEM, V262, P2275; IKEWAKI K, 1995, J CLIN INVEST, V96, P1573, DOI 10.1172/JCI118196; INAZU A, 1990, NEW ENGL J MED, V323, P1234, DOI 10.1056/NEJM199011013231803; JIANG XC, 1993, J BIOL CHEM, V268, P27406; KOIZUMI J, 1985, ATHEROSCLEROSIS, V58, P175, DOI 10.1016/0021-9150(85)90064-4; LINLEE YC, 1985, BIOCHEMISTRY-US, V24, P3751, DOI 10.1021/bi00335a050; LU XM, 1994, J NUCL MED, V35, P269; MANN CJ, 1991, J CLIN INVEST, V88, P2059, DOI 10.1172/JCI115535; MAROTTI KR, 1993, NATURE, V364, P73, DOI 10.1038/364073a0; MORISHITA R, 1994, J CLIN INVEST, V93, P1458, DOI 10.1172/JCI117123; MORISHITA R, 1993, P NATL ACAD SCI USA, V90, P8474, DOI 10.1073/pnas.90.18.8474; NAGASHIMA M, 1988, J LIPID RES, V29, P1643; PAPE ME, 1991, ARTERIOSCLER THROMB, V11, P1759, DOI 10.1161/01.ATV.11.6.1759; PIWNICAWORMS D, 1994, J NUCL MED, V35, P1064; QUINET E, 1991, J CLIN INVEST, V87, P1559, DOI 10.1172/JCI115169; QUINET EM, 1990, J CLIN INVEST, V85, P357, DOI 10.1172/JCI114446; SAITO F, 1984, METABOLISM, V33, P629, DOI 10.1016/0026-0495(84)90061-1; SPADY DK, 1985, J LIPID RES, V26, P465; SPADY DK, 1983, P NATL ACAD SCI-BIOL, V80, P3499, DOI 10.1073/pnas.80.11.3499; STEIN CA, 1993, SCIENCE, V261, P1004, DOI 10.1126/science.8351515; SUGANO M, 1991, CIRCULATION, V84, pA378; TALL AR, 1986, J LIPID RES, V27, P361; TOMITA N, 1995, HYPERTENSION, V26, P131, DOI 10.1161/01.HYP.26.1.131; WARNICK GR, 1978, J LIPID RES, V19, P65; WU GY, 1987, J BIOL CHEM, V262, P4429; WU GY, 1991, J BIOL CHEM, V266, P14338; YEN FT, 1989, J CLIN INVEST, V83, P2018, DOI 10.1172/JCI114112; YOKODE M, 1990, SCIENCE, V250, P1273, DOI 10.1126/science.2244210	35	43	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19080	19083		10.1074/jbc.271.32.19080	http://dx.doi.org/10.1074/jbc.271.32.19080			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702580	hybrid			2022-12-25	WOS:A1996VB68400014
J	Li, Q; Jungmann, V; Kiyatkin, A; Low, PS				Li, Q; Jungmann, V; Kiyatkin, A; Low, PS			Prostaglandin E(2) stimulates a Ca2+-dependent K+ channel in human erythrocytes and alters cell volume and filterability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRREVERSIBLY SICKLED CELLS; MEMBRANE NUCLEAR FILTERS; RED BLOOD-CELLS; GEOMETRICAL PARAMETERS; MECHANICAL-PROPERTIES; THEORETICAL-MODEL; AGGREGATION; INHIBITION; TRANSPORT; CLOTRIMAZOLE	To understand the mechanism by which human red blood cells (RBCs) contribute to hemostasis and thrombosis, we have examined the effects of metabolites released by activated platelets on intact RBCs, Prostaglandin E(2) (PGE(2)), a signal molecule produced by activated platelets, was observed to lower the filterability of human erythrocytes by similar to 30% at 10(-10) M. PGE(2) also caused a reduction in mean cell volume of similar to 10%. The shrinkage of red cells after PGE(2) treatment was confirmed by documenting a decrease in osmotic fragility and an increase in cell density following exposure to the hormone. Careful analysis, however, revealed that only similar to 15% of the erythrocytes responded to stimulation with PGE(2). Examination of the cause of cell shrinkage showed that induction of a PGE(2)-stimulated K+ efflux pathway leading to rapid loss of cellular K+ was responsible, The PGE(2)-stimulated K+ loss was also observed to be Ca2+-dependent, suggesting the possible involvement of the Gardos channel, Gardos channel participation was supported by the observation that two Gardos channel inhibitors, charybdotoxin and clotrimazole, independently blocked the PGE(2)-stimulated K+ efflux, Further evidence for Gardos channel activation came from experiments aimed at characterizing the efflux pathway followed by the obligatory counterion. Thus, K+ efflux was readily stimulated even when NOB was substituted for Cl-, suggesting that neither KCl cotransport nor Na/K/2Cl cotransport plays a prominent role in the PGE(2)-induced cell shrinkage, Further, the anion transporter band 3 was implicated as the counterion efflux route, since DIDS inhibited the PGE(2) stimulated cell volume change without blocking the change in membrane potential, Taken together, we propose that release of PGE(2) by activated platelets constitutes part of a mechanism by which activated platelets may recruit adjacent erythrocytes to assist in clot formation.	PURDUE UNIV, DEPT CHEM, W LAFAYETTE, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus			Kiyatkin, Anatoly/A-8707-2009	Kiyatkin, Anatoly/0000-0002-5060-6081; Low, Philip/0000-0001-9042-5528	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM024417, R01GM024417] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM24417] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN JE, 1971, SCIENCE, V174, P512, DOI 10.1126/science.174.4008.512; Ambrosioni E, 1993, Ann Ital Med Int, V8 Suppl, p59S; ATAULLAHANOV FI, 1994, BIOFIZIKA+, V39, P672; BRUGNARA C, 1993, J BIOL CHEM, V268, P8760; BRUGNARA C, 1995, J PHARMACOL EXP THER, V273, P266; BRUGNARA C, 1993, J CLIN INVEST, V92, P520, DOI 10.1172/JCI116597; CORASH LM, 1974, J LAB CLIN MED, V84, P147; Dawson R. M. C., 1986, DATA BIOCH RES, V3rd; DOWNEY GP, 1995, J CELL PHYSIOL, V163, P96, DOI 10.1002/jcp.1041630111; Duke WW, 1910, J AMER MED ASSOC, V55, P1185, DOI 10.1001/jama.1910.04330140029009; FUNDER J, 1967, ACTA PHYSIOL SCAND, V71, P113, DOI 10.1111/j.1748-1716.1967.tb03716.x; GARDOS G, 1958, BIOCHIM BIOPHYS ACTA, V30, P653, DOI 10.1016/0006-3002(58)90124-0; GECK P, 1980, BIOCHIM BIOPHYS ACTA, V600, P432, DOI 10.1016/0005-2736(80)90446-0; GLADER BE, 1978, BLOOD, V51, P983; HELLEM AJ, 1961, BRIT J HAEMATOL, V7, P42, DOI 10.1111/j.1365-2141.1961.tb00318.x; HELLEM ARVID JOHN, 1960, SCAND JOUR CLIN AND LAB INVEST, V12, P1; HLADKY SB, 1976, J PHYSIOL-LONDON, V263, P287, DOI 10.1113/jphysiol.1976.sp011632; JOHNSON RM, 1992, BIOCHIM BIOPHYS ACTA, V1107, P314, DOI 10.1016/0005-2736(92)90418-L; KAJI DM, 1993, AM J PHYSIOL, V264, pC376, DOI 10.1152/ajpcell.1993.264.2.C376; LISOVSKAYA IL, 1994, BIOFIZIKA+, V39, P864; LIVIO M, 1982, LANCET, V2, P1013; MORRIS GP, 1984, CAN J PHYSIOL PHARM, V62, P1065, DOI 10.1139/y84-178; MULLANEY PF, 1970, BIOPHYS J, V10, P764, DOI 10.1016/S0006-3495(70)86334-2; MUSTARD JF, 1970, PHARMACOL REV, V22, P97; NAKAHATA N, 1992, FOLIA PHARMACOL JPN, V99, P1, DOI 10.1254/fpj.99.1; OHNISHI ST, 1989, BIOCHIM BIOPHYS ACTA, V1010, P199; RASMUSSEN H, 1975, BIOCHIM BIOPHYS ACTA, V411, P63, DOI 10.1016/0304-4165(75)90285-8; SANIABADI AR, 1985, THROMB RES, V38, P225, DOI 10.1016/0049-3848(85)90150-1; SANTOS MT, 1991, J CLIN INVEST, V87, P571, DOI 10.1172/JCI115032; SMITH JB, 1973, J CLIN INVEST, V52, P965, DOI 10.1172/JCI107262; TOKUDA H, 1992, PROSTAGLANDINS, V43, P271, DOI 10.1016/0090-6980(92)90095-B; TOMIMOTO Y, 1991, NIPPON JINZO GAKKAIS, V30, P1141; TORIYAMA K, 1992, PROSTAG LEUKOTR ESS, V46, P15, DOI 10.1016/0952-3278(92)90053-L; VALLES J, 1991, BLOOD, V78, P154; ZOLTAY G, 1994, NEUROCHEM RES, V19, P1211, DOI 10.1007/BF00965158	35	79	81	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18651	18656		10.1074/jbc.271.31.18651	http://dx.doi.org/10.1074/jbc.271.31.18651			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702518	hybrid			2022-12-25	WOS:A1996VB68300056
J	Mignaco, JA; Barrabin, H; Scofano, HM				Mignaco, JA; Barrabin, H; Scofano, HM			Effects of photo-oxidizing analogs of fluorescein on the sarcoplasmic reticulum Ca2+-ATPase - Functional consequences for substrate hydrolysis and effects on the partial reactions of the hydrolytic cycle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-BINDING SITES; CALCIUM ADENOSINE-TRIPHOSPHATASE; (NA+ + K+)-ATPASE; ATP-BINDING; CA-ATPASE; CA-2+ TRANSPORT; PLASMA-MEMBRANE; CATALYTIC SITE; ACTIVE-SITE; CA-2+-ATPASE	Erythrosin B was used to photo oxidize the sarcoplasmic reticulum Ca2+-ATPase. The ATPase activity is rapidly and irreversibly inhibited by photo-oxidation with erythrosin. This inhibition is protected by the presence of ATP during the photo-oxidation period. After photooxidation, the steady-state phosphorylation by ATP remains almost unchanged, whereas phosphorylation by inorganic phosphate is impaired, The pseudo-first order rate constants for phosphorylation by 15 mu M ATP at 25 degrees C are strongly inhibited when starting from either a Ca2+-bound or a Ca2+-free enzyme form, decreasing from 145 to 23 s(-1) for the Ca2+-bound form and from 50 to 18 s(-1) for the Ca2+-free form. Concurrently, the rate constants for dephosphorylation are also severely inhibited, changing from a fast double exponential to a very slow single exponential decay in the reverse direction and from a moderately slow single to a very slow single exponential decay in the forward direction. Ca2+ binding data show that the phosphorylated intermediate formed by the photo-oxidized enzyme contains two occluded Ca2+, and TNP-ATP fluorescence measurements indicate that it accumulates in a E(1)-P . Ca-2-like conformation. Protection by ADP against glutaraldehyde-induced cross-linking indicates that ADP binding to Ca2+-ATPase is not impaired by photo-oxidation nor by free erythrosin. These data support the view that an ADP-insensitive, Ca2+-bound, slowly interconverting phosphoenzyme is formed. Thus, photo-oxidation with erythrosin B leads to impairment of phosphoryl transfer reactions and related conformational changes.	FED UNIV RIO DE JANEIRO, CCS, ICB, DEPT BIOQUIM MED, BR-21941590 RIO DE JANEIRO, BRAZIL	Universidade Federal do Rio de Janeiro			Mignaco, Julio A/J-3469-2013	Mignaco, Julio A/0000-0002-8491-092X				ALONSO GL, 1990, J THEOR BIOL, V147, P161, DOI 10.1016/S0022-5193(05)80050-5; BERMAN MC, 1986, J BIOL CHEM, V261, P6494; BIRMACHU W, 1990, BIOCHEMISTRY-US, V29, P3904, DOI 10.1021/bi00468a017; BISHOP JE, 1987, J BIOL CHEM, V262, P4658; BRANDL CJ, 1986, CELL, V44, P597, DOI 10.1016/0092-8674(86)90269-2; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; CLARKE DM, 1990, J BIOL CHEM, V265, P22223; COAN C, 1990, J BIOL CHEM, V265, P5376; COFFEY RL, 1975, ARCH BIOCHEM BIOPHYS, V170, P37, DOI 10.1016/0003-9861(75)90095-8; DAGLORIA M, 1976, J BIOL CHEM, V251, P3629; DAIHO T, 1994, J BIOL CHEM, V269, P11060; DEMICHELIS MI, 1993, BOT ACTA, V106, P20, DOI 10.1111/j.1438-8677.1993.tb00333.x; DUPONT Y, 1977, EUR J BIOCHEM, V72, P185, DOI 10.1111/j.1432-1033.1977.tb11238.x; EBASHI S, 1962, J CELL BIOL, V14, P389, DOI 10.1083/jcb.14.3.389; ELETR S, 1972, BIOCHIM BIOPHYS ACTA, V282, P174, DOI 10.1016/0005-2736(72)90321-5; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FUJIMORI T, 1992, J BIOL CHEM, V267, P18466; GATTO C, 1993, AM J PHYSIOL, V264, pC1577, DOI 10.1152/ajpcell.1993.264.6.C1577; GRUBMEYER C, 1981, J BIOL CHEM, V256, P3728; HALLIWELL B, 1989, FREE RADICAL BIO MED, P69; HASSELBACH W, 1961, BIOCHEM Z, V333, P518; HECHT JP, 1990, COMPUT METH PROG BIO, V33, P13, DOI 10.1016/0169-2607(90)90018-5; HELMICHDEJONG ML, 1986, BIOCHIM BIOPHYS ACTA, V858, P254, DOI 10.1016/0005-2736(86)90330-5; INESI G, 1989, J BIOL CHEM, V264, P5929; INESI G, 1987, J BIOL CHEM, V262, P16338; INESI G, 1982, Z NATURFORSCH C, V37, P685; JACOBSBERG L, 1975, J BIOL CHEM, V250, P9238; KESSLER RJ, 1986, ANAL BIOCHEM, V158, P117, DOI 10.1016/0003-2697(86)90598-1; KNOWLES AF, 1975, J BIOL CHEM, V250, P1949; LACAPERE JJ, 1990, J BIOL CHEM, V265, P348; LACAPERE JJ, 1993, BIOCHEMISTRY-US, V32, P3414, DOI 10.1021/bi00064a027; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN TI, 1977, ANAL BIOCHEM, V77, P10, DOI 10.1016/0003-2697(77)90284-6; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUNDBLAD RL, 1984, CHEM REAGENTS PROTEI, V1, P105; MARTONOSI A, 1973, COLD SPRING HARB SYM, V37, P455, DOI 10.1101/SQB.1973.037.01.057; MARUYAMA K, 1988, P NATL ACAD SCI USA, V85, P3314, DOI 10.1073/pnas.85.10.3314; MARUYAMA K, 1989, J BIOL CHEM, V264, P13038; MCINTOSH DB, 1992, J BIOL CHEM, V267, P22328; MEISSNER G, 1973, BIOCHIM BIOPHYS ACTA, V298, P246, DOI 10.1016/0005-2736(73)90355-6; MIGNACO J, 1990, BIOCHIM BIOPHYS ACTA, V1039, P305, DOI 10.1016/0167-4838(90)90263-F; MITCHINSON C, 1982, FEBS LETT, V146, P87, DOI 10.1016/0014-5793(82)80710-2; MORRIS SJ, 1982, BIOCHEM BIOPH RES CO, V104, P1306, DOI 10.1016/0006-291X(82)91392-4; MUGICA H, 1984, ACTA PHYSIOL PHARM L, V34, P163; MUNKONGE F, 1988, BIOCHEMISTRY-US, V27, P6800, DOI 10.1021/bi00418a023; MURPHY AJ, 1988, BIOCHIM BIOPHYS ACTA, V946, P57, DOI 10.1016/0005-2736(88)90457-9; NAKAMURA Y, 1986, J BIOL CHEM, V261, P3090; NESLUND GG, 1984, CURR TOP CELL REGUL, V24, P447; PAPP S, 1987, BIOPHYS J, V51, P205, DOI 10.1016/S0006-3495(87)83326-X; PETITHORY JR, 1988, BIOCHEMISTRY-US, V27, P5553, DOI 10.1021/bi00415a025; PICK U, 1981, FEBS LETT, V123, P127, DOI 10.1016/0014-5793(81)80035-X; PICK U, 1981, EUR J BIOCHEM, V121, P187, DOI 10.1111/j.1432-1033.1981.tb06448.x; PICKART CM, 1984, J BIOL CHEM, V259, P1629; PICKART CM, 1982, J BIOL CHEM, V257, P5319; RAY WJ, 1962, J BIOL CHEM, V237, P2493; SCHWARZENBACH G, 1957, HELV CHIM ACTA, V40, P1886, DOI 10.1002/hlca.19570400640; SCOFANO HM, 1979, J BIOL CHEM, V254, P227; SKOU JC, 1983, BIOCHIM BIOPHYS ACTA, V727, P101, DOI 10.1016/0005-2736(83)90373-5; SKOU JC, 1981, BIOCHIM BIOPHYS ACTA, V647, P232, DOI 10.1016/0005-2736(81)90251-0; SOMERVILLE LL, 1977, BIOCHIM BIOPHYS ACTA, V481, P493, DOI 10.1016/0005-2744(77)90282-0; STAHL N, 1987, BIOCHEMISTRY-US, V26, P7654, DOI 10.1021/bi00398a019; STOKES DL, 1994, FEBS LETT, V346, P32, DOI 10.1016/0014-5793(94)00297-5; STUART J, 1992, ARCH BIOCHEM BIOPHYS, V292, P512, DOI 10.1016/0003-9861(92)90024-Q; TAYLOR WR, 1989, EUR J BIOCHEM, V179, P241, DOI 10.1111/j.1432-1033.1989.tb14547.x; TERUEL JA, 1987, J BIOL CHEM, V262, P13055; VILSEN B, 1991, J BIOL CHEM, V266, P16157; VOSS J, 1991, BIOCHEMISTRY-US, V30, P7498, DOI 10.1021/bi00244a019; WACH A, 1991, EUR J BIOCHEM, V201, P91, DOI 10.1111/j.1432-1033.1991.tb16260.x; WALSETH TF, 1979, BIOCHIM BIOPHYS ACTA, V562, P11, DOI 10.1016/0005-2787(79)90122-9; WASSARMAN PM, 1971, J MOL BIOL, V60, P509, DOI 10.1016/0022-2836(71)90185-9; YAMAGATA K, 1993, J BIOL CHEM, V268, P20930; YIP BP, 1976, J BIOL CHEM, V251, P7157; YU BP, 1974, BIOCHEMISTRY-US, V13, P5083, DOI 10.1021/bi00722a004; YU BP, 1967, NATURE, V216, P822, DOI 10.1038/216822a0	74	7	7	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18423	18430		10.1074/jbc.271.31.18423	http://dx.doi.org/10.1074/jbc.271.31.18423			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702486	hybrid			2022-12-25	WOS:A1996VB68300024
J	Luo, W; Skalnik, DG				Luo, W; Skalnik, DG			CCAAT displacement protein competes with multiple transcriptional activators for binding to four sites in the proximal gp91(phox) promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC GRANULOMATOUS-DISEASE; SENSORY ORGAN IDENTITY; DROSOPHILA WING MARGIN; LEUKEMIA CELL-LINE; DNA-BINDING; HOMEODOMAIN PROTEIN; GENE-TRANSCRIPTION; CD11B PROMOTER; CUT REPEATS; GLOBIN GENE	CCAAT displacement protein (CDP) competes with transcriptional activating proteins for binding to each of four elements within the myeloid-specific gp91(phox) promoter. CDP exhibits the strongest affinity for a site centered at -110 base pairs (bp) of the promoter and progressively weaker affinities for three more distal binding sites. CDP binding to each site is down-regulated during terminal phagocytic differentiation, coincident with induction of gp91(phox) expression, Deletion of the high affinity CDP-binding site at -110 bp leads to inappropriate gp91(phox) promoter activity in HeLa, K562, and HEL cells. An overlapping binding site for the CCAAT box-binding factor CP1 is required for derepressed promoter activity in HeLa and K562 cells, but is dispensable in HEL cells, indicating that different cell types require distinct cis-elements for gp91(phox) pro meter activity, Derepressed gp91(phox) promoter activity is further increased upon removal of a second CDP-binding site centered at -150 bp, revealing that CDP represses gp91(phox) expression via multiple cis-elements, We present a model in which restriction of gp91(phox) expression to mature myeloid cells involves competition between transcriptional activators and repressors for binding to multiple sites within the promoter.	INDIANA UNIV,SCH MED,SECT PEDIAT HEMATOL ONCOL,HERMAN B WELLS CTR PEDIAT RES,INDIANAPOLIS,IN 46202; INDIANA UNIV,SCH MED,DEPT PEDIAT,INDIANAPOLIS,IN 46202; INDIANA UNIV,SCH MED,DEPT BIOCHEM,INDIANAPOLIS,IN 46202; INDIANA UNIV,SCH MED,DEPT MOL BIOL,INDIANAPOLIS,IN 46202	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis					NATIONAL CANCER INSTITUTE [R29CA058947, R01CA058947] Funding Source: NIH RePORTER; NCI NIH HHS [CA58947] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHNE B, 1994, J BIOL CHEM, V269, P17794; ANDRES V, 1994, GENE DEV, V8, P245, DOI 10.1101/gad.8.2.245; ANDRES V, 1992, DEVELOPMENT, V116, P321; AUFIERO B, 1994, P NATL ACAD SCI USA, V91, P7757, DOI 10.1073/pnas.91.16.7757; AUSTIN RJ, 1995, MOL CELL BIOL, V15, P4683; BARBERIS A, 1987, CELL, V50, P347, DOI 10.1016/0092-8674(87)90489-2; BLOCHLINGER K, 1993, DEVELOPMENT, V117, P441; BLOCHLINGER K, 1990, GENE DEV, V4, P1322, DOI 10.1101/gad.4.8.1322; BLOCHLINGER K, 1991, GENE DEV, V5, P1124, DOI 10.1101/gad.5.7.1124; BLOCHLINGER K, 1988, NATURE, V333, P629, DOI 10.1038/333629a0; BODMER R, 1987, CELL, V51, P293, DOI 10.1016/0092-8674(87)90156-5; BURK O, 1993, EMBO J, V12, P2027, DOI 10.1002/j.1460-2075.1993.tb05852.x; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN HM, 1993, J BIOL CHEM, V268, P8230; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DORN A, 1987, CELL, V50, P863, DOI 10.1016/0092-8674(87)90513-7; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; EKLUND EA, 1995, J BIOL CHEM, V270, P8267, DOI 10.1074/jbc.270.14.8267; FALB D, 1992, GENE DEV, V6, P454, DOI 10.1101/gad.6.3.454; GEY GO, 1952, CANCER RES, V12, P264; HARADA R, 1994, J BIOL CHEM, V269, P2062; HUANG JD, 1993, GENE DEV, V7, P694, DOI 10.1101/gad.7.4.694; INNIS MA, 1990, PCR PROTOCOLS; JACK J, 1992, GENETICS, V131, P353; JACK J, 1991, DEVELOPMENT, V113, P735; JACKSON SM, 1992, MOL CELL BIOL, V12, P2708, DOI 10.1128/MCB.12.6.2708; KATZ S, 1993, EMBO J, V12, P1321, DOI 10.1002/j.1460-2075.1993.tb05777.x; KOMINATO Y, 1995, MOL CELL BIOL, V15, P59; KURIBAYASHI F, 1995, BIOCHEM BIOPH RES CO, V209, P146, DOI 10.1006/bbrc.1995.1482; LETO TL, 1990, SCIENCE, V248, P727, DOI 10.1126/science.1692159; LIEVENS PMJ, 1995, J BIOL CHEM, V270, P12745, DOI 10.1074/jbc.270.21.12745; LOMAX KJ, 1989, SCIENCE, V245, P409, DOI 10.1126/science.2547247; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; MACLEOD K, 1991, MOL CELL BIOL, V11, P4324, DOI 10.1128/MCB.11.9.4324; MANTOVANI R, 1992, EMBO J, V11, P3315, DOI 10.1002/j.1460-2075.1992.tb05410.x; MARTIN P, 1982, SCIENCE, V216, P1233, DOI 10.1126/science.6177045; NEUFELD EJ, 1992, NAT GENET, V1, P50, DOI 10.1038/ng0492-50; NEWBURGER PE, 1994, J CLIN INVEST, V94, P1205, DOI 10.1172/JCI117437; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; ORKIN SH, 1992, BLOOD, V80, P575; PAHL HL, 1993, J BIOL CHEM, V268, P5014; PARKOS CA, 1987, J CLIN INVEST, V80, P732, DOI 10.1172/JCI113128; PEREZ C, 1994, MOL CELL BIOL, V14, P5023, DOI 10.1128/MCB.14.8.5023; ROYERPOKORA B, 1986, NATURE, V322, P32, DOI 10.1038/322032a0; Sambrook J., 2002, MOL CLONING LAB MANU; SIMON AM, 1993, MOL CELL BIOL, V13, P5133, DOI 10.1128/MCB.13.9.5133; SKALNIK DG, 1991, J BIOL CHEM, V266, P16736; SKALNIK DG, 1991, P NATL ACAD SCI USA, V88, P8505, DOI 10.1073/pnas.88.19.8505; SUPERTIFURGA G, 1989, BIOCHIM BIOPHYS ACTA, V1007, P237, DOI 10.1016/0167-4781(89)90046-8; SWICK AG, 1992, P NATL ACAD SCI USA, V89, P7895, DOI 10.1073/pnas.89.17.7895; TANAKA N, 1993, MOL CELL BIOL, V13, P4531, DOI 10.1128/MCB.13.8.4531; TENHARMSEL A, 1993, MOL CELL BIOL, V13, P2742, DOI 10.1128/MCB.13.5.2742; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; TUCKER KA, 1987, BLOOD, V70, P372; VALARCHE I, 1993, DEVELOPMENT, V119, P881; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; XU WH, 1995, MOL CELL BIOL, V15, P5369; YOON SO, 1994, J BIOL CHEM, V269, P18453; ZHANG DE, 1994, J BIOL CHEM, V269, P11425; ZHANG DE, 1994, MOL CELL BIOL, V14, P373, DOI 10.1128/MCB.14.1.373	60	91	100	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					18203	18210		10.1074/jbc.271.30.18203	http://dx.doi.org/10.1074/jbc.271.30.18203			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663528	hybrid			2022-12-25	WOS:A1996UY93500092
J	Harwood, FG; Frazier, MW; Krajewski, S; Reed, JC; Houghton, JA				Harwood, FG; Frazier, MW; Krajewski, S; Reed, JC; Houghton, JA			Acute and delayed apoptosis induced by thymidine deprivation correlates with expression of p53 and p53-regulated genes in colon carcinoma cells	ONCOGENE			English	Article						p53 heterozygosity; apoptosis; cytostasis	WILD-TYPE P53; COLORECTAL-CARCINOMA; MUTANT CONFORMATION; DNA DAMAGE; BCL-2; RESISTANCE; PROTEIN; FLUOROURACIL; AMPLIFICATION; CYTOTOXICITY	The endogenous expression of p53 and p53-regulated genes has been examined in a thymidylate synthase-deficient colon carcinoma cell line (TS-) and a derived mutant clone (Thy4) that exhibit acute or delayed apoptotic responses, respectively, when released from G0 synchrony under conditions of dThd starvation. These cell clones demonstrate heterozygosity in p53, thereby expressing one wt allele and one with an A-->C point mutation at codon 240. Following release from G0, upregulated expression of both alleles occurred. During apoptosis in TS-, a wtp53 phenotype was expressed and in Thy4 during cytostasis, a mp53 phenotype was manifested, as determined from the ratios of wtp53/mp53 proteins, transactivation of p50-2 (a wtp53-responsive CAT reporter construct) and the endogenous expression of MDM2. Neither cytotoxicity nor cytostasis correlated with expression of p21(Waf1/Cip1) ThY4 cells sustained accumulation of high levels of Bax in a wtp53-independent and dThd-independent manner and survival was associated with upregulated expression of Bcl-2. In contrast, Bax expression decreased in TS- during apoptosis, except in a highly resistant subpopulation that retained high levels of Bax. Data suggest that resistant cells (Thy4) can sustain high Bax expression and that Bcl-2 is upregulated in response to an apoptotic stimulus due to the absence of negative regulation by wtp53.	ST JUDE CHILDRENS RES HOSP, DEPT MOLEC PHARMACOL, MEMPHIS, TN 38105 USA; LA JOLLA CANC RES FDN, CANC RES CTR, LA JOLLA, CA 92037 USA	St Jude Children's Research Hospital; Sanford Burnham Prebys Medical Discovery Institute					NCI NIH HHS [R37 CA32613, CA60181, CA21765] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA060181, P30CA021765, R37CA032613] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BRISTOW RG, 1994, ONCOGENE, V9, P1527; BRONNER MP, 1995, AM J PATHOL, V146, P20; CANMAN CE, 1992, P NATL ACAD SCI USA, V89, P10474, DOI 10.1073/pnas.89.21.10474; CHIOU SK, 1994, MOL CELL BIOL, V14, P2556, DOI 10.1128/MCB.14.4.2556; CHITTENDEN T, 1995, NATURE, V374, P733, DOI 10.1038/374733a0; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DOLE M, 1994, CANCER RES, V54, P3253; DONCHOWER LA, 1992, NATURE, V356, P215; DOROSHOW JH, 1990, J CLIN ONCOL, V8, P491, DOI 10.1200/JCO.1990.8.3.491; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ERLICHMAN C, 1988, J CLIN ONCOL, V6, P469, DOI 10.1200/JCO.1988.6.3.469; EUSTICE DC, 1991, BIOTECHNIQUES, V11, P739; FARROW SN, 1995, NATURE, V374, P731, DOI 10.1038/374731a0; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FISHER TC, 1993, CANCER RES, V53, P3321; FREBOURG T, 1994, CANCER RES, V54, P878; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; HOCKENBERY D, 1991, NATURE, V349, P254; HOUGHTON JA, 1994, CANCER RES, V54, P4967; Houghton JA, 1995, CLIN CANCER RES, V1, P723; HOUGHTON PJ, 1989, P NATL ACAD SCI USA, V86, P1377, DOI 10.1073/pnas.86.4.1377; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; KAMESAKI S, 1993, CANCER RES, V53, P4251; KASTAN MB, 1991, CANCER RES, V51, P6304; KEURBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491; KIEFER MC, 1995, NATURE, V374, P736, DOI 10.1038/374736a0; KRAJEWSKI S, 1995, CANCER RES, V55, P4471; KRAJEWSKI S, 1994, CANCER RES, V54, P5501; LEE JM, 1993, P NATL ACAD SCI USA, V90, P5742, DOI 10.1073/pnas.90.12.5742; LEONARDO AD, 1994, GENE DEV, V8, P2540; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; LU QL, 1993, J PATHOL, V169, P431, DOI 10.1002/path.1711690408; MCILWRATH AJ, 1994, CANCER RES, V54, P3718; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1992, CANCER RES, V52, P5407; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MIYASHITA T, 1994, CANCER RES, V54, P3131; OLIVER FJ, 1993, BIOCHEM BIOPH RES CO, V194, P126, DOI 10.1006/bbrc.1993.1794; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; OTLVAI ZN, 1993, CELL, V74, P609; PETRELLI N, 1987, J CLIN ONCOL, V5, P1559, DOI 10.1200/JCO.1987.5.10.1559; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; PIETENPOL JA, 1994, CANCER RES, V54, P3714; POON MA, 1989, J CLIN ONCOL, V7, P1407, DOI 10.1200/JCO.1989.7.10.1407; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; SELVAKUMARAN M, 1994, ONCOGENE, V9, P1791; STEPHEN CW, 1992, J MOL BIOL, V225, P577, DOI 10.1016/0022-2836(92)90386-X; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; WALTON MI, 1993, CANCER RES, V53, P1853; WANG YS, 1993, ONCOGENE, V8, P3427; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZAMBETTI GP, 1993, FASEB J, V7, P855, DOI 10.1096/fasebj.7.10.8344485; ZHAN QM, 1994, ONCOGENE, V9, P3743	63	23	24	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 16	1996	12	10					2057	2067						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UP283	8668331				2022-12-25	WOS:A1996UP28300004
J	Glerum, DM; Shtanko, A; Tzagoloff, A				Glerum, DM; Shtanko, A; Tzagoloff, A			SCO1 and SCO2 act as high copy suppressors of a mitochondrial copper recruitment defect Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C-OXIDASE; ESCHERICHIA-COLI; MEMBRANE SYSTEM; PROTEIN; GENE; CLONING; EXPRESSION; SITES; DNA; ENCODES	C129/U1 is a respiratory defective mutant of Saccharomyces cerevisiae arrested in cytochrome oxidase assembly due to a mutation in COX17, a nuclear gene encoding a low molecular weight cytoplasmic protein proposed to function in mitochondrial copper recruitment. In the present study we show that the respiratory defect of C129/U1 is rescuable by two multicopy suppressors, SCO1 and SCO2. SCO1 was earlier reported to code for a mitochondrial inner membrane protein with an essential function in cytochrome oxidase assembly (Buchwald, P., Krummeck, G., and Rodel, G. (1991) Mol. Gen, Genet, 229, 413-420). SCO2 is a homologue of SCO1, whose product is also localized in the mitochondrial membrane but is not required for respiration. SCO1 also suppresses a cox17 null mutant, indicating that overexpression of Sco1p can compensate for the absence of Cox17p, In contrast, neither copper, COX17 on a multicopy plasmid, or a combination of the two is able to restore respiration in sco1 mutants, Rescue of cox17 mutants by Sco1p suggests that this mitochondrial protein plays a role either in mitochondrial copper transport or insertion of copper into the active site of cytochrome oxidase, Although SCO2 can also partially restore respiratory growth in the cox17 null mutant, rescue in this case requires addition of copper to the growth medium, SCO2 does not suppress a sco1 null mutant, although it is able to partially rescue a sco1 point mutant, We interpret the ability of SCO2 to restore respiration in cox17, but not in sco1 mutants, to indicate that Sco1p and Sco2p have overlapping but not identical functions.	COLUMBIA UNIV, DEPT BIOL SCI, NEW YORK, NY 10027 USA	Columbia University			Glerum, Moira/AHD-3271-2022		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050187] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM50187, R01 GM050187] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASKWITH C, 1994, CELL, V76, P403, DOI 10.1016/0092-8674(94)90346-8; BOTSTEIN D, 1982, MOL BIOL YEAST SACCH, P607; BUCHWALD P, 1991, MOL GEN GENET, V229, P413, DOI 10.1007/BF00267464; BUGGY J, 1995, J BACTERIOL, V177, P6958, DOI 10.1128/jb.177.23.6958-6965.1995; CORUZZI G, 1979, J BIOL CHEM, V254, P9324; CRONAN JE, 1990, J BIOL CHEM, V265, P10327; CUYPERS H, 1993, J BACTERIOL, V175, P7236, DOI 10.1128/JB.175.22.7236-7246.1993; DANCIS A, 1994, CELL, V76, P393, DOI 10.1016/0092-8674(94)90345-X; FAYE G, 1974, J MOL BIOL, V88, P105, DOI 10.1016/0022-2836(74)90304-0; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; Glerum DM, 1996, J BIOL CHEM, V271, P14504, DOI 10.1074/jbc.271.24.14504; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; KOERNER TJ, 1991, METHOD ENZYMOL, V194, P477; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAHAN SM, 1994, MICROBIOL-SGM, V140, P2135, DOI 10.1099/13500872-140-8-2135; Maniatis T., 1982, MOL CLONING; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MURTIF VL, 1985, P NATL ACAD SCI USA, V82, P5617, DOI 10.1073/pnas.82.17.5617; MYERS AM, 1985, EMBO J, V4, P2087, DOI 10.1002/j.1460-2075.1985.tb03896.x; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SCHMIDT RJ, 1984, MOL BIOL EVOL, V1, P317; SCHULZE M, 1989, MOL GEN GENET, V216, P37, DOI 10.1007/BF00332228; SMITS PHM, 1994, YEAST, V10, pS75, DOI 10.1002/yea.320100010; TSUKIHARA T, 1995, SCIENCE, V269, P1069, DOI 10.1126/science.7652554; TZAGOLOFF A, 1990, MICROBIOL REV, V54, P211, DOI 10.1128/MMBR.54.3.211-225.1990; TZAGOLOFF A, 1975, J BIOL CHEM, V250, P8228; VISSER ES, 1992, INFECT IMMUN, V60, P5139, DOI 10.1128/IAI.60.12.5139-5144.1992; WEISIGER RA, 1973, J BIOL CHEM, V248, P4793	30	270	274	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20531	20535		10.1074/jbc.271.34.20531	http://dx.doi.org/10.1074/jbc.271.34.20531			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702795	hybrid			2022-12-25	WOS:A1996VD33700047
J	Hinoi, T; Kishida, S; Koyama, S; Ikeda, M; Matsuura, Y; Kikuchi, A				Hinoi, T; Kishida, S; Koyama, S; Ikeda, M; Matsuura, Y; Kikuchi, A			Post-translational modifications of Ras and Ral are important for the action of Ral GDP dissociation stimulator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEINS; C-TERMINAL REGION; GUANINE-NUCLEOTIDE EXCHANGE; PLASMA-MEMBRANE; ACTIVATING PROTEIN; P21; IDENTIFICATION; EFFECTOR; RAC1; GTPASES	Ral GDP dissociation stimulator (RalGDS) is a GDP/GTP exchange protein of Ral and a new effector protein of Ras. Therefore, there may be a new signaling pathway from Ras to Ral. In this paper, we examined the roles of the post-translational modifications of Ras and Ral on this new signal transduction pathway. The post-translationally modified form of Ras bound to RalGDS more effectively than the unmodified form. The modification of Ras was required to regulate the distribution of RalGDS between the cytosol and membrane fractions in COS cells. The post-translational modification of Ral enhanced the activities of RalGDS to stimulate the dissociation of GDP from and the binding of GTP to Ral. Furthermore, the modified form of Ral bound to Ral-binding protein 1 (RalBP1), a putative effector protein of Ral, more effectively than the unmodified form. Taken together with the observations that Ras and Ral are localized to the membranes, these results suggest that the post-translational modifications of Ras and Ral play a role for transmitting the signal effectively on the membranes in the signal transduction pathway of Ras/RalGDS/Ral/RalBP1.	HIROSHIMA UNIV,SCH MED,DEPT BIOCHEM,MINAMI KU,HIROSHIMA 734,JAPAN; NATL INST HLTH,DEPT VIROL 2,SHINJUKU KU,TOKYO 162,JAPAN	Hiroshima University			Hinoi, Takao/AAI-1443-2020	Hinoi, Takao/0000-0003-0462-6177				ALBRIGHT CF, 1993, EMBO J, V12, P339, DOI 10.1002/j.1460-2075.1993.tb05662.x; ARAKI S, 1991, MOL CELL BIOL, V11, P1438, DOI 10.1128/MCB.11.3.1438; BARBIERI MA, 1994, J BIOL CHEM, V269, P18720; BIELINSKI DF, 1993, BIOCHIM BIOPHYS ACTA, V1151, P246, DOI 10.1016/0005-2736(93)90109-D; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CANTOR SB, 1995, MOL CELL BIOL, V15, P4578; CHARDIN P, 1986, EMBO J, V5, P2203, DOI 10.1002/j.1460-2075.1986.tb04485.x; CHARDIN P, 1989, NUCLEIC ACIDS RES, V17, P4380, DOI 10.1093/nar/17.11.4380; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; EMKEY R, 1991, J BIOL CHEM, V266, P9703; FARNSWORTH CL, 1991, MOL CELL BIOL, V11, P4822, DOI 10.1128/MCB.11.10.4822; FEIG LA, 1993, RAS SUPERFAMILY GTPA, P247; FRECH M, 1990, J BIOL CHEM, V265, P6353; GLOMSET JA, 1990, TRENDS BIOCHEM SCI, V15, P139, DOI 10.1016/0968-0004(90)90213-U; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GORMAN C, 1985, DNA CLONING PRACTICA, V2; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P757; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HIROYOSHI M, 1991, J BIOL CHEM, V266, P2962; HOFER F, 1994, P NATL ACAD SCI USA, V91, P11089, DOI 10.1073/pnas.91.23.11089; HORI Y, 1991, ONCOGENE, V6, P515; HORIUCHI H, 1992, MOL CELL BIOL, V12, P4515, DOI 10.1128/MCB.12.10.4515; HUBER LA, 1993, J CELL BIOL, V123, P35, DOI 10.1083/jcb.123.1.35; IKEDA M, 1995, FEBS LETT, V375, P37, DOI 10.1016/0014-5793(95)01169-F; ITOH T, 1993, J BIOL CHEM, V268, P3025; JIANG H, 1995, NATURE, V378, P409, DOI 10.1038/378409a0; JULLIENFLORES V, 1995, J BIOL CHEM, V270, P22473, DOI 10.1074/jbc.270.38.22473; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KIKUCHI A, 1994, J BIOL CHEM, V269, P20054; Kikuchi A, 1996, J BIOL CHEM, V271, P588, DOI 10.1074/jbc.271.1.588; KIKUCHI A, 1988, J BIOL CHEM, V263, P2897; KIKUCHI A, 1994, MOL CELL BIOL, V14, P7483, DOI 10.1128/MCB.14.11.7483; KINSELLA BT, 1991, J BIOL CHEM, V266, P9786; Koyama S, 1996, FEBS LETT, V380, P113, DOI 10.1016/0014-5793(96)00018-X; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LOMBARDI D, 1993, EMBO J, V12, P677, DOI 10.1002/j.1460-2075.1993.tb05701.x; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MARUTA H, 1991, J BIOL CHEM, V266, P11661; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MISTOU MY, 1992, EMBO J, V11, P2391, DOI 10.1002/j.1460-2075.1992.tb05303.x; MIZUNO T, 1991, P NATL ACAD SCI USA, V88, P6442, DOI 10.1073/pnas.88.15.6442; NGSEE JK, 1991, J BIOL CHEM, V266, P2675; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OLOFSSON B, 1988, ONCOGENE, V3, P231; ORITA S, 1993, J BIOL CHEM, V268, P25542; Park SH, 1995, ONCOGENE, V11, P2349; POLAKIS P, 1993, J BIOL CHEM, V268, P9157; POLAKIS PG, 1989, J BIOL CHEM, V264, P16383; PORFIRI E, 1994, J BIOL CHEM, V269, P22672; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QUILLIAM LA, 1994, MOL CELL BIOL, V14, P1113, DOI 10.1128/MCB.14.2.1113; SHOJI I, 1989, BIOCHEM BIOPH RES CO, V162, P273, DOI 10.1016/0006-291X(89)91992-X; SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P12609, DOI 10.1073/pnas.91.26.12609; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; Summers MD, 1987, MANUAL METHODS BACUL; TAKAI Y, 1992, INT REV CYTOL, V133, P187, DOI 10.1016/S0074-7696(08)61861-6; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; WILDEY GM, 1993, BIOCHEM BIOPH RES CO, V194, P552, DOI 10.1006/bbrc.1993.1855; WILLUMSEN BM, 1984, EMBO J, V3, P2581, DOI 10.1002/j.1460-2075.1984.tb02177.x; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; YAMAMORI B, 1995, J BIOL CHEM, V270, P11723, DOI 10.1074/jbc.270.20.11723	65	39	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					19710	19716		10.1074/jbc.271.33.19710	http://dx.doi.org/10.1074/jbc.271.33.19710			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702675	hybrid			2022-12-25	WOS:A1996VC66900016
J	Takeshima, H; Ikemoto, T; Nishi, M; Nishiyama, N; Shimuta, M; Sugitani, Y; Kuno, J; Saito, I; Saito, H; Endo, M; Iino, M; Noda, T				Takeshima, H; Ikemoto, T; Nishi, M; Nishiyama, N; Shimuta, M; Sugitani, Y; Kuno, J; Saito, I; Saito, H; Endo, M; Iino, M; Noda, T			Generation and characterization of mutant mice lacking ryanodine receptor type 3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-RELEASE CHANNEL; BINDING-PROTEIN ISOFORMS; BULLFROG SKELETAL-MUSCLE; SARCOPLASMIC-RETICULUM; RABBIT BRAIN; CA2+ RELEASE; DNA; EXPRESSION; GENE	The ryanodine receptor type 3 (RyR-3) functions as a Ca2+-induced Ca2+ release (CICR) channel and is distributed in a wide variety of cell types including skeletal muscle and smooth muscle cells, neurons, and certain non-excitable cells. However, the physiological roles of RyR-3 are totally unclear. To gain an insight into the function of RyR-3 in vivo, we have generated mice lacking RyR-3 by means of the gene targeting technique. The mutant mice thus obtained showed apparently normal growth and reproduction. Although Ca2+-induced Ca2+ release from intracellular Ca2+ stores of the mutant skeletal muscle differed in Ca2+ sensitivity from that of wild-type muscle, excitation-contraction coupling of the mutant muscle seemed to be normal. Moreover, we could not find any significant disturbance in the smooth muscle and lymphocytes from the mutant mice. On the other hand, the mutant mice showed increased locomotor activity, which was about a-fold greater than that of the control mice. These results indicate that the loss of RyR-3 causes no gross abnormalities and suggest that the lack of RyR-3-mediated Ca2+ signaling results in abnormalities of certain neurons in the central nervous system.	SAITAMA MED SCH, DEPT PHARMACOL, MOROYAMA, SAITAMA 35001, JAPAN; TOKYO INST PSYCHIAT, DEPT NEUROCHEM, SETAGAYA KU, TOKYO 156, JAPAN; UNIV TOKYO, FAC PHARMACEUT SCI, DEPT CHEM PHARMACOL, BUNKYO KU, TOKYO 113, JAPAN; TOKYO MED & DENT UNIV, MED RES INST, DIV IMMUNOL DIS, BUNKYO KU, TOKYO 113, JAPAN; JAPANESE FDN CANC RES, INST CANC, DEPT CELL BIOL, TOSHIMA KU, TOKYO 170, JAPAN	Saitama Medical University; Tokyo Institute of Psychiatry; University of Tokyo; Tokyo Medical & Dental University (TMDU); Japanese Foundation for Cancer Research	Takeshima, H (corresponding author), UNIV TOKYO, FAC MED, DEPT PHARMACOL, BUNKYO KU, HONGO 7-3-1, TOKYO 113, JAPAN.		Noda, Tetsuo/B-1667-2016; Tuluc, Petronel/C-2527-2011	Takeshima, Hiroshi/0000-0003-4525-3725				BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BRILLANTES AMB, 1994, CELL, V77, P513, DOI 10.1016/0092-8674(94)90214-3; CHRIST M, 1994, J IMMUNOL, V153, P1936; ENDO M, 1977, PHYSIOL REV, V57, P71, DOI 10.1152/physrev.1977.57.1.71; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FLEISCHER S, 1989, ANNU REV BIOPHYS BIO, V18, P333, DOI 10.1146/annurev.bb.18.060189.002001; FURUICHI T, 1994, J NEUROSCI, V14, P4794; GIANNINI G, 1995, J CELL BIOL, V128, P893, DOI 10.1083/jcb.128.5.893; GIANNINI G, 1992, SCIENCE, V257, P91, DOI 10.1126/science.1320290; HAKAMATA Y, 1994, FEBS LETT, V352, P206, DOI 10.1016/0014-5793(94)00955-4; HAKAMATA Y, 1992, FEBS LETT, V312, P229, DOI 10.1016/0014-5793(92)80941-9; INO M, 1989, J GEN PHYSIOL, V94, P363, DOI 10.1085/jgp.94.2.363; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; MCPHERSON PS, 1993, J BIOL CHEM, V268, P13765; MEISSNER G, 1994, ANNU REV PHYSIOL, V56, P485, DOI 10.1146/annurev.ph.56.030194.002413; MURAYAMA T, 1992, J BIOCHEM, V112, P514, DOI 10.1093/oxfordjournals.jbchem.a123931; Ottini L, 1996, BIOCHEM J, V315, P207, DOI 10.1042/bj3150207; OYAMADA H, 1994, J BIOL CHEM, V269, P17206; RIOS E, 1994, PHYSIOL REV, V71, P840; Southern E, 1979, Methods Enzymol, V68, P152; SUTKO JL, 1991, J CELL BIOL, V113, P793, DOI 10.1083/jcb.113.4.793; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; TAKESHIMA H, 1995, EMBO J, V14, P2999, DOI 10.1002/j.1460-2075.1995.tb07302.x; TAKESHIMA H, 1994, NATURE, V369, P556, DOI 10.1038/369556a0; TIMERMAN AP, 1993, J BIOL CHEM, V268, P22992; ZHANG YX, 1994, BRAIN RES, V658, P127, DOI 10.1016/S0006-8993(09)90018-X	26	147	152	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					19649	19652		10.1074/jbc.271.33.19649	http://dx.doi.org/10.1074/jbc.271.33.19649			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702664	hybrid			2022-12-25	WOS:A1996VC66900005
J	Wolfe, AM; Wray, S; Westphal, H; Radovick, S				Wolfe, AM; Wray, S; Westphal, H; Radovick, S			Cell-specific expression of the human gonadotropin-releasing hormone gene in transgenic animals	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMORTALIZED HYPOTHALAMIC NEURONS; GNRH MESSENGER-RNA; POU-DOMAIN; FEMALE RAT; TRANSCRIPTION FACTORS; INSITU HYBRIDIZATION; KALLMANN SYNDROME; ESTROGEN; LHRH; MOLECULES	We have previously demonstrated that 1131 base pairs (bp) of the human gonadotropin-releasing hormone (hGnRN) gene promoter can target simian virus 40 T antigen expression to GnRH neurons in transgenic mice. In these animals, GnRH neurons were transformed before they migrated to their final location in the rostral hypothalamus, complicating an analysis of cell-specific expression. To localize regions of the hGnRB promoter that are important for cell-specific expression, we created transgenic mice with various 5'-flanking regions of the hGnRH gene fused to the luciferase reporter gene, When 3828 or 1131 bp of the hGnRH promoter 5'-flanking DNA were used (-3828/+5LUC and -1131/+5LUC, respectively), luciferase expression in adult transgenic mice was observed in the rostral hypothalamus and olfactory tissues, regions which have been shown to be loci of GnRH-expressing neurons, Luciferase expression was not observed in other brain or peripheral tissues. Double-labeled in situ hybridization further demonstrated that luciferase expression was invariably colocalized with GnRH expression. When transgenic animals were created with a construct consisting of 484 bp of the hGnRH 5'-flanking DNA fused to the luciferase gene (-484/+5LUC), luciferase expression was not observed in the hypothalamus or in olfactory tissues. This is the first report localizing DNA sequences responsible for cell-specific expression of the GnRH gene in vivo.	CHILDRENS HOSP,DIV ENDOCRINOL,BOSTON,MA 02115; NINCDS,NIH,BETHESDA,MD 20892; NICHHD,NIH,BETHESDA,MD 20892	Harvard University; Boston Children's Hospital; National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)			Wray, Susan/AAT-2088-2021	wray, susan/0000-0001-7670-3915	NICHD NIH HHS [HD30040-02] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R29HD030040] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ADELMAN JP, 1986, P NATL ACAD SCI USA, V83, P179, DOI 10.1073/pnas.83.1.179; Barry J., 1985, Handbook of Chemical Neuroanatomy, V4, P166; BESECKE LM, 1994, ENDOCRINOLOGY, V135, P1621, DOI 10.1210/en.135.4.1621; BOND CT, 1989, MOL ENDOCRINOL, V3, P1257, DOI 10.1210/mend-3-8-1257; BOSMA MM, 1993, J MEMBRANE BIOL, V136, P85; CLARK ME, 1995, MOL CELL BIOL, V15, P6169; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DONG KW, 1993, MOL ENDOCRINOL, V7, P1654, DOI 10.1210/me.7.12.1654; DUTLOW CM, 1992, J CLIN INVEST, V90, P2496, DOI 10.1172/JCI116142; FRANCO B, 1991, NATURE, V353, P529, DOI 10.1038/353529a0; GORE AC, 1995, ENDOCRINOLOGY, V136, P879; HAYFLICK JS, 1989, NUCLEIC ACIDS RES, V17, P6403, DOI 10.1093/nar/17.15.6403; INGRAHAM HA, 1990, ANNU REV PHYSIOL, V52, P773; KELLY MJ, 1989, NEUROENDOCRINOLOGY, V49, P88, DOI 10.1159/000125095; KEPA JK, 1992, NUCLEIC ACIDS RES, V20, P1393, DOI 10.1093/nar/20.6.1393; KRSMANOVIC LZ, 1993, P NATL ACAD SCI USA, V90, P3908, DOI 10.1073/pnas.90.9.3908; LEGOUIS R, 1991, CELL, V67, P423, DOI 10.1016/0092-8674(91)90193-3; LI P, 1993, GENE DEV, V7, P2483, DOI 10.1101/gad.7.12b.2483; MALIK KF, 1991, ANAT REC, V231, P457, DOI 10.1002/ar.1092310408; MARKS DL, 1994, ENDOCRINOLOGY, V134, P1991, DOI 10.1210/en.134.5.1991; MASON AJ, 1986, SCIENCE, V234, P1366, DOI 10.1126/science.3024317; MELLON PL, 1990, NEURON, V5, P1, DOI 10.1016/0896-6273(90)90028-E; MULLER MM, 1988, NATURE, V336, P544, DOI 10.1038/336544a0; PARK O, 1990, ENDOCRINOLOGY, V127, P275; PETERSEN SL, 1995, ENDOCRINOLOGY, V136, P3604, DOI 10.1210/en.136.8.3604; RADOVICK S, 1991, J CLIN INVEST, V88, P1649, DOI 10.1172/JCI115479; RADOVICK S, 1991, P NATL ACAD SCI USA, V88, P3402, DOI 10.1073/pnas.88.8.3402; RADOVICK S, 1990, MOL ENDOCRINOL, V4, P476, DOI 10.1210/mend-4-3-476; ROBERTS JL, 1989, MOL BRAIN RES, V6, P127, DOI 10.1016/0169-328X(89)90046-6; ROSENFELD MG, 1991, GENE DEV, V5, P897, DOI 10.1101/gad.5.6.897; ROSIE R, 1990, J ENDOCRINOL, V124, P285, DOI 10.1677/joe.0.1240285; ROTHFELD J, 1989, MOL BRAIN RES, V6, P121, DOI 10.1016/0169-328X(89)90045-4; SCHWANZELFUKUDA M, 1989, MOL BRAIN RES, V6, P311, DOI 10.1016/0169-328X(89)90076-4; SEEBURG PH, 1987, RECENT PROG HORM RES, V43, P69; Silverman Ann-Judith, 1994, P1683; STURM RA, 1988, GENE DEV, V2, P1582, DOI 10.1101/gad.2.12a.1582; TORANZO D, 1989, MOL ENDOCRINOL, V3, P1748, DOI 10.1210/mend-3-11-1748; WEINER RI, 1993, HUM REPROD, V8, P13, DOI 10.1093/humrep/8.suppl_2.13; WETSEL WC, 1991, ENDOCRINOLOGY, V129, P1584, DOI 10.1210/endo-129-3-1584; WETSEL WC, 1993, ENDOCRINOLOGY, V132, P2360, DOI 10.1210/en.132.6.2360; WHYTE DB, 1995, MOL ENDOCRINOL, V9, P467, DOI 10.1210/me.9.4.467; WILSON TM, 1995, MOL ENDOCRINOL, V9, P44, DOI 10.1210/me.9.1.44; WRAY S, 1989, P NATL ACAD SCI USA, V86, P8132, DOI 10.1073/pnas.86.20.8132; ZOELLER RT, 1988, ENDOCRINOLOGY, V122, P2570, DOI 10.1210/endo-122-6-2570	44	49	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					20018	20023		10.1074/jbc.271.33.20018	http://dx.doi.org/10.1074/jbc.271.33.20018			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702719	hybrid			2022-12-25	WOS:A1996VC66900060
J	Xu, BXC; Wang, XZ; Darns, CJ; Kopchick, JJ				Xu, BXC; Wang, XZ; Darns, CJ; Kopchick, JJ			Growth hormone promotes the association of transcription factor STAT5 with the growth hormone receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE L-CELLS; TYROSINE-PHOSPHORYLATED PROTEINS; SIGNAL-TRANSDUCTION; CYTOKINE RECEPTORS; INTERFERON-GAMMA; GH RECEPTORS; DNA-BINDING; BETA-CHAIN; ACTIVATION; PROLACTIN	Members of the cytokine/growth hormone (GH)/prolactin receptor superfamily transduce signals by association and activation of JAK tyrosine kinases. For GH receptor (GHR), both JAK2 and the GHR undergo tyrosine phosphorylation upon GH stimulation. Also, GH has recently been shown to activate the transcription factor STAT5 by tyrosine phosphorylation. In the present study, we demonstrate that GH induces rapid tyrosine phosphorylation of different isoforms of STAT5 in mouse L cells stably transfected with a cDNA encoding porcine GHR (pGHR). In this cell system, STAT5 directly interacts with the GHR in a GH-dependent manner. Additionally, GH-induced tyrosine phosphorylation of STAT5 and the interaction of STATE with GHR can be observed in mouse 3T3-F442A cells which express endogenous mouse GHR. Interestingly; when cDNAs encoding the two mouse STAT5 homologs (STAT5A and STAT5B) were individually transfected into mouse L cells expressing pGHR, only STAT5A demonstrated the ability to interact with the pGHR and subsequently underwent GH-dependent tyrosine phosphorylation. STAT5B did not. Therefore, the GH-dependent interaction of a particular STATE with tyrosine-phosphorylated GHR may play an important role in GH-mediated signal transduction.	OHIO UNIV,EDISON BIOTECHNOL INST,KONNEKER RES LABS THE RIDGES,MOL & CELLULAR BIOL PROGRAM,ATHENS,OH 45701; OHIO UNIV,DEPT SCI BIOL,ATHENS,OH 45701; MASSACHUSETTS GEN HOSP,GENE THERAPY CTR,BOSTON,MA 02114	University System of Ohio; Ohio University; University System of Ohio; Ohio University; Harvard University; Massachusetts General Hospital								ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; BARAHMANDPOUR F, 1995, FEBS LETT, V360, P29, DOI 10.1016/0014-5793(95)00072-H; BAZAN JF, 1989, BIOCHEM BIOPH RES CO, V164, P788, DOI 10.1016/0006-291X(89)91528-3; CAMPBELL GS, 1994, P NATL ACAD SCI USA, V91, P5232, DOI 10.1073/pnas.91.12.5232; CHOW JC, 1996, IN PRESS ENDOCRINOLO; COSMAN D, 1990, TRENDS BIOCHEM SCI, V15, P265, DOI 10.1016/0968-0004(90)90051-C; FOSTER CM, 1988, BIOCHEMISTRY-US, V27, P326, DOI 10.1021/bi00401a049; FU XY, 1993, CELL, V74, P1135, DOI 10.1016/0092-8674(93)90734-8; FUJII H, 1995, P NATL ACAD SCI USA, V92, P5482, DOI 10.1073/pnas.92.12.5482; GOUILLEUX F, 1994, EMBO J, V13, P4361, DOI 10.1002/j.1460-2075.1994.tb06756.x; GREENLUND AC, 1994, EMBO J, V13, P1591, DOI 10.1002/j.1460-2075.1994.tb06422.x; Hansen LH, 1996, J BIOL CHEM, V271, P12669, DOI 10.1074/jbc.271.21.12669; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; KELLY PA, 1991, ENDOCR REV, V12, P235, DOI 10.1210/edrv-12-3-235; LAI CF, 1995, J BIOL CHEM, V270, P23254, DOI 10.1074/jbc.270.40.23254; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; MAHARAJAN P, 1993, EXPERIENTIA, V49, P980, DOI 10.1007/BF02125645; MEYER DJ, 1994, J BIOL CHEM, V269, P4701; MIYAJIMA A, 1992, ANNU REV IMMUNOL, V10, P295, DOI 10.1146/annurev.immunol.10.1.295; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; ONEAL KD, 1993, LYMPHOKINE CYTOK RES, V12, P309; PALLARD C, 1995, J BIOL CHEM, V270, P15942, DOI 10.1074/jbc.270.27.15942; Ram PA, 1996, J BIOL CHEM, V271, P5929, DOI 10.1074/jbc.271.10.5929; SILVA CM, 1993, ENDOCRINOLOGY, V132, P101, DOI 10.1210/en.132.1.101; SILVA CM, 1994, J BIOL CHEM, V269, P27532; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; STAHL N, 1993, CELL, V74, P587, DOI 10.1016/0092-8674(93)90506-L; STAHL N, 1995, SCIENCE, V267, P1350; TANNER JW, 1995, J BIOL CHEM, V270, P6523, DOI 10.1074/jbc.270.12.6523; UDDIN S, 1995, J BIOL CHEM, V270, P15938, DOI 10.1074/jbc.270.27.15938; VANDERKUUR JA, 1994, J BIOL CHEM, V269, P21709; VANDERKUUR JA, 1995, J BIOL CHEM, V270, P21738, DOI 10.1074/jbc.270.37.21738; WAKAO H, 1992, J BIOL CHEM, V267, P16365; WAKAO H, 1995, EMBO J, V14, P2527, DOI 10.1002/j.1460-2075.1995.tb07250.x; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; WANG XY, 1993, J BIOL CHEM, V268, P3573; WANG XZ, 1995, J BIOL CHEM, V270, P6261, DOI 10.1074/jbc.270.11.6261; WANG XZ, 1993, MOL CELL ENDOCRINOL, V94, P89, DOI 10.1016/0303-7207(93)90055-O; WANG XZ, 1994, P NATL ACAD SCI USA, V91, P1391, DOI 10.1073/pnas.91.4.1391; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; WOOD TJJ, 1995, J BIOL CHEM, V270, P9448, DOI 10.1074/jbc.270.16.9448; XU BC, 1995, RECEPTOR, V5, P105; ZHOU YH, 1994, RECEPTOR, V4, P143	43	45	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					19768	19773		10.1074/jbc.271.33.19768	http://dx.doi.org/10.1074/jbc.271.33.19768			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702683	hybrid			2022-12-25	WOS:A1996VC66900024
J	Deleersnijder, W; Hong, GZ; Cortvrindt, R; Poirier, C; Tylzanowski, P; Pittois, K; VanMarck, E; Merregaert, J				Deleersnijder, W; Hong, GZ; Cortvrindt, R; Poirier, C; Tylzanowski, P; Pittois, K; VanMarck, E; Merregaert, J			Isolation of markers for chondro-osteogenic differentiation using cDNA library subtraction - Molecular cloning and characterization of a gene belonging to a novel multigene family of integral membrane proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA DEGRADATION; MESENCHYMAL STEM-CELLS; MANDIBULAR CONDYLES; SECONDARY CARTILAGE; HUMAN BONE; HYBRIDIZATION; OSTEOBLASTS; CLONES; EXPRESSION; MOUSE	To identify novel marker molecules associated with chondro-osteogenic differentiation, we have set up a differential screening system based on a cDNA library subtraction in organ cultures of prenatal mouse mandibular condyles, Differential screening of a cDNA library constructed from in vitro cultured condyles allowed the isolation of a novel gene, named E25, Full-length E25 cDNA is predicted to encode a type II integral membrane protein of 263 amino acid residues, In situ hybridization experiments show that E25 is expressed in the outer perichondrial rim of the postnatal mandibular condyle, which contains the proliferating progenitor cells, but not in the deeper layers of the condyle containing the more differentiated chondroblasts and chondrocytes, Other cartilagenous tissues and their perichondrium were negative, Strong in situ hybridization signals were also detected on bone trabeculae of mature bone in tooth germs and in hair follicles, Northern blot analysis showed strong expression in osteogenic tissues, such as neonatal mouse calvaria, paws, tail, and in skin, This expression profile suggests that E25 could be a useful marker for chondro-osteogenic differentiation. Homology searches of DNA databanks showed that E25 belongs to a novel multigene family, containing three members both in man and mouse. The mouse E25 gene locus (Itm2) was mapped to the X chromosome.	UNIV ANTWERP,DEPT BIOCHEM,LAB MOL BIOTECHNOL,B-2610 WILRIJK,BELGIUM; UNIV ANTWERP,DEPT PATHOL,B-2610 WILRIJK,BELGIUM; NV INNOGENET,GHENT,BELGIUM; INST PASTEUR,UNITE GENET MAMMIFERES,F-75724 PARIS,FRANCE	University of Antwerp; University of Antwerp; Innogenetics NV; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris			Tylzanowski, Przemko/G-8881-2013	Tylzanowski, Przemko/0000-0003-0769-559X				AARONSON SA, 1968, J CELL PHYSIOL, V72, P141, DOI 10.1002/jcp.1040720208; AHRENS M, 1993, DNA CELL BIOL, V12, P871, DOI 10.1089/dna.1993.12.871; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BENAMI Y, 1993, CELL TISSUE RES, V271, P317, DOI 10.1007/BF00318618; BENNETT JH, 1991, J CELL SCI, V99, P131; BIANCO P, 1991, CALCIFIED TISSUE INT, V49, P421, DOI 10.1007/BF02555854; BREEN M, 1994, HUM MOL GENET, V3, P621, DOI 10.1093/hmg/3.4.621; BRUDER SP, 1994, J CELL BIOCHEM, V56, P283, DOI 10.1002/jcb.240560303; BRUDER SP, 1990, BONE, V11, P189, DOI 10.1016/8756-3282(90)90213-I; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CSERJESI P, 1995, DEVELOPMENT, V121, P1099; DENIS MG, 1992, INT J CANCER, V50, P930, DOI 10.1002/ijc.2910500619; FRIEMERT C, 1991, GENE, V103, P259, DOI 10.1016/0378-1119(91)90283-H; GLASSTONE S, 1968, NATURE, V220, P705, DOI 10.1038/220705a0; GRIGORIADIS AE, 1990, DEV BIOL, V142, P313, DOI 10.1016/0012-1606(90)90352-J; GRIGORIADIS AE, 1988, J CELL BIOL, V106, P2139, DOI 10.1083/jcb.106.6.2139; HALL BK, 1987, CLIN ORTHOP RELAT R, V225, P255; HAO Y, 1993, NATURE, V365, P764, DOI 10.1038/365764a0; Hong GZ, 1996, GENOMICS, V31, P295, DOI 10.1006/geno.1996.0051; KATAGIRI T, 1994, J CELL BIOL, V127, P1755, DOI 10.1083/jcb.127.6.1755; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LANAHAN A, 1992, MOL CELL BIOL, V12, P3919, DOI 10.1128/MCB.12.9.3919; LANSKE B, 1992, VERH DTSCH GES PATHO, V76, P377; LEE SW, 1991, P NATL ACAD SCI USA, V88, P2825, DOI 10.1073/pnas.88.7.2825; MONTAGUTELLI X, 1990, J HERED, V81, P490, DOI 10.1093/oxfordjournals.jhered.a111033; Murray P. D. F., 1965, Australian Journal of Zoology, V13, P351, DOI 10.1071/ZO9650351; OKAZAKI M, 1994, J BIOL CHEM, V269, P12092; PALAZZOLO MJ, 1989, NEURON, V3, P527, DOI 10.1016/0896-6273(89)90211-0; ROSEN V, 1994, J BONE MINER RES, V9, P1759; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; Sambrook J., 2002, MOL CLONING LAB MANU; SCHWEINFEST CW, 1992, INT J ONCOL, V1, P499; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SILBERMANN M, 1987, J CRAN GENET DEV BIO, V7, P59; SILBERMANN M, 1983, ANAT REC, V206, P373, DOI 10.1002/ar.1092060404; SINGER SJ, 1990, ANNU REV CELL BIOL, V6, P247, DOI 10.1146/annurev.cb.06.110190.001335; SIVE HL, 1988, NUCLEIC ACIDS RES, V16, P10937, DOI 10.1093/nar/16.22.10937; STEIN GS, 1993, ENDOCR REV, V14, P424, DOI 10.1210/er.14.4.424; STRAUSS PG, 1990, J CELL BIOL, V110, P1369, DOI 10.1083/jcb.110.4.1369; TAKESHITA S, 1993, BIOCHEM J, V294, P271, DOI 10.1042/bj2940271; TAYLOR SM, 1979, CELL, V17, P771, DOI 10.1016/0092-8674(79)90317-9; TEZUKA K, 1990, BIOCHEM BIOPH RES CO, V173, P246, DOI 10.1016/S0006-291X(05)81048-4; VINKKAPUHAKKA H, 1993, ARCH ORAL BIOL, V38, P49, DOI 10.1016/0003-9969(93)90154-E; VUORIO E, 1990, ANNU REV BIOCHEM, V59, P837, DOI 10.1146/annurev.bi.59.070190.004201; WALSH S, 1994, J BONE MINER RES, V9, P1687; WANG EA, 1993, GROWTH FACTORS, V9, P57, DOI 10.3109/08977199308991582; WAYE MMY, 1994, J CELL BIOCHEM, V54, P273, DOI 10.1002/jcb.240540303; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3; YEH WC, 1995, GENE DEV, V9, P168, DOI 10.1101/gad.9.2.168	51	91	97	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19475	19482		10.1074/jbc.271.32.19475	http://dx.doi.org/10.1074/jbc.271.32.19475			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702637	hybrid			2022-12-25	WOS:A1996VB68400071
J	Dong, LM; Weisgraber, KH				Dong, LM; Weisgraber, KH			Human apolipoprotein E4 domain interaction - Arginine 61 and glutamic acid 255 interact to direct the preference for very low density lipoproteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-PLASMA-LIPOPROTEINS; RECEPTOR-BINDING ACTIVITY; CORONARY HEART-DISEASE; ALZHEIMERS-DISEASE; E ISOFORMS; AQUEOUS-SOLUTION; E POLYMORPHISM; E APOPROTEIN; IN-VITRO; A-I	Human apolipoprotein (apo) E contains an amino- and a carboxyl-terminal domain, which are connected by a hinge region (approximately residues 165 to 215), The interaction of the two domains has been suggested to be responsible for the apoE4-binding preference for very low density lipoproteins (VLDL), In the absence of this interaction in apoE3, the preference is for high density lipoproteins (HDL), To exclude the possibility that the interaction of apoE with other apolipoproteins on the native particles may contribute to the isoform-specific preferences, VLDL like emulsion particles were incubated with apoE, and the lipid-bound apoE was separated from free apoE on a Superose 6 column, The apoE4 bound more effectively to these particles than did apoE3, indicating that the apoE4 preference for VLDL is due not to interactions with other apolipoproteins but to an intrinsic property of apoE4, likely related to domain interaction, Previously, arginine 61 was shown to be critical for the isoform preferences, suggesting that it interacted with an acidic residue(s) in the carboxyl terminus. Substitution of arginine 61 with lysine did not alter the preference of apoE4 for VLDL, demonstrating that a positive charge rather than a specific requirement for arginine is critical for domain interaction, To identify the acidic residue(s) in the carboxyl terminus interacting with arginine 61, the six acidic residues (244, 245, 255, 266, 270, and 271) in a region known to be important for both lipoprotein association and isoform-specific preferences were substituted individually with alanine in apoE4, Only substitution of glutamic acid 255 altered the preference of apoE4 from VLDL to HDL, indicating that this was the sole residue in the carboxyl terminus that interacts with arginine 61, The participation of the hinge region in domain interaction was examined with internal deletion mutants, Deletion of the residues 186-202 or 186-223, representing major portions of the hinge region, had no effect on the apoE4 preference for VLDL, This suggests that the hinge region may act as a spacer that connects the two domains, Further deletion into the carboxyl-terminal domain (to residue 244) results in a loss of apoE4 VLDL binding, These studies establish that interaction of arginine 61 and glutamic acid 255 mediates apoE4 domain interaction.	UNIV CALIF SAN FRANCISCO,GLADSTONE INST CARDIOVASC DIS,CARDIOVASC RES INST,SAN FRANCISCO,CA 94141; UNIV CALIF SAN FRANCISCO,DEPT PATHOL,SAN FRANCISCO,CA 94141	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041633] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL41633] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGGERBECK LP, 1988, J BIOL CHEM, V263, P6249; BELLOSTA S, 1995, J BIOL CHEM, V270, P27063, DOI 10.1074/jbc.270.45.27063; Bergeron N, 1996, J CLIN INVEST, V97, P65, DOI 10.1172/JCI118408; BOYLES JK, 1989, J CLIN INVEST, V83, P1015, DOI 10.1172/JCI113943; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; DAVIGNON J, 1988, ARTERIOSCLEROSIS, V8, P1, DOI 10.1161/01.ATV.8.1.1; DONG LM, 1994, J BIOL CHEM, V269, P22358; GIANTURCO SH, 1983, J BIOL CHEM, V258, P4526; GREGG RE, 1986, J CLIN INVEST, V78, P815, DOI 10.1172/JCI112645; IGNATIUS MJ, 1986, P NATL ACAD SCI USA, V83, P1125, DOI 10.1073/pnas.83.4.1125; INNERARITY TL, 1983, J BIOL CHEM, V258, P2341; INNERARITY TL, 1984, J BIOL CHEM, V259, P7261; INNERARITY TL, 1979, J BIOL CHEM, V254, P4186; LALAZAR A, 1988, J BIOL CHEM, V263, P3542; LALAZAR A, 1989, J BIOL CHEM, V264, P8447; MA JY, 1994, NATURE, V372, P92, DOI 10.1038/372092a0; Mahley Robert W., 1995, Current Opinion in Lipidology, V6, P86, DOI 10.1097/00041433-199504000-00005; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MULLER HW, 1985, SCIENCE, V228, P499, DOI 10.1126/science.3983637; NATHAN BP, 1994, SCIENCE, V264, P850, DOI 10.1126/science.8171342; NOLTE RT, 1992, BIOPHYS J, V63, P1221, DOI 10.1016/S0006-3495(92)81698-3; PITAS RE, 1987, J BIOL CHEM, V262, P14352; PITTMAN RC, 1987, J BIOL CHEM, V262, P2435; RALL SC, 1986, METHOD ENZYMOL, V128, P273; SANAN DA, 1994, J CLIN INVEST, V94, P860, DOI 10.1172/JCI117407; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; SEGREST JP, 1992, J LIPID RES, V33, P141; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SPOONER PJR, 1988, J BIOL CHEM, V263, P1444; STEINMETZ A, 1989, ARTERIOSCLEROSIS, V9, P405, DOI 10.1161/01.ATV.9.3.405; STENGARD JH, 1995, CIRCULATION, V91, P265, DOI 10.1161/01.CIR.91.2.265; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P8098, DOI 10.1073/pnas.90.17.8098; STRITTMATTER WJ, 1995, P NATL ACAD SCI USA, V92, P4725, DOI 10.1073/pnas.92.11.4725; TIRET L, 1994, ARTERIOSCLER THROMB, V14, P1617, DOI 10.1161/01.ATV.14.10.1617; UTERMANN G, 1979, CLIN GENET, V15, P63; WARDELL MR, 1989, J BIOL CHEM, V264, P21205; WEINTRAUB MS, 1987, J CLIN INVEST, V80, P1571, DOI 10.1172/JCI113243; WEISGRABER KH, 1994, CURR OPIN STRUC BIOL, V4, P507, DOI 10.1016/S0959-440X(94)90212-7; WEISGRABER KH, 1983, J BIOL CHEM, V258, P2348; WEISGRABER KH, 1990, J LIPID RES, V31, P1503; WEISGRABER KH, 1981, J BIOL CHEM, V256, P9077; WEISGRABER KH, 1994, ADV PROTEIN CHEM, V45, P249; WEISGRABER KH, 1996, IN PRESS FASEB J; WESTERLUND JA, 1993, J BIOL CHEM, V268, P15745; WETTERAU JR, 1988, J BIOL CHEM, V263, P6240; WILSON PWF, 1995, CLIN CHEM, V41, P165; WISNIEWSKI T, 1994, AM J PATHOL, V145, P1030	47	256	263	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19053	19057		10.1074/jbc.271.32.19053	http://dx.doi.org/10.1074/jbc.271.32.19053			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702576	hybrid			2022-12-25	WOS:A1996VB68400010
J	Faber, C; Lindemann, A; Sticht, H; Ejchart, A; Kungl, A; Susani, M; Frank, RW; Kraft, D; Breitenbach, M; Rosch, P				Faber, C; Lindemann, A; Sticht, H; Ejchart, A; Kungl, A; Susani, M; Frank, RW; Kraft, D; Breitenbach, M; Rosch, P			Secondary structure and tertiary fold of the birch pollen allergen Bet v 1 in solution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR MAGNETIC-RESONANCE; 3-DIMENSIONAL NMR-SPECTROSCOPY; MULTIPLE QUANTUM COHERENCE; COMMON AMINO-ACIDS; STRUCTURE PREDICTION; DISTANCE GEOMETRY; CHEMICAL-SHIFTS; MAJOR ALLERGEN; PROTEIN STRUCTURES; HETERONUCLEAR NMR	Bet v 1 is the major birch pollen allergen and therefore the main cause of type I allergies observed in early spring. It is composed of 159 amino acid residues adding up to a molecular mass of 17 kDa. We determined the secondary structure and tertiary fold of full-length Bet v 1 by NMR spectroscopy. Two- and three-dimensional NMR measurements suggest that Bet v 1 is a globular monomer in solution with a high content of well defined secondary structure. Of the total of 159 residues, 135 could be sequentially assigned, using an improved assignment strategy based mainly on heteronuclear experiments. An improved strategy for structure calculation revealed three helices and two beta-sheets as major elements of secondary structure. The globular tertiary structure is mainly stabilized by two antiparallel beta-sheets, The two helices at the C terminus are in accordance with the results from the solution structure of the chemically synthesized peptide Bet v 1-(125-154). This peptide is composed of two helices connected by a hinge. The structural features of Bet v 1 are highly similar to those found in the Ambrosia allergen Amb t V.	UNIV BAYREUTH,LEHRSTUHL BIOPOLYMERE,D-95447 BAYREUTH,GERMANY; SALZBURG UNIV,INST BIOL ALLGEMEINE GENET,A-5020 SALZBURG,AUSTRIA; ZENTRUM MOL BIOL,ZMBH,D-69120 HEIDELBERG,GERMANY; ADV BIOL SYST,A-5020 SALZBURG,AUSTRIA; SANDOZ INST MED RES,A-1235 VIENNA,AUSTRIA; INST ALLGEMEINE & EXPT PATHOL,A-1090 VIENNA,AUSTRIA	University of Bayreuth; Salzburg University; Ruprecht Karls University Heidelberg; Novartis; Sandoz			Rösch, Paul/I-5445-2014; Faber, Cornelius/Q-2689-2016	Rösch, Paul/0000-0003-3330-2446; Faber, Cornelius/0000-0001-7683-7710; Sticht, Heinrich/0000-0001-5644-045X; Kungl, Andreas/0000-0003-3362-797X				BAX A, 1983, J MAGN RESON, V55, P301, DOI 10.1016/0022-2364(83)90241-X; BREITENEDER H, 1992, J ALLERGY CLIN IMMUN, V90, P909, DOI 10.1016/0091-6749(92)90463-C; BREITENEDER H, 1993, EUR J BIOCHEM, V212, P355, DOI 10.1111/j.1432-1033.1993.tb17669.x; BREITENEDER H, 1989, EMBO J, V8, P1935, DOI 10.1002/j.1460-2075.1989.tb03597.x; BRUNGER AT, 1993, XPLOR 3 1 MANUAL; CLORE GM, 1987, BIOCHEMISTRY-US, V26, P8012, DOI 10.1021/bi00398a069; DELEAGE G, 1987, PROTEIN ENG, V1, P289, DOI 10.1093/protein/1.4.289; EBNER C, 1993, J IMMUNOL, V150, P1047; Ernst R.R., 1992, ANGEW CHEM, V104, P817; FERREIRA FD, 1993, J BIOL CHEM, V268, P19574; FESIK SW, 1989, BIOCHEM BIOPH RES CO, V159, P842, DOI 10.1016/0006-291X(89)90071-5; FESIK SW, 1988, J MAGN RESON, V78, P588, DOI 10.1016/0022-2364(88)90144-8; Frank R., 1988, MODERN METHODS PROTE, V3, P41; GEOURJON C, 1994, PROTEIN ENG, V7, P157, DOI 10.1093/protein/7.2.157; GIBRAT JF, 1987, J MOL BIOL, V198, P425, DOI 10.1016/0022-2836(87)90292-0; GRONENBORN AM, 1989, FEBS LETT, V243, P93, DOI 10.1016/0014-5793(89)81224-4; GRONENBORN AM, 1989, BIOCHEMISTRY-US, V28, P5081, DOI 10.1021/bi00438a027; GUNTERT P, 1992, J MAGN RESON, V96, P403, DOI 10.1016/0022-2364(92)90095-O; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KRAULIS PJ, 1989, BIOCHEMISTRY-US, V28, P7241, DOI 10.1021/bi00444a016; LARSEN JN, 1992, MOL IMMUNOL, V29, P703, DOI 10.1016/0161-5890(92)90180-6; LEVIN JM, 1986, FEBS LETT, V205, P303, DOI 10.1016/0014-5793(86)80917-6; LINDEMANN A, 1995, THESIS U BAYREUTH GE; MARGALIT H, 1987, J IMMUNOL, V138, P2213; MARION D, 1983, BIOCHEM BIOPH RES CO, V113, P967, DOI 10.1016/0006-291X(83)91093-8; MARION D, 1989, J AM CHEM SOC, V111, P1515, DOI 10.1021/ja00186a066; MARION D, 1989, BIOCHEMISTRY-US, V28, P6150, DOI 10.1021/bi00441a004; METZLER WJ, 1992, BIOCHEMISTRY-US, V31, P5177; MULLER L, 1979, J AM CHEM SOC, V101, P4481; NELSON JW, 1989, BIOCHEMISTRY-US, V28, P5256, DOI 10.1021/bi00438a050; NILGES M, 1995, J MOL BIOL, V245, P645, DOI 10.1006/jmbi.1994.0053; QI PX, 1994, BIOCHEMISTRY-US, V33, P6408, DOI 10.1021/bi00187a004; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; ROST B, 1994, COMPUT APPL BIOSCI, V10, P53; ROST B, 1995, 3 INT C INT SYST MOL, P314; SCHMIDT JM, 1991, EUR J BIOCHEM, V197, P643, DOI 10.1111/j.1432-1033.1991.tb15954.x; SONNICHSEN FD, 1992, BIOCHEMISTRY-US, V31, P8790, DOI 10.1021/bi00152a015; WAGNER G, 1987, J MOL BIOL, V196, P611, DOI 10.1016/0022-2836(87)90037-4; WISHART DS, 1995, J BIOMOL NMR, V5, P67, DOI 10.1007/BF00227471; WISHART DS, 1992, BIOCHEMISTRY-US, V31, P1647, DOI 10.1021/bi00121a010; WUTHRICH K, 1983, J MOL BIOL, V169, P949, DOI 10.1016/S0022-2836(83)80144-2; Wuthrich K, 1986, NMR PROTEINS NUCL AC; ZHOU NE, 1992, J AM CHEM SOC, V114, P4320, DOI 10.1021/ja00037a042; ZUIDERWEG ERP, 1989, BIOCHEMISTRY-US, V28, P2387, DOI 10.1021/bi00432a008	44	26	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19243	19250		10.1074/jbc.271.32.19243	http://dx.doi.org/10.1074/jbc.271.32.19243			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702605	hybrid			2022-12-25	WOS:A1996VB68400039
J	Falla, TJ; Karunaratne, DN; Hancock, REW				Falla, TJ; Karunaratne, DN; Hancock, REW			Mode of action of the antimicrobial peptide indolicidin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPID BILAYER-MEMBRANES; PSEUDOMONAS-AERUGINOSA; OUTER-MEMBRANE; ANTIBACTERIAL PEPTIDES; ESCHERICHIA-COLI; BACTERICIDAL ACTIVITY; SECONDARY STRUCTURE; BOVINE NEUTROPHILS; MAGAININ-2 AMIDE; PIG INTESTINE	Indolicidin is a cationic antimicrobial peptide isolated from bovine neutrophils. It consists of only 13 amino acids, has the highest tryptophan content of any known protein, and is amidated at the carboxyl terminus in nature. By circular dichroism spectroscopy a weak poly-L-proline II extended helix structure was observed that became substantially more pronounced upon interaction with liposomes, Indolicidin bound purified surface lipopolysaccharide with high affinity and permeabilized the outer membrane of Escherichia coli to the small hydrophobic molecule 1-N-phenylnapthylamine (M(x) 200), results consistent with indolicidin crossing the outer membrane via the self-promoted uptake pathway. The methyl esterification of indolicidin's carboxyl terminus increased its activity for Gram-negative and Gram-positive bacteria, In Gram-negative bacteria this was associated with an increased binding to lipopolysaccharide and increased permeabilization of the outer membrane, The cytoplasmic membrane was the site of action of indolicidin as assayed in E. coli by the unmasking of cytoplasmic beta-galactosidase due to membrane permeabilization, The mechanism for this activity was shown to be the ability of the peptide to cause an increase in the transmembrane current of planar lipid bilayers, This current increase was activated by transmembrane potentials in excess of -70 to -80 mV. Consistent with this, there was a substantial decrease in indolicidin-mediated bacterial killing and permeabilization of the cytoplasmic membrane of E. coli that had been pretreated with the uncoupler carbonyl cyanide-m-chlorophenyl hydrazone, In planar bilayers, indolicidin induced the formation of discrete channels, which ranged in conductance from 0.05-0.15 nS. Thus despite the small size and unique composition of indolicidin, it was capable of killing Gram-negative bacteria by crossing the outer membrane and causing disruption of the cytoplasmic membrane by channel formation.	UNIV BRITISH COLUMBIA, DEPT MICROBIOL & IMMUNOL, VANCOUVER, BC V6T 1Z3, CANADA	University of British Columbia			Hancock, Robert E. W./E-1145-2013	Hancock, Robert E. W./0000-0001-5989-8503				AGERBERTH B, 1991, EUR J BIOCHEM, V202, P849, DOI 10.1111/j.1432-1033.1991.tb16442.x; AHMAD I, 1995, BBA-BIOMEMBRANES, V1237, P109, DOI 10.1016/0005-2736(95)00087-J; ALEY SB, 1994, INFECT IMMUN, V62, P5397, DOI 10.1128/IAI.62.12.5397-5403.1994; Amsterdam D., 1991, ANTIBIOTICS LAB MED, P72; ANGUS BL, 1982, ANTIMICROB AGENTS CH, V21, P299, DOI 10.1128/AAC.21.2.299; BENZ R, 1981, BIOCHIM BIOPHYS ACTA, V646, P298, DOI 10.1016/0005-2736(81)90336-9; BOHEIM G, 1974, J MEMBRANE BIOL, V19, P277, DOI 10.1007/BF01869983; BOMAN HG, 1993, INFECT IMMUN, V61, P2978, DOI 10.1128/IAI.61.7.2978-2984.1993; CABIAUX V, 1994, EUR J BIOCHEM, V224, P1019, DOI 10.1111/j.1432-1033.1994.01019.x; CHRISTENSEN B, 1988, P NATL ACAD SCI USA, V85, P5072, DOI 10.1073/pnas.85.14.5072; COCIANCICH S, 1993, J BIOL CHEM, V268, P19239; DAVID SA, 1992, BIOCHIM BIOPHYS ACTA, V1123, P269, DOI 10.1016/0005-2760(92)90006-H; FIELDS PI, 1989, SCIENCE, V243, P1059, DOI 10.1126/science.2646710; GENNARO R, 1989, INFECT IMMUN, V57, P3142, DOI 10.1128/IAI.57.10.3142-3146.1989; Hancock R E, 1995, Adv Microb Physiol, V37, P135, DOI 10.1016/S0065-2911(08)60145-9; HANCOCK REW, 1981, ANTIMICROB AGENTS CH, V19, P777, DOI 10.1128/AAC.19.5.777; HANCOCK REW, 1979, J BACTERIOL, V140, P902, DOI 10.1128/JB.140.3.902-910.1979; HILL CP, 1991, SCIENCE, V251, P1481, DOI 10.1126/science.2006422; JURETIC D, 1989, FEBS LETT, V249, P219, DOI 10.1016/0014-5793(89)80627-1; KADABA PK, 1972, SYNTH-INT J METHODS, P628; KAGAN BL, 1990, P NATL ACAD SCI USA, V87, P210, DOI 10.1073/pnas.87.1.210; KORDEL M, 1988, J BACTERIOL, V170, P84, DOI 10.1128/jb.170.1.84-88.1988; KREISWIRTH BN, 1983, NATURE, V305, P709, DOI 10.1038/305709a0; LEHRER RI, 1989, J CLIN INVEST, V84, P553, DOI 10.1172/JCI114198; LOH B, 1984, ANTIMICROB AGENTS CH, V26, P546, DOI 10.1128/AAC.26.4.546; MAYER LD, 1985, BIOCHIM BIOPHYS ACTA, V817, P193, DOI 10.1016/0005-2736(85)90084-7; MOORE RA, 1986, ANTIMICROB AGENTS CH, V29, P496, DOI 10.1128/AAC.29.3.496; PIERS KL, 1994, MOL MICROBIOL, V12, P951, DOI 10.1111/j.1365-2958.1994.tb01083.x; RAJ PA, 1995, FEBS LETT, V368, P526, DOI 10.1016/0014-5793(95)00712-I; RANA FR, 1990, FEBS LETT, V261, P464, DOI 10.1016/0014-5793(90)80616-Q; RICHMOND MH, 1976, ANTIMICROB AGENTS CH, V10, P215, DOI 10.1128/AAC.10.2.215; ROMEO D, 1988, J BIOL CHEM, V263, P9573; RONISH EW, 1974, BIOPOLYMERS, V13, P1635, DOI 10.1002/bip.1974.360130810; SAWYER JG, 1988, INFECT IMMUN, V56, P693, DOI 10.1128/IAI.56.3.693-698.1988; SCHINDLER PRG, 1975, ANTIMICROB AGENTS CH, V8, P95, DOI 10.1128/AAC.8.1.95; SCHLUESENER HJ, 1993, J NEUROIMMUNOL, V47, P199, DOI 10.1016/0165-5728(93)90030-3; SELSTED ME, 1992, J BIOL CHEM, V267, P4292; SKERLAVAJ B, 1990, INFECT IMMUN, V58, P3724, DOI 10.1128/IAI.58.11.3724-3730.1990; STEINER H, 1982, FEBS LETT, V137, P283, DOI 10.1016/0014-5793(82)80368-2; WEINSTEIN S, 1980, J MOL BIOL, V143, P1, DOI 10.1016/0022-2836(80)90121-7; ZASLOFF M, 1987, P NATL ACAD SCI USA, V84, P5449, DOI 10.1073/pnas.84.15.5449	41	380	412	2	64	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19298	19303		10.1074/jbc.271.32.19298	http://dx.doi.org/10.1074/jbc.271.32.19298			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702613	hybrid			2022-12-25	WOS:A1996VB68400047
J	King, SM; Barbarese, E; Dillman, JF; PatelKing, RS; Carson, JH; Pfister, KK				King, SM; Barbarese, E; Dillman, JF; PatelKing, RS; Carson, JH; Pfister, KK			Brain cytoplasmic and flagellar outer arm dyneins share a highly conserved M(r) 8,000 light chain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERMEDIATE CHAIN; CHLAMYDOMONAS FLAGELLA; POLYPEPTIDE COMPOSITION; RETROGRADE TRANSPORT; MOLECULAR ANALYSIS; PROTEIN; LOCALIZATION; PURIFICATION; MOTOR; IDENTIFICATION	Sequence comparisons with the M(r) 8,000 light chain from Chlamydomonas outer arm dynein revealed the presence of highly conserved homologues (up to 90% identity) in the expressed sequence tag data base (King, S. M. & Patel-King, R. S. (1995a) J. Biol. Chem. 270, 11445-11452). Several of these homologous sequences were derived from organisms and/or tissues that lack motile cilia/flagella, suggesting that these proteins may function in the cytoplasm. In Drosophila, lack of the homologous protein results in embryonic lethality (Dick, T., Ray, K., Salz, H. K. & Chia, W. (1996) Mol. Cell. Biol., 16, 1966-1977). Fractionation of mammalian brain homogenates reveals three distinct cytosolic pools of the homologous protein, one of which specifically copurifies with cytoplasmic dynein following both ATP-sensitive microtubule affinity/sucrose density gradient centrifugation and immunoprecipitation with a monoclonal antibody specific for the 74-kDa intermediate chain (IC74). Quantitative densitometry indicates that there is one copy of the M(r) 8,000 polypeptide per IC74. Dual channel confocal immunofluorescent microscopy revealed that the M(r) 8,000 protein is significantly colocalized with cytoplasmic dynein but not with kinesin in punctate structures (many of which are associated with microtubules) within mammalian oligodendrocytes. Thus, it appears that flagellar outer arm and brain cytoplasmic dyneins share a highly conserved light chain polypeptide that, at least in Drosophila, is essential for viability.	UNIV CONNECTICUT, CTR HLTH, DEPT NEUROL, FARMINGTON, CT 06032 USA; UNIV CONNECTICUT, CTR HLTH, CTR BIOMED IMAGING TECHNOL, FARMINGTON, CT 06032 USA; UNIV VIRGINIA, HLTH SCI CTR, DEPT CELL BIOL, CHARLOTTESVILLE, VA 22908 USA	University of Connecticut; University of Connecticut; University of Virginia	King, SM (corresponding author), UNIV CONNECTICUT, CTR HLTH, DEPT BIOCHEM, 263 FARMINGTON AVE, FARMINGTON, CT 06032 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051293] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS015190, R01NS019943, R56NS015190] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 51293] Funding Source: Medline; NINDS NIH HHS [NS 19943, NS 15190] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADAMS MD, 1995, NATURE, V377, P3; AINGER K, 1993, J CELL BIOL, V123, P431, DOI 10.1083/jcb.123.2.431; BARBARESE E, 1995, J CELL SCI, V108, P2781; BARKALOW K, 1994, J CELL BIOL, V126, P727, DOI 10.1083/jcb.126.3.727; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; Corthesy-Theulaz I, 1992, J CELL BIOL, V118, P1333, DOI [10.1083/jcb.118.6.1333, DOI 10.1083/JCB.118.6.1333]; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; Dick T, 1996, MOL CELL BIOL, V16, P1966; DILLMAN JF, 1994, J CELL BIOL, V127, P1671, DOI 10.1083/jcb.127.6.1671; GATTI JL, 1989, J BIOL CHEM, V264, P11450; GILL SR, 1994, MOL BIOL CELL, V5, P645, DOI 10.1091/mbc.5.6.645; HAYS TS, 1994, J CELL SCI, V107, P1557; Holzbaur Erika L. F., 1994, V13, P251; HUGHES SM, 1995, J CELL SCI, V108, P17; KARKI S, 1995, J BIOL CHEM, V270, P28806, DOI 10.1074/jbc.270.48.28806; KING SM, 1986, METHOD ENZYMOL, V134, P291; KING SM, 1995, J CELL SCI, V108, P3757; KING SM, 1990, J BIOL CHEM, V265, P19807; KING SM, 1995, J BIOL CHEM, V270, P11445, DOI 10.1074/jbc.270.19.11445; KING SM, 1991, J BIOL CHEM, V266, P8401; KING SM, 1995, J CELL BIOL, V131, P399, DOI 10.1083/jcb.131.2.399; King SM, 1989, CELL MOVEMENT DYNEIN, V1, P61; LI MG, 1994, J CELL BIOL, V126, P1475, DOI 10.1083/jcb.126.6.1475; LI YY, 1993, P NATL ACAD SCI USA, V90, P10096, DOI 10.1073/pnas.90.21.10096; Luck D.J.L., 1989, CELL MOVEMENT, V1, P49; MATSUKI Y, 1995, J DENT RES, V74, P307, DOI 10.1177/00220345950740010401; MERRIL CR, 1981, SCIENCE, V211, P1437, DOI 10.1126/science.6162199; MIKAMI A, 1993, NEURON, V10, P787, DOI 10.1016/0896-6273(93)90195-W; MITCHELL DR, 1986, CELL MOTIL CYTOSKEL, V6, P510, DOI 10.1002/cm.970060510; MITCHELL DR, 1994, INT REV CYTOL, V155, P141, DOI 10.1016/S0074-7696(08)62098-7; MITCHELL DR, 1991, J CELL BIOL, V113, P835, DOI 10.1083/jcb.113.4.835; MITCHELL DR, 1993, J CELL SCI, V105, P1069; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; OGAWA K, 1995, MOL BIOL CELL, V6, P685, DOI 10.1091/mbc.6.6.685; OLMSTED JB, 1986, METHOD ENZYMOL, V134, P467; PASCHAL BM, 1993, J BIOL CHEM, V268, P15318; PASCHAL BM, 1991, METHOD ENZYMOL, V196, P181; PASCHAL BM, 1987, NATURE, V330, P181, DOI 10.1038/330181a0; PASCHAL BM, 1992, J CELL BIOL, V118, P1133, DOI 10.1083/jcb.118.5.1133; PatelKing RS, 1996, J BIOL CHEM, V271, P6283, DOI 10.1074/jbc.271.11.6283; PFARR CM, 1990, NATURE, V345, P263, DOI 10.1038/345263a0; PFISTER KK, 1982, CELL MOTIL CYTOSKEL, V2, P525, DOI 10.1002/cm.970020604; Pfister KK, 1996, MOL BIOL CELL, V7, P331, DOI 10.1091/mbc.7.2.331; Pfister KK, 1996, J BIOL CHEM, V271, P1687, DOI 10.1074/jbc.271.3.1687; PFISTER KK, 1989, J CELL BIOL, V108, P1453, DOI 10.1083/jcb.108.4.1453; PFISTER KK, 1984, J BIOL CHEM, V259, P2072; PIPERNO G, 1979, J BIOL CHEM, V254, P3084; SALE WS, 1985, J CELL BIOL, V101, P1400, DOI 10.1083/jcb.101.4.1400; SAUNDERS WS, 1995, J CELL BIOL, V128, P617, DOI 10.1083/jcb.128.4.617; SCHROER TA, 1989, CELL, V56, P937, DOI 10.1016/0092-8674(89)90627-2; STEPHENS RE, 1992, J CELL SCI, V103, P999; STEUER ER, 1990, NATURE, V345, P266, DOI 10.1038/345266a0; VAUGHAN KT, 1995, J CELL BIOL, V131, P1507, DOI 10.1083/jcb.131.6.1507; Warner F.D., 1989, CELL MOVEMENT, V1; WILKERSON CG, 1995, J CELL BIOL, V129, P169, DOI 10.1083/jcb.129.1.169; WILKERSON CG, 1994, J CELL SCI, V107, P497; WITMAN GB, 1986, METHOD ENZYMOL, V134, P280; WITMAN GB, 1991, SERONO SYM, V75, P439; Witman George B., 1994, V13, P229; XIANG X, 1994, P NATL ACAD SCI USA, V91, P2100, DOI 10.1073/pnas.91.6.2100	60	187	191	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19358	19366		10.1074/jbc.271.32.19358	http://dx.doi.org/10.1074/jbc.271.32.19358			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702622	hybrid			2022-12-25	WOS:A1996VB68400056
J	Pickard, RT; Chiou, XG; Strifler, BA; DeFelippis, MR; Hyslop, PA; Tebbe, AL; Yee, YK; Reynolds, LJ; Dennis, EA; Kramer, RM; Sharp, JD				Pickard, RT; Chiou, XG; Strifler, BA; DeFelippis, MR; Hyslop, PA; Tebbe, AL; Yee, YK; Reynolds, LJ; Dennis, EA; Kramer, RM; Sharp, JD			Identification of essential residues for the catalytic function of 85-kDa cytosolic phospholipase A(2) - Probing the role of histidine, aspartic acid, cysteine, and arginine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; PLATELET-ACTIVATING-FACTOR; ACTIVE-SITE; SERINE PROTEASES; ESCHERICHIA-COLI; ACYL-TRANSFER; TRIAD FORMS; MECHANISM; HYDROLYSIS; LIPASE	Cytosolic phospholipase A(2) (cPLA(2)) hydrolyzes the sna-acyl ester bond of phospholipids and shows a preference for arachidonic acid-containing substrates. We found previously that Ser-228 is essential for enzyme activity and is likely to function as a nucleophile in the catalytic center of the enzyme (Sharp, J. D., White, D. L., Chiou, X. G., Goodson, T., Gamboa, G. C., McClure, D., Burgett, S., Hoskins, J., Skatrud, P. L., Sportsman, J. R., Becker, G. W., Kang, L. H., Roberts, E. F., and Kramer, R. M. (1991) J. Biol. Chem. 266, 14850-14853). cPLA, contains a catalytic aspartic acid motif common to the subtilisin family of serine proteases. Substitution within this motif of Ala for Asp-549 completely inactivated the enzyme, and substitutions with either glutamic acid or asparagine reduced activity 2000- and 300-fold, respectively. Additionally, using mutants with cysteine replaced by alanine, we found that Cys-331 is responsible for the enzyme's sensitivity to N-ethylmaleimide, Surprisingly, substituting alanine for any of the 19 histidines did not produce inactive enzyme, demonstrating that a classical serine-histidine-aspartate mechanism does not operate in this hydrolase. We found that substituting alanine or histidine for Arg-200 did produce inactive enzyme, while substituting lysine reduced activity 200-fold. Results obtained with the lysine mutant (R200K) and a coumarin ester substrate suggest no specific interaction between Arg-200 and the phosphoryl group of the phospholipid substrate. Arg-200, Ser-228, and Asp-549 are conserved in cPLA, from six species and also in four nonmammalian phospholipase B enzymes. Our results, supported by circular dichroism, provide evidence that Asp-549 and Arg-200 are critical to the enzyme's function and suggest that the cPLA(2) catalytic center is novel.	ELI LILLY & CO, LILLY CORP CTR, LILLY RES LABS, INDIANAPOLIS, IN 46285 USA; UNIV CALIF SAN DIEGO, DEPT CHEM & BIOCHEM, LA JOLLA, CA 92093 USA	Eli Lilly; University of California System; University of California San Diego			Dennis, Edward A./M-5554-2019	Dennis, Edward A./0000-0003-3738-3140	NIGMS NIH HHS [GM-51606] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABELES RH, 1992, BIOCHEMISTRY-US, P71; BARFORD D, 1991, J MOL BIOL, V218, P233, DOI 10.1016/0022-2836(91)90887-C; BECKER GW, 1994, BIO-TECHNOL, V12, P69, DOI 10.1038/nbt0194-69; BLOW D, 1990, NATURE, V343, P694, DOI 10.1038/343694a0; BONNER TI, 1988, NEURON, V1, P403, DOI 10.1016/0896-6273(88)90190-0; BRADY L, 1990, NATURE, V343, P767, DOI 10.1038/343767a0; CARMAN GM, 1995, J BIOL CHEM, V270, P18711, DOI 10.1074/jbc.270.32.18711; CARTER P, 1988, NATURE, V332, P764; CHEAH KC, 1990, J BIOL CHEM, V265, P7180; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; CLELAND WW, 1994, SCIENCE, V264, P1887, DOI 10.1126/science.8009219; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; Damblon C, 1996, P NATL ACAD SCI USA, V93, P1747, DOI 10.1073/pnas.93.5.1747; DAVIDSON FF, 1990, J MOL EVOL, V31, P228, DOI 10.1007/BF02109500; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; DUGGLEBY HJ, 1995, NATURE, V373, P264, DOI 10.1038/373264a0; DUPUREUR CM, 1990, J AM CHEM SOC, V112, P7074, DOI 10.1021/ja00175a060; FAUSTINELLA F, 1992, BIOCHEMISTRY-US, V31, P7219, DOI 10.1021/bi00147a002; FREY PA, 1994, SCIENCE, V264, P1927, DOI 10.1126/science.7661899; Genetic Computer Group, 1994, PROGR MAN WISC PACK; GERLT JA, 1993, BIOCHEMISTRY-US, V32, P11943, DOI 10.1021/bi00096a001; HANEL AM, 1995, BIOCHEMISTRY-US, V34, P7807, DOI 10.1021/bi00024a004; Huang Z, 1996, BIOCHEMISTRY-US, V35, P3712, DOI 10.1021/bi952541k; HUANG Z, 1994, ANAL BIOCHEM, V222, P110, DOI 10.1006/abio.1994.1461; HUTCHISON CA, 1978, J BIOL CHEM, V253, P6551; KANAYA S, 1990, BIOCHEM J, V271, P59, DOI 10.1042/bj2710059; KIM EE, 1991, J MOL BIOL, V218, P449, DOI 10.1016/0022-2836(91)90724-K; KRAMER RM, 1988, BIOCHIM BIOPHYS ACTA, V959, P269, DOI 10.1016/0005-2760(88)90200-7; KRAMER RM, 1991, J BIOL CHEM, V266, P5268; KRAMER RM, 1995, AGENT ACTION SUPPL, V46, P65; KUIPERS OP, 1990, PROTEIN ENG, V4, P199, DOI 10.1093/protein/4.2.199; KUMAR A, 1994, PROTEIN SCI, V3, P2082, DOI 10.1002/pro.5560031121; LESLIE CC, 1988, BIOCHIM BIOPHYS ACTA, V963, P476, DOI 10.1016/0005-2760(88)90316-5; LI B, 1994, BIOCHEMISTRY-US, V33, P8594, DOI 10.1021/bi00194a026; Li B, 1996, BIOCHEMISTRY-US, V35, P3156, DOI 10.1021/bi952141x; LIN LL, 1989, J MOL BIOL, V210, P439, DOI 10.1016/0022-2836(89)90121-6; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; LUGTIGHEID RB, 1993, EUR J BIOCHEM, V213, P517, DOI 10.1111/j.1432-1033.1993.tb17789.x; NALEFSKI EA, 1994, J BIOL CHEM, V269, P18239; PHILLIPS MA, 1990, J BIOL CHEM, V265, P20692; REYNOLDS LJ, 1993, BIOCHIM BIOPHYS ACTA, V1167, P272, DOI 10.1016/0005-2760(93)90229-3; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; SCHRAG JD, 1991, NATURE, V351, P761, DOI 10.1038/351761a0; SCOTT DL, 1990, SCIENCE, V250, P1541, DOI 10.1126/science.2274785; SHARP JD, 1991, J BIOL CHEM, V266, P14850; SHARP JD, 1994, J BIOL CHEM, V269, P23250; SIEZEN RJ, 1991, PROTEIN ENG, V4, P19; SLILATY SN, 1991, PROTEIN ENG, V4, P919, DOI 10.1093/protein/4.8.919; STRYNADKA NCJ, 1992, NATURE, V359, P700, DOI 10.1038/359700a0; SUSSMAN JL, 1991, SCIENCE, V253, P872, DOI 10.1126/science.1678899; TAMAI K, 1991, BIOCHEM BIOPH RES CO, V179, P790, DOI 10.1016/0006-291X(91)91886-H; TJOELKER LW, 1995, J BIOL CHEM, V270, P25481, DOI 10.1074/jbc.270.43.25481; TSCHANTZ WR, 1993, J BIOL CHEM, V268, P27349; VANDIJL JM, 1995, J BIOL CHEM, V270, P3611, DOI 10.1074/jbc.270.8.3611; VERHEIJ HM, 1980, BIOCHEMISTRY-US, V19, P743, DOI 10.1021/bi00545a021; WINKLER FK, 1990, NATURE, V343, P771, DOI 10.1038/343771a0; Yuan L, 1996, J BIOL CHEM, V271, P3417	57	93	96	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19225	19231		10.1074/jbc.271.32.19225	http://dx.doi.org/10.1074/jbc.271.32.19225			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702602	hybrid			2022-12-25	WOS:A1996VB68400036
J	Rana, A; Gallo, K; Godowski, P; Hirai, S; Ohno, S; Zon, L; Kyriakis, JM; Avruch, J				Rana, A; Gallo, K; Godowski, P; Hirai, S; Ohno, S; Zon, L; Kyriakis, JM; Avruch, J			The mixed lineage kinase SPRK phosphorylates and activates the stress-activated protein kinase activator, SEK-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAY; AMINO-TERMINAL KINASES; C-JUN; MAP KINASES; IDENTIFICATION; CASCADE; GTPASES; DOMAIN; CDC42; RAS	SPRK (also called PTK-1 and MLK-3), a member of the mixed lineage kinase subfamily of (Ser/Thr) protein kinases, encodes an amino-terminal SH3 domain followed by a kinase catalytic domain, two leucine zippers interrupted by a short spacer, a Rac/Cdc42 binding domain, and a long carboxyl-terminal proline-rich region. We report herein that SPRK activates the stress-activated protein kinases (SAPKs) but not ERK-1 during transient expression in COS cells; the p38 kinase is activated modestly (1.3-2 fold) but consistently. SPRK also activates cotransfected SEK 1/MKK-4, a dual specificity kinase which phosphorylates and activates SAPK. Reciprocally, expression of mutant, inactive SEK-1 inhibits completely the basal and SPRK-activated SAPK activity. Immunoprecipitated recombinant SPRK is able to phosphorylate and activate recombinant SEK-1 in vitro to an extent comparable to that achieved by MEK kinase-1. These results identify SPRK as a candidate upstream activator of the stress-activated protein kinases, acting through the phosphorylation and activation of SEK-1.	MASSACHUSETTS GEN HOSP,MED SERV,CHARLESTOWN,MA 02129; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115; MICHIGAN STATE UNIV,DEPT PHYSIOL,E LANSING,MI 48824; GENENTECH INC,DEPT BIOL MOL,S SAN FRANCISCO,CA 94080; YOKOHAMA CITY UNIV,SCH MED,DEPT BIOL MOL,KANAZAWA KU,YOKOHAMA,KANAGAWA 236,JAPAN; CHILDRENS HOSP,HOWARD HUGHES MED INST,BOSTON,MA 02115; CHILDRENS HOSP,DIV HEMATOL ONCOL,BOSTON,MA 02115; DANA FARBER CANC INST,BOSTON,MA 02115	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Michigan State University; Roche Holding; Genentech; Yokohama City University; Harvard University; Boston Children's Hospital; Howard Hughes Medical Institute; Harvard University; Boston Children's Hospital; Harvard University; Dana-Farber Cancer Institute	Rana, A (corresponding author), MASSACHUSETTS GEN HOSP,DIABET UNIT,149 13TH ST,CHARLESTOWN,MA 02129, USA.		Ohno, Shigeo/B-1768-2010; Rana, Ajay/ABE-3739-2020	Ohno, Shigeo/0000-0002-1294-5269; Rana, Ajay/0000-0003-0951-2566				AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; EZOE K, 1994, ONCOGENE, V9, P935; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; GALLO KA, 1994, J BIOL CHEM, V269, P15092; GILLE H, 1995, CURR BIOL, V5, P1191, DOI 10.1016/S0960-9822(95)00235-1; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Hirai S, 1996, ONCOGENE, V12, P641; HOLZMAN LB, 1994, J BIOL CHEM, V269, P30808; ING YL, 1994, ONCOGENE, V9, P1745; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MORIGUCHI T, 1995, J BIOL CHEM, V270, P12969, DOI 10.1074/jbc.270.22.12969; POMBO CM, 1995, NATURE, V377, P750, DOI 10.1038/377750a0; POMBO CM, 1994, J BIOL CHEM, V269, P26546; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; REDDY UR, 1994, BIOCHEM BIOPH RES CO, V202, P613, DOI 10.1006/bbrc.1994.1972; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; YAN MH, 1994, NATURE, V372, P798; ZERVOS AS, 1995, P NATL ACAD SCI USA, V92, P10531, DOI 10.1073/pnas.92.23.10531; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934	31	204	208	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19025	19028		10.1074/jbc.271.32.19025	http://dx.doi.org/10.1074/jbc.271.32.19025			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702571	Green Published, hybrid			2022-12-25	WOS:A1996VB68400005
J	Wilkins, JF; Bitensky, MW; Willardson, BM				Wilkins, JF; Bitensky, MW; Willardson, BM			Regulation of the kinetics of phosducin phosphorylation in retinal rods	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; PHOTO-EXCITED RHODOPSIN; BETA-GAMMA-SUBUNITS; OUTER SEGMENTS; PHOTOEXCITED RHODOPSIN; 48-KDA PROTEIN; PINEAL-GLAND; CYCLIC-GMP; LIGHT; BINDING	Phosducin (Pd) is a widely expressed phosphoprotein that regulates G-protein (G) signaling, Unphosphorylated Pd binds to G beta gamma subunits and blocks their interaction with G alpha, This binding sequesters G beta gamma and inhibits both receptor-mediated activation of G alpha and direct interactions between G beta gamma and effector enzymes. When phosphorylated by cAMP-dependent protein kinase, Pd does not affect these functions of G beta gamma. To further understand the role of Pd in regulating G-protein signaling in retinal rod photoreceptor cells, we have measured the abundance of Pd in rods and examined factors that control the rate of Pd phosphorylation, Pd is expressed at a copy number comparable to that for the rod G-protein, transducin (G(t)). The ratio of rhodopsin (Rho) to Pd is 15.5 +/- 3.5 to 1, The rate of Pd phosphorylation in rod outer segment preparations was dependent on [cAMP]. K-1/2 for cAMP was 0.56 +/- 0.09 mu M, and the maximal rate of phosphorylation was similar to 500 pmol PO4 incorporated/min/nmol Rho, In the presence of G(t) beta gamma this rate was decreased similar to 50-fold. From these data, one can estimate a t(1/2) of similar to 3 min for the rephosphorylation of Pd in rods during the recovery period after a light response. This relatively slow rephosphorylation of the Pd . G(t) beta gamma complex may provide a period of molecular memory in which sensitivity to further light stimuli is reduced as a result of sequestration of G(t) beta gamma by Pd.	LOS ALAMOS NATL LAB,DIV PHYS,BIOPHYS GRP,LOS ALAMOS,NM 87545	United States Department of Energy (DOE); Los Alamos National Laboratory			Wilkins, Jon/A-4984-2009	Wilkins, Jon/0000-0001-6405-6538; Willardson, Barry/0000-0002-8503-2268	NEI NIH HHS [EY 06816] Funding Source: Medline	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ABE T, 1990, GENE, V91, P209, DOI 10.1016/0378-1119(90)90090-E; BAEHR W, 1982, J BIOL CHEM, V257, P6452; BAUER PH, 1992, NATURE, V358, P73, DOI 10.1038/358073a0; BEEBE SJ, 1992, J BIOL CHEM, V267, P25505; BENNETT N, 1988, BIOCHEMISTRY-US, V27, P1710, DOI 10.1021/bi00405a049; BLAYZINSKI C, 1984, EXP EYE RES, V38, P279; BLAZYNSKI C, 1986, J BIOL CHEM, V261, P14142; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CHENG HC, 1986, J BIOL CHEM, V261, P989; COTE RH, 1984, J BIOL CHEM, V259, P9635; CRAFT CM, 1991, GENOMICS, V10, P400, DOI 10.1016/0888-7543(91)90325-9; DEVRIES GW, 1978, J NEUROCHEM, V31, P1345, DOI 10.1111/j.1471-4159.1978.tb06559.x; HAMM H, 1990, J GEN PHYSIOL, V95, P545, DOI 10.1085/jgp.95.3.545; HAMM HE, 1986, BIOCHEMISTRY-US, V25, P4512, DOI 10.1021/bi00364a010; HARGRAVE PA, 1992, FASEB J, V6, P2323, DOI 10.1096/fasebj.6.6.1544542; HAWES BE, 1994, J BIOL CHEM, V269, P29825; HAWKES R, 1982, ANAL BIOCHEM, V123, P143, DOI 10.1016/0003-2697(82)90634-0; HEKMAN M, 1994, FEBS LETT, V343, P120, DOI 10.1016/0014-5793(94)80302-1; KAWAMURA S, 1993, NATURE, V362, P855, DOI 10.1038/362855a0; KOCH KW, 1988, NATURE, V334, P64, DOI 10.1038/334064a0; KUHN H, 1981, P NATL ACAD SCI-BIOL, V78, P6873, DOI 10.1073/pnas.78.11.6873; KUO CH, 1993, BIOCHEM BIOPH RES CO, V191, P1097, DOI 10.1006/bbrc.1993.1329; KUO CH, 1989, MOL BRAIN RES, V6, P1, DOI 10.1016/0169-328X(89)90022-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE RH, 1990, J BIOL CHEM, V265, P15860; LEE RH, 1984, BIOCHEMISTRY-US, V23, P1972, DOI 10.1021/bi00304a014; LEE RH, 1992, J BIOL CHEM, V267, P25104; MCNAUGHTON PA, 1990, PHYSIOL REV, V70, P847, DOI 10.1152/physrev.1990.70.3.847; MIKI N, 1975, J BIOL CHEM, V250, P6320; NAKATANI K, 1988, J PHYSIOL-LONDON, V395, P731, DOI 10.1113/jphysiol.1988.sp016943; PFISTER C, 1983, EUR J BIOCHEM, V136, P489, DOI 10.1111/j.1432-1033.1983.tb07767.x; PFISTER C, 1985, SCIENCE, V228, P891, DOI 10.1126/science.2988124; SCHNETKAMP PPM, 1979, BIOCHIM BIOPHYS ACTA, V552, P379, DOI 10.1016/0005-2736(79)90182-2; STRYER L, 1991, J BIOL CHEM, V266, P10711; TAL M, 1985, J BIOL CHEM, V260, P9976; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; WILDEN U, 1986, P NATL ACAD SCI USA, V83, P1174, DOI 10.1073/pnas.83.5.1174; Willardson BM, 1996, P NATL ACAD SCI USA, V93, P1475, DOI 10.1073/pnas.93.4.1475; WOODRUFF ML, 1979, J GEN PHYSIOL, V73, P629, DOI 10.1085/jgp.73.5.629; XU J, 1995, P NATL ACAD SCI USA, V92, P2086, DOI 10.1073/pnas.92.6.2086; YOSHIDA T, 1994, J BIOL CHEM, V269, P24050	41	43	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19232	19237		10.1074/jbc.271.32.19232	http://dx.doi.org/10.1074/jbc.271.32.19232			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702603	hybrid			2022-12-25	WOS:A1996VB68400037
J	Kim, J; Parvin, JD; Shykind, BM; Sharp, PA				Kim, J; Parvin, JD; Shykind, BM; Sharp, PA			A negative cofactor containing Dr1/p19 modulates transcription with TFIIA in a promoter-specific fashion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; TATA-BINDING PROTEIN; SACCHAROMYCES-CEREVISIAE; GENE-TRANSCRIPTION; BASAL TRANSCRIPTION; GLOBAL REPRESSOR; TBP-BINDING; YEAST; DNA; COMPLEX	An activity that modulated the relative levels of transcription from the adenovirus major late promoter (MLP), and the immunoglobulin heavy chain mu promoter (mu) was purified as a 90-kDa factor, This factor is suggested to be a heterotetramer of two subunits: a 20-kDa polypeptide identical to the previously described Dr1/p19 and a novel 30-kDa polypeptide. The Dr1/p19 protein has been characterized as a repressor of transcription, and the 30-kDa protein is related to a recently identified yeast gene proposed to encode a repressor of transcription, The 90-kDa factor forms a complex with TATA-binding protein on DNA and at high concentrations of both factors protects over a 150-base pair region around the promoter from DNase I cleavage, The conformation of this complex as assayed by footprinting analysis is altered by the transcription factor TFIIA on the MLP but not on the mu promoter. Similarly, TFIIA reverses the repression of transcription by the 90-kDa factor on the MLP but not on the mu promoter, Thus, the interactions of TATA-binding protein, TFIIA, and the 90-kDa factor are promoter-specific.	MIT,CTR CANC RES,CAMBRIDGE,MA 02139; MIT,DEPT BIOL,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)			Parvin, Jeffrey D/C-8955-2009		NCI NIH HHS [P30-CA14051, P01-CA42063] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA014051, P01CA042063] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; AUBLE DT, 1994, GENE DEV, V8, P1920, DOI 10.1101/gad.8.16.1920; BAXEVANIS AD, 1995, NUCLEIC ACIDS RES, V23, P2685, DOI 10.1093/nar/23.14.2685; BURATOWSKI S, 1988, NATURE, V334, P37, DOI 10.1038/334037a0; BURATOWSKI S, 1994, CELL, V77, P1, DOI 10.1016/0092-8674(94)90226-7; CARTHEW RW, 1988, J BIOL CHEM, V263, P17128; CHASMAN DI, 1993, P NATL ACAD SCI USA, V90, P8174, DOI 10.1073/pnas.90.17.8174; CHEN S, 1993, GENETICS, V134, P701; COLLART MA, 1994, GENE DEV, V8, P525, DOI 10.1101/gad.8.5.525; Croston GE, 1993, CURR OPIN CELL BIOL, V5, P417, DOI 10.1016/0955-0674(93)90006-C; HIRSCHHORN JN, 1992, GENE DEV, V6, P2288, DOI 10.1101/gad.6.12a.2288; IMBALZANO AN, 1994, NATURE, V370, P481, DOI 10.1038/370481a0; INOSTROZA JA, 1992, CELL, V70, P477; KIM TK, 1995, J BIOL CHEM, V270, P10976, DOI 10.1074/jbc.270.18.10976; KOLESKE AJ, 1995, TRENDS BIOCHEM SCI, V20, P113, DOI 10.1016/S0968-0004(00)88977-X; KRAUS VB, 1994, P NATL ACAD SCI USA, V91, P6279, DOI 10.1073/pnas.91.14.6279; KWON H, 1994, NATURE, V370, P477, DOI 10.1038/370477a0; LEE NH, 1995, P NATL ACAD SCI USA, V92, P8303, DOI 10.1073/pnas.92.18.8303; MALDONADO E, 1995, CURR OPIN CELL BIOL, V7, P352, DOI 10.1016/0955-0674(95)80090-5; MCNABB DS, 1995, GENE DEV, V9, P47, DOI 10.1101/gad.9.1.47; MEISTERERNST M, 1991, CELL, V66, P981, DOI 10.1016/0092-8674(91)90443-3; MEISTERERNST M, 1991, CELL, V67, P557, DOI 10.1016/0092-8674(91)90530-C; MERINO A, 1993, NATURE, V365, P227, DOI 10.1038/365227a0; PARANJAPE SM, 1994, ANNU REV BIOCHEM, V63, P265, DOI 10.1146/annurev.biochem.63.1.265; PARVIN JD, 1994, J BIOL CHEM, V269, P18414; PARVIN JD, 1992, CELL, V68, P1135, DOI 10.1016/0092-8674(92)90084-P; SHYKIND BM, 1995, GENE DEV, V9, P1354, DOI 10.1101/gad.9.11.1354; SWANSON MS, 1992, GENETICS, V132, P325; THOMPSON CM, 1993, CELL, V73, P1361, DOI 10.1016/0092-8674(93)90362-T; THOMPSON CM, 1995, P NATL ACAD SCI USA, V92, P4587, DOI 10.1073/pnas.92.10.4587; TIMMERS HTM, 1991, GENE DEV, V5, P1946, DOI 10.1101/gad.5.11.1946; WINSTON F, 1992, TRENDS GENET, V8, P387, DOI 10.1016/0168-9525(92)90167-3; XING YY, 1993, EMBO J, V12, P4647, DOI 10.1002/j.1460-2075.1993.tb06153.x; YAMASHITA I, 1993, MOL GEN GENET, V241, P616, DOI 10.1007/BF00279904; YEUNG KC, 1994, GENE DEV, V8, P2097, DOI 10.1101/gad.8.17.2097; ZAWEL L, 1995, ANNU REV BIOCHEM, V64, P533	36	19	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18405	18412		10.1074/jbc.271.31.18405	http://dx.doi.org/10.1074/jbc.271.31.18405			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702484	hybrid			2022-12-25	WOS:A1996VB68300022
J	Gibbins, J; Asselin, J; Farndale, R; Barnes, M; Law, CL; Watson, SP				Gibbins, J; Asselin, J; Farndale, R; Barnes, M; Law, CL; Watson, SP			Tyrosine phosphorylation of the Fc receptor gamma-chain in collagen-stimulated platelets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WHEAT-GERM-AGGLUTININ; AFFINITY IGE RECEPTOR; GLYCOPROTEIN-IV; KINASE P72(SYK); PHOSPHOLIPASE C-GAMMA-2; CALCIUM MOBILIZATION; IMMUNOGLOBULIN-G; AGGREGATION; ACTIVATION; DEFICIENT	Stimulation of platelets by the extracellular matrix protein collagen leads to activation of a tyrosine kinase-dependent mechanism resulting in secretion and aggregation. Tyrosine phosphorylation of the tyrosine kinase Syk. and phospholipase C(gamma)2 are early events in collagen-induced activation. We recently proposed that collagen-signaling in platelets involves a receptor or a receptor-associated protein containing an immunoreceptor tyrosine based activation motif (ITAM) enabling interaction with Syk. In this report we show that collagen stimulation of platelets causes rapid tyrosine phosphorylation of the ITAM containing Fe receptor gamma-chain and that this is precipitated by the tandem Src homology 2 (SH2) domains of Syk expressed as a fusion protein. In addition we demonstrate an association between the Fc receptor gamma-chain with endogenous Syk in collagen stimulated platelets. The Fc receptor gamma-chain undergoes tyrosine phosphorylation in platelets stimulated by a collagen-related peptide which does not bind the integrin alpha(2) beta(1) and by the lectin wheat germ agglutinin. In contrast, cross-linking of the platelet low affinity receptor for immune complexes, Fc gamma RIIA, or stimulation by thrombin does not induce phosphorylation of the Fc receptor gamma-chain. The present results provide a molecular basis for collagen activation of platelets which is independent of the integrin alpha(2) beta(1) and involves phosphorylation of the Pc receptor gamma-chain, its association with Syk and subsequent phosphorylation of phospholipase C(gamma)2. Collagen is the first example of a nonimmune receptor stimulus to signal through a pathway closely related to signaling by immune receptors.	UNIV CAMBRIDGE,DEPT BIOCHEM,CAMBRIDGE CB2 1QW,ENGLAND; STRANGEWAYS RES LAB,CAMBRIDGE CB1 4RN,ENGLAND; UNIV WASHINGTON,DEPT MICROBIOL,SEATTLE,WA 98195	University of Cambridge; University of Washington; University of Washington Seattle	Gibbins, J (corresponding author), UNIV OXFORD,DEPT PHARMACOL,MANSFIELD RD,OXFORD OX1 3QT,ENGLAND.		Watson, Stephen P/Q-6292-2016	Watson, Stephen P/0000-0002-7846-7423; Gibbins, Jonathan/0000-0002-0372-5352	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BENHAMOU M, 1993, J BIOL CHEM, V268, P23318; BLAKE RA, 1994, FEBS LETT, V353, P212, DOI 10.1016/0014-5793(94)01037-4; CHACKO GW, 1994, J BIOL CHEM, V269, P32435; CHENG AM, 1995, NATURE, V378, P303, DOI 10.1038/378303a0; CHIANG TM, 1982, J BIOL CHEM, V257, P7581; DANIEL JL, 1994, BIOCHEM J, V302, P617, DOI 10.1042/bj3020617; DANIEL JL, 1994, THROMB HAEMOSTASIS, V71, P353; DECKMYN H, 1992, BLOOD, V79, P1466, DOI 10.1182/blood.V79.6.1466.bloodjournal7961466; DUCHEMIN AM, 1994, J BIOL CHEM, V269, P12111; DURDEN DL, 1994, BIOCHEM J, V299, P569, DOI 10.1042/bj2990569; EISEMAN E, 1992, NATURE, V355, P78; GANGULY CL, 1985, BIOCHEM BIOPH RES CO, V132, P313, DOI 10.1016/0006-291X(85)91024-1; GREENBERG S, 1994, J BIOL CHEM, V269, P3897; Higashihara M, 1985, FEBS Lett, V183, P433; INAZU T, 1991, BIOCHEM BIOPH RES CO, V174, P1154, DOI 10.1016/0006-291X(91)91541-J; JOHNSON SA, 1995, J IMMUNOL, V155, P4596; Jouvin M H, 1995, Semin Immunol, V7, P29, DOI 10.1016/1044-5323(95)90005-5; JOUVIN MHE, 1994, J BIOL CHEM, V269, P5918; KEHREL B, 1993, BLOOD, V82, P3364; KIHARA H, 1994, J BIOL CHEM, V269, P22427; LETOURNEUR O, 1991, J IMMUNOL, V147, P2652; MCKEOWN L, 1994, BLOOD, V83, P2866, DOI 10.1182/blood.V83.10.2866.2866; MOROI M, 1989, J CLIN INVEST, V84, P1440, DOI 10.1172/JCI114318; MORTON HC, 1995, J BIOL CHEM, V270, P29781; MORTON LF, 1995, BIOCHEM J, V306, P337, DOI 10.1042/bj3060337; OHTA S, 1992, BIOCHEM BIOPH RES CO, V185, P1128, DOI 10.1016/0006-291X(92)91743-A; PAOLINI R, 1995, J EXP MED, V181, P247, DOI 10.1084/jem.181.1.247; PAOLINI R, 1991, NATURE, V353, P855, DOI 10.1038/353855a0; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; RYO R, 1992, AM J HEMATOL, V39, P25, DOI 10.1002/ajh.2830390107; SANTORO SA, 1988, BIOCHEM BIOPH RES CO, V153, P217, DOI 10.1016/S0006-291X(88)81211-7; SHIUE L, 1995, MOL CELL BIOL, V15, P272, DOI 10.1128/MCB.15.1.272; TAKAI T, 1994, CELL, V76, P519, DOI 10.1016/0092-8674(94)90115-5; TANDON NN, 1989, J BIOL CHEM, V264, P7576; TANIGUCHI T, 1993, J BIOL CHEM, V268, P2277; TURNER M, 1995, NATURE, V378, P298, DOI 10.1038/378298a0; YANAGA F, 1995, BIOCHEM J, V311, P471, DOI 10.1042/bj3110471; YATOMI Y, 1993, BIOCHEM BIOPH RES CO, V191, P453, DOI 10.1006/bbrc.1993.1239	38	190	193	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					18095	18099		10.1074/jbc.271.30.18095	http://dx.doi.org/10.1074/jbc.271.30.18095			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663460	hybrid			2022-12-25	WOS:A1996UY93500076
J	Gu, HH; Ahn, J; Caplan, MJ; Blakely, RD; Levey, AI; Rudnick, G				Gu, HH; Ahn, J; Caplan, MJ; Blakely, RD; Levey, AI; Rudnick, G			Cell-specific sorting of biogenic amine transporters expressed in epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-BRAIN; HIPPOCAMPAL-NEURONS; UPTAKE SITES; MDCK CELLS; NOREPINEPHRINE TRANSPORTER; SUBSTANTIA-NIGRA; POLARIZED CELLS; DOPAMINE; SEROTONIN; COCAINE	We have utilized polarized epithelial cells stably expressing neurotransmitter transporters to analyze the sorting behavior of these membrane proteins. The transporters for serotonin (5-HT), dopamine (DA), and norepinephrine (NE) are expected to be present in situ in the most distal extremities of axonal membranes, where they terminate the action of their biogenic amine substrates. Both Madin-Darby canine kidney (MDCK) and LLC-PK1 cells were stably transfected with cDNAs encoding either the rat 5-HT transporter (SERT), the human NE transporter (NET), or the rat or human DA transporter (DAT), These cells were grown on permeable filter supports, and the transporters were localized by three independent techniques, Confocal immunofluorescence microscopy indicated that each of the transporters expressed in LLC-PK1 cells was sorted to the basolateral membrane, co-localizing with the Na+/K+-ATPase. In MDCK cells, however, DAT was located primarily on the apical surface, while SERT and NET were found on the basolateral membranes, Cell surface biotinylation using an impermeant biotinylating reagent confirmed the immunocytochemistry results, Thus, SERT and NET in MDCK cells were labeled more efficiently from the basolateral medium than the apical medium, and DAT in MDCK cells was labeled more efficiently from the apical side than the basolateral side, Transport measurements in transfected MDCK cells agreed with the immunocytochemistry and biotinylation results, These results suggest the existence of cell-specific mechanisms that discriminate between neurotransmitter transporters for surface expression and render unlikely any simple hypothesis that sorting mechanisms in neurons and epithelia are identical.	YALE UNIV, SCH MED, DEPT PHARMACOL, NEW HAVEN, CT 06510 USA; YALE UNIV, SCH MED, DEPT CELLULAR & MOLEC PHYSIOL, NEW HAVEN, CT 06510 USA; EMORY UNIV, SCH MED, DEPT ANAT & CELL BIOL, ATLANTA, GA 30322 USA; EMORY UNIV, SCH MED, DEPT NEUROL, ATLANTA, GA 30322 USA	Yale University; Yale University; Emory University; Emory University			Levey, Allan/F-2104-2011	Levey, Allan/0000-0002-3153-502X; Caplan, Michael/0000-0001-5768-4405	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042136] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA007390, R01DA008213] Funding Source: NIH RePORTER; NIDA NIH HHS [DA-07390, DA-08213] Funding Source: Medline; NIGMS NIH HHS [GM-42136] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahn J, 1996, J BIOL CHEM, V271, P6917, DOI 10.1074/jbc.271.12.6917; BALKOVETZ DF, 1989, J BIOL CHEM, V264, P2195; BARR LC, 1992, J CLIN PSYCHIAT, V53, P17; BERGER UV, 1992, EUR J PHARMACOL, V215, P153, DOI 10.1016/0014-2999(92)90023-W; BORDEN LA, 1992, J BIOL CHEM, V267, P21098; BUCK KJ, 1994, P NATL ACAD SCI USA, V91, P12584, DOI 10.1073/pnas.91.26.12584; CAPLAN M, 1989, FUNCTIONAL EPITHELIA, P71; CAPLAN MJ, 1986, CELL, V46, P623, DOI 10.1016/0092-8674(86)90888-3; CHERAMY A, 1981, NATURE, V289, P537, DOI 10.1038/289537a0; CHO AK, 1990, SCIENCE, V249, P631, DOI 10.1126/science.249.4969.631; CILIAX BJ, 1995, J NEUROSCI, V15, P1714, DOI 10.1523/JNEUROSCI.15-03-01714.1995; COPPEN AJ, 1990, J CLIN PSYCHIAT, V51, P3; DESOUZA EB, 1987, SYNAPSE, V1, P488, DOI 10.1002/syn.890010513; DOTTI CG, 1991, NATURE, V349, P158, DOI 10.1038/349158a0; DOTTI CG, 1990, CELL, V62, P63, DOI 10.1016/0092-8674(90)90240-F; GEFFEN LB, 1976, NATURE, V260, P258, DOI 10.1038/260258a0; GIROS B, 1994, J BIOL CHEM, V269, P15985; GOTTARDI CJ, 1995, AM J PHYSIOL-RENAL, V268, pF285, DOI 10.1152/ajprenal.1995.268.2.F285; GOTTARDI CJ, 1994, CURR TOP MEMBR, V41, P143, DOI 10.1016/S0070-2161(08)60458-X; GU H, 1994, J BIOL CHEM, V269, P7124; HAASS C, 1994, P NATL ACAD SCI USA, V91, P1564, DOI 10.1073/pnas.91.4.1564; Hersch S. M., 1995, Society for Neuroscience Abstracts, V21, P781; Lee F. J. S., 1995, Society for Neuroscience Abstracts, V21, P374; LITTLE KY, 1993, J NEUROCHEM, V61, P1996, DOI 10.1111/j.1471-4159.1993.tb07435.x; LOPEZIBOR JJ, 1992, INT CLIN PSYCHOPHARM, V7, P5, DOI 10.1097/00004850-199210002-00003; MELIKIAN HE, 1994, J BIOL CHEM, V269, P12290; NELSON N, 1994, J EXP BIOL, V196, P213; Nirenberg MJ, 1996, J NEUROSCI, V16, P436; PEREZVELAZQUEZ JL, 1993, NATURE, V361, P457, DOI 10.1038/361457a0; PIETRINI G, 1994, J BIOL CHEM, V269, P4668; PIETRINI G, 1992, P NATL ACAD SCI USA, V89, P8414, DOI 10.1073/pnas.89.18.8414; PIFL C, 1993, J NEUROSCI, V13, P4246, DOI 10.1523/jneurosci.13-10-04246.1993; QIAN Y, 1995, J NEUROSCI, V15, P1261; RADIAN R, 1990, J NEUROSCI, V10, P1319; RAMAMOORTHY S, 1993, BIOCHEMISTRY-US, V32, P1346, DOI 10.1021/bi00056a021; RICHFIELD EK, 1991, BRAIN RES, V540, P1, DOI 10.1016/0006-8993(91)90486-F; RITZ MC, 1987, SCIENCE, V237, P1219, DOI 10.1126/science.2820058; RODRIGUEZBOULAN E, 1989, SCIENCE, V245, P718, DOI 10.1126/science.2672330; RUDNICK G, 1993, BIOCHIM BIOPHYS ACTA, V1144, P249, DOI 10.1016/0005-2728(93)90109-S; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SARGIACOMO M, 1989, J MEMBRANE BIOL, V107, P277, DOI 10.1007/BF01871942; TATE CG, 1994, J BIOL CHEM, V269, P26303; TEJANIBUTT SM, 1992, J PHARMACOL EXP THER, V260, P427; VEYHL M, 1993, J BIOL CHEM, V268, P25041; YAMAUCHI A, 1991, AM J PHYSIOL, V261, pF197, DOI 10.1152/ajprenal.1991.261.1.F197	45	58	59	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					18100	18106		10.1074/jbc.271.30.18100	http://dx.doi.org/10.1074/jbc.271.30.18100			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663573	hybrid			2022-12-25	WOS:A1996UY93500077
J	Welihinda, AA; Kaufman, RJ				Welihinda, AA; Kaufman, RJ			The unfolded protein response pathway in Saccharomyces cerevisiae - Oligomerization and trans-phosphorylation of Ire1p (Ern1p) are required for kinase activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSE-REGULATED PROTEINS; ENDOPLASMIC-RETICULUM; TRANSMEMBRANE PROTEIN; SIGNAL-TRANSDUCTION; BINDING-PROTEIN; INDUCTION; YEAST; PHOSPHATASE; SEQUENCE; ENCODES	In eukaryotic cells, accumulation of unfolded proteins in the endoplasmic reticulum (ER) results in a transcriptional induction of a number of ER chaperone proteins. In Saccharomyces cerevisiae, the putative transmembrane receptor kinase, Ire1p (Ern1p), has been implicated as the sensor of unfolded proteins in the ER that initiates transmittance of the unfolded protein signal from the ER to the nucleus. We have shown that the cytoplasmic domain of Ire1p receptor indeed has intrinsic Ser/Thr kinase activity and contains Ser/Thr phosphorylation sites as well. The cytoplasmic domain is also shown to form oligomers in vivo and in vitro. The ability to form oligomers primarily resides within the last 130 amino acids of the cytoplasmic domain, a region that is dispensable for in vitro kinase activity of the receptor. Oligomerization of the cytoplasmic domains is required for receptor trans-phosphorylation and subsequent activation of the kinase function. The activated kinase may transmit the unfolded protein signal from the ER to the nucleus to activate the transcription of the chaperone genes in the nucleus.	UNIV MICHIGAN, MED CTR, DEPT BIOL CHEM, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, MED CTR, HOWARD HUGHES MED INST, ANN ARBOR, MI 48109 USA	University of Michigan System; University of Michigan; Howard Hughes Medical Institute; University of Michigan System; University of Michigan				Welihinda, Ajith/0000-0002-0049-0850				BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; COX JS, 1993, CELL, V73, P1197, DOI 10.1016/0092-8674(93)90648-A; DORNER AJ, 1989, J BIOL CHEM, V264, P20602; DORNER AJ, 1992, EMBO J, V11, P1562; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HARDWICK KG, 1990, EMBO J, V6, P620; Harlow E., 1988, ANTIBODIES LAB MANUA; IZUKA M, 1989, J BACTERIOL, V171, P6039; KOZUTSUMI Y, 1988, NATURE, V332, P462, DOI 10.1038/332462a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMANTIA M, 1991, P NATL ACAD SCI USA, V88, P4453, DOI 10.1073/pnas.88.10.4453; LEMMON MA, 1994, TRENDS BIOCHEM SCI, V19, P459, DOI 10.1016/0968-0004(94)90130-9; LI LJ, 1992, J CELL PHYSIOL, V153, P575, DOI 10.1002/jcp.1041530319; LINDBERG RA, 1992, TRENDS BIOCHEM SCI, V17, P114, DOI 10.1016/0968-0004(92)90248-8; MORI K, 1992, EMBO J, V11, P2583, DOI 10.1002/j.1460-2075.1992.tb05323.x; MORI K, 1993, CELL, V74, P743; NIKAWA JI, 1992, MOL MICROBIOL, V6, P1441, DOI 10.1111/j.1365-2958.1992.tb00864.x; NORMINGTON K, 1989, CELL, V57, P1223, DOI 10.1016/0092-8674(89)90059-7; OOI J, 1995, ONCOGENE, V10, P1621; PARTALEDIS JA, 1993, P NATL ACAD SCI USA, V90, P5450, DOI 10.1073/pnas.90.12.5450; PICCOLOMINI R, 1989, J GEN MICROBIOL, V135, P3119; ROSE MD, 1989, CELL, V57, P1211, DOI 10.1016/0092-8674(89)90058-5; Rowling P J, 1993, Subcell Biochem, V21, P41; Shamu Caroline E., 1994, Trends in Cell Biology, V4, P56, DOI 10.1016/0962-8924(94)90011-6; Sherman F., 1986, METHODS YEAST GENETI; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WILLIAMS FE, 1991, MOL CELL BIOL, V11, P3307, DOI 10.1128/MCB.11.6.3307	32	144	155	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					18181	18187		10.1074/jbc.271.30.18181	http://dx.doi.org/10.1074/jbc.271.30.18181			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663458	hybrid			2022-12-25	WOS:A1996UY93500089
J	Distelhorst, CW; Lam, M; McCormick, TS				Distelhorst, CW; Lam, M; McCormick, TS			Bcl-2 inhibits hydrogen peroxide-induced ER Ca2+ pool depletion	ONCOGENE			English	Article						Bcl-2; oxygen radical; apoptosis; programmed cell death; calcium; thapsigargin	PROGRAMMED CELL-DEATH; INTRACELLULAR CALCIUM HOMEOSTASIS; C-FOS; ENDOPLASMIC-RETICULUM; MEMBRANE PROTEIN; CIS-FOS; EXPRESSION; TRANSLOCATION; APOPTOSIS; DNA	The mechanism by which Bcl-2 inhibits apoptosis is unknown, The Bcl-2 protein is localized to intracellular membranes, including the endoplasmic reticulum (ER), The ER is the major intracellular reservoir of Ca2+ in non-muscle cells, sequestering Ca2+ for use in intracellular signaling, and is a prime target of oxidative damage, Because of the recent suggestion that Bcl-2 acts in an antioxidant pathway, we wondered whether Bcl-2 might protect the ER Ca2+ pool in cells exposed to reactive oxygen species. To test this hypothesis, we assessed the effect of hydrogen peroxide (H2O2) treatment on the ER Ca2+ pool in WEH17.2 cells, which do not express Bcl-2, and two stable transfectants, W.Hb13 and W.Hb12, The Bcl-2 level by Western blotting is 4-fold higher in W.Hb12 cells compared to W.Hb13 cells, The ER Ca2+ pool in H2O2-treated and untreated cells was measured according to the amount of Ca2+ mobilized from the ER lumen into the cytoplasm by thapsigargin (TG), a selective inhibitor of the ER Ca2+-ATPase, H2O2 treatment produced a significant reduction in the TG-mobilizable Ca2+ pool in WEH17.2 and W.Hb13 cells, but not in W.Hb12 cells, indicating that overexpression of Bcl-2 preserves the integrity of the ER Ca2+ pool in cells exposed to reactive oxygen species.	CASE WESTERN RESERVE UNIV, DEPT PHARMACOL, CLEVELAND, OH 44106 USA	Case Western Reserve University	Distelhorst, CW (corresponding author), CASE WESTERN RESERVE UNIV, SCH MED, DEPT MED, BRB329, 10900 EUCLID AVE, CLEVELAND, OH 44106 USA.			McCormick, Thomas/0000-0002-3294-0326	NCI NIH HHS [T32 CA59366, R01 CA42755-08] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042755, T32CA059366] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALNEMRI ES, 1992, P NATL ACAD SCI USA, V89, P7295, DOI 10.1073/pnas.89.16.7295; BAFFY G, 1993, J BIOL CHEM, V268, P6511; BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; BROSTROM CO, 1990, ANNU REV PHYSIOL, V52, P577; BUTTKE TM, 1994, IMMUNOL TODAY, V15, P7, DOI 10.1016/0167-5699(94)90018-3; CARAFOLI E, 1987, ANNU REV BIOCHEM, V56, P395, DOI 10.1146/annurev.biochem.56.1.395; CHENLEVY Z, 1989, MOL CELL BIOL, V9, P701, DOI 10.1128/MCB.9.2.701; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; COHEN JJ, 1991, ADV IMMUNOL, V50, P55; COLOTTA F, 1992, J BIOL CHEM, V267, P18278; COWAN WM, 1984, SCIENCE, V225, P1258, DOI 10.1126/science.6474175; CRAWFORD D, 1988, ONCOGENE, V3, P27; DUBYAK GR, 1986, ARCH BIOCHEM BIOPHYS, V245, P84, DOI 10.1016/0003-9861(86)90192-X; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HALLIWELL B, 1984, BIOCHEM J, V219, P1, DOI 10.1042/bj2190001; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; JACOBSON MD, 1995, NATURE, V374, P814, DOI 10.1038/374814a0; JACOBSON MD, 1993, NATURE, V361, P365, DOI 10.1038/361365a0; JIANG S, 1994, EXP CELL RES, V212, P84, DOI 10.1006/excr.1994.1121; JONES DP, 1983, J BIOL CHEM, V258, P6390; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; LAM M, 1993, MOL ENDOCRINOL, V7, P686, DOI 10.1210/me.7.5.686; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; LODISH HF, 1992, J BIOL CHEM, V267, P12753; MIYASHITA T, 1992, CANCER RES, V52, P5407; MONAGHAN P, 1992, J HISTOCHEM CYTOCHEM, V40, P1819, DOI 10.1177/40.12.1453000; MUSCHEL RJ, 1995, CANCER RES, V55, P995; ORRENIUS S, 1992, ANN NEUROL, V32, pS33, DOI 10.1002/ana.410320708; REED DJ, 1990, CHEM RES TOXICOL, V3, P495, DOI 10.1021/tx00018a002; RENARD DC, 1992, BIOCHEM J, V284, P507, DOI 10.1042/bj2840507; SCHONTHAL A, 1991, P NATL ACAD SCI USA, V88, P7096, DOI 10.1073/pnas.88.16.7096; SHIBANUMA M, 1988, ONCOGENE, V3, P17; SHIMIZU S, 1995, NATURE, V374, P811, DOI 10.1038/374811a0; SHORT AD, 1993, P NATL ACAD SCI USA, V90, P4986, DOI 10.1073/pnas.90.11.4986; SMEYNE RJ, 1993, NATURE, V363, P166, DOI 10.1038/363166a0; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; VAUX DL, 1993, P NATL ACAD SCI USA, V90, P786, DOI 10.1073/pnas.90.3.786; WERLEN G, 1993, J BIOL CHEM, V268, P16596; ZEHAVA CL, 1990, J BIOL CHEM, V265, P4929; ZHONG LT, 1993, P NATL ACAD SCI USA, V90, P4533, DOI 10.1073/pnas.90.10.4533	44	96	101	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 16	1996	12	10					2051	2055						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UP283	8668330				2022-12-25	WOS:A1996UP28300003
J	Chen, Y; Houghton, LA; Brenna, JT; Noy, N				Chen, Y; Houghton, LA; Brenna, JT; Noy, N			Docosahexaenoic acid modulates the interactions of the interphotoreceptor retinoid-binding protein with 11-cis-retinal	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PIGMENT-EPITHELIUM; FATTY-ACIDS; LIPID BILAYERS; PHOTORECEPTORS; PURIFICATION; AFFINITIES; RHODOPSIN; MECHANISM; VESICLES; RELEASE	Rapid transport of retinoids across the interphotoreceptor matrix is a critical part of the visual cycle, since it serves to replenish bleached rhodopsin with its chromophore 11-cis-retinal. The transport of retinoids in the interphotoreceptor matrix is believed to be mediated by the interphotoreceptor retinoid-binding protein (IRBP), a protein that, in addition to possessing two retinoid-binding sites, associates in vivo with long chain fatty acids. Here, the interrelationships between binding of the two types of ligands to IRBP were studied, The composition of fatty acids associated with IRBP in bovine retina was determined, and it was found that polyunsaturated fatty acids constitute a significant fraction of those, It was further found that docosahexaenoic acid, but not palmitic acid, induced a rapid and specific release of 11-cis-retinal from one of the protein's retinoid-binding sites, Based on these results and on the additional observation that a steep concentration gradient of docosahexaenoic acid exists between photoreceptor and pigment epithelium cells, a model for the mechanism by which IRBP may target 11-cis-retinal to photoreceptor cells is proposed.	CORNELL UNIV,DIV NUTR SCI,ITHACA,NY 14853	Cornell University			Brenna, James T/A-4167-2008	Brenna, James Thomas/0000-0001-9494-4245	NEI NIH HHS [F32 EY06575, EY09296] Funding Source: Medline; NATIONAL EYE INSTITUTE [F32EY006575, R01EY009296] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ADLER AJ, 1991, EXP EYE RES, V53, P337, DOI 10.1016/0014-4835(91)90239-B; ADLER AJ, 1985, INVEST OPHTH VIS SCI, V26, P273; ANDERSON RE, 1976, EXP EYE RES, V23, P9; BAZAN NG, 1985, J BIOL CHEM, V260, P3677; CARLSON A, 1992, BIOCHEMISTRY-US, V31, P9056, DOI 10.1021/bi00152a049; CHEN HM, 1992, EXP EYE RES, V55, P93, DOI 10.1016/0014-4835(92)90097-C; CHEN Y, 1993, BIOCHEMISTRY-US, V32, P11311, DOI 10.1021/bi00093a007; CHEN Y, 1994, BIOCHEMISTRY-US, V33, P10658, DOI 10.1021/bi00201a013; COGAN U, 1976, EUR J BIOCHEM, V65, P71, DOI 10.1111/j.1432-1033.1976.tb10390.x; CONNORS KA, 1987, BINDING CONSTANTS, P175; CROUCH RK, 1992, PHOTOCHEM PHOTOBIOL, V56, P251, DOI 10.1111/j.1751-1097.1992.tb02154.x; DANIELS C, 1985, BIOCHEMISTRY-US, V24, P3286, DOI 10.1021/bi00334a032; Dittmer J, 1969, METHOD ENZYMOL, V14, P482, DOI [DOI 10.1016/S0076-6879(69)14055-0, 10.1016/S0076-6879(69)14055-0]; FLANNERY JG, 1990, EXP EYE RES, V51, P717, DOI 10.1016/0014-4835(90)90057-2; FLEISLER SJ, 1983, PROG LIPID RES, V22, P79; FONG SL, 1984, J BIOL CHEM, V259, P6534; HO MTP, 1989, J BIOL CHEM, V264, P928; JONES GJ, 1989, P NATL ACAD SCI USA, V86, P9606, DOI 10.1073/pnas.86.23.9606; KAMP F, 1995, BIOCHEMISTRY-US, V34, P11928, DOI 10.1021/bi00037a034; LEE RH, 1982, METHOD ENZYMOL, V81, P496; NORRIS AW, 1994, BBA-PROTEIN STRUCT M, V1209, P10, DOI 10.1016/0167-4838(94)90130-9; NOY N, 1990, BIOCHEMISTRY-US, V29, P3878, DOI 10.1021/bi00468a012; NOY N, 1991, BIOCHEMISTRY-US, V30, P6380, DOI 10.1021/bi00240a005; NOY N, 1990, BIOCHEMISTRY-US, V29, P3883, DOI 10.1021/bi00468a013; NOY N, 1995, J LIPID RES, V36, P375; OKAJIMA TIL, 1989, EXP EYE RES, V49, P629, DOI 10.1016/S0014-4835(89)80059-4; OKAJIMA TIL, 1990, P NATL ACAD SCI USA, V87, P6907, DOI 10.1073/pnas.87.17.6907; OKAJIMA TIL, 1994, J BIOL CHEM, V269, P21983; Ong D, 1980, Methods Enzymol, V67, P288; OTTONELLO S, 1984, CURR EYE RES, V3, P1085, DOI 10.3109/02713688409000806; PEPPERBERG DR, 1993, MOL NEUROBIOL, V7, P61, DOI 10.1007/BF02780609; ROYER CA, 1992, METHOD ENZYMOL, V210, P481; SAARI JC, 1985, J BIOL CHEM, V260, P195; SAARI JC, 1988, EXP EYE RES, V44, P569; Saari John C., 1994, P351	35	62	70	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20507	20515		10.1074/jbc.271.34.20507	http://dx.doi.org/10.1074/jbc.271.34.20507			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702792	hybrid			2022-12-25	WOS:A1996VD33700044
J	Hamelryck, TW; DaoThi, MH; Poortmans, F; Chrispeels, MJ; Wyns, L; Loris, R				Hamelryck, TW; DaoThi, MH; Poortmans, F; Chrispeels, MJ; Wyns, L; Loris, R			The crystallographic structure of phytohemagglutinin-L	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE DETERMINATION; BEANS PHASEOLUS-LUNATUS; ADENINE BINDING-SITES; ARCELIN SEED PROTEIN; LEGUME LECTIN; 2.3-ANGSTROM RESOLUTION; MOLECULAR RECOGNITION; ESCHERICHIA-COLI; LENTIL LECTIN; VULGARIS	The structure of phytohemagglutinin-L (PHA-L), a leucoagglutinating seed lectin from Phaseolus vulgaris, has been solved with molecular replacement using the coordinates of lentil lectin as model, and refined at a resolution of 2.8 Angstrom. The final R-factor of the structure is 20.0%. The quaternary structure of the PHA-L tetramer differs from the structures of the concanavalin A and peanut lectin tetramers, but resembles the structure of the soybean agglutinin tetramer. PHA-L consists of two canonical legume lectin dimers that pack together through the formation of a close contact between two beta-strands. Of the two covalently bound oligosaccharides per monomer, only one GlcNAc residue per monomer is visible in the electron density. In this article we describe the structure of PHA-L, and we discuss the putative position of the high affinity adenine binding site present in a number of legume lectins. A comparison with transthyretin, a protein that shows a remarkable resemblance to PHA-L, gives further ground to our proposal.	VLAAMSE INSTELLING TECHNOL ONDERZOEK, B-2400 MOL, BELGIUM; UNIV CALIF SAN DIEGO, DEPT BIOL, LA JOLLA, CA 92093 USA	VITO; University of California System; University of California San Diego	Hamelryck, TW (corresponding author), FREE UNIV BRUSSELS VIB, DIENST ULTRASTRUCT, PAARDENSTRAAT 65, B-1640 RHODE ST GENESE, BELGIUM.		Loris, Remy/GPG-0894-2022; Hamelryck, Thomas/A-3923-2012	Hamelryck, Thomas/0000-0003-2917-3602; Loris, Remy/0000-0002-8862-3338				ANDREAS JR, 1986, THEOR APPL GENET, V72, P123, DOI 10.1007/BF00261467; BANERJEE R, 1994, P NATL ACAD SCI USA, V91, P227, DOI 10.1073/pnas.91.1.227; BECKER JW, 1975, J BIOL CHEM, V250, P1513; BLAKE CCF, 1977, NATURE, V268, P115, DOI 10.1038/268115a0; BLAKE CCF, 1978, J MOL BIOL, V121, P339, DOI 10.1016/0022-2836(78)90368-6; BOURNE Y, 1990, PROTEINS, V8, P365, DOI 10.1002/prot.340080410; BOURNE Y, 1994, STRUCTURE, V2, P209, DOI 10.1016/S0969-2126(00)00022-8; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; BRUNGER AT, 1993, ACTA CRYSTALLOGR D, V49, P24, DOI 10.1107/S0907444992007352; CASSET F, 1995, J BIOL CHEM, V270, P25619, DOI 10.1074/jbc.270.43.25619; CHOTHIA C, 1981, P NATL ACAD SCI-BIOL, V78, P4146, DOI 10.1073/pnas.78.7.4146; CHRISPEELS MJ, 1991, PLANT CELL, V3, P1, DOI 10.1105/tpc.3.1.1; CISZAK E, 1992, P NATL ACAD SCI USA, V89, P6644, DOI 10.1073/pnas.89.14.6644; DaoThi MH, 1996, PROTEINS, V24, P134, DOI 10.1002/(SICI)1097-0134(199601)24:1<134::AID-PROT9>3.0.CO;2-K; DELBAERE LTJ, 1990, CAN J CHEM, V68, P1116, DOI 10.1139/v90-172; DESSEN A, 1995, BIOCHEMISTRY-US, V34, P4933, DOI 10.1021/bi00015a004; DIAZ CL, 1989, NATURE, V338, P579, DOI 10.1038/338579a0; EINSPAHR H, 1986, J BIOL CHEM, V261, P6518; FERGUSON RN, 1975, BIOCHEMISTRY-US, V14, P282, DOI 10.1021/bi00673a014; GALLAGHER T, 1993, J MOL BIOL, V230, P516, DOI 10.1006/jmbi.1993.1168; GEGG CV, 1992, BIOCHEMISTRY-US, V31, P6938, DOI 10.1021/bi00145a011; GOOSSENS A, 1994, EUR J BIOCHEM, V225, P787, DOI 10.1111/j.1432-1033.1994.0787b.x; HAMMARSTROM S, 1982, P NATL ACAD SCI-BIOL, V79, P1611, DOI 10.1073/pnas.79.5.1611; HARTWECK LM, 1991, PLANT PHYSIOL, V97, P204, DOI 10.1104/pp.97.1.204; HOFFMAN LM, 1985, EMBO J, V4, P883, DOI 10.1002/j.1460-2075.1985.tb03714.x; JORDAN ET, 1994, J BIOL CHEM, V269, P7674; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LORIS R, 1994, J BIOL CHEM, V269, P26722; LORIS R, 1993, BIOCHEMISTRY-US, V32, P8772, DOI 10.1021/bi00085a007; MALIARIK MJ, 1988, J BIOL CHEM, V263, P11274; McDonald I, 1993, HBPLUS COMPUTER PROG; MILLER S, 1989, PROTEIN ENG, V3, P77, DOI 10.1093/protein/3.2.77; MORENO J, 1989, P NATL ACAD SCI USA, V86, P7885, DOI 10.1073/pnas.86.20.7885; MURZIN AG, 1994, CURR OPIN STRUC BIOL, V4, P441, DOI 10.1016/S0959-440X(94)90114-7; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; OSBORN TC, 1988, SCIENCE, V240, P207, DOI 10.1126/science.240.4849.207; PFLUGRATH JW, 1989, MADNESS MANUAL FAST; ROBERTS DD, 1982, J BIOL CHEM, V257, P1274; ROBERTS DD, 1983, J BIOL CHEM, V258, P3820; ROBERTS DD, 1983, CHEM TAXONOMY MOL BI, P131; SHAANAN B, 1991, SCIENCE, V254, P862, DOI 10.1126/science.1948067; SHADE RE, 1994, BIO-TECHNOL, V12, P793, DOI 10.1038/nbt0894-793; SHARON N, 1990, FASEB J, V4, P3198, DOI 10.1096/fasebj.4.14.2227211; STURM A, 1986, PLANT PHYSIOL, V81, P320, DOI 10.1104/pp.81.1.320; WOJTCZAK A, 1992, J BIOL CHEM, V267, P353; YOUNG NM, 1995, J BIOL CHEM, V270, P2563, DOI 10.1074/jbc.270.6.2563	48	110	114	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20479	20485		10.1074/jbc.271.34.20479	http://dx.doi.org/10.1074/jbc.271.34.20479			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702788	hybrid			2022-12-25	WOS:A1996VD33700040
J	Imbalzano, AN; Schnitzler, GR; Kingston, RE				Imbalzano, AN; Schnitzler, GR; Kingston, RE			Nucleosome disruption by human SWI/SNF is maintained in the absence of continued ATP hydrolysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR-BINDING; TUMOR VIRUS PROMOTER; RNA-POLYMERASE-II; HEAT-SHOCK FACTOR; SACCHAROMYCES-CEREVISIAE; GLUCOCORTICOID RECEPTOR; DNA-BINDING; POSITIONED NUCLEOSOMES; MULTISUBUNIT COMPLEX; FACILITATED BINDING	We have examined the requirement for ATP in human (h) SWI/SNF-mediated alteration of nucleosome structure and facilitation of transcription factor binding to nucleosomal DNA. hSWI-SNF-mediated nucleosome alteration requires hydrolysis of ATP or dATP. The alteration is stable upon removal of ATP from the reaction or upon inhibition of activity by excess ATP gamma S, indicating that continued ATP hydrolysis is not required to maintain the altered nucleosome structure, This stable alteration is sufficient to facilitate binding of a transcriptional activator protein; concurrent ATP hydrolysis was not required to facilitate binding. These data suggest sequential steps that can occur in the process by which transcription factors gain access to nucleosomal DNA.	MASSACHUSETTS GEN HOSP,DEPT MOL BIOL,BOSTON,MA 02114; HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School								ADAMS CC, 1995, MOL CELL BIOL, V15, P1405; ARCHER TK, 1991, MOL CELL BIOL, V11, P688, DOI 10.1128/MCB.11.2.688; CAIRNS BR, 1994, P NATL ACAD SCI USA, V91, P1950, DOI 10.1073/pnas.91.5.1950; CAREY MF, 1995, CURR BIOL, V5, P1003, DOI 10.1016/S0960-9822(95)00201-6; CHEN H, 1994, EMBO J, V13, P380, DOI 10.1002/j.1460-2075.1994.tb06272.x; CHIBA H, 1994, NUCLEIC ACIDS RES, V22, P1815, DOI 10.1093/nar/22.10.1815; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7; ELFRING LK, 1994, MOL CELL BIOL, V14, P2225, DOI 10.1128/MCB.14.4.2225; EMILI A, 1995, CURR OPIN GENET DEV, V5, P204, DOI 10.1016/0959-437X(95)80009-3; GINIGER E, 1985, CELL, V40, P767, DOI 10.1016/0092-8674(85)90336-8; GODDE JS, 1995, J BIOL CHEM, V270, P27399, DOI 10.1074/jbc.270.46.27399; HIRSCHHORN JN, 1992, GENE DEV, V6, P2288, DOI 10.1101/gad.6.12a.2288; IMBALZANO AN, 1994, J BIOL CHEM, V269, P8280; IMBALZANO AN, 1994, NATURE, V370, P481, DOI 10.1038/370481a0; KALPANA GV, 1994, SCIENCE, V266, P2002, DOI 10.1126/science.7801128; KHAVARI PA, 1993, NATURE, V366, P170, DOI 10.1038/366170a0; KOLESKE AJ, 1995, TRENDS BIOCHEM SCI, V20, P113, DOI 10.1016/S0968-0004(00)88977-X; KRUGER W, 1995, GENE DEV, V9, P2770, DOI 10.1101/gad.9.22.2770; KRUGER W, 1991, MOL CELL BIOL, V11, P4135, DOI 10.1128/MCB.11.8.4135; KWON H, 1994, NATURE, V370, P477, DOI 10.1038/370477a0; LAURENT BC, 1992, GENE DEV, V6, P1707, DOI 10.1101/gad.6.9.1707; LAURENT BC, 1990, MOL CELL BIOL, V10, P5616, DOI 10.1128/MCB.10.11.5616; LAURENT BC, 1991, P NATL ACAD SCI USA, V88, P2687, DOI 10.1073/pnas.88.7.2687; LEE DY, 1993, CELL, V72, P73, DOI 10.1016/0092-8674(93)90051-Q; LI BY, 1994, J BIOL CHEM, V269, P7756; LI Q, 1993, GENE DEV, V7, P2471, DOI 10.1101/gad.7.12a.2471; LI Q, 1995, MOL CELL BIOL, V15, P43275; LIN YS, 1988, CELL, V54, P659, DOI 10.1016/S0092-8674(88)80010-2; MATALLANA E, 1992, MOL GEN GENET, V231, P395, DOI 10.1007/BF00292708; MUCHARDT C, 1993, EMBO J, V12, P4279, DOI 10.1002/j.1460-2075.1993.tb06112.x; PAZIN MJ, 1994, SCIENCE, V266, P2007, DOI 10.1126/science.7801129; PERLMANN T, 1988, EMBO J, V7, P3073, DOI 10.1002/j.1460-2075.1988.tb03172.x; PETERSON CL, 1992, CELL, V68, P573, DOI 10.1016/0092-8674(92)90192-F; PETERSON CL, 1994, P NATL ACAD SCI USA, V91, P2905, DOI 10.1073/pnas.91.8.2905; PETERSON CL, 1991, CELL, V64, P1135, DOI 10.1016/0092-8674(91)90268-4; PHAM TA, 1992, BIOCHEMISTRY-US, V31, P1570, DOI 10.1021/bi00120a039; PINA B, 1990, CELL, V60, P719, DOI 10.1016/0092-8674(90)90087-U; Quinn J, 1996, NATURE, V379, P844, DOI 10.1038/379844a0; RHODES D, 1985, EMBO J, V4, P3473, DOI 10.1002/j.1460-2075.1985.tb04106.x; TAYLOR ICA, 1991, GENE DEV, V5, P1285, DOI 10.1101/gad.5.7.1285; TSUKIYAMA T, 1994, NATURE, V367, P525, DOI 10.1038/367525a0; TSUKIYAMA T, 1995, CELL, V83, P1011, DOI 10.1016/0092-8674(95)90216-3; TSUKIYAMA T, 1995, CELL, V83, P1021, DOI 10.1016/0092-8674(95)90217-1; VARGAWEISZ PD, 1995, EMBO J, V14, P2209, DOI 10.1002/j.1460-2075.1995.tb07215.x; WALL G, 1995, EMBO J, V14, P1727, DOI 10.1002/j.1460-2075.1995.tb07162.x; WALTER PP, 1995, MOL CELL BIOL, V15, P6178; WECHSLER DS, 1994, MOL CELL BIOL, V14, P4097, DOI 10.1128/MCB.14.6.4097; Wilson CJ, 1996, CELL, V84, P235, DOI 10.1016/S0092-8674(00)80978-2; WINSTON F, 1992, TRENDS GENET, V8, P387, DOI 10.1016/0168-9525(92)90167-3; WORKMAN JL, 1991, METHOD CELL BIOL, V35, P419; WORKMAN JL, 1991, CELL, V64, P533, DOI 10.1016/0092-8674(91)90237-S; WORKMAN JL, 1992, SCIENCE, V258, P1780, DOI 10.1126/science.1465613; YOSHINAGA SK, 1992, SCIENCE, V258, P1598, DOI 10.1126/science.1360703	54	85	86	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20726	20733		10.1074/jbc.271.34.20726	http://dx.doi.org/10.1074/jbc.271.34.20726			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702824	hybrid			2022-12-25	WOS:A1996VD33700076
J	Kim, DR; McHenry, CS				Kim, DR; McHenry, CS			Identification of the beta-binding domain of the alpha subunit of Escherichia coli polymerase III holoenzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMOSOMAL REPLICATION MACHINE; 2 DNA-POLYMERASES; GAMMA-SUBUNIT; SLIDING CLAMPS; PROTEIN; TAU; MECHANISM; TEMPLATE; PURIFICATION; PRODUCTS	Rapid and processive DNA synthesis by Escherichia coli DNA polymerase III holoenzyme is achieved by the direct interaction between the alpha subunit of DNA polymerase III core and the beta sliding clamp (LaDuca, R. J,, Crute, J. J,, McHenry, C, S,, and Bambara, R, A. (1986) J, Biol. Chen, 261, 7550-7557; Stukenberg, T. P., Studwell-Vaughan, P, S., and O'Donnell, M, (1991) J. Biol. Chem. 266, 11328-11334), In this study, we localized the beta-binding domain of alpha to a carboxyl-terminal region by quantifying the interaction of beta with a series of alpha deletion proteins. Purification and binding analysis was facilitated by insertion of hexahistidine and short biotinylation sequences on the deletion terminus of alpha. Interaction of beta with alpha deletion proteins was studied by gel filtration and surface plasmon resonance, alpha lacking 169 COOH-terminal residues still possessed beta-binding activity; whereas deletion of 342 amino acids from the COOH terminus abolished beta binding, Deletion of 542 amino acids from the NH2 terminus of the 1160 residue alpha subunit resulted in a protein that bound beta 10-20-fold more strongly than native alpha. Hence, portions of alpha between residues 542 and 991 are involved in beta binding, DNA binding to alpha apparently triggers an increased affinity for beta (Naktinis, V., Turner, J., and O'Donnell, M. (1996) Cell 84, 137-145), Our findings extend this observation by implicating the amino-terminal polymerase domain in inducing a low affinity taut conformation in the carboxyl-terminal beta-binding domain. Deletion of the polymerase domain (or, presumably, its occupancy by DNA) relaxes the COOH-terminal domain, permitting it to assume a conformation with high affinity for beta.			Kim, DR (corresponding author), UNIV COLORADO,HLTH SCI CTR,DEPT BIOCHEM BIOPHYS & GENET,DENVER,CO 80262, USA.							BLINKOWA AL, 1990, NUCLEIC ACIDS RES, V18, P1725, DOI 10.1093/nar/18.7.1725; DALLMANN HG, 1995, J BIOL CHEM, V270, P29555, DOI 10.1074/jbc.270.49.29555; DALLMANN HG, 1995, J BIOL CHEM, V270, P29563, DOI 10.1074/jbc.270.49.29563; FAY PJ, 1982, J BIOL CHEM, V257, P5692; FLOWER AM, 1990, P NATL ACAD SCI USA, V87, P3713, DOI 10.1073/pnas.87.10.3713; JOHANSON KO, 1986, J BIOL CHEM, V261, P1460; Kim DR, 1996, J BIOL CHEM, V271, P20690, DOI 10.1074/jbc.271.34.20690; Kim S, 1996, J BIOL CHEM, V271, P4315; Kim SS, 1996, CELL, V84, P643, DOI 10.1016/S0092-8674(00)81039-9; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; KUWABARA N, 1981, P NATL ACAD SCI-BIOL, V78, P5764, DOI 10.1073/pnas.78.9.5764; LADUCA RJ, 1986, J BIOL CHEM, V261, P7550; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBOWITZ JH, 1986, J BIOL CHEM, V261, P4738; LEE SH, 1987, P NATL ACAD SCI USA, V84, P2713, DOI 10.1073/pnas.84.9.2713; MCHENRY CS, 1982, J BIOL CHEM, V257, P2657; MCHENRY CS, 1989, MOL MECH DNA REPLICA, P115; MCMACKEN R, 1977, P NATL ACAD SCI USA, V74, P4190, DOI 10.1073/pnas.74.10.4190; Naktinis V, 1996, CELL, V84, P137, DOI 10.1016/S0092-8674(00)81000-4; ODONNELL ME, 1987, J BIOL CHEM, V262, P16558; ONRUST R, 1991, J BIOL CHEM, V266, P21681; ONRUST R, 1995, J BIOL CHEM, V270, P13366, DOI 10.1074/jbc.270.22.13366; ONRUST R, 1995, J BIOL CHEM, V270, P13348, DOI 10.1074/jbc.270.22.13348; REEMS JA, 1995, J BIOL CHEM, V270, P5606, DOI 10.1074/jbc.270.10.5606; STUDWELLVAUGHAN PS, 1991, J BIOL CHEM, V266, P19833; STUKENBERG PT, 1991, J BIOL CHEM, V266, P11328; TONGU K, 1994, J BIOL CHEM, V269, P4675; TSUCHIHASHI Z, 1989, J BIOL CHEM, V264, P17790; TSUCHIHASHI Z, 1990, P NATL ACAD SCI USA, V87, P2516, DOI 10.1073/pnas.87.7.2516; WICKNER S, 1976, P NATL ACAD SCI USA, V73, P3511, DOI 10.1073/pnas.73.10.3511; WU CA, 1992, J BIOL CHEM, V267, P4030	31	44	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20699	20704		10.1074/jbc.271.34.20699	http://dx.doi.org/10.1074/jbc.271.34.20699			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702820	hybrid			2022-12-25	WOS:A1996VD33700072
J	Lavoie, JN; LAllemain, G; Brunet, A; Muller, R; Pouyssegur, J				Lavoie, JN; LAllemain, G; Brunet, A; Muller, R; Pouyssegur, J			Cyclin D1 expression is regulated positively by the p42/p44(MAPK) and negatively by the p38/HOG(MAPK) pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; INITIATION-FACTOR 4E; C-JUN; GROWTH-FACTORS; CELL-CYCLE; SIGNAL-TRANSDUCTION; MAMMALIAN-CELLS; MAP KINASES; RETINOBLASTOMA PROTEIN; TRANSLATION INITIATION	Ne have previously shown that the persistent activation of p42/p44(MAPK) is required to pass the G(1) restriction point in fibroblasts (Pages, G., Lenormand, P., L'Allemain, G., Chambard, J. C., Meloche, S., and Pouyssegur, J. (1993) Proc. Natl. Acad Sci. U.S. A. 90, 8319-8323) and postulated that MAPKs control the activation of G, cyclin-dependent complexes. Ne examined the mitogen dependent-induction of cyclin D1 expression, one of the earliest cell cycle-related events to occur during the G(0)/G(1) to S-phase transition, as a potential target of MAPK regulation, Effects exerted either by the p42/p44(MAPK) or the p38/HOG(MAPK) cascade on the regulation of cyclin D1 promoter activity or cyclin D1 expression were compared in CCL39 cells, using a co-transfection procedure. Ne found that inhibition of the p42/p44(MAPK) signaling by expression of dominant-negative forms of either mitogen-activated protein kinase kinase 1 (MKK1) or p44(MAPK), gp by expression of the MAP kinase phosphatase, MKP-1, strongly inhibited expression of a reporter gene driven by the human cyclin D1 promoter as well as the endogenous cyclin D1 protein. Conversely, activation of this signaling pathway by expression of a constitutively active MKK1 mutant dramatically increased cyclin D1 promoter activity and cyclin D1 protein expression, in a growth factor-independent manner. Moreover, the use of a CCL39-derived cell line that stably expresses an inducible chimera of the estrogen receptor fused to a constitutively active Raf-1 mutant (Delta Raf-1:ER) revealed that in absence of growth factors, activation of the Raf > MKK1 > p42/p44MAPK cascade is sufficient to fully induce cyclin D1, In marked contrast, the p38(MAPK) cascade showed an opposite effect on the regulation of cyclin D1 expression. In cells co-expressing high levels of the p38(MAPK) kinase (MKK3) together with the p38(MAPK), significant inhibition of mitogen-induced cyclin D1 expression was observed. Furthermore, inhibition of p38(MAPK) activity with the specific inhibitor, SB203580, enhanced cyclin D1 transcription and protein level. Altogether, these results support the notion that MAPK cascades drive specific cell cycle responses to extracellular stimuli, at least in part, through the modulation of cyclin D1 expression and associated cdk activities.	FAC SCI,CTR BIOCHIM,CNRS,UMR 134,F-06108 NICE 02,FRANCE; UNIV MARBURG,INST MOL BIOL & TUMORFORSCH,D-35037 MARBURG,GERMANY	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; Philipps University Marburg			Müller, Rolf/L-4997-2016	Müller, Rolf/0000-0003-3339-4248				ADLER V, 1994, J BIOL CHEM, V269, P11186; ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BARTKOVA J, 1995, CANCER RES, V55, P949; BRONDELLO JM, 1995, ONCOGENE, V10, P1895; BRUNET A, 1994, ONCOGENE, V9, P3379; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; COUNILLON L, 1993, MOL PHARMACOL, V44, P1041; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DECOFFER P, 1994, ONCOGENE, V9, P911; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DEVOTO SH, 1992, CELL, V68, P167, DOI 10.1016/0092-8674(92)90215-X; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; GRANA X, 1995, ONCOGENE, V11, P211; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HATAKEYAMA M, 1994, GENE DEV, V8, P1759, DOI 10.1101/gad.8.15.1759; HERBER B, 1994, ONCOGENE, V9, P1295; HORTON LE, 1995, CELL GROWTH DIFFER, V6, P395; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; JIANG W, 1993, ONCOGENE, V8, P3447; KAHAN C, 1992, J BIOL CHEM, V267, P13369; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; KORTENJANN M, 1994, MOL CELL BIOL, V14, P4815, DOI 10.1128/MCB.14.7.4815; LALLEMAIN G, 1991, CELL REGUL, V2, P675, DOI 10.1091/mbc.2.8.675; LAVOIE JN, 1995, MOL CELL BIOL, V15, P505, DOI 10.1128/MCB.15.1.505; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LEES E, 1995, CURR OPIN CELL BIOL, V7, P773, DOI 10.1016/0955-0674(95)80060-3; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721; LIVINGSTONE C, 1995, EMBO J, V14, P1785, DOI 10.1002/j.1460-2075.1995.tb07167.x; LUKAS J, 1995, MOL CELL BIOL, V15, P2600; LUKAS J, 1995, ONCOGENE, V10, P2125; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MATSUSHIME H, 1991, COLD SH Q B, V56, P69; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MELOCHE S, 1992, MOL ENDOCRINOL, V6, P845, DOI 10.1210/me.6.5.845; MULLER R, 1995, TRENDS GENET, V11, P173, DOI 10.1016/S0168-9525(00)89039-3; Muthukkumar S, 1996, J BIOL CHEM, V271, P5733, DOI 10.1074/jbc.271.10.5733; Noel J, 1996, J CELL SCI, V109, P929; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PAGES G, 1994, EMBO J, V13, P3003, DOI 10.1002/j.1460-2075.1994.tb06599.x; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; POUYSSEGUR J, 1984, P NATL ACAD SCI-BIOL, V81, P4833, DOI 10.1073/pnas.81.15.4833; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; ROSENWALD IB, 1995, J BIOL CHEM, V270, P21176, DOI 10.1074/jbc.270.36.21176; ROSENWALD IB, 1993, MOL CELL BIOL, V13, P7358, DOI 10.1128/MCB.13.12.7358; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; ROUSSEL MF, 1995, P NATL ACAD SCI USA, V92, P6837, DOI 10.1073/pnas.92.15.6837; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; SEWING A, 1993, J CELL SCI, V104, P545; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; SUN H, 1993, CELL, V75, P437; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; VANOBBERGHENSCHILLING E, 1985, EMBO J, V4, P2927, DOI 10.1002/j.1460-2075.1985.tb04025.x; WASYLYK B, 1993, P NATL ACAD SCI USA, V90, P7739; WESTWICK JK, 1994, P NATL ACAD SCI USA, V91, P6030, DOI 10.1073/pnas.91.13.6030; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326	70	1067	1091	0	33	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20608	20616		10.1074/jbc.271.34.20608	http://dx.doi.org/10.1074/jbc.271.34.20608			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702807	hybrid			2022-12-25	WOS:A1996VD33700059
J	Eiserich, JP; Cross, CE; Jones, AD; Halliwell, B; vanderVliet, A				Eiserich, JP; Cross, CE; Jones, AD; Halliwell, B; vanderVliet, A			Formation of nitrating and chlorinating species by reaction of nitrite with hypochlorous acid - A novel mechanism for nitric oxide-mediated protein modification	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROXYL RADICAL PRODUCTION; HUMAN-NEUTROPHILS; AQUEOUS-SOLUTION; NITROGEN-OXIDES; SYNOVIAL-FLUID; ONE-ELECTRON; L-ARGININE; PEROXYNITRITE; SUPEROXIDE; OXIDATION	Detection of 3-nitrotyrosine has served as an in vivo marker for the production of the cytotoxic species peroxynitrite (ONOO-). We show here that reaction of nitrite (NO2-), the autoxidation product of nitric oxide ((NO)-N-.), with hypochlorous acid (HOCl) forms reactive intermediate species that are also capable of nitrating phenolic substrates such as tyrosine and 4-hydroxy-phenylacetic acid, with maximum yields obtained at physiological pH. Monitoring the reaction of NO2- with HOCl by continuous flow photodiode array spectrophotometry indicates the formation of a transient species with spectral characteristics similar to those of nitryl chloride (Cl-NO2). Reaction of synthetic Cl-NO2 with N-acetyl-L-tyrosine results in the formation of 3-chlorotyrosine and 3-nitrotyrosine in ratios that are similar to those obtained by the NO2-/HOCl reaction (4:1). Tyrosine residues in bovine serum albumin are also nitrated and chlorinated by NO2-/HOCl and synthetic Cl-NO2. The reaction of N-acetyl-L-tyrosine with NO2-/HOCl or authentic Cl-NO2 also produces dityrosine, suggesting that free radical intermediates are involved in the reaction mechanism. Our data indicate that while chlorination reactions of Cl-NO2 are mediated by direct electrophilic addition to the aromatic ring, a free radical mechanism appears to be operative in nitrations mediated by NO,1 HOCl or Cl-NO2, probably involving the combination of nitrogen dioxide ((NO2)-N-.) and tyrosyl radical. We propose that NO2- reacts with HOCl by Cl+ transfer to form both cis- and trans-chlorine nitrite (Cl-ONO) and CI-NO2 as intermediates that modify tyrosine by either direct re action or after decomposition to reactive free and solvent-caged Cl-. and (NO2)-N-. as reactive species. Formation of Cl-NO2 and/or Cl-ONO in vivo may represent previously unrecognized mediators of inflammation-mediate protein modification and tissue injury, and offers an additional mechanism of tyrosine nitration independent of ONOO-.	UNIV CALIF DAVIS,FACIL ADV INSTRUMENTAT,DAVIS,CA 95616; UNIV LONDON KINGS COLL,PHARMACOL GRP,NEURODEGENERAT DIS RES CTR,LONDON SW3 6LX,ENGLAND	University of California System; University of California Davis; University of London; King's College London	Eiserich, JP (corresponding author), UNIV CALIF DAVIS,DEPT INTERNAL MED,DIV PULM CRIT CARE MED,MED SPONSORED PROGRAMS,TB 150,DAVIS,CA 95616, USA.		Jones, Arthur D/C-2670-2013; Halliwell, Barry/C-8318-2009	Jones, A. Daniel/0000-0002-7408-6690	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047628] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL47628] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANBAR M, 1958, J AM CHEM SOC, V80, P1073, DOI 10.1021/ja01538a015; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BECKMAN JS, 1992, ARCH BIOCHEM BIOPHYS, V298, P438, DOI 10.1016/0003-9861(92)90432-V; BECKMAN JS, 1994, METHOD ENZYMOL, V233, P229; BECKMANN JS, 1994, BIOL CHEM H-S, V375, P81, DOI 10.1515/bchm3.1994.375.2.81; BRUNELLI L, 1995, ARCH BIOCHEM BIOPHYS, V316, P327, DOI 10.1006/abbi.1995.1044; CARRERAS MC, 1994, FEBS LETT, V341, P65, DOI 10.1016/0014-5793(94)80241-6; CHESTER AH, 1990, LANCET, V336, P897, DOI 10.1016/0140-6736(90)92269-N; COLLIS MJ, 1958, J CHEM SOC, P445; DAUGHERTY A, 1994, J CLIN INVEST, V94, P437, DOI 10.1172/JCI117342; DOMIGAN NM, 1995, J BIOL CHEM, V270, P16542, DOI 10.1074/jbc.270.28.16542; EISERICH JP, 1995, BIOCHEM J, V310, P745, DOI 10.1042/bj3100745; FARRELL AJ, 1992, ANN RHEUM DIS, V51, P1219, DOI 10.1136/ard.51.11.1219; GASTON B, 1994, AM J RESP CRIT CARE, V149, P538, DOI 10.1164/ajrccm.149.2.7508323; GASTON B, 1993, P NATL ACAD SCI USA, V90, P10957, DOI 10.1073/pnas.90.23.10957; GINTZ FP, 1958, J CHEM SOC, P445, DOI 10.1039/jr9580000445; GOLDSTEIN S, 1995, INORG CHEM, V34, P4041, DOI 10.1021/ic00120a006; HADDAD IY, 1994, J CLIN INVEST, V94, P2407, DOI 10.1172/JCI117607; HALFPENNY E, 1952, J CHEM SOC, P939, DOI 10.1039/jr9520000939; HASZELDINE RN, 1953, J CHEM SOC, P2525, DOI 10.1039/jr9530002525; HOOPER DC, 1995, P NATL ACAD SCI USA, V92, P5312, DOI 10.1073/pnas.92.12.5312; HUIE RE, 1993, FREE RADICAL RES COM, V18, P195, DOI 10.3109/10715769309145868; IGNARRO LJ, 1993, P NATL ACAD SCI USA, V90, P8103, DOI 10.1073/pnas.90.17.8103; ISCHIROPOULOS H, 1992, ARCH BIOCHEM BIOPHYS, V298, P446, DOI 10.1016/0003-9861(92)90433-W; ISHIROPOULOS H, 1995, FEBS LETT, V364, P279; JOHNSON DW, 1991, INORG CHEM, V30, P4845, DOI 10.1021/ic00025a031; KAUR H, 1994, FEBS LETT, V350, P9, DOI 10.1016/0014-5793(94)00722-5; Kettle AJ, 1996, FEBS LETT, V379, P103, DOI 10.1016/0014-5793(95)01494-2; KLEBANOFF SJ, 1993, FREE RADICAL BIO MED, V14, P351, DOI 10.1016/0891-5849(93)90084-8; KNOWLES RG, 1994, BIOCHEM J, V298, P249, DOI 10.1042/bj2980249; Kono Y, 1995, BIOCHEM MOL BIOL INT, V36, P275; KOOY NW, 1994, ARCH BIOCHEM BIOPHYS, V310, P352, DOI 10.1006/abbi.1994.1178; KOPPENOL WH, 1994, FEBS LETT, V347, P5, DOI 10.1016/0014-5793(94)00494-3; KOPPENOL WH, 1992, CHEM RES TOXICOL, V5, P834, DOI 10.1021/tx00030a017; LEE TJ, 1994, J PHYS CHEM-US, V98, P111, DOI 10.1021/j100052a019; LEPOIVRE M, 1994, J BIOL CHEM, V269, P21891; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; MALINSKI T, 1993, J CEREBR BLOOD F MET, V13, P355, DOI 10.1038/jcbfm.1993.48; MARLETTA MA, 1988, BIOCHEMISTRY-US, V27, P8706, DOI 10.1021/bi00424a003; MILES AM, 1995, J LEUKOCYTE BIOL, V58, P616, DOI 10.1002/jlb.58.5.616; MILLER RA, 1995, J INVEST MED, V43, P39; MOHAMMED JR, 1988, J LAB CLIN MED, V112, P711; MONCADA S, 1991, PHARMACOL REV, V43, P109; NICKELSEN MG, 1991, CHEM RES TOXICOL, V4, P94, DOI 10.1021/tx00019a013; OBERMEYER A, 1995, J AM CHEM SOC, V117, P7887, DOI 10.1021/ja00135a006; PERRIN CL, 1977, J AM CHEM SOC, V99, P5516, DOI 10.1021/ja00458a065; PRICE CC, 1953, J AM CHEM SOC, V75, P3276, DOI 10.1021/ja01109a510; PRUTZ WA, 1985, ARCH BIOCHEM BIOPHYS, V243, P125, DOI 10.1016/0003-9861(85)90780-5; PRYOR WA, 1994, P NATL ACAD SCI USA, V91, P11173, DOI 10.1073/pnas.91.23.11173; PRYOR WA, 1995, AM J PHYSIOL-LUNG C, V268, pL699, DOI 10.1152/ajplung.1995.268.5.L699; RADI R, 1991, J BIOL CHEM, V266, P4244; SCHMIDT HHHW, 1994, CELL, V78, P919, DOI 10.1016/0092-8674(94)90267-4; SHECHTER H, 1952, J AM CHEM SOC, V74, P3052, DOI 10.1021/ja01132a029; SQUADRITO GL, 1995, CHEM-BIOL INTERACT, V96, P203, DOI 10.1016/0009-2797(94)03591-U; STAMLER JS, 1992, SCIENCE, V258, P1898, DOI 10.1126/science.1281928; TEVAULT DE, 1977, J CHEM PHYS, V67, P3777, DOI 10.1063/1.435319; TSAI JHM, 1994, J AM CHEM SOC, V116, P4115, DOI 10.1021/ja00088a072; VANDERVLIET A, 1995, ARCH BIOCHEM BIOPHYS, V319, P341, DOI 10.1006/abbi.1995.1303; VANDERVLIET A, 1994, FEBS LETT, V339, P89, DOI 10.1016/0014-5793(94)80391-9; WARDMAN P, 1989, J PHYS CHEM REF DATA, V18, P1637, DOI 10.1063/1.555843; WATSON WD, 1974, J ORG CHEM, V39, P1160, DOI 10.1021/jo00922a034; WEISS SJ, 1986, SCIENCE, V234, P200, DOI 10.1126/science.3018933; WEISS SJ, 1983, SCIENCE, V222, P625, DOI 10.1126/science.6635660; Winterbourn C.C., 1990, OXYGEN RADICALS SYST, P31	64	366	372	3	33	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19199	19208		10.1074/jbc.271.32.19199	http://dx.doi.org/10.1074/jbc.271.32.19199			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702599	hybrid			2022-12-25	WOS:A1996VB68400033
J	Meier, UT				Meier, UT			Comparison of the rat nucleolar protein Nopp140 with its yeast homolog SRP40 - Differential phosphorylation in vertebrates and yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CASEIN KINASE-II; NUCLEAR-LOCALIZATION SEQUENCES; RIBOSOMAL-RNA; SACCHAROMYCES-CEREVISIAE; MAMMALIAN NUCLEOLIN; MOLECULAR-WEIGHT; BINDING-PROTEIN; CDNA CLONING; GENE-PRODUCT; IDENTIFICATION	Rat Nopp140, a nonribosomal protein of the nucleolus and coiled bodies, was characterized as one of the most highly phosphorylated proteins in the cell. Based on its subcellular location, its nuclear localization signal binding capacity, and its shuttling between the nucleolus and the cytoplasm, Nopp140 was proposed to function as a chaperone in ribosome biogenesis, This study shows that casein kinase II phosphorylates Nopp140 to its unusual high degree and identifies the yeast SRP40 gene product as immunologically and structurally related to rat Nopp140. SRP40 encodes an acidic (pI = 3.9), serine-rich (49%) protein of 41 kDa whose carboxyl terminus exhibits 59% sequence identity to that of Nopp140 SRP40 localizes to the yeast nucleolus and is required at a specific cellular concentration for optimal growth as indicated by the negative effect on cell growth of both overexpression and deletion of its gene. Like Nopp140, SRP40 is phosphosylated by casein kinase II, but to a much lesser extent, While the parallels between these two proteins suggest that SRP40 is the bona fide yeast Nopp140 homolog, their disparities reflect the differences in nucleolar dynamics and regulation of ribosome biogenesis between yeast and vertebrates.			Meier, UT (corresponding author), ALBERT EINSTEIN COLL MED, DEPT ANAT & STRUCT BIOL, 1300 MORRIS PK AVE, BRONX, NY 10461 USA.				NIGMS NIH HHS [GM50725] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050725] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ARIS JP, 1991, P NATL ACAD SCI USA, V88, P931, DOI 10.1073/pnas.88.3.931; ARIS JP, 1988, J CELL BIOL, V107, P17, DOI 10.1083/jcb.107.1.17; Ausubel F.M., 1993, CURRENT PROTOCOLS MO; BELENGUER P, 1990, MOL CELL BIOL, V10, P3607, DOI 10.1128/MCB.10.7.3607; BENTON BM, 1994, J CELL BIOL, V127, P623, DOI 10.1083/jcb.127.3.623; BERGES T, 1994, EMBO J, V13, P3136, DOI 10.1002/j.1460-2075.1994.tb06612.x; BOU G, 1993, YEAST, V9, P1349, DOI 10.1002/yea.320091209; CAIRNS C, 1995, J CELL SCI, V108, P3339; CAJAL SR, 1910, TRAB LAB INVEST BIOL, V8, P1; CHELSKY D, 1989, MOL CELL BIOL, V9, P2487, DOI 10.1128/MCB.9.6.2487; CHENWU JLP, 1988, MOL CELL BIOL, V8, P4981, DOI 10.1128/MCB.8.11.4981; DEBEUS E, 1994, J CELL BIOL, V127, P1799, DOI 10.1083/jcb.127.6.1799; ESPINET C, 1995, YEAST, V11, P25, DOI 10.1002/yea.320110104; FASMAN GD, 1978, CRC HDB BIOCH MOL BI, V1; FREEMAN JW, 1988, CANCER RES, V48, P1244; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GIRARD JP, 1992, EMBO J, V11, P673, DOI 10.1002/j.1460-2075.1992.tb05099.x; GODAY A, 1994, PLANT CELL, V6, P351, DOI 10.1105/tpc.6.3.351; GRANOT D, 1991, CELL MOTIL CYTOSKEL, V20, P47, DOI 10.1002/cm.970200106; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; GUARENTE L, 1982, P NATL ACAD SCI-BIOL, V79, P7410, DOI 10.1073/pnas.79.23.7410; GULLI MP, 1995, NUCLEIC ACIDS RES, V23, P1912, DOI 10.1093/nar/23.11.1912; JANSEN R, 1993, EMBO J, V12, P2549, DOI 10.1002/j.1460-2075.1993.tb05910.x; JANSEN RP, 1991, J CELL BIOL, V113, P715, DOI 10.1083/jcb.113.4.715; JANTZEN HM, 1990, NATURE, V344, P830, DOI 10.1038/344830a0; JIANG WD, 1993, MOL CELL BIOL, V13, P4884, DOI 10.1128/MCB.13.8.4884; KONDO K, 1992, J BIOL CHEM, V267, P16252; KUMAR A, 1972, J MOL BIOL, V63, P233, DOI 10.1016/0022-2836(72)90372-5; LAFARGA M, 1983, ANAT EMBRYOL, V166, P19, DOI 10.1007/BF00317942; LALO D, 1993, P NATL ACAD SCI USA, V90, P5524, DOI 10.1073/pnas.90.12.5524; LAPEYRE B, 1987, P NATL ACAD SCI USA, V84, P1472, DOI 10.1073/pnas.84.6.1472; LEE WC, 1991, J CELL BIOL, V113, P1, DOI 10.1083/jcb.113.1.1; LEFEBVRE O, 1994, J BIOL CHEM, V269, P23374; Maniatis T, 1989, MOL CLONING; MARIN O, 1990, INT J PEPT PROT RES, V36, P374; Marston F. A. O., 1987, DNA CLONING, P59; MEIER UT, 1994, J CELL BIOL, V127, P1505, DOI 10.1083/jcb.127.6.1505; MEIER UT, 1992, CELL, V70, P127; MEIER UT, 1990, J CELL BIOL, V111, P2235, DOI 10.1083/jcb.111.6.2235; Nomura N, 1994, DNA Res, V1, P27, DOI 10.1093/dnares/1.1.27; Nomura N, 1994, DNA Res, V1, P47, DOI 10.1093/dnares/1.1.47; OCHS RL, 1985, BIOL CELL, V54, P123, DOI 10.1111/j.1768-322X.1985.tb00387.x; PADMANABHA R, 1990, MOL CELL BIOL, V10, P4089, DOI 10.1128/MCB.10.8.4089; PAI CY, 1995, J CELL SCI, V108, P1911; PETER M, 1990, CELL, V60, P791, DOI 10.1016/0092-8674(90)90093-T; PFAFF M, 1988, BIOCHIM BIOPHYS ACTA, V969, P100, DOI 10.1016/0167-4889(88)90093-6; PFEIFLE J, 1984, EUR J BIOCHEM, V139, P417, DOI 10.1111/j.1432-1033.1984.tb08021.x; PFEIFLE J, 1986, EXP CELL RES, V162, P11, DOI 10.1016/0014-4827(86)90422-2; PRESTAYKO AW, 1974, BIOCHEMISTRY-US, V13, P1945, DOI 10.1021/bi00706a026; PRINGLE JR, 1991, METHOD ENZYMOL, V194, P565; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; ROBINOW CF, 1966, J CELL BIOL, V29, P129, DOI 10.1083/jcb.29.1.129; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; SATOH K, 1981, CELL BIOL INT REP, V5, P857, DOI 10.1016/0309-1651(81)90200-9; SCHMIDTZACHMANN MS, 1984, EXP CELL RES, V153, P327, DOI 10.1016/0014-4827(84)90604-9; SHAN XY, 1994, J CELL BIOL, V126, P853, DOI 10.1083/jcb.126.4.853; Shaw PJ, 1995, ANNU REV CELL DEV BI, V11, P93, DOI 10.1146/annurev.cb.11.110195.000521; Sherman F., 1986, METHODS YEAST GENETI; SIKORSKI RS, 1989, GENETICS, V122, P19; SMITH S, 1994, P NATL ACAD SCI USA, V91, P10124, DOI 10.1073/pnas.91.21.10124; SOEIRO R, 1973, J MOL BIOL, V79, P507, DOI 10.1016/0022-2836(73)90402-6; SUN C, 1994, EMBO J, V13, P3127, DOI 10.1002/j.1460-2075.1994.tb06611.x; TOLLERVEY D, 1993, CELL, V72, P443, DOI 10.1016/0092-8674(93)90120-F; TRAUB P, 1968, P NATL ACAD SCI USA, V59, P777, DOI 10.1073/pnas.59.3.777; VILARDELL J, 1990, PLANT MOL BIOL, V14, P423, DOI 10.1007/BF00028778; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; XUE ZX, 1993, EUR J CELL BIOL, V62, P13	68	70	72	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19376	19384						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702624				2022-12-25	WOS:A1996VB68400058
J	Persechini, A; Gansz, KJ; Paresi, RJ				Persechini, A; Gansz, KJ; Paresi, RJ			A role in enzyme activation for the N-terminal leader sequence in calmodulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-CHAIN KINASE; PEPTIDE COMPLEX; BASIC RESIDUES; TROPONIN-C; BINDING; FRAGMENTS	We have found that deletion of residues 2-8 from the N-terminal leader sequence: Ala(1)-Asp(2)-Gln-Leu(4)-Thr-Glu(6)-Glu-Gln(8), in calmodulin abolishes calmodulin-dependent activation of skeletal muscle myosin light chain kinase activity and reduces calmodulin-dependent activation of smooth muscle myosin light chain kinase activity to similar to 50% of the maximum level measured at a saturating calmodulin concentration, Calmodulin dependent activation of cerebellar nitric oxide synthase activity is not affected by this deletion. Overlapping tripeptide deletions from the leader sequence indicate that the acidic cluster, Glu(6)-Glu-Gln(8), contains the determinants necessary for activation of myosin light chain kinase activity, Deletion of Asp(2)-Gln-Leu(4) has no effect on activation of enzyme activity, Based on enzyme kinetic analyses, deletions in the leader sequence have little or no effect on the apparent affinities of calmodulin for the synthase or the two kinases, Since the N-terminal leader does not appear to play a significant structural role in the complexes between calmodulin and peptides representing the calmodulin-binding domains in the two kinases, our results indicate that it participates in secondary interactions with these enzymes that are important to activation, but not to recognition or binding of calmodulin.			Persechini, A (corresponding author), UNIV ROCHESTER,MED CTR,DEPT PHYSIOL & PHARMACOL,ROCHESTER,NY 14642, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK044322] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK44322] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BABU YS, 1988, J MOL BIOL, V204, P191, DOI 10.1016/0022-2836(88)90608-0; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; Colbran R J, 1990, Curr Top Cell Regul, V31, P181; FITZSIMONS DP, 1992, J BIOL CHEM, V267, P23903; GEORGE SE, 1993, J BIOL CHEM, V268, P25213; HEIDORN DB, 1988, BIOCHEMISTRY-US, V27, P909, DOI 10.1021/bi00403a011; HERRING BP, 1991, J BIOL CHEM, V266, P11838; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; KRUEGER JK, 1995, J BIOL CHEM, V270, P16848, DOI 10.1074/jbc.270.28.16848; MANALAN AS, 1984, ADV CYCLIC NUCL PROT, V18, P227; MCMILLAN K, 1992, P NATL ACAD SCI USA, V89, P11141, DOI 10.1073/pnas.89.23.11141; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; NEWTON DL, 1984, J BIOL CHEM, V259, P4419; PERSECHINI A, 1994, J BIOL CHEM, V269, P16148; PERSECHINI A, 1988, J BIOL CHEM, V263, P12175; Persechini A, 1996, BIOCHEMISTRY-US, V35, P224, DOI 10.1021/bi952383x; SAIMI Y, 1994, FEBS LETT, V350, P155, DOI 10.1016/0014-5793(94)00782-9; TRIPATHY A, 1995, BIOPHYS J, V69, P106, DOI 10.1016/S0006-3495(95)79880-0; VANBERKUM MFA, 1991, J BIOL CHEM, V266, P21488	19	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19279	19282		10.1074/jbc.271.32.19279	http://dx.doi.org/10.1074/jbc.271.32.19279			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702610	hybrid			2022-12-25	WOS:A1996VB68400044
J	Benaroudj, N; Triniolles, F; Ladjimi, MM				Benaroudj, N; Triniolles, F; Ladjimi, MM			Effect of nucleotides, peptides, and unfolded proteins on the self-association of the molecular chaperone HSC70	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHOCK COGNATE PROTEIN; UNCOATING ATPASE; ESCHERICHIA-COLI; CLATHRIN TRISKELIA; BINDING DOMAIN; HSP70; PURIFICATION; AGGREGATION; KINETICS; HYDROLYSIS	In a previous study, we showed that the molecular chaperone HSC70 self-associates in solution in a reversible and likely unlimited fashion, Here, we examine the influence of nucleotides, nucleotide analogs, peptides, and unfolded proteins on the self-association properties of this protein. Whereas in the presence of ADP, HSC70 exists as a slow, concentration- and temperature-dependent monomer-oligomer equilibrium, in the presence of ATP, the protein is essentially monomeric, indicating that ATP shifts this equilibrium toward the monomer by stabilizing the monomer, Dissociation of oligomers into monomers is also obtained with the slowly hydrolyzable ATP analogs, adenosine 5'-O-(thiotriphosphate) and 5'-adenylyl-beta,gamma-imidodiphosphate, or the complex between ADP and the phosphate analog, BeF3, indicating that binding but not hydrolysis of ATP is necessary and sufficient for the stabilization of HSC70 monomer, Furthermore, binding of short peptides or permanently unfolded proteins to thepeptide binding site of HSC70 promotes the dissociation of oligomers into monomers, suggesting that protein substrates are able to compete with HSC70 for the same binding site, Because the release of peptides or unfolded proteins from HSC70 has also been shown to require ATP binding, these results indicate that dissociation of oligomers is controlled by a mechanism similar to that of release of protein substrates and suggest that binding of HSC70 to itself occurs via the peptide binding site and mimics binding of HSC70 to protein substrates.	CNRS,LAB ENZYMOL & BIOCHIM STRUCT,F-91198 GIF SUR YVETTE,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay				Benaroudj, Nadia/0000-0002-6475-0041				ANDERSON JV, 1994, PLANT PHYSIOL, V104, P1371, DOI 10.1104/pp.104.4.1371; BENAROUDJ N, 1994, EUR J BIOCHEM, V221, P121, DOI 10.1111/j.1432-1033.1994.tb18720.x; BENAROUDJ N, 1994, BIOCHEMISTRY-US, V34, P15282; BHATTACHARYYA T, 1995, J BIOL CHEM, V270, P1705, DOI 10.1074/jbc.270.4.1705; BLONDELGUINDI S, 1993, J BIOL CHEM, V268, P12730; BOHEN SP, 1995, SCIENCE, V268, P1303, DOI 10.1126/science.7761850; BRAELL WA, 1984, J CELL BIOL, V99, P734, DOI 10.1083/jcb.99.2.734; BROWN CR, 1993, J CELL BIOL, V120, P1101, DOI 10.1083/jcb.120.5.1101; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; CARLINO A, 1992, P NATL ACAD SCI USA, V89, P2081, DOI 10.1073/pnas.89.6.2081; CHABRE M, 1990, TRENDS BIOCHEM SCI, V15, P6, DOI 10.1016/0968-0004(90)90117-T; CHAPPELL TG, 1987, J BIOL CHEM, V262, P746; CHAPPELL TG, 1986, CELL, V45, P3, DOI 10.1016/0092-8674(86)90532-5; CHEETHAM ME, 1994, EUR J BIOCHEM, V226, P99, DOI 10.1111/j.1432-1033.1994.tb20030.x; CYR DM, 1992, J BIOL CHEM, V267, P20927; DELUCAFLAHERTY C, 1990, CELL, V62, P875, DOI 10.1016/0092-8674(90)90263-E; FLAHERTY KM, 1990, NATURE, V346, P623, DOI 10.1038/346623a0; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; FOURIE AM, 1994, J BIOL CHEM, V269, P30470; FREIDEN PJ, 1992, EMBO J, V11, P63, DOI 10.1002/j.1460-2075.1992.tb05028.x; GAO BC, 1994, BIOCHEMISTRY-US, V33, P2048, DOI 10.1021/bi00174a010; GAO BC, 1993, J BIOL CHEM, V268, P8507; GREENE LE, 1995, J BIOL CHEM, V270, P2967, DOI 10.1074/jbc.270.7.2967; GUIDON PT, 1986, BIOCHEMISTRY-US, V25, P3231, DOI 10.1021/bi00359a023; HA JH, 1994, BIOCHEMISTRY-US, V33, P14625, DOI 10.1021/bi00252a031; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HEUSER J, 1989, J CELL BIOL, V109, P1457, DOI 10.1083/jcb.109.4.1457; Hightower LE, 1994, BIOL HEAT SHOCK PROT, P179; KIEFHABER T, 1991, BIO-TECHNOL, V9, P825, DOI 10.1038/nbt0991-825; KIM DH, 1992, J CELL PHYSIOL, V153, P353, DOI 10.1002/jcp.1041530215; KING C, 1995, J BIOL CHEM, V270, P22535, DOI 10.1074/jbc.270.38.22535; KWON OS, 1994, J BIOL CHEM, V269, P266; LAM KT, 1992, BIOCHEM BIOPH RES CO, V184, P167, DOI 10.1016/0006-291X(92)91174-O; LIN TH, 1991, J BIOL CHEM, V266, P1635; MCCARTY JS, 1995, J MOL BIOL, V249, P126, DOI 10.1006/jmbi.1995.0284; MCKAY DB, 1993, ADV PROTEIN CHEM, V44, P67, DOI 10.1016/S0065-3233(08)60564-1; MCKAY DB, 1994, BIOL HEAT SHOCK PROT, P153; MORSHAUSER RC, 1995, BIOCHEMISTRY-US, V34, P6261, DOI 10.1021/bi00019a001; ORSINI G, 1978, J BIOL CHEM, V253, P3453; PALLEROS DR, 1991, P NATL ACAD SCI USA, V88, P5719, DOI 10.1073/pnas.88.13.5719; PALLEROS DR, 1993, FEBS LETT, V336, P124, DOI 10.1016/0014-5793(93)81624-9; PALLEROS DR, 1993, NATURE, V365, P664, DOI 10.1038/365664a0; RANDALL LL, 1995, TRENDS BIOCHEM SCI, V20, P65, DOI 10.1016/S0968-0004(00)88959-8; RUTHERFORD SL, 1994, CELL, V79, P1129, DOI 10.1016/0092-8674(94)90003-5; SADIS S, 1992, BIOCHEMISTRY-US, V31, P9406, DOI 10.1021/bi00154a012; SCHLOSSMAN DM, 1984, J CELL BIOL, V99, P723, DOI 10.1083/jcb.99.2.723; SCHMID D, 1994, SCIENCE, V263, P971, DOI 10.1126/science.8310296; SCHMID SL, 1985, J BIOL CHEM, V260, P57; SCHONFELD HJ, 1995, J BIOL CHEM, V270, P2183, DOI 10.1074/jbc.270.5.2183; UNGEWICKELL E, 1985, EMBO J, V4, P3385, DOI 10.1002/j.1460-2075.1985.tb04094.x; WANG C, 1993, BIOCHEM J, V294, P69, DOI 10.1042/bj2940069; WANG TF, 1993, J BIOL CHEM, V268, P26049; WILBANKS SM, 1994, J BIOL CHEM, V269, P12893; WILBANKS SM, 1995, BIOCHEMISTRY-US, V34, P12095, DOI 10.1021/bi00038a002; ZETTLMEISSL G, 1979, BIOCHEMISTRY-US, V18, P5567, DOI 10.1021/bi00592a007; [No title captured]; [No title captured]	57	59	59	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18471	18476		10.1074/jbc.271.31.18471	http://dx.doi.org/10.1074/jbc.271.31.18471			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702492	hybrid			2022-12-25	WOS:A1996VB68300030
J	Narayan, S; He, F; Wilson, SH				Narayan, S; He, F; Wilson, SH			Activation of the human DNA polymerase beta promoter by a DNA-alkylating agent through induced phosphorylation of cAMP response element-binding protein-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR CREB; HAMSTER OVARY CELLS; GENE-TRANSCRIPTION; II TRANSCRIPTION; KINASE-A; RNA; EXTRACT; REPAIR; INDUCTION; EXCISION	Treatment of cells with the DNA-alkylating agent N-methyl-N'-nitro-N-nitrosoguanidine (MNNG) induces expression of the endogenous mammalian DNA polymerase beta (beta-pol) gene and of the cloned promoter in transient expression studies, The lone cAMP response element (CRE) in the core promoter, along with functional protein kinase A, is critical for the MNNG-induced upregulation, Recently, we described a kinetic mechanism for transcriptional regulation of the beta-pol promoter in vitro and found that CRE-binding protein (CREB) from MNNG-treated cells differentially up-regulates the promoter by stimulating formation of closed preinitiation complex (RP(c)), Here, using a CRE-dependent chimeric beta-pol promoter, we purified the RP(c) assembled with nuclear extract from MNNG-treated and control HeLa cells, Comparison of proteins in the purified RP(c) samples revealed that the MNNG induction is associated with a strong increase in the Ser(133)-phosphorylated form of recombinant CREB (CREB-1), CREB depletion of the nuclear extracts diminished transcriptional activity, and addition of purified Ser(133)-phosphorylated CREB-1 restored activity, whereas unphosphorylated CREB-1 did not, Addition of phosphorylated CREB-1 to the control cell extract mimicked the MNNG-induced up-regulation of transcriptional activity, These results indicate that phosphorylation of CREB-1 is the probable mechanism of activation of the beta-pol promoter after treatment of cells with the DNA-alkylating agent MNNG.	UNIV TEXAS,MED BRANCH,SEALY CTR MOL SCI,GALVESTON,TX 77555	University of Texas System; University of Texas Medical Branch Galveston			Wilson, Samuel H/E-6644-2019	Wilson, Samuel H/0000-0002-1702-5293	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES006492] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES06492] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ALBERTS AS, 1994, J BIOL CHEM, V269, P7623; ARIAS JA, 1989, J BIOL CHEM, V264, P3223; Brindle PK, 1992, CURR OPIN GENET DEV, V2, P199, DOI 10.1016/S0959-437X(05)80274-6; CHEN KH, 1995, GENE, V164, P323, DOI 10.1016/0378-1119(95)00498-U; CHODOSH LA, 1986, MOL CELL BIOL, V6, P4723, DOI 10.1128/MCB.6.12.4723; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; DELMAS V, 1994, REV PHYSIOL BIOCH P, V124, P1, DOI 10.1007/BFb0031030; DIANOV G, 1992, MOL CELL BIOL, V12, P1605, DOI 10.1128/MCB.12.4.1605; ENGLANDER EW, 1992, NUCLEIC ACIDS RES, V20, P5527, DOI 10.1093/nar/20.21.5527; ENGLANDER EW, 1992, DNA CELL BIOL, V11, P61, DOI 10.1089/dna.1992.11.61; ENGLANDER EW, 1992, CURR PERSPECT MOL CE, V1, P111; FORNACE AJ, 1989, MOL CELL BIOL, V9, P851, DOI 10.1128/MCB.9.2.851; FRANKLIN CC, 1992, P NATL ACAD SCI USA, V89, P7247, DOI 10.1073/pnas.89.15.7247; GINTY DD, 1993, SCIENCE, V260, P238, DOI 10.1126/science.8097062; GONZALEZ GA, 1991, MOL CELL BIOL, V11, P1306, DOI 10.1128/MCB.11.3.1306; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; HAGIWARA M, 1992, CELL, V70, P105, DOI 10.1016/0092-8674(92)90537-M; He F, 1996, BIOCHEMISTRY-US, V35, P1775, DOI 10.1021/bi9525987; JENKINS TM, 1992, SCIENCE, V258, P745; KEDAR PS, 1991, P NATL ACAD SCI USA, V88, P3729, DOI 10.1073/pnas.88.9.3729; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LEE CQ, 1990, EMBO J, V9, P4455, DOI 10.1002/j.1460-2075.1990.tb07896.x; MATSUMOTO Y, 1989, MOL CELL BIOL, V9, P3750, DOI 10.1128/MCB.9.9.3750; MEYER TE, 1993, ENDOCR REV, V14, P269, DOI 10.1210/er.14.3.269; NARAYAN S, 1994, J BIOL CHEM, V269, P12755; NARAYAN S, 1995, BIOCHEMISTRY-US, V34, P73, DOI 10.1021/bi00001a009; NICHOLS M, 1992, EMBO J, V11, P3337, DOI 10.1002/j.1460-2075.1992.tb05412.x; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; SINGHAL RK, 1993, J BIOL CHEM, V268, P15906; SINGHAL RK, 1995, J BIOL CHEM, V270, P949, DOI 10.1074/jbc.270.2.949; Sobol RW, 1996, NATURE, V379, P183, DOI 10.1038/379183a0; SRIVASTAVA DK, 1995, J BIOL CHEM, V270, P16402, DOI 10.1074/jbc.270.27.16402; STRUTHERS RS, 1991, NATURE, V350, P622, DOI 10.1038/350622a0; SUN PQ, 1992, MOL ENDOCRINOL, V6, P1858, DOI 10.1210/me.6.11.1858; WADZINSKI BE, 1993, MOL CELL BIOL, V13, P2822, DOI 10.1128/MCB.13.5.2822; WIDEN SG, 1988, J BIOL CHEM, V263, P16992; YAMAGUCHI M, 1994, EUR J BIOCHEM, V221, P227, DOI 10.1111/j.1432-1033.1994.tb18733.x; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0; ZAWEL L, 1995, GENE DEV, V9, P1479, DOI 10.1101/gad.9.12.1479	39	54	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18508	18513		10.1074/jbc.271.31.18508	http://dx.doi.org/10.1074/jbc.271.31.18508			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702497	hybrid			2022-12-25	WOS:A1996VB68300035
J	Parent, CA; Devreotes, PN				Parent, CA; Devreotes, PN			Constitutively active adenylyl cyclase mutant requires neither G proteins nor cytosolic regulators	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; DICTYOSTELIUM DEVELOPMENT; RAT-BRAIN; EXPRESSION; DISCOIDEUM; RECEPTOR; SYSTEM; CRAC	Receptor-mediated G protein-linked adenylyl cyclase systems are universal signal transducers. We exploited the essential role of this cascade in Dictyostelium development to screen for random mutations in the catalytic component, ACA. This enzyme is activated by G protein beta gamma-subunits acting in concert with a novel cytosolic regulator, CRAC. By suppression of the CRAC-null phenotype, we isolated constitutively active versions of the enzyme that require neither exogenous stimuli nor in ternal regulators. One mutant displayed a 15-fold increase in its V-max. It harbors a single amino acid substitution (L394S) affecting a conserved residue located in the first cytoplasmic loop near the N-terminal hydrophobic domain of ACA. The screening procedure can be adapted for isolation of constitutive mutations in mammalian adenylyl cyclases.	JOHNS HOPKINS UNIV,SCH MED,DEPT BIOL CHEM,BALTIMORE,MD 21205	Johns Hopkins University								BAKALYAR HA, 1990, SCIENCE, V250, P1403, DOI 10.1126/science.2255909; CALI JJ, 1994, J BIOL CHEM, V269, P12190; DEVREOTES P, 1989, SCIENCE, V245, P1054, DOI 10.1126/science.2672337; DEVREOTES P, 1987, METHOD CELL BIOL, V28, P299; DEVREOTES PN, 1994, NEURON, V12, P235, DOI 10.1016/0896-6273(94)90267-4; FEINSTEIN PG, 1991, P NATL ACAD SCI USA, V88, P10173, DOI 10.1073/pnas.88.22.10173; GAO BN, 1991, P NATL ACAD SCI USA, V88, P10178, DOI 10.1073/pnas.88.22.10178; HOWARD PK, 1988, NUCLEIC ACIDS RES, V16, P2613, DOI 10.1093/nar/16.6.2613; INSALL R, 1994, J CELL BIOL, V126, P1537, DOI 10.1083/jcb.126.6.1537; ISHIKAWA Y, 1992, J BIOL CHEM, V267, P13553; KRUPINSKI J, 1989, SCIENCE, V244, P1558, DOI 10.1126/science.2472670; LILLY P, 1993, GENE DEV, V7, P986, DOI 10.1101/gad.7.6.986; LILLY PJ, 1995, J CELL BIOL, V129, P1659, DOI 10.1083/jcb.129.6.1659; NELLEN W, 1987, METHOD CELL BIOL, V28, P67; PARENT CA, 1995, J BIOL CHEM, V270, P22693, DOI 10.1074/jbc.270.39.22693; Parent CA, 1996, ANNU REV BIOCHEM, V65, P411; PIERONI JP, 1995, J BIOL CHEM, V270, P21368, DOI 10.1074/jbc.270.36.21368; PITT GS, 1992, CELL, V69, P305, DOI 10.1016/0092-8674(92)90411-5; PREMONT RT, 1992, P NATL ACAD SCI USA, V89, P9809, DOI 10.1073/pnas.89.20.9809; Premont RT, 1996, J BIOL CHEM, V271, P13900, DOI 10.1074/jbc.271.23.13900; PUPILLO M, 1992, MOL BIOL CELL, V3, P1229, DOI 10.1091/mbc.3.11.1229; RAYMOND JR, 1994, AM J PHYSIOL, V266, pF163, DOI 10.1152/ajprenal.1994.266.2.F163; SUSSMAN M, 1987, METHOD CELL BIOL, V28, P9; TANG WJ, 1995, BIOCHEMISTRY-US, V34, P14563, DOI 10.1021/bi00044a035; TANG WJ, 1995, SCIENCE, V268, P1769, DOI 10.1126/science.7792604; TANG WJ, 1991, J BIOL CHEM, V266, P8595; TAUSSIG R, 1995, J BIOL CHEM, V270, P1, DOI 10.1074/jbc.270.1.1; WALLACH J, 1994, FEBS LETT, V338, P257, DOI 10.1016/0014-5793(94)80279-3; WATSON PA, 1994, J BIOL CHEM, V269, P28893; WU LJ, 1995, J CELL BIOL, V129, P1667, DOI 10.1083/jcb.129.6.1667; Yan SZ, 1996, J BIOL CHEM, V271, P10941, DOI 10.1074/jbc.271.18.10941	31	27	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18333	18336		10.1074/jbc.271.31.18333	http://dx.doi.org/10.1074/jbc.271.31.18333			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702473	hybrid			2022-12-25	WOS:A1996VB68300011
J	Suzuki, H; ONeill, BC; Suzuki, Y; Denisenko, ON; Bomsztyk, K				Suzuki, H; ONeill, BC; Suzuki, Y; Denisenko, ON; Bomsztyk, K			Activation of a nuclear DNA-binding protein recognized by a transcriptional element, bcn-1, from the laminin B2 chain gene promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; TRANSFORMING GROWTH FACTOR-BETA-1; GLOMERULAR EPITHELIAL-CELLS; MESANGIAL CELLS; BASEMENT-MEMBRANES; EXTRACELLULAR-MATRIX; RESPONSIVE ELEMENT; SYNAPTIC CLEFT; PHORBOL ESTER; EXPRESSION	Treatment of mesangial cells with either phorbol 12-myristate 13-acetate (PMA) or interleukin-1 beta induces an increase in laminin B2 chain mRNA levels, In other systems, activation of gene expression by these agents is transcriptionally mediated, To identify transcription factors that control expression of laminin B2 chain gene, we employed a strategy consisting of a computer-based analysis of murine and human gene promoter sequences and gel shift assays, Although overall the laminin B2 chain promoters from the two species have low sequence similarity, the mouse promoter contained sequences that were also contained in one motif, 5'-CCCCGCCCACCTCGCGCGC-3', designated bcn-1, from the human promoter. Treatment of mesangial cells with either PMA or interleukin-1 beta induced a transient increase in nuclear DNA binding activity, designated BCN-1, recognized the bcn-1 motif in a gel shift assay, A single nucleotide replacement in the bcn-1 motif abolished DNA binding, indicating that bcn-1 . BCN-1 complex formation is highly specific, In transient transfections, the ability of PMA to induce the laminin B2 chain promoter was abolished by mutating the bcn-1 motif. These results suggest that the bcn-1 element and its cognate inducible BCN-1 protein regulate laminin B2 chain gene transcription.	UNIV WASHINGTON, DEPT MED, SEATTLE, WA 98195 USA	University of Washington; University of Washington Seattle					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK045978, R01DK045978] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045134, P01GM042508] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK45978] Funding Source: Medline; NIGMS NIH HHS [GM45134, GM42508] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMSON DR, 1986, J PATHOL, V149, P257, DOI 10.1002/path.1711490402; ABRAHAMSON DR, 1993, KIDNEY INT, V43, P73, DOI 10.1038/ki.1993.13; ADLER S, 1986, J CLIN INVEST, V77, P762, DOI 10.1172/JCI112372; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BHANDARI B, 1995, J BIOL CHEM, V270, P5541, DOI 10.1074/jbc.270.10.5541; BOMSZTYK K, 1991, CELL REGUL, V2, P329, DOI 10.1091/mbc.2.4.329; BOMSZTYK K, 1990, J BIOL CHEM, V265, P9413; BORDER WA, 1990, NATURE, V346, P371, DOI 10.1038/346371a0; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; CAMPBELL MJ, 1995, BIOTECHNIQUES, V18, P1027; CHEDID M, 1991, J IMMUNOL, V147, P867; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DURKIN ME, 1988, BIOCHEMISTRY-US, V27, P5198, DOI 10.1021/bi00414a038; EHRIG K, 1990, P NATL ACAD SCI USA, V87, P3264, DOI 10.1073/pnas.87.9.3264; EKBLOM P, 1991, AM J KIDNEY DIS, V17, P603, DOI 10.1016/S0272-6386(12)80329-5; FLOEGE J, 1992, LAB INVEST, V66, P485; FUKATSU A, 1988, HUM PATHOL, V19, P64, DOI 10.1016/S0046-8177(88)80317-4; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREEN TL, 1992, J BIOL CHEM, V267, P2014; GRIMM S, 1993, BIOCHEM J, V290, P297, DOI 10.1042/bj2900297; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; HUNTER DD, 1989, NATURE, V338, P229, DOI 10.1038/338229a0; ISAKA Y, 1993, J CLIN INVEST, V92, P2597, DOI 10.1172/JCI116874; IWASAKI T, 1993, CYTOKINE, V5, P416, DOI 10.1016/1043-4666(93)90031-Y; JOHNSON R, 1992, J AM SOC NEPHROL, V2, P1388; KALLUNKI P, 1992, J CELL BIOL, V119, P679, DOI 10.1083/jcb.119.3.679; KALLUNKI T, 1991, J BIOL CHEM, V266, P221; LOVETT DH, 1988, J CLIN INVEST, V82, P115, DOI 10.1172/JCI113558; MARTIN GR, 1987, ANNU REV CELL BIOL, V3, P57, DOI 10.1146/annurev.cellbio.3.1.57; MATSUO S, 1986, AM J PATHOL, V122, P36; MELCION C, 1982, TRANSPLANT P, V14, P559; NAKAMURA T, 1992, KIDNEY INT, V41, P1213, DOI 10.1038/ki.1992.183; OGAWA K, 1988, J BIOL CHEM, V263, P8384; OSTROWSKI J, 1991, J BIOL CHEM, V266, P12722; RICHARDSON CA, 1995, AM J PHYSIOL-RENAL, V268, pF273, DOI 10.1152/ajprenal.1995.268.2.F273; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASAKI M, 1987, J BIOL CHEM, V262, P17111; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SMITH JD, 1988, J BIOL CHEM, V263, P8300; STRULOVICI B, 1989, IMMUNOLOGY, V67, P210; TIMPL R, 1979, J BIOL CHEM, V254, P9933; VADEN HGB, 1993, AM J PHYSIOL, V256, pF293; VASIOS G, 1991, EMBO J, V10, P1149, DOI 10.1002/j.1460-2075.1991.tb08055.x; VASIOS GW, 1989, P NATL ACAD SCI USA, V86, P9099, DOI 10.1073/pnas.86.23.9099; WALLENSTEIN S, 1980, CIRC RES, V47, P1, DOI 10.1161/01.RES.47.1.1; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557	49	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18981	18988		10.1074/jbc.271.31.18981	http://dx.doi.org/10.1074/jbc.271.31.18981			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702563	hybrid			2022-12-25	WOS:A1996VB68300101
J	Dahl, E; Manthey, D; Chen, Y; Schwarz, HJ; Chang, YS; Lalley, PA; Nicholson, BJ; Willecke, K				Dahl, E; Manthey, D; Chen, Y; Schwarz, HJ; Chang, YS; Lalley, PA; Nicholson, BJ; Willecke, K			Molecular cloning and functional expression of mouse connexin-30, a gap junction gene highly expressed in adult brain and skin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SOMATIC-CELL HYBRIDIZATION; CHROMOSOMAL ASSIGNMENTS; PROTEINS; SEQUENCE; VOLTAGE; RNA; XENOPUS; FAMILY; LIVER; CONDUCTANCE	A new gap junction gene isolated from the mouse genome codes for a connexin protein of 261 amino acids, Because of its theoretical molecular mass of 30.366 kDa, it is named connexin-30. Within the connexin gene family, this protein is most closely related to connexin-ae (77% amino acid sequence identity). The coding region of mouse connexin-30 is uninterrupted by introns and is detected in the mouse genome as a single copy gene that is assigned to mouse chromosome 14 by analysis of mouse x hamster somatic cell hybrids. Abundant amounts of connexin-30 mRNA (two transcripts of 2.0 and 2.3 kilobase pairs) were found after 4 weeks of postnatal development in mouse brain and skin, Microinjection of connexin-30 cRNA into Xenopus oocytes induced formation of functional gap junction channels that gated somewhat asymmetrically in response to transjunctional voltage and at significantly lower voltage (V-o = +38 and -46 mV) than the closely homologous connexin-26 channels (V-o = 89 mV). Heterotypic pairings of connexin-30 with connexin-as and connexin-32 produced channels with highly asymmetric and rectifying voltage gating, respectively. This suggests that the polarity of voltage gating and the cationic selectivity of connexin-30 are similar to those of its closest homologue, connexin-26.	UNIV BONN, INST GENET, MOLEK BIOL ABT, D-53117 BONN, GERMANY; GSF FORSCHUNGSZENTRUM UNWELT & GESUNDHEIT GMBH, D-85764 OBERSCHLEISSHEIM, GERMANY; SUNY BUFFALO, DEPT BIOL SCI, BUFFALO, NY 14260 USA; ROCHESTER INST TECHNOL, NATL TECH INST DEAF, ROCHESTER, NY 14623 USA	University of Bonn; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Rochester Institute of Technology				Nicholson, Bruce/0000-0003-1649-7173; Chen-Izu, Ye/0000-0003-4818-9570	NATIONAL CANCER INSTITUTE [R01CA048049] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048773] Funding Source: NIH RePORTER; NCI NIH HHS [CA-48049] Funding Source: Medline; NHLBI NIH HHS [HL-48773] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARRIO LC, 1991, P NATL ACAD SCI USA, V88, P8410, DOI 10.1073/pnas.88.19.8410; BENNETT MVL, 1991, NEURON, V6, P305, DOI 10.1016/0896-6273(91)90241-Q; BEYER EC, 1987, J CELL BIOL, V105, P2621, DOI 10.1083/jcb.105.6.2621; BEYER EC, 1993, INT REV CYTOL C, V173, P1; BRUZZONE R, 1993, MOL BIOL CELL, V4, P7, DOI 10.1091/mbc.4.1.7; BUKAUSKAS FF, 1995, PFLUG ARCH EUR J PHY, V429, P870, DOI 10.1007/BF00374812; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAHL G, 1992, BIOPHYS J, V62, P172, DOI 10.1016/S0006-3495(92)81803-9; DERMIETZEL R, 1989, P NATL ACAD SCI USA, V86, P10148, DOI 10.1073/pnas.86.24.10148; DERMIETZEL R, 1993, TRENDS NEUROSCI, V16, P186, DOI 10.1016/0166-2236(93)90151-B; EBIHARA L, 1989, SCIENCE, V243, P1194, DOI 10.1126/science.2466337; ELFGANG C, 1995, J CELL BIOL, V129, P805, DOI 10.1083/jcb.129.3.805; FISHMAN GI, 1991, GENOMICS, V10, P250, DOI 10.1016/0888-7543(91)90507-B; GIMLICH RL, 1988, J CELL BIOL, V107, P1065, DOI 10.1083/jcb.107.3.1065; GIMLICH RL, 1990, J CELL BIOL, V110, P597, DOI 10.1083/jcb.110.3.597; HAEFLIGER JA, 1992, J BIOL CHEM, V267, P2057; HARLEY CB, 1987, GENE ANAL TECH, V4, P17, DOI 10.1016/0735-0651(87)90013-6; HARRIS AL, 1981, J GEN PHYSIOL, V77, P95, DOI 10.1085/jgp.77.1.95; HENNEMANN H, 1992, EUR J CELL BIOL, V57, P51; HENNEMANN H, 1992, EUR J CELL BIOL, V58, P81; HENNEMANN H, 1992, J BIOL CHEM, V267, P17225; HENNEMANN H, 1992, J CELL BIOL, V117, P1299, DOI 10.1083/jcb.117.6.1299; JOHN SA, 1991, BIOCHEM BIOPH RES CO, V178, P1312, DOI 10.1016/0006-291X(91)91037-D; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; MILKS LC, 1988, EMBO J, V7, P2967, DOI 10.1002/j.1460-2075.1988.tb03159.x; MORENO AP, 1994, BIOPHYS J, V67, P113, DOI 10.1016/S0006-3495(94)80460-6; NEUHAUS IM, 1995, GENE, V158, P257, DOI 10.1016/0378-1119(94)00899-4; PAUL DL, 1995, CURR OPIN CELL BIOL, V7, P665, DOI 10.1016/0955-0674(95)80108-1; PAUL DL, 1986, J CELL BIOL, V103, P123, DOI 10.1083/jcb.103.1.123; RAO JKM, 1986, BIOCHIM BIOPHYS ACTA, V869, P197, DOI 10.1016/0167-4838(86)90295-5; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHWARZ HJ, 1994, SOMAT CELL MOLEC GEN, V20, P243, DOI 10.1007/BF02254763; SCHWARZ HJ, 1992, SOMAT CELL MOLEC GEN, V18, P351, DOI 10.1007/BF01235758; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; Sohl G, 1996, EUR J CELL BIOL, V69, P267; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; VERSELIS VK, 1994, NATURE, V368, P348, DOI 10.1038/368348a0; WHITE TW, 1995, KIDNEY INT, V48, P1148, DOI 10.1038/ki.1995.398; WHITE TW, 1992, MOL BIOL CELL, V3, P711, DOI 10.1091/mbc.3.7.711; WILLECKE K, 1991, EUR J CELL BIOL, V56, P1; WILLECKE K, 1991, J CELL BIOL, V114, P1049, DOI 10.1083/jcb.114.5.1049; YANCEY SB, 1989, J CELL BIOL, V108, P2241, DOI 10.1083/jcb.108.6.2241; YU W, 1994, P ROY SOC B-BIOL SCI, V255, P125, DOI 10.1098/rspb.1994.0018; ZHANG JT, 1994, J MEMBRANE BIOL, V139, P15; ZHANG JT, 1989, J CELL BIOL, V109, P3391, DOI 10.1083/jcb.109.6.3391	45	158	167	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					17903	17910		10.1074/jbc.271.30.17903	http://dx.doi.org/10.1074/jbc.271.30.17903			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663509	hybrid			2022-12-25	WOS:A1996UY93500049
J	Milne, DM; McKendrick, L; Jardine, LJ; Deacon, E; Lord, JM; Meek, DW				Milne, DM; McKendrick, L; Jardine, LJ; Deacon, E; Lord, JM; Meek, DW			Murine p53 is phosphorylated within the PAb421 epitope by protein kinase C in vitro, but not in vivo, even after stimulation with the phorbol ester o-tetradecanoylphorbol 13-acetate	ONCOGENE			English	Article						p53; phosphorylation; protein kinase C; PAb421 epitope	WILD-TYPE P53; TUMOR SUPPRESSOR PROTEIN; CELL-CYCLE; GENE AMPLIFICATION; IRRADIATION; APOPTOSIS; ARREST	The p53 tumour suppressor protein is thought to play a major role in the defence of the cell against agents which damage DIVA, p53 is phosphorylated at multiple sites in vivo and by several different protein kinases in vitro. In this report, we have examined the phosphorylation of murine p53 by protein kinase C (PKC). Phosphopeptide mapping, phosphoamino acid analysis and radiosequence analysis of p53 phosphorylated by PKC in vitro indicated that serine 370 and threonine 377 were the major targets for phosphorylation and suggested that serine 372 and threonines 365 and 371 were minor phosphorylation sites, Site-directed mutagenesis confirmed that residues 370-372, all of which lie within the epitope for monoclonal antibody PAb421, were phosphorylated in vitro. The p53 from P-32-labelled SV3T3 cells showed a phosphopeptide pattern which includes peptides with mobilities similar to those arising from phosphorylation of residues 370-372 by PKC in vitro. Only two of these in vivo-labelled phosphopeptides co-migrated in two dimensions with peptides labelled in vitro within the PAb421 eptiope and their phosphorylation was not stimulated by the addition of the PKC activator o-tetradecanoylphorbol 13-acetate (TPA) to the cells, even though this treatment led to a fourfold stimulation of p53 phosphorylation by MAP kinase, Moreover, when the p53 proteins containing mutations at residues 370-372 were expressed in COS cells, there was no loss of any of the in vivo phosphopeptides, indicating that phosphorylation within the PAb421 epitope was undetectable in the cell, These data suggest that p53 and PKC may not interact in vivo. The two-dimensional migration pattern of the novel group of peptides is consistent with phosphorylation of previously uncharacterised sites within the central DNA binding region of p53.	UNIV DUNDEE, NINEWELLS HOSP & MED SCH, BIOMED RES CTR, DUNDEE DD1 9SY, SCOTLAND; UNIV BIRMINGHAM, SCH MED, DEPT IMMUNOL, BIRMINGHAM B15 2TT, W MIDLANDS, ENGLAND	University of Dundee; University of Birmingham				Lord, Janet/0000-0003-1030-6786				BAUDIER J, 1992, P NATL ACAD SCI USA, V89, P11627, DOI 10.1073/pnas.89.23.11627; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DELPHIN C, 1994, J BIOL CHEM, V269, P29579; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUPP TR, 1994, COLD SPRING HARB SYM, V59, P195, DOI 10.1101/SQB.1994.059.01.024; KASTAN MB, 1991, CANCER RES, V51, P6304; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MCKENDRICK L, 1994, CELL MOL BIOL RES, V40, P555; MEEK DW, 1994, SEMIN CANCER BIOL, V5, P203; MEEK DW, 1988, MOL CELL BIOL, V8, P461, DOI 10.1128/MCB.8.1.461; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MILNE DM, 1994, J BIOL CHEM, V269, P9253; MILNER J, 1990, ONCOGENE, V5, P1683; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; SCHARER E, 1992, NUCLEIC ACIDS RES, V20, P1539, DOI 10.1093/nar/20.7.1539; Shaw P, 1996, ONCOGENE, V12, P921; SOUSSI T, 1990, ONCOGENE, V5, P945; TAKENAKA I, 1995, J BIOL CHEM, V270, P5405, DOI 10.1074/jbc.270.10.5405; ULLRICH SJ, 1992, ONCOGENE, V7, P1635; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7	29	54	54	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 4	1996	13	1					205	211						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UX319	8700548				2022-12-25	WOS:A1996UX31900024
J	Murty, VVVS; Reuter, VE; Bosl, GJ; Chaganti, RSK				Murty, VVVS; Reuter, VE; Bosl, GJ; Chaganti, RSK			Deletion mapping identifies loss of heterozygosity at 5p15.1-15.2, 5q11 and 5q34-35 in human male germ cell tumors	ONCOGENE			English	Article						male germ cell tumor; chromosome 5; loss of heterozygosity; monosomy; tumor suppressor gene	HEPATOCELLULAR-CARCINOMA; GENE; CHROMOSOME-5Q	Cytogenetic and loss of heterozygosity (LOH) studies of chromosome 5 in male germ cell tumors (GCTs) previously reported suggested the presence of one or more tumor suppressor genes (TSGs) on this chromosome which may play a role in the development of these tumors, In an attempt to further characterize allelic deletions on chromosome 5, we performed a detailed deletion mapping utilizing 66 normal-tumor DNAs from male GCTs assaying 24 polymorphic markers mapped to both the short and long arms, Thirty-seven (56%) tumors exhibited LOH at one or more loci, Loss of one allele at all informative loci was found in 15 of 37 (40.5%) cases suggesting monosomy of chromosome 5, The pattern of LOH in the remaining 22 (59.5%) tumors revealed regional losses identifying three common sites of deletions at 5p15.1-15.2, 5q11, and 5q34-35, respectively, The distribution of allelic deletions was found to be similar in all histologic subtypes with predominance of monosomy in teratomas, Thus, the present study revealed 2 types of chromosome 5 abnormalities in male GCTs, genetic monosomy and regional deletion, the latter identifying three novel sites of candidate TSGs, These data suggest that loss of genetic information on chromosome 5 plays an important role in male GCT development.	MEM SLOAN KETTERING CANC CTR,PROGRAM GENET & CELL BIOL,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,DEPT HUMAN GENET,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,DEPT PATHOL,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,DEPT MED,SOLID TUMOR DIV,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center					NCI NIH HHS [CA05826] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA005826] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALJEHANI RMA, 1995, GENE CHROMOSOME CANC, V13, P249, DOI 10.1002/gcc.2870130404; ASADA Y, 1994, NAT GENET, V6, P363, DOI 10.1038/ng0494-363; DING SF, 1993, CANCER DETECT PREV, V17, P405; DING SF, 1991, BRIT J CANCER, V64, P1083, DOI 10.1038/bjc.1991.468; GODDARD AD, 1993, ADV HUM GENET, V21, P321; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HOSOE S, 1994, CANCER RES, V54, P1787; KINZLER KW, 1991, SCIENCE, V251, P1366, DOI 10.1126/science.1848370; MITRA AB, 1995, J NATL CANCER I, V87, P742, DOI 10.1093/jnci/87.10.742; MITRA AB, 1994, CANCER RES, V54, P4481; MURTY VVVS, 1994, CANCER RES, V54, P3983; MURTY VVVS, 1992, P NATL ACAD SCI USA, V89, P11006, DOI 10.1073/pnas.89.22.11006; MURTY VVVS, 1994, ONCOGENE, V9, P2245; PENG HQ, 1995, CANCER RES, V55, P2871; RASHEED BKA, 1995, ONCOGENE, V10, P2243; RODRIGUEZ E, 1992, CANCER RES, V52, P2285; Tamura G, 1996, CANCER RES, V56, P612; Wieland I, 1996, ONCOGENE, V12, P97; WIELAND I, 1994, CANCER RES, V54, P1772	20	30	30	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 20	1996	12	12					2719	2723						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UW487	8700532				2022-12-25	WOS:A1996UW48700027
J	Brechler, V; Chu, WN; Baxter, JD; Thibault, G; Reudelhuber, TL				Brechler, V; Chu, WN; Baxter, JD; Thibault, G; Reudelhuber, TL			A protease processing site is essential for prorenin sorting to the regulated secretory pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PITUITARY ATT-20 CELLS; HUMAN RENIN; GRANULES; PROPEPTIDE; PROTEINS; SEQUENCE; STORAGE; FURIN; PROOPIOMELANOCORTIN; PROSOMATOSTATIN	Transfected mouse pituitary AtT-20 cells were used to examine the sorting of human prorenin to dense core secretory granules and the regulated secretory pathway, These cells secrete prorenin constitutively and sort a portion of the prorenin to secretory granules, where it is converted to active renin by proteolytic processing. Pulse chase labeling of transfected AtT-20 cells demonstrated that regulated secretion of prorenin was prevented by: 1) the mutagenic deletion of the prosegment, 2) the premature proteolytic removal of the prosegment by a Golgi-resident processing protease, or 3) the mutation of the native cleavage site so as to prevent removal of the prosegment. In addition, expression of fusion proteins containing portions of the prorenin prosegment demonstrated that exposure of potential proteolytic cleavage sites was sufficient to confer cleavage-dependent regulated secretion of the corresponding protein. These data implicate the protease cleavage event in the regulated secretion of prorenin and are consistent with the involvement of a subclass of processing proteases in the sorting of certain proteins to secretory granules in AtT-20 cells.	CLIN RES INST MONTREAL,LAB MOL BIOCHEM HYPERTENS,MONTREAL,PQ H2W 1R7,CANADA; CLIN RES INST MONTREAL,LAB CELL BIOL HYPERTENS,MONTREAL,PQ H2W 1R7,CANADA; UNIV CALIF SAN FRANCISCO,METAB RES UNIT,SAN FRANCISCO,CA 94143	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; University of California System; University of California San Francisco								ARRANDALE JM, 1994, MOL ENDOCRINOL, V8, P1083, DOI 10.1210/me.8.8.1083; BRAKCH N, 1994, BIOCHEM BIOPH RES CO, V205, P221, DOI 10.1006/bbrc.1994.2653; BURGESS TL, 1987, ANNU REV CELL BIOL, V3, P243, DOI 10.1146/annurev.cellbio.3.1.243; CHEVRIER D, 1993, MOL CELL ENDOCRINOL, V94, P213, DOI 10.1016/0303-7207(93)90170-O; CHIDGEY MAJ, 1990, EUR J BIOCHEM, V190, P139, DOI 10.1111/j.1432-1033.1990.tb15556.x; CHU WN, 1990, MOL ENDOCRINOL, V4, P1905, DOI 10.1210/mend-4-12-1905; CHUNG KN, 1989, SCIENCE, V243, P192, DOI 10.1126/science.2911732; FRITZ LC, 1987, J BIOL CHEM, V262, P12409; GORR SU, 1989, AM J PHYSIOL, V257, pE247, DOI 10.1152/ajpendo.1989.257.2.E247; HALBAN PA, 1994, BIOCHEM J, V299, P1; HATSUZAWA K, 1990, J BIOL CHEM, V265, P22075; HEINRIKSON RL, 1989, AM J HYPERTENS, V2, P367, DOI 10.1093/ajh/2.5.367; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; HOSAKA M, 1991, J BIOL CHEM, V266, P12127; HUTTNER WB, 1991, TRENDS BIOCHEM SCI, V16, P27, DOI 10.1016/0968-0004(91)90012-K; KARRENBAUER A, 1990, CELL, V63, P259, DOI 10.1016/0092-8674(90)90159-C; KULIAWAT R, 1994, J CELL BIOL, V126, P77, DOI 10.1083/jcb.126.1.77; KULIAWAT R, 1992, J CELL BIOL, V118, P521, DOI 10.1083/jcb.118.3.521; MAINS RE, 1978, J BIOL CHEM, V253, P651; MERCURE C, 1995, J BIOL CHEM, V270, P16355, DOI 10.1074/jbc.270.27.16355; MOLLOY SS, 1994, EMBO J, V13, P18, DOI 10.1002/j.1460-2075.1994.tb06231.x; NAGAHAMA M, 1991, EUR J BIOCHEM, V197, P135, DOI 10.1111/j.1432-1033.1991.tb15891.x; NAGAHAMA M, 1990, FEBS LETT, V264, P67, DOI 10.1016/0014-5793(90)80766-C; NAKAYAMA K, 1989, FEBS LETT, V257, P89, DOI 10.1016/0014-5793(89)81793-4; REAVES BJ, 1991, MOL CELL ENDOCRINOL, V79, pC141, DOI 10.1016/0303-7207(91)90085-7; Reudelhuber Timothy L., 1995, P1621; Sealey Jean E., 1995, P1763; Seidah N G, 1992, NIDA Res Monogr, V126, P132; SEVARINO KA, 1989, CELL, V57, P11, DOI 10.1016/0092-8674(89)90167-0; STOLLER TJ, 1989, J CELL BIOL, V108, P1647, DOI 10.1083/jcb.108.5.1647; TAM WWH, 1993, EUR J CELL BIOL, V62, P294; THIBAULT G, 1987, BIOCHEM J, V241, P265, DOI 10.1042/bj2410265; TOOZE SA, 1991, FEBS LETT, V285, P220, DOI 10.1016/0014-5793(91)80805-D; TUCKER PW, 1979, SCIENCE, V206, P1299, DOI 10.1126/science.117548; VINDROLA O, 1992, MOL ENDOCRINOL, V6, P1088, DOI 10.1210/me.6.7.1088; VONZASTROW M, 1987, J CELL BIOL, V105, P2675, DOI 10.1083/jcb.105.6.2675; Yoo SH, 1996, J BIOL CHEM, V271, P1558	37	72	72	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20636	20640		10.1074/jbc.271.34.20636	http://dx.doi.org/10.1074/jbc.271.34.20636			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702811	hybrid			2022-12-25	WOS:A1996VD33700063
J	Canet, D; Forge, V; Guillain, F; Mintz, E				Canet, D; Forge, V; Guillain, F; Mintz, E			Ca2+ translocation across sarcoplasmic reticulum ATPase randomizes the two transported ions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+-DEPENDENT ADENOSINE-TRIPHOSPHATASE; CALCIUM-BINDING; HIGH-AFFINITY; REACTION-MECHANISM; SITES; CA2+-ATPASE; PUMP; DISSOCIATION; TEMPERATURE; SUBSTRATE	Cytoplasmic Ca2+ dissociation is sequential, and the Ca2+ ions bound to the nonphosphorylated ATPase are commonly represented as superimposed on each other, so that the superficial Ca2+ is freely exchangeable from the cytoplasm, whereas the deeper Ca2+ is not. Under conditions where ADP-sensitive phosphoenzyme accumulates (leaky vesicles, 5 degrees C, pH 8, 300 mM K+), luminal Ca2+ dissociation is sequential as well, so that the representation of two superimposed Ca2+ ions still holds on the phosphoenzyme, with the superficial Ca2+ facing the lumen freely exchangeable and the deeper Ca2+ blocked by the superficial Ca2(+). Under the same conditions, we have investigated whether a prebuilt Ca2+ order is maintained during membrane translocation, Starting from a prebuilt order on the cytoplasmic side, we showed that the Ca2+ ions cannot be identified after translocation to the luminal side, The same result was obtained starting from a prebuilt order on the luminal side and following the luminal to cytoplasmic translocation, We conclude that the two Ca2+ ions are mixed during ATP-induced phosphorylation as well as during ADP-induced dephosphorylation.	CTR ETUD SACLAY,DEPT BIOL CELLULAIRE & MOL,SECT BIOPHYS PROT & MEMBRANES,CNRS,UNITE RECH 2096,F-91191 GIF SUR YVETTE,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Canet, D (corresponding author), CEA,F-91191 GIF SUR YVETTE,FRANCE.							ANDERSEN JP, 1994, J BIOL CHEM, V269, P15931; Andersen JP, 1995, BIOSCIENCE REP, V15, P243, DOI 10.1007/BF01788358; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; DEMEIS L, 1980, BIOCHEMISTRY-US, V19, P4252, DOI 10.1021/bi00559a017; DUPONT Y, 1982, BIOCHIM BIOPHYS ACTA, V688, P75, DOI 10.1016/0005-2736(82)90580-6; DUPONT Y, 1984, ANAL BIOCHEM, V142, P504, DOI 10.1016/0003-2697(84)90496-2; FORGE V, 1995, J BIOL CHEM, V270, P18271, DOI 10.1074/jbc.270.31.18271; FORGE V, 1993, J BIOL CHEM, V268, P10953; HANEL AM, 1991, BIOCHEMISTRY-US, V30, P11320, DOI 10.1021/bi00111a019; INESI G, 1987, J BIOL CHEM, V262, P16338; INESI G, 1990, J MEMBRANE BIOL, V116, P1, DOI 10.1007/BF01871666; INESI G, 1980, J BIOL CHEM, V255, P3025; Inesi G, 1995, BIOSCIENCE REP, V15, P327, DOI 10.1007/BF01788365; JENCKS WP, 1993, BIOCHEMISTRY-US, V32, P7030, DOI 10.1021/bi00078a031; LACAPERE JJ, 1993, EUR J BIOCHEM, V211, P117, DOI 10.1111/j.1432-1033.1993.tb19877.x; Martonosi AN, 1995, BIOSCIENCE REP, V15, P263, DOI 10.1007/BF01788359; MESZAROS LG, 1992, BIOCHEMISTRY-US, V31, P1195, DOI 10.1021/bi00119a032; MESZAROS LG, 1993, BIOCHEMISTRY-US, V32, P10085, DOI 10.1021/bi00089a025; MOUTIN MJ, 1991, J BIOL CHEM, V266, P5580; MYUNG J, 1994, BIOCHEMISTRY-US, V33, P8775, DOI 10.1021/bi00195a020; ORLOWSKI S, 1991, BIOCHEMISTRY-US, V30, P11331, DOI 10.1021/bi00111a020; SHIGEKAWA M, 1983, J BIOL CHEM, V258, P8698; SHIGEKAWA M, 1979, J BIOL CHEM, V254, P4726; TOYOSHIMA C, 1993, NATURE, V362, P469, DOI 10.1038/362469a0; VILSEN B, 1992, J BIOL CHEM, V267, P25739	25	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20566	20572		10.1074/jbc.271.34.20566	http://dx.doi.org/10.1074/jbc.271.34.20566			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702801	hybrid			2022-12-25	WOS:A1996VD33700053
J	ODoherty, RM; Lehman, DL; Seoane, J; GomezFoix, AM; Guinovart, JJ; Newgard, CB				ODoherty, RM; Lehman, DL; Seoane, J; GomezFoix, AM; Guinovart, JJ; Newgard, CB			Differential metabolic effects of adenovirus-mediated glucokinase and hexokinase I overexpression in rat primary hepatocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATED INSULIN-SECRETION; GLYCOGEN-SYNTHASE; GLUCOSE-METABOLISM; REGULATORY PROTEIN; TRANSLOCATION; CELLS; LIVER; GENE; GLUCOSE-6-PHOSPHATE; PHOSPHORYLASE	The first step of glucose metabolism is the phosphorylation of glucose, catalyzed by the hexokinase family of enzymes. To address the metabolic impact of increasing glucose phosphorylation capacity in liver, rat primary hepatocytes were treated with recombinant adenoviruses containing the cDNAs encoding either rat Liver glucokinase (AdCMV-GKL) or rat hexokinase I (Ad-CMV-HKI). Maximal glucose phosphorylation in Ad-CMV-GKL- and AdCMV-HKI-treated hepatocytes was increased 7.1 +/- 1.2- and 6.3 +/- 0.8-fold, respectively, over hepatocytes treated with an adenovirus expressing beta-galactosidase. Glucose usage (measured with 3 and 20 mM 2-[H-3]glucose and 5-[H-3]glucose) was significantly increased in AdCMV-GKL-treated cells preincubated in 1 or 25 mM glucose. Treatment of hepatocytes with Ad-CMV-HKI also caused enhanced glucose utilization, but the increases were smaller and were less apparent in cells preincubated in high (25 mM) glucose. AdCMV-GKL-treated hepatocytes incubated for 48 h in the presence of variable glucose concentrations had glycogen levels that were maximally 15.0 +/- 0.6-fold greater than levels in corresponding control cells. AdCMV-HKI-treated hepatocytes incubated under similar conditions had unchanged glycogen levels relative to controls. In AdCMV-GKL-treated cells, lactate output was increased to a maximum of 3.0 +/- 0.4-fold (at 25 mM glucose), glucose oxidation was increased 3.5 +/- 0.3-fold, and triglyceride production was unchanged relative to untreated cells. Among these three parameters, only lactate production was increased in AdCMV-HKI-treated cells, and then only at low glucose concentrations. We conclude that overexpression of glucokinase has potent effects on glucose storage and utilization in hepatocytes and that these effects are not matched by overexpression of hexokinase I.	UNIV TEXAS,SW MED CTR,GIFFORD LABS DIABET RES,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT INTERNAL MED,DALLAS,TX 75235; UNIV BARCELONA,FAC QUIM,DEPT BIOQUIM & BIOL MOL,E-08028 BARCELONA,SPAIN	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Barcelona			Seoane, Joan/AAG-9173-2019	Seoane, Joan/0000-0002-6541-5974	PHS HHS [1P50H2598801] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AGIUS L, 1993, BIOCHEM J, V296, P785, DOI 10.1042/bj2960785; AGIUS L, 1994, BIOCHEM J, V303, P841, DOI 10.1042/bj3030841; BARZILAI N, 1993, J BIOL CHEM, V268, P25019; Becker TC, 1996, J BIOL CHEM, V271, P390, DOI 10.1074/jbc.271.1.390; BECKER TC, 1994, J BIOL CHEM, V269, P21234; CARABAZA A, 1992, FEBS LETT, V296, P211, DOI 10.1016/0014-5793(92)80381-P; CIUDAD CJ, 1988, ARCH BIOCHEM BIOPHYS, V264, P30, DOI 10.1016/0003-9861(88)90566-8; CIUDAD CJ, 1986, BIOCHEM BIOPH RES CO, V141, P1195, DOI 10.1016/S0006-291X(86)80171-1; FERNANDEZNOVELL JM, 1992, BIOCHEM J, V281, P443, DOI 10.1042/bj2810443; FERNANDEZNOVELL JM, 1992, BIOCHEM J, V288, P497, DOI 10.1042/bj2880497; GOMEZFOIX AM, 1992, J BIOL CHEM, V267, P25129; HERZ J, 1993, P NATL ACAD SCI USA, V90, P2812, DOI 10.1073/pnas.90.7.2812; HUGHES SD, 1992, P NATL ACAD SCI USA, V89, P688, DOI 10.1073/pnas.89.2.688; HUGHES SD, 1993, J BIOL CHEM, V268, P15205; ISHIBASHI S, 1993, J CLIN INVEST, V92, P883, DOI 10.1172/JCI116663; KOZARSKY KF, 1994, J BIOL CHEM, V269, P13695; KUWAJIMA M, 1986, J BIOL CHEM, V261, P8849; MASSAGUE J, 1978, BIOCHIM BIOPHYS ACTA, V543, P269, DOI 10.1016/0304-4165(78)90073-9; MEGLASSON M D, 1986, Diabetes Metabolism Reviews, V2, P163; MILBURN JL, 1995, J BIOL CHEM, V270, P1295, DOI 10.1074/jbc.270.3.1295; NEWGARD CB, 1995, ANNU REV BIOCHEM, V64, P689, DOI 10.1146/annurev.biochem.64.1.689; ROSSETTI L, 1993, J CLIN INVEST, V92, P1126, DOI 10.1172/JCI116681; TOYODA Y, 1995, BIOCHEM BIOPH RES CO, V215, P467, DOI 10.1006/bbrc.1995.2488; TOYODA Y, 1994, BIOCHEM BIOPH RES CO, V204, P252, DOI 10.1006/bbrc.1994.2452; VALERA A, 1994, EUR J BIOCHEM, V222, P533, DOI 10.1111/j.1432-1033.1994.tb18895.x; VANSCHAFTINGEN E, 1994, FASEB J, V8, P414, DOI 10.1096/fasebj.8.6.8168691; WEINHOUSE S, 1976, CURR TOP CELL REGUL, V11, P1; WILSON JE, 1984, REGULATION CARBOHYDR, P45	28	66	67	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20524	20530		10.1074/jbc.271.34.20524	http://dx.doi.org/10.1074/jbc.271.34.20524			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702794	hybrid			2022-12-25	WOS:A1996VD33700046
J	Vadlamudi, RK; Joung, I; Strominger, JL; Shin, J				Vadlamudi, RK; Joung, I; Strominger, JL; Shin, J			p62, a phosphotyrosine-independent ligand of the SH2 domain of p56(lck), belongs to a new class of ubiquitin-binding proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article								p62 is a novel cellular protein which was initially identified as a phosphotyrosine-independent ligand of the SH2 domain of p56(lck). In the yeast two-hybrid system, p62 specifically interacted with ubiquitin in vivo. Furthermore, p62 bound to ubiquitin-conjugated Sepharose beads in vitro and was efficiently competed by soluble ubiquitin. The interaction was independent of ATP hydrolysis, and its dissociation did not require a reducing agent. Thus, p62 binds to ubiquitin noncovalently. Further analysis showed that the C-terminal 80 amino acids of p62 were indispensable for its interaction with ubiquitin. However, p62 has homology neither with ubiquitin C-terminal hydrolases nor with the S5a subunit of the 26 S proteasome complex, the only proteins known to bind to ubiquitin noncovalently. These results suggest that p62 belongs to a new class of ubiquitinbinding proteins and that p62 affects signal transduction at least partly through ubiquitination-mediated protein degradation.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV TUMOR VIROL,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School					NATIONAL CANCER INSTITUTE [R35CA047554] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM048961] Funding Source: NIH RePORTER; NCI NIH HHS [CA47554] Funding Source: Medline; NIGMS NIH HHS [GM48961] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKER RT, 1991, NUCLEIC ACIDS RES, V19, P1035, DOI 10.1093/nar/19.5.1035; CIECHANOVER A, 1978, BIOCHEM BIOPH RES CO, V81, P1100, DOI 10.1016/0006-291X(78)91249-4; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; CLEGHON V, 1994, J BIOL CHEM, V269, P17749; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; Ferrell K, 1996, FEBS LETT, V381, P143, DOI 10.1016/0014-5793(96)00101-9; HADARI T, 1992, J BIOL CHEM, V267, P719; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; Joung I, 1996, P NATL ACAD SCI USA, V93, P5991, DOI 10.1073/pnas.93.12.5991; MALEK SN, 1994, J BIOL CHEM, V269, P33009; MAYER AN, 1989, BIOCHEMISTRY-US, V28, P166, DOI 10.1021/bi00427a024; Park I, 1995, P NATL ACAD SCI USA, V92, P12338, DOI 10.1073/pnas.92.26.12338; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PREDERGAST JA, 1995, J BIOL CHEM, V270, P9347; SCHEFFNER M, 1995, NATURE, V373, P81, DOI 10.1038/373081a0; WANG J, 1995, J BIOL CHEM, V270, P12774, DOI 10.1074/jbc.270.21.12774	16	243	252	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20235	20237		10.1074/jbc.271.34.20235	http://dx.doi.org/10.1074/jbc.271.34.20235			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702753	hybrid			2022-12-25	WOS:A1996VD33700005
J	Priest, JW; Hajduk, SL				Priest, JW; Hajduk, SL			In vitro import of the Rieske iron-sulfur protein by trypanosome mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C REDUCTASE; PRECURSOR PROTEINS; INNER MEMBRANE; INTERMEMBRANE SPACE; YEAST MITOCHONDRIA; DEVELOPMENTAL REGULATION; BLOOD-STREAM; MATRIX ATP; HEME LYASE; SACCHAROMYCES-CEREVISIAE	Most of the proteins present in the mitochondrion are imported to that location from the cytosol. While this process has been studied extensively in fungal and mammalian systems, little work has been done in other eukaryotic organisms. We are particularly interested in the Trypanosoma brucei system because this organism developmentally regulates mitochondrial function during its life cycle and because one of the imported proteins lacks a conventional targeting sequence. We report here the development of an in vitro import system using crude trypanosome mitochondria and a nuclear encoded, mitochondrial protein. Import of the Rieske iron-sulfur protein subunit of the cytochrome c reductase complex requires a membrane potential, ATP, and a protein component on the mitochondrial surface. The precursor protein is sequentially processed to the mature form in two steps by peptidases that require divalent metal ions far activity. As in other eukaryotic systems, the first processing event occurs inside the inner membrane and is probably catalyzed by a matrix-processing protease. Surprisingly, the second processing activity is located outside the inner membrane. Both processing steps require ATP but are independent of a membrane potential. We suggest that the trypanosome iron-sulfur protein is imported along a ''conservative sorting pathway'' but that the assembly mechanism of the reductase complex may be unique to trypanosomes.	UNIV ALABAMA,DEPT MOL GENET & BIOCHEM,BIRMINGHAM,AL 35294; UNIV ALABAMA,SCH MED & DENT,DEPT MED,BIRMINGHAM,AL 35294	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI021401, P01AI028780, R01AI021401, F32AI008259] Funding Source: NIH RePORTER; NIAID NIH HHS [AI28780, AI21401, AI08259] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BERTHOLD J, 1995, CELL, V81, P1085, DOI 10.1016/S0092-8674(05)80013-3; BOHNI PC, 1983, J BIOL CHEM, V258, P4937; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRINGAUD F, 1995, MOL BIOCHEM PARASIT, V71, P65, DOI 10.1016/0166-6851(95)00023-T; CYR DM, 1993, J BIOL CHEM, V268, P23751; EFFRON PN, 1993, MOL BIOCHEM PARASIT, V59, P191, DOI 10.1016/0166-6851(93)90217-L; ELSE AJ, 1994, MOL BIOCHEM PARASIT, V64, P233, DOI 10.1016/0166-6851(93)00016-3; FU W, 1990, J BIOL CHEM, V265, P16541; GLICK BS, 1992, TRENDS BIOCHEM SCI, V17, P453, DOI 10.1016/0968-0004(92)90487-T; GLICK BS, 1992, CELL, V69, P809, DOI 10.1016/0092-8674(92)90292-K; GRAHAM LA, 1993, J BIOENERG BIOMEMBR, V25, P245, DOI 10.1007/BF00762586; GRAHAM LA, 1991, J BIOL CHEM, V266, P22485; HARKNESS TAA, 1994, J CELL BIOL, V124, P637, DOI 10.1083/jcb.124.5.637; HARRIS ME, 1990, J BIOL CHEM, V265, P11368; HARTL FU, 1987, CELL, V51, P1027, DOI 10.1016/0092-8674(87)90589-7; HARTL FU, 1986, CELL, V47, P939, DOI 10.1016/0092-8674(86)90809-3; HARTL FU, 1989, BIOCHIM BIOPHYS ACTA, V988, P1, DOI 10.1016/0304-4157(89)90002-6; HAUCKE V, 1995, J BIOL CHEM, V270, P5565, DOI 10.1074/jbc.270.10.5565; Hauser R, 1996, J CELL SCI, V109, P517; HAWLITSCHEK G, 1988, CELL, V53, P795, DOI 10.1016/0092-8674(88)90096-7; HENDRICK JP, 1989, P NATL ACAD SCI USA, V86, P4056, DOI 10.1073/pnas.86.11.4056; HWANG ST, 1991, J BIOL CHEM, V266, P21083; ISAYA G, 1994, MOL CELL BIOL, V14, P5603, DOI 10.1128/MCB.14.8.5603; ISAYA G, 1992, J BIOL CHEM, V267, P7904; JACKSON RJ, 1983, METHOD ENZYMOL, V96, P51; JAPA S, 1994, ARCH BIOCHEM BIOPHYS, V312, P414, DOI 10.1006/abbi.1994.1327; KANG PJ, 1990, NATURE, V348, P137, DOI 10.1038/348137a0; KIEBLER M, 1993, CELL, V74, P483, DOI 10.1016/0092-8674(93)80050-O; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LILL R, 1992, EMBO J, V11, P449, DOI 10.1002/j.1460-2075.1992.tb05074.x; MAHLKE K, 1990, EUR J BIOCHEM, V192, P551, DOI 10.1111/j.1432-1033.1990.tb19260.x; MARTIN J, 1991, J BIOL CHEM, V266, P18051; MURAKAMI H, 1988, J CELL BIOL, V107, P2051, DOI 10.1083/jcb.107.6.2051; NICHOLSON DW, 1987, EUR J BIOCHEM, V164, P147, DOI 10.1111/j.1432-1033.1987.tb11006.x; NICHOLSON DW, 1989, J BIOL CHEM, V264, P10156; NOLAN DP, 1992, EUR J BIOCHEM, V209, P207, DOI 10.1111/j.1432-1033.1992.tb17278.x; NUNNARI J, 1993, SCIENCE, V262, P1997, DOI 10.1126/science.8266095; OSTERMANN J, 1989, NATURE, V341, P125, DOI 10.1038/341125a0; OU WJ, 1989, EMBO J, V8, P2605, DOI 10.1002/j.1460-2075.1989.tb08400.x; PETERSON GC, 1993, MOL BIOCHEM PARASIT, V58, P63, DOI 10.1016/0166-6851(93)90091-B; PFALLER R, 1988, J CELL BIOL, V107, P2483, DOI 10.1083/jcb.107.6.2483; PFANNER N, 1987, CELL, V49, P815, DOI 10.1016/0092-8674(87)90619-2; PFANNER N, 1986, FEBS LETT, V209, P152, DOI 10.1016/0014-5793(86)81101-2; PFANNER N, 1985, EMBO J, V4, P2819, DOI 10.1002/j.1460-2075.1985.tb04009.x; PFANNER N, 1990, J BIOL CHEM, V265, P16324; PRIEST JW, 1992, J BIOL CHEM, V267, P20188; PRIEST JW, 1994, MOL BIOCHEM PARASIT, V65, P291, DOI 10.1016/0166-6851(94)90080-9; PRIEST JW, 1995, BBA-MOL CELL RES, V1269, P201, DOI 10.1016/0167-4889(95)00154-6; PRIEST JW, 1993, BIOCHIM BIOPHYS ACTA, V1144, P229, DOI 10.1016/0005-2728(93)90178-I; PRIEST JW, 1994, J BIOENERG BIOMEMBR, V26, P179, DOI 10.1007/BF00763067; RAMABADRAN RS, 1992, ARCH BIOCHEM BIOPHYS, V296, P279, DOI 10.1016/0003-9861(92)90573-F; REID GA, 1982, J BIOL CHEM, V257, P3062; ROJO EE, 1995, EMBO J, V14, P3445, DOI 10.1002/j.1460-2075.1995.tb07350.x; Sambrook J., 2002, MOL CLONING LAB MANU; SCHLEYER M, 1985, CELL, V43, P339, DOI 10.1016/0092-8674(85)90039-X; SCHLOSSMANN J, 1994, J BIOL CHEM, V269, P11893; SCHWAIGER M, 1987, J CELL BIOL, V105, P235, DOI 10.1083/jcb.105.1.235; SOLLNER T, 1989, CELL, V59, P1061, DOI 10.1016/0092-8674(89)90762-9; SOLLNER T, 1990, CELL, V62, P107, DOI 10.1016/0092-8674(90)90244-9; STEGER HF, 1990, J CELL BIOL, V111, P2353, DOI 10.1083/jcb.111.6.2353; STUART RA, 1994, EUR J BIOCHEM, V220, P9, DOI 10.1111/j.1432-1033.1994.tb18593.x; TORRI AF, 1988, MOL CELL BIOL, V8, P4625, DOI 10.1128/MCB.8.11.4625; TORRI AF, 1993, MOL BIOCHEM PARASIT, V57, P305, DOI 10.1016/0166-6851(93)90206-D; VANLOON APGM, 1987, EMBO J, V6, P2441, DOI 10.1002/j.1460-2075.1987.tb02523.x; VERCESI AE, 1992, MOL BIOCHEM PARASIT, V56, P251, DOI 10.1016/0166-6851(92)90174-I; VICKERMAN K, 1965, NATURE, V208, P762, DOI 10.1038/208762a0; VICKERMAN K, 1985, BRIT MED BULL, V41, P105, DOI 10.1093/oxfordjournals.bmb.a072036; WACHTER C, 1994, MOL BIOL CELL, V5, P465, DOI 10.1091/mbc.5.4.465; WILLIAMS N, 1991, ARCH BIOCHEM BIOPHYS, V288, P509, DOI 10.1016/0003-9861(91)90228-B; ZWIZINSKI C, 1984, J BIOL CHEM, V259, P7850; ZWIZINSKI C, 1983, J BIOL CHEM, V258, P3340	71	31	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					20060	20069		10.1074/jbc.271.33.20060	http://dx.doi.org/10.1074/jbc.271.33.20060			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702725	hybrid			2022-12-25	WOS:A1996VC66900066
J	Rooney, TA; Joseph, SK; Queen, C; Thomas, AP				Rooney, TA; Joseph, SK; Queen, C; Thomas, AP			Cyclic GMP induces oscillatory calcium signals in rat hepatocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR; VASCULAR SMOOTH-MUSCLE; NITRIC-OXIDE SYNTHASE; CA2+ MOBILIZATION; PERMEABILIZED HEPATOCYTES; TRISPHOSPHATE RECEPTORS; SARCOPLASMIC-RETICULUM; INTRACELLULAR CA2+; CA-2+ LEVELS	The ability of guanosine-3',5'-cyclic monophosphate (cGMP) to induce increases in the intracellular free calcium ion concentration ([Ca2+](i)) was studied at the single cell level in fura-a-loaded rat hepatocytes. Both 8-bromo-cGMP (Br-cGMP) and dibutyryl cGMP (db-cGMP) produced oscillatory [Ca2+](i) increases in hepato cytes. In addition, Br-cGMP increased the frequency of agonist-induced spiking or converted [Ca2+](i) oscillations into sustained nonoscillatory [Ca2+](i) responses, Addition of the nitric oxide donor sodium nitroprusside also produced oscillatory [Ca2+](i) increases similar to those generated by cGMP analogues. In the absence of extracellular Ca2+, cGMP-induced [Ca2+](i) responses were significantly reduced and mainly appeared as single transient [Ca2+](i) increases. The effects of cGMP analogues do not appear to be mediated by a secondary increase in cAMP or activation of cAMP-dependent protein kinase (PKA), since [Ca2+](i) responses to cGMP analogues were inhibited by the G-kinase inhibitor 8-bromoguanosine-3',5'-cyclic monophosphorothioate (RpBr-cGMP[S]). Both Br-cGMP and db-cGMP also increased [Ca2+](i) in the presence of the PKA inhibitor 8-bromoadenosine-3',5' cyclic monophosphorothioate (Rp-Br-cAMP[S]) and when the cGMP-inhibitable cAMP phosphodiesterase activity was inhibited by pretreatment with siguazodan. Br-cGMP stimulated the Mn2+ induced quench of compartmentalized fura-2 in intact hepatocytes, indicating a site of action at the level of the Ca2+ stores. This locus was further supported by the finding that pretreatment of hepatocytes with Br-cGMP potentiated submaximal inositol 1,4,5-trisphosphate (InsP(3))-induced Mn2+ quench in subsequently permeabilized hepatocytes, db-cGMP also decreased PKA-mediated back phosphorylation of the hepatic type-1 InsP(3) receptor, indicating that G-kinase phosphorylates the InsP(3) receptor at sites targeted by PKA. These data indicate that phosphorylation of the hepatic InsP(3) receptor by G-kinase increases the sensitivity to InsP(3) for [Ca2+](i) release and is associated with the production of [Ca2+](i) oscillations in single rat hepatocytes.	THOMAS JEFFERSON UNIV, DEPT PATHOL ANAT & CELL BIOL, PHILADELPHIA, PA 19107 USA	Jefferson University			Thomas, Andrew/C-6755-2013	Thomas, Andrew/0000-0002-9026-7467	NIAAA NIH HHS [AA10413] Funding Source: Medline; NIDDK NIH HHS [DK38422, DK34804] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK038422, R01DK034804, R01DK038422] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R29AA010413] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		BAHNSON TD, 1993, J BIOL CHEM, V268, P10808; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BILLIAR TR, 1992, AM J PHYSIOL, V262, pC1077, DOI 10.1152/ajpcell.1992.262.4.C1077; BIRD GS, 1993, J BIOL CHEM, V268, P17917; BREDT DS, 1992, NEURON, V8, P3, DOI 10.1016/0896-6273(92)90104-L; BURGESS GM, 1991, J BIOL CHEM, V266, P4772; BURGSTAHLER AD, 1995, AM J PHYSIOL-GASTR L, V269, pG789, DOI 10.1152/ajpgi.1995.269.5.G789; BUTT E, 1990, FEBS LETT, V263, P47, DOI 10.1016/0014-5793(90)80702-K; CHIAVAROLI C, 1994, J BIOL CHEM, V269, P25570; CLEMENTI E, 1995, J BIOL CHEM, V270, P22277, DOI 10.1074/jbc.270.38.22277; Clementi E, 1995, MOL PHARMACOL, V48, P1068; CORNWELL TL, 1989, J BIOL CHEM, V264, P1146; CORNWELL TL, 1991, MOL PHARMACOL, V40, P923; CORNWELL TL, 1994, AM J PHYSIOL-CELL PH, V267, pC1405, DOI 10.1152/ajpcell.1994.267.5.C1405; DUFOUR JFJ, 1995, GASTROENTEROLOGY, V108, P841, DOI 10.1016/0016-5085(95)90459-X; FERRIS CD, 1991, BIOCHEM BIOPH RES CO, V175, P192, DOI 10.1016/S0006-291X(05)81219-7; FORTE LR, 1989, MOL PHARMACOL, V34, P506; Furuichi Teiichi, 1994, Current Opinion in Neurobiology, V4, P294, DOI 10.1016/0959-4388(94)90089-2; GALIONE A, 1993, NATURE, V365, P456, DOI 10.1038/365456a0; GEIGER J, 1992, P NATL ACAD SCI USA, V89, P1031, DOI 10.1073/pnas.89.3.1031; GELLER DA, 1993, P NATL ACAD SCI USA, V90, P3491, DOI 10.1073/pnas.90.8.3491; HAJNOCZKY G, 1994, J BIOL CHEM, V269, P10280; HAJNOCZKY G, 1993, BIOCHEM J, V293, P413, DOI 10.1042/bj2930413; Joseph SK, 1996, CELL SIGNAL, V8, P1, DOI 10.1016/0898-6568(95)02012-8; JOSEPH SK, 1995, J BIOL CHEM, V270, P23310, DOI 10.1074/jbc.270.40.23310; JOSEPH SK, 1993, J BIOL CHEM, V268, P23059; KOMALAVILAS P, 1994, J BIOL CHEM, V269, P8701; MATTER N, 1993, J BIOL CHEM, V268, P732; MERY PF, 1991, P NATL ACAD SCI USA, V88, P1197, DOI 10.1073/pnas.88.4.1197; MILBOURNE EA, 1995, CELL CALCIUM, V18, P207, DOI 10.1016/0143-4160(95)90065-9; MILBOURNE EA, 1995, CELL SIGNAL, V7, P313, DOI 10.1016/0898-6568(95)00005-A; MONKAWA T, 1995, J BIOL CHEM, V270, P14700, DOI 10.1074/jbc.270.24.14700; MURTHY KS, 1993, AM J PHYSIOL, V264, pG967, DOI 10.1152/ajpgi.1993.264.5.G967; NAKADE S, 1994, J BIOL CHEM, V269, P6735; OHSHIMA H, 1992, BIOCHEM BIOPH RES CO, V183, P238, DOI 10.1016/0006-291X(92)91634-3; PFEIFER A, 1995, J BIOL CHEM, V270, P9052, DOI 10.1074/jbc.270.16.9052; QUINTON TM, 1992, BIOCHEM BIOPH RES CO, V184, P893, DOI 10.1016/0006-291X(92)90675-B; RAEYMAEKERS L, 1988, BIOCHEM J, V252, P269, DOI 10.1042/bj2520269; RASHATWAR SS, 1987, P NATL ACAD SCI USA, V84, P5685, DOI 10.1073/pnas.84.16.5685; RENARDROONEY DC, 1993, J BIOL CHEM, V268, P23601; ROBBGASPERS LD, 1995, J BIOL CHEM, V270, P8102, DOI 10.1074/jbc.270.14.8102; ROONEY TA, 1990, J BIOL CHEM, V265, P10792; ROONEY TA, 1993, CELL CALCIUM, V14, P674, DOI 10.1016/0143-4160(93)90094-M; ROONEY TA, 1989, J BIOL CHEM, V264, P17131; ROONEY TA, 1991, J BIOL CHEM, V266, P12272; SARCEVIC B, 1989, J BIOL CHEM, V264, P20648; SHORT AD, 1993, J BIOL CHEM, V268, P25887; SUPATTAPONE S, 1988, P NATL ACAD SCI USA, V85, P8747, DOI 10.1073/pnas.85.22.8747; TAYLOR CW, 1991, PHARMACOL THERAPEUT, V51, P97, DOI 10.1016/0163-7258(91)90043-L; THOMAS AP, 1991, CELL CALCIUM, V12, P111, DOI 10.1016/0143-4160(91)90013-5; THOMAS AP, 1995, CIBA F SYMP, V188, P18; THOMAS AP, 1983, J BIOL CHEM, V258, P5716; TOESCU EC, 1995, AM J PHYSIOL-GASTR L, V269, pG173, DOI 10.1152/ajpgi.1995.269.2.G173; XU X, 1994, J BIOL CHEM, V269, P12645; YAMAMOTOHINO M, 1994, RECEPTOR CHANNEL, V2, P9; YOSHIDA Y, 1991, J BIOL CHEM, V266, P19819; ZHANG BX, 1993, J BIOL CHEM, V268, P10997	57	57	58	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					19817	19825		10.1074/jbc.271.33.19817	http://dx.doi.org/10.1074/jbc.271.33.19817			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702690	hybrid			2022-12-25	WOS:A1996VC66900031
J	Sasaoka, T; Ishihara, H; Sawa, T; Ishiki, M; Morioka, H; Imamura, T; Usui, I; Takata, Y; Kobayashi, M				Sasaoka, T; Ishihara, H; Sawa, T; Ishiki, M; Morioka, H; Imamura, T; Usui, I; Takata, Y; Kobayashi, M			Functional importance of amino-terminal domain of Shc for interaction with insulin and epidermal growth factor receptors in phosphorylation-independent manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOTYROSINE INTERACTION DOMAIN; MITOGENIC SIGNAL-TRANSDUCTION; FACTOR-I; AUTOPHOSPHORYLATION SITES; BINDING-SITES; SUBSTRATE-1; GRB2; ACTIVATION; PROTEIN; MOTIF	Shc has two distinct domains, amino-terminal and SH2 domain, which cam interact with activated growth factor receptors. Shc interacts with insulin receptor via Shc-amino-terminal (N) domain, whereas Shc associates with epidermal growth factor (EGF) receptor through both Shc-N and -SH2 domains. In accordance with the different functional roles between insulin and EGF receptors, EGF stimulated tyrosine phosphorylation of Shc faster than insulin, To clarify the functional importance of three distinct Shc domains on insulin and EGF signaling, we microinjected glutathione S-transferase (GST) fusion proteins containing the amino terminus plus collagen homology domain (NCH), collagen homology domain (CM), and Src homology 2 domain (SH2) into Rat1 fibroblasts expressing insulin receptors (HIRc). Bromodeoxyuridine (BrdUrd) incorporation into newly synthesized DNA was subsequently studied to assess the importance of the three distinct domains of Shc, Microinjection of the NCH-GST fusion protein inhibited BrdUrd incorporation induced by both EGF and insulin, whereas microinjection of the SH2-GST fusion protein inhibited EGF, but not insulin stimulation of DNA syn thesis, Neither EGF- nos insulin-induced BrdUrd incorporation was inhibited by the CH-GST fusion protein, Following EGF or insulin stimulation, Shc is phosphorylated on single Tyr-317 residue serving as a docking site for Grb2. Microinjection of Shc-N+CH GST fusion protein with Tyr-317 --> Phe replacement (Y317F) also inhibited insulin stimulation of DNA synthesis, Next, we stably overexpressed wild-type Shc or Y317F mutant She into HIRc cells, Insulin-induced tyrosine phosphorylation of IRS-1 was compared among the transfected cell lines, since IRS-1 and Shc could competitively interact with insulin receptor, Insulin-stimulated tyrosine phosphorylation of IRS-1 was decreased in both WT-Shc and Y317F-Shc cells compared with that in HIRc cells, Furthermore, overexpression of the Shc-SH2 domain or Shc-N+CH domain with Y317F mutation interfered with EGF-stimulated endogenous She phosphorylation. These results suggest that the amino terminus domain of Shc is functionally important in insulin- and EGF-induced cell cycle progression and that the phosphorylation of Shc Tyr-317 residue is independent of Shc interaction with these receptors.			Sasaoka, T (corresponding author), TOYAMA MED & PHARMACEUT UNIV,DEPT MED 1,TOYAMA 93001,JAPAN.							BATZER AG, 1995, MOL CELL BIOL, V15, P4403; BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; CAMPBELL KS, 1994, P NATL ACAD SCI USA, V91, P6344, DOI 10.1073/pnas.91.14.6344; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CHUANG LM, 1993, P NATL ACAD SCI USA, V90, P5172, DOI 10.1073/pnas.90.11.5172; DECKER SJ, 1992, J BIOL CHEM, V267, P1104; DECKER SJ, 1993, J BIOL CHEM, V268, P9176; GIORGETTI S, 1994, EUR J BIOCHEM, V223, P195, DOI 10.1111/j.1432-1033.1994.tb18983.x; GOTOH N, 1994, P NATL ACAD SCI USA, V91, P167, DOI 10.1073/pnas.91.1.167; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; HE WM, 1995, J BIOL CHEM, V270, P23258, DOI 10.1074/jbc.270.40.23258; KASHISHIAN A, 1992, EMBO J, V11, P1373, DOI 10.1002/j.1460-2075.1992.tb05182.x; MCCLAIN DA, 1987, J BIOL CHEM, V262, P14663; OKABAYASHI Y, 1994, J BIOL CHEM, V269, P18674; ONEILL TJ, 1994, MOL CELL BIOL, V14, P6433, DOI 10.1128/MCB.14.10.6433; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PRONK GJ, 1994, MOL CELL BIOL, V14, P1575, DOI 10.1128/MCB.14.3.1575; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; RAVICHANDRAN KS, 1995, MOL CELL BIOL, V15, P593; RORDORFNIKOLIC T, 1995, J BIOL CHEM, V270, P3662, DOI 10.1074/jbc.270.8.3662; ROSE DW, 1994, P NATL ACAD SCI USA, V91, P797, DOI 10.1073/pnas.91.2.797; SASAOKA T, 1994, J BIOL CHEM, V269, P32621; Sasaoka T, 1996, J BIOL CHEM, V271, P8338, DOI 10.1074/jbc.271.14.8338; SASAOKA T, 1994, J BIOL CHEM, V269, P10734; SASAOKA T, 1994, J BIOL CHEM, V269, P13689; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SONGYANG Z, 1995, J BIOL CHEM, V270, P14863, DOI 10.1074/jbc.270.25.14863; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; SUN XJ, 1992, J BIOL CHEM, V267, P22662; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; WATERS SB, 1993, J BIOL CHEM, V268, P22231; WELLS A, 1990, SCIENCE, V247, P962, DOI 10.1126/science.2305263; WOLF G, 1995, J BIOL CHEM, V270, P27407, DOI 10.1074/jbc.270.46.27407; WRIGHT JD, 1995, J BIOL CHEM, V270, P12085, DOI 10.1074/jbc.270.20.12085; YAMAUCHI K, 1994, J BIOL CHEM, V269, P31107; YAMAUCHI K, 1994, MOL CELL BIOL, V14, P4427, DOI 10.1128/MCB.14.7.4427; YONEZAWA K, 1994, J BIOL CHEM, V269, P4634; ZHOU MM, 1995, NATURE, V378, P584, DOI 10.1038/378584a0	40	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					20082	20087		10.1074/jbc.271.33.20082	http://dx.doi.org/10.1074/jbc.271.33.20082			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702728	hybrid			2022-12-25	WOS:A1996VC66900069
J	Schrader, M; Danielsson, C; Wiesenberg, I; Carlberg, C				Schrader, M; Danielsson, C; Wiesenberg, I; Carlberg, C			Identification of natural monomeric response elements of the nuclear receptor RZR/ROR - They also bind COUP-TF homodimers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOIC ACID RECEPTORS; HUMAN-BREAST-CANCER; GLAND HORMONE MELATONIN; BONE SIALOPROTEIN GENE; THYROID-HORMONE; MAMMALIAN-TISSUES; ROR-ALPHA; VITAMIN-D; ORPHAN; PROMOTER	The receptor RZR/ROR is an important member of the nuclear receptor superfamily and has recently been shown to be the nuclear receptor for the pineal gland hormone melatonin, RZR/ROR binds as a monomer to DNA, and the human 5-lipoxygenase gene has been identified as the first RZR/ROR/melatonin-responding gene. Another prominent nuclear receptor is COUP-TF, which binds as a dimer to DNA. In this study, the sequences of known promoter regions of genes that may be involved in the physiological action of melatonin have been screened for putative monomeric RZR/ROR response elements. The binding of RZR/ROR and COUP-TF was compared and quantified on a set of 12 putative response elements, Interestingly, COUP-TF homodimers were found to bind with high affinity to some of the monomeric RZR/ROR response elements, Four RZR/ROR response elements, found in the genes of the mouse bifunctional enzyme, the rat bone sialoprotein, mouse Purkinje cell protein 2, and human p21(WAF1/CIP1), were shown to be inducible by melatonin under conditions of low constitutive activity, Surprisingly, the constitutive activity of COUP-TF was also stimulated by an unknown serum compound. The novel Purkinje cell protein 2 and p21(WAF1/CIP1) RZR/ROR/melatonin-responding genes may be the key for understanding the role of RZR/ROR alpha in the mouse mutation staggerer and the antiproliferative action of melatonin, respectively.	HOP CANTONAL UNIV GENEVA, DERMATOL CLIN, CH-1211 GENEVA 14, SWITZERLAND; CIBA GEIGY AG, PHARMA FORSCH, CH-4002 BASEL, SWITZERLAND	University of Geneva; Novartis			Carlberg, Carsten/C-9075-2011	Carlberg, Carsten/0000-0003-2633-0684				ACUNACASTROVIEJO D, 1994, J PINEAL RES, V16, P100, DOI 10.1111/j.1600-079X.1994.tb00089.x; ACUNACASTROVIEJO D, 1993, RES COMMUN CHEM PATH, V82, P253; BARDOT O, 1993, BIOCHEM BIOPH RES CO, V192, P37, DOI 10.1006/bbrc.1993.1378; BECKERANDRE M, 1993, BIOCHEM BIOPH RES CO, V194, P1371, DOI 10.1006/bbrc.1993.1976; BECKERANDRE M, 1994, J BIOL CHEM, V269, P28531; BELLAHCENE A, 1994, CANCER RES, V54, P2823; BIANCO P, 1991, CALCIFIED TISSUE INT, V49, P421, DOI 10.1007/BF02555854; BLASK DE, 1986, J NEURAL TRANSM, P433; CARLBERG C, 1994, MOL ENDOCRINOL, V8, P757, DOI 10.1210/me.8.6.757; CARLBERG C, 1995, J PINEAL RES, V18, P171, DOI 10.1111/j.1600-079X.1995.tb00157.x; CARLBERG C, 1993, NATURE, V361, P657, DOI 10.1038/361657a0; CARLBERG C, 1995, EUR J BIOCHEM, V231, P517, DOI 10.1111/j.1432-1033.1995.0517d.x; COONEY AJ, 1992, MOL CELL BIOL, V12, P4153, DOI 10.1128/MCB.12.9.4153; COONEY AJ, 1993, J BIOL CHEM, V268, P4152; COS S, 1991, J PINEAL RES, V10, P36, DOI 10.1111/j.1600-079X.1991.tb00007.x; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELDEIRY WS, 1995, CANCER RES, V55, P2910; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; GIGUERE V, 1994, GENE DEV, V8, P538, DOI 10.1101/gad.8.5.538; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; GREEN S, 1993, NATURE, V361, P590, DOI 10.1038/361590a0; Hamilton BA, 1996, NATURE, V379, P736, DOI 10.1038/379736a0; HARPER JW, 1993, CELL, V75, P805; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; HILL SM, 1988, CANCER RES, V48, P6121; HIROSE T, 1994, BIOCHEM BIOPH RES CO, V205, P1976, DOI 10.1006/bbrc.1994.2902; KIM RH, 1994, MATRIX BIOL, V14, P31, DOI 10.1016/0945-053X(94)90027-2; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; LAUDET V, 1995, CURR BIOL, V5, P124, DOI 10.1016/S0960-9822(95)00031-5; LAUDET V, 1992, EMBO J, V11, P1003, DOI 10.1002/j.1460-2075.1992.tb05139.x; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; LI JJ, 1995, BIOCHEM J, V310, P33, DOI 10.1042/bj3100033; LI JJ, 1993, BIOCHEM J, V289, P625, DOI 10.1042/bj2890625; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MENENDEZPELAEZ A, 1993, J PINEAL RES, V15, P59, DOI 10.1111/j.1600-079X.1993.tb00511.x; MENENDEZPELAEZ A, 1993, J CELL BIOCHEM, V53, P373, DOI 10.1002/jcb.240530415; POTHIER F, 1992, DNA CELL BIOL, V11, P83, DOI 10.1089/dna.1992.11.83; POWER RF, 1991, SCIENCE, V252, P1546, DOI 10.1126/science.2047861; Qiu Y, 1996, J STEROID BIOCHEM, V56, P81, DOI 10.1016/0960-0760(95)00225-1; QIU YH, 1994, TRENDS ENDOCRIN MET, V5, P234, DOI 10.1016/1043-2760(94)P3081-H; REITER RJ, 1995, FRONT NEUROENDOCRIN, V16, P383, DOI 10.1006/frne.1995.1014; SCHNEIDER I, 1972, J EMBRYOL EXP MORPH, V27, P353; SMITH WC, 1991, EMBO J, V10, P2223, DOI 10.1002/j.1460-2075.1991.tb07758.x; STEINHILBER D, 1995, J BIOL CHEM, V270, P7037, DOI 10.1074/jbc.270.13.7037; TINI M, 1995, J BIOL CHEM, V270, P20156, DOI 10.1074/jbc.270.34.20156; TINI M, 1993, GENE DEV, V7, P295, DOI 10.1101/gad.7.2.295; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; VANDAELE S, 1991, GENE DEV, V5, P1136, DOI 10.1101/gad.5.7.1136; WAHLSTROM GM, 1992, MOL ENDOCRINOL, V6, P1013, DOI 10.1210/me.6.7.1013; WIESENBERG I, 1995, NUCLEIC ACIDS RES, V23, P327, DOI 10.1093/nar/23.3.327; ZHANG BW, 1992, P NATL ACAD SCI USA, V89, P7541, DOI 10.1073/pnas.89.16.7541; ZOU LL, 1994, J BIOL CHEM, V269, P13346	54	100	101	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					19732	19736		10.1074/jbc.271.33.19732	http://dx.doi.org/10.1074/jbc.271.33.19732			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702678	hybrid			2022-12-25	WOS:A1996VC66900019
J	Brouns, GS; deVries, E; Neefjes, JJ; Borst, J				Brouns, GS; deVries, E; Neefjes, JJ; Borst, J			Assembled pre-B cell receptor complexes are retained in the endoplasmic reticulum by a mechanism that is not selective for the pseudo-light chain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYMPHOCYTES-B; HEAVY-CHAIN; IMMUNOGLOBULIN HEAVY; TARGETED DISRUPTION; ANTIGEN RECEPTORS; ALLELIC EXCLUSION; TYROSINE KINASE; MEMBRANE EXON; BONE-MARROW; SURFACE	The pre-B cell receptor (BCR) complex, consisting of mu heavy chain, a pseudo-light drain, and the Mb-1/B29 heterodimer, directs the transition to the mature B cell stage, Plasma membrane expression of the pre-BCR is extremely low, despite its presumed signaling function, We have compared assembly and intracellular transport of the pre-BCR complex with that of the BCR complex in mature B cells, Synthesis and assembly rate of pre-BCR and BCR components are comparable, However, the pre-BCR is subject to a highly efficient retention mechanism, which only allows exit of a few percent of the complexes from the endoplasmic reticulum (ER). This small transported pool of pre-BCR complexes is significantly enriched for protein-tyrosine kinase activity, as compared with the ER-localized receptor pool, Accordingly, the Src-related tyrosine kinase Lyn was found in the transported glycoprotein action but not in association with ER-localized glycoproteins. Upon introduction of a conventional light chain into pre-B cells, plasma membrane receptor levels increased, but the efficiency of intracellular transport of the receptor complex was not restored to that in mature B cells. This indicates that the ER retention mechanism is not selective for the pseudo-light chain and may be inherent to pre-B cells, We propose that this retention mechanism contributes to the regulation of pre-BCR-mediated signal transduction.	NETHERLANDS CANC INST,DIV CELLULAR BIOCHEM,NL-1066 CX AMSTERDAM,NETHERLANDS	Netherlands Cancer Institute			Neefjes, Jacques J.C./H-8780-2017	Neefjes, Jacques J.C./0000-0001-6763-2211; Borst, Jannie/0000-0002-8043-5009				BORST J, 1993, IMMUNOL REV, V132, P49, DOI 10.1111/j.1600-065X.1993.tb00837.x; BOSSY D, 1993, INT IMMUNOL, V5, P467, DOI 10.1093/intimm/5.5.467; BROUNS GS, 1995, INT IMMUNOL, V7, P359, DOI 10.1093/intimm/7.3.359; BROUNS GS, 1993, EUR J IMMUNOL, V23, P1088, DOI 10.1002/eji.1830230517; CHERAYIL BJ, 1991, J EXP MED, V173, P111, DOI 10.1084/jem.173.1.111; CLARK MR, 1992, J IMMUNOL, V149, P2857; EHLICH A, 1993, CELL, V72, P695, DOI 10.1016/0092-8674(93)90398-A; GUELPAFONLUPT V, 1994, EUR J IMMUNOL, V24, P257, DOI 10.1002/eji.1830240140; HENDERSHOT L, 1987, J CELL BIOL, V104, P761, DOI 10.1083/jcb.104.3.761; JACOBS H, 1994, EUR J IMMUNOL, V24, P934, DOI 10.1002/eji.1830240423; KARASUYAMA H, 1990, J EXP MED, V172, P969, DOI 10.1084/jem.172.3.969; Kerr W G, 1989, Int Immunol, V1, P355, DOI 10.1093/intimm/1.4.355; KITAMURA D, 1992, NATURE, V356, P154, DOI 10.1038/356154a0; KITAMURA D, 1992, CELL, V69, P823, DOI 10.1016/0092-8674(92)90293-L; KITAMURA D, 1991, NATURE, V350, P423, DOI 10.1038/350423a0; KORNFELD R, 1976, ANNU REV BIOCHEM, V45, P217, DOI 10.1146/annurev.bi.45.070176.001245; LASSOUED K, 1993, CELL, V73, P73, DOI 10.1016/0092-8674(93)90161-I; LEPRINCE C, 1992, EUR J IMMUNOL, V22, P2093, DOI 10.1002/eji.1830220820; MASON DY, 1991, J IMMUNOL, V147, P2474; MASON DY, 1995, BLOOD, V86, P1453, DOI 10.1182/blood.V86.4.1453.bloodjournal8641453; NAKAMURA T, 1992, P NATL ACAD SCI USA, V89, P8522, DOI 10.1073/pnas.89.18.8522; NISHIMOTO N, 1991, P NATL ACAD SCI USA, V88, P6284, DOI 10.1073/pnas.88.14.6284; NOMURA J, 1991, INT IMMUNOL, V3, P117, DOI 10.1093/intimm/3.2.117; PAPAVASILIOU F, 1995, SCIENCE, V268, P408, DOI 10.1126/science.7716544; RETH M, 1992, ANNU REV IMMUNOL, V10, P97, DOI 10.1146/annurev.iy.10.040192.000525; SAINTRUF C, 1994, SCIENCE, V266, P1208, DOI 10.1126/science.7973703; SALAMERO J, 1995, EUR J IMMUNOL, V25, P2757, DOI 10.1002/eji.1830251007; SHACHAR I, 1992, J BIOL CHEM, V267, P24241; SITIA R, 1990, CELL, V60, P781, DOI 10.1016/0092-8674(90)90092-S; TAKEMORI T, 1990, EMBO J, V9, P2493, DOI 10.1002/j.1460-2075.1990.tb07428.x; TSUBATA T, 1990, J EXP MED, V172, P973, DOI 10.1084/jem.172.3.973; WILLIAMS GT, 1990, J EXP MED, V171, P947, DOI 10.1084/jem.171.3.947; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903	33	37	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19272	19278		10.1074/jbc.271.32.19272	http://dx.doi.org/10.1074/jbc.271.32.19272			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702609	hybrid			2022-12-25	WOS:A1996VB68400043
J	Deng, L; Hagler, J; Shuman, S				Deng, L; Hagler, J; Shuman, S			Factor-dependent release of nascent RNA by ternary complexes of vaccinia RNA polymerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION TERMINATION FACTOR; VIRUS EARLY TRANSCRIPTION; MESSENGER-RNA; CAPPING ENZYME; EARLY GENES; ELONGATION; PROMOTER; CLEAVAGE; NUSG; SII	Factor-dependent transcription termination during synthesis of vaccinia early mRNAs occurs at heterogeneous sites downstream of a UUUUUNU signal in the nascent transcript. The choice of termination site is flexible and is determined by a kinetic balance between nascent chain elongation and the transmission of the RNA signal to the polymerase. To eliminate ongoing elongation as a variable, we have established a system to study transcript release by purified ternary complexes halted at st defined template position 50-nucleotides 3' of the first U residue of the termination signal. Release of the nascent RNA depends on the vaccinia termination factor (VTF) and an ATP cofactor. Transcript release is blocked by BrUMP substitution within the termination signal of the nascent RNA, in these respects, the release reaction faithfully mimics the properties of the termination event. We demonstrate that ternary complexes are refractory to VTF-mediated transcript release when the first U of the UUUUUNU signal is situated 20 nucleotides from the growing point of the nascent chain. Ribonuclease footprinting of the arrested ternary complexes defines a nascent RNA binding site oil the polymerase elongation complex that encompasses a 16-21 nucleotide RNA segment extending proximally from the 3' end of the chain. We surmise that access of VTF to the signal sequence is prevented when UUUUUNU is bound within the nascent RNA binding site. Hence, physical not kinetic constraints determine the minimal distance between the signal and potential sites of 3' end formation.	SLOAN KETTERING INST,PROGRAM MOL BIOL,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042498] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM42498] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHN BY, 1992, P NATL ACAD SCI USA, V89, P3536, DOI 10.1073/pnas.89.8.3536; AHN BY, 1994, J BIOL CHEM, V269, P7552; BALDICK CJ, 1994, J VIROL, V68, P6052, DOI 10.1128/JVI.68.9.6052-6056.1994; BROYLES SS, 1988, J BIOL CHEM, V263, P10754; BURNS CM, 1995, P NATL ACAD SCI USA, V92, P4738, DOI 10.1073/pnas.92.11.4738; Chamberlin M.J., 1994, HARVEY LECT, V88, P1; CONG PJ, 1995, MOL CELL BIOL, V15, P6222; DENG L, 1994, J BIOL CHEM, V269, P14323; HAGLER J, 1992, SCIENCE, V255, P983, DOI 10.1126/science.1546295; HAGLER J, 1994, J BIOL CHEM, V269, P10050; HAGLER J, 1993, J BIOL CHEM, V268, P2166; HAGLER J, 1992, J VIROL, V66, P2982, DOI 10.1128/JVI.66.5.2982-2989.1992; HAGLER J, 1992, J BIOL CHEM, V267, P7644; HAGLER J, 1992, P NATL ACAD SCI USA, V89, P10009; IZBAN MG, 1992, GENE DEV, V6, P1342, DOI 10.1101/gad.6.7.1342; IZBAN MG, 1993, J BIOL CHEM, V268, P12874; IZBAN MG, 1993, J BIOL CHEM, V268, P12864; KANE EM, 1992, J VIROL, V66, P5752, DOI 10.1128/JVI.66.10.5752-5762.1992; LI J, 1993, GENE DEV, V7, P161, DOI 10.1101/gad.7.1.161; LI J, 1993, J BIOL CHEM, V268, P2773; LUO Y, 1991, J BIOL CHEM, V266, P13303; LUO Y, 1995, J VIROL, V69, P3852, DOI 10.1128/JVI.69.6.3852-3856.1995; MOSS B, 1990, ANNU REV BIOCHEM, V59, P661, DOI 10.1146/annurev.biochem.59.1.661; NEHRKE KW, 1994, J MOL BIOL, V243, P830, DOI 10.1006/jmbi.1994.1685; NUDLER E, 1994, SCIENCE, V265, P793, DOI 10.1126/science.8047884; SHUMAN S, 1987, J BIOL CHEM, V262, P12372; SHUMAN S, 1989, J BIOL CHEM, V264, P21356; SHUMAN S, 1988, J BIOL CHEM, V263, P6220; WHITEHALL SK, 1994, J BIOL CHEM, V269, P2299; YUEN L, 1987, P NATL ACAD SCI USA, V84, P6417, DOI 10.1073/pnas.84.18.6417; ZHANG YF, 1994, J VIROL, V68, P1360, DOI 10.1128/JVI.68.3.1360-1370.1994	31	32	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19556	19562		10.1074/jbc.271.32.19556	http://dx.doi.org/10.1074/jbc.271.32.19556			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702649	hybrid			2022-12-25	WOS:A1996VB68400083
J	Arnaud, M; Debarbouille, M; Rapoport, G; Saier, MH; Reizer, J				Arnaud, M; Debarbouille, M; Rapoport, G; Saier, MH; Reizer, J			In vitro reconstitution of transcriptional antitermination by the SacT and SacY proteins of Bacillus subtilis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GLUCOSIDE UTILIZATION; SUGAR PHOSPHOTRANSFERASE SYSTEM; ESCHERICHIA-COLI; BGL OPERON; NUCLEOTIDE-SEQUENCE; PHOSPHORYLATION; PHOSPHOENOLPYRUVATE; FAMILY; GENES; LEVANSUCRASE	Expression of the sacPA and sacB genes of Bacillus subtilis is positively modulated by transcriptional regulatory proteins encoded by the sacT and sacY genes, respectively. Previous genetic studies led to the suggestion that SacT and SacY function as nascent mRNA binding proteins preventing early termination of transcription at terminators located in the leader regions of the corresponding genes. Here we report the overproduction, purification to near homogeneity, and characterization of the two antiterminators, SacT and SacY. Using mRNA band migration retardation assays and a reconstituted transcriptional antitermination system, the mRNA binding functions and antitermination activities of purified SacT and SacY are demonstrated under in vitro conditions. The results establish for the first time that members of the BglG family of antiterminators function in antitermination in the absence of other proteins in vitro. Purified SacT is shown to be phosphorylated by phosphoenolpyruvate in a phosphotransferase-catalyzed reaction dependent on Enzyme I and HPr. Unexpectedly, the purified SacT is shown to be functional in mRNA binding and in transcriptional antitermination independently of its phosphorylation state.	INST PASTEUR,URA 1300 CNRS,UNITE BIOCHIM MICROBIENNE,F-75724 PARIS 15,FRANCE; UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; University of California System; University of California San Diego					NIAID NIH HHS [AI GM21702-13A1] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021702] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMSTERCHODER O, 1992, SCIENCE, V257, P1395, DOI 10.1126/science.1382312; AMSTERCHODER O, 1989, CELL, V58, P847, DOI 10.1016/0092-8674(89)90937-9; AMSTERCHODER O, 1993, J CELL BIOCHEM, V51, P83, DOI 10.1002/jcb.240510115; ARNAUD M, 1992, J BACTERIOL, V174, P3161, DOI 10.1128/jb.174.10.3161-3170.1992; AYMERICH S, 1987, MOL GEN GENET, V208, P114, DOI 10.1007/BF00330431; AYMERICH S, 1992, P NATL ACAD SCI USA, V89, P10410, DOI 10.1073/pnas.89.21.10410; BABITZKE P, 1995, P NATL ACAD SCI USA, V92, P7916, DOI 10.1073/pnas.92.17.7916; BARDOWSKI J, 1994, J BACTERIOL, V176, P5681, DOI 10.1128/JB.176.18.5681-5685.1994; BELFORT M, 1995, J BACTERIOL, V177, P3897, DOI 10.1128/jb.177.14.3897-3903.1995; CRUTZ AM, 1990, J BACTERIOL, V172, P1043, DOI 10.1128/jb.172.2.1043-1050.1990; DEBARBOUILLE M, 1990, J BACTERIOL, V172, P3966, DOI 10.1128/jb.172.7.3966-3973.1990; DEBARBOUILLE M, 1991, P NATL ACAD SCI USA, V88, P2212, DOI 10.1073/pnas.88.6.2212; ELHASSOUNI M, 1992, J BACTERIOL, V174, P765, DOI 10.1128/jb.174.3.765-777.1992; FRIEDMAN DI, 1995, MOL MICROBIOL, V18, P191, DOI 10.1111/j.1365-2958.1995.mmi_18020191.x; GREENBLATT J, 1993, NATURE, V364, P401, DOI 10.1038/364401a0; HEINRICH T, 1995, J BACTERIOL, V177, P3793, DOI 10.1128/jb.177.13.3793-3800.1995; HENKIN TM, 1994, MOL MICROBIOL, V13, P381, DOI 10.1111/j.1365-2958.1994.tb00432.x; HOUMAN F, 1990, CELL, V62, P1153, DOI 10.1016/0092-8674(90)90392-R; KRUGER S, 1995, J BACTERIOL, V177, P5590; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATTOO RL, 1983, ANAL BIOCHEM, V128, P245, DOI 10.1016/0003-2697(83)90372-X; NAGAI K, 1994, RNA PROTEIN INTERACT, P52; PTASHNE M, 1992, GENETIC SWITCH PHAGE, P50; REDDY P, 1989, NUCLEIC ACIDS RES, V17, P10473, DOI 10.1093/nar/17.24.10473; Rees WA, 1996, P NATL ACAD SCI USA, V93, P342, DOI 10.1073/pnas.93.1.342; REIZER J, 1992, J BIOL CHEM, V267, P9158; REIZER J, 1989, EMBO J, V8, P2111, DOI 10.1002/j.1460-2075.1989.tb03620.x; SAIER MH, 1992, J BACTERIOL, V174, P1433, DOI 10.1128/jb.174.5.1433-1438.1992; SANGER F, 1978, FEBS LETT, V87, P107, DOI 10.1016/0014-5793(78)80145-8; SCHNETZ K, 1990, P NATL ACAD SCI USA, V87, P5074, DOI 10.1073/pnas.87.13.5074; SCHNETZ K, 1988, EMBO J, V7, P3271, DOI 10.1002/j.1460-2075.1988.tb03194.x; SCHNETZ K, 1987, J BACTERIOL, V169, P2579, DOI 10.1128/jb.169.6.2579-2590.1987; Schnetz K, 1996, J BACTERIOL, V178, P1971, DOI 10.1128/jb.178.7.1971-1979.1996; STULKE J, 1995, J BACTERIOL, V177, P6928; SUTRINA SL, 1990, J BIOL CHEM, V265, P18581; WIEDMANN B, 1994, NATURE, V370, P434, DOI 10.1038/370434a0; ZUBER M, 1987, P NATL ACAD SCI USA, V84, P4514, DOI 10.1073/pnas.84.13.4514; ZUKOWSKI MM, 1990, GENE, V90, P153, DOI 10.1016/0378-1119(90)90453-X	38	57	57	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18966	18972		10.1074/jbc.271.31.18966	http://dx.doi.org/10.1074/jbc.271.31.18966			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702561	hybrid			2022-12-25	WOS:A1996VB68300099
J	Fauman, EB; Yuvaniyama, C; Schubert, HL; Stuckey, JA; Saper, MA				Fauman, EB; Yuvaniyama, C; Schubert, HL; Stuckey, JA; Saper, MA			The x-ray crystal structures of Yersinia tyrosine phosphatase with bound tungstate and nitrate - Mechanistic implications	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALKALINE-PHOSPHATASE; PHOSPHORYL-TRANSFER; VIRULENCE DETERMINANT; TRANSITION-STATE; HYDROLYSIS; INTERMEDIATE; CATALYSIS; PROTEINS; CYSTEINE; DETECTOR	X-ray crystal structures of the Yersinia tyrosine phosphatase (PTPase) in complex with tungstate and nitrate have been solved to 2.4-Angstrom resolution, Tetrahedral tungstate, WO42-, is a competitive inhibitor of the enzyme and is isosteric with the substrate and product of the catalyzed reaction, Planar nitrate, NO3-, is isosteric with the PO3 moiety of a phosphotransfer transition state, The crystal structures of the Yersinia PTPase with and without ligands, together with biochemical data, permit modeling of key steps along the reaction pathway, These energy-minimized models are consistent with a general acid-catalyzed, in-line displacement of the phosphate moiety to Cys(403) On the enzyme, followed by attack by a nucleophilic water molecule to release orthophosphate, This nucleophilic water molecule is identified in the crystal structure of the nitrate complex, The active site structure of the PTPase is compared to alkaline phosphatase, which employs a similar phosphomonoester hydrolysis mechanism, Both enzymes must stabilize charges at the nucleophile, the PO3 moiety of the transition state, and the leaving group, Both an associative (bond formation preceding bond cleavage) and a dissociative (bond cleavage preceding bond formation) mechanism were modeled, but a dissociative-like mechanism is favored for steric and chemical reasons, Since nearly all of the 47 invariant or highly conserved residues of the PTPase domain are clustered at the active site, we suggest that the mechanism postulated for the Yersinia enzyme is applicable to all the PTPases.	UNIV MICHIGAN,DIV BIOPHYS RES,ANN ARBOR,MI 48109; UNIV MICHIGAN,DEPT BIOL CHEM,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan			Fauman, Eric/AAC-8275-2020	Fauman, Eric/0000-0002-9739-0249	NIAID NIH HHS [AI34095] Funding Source: Medline; NIAMS NIH HHS [P60-AR20557] Funding Source: Medline; NIDDK NIH HHS [DK18849] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034095] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR020557] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK018849] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKERFELDT S, 1960, ACTA CHEM SCAND, V14, P1980, DOI 10.3891/acta.chem.scand.14-1980; BASCH H, 1991, J MOL STRUC-THEOCHEM, V235, P277; Benkovic S. J, 1973, ENZYMES, P201; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BLISKA JB, 1991, P NATL ACAD SCI USA, V88, P1187, DOI 10.1073/pnas.88.4.1187; BROWNER MF, 1992, BIOCHEMISTRY-US, V31, P11297, DOI 10.1021/bi00161a006; BRUNGER AT, 1987, XPLOR VERSION 3 1; CAUGHLAN CN, 1967, INORG CHEM, V6, P1998, DOI 10.1021/ic50057a014; CHO HJ, 1992, J AM CHEM SOC, V114, P7296, DOI 10.1021/ja00044a052; CLELAND WW, 1990, FASEB J, V4, P2899, DOI 10.1096/fasebj.4.11.2199287; COLEMAN JE, 1992, ANNU REV BIOPH BIOM, V21, P441, DOI 10.1146/annurev.biophys.21.1.441; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; GLOWIAK T, 1986, J CRYST SPECTROSC, V16, P79, DOI 10.1007/BF01566048; GLOWIAK T, 1985, ACTA CRYSTALLOGR C, V41, P324, DOI 10.1107/S010827018500378X; GUAN KL, 1990, SCIENCE, V249, P553, DOI 10.1126/science.2166336; GUAN KL, 1991, J BIOL CHEM, V266, P17026; HASSETT A, 1982, BIOCHEMISTRY-US, V21, P6335, DOI 10.1021/bi00268a002; HENGGE AC, 1995, BIOCHEMISTRY-US, V34, P13982, DOI 10.1021/bi00043a003; HERR EB, 1957, BIOCHIM BIOPHYS ACTA, V25, P219, DOI 10.1016/0006-3002(57)90456-0; HERSCHLAG D, 1989, J AM CHEM SOC, V111, P7579, DOI 10.1021/ja00201a047; HERSCHLAG D, 1990, BIOCHEMISTRY-US, V29, P5172, DOI 10.1021/bi00473a025; HERSCHLAG D, 1987, J AM CHEM SOC, V109, P4665, DOI 10.1021/ja00249a033; JIA ZC, 1995, SCIENCE, V268, P1754, DOI 10.1126/science.7540771; JONES JP, 1991, BIOCHEMISTRY-US, V30, P3634, DOI 10.1021/bi00229a007; JONES PG, 1984, ACTA CRYSTALLOGR C, V40, P550, DOI 10.1107/S0108270184004820; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KARLE JM, 1991, ACTA CRYSTALLOGR C, V47, P1241; KENNARD O, 1979, ACTA CRYSTALLOGR B, V35, P2331; KIM EE, 1991, J MOL BIOL, V218, P449, DOI 10.1016/0022-2836(91)90724-K; KOSTER AS, 1969, ACTA CRYSTALL B-STRU, VB 25, P1704, DOI 10.1107/S0567740869004602; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; MESSERSCHMIDT A, 1987, J APPL CRYSTALLOGR, V20, P306, DOI 10.1107/S002188988708662X; MICHIELS T, 1988, MICROB PATHOGENESIS, V5, P449, DOI 10.1016/0882-4010(88)90006-X; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; PAULING L, 1947, J AM CHEM SOC, V69, P542, DOI 10.1021/ja01195a024; PONDER JW, 1987, J MOL BIOL, V193, P775, DOI 10.1016/0022-2836(87)90358-5; SCHUBERT HL, 1995, PROTEIN SCI, V4, P1904, DOI 10.1002/pro.5560040924; STUCKEY JA, 1994, NATURE, V370, P571, DOI 10.1038/370571a0; WEISS PM, 1989, J AM CHEM SOC, V111, P1928, DOI 10.1021/ja00187a084; WESTHEIMER FH, 1987, SCIENCE, V235, P1173, DOI 10.1126/science.2434996; Zhang ZY, 1995, BIOCHEMISTRY-US, V34, P16389, DOI 10.1021/bi00050a020; ZHANG ZY, 1992, J BIOL CHEM, V267, P23759; ZHANG ZY, 1993, BIOCHEMISTRY-US, V32, P9340, DOI 10.1021/bi00087a012; ZHANG ZY, 1994, J BIOL CHEM, V269, P8140; ZHANG ZY, 1994, BIOCHEMISTRY-US, V33, P2285, DOI 10.1021/bi00174a040; ZHANG ZY, 1994, ADV ENZYMOL RAMB, V68, P1; ZHANG ZY, 1994, P NATL ACAD SCI USA, V91, P1624, DOI 10.1073/pnas.91.5.1624; ZHANG ZY, 1994, BIOCHEMISTRY-US, V33, P15266, DOI 10.1021/bi00255a007	50	107	112	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18780	18788		10.1074/jbc.271.31.18780	http://dx.doi.org/10.1074/jbc.271.31.18780			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702535	hybrid			2022-12-25	WOS:A1996VB68300073
J	Fukuda, M; Mikoshiba, K				Fukuda, M; Mikoshiba, K			Structure-function relationships of the mouse Gap1(m) - Determination of the inositol 1,3,4,5-tetrakisphosphate-binding domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; 1,4,5-TRISPHOSPHATE BINDING DOMAIN; SQUID GIANT SYNAPSE; SIGNALING PROTEINS; TYROSINE KINASE; GENE-PRODUCT; PH DOMAIN; TRISPHOSPHATE; RECEPTOR; CALCIUM	Gap1(IP4BP), one of a member of Ras GTPase-activating proteins, has been identified as a specific inositol 1,3,4,5-tetrakisphosphate (IP4)-binding protein (Cullen, P. J., Hsuan, J, J., Truong, O., Letcher, A, J,, Jackson, T, R., Dawson, A. P., and Irvine, R. F. (1995) Nature 386, 527-530). In this paper we describe Gap1(m), which is closely related to Gap1(IP4BP), to also be an IP4-binding protein and show that the pleckstrin homology domain (PH) is the central IP4-binding domain by expressing fragments of the mouse Gap1(m) in Escherichia coli as fusion proteins and examining their activities. However, in addition to the PH domain, an adjacent GAP-related domain and carboxyl terminus are required for high affinity specific IP4 binding. The PH domain is highly conserved in the Gap1 family and also has striking homology to the amino-terminal region of Bruton's tyrosine kinase. Substitution of Cys for Arg at position 628 in the PH domain corresponding to the mutation of Bruton's tyrosine kinase observed in X-linked immunodeficiency mice results in a dramatic reduction of IP4 binding activity as well as phospholipid binding capacity of Gap1(m). This mutant also showed the GAP activity against Ha-Pas to be similar to that of the wild type Gap1(m). Our results suggest that the PH domain of Gap1(m) functions as a modulatory domain of GAP activity by binding IF4 and phospholipids.	UNIV TOKYO,INST MED SCI,DEPT MOL NEUROBIOL,TOKYO 108,JAPAN; ERATO,CALCIOSIGNAL NET PROJECT,MEGURO KU,TOKYO 153,JAPAN	University of Tokyo	Fukuda, M (corresponding author), RIKEN,INST PHYS & CHEM RES,TSUKUBA LIFE SCI CTR,MOL NEUROBIOL LAB,3-1-1 KOYADAI,TSUKUBA,IBARAKI 305,JAPAN.		Mikoshiba, Katsuhiko/N-7943-2015; Fukuda, MItsunori/I-1511-2015	Fukuda, MItsunori/0000-0002-8620-5853				BABA H, 1995, J NEUROSCI RES, V41, P846, DOI 10.1002/jnr.490410615; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BOLLAG G, 1991, NATURE, V351, P576, DOI 10.1038/351576a0; CALES C, 1988, NATURE, V332, P548, DOI 10.1038/332548a0; CHANGYA L, 1989, FEBS LETT, V251, P43, DOI 10.1016/0014-5793(89)81425-5; CULLEN PJ, 1995, BIOCHEM J, V305, P139, DOI 10.1042/bj3050139; CULLEN PJ, 1995, NATURE, V376, P527, DOI 10.1038/376527a0; CULLEN PJ, 1995, FEBS LETT, V358, P240, DOI 10.1016/0014-5793(94)01435-4; DAVLETOV BA, 1993, J BIOL CHEM, V268, P26386; ELY JA, 1990, BIOCHEM J, V268, P333, DOI 10.1042/bj2680333; Fukuda M, 1996, J BIOL CHEM, V271, P8430, DOI 10.1074/jbc.271.14.8430; FUKUDA M, 1994, J BIOL CHEM, V269, P29206; FUKUDA M, 1995, J BIOL CHEM, V270, P26523, DOI 10.1074/jbc.270.44.26523; FUKUDA M, 1995, P NATL ACAD SCI USA, V92, P10708, DOI 10.1073/pnas.92.23.10708; FURUICHI T, 1995, J NEUROCHEM, V64, P953, DOI 10.1046/j.1471-4159.1995.64030953.x; GAUL U, 1992, CELL, V68, P1007, DOI 10.1016/0092-8674(92)90073-L; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HASIAM RJ, 1993, NATURE, V363, P309; HILL TD, 1988, SCIENCE, V242, P1176, DOI 10.1126/science.2847317; HIRATA M, 1994, BIOCHEM BIOPH RES CO, V205, P1563, DOI 10.1006/bbrc.1994.2845; HYVONEN M, 1995, EMBO J, V14, P4676, DOI 10.1002/j.1460-2075.1995.tb00149.x; IRVINE RF, 1986, NATURE, V320, P631, DOI 10.1038/320631a0; IRVINE RF, 1987, BIOCHEM BIOPH RES CO, V146, P284, DOI 10.1016/0006-291X(87)90723-6; LI C, NATURE, V385, P594; LLINAS R, 1994, P NATL ACAD SCI USA, V91, P12990, DOI 10.1073/pnas.91.26.12990; MAEKAWA M, 1994, MOL CELL BIOL, V14, P6879, DOI 10.1128/MCB.14.10.6879; MAEKAWA M, 1993, J BIOL CHEM, V268, P22948; MAYER BJ, 1993, CELL, V73, P629, DOI 10.1016/0092-8674(93)90244-K; MIKOSHIBA K, 1995, P NATL ACAD SCI USA, V92, P10703, DOI 10.1073/pnas.92.23.10703; MOCHIDA S, 1995, SAT S 15 ISN M JUN 2, P124; MORRIS AP, 1987, NATURE, V330, P653, DOI 10.1038/330653a0; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; OHARAIMAIZUMI M, 1995, SAT S 15 ISN M JUN 2, P125; PARKER I, 1987, PROC R SOC SER B-BIO, V232, P59, DOI 10.1098/rspb.1987.0061; RAWLINGS DJ, 1993, SCIENCE, V261, P358, DOI 10.1126/science.8332901; SNYDER PM, 1988, J BIOL CHEM, V263, P11048; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; YAGISAWA H, 1994, J BIOL CHEM, V269, P20179; YOO SH, 1991, BIOCHEM J, V278, P381, DOI 10.1042/bj2780381	39	74	75	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18838	18842		10.1074/jbc.271.31.18838	http://dx.doi.org/10.1074/jbc.271.31.18838			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702543	hybrid			2022-12-25	WOS:A1996VB68300081
J	Liang, BT; Morley, JF				Liang, BT; Morley, JF			A new cyclic AMP-independent, G(s)-mediated stimulatory mechanism via the adenosine A(2a) receptor in the intact cardiac cell	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; CHICK HEART-CELLS; VENTRICULAR CELLS; ADENYLATE-CYCLASE; CAMP; MYOCYTES; PHOSPHORYLATION; MODULATION; CARDIOMYOCYTES; PURINOCEPTORS	The objectives of this study were to investigate the mechanism underlying the adenosine A(2a) receptor (A(2a)R)-mediated positive inotropic response and to define its contractile function using chick embryo ventricular cells as a model, Activation of the A(2a)R caused a marked stimulation of calcium entry and cell contractility, which were blocked by verapamil or nifedipine, The effects elicited by maximal concentrations of the A(2a)R agonist 2-[4-(2-carboxyethyl)phenylethylamino]-5'-N-ethylcarboxamidoadenosine and the beta-adrenergic agonist isoproterenol were additive, indicating that the two receptors do not share a common stimulatory mechanism, The cAMP antagonist (R(p))-adenosine cyclic 3':5'-monophosphorothioate was ineffective in inhibiting the A(2a)R-mediated stimulation of contractility or the L-type calcium channel, while it completely abolished the iso-proterenol effects, Activation of the A(2a)R had no effect on Na+/Ca2+ exchange or inositol 1,4,5-trisphosphate accumulation, Blocking of the A(2a)R resulted in unopposed A(1) receptor-mediated inhibitory effects and led to an inhibition of basal contractility and an enhanced anti-adrenergic effect by A(1) agonist, The adenosine A(2a) receptor mediates a new cyclic AMP-independent mechanism and a new contractile function in the cardiac cell.	UNIV PENN,MED CTR,DEPT PHARMACOL,PHILADELPHIA,PA 19104; UNIV PENN,MED CTR,DIV CARDIOVASC,PHILADELPHIA,PA 19104	University of Pennsylvania; University of Pennsylvania	Liang, BT (corresponding author), UNIV PENN,MED CTR,DEPT MED,504 JOHNSON PAVIL,3610 HAMILTON WALK,PHILADELPHIA,PA 19104, USA.				NHLBI NIH HHS [R01-HL48225] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048225] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARRY WH, 1982, J PHYSIOL-LONDON, V325, P243, DOI 10.1113/jphysiol.1982.sp014148; BELARDINELLI LB, 1989, PROG CARDIOVASC DIS, V32, P93; BOTELHO LHP, 1988, METHOD ENZYMOL, V159, P159; BROWN JH, 1985, CIRC RES, V57, P532, DOI 10.1161/01.RES.57.4.532; BRUNS RF, 1986, MOL PHARMACOL, V29, P331; BUCKNER R, 1984, BRIT J PHARMACOL, V82, P223; CONNELLY PA, 1987, J BIOL CHEM, V262, P4324; DEHAAN RL, 1967, DEV BIOL, V16, P216, DOI 10.1016/0012-1606(67)90025-5; FREDHOLM BB, 1994, PHARMACOL REV, V46, P143; GALPER JB, 1978, P NATL ACAD SCI USA, V75, P5831, DOI 10.1073/pnas.75.12.5831; GU ZF, 1992, AM J PHYSIOL, V263, pG360, DOI 10.1152/ajpgi.1992.263.3.G360; HARTZELL HC, 1991, NATURE, V351, P573, DOI 10.1038/351573a0; KAMEYAMA M, 1986, PFLUG ARCH EUR J PHY, V407, P123, DOI 10.1007/BF00580662; LAURENT S, 1985, CIRC RES, V56, P676, DOI 10.1161/01.RES.56.5.676; LAURENT S, 1986, J CLIN INVEST, V77, P1436, DOI 10.1172/JCI112455; LIANG BT, 1992, TRENDS CARDIOVAS MED, V2, P100, DOI 10.1016/1050-1738(92)90014-J; LIANG BT, 1986, J BIOL CHEM, V261, P9011; LIANG BT, 1995, CIRC RES, V76, P242, DOI 10.1161/01.RES.76.2.242; LIANG BT, 1989, J PHARMACOL EXP THER, V249, P775; MARSH JD, 1985, CIRC RES, V57, P171, DOI 10.1161/01.RES.57.1.171; OLSSON RA, 1990, PHYSIOL REV, V70, P761, DOI 10.1152/physrev.1990.70.3.761; OTANI H, 1988, CIRC RES, V62, P8, DOI 10.1161/01.RES.62.1.8; PELZER S, 1993, J PHYSIOL-LONDON, V459, pP228; PEREIRA ME, 1987, J BIOL CHEM, V262, P6093; STEINBERG SF, 1987, ENDOCRINOLOGY, V120, P1889, DOI 10.1210/endo-120-5-1889; STILES GL, 1992, J BIOL CHEM, V267, P6451; STIMERS JR, 1991, J GEN PHYSIOL, V98, P815, DOI 10.1085/jgp.98.4.815; WALSH DA, 1979, BIOCHEMISTRY-US, V18, P871, DOI 10.1021/bi00572a021; WALSH DA, 1994, FASEB J, V8, P1227, DOI 10.1096/fasebj.8.15.8001734; WANG LY, 1991, SCIENCE, V253, P1132, DOI 10.1126/science.1653455; XU D, 1992, CIRC RES, V70, P56, DOI 10.1161/01.RES.70.1.56; XU H, 1992, NUCLEIC ACIDS RES, V20, P6425, DOI 10.1093/nar/20.23.6425; YATANI A, 1989, SCIENCE, V245, P71, DOI 10.1126/science.2544999	33	32	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18678	18685		10.1074/jbc.271.31.18678	http://dx.doi.org/10.1074/jbc.271.31.18678			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702522	hybrid			2022-12-25	WOS:A1996VB68300060
J	Erhardt, P; Cooper, GM				Erhardt, P; Cooper, GM			Activation of the CPP32 apoptotic protease by distinct signaling pathways with differential sensitivity to Bcl-x(L)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; ELEGANS; BCL-2; SURVIVAL; ENCODES	In the absence of growth factors, many types of mam malian cells undergo apoptosis. We and others have shown recently that growth factors promote cell survival by activating phosphatidylinositol 3-kinase (PI 3-kinase) in several cell types, In the present study, we have compared downstream elements of the apoptotic pathways induced by PI 3-kinase inhibitors and other stimuli. In U937 cells, both PI 3-kinase inhibitors (wortmannin and LY294002) and etoposide activated the CPP32 apoptotic protease by cleavage to active p17 subunits, In contrast, treatment with tumor necrosis factor alpha (TNF alpha) resulted in the accumulation of a distinct active CPP32 subunit, p20. Furthermore, overexpression of Bcl-x(L) blocked DNA fragmentation, CPP32 activation and cleavage of poly(ADP ribose) polymerase in U937 cells treated with both PI 3-kinase inhibitors and etoposide, but not in cells treated with TNF alpha. Distinct patterns of CPP32 activation and differential sensitivities to Bcl-x(L) thus distinguish the cell death pathways activated by PI 3-kinase inhibition and DNA damage from that activated by TNF alpha.	DANA FARBER CANC INST,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School					NATIONAL CANCER INSTITUTE [R01CA018689] Funding Source: NIH RePORTER; NCI NIH HHS [CA18689] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Boise L H, 1995, Curr Top Microbiol Immunol, V200, P107; CAI YC, 1995, IMMUNITY, V3, P417, DOI 10.1016/1074-7613(95)90171-X; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; DATTA R, 1995, CELL GROWTH DIFFER, V6, P363; Duan HJ, 1996, J BIOL CHEM, V271, P1621, DOI 10.1074/jbc.271.3.1621; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; ENOCH T, 1995, TRENDS BIOCHEM SCI, V20, P426, DOI 10.1016/S0968-0004(00)89093-3; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P6045; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P2737; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; GOTTSCHALK AR, 1994, P NATL ACAD SCI USA, V91, P7350, DOI 10.1073/pnas.91.15.7350; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HENGARTNER MO, 1994, CURR OPIN GENET DEV, V4, P581, DOI 10.1016/0959-437X(94)90076-F; JAATTELA M, 1995, ONCOGENE, V10, P2297; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LI P, 1995, CELL, V80, P401, DOI 10.1016/0092-8674(95)90490-5; Lippke JA, 1996, J BIOL CHEM, V271, P1825, DOI 10.1074/jbc.271.4.1825; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MEMON SA, 1995, J IMMUNOL, V155, P4644; Minshall C, 1996, J IMMUNOL, V156, P939; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; RAFF MC, 1993, SCIENCE, V262, P695, DOI 10.1126/science.8235590; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; SCHEID MP, 1995, BIOCHEM J, V312, P159, DOI 10.1042/bj3120159; Schlegel J, 1996, J BIOL CHEM, V271, P1841, DOI 10.1074/jbc.271.4.1841; SHIMIZU S, 1995, NATURE, V374, P811, DOI 10.1038/374811a0; Strasser A, 1995, EMBO J, V14, P6136, DOI 10.1002/j.1460-2075.1995.tb00304.x; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Vaux DL, 1996, P NATL ACAD SCI USA, V93, P2239, DOI 10.1073/pnas.93.6.2239; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Wymann MP, 1996, MOL CELL BIOL, V16, P1722; YAO R, 1996, IN PRESS ONCOGENE; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	39	120	124	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					17601	17604		10.1074/jbc.271.30.17601	http://dx.doi.org/10.1074/jbc.271.30.17601			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663611	hybrid			2022-12-25	WOS:A1996UY93500003
J	Morana, SJ; Wolf, CM; Li, JF; Reynolds, JE; Brown, MK; Eastman, A				Morana, SJ; Wolf, CM; Li, JF; Reynolds, JE; Brown, MK; Eastman, A			The involvement of protein phosphatases in the activation of ICE/CED-3 protease, intracellular acidification, DNA digestion, and apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ETOPOSIDE-INDUCED APOPTOSIS; DEATH GENE CED-3; CELL-DEATH; NA+/H+ ANTIPORTER; OKADAIC ACID; RETINOBLASTOMA PROTEIN; CALYCULIN-A; PHOSPHORYLATION; INHIBITOR; MECHANISM	Many events in apoptosis have been identified but their temporal relationships remain obscure, Apoptosis in human ML-1 cells induced by etoposide is characterized by intracellular acidification, enhanced Hoechst 33342 fluorescence, DNA digestion, chromatin condensation, and proteolysis of poly(ADP-ribose) polymerase, This proteolysis is a marker for the action of ICE/CED-3 proteases, which are critical activators of apoptosis, We observed that three serine/threonine protein phosphatase inhibitors, okadaic acid, calyculin A, and cantharidin, din, prevented all of these apoptotic characteristics. To determine which protein phosphatase was involved, we investigated the dephosphorylation of the retinoblastoma susceptibility protein Rb, a substrate for protein phosphatase 1 but not protein phosphatase 2A. Rb was dephosphorylated during apoptosis, and each inhibitor prevented this dephosphorylation at the same concentrations that prevented apoptosis, No increase in protein phosphatase 1 activity was observed in apoptotic cells suggesting that dephosphorylation of Rb may result from loss of Rb kinase activity in the presence of a constant level of protein phosphatase activity, Long term inhibition of protein phosphatase 1 (> 8 h) also led to the appearance of dephosphorylated Rb, cleavage of poly(ADP-ribose) polymerase and apoptosis, suggesting these events are not solely dependent upon protein phosphatase 1, Rb dephosphorylation was also observed in several other models of apoptosis, Hence, an imbalance between protein phosphatase 1 and Rb kinase may be a common means to activate ICE/CED-3 proteases resulting in the subsequent events of apoptosis.	DARTMOUTH COLL SCH MED, DEPT PHARMACOL & TOXICOL, HANOVER, NH 03755 USA; DARTMOUTH COLL SCH MED, NORRIS COTTON CANC CTR, HANOVER, NH 03755 USA	Dartmouth College; Dartmouth College; Norris Cotton Cancer Center					NATIONAL CANCER INSTITUTE [P30CA023108, R55CA050224, R01CA050224, T32CA009658] Funding Source: NIH RePORTER; NCI NIH HHS [CA50224, CA23108, CA09658] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARRY MA, 1993, CANCER RES, V53, P2349; BARRY MA, 1993, ARCH BIOCHEM BIOPHYS, V300, P440, DOI 10.1006/abbi.1993.1060; BARRY MA, 1992, BIOCHEM BIOPH RES CO, V186, P782, DOI 10.1016/0006-291X(92)90814-2; BIANCHINI L, 1991, J BIOL CHEM, V266, P15406; COHEN P, 1989, FEBS LETT, V250, P596, DOI 10.1016/0014-5793(89)80803-8; DIVE C, 1992, BIOCHIM BIOPHYS ACTA, V1133, P275, DOI 10.1016/0167-4889(92)90048-G; DOHADWALA M, 1994, P NATL ACAD SCI USA, V91, P6408, DOI 10.1073/pnas.91.14.6408; DOU QP, 1995, CANCER RES, V55, P5222; DOU QP, 1995, P NATL ACAD SCI USA, V92, P9019, DOI 10.1073/pnas.92.20.9019; DUKE RC, 1992, CURRENT PROTOCOLS IM, V1; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; EASTMAN A, 1995, METHOD CELL BIOL, V46, P41; EASTMAN A, 1995, SEMIN CANCER BIOL, V6, P45, DOI 10.1006/scbi.1995.0006; GUIZOUARN H, 1995, AM J PHYSIOL-CELL PH, V268, pC434, DOI 10.1152/ajpcell.1995.268.2.C434; ISHIHARA H, 1989, BIOCHEM BIOPH RES CO, V159, P871, DOI 10.1016/0006-291X(89)92189-X; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LI JF, 1995, J BIOL CHEM, V270, P3203, DOI 10.1074/jbc.270.7.3203; LI YM, 1993, BIOCHEM PHARMACOL, V46, P1435, DOI 10.1016/0006-2952(93)90109-A; LUDLOW JW, 1993, MOL CELL BIOL, V13, P367, DOI 10.1128/MCB.13.1.367; MACKINTOSH RW, 1995, FEBS LETT, V371, P236, DOI 10.1016/0014-5793(95)00888-G; MALY K, 1989, J BIOL CHEM, V264, P11839; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MORANA S, 1994, INT J ONCOL, V5, P153; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; ORMEROD MG, 1993, CYTOMETRY, V14, P595, DOI 10.1002/cyto.990140603; PEREZSALA D, 1995, J BIOL CHEM, V270, P6235, DOI 10.1074/jbc.270.11.6235; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; REBOLLO A, 1995, EXP CELL RES, V218, P581, DOI 10.1006/excr.1995.1195; REYNOLDS JE, 1996, IN PRESS EXP CELL RE, V225; SARDET C, 1990, SCIENCE, V247, P723, DOI 10.1126/science.2154036; SARDET C, 1989, CELL, V56, P271, DOI 10.1016/0092-8674(89)90901-X; SCHWARTZ MA, 1991, P NATL ACAD SCI USA, V88, P7849, DOI 10.1073/pnas.88.17.7849; SONG QZ, 1992, J CELL PHYSIOL, V153, P550, DOI 10.1002/jcp.1041530316; SONG QZ, 1993, BIOCHEM BIOPH RES CO, V190, P47, DOI 10.1006/bbrc.1993.1009; SORENSON CM, 1988, CANCER RES, V48, P4484; SWANN K, 1985, NATURE, V314, P274, DOI 10.1038/314274a0; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Troppmair J, 1992, Curr Top Microbiol Immunol, V182, P453; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Wyllie A H, 1980, Int Rev Cytol, V68, P251; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	44	133	135	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					18263	18271		10.1074/jbc.271.30.18263	http://dx.doi.org/10.1074/jbc.271.30.18263			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663484	hybrid			2022-12-25	WOS:A1996UY93500100
J	Wang, Y; Sostman, A; Roman, R; Stribling, S; Vigna, S; Hannun, Y; Raymond, J; Fitz, JG				Wang, Y; Sostman, A; Roman, R; Stribling, S; Vigna, S; Hannun, Y; Raymond, J; Fitz, JG			Metabolic stress opens K+ channels in hepatoma cells through a Ca2+- and protein kinase C alpha-dependent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE POTASSIUM CHANNELS; RAT-LIVER; MUSCLE-CELLS; HEPATOCYTES; CALCIUM; INHIBITION; CATION; ATP; CYTOTOXICITY; CONDUCTANCE	These studies of a model liver cell line evaluate the mechanisms responsible for regulated release of K+ ions during metabolic stress, Metabolic inhibition of HTC hepatoma cells by exposure to 2,4-dinitrophenol (50 mu M) and 2-deoxy-D-glucose (10 mM) stimulated outward currents carried by K+ of 974 +/- 75 pA at 0 mV (n = 20, p < 0.001), Currents were inhibited by chelation of intracellular Ca2+ or exposure to apamin (50 nM), an inhibitor of SKCa channels, In cell-attached recordings from intact cells, removal of metabolic substrates (25/28 cells) or exposure to metabolic inhibitors (32/40 cells) opened K+-selective channels with a conductance of 6.5 +/- 0.2 pS, Channels had an open probability of 0.31 +/- 0.08 and opened in bursts averaging 3.55 +/- 0.27 ms in duration (n = 6), Metabolic stress was associated with rapid translocation of the alpha isoform of protein kinase C (PKC alpha) from cytosol to membrane; and down-regulation of PKC alpha by phorbol esters or exposure to the PKC inhibitor chelerythrine (10 mu M) each inhibited currents, Moreover, intracellular perfusion with purified PKC alpha activated currents in a Ca2+- and concentration-dependent manner, These findings indicate that metabolic stress leads to opening of apamin-sensitive SKCa, channels in hepatoma cells through a Ca2+- and PKC-dependent mechanism and suggest that PKC alpha may be selectively involved in the response, This mechanism functionally couples the metabolic state of cells to membrane K+ permeability and represents a potential target for modification of liver injury associated with ischemia and preservation.	DUKE UNIV, MED CTR, DEPT MED, DURHAM, NC 27710 USA	Duke University					NIDDK NIH HHS [DK43278, DK46082] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK046082, R01DK046082, R01DK043278] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARNARD GF, 1984, J CLIN INVEST, V74, P173, DOI 10.1172/JCI111399; BERGER HA, 1993, J BIOL CHEM, V268, P2037; BREDT DS, 1989, BIOCHEM BIOPH RES CO, V159, P376; CAPIOD T, 1989, J PHYSIOL-LONDON, V409, P285, DOI 10.1113/jphysiol.1989.sp017497; CHANG D, 1988, COMPUT BIOL MED, V18, P351, DOI 10.1016/0010-4825(88)90022-4; CURRIN RT, 1991, FASEB J, V5, P207, DOI 10.1096/fasebj.5.2.2004664; DENGLER WA, 1995, ANTI-CANCER DRUG, V6, P522, DOI 10.1097/00001813-199508000-00005; FITZ JG, 1994, AM J PHYSIOL, V266, pG677, DOI 10.1152/ajpgi.1994.266.4.G677; FITZ JG, 1994, AM J PHYSIOL, V266, pG544, DOI 10.1152/ajpgi.1994.266.4.G544; FITZ JG, 1987, AM J PHYSIOL, V252, pG56, DOI 10.1152/ajpgi.1987.252.1.G56; FITZ JG, 1992, P NATL ACAD SCI USA, V89, P4197, DOI 10.1073/pnas.89.9.4197; FRIEDMANN N, 1980, BIOCHIM BIOPHYS ACTA, V596, P180, DOI 10.1016/0005-2736(80)90352-1; GASBARRINI A, 1992, J BIOL CHEM, V267, P6654; GETTYS TW, 1994, ANAL BIOCHEM, V220, P82, DOI 10.1006/abio.1994.1302; GRAF J, 1983, AM J PHYSIOL, V244, pG233, DOI 10.1152/ajpgi.1983.244.3.G233; GROSCHNER K, 1991, PFLUG ARCH EUR J PHY, V417, P517, DOI 10.1007/BF00370948; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HALLBRUCKER C, 1993, EUR J BIOCHEM, V211, P449, DOI 10.1111/j.1432-1033.1993.tb17570.x; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HEATON JH, 1984, J BIOL CHEM, V259, P2396; HERBERT JM, 1990, BIOCHEM BIOPH RES CO, V172, P993, DOI 10.1016/0006-291X(90)91544-3; HOWARD LD, 1987, J MEMBRANE BIOL, V100, P53, DOI 10.1007/BF02209140; KAZANIETZ MG, 1993, MOL PHARMACOL, V44, P298; KEHRER JP, 1990, TOXICOL APPL PHARM, V106, P165, DOI 10.1016/0041-008X(90)90238-P; KOMARU T, 1991, CIRC RES, V69, P1146, DOI 10.1161/01.RES.69.4.1146; LIDOFSKY SD, 1993, J BIOL CHEM, V268, P14632; LIDOFSKY SD, 1995, IN PRESS P NATL ACAD; LYNCH CJ, 1984, PHARMACOLOGY, V28, P74, DOI 10.1159/000137952; MATSUMURA T, 1984, EUR J BIOCHEM, V140, P229, DOI 10.1111/j.1432-1033.1984.tb08091.x; METS B, 1993, HEPATOLOGY, V17, P668, DOI 10.1002/hep.1840170422; MILLER AL, 1993, AM J PHYSIOL, V265, pH2184, DOI 10.1152/ajpheart.1993.265.6.H2184; MURTHY KS, 1992, J PHARMACOL EXP THER, V260, P90; NICHOLS CG, 1991, AM J PHYSIOL, V261, pH1675, DOI 10.1152/ajpheart.1991.261.6.H1675; ROSSER BG, 1995, GASTROENTEROLOGY, V108, P252, DOI 10.1016/0016-5085(95)90032-2; SILBERBERG SD, 1992, PFLUG ARCH EUR J PHY, V420, P118, DOI 10.1007/BF00378653; STABEL S, 1991, METHOD ENZYMOL, V200, P670; THOMAS AP, 1991, CELL CALCIUM, V12, P111, DOI 10.1016/0143-4160(91)90013-5; TOHKIN M, 1988, JPN J PHARMACOL, V46, P61, DOI 10.1254/jjp.46.61; WANG K, 1992, AM J PHYSIOL, V262, pG566; WANG WH, 1991, P NATL ACAD SCI USA, V88, P9722, DOI 10.1073/pnas.88.21.9722; WETSEL WC, 1992, J CELL BIOL, V117, P121, DOI 10.1083/jcb.117.1.121; WONDERGEM R, 1980, J CELL PHYSIOL, V104, P53, DOI 10.1002/jcp.1041040109; WORRELL RT, 1991, AM J PHYSIOL, V260, pC877, DOI 10.1152/ajpcell.1991.260.4.C877	43	32	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					18107	18113		10.1074/jbc.271.30.18107	http://dx.doi.org/10.1074/jbc.271.30.18107			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663472	hybrid			2022-12-25	WOS:A1996UY93500078
J	David, M; Zhou, GC; Pine, R; Dixon, JE; Larner, AC				David, M; Zhou, GC; Pine, R; Dixon, JE; Larner, AC			The SH2 domain-containing tyrosine phosphatase PTP1D is required for interferon alpha/beta-induced gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SH2-CONTAINING PHOSPHOTYROSINE PHOSPHATASE; TRANSCRIPTION FACTOR ISGF3; GAMMA SIGNAL-TRANSDUCTION; INVITRO ACTIVATION; KINASE; RECEPTOR; PHOSPHORYLATION; CORKSCREW; PATHWAY; HOMOLOG	Interferons (IFNs) induce early response genes by stimulating Janus family (Jak) tyrosine kinases, leading to tyrosine phosphorylation of Stat (signal transducer and activator of transcription) proteins. Previous studies demonstrated that a protein-tyrosine phosphatase (PTP) is required for activation of the ISGF3 transcription complex by IFN alpha/beta, but the specific PTP responsible remained unidentified. We now show that the SH2 domain containing tyrosine phosphatase PTP1D (also designated as SHPTP2, SHPTP3, PTP2C, or Syp) is constitutively associated with the IFN alpha/beta receptor and becomes tyrosine-phosphorylated in response to ligand. Furthermore, transient expression of a phosphatase-inactive mutant or the COOH-terminal SH2 domain of PTP1D causes a dominant negative effect on IFN alpha/beta-induced early response gene expression. These results provide strong evidence that PTP1D functions as a positive regulator of the IFN alpha/beta-induced Jak/Stat signal transduction pathway.	US FDA,DIV CYTOKINE BIOL,CTR BIOL EVALUAT & RES,BETHESDA,MD 20892; UNIV MICHIGAN,SCH MED,DEPT BIOL CHEM,ANN ARBOR,MI 48109; PUBL HLTH RES INST,NEW YORK,NY 10016	US Food & Drug Administration (FDA); University of Michigan System; University of Michigan					PHS HHS [18849] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		COLAMONICI O, 1994, MOL CELL BIOL, V14, P8133, DOI 10.1128/MCB.14.12.8133; COLAMONICI OR, 1994, J BIOL CHEM, V269, P3518; DAVID M, 1994, P NATL ACAD SCI USA, V91, P7174, DOI 10.1073/pnas.91.15.7174; DAVID M, 1993, J BIOL CHEM, V268, P6593; David M, 1996, J BIOL CHEM, V271, P4585; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; DAVID M, 1995, MOL CELL BIOL, V15, P7050; DOMANSKI P, 1995, J BIOL CHEM, V270, P21606, DOI 10.1074/jbc.270.37.21606; FELDMAN G, 1994, J BIOL CHEM, V264, P10747; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; FU XY, 1992, CELL, V70, P323, DOI 10.1016/0092-8674(92)90106-M; FU XY, 1990, P NATL ACAD SCI USA, V87, P8555, DOI 10.1073/pnas.87.21.8555; IGARASHI K, 1993, MOL CELL BIOL, V13, P3984, DOI 10.1128/MCB.13.7.3984; IGARASHI K, 1993, MOL CELL BIOL, V13, P1634, DOI 10.1128/MCB.13.3.1634; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; LARNER AC, 1995, BBA-MOL CELL RES, V1266, P278, DOI 10.1016/0167-4889(95)00015-K; LARNER AC, 1993, SCIENCE, V261, P1730, DOI 10.1126/science.8378773; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P13434; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; LEVY DE, 1990, EMBO J, V9, P1105, DOI 10.1002/j.1460-2075.1990.tb08216.x; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; NOVICK D, 1994, CELL, V77, P391, DOI 10.1016/0092-8674(94)90154-6; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; RIVARD N, 1995, J BIOL CHEM, V270, P11017, DOI 10.1074/jbc.270.18.11017; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SHUAL K, 1993, NATURE, V366, P580, DOI 10.1038/366580a0; TANG TL, 1995, CELL, V80, P473, DOI 10.1016/0092-8674(95)90498-0; UZE G, 1990, CELL, V60, P225, DOI 10.1016/0092-8674(90)90738-Z; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; WILSON KC, 1992, P NATL ACAD SCI USA, V89, P11964, DOI 10.1073/pnas.89.24.11964; XIAO S, 1994, J BIOL CHEM, V269, P21244; YAMAUCHI K, 1995, J BIOL CHEM, V270, P14871, DOI 10.1074/jbc.270.25.14871; YAMAUCHI K, 1995, P NATL ACAD SCI USA, V92, P664, DOI 10.1073/pnas.92.3.664	37	94	99	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1996	271	27					15862	15865		10.1074/jbc.271.27.15862	http://dx.doi.org/10.1074/jbc.271.27.15862			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UW352	8663536	hybrid			2022-12-25	WOS:A1996UW35200005
J	Moscatello, DK; Montgomery, RB; Sundareshan, P; McDanel, H; Wong, MY; Wong, AJ				Moscatello, DK; Montgomery, RB; Sundareshan, P; McDanel, H; Wong, MY; Wong, AJ			Transformation and altered signal transduction by a naturally occurring mutant EGF receptor	ONCOGENE			English	Article						EGF receptor; mutant; EGFRvIII; neoplastic transformation	GROWTH-FACTOR RECEPTOR; HUMAN-BRAIN-TUMORS; TYROSINE PHOSPHORYLATION; MONOCLONAL-ANTIBODIES; PROTEIN-KINASE; HUMAN GLIOMAS; BINDING SITE; GENE; EXPRESSION; RAS	An amino-truncated variant form of the epidermal growth factor receptor (EGFRvIII) has been identified in human brain, breast, lung and ovarian tumors, We have found that overexpression of this mutant EGF receptor in NIH3T3 cells results in transformation as a result of the activation of the receptor kinase via ligand-independent dimerization, Transformation was correlated with tyrosine phosphorylation of only a subset of the proteins observed in cells overexpressing the normal EGF receptor. This suggested that further studies on cells expressing the EGFRvIII might provide insights into the pathways most relevant to transformation, In clones expressing high levels of mutant EGF receptor, the levels of both Grb2 and SHC were decreased, Despite this decrease, much of the endogenous Grb2 immunoprecipitated with EGFRvIII, Interestingly, no increase in ras-GTP loading was found in clones expressing the EGFRvIII and MAP kinase assays indicated only a small increase in activity, These results indicate that high-level expression of the EGFRvIII induces downregulation of the ras-MAP kinase pathway and that other components involved in EGF receptor signal transduction may play a greater role in neoplastic transformation by the EGFRvIII.	THOMAS JEFFERSON UNIV,JEFFERSON CANC INST,DEPT PHARMACOL,PHILADELPHIA,PA 19107; THOMAS JEFFERSON UNIV,JEFFERSON CANC INST,DEPT MICROBIOL & IMMUNOL,PHILADELPHIA,PA 19107; VET ADM MED CTR,DIV ONCOL,SEATTLE,WA 98108	Jefferson University; Jefferson University; US Department of Veterans Affairs; Veterans Health Administration (VHA)					NATIONAL CANCER INSTITUTE [T32CA009678, R01CA051093, R01CA053149] Funding Source: NIH RePORTER; NCI NIH HHS [CA51093, CA53149, 5-T32 CA09678-03] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BASU T, 1994, ONCOGENE, V9, P3483; BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; BAZENET CE, 1993, ONCOGENE, V9, P517; BENLEVY R, 1994, EMBO J, V13, P3302, DOI 10.1002/j.1460-2075.1994.tb06632.x; BERGER MS, 1987, BRIT J CANCER, V56, P533, DOI 10.1038/bjc.1987.238; BIGNER SH, 1990, CANCER RES, V50, P8017; BIRGE RB, 1993, SCIENCE, V262, P1522, DOI 10.1126/science.7504323; BLUMENSTOCK M, 1991, ANTICANCER RES, V11, P1353; BUDAY L, 1993, CELL, V73, P169; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; DECKER SJ, 1992, J BIOL CHEM, V267, P1104; DENG TL, 1994, NATURE, V371, P171, DOI 10.1038/371171a0; DEPALAZZO IEG, 1993, CANCER RES, V53, P3217; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; EKSTRAND AJ, 1994, ONCOGENE, V9, P2313; EKSTRAND AJ, 1992, P NATL ACAD SCI USA, V89, P4309, DOI 10.1073/pnas.89.10.4309; EKSTRAND AJ, 1995, ONCOGENE, V13, P1455; FAN Z, 1993, J BIOL CHEM, V268, P21073; GOTOH N, 1994, P NATL ACAD SCI USA, V91, P167, DOI 10.1073/pnas.91.1.167; Harris A L, 1989, Recent Results Cancer Res, V113, P70; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; HUMPHREY PA, 1990, P NATL ACAD SCI USA, V87, P4207, DOI 10.1073/pnas.87.11.4207; HUMPHREY PA, 1988, CANCER RES, V48, P2231; JACKMAN JK, 1995, J BIOL CHEM, V270, P7029, DOI 10.1074/jbc.270.13.7029; KASHLES O, 1991, MOL CELL BIOL, V11, P1454, DOI 10.1128/MCB.11.3.1454; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LAX I, 1991, CELL REGUL, V2, P337, DOI 10.1091/mbc.2.5.337; LAX I, 1989, EMBO J, V8, P421, DOI 10.1002/j.1460-2075.1989.tb03393.x; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LI NX, 1994, ONCOGENE, V9, P3457; LIBERMANN TA, 1985, NATURE, V313, P144, DOI 10.1038/313144a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MASUI H, 1991, CANCER RES, V51, P6170; MCPHERSON PS, 1994, P NATL ACAD SCI USA, V91, P6486, DOI 10.1073/pnas.91.14.6486; MEYER S, 1994, MOL CELL BIOL, V14, P3253, DOI 10.1128/MCB.14.5.3253; Montgomery RB, 1995, J BIOL CHEM, V270, P30562, DOI 10.1074/jbc.270.51.30562; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; MOSCATELLO DK, 1995, CANCER RES, V55, P5536; NISHIKAWA R, 1994, P NATL ACAD SCI USA, V91, P7727, DOI 10.1073/pnas.91.16.7727; OZANNE B, 1986, J PATHOL, V149, P9, DOI 10.1002/path.1711490104; PAWSON T, 1994, ADV CANCER RES, V64, P87, DOI 10.1016/S0065-230X(08)60835-0; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; Porfiri E, 1996, J BIOL CHEM, V271, P5871, DOI 10.1074/jbc.271.10.5871; RAVICHANDRAN KS, 1995, MOL CELL BIOL, V15, P593; REIST CJ, 1995, CANCER RES, V55, P4375; SALGALLER M, 1991, CANCER LETT, V57, P243, DOI 10.1016/0304-3835(91)90164-D; SCHLEGEL J, 1994, INT J CANCER, V56, P72; SCHLOTTER NE, 1990, APPL PHYS LETT, V56, P13, DOI 10.1063/1.102648; SEEDORF K, 1994, J BIOL CHEM, V269, P16009; SOLER C, 1994, ONCOGENE, V9, P2207; VELU TJ, 1990, MOL CELL ENDOCRINOL, V70, P205, DOI 10.1016/0303-7207(90)90211-P; WALTON GM, 1990, J BIOL CHEM, V265, P1750; WATERS SB, 1995, MOL CELL BIOL, V15, P2791; WELLS A, 1990, SCIENCE, V247, P962, DOI 10.1126/science.2305263; WIKSTRAND CJ, 1995, CANCER RES, V55, P3140; WILLIAMS R, 1993, J BIOL CHEM, V268, P18213; WONG AJ, 1992, P NATL ACAD SCI USA, V89, P2965, DOI 10.1073/pnas.89.7.2965; WONG AJ, 1987, P NATL ACAD SCI USA, V84, P6899, DOI 10.1073/pnas.84.19.6899; WU DG, 1989, J BIOL CHEM, V264, P17469; YAMAZAKI H, 1988, MOL CELL BIOL, V8, P1816, DOI 10.1128/MCB.8.4.1816; YAMAZAKI H, 1990, JPN J CANCER RES, V81, P773, DOI 10.1111/j.1349-7006.1990.tb02644.x	64	186	207	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 4	1996	13	1					85	96						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UX319	8700557				2022-12-25	WOS:A1996UX31900010
J	Walker, AK; Enrietto, PJ				Walker, AK; Enrietto, PJ			Analysis of the role of v-rel in transcriptional regulation of high mobility group protein 14	ONCOGENE			English	Article						v-rel; oncogenes; gene expression; HMG proteins; chromatin	NF-KAPPA-B; PHENOL-CHLOROFORM EXTRACTION; ENHANCER-BINDING-PROTEIN; RECEPTOR FUSION PROTEIN; SINGLE-STEP METHOD; HUMAN C-REL; CHROMOSOMAL-PROTEINS; NUCLEAR FACTORS; RNA ISOLATION; PROMOTER	The oncogene v-rel is a member of the rel/NF-kappa B family of transcription factors. It causes a rapidly fatal lymphoma in young chicks and is capable of transforming both fibroblasts and primitive hematopoietic cells in culture. To understand the role of v-rel in transformation we constructed an inducible form of v-rel and used it to identify potential cellular target genes for v-rel regulation. In this paper we show that High Mobility Group Protein 14 (HMG 14) is expressed in a wide variety of v-rel transformed cell types. In addition we show that v-rel participates in the transcriptional regulation of HMG 14 and that extracts from v-relER cells interact with the HMG 14 promoter. These experiments suggest a role for v-rel in the regulation of a unique gene whose protein product may influence gene transcription in a global fashion.	SUNY STONY BROOK,DEPT MICROBIOL,STONY BROOK,NY 11794	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook					NATIONAL CANCER INSTITUTE [R01CA051792, T32CA009176] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 51792, CA 09176] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BALDWIN AS, 1988, P NATL ACAD SCI USA, V85, P723, DOI 10.1073/pnas.85.3.723; BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BEUG H, 1982, CELL, V39, P5479; BLANAR MA, 1989, MOL CELL BIOL, V9, P844, DOI 10.1128/MCB.9.2.844; BOEHMELT G, 1995, CELL, V80, P341, DOI 10.1016/0092-8674(95)90417-4; BOEHMELT G, 1992, EMBO J, V11, P4641, DOI 10.1002/j.1460-2075.1992.tb05566.x; BOSE HR, 1992, BIOCHIM BIOPHYS ACTA, V1114, P1, DOI 10.1016/0304-419X(92)90002-G; BURK O, 1991, EMBO J, V10, P3713, DOI 10.1002/j.1460-2075.1991.tb04939.x; BUSTIN M, 1991, NUCLEIC ACIDS RES, V19, P3115, DOI 10.1093/nar/19.11.3115; BUSTIN M, 1990, J BIOL CHEM, V265, P20077; BUSTIN M, 1990, BIOCHIM BIOPHYS ACTA, V1049, P231, DOI 10.1016/0167-4781(90)90092-G; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CRIPPA MP, 1991, J BIOL CHEM, V266, P2712; CRIPPA MP, 1993, EMBO J, V12, P3855, DOI 10.1002/j.1460-2075.1993.tb06064.x; DEDRICK RL, 1990, MOL CELL BIOL, V10, P593, DOI 10.1128/MCB.10.2.593; DEMARTIN R, 1993, EMBO J, V12, P2773, DOI 10.1002/j.1460-2075.1993.tb05938.x; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DING HF, 1994, SCIENCE, V265, P796, DOI 10.1126/science.8047885; DOLAN JW, 1989, P NATL ACAD SCI USA, V86, P5703, DOI 10.1073/pnas.86.15.5703; Enrietto P J, 1990, Semin Cancer Biol, V1, P399; GILMORE TD, 1991, TRENDS GENET, V7, P318, DOI 10.1016/0168-9525(91)90200-A; GILMORE TD, 1992, CANCER SURV, V15, P69; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GRILLI M, 1993, INT REV CYTOL, V143, P1; HRDLICKOVA R, 1994, J VIROL, V68, P308; HRDLICKOVA R, 1994, J VIROL, V68, P2371; KABRUN N, 1991, P NATL ACAD SCI USA, V88, P1783, DOI 10.1073/pnas.88.5.1783; KABRUN N, 1990, MOL CELL BIOL, V10, P4788, DOI 10.1128/MCB.10.9.4788; KABRUN N, 1994, SEMIN CANCER BIOL, V5, P103; KANNO M, 1989, EMBO J, V8, P4205, DOI 10.1002/j.1460-2075.1989.tb08606.x; KAWAKAMI K, 1988, P NATL ACAD SCI USA, V85, P4700, DOI 10.1073/pnas.85.13.4700; KUNSCH C, 1993, MOL CELL BIOL, V13, P6137, DOI 10.1128/MCB.13.10.6137; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAROSA FA, 1994, MOL CELL BIOL, V14, P1039, DOI 10.1128/MCB.14.2.1039; LEBAIL O, 1993, EMBO J, V12, P5043, DOI 10.1002/j.1460-2075.1993.tb06197.x; LEE JH, 1991, ONCOGENE, V6, P665; LENARDO MJ, 1988, P NATL ACAD SCI USA, V85, P8825, DOI 10.1073/pnas.85.23.8825; LEWIN B, 1991, CELL, V64, P303, DOI 10.1016/0092-8674(91)90640-K; Liou HC, 1993, CURR OPIN CELL BIOL, V5, P477, DOI 10.1016/0955-0674(93)90014-H; LU D, 1991, ONCOGENE, V6, P1235; MORRISON LE, 1991, ONCOGENE, V6, P1657; MORRISON LE, 1989, ONCOGENE, V4, P677; MORRISON LE, 1992, ONCOGENE, V7, P1137; NERI A, 1991, CELL, V67, P1075, DOI 10.1016/0092-8674(91)90285-7; PASH JM, 1993, J BIOL CHEM, V268, P13632; PUISSANT C, 1990, BIOTECHNIQUES, V8, P148; ROBINSON FR, 1974, AVIAN DIS, V18, P278, DOI 10.2307/1589142; SAMBROOK PL, 1989, MOL CLONING LAB MANU; SAMBUCETTI LC, 1989, EMBO J, V8, P4251, DOI 10.1002/j.1460-2075.1989.tb08610.x; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SHAKOORI AR, 1993, J CELL BIOCHEM, V51, P479, DOI 10.1002/jcb.2400510413; SHIMIZU H, 1990, MOL CELL BIOL, V10, P561, DOI 10.1128/MCB.10.2.561; SMARDOVA J, 1995, ONCOGENE, V10, P2017; SRIKANTHA T, 1990, J MOL BIOL, V211, P49, DOI 10.1016/0022-2836(90)90010-J; TAN TH, 1992, MOL CELL BIOL, V12, P4067, DOI 10.1128/MCB.12.9.4067; TEN RM, 1992, EMBO J, V11, P195, DOI 10.1002/j.1460-2075.1992.tb05042.x; TRIESCHMANN L, 1995, EMBO J, V14, P1478, DOI 10.1002/j.1460-2075.1995.tb07134.x; ZHANG GQ, 1995, MOL CELL BIOL, V15, P1806	61	9	9	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 20	1996	12	12					2515	2525						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UW487	8700510				2022-12-25	WOS:A1996UW48700005
J	Giusti, P; Lipartiti, M; Franceschini, D; Schiavo, N; Floreani, M; Manev, H				Giusti, P; Lipartiti, M; Franceschini, D; Schiavo, N; Floreani, M; Manev, H			Neuroprotection by melatonin from kainate-induced excitotoxicity in rats	FASEB JOURNAL			English	Article						glutamate; reactive oxygen species	KAINIC ACID; OXIDATIVE STRESS; GLUTAMATE; DAMAGE; BRAIN	In this study, we injected 10 mg/kg kainate i.p. into rats, This resulted in a brain injury, which we quantified in the hippocampus, the amygdala, and the pyriform cortex, Neuronal damage was preceded by a set of typical behavioral signs and by biochemical changes (noradrenaline decrease and 5-hydroxyindoleacetic acid increase) in the affected brain areas, Melatonin (2.5 mg/kg) was injected i.p. four times: 20 min before kainate, immediately after, and 1 and 2 h after the kainate, The cumulative dose of 10 mg/kg melatonin prevented kainate-induced neuronal death as well as behavioral and biochemical disturbances, A possible mechanism of melatonin-provided neuroprotection Lies in its antioxidant action, Our results suggest that melatonin holds potential for the treatment of pathologies such as epilepsy-associated brain damage, stroke, and brain trauma.	UNIV PADUA,DEPT PHARMACOL,I-35131 PADUA,ITALY; MED COLL PENN & HAHNEMANN UNIV,DEPT PSYCHIAT,PITTSBURGH,PA 15212; MED COLL PENN & HAHNEMANN UNIV,DEPT PHARMACOL,PITTSBURGH,PA 15212	University of Padua; Drexel University; Drexel University				GIUSTi, Pietro/0000-0001-9352-4046	NATIONAL INSTITUTE ON AGING [K07AG000532] Funding Source: NIH RePORTER; NIA NIH HHS [KO7AG00532] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AMBROSINI A, 1995, MOL PHARMACOL, V47, P1057; Anton-Tay F, 1974, Adv Biochem Psychopharmacol, V11, P315; BENARI Y, 1979, BRAIN RES, V165, P362, DOI 10.1016/0006-8993(79)90571-7; BONDY SC, 1993, BRAIN RES, V610, P229, DOI 10.1016/0006-8993(93)91405-H; CADET JL, 1994, TRENDS NEUROSCI, V17, P192; CAGNOLI CM, 1995, J PINEAL RES, V18, P222, DOI 10.1111/j.1600-079X.1995.tb00163.x; CASTROVIEJO DA, 1986, NEUROENDOCRINOLOGY, V43, P24; CHUANG JI, 1994, J PINEAL RES, V17, P11, DOI 10.1111/j.1600-079X.1994.tb00107.x; COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908; DYKENS JA, 1987, J NEUROCHEM, V49, P1222, DOI 10.1111/j.1471-4159.1987.tb10014.x; FILIPKOWSKI RK, 1994, NEUROREPORT, V5, P1538, DOI 10.1097/00001756-199407000-00032; GIUSTI P, 1995, EXP NEUROL, V131, P39, DOI 10.1016/0014-4886(95)90005-5; GOTZ ME, 1994, PHARMACOL THERAPEUT, V63, P37, DOI 10.1016/0163-7258(94)90055-8; LEBARS D, 1991, NUCL MED BIOL, V18, P357; LIPARTITI M, 1991, EXP NEUROL, V113, P301, DOI 10.1016/0014-4886(91)90019-9; LIPTON SA, 1994, NEW ENGL J MED, V330, P613; MANEV H, 1994, NEUROREPORT, V5, P2661, DOI 10.1097/00001756-199412000-00064; Maney H., 1995, Society for Neuroscience Abstracts, V21, P1518; MELCHIORRI D, 1995, FASEB J, V9, P1205, DOI 10.1096/fasebj.9.12.7672513; MELCHIORRI D, 1994, LIFE SCI, V56, P83, DOI 10.1016/0024-3205(94)00928-7; NAKANISHI S, 1992, SCIENCE, V258, P597, DOI 10.1126/science.1329206; NORLUND JJ, 1977, J CLIN ENDOCR METAB, V45, P768; OHTA K, 1994, NEUROSCI RES, V21, P83, DOI 10.1016/0168-0102(94)90071-X; OLNEY JW, 1974, BRAIN RES, V77, P507, DOI 10.1016/0006-8993(74)90640-4; Paxinos G., 2004, J CHEM INF MODEL, V5th; PELLEGRINIGIAMPIETRO DE, 1990, J NEUROSCI, V10, P1035, DOI 10.1523/jneurosci.10-03-01035.1990; POEGGELER B, 1993, J PINEAL RES, V14, P151, DOI 10.1111/j.1600-079X.1993.tb00498.x; PUTTFARCKEN PS, 1993, BRAIN RES, V624, P223, DOI 10.1016/0006-8993(93)90081-W; REITER RJ, 1995, FASEB J, V9, P526, DOI 10.1096/fasebj.9.7.7737461; REPPERT SM, 1995, P NATL ACAD SCI USA, V92, P8734, DOI 10.1073/pnas.92.19.8734; REPPERT SM, 1994, NEURON, V13, P1177, DOI 10.1016/0896-6273(94)90055-8; SAKHI S, 1994, P NATL ACAD SCI USA, V91, P9525; SPERK G, 1983, NEUROSCIENCE, V10, P1301, DOI 10.1016/0306-4522(83)90113-6; SPERK G, 1994, PROG NEUROBIOL, V42, P1, DOI 10.1016/0301-0082(94)90019-1; Tan DX, 1993, ENDOCR J, V1, P57; TSIRKA SE, 1995, NATURE, V377, P340, DOI 10.1038/377340a0	36	151	152	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUN	1996	10	8					891	896		10.1096/fasebj.10.8.8666166	http://dx.doi.org/10.1096/fasebj.10.8.8666166			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	UQ456	8666166				2022-12-25	WOS:A1996UQ45600011
J	Amano, M; Ito, M; Kimura, K; Fukata, Y; Chihara, K; Nakano, T; Matsuura, Y; Kaibuchi, K				Amano, M; Ito, M; Kimura, K; Fukata, Y; Chihara, K; Nakano, T; Matsuura, Y; Kaibuchi, K			Phosphorylation and activation of myosin by Rho-associated kinase (Rho-kinase)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE MYOSIN; GTP-BINDING-PROTEIN; LIGHT CHAIN KINASE; ADP-RIBOSYLATION; SIGNAL-TRANSDUCTION; INVOLVEMENT; INHIBITION; TYROSINE; CELLS; P21	The small GTPase Rho is implicated in physiological functions associated with actin-myosin filaments such as cytokinesis, cell motility, and smooth muscle contraction. We have recently identified and molecularly cloned Rho-associated serine/threonine kinase (Rho-kinase), which is activated by GTP-Rho (Matsui, T., Amano, M., Yamamoto, T., Chihara, K., Nakafuku, M., Ito, M., Nakano, T., Okawa, H., Iwamatsu, A., and Kaibuchi, K. (1996) EMBO J. 15, 2208-2216). Here we found that Rho-kinase stoichiometrically phosphorylated myosin light chain (MLC). Peptide mapping and phosphoamino acid analyses revealed that the primary phosphorylation site of MLC by Rho-kinase was Ser-19, which is the site phosphorylated by MLC kinase. Rho-kinase phosphorylated recombinant MLC, whereas it failed to phosphorylate recombinant MLC, which contained Ala substituted for both Thr-18 and Ser-19. We also found that the phosphorylation of MLC by Rho-kinase resulted in the facilitation of the actin activation of myosin ATPase. Thus, it is likely that once Rho is activated, then it can interact with Rho-kinase and activate it. The activated Rho-kinase subsequently phosphorylates MLC. This may partly account for the mechanism by which Rho regulates cytokinesis, cell motility, or smooth muscle contraction.	NARA INST SCI & TECHNOL,PLANT MOL GENET LAB,DIV SIGNAL TRANSDUCT,NARA 63001,JAPAN; MIE UNIV,SCH MED,DEPT INTERNAL MED 1,TSU,MIE 514,JAPAN; KYOTO UNIV,FAC MED,DEPT ANAT 2,KYOTO 606,JAPAN; NATL INST HLTH,DEPT VIROL 2,TOKYO 162,JAPAN	Nara Institute of Science & Technology; Mie University; Kyoto University			Amano, Mutsuki/M-4820-2014; Kimura, Kazushi/ABB-4007-2020	Amano, Mutsuki/0000-0002-0662-1524; Fukata, Yuko/0000-0001-7724-8643				Amano M, 1996, SCIENCE, V271, P648, DOI 10.1126/science.271.5249.648; BENGUR AR, 1987, J BIOL CHEM, V262, P7613; BRADLEY AB, 1987, J PHYSIOL-LONDON, V385, P437, DOI 10.1113/jphysiol.1987.sp016500; BRESNICK AR, 1995, BIOCHEMISTRY-US, V34, P12576, DOI 10.1021/bi00039a012; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; HARTSHORNE DJ, 1987, PHYSL GASTROINTESTIN, P423; HATHAWAY DR, 1983, ANAL BIOCHEM, V135, P37, DOI 10.1016/0003-2697(83)90726-1; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HIRATA K, 1992, J BIOL CHEM, V267, P8719; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; HUTTENLOCHER A, 1995, CURR OPIN CELL BIOL, V7, P697, DOI 10.1016/0955-0674(95)80112-X; IKEBE M, 1990, BIOCHEMISTRY-US, V29, P2713, DOI 10.1021/bi00463a014; IKEBE M, 1984, BIOCHEMISTRY-US, V23, P5062, DOI 10.1021/bi00316a036; IKEBE M, 1985, J BIOL CHEM, V260, P27; KAMISOYAMA H, 1994, BIOCHEMISTRY-US, V33, P840, DOI 10.1021/bi00169a027; KAMM KE, 1985, ANNU REV PHARMACOL, V25, P593, DOI 10.1146/annurev.pharmtox.25.1.593; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; KISHI K, 1993, J CELL BIOL, V120, P1187, DOI 10.1083/jcb.120.5.1187; KITAZAWA T, 1991, P NATL ACAD SCI USA, V88, P9307, DOI 10.1073/pnas.88.20.9307; KUMAGAI N, 1993, J BIOL CHEM, V268, P24535; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEUNG T, 1995, J BIOL CHEM, V270, P29051, DOI 10.1074/jbc.270.49.29051; Mabuchi I, 1993, ZYGOTE, V1, P325, DOI 10.1017/S0967199400001659; Matsui T, 1996, EMBO J, V15, P2208, DOI 10.1002/j.1460-2075.1996.tb00574.x; MATSUURA Y, 1987, J GEN VIROL, V68, P1233, DOI 10.1099/0022-1317-68-5-1233; MCCORMICK F, 1994, CURR OPIN GENET DEV, V4, P71, DOI 10.1016/0959-437X(94)90093-0; MORELAND S, 1992, AM J PHYSIOL, V263, pC540, DOI 10.1152/ajpcell.1992.263.2.C540; NAKA M, 1983, NATURE, V306, P490, DOI 10.1038/306490a0; NISHIKAWA M, 1984, J BIOL CHEM, V259, P8808; NOBES C, 1994, CURR OPIN GENET DEV, V4, P77, DOI 10.1016/0959-437X(94)90094-9; NODA M, 1995, FEBS LETT, V367, P246, DOI 10.1016/0014-5793(95)00573-R; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; RIDLEY AJ, 1994, EMBO J, V13, P2600, DOI 10.1002/j.1460-2075.1994.tb06550.x; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SATOH T, 1992, J BIOL CHEM, V267, P24149; Sellers JR, 1987, ENZYMES, V18, ppp381, DOI 10.1016/S1874-6047(08)60264-4; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; TAKAI Y, 1995, TRENDS BIOCHEM SCI, V20, P227, DOI 10.1016/S0968-0004(00)89022-2; TAKAISHI K, 1994, ONCOGENE, V9, P273; TAN JL, 1992, ANNU REV BIOCHEM, V61, P721, DOI 10.1146/annurev.bi.61.070192.003445; TOMINAGA T, 1993, J CELL BIOL, V120, P1529, DOI 10.1083/jcb.120.6.1529; ZHANG J, 1995, J BIOL CHEM, V270, P6589, DOI 10.1074/jbc.270.12.6589; ZHANG J, 1993, J BIOL CHEM, V268, P22251	43	1593	1635	0	67	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20246	20249		10.1074/jbc.271.34.20246	http://dx.doi.org/10.1074/jbc.271.34.20246			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702756	hybrid			2022-12-25	WOS:A1996VD33700008
J	Rodriguez, K; Wang, ZG; Friedberg, EC; Tomkinson, AE				Rodriguez, K; Wang, ZG; Friedberg, EC; Tomkinson, AE			Identification of functional domains within the RAD1 center dot RAD10 repair and recombination endonuclease of Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCISION-REPAIR; YEAST DNA-REPAIR; PIGMENTOSUM GROUP-F; PROTEINS RAD1; MITOTIC RECOMBINATION; GENE; COMPLEX; ERCC1; PURIFICATION; ASSOCIATION	hSaccharomyces cerevisiae rad1 and rad10 mutants are unable to carry out nucleotide excision repair and are also defective in a mitotic intrachromosomal. recombination pathway. The products of these genes are subunits of an endonuclease which recognizes DNA duplex/single-strand junctions and specifically cleaves the 3' single-strand extension at or near the junction. It has been suggested that such junctions arise as a consequence of DNA lesion processing during nucleotide excision repair and the processing of double-strand breaks during intrachromosomal recombination. In this study we show that the RAD1 . RAD10 complex also cleaves a more complex junction structure consisting of a duplex with a protruding 3' single strand branch that resembles putative recombination intermediates in the RAD1 . RAD10-mediated single-strand annealing pathway of mitotic recombination. Using monoclonal antibodies, we have identified two regions of RAD1 that are required for the cleavage of duplex/single-strand junctions, These reagents also inhibit nucleotide excision repair in vitro, confirming the essential role of the RAD1 . RAD10 endonuclease in this pathway.	UNIV TEXAS,HLTH SCI CTR,INST BIOTECHNOL CTR MOL MED,SAN ANTONIO,TX 78245; UNIV TEXAS,SW MED CTR,DEPT PATHOL,LAB MOL PATHOL,DALLAS,TX 75225	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			Rodriguez, Karl A/F-2689-2012		NCI NIH HHS [CA/OD67978, CA-12428] Funding Source: Medline; NCRR NIH HHS [RR07187-14] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA012428, R01CA067978, R55CA067978, R37CA012428] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S07RR007187] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ABOUSSEKHRA A, 1995, CELL, V80, P859, DOI 10.1016/0092-8674(95)90289-9; AGUILERA A, 1989, GENETICS, V123, P683; APLAN PD, 1992, EMBO J, V11, P4073, DOI 10.1002/j.1460-2075.1992.tb05500.x; BAILLY V, 1992, P NATL ACAD SCI USA, V89, P8273, DOI 10.1073/pnas.89.17.8273; BARDWELL AJ, 1993, MOL MICROBIOL, V8, P1177, DOI 10.1111/j.1365-2958.1993.tb01662.x; BARDWELL AJ, 1994, SCIENCE, V265, P2082, DOI 10.1126/science.8091230; BARDWELL L, 1992, MOL CELL BIOL, V12, P3041, DOI 10.1128/MCB.12.7.3041; BIGGERSTAFF M, 1993, EMBO J, V12, P3685, DOI 10.1002/j.1460-2075.1993.tb06043.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROOKMAN KW, 1994, ENV MOL MUTAGEN S23, V23, P6; CARR AM, 1994, MOL CELL BIOL, V14, P2029, DOI 10.1128/MCB.14.3.2029; DAVIES AA, 1995, J BIOL CHEM, V270, P24638, DOI 10.1074/jbc.270.42.24638; ESPEJO RT, 1968, VIROLOGY, V34, P738, DOI 10.1016/0042-6822(68)90094-9; FISHMANLOBELL J, 1992, SCIENCE, V258, P480, DOI 10.1126/science.1411547; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES, P233; FUKITA Y, 1993, J BIOL CHEM, V268, P17463; GUZDER SN, 1995, J BIOL CHEM, V270, P12973, DOI 10.1074/jbc.270.22.12973; HABRAKEN Y, 1994, NATURE, V371, P531, DOI 10.1038/371531a0; HABRAKEN Y, 1993, NATURE, V366, P365, DOI 10.1038/366365a0; HE ZG, 1995, NATURE, V374, P566, DOI 10.1038/374566a0; HIGGINS DG, 1992, COMPUT APPL BIOSCI, V8, P189; HIGGINS DR, 1983, GENE, V26, P119, DOI 10.1016/0378-1119(83)90181-6; IVANOV EL, 1995, MOL CELL BIOL, V15, P2245; KUHNLEIN U, 1976, P NATL ACAD SCI USA, V73, P1169, DOI 10.1073/pnas.73.4.1169; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI L, 1995, MOL CELL BIOL, V15, P1993; LI L, 1994, P NATL ACAD SCI USA, V91, P5012, DOI 10.1073/pnas.91.11.5012; MATSUNAGA T, 1995, J BIOL CHEM, V270, P20862, DOI 10.1074/jbc.270.35.20862; ODONOVAN A, 1994, J BIOL CHEM, V269, P15965; ODONOVAN A, 1994, NATURE, V371, P432, DOI 10.1038/371432a0; PARK CH, 1994, P NATL ACAD SCI USA, V91, P5017, DOI 10.1073/pnas.91.11.5017; PARK CH, 1995, J BIOL CHEM, V270, P22657, DOI 10.1074/jbc.270.39.22657; PRAKASH L, 1977, MOL GEN GENET, V153, P125; QIAN YW, 1993, NATURE, V364, P649; REYNOLDS P, 1987, MOL CELL BIOL, V7, P1012, DOI 10.1128/MCB.7.3.1012; REYNOLDS P, 1985, EMBO J, V4, P3548; REYNOLDS RJ, 1981, J BACTERIOL, V146, P692, DOI 10.1128/JB.146.2.692-704.1981; SCHIESTL RH, 1990, MOL CELL BIOL, V10, P2485, DOI 10.1128/MCB.10.6.2485; SCHIESTL RH, 1988, MOL CELL BIOL, V8, P3619, DOI 10.1128/MCB.8.9.3619; SCHNEIDER R, 1991, FEBS LETT, V283, P203, DOI 10.1016/0014-5793(91)80588-T; SUNG P, 1993, J BIOL CHEM, V268, P26391; SUNG P, 1992, NATURE, V355, P743, DOI 10.1038/355743a0; SVEJSTRUP JQ, 1995, CELL, V80, P21, DOI 10.1016/0092-8674(95)90447-6; THOMAS BJ, 1989, GENETICS, V123, P725; TOMKINSON AE, 1994, BIOCHEMISTRY-US, V33, P5305, DOI 10.1021/bi00183a038; TOMKINSON AE, 1993, NATURE, V362, P860, DOI 10.1038/362860a0; UNRAU P, 1971, MOL GEN GENET, V354, P359; VANDUIN M, 1986, CELL, V44, P913, DOI 10.1016/0092-8674(86)90014-0; VANVUUREN AJ, 1993, EMBO J, V12, P3693, DOI 10.1002/j.1460-2075.1993.tb06044.x; WANG ZG, 1993, P NATL ACAD SCI USA, V90, P4907, DOI 10.1073/pnas.90.11.4907; WILCOX DR, 1981, J BACTERIOL, V148, P618, DOI 10.1128/JB.148.2.618-623.1981	51	20	20	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20551	20558		10.1074/jbc.271.34.20551	http://dx.doi.org/10.1074/jbc.271.34.20551			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702799	hybrid			2022-12-25	WOS:A1996VD33700051
J	Timerman, AP; Onoue, H; Xin, HB; Barg, S; Copello, J; Wiederrecht, G; Fleischer, S				Timerman, AP; Onoue, H; Xin, HB; Barg, S; Copello, J; Wiederrecht, G; Fleischer, S			Selective binding of FKBP12.6 by the cardiac ryanodine receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-RELEASE CHANNEL; SARCOPLASMIC-RETICULUM; SKELETAL-MUSCLE; TERMINAL CISTERNAE; FK-506-BINDING PROTEIN; FKBP-12; FK-506; CALCINEURIN; ASSOCIATION; COMPLEX	The calcium release channels (CRC)/ryanodine receptors of skeletal (Sk) and cardiac (C) muscle sarcoplasmic reticulum (SR) are hetero-oligomeric complexes with the structural formulas (ryanodine recepter (RyR)1 protomer)(4)(FKBP12)(4) and (RyR2 protomer)(4)(FKBP12.6)(4), respectively, where FKBP12 and FKBP12.6 are isoforms of the 12-kDa receptor for the immunosuppressant drug FK506. The sequence similarity between the RyR protomers and FKBP12 isoforms is 63 and 85%, respectively. Using S-35-labeled FKBP12 and S-35-labeled FKBP12.6 as probes to study the interaction with CRC, we find that: 1) analogous to its action in skeletal muscle sarcoplasmic reticulum (SkMSR), FK506 (or analog FK590) dissociates FKBP12.6 from CSR; 2) both FKBP isoforms bind to FKBP-stripped SkMSR and exchange with endogenously bound FKBP12 of SkMSR; and 3) by contrast, only FKBP12.6 exchanges with endogenously bound FKBP12.6 or rebinds to FKBP-stripped CSR. This selective binding appears to explain why the cardiac CRC is isolated as a complex with FKBP12.6, whereas the skeletal muscle CRC is isolated as a complex with FKBP12, although only FKBP12 is detectable in the myoplasm of both muscle types. Also, in contrast to the activation of the channel by removal of FKBP from skeletal muscle, no activation is detected in CRC activity in FKBP-stripped CSR. This differential action of FKBP may reflect a fundamental difference in the modulation of excitation-contraction coupling in heart versus skeletal muscle.	VANDERBILT UNIV, DEPT MOL BIOL, NASHVILLE, TN 37235 USA; MERCK RES LABS, DEPT IMMUNOL, RAHWAY, NJ 07065 USA	Vanderbilt University; Merck & Company			Barg, Sebastian/F-9523-2010	Barg, Sebastian/0000-0003-4661-5724	NHLBI NIH HHS [HL46681, HL32711] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL046681, R01HL032711] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AHERN GP, 1994, FEBS LETT, V352, P369, DOI 10.1016/0014-5793(94)01001-3; BRILLANTES AMB, 1994, CELL, V77, P513, DOI 10.1016/0092-8674(94)90214-3; CHAMBERLAIN BK, 1983, J BIOL CHEM, V258, P6602; COLLINS JH, 1991, BIOCHEM BIOPH RES CO, V178, P1288, DOI 10.1016/0006-291X(91)91033-9; FABIATO A, 1988, METHOD ENZYMOL, V157, P378; FLEISCHER S, 1985, P NATL ACAD SCI USA, V82, P7256, DOI 10.1073/pnas.82.21.7256; INUI M, 1987, J BIOL CHEM, V262, P15637; JAYARAMAN T, 1992, J BIOL CHEM, V267, P9474; LAM E, 1995, J BIOL CHEM, V270, P26511, DOI 10.1074/jbc.270.44.26511; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; MACK MM, 1994, J BIOL CHEM, V269, P23236; MAYRLEITNER M, 1995, CELL CALCIUM, V18, P197, DOI 10.1016/0143-4160(95)90064-0; MAYRLEITNER M, 1994, CELL CALCIUM, V15, P99, DOI 10.1016/0143-4160(94)90048-5; MCGREW SG, 1989, BIOCHEMISTRY-US, V28, P1686, DOI 10.1021/bi00430a039; ROBERTSON S, 1984, METHOD PHARMACOL, V5, P63, DOI DOI 10.1007/978-1-4684-4778-1_6; SAITO A, 1984, J CELL BIOL, V99, P875, DOI 10.1083/jcb.99.3.875; SEWELL TJ, 1994, J BIOL CHEM, V269, P21094; TIMERMAN AP, 1995, J BIOL CHEM, V270, P2451, DOI 10.1074/jbc.270.6.2451; TIMERMAN AP, 1994, BIOCHEM BIOPH RES CO, V198, P701, DOI 10.1006/bbrc.1994.1101; TIMERMAN AP, 1993, J BIOL CHEM, V268, P22992; Wiederrecht Greg, 1994, Perspectives in Drug Discovery and Design, V2, P57, DOI 10.1007/BF02171737; XIN HB, 1995, BIOCHEM BIOPH RES CO, V214, P263, DOI 10.1006/bbrc.1995.2283	22	209	216	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20385	20391		10.1074/jbc.271.34.20385	http://dx.doi.org/10.1074/jbc.271.34.20385			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702774	hybrid			2022-12-25	WOS:A1996VD33700026
J	Bushnell, DA; Bamdad, C; Kornberg, RD				Bushnell, DA; Bamdad, C; Kornberg, RD			A minimal set of RNA polymerase II transcription protein interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							START SITE SELECTION; FACTOR-B; INITIATION; YEAST; PURIFICATION; IDENTIFICATION; HOLOENZYME; CLONING; SUBUNIT; COMPLEX	All pairwise interactions of RNA polymerase II and general transcription factors (TF) IIB, E, F, and H have been quantitated by surface plasmon resonance with the use of a Ni2+ chelate on the sensor surface where necessary to attain higher sensitivity. Only 4 of 10 possible interactions were found above the detection limit: TFIIB, -E, and -F binding RNA polymerase II and TFIIE binding to TFIIH. These four interactions constitute a minimal set for the formation of a transcription initiation complex and may represent the primary interactions involved in assembly of the complex. Point mutations in TFIIB that alter the location of transcription start sites in vivo markedly diminished the affinity of TFIIB binding to RNA polymerase II. Protein blotting revealed an interaction between the largest subunit of TFIIE and third largest subunit of TFIIH, which may be responsible for the TFIIE binding to TFIIH.	STANFORD UNIV,SCH MED,DEPT BIOL STRUCT,STANFORD,CA 94027; HARVARD UNIV,DEPT MOL & CELLULAR BIOL,CAMBRIDGE,MA 02138	Stanford University; Harvard University					NIAID NIH HHS [AI21144] Funding Source: Medline; NIGMS NIH HHS [GM070276-20, GM36659] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021144] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036659, R37GM036659] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARBERIS A, 1995, CELL, V81, P359, DOI 10.1016/0092-8674(95)90389-5; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CONAWAY RC, 1993, ANNU REV BIOCHEM, V62, P161; EDWARDS AM, 1990, P NATL ACAD SCI USA, V87, P2122, DOI 10.1073/pnas.87.6.2122; FEAVER WJ, 1991, J BIOL CHEM, V266, P19000; FEAVER WJ, 1994, J BIOL CHEM, V269, P27549; FLANAGAN PM, 1990, J BIOL CHEM, V265, P11105; FLORES O, 1989, J BIOL CHEM, V264, P8913; FLORES O, 1991, P NATL ACAD SCI USA, V88, P9999, DOI 10.1073/pnas.88.22.9999; FLORES O, 1992, J BIOL CHEM, V267, P2786; GILEADI O, 1992, SCIENCE, V257, P1389, DOI 10.1126/science.1445600; HENRY NL, 1994, GENE DEV, V8, P2868, DOI 10.1101/gad.8.23.2868; HENRY NL, 1992, J BIOL CHEM, V267, P23388; JOHNSSON B, 1991, ANAL BIOCHEM, V198, P268, DOI 10.1016/0003-2697(91)90424-R; LI Y, 1994, P NATL ACAD SCI USA, V91, P2362, DOI 10.1073/pnas.91.6.2362; LI Y, 1994, SCIENCE, V263, P805, DOI 10.1126/science.8303296; LOFAS S, 1990, J CHEM SOC CHEM COMM, V21, P1526; MAXON ME, 1994, GENE DEV, V8, P515, DOI 10.1101/gad.8.5.515; Meredith GD, 1996, J MOL BIOL, V258, P413, DOI 10.1006/jmbi.1996.0258; OHKUMA Y, 1994, NATURE, V368, P160, DOI 10.1038/368160a0; PAN GH, 1994, J BIOL CHEM, V269, P30101; PINTO I, 1994, J BIOL CHEM, V269, P30569; REINBERG D, 1987, J BIOL CHEM, V262, P3310; SAYRE MH, 1992, J BIOL CHEM, V267, P23383; SERIZAWA H, 1994, TRANSCRIPTION MECHAN, P27; SOPTA M, 1985, J BIOL CHEM, V260, P353; SVEJSTRUP JQ, 1994, J BIOL CHEM, V269, P28044; TAN SY, 1994, J BIOL CHEM, V269, P25684; TSCHOCHNER H, 1992, P NATL ACAD SCI USA, V89, P11292, DOI 10.1073/pnas.89.23.11292; ZAWEL L, 1995, ANNU REV BIOCHEM, V64, P533	30	62	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					20170	20174		10.1074/jbc.271.33.20170	http://dx.doi.org/10.1074/jbc.271.33.20170			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702741	hybrid			2022-12-25	WOS:A1996VC66900083
J	Chen, Y; Knudsen, ES; Wang, JYJ				Chen, Y; Knudsen, ES; Wang, JYJ			Cells arrested in G(1) by the v-Abl tyrosine kinase do not express cyclin A despite the hyperphosphorylation of RB	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOBLASTOMA PROTEIN; A GENE; MAMMALIAN FIBROBLASTS; CONTACT INHIBITION; PHASE-TRANSITION; TGF-BETA; GROWTH; TRANSCRIPTION; P27(KIP1); SITE	The v-Abl tyrosine kinase encoded by the Abelson murine leukemia virus (A-MuLV) can either stimulate or inhibit cell proliferation, depending on the cell context. In a NIH-3T3-derived cell line, N3T3, v-Abl blocks the serum-induced entry into S phase. In these G(1)-arrested cells v-Abl does not interfere with the activation of cyclin D1 or cyclin E-dependent kinases. As a result, v-Abl does not block the hyperphosphorylation and inactivation of the retinoblastoma protein RE. However, activation of cyclin A-dependent kinase is inhibited due to a v-Abl-induced block in the accumulation of cyclin A mRNA and protein. Ectopic expression of cyclin A enabled the v-Abl-arrested cells to enter S phase, whereas cyclins E and D1, or E2Fs 1 and 4 could not overcome the v-Abl arrest. Taken together, these results suggest that v-Abl tyrosine kinase arrests cell cycle progression in G(1) by inhibiting the expression of cyclin A.	UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,CTR MOL GENET,LA JOLLA,CA 92093	University of California System; University of California San Diego; University of California System; University of California San Diego					NCI NIH HHS [R01 CA043054, R01 CA058320, CA50528, CA58320] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA050528, R01CA043054, R01CA058320] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; DESDOUETS C, 1995, MOL CELL BIOL, V15, P3301; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; GENE Y, 1996, ONCOGENE, V12, P1173; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HENGLEIN B, 1994, P NATL ACAD SCI USA, V91, P5490, DOI 10.1073/pnas.91.12.5490; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HUANG TS, 1995, P NATL ACAD SCI USA, V92, P4793, DOI 10.1073/pnas.92.11.4793; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; Knudsen ES, 1996, J BIOL CHEM, V271, P8313, DOI 10.1074/jbc.271.14.8313; Kramer A, 1996, J BIOL CHEM, V271, P6579; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; LIN BTY, 1991, EMBO J, V10, P857, DOI 10.1002/j.1460-2075.1991.tb08018.x; Nasmyth K, 1993, CURR OPIN CELL BIOL, V5, P166, DOI 10.1016/0955-0674(93)90099-C; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; Pines Jonathon, 1994, Seminars in Cell Biology, V5, P399, DOI 10.1006/scel.1994.1047; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RENSHAW MW, 1995, MOL CELL BIOL, V15, P1286; RENSHAW MW, 1992, EMBO J, V11, P3941, DOI 10.1002/j.1460-2075.1992.tb05488.x; RESNITZKY D, 1995, MOL CELL BIOL, V15, P4347; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; SCHULZE A, 1995, P NATL ACAD SCI USA, V92, P11264, DOI 10.1073/pnas.92.24.11264; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; WANG JYJ, 1994, ADV CANCER RES, V64, P25, DOI 10.1016/S0065-230X(08)60834-9; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WELCH PJ, 1995, GENE DEV, V9, P31, DOI 10.1101/gad.9.1.31; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; YOSHIZUMI M, 1995, MOL CELL BIOL, V15, P3266; ZWICKER J, 1995, EMBO J, V14, P4514, DOI 10.1002/j.1460-2075.1995.tb00130.x	36	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					19637	19640		10.1074/jbc.271.33.19637	http://dx.doi.org/10.1074/jbc.271.33.19637			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702661	hybrid			2022-12-25	WOS:A1996VC66900002
J	Summerfield, AE; Hudnall, AK; Lukas, TJ; Guyer, CA; Staros, JV				Summerfield, AE; Hudnall, AK; Lukas, TJ; Guyer, CA; Staros, JV			Identification of residues of the epidermal growth factor receptor proximal to residue 45 of bound epidermal growth factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; FACTOR EGF RECEPTOR; FACTOR-ALPHA; BINDING-SITE; EXTRACELLULAR DOMAIN; HIGH-AFFINITY; EXPRESSION; MUTANT; LOCALIZATION; RESONANCE	A triple mutant of murine epidermal growth factor (mEGF), N1Q/H22Y/R45K-mEGF, was constructed by site-directed mutagenesis, expressed, purified, and characterized for use in an affinity cross-linking study to identify aminoacyl residues of the EGF receptor adjacent to a residue in the carboxyl-terminal domain of bound EGF thought to be important in distinguishing between EGF and transforming growth factor-alpha in their recognition by the receptor. Cyclization of Gln(1) to form pyroglutamate (pE) limited the site of cross-linking in the mutant to Lys(45), permitting identification of receptor residues that are proximal to this residue of bound EGF. The resulting N1pE/H22Y/R45K-mEGF was shown to be comparable to wild-type mEGF in receptor binding and stimulation of receptor autophosphorylation. I-125-Labeled N1pE/H22Y/R45K-mEGF was reacted with the heterobifunctional cross-linking reagent sulfo-N-succinimidyl-4-(fluorosulfonyl)benzoate, and the resulting modified EGF was incubated with A431 membrane vesicles bearing EGF receptors. Incubation resulted in specific cross-linking of the labeled N1pE/H22Y/R45K-mEGF to EGF receptors. The resulting cross-linked complex was then partially purified, denatured, reduced, and carboxyamidomethylated. Digestion with endoprotease LysC resulted in a unique radiolabeled peptide that could be immunoprecipitated using antibodies to mEGF. This immunoprecipitated fragment was purified by gel electrophoresis and subjected to microsequencing. The resulting sequence was matched to that of a LysC fragment of the receptor, which begins with Thr(464) and is near the interface of receptor subdomains III and IV. Loss of signal at cycle 2 suggests that the point of attachment of cross-linked N1pE/H22Y/R45K is Lys(465) of the receptor.	VANDERBILT UNIV, DEPT MOL BIOL, NASHVILLE, TN 37235 USA; NORTHWESTERN UNIV, SCH MED, DEPT MOL PHARMACOL & BIOL CHEM, CHICAGO, IL 60611 USA	Vanderbilt University; Northwestern University					NCI NIH HHS [T32 CA09582] Funding Source: Medline; NIDDK NIH HHS [R01 DK25489] Funding Source: Medline; NIGMS NIH HHS [R01 GM30861] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009582] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK025489] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030861] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANJANEYULU PSR, 1987, INT J PEPT PROT RES, V30, P117; BROWN PM, 1994, EUR J BIOCHEM, V225, P223, DOI 10.1111/j.1432-1033.1994.00223.x; CAMPION SR, 1992, J CELL BIOCHEM, V50, P35; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; CARPENTER G, 1976, J CELL BIOL, V71, P159, DOI 10.1083/jcb.71.1.159; CARPENTER G, 1990, HDB EXPT PHARM, V95, P69; COHEN S, 1982, J BIOL CHEM, V257, P1523; DERYNCK R, 1984, CELL, V38, P287, DOI 10.1016/0092-8674(84)90550-6; DERYNCK R, 1992, ADV CANCER RES, V58, P27, DOI 10.1016/S0065-230X(08)60289-4; FRY MJ, 1993, PROTEIN SCI, V2, P1785, DOI 10.1002/pro.5560021102; GREGORY H, 1975, NATURE, V257, P325, DOI 10.1038/257325a0; HOMMEL U, 1992, J MOL BIOL, V227, P271, DOI 10.1016/0022-2836(92)90697-I; HOMMEL U, 1991, BIOCHEMISTRY-US, V30, P8891, DOI 10.1021/bi00100a024; KOHDA D, 1992, BIOCHEMISTRY-US, V31, P11928, DOI 10.1021/bi00162a036; KRAMER RH, 1994, J BIOL CHEM, V269, P8708; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAX I, 1988, MOL CELL BIOL, V8, P1970, DOI 10.1128/MCB.8.5.1970; LAX I, 1988, MOL CELL BIOL, V8, P1831, DOI 10.1128/MCB.8.4.1831; LAX I, 1991, CELL REGUL, V2, P337, DOI 10.1091/mbc.2.5.337; LAX I, 1989, EMBO J, V8, P421, DOI 10.1002/j.1460-2075.1989.tb03393.x; MATSUNAMI RK, 1991, J CELL BIOCHEM, V46, P242, DOI 10.1002/jcb.240460307; MONTELIONE GT, 1992, BIOCHEMISTRY-US, V31, P236, DOI 10.1021/bi00116a033; RAY P, 1988, BIOCHEMISTRY-US, V27, P7289, DOI 10.1021/bi00419a017; ROUSSEAU DL, 1995, BIOCHEMISTRY-US, V34, P14508, DOI 10.1021/bi00044a029; ROUSSEAU DL, 1993, BIOCHEMISTRY-US, V32, P7893, DOI 10.1021/bi00082a009; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SAVAGE CR, 1972, J BIOL CHEM, V247, P7609; SAVAGE CR, 1972, J BIOL CHEM, V247, P7612; Staros JV, 1995, BIOORG CHEM, V23, P369, DOI 10.1006/bioo.1995.1025; STONE KL, 1989, PRACTICAL GUIDE TO PROTEIN AND PEPTIDE PURIFICATION FOR MICROSEQUENCING, P31; TAYLOR JM, 1972, J BIOL CHEM, V247, P5928; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; VANDEPOLL MLM, 1995, J BIOL CHEM, V270, P22337, DOI 10.1074/jbc.270.38.22337; WOLTJER RL, 1992, BIOCHEMISTRY-US, V31, P7341, DOI 10.1021/bi00147a019; WOLTJER RL, 1992, P NATL ACAD SCI USA, V89, P7801, DOI 10.1073/pnas.89.16.7801; WU DG, 1989, J BIOL CHEM, V264, P17469	36	35	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					19656	19659		10.1074/jbc.271.33.19656	http://dx.doi.org/10.1074/jbc.271.33.19656			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702666	hybrid			2022-12-25	WOS:A1996VC66900007
J	Monteclaro, FS; Charo, IF				Monteclaro, FS; Charo, IF			The amino-terminal extracellular domain of the MCP-1 receptor, but not the RANTES/MIP-1 alpha receptor, confers chemokine selectivity - Evidence for a two-step mechanism for MCP-1 receptor activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHEMOATTRACTANT PROTEIN-1 RECEPTOR; FORMYL PEPTIDE RECEPTOR; LIGAND-BINDING; FUNCTIONAL EXPRESSION; MOLECULAR-CLONING; THROMBIN-RECEPTOR; A RECEPTOR; IDENTIFICATION; CELLS; CHORIOGONADOTROPIN	The chemoattractant cytokines, MCP-1 (monocyte chemoattractant protein) and MIP-1 alpha (macrophage inflammatory protein), are recognized by highly homologous but distinct receptors, To identify receptor domains involved ill determining ligand specificity, we created a series of chimeric MCP-1 and RANTES (regulated on activation, normal T cell expressed and secreted)/MIP-1 alpha receptors that progressively interchanged the amino terminus and each of the three extracellular loops. Radiolabeled MCP-1 bound with high affinity to the wild-type MCP-1 receptor, but not to the RANTES/MLP-1 alpha receptor (C-C CKR-1), Chimeras that retained the amino-terminal extension of the MCP-I receptor bound MCP-1 with high affinity, In contrast, chimeric MCP-I receptors, in which the wild-type amino terminus was replaced with the corresponding portion of the RANTES/MIP-1 alpha: receptor, bound MIP-1 with low affinity, These data indicate that the amino terminus of the MCP-1 receptor is necessary for high affinity binding of the ligand, Very different results were obtained using the RANTES/MIP-1 alpha: receptor, Radiolabeled MIP-1 alpha bound with high affinity to chimeras that expressed the extracellular loops of the RANTES/MIP-1 alpha receptor, In contrast to the MCP-1 receptor; substitution of the wild-type amino-terminal extension had little or no effect on MIP-1 alpha binding, For the MCP-1, but not the RANTES/MIP-1 alpha receptor, the presence of the wild-type amino terminus also significantly lowered the ligand concentration required for maximal signaling, We conclude that the amino-terminal extension of the MCP-1 receptor, but not the RANTES/MIP-1 alpha receptor, is critically involved in ligand binding and signal transduction. These data reveal significant functional differences between the two C-C chemokine receptors and suggest a two-step mechanism for activation of the MCP-1 receptor.	UNIV CALIF SAN FRANCISCO,GLADSTONE INST CARDIOVASC DIS,CARDIOVASC RES INST,SAN FRANCISCO,CA 94141; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94141; UNIV CALIF SAN FRANCISCO,DAIICHI RES CTR,SAN FRANCISCO,CA 94141	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of California System; University of California San Francisco					NHLBI NIH HHS [HL52773] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052773] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADACHI M, 1994, EUR J BIOCHEM, V220, P37, DOI 10.1111/j.1432-1033.1994.tb18596.x; Ahuja SK, 1996, J BIOL CHEM, V271, P225, DOI 10.1074/jbc.271.1.225; BAGGIOLINI M, 1994, IMMUNOL TODAY, V15, P127, DOI 10.1016/0167-5699(94)90156-2; CHARO IF, 1994, P NATL ACAD SCI USA, V91, P2752, DOI 10.1073/pnas.91.7.2752; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; COMBADIERE C, 1995, J BIOL CHEM, V270, P29671; COMBADIERE C, 1995, J BIOL CHEM, V270, P16491, DOI 10.1074/jbc.270.28.16491; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; FRANCI C, 1995, J IMMUNOL, V154, P6511; GAO JL, 1993, J EXP MED, V177, P1421, DOI 10.1084/jem.177.5.1421; GAYLE RB, 1993, J BIOL CHEM, V268, P7283; GERARD C, 1994, ANNU REV IMMUNOL, V12, P775, DOI 10.1146/annurev.iy.12.040194.004015; GERSZTEN RE, 1994, NATURE, V368, P648, DOI 10.1038/368648a0; HEBERT CA, 1993, J BIOL CHEM, V268, P18549; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HUGLI TE, 1981, MOL CELL BIOCHEM, V41, P59; ISHII K, 1993, J BIOL CHEM, V268, P9780; JI I, 1991, J BIOL CHEM, V266, P13076; JOSE PJ, 1994, J EXP MED, V179, P881, DOI 10.1084/jem.179.3.881; KELNER GS, 1994, SCIENCE, V266, P1395, DOI 10.1126/science.7973732; MERY L, 1994, J BIOL CHEM, V269, P3457; MOYLE WR, 1991, J BIOL CHEM, V266, P10807; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.iy.12.040194.003113; MYERS SJ, 1995, J BIOL CHEM, V270, P5786, DOI 10.1074/jbc.270.11.5786; NATHANS J, 1992, BIOCHEMISTRY-US, V31, P4923, DOI 10.1021/bi00136a001; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; POWER CA, 1995, J BIOL CHEM, V270, P19495, DOI 10.1074/jbc.270.33.19495; PROSSNITZ ER, 1993, BIOCHEM J, V294, P581, DOI 10.1042/bj2940581; QUEBENBERGER O, 1993, J BIOL CHEM, V268, P18167; RADEL SJ, 1994, INFECT IMMUN, V62, P1726, DOI 10.1128/IAI.62.5.1726-1732.1994; SCHALL TJ, 1994, CYTOKINE HDB, P419; SCHIFFMANN E, 1975, P NATL ACAD SCI USA, V72, P1059, DOI 10.1073/pnas.72.3.1059; Schwartz Thue W., 1994, Current Opinion in Biotechnology, V5, P434, DOI 10.1016/0958-1669(94)90054-X; SICILIANO SJ, 1994, P NATL ACAD SCI USA, V91, P1214, DOI 10.1073/pnas.91.4.1214; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; VADDI K, 1994, J IMMUNOL, V153, P4721; VU TKH, 1991, NATURE, V353, P674, DOI 10.1038/353674a0; WADSWORTH HL, 1990, SCIENCE, V249, P1423, DOI 10.1126/science.2169649; WALKER P, 1994, J BIOL CHEM, V269, P2863; XUE JC, 1994, J BIOL CHEM, V269, P30195	41	184	188	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19084	19092		10.1074/jbc.271.32.19084	http://dx.doi.org/10.1074/jbc.271.32.19084			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702581	hybrid			2022-12-25	WOS:A1996VB68400015
J	Stefano, GB; Liu, Y; Goligorsky, MS				Stefano, GB; Liu, Y; Goligorsky, MS			Cannabinoid receptors are coupled to nitric oxide release in invertebrate immunocytes, microglia, and human monocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; PHAGOCYTIC-ACTIVITY; MYTILUS-EDULIS; INHIBITION; DELTA-9-TETRAHYDROCANNABINOL; MACROPHAGES; INVITRO; BRAIN; SUPPRESSION; EXPRESSION	The present study demonstrates that stereoselective binding sites for anandamide, a naturally occurring cannabinoid substance, can be found ill invertebrate immunocytes and microglia. The anandamide-binding site is monophasic and of high affinity, exhibiting a K-d of 34.3 nw with a B-max of 441 fmol/mg protein. These sites are highly selective, as demonstrated by the inability of other types of signaling molecules to displace [H-3]anandamide, Furthermore, this binding site is coupled to nitric oxide release in the invertebrate tissues examined as well as in human monocytes, Interestingly, the cannabinoid stimulated release of nitric oxide. initiates cell rounding. Thus, these cannabinoid actions resemble those of opiate alkaloids, In this regard, we demonstrate that these signaling systems use the same effector system, i.e, nitric oxide release, but separate receptors, Last., the presence of a cannabinoid receptor in selected evolutionary diverse organisms indicates that this signaling system has been conserved for more than 500 million years.	SUNY STONY BROOK,DEPT MED,STONY BROOK,NY 11794; SUNY STONY BROOK,DEPT PHYSIOL,STONY BROOK,NY 11794	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Stefano, GB (corresponding author), SUNY COLL OLD WESTBURY,NEUROSCI RES INST,POB 210,OLD WESTBURY,NY 11568, USA.		Stefano, George Bogdan/ABD-9152-2021	Stefano, George Bogdan/0000-0002-8146-0740	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK041573] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [T34MH017138] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R24DA009010] Funding Source: NIH RePORTER; NIDA NIH HHS [DA 09010] Funding Source: Medline; NIDDK NIH HHS [DK 41573] Funding Source: Medline; NIMH NIH HHS [MH/DA 17138] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BURNETTECURLEY D, 1995, P SOC EXP BIOL MED, V210, P64, DOI 10.3181/00379727-210-43926; BURROWES WR, 1983, LIFE SCI, V33, P381, DOI 10.1016/0024-3205(83)90522-2; CABRAL GA, 1994, LIFE SCI, V54, P1831, DOI 10.1016/0024-3205(94)90122-8; CHILDERS SR, 1992, ANN NY ACAD SCI, V654, P33, DOI 10.1111/j.1749-6632.1992.tb25954.x; DEVANE WA, 1986, J NEUROCHEM, V46, P1929; DEVANE WA, 1988, MOL PHARMACOL, V34, P605; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; DIMARZO V, 1994, NATURE, V372, P686, DOI 10.1038/372686a0; FRIEDMAN M, 1986, P SOC EXP BIOL MED, V182, P225; HOLLISTER LE, 1992, J PSYCHOACTIVE DRUGS, V24, P159, DOI 10.1080/02791072.1992.10471635; HUGHES TK, 1991, ADV NEUROIMMUNOL, V1, P59, DOI 10.1016/S0960-5428(06)80032-X; HUGHES TK, 1990, P NATL ACAD SCI USA, V87, P4426, DOI 10.1073/pnas.87.12.4426; LIU Y, 1996, IN PRESS BRAIN RES; LOPEZCEPERO M, 1986, J LEUKOCYTE BIOL, V39, P679, DOI 10.1002/jlb.39.6.679; MATSUDA LA, 1990, NATURE, V346, P561, DOI 10.1038/346561a0; MCCOY KL, 1995, J PHARMACOL EXP THER, V273, P1216; MUNRO S, 1993, NATURE, V365, P61, DOI 10.1038/365061a0; OBRIEN CP, 1996, PHARMACOL BASIS THER, P557; OTTAVIANI E, 1993, EUR J PHARM-ENVIRON, V248, P319, DOI 10.1016/0926-6917(93)90006-C; SCHON JC, 1991, ADV NEUROIMMUNOL, V1, P252, DOI 10.1016/S0960-5428(06)80015-X; SHIPP MA, 1991, BLOOD, V78, P1834; SHIVERS SC, 1994, LIFE SCI, V54, P1281, DOI 10.1016/0024-3205(94)00856-6; SONETTI D, 1994, P NATL ACAD SCI USA, V91, P9180, DOI 10.1073/pnas.91.19.9180; SPECTER S, 1991, J LEUKOCYTE BIOL, V50, P423, DOI 10.1002/jlb.50.5.423; STEFANO GB, 1993, P NATL ACAD SCI USA, V90, P11099, DOI 10.1073/pnas.90.23.11099; STEFANO GB, 1994, ELECTRO MAGNETOBIOL, V13, P123, DOI 10.3109/15368379409030706; STEFANO GB, 1989, P NATL ACAD SCI USA, V86, P6307, DOI 10.1073/pnas.86.16.6307; STEFANO GB, 1992, P NATL ACAD SCI USA, V89, P9316, DOI 10.1073/pnas.89.19.9316; Stefano GB, 1995, J BIOL CHEM, V270, P30290, DOI 10.1074/jbc.270.51.30290; STEFANO GB, 1996, IN PRESS COMP BIOCH; TANG JL, 1992, INT J IMMUNOPHARMACO, V14, P253; WELCH SP, 1994, PHARMACOL BIOCHEM BE, V49, P929, DOI 10.1016/0091-3057(94)90245-3; ZHENG ZM, 1992, INT J IMMUNOPHARMACO, V14, P1445	33	155	161	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19238	19242		10.1074/jbc.271.32.19238	http://dx.doi.org/10.1074/jbc.271.32.19238			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702604	hybrid			2022-12-25	WOS:A1996VB68400038
J	Mikhailov, VS; Bogenhagen, DF				Mikhailov, VS; Bogenhagen, DF			Effects of Xenopus laevis mitochondrial single-stranded DNA-binding protein on primer-template binding and 3'->5' exonuclease activity of DNA polymerase gamma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; REPLICATION; SSB; STIMULATION; SEQUENCE	Mitochondrial DNA (mtDNA) is replicated by DNA polymerase gamma by a strand displacement mechanism involving mitochondrial single-stranded DNA-binding protein (mtSSB). mtSSB stimulates the overall rate of DNA synthesis on singly-primed M13 DNA mainly by stimulating the processivity of DNA synthesis rather than by stimulating primer recognition, We used electrophoretic mobility shift methods to study the effects of mtSSB on primer template recognition by DNA pol gamma, Preliminary experiments showed that single mtSSB tetramers bind tightly to oligo(dT) single strands containing 32 to 48 residues. An oligonucleotide primer-template was designed with an 18-mer primer annealed to the 3'-portion of a 71-mer template containing 40 dT residues at its 5'-end as a binding site for mtSSB. DNA pol gamma bound to this primer-template either in the absence or presence of mtSSB in complexes that remained intact and enzymatically active following native gel electrophoresis. Association of mtSSB with the 5'-dT(40)-tail in the 18:71-mer primer-template reduced the binding of DNA polymerase gamma and the efficiency of primer extension. Binding of mtSSB to single-stranded DNA was also observed to block the action of the 3'-->5' exonuclease of DNA polymerase gamma. The size of fragments protected from 3'-->5' exonuclease trimming increases with increasing ionic strength in a manner consistent with the known salt dependence of the binding site size of Escherichia coli SSB.	RUSSIAN ACAD SCI,KOLTZOV INST DEV BIOL,MOSCOW 117808,RUSSIA	Russian Academy of Sciences; Koltzov Institute of Developmental Biology of the Russian Academy of Sciences	Mikhailov, VS (corresponding author), SUNY STONY BROOK,DEPT PHARMACOL SCI,STONY BROOK,NY 11794, USA.		Mikhailov, Victor S/O-2063-2016	Mikhailov, Victor/0000-0002-3324-8921	NIEHS NIH HHS [P01ES04068] Funding Source: Medline; NIGMS NIH HHS [GM29681] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES004068] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029681] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAIRNS SS, 1987, THESIS STATE U NEW Y; CHRYSOGELOS S, 1982, P NATL ACAD SCI-BIOL, V79, P5803, DOI 10.1073/pnas.79.19.5803; CLAYTON DA, 1982, CELL, V28, P693, DOI 10.1016/0092-8674(82)90049-6; CURTH U, 1994, EUR J BIOCHEM, V221, P435, DOI 10.1111/j.1432-1033.1994.tb18756.x; DORNREITER I, 1992, EMBO J, V11, P769, DOI 10.1002/j.1460-2075.1992.tb05110.x; GENUARIO R, 1993, CELL MOL BIOL RES, V39, P625; GHRIR R, 1991, ARCH BIOCHEM BIOPHYS, V291, P395, DOI 10.1016/0003-9861(91)90152-9; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; HOKE GD, 1990, ARCH BIOCHEM BIOPHYS, V282, P116, DOI 10.1016/0003-9861(90)90094-F; INSDORF NF, 1989, J BIOL CHEM, V264, P21498; INSDORF NF, 1989, J BIOL CHEM, V264, P21491; KOWALCZYKOWSKI SC, 1981, J MOL BIOL, V145, P75, DOI 10.1016/0022-2836(81)90335-1; LOHMAN TM, 1988, TRENDS BIOCHEM SCI, V13, P250; LOHMAN TM, 1994, ANNU REV BIOCHEM, V63, P527, DOI 10.1146/annurev.biochem.63.1.527; MAHOUNGOU C, 1988, FEBS LETT, V235, P267, DOI 10.1016/0014-5793(88)81276-6; MEYER RR, 1990, MICROBIOL REV, V54, P342, DOI 10.1128/MMBR.54.4.342-380.1990; MIGNOTTE B, 1985, NUCLEIC ACIDS RES, V13, P1703, DOI 10.1093/nar/13.5.1703; MIGNOTTE B, 1988, EUR J BIOCHEM, V174, P479, DOI 10.1111/j.1432-1033.1988.tb14123.x; PAVCO PA, 1985, J CELL BIOL, V100, P258, DOI 10.1083/jcb.100.1.258; SHOFFNER JM, 1989, P NATL ACAD SCI USA, V86, P7952, DOI 10.1073/pnas.86.20.7952; STROUMBAKIS ND, 1994, GENE, V143, P171, DOI 10.1016/0378-1119(94)90093-0; THOMMES P, 1995, J BIOL CHEM, V270, P21137, DOI 10.1074/jbc.270.36.21137; TIRANTI V, 1991, NUCLEIC ACIDS RES, V19, P4291, DOI 10.1093/nar/19.15.4291; TIRANTI V, 1993, GENE, V126, P219, DOI 10.1016/0378-1119(93)90370-I; VANDYCK E, 1992, EMBO J, V11, P3421, DOI 10.1002/j.1460-2075.1992.tb05421.x; VANTUYLE GC, 1985, J CELL BIOL, V100, P251, DOI 10.1083/jcb.100.1.251; WILLIAMS AJ, 1995, J BIOL CHEM, V270, P860, DOI 10.1074/jbc.270.2.860; ZEVIANI M, 1992, J INHERIT METAB DIS, V15, P456, DOI 10.1007/BF01799604	29	28	28	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18939	18946		10.1074/jbc.271.31.18939	http://dx.doi.org/10.1074/jbc.271.31.18939			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702557	hybrid			2022-12-25	WOS:A1996VB68300095
J	Chang, W; Zhou, W; Theill, LE; Baxter, JD; Schaufele, F				Chang, W; Zhou, W; Theill, LE; Baxter, JD; Schaufele, F			An activation function in Pit-1 required selectively for synergistic transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-HORMONE GENE; RESPONSE ELEMENTS; CYCLIC-AMP; PROMOTER; RECEPTOR; BINDING; EXPRESSION; PROTEIN; DOMAINS; DNA	Synergistic transcription activation is a key component in the generation of the spectrum of eukaryotic promoter activities by a limited number of transcription factors, Various mechanisms could account for synergy, but a central question remains of whether synergism requires transcription factor functions that differ from those that direct independent activation, The rat growth hormone promoter is synergistically activated by the pituitary-specific transcription factor, Pit-1, and the thyroid hormone receptor (TR), Mutations that disrupted the previously described DNA binding and transcriptional activation domains of both Pit-1 and TR reduced Pit-1/TR synergy in parallel with their effects on the much weaker, independent Pit-1 and TR activations of the rat growth hormone promoter, Thus, Pit-1 and TR amplify each other's intrinsic activities, Mutations of Pit-1 that selectively inhibited synergism with the TR without affecting independent Pit-1 activity were also identified, Pit-1/TR synergy is therefore a consequence of a novel synergism-selective activity and synergism-independent Pit-1 and TR functions.	UNIV CALIF SAN FRANCISCO,METAB RES UNIT,SAN FRANCISCO,CA 94143; AMGEN INC,THOUSAND OAKS,CA 91320	University of California System; University of California San Francisco; Amgen								ADAMS CC, 1995, MOL CELL BIOL, V15, P1405; BACH I, 1995, P NATL ACAD SCI USA, V92, P2720, DOI 10.1073/pnas.92.7.2720; BRADFORD AP, 1995, MOL CELL BIOL, V15, P2849; BRENT GA, 1991, MOL ENDOCRINOL, V5, P542, DOI 10.1210/mend-5-4-542; CAREY M, 1990, NATURE, V345, P361, DOI 10.1038/345361a0; CHANG CB, 1994, MOL CELL BIOL, V14, P5175, DOI 10.1128/MCB.14.8.5175; CHI TH, 1995, NATURE, V377, P254, DOI 10.1038/377254a0; COWELL IG, 1994, TRENDS BIOCHEM SCI, V19, P38, DOI 10.1016/0968-0004(94)90172-4; DAY RN, 1990, MOL ENDOCRINOL, V4, P1964, DOI 10.1210/mend-4-12-1964; EMAMI KH, 1992, EMBO J, V11, P5005, DOI 10.1002/j.1460-2075.1992.tb05607.x; GAIDDON C, 1995, ENDOCRINOLOGY, V136, P4331, DOI 10.1210/en.136.10.4331; GEGONNE A, 1993, EMBO J, V12, P1169, DOI 10.1002/j.1460-2075.1993.tb05758.x; GETZENBERG RH, 1994, J CELL BIOCHEM, V55, P22, DOI 10.1002/jcb.240550105; HAUGEN BR, 1993, J BIOL CHEM, V268, P20818; HERBOMEL P, 1990, New Biologist, V2, P1063; HOLLOWAY JM, 1995, GENE DEV, V9, P1992, DOI 10.1101/gad.9.16.1992; JOUNG JK, 1994, SCIENCE, V265, P1863, DOI 10.1126/science.8091212; KAPILOFF MS, 1991, SCIENCE, V253, P786, DOI 10.1126/science.1652153; KUNSCH C, 1994, J IMMUNOL, V153, P153; KUSHNER PJ, 1994, MOL ENDOCRINOL, V8, P405, DOI 10.1210/me.8.4.405; LACASSE EC, 1993, ENDOCRINOLOGY, V132, P1017, DOI 10.1210/en.132.3.1017; LEW D, 1993, GENE DEV, V7, P683, DOI 10.1101/gad.7.4.683; LIN YS, 1990, NATURE, V345, P359, DOI 10.1038/345359a0; LIPKIN SM, 1993, GENE DEV, V7, P1674, DOI 10.1101/gad.7.9.1674; MERIKA M, 1995, MOL CELL BIOL, V15, P2437; MULLER M, 1991, MOL ENDOCRINOL, V5, P1498, DOI 10.1210/mend-5-10-1498; NAGULAPALLI S, 1995, J IMMUNOL, V155, P4330; NAKAE K, 1995, J BIOL CHEM, V270, P23795, DOI 10.1074/jbc.270.40.23795; NISHIZUKA Y, 1983, TRENDS BIOCHEM SCI, V8, P13, DOI 10.1016/0968-0004(83)90061-0; OHASHI Y, 1994, MOL CELL BIOL, V14, P2731, DOI 10.1128/MCB.14.4.2731; OLIVIERO S, 1991, P NATL ACAD SCI USA, V88, P224, DOI 10.1073/pnas.88.1.224; PTASHNE M, 1990, NATURE, V346, P329, DOI 10.1038/346329a0; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; RHODES SJ, 1994, CURR OPIN GENET DEV, V4, P709, DOI 10.1016/0959-437X(94)90138-S; SCHAUFELE F, 1990, J BIOL CHEM, V265, P17189; SCHAUFELE F, 1992, MOL ENDOCRINOL, V6, P656, DOI 10.1210/me.6.4.656; SCHAUFELE F, 1994, PITUITARY GLAND, P91; SEAMON KB, 1981, J CYCLIC NUCL PROT, V7, P201; SIGLER PB, 1988, NATURE, V333, P210, DOI 10.1038/333210a0; SIMMONS DM, 1990, GENE DEV, V4, P695, DOI 10.1101/gad.4.5.695; SZYMANSKI P, 1995, EMBO J, V14, P2229, DOI 10.1002/j.1460-2075.1995.tb07217.x; TANESE N, 1991, GENE DEV, V5, P2212, DOI 10.1101/gad.5.12a.2212; TANSEY WP, 1993, J BIOL CHEM, V268, P14906; THEILL LE, 1989, NATURE, V342, P945, DOI 10.1038/342945a0; THEILL LE, 1993, ENDOCR REV, V14, P670, DOI 10.1210/er.14.6.670; THOMPSON CC, 1989, P NATL ACAD SCI USA, V86, P3494, DOI 10.1073/pnas.86.10.3494; TIAN J, 1995, MOL CELL ENDOCRINOL, V112, P249, DOI 10.1016/0303-7207(95)03614-D; WEST BL, 1987, MOL CELL BIOL, V7, P1193, DOI 10.1128/MCB.7.3.1193; WU KJ, 1994, J BIOL CHEM, V269, P1177; YE ZS, 1987, J BIOL CHEM, V262, P6313	50	32	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					17733	17738		10.1074/jbc.271.30.17733	http://dx.doi.org/10.1074/jbc.271.30.17733			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663468	hybrid			2022-12-25	WOS:A1996UY93500024
J	Kawamoto, S				Kawamoto, S			Neuron-specific alternative splicing of nonmuscle myosin II heavy chain-B pre-mRNA requires a cis-acting intron sequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; GENE; EXON; MOLECULE; CLONING; ISOFORM; ELEMENT; REGION; CELLS; SITE	In addition to the ubiquitously expressed form of nonmuscle myosin II heavy chain-B (MHC-B), the existence of a neuron-specific MHC-B isoform, which contains a 30-nucleotide inserted sequence near the ATP binding region, has been reported (Takahashi, M,, Kawamoto, S,, and Adelstein, R, S, (1992) J. Biol, Chem, 267, 17864-17871), In this study, the genomic location of the neuron-specific inserted 30-nucleotide sequence found in the cDNA is determined to be a single cassette type exon, N30, in the human nonmuscle MHC-B gene, Inclusion or exclusion of exon N30 is cell type-specific, with inclusion being restricted to neuronal cells and being regulated during cell differentiation. Expression of a minigene construct that contains the alternative exon N30 along with the flanking introns and exons was studied in human neuronal retinoblastoma Y79 cells, Inclusion of the N30 exon in the mRNA from the transfected minigene occurs in differentiated Y79 cells that have been treated with butyrate but not in the undifferentiated Y79 cells and non-neuronal cell lines, Systematic deletion and mutation analysis of the minigene construct established that neuron-specific N30 exon recognition requires a cis-acting RNA sequence located similar to 1.5 kilobases downstream of the N30 exon.			Kawamoto, S (corresponding author), NHLBI,NIH,MOLEC CARDIOL LAB,BLDG 10,RM 8N202,10 CTR DR,MSC 1762,BETHESDA,MD 20892, USA.							BABIJ P, 1991, P NATL ACAD SCI USA, V88, P10676, DOI 10.1073/pnas.88.23.10676; BABIJ P, 1993, NUCLEIC ACIDS RES, V21, P1467, DOI 10.1093/nar/21.6.1467; BLACK DL, 1992, CELL, V69, P795, DOI 10.1016/0092-8674(92)90291-J; DIRKSEN WP, 1994, J BIOL CHEM, V269, P6431; EMESON RB, 1989, NATURE, V341, P76, DOI 10.1038/341076a0; Gilliland G., 1990, PCR PROTOCOLS GUIDE, P60; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; GUO W, 1991, GENE DEV, V5, P2096, DOI 10.1101/gad.5.11.2096; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HUH GS, 1994, GENE DEV, V8, P1561, DOI 10.1101/gad.8.13.1561; ITOH K, 1995, J BIOL CHEM, V270, P14533, DOI 10.1074/jbc.270.24.14533; KATSURAGAWA Y, 1989, EUR J BIOCHEM, V184, P611, DOI 10.1111/j.1432-1033.1989.tb15057.x; KAWAMOTO S, 1994, J BIOL CHEM, V269, P15101; Mansfield SG, 1996, J MOL BIOL, V255, P98; MIN HS, 1995, GENE DEV, V9, P2659, DOI 10.1101/gad.9.21.2659; Pato MD, 1996, J BIOL CHEM, V271, P2689, DOI 10.1074/jbc.271.5.2689; PHILLIPS CL, 1995, J MUSCLE RES CELL M, V16, P379, DOI 10.1007/BF00114503; REED R, 1986, CELL, V46, P681, DOI 10.1016/0092-8674(86)90343-0; SELLERS JR, 1995, PROTEIN PROFILE, V2, P1323; SHARP PA, 1994, CELL, V77, P805, DOI 10.1016/0092-8674(94)90130-9; SHOHET RV, 1989, P NATL ACAD SCI USA, V86, P7726, DOI 10.1073/pnas.86.20.7726; SPUDICH JA, 1989, CELL REGUL, V1, P1; STAMM S, 1994, NUCLEIC ACIDS RES, V22, P1515, DOI 10.1093/nar/22.9.1515; TACKE R, 1991, GENE DEV, V5, P1416, DOI 10.1101/gad.5.8.1416; TAKAHASHI M, 1992, J BIOL CHEM, V267, P17864; WIECHMANN AF, 1990, J NEUROCHEM, V55, P208, DOI 10.1111/j.1471-4159.1990.tb08840.x; XU RS, 1993, MOL CELL BIOL, V13, P3660, DOI 10.1128/MCB.13.6.3660; ZUKER M, 1989, SCIENCE, V244, P48, DOI 10.1126/science.2468181	28	67	67	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					17613	17616						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663598				2022-12-25	WOS:A1996UY93500006
J	Yao, KW; Schulz, H				Yao, KW; Schulz, H			Intermediate channeling on the trifunctional beta-oxidation complex from pig heart mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID OXIDATION; RAT-LIVER MITOCHONDRIA; ACYL-COA DEHYDROGENASE; CHAIN; COENZYME; PURIFICATION; ENZYMES; <U-C-14>HEXADECANOATE; DERIVATIVES; THIOLASE	The kinetic properties of the purified trifunctional beta-oxidation complex (TOC) from pig heart mitochondria were analyzed with the aim of elucidating the functional consequence of having three sequentially acting enzymes of beta-oxidation associated in one complex, The kinetic parameters of TOC and of the component enzymes of TOC, long-chain enoyl-CoA hydratase, long-chain 3-hydroxyacyl-CoA dehydrogenase, and long-chain 3-ketoacyl-CoA thiolase, were determined with substrates having acyl chains with 16 carbon atoms, Quantification by high performance liquid chromatography of intermediates formed during the degradation of 2-trans-hexadecanoyl-CoA to myristoyl-CoA and acetyl-CoA by TOC revealed the accumulation of 3-hydroxyhexadecanoyl-CoA, whereas 3-ketohexadecanoyl-CoA was undetectable, The observed rates of NADH and acetyl-CoA formation were higher than the theoretical rates calculated by use of the kinetic parameters and measured concentrations of intermediates, When the sequence of reactions catalyzed by TOC was inhibited by acetyl-CoA, the steady-state concentration of the 3-hydroxyacyl-CoA intermediate was not affected, whereas a small amount of 3-ketohexadecanoyl-CoA was detected, The differences between observed and predicted reaction rates and between measured and expected concentrations of intermediates are best explained by the operation of a channeling mechanism. As a consequence of intermediate channeling between the active sites on the complex, more coenzyme A is available in the mitochondrial matrix and metabolites like 3-ketoacyl-CoA thioesters, which are strong inhibitors of several beta-oxidation enzymes, do not accumulate.	CUNY CITY COLL,DEPT CHEM,NEW YORK,NY 10031	City University of New York (CUNY) System; City College of New York (CUNY)					NCRR NIH HHS [RR03060] Funding Source: Medline; NHLBI NIH HHS [HL18089, HL30847] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL030847, R01HL018089] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CARPENTER K, 1992, BIOCHEM BIOPH RES CO, V183, P443, DOI 10.1016/0006-291X(92)90501-B; DAVIDSON B, 1982, ARCH BIOCHEM BIOPHYS, V213, P155, DOI 10.1016/0003-9861(82)90450-7; EATON S, 1993, BIOCHEM J, V289, P161, DOI 10.1042/bj2890161; EATON S, 1994, EUR J BIOCHEM, V220, P671, DOI 10.1111/j.1432-1033.1994.tb18668.x; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; FONG JC, 1981, METHOD ENZYMOL, V70, P390; FREUND K, 1985, BIOCHEMISTRY-US, V24, P5996, DOI 10.1021/bi00342a046; GARLAND PB, 1965, BIOCHEM J, V97, P587, DOI 10.1042/bj0970587; GARLAND PB, 1967, MITOCHONDRIAL STRUCT, P385; Greville G D, 1968, Essays Biochem, V4, P155; HANSFORD RG, 1975, J BIOL CHEM, V250, P8361; HE XY, 1992, ARCH BIOCHEM BIOPHYS, V298, P527, DOI 10.1016/0003-9861(92)90445-3; HE XY, 1989, ANAL BIOCHEM, V180, P105, DOI 10.1016/0003-2697(89)90095-X; IZAI K, 1992, J BIOL CHEM, V267, P1027; JIN SJ, 1992, J BIOL CHEM, V267, P119; KLER RS, 1991, J BIOL CHEM, V266, P22932; LUO MJ, 1993, ARCH BIOCHEM BIOPHYS, V304, P266, DOI 10.1006/abbi.1993.1348; NADA MA, 1995, J BIOL CHEM, V270, P530, DOI 10.1074/jbc.270.2.530; POWELL PJ, 1987, BIOCHEMISTRY-US, V26, P3704, DOI 10.1021/bi00386a066; SCHIFFERDECKER J, 1974, LIFE SCI, V14, P1487, DOI 10.1016/0024-3205(74)90159-3; SCHULZ H, 1994, J NUTR, V124, P165, DOI 10.1093/jn/124.2.165; STAACK H, 1978, J BIOL CHEM, V253, P1827; STANLEY KK, 1975, BIOCHEM J, V150, P77, DOI 10.1042/bj1500077; SUMEGI B, 1991, BIOCHIM BIOPHYS ACTA, V1081, P121, DOI 10.1016/0005-2760(91)90016-B; THORPE C, 1986, ANAL BIOCHEM, V155, P391, DOI 10.1016/0003-2697(86)90452-5; UCHIDA Y, 1992, J BIOL CHEM, V267, P1034; WANG CS, 1975, ANAL BIOCHEM, V63, P414, DOI 10.1016/0003-2697(75)90363-2; WATMOUGH NJ, 1989, BIOCHEM J, V262, P261, DOI 10.1042/bj2620261	28	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					17816	17820		10.1074/jbc.271.30.17816	http://dx.doi.org/10.1074/jbc.271.30.17816			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663442	hybrid			2022-12-25	WOS:A1996UY93500037
J	Payson, RA; Wu, J; Liu, Y; Chiu, IM				Payson, RA; Wu, J; Liu, Y; Chiu, IM			The human FGF-8 gene localizes on chromosome 10q24 and is subjected to induction by androgen in breast cancer cells	ONCOGENE			English	Article						breast cancer; steroid hormone; fibroblast growth factor; cloning; fluorescence in situ hybridization	GROWTH-FACTOR; EXPRESSION; CLONING; MOUSE; TISSUES; FAMILY; ACID	Androgen-induced growth factor (AIGP or FGF-8) was originally isolated from the conditioned medium of an androgen-dependent Shionogi carcinoma, SC-3, cell line, It shares structural similarity with other members of the FGF family, The temporal and spatial expression patterns of the FGF-8 gene suggest its involvement in gastrulation, regionalization of the brain, and organogenesis of the limb and face as an embryonic epithelial factor, In the adult, expression of FGF-8 is restricted to gonads including testes and ovaries, Since FGF-8 is identified as a corroborating gene in MMTV-induced mammary tumors in Wnt-1 transgenic mice and because FGF-8 manifested its autocrine mitogenic activity in SC-3 cells, it is possible that aberrant expression of FGF-8 may be present in human cancers which are hormone dependent. However, very little is known about human FGF-8, To determine whether FGF-8 plays a role in human breast cancer, we have isolated the full-length cDNA from SK-BR-3 breast cancer cells. We have also isolated the corresponding genomic DNA in a P1 cloning vector, The FGF-8 gene has been mapped to chromosome 10q24 using both somatic cell hybrid genetic analysis and fluorescence in situ hybridization. Finally, we show that FGF-8 gene expression in a human breast cancer cell line, MDA-MB-231, is inducible by androgen, The findings presented here will facilitate our understanding of the molecular mechanism underlying hormone-responsive breast and prostate cancers.	OHIO STATE UNIV,DEPT INTERNAL MED,COLUMBUS,OH 43210; OHIO STATE UNIV,CTR COMPREHENS CANC,COLUMBUS,OH 43210	University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University			Chiu, Ing-Ming/B-1534-2008		NATIONAL CANCER INSTITUTE [R01CA045611, K04CA001369] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047506] Funding Source: NIH RePORTER; NCI NIH HHS [K04 CA01369, R01 CA45611] Funding Source: Medline; NIDDK NIH HHS [R01 DK47506] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COHN MJ, 1995, CELL, V80, P739, DOI 10.1016/0092-8674(95)90352-6; CROSSLEY PH, 1995, DEVELOPMENT, V121, P439; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; HALL RE, 1992, INT J CANCER, V52, P778, DOI 10.1002/ijc.2910520518; HEIKINHEIMO M, 1994, MECH DEVELOP, V48, P129, DOI 10.1016/0925-4773(94)90022-1; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; KASID A, 1985, SCIENCE, V228, P725, DOI 10.1126/science.4039465; KOUHARA H, 1994, ONCOGENE, V9, P455; LANG FF, 1994, J NEUROSURG, V81, P427, DOI 10.3171/jns.1994.81.3.0427; LORENZI MV, 1995, ONCOGENE, V10, P2051; MACARTHUR CA, 1995, CELL GROWTH DIFFER, V6, P817; MACARTHUR CA, 1995, J VIROL, V69, P2501, DOI 10.1128/JVI.69.4.2501-2507.1995; MARCHUK D, 1991, NUCLEIC ACIDS RES, V19, P1154, DOI 10.1093/nar/19.5.1154; MASON IJ, 1994, CELL, V78, P547, DOI 10.1016/0092-8674(94)90520-7; MYERS RL, 1995, ONCOGENE, V11, P785; MYERS RL, 1995, J BIOL CHEM, V270, P8257, DOI 10.1074/jbc.270.14.8257; NGUYEN M, 1994, J NATL CANCER I, V86, P356, DOI 10.1093/jnci/86.5.356; OHUCHI H, 1994, BIOCHEM BIOPH RES CO, V204, P882, DOI 10.1006/bbrc.1994.2542; ORRURTREGER A, 1993, DEV BIOL, V158, P475, DOI 10.1006/dbio.1993.1205; PENAULTLLORCA F, 1995, INT J CANCER, V61, P170, DOI 10.1002/ijc.2910610205; PETERS KG, 1992, DEVELOPMENT, V114, P233; POULIN ML, 1993, DEVELOPMENT, V119, P353; POULIN ML, 1995, DEV DYNAM, V202, P378, DOI 10.1002/aja.1002020407; PRIEST JH, 1977, MED CYTOGENETICS CEL; RUOHOLA JK, 1995, ENDOCRINOLOGY, V136, P2179, DOI 10.1210/en.136.5.2179; Sambrook J., 2002, MOL CLONING LAB MANU; SATO B, 1993, J STEROID BIOCHEM, V47, P91, DOI 10.1016/0960-0760(93)90061-Z; SHACKLEFORD GM, 1993, P NATL ACAD SCI USA, V90, P740, DOI 10.1073/pnas.90.2.740; SHEPHERD NS, 1994, P NATL ACAD SCI USA, V91, P2629, DOI 10.1073/pnas.91.7.2629; TABIN C, 1995, CELL, V80, P671, DOI 10.1016/0092-8674(95)90343-7; TANAKA A, 1995, FEBS LETT, V363, P226, DOI 10.1016/0014-5793(95)00324-3; TANAKA A, 1992, P NATL ACAD SCI USA, V89, P8928, DOI 10.1073/pnas.89.19.8928; WANG WP, 1989, MOL CELL BIOL, V9, P2387, DOI 10.1128/MCB.9.6.2387; YAMANISHI H, 1995, J STEROID BIOCHEM, V52, P49, DOI 10.1016/0960-0760(94)00148-F; YAN GC, 1992, MOL ENDOCRINOL, V6, P2123, DOI 10.1210/me.6.12.2123	37	39	46	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 4	1996	13	1					47	53						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UX319	8700553				2022-12-25	WOS:A1996UX31900006
J	Xu, X; Heidenreich, O; Kitajima, I; McGuire, K; Li, QH; Su, B; Nerenberg, M				Xu, X; Heidenreich, O; Kitajima, I; McGuire, K; Li, QH; Su, B; Nerenberg, M			Constitutively activated JNK is associated with HTLV-1 mediated tumorigenesis	ONCOGENE			English	Article						JNK; HTLV-1; tumorigenesis; tax; leukemia	VIRUS TYPE-I; T-CELL LEUKEMIA; NF-KAPPA-B; TRANSCRIPTIONAL ACTIVATOR; TAX; PROTEIN; GENE; KINASE; IDENTIFICATION; TRANSFORMATION	Human T cell leukemia virus type 1 (HTLV-1) is the etiologic agent of adult T-cell leukiemia (ATL) and HTLV-1 associated myelopathy, also called tropical spastic paraparesis (HAM/TSP). Both clinical and in vitro evidence have demonstrated that the virus or its transactivator Tax, are transforming, However, transformation appears to require additional, as yet poorly characterized, genetic changes in infected cells, JNK is a recently characterized member of the MAP kinase family. Its signaling cascade is distinct from other members and has been demonstrated to play an important role in T-cell activation, at least partially through its downstream targets, c-jun and ATF-2. Here we demonstrate constitutive activation of the JNK cascade in human lymphocytes transformed in vitro by HTLV-1 and also in Tax transformed murine fibroblasts. Such activation is not induced by Tax expression alone, and occurs only when infected lymphocytes become IL-2 independent or immortalized. Constitutive JNK activation was also found in leukocytes isolated from ATL patients. The acquisition of constitutive JNK activation may represent an important later event in HTLV-1 tumorigenesis.	SCRIPPS RES INST, DEPT MOLEC & EXPTL MED, LA JOLLA, CA 92037 USA; KAGOSHIMA UNIV, DEPT LAB MED, KAGOSHIMA 890, JAPAN; SAN DIEGO STATE UNIV, DEPT BIOL, SAN DIEGO, CA 92182 USA; SAN DIEGO STATE UNIV, INST MOLEC BIOL, SAN DIEGO, CA 92182 USA; UNIV TEXAS, MD ANDERSON CANC CTR, DEPT IMMUNOL, HOUSTON, TX 77030 USA	Scripps Research Institute; Kagoshima University; California State University System; San Diego State University; California State University System; San Diego State University; University of Texas System; UTMD Anderson Cancer Center			Heidenreich, Olaf/AAP-5045-2021	Heidenreich, Olaf/0000-0001-5404-6483				BARANGER AM, 1995, NATURE, V376, P606, DOI 10.1038/376606a0; BENN J, 1994, P NATL ACAD SCI USA, V91, P10350, DOI 10.1073/pnas.91.22.10350; BROWN DA, 1994, TRANSGENICS, V1, P377; BRUNET A, 1994, ONCOGENE, V9, P3379; CANN AJ, 1985, NATURE, V318, P571, DOI 10.1038/318571a0; COBB HM, 1995, J BIOL CHEM, V270, P14843; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; FELBER BK, 1985, SCIENCE, V229, P675, DOI 10.1126/science.2992082; FUJII M, 1991, ONCOGENE, V6, P1023; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; GESSAIN A, 1985, LANCET, V2, P407; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HIRAI H, 1992, ONCOGENE, V7, P1737; HOLLSBERG P, 1993, NEW ENGL J MED, V328, P1173, DOI 10.1056/NEJM199304223281608; HOLLSBERG P, 1992, J IMMUNOL, V148, P3256; HSUEH YP, 1995, J BIOL CHEM, V270, P18094, DOI 10.1074/jbc.270.30.18094; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; KITAJIMA I, 1992, SCIENCE, V258, P1792, DOI 10.1126/science.1299224; KITAJIMA I, 1992, J BIOL CHEM, V267, P25881; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LIU YS, 1995, J BIOL CHEM, V270, P8377, DOI 10.1074/jbc.270.15.8377; MAEDA M, 1987, BLOOD, V70, P1407; MCGUIRE KL, 1993, J VIROL, V67, P1590, DOI 10.1128/JVI.67.3.1590-1599.1993; MIGONE TS, 1995, SCIENCE, V269, P79, DOI 10.1126/science.7604283; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; NERENBERG M, 1987, SCIENCE, V237, P1324, DOI 10.1126/science.2888190; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; PERINI G, 1995, NATURE, V376, P602, DOI 10.1038/376602a0; POIESZ BJ, 1981, NATURE, V294, P268, DOI 10.1038/294268a0; POZZATTI R, 1990, MOL CELL BIOL, V10, P413, DOI 10.1128/MCB.10.1.413; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; ROHWER F, 1994, INT J ONCOL, V5, P1163; SAGGIORO D, 1990, CANCER RES, V50, P4968; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; SONTAG E, 1993, CELL, V75, P887, DOI 10.1016/0092-8674(93)90533-V; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; WAGNER S, 1993, SCIENCE, V262, P395, DOI 10.1126/science.8211160; WESTWICK JK, 1995, J CLIN INVEST, V95, P803, DOI 10.1172/JCI117730; XU X, 1995, J CLIN INVEST, V96, P1548, DOI 10.1172/JCI118193; XU X, 1994, MOL CELL BIOL, V14, P5371, DOI 10.1128/MCB.14.8.5371; XU X, 1996, IN PRESS VIROLOGY; YAMAGUCHI K, 1990, HUMAN RETROVIROLOGY : HTLV, P163; YAN MH, 1994, NATURE, V372, P798	49	89	90	1	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 4	1996	13	1					135	142						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UX319	8700539				2022-12-25	WOS:A1996UX31900015
J	Christiansen, JH; Monkley, SJ; Wainwright, BJ				Christiansen, JH; Monkley, SJ; Wainwright, BJ			Murine WNT11 is a secreted glycoprotein that morphologically transforms mammary epithelial cells	ONCOGENE			English	Article						WNT; mammary tumorigenesis; C57MG	PROTO-ONCOGENE INT-1; EXPRESSION; WNT-1; GENE; LINE; GLAND; HYPERPLASIA; PRODUCTS; INVITRO; VECTOR	Wnt genes encode a set of structurally related cell surface glycoproteins that appear to have roles in cell-cell signalling. The ectopic expression of several murine Wnt genes has been implicated in the transformation of mammary epithelial and the onset of mammary tumours. Wnt11 is expressed in the developing embryo in a variety of structures including the dermatome/myotome junction of the somites, the truncus ateriosus region of the heart and limb mesenchyme. Here we report that Wnt11 encodes a glycoprotein that is secreted from expressing cells and becomes associated with the extracellular matrix. In addition, Rat2 fibroblasts expressing WNT11 (which are not morphologically altered themselves) are able to induce the transformation of adjacent C57MG mammary epithelial cells in co-culture experiments. These results suggest that WNT11 functions via a paracrine signalling mechanism to have a direct effect on the morphology and growth characteristics of mammary epithelial cells.	UNIV QUEENSLAND,CTR CELLULAR & MOLEC BIOL,ST LUCIA,QLD 4072,AUSTRALIA	University of Queensland				Monkley, Susan/0000-0001-9174-6278; Wainwright, Brandon/0000-0003-0406-2092; Christiansen, Jeff/0000-0002-8146-1225				ADAMSON MC, 1994, GENOMICS, V24, P9, DOI 10.1006/geno.1994.1575; BLASBAND A, 1992, ONCOGENE, V7, P153; BRADLEY RS, 1990, EMBO J, V9, P1565; BROWN AMC, 1987, MOL CELL BIOL, V7, P3971, DOI 10.1128/MCB.7.11.3971; BROWN AMC, 1986, CELL, V46, P1001, DOI 10.1016/0092-8674(86)90699-9; BUHLER TA, 1993, DEV BIOL, V155, P87, DOI 10.1006/dbio.1993.1009; BURRUS LW, 1995, EXP CELL RES, V220, P363, DOI 10.1006/excr.1995.1327; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTIANSEN JH, 1995, MECH DEVELOP, V51, P341, DOI 10.1016/0925-4773(95)00383-5; EDWARDS PAW, 1992, ONCOGENE, V7, P2041; FUNG YKT, 1985, MOL CELL BIOL, V5, P3337, DOI 10.1128/MCB.5.12.3337; GAVIN BJ, 1992, MOL CELL BIOL, V12, P2418, DOI 10.1128/MCB.12.5.2418; Harlow E., 1988, ANTIBODIES LAB MANUA; HUBBARD SC, 1981, ANNU REV BIOCHEM, V50, P555, DOI 10.1146/annurev.bi.50.070181.003011; JUE SF, 1992, MOL CELL BIOL, V12, P321, DOI 10.1128/MCB.12.1.321; KITAJEWSKI J, 1992, MOL CELL BIOL, V12, P784, DOI 10.1128/MCB.12.2.784; KRUMLAUF R, 1991, GENE TRANSFER EXPRES, P307; KU M, 1993, DEVELOPMENT, V119, P1161; LEE FS, 1995, P NATL ACAD SCI USA, V92, P2268, DOI 10.1073/pnas.92.6.2268; MASON JO, 1992, MOL BIOL CELL, V3, P521, DOI 10.1091/mbc.3.5.521; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MOON RT, 1993, BIOESSAYS, V15, P91, DOI 10.1002/bies.950150204; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; NUSSE R, 1982, CELL, V23, P311; OLSON DJ, 1994, CELL GROWTH DIFFER, V5, P197; PAPKOFF J, 1989, MOL CELL BIOL, V9, P3377, DOI 10.1128/MCB.9.8.3377; PAPKOFF J, 1987, MOL CELL BIOL, V7, P3978, DOI 10.1128/MCB.7.11.3978; PARR BA, 1994, CURR OPIN GENET DEV, V4, P523, DOI 10.1016/0959-437X(94)90067-D; PARR BA, 1993, DEVELOPMENT, V119, P247; RIJSEWIJK F, 1987, EMBO J, V6, P127, DOI 10.1002/j.1460-2075.1987.tb04729.x; ROBBINS PW, 1984, J BIOL CHEM, V259, P7577; ROELINK H, 1990, P NATL ACAD SCI USA, V87, P4519, DOI 10.1073/pnas.87.12.4519; SIEGFRIED E, 1994, BIOESSAYS, V16, P395, DOI 10.1002/bies.950160607; SONNENBERG A, 1986, CANCER RES, V46, P5913; TOPP WC, 1981, VIROLOGY, V113, P408, DOI 10.1016/0042-6822(81)90168-9; TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092-8674(88)90220-6; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VAIDYA AB, 1978, VIROLOGY, V90, P12, DOI 10.1016/0042-6822(78)90328-8; VANHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683; WEBERHALL SJ, 1994, DIFFERENTIATION, V57, P205, DOI 10.1046/j.1432-0436.1994.5730205.x; WILKINSON DG, 1987, CELL, V50, P79, DOI 10.1016/0092-8674(87)90664-7; WONG GT, 1994, MOL CELL BIOL, V14, P6278, DOI 10.1128/MCB.14.9.6278	42	22	23	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 20	1996	12	12					2705	2711						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UW487	8700530				2022-12-25	WOS:A1996UW48700025
J	Hardin, JD; Boast, S; Mendelsohn, M; delosSantos, K; Goff, SP				Hardin, JD; Boast, S; Mendelsohn, M; delosSantos, K; Goff, SP			Transgenes encoding both type I and type IV c-abl proteins rescue the lethality of c-abl mutant mice	ONCOGENE			English	Article						c-abl, transgene; tyrosine kinase; rescue	TARGETED GENE DISRUPTION; VIRUS TRANSFORMING GENE; TYROSINE KINASE; DIFFERENTIAL EXPRESSION; MESSENGER-RNAS; MOUSE-TISSUES; CELL; DNA; BINDING; RECOMBINATION	Mice carrying homozygous mutations in the c-abl gene (abl(ml) or abl(2)) exhibit severe, though variable phenotypes, including a high rate of postnatal mortality, runting, morphological abnormalities, a susceptibility to infections, and selected immune system defects, To further determine the role of the c-Abl protein in vivo, we have generated three lines of mice expressing c-abl transgenes, These minigenes encode the two major forms of the c-abl gene product (c-Abl types I and IV) and a kinase defective type IV c-Abl. The transgenic lines, in Abl-positive genetic backgrounds, were phenotypically almost indistinguishable from their non-transgene littermates and expressed the c-ab! transgene in a variety of tissues at levels comparable to that of the endogenous c-abl gene. When the transgenes were introduced into a mutant c-abl strain by mating, the mutant c-abl phenotype was almost completely rescued by either of the c-abl type I or type IV transgenes, but not by the kinase-defective transgene, These findings suggest that either of the two alternatively spliced c-abl gene products can provide the in vivo functions of c-Abl, and that these functions are dependent on kinase activity.	COLUMBIA UNIV COLL PHYS & SURG,DEPT MICROBIOL,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,DEPT BIOCHEM & MOLEC BIOPHYS,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,CTR NEUROBIOL & BEHAV,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,HOWARD HUGHES MED INST,NEW YORK,NY 10032	Columbia University; Columbia University; Columbia University; Columbia University; Howard Hughes Medical Institute			Goff, Stephen P/K-6337-2014	Goff, Stephen P/0000-0003-0693-5547	NCI NIH HHS [P01 CA23767] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA023767] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABELSON HT, 1970, CANCER RES, V30, P2213; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BEN-NERIAH Y, 1986, CELL, V44, P577, DOI 10.1016/0092-8674(86)90267-9; BERNARDS A, 1988, ONCOGENE, V2, P297; BOULTER CA, 1988, EXP CELL RES, V179, P214, DOI 10.1016/0014-4827(88)90360-6; DALEY GQ, 1992, MOL CELL BIOL, V12, P1864, DOI 10.1128/MCB.12.4.1864; GOFF SP, 1982, J VIROL, V41, P271, DOI 10.1128/JVI.41.1.271-285.1982; GOFF SP, 1980, CELL, V22, P777, DOI 10.1016/0092-8674(80)90554-1; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; HARDIN JD, 1995, CELL IMMUNOL, V165, P44, DOI 10.1006/cimm.1995.1185; HARDIN JD, 1995, UNPUB; HARIHARAN IK, 1989, MOL CELL BIOL, V9, P2798, DOI 10.1128/MCB.9.7.2798; Heisterkamp Nora, 1991, Transgenic Research, V1, P45, DOI 10.1007/BF02512996; HENKEMEYER M, 1990, CELL, V63, P949, DOI 10.1016/0092-8674(90)90498-4; HOGAN B, 1986, MANIPULATING MOUSE E; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; KIPREOS ET, 1992, SCIENCE, V256, P382, DOI 10.1126/science.256.5055.382; KRUH GD, 1990, P NATL ACAD SCI USA, V87, P5802, DOI 10.1073/pnas.87.15.5802; MCWHIRTER JR, 1991, MOL CELL BIOL, V11, P1553, DOI 10.1128/MCB.11.3.1553; MULLER R, 1982, NATURE, V299, P640, DOI 10.1038/299640a0; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PUISSANT C, 1990, BIOTECHNIQUES, V8, P148; RAY P, 1991, GENE DEV, V5, P2265, DOI 10.1101/gad.5.12a.2265; RENSHAW MW, 1988, MOL CELL BIOL, V8, P4547, DOI 10.1128/MCB.8.10.4547; RENSHAW MW, 1992, EMBO J, V11, P3941, DOI 10.1002/j.1460-2075.1992.tb05488.x; RESH MD, 1989, CELL, V58, P281, DOI 10.1016/0092-8674(89)90842-8; ROSENBAUM H, 1990, EMBO J, V9, P897, DOI 10.1002/j.1460-2075.1990.tb08187.x; Sambrook J., 2002, MOL CLONING LAB MANU; SAWYERS CL, 1994, CELL, V77, P121, DOI 10.1016/0092-8674(94)90240-2; SCHWARTZBERG PL, 1990, P NATL ACAD SCI USA, V87, P3210, DOI 10.1073/pnas.87.8.3210; SCHWARTZBERG PL, 1991, CELL, V65, P1165, DOI 10.1016/0092-8674(91)90012-N; SCHWARTZBERG PL, 1989, SCIENCE, V246, P799, DOI 10.1126/science.2554496; SHAW AS, 1989, CELL, V59, P627, DOI 10.1016/0092-8674(89)90008-1; SHTIVELMAN E, 1986, CELL, V47, P277, DOI 10.1016/0092-8674(86)90450-2; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; VANETTEN RA, 1993, ONCOGENES TUMOR SUPP; WANG JYJ, 1983, MOL CELL BIOL, V3, P773, DOI 10.1128/MCB.3.5.773; WANG JYJ, 1984, CELL, V36, P349; ZIEGLER SF, 1981, CELL, V27, P477, DOI 10.1016/0092-8674(81)90389-5	40	20	20	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 20	1996	12	12					2669	2677						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UW487	8700526				2022-12-25	WOS:A1996UW48700021
J	Ray, ME; Su, YA; Meltzer, PS; Trent, JM				Ray, ME; Su, YA; Meltzer, PS; Trent, JM			Isolation and characterization of genes associated with chromosome-6 mediated tumor suppression in human malignant melanoma	ONCOGENE			English	Article						malignant melanoma; chromosome 6; tumor suppression	LONG ARM; EXPRESSION; IDENTIFICATION; SEARCH	Melanocytic transformation is thought to occur by the sequential accumulation of genetic alterations, Evidence implicating human chromosome-6 as a site for a gene(s) involved in melanoma suppression comes from studies of LOH [loss of heterozygosity], cytogenetics and biologic reversion of tumorigenicity following the introduction of a normal chromosome 6 by microcell-mediated chromosome transfer (Trent et al., 1990), Using a tumorigenic melanoma cell line (UACC 903) and a chromosome-6 suppressed melanoma subline [UACC 903 (+6)], we have isolated a series of genes uniquely expressed in the suppressed subline, A modified PCR-based cDNA subtraction technique was used to generate subtracted cDNA sublibraries for both the parental and (+6) suppressed cells, A total of 32 randomly selected clones from the suppressed sublibrary were isolated and examined, with 24 detecting a transcript by Northern analysis, Of these 24 clones, 21 (88%) demonstrated elevated expressed by Northern analysis in the suppressed subline relative to the tumorigenic parental cell line, In 6/21 differentially expressed clones (29%), expression was exclusive to the suppressed subline, Partial sequence analysis and database searching of these clones indicated that 5/6 were novel with one representing a previously characterized gene, Chromosomal localization of the five novel clones was performed following PCR amplification of a human/rodent somatic cell hybrid mapping panel or fluorescent in situ hybridization, One cDNA (termed AIM1) was localized to a band-region of chromosome 6 frequently deleted in melanomas (6q21), This novel approach should facilitate the identification of genes whose expression is causally related to the suppressed phenotype.	NIH,NATL CTR HUMAN GENOME RES,CANC GENET LAB,BETHESDA,MD 20892; UNIV MICHIGAN,SCH MED,DEPT HUMAN GENET,ANN ARBOR,MI 48109	National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); University of Michigan System; University of Michigan								ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; *ANN CANC STAT REV, 1988, 882789 NIH NCI; BROWN T, 1993, CURRENT PROTOCOLS GR; ENGEBRECHT J, 1991, CURRENT PROTOCOLS; FUNASAKA Y, 1992, MOL BIOL CELL, V3, P197, DOI 10.1091/mbc.3.2.197; GISH W, 1993, NAT GENET, V3, P266, DOI 10.1038/ng0393-266; HALABAN R, 1993, RECENT RES CANCER, V128, P133; JACKSON IJ, 1994, ANNU REV GENET, V28, P189, DOI 10.1146/annurev.ge.28.120194.001201; KINGSTON RE, 1991, CURRENT PROTOCOLS; LASSAM N, 1992, ONCOGENE, V7, P51; MARTIN FH, 1990, CELL, V63, P203, DOI 10.1016/0092-8674(90)90301-T; MATHEW S, 1992, GENOMICS, V14, P775, DOI 10.1016/S0888-7543(05)80184-3; MELTZER PS, 1993, NAT GENET, V4, P252, DOI 10.1038/ng0793-252; MILLIKIN D, 1991, CANCER RES, V51, P5449; NATALI PG, 1992, INT J CANCER, V52, P197, DOI 10.1002/ijc.2910520207; THOMPSON FH, 1995, CANCER GENET CYTOGEN, V83, P93, DOI 10.1016/0165-4608(95)00057-V; TRENT JM, 1989, CANCER RES, V49, P420; TRENT JM, 1990, SCIENCE, V247, P568, DOI 10.1126/science.2300817; WALKER GJ, 1994, INT J CANCER, V58, P203, DOI 10.1002/ijc.2910580210; WANG Z, 1991, P NATL ACAD SCI USA, V88, P11505, DOI 10.1073/pnas.88.24.11505; WELCH DR, 1994, ONCOGENE, V9, P255	21	51	54	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 20	1996	12	12					2527	2533						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UW487	8700511				2022-12-25	WOS:A1996UW48700006
J	Karlsson, A; Mesnildrey, S; Xu, YW; Morera, S; Janin, J; Veron, M				Karlsson, A; Mesnildrey, S; Xu, YW; Morera, S; Janin, J; Veron, M			Nucleoside diphosphate kinase - Investigation of the intersubunit contacts by site-directed mutagenesis and crystallography	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY STRUCTURE; CRYSTAL-STRUCTURE; DICTYOSTELIUM-DISCOIDEUM; LETHAL INTERACTION; HEXAMERIC ENZYME; TUMOR-METASTASIS; ESCHERICHIA-COLI; ACTIVE-SITE; DROSOPHILA; RESOLUTION	NDP kinase from Dictyostelium was mutated by site-directed mutagenesis at positions indicated by structural data to be involved in the trimer interface. The mutants were substitutions at residue Pro-100 (P100S and P100G) and deletions of 1-5 residues at the C terminus. Single mutants yielded proteins that kept both activity and hexameric structure. However, they were severely affected in their stability toward temperature and urea denaturation. When the P100S mutation was combined with any of the C-terminal deletions, the enzyme lost most of its activity and dissociated into dimers. Crystallographic analysis of the P100S protein was performed at 2.6 Angstrom resolution. The x-ray structure showed no direct alteration of intersubunits contacts at residue 100, but an induced disruption of the interaction between Asp-115 and the C terminus of another subunit. The substitution of proline 100 to serine corresponds to the Killer-of-prune mutation in Drosophila. Consequences of the mutation are discussed in view of the structural and biochemical properties observed in the mutant Dictyostelium protein.	INST PASTEUR,UNITE REGULAT ENZYMAT ACT CELLULAIRES,CNRS,URA 1149,F-75724 PARIS 15,FRANCE; LAB ENZYMOL & BIOCHIM STRUCT,CNRS,UPR 9063,F-91198 GIF SUR YVETTE,FRANCE	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay			Karlsson, Anna/E-7945-2018; Janin, Joel/I-2958-2012	Karlsson, Anna/0000-0001-6843-6685				ALMAULA N, 1995, J BACTERIOL, V177, P2524, DOI 10.1128/jb.177.9.2524-2529.1995; [Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; BIGGS J, 1988, GENE DEV, V2, P1333, DOI 10.1101/gad.2.10.1333; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CHERFILS J, 1994, BIOCHEMISTRY-US, V33, P9062, DOI 10.1021/bi00197a006; CHIADMI M, 1993, STRUCTURE, V1, P283, DOI 10.1016/0969-2126(93)90016-A; DELAROSA A, 1995, BIOESSAYS, V17, P53, DOI 10.1002/bies.950170111; DUMAS C, 1992, EMBO J, V11, P3203, DOI 10.1002/j.1460-2075.1992.tb05397.x; ENGEL M, 1995, EUR J BIOCHEM, V234, P200, DOI 10.1111/j.1432-1033.1995.200_c.x; GIARTOSIO A, 1996, IN PRESS J BIOL CHEM; GILLES AM, 1991, J BIOL CHEM, V266, P8784; HILDEBRANDT M, 1995, NUCLEIC ACIDS RES, V23, P3858, DOI 10.1093/nar/23.19.3858; Inoue H, 1996, BIOCHEM BIOPH RES CO, V218, P887, DOI 10.1006/bbrc.1996.0158; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LASCU I, 1993, J BIOL CHEM, V268, P20268; LASCU I, 1992, J BIOL CHEM, V267, P12775; LASCU I, 1994, J BIOL CHEM, V269, P7046; Leslie AGW, 1986, PROTEIN CRYSTALLOGR, V18, P33; MORERA S, 1994, BIOCHEMISTRY-US, V33, P459, DOI 10.1021/bi00168a010; Morera S, 1995, STRUCTURE, V3, P1307, DOI 10.1016/S0969-2126(01)00268-4; MORERA S, 1994, J MOL BIOL, V243, P873, DOI 10.1006/jmbi.1994.1689; OHTSUKI K, 1984, BIOCHEM INT, V8, P715; Parks R.E., 1973, ENZYMES, V8, P307, DOI [10.1016/S1874-6047(08)60069-4, DOI 10.1016/S1874-6047(08)60069-4]; POSTEL EH, 1993, SCIENCE, V261, P478, DOI 10.1126/science.8392752; POSTEL EH, 1994, J BIOL CHEM, V269, P8627; POSTEL EH, 1996, IN PRESS P NATL ACAD; SCHULZ GE, 1992, CURR OPIN STRUC BIOL, V2, P61; STURTEVANT AH, 1956, GENETICS, V41, P118; Surette MG, 1996, J BIOL CHEM, V271, P939, DOI 10.1074/jbc.271.2.939; TEPPER AD, 1994, J BIOL CHEM, V269, P32175; TIMMONS L, 1995, J BIOL CHEM, V270, P23021, DOI 10.1074/jbc.270.39.23021; WAGNER PD, 1995, J BIOL CHEM, V270, P21758, DOI 10.1074/jbc.270.37.21758; WALLET V, 1990, J NATL CANCER I, V82, P1199, DOI 10.1093/jnci/82.14.1199; WEBB PA, 1995, J MOL BIOL, V251, P574, DOI 10.1006/jmbi.1995.0457; WILLIAMS RL, 1993, J MOL BIOL, V234, P1230, DOI 10.1006/jmbi.1993.1673	36	43	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					19928	19934		10.1074/jbc.271.33.19928	http://dx.doi.org/10.1074/jbc.271.33.19928			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702707	hybrid			2022-12-25	WOS:A1996VC66900048
J	Allen, PB; Wiedemann, LM				Allen, PB; Wiedemann, LM			An activating mutation in the ATP binding site of the ABL kinase domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOTYROSINE-CONTAINING PROTEINS; HEMATOPOIETIC-CELL LINE; MURINE LEUKEMIA-VIRUS; C-ABL; TYROSINE KINASE; REGULATORY DOMAIN; TRANSFORMING ABILITY; CARBOXY TERMINUS; GENE-PRODUCTS; BCR SEQUENCES	A number of structural alterations have been shown to activate the leukemogenic potential of the ABL oncogene, but there is little understanding of the regulatory mechanisms that are subverted by such changes. We have used directed mutagenesis to examine a potential regulatory motif in cABL, which could directly influence ABL tyrosine kinase activity. A tyrosine to phenylalanine substitution within the ATP binding fold of the ABL kinase domain is sufficient to activate cABL enzymatic activity, and the mutant protein will alleviate growth factor dependence when expressed in the BA/F3 cell line. This growth promotion is dependent upon the structure of the amino terminus of the protein, and the ABL mutation will cooperate with certain BCR sequences in BCR/ABL fusion proteins to deregulate ABL kinase activity.	INST CANC RES, LEUKAEMIA RES FUND CTR, CHESTER BEATTY LABS, LONDON SW3 6JB, ENGLAND	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK			Wiedemann, Leanne/E-3316-2010	Wiedemann, Leanne/0000-0002-0964-4676				ABELSON HT, 1970, CANCER RES, V30, P2213; ALLEN PB, 1992, BAILLIERE CLIN HAEM, V5, P897, DOI 10.1016/S0950-3536(11)80051-X; ATHERTONFESSLER S, 1993, MOL CELL BIOL, V13, P1675, DOI 10.1128/MCB.13.3.1675; BEN-NERIAH Y, 1986, CELL, V44, P577, DOI 10.1016/0092-8674(86)90267-9; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHENG SH, 1988, MOL CELL BIOL, V8, P1736, DOI 10.1128/MCB.8.4.1736; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; COOPER JA, 1986, MOL CELL BIOL, V6, P4467, DOI 10.1128/MCB.6.12.4467; COURTNEIDGE SA, 1985, EMBO J, V4, P1471, DOI 10.1002/j.1460-2075.1985.tb03805.x; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; DALEY GQ, 1992, MOL CELL BIOL, V12, P1864, DOI 10.1128/MCB.12.4.1864; DALEY GQ, 1991, ADV CANCER RES, V57, P151; DALEY GQ, 1987, SCIENCE, V237, P532, DOI 10.1126/science.2440107; DIKSTEIN R, 1992, CELL, V69, P751, DOI 10.1016/0092-8674(92)90287-M; Doree M, 1990, CURR OPIN CELL BIOL, V2, P269, DOI 10.1016/0955-0674(90)90018-A; DUYSTER J, 1995, P NATL ACAD SCI USA, V92, P1555, DOI 10.1073/pnas.92.5.1555; ELLEDGE SJ, 1994, CURR OPIN CELL BIOL, V6, P847, DOI 10.1016/0955-0674(94)90055-8; FRANZ WM, 1989, EMBO J, V8, P137, DOI 10.1002/j.1460-2075.1989.tb03358.x; GOFF SP, 1980, CELL, V22, P777, DOI 10.1016/0092-8674(80)90554-1; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; JACKSON PK, 1993, ONCOGENE, V8, P1943; KIPREOS ET, 1992, SCIENCE, V256, P382, DOI 10.1126/science.256.5055.382; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; KONOPKA JB, 1985, MOL CELL BIOL, V5, P3116, DOI 10.1128/MCB.5.11.3116; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAKER C, 1987, P NATL ACAD SCI USA, V84, P8458, DOI 10.1073/pnas.84.23.8458; MATHEYPREVOT B, 1986, MOL CELL BIOL, V6, P4133, DOI 10.1128/MCB.6.11.4133; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; MAYER BJ, 1990, P NATL ACAD SCI USA, V87, P2638, DOI 10.1073/pnas.87.7.2638; MCWHIRTER JR, 1993, MOL CELL BIOL, V13, P7587, DOI 10.1128/MCB.13.12.7587; MCWHIRTER JR, 1991, MOL CELL BIOL, V11, P1553, DOI 10.1128/MCB.11.3.1553; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PENDERGAST AM, 1991, P NATL ACAD SCI USA, V88, P5927, DOI 10.1073/pnas.88.13.5927; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; PENDERGAST AM, 1991, CELL, V66, P161, DOI 10.1016/0092-8674(91)90148-R; PENDERGAST AM, 1987, CHRONIC MYELOID LEUK, P1001; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; PONTICELLI AS, 1982, CELL, V29, P953, DOI 10.1016/0092-8674(82)90458-5; ROSENBERG N, 1976, J EXP MED, V143, P1453, DOI 10.1084/jem.143.6.1453; SAWYERS CL, 1994, CELL, V77, P121, DOI 10.1016/0092-8674(94)90240-2; SHTIVELMAN E, 1986, CELL, V47, P277, DOI 10.1016/0092-8674(86)90450-2; SHU HKG, 1990, P NATL ACAD SCI USA, V87, P9103, DOI 10.1073/pnas.87.23.9103; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; WANG JYJ, 1988, ONCOGENE RES, V3, P293; WELCH PJ, 1995, MOL CELL BIOL, V15, P5542; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; WHITLOCK CA, 1983, CELL, V32, P903, DOI 10.1016/0092-8674(83)90075-2; WHITLOCK CA, 1981, J VIROL, V40, P577, DOI 10.1128/JVI.40.2.577-584.1981	56	32	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19585	19591		10.1074/jbc.271.32.19585	http://dx.doi.org/10.1074/jbc.271.32.19585			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702653	hybrid			2022-12-25	WOS:A1996VB68400087
J	Jiracek, J; Yiotakis, A; Vincent, B; Checler, F; Dive, V				Jiracek, J; Yiotakis, A; Vincent, B; Checler, F; Dive, V			Development of the first potent and selective inhibitor of the zinc endopeptidase neurolysin using a systematic approach based on combinatorial chemistry of phosphinic peptides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING ENZYME-INHIBITORS; PZ-PEPTIDASE; RAT-BRAIN; MICROSOMAL ENDOPEPTIDASE; PROCESSING PROPROTEINS; BACTERIAL COLLAGENASE; SUBSTRATE-SPECIFICITY; MOLECULAR-CLONING; SLOW-BINDING; PURIFICATION	A mew systematic approach, based on combinatorial chemistry of phosphinic peptides, is proposed for rapid development of highly potent and selective inhibitors of zinc metalloproteases. This strategy first evaluates the effects on the inhibitory potency and selectivity of the following parameters: 1) size of the phosphinic peptides, 2) position of the phosphinic bond in the sequence, and 3) the state (free or blocked) of the peptide extremities. After this selection step, the influence of the inhibitor sequence is analyzed in order to determine the identity of the residues that optimized both the potency and the selectivity, We demonstrate the efficiency of this novel approach in rapid identification of the first potent inhibitor of the mammalian zinc endopeptidase neurolysin (24-16), able to discriminate between this enzyme and the related zinc endopeptidase thimet oligopeptidase (24-15). The most potent and selective inhibitor developed in this study, Pro-LPhe Psi(PO2CH2)Gly-Pro, displays a K-i value of 4 nM for 24-16 and is 2000 times less potent on 24-15. The specific recognition of such a free phosphinic tetrapeptide by 24-16, as well as the unique specificity of the 24-16 S-2 and S-2' subsites for proline, unveiled by this study, are discussed ill terms of their possible significance for the function of this enzyme and its related zinc endopeptidase activities.	CENS,CEA,DEPT INGN & ETUD PROT,DSV,F-91191 GIF SUR YVETTE,FRANCE; UNIV ATHENS,ORGAN CHEM LAB,DEPT ORGAN CHEM,ZOGRAFOS 15771,ATHENS,GREECE; UNIV NICE,INST PHARMACOL MOL & CELLULAIRE,F-06560 VALBONNE,FRANCE	CEA; UDICE-French Research Universities; Universite Paris Saclay; National & Kapodistrian University of Athens; UDICE-French Research Universities; Universite Cote d'Azur			Jiracek, Jiri/Y-6703-2019; Jiracek, Jiri/A-7124-2008; Checler, Frederic/C-1241-2009	Jiracek, Jiri/0000-0003-3848-2773; Jiracek, Jiri/0000-0003-3848-2773; Checler, Frederic/0000-0003-2098-1750; Vincent, Bruno/0000-0003-3876-2118				ACKER GR, 1987, J NEUROCHEM, V48, P284, DOI 10.1111/j.1471-4159.1987.tb13160.x; ASWANIKUMAR S, 1975, BIOCHIM BIOPHYS ACTA, V384, P194, DOI 10.1016/0005-2744(75)90108-4; BARELLI H, 1992, BIOCHEM J, V287, P621, DOI 10.1042/bj2870621; BARELLI H, 1991, NEUROCHEM LIFE SCI A, V10, P115; BARRETT AJ, 1989, BIOCHEM J, V261, P1047, DOI 10.1042/bj2611047; CAMPBELL DA, 1995, J AM CHEM SOC, V117, P5381, DOI 10.1021/ja00124a030; CHECLER F, 1986, J BIOL CHEM, V261, P1274; DAHMS P, 1992, EUR J BIOCHEM, V208, P145, DOI 10.1111/j.1432-1033.1992.tb17168.x; DAUCH P, 1991, EUR J BIOCHEM, V202, P269, DOI 10.1111/j.1432-1033.1991.tb16372.x; DAUCH P, 1991, BIOCHEM J, V280, P421, DOI 10.1042/bj2800421; DAUCH P, 1995, J BIOL CHEM, V270, P27266, DOI 10.1074/jbc.270.45.27266; EICHLER J, 1993, BIOCHEMISTRY-US, V32, P11035, DOI 10.1021/bi00092a013; GRECO WR, 1979, J BIOL CHEM, V254, P2104; GROBELNY D, 1989, BIOCHEMISTRY-US, V28, P4948, DOI 10.1021/bi00438a006; HARRIS ED, 1972, BIOCHIM BIOPHYS ACTA, V258, P566, DOI 10.1016/0005-2744(72)90249-5; ITO A, 1987, CLIN CHIM ACTA, V170, P291, DOI 10.1016/0009-8981(87)90139-2; JIRACEK J, 1995, J BIOL CHEM, V270, P21701, DOI 10.1074/jbc.270.37.21701; KAWABATA S, 1992, J BIOL CHEM, V267, P10331; KAWABATA S, 1993, J BIOL CHEM, V268, P12498; MORALES TI, 1977, J BIOL CHEM, V252, P4855; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; MORRISON JF, 1982, TRENDS BIOCHEM SCI, V7, P102, DOI 10.1016/0968-0004(82)90157-8; ORLOWSKI M, 1983, EUR J BIOCHEM, V135, P81, DOI 10.1111/j.1432-1033.1983.tb07620.x; PETRILLO EW, 1983, PEPTIDES STRUCTURE F, P541; Rich D. H., 1990, COMPREHENSIVE MED CH, V2, P391; SAKYO K, 1983, J BIOCHEM, V94, P1913, DOI 10.1093/oxfordjournals.jbchem.a134545; SERIZAWA A, 1995, J BIOL CHEM, V270, P2092, DOI 10.1074/jbc.270.5.2092; Smith, 1989, DESIGN ENZYME INHIBI; STOCKER W, 1995, PROTEIN SCI, V4, P823; SUGIURA N, 1992, J BIOL CHEM, V267, P18067; TILSJAR U, 1990, ANAL BIOCHEM, V186, P112; TISLJAR U, 1990, BIOCHEM J, V267, P531, DOI 10.1042/bj2670531; VINCENT B, 1995, BRIT J PHARMACOL, V115, P1053, DOI 10.1111/j.1476-5381.1995.tb15918.x; WUNSH E, 1963, HOPPESEYLERS Z PHYSL, V349, P171; YIOTAKIS A, 1994, BIOCHEM J, V303, P323, DOI 10.1042/bj3030323; YIOTAKIS A, 1994, J MED CHEM, V37, P2713, DOI 10.1021/jm00043a011	36	86	93	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19606	19611		10.1074/jbc.271.32.19606	http://dx.doi.org/10.1074/jbc.271.32.19606			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702656	hybrid			2022-12-25	WOS:A1996VB68400090
J	Nakamura, N; Chin, H; Miyasaka, N; Miura, O				Nakamura, N; Chin, H; Miyasaka, N; Miura, O			An epidermal growth factor receptor Jak2 tyrosine kinase domain chimera induces tyrosine phosphorylation of Stat5 and transduces a growth signal in hematopoietic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; ERYTHROPOIETIN RECEPTOR; CYTOKINE RECEPTORS; PROTEIN-KINASE; BETA(C) CHAIN; ACTIVATION; INTERLEUKIN-3; ASSOCIATION; MITOGENESIS; EXPRESSION	The Jak family of tyrosine kinases and the Stat family of transcription factors have been implicated in transducing signals from the hematopoietic growth factor receptors. To explore the role played by a member of the Jak family, Jak2, in hematopoietic cell growth signaling, we constructed a chimeric cDNA coding for the Jak2 tyrosine kinase domain linked to the extracellular and transmembrane regions of the epidermal growth factor (EGF) receptor (EGFR) and expressed the chimera in an interleukin (IL)-3-dependent cell line, 32D. When deprived of IL-3, EGF prevented apoptosis of the transfected cells, induced dose dependent proliferation, and supported long-term growth. EGF stimulation of the transfectants induced dose-dependent tyrosine phosphorylation of the EGFR/Jak2 chimera and Stat5, which correlated with the EGF dose dependence of cell proliferation. On the other hand, EGF did not induce tyrosine phosphorylation of other factors implicated in cytokine receptor signaling, including the IL-3 receptor beta subunit, Jak kinases, Stat proteins other than Stat5, Shc, Syp, and mitogen-activated protein kinases. These results suggest that the activation of Jak2 may be sufficient for transducing a growth signal in hematopoietic cells by activating the Stat5 pathway or previously unidentified signaling pathways. In addition, because EGF induces homodimerization of the EGFR to activate its tyrosine kinase activity, the present study, which shows EGF-dependent activation of the EGFR/Jak2 chimera, implies that Jak2 may also become activated by homodimerization.	TOKYO MED & DENT UNIV,DEPT INTERNAL MED 1,BUNKYO KU,TOKYO 113,JAPAN	Tokyo Medical & Dental University (TMDU)				Miura, Osamu/0000-0002-0981-3054				AZAM M, 1995, EMBO J, V14, P1402, DOI 10.1002/j.1460-2075.1995.tb07126.x; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; DAMEN JE, 1995, EMBO J, V14, P5557, DOI 10.1002/j.1460-2075.1995.tb00243.x; EVANS GA, 1995, J BIOL CHEM, V270, P28858, DOI 10.1074/jbc.270.48.28858; FRANK SJ, 1995, J BIOL CHEM, V270, P14776, DOI 10.1074/jbc.270.24.14776; FUJII H, 1995, P NATL ACAD SCI USA, V92, P5482, DOI 10.1073/pnas.92.12.5482; GOUILLEUX F, 1995, EMBO J, V14, P2005, DOI 10.1002/j.1460-2075.1995.tb07192.x; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; IHLE JN, 1995, ANNU REV IMMUNOL, V13, P369, DOI 10.1146/annurev.iy.13.040195.002101; ISHIDA Y, 1992, EMBO J, V11, P3887, DOI 10.1002/j.1460-2075.1992.tb05481.x; KINOSHITA T, 1995, ONCOGENE, V10, P2207; MIURA O, 1991, MOL CELL BIOL, V11, P4895, DOI 10.1128/MCB.11.10.4895; MIURA O, 1994, BLOOD, V84, P1501; MIURA O, 1993, MOL CELL BIOL, V13, P1788, DOI 10.1128/MCB.13.3.1788; MIURA O, 1994, J BIOL CHEM, V269, P614; MIURA O, 1994, BLOOD, V84, P4135, DOI 10.1182/blood.V84.12.4135.bloodjournal84124135; MIURA Y, 1994, J BIOL CHEM, V269, P29962; MIYAJIMA A, 1992, ANNU REV IMMUNOL, V10, P295, DOI 10.1146/annurev.immunol.10.1.295; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; OHASHI H, 1994, P NATL ACAD SCI USA, V91, P158, DOI 10.1073/pnas.91.1.158; PALLARD C, 1995, J BIOL CHEM, V270, P15942, DOI 10.1074/jbc.270.27.15942; PALLARD C, 1995, EMBO J, V14, P2847, DOI 10.1002/j.1460-2075.1995.tb07284.x; PIERCE JH, 1988, SCIENCE, V239, P628, DOI 10.1126/science.3257584; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; QUELLE FW, 1995, MOL CELL BIOL, V15, P3336; SAKAI I, 1995, J BIOL CHEM, V270, P18420, DOI 10.1074/jbc.270.31.18420; SATO N, 1993, EMBO J, V12, P4181, DOI 10.1002/j.1460-2075.1993.tb06102.x; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; TERADA K, 1995, J BIOL CHEM, V270, P27880, DOI 10.1074/jbc.270.46.27880; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VELU TJ, 1987, SCIENCE, V238, P1408, DOI 10.1126/science.3500513; WAKAO H, 1995, EMBO J, V14, P2527, DOI 10.1002/j.1460-2075.1995.tb07250.x; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; WATOWICH SS, 1994, MOL CELL BIOL, V14, P3535, DOI 10.1128/MCB.14.6.3535; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; YAMAMOTO K, 1994, MOL CELL BIOL, V14, P4342, DOI 10.1128/MCB.14.7.4342; ZHAO YM, 1995, J BIOL CHEM, V270, P13814, DOI 10.1074/jbc.270.23.13814; ZHNANG H, 1994, J BIOL CHEM, V269, P21411; ZHUANG HM, 1995, J BIOL CHEM, V270, P14500, DOI 10.1074/jbc.270.24.14500; Ziemiecki Andrew, 1994, Trends in Cell Biology, V4, P207, DOI 10.1016/0962-8924(94)90143-0	42	74	97	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19483	19488		10.1074/jbc.271.32.19483	http://dx.doi.org/10.1074/jbc.271.32.19483			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702638	hybrid			2022-12-25	WOS:A1996VB68400072
J	Nediani, C; Fiorillo, C; Marchetti, E; Pacini, A; Liguri, G; Nassi, P				Nediani, C; Fiorillo, C; Marchetti, E; Pacini, A; Liguri, G; Nassi, P			Stimulation of cardiac sarcoplasmic reticulum calcium pump by acylphosphatase - Relationship to phospholamban phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3'-5'-MONOPHOSPHATE-DEPENDENT PROTEIN-KINASE; HEART SARCOLEMMA; TRANSPORT; MECHANISM; ATPASE; CALMODULIN; PHOSPHATE; COMPONENT; MUSCLE; ASSAY	Ca2+ transport by cardiac sarcoplasmic reticulum is tightly coupled with the enzymatic activity of Ca2+-dependent ATPase, which forms and decomposes an intermediate phosphoenzyme, Heart sarcoplasmic reticulum Ca2+ pump is regulated by cAMP-dependent protein kinase (PRA) phospholamban phosphorylation, which results in a stimulation of the initial rates of Ca2+ transport and Ca2+ ATPase activity. In the present studies we found that acylphosphatase from heart muscle, used at concentrations within the physiological range, actively hydrolyzes the phosphoenzyme of cardiac sarcoplasmic reticulum Ca2+ pump, with all apparent K-m on the order of 10(-7) M, suggesting an high affinity of the enzyme for this special substrate. In umphosphorylated vesicles acylphosphatase enhanced the rate of ATP hydrolysis and Ca2+ uptake with a concomitant significant decrease in apparent K-m, for Ca2+ and ATP. In vesicles whose phospholamban was PKA-phosphorylated, acylphosphatase also stimulated the rate of Ca2+ uptake and ATP hydrolysis but to a lesser extent, and the K-m values for Ca2+ and ATP were not significantly different with respect to those found in the absence of acylphosphatase. These findings suggest that acylphosphatase, owing to its hydrolytic effect, accelerates the turnover of the phosphoenzyme intermediate with the consequence of an enhanced activity of Ca2+ pump, It is known that phosphorylation of phospholamban results in an increase of the rate at which the phosphoenzyme is decomposed. Thus, as discussed, a competition between phospholamban and acylphosphatase effect on the phosphoenzyme might be proposed to explain why the stimulation induced by this enzyme is less marked in PKA-phosphorylated than in unphosphorylated heart vesicles.	UNIV FLORENCE, DIPARTIMENTO SCI BIOCHIM, I-50134 FLORENCE, ITALY	University of Florence			Nediani, Chiara/R-2201-2019; Nediani, Chiara/AAO-8919-2020	Nediani, Chiara/0000-0003-3190-3539; Fiorillo, Claudia/0000-0003-1165-1581	Telethon [686] Funding Source: Medline	Telethon(Fondazione Telethon)		BASTIDE F, 1973, J BIOL CHEM, V248, P8485; BAYKOV AA, 1988, ANAL BIOCHEM, V171, P266, DOI 10.1016/0003-2697(88)90484-8; BEEKMAN RE, 1989, BIOCHEM J, V259, P229, DOI 10.1042/bj2590229; BEISENHERZ G, 1953, Z NATURFORSCH B, V8, P555; BERTI A, 1987, ITAL J BIOCHEM, V36, P82; BERTI A, 1977, ITAL J BIOCHEM, V26, P377; CAMICI G, 1976, EXPERIENTIA, V32, P535, DOI 10.1007/BF01920843; CARONI P, 1983, EUR J BIOCHEM, V132, P451, DOI 10.1111/j.1432-1033.1983.tb07383.x; CHAMBERLAIN BK, 1983, J BIOL CHEM, V258, P6602; GUPTA RC, 1988, MEMBRANE BIOCHEM, V7, P73; HICKS MJ, 1979, CIRC RES, V44, P384, DOI 10.1161/01.RES.44.3.384; INESI G, 1985, ANNU REV PHYSIOL, V47, P573, DOI 10.1146/annurev.ph.47.030185.003041; JONES LR, 1979, J BIOL CHEM, V254, P530; KATZ AM, 1970, BIOCHIM BIOPHYS ACTA, V205, P473, DOI 10.1016/0005-2728(70)90113-1; KIRCHBERGER MA, 1974, J BIOL CHEM, V249, P6166; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LU YZ, 1993, BIOCHEMISTRY-US, V32, P3105, DOI 10.1021/bi00063a023; MARTONOSI A, 1969, J BIOL CHEM, V244, P613; MOVSESIAN MA, 1992, BASIC RES CARDIOL, V87, P92; NASSI P, 1991, J BIOL CHEM, V266, P10867; NASSI P, 1993, BIOCHIM BIOPHYS ACTA, V1147, P19, DOI 10.1016/0005-2736(93)90311-M; NEDIANI C, 1992, BIOCHEM INT, V26, P715; PASTORE A, 1992, J MOL BIOL, V224, P427, DOI 10.1016/0022-2836(92)91005-A; PLANK B, 1983, BIOCHIM BIOPHYS ACTA, V732, P99, DOI 10.1016/0005-2736(83)90191-8; RAMPONI G, 1966, EXPERIENTIA, V22, P705, DOI 10.1007/BF01901326; RAMPONI G, 1967, EXPERIENTIA, V23, P1019, DOI 10.1007/BF02136422; RAMPONI G, 1969, ARCH BIOCHEM BIOPHYS, V130, P362, DOI 10.1016/0003-9861(69)90045-9; RAMPONI G, 1961, G BIOCH, V10, P189; REMACLE JA, 1980, BIOCHIM BIOPHYS ACTA, V630, P57, DOI 10.1016/0304-4165(80)90137-3; SASAKI T, 1992, J BIOL CHEM, V267, P1674; SHIGEKAWA M, 1976, J BIOL CHEM, V251, P6894; SHIGEKAWA M, 1979, J BIOL CHEM, V254, P4726; STEFANI M, 1985, ITAL J BIOCHEM, V34, P94; TADA M, 1975, J BIOL CHEM, V250, P2640; TADA M, 1979, J BIOL CHEM, V254, P319; TADA M, 1974, J BIOL CHEM, V249, P6174; TADA M, 1982, ANNU REV PHYSIOL, V44, P401, DOI 10.1146/annurev.ph.44.030182.002153; TADA M, 1988, METHOD ENZYMOL, V157, P107; Taddei N, 1996, BIOCHEMISTRY-US, V35, P7077, DOI 10.1021/bi952900b; TOYOFUKU T, 1994, J BIOL CHEM, V269, P3088; WUYTACK F, 1980, BIOCHEM J, V190, P827, DOI 10.1042/bj1900827; XU ZC, 1989, J BIOL CHEM, V264, P16644	42	34	36	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19066	19073		10.1074/jbc.271.32.19066	http://dx.doi.org/10.1074/jbc.271.32.19066			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702578	hybrid			2022-12-25	WOS:A1996VB68400012
J	Sleat, DE; Sohar, I; Lackland, H; Majercak, J; Lobel, P				Sleat, DE; Sohar, I; Lackland, H; Majercak, J; Lobel, P			Rat brain contains high levels of mannose-6-phosphorylated glycoproteins including lysosomal enzymes and palmitoyl-protein thioesterase, an enzyme implicated in infantile neuronal lipofuscinosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANNOSE 6-PHOSPHATE RECEPTOR; ALPHA-L-IDURONIDASE; CATHEPSIN-D; PROTECTIVE PROTEIN; BETA-GALACTOSIDASE; ARYLSULFATASE-A; MOLECULAR-CLONING; ACID-HYDROLASES; MESSENGER-RNA; EXPRESSION	Mannose 6-phosphate (Man-B-P) is a posttranslational carbohydrate modification typical of newly synthesized acid hydrolases that signals targeting from the Gels apparatus to the lysosome via Man-B-P receptors (MPRs), Using iodinated cation independent MPR as a probe in a Western blot assay, we surveyed levels of Man-B-P glycoproteins in a number of different rat tissues, Considerable variation was observed with respect to total amounts and types of Man-B-P glycoproteins in the different tissues, Brain contained 2-8-fold more Man-B-P glycoproteins than other tissues, with relative abundance being brain much greater than testis approximate to heart > lung approximate to kidney approximate to ovary approximate to spleen > skeletal muscle approximate to liver approximate to serum, Analysis of 16 different lysosomal enzyme activities revealed that brain contains lower activities than other tissues which suggested that decreased removal of Man-6-P results in increased levels of Man-B-P glycoproteins, This was directly demonstrated by comparing activities of phosphorylated lysosomal enzymes, purified by im mobilized MPR affinity chromatography, with total activities, The phosphorylated forms accounted for a considerable proportion of the MPR-targeted activities measured in brain (on average, 36.2%) but very little in lung, kidney, and liver (on average, 5.5, 2.3, and 0.7%, respectively), Man-B-P glycoproteins were also isolated from rat brain by MPR affinity chromatography on a preparative scale. Of the 18 bands resolvable by SDS-polyacrylamide gel electrophoresis, seven bands were NH2-terminally sequenced and identified as the known lysosomal enzymes cathepsin L, cathepsin A, cathepsin D, alpha-galactosidase A, arylsulfatase A, and alpha-iduronidase, One of the major Man-6-P glycoproteins was identified as palmitoyl protein thioesterase, which was not previously thought to be lysosomal, This finding raises important questions about the cellular location and function of palmitoyl protein thioesterase, mutations in which result in the neurodegenerative disorder, infantile neuronal ceroid lipofuscinosis.	RUTGERS STATE UNIV,CTR ADV BIOTECHNOL & MED,PISCATAWAY,NJ 08854; UNIV MED & DENT NEW JERSEY,GRAD PROGRAM MOL BIOL & BIOCHEM,PISCATAWAY,NJ 08854; UNIV MED & DENT NEW JERSEY,DEPT PHARMACOL,PISCATAWAY,NJ 08854	Rutgers State University New Brunswick; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center					NIDDK NIH HHS [DK45992] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045992] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BALLESTEROS M, 1990, BIOCHEM BIOPH RES CO, V172, P775, DOI 10.1016/0006-291X(90)90741-5; BARRETT AJ, 1981, METHOD ENZYMOL, V80, P535; Barrett AJ, 1977, LYSOSOMES LABORATORY, P19; BHAVSAR JH, 1994, ANAL BIOCHEM, V221, P234, DOI 10.1006/abio.1994.1407; BIRCH NP, 1990, NUCLEIC ACIDS RES, V18, P6445, DOI 10.1093/nar/18.21.6445; BRUNETTI CR, 1994, J BIOL CHEM, V269, P17067; BUTOR C, 1995, J CELL SCI, V108, P2213; CAMP LA, 1993, J BIOL CHEM, V268, P22566; CAMP LA, 1994, J BIOL CHEM, V269, P23212; CLARKE LA, 1994, GENOMICS, V24, P311, DOI 10.1006/geno.1994.1621; DONG JM, 1989, J BIOL CHEM, V264, P7377; EINSTEIN R, 1989, J CELL BIOL, V109, P1037, DOI 10.1083/jcb.109.3.1037; EINSTEIN R, 1991, J CELL BIOL, V112, P81, DOI 10.1083/jcb.112.1.81; FAUST PL, 1987, J CELL BIOL, V105, P1947, DOI 10.1083/jcb.105.5.1947; FAUST PL, 1985, P NATL ACAD SCI USA, V82, P4910, DOI 10.1073/pnas.82.15.4910; FUJII T, 1992, BIOCHIM BIOPHYS ACTA, V1122, P93, DOI 10.1016/0167-4838(92)90132-W; GABEL CA, 1983, P NATL ACAD SCI-BIOL, V80, P775, DOI 10.1073/pnas.80.3.775; GABEL CA, 1993, MECH INTRACELLULAR T, P103; GALJART NJ, 1988, CELL, V54, P755, DOI 10.1016/S0092-8674(88)90999-3; GALJART NJ, 1990, J BIOL CHEM, V265, P4678; GARCIA M, 1990, ONCOGENE, V5, P1809; *GEN COMP GROUP, 1991, PROGR MAN GCG PACK V; Harlow E., 1988, ANTIBODIES LAB MANUA; HERZOG V, 1987, EMBO J, V6, P555, DOI 10.1002/j.1460-2075.1987.tb04790.x; HOFLACK B, 1993, ADV CELL MOL BIOL M, V1, P51; HOOGEVEEN AT, 1983, J BIOL CHEM, V258, P2143; HUANG JS, 1979, J BIOL CHEM, V254, P1405; ISHIDOH K, 1987, FEBS LETT, V223, P69, DOI 10.1016/0014-5793(87)80511-2; KIRSCHKE H, 1977, EUR J BIOCHEM, V74, P293, DOI 10.1111/j.1432-1033.1977.tb11393.x; KOLODNY EH, 1976, CLIN CHIM ACTA, V70, P247, DOI 10.1016/0009-8981(76)90426-5; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; KREYSING J, 1994, GENOMICS, V19, P249, DOI 10.1006/geno.1994.1055; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAZZARINO D, 1990, J BIOL CHEM, V265, P11864; LEE SJ, 1988, J BIOL CHEM, V263, P3521; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAYES JS, 1977, BIOCHIM BIOPHYS ACTA, V484, P408, DOI 10.1016/0005-2744(77)90096-1; MORREAU H, 1992, J BIOL CHEM, V267, P17949; MYEROWITZ R, 1981, J BIOL CHEM, V256, P3044; O'Brien D. A., 1994, Molecular Biology of the Cell, V5, p221A; OELTJEN JC, 1995, L46651; PURCHIO AF, 1988, J BIOL CHEM, V263, P14211; RICHO GR, 1994, J BIOL CHEM, V269, P14806; SCOTT HS, 1991, P NATL ACAD SCI USA, V88, P9695, DOI 10.1073/pnas.88.21.9695; SKLAR MM, 1989, J BIOL CHEM, V264, P16733; SLEAT DE, 1995, CANCER RES, V55, P3424; SOHAR I, 1972, BIOL CHEM HOPPESEYLE, V373, P567; STEIN C, 1989, J BIOL CHEM, V264, P1252; STOLTZFUS LJ, 1992, J BIOL CHEM, V267, P6570; TODDERUD G, 1988, J BIOL CHEM, V263, P17893; TOWATARI T, 1988, FEBS LETT, V236, P57, DOI 10.1016/0014-5793(88)80285-0; TSUJI S, 1987, EUR J BIOCHEM, V165, P275, DOI 10.1111/j.1432-1033.1987.tb11438.x; VALENZANO KJ, 1993, ANAL BIOCHEM, V209, P156, DOI 10.1006/abio.1993.1096; VESA J, 1995, NATURE, V376, P584, DOI 10.1038/376584a0; YONEZAWA S, 1988, J BIOL CHEM, V263, P16504	55	97	98	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19191	19198		10.1074/jbc.271.32.19191	http://dx.doi.org/10.1074/jbc.271.32.19191			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702598	hybrid			2022-12-25	WOS:A1996VB68400032
J	Bastian, LS; Yagi, M; Chan, C; Roth, GJ				Bastian, LS; Yagi, M; Chan, C; Roth, GJ			Analysis of the megakaryocyte glycoprotein IX promoter identifies positive and negative regulatory domains and functional GATA and Ets sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BERNARD-SOULIER-SYNDROME; LEUCINE-RICH GLYCOPROTEINS; ERYTHROLEUKEMIA CELL-LINE; PU.1 TRANSCRIPTION FACTOR; PLATELET FACTOR-IV; IB-IX; GENE-EXPRESSION; MEMBRANE-GLYCOPROTEINS; GEL-ELECTROPHORESIS; BINDING PROTEINS	The glycoprotein (GP) Ib-V-IX multisubunit complex binds to von Willebrand factor and mediates the adhesion of platelets to the subendothelium of damaged blood vessels, Expression of the GPIX subunit is required for stability of the complex, and its absence in platelets is associated with the rare bleeding disorder Bernard-Soulier syndrome, Comparative analyses indicate that the four GPIb-V-IX subunits are members of the leucine rich repeat family and suggest that GPIX resembles a possible primitive progenitor of this group, To characterize GPIX transcriptional regulation, a series of 5' deletion constructs was made linking the GPIX upstream flanking sequence to the luciferase marker gene, and promoter activity was measured in transiently transfected human erythroleukemia cells. This analysis identified two negative regulatory domains between -686 to -423 and -311 to -203 and two positive regulatory domains at -323 to -311 and -151 to -100 relative to the GPIX transcription start site. In addition, site-directed mutagenesis experiments and in vitro gel retardation assays identified Ets and GATA elements at -42 and -65, which positively regulate GPIX promoter activity and specifically bind nuclear factors derived from human erythroleukemia cells, DNase I protection experiments identified a protein-dependent ''footprint'' and hypersensitive site within the GPIX Ets sequence, These results provide a framework for comparison of the GPIX promoter with others of the GPIb-V-IX system, other megakaryocyte-specific genes, and other members of the leucine-rich repeat family.	VET AFFAIRS MED CTR, MED SERV, HEMATOL SECT, SEATTLE, WA 98108 USA; VET AFFAIRS MED CTR, RES SERV, SEATTLE, WA 98108 USA; UNIV WASHINGTON, DEPT MED, DIV HEMATOL, SEATTLE, WA 98195 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Washington; University of Washington Seattle					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL009265, R01HL039947] Funding Source: NIH RePORTER; NHLBI NIH HHS [T32 HL0793, HL39947, F32 HL09265] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSSON LC, 1979, INT J CANCER, V23, P143, DOI 10.1002/ijc.2910230202; AUSABEL FM, 1991, CURRENT PROTOCOLS MO; BERKOW RL, 1984, J LAB CLIN MED, V103, P811; BLOCK KL, 1995, STEM CELLS, V13, P135, DOI 10.1002/stem.5530130205; BLOCK KL, 1994, BLOOD, V84, P3385; BOCKAMP EO, 1994, BIOESSAYS, V16, P481, DOI 10.1002/bies.950160707; BRETONGORIUS J, 1986, SEMIN HEMATOL, V23, P43; CALVERLEY DC, 1995, BLOOD, V86, P1361, DOI 10.1182/blood.V86.4.1361.bloodjournal8641361; CHAN GCK, 1991, J BIOL CHEM, V266, P22634; CLEMETSON KJ, 1982, J CLIN INVEST, V70, P304, DOI 10.1172/JCI110618; DAI W, 1993, BLOOD, V81, P1214; DORFMAN DM, 1992, J BIOL CHEM, V267, P1279; DU XP, 1994, J BIOL CHEM, V269, P18287; DU XP, 1987, BLOOD, V69, P1524; DUESTER G, 1991, MOL CELL BIOL, V11, P1638, DOI 10.1128/MCB.11.3.1638; EISMAN R, 1990, BLOOD, V76, P336; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; FONG AM, 1994, J BIOL CHEM, V269, P18441; FOX JEB, 1987, J BIOL CHEM, V262, P12627; GEORGE KM, 1994, DEVELOPMENT, V120, P2673; GOEBL MG, 1990, CELL, V61, P1165, DOI 10.1016/0092-8674(90)90676-6; GORDON JI, 1976, PLATELETS BIOL PATHO; Gumina RJ, 1995, BLOOD, V86, P1797; HASHIMOTO Y, 1995, J BIOL CHEM, V270, P24532, DOI 10.1074/jbc.270.41.24532; HICKEY MJ, 1989, P NATL ACAD SCI USA, V86, P6773, DOI 10.1073/pnas.86.17.6773; HICKEY MJ, 1993, P NATL ACAD SCI USA, V90, P8327, DOI 10.1073/pnas.90.18.8327; HICKEY MJ, 1993, J BIOL CHEM, V268, P3438; HO IC, 1991, EMBO J, V10, P1187, DOI 10.1002/j.1460-2075.1991.tb08059.x; HROMAS R, 1993, BLOOD, V82, P2998; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KOBE B, 1994, TRENDS BIOCHEM SCI, V19, P415, DOI 10.1016/0968-0004(94)90090-6; KORNHAUSER JM, 1994, MOL BRAIN RES, V23, P100, DOI 10.1016/0169-328X(94)90216-X; LEMARCHANDEL V, 1993, MOL CELL BIOL, V13, P668, DOI 10.1128/MCB.13.1.668; LI CY, 1995, BLOOD, V86, P3805, DOI 10.1182/blood.V86.10.3805.bloodjournal86103805; LONG MW, 1981, BLOOD, V58, P1032; LOPEZ JA, 1988, P NATL ACAD SCI USA, V85, P2135, DOI 10.1073/pnas.85.7.2135; LOPEZ JA, 1992, J BIOL CHEM, V267, P12851; LOPEZ JA, 1994, BLOOD COAGUL FIBRIN, V5, P97; Ludlow LB, 1995, BLOOD, V86, P314; MACLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251, DOI 10.1016/0968-0004(92)90404-W; MAJUMDAR S, 1991, J BIOL CHEM, V266, P5785; MARTIN DIK, 1990, NATURE, V344, P444, DOI 10.1038/344444a0; MARTIN F, 1993, J BIOL CHEM, V268, P21606; MARTIN ME, 1988, P NATL ACAD SCI USA, V85, P5839, DOI 10.1073/pnas.85.16.5839; MARTIN P, 1982, SCIENCE, V216, P1233, DOI 10.1126/science.6177045; MAZUR EM, 1994, THROMBOSIS HEMORRHAG, P161; MEYER SC, 1995, J BIOL CHEM, V270, P14693, DOI 10.1074/jbc.270.24.14693; MICHAEL SF, 1994, BIOTECHNIQUES, V16, P410; MILLER JL, 1992, BLOOD, V79, P439; MODDERMAN PW, 1992, J BIOL CHEM, V267, P364; MOLNAR A, 1994, MOL CELL BIOL, V14, P8292, DOI 10.1128/MCB.14.12.8292; MOUTHON MA, 1993, BLOOD, V81, P647; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; OGURA M, 1985, BLOOD, V66, P1384; ORKIN SH, 1995, J BIOL CHEM, V270, P4955, DOI 10.1074/jbc.270.10.4955; PAN JL, 1993, J BIOL CHEM, V268, P22600; PAUL R, 1991, J VIROL, V65, P464, DOI 10.1128/JVI.65.1.464-467.1991; PHILLIPS DR, 1977, J BIOL CHEM, V252, P2121; PRANDINI MH, 1992, J BIOL CHEM, V267, P10370; Prandini MH, 1995, BLOOD, V86, P2198; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; RAMACHANDRAN B, 1995, EXP HEMATOL, V23, P49; RAVID K, 1991, MOL CELL BIOL, V11, P6116, DOI 10.1128/MCB.11.12.6116; REDDY ESP, 1988, ONCOGENE RES, V3, P239; ROMEO PH, 1990, NATURE, V344, P447, DOI 10.1038/344447a0; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P704; ROSMARIN AG, 1995, P NATL ACAD SCI USA, V92, P801, DOI 10.1073/pnas.92.3.801; ROTH GJ, 1995, MOL BASIS THROMBOSIS, P561; SCHWARZENBACH H, 1995, J BIOL CHEM, V270, P898, DOI 10.1074/jbc.270.2.898; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; SHIVDASANI RA, 1995, CELL, V81, P695, DOI 10.1016/0092-8674(95)90531-6; TABILIO A, 1984, EMBO J, V3, P453, DOI 10.1002/j.1460-2075.1984.tb01827.x; TAKAHASHI N, 1985, P NATL ACAD SCI USA, V82, P1906, DOI 10.1073/pnas.82.7.1906; THIEBAUD P, 1990, GENE DEV, V4, P1999, DOI 10.1101/gad.4.11.1999; VICENTE V, 1990, J BIOL CHEM, V265, P274; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; WEISS MJ, 1995, EXP HEMATOL, V23, P99; WRIGHT SD, 1993, BLOOD, V81, P2339; Yagi M, 1995, BIOCHEMISTRY-US, V34, P16132, DOI 10.1021/bi00049a028	80	44	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18554	18560		10.1074/jbc.271.31.18554	http://dx.doi.org/10.1074/jbc.271.31.18554			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702504	hybrid			2022-12-25	WOS:A1996VB68300042
J	Kupiec, JJ; Hazebrouck, S; LesteLasserre, T; Sonigo, P				Kupiec, JJ; Hazebrouck, S; LesteLasserre, T; Sonigo, P			Conversion of thymidylate synthase into an HIV protease substrate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS PROTEASE; ESCHERICHIA-COLI; RETROVIRAL PROTEASES; SITE; SELECTION; SYSTEM; GENE	Thymidylate synthase (TS) is an essential enzyme of DNA metabolism. We have carried out an extensive insertional mutagenesis of the Escherichia coli TS gene (thyA) using three different methods. Insertion of exogenous sequences at unique restriction sites or at random positions produced defective mutants, whereas comparison of TS sequences from different species allowed us to identify six zones permissive for insertions of exogenous sequences. The insertion of Human immunodeficiency virus type 1 (HIV-1) protease substrate sequences into the permissive sites converted TS to an HIV-1 protease substrate, and the in vivo cleavage of these insertions by the cloned HIV-1 protease conferred a thymidylate synthase-deficient phenotype in some of our E. coli mutant strains, In agreement with crystallographic data, these results show that the permissive sites are located in regions of the TS protein not essential for enzyme activity and accessible to cleavage by HIV protease, These results also show that it is possible to control a growth phenotype in E. coli through the protease-mediated destruction of an essential metabolic enzyme, Because both wild type and thymidylate synthase-deficient phenotypes are selectable on the appropriate growth medium, these thyA mutants could be used for genetic selections of protease inhibitors and analysis of protease specificities.	INST COCHIN GENET MOL, CNRS UPR 415, F-75014 PARIS, FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite				Sonigo, Pierre/0000-0003-2686-1303				BALINT RF, 1995, BIO-TECHNOL, V13, P507, DOI 10.1038/nbt0595-507; BAUM EZ, 1990, P NATL ACAD SCI USA, V87, P10023, DOI 10.1073/pnas.87.24.10023; BAUM EZ, 1990, P NATL ACAD SCI USA, V87, P5573, DOI 10.1073/pnas.87.14.5573; BELFORT M, 1983, P NATL ACAD SCI-BIOL, V80, P4914, DOI 10.1073/pnas.80.16.4914; BELFORT M, 1984, J BACTERIOL, V160, P371, DOI 10.1128/JB.160.1.371-378.1984; BEYNON RJ, 1994, PROTEOLYTIC ENZYMES; BLOCK TM, 1990, ANTIMICROB AGENTS CH, V34, P2337, DOI 10.1128/AAC.34.12.2337; CARRERAS CW, 1994, J BIOL CHEM, V269, P12444; DEBOUCK C, 1987, P NATL ACAD SCI USA, V84, P8903, DOI 10.1073/pnas.84.24.8903; FARMERIE WG, 1987, SCIENCE, V236, P305, DOI 10.1126/science.2436298; FITZGERALD PMD, 1991, ANNU REV BIOPHYS BIO, V20, P299, DOI 10.1146/annurev.biophys.20.1.299; GOLDBERG AL, 1972, P NATL ACAD SCI USA, V69, P422, DOI 10.1073/pnas.69.2.422; HARDY LW, 1987, SCIENCE, V235, P448, DOI 10.1126/science.3099389; Hellen Christopher U. T., 1992, Current Opinion in Biotechnology, V3, P643, DOI 10.1016/0958-1669(92)90010-G; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; MARTINEZ E, 1988, GENE, V68, P159, DOI 10.1016/0378-1119(88)90608-7; MATTHEWS DA, 1990, J MOL BIOL, V214, P937, DOI 10.1016/0022-2836(90)90347-O; MCCALL JO, 1994, BIO-TECHNOL, V12, P1012, DOI 10.1038/nbt1094-1012; MICHAELS ML, 1990, P NATL ACAD SCI USA, V87, P3957, DOI 10.1073/pnas.87.10.3957; ROBERTS D, 1966, BIOCHEMISTRY-US, V5, P3546, DOI 10.1021/bi00875a022; SCHARPE S, 1991, BIOCHIMIE, V73, P121, DOI 10.1016/0300-9084(91)90084-E; STACEY KA, 1965, J BACTERIOL, V90, P554, DOI 10.1128/JB.90.2.554-555.1965; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; TOMASSELLI AG, 1994, METHOD ENZYMOL, V241, P279	24	10	10	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18465	18470		10.1074/jbc.271.31.18465	http://dx.doi.org/10.1074/jbc.271.31.18465			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702491	hybrid			2022-12-25	WOS:A1996VB68300029
J	McIntosh, DB; Parrish, JC; Wallace, CJA				McIntosh, DB; Parrish, JC; Wallace, CJA			Definition of a nucleotide binding site on cytochrome c by photoaffinity labeling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOPLASMIC-RETICULUM CA2+-ATPASE; LIVER ALCOHOL-DEHYDROGENASE; ELECTRON-TRANSFER ACTIVITY; ATP-BINDING; PURINE NUCLEOSIDES; OXIDATION-STATE; CHEMICAL MODIFICATION; IONIC-STRENGTH; OXIDASE; CONFORMATION	We have used TNP-8N(3)-AMP (2'(3')-O-(2,4,6-trinitrophenyl)-8-azidoadenosine monophosphate) and TNP-8N(3)-ATP to probe the ATP binding site(s) of cytochrome c. Irradiation of cytochrome c with close to stoichiometric amounts of TNP-8N(3)-AMP at low ionic strength derivatized approximately half of the protein, with the mono-derivatized species being associated with four peaks (B, 6%; C, 17%; D, 24%; E, 4%) eluted from a cation exchange column, Irradiation in the presence of ATP suggested that the main peaks C and D resulted from more specific nucleotide binding, Thermolysin digestion and TNP-peptide purification and sequencing revealed that peak C was associated with derivatization of mainly Lys-86 and to a lesser extent Lys-72 and peak D with mainly Lys-87 and less so with Lys-72, Minor peaks B and E could not be identified, TNP-8N(3)-ATP photolabeling produced similar results, showing favored interaction of the adenyl ring with Lys-86 and Lys-87 and to a lesser extent with Lys-72, The results are compatible with previous findings that suggest that the principal locus of ATP binding is at nearby Arg-91 (Corthesy, B. E., and Wallace, C, J. A. (1986) Biochem, J. 236, 359-364), Molecular modeling with energy-minimized docking of ATP between the 60s helix and the 80s stretch with the gamma-phosphate constrained to interact with Arg-91, places the 8 position close to Lys-86 and Lys-87 in the anti conformation about the glycosidic bond and to Lys-72 in the syn conformation, and the ribose hydroxyls within H-bonding distance of Glu-69.	DALHOUSIE UNIV,DEPT BIOCHEM,HALIFAX,NS B3H 4H7,CANADA; UNIV CAPE TOWN,SCH MED,MRC,BIOMEMBRANE RES UNIT,ZA-7925 CAPE TOWN,SOUTH AFRICA; UNIV CAPE TOWN,SCH MED,DEPT CHEM PATHOL,ZA-7925 CAPE TOWN,SOUTH AFRICA	Dalhousie University; University of Cape Town; University of Cape Town								ABDALLAH MA, 1975, EUR J BIOCHEM, V50, P475, DOI 10.1111/j.1432-1033.1975.tb09885.x; BRAUTIGAN DL, 1978, J BIOL CHEM, V253, P130; BUSHNELL GW, 1990, J MOL BIOL, V214, P585, DOI 10.1016/0022-2836(90)90200-6; CORTHESY BE, 1988, BIOCHEM J, V252, P349, DOI 10.1042/bj2520349; CORTHESY BE, 1986, BIOCHEM J, V236, P359, DOI 10.1042/bj2360359; CRAIG DB, 1995, BIOCHEMISTRY-US, V34, P2686, DOI 10.1021/bi00008a036; CRAIG DB, 1991, BIOCHEM J, V279, P781, DOI 10.1042/bj2790781; CRAIG DB, 1993, PROTEIN SCI, V2, P966, DOI 10.1002/pro.5560020610; FERGUSONMILLER S, 1978, J BIOL CHEM, V253, P149; FERGUSONMILLER S, 1976, J BIOL CHEM, V251, P1104; GLYNN IM, 1964, BIOCHEM J, V90, P147, DOI 10.1042/bj0900147; GRONENBORN AM, 1982, J MOL BIOL, V157, P155, DOI 10.1016/0022-2836(82)90518-6; HIRATSUKA T, 1985, J BIOL CHEM, V260, P4784; IKEHARA M, 1972, BIOCHEMISTRY-US, V11, P830, DOI 10.1021/bi00755a023; KOPPENOL WH, 1978, BIOCHIM BIOPHYS ACTA, V503, P499, DOI 10.1016/0005-2728(78)90149-4; LAPPALAINEN P, 1995, BIOCHEMISTRY-US, V34, P5824, DOI 10.1021/bi00017a014; LIN J, 1995, BIOCHEMISTRY-US, V34, P2678, DOI 10.1021/bi00008a035; MARGALIT R, 1973, EUR J BIOCHEM, V32, P500, DOI 10.1111/j.1432-1033.1973.tb02634.x; MARGOLIASH E, 1983, TRENDS BIOCHEM SCI, V8, P316, DOI 10.1016/0968-0004(83)90100-7; MARGOLIASH E, 1970, NATURE, V228, P723, DOI 10.1038/228723a0; MCINTOSH DB, 1994, J BIOL CHEM, V269, P21587; MCINTOSH DB, 1992, J BIOL CHEM, V267, P5301; NAKAMOTO RK, 1984, J BIOL CHEM, V259, P2961; NICHOLLS P, 1974, BIOCHIM BIOPHYS ACTA, V346, P261, DOI 10.1016/0304-4173(74)90003-2; PELLETIER H, 1992, SCIENCE, V258, P1748, DOI 10.1126/science.1334573; Pettigrew G.W., 1987, CYTOCHROME C BIOL AS; RYTOMAA M, 1992, J BIOL CHEM, V267, P22243; RYTOMAA M, 1994, J BIOL CHEM, V269, P1770; SEEBREGTS CJ, 1989, J BIOL CHEM, V264, P2043; SPECK SH, 1983, FEBS LETT, V164, P379, DOI 10.1016/0014-5793(83)80321-4; STELLWAG.E, 1973, J MOL BIOL, V75, P683, DOI 10.1016/0022-2836(73)90301-X; STOLARSKI R, 1984, EUR J BIOCHEM, V138, P187, DOI 10.1111/j.1432-1033.1984.tb07898.x; TABORSKY G, 1978, J BIOL CHEM, V254, P7069; TAKENAKA H, 1978, P NATL ACAD SCI USA, V75, P4229, DOI 10.1073/pnas.75.9.4229; TAVALE SS, 1970, J MOL BIOL, V48, P109, DOI 10.1016/0022-2836(70)90222-6; VIK SB, 1981, P NATL ACAD SCI-BIOL, V78, P1456, DOI 10.1073/pnas.78.3.1456; WALLACE CJA, 1986, PROTEIN ENG, V1, P23, DOI 10.1093/protein/1.1.23; WANIO NW, 1960, J BIOL CHEM, V235, P1521; YU CA, 1975, J BIOL CHEM, V250, P1383	39	21	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18379	18386		10.1074/jbc.271.31.18379	http://dx.doi.org/10.1074/jbc.271.31.18379			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702481	hybrid			2022-12-25	WOS:A1996VB68300019
J	Ohnuma, S; Hirooka, K; Hemmi, H; Ishida, C; Ohto, C; Nishino, T				Ohnuma, S; Hirooka, K; Hemmi, H; Ishida, C; Ohto, C; Nishino, T			Conversion of product specificity of archaebacterial geranylgeranyl-diphosphate synthase - Identification of essential amino acid residues for chain length determination of prenyltransferase reaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; SACCHAROMYCES-CEREVISIAE; MOLECULAR-CLONING; PYROPHOSPHATE SYNTHETASE; ESCHERICHIA-COLI; ARTIFICIAL SUBSTRATE; BIOSYNTHETIC-PATHWAY; CONSERVED ASPARTATE; DOLICHYL PHOSPHATE; DOMAIN-II	Prenyltransferases catalyze the consecutive condensation of isopentenyl diphosphate with allylic diphosphates to produce prenyl diphosphates whose chain lengths are absolutely determined by each enzyme, To investigate the mechanism of the consecutive reaction and the determination of the ultimate chain length, a random mutational approach was planned, A geranylgeranyl-diphosphate synthase gene from Sulfolobus acidocaldarius was randomly mutagenized by NaNO2 treatment to construct a library of mutated geranylgeranyl-diphosphate synthase genes on a yeast expression vector, The library was screened for suppression of a pet phenotype of yeast C296-LH(3), which is deficient in hexaprenyl diphosphate synthase, Five mutants that could grow on a YEPG plate, which contained only glycerol as an energy source instead of glucose, were selected from similar to 1,400 mutants, All selected mutated enzymes catalyzed the formation of polyprenyl diphosphates with prenyl chains longer than geranylgeranyl diphosphate. Especially mutants 1, 3, and 5 showed the strongest elongation activity to produce large amounts of geranylfarnesyl diphosphate with a concomitant amount of hexaprenyl diphosphate. Sequence analysis revealed that each mutant contained a few amino acid substitutions and that the mutation of Phe-77, which is located on the fifth amino acid upstream from the first aspartate-rich consensus motif, is the most effective for elongating the ultimate product, Amino acid alignment of known prenyltransferases around this position and our previous observations on farnesyl-diphosphate synthase (Ohnuma, S.-i,, Nakazawa, T., Hemmi, H,, Hallberg, A.-M,, Koyama, T,, Ogura, K,, and Nishino, T, (1996) J, Biol, Chem, 271, 10087-10095) clearly indicate that the amino acid at the position of all prenyltransferases must regulate the chain elongation.	TOYOTA MOTOR CO LTD,BIORES LAB,TOYOTA 47171,JAPAN	Toyota Motor Corporation	Ohnuma, S (corresponding author), TOHOKU UNIV,DEPT BIOCHEM & ENGN,AOBA KU,SENDAI,MIYAGI 98077,JAPAN.		Hemmi, Hisashi/I-6868-2014; Hirooka, Kazutake/K-9827-2017; Ohto, Chikara/GQB-4702-2022	Hemmi, Hisashi/0000-0002-9538-809X; Hirooka, Kazutake/0000-0001-5879-936X; Ohnuma, Shin-ichi/0000-0002-3305-5126				ANDERSON MS, 1989, J BIOL CHEM, V264, P19176; ASAI K, 1994, BIOCHEM BIOPH RES CO, V202, P340, DOI 10.1006/bbrc.1994.1933; ASHBY MN, 1990, J BIOL CHEM, V265, P13157; BLANCHARD L, 1993, GENE, V125, P185, DOI 10.1016/0378-1119(93)90326-X; CARATTOLI A, 1991, J BIOL CHEM, V266, P5854; CASEY AC, 1973, CANCER RES, V33, P1183; CHEN AJ, 1994, PROTEIN SCI, V3, P600; CLARKE CF, 1987, MOL CELL BIOL, V7, P3138, DOI 10.1128/MCB.7.9.3138; CRICK DC, 1989, BIOCHIM BIOPHYS ACTA, V1004, P180, DOI 10.1016/0005-2760(89)90266-X; EGGENS I, 1983, BIOCHIM BIOPHYS ACTA, V751, P355, DOI 10.1016/0005-2760(83)90294-1; FUJII H, 1982, BIOCHIM BIOPHYS ACTA, V712, P716; FUJII H, 1980, BIOCHEM BIOPH RES CO, V96, P1648, DOI 10.1016/0006-291X(80)91363-7; FUJISAKI S, 1990, J BIOCHEM-TOKYO, V108, P995, DOI 10.1093/oxfordjournals.jbchem.a123327; ITOH N, 1984, J BIOL CHEM, V259, P3923; JOLY A, 1993, J BIOL CHEM, V268, P26983; KOIKETAKESHITA A, 1995, J BIOL CHEM, V270, P18396, DOI 10.1074/jbc.270.31.18396; KOYAMA T, 1988, TETRAHEDRON LETT, V29, P3807, DOI 10.1016/S0040-4039(00)82120-6; KOYAMA T, 1994, CAN J CHEM, V72, P75, DOI 10.1139/v94-012; KOYAMA T, 1993, J BIOCHEM-TOKYO, V113, P355, DOI 10.1093/oxfordjournals.jbchem.a124051; MARRERO PF, 1992, J BIOL CHEM, V267, P21873; MATH SK, 1992, P NATL ACAD SCI USA, V89, P6761, DOI 10.1073/pnas.89.15.6761; MATSUOKA S, 1991, J BIOL CHEM, V266, P3464; MISAWA N, 1990, J BACTERIOL, V172, P6704, DOI 10.1128/jb.172.12.6704-6712.1990; MYERS RM, 1985, SCIENCE, V229, P242, DOI 10.1126/science.2990046; NAZIR DJ, 1964, BIOCHEM J, V90, P268, DOI 10.1042/bj0900268; NISHINO T, 1977, BIOCHEMISTRY-US, V16, P605, DOI 10.1021/bi00623a008; OHNUMA S, 1992, J BIOCHEM-TOKYO, V112, P743, DOI 10.1093/oxfordjournals.jbchem.a123969; OHNUMA S, 1989, TETRAHEDRON, V45, P6145, DOI 10.1016/S0040-4020(01)85127-9; OHNUMA S, 1994, J BIOL CHEM, V269, P14792; OHNUMA S, 1993, BIOCHEM BIOPH RES CO, V192, P407, DOI 10.1006/bbrc.1993.1430; Ohnuma SI, 1996, J BIOL CHEM, V271, P10087, DOI 10.1074/jbc.271.17.10087; OHNUMA SI, 1989, FEBS LETT, P71; PENNOCK JF, 1983, BIOSYNTHESIS ISOPREN, P191; POULTER CD, 1982, BIOSYNTHESIS ISOPREN, P161; SAKAKIHARA Y, 1985, J NEUROCHEM, V44, P1535, DOI 10.1111/j.1471-4159.1985.tb08792.x; Sambrook J., 2002, MOL CLONING LAB MANU; SCHNEIDER H, 1982, J BIOL CHEM, V257, P789; SONG LS, 1994, P NATL ACAD SCI USA, V91, P3044, DOI 10.1073/pnas.91.8.3044; TZAGOLOFF A, 1990, MICROBIOL REV, V54, P211, DOI 10.1128/MMBR.54.3.211-225.1990; TZAGOLOFF A, 1975, J BACTERIOL, V122, P826, DOI 10.1128/JB.122.3.826-831.1975; WILKIN DJ, 1990, J BIOL CHEM, V265, P4607	41	111	124	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18831	18837		10.1074/jbc.271.31.18831	http://dx.doi.org/10.1074/jbc.271.31.18831			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702542	hybrid			2022-12-25	WOS:A1996VB68300080
J	Whitehead, IP; KhosraviFar, R; Kirk, H; TrigoGonzalez, G; Her, CJ; Kay, R				Whitehead, IP; KhosraviFar, R; Kirk, H; TrigoGonzalez, G; Her, CJ; Kay, R			Expression cloning of lsc, a novel oncogene with structural similarities to the Dbl family of guanine nucleotide exchange factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEINS; ACTIN STRESS FIBERS; RAS TRANSFORMATION; SEQUENCE SIMILARITY; SIGNALING PATHWAYS; MOLECULAR-CLONING; CDNA LIBRARIES; CDC42 GTPASES; RHO; GENE	In a screen for genes with oncogenic potential expressed by the murine B6SUtA(1) myeloid progenitor cell line, we isolated a 2.5-kilobase pair cDNA whose expression causes strong morphological transformation and deregulated proliferation of NIH 3T3 cells. The transforming cDNA encodes a truncated protein (designated Lsc) with a region of sequence similarity to the product of the lbc oncogene. This region includes the tandem Dbl homology and pleckstrin homology domains that are hallmarks of the Dbl-like proteins, a family of presumptive or demonstrated guanine nucleotide exchange factors that act on Rho family GTPases. Lsc requires intact Dbl homology and pleckstrin homology domains for its oncogenic activity. The transforming activity of Lsc in NIH 3T3 cells is reduced by cotransfection with p190 (a GTPase activating protein for Rho family GTPases) and the Rho family dominant-negative mutants RhoA(19N), CDC42(17N), and Racl(17N), These results indicate a role for the Rho family of GTPases in mediating the transforming activity of Lsc and are consistent with the exchange specificities that have been attributed to Dbl family members. The Ise gene is expressed in a variety of tissues and is particularly abundant in hemopoietic tissues (thymus, spleen, and bone marrow). Lsc is a member of a growing family of proteins that may function as activators of Rho family GTPases in a developmental or tissue-specific manner.	BRITISH COLUMBIA CANC AGCY,TERRY FOX LAB,VANCOUVER,BC V5Z 4E6,CANADA; UNIV BRITISH COLUMBIA,DEPT MED GENET,VANCOUVER,BC V6T 1Z1,CANADA; UNIV N CAROLINA,LINEBERGER COMPREHENS CANC CTR,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT PHARMACOL,CHAPEL HILL,NC 27599; UNIV N CAROLINA,CURRICULUM GENET & MOL BIOL,CHAPEL HILL,NC 27599	British Columbia Cancer Agency; University of British Columbia; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill			Khosravi-Far, Roya/C-3789-2008	Der, Channing/0000-0002-7751-2747				ADAMS JM, 1992, ONCOGENE, V7, P611; ADAMS MD, 1993, NAT GENET, V4, P373, DOI 10.1038/ng0893-373; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BRTVA TR, 1995, J BIOL CHEM, V270, P9809, DOI 10.1074/jbc.270.17.9809; BUSTELO XR, 1994, ONCOGENE, V9, P2405; CEN H, 1992, EMBO J, V11, P4007, DOI 10.1002/j.1460-2075.1992.tb05494.x; CHAN AML, 1994, ONCOGENE, V9, P1057; CHANT J, 1995, CELL, V81, P1, DOI 10.1016/0092-8674(95)90363-1; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARK GJ, 1995, METHOD ENZYMOL, V255, P395; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; DRUBIN DG, 1991, CELL, V65, P1093, DOI 10.1016/0092-8674(91)90001-F; ENGLERBLUM G, 1993, ANAL BIOCHEM, V210, P235, DOI 10.1006/abio.1993.1189; EVA A, 1985, NATURE, V316, P273, DOI 10.1038/316273a0; FARNSWORTH CL, 1991, MOL CELL BIOL, V11, P4822, DOI 10.1128/MCB.11.10.4822; FEIG LA, 1993, SCIENCE, V260, P767, DOI 10.1126/science.8484117; Goldschmidt-Clermont P. J., 1992, Current Biology, V2, P669, DOI 10.1016/0960-9822(92)90135-W; GORMAN CM, 1983, NUCLEIC ACIDS RES, V11, P7631, DOI 10.1093/nar/11.21.7631; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; GULBINS E, 1994, MOL CELL BIOL, V14, P4749, DOI 10.1128/MCB.14.7.4749; GULBINS E, 1993, SCIENCE, V260, P822, DOI 10.1126/science.8484124; GULBINS E, 1994, MOL CELL BIOL, V14, P906, DOI 10.1128/MCB.14.2.906; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; HARIHARAN IK, 1987, EMBO J, V6, P115, DOI 10.1002/j.1460-2075.1987.tb04727.x; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HART MJ, 1994, J BIOL CHEM, V269, P62; HART MJ, 1992, SCIENCE, V258, P812, DOI 10.1126/science.1439791; HEISTERKAMP N, 1993, J BIOL CHEM, V268, P16903; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HODGSON CP, 1987, NUCLEIC ACIDS RES, V15, P6295, DOI 10.1093/nar/15.15.6295; HORII Y, 1994, EMBO J, V13, P4776, DOI 10.1002/j.1460-2075.1994.tb06803.x; INGLESE J, 1995, TRENDS BIOCHEM SCI, V20, P151, DOI 10.1016/S0968-0004(00)88992-6; JACOBSON A, 1987, METHOD ENZYMOL, V152, P254; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KHOSRAVIFAR R, 1994, MOL CELL BIOL, V14, P6848, DOI 10.1128/MCB.14.10.6848; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KOZAK M, 1991, J BIOL CHEM, V266, P19867; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; LAMARCHE N, 1994, TRENDS GENET, V10, P436, DOI 10.1016/0168-9525(94)90114-7; LUTHMAN H, 1983, NUCLEIC ACIDS RES, V11, P1295, DOI 10.1093/nar/11.5.1295; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; MIKI T, 1993, NATURE, V362, P462, DOI 10.1038/362462a0; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; PASTERIS NG, 1994, CELL, V79, P669; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QUILLIAM LA, 1995, BIOESSAYS, V17, P309; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RON D, 1991, NEW BIOL, V3, P372; SCHWEIGHOFFER F, 1993, MOL CELL BIOL, V13, P39, DOI 10.1128/MCB.13.1.39; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SETTLEMAN J, 1992, NATURE, V359, P153, DOI 10.1038/359153a0; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; TAN EC, 1993, J BIOL CHEM, V268, P27291; TOKSOZ D, 1994, ONCOGENE, V9, P621; VOGELI G, 1985, ANAL BIOCHEM, V151, P442, DOI 10.1016/0003-2697(85)90202-7; WHITEHEAD I, 1995, ONCOGENE, V10, P713; WHITEHEAD I, 1995, J BIOL CHEM, V270, P18388, DOI 10.1074/jbc.270.31.18388; WHITEHEAD I, 1995, MOL CELL BIOL, V15, P704; ZHENG Y, 1995, J BIOL CHEM, V270, P9031, DOI 10.1074/jbc.270.16.9031; ZHENG Y, 1994, J BIOL CHEM, V269, P2369	72	85	90	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18643	18650		10.1074/jbc.271.31.18643	http://dx.doi.org/10.1074/jbc.271.31.18643			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702517	Green Published, hybrid			2022-12-25	WOS:A1996VB68300055
J	Bai, XM; Esko, JD				Bai, XM; Esko, JD			An animal cell mutant defective in heparan sulfate hexuronic acid 2-O-sulfation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST GROWTH-FACTOR; POLYMER-MODIFICATION REACTIONS; BIOLOGICAL-ACTIVITIES; N-SULFOTRANSFERASE; PROTEIN INTERACTIONS; DIMETHYL-SULFOXIDE; BIOSYNTHESIS; GLYCOSAMINOGLYCANS; DEPOLYMERIZATION; OLIGOSACCHARIDES	The interaction of heparan sulfate with protein ligands depends on unique oligosaccharide sequences containing iduronic acid (IdUA), N-sulfated glucosamine residues, and O-sulfated sugars, To study the role of O-sulfation in greater detail, we isolated a Chinese hamster ovary cell mutant defective in 2-O-sulfation of iduronic acid, The mutant, pgsF-17, was identified by a colony blotting assay in which colonies of mutagen-treated cells were replica plated to two disks of polyester cloth, One disk was blotted with I-125-labeled basic fibroblast growth factor (bFGF) to measure binding to cell surface proteoglycans. The other disk was incubated with (SO4)-S-35, to measure proteoglycan biosynthesis. Autoradiography revealed a colony that did not bind I-125-bFGF, but incorporated (SO4)-S-35, normally (mutant pgsF-17), Complete deaminative cleavage of heparan sulfate revealed that material from pgsF-17 lacked IdUA(2OSO(3))-GlcNSO(3) and IdUA(2OSO(3))-GlcNSO(3)(6OSO(3)), but contained a higher proportion of glucuronic acid GlcUA-GlcNSO(3)(6OSO(3)) and IdUA-GlcNSO(3)(6OSO(3)). Assay of the 2-O-sulfotransferase that acts on IdUA residues showed that mutant 17 lacked enzyme activity, Interestingly, the alteration resulted in accumulation of Glc NSO3 groups, suggesting that under normal conditions 2-O-sulfation decreases GlcNAc N-deacetylation/N-sulfation, and that the reactions occur simultaneously, The formation of IdUA and 6-O-sulfated glucosaminyl residues appears to be independent of a O-sulfation. pgsF-17 also lacks 2-O-sulfated GlcUA residues, suggesting that the same enzyme is responsible for 2-O-sulfation of IdUA and GlcUA residues, Mutant 17 provides a useful tool for studying the regulation of heparan sulfate biosynthesis and the relationship of heparan sulfate fine structure to its biological function.	UNIV ALABAMA, SCH MED, DEPT MOLEC GENET & BIOCHEM, BIRMINGHAM, AL 35294 USA; UNIV ALABAMA, SCH DENT, BIRMINGHAM, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham								ASHIKARI S, 1995, J BIOL CHEM, V270, P29586, DOI 10.1074/jbc.270.49.29586; BAME KJ, 1994, BIOCHEM J, V303, P81, DOI 10.1042/bj3030081; BAME KJ, 1991, J BIOL CHEM, V266, P10287; BAME KJ, 1989, J BIOL CHEM, V264, P8059; BAME KJ, 1991, J BIOL CHEM, V266, P12461; BIENKOWSKI MJ, 1985, J BIOL CHEM, V260, P356; BOURIN MC, 1993, BIOCHEM J, V289, P313, DOI 10.1042/bj2890313; COLLIECJOUAULT S, 1994, J BIOL CHEM, V269, P24953; DEAGOSTINI AL, 1990, P NATL ACAD SCI USA, V87, P9784, DOI 10.1073/pnas.87.24.9784; DULBECCO R, 1954, J EXP MED, V99, P167, DOI 10.1084/jem.99.2.167; ELGAVISH A, 1988, J BIOL CHEM, V263, P18607; ESKO JD, 1987, J BIOL CHEM, V262, P12189; ESKO JD, 1986, J BIOL CHEM, V261, P5725; ESKO JD, 1985, P NATL ACAD SCI USA, V82, P3197, DOI 10.1073/pnas.82.10.3197; ESKO JD, 1989, METHOD CELL BIOL, V32, P387; Esko JD, 1991, CURR OPIN CELL BIOL, V3, P805, DOI 10.1016/0955-0674(91)90054-3; FRITZ TA, 1994, J BIOL CHEM, V269, P28809; GUIMOND S, 1993, J BIOL CHEM, V268, P23906; GUO Y, 1989, ANAL BIOCHEM, V176, P96, DOI 10.1016/0003-2697(89)90278-9; GUO YC, 1988, ANAL BIOCHEM, V168, P54, DOI 10.1016/0003-2697(88)90009-7; HABUCHI H, 1992, BIOCHEM J, V285, P805, DOI 10.1042/bj2850805; HABUCHI H, 1995, J BIOL CHEM, V270, P4172, DOI 10.1074/jbc.270.8.4172; HAM RG, 1965, P NATL ACAD SCI USA, V53, P288, DOI 10.1073/pnas.53.2.288; INOUE Y, 1976, CARBOHYD RES, V46, P87, DOI 10.1016/S0008-6215(00)83533-8; ISHIHARA M, 1992, ANAL BIOCHEM, V206, P400, DOI 10.1016/0003-2697(92)90385-K; ISHIHARA M, 1994, GLYCOBIOLOGY, V4, P451, DOI 10.1093/glycob/4.4.451; ISHIHARA M, 1995, J BIOCHEM-TOKYO, V118, P1255, DOI 10.1093/oxfordjournals.jbchem.a125015; ISHIHARA M, 1993, J BIOL CHEM, V268, P4675; JACKSON RL, 1991, PHYSIOL REV, V71, P481, DOI 10.1152/physrev.1991.71.2.481; JACOBSSON I, 1980, J BIOL CHEM, V255, P5094; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; Kobayashi M, 1996, J BIOL CHEM, V271, P7645, DOI 10.1074/jbc.271.13.7645; KUSCHE M, 1990, J BIOL CHEM, V265, P15403; LIDHOLT K, 1992, P NATL ACAD SCI USA, V89, P2267, DOI 10.1073/pnas.89.6.2267; LIU ZC, 1992, CARBOHYD RES, V228, P29, DOI 10.1016/S0008-6215(00)90546-9; LLOYD AG, 1971, BIOCHEM PHARMACOL, V20, P637, DOI 10.1016/0006-2952(71)90150-X; LYON M, 1994, J BIOL CHEM, V269, P11216; MACCARANA M, 1993, J BIOL CHEM, V268, P23898; MATALON R, 1971, BIOCHEM BIOPH RES CO, V42, P340, DOI 10.1016/0006-291X(71)90108-2; NAGASAWA K, 1977, CARBOHYD RES, V58, P47, DOI 10.1016/S0008-6215(00)83402-3; NORGARDSUMNICHT KE, 1995, J BIOL CHEM, V270, P27634, DOI 10.1074/jbc.270.46.27634; OLWIN BB, 1990, J CELL BIOL, V110, P503, DOI 10.1083/jcb.110.2.503; PARTHASARATHY N, 1994, J BIOL CHEM, V269, P22391; RAETZ CRH, 1982, P NATL ACAD SCI-BIOL, V79, P3223, DOI 10.1073/pnas.79.10.3223; Razi N, 1995, GLYCOBIOLOGY, V5, P807, DOI 10.1093/glycob/5.8.807; RENOSTO F, 1977, ARCH BIOCHEM BIOPHYS, V180, P416, DOI 10.1016/0003-9861(77)90056-X; ROBBINS PW, 1962, METHOD ENZYMOL, V5, P964, DOI 10.1016/S0076-6879(62)05343-4; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3943, DOI 10.1021/bi00663a006; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3932, DOI 10.1021/bi00663a005; SHWORAK NW, 1994, J BIOL CHEM, V269, P24941; SPILLMANN D, 1994, CURR OPIN STRUC BIOL, V4, P677, DOI 10.1016/S0959-440X(94)90165-1; Toma L, 1996, J BIOL CHEM, V271, P3897; TURNBULL JE, 1992, J BIOL CHEM, V267, P10337; TYRRELL DJ, 1993, J BIOL CHEM, V268, P4684; vandenBorn J, 1995, J BIOL CHEM, V270, P31303, DOI 10.1074/jbc.270.52.31303; WLAD H, 1994, J BIOL CHEM, V269, P24538	56	110	113	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					17711	17717		10.1074/jbc.271.30.17711	http://dx.doi.org/10.1074/jbc.271.30.17711			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663454	hybrid			2022-12-25	WOS:A1996UY93500021
J	Feinstein, DL; Galea, E; Aquino, DA; Li, GC; Xu, H; Reis, DJ				Feinstein, DL; Galea, E; Aquino, DA; Li, GC; Xu, H; Reis, DJ			Heat shock protein 70 suppresses astroglial-inducible nitric-oxide synthase expression by decreasing NF kappa B activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CNS GLIAL-CELLS; INTERFERON-GAMMA; STRESS PROTEINS; GLUCOCORTICOID RECEPTOR; MAMMALIAN-CELLS; GLIOMA-CELLS; INDUCTION; HSP70; ASTROCYTES; GENE	In brain glial cells, expression of calcium independent nitric oxide synthase (NOS-2) is induced following stimulation with bacterial endotoxin (lipopolysaccharide (LPS)) and/or pro-inflammatory cytokines. We have investigated the effects of heat shock (HS), which can re duce inflammatory responses in several cell types, on the induction of glial NOS-2 expression. Preincubation of cells for 20-60 min at 43 degrees C decreased subsequent levels of NOS-2 induction, with a maximal 80% reduction after 60 min of HS. Following HS, cells were refractory to NOS inducers for up to 4 h, after which time little or no suppression was observed. HS reduced cytosolic NOS-2 enzymatic activity (3-fold), steady state mRNA levels (2-3-fold), and gene promoter activity (by 50%). HS also reduced LPS induced nuclear accumulation of transcription factor NF kappa B p65 subunit, suggesting perturbation of NF kappa B activation. A role for HS protein (HSP) 70 in NOS-2 suppression by HS is supported by the demonstration that 1) transfection with human HSP70 cDNA partially replicated HS effects; 2) antisense, but not sense, oligonucleotides directed against rat HSP70 partially blocked HS effects; and 3) rat fibroblasts stably expressing human HSP70 did not express NOS-2 in response to LPS plus cytokines. As with heat-shocked cells, HSP70 expressing cells also exhibited decreased NF kappa B p65 subunit nuclear accumulation. These results demonstrate that in glial cells, as well as other cell types, NOS-2 induction can be modulated by the HS response, mediated at least in part by HSP70 expression.	YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT NEUROL, BRONX, NY 10461 USA; MEM SLOAN KETTERING CANC CTR, RADIAT & HYPERTHERMIA BIOL LAB, NEW YORK, NY 10021 USA	Yeshiva University; Albert Einstein College of Medicine; Memorial Sloan Kettering Cancer Center	Feinstein, DL (corresponding author), CORNELL UNIV, COLL MED, DIV NEUROBIOL, 411 E 69TH ST, NEW YORK, NY 10021 USA.		Galea, Elena/E-1362-2011; feinstein, doug/M-9414-2019	Galea, Elena/0000-0003-4537-9897; 				BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BO L, 1994, ANN NEUROL, V36, P778, DOI 10.1002/ana.410360515; Bohen SP., 1994, BIOL HEAT SHOCK PROT, V26, P313; BROSNAN CF, 1994, DEV NEUROSCI-BASEL, V16, P152, DOI 10.1159/000112102; CHANDLER LJ, 1995, AM J PHYSIOL-CELL PH, V268, pC700, DOI 10.1152/ajpcell.1995.268.3.C700; COLASANTI M, 1995, J BIOL CHEM, V270, P26731, DOI 10.1074/jbc.270.45.26731; CORBETT JA, 1993, FASEB J, V7, P369, DOI 10.1096/fasebj.7.2.8440413; CROSS AH, 1994, J CLIN INVEST, V93, P2684, DOI 10.1172/JCI117282; DANG CV, 1989, J BIOL CHEM, V264, P18019; DIEHL EE, 1993, BIOCHEMISTRY-US, V32, P13510, DOI 10.1021/bi00212a016; DONG ZY, 1993, J LEUKOCYTE BIOL, V53, P53, DOI 10.1002/jlb.53.1.53; ENDOH M, 1993, NEUROSCI LETT, V154, P125, DOI 10.1016/0304-3940(93)90187-P; FEINSTEIN DL, 1993, J NEUROCHEM, V60, P1945, DOI 10.1111/j.1471-4159.1993.tb13425.x; FEINSTEIN DL, 1994, J NEUROCHEM, V62, P811; FEINSTEIN DL, 1994, J NEUROCHEM, V62, P315; GALEA E, 1994, J NEUROSCI RES, V37, P406, DOI 10.1002/jnr.490370313; Galea E, 1996, J NEUROIMMUNOL, V64, P19, DOI 10.1016/0165-5728(95)00143-3; GALEA E, 1992, P NATL ACAD SCI USA, V89, P10945, DOI 10.1073/pnas.89.22.10945; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; GRISCAVAGE JM, 1993, J IMMUNOL, V151, P6329; HEWETT SJ, 1993, NEUROSCI LETT, V164, P229, DOI 10.1016/0304-3940(93)90898-U; HOTCHKISS R, 1993, AM J PHYSIOL, V265, pR1447, DOI 10.1152/ajpregu.1993.265.6.R1447; HUNT C, 1985, P NATL ACAD SCI USA, V82, P6455, DOI 10.1073/pnas.82.19.6455; IMATAKA H, 1994, J BIOL CHEM, V269, P20668; JAATTELA M, 1993, J IMMUNOL, V151, P4286; KATO K, 1993, J BIOCHEM-TOKYO, V114, P640, DOI 10.1093/oxfordjournals.jbchem.a124230; KERTH V, 1994, EUR J PHARMACOL, V265, P83; KOPROWSKI H, 1993, P NATL ACAD SCI USA, V90, P3024, DOI 10.1073/pnas.90.7.3024; KOST SL, 1989, MOL CELL BIOL, V9, P3829, DOI 10.1128/MCB.9.9.3829; LEE SC, 1993, J NEUROIMMUNOL, V46, P19, DOI 10.1016/0165-5728(93)90229-R; LI GC, 1991, P NATL ACAD SCI USA, V88, P1681, DOI 10.1073/pnas.88.5.1681; LI GC, 1992, P NATL ACAD SCI USA, V89, P2036, DOI 10.1073/pnas.89.6.2036; MARBER MS, 1995, J CLIN INVEST, V95, P1446, DOI 10.1172/JCI117815; MARGULIS BA, 1991, DIABETES, V40, P1418, DOI 10.2337/diabetes.40.11.1418; MAULIK N, 1994, MOL CELL BIOCHEM, V137, P17, DOI 10.1007/BF00926035; MESTRIL R, 1994, BIOCHEM J, V298, P561, DOI 10.1042/bj2980561; MILLER EK, 1991, J NEUROCHEM, V56, P2060, DOI 10.1111/j.1471-4159.1991.tb03467.x; MULSCH A, 1993, FEBS LETT, V321, P215, DOI 10.1016/0014-5793(93)80111-7; MURPHY S, 1993, TRENDS NEUROSCI, V16, P323, DOI 10.1016/0166-2236(93)90109-Y; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; NISHIMURA RN, 1988, J NEUROSCI RES, V20, P12, DOI 10.1002/jnr.490200103; ORTREMSKI I, 1994, BR J RHEUMATOL, V33, P721; PARK SK, 1994, NEUROPHARMACOLOGY, V33, P1419, DOI 10.1016/0028-3908(94)90044-2; PARK SK, 1994, BIOCHEM BIOPH RES CO, V201, P762, DOI 10.1006/bbrc.1994.1766; PENG HB, 1995, J BIOL CHEM, V270, P14214, DOI 10.1074/jbc.270.23.14214; PRATT WB, 1990, MOL CELL ENDOCRINOL, V74, pC69, DOI 10.1016/0303-7207(90)90198-H; RADOMSKI MW, 1990, P NATL ACAD SCI USA, V87, P10043, DOI 10.1073/pnas.87.24.10043; RIBEIRO SP, 1993, AM REV RESPIR DIS, V147, pA95; RICE NR, 1993, EMBO J, V12, P4685, DOI 10.1002/j.1460-2075.1993.tb06157.x; SAMBROOK J, 1989, MOL CLONING LABORATO, P192; SANCHEZ ER, 1990, J BIOL CHEM, V265, P20123; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SILVER PA, 1991, CELL, V64, P489, DOI 10.1016/0092-8674(91)90233-O; SIMMONS ML, 1993, EUR J NEUROSCI, V5, P825, DOI 10.1111/j.1460-9568.1993.tb00934.x; SIMMONS ML, 1992, J NEUROCHEM, V59, P897, DOI 10.1111/j.1471-4159.1992.tb08328.x; SIMON MM, 1995, J CLIN INVEST, V95, P926, DOI 10.1172/JCI117800; SNYDER YM, 1992, J LEUKOCYTE BIOL, V51, P181, DOI 10.1002/jlb.51.2.181; SORGER PK, 1987, EMBO J, V6, P993, DOI 10.1002/j.1460-2075.1987.tb04850.x; SRINIVASAN G, 1994, MOL ENDOCRINOL, V8, P189, DOI 10.1210/me.8.2.189; VILLAR J, 1993, AM REV RESPIR DIS, V147, P177, DOI 10.1164/ajrccm/147.1.177; VODOVOTZ Y, 1993, J EXP MED, V178, P605, DOI 10.1084/jem.178.2.605; WALLACE MN, 1994, NEUROSCIENCE, V59, P905, DOI 10.1016/0306-4522(94)90294-1; WELCH WJ, 1984, J BIOL CHEM, V259, P4501; WELCH WJ, 1992, PHYSIOL REV, V72, P1063, DOI 10.1152/physrev.1992.72.4.1063; Wong HR, 1995, AM J PHYSIOL-LUNG C, V269, pL843, DOI 10.1152/ajplung.1995.269.6.L843; XIE QW, 1994, J BIOL CHEM, V269, P4705; XIE QW, 1993, J EXP MED, V177, P1779, DOI 10.1084/jem.177.6.1779	67	251	274	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					17724	17732		10.1074/jbc.271.30.17724	http://dx.doi.org/10.1074/jbc.271.30.17724			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663604	hybrid			2022-12-25	WOS:A1996UY93500023
J	Feng, ZY; Aggeler, R; Haughton, MA; Capaldi, RA				Feng, ZY; Aggeler, R; Haughton, MA; Capaldi, RA			Conformational changes in the Escherichia coli ATP synthase (ECF(1)F(0)) monitored by nucleotide-dependent differences in the reactivity of Cys-87 of the gamma subunit in the mutant beta Glu-381->Ala	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							F1 ADENOSINE-TRIPHOSPHATASE; COUPLING FACTOR-I; CRYOELECTRON MICROSCOPY; EPSILON-SUBUNIT; CATALYTIC SITES; MONOCLONAL-ANTIBODIES; STRUCTURAL-CHANGES; CYSTEINE RESIDUES; N-ETHYLMALEIMIDE; CROSS-LINKING	Cys-87, one of two intrinsic cysteines of the gamma subunit of the Escherichia coli ATP synthase (ECF(1)F(0)), is in a short segment of this subunit that binds to the bottom domain of a beta subunit close to a glutamate (Glu-381), Cys-87 was unreactive to maleimides under all conditions in wild-type ECF(1) and ECF(1)F(0) but became reactive when Glu-381 of beta was replaced by a cysteine or alanine, The reactivity of Cys-87 with maleimides was nucleotide-dependent, occurring with ATP or ADP + EDTA in catalytic sites, in the presence of AMP PNP + Mg2+ but not with ADP + Mg2+ bound, whether P-i was present or not, and not when nucleotide binding sites were empty, Binding of N-ethylmaleimide had no effect, whereas 7 diethyl-amino 3-(4'-maleimidylphenyl)-4-methylcoumarin increased the ATPase activity of ECF, more than 2-fold by reaction with Cys-87, In ECF(1)F(0), these reagents inhibited activity, The nucleotide dependence of the reaction of Cys-87 of the gamma subunit depended on the presence of the epsilon subunit, In epsilon subunit-free ECF(1), maleimides reacted with Cys-87 under all nucleotide conditions, including when catalytic sites were empty, These results are discussed in terms of nucleotide-dependent movements of the gamma subunit during functioning of the F1F0-type ATPase.	UNIV OREGON,INST MOL BIOL,EUGENE,OR 97403	University of Oregon			Haughton, Margaret/F-8033-2010		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL024526] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL24526] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; AGGELER R, 1993, J BIOL CHEM, V268, P14576; AGGELER R, 1992, J BIOL CHEM, V267, P21355; AGGELER R, 1995, J BIOL CHEM, V270, P9185, DOI 10.1074/jbc.270.16.9185; AGGELER R, 1992, BIOCHEMISTRY-US, V31, P2956, DOI 10.1021/bi00126a016; AGGELER R, 1987, BIOCHEMISTRY-US, V26, P7107, DOI 10.1021/bi00396a036; BOYER PD, 1993, BIOCHIM BIOPHYS ACTA, V1140, P215, DOI 10.1016/0005-2728(93)90063-L; CAPALDI RA, 1994, TRENDS BIOCHEM SCI, V19, P284, DOI 10.1016/0968-0004(94)90006-X; DOWNER NW, 1976, BIOCHEMISTRY-US, V15, P2930, DOI 10.1021/bi00658a036; DUNCAN TM, 1995, P NATL ACAD SCI USA, V92, P10964, DOI 10.1073/pnas.92.24.10964; DUNCAN TM, 1995, T BIOCH SOC, V23, P736; DUNN SD, 1986, ANAL BIOCHEM, V159, P35, DOI 10.1016/0003-2697(86)90304-0; FOSTER DL, 1979, J BIOL CHEM, V254, P8230; FUTAI M, 1989, ANNU REV BIOCHEM, V58, P111; GOGOL EP, 1989, BIOCHEMISTRY-US, V28, P4717, DOI 10.1021/bi00437a031; GOGOL EP, 1987, FEBS LETT, V219, P274, DOI 10.1016/0014-5793(87)80234-X; GOGOL EP, 1990, P NATL ACAD SCI USA, V87, P9585, DOI 10.1073/pnas.87.24.9585; GOGOL EP, 1989, BIOCHEMISTRY-US, V28, P4709, DOI 10.1021/bi00437a030; Gruber G, 1996, BIOCHEMISTRY-US, V35, P3875, DOI 10.1021/bi952949h; HATEFI Y, 1993, EUR J BIOCHEM, V218, P759, DOI 10.1111/j.1432-1033.1993.tb18431.x; HAUGHTON MA, 1995, J BIOL CHEM, V270, P20568, DOI 10.1074/jbc.270.35.20568; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOTSCHER HR, 1984, BIOCHEMISTRY-US, V23, P4140, DOI 10.1021/bi00313a020; LUCKEN U, 1990, BIOCHEMISTRY-US, V29, P5339; MCCARTY RE, 1973, BIOCHEMISTRY-US, V12, P1503, DOI 10.1021/bi00732a006; MENDELHARTVIG J, 1991, BIOCHIM BIOPHYS ACTA, V1060, P115, DOI 10.1016/S0005-2728(05)80126-4; MORONEY JV, 1984, J BIOL CHEM, V259, P7281; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; SENIOR AE, 1988, PHYSIOL REV, V68, P177, DOI 10.1152/physrev.1988.68.1.177; SOTEROPOULOS P, 1994, J BIOL CHEM, V269, P19810; TIEDGE H, 1985, P NATL ACAD SCI USA, V82, P7874, DOI 10.1073/pnas.82.23.7874; TURINA P, 1994, J BIOL CHEM, V269, P13465; TURINA P, 1994, BIOCHEMISTRY-US, V33, P14275, DOI 10.1021/bi00251a040; WATTS SD, 1995, FEBS LETT, V368, P235, DOI 10.1016/0014-5793(95)00658-V; WEBER J, 1994, J BIOL CHEM, V269, P20462; WISE JG, 1981, J BIOL CHEM, V256, P383; ZIEGLER M, 1994, J BIOL CHEM, V269, P4233	38	17	17	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					17986	17989		10.1074/jbc.271.30.17986	http://dx.doi.org/10.1074/jbc.271.30.17986			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663500	hybrid			2022-12-25	WOS:A1996UY93500062
J	Higazi, AAR; Ganz, T; Kariko, K; Cines, DB				Higazi, AAR; Ganz, T; Kariko, K; Cines, DB			Defensin modulates tissue-type plasminogen activator and plasminogen binding to fibrin and endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SEQUENCE; NEUTROPHIL DEFENSINS; PEPTIDE DEFENSINS; CRYSTAL-STRUCTURE; PANETH CELLS; HUMAN-PLASMA; ANNEXIN-II; T-PA; RECEPTOR; IDENTIFICATION	Defensins are naturally occurring antimicrobial peptides that may participate in host defense against microorganisms. We previously reported that the amino acid sequence of leukocyte defensins resembles the lysine-binding site in the kringles of plasminogen and that defensin inhibits fibrinolysis mediated by tissue-type plasminogen activator (tPA) and plasminogen. In the present paper we analyze the mechanisms of this inhibition. Defensin binds specifically to cultured human umbilical vein endothelial cells (HUVEC) (half maximal binding = 3 mu M) as well as to fibrin. At saturating concentrations (5-10 mu M), defensin stimulates the maximum binding of plasminogen to HUVEC and to fibrin approximately 10-fold. However, defensin inhibits plasminogen binding to both surfaces at concentrations >10 mu M. Defensin also inhibits tPA and plasminogen-mediated fibrinolysis in a dose-dependent manner at all concentrations tested. Fibrinolysis is almost totally inhibited by 6 mu M defensin, a concentration that stimulates the binding of plasminogen to fibrin. Discordance between the enhancement of plasminogen binding and its activation cannot be explained by an inhibitory effect of defensin on tPA binding nor by inhibition of plasmin activity, each of which occur only at higher concentrations. Rather, these results suggest that plasminogen bound to fibrin in the presence of defensin is less susceptible to activation by tPA.	UNIV PENN,DEPT PATHOL & LAB MED,PHILADELPHIA,PA 19104; UNIV PENN,DEPT NEUROSURG,PHILADELPHIA,PA 19104; UNIV CALIF LOS ANGELES,DEPT MED,DIV PULM & CRIT CARE,LOS ANGELES,CA 90095	University of Pennsylvania; University of Pennsylvania; University of California System; University of California Los Angeles			Ganz, Tomas/AAN-3308-2020; Ganz, Tomas/D-4567-2009	Ganz, Tomas/0000-0002-2830-5469	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL040387, R01HL049517] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL50970, HL49517, HL40387] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARNATHAN ES, 1988, J BIOL CHEM, V263, P7792; BEEBE DP, 1989, BLOOD, V74, P2034; BENSCH KW, 1995, FEBS LETT, V368, P331, DOI 10.1016/0014-5793(95)00687-5; CESARMAN GM, 1994, J BIOL CHEM, V269, P21198; CINES DB, 1984, J CLIN INVEST, V73, P611, DOI 10.1172/JCI111251; DEUTSCH DG, 1970, SCIENCE, V170, P1095, DOI 10.1126/science.170.3962.1095; DEVOS AM, 1992, BIOCHEMISTRY-US, V31, P270, DOI 10.1021/bi00116a037; EATON DL, 1987, P NATL ACAD SCI USA, V84, P3224, DOI 10.1073/pnas.84.10.3224; EDWARDS RL, 1978, SCIENCE, V200, P541, DOI 10.1126/science.644314; FLESS GM, 1984, J BIOL CHEM, V259, P1470; GANZ T, 1985, J CLIN INVEST, V76, P1427, DOI 10.1172/JCI112120; GANZ T, 1987, INFECT IMMUN, V55, P568, DOI 10.1128/IAI.55.3.568-571.1987; GRAINGER DJ, 1994, NATURE, V370, P460, DOI 10.1038/370460a0; HAJJAR KA, 1990, J BIOL CHEM, V265, P2908; HAJJAR KA, 1986, J BIOL CHEM, V261, P1656; HAJJAR KA, 1988, J CLIN INVEST, V82, P1769, DOI 10.1172/JCI113790; HAJJAR KA, 1994, J BIOL CHEM, V269, P21191; HARWIG SSL, 1994, METHOD ENZYMOL, V236, P160; HIGAZI AA, 1994, BIOCHEM J, V300, P251, DOI 10.1042/bj3000251; HIGAZI AAR, 1995, J BIOL CHEM, V270, P9472, DOI 10.1074/jbc.270.16.9472; HILL CP, 1991, SCIENCE, V251, P1481, DOI 10.1126/science.2006422; HU CK, 1994, BIOCHEMISTRY-US, V33, P11760, DOI 10.1021/bi00205a011; JONES DE, 1993, FEBS LETT, V315, P187, DOI 10.1016/0014-5793(93)81160-2; JONES DE, 1992, J BIOL CHEM, V267, P23216; KAGAN BL, 1994, TOXICOLOGY, V87, P131, DOI 10.1016/0300-483X(94)90158-9; LICHTENSTEIN A, 1986, BLOOD, V68, P1407; LICHTENSTEIN AK, 1988, J IMMUNOL, V140, P2686; LICHTENSTEIN AK, 1988, CELL IMMUNOL, V114, P104, DOI 10.1016/0008-8749(88)90258-4; LIU JN, 1994, BIOCHEMISTRY-US, V33, P2554, DOI 10.1021/bi00175a026; Menkin V, 1938, PHYSIOL REV, V18, P366, DOI 10.1152/physrev.1938.18.3.366; MILES LA, 1991, BIOCHEMISTRY-US, V30, P1682, DOI 10.1021/bi00220a034; OKRENT DG, 1990, AM REV RESPIR DIS, V141, P179, DOI 10.1164/ajrccm/141.1.179; PANYUTICH A, 1991, AM J RESP CELL MOL, V5, P101, DOI 10.1165/ajrcmb/5.2.101; PANYUTICH AV, 1995, AM J RESP CELL MOL, V12, P351, DOI 10.1165/ajrcmb.12.3.7873202; PANYUTICH AV, 1993, J LAB CLIN MED, V122, P202; PANYUTICH AV, 1994, FEBS LETT, V356, P169, DOI 10.1016/0014-5793(94)01261-X; SELSTED ME, 1985, J CLIN INVEST, V76, P1436, DOI 10.1172/JCI112121; SELSTED ME, 1989, J BIOL CHEM, V264, P4003; VICTOR J., 1994, HEMOSTASIS THROMBOSI, P1023	39	61	66	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					17650	17655		10.1074/jbc.271.30.17650	http://dx.doi.org/10.1074/jbc.271.30.17650			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663495	hybrid			2022-12-25	WOS:A1996UY93500013
J	Johnson, MD; Wang, XH				Johnson, MD; Wang, XH			Differentially expressed forms of 1-L-myo-inositol-1-phosphate synthase (EC 5.5.1.4) in Phaseolus vulgaris	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYO-INOSITOL-1-PHOSPHATE SYNTHASE; CATALYTIC PROPERTIES; STRUCTURAL GENE; TRANSIT PEPTIDE; INOSITOL; BIOSYNTHESIS; PURIFICATION; 1-PHOSPHATE; PROTEINS; 6-PHOSPHATE	We have characterized two distinct polypeptides with 1-L-myo-inositol-1-phosphate synthase (MI-1-P synthase) activity that are differentially expressed during development in Phaseolus vulgaris. Western analyses, enzyme assays, and partial purification of MI-1-P synthase during embryonic and postembryonic development show that its expression is temporally and spatially regulated. Developmental Western analyses of soluble proteins detect a small protein, approximately 33 kDa, with MI-1-P synthase activity during the globular stage (stage II) of embryogenesis and in mature roots. Expression of this small protein is also enriched in thylakoidal membranes of fractionated leaf chloroplasts, although Western analyses of total soluble leaf proteins show no cross-reacting material, In contrast, a larger protein, approximately 56 kDa, with MI-1-P synthase activity is present during the cotyledonary phase (stage IV) of embryogenesis in green cotyledons of seedlings and in young roots.			Johnson, MD (corresponding author), UNIV ALABAMA, DEPT SCI BIOL, BOX 870344, TUSCALOOSA, AL 35487 USA.							ADHIKARI J, 1987, PLANT PHYSIOL, V85, P611, DOI 10.1104/pp.85.3.611; BARNETT JEG, 1970, BIOCHEM J, V119, P183, DOI 10.1042/bj1190183; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAI D, 1993, PLANT J, V3, P383, DOI 10.1046/j.1365-313X.1993.t01-21-00999.x; CERFF R, 1982, METHODS CHLOROPLAST, P683; CHEN IW, 1966, J BIOL CHEM, V241, P2194; Colas de Francs C., 1985, PLANT PHYSIOL, V78, P178; DEANJOHNSON M, 1989, J BIOL CHEM, V264, P1274; DONAHUE TF, 1981, J BIOL CHEM, V256, P7077; DROBAK BK, 1992, BIOCHEM J, V288, P697, DOI 10.1042/bj2880697; EISENBERG F, 1964, BIOCHEM BIOPH RES CO, V14, P419, DOI 10.1016/0006-291X(64)90079-8; EISENBERG F, 1963, BIOCHEM BIOPH RES CO, V12, P72, DOI 10.1016/0006-291X(63)90416-9; HILL R, 1960, NATURE, V186, P136, DOI 10.1038/186136a0; HOKIN LE, 1985, ANNU REV BIOCHEM, V54, P205, DOI 10.1146/annurev.biochem.54.1.205; IMHOFF V, 1973, PHYTOCHEMISTRY, V12, P331, DOI 10.1016/0031-9422(73)80014-7; JOHNSON MD, 1995, PLANT PHYSIOL, V107, P613, DOI 10.1104/pp.107.2.613; JOHNSON MD, 1994, PLANT PHYSIOL, V105, P1023, DOI 10.1104/pp.105.3.1023; JOHNSON MD, 1995, PLANT PHYSIOL, V109, P721; KIELY DE, 1975, J AM CHEM SOC, V97, P6810, DOI 10.1021/ja00856a035; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMPPA GK, 1988, J BIOL CHEM, V263, P14996; LOEWUS FA, 1962, BIOCHEM BIOPH RES CO, V7, P204, DOI 10.1016/0006-291X(62)90175-4; LOEWUS FA, 1990, INOSITOL METABOLISM, V9, P13; LOEWUS MW, 1971, PLANT PHYSIOL, V48, P255, DOI 10.1104/pp.48.3.255; LOEWUS MW, 1986, ACTA BOT NEERL, V35, P347, DOI 10.1111/j.1438-8677.1986.tb01296.x; LOEWUS MW, 1973, PLANT SCI LETT, V1, P65; LUCK H, 1962, CATALASE METHODS ENZ, P885; MAEDA T, 1980, J BIOL CHEM, V255, P8458; OGUNYEMI EO, 1978, H-S Z PHYSIOL CHEM, V359, P613; ROBINSON C, 1988, ISOLATION ANAL CHLOR, P1; SHERMAN WR, 1977, J BIOL CHEM, V252, P5672; SMITH IK, 1973, BIOCHIM BIOPHYS ACTA, V321, P156, DOI 10.1016/0005-2744(73)90069-7; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TREVELYAN WE, 1950, NATURE, V166, P444, DOI 10.1038/166444b0; VIITANEN PV, 1988, J BIOL CHEM, V263, P15000; WALBOT V, 1972, PHYTOMORPHOLOGY, V22, P59; WANG CT, 1971, BIOCHIM BIOPHYS ACTA, V241, P200, DOI 10.1016/0005-2736(71)90317-8; WANG X, 1995, PLANT PHYSIOL, V110, P336; WONG YHH, 1985, J BIOL CHEM, V260, P1083	41	34	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					17215	17218		10.1074/jbc.271.29.17215	http://dx.doi.org/10.1074/jbc.271.29.17215			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663488	hybrid			2022-12-25	WOS:A1996UX94300038
J	Oates, AJ; Barraclough, R; Rudland, PS				Oates, AJ; Barraclough, R; Rudland, PS			The identification of osteopontin as a metastasis-related gene product in a rodent mammary tumour model	ONCOGENE			English	Article						mammary metastasis; subtractive hybridization; osteopontin (OPN)	EPITHELIAL-CELL LINE; RAT; HYBRIDIZATION; TRANSFECTION; VARIANTS; PROTEIN; CANCER; BONE	The rat mammary epithelial cell line, Rama 37, yields benign, non-metastasizing adenomatous tumours in syngeneic Furth-Wistar rats. Transfection of this stably diploid cell line with genomic DNA fragments from a human metastasizing breast cancer cell line yields cells which, when injected subcutaneously in syngeneic rats, give rise to secondary tumours in a number of the animals. From one such secondary lung tumour, a cell line was established designated Ca2-5-LT1. This cell line, when introduced into the syngeneic rat host, also showed the ability to metastasise. To determine key changes in gene expression that occur during the progression from Rama 37, the benign tumour-inducing cell line, to the metastatic derivative Ca2-5-LT1, a general method of subtractive hybridization has been employed. This procedure in conjunction with Northern blotting and nucleic acid sequencing has been used to identify mRNAs expressed differentially between the metastatic and nonmetastatic cell lines described above. So far, of the subtracted cDNAs that have been identified which represent differentially expressed mRNAs, a large proportion of these cDNAs corresponded to the mRNA for rat osteopontin (OPN). The mRNA for OPN was expressed at a ninefold higher level in the metastatic Ca2-5-LT1 cell Une when compared to the nonmetastatic parental Rama 37 cell Line. Rama 37 cells transfected with DNA from a human benign cell line failed to show elevated levels of OPN mRNA. Following transfection of Rama 37 cells with an expression-construct producing elevated levels of OPN, the newly-transfected cells, when introduced into the rat host, developed metastases in 55% of the animals that produced primary tumours. These experiments show that increasing the expression of OPN in a previously benign cell line is sufficient to produce a metastatic phenotype in this particular rat mammary model.	UNIV LIVERPOOL,DEPT BIOCHEM,CANC & POLIO RES FUND LABS,LIVERPOOL L69 3BX,MERSEYSIDE,ENGLAND	University of Liverpool			Barraclough, Roger/AAH-6516-2020	Barraclough, Roger/0000-0002-7203-1194				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BARRACLOUGH R, 1987, J CELL PHYSIOL, V131, P393, DOI 10.1002/jcp.1041310311; BEHREND EI, 1994, CANCER RES, V54, P832; BROWN LF, 1992, MOL BIOL CELL, V3, P1169, DOI 10.1091/mbc.3.10.1169; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DAVIES BR, 1993, ONCOGENE, V8, P999; DAVIES BR, 1994, CANCER RES, V54, P2785; DENHARDT DT, 1993, FASEB J, V7, P1475, DOI 10.1096/fasebj.7.15.8262332; DERRICO JA, 1995, J PERIODONTAL RES, V30, P34, DOI 10.1111/j.1600-0765.1995.tb01250.x; DUNNINGTON DJ, 1983, J NATL CANCER I, V71, P1227; DUNNINGTON DJ, 1984, CANCER RES, V44, P5338; FELDINGHABERMANN B, 1992, J BIOL CHEM, V267, P5070; FENG B, 1995, CLIN EXP METASTAS, V13, P453, DOI 10.1007/BF00118184; GARDNER HAR, 1994, ONCOGENE, V9, P2321; HAN JH, 1987, BIOCHEMISTRY-US, V26, P1617, DOI 10.1021/bi00380a020; HOLMES DS, 1981, ANAL BIOCHEM, V114, P193, DOI 10.1016/0003-2697(81)90473-5; JAMIESON S, 1990, PATHOBIOLOGY, V58, P329, DOI 10.1159/000163605; MIYAUCHI A, 1991, J BIOL CHEM, V266, P20369; OWENS GP, 1991, MOL CELL BIOL, V11, P4177, DOI 10.1128/MCB.11.8.4177; PRINCE CW, 1987, J BIOL CHEM, V262, P2900; REINHOLT FP, 1990, P NATL ACAD SCI USA, V87, P4473, DOI 10.1073/pnas.87.12.4473; RUBENSTEIN JLR, 1990, NUCLEIC ACIDS RES, V18, P4833, DOI 10.1093/nar/18.16.4833; RUDLAND PS, 1985, CANCER RES, V45, P3864; Sambrook J., 2002, MOL CLONING LAB MANU; SCHWEINFEST CW, 1992, INT J ONCOL, V1, P499; SIVE HL, 1988, NUCLEIC ACIDS RES, V16, P10937, DOI 10.1093/nar/16.22.10937	26	155	166	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 4	1996	13	1					97	104						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UX319	8700559				2022-12-25	WOS:A1996UX31900011
J	Wallace, H; Clarke, AR; Harrison, DJ; Hooper, ML; Bishop, JO				Wallace, H; Clarke, AR; Harrison, DJ; Hooper, ML; Bishop, JO			Ganciclovir-induced ablation of non-proliferating thyrocytes expressing herpesvirus thymidine kinase occurs by p53-independent apoptosis	ONCOGENE			English	Article						herpes simplex virus; thymidine kinase; apoptosis; p53; transgenic mice	CELLS; DNA; GROWTH	In adult mice of the transgenic strain TG66.19, in which expression of herpes simplex type 1 virus thymidine kinase (HSV1-TK) is driven in thyrocytes from the thyroglobulin promoter, the drug Ganciclovir causes the death (ablation) of thyrocytes. Ablation occurred in the absence of thyrocyte proliferation or nuclear DNA synthesis, but was accompanied by transient expression of proliferating cell nuclear antigen and the dying thyrocytes exhibited the ultrastructural features of apoptosis, Control experiments show that the apoptosis is a result of the production of Ganciclovir phosphates in thyrocytes that express HSV1-TK. However, cell death was not dependent upon the presence of a functional copy of the oncosuppressor gene p53, We conclude that the apoptosis is probably not mediated by induction of DNA damage and occurs via a pathway that is independent of p53, The fact that Ganciclovir phosphate can kill cells by a p53-independent apoptotic pathway is encouraging in relation to tumour ablation by methods based on transfection with HSV1-tk genes and administration of Ganciclovir.	UNIV EDINBURGH, CTR GENOME RES, EDINBURGH EH9 3JQ, MIDLOTHIAN, SCOTLAND; UNIV EDINBURGH, DEPT PATHOL, CRC LABS, EDINBURGH EH8 9AG, MIDLOTHIAN, SCOTLAND	University of Edinburgh; University of Edinburgh			clarke, alan r/P-2820-2014; Clarke, Alan R/A-6256-2008	Clarke, Alan/0000-0002-4281-426X				BELLAMY COC, 1995, SEMIN CANCER BIOL, V6, P3, DOI 10.1006/scbi.1995.0002; BURTON K, 1967, METHOD ENZYMOL, V8, P162; CHENG YC, 1983, P NATL ACAD SCI-BIOL, V80, P2767, DOI 10.1073/pnas.80.9.2767; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CLARKE AR, 1995, ONCOGENE, V11, P1913; CLARKE AR, 1994, ONCOGENE, V9, P1767; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; COLOMBEL M, 1992, CANCER RES, V52, P4313; COLOMBO BM, 1995, HUM GENE THER, V6, P763, DOI 10.1089/hum.1995.6.6-763; CULVER KW, 1994, TRENDS GENET, V10, P174, DOI 10.1016/0168-9525(94)90095-7; DEMARTYNOFF G, 1987, EUR J BIOCHEM, V164, P591, DOI 10.1111/j.1432-1033.1987.tb11168.x; FARQUHARSON C, 1990, BONE MINER, V10, P121, DOI 10.1016/0169-6009(90)90087-V; FREEMAN SM, 1993, CANCER RES, V53, P5274; GREENLUND LJS, 1995, NEURON, V14, P303, DOI 10.1016/0896-6273(95)90287-2; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HOWIE SEM, 1994, CLIN EXP IMMUNOL, V95, P195; JACOBSON MD, 1993, NATURE, V361, P365, DOI 10.1038/361365a0; KANEKO Y, 1995, CANCER LETT, V96, P105, DOI 10.1016/0304-3835(95)03919-N; Kato Kyozo, 1994, Neurologia Medico-Chirurgica, V34, P339, DOI 10.2176/nmc.34.339; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; Maxam A M, 1980, Methods Enzymol, V65, P499; MERRITT AJ, 1994, CANCER RES, V54, P614; ROUACH EY, 1991, NATURE, V352, P345; RUBNITZ J, 1985, MOL CELL BIOL, V5, P529, DOI 10.1128/MCB.5.3.529; SAMEJIMA Y, 1995, GENE THER, V2, P50; SANDSTROM PA, 1993, P NATL ACAD SCI USA, V90, P4708, DOI 10.1073/pnas.90.10.4708; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; SMEDS S, 1983, ENDOCRINOLOGY, V112, P1718, DOI 10.1210/endo-112-5-1718; SMEE DF, 1983, ANTIMICROB AGENTS CH, V23, P676, DOI 10.1128/AAC.23.5.676; STCLAIR MH, 1987, ANTIMICROB AGENTS CH, V31, P844, DOI 10.1128/AAC.31.6.844; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; TOSCHI L, 1988, J CELL BIOL, V107, P1623, DOI 10.1083/jcb.107.5.1623; UEDA N, 1992, J CLIN INVEST, V90, P2593, DOI 10.1172/JCI116154; WALLACE H, 1995, J ENDOCRINOL, V145, P251, DOI 10.1677/joe.0.1450251; WALLACE H, 1991, ENDOCRINOLOGY, V129, P3217, DOI 10.1210/endo-129-6-3217; WALLACE H, 1994, J ENDOCRINOL, V143, P107, DOI 10.1677/joe.0.1430107; WARTERS RL, 1992, CANCER RES, V52, P883; WOLVETANG EJ, 1994, FEBS LETT, V339, P40, DOI 10.1016/0014-5793(94)80380-3	38	37	40	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 4	1996	13	1					55	61						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UX319	8700554				2022-12-25	WOS:A1996UX31900007
J	Spitkovsky, D; JansenDurr, P; Karsenti, E; Hoffmann, I				Spitkovsky, D; JansenDurr, P; Karsenti, E; Hoffmann, I			S-phase induction by adenovirus E1A requires activation of cdc25A tyrosine phosphatase	ONCOGENE			English	Article						E1A; oncogene; cdc25 phosphatase; cell cycle	CELL-CYCLE; PROTEIN-KINASE; PHOSPHORYLATION; IDENTIFICATION; MICROINJECTION; MITOSIS; BINDING; SYSTEM; GROWTH; CDK2	Adenovirus EIA proteins can induce quiescent cells to enter S-phase and also affect the expression of cellular genes including various cell cycle regulators. Here we show that human cdc25A, a tyrosine phosphatase involved in regulation of the G1/S-phase transition of the cell cycle, is a target of the adenovirus E1A protein in virus-infected human fibroblasts, Expression of E1A in quiescent fibroblasts leads to a rapid increase in cdc25A phosphatase activity and also increases both cdc25A and cyclin E gene expression. Inhibition of cdc25A function by antibody injection prevents virus-induced entry into S-phase. These results indicate that induction of high levels of cdc25A and its potential positive regulator cyclin E mediates the ability of E1A to induce S-phase in the presence of antiproliferative signals.	DEUTSCH KREBSFORSCHUNGSZENTRUM, D-69120 HEIDELBERG, GERMANY; EUROPEAN MOLEC BIOL LAB, CELL BIOL PROGRAMME, D-69012 HEIDELBERG, GERMANY	Helmholtz Association; German Cancer Research Center (DKFZ); European Molecular Biology Laboratory (EMBL)			Jansen-Dürr, Pidder/ABG-2466-2020	Jansen-Dürr, Pidder/0000-0001-7771-3429				ANSORGE W, 1988, J BIOCHEM BIOPH METH, V16, P283, DOI 10.1016/0165-022X(88)90062-0; BERK AJ, 1986, ANNU REV GENET, V20, P45, DOI 10.1146/annurev.ge.20.120186.000401; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; DYSON N, 1992, J VIROL, V66, P6893, DOI 10.1128/JVI.66.12.6893-6902.1992; FAHA B, 1993, J VIROL, V67, P2456, DOI 10.1128/JVI.67.5.2456-2465.1993; GALAKTIONOV K, 1991, CELL, V67, P1181, DOI 10.1016/0092-8674(91)90294-9; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HOFFMANN I, 1993, EMBO J, V12, P53, DOI 10.1002/j.1460-2075.1993.tb05631.x; HOFFMANN I, 1994, EMBO J, V13, P4302, DOI 10.1002/j.1460-2075.1994.tb06750.x; HOFFMANN I, 1994, J CELL SCI, P75; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; KREK W, 1991, EMBO J, V10, P305, DOI 10.1002/j.1460-2075.1991.tb07951.x; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MORRIS GF, 1994, MOL CELL BIOL, V14, P543, DOI 10.1128/MCB.14.1.543; MURRAY A, 1994, CURR OPIN CELL BIOL, V6, P872, DOI 10.1016/0955-0674(94)90059-0; NORBURY C, 1991, EMBO J, V10, P3321, DOI 10.1002/j.1460-2075.1991.tb04896.x; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PAGANO M, 1992, ONCOGENE, V7, P1681; PEPPERKOK R, 1988, P NATL ACAD SCI USA, V85, P6748, DOI 10.1073/pnas.85.18.6748; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; SEBASTIAN B, 1993, P NATL ACAD SCI USA, V90, P3521, DOI 10.1073/pnas.90.8.3521; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SOLOMON MJ, 1992, MOL BIOL CELL, V3, P13, DOI 10.1091/mbc.3.1.13; SPITKOVSKY D, 1994, J VIROL, V68, P2206, DOI 10.1128/JVI.68.4.2206-2214.1994; WANG HGH, 1993, J VIROL, V67, P476, DOI 10.1128/JVI.67.1.476-488.1993; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7	32	37	37	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 20	1996	12	12					2549	2554						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UW487	8700513				2022-12-25	WOS:A1996UW48700008
J	Zippel, R; Orecchia, S; Sturani, E; Martegani, E				Zippel, R; Orecchia, S; Sturani, E; Martegani, E			The brain specific ras exchange factor CDC25(Mm): Modulation of its activity through Gi-protein-mediated signals	ONCOGENE			English	Article						Ras; exchange factors; GEF; LPA; Ras-GRF	NUCLEOTIDE-RELEASING FACTOR; GROWTH-FACTOR; RECEPTOR; GRB2; IDENTIFICATION; P21(RAS); FIBROBLASTS; ACTIVATION; EXPRESSION; COMPLEX	CDC25(Mm) is a mouse guanine nucleotide exchange factor specific for Ras, exclusively expressed in the Brain. We used a reporter gene containing a Ras-responsive fos-promoter in order to gain information on the role played by this exchange factor in signal transduction. Transient expression of CDC25(Mm) in CHO cells activates Ras, Moreover serum, but not insulin, can upregulate the response mediated by CDC25(Mm) and this modulation requires that the CDC25(Mm) maintains its N-terminal region, NIH3T3 fibroblasts, stably overexpressing this exchange factor, show a partially transformed phenotype, suggesting that the Ras-dependent pathway is constitutively active. In these cells serum and lysophosphatidic acid (LPA) stimulate Ras activity above the basal level while PDGF does not. Both serum and LPA-induced Ras activations in CDC25(Mm) overexpressing cells can be completely inhibited by pertussis toxin, Moreover, these responses are strongly reduced by coexpression of a truncated version of CDC25(Mm) lacking the C-terminal catalytic portion, This construct behaves in a dominant negative manner suggesting that it may compete with CDC25(Mm) by sequestering in an unproductive way signalling components activated by these factors, The data presented indicate that CDC25(Mm) does not participate in connecting tyrosine, kinase receptors with Ras, while it could mediate Ras activation induced by pertussis toxin sensitive Gi-coupled receptors.			Zippel, R (corresponding author), UNIV MILAN,DEPT GEN PHYSIOL & BIOCHEM,VIA CELORIA 26,I-20133 MILAN,ITALY.			Martegani, Enzo/0000-0001-9196-4224				BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOLLAG G, 1991, ANNU REV CELL BIOL, V7, P601, DOI 10.1146/annurev.cellbio.7.1.601; BOURNE HR, 1995, NATURE, V376, P727, DOI 10.1038/376727a0; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CEN H, 1992, EMBO J, V11, P4007, DOI 10.1002/j.1460-2075.1992.tb05494.x; CEN H, 1993, MOL CELL BIOL, V13, P7718, DOI 10.1128/MCB.13.12.7718; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; COCCETTI P, 1995, BIOCHEM BIOPH RES CO, V206, P253, DOI 10.1006/bbrc.1995.1035; FARNSWORTH CL, 1995, NATURE, V376, P524, DOI 10.1038/376524a0; FEIG LA, 1994, CURR OPIN CELL BIOL, V6, P204, DOI 10.1016/0955-0674(94)90137-6; FERRARI C, 1994, EXP CELL RES, V210, P353, DOI 10.1006/excr.1994.1048; GIBSON TJ, 1994, TRENDS BIOCHEM SCI, V19, P349, DOI 10.1016/0968-0004(94)90108-2; HOWE LR, 1993, J BIOL CHEM, V268, P20717; JACQUET E, 1992, J BIOL CHEM, V267, P24181; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MARTEGANI E, 1992, EMBO J, V11, P2151, DOI 10.1002/j.1460-2075.1992.tb05274.x; MARTEGANI E, 1993, EUR J HISTHCEM, V37, P73; MEDEMA RH, 1991, MOL CELL BIOL, V11, P5963, DOI 10.1128/MCB.11.12.5963; MOOLENAAR WH, 1995, CURR OPIN CELL BIOL, V7, P203, DOI 10.1016/0955-0674(95)80029-8; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SCHWEIGHOFFER F, 1993, ONCOGENE, V8, P1477; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; SHOU CC, 1995, ONCOGENE, V10, P1887; STURANI E, 1989, FEBS LETT, V255, P191, DOI 10.1016/0014-5793(89)81089-0; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; VANCORVEN EJ, 1993, P NATL ACAD SCI USA, V90, P1257, DOI 10.1073/pnas.90.4.1257; WEI W, 1994, GENE, V151, P279, DOI 10.1016/0378-1119(94)90671-8; WEI W, 1993, MOL BRAIN RES, V19, P339, DOI 10.1016/0169-328X(93)90136-D; ZIPPEL R, 1986, BIOCHIM BIOPHYS ACTA, V881, P54, DOI 10.1016/0304-4165(86)90096-6; ZIPPEL R, 1994, INT J ONCOL, V4, P175	34	35	37	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 20	1996	12	12					2697	2703						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UW487	8700529				2022-12-25	WOS:A1996UW48700024
J	Caldenhoven, E; vanDijk, TB; Solari, R; Armstrong, J; Raaijmakers, JAM; Lammers, JWJ; Koenderman, L; deGroot, RP				Caldenhoven, E; vanDijk, TB; Solari, R; Armstrong, J; Raaijmakers, JAM; Lammers, JWJ; Koenderman, L; deGroot, RP			STAT3 beta, a splice variant of transcription factor STAT3, is a dominant negative regulator of transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; HUMAN EOSINOPHILS; INTERFERON-ALPHA; TYROSINE PHOSPHORYLATION; HUMAN INTERLEUKIN-5; MESSENGER-RNA; GM-CSF; ACTIVATOR; RECEPTOR; GENE	The 89-kDa STAT3 protein is a latent transcription factor which is activated in response to cytokines (interleukin (IL)-5 and -6) and growth factors (epidermal growth factor). Binding of IL-5 to its specific receptor activates JAK2 which leads to the tyrosine phosphorylation of STAT3 proteins. Here we report the cloning of a cDNA encoding a variant of the transcription factor STAT3 (named STAT3 beta) which was isolated by screening an eosinophil cDNA library. Compared to wild-type STAT3, STAT3 beta lacks an internal domain of 50 base pairs located near the C terminus, This splice product is a naturally occurring isoform of STAT3 and encodes a 80-kDa protein. We found by reconstitution of the human IL-5R in COS cells that like STAT3, STAT3 beta is phosphorylated on tyrosine and binds to the pIRE from the ICAM-1 promoter after IL-5 stimulation. However, STAT3 beta fails to activate a pIRE containing promoter in transient transfection assays. Instead, co-expression of STAT3 beta inhibits the transactivation potential of STAT3. These results suggests that STAT3 beta functions as a negative regulator of transcription.	UNIV UTRECHT HOSP,DEPT PULM DIS,3584 CX UTRECHT,NETHERLANDS; GLAXO WELLCOME MED RES CTR,STEVENAGE SG1 2NY,HERTS,ENGLAND	Utrecht University; Utrecht University Medical Center; GlaxoSmithKline			Koenderman, Leo/AAE-7870-2020	Koenderman, Leo/0000-0002-5636-6453	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; ARAI K, 1990, ANNU REV BIOCHEM, V59, P783, DOI 10.1146/annurev.biochem.59.1.783; BOULTON TG, 1995, P NATL ACAD SCI USA, V92, P6915, DOI 10.1073/pnas.92.15.6915; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; CALDENHOVEN E, 1994, J BIOL CHEM, V269, P21146; CALDENHOVEN E, 1995, J BIOL CHEM, V270, P25778, DOI 10.1074/jbc.270.43.25778; CAMPBELL HD, 1987, P NATL ACAD SCI USA, V84, P6629, DOI 10.1073/pnas.84.19.6629; CHIHARA J, 1990, J EXP MED, V172, P1347, DOI 10.1084/jem.172.5.1347; CLUTTERBUCK EJ, 1989, BLOOD, V73, P1504; DEGROOT RP, 1993, EMBO J, V12, P3903, DOI 10.1002/j.1460-2075.1993.tb06068.x; DELMAS V, 1992, P NATL ACAD SCI USA, V89, P4226, DOI 10.1073/pnas.89.10.4226; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; Fattah D, 1996, CYTOKINE, V8, P248, DOI 10.1006/cyto.1996.0034; FOULKES NS, 1992, CELL, V68, P411, DOI 10.1016/0092-8674(92)90178-F; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; FU XY, 1992, P NATL ACAD SCI USA, V89, P7840, DOI 10.1073/pnas.89.16.7840; FU XY, 1990, P NATL ACAD SCI USA, V87, P8555, DOI 10.1073/pnas.87.21.8555; FUJISAWA T, 1990, J IMMUNOL, V144, P642; GOUILLEUX F, 1994, EMBO J, V13, P4361, DOI 10.1002/j.1460-2075.1994.tb06756.x; GOUILLEUX F, 1995, EMBO J, V14, P2005, DOI 10.1002/j.1460-2075.1995.tb07192.x; GRAHAM FL, 1973, MOL CELL BIOL, V2, P607; HANSEL TT, 1991, J IMMUNOL METHODS, V145, P105, DOI 10.1016/0022-1759(91)90315-7; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; INGLEY E, 1991, BLOOD, V78, P339; JACOBSON NG, 1995, J EXP MED, V181, P1755, DOI 10.1084/jem.181.5.1755; KRESS C, 1990, DEVELOPMENT, V109, P775; KUANG AA, 1993, MOL CELL BIOL, V13, P2536, DOI 10.1128/MCB.13.4.2536; LOPEZ AF, 1988, J EXP MED, V167, P219, DOI 10.1084/jem.167.1.219; LOPEZ AF, 1992, IMMUNOL TODAY, V13, P495, DOI 10.1016/0167-5699(92)90025-3; LUTTICKEN C, 1995, FEBS LETT, V360, P137, DOI 10.1016/0014-5793(95)00076-L; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; NAKABEPPU Y, 1991, CELL, V64, P751, DOI 10.1016/0092-8674(91)90504-R; OGAWA M, 1993, BLOOD, V81, P2844; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; ROMAN C, 1991, SCIENCE, V254, P94, DOI 10.1126/science.1840705; SANDERSON CJ, 1985, J EXP MED, V162, P60, DOI 10.1084/jem.162.1.60; SATO S, 1994, J EXP MED, V180, P2101, DOI 10.1084/jem.180.6.2101; SCHAEFER TS, 1995, P NATL ACAD SCI USA, V92, P9097, DOI 10.1073/pnas.92.20.9097; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SHEN S, 1993, MECH DEVELOP, V40, P177, DOI 10.1016/0925-4773(93)90075-9; SILBERSTEIN DS, 1986, J IMMUNOL, V137, P3290; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; TAVERNIER J, 1991, CELL, V66, P1175, DOI 10.1016/0092-8674(91)90040-6; TRUSS M, 1993, ENDOCR REV, V14, P459, DOI 10.1210/er.14.4.459; VANDERBRUGGEN T, 1994, J IMMUNOL, V153, P2729; VANDERBRUGGEN T, 1995, BLOOD, V85, P1442, DOI 10.1182/blood.V85.6.1442.bloodjournal8561442; VANDERBRUGGEN T, 1993, J LEUKOCYTE BIOL, V53, P347, DOI 10.1002/jlb.53.4.347; WEGENKA UM, 1994, MOL CELL BIOL, V14, P3186, DOI 10.1128/MCB.14.5.3186; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; YAMAMOTO K, 1994, MOL CELL BIOL, V14, P4342, DOI 10.1128/MCB.14.7.4342; YAN RQ, 1995, NUCLEIC ACIDS RES, V23, P459, DOI 10.1093/nar/23.3.459; ZANDERS ED, 1994, EUR CYTOKINE NETW, V5, P35; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	61	306	319	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					13221	13227		10.1074/jbc.271.22.13221	http://dx.doi.org/10.1074/jbc.271.22.13221			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8675499	hybrid			2022-12-25	WOS:A1996UN47400082
J	Olney, JJ; Sellers, JR; Cremo, CR				Olney, JJ; Sellers, JR; Cremo, CR			Structure and function of the 10S conformation of smooth muscle myosin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATORY LIGHT-CHAIN; HEAVY-MEROMYOSIN; ACTIVE-SITE; ATPASE ACTIVITY; GIZZARD MYOSIN; PHOSPHORYLATION; FILAMENTS; IDENTIFICATION; CONTRACTION; TRANSITION	Smooth myosin regulatory light chain (RLC) was exchanged with RLC labeled with benzophenone-4-iodoacetamide at Cys-108. Irradiation under conditions that favor the folded (10 S) conformation resulted in 10 S cross-linked myosin that could not unfold. Purified 10 S cross-linked myosin was cross-linked between the RLC of one head to light meromyosin between leucine 1554 and glutamate 1583, adjacent to a predicted noncoiled region, approximately 60 nn from the tip of the tail. At high ionic strength without actin, product release from one-half of the heads was slow (like 10 S) whereas the other half were activated. This suggests that tail binding to the RLC carboxyl-terminal domain stabilizes ionic interactions important to slow nucleotide release. With actin, product release from both (un)phosphorylated 10 S cross-linked myosin was from one slow population similar to unphosphorylated filaments. 10 S cross-linked myosin weakly bound actin (dissociation constant > 500 mu M) and did not move actin in vitro. Single-headed myosin did not fold or trap nucleotide, These and other data suggest that ''trapping'' occurs only with both heads and the tail binds to a newly formed site, which includes the RLC carboxyl-terminal domain, once trapping has occurred.	WASHINGTON STATE UNIV, DEPT BIOCHEM & BIOPHYS, PULLMAN, WA 99164 USA; NHLBI, MOL CARDIOL LAB, NIH, BETHESDA, MD 20892 USA	Washington State University; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)								ADELSTEIN RS, 1982, METHOD ENZYMOL, V85, P298; ANDERSON WL, 1975, ANAL BIOCHEM, V67, P493, DOI 10.1016/0003-2697(75)90323-1; ANKRETT RJ, 1991, J MOL BIOL, V217, P323, DOI 10.1016/0022-2836(91)90546-I; APPLEGATE D, 1992, J CELL BIOL, V117, P1223, DOI 10.1083/jcb.117.6.1223; BERGER B, 1995, P NATL ACAD SCI USA, V92, P8259, DOI 10.1073/pnas.92.18.8259; Blough ER, 1996, ANAL BIOCHEM, V233, P31, DOI 10.1006/abio.1996.0003; CHALOVICH JM, 1992, PHARMACOL THERAPEUT, V55, P95, DOI 10.1016/0163-7258(92)90013-P; CITI S, 1989, J CELL BIOL, V109, P549, DOI 10.1083/jcb.109.2.549; COLE DG, 1990, J BIOL CHEM, V265, P22537; COLE DG, 1992, BIOCHEMISTRY-US, V31, P6186, DOI 10.1021/bi00142a003; CRAIG R, 1987, J CELL BIOL, V105, P1319, DOI 10.1083/jcb.105.3.1319; CREMO CR, 1995, J BIOL CHEM, V270, P2171, DOI 10.1074/jbc.270.5.2171; CREMO CR, 1991, METHOD ENZYMOL, V196, P442; CROSS RA, 1988, J MOL BIOL, V203, P173, DOI 10.1016/0022-2836(88)90100-3; CROSS RA, 1986, EMBO J, V5, P2637, DOI 10.1002/j.1460-2075.1986.tb04545.x; CROSS RA, 1988, J MUSCLE RES CELL M, V9, P108, DOI 10.1007/BF01682153; DORMAN G, 1994, BIOCHEMISTRY-US, V33, P5661, DOI 10.1021/bi00185a001; DREW JS, 1993, CELL MOTIL CYTOSKEL, V26, P291, DOI 10.1002/cm.970260404; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; FACEMYER KC, 1992, BIOCONJUGATE CHEM, V3, P408, DOI 10.1021/bc00017a009; FERAH CS, 1995, FASEB J, V9, P755; HALL LD, 1980, CARBOHYD RES, V78, pC4, DOI 10.1016/S0008-6215(00)83677-0; HIGASHIHARA M, 1989, BIOCHEMISTRY-US, V28, P1642, DOI 10.1021/bi00430a032; HOMSHER E, 1992, AM J PHYSIOL, V262, pC714, DOI 10.1152/ajpcell.1992.262.3.C714; HOROWITZ A, 1994, J CELL BIOL, V126, P1195, DOI 10.1083/jcb.126.5.1195; IKEBE M, 1994, J BIOL CHEM, V269, P28173; IKEBE M, 1994, P NATL ACAD SCI USA, V91, P9096, DOI 10.1073/pnas.91.19.9096; IKEBE M, 1985, J BIOL CHEM, V260, P3146; IKEBE M, 1985, BIOCHEMISTRY-US, V24, P2380, DOI 10.1021/bi00330a038; IKEBE M, 1986, BIOCHEMISTRY-US, V25, P6177, DOI 10.1021/bi00368a052; IKEHARA M, 1968, BIOCHIM BIOPHYS ACTA, V155, P82, DOI 10.1016/0005-2787(68)90337-7; JACKSON AP, 1988, BIOCHEM J, V251, P515, DOI 10.1042/bj2510515; KATAYAMA E, 1995, J BIOL CHEM, V270, P3919, DOI 10.1074/jbc.270.8.3919; KORN ED, 1988, ANNU REV BIOPHYS BIO, V17, P23; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVINE RJC, 1993, J STRUCT BIOL, V110, P99, DOI 10.1006/jsbi.1993.1010; MCLACHLAN AD, 1982, NATURE, V299, P226, DOI 10.1038/299226a0; MORITA JI, 1991, BIOCHEMISTRY-US, V30, P9539, DOI 10.1021/bi00103a022; OFFER G, 1990, J MOL BIOL, V216, P213, DOI 10.1016/S0022-2836(05)80309-2; ONEIL KT, 1989, J BIOL CHEM, V264, P14571; ONISHI H, 1982, J BIOCHEM-TOKYO, V92, P871, DOI 10.1093/oxfordjournals.jbchem.a134001; RAYMENT I, 1993, SCIENCE, V261, P1; ROSENFELD SS, 1994, J BIOL CHEM, V269, P30187; ROWE T, 1992, EMBO J, V11, P4715, DOI 10.1002/j.1460-2075.1992.tb05576.x; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SELLERS JR, 1985, J CELL BIOL, V101, P1897, DOI 10.1083/jcb.101.5.1897; SELLERS JR, 1995, PROTEIN PROFILE, V2, P1323; Sellers JR, 1987, ENZYMES, V18, ppp381, DOI 10.1016/S1874-6047(08)60264-4; SHIRINSKY VP, 1992, J BIOL CHEM, V267, P15886; SHIRINSKY VP, 1993, J BIOL CHEM, V268, P16578; SMILLIE LB, 1982, METHOD ENZYMOL, V85, P234; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SOMLYO AV, 1981, NATURE, V294, P567, DOI 10.1038/294567a0; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; SUZUKI H, 1985, J BIOL CHEM, V260, P4810; TAKAHASHI M, 1989, J BIOCHEM-TOKYO, V105, P149, DOI 10.1093/oxfordjournals.jbchem.a122628; Trybus KM, 1991, CURR OPIN CELL BIOL, V3, P105, DOI 10.1016/0955-0674(91)90172-U; TRYBUS KM, 1988, J BIOL CHEM, V263, P16485; TRYBUS KM, 1989, J CELL BIOL, V109, P2887, DOI 10.1083/jcb.109.6.2887; TRYBUS KM, 1982, P NATL ACAD SCI-BIOL, V79, P6151, DOI 10.1073/pnas.79.20.6151; TRYBUS KM, 1993, J BIOL CHEM, V268, P4412; TRYBUS KM, 1984, J BIOL CHEM, V259, P8564; WHITE HD, 1985, J BIOL CHEM, V260, P982; YANAGISAWA M, 1987, J MOL BIOL, V198, P143, DOI 10.1016/0022-2836(87)90302-0	64	41	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20375	20384		10.1074/jbc.271.34.20375	http://dx.doi.org/10.1074/jbc.271.34.20375			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702773	hybrid			2022-12-25	WOS:A1996VD33700025
J	Fukuda, M; Gotoh, I; Gotoh, Y; Nishida, E				Fukuda, M; Gotoh, I; Gotoh, Y; Nishida, E			Cytoplasmic localization of mitogen-activated protein kinase kinase directed by its NH2-terminal, leucine-rich short amino acid sequence, which acts as a nuclear export signal	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XENOPUS-OOCYTE MATURATION; NIH 3T3 CELLS; MAP KINASE; MESODERM INDUCTION; PLASMA-MEMBRANE; RAF; CASCADE; PHOSPHORYLATION; TRANSFORMATION; IDENTIFICATION	Mitogen-activated protein kinase (MAPK) is activated in cytoplasm in response to extracellular signals and then is translocated to nucleus. A directed activator for MAPK, MAPK kinase (MAPKK), stays in cytoplasm to transmit the signal from the plasma membrane to MAPK. Here we show that MAPK contains a short amino acid sequence in the N-terminal region (residues 32-44), which acts as a nuclear export signal (NES) and thus is required for cytoplasmic localization of MAPKK. This NES sequence of MAPKK, like that of protein kinase inhibitor of cAMP-dependent protein kinase or Rev, is rich in leucine residues, which are crucial for the NES activity. Furthermore, the NES peptide of protein kinase inhibitor, as well as the NES peptide of MAPKK, inhibited the nuclear export of ovalbumin conjugated to the NES peptide of MAPKK. These results may suggest a common mechanism of nuclear export using a general leucine-rich NES.	KYOTO UNIV,INST VIRUS RES,DEPT GENET & MOL BIOL,SAKYO KU,KYOTO 60601,JAPAN	Kyoto University			Fukuda, Makoto/S-9748-2019; Fukuda, Makoto/C-9745-2009; Fukuda, Makoto/I-7915-2014	Fukuda, Makoto/0000-0003-0112-9925; Fukuda, Makoto/0000-0003-0112-9925; Fukuda, Makoto/0000-0003-0112-9925				Ahn Natalie G., 1992, Current Opinion in Cell Biology, V4, P992, DOI 10.1016/0955-0674(92)90131-U; ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; BOGERD HP, 1995, CELL, V82, P485, DOI 10.1016/0092-8674(95)90437-9; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; FROST JA, 1994, P NATL ACAD SCI USA, V91, P3844, DOI 10.1073/pnas.91.9.3844; FUKUDA M, 1995, ONCOGENE, V11, P239; GERACE L, 1995, CELL, V82, P341, DOI 10.1016/0092-8674(95)90420-4; GONZALEZ FA, 1993, J CELL BIOL, V122, P1089, DOI 10.1083/jcb.122.5.1089; GOTOH Y, 1995, EMBO J, V14, P2491, DOI 10.1002/j.1460-2075.1995.tb07246.x; GOTOH Y, 1994, ONCOGENE, V9, P1891; GOTOH Y, 1995, J BIOL CHEM, V270, P25898, DOI 10.1074/jbc.270.43.25898; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; KOSAKO H, 1994, EMBO J, V13, P2131, DOI 10.1002/j.1460-2075.1994.tb06489.x; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LABONNE C, 1995, DEVELOPMENT, V121, P1475; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MEYER BE, 1994, GENE DEV, V8, P1538, DOI 10.1101/gad.8.13.1538; MORIGUCHI T, 1995, EUR J BIOCHEM, V234, P32, DOI 10.1111/j.1432-1033.1995.032_c.x; NISHIDA E, 1992, INT REV CYTOL, V138, P211, DOI 10.1016/S0074-7696(08)61589-2; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; ONEIL KT, 1990, SCIENCE, V250, P646, DOI 10.1126/science.2237415; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; SONTAG E, 1993, CELL, V75, P887, DOI 10.1016/0092-8674(93)90533-V; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; STUTZ F, 1995, CELL, V82, P495, DOI 10.1016/0092-8674(95)90438-7; THOMAS G, 1992, CELL, V68, P1; TRAVERSE S, 1993, ONCOGENE, V8, P3175; TROPPMAIR J, 1994, J BIOL CHEM, V269, P7030; UMBHAUER M, 1995, NATURE, V376, P58, DOI 10.1038/376058a0; VERON M, 1993, P NATL ACAD SCI USA, V90, P10618, DOI 10.1073/pnas.90.22.10618; WARTMANN M, 1994, J BIOL CHEM, V269, P6695; WEN W, 1994, J BIOL CHEM, V269, P32214; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; ZHENG CF, 1994, J BIOL CHEM, V269, P19947; ZHENG CF, 1994, EMBO J, V13, P1123, DOI 10.1002/j.1460-2075.1994.tb06361.x	43	294	299	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					20024	20028		10.1074/jbc.271.33.20024	http://dx.doi.org/10.1074/jbc.271.33.20024			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702720	hybrid			2022-12-25	WOS:A1996VC66900061
J	Vincenz, C; Dixit, VM				Vincenz, C; Dixit, VM			14-3-3 proteins associate with A20 in an isoform-specific manner and function both as chaperone and adapter molecules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; ZINC FINGER PROTEIN; IN-VIVO; KAPPA-B; 14-3-3-PROTEINS; RAF; KINASE; CELLS; ACTIVATION; BRAIN	A20, a novel zinc finger protein, is an inhibitor of tumor necrosis factor-induced apoptosis. The mechanism by which A20 exerts its protective effect is currently unknown. Several isoforms of the 14-3-3 proteins were found to interact with A20 in a yeast two-hybrid screen, A20 bound several 14-3-3 isoforms in vitro. Moreover, transfected A20 was found to preferentially bind the endogenous eta 14-3-3 isoform, whereas the beta/zeta isoforms co-immunoprecipitated much less efficiently, and epsilon 14-3-3 had an intermediate affinity. Importantly, c-Raf, a previously described 14-3-3-interacting protein, also preferentially bound the eta isoform. The cellular localization and subcellular fractionation of A20 was dramatically altered by co-transfected 14-3-3, providing the first experimental evidence for the notion that 14-3-3 can function as a chaperone, Furthermore, c-Raf and A20 co-immunoprecipitated in a 14-3-3-dependent manner, suggesting that 14-3-3 can function as a bridging or adapter molecule.	UNIV MICHIGAN,SCH MED,DEPT PATHOL,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan			dixit, vishva m/A-4496-2012	dixit, vishva m/0000-0001-6983-0326	NCI NIH HHS [CA61348] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA061348] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AITKEN A, 1995, J BIOL CHEM, V270, P5706, DOI 10.1074/jbc.270.11.5706; AITKEN A, 1995, TRENDS BIOCHEM SCI, V20, P95, DOI 10.1016/S0968-0004(00)88971-9; AITKEN A, 1992, TRENDS BIOCHEM SCI, V17, P498, DOI 10.1016/0968-0004(92)90339-B; Ausubel F.M., 1994, CURRENT PROTOCOLS MO, V1; BONNEFOYBERARD N, 1995, P NATL ACAD SCI USA, V92, P10142, DOI 10.1073/pnas.92.22.10142; BRASELMANN S, 1995, EMBO J, V14, P4839, DOI 10.1002/j.1460-2075.1995.tb00165.x; CONKLIN DS, 1995, P NATL ACAD SCI USA, V92, P7892, DOI 10.1073/pnas.92.17.7892; DIXIT VM, 1990, J BIOL CHEM, V265, P2973; DU XP, 1994, J BIOL CHEM, V269, P18287; Du XP, 1996, J BIOL CHEM, V271, P7362, DOI 10.1074/jbc.271.13.7362; Duan HJ, 1996, J BIOL CHEM, V271, P1621, DOI 10.1074/jbc.271.3.1621; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; FANTL WJ, 1994, NATURE, V371, P612, DOI 10.1038/371612a0; FORD JC, 1994, SCIENCE, V265, P533, DOI 10.1126/science.8036497; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; FU H, 1994, SCIENCE, V266, P126, DOI 10.1126/science.7939632; HARPER JW, 1993, CELL, V75, P805; IRIE K, 1994, SCIENCE, V265, P1716, DOI 10.1126/science.8085159; Jaattela M, 1996, J IMMUNOL, V156, P1166; JONES DH, 1995, FEBS LETT, V368, P55, DOI 10.1016/0014-5793(95)00598-4; KOYAMA S, 1995, FEBS LETT, V368, P321, DOI 10.1016/0014-5793(95)00686-4; KRIKOS A, 1992, J BIOL CHEM, V267, P17971; LAHERTY CD, 1992, J BIOL CHEM, V267, P24157; LI SF, 1995, EMBO J, V14, P685, DOI 10.1002/j.1460-2075.1995.tb07047.x; MARTIN H, 1993, FEBS LETT, V331, P296, DOI 10.1016/0014-5793(93)80356-Y; MICHAUD NR, 1995, MOL CELL BIOL, V15, P3390; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; OPIPARI AW, 1990, J BIOL CHEM, V265, P14705; OPIPARI AW, 1992, J BIOL CHEM, V267, P12424; OROURKE KM, 1992, J BIOL CHEM, V267, P24921; PALLAS DC, 1994, SCIENCE, V265, P535, DOI 10.1126/science.8036498; REUTHER GW, 1994, SCIENCE, V266, P129, DOI 10.1126/science.7939633; Song HY, 1996, P NATL ACAD SCI USA, V93, P6721, DOI 10.1073/pnas.93.13.6721; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; WOLF FW, 1994, J BIOL CHEM, V269, P3633; YAMAMORI B, 1995, J BIOL CHEM, V270, P11723, DOI 10.1074/jbc.270.20.11723	36	154	155	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					20029	20034		10.1074/jbc.271.33.20029	http://dx.doi.org/10.1074/jbc.271.33.20029			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702721	hybrid			2022-12-25	WOS:A1996VC66900062
J	Jacob, M; Weech, PK; Salesse, C				Jacob, M; Weech, PK; Salesse, C			Presence of a light-independent phospholipase A(2) in bovine retina but not in rod outer segments	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PIGMENT EPITHELIAL-CELLS; CYTOSOLIC PHOSPHOLIPASE-A2; MOLECULAR MECHANISM; G-PROTEINS; PURIFICATION; MEMBRANES; RAT; TRANSDUCIN; ACTIVATION; INHIBITION	Rod outer segments (ROS) are responsible for the visual transduction process, Rhodopsin, which constitutes 85-90% of ROS proteins, absorbs light photons, changes its conformation, and then binds to a heterotrimeric G-protein called transducin, As a consequence, transducin dissociates into T alpha and T beta gamma subunits, The presence in ROS of a phospholipase A, (PLA,) stimulated by light and guanosine 5'-O-(3-thio)triphosphate was first demonstrated in 1987 (Jelsema, C. L. (1987) J. Biol, Chem, 262, 163-168), This led that author to conclude that ROS PLA(2) could be involved in the phototransduction process, and raised the possibility of receptor-mediated activation of PLA(2) via G-proteins in cell types other than rods, However, the biochemical characteristics and the role of this PLA(2) have not been fully elucidated, We have tried to reproduce some of the results previously reported in order to further characterize this enzyme, We have found that, in our hands, there is neither light-dependent nor GTP-dependent PLA(2) activity in intact purified ROS, We also failed to detect PLA(2) activity in those ROS preparations, Nevertheless, we detected significant amounts of PLA(2) activity in two subretinal fractions adjacent to ROS: RPE (enriched with retinal pigment epithelial cells) and P200 (presumably containing neuronal cells, Muller cells, and rod inner segments), The enzyme present both in RPE and P200 is light- and GTP-independent, Ca2+- and Mg2+-independent, and seems to be optimally active in the alkaline pH range, Our results suggest that there is, if any, vanishingly little PLA(2) or PLA(1) activity in intact purified ROS and that the activity levels previously reported in the literature could have been due to a contamination by either RPE or P200. This is supported by our observation that some contaminated ROS preparations were ''PLA(2) active.''	UNIV QUEBEC,CTR RECH PHOTOBIOPHYS,TROIS RIVIERES,PQ G9A 5H7,CANADA; MERCK FROSST CTR THERAPEUT RES,POINTE CLAIRE,PQ M9R 4P8,CANADA	University of Quebec; University of Quebec Trois Rivieres; Merck & Company				Salesse, Christian/0000-0003-1795-7338				APITZCASTRO RJ, 1979, BIOCHEM BIOPH RES CO, V91, P63, DOI 10.1016/0006-291X(79)90583-7; AXELROD J, 1995, TRENDS NEUROSCI, V18, P64; BERMAN ER, 1974, INVEST OPHTH VISUAL, V13, P675; CASTAGNET PI, 1993, EXP EYE RES, V56, P709, DOI 10.1006/exer.1993.1088; CHABRE M, 1989, EUR J BIOCHEM, V179, P255, DOI 10.1111/j.1432-1033.1989.tb14549.x; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; FEENEYBURNS L, 1982, METHOD ENZYMOL, V81, P95; FLIESLER SJ, 1983, PROG LIPID RES, V22, P79; GARDINER FJ, 1968, ELECTROOPTICS HDB CO; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GLASER KB, 1993, TRENDS PHARMACOL SCI, V14, P92, DOI 10.1016/0165-6147(93)90071-Q; GRONICH JH, 1990, BIOCHEM J, V271, P37, DOI 10.1042/bj2710037; HARGRAVE PA, 1993, METHODS NEUROSCI, V15; HAZEN SL, 1990, J BIOL CHEM, V265, P10622; HELLER J, 1980, EXP EYE RES, V30, P481, DOI 10.1016/0014-4835(80)90032-9; HIRASHIMA Y, 1992, J NEUROCHEM, V59, P708, DOI 10.1111/j.1471-4159.1992.tb09426.x; IRVINE RF, 1982, BIOCHEM J, V204, P3, DOI 10.1042/bj2040003; JELSEMA CL, 1987, J BIOL CHEM, V262, P163; JELSEMA CL, 1987, P NATL ACAD SCI USA, V84, P3623, DOI 10.1073/pnas.84.11.3623; JORDAN LM, 1992, J CHROMATOGR, V597, P299, DOI 10.1016/0021-9673(92)80124-D; JUNG H, 1994, GRAEF ARCH CLIN EXP, V232, P167, DOI 10.1007/BF00176787; KRAMER RM, 1978, BIOCHIM BIOPHYS ACTA, V507, P381, DOI 10.1016/0005-2736(78)90348-6; KRAMER RM, 1991, J BIOL CHEM, V266, P5268; KREBS W, 1977, EXP EYE RES, V25, P511, DOI 10.1016/0014-4835(77)90180-4; LIEBMAN PA, 1987, ANNU REV PHYSIOL, V49, P765, DOI 10.1146/annurev.ph.49.030187.004001; MARSHALL LA, 1992, BIOCHEM PHARMACOL, V44, P1849, DOI 10.1016/0006-2952(92)90081-S; MAYER RJ, 1993, FASEB J, V7, P339, DOI 10.1096/fasebj.7.2.8440410; MCCONNELL DG, 1981, J BIOL CHEM, V256, P4913; MCDOWELL JH, 1977, BIOCHEMISTRY-US, V16, P4054, DOI 10.1021/bi00637a018; MILJANICH GP, 1978, THESIS U CALIFORNIA; NEAGOS GR, 1993, AM J PHYSIOL, V264, pL261, DOI 10.1152/ajplung.1993.264.3.L261; NEEDLEMAN P, 1986, ANNU REV BIOCHEM, V55, P69, DOI 10.1146/annurev.biochem.55.1.69; NEER EJ, 1988, NATURE, V333, P129, DOI 10.1038/333129a0; New R.R.C., 1990, LIPOSOMES PRACTICAL, P44; PETIT K, 1992, BIOCHIM BIOPHYS ACTA, V1125, P150, DOI 10.1016/0005-2760(92)90039-X; PFISTER C, 1993, CELL SIGNAL, V5, P235, DOI 10.1016/0898-6568(93)90015-E; PIND S, 1987, BIOCHIM BIOPHYS ACTA, V901, P78, DOI 10.1016/0005-2736(87)90258-6; RAUBACH RA, 1974, VISION RES, V14, P335, DOI 10.1016/0042-6989(74)90092-3; REYNOLDS LJ, 1993, BIOCHIM BIOPHYS ACTA, V1167, P272, DOI 10.1016/0005-2760(93)90229-3; RONKKO S, 1992, INT J BIOCHEM, V24, P869, DOI 10.1016/0020-711X(92)90091-E; SALESSE C, 1984, ANAL BIOCHEM, V142, P258, DOI 10.1016/0003-2697(84)90462-7; SCHNETKAMP PPM, 1981, BIOCHIM BIOPHYS ACTA, V672, P307, DOI 10.1016/0304-4165(81)90298-1; SEHRAN CN, 1994, BIOCHIM BIOPHYS ACTA, V1212, P1; SMITH WL, 1989, BIOCHEM J, V259, P315, DOI 10.1042/bj2590315; STONE WL, 1979, EXP EYE RES, V28, P387, DOI 10.1016/0014-4835(79)90114-3; ULEVITCH RJ, 1988, J BIOL CHEM, V263, P3079; YAMAMOTO S, 1992, BIOCHIM BIOPHYS ACTA, V1128, P117, DOI 10.1016/0005-2760(92)90297-9; ZIMMERMAN WF, 1982, METHOD ENZYMOL, V81, P52; ZIMMERMAN WF, 1988, EXP EYE RES, V47, P247, DOI 10.1016/0014-4835(88)90008-5; Zinn K., 1979, RETINAL PIGMENT EPIT, P3	50	8	8	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19209	19218		10.1074/jbc.271.32.19209	http://dx.doi.org/10.1074/jbc.271.32.19209			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702600	hybrid			2022-12-25	WOS:A1996VB68400034
J	Luttrell, LM; Hawes, BE; vanBiesen, T; Luttrell, DK; Lansing, TJ; Lefkowitz, RJ				Luttrell, LM; Hawes, BE; vanBiesen, T; Luttrell, DK; Lansing, TJ; Lefkowitz, RJ			Role of c-Src tyrosine kinase in G protein-coupled receptor- and G beta gamma subunit-mediated activation of mitogen-activated protein kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; HETEROTRIMERIC G-PROTEINS; DOMINANT-NEGATIVE MUTANT; GROWTH-FACTOR RECEPTOR; SHC ADAPTER PROTEIN; LYSOPHOSPHATIDIC ACID; MAP KINASE; SIGNALING PATHWAYS; PHOSPHOINOSITIDE-3 KINASE; ANGIOTENSIN-II	Several G protein-coupled receptors that interact with pertussis toxin-sensitive heterotrimeric G proteins mediate Ras-dependent activation of mitogen-activated protein (MAP) kinases, The mechanism involves G beta gamma subunit-mediated increases in tyrosine phosphorylation of the She adapter protein, Shc-Grb2 complex formation, and recruitment of Pas guanine nucleotide exchange factor activity. We have investigated the role of the ubiquitous nonreceptor tyrosine kinase c-Src in activation of the MAP kinase pathway via endogenous G protein-coupled lysophosphatidic acid (LPA) receptors or by transient expression of G beta gamma subunits in COS-7 cells. In vitro kinase assays of She immunoprecipitates following LPA stimulation demonstrated rapid, transient recruitment of tyrosine kinase activity into She immune complexes, Recruitment of tyrosine kinase activity was pertussis toxin sensitive and mimicked by cellular expression of G beta gamma subunits. Immunoblots for coprecipitated proteins in She immunoprecipitates revealed a transient association of Shc and c-Src following LPA stimulation, which coincided with increases in Shc-associated tyrosine kinase activity and She tyrosine phosphorylation. LPA stimulation or expression of G beta gamma subunits resulted in c-Src activation, as assessed by increased c-Src autophosphorylation, Overexpression of wild-type or constitutively active mutant c-Src, but not kinase inactive mutant c-Src, lead to increased tyrosine kinase activity in She immunoprecipitates, increased She tyrosine phosphorylation, and Shc-Grb2 complex formation, MAP kinase activation resulting from LPA receptor stimulation, expression of G beta gamma subunits, or expression of c-Src was sensitive to dominant negatives of mSos, Pas, and Raf. Coexpression of Csk, which inactivates Src family kinases by phosphorylating the regulatory C-terminal tyrosine residue, inhibited LPA stimulation of Shc tyrosine phosphorylation, Shc-Grb2 complex formation, and MAP kinase activation, These data suggest that G beta gamma subunit-mediated formation of Shc-c-Src complexes and c-Src kinase activation are early events in Ras-dependent activation of MAP kinase via pertussis toxin-sensitive G protein coupled receptors.	DUKE UNIV, MED CTR, HOWARD HUGHES MED INST, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT MED, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT BIOCHEM, DURHAM, NC 27710 USA; GLAXO WELLCOME INC, DEPT MOL CELL BIOL, RES TRIANGLE PK, NC 27709 USA	Duke University; Howard Hughes Medical Institute; Duke University; Duke University; GlaxoSmithKline			Lefkowitz, Robert/AAW-2649-2021	Luttrell, Louis/0000-0003-2805-6949	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL016037, R01HL016037] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL16037] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; CAZAUBON SM, 1994, J BIOL CHEM, V269, P24805; CHAN TO, 1990, MOL CELL BIOL, V10, P3280, DOI 10.1128/MCB.10.6.3280; CHEN YH, 1994, J BIOL CHEM, V269, P27372; CHENG GH, 1994, P NATL ACAD SCI USA, V91, P8152, DOI 10.1073/pnas.91.17.8152; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Dhanasekaran N., 1995, Endocrine Reviews, V16, P259; FAURE M, 1994, J BIOL CHEM, V269, P7851; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; GIBBS CP, 1985, J VIROL, V53, P19, DOI 10.1128/JVI.53.1.19-24.1985; GRABER SG, 1992, J BIOL CHEM, V267, P13123; HAWES BE, 1995, J BIOL CHEM, V270, P17148, DOI 10.1074/jbc.270.29.17148; HORDIJK PL, 1994, J BIOL CHEM, V269, P645; HOWE LR, 1993, J BIOL CHEM, V268, P20717; HOWELL BW, 1994, MOL CELL BIOL, V14, P5402, DOI 10.1128/MCB.14.8.5402; INGLESE J, 1994, P NATL ACAD SCI USA, V91, P3637, DOI 10.1073/pnas.91.9.3637; ISHIDA M, 1995, CIRC RES, V77, P1053, DOI 10.1161/01.RES.77.6.1053; ITO A, 1995, FEBS LETT, V368, P183, DOI 10.1016/0014-5793(95)00643-N; JALINK K, 1993, CELL GROWTH DIFFER, V4, P247; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; KOCH WJ, 1994, J BIOL CHEM, V269, P6193; LANGHANSRAJASEKARAN SA, 1995, P NATL ACAD SCI USA, V92, P8601, DOI 10.1073/pnas.92.19.8601; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; LINSEMAN DA, 1995, J BIOL CHEM, V270, P12563, DOI 10.1074/jbc.270.21.12563; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; LUTTRELL DK, 1994, P NATL ACAD SCI USA, V91, P83, DOI 10.1073/pnas.91.1.83; MAHAJAN S, 1995, MOL CELL BIOL, V15, P5304; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; MELOCHE S, 1992, MOL BIOL CELL, V3, P63, DOI 10.1091/mbc.3.1.63; MOOLENAAR WH, 1995, J BIOL CHEM, V270, P12949, DOI 10.1074/jbc.270.22.12949; MUKHOPADHYAY D, 1995, NATURE, V375, P577, DOI 10.1038/375577a0; NADA S, 1993, CELL, V73, P1125, DOI 10.1016/0092-8674(93)90642-4; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; OHMICHI M, 1994, J BIOL CHEM, V269, P3783; OKADA S, 1995, J BIOL CHEM, V270, P20737, DOI 10.1074/jbc.270.35.20737; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; PTASZNIK A, 1995, J BIOL CHEM, V270, P19969, DOI 10.1074/jbc.270.34.19969; RAO GN, 1995, J BIOL CHEM, V270, P27871, DOI 10.1074/jbc.270.46.27871; SAKAUE M, 1995, MOL CELL BIOL, V15, P379, DOI 10.1128/MCB.15.1.379; SATOH T, 1992, J BIOL CHEM, V267, P24149; SCHAAP D, 1993, J BIOL CHEM, V268, P20232; SNYDER MA, 1985, MOL CELL BIOL, V5, P1772, DOI 10.1128/MCB.5.7.1772; SPANDIDOS DA, 1984, NATURE, V310, P469, DOI 10.1038/310469a0; STEPHENS L, 1994, CELL, V77, P83, DOI 10.1016/0092-8674(94)90237-2; STOVER DR, 1995, J BIOL CHEM, V270, P15591, DOI 10.1074/jbc.270.26.15591; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; THOMASON PA, 1994, J BIOL CHEM, V269, P16525; TOUHARA K, 1995, P NATL ACAD SCI USA, V92, P9284, DOI 10.1073/pnas.92.20.9284; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; VANCORVEN EJ, 1993, P NATL ACAD SCI USA, V90, P1257, DOI 10.1073/pnas.90.4.1257; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; VANDERBEND RL, 1992, EMBO J, V11, P2495, DOI 10.1002/j.1460-2075.1992.tb05314.x; YAMAJI Y, 1995, P NATL ACAD SCI USA, V92, P6274, DOI 10.1073/pnas.92.14.6274; YATSUNAMI K, 1985, P NATL ACAD SCI USA, V82, P1936, DOI 10.1073/pnas.82.7.1936	57	484	489	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19443	19450		10.1074/jbc.271.32.19443	http://dx.doi.org/10.1074/jbc.271.32.19443			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702633	hybrid			2022-12-25	WOS:A1996VB68400067
J	Mitchell, DC; Lawrence, JTR; Litman, BJ				Mitchell, DC; Lawrence, JTR; Litman, BJ			Primary alcohols modulate the activation of the G protein-coupled receptor rhodopsin by a lipid-mediated mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHAIN PHOSPHATIDYLCHOLINE VESICLES; HIGHER-ORDER ANALYSIS; METARHODOPSIN-II; ACETYLCHOLINE-RECEPTOR; RECOMBINANT MEMBRANES; GENERAL-ANESTHETICS; ANISOTROPY DECAY; EQUILIBRIUM; BOVINE; CHOLESTEROL	The visual pigment rhodopsin is a prototypical member of the G protein-coupled receptor superfamily. In this study, we have investigated the effect of a series of n-alcohols on the formation of metarhodopsin II (MII), the photoactivated conformation of rhodopsin, which binds and activates transducin. When rhodopsin was photolyzed in the presence of several n-alcohols, increased MII formation was observed in the order ethanol > butanol > hexanol, whereas longer chain n-alcohols inhibited MII formation with decanol > octanol, The magnitude of the stimulatory effects was greater in a more highly unsaturated phospholipid, Alcohols, which enhanced MII formation also increased phospholipid acyl chain packing free volume, while those that decreased this bilayer property inhibited MII formation, An apparent discontinuity in the effect of these alcohols results when their potency is calculated in terms of the total aqueous alcohol concentration. In sharp contrast, a continuous variation in their behavior is observed, when their potency is calculated in terms of the amount of alcohol partitioned in the membrane, Our findings strongly support a lipid-mediated mechanism of action for alcohols on rhodopsin and, by analogy, for other G protein-coupled receptors.	NIAAA,SECT FLUORESCENCE STUDIES,LAB MEMBRANE BIOCHEM & BIOPHYS,DIV INTRAMURAL CLIN & BIOL RES,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)								[Anonymous], [No title captured]; APPLEBURY ML, 1984, VISION RES, V24, P1445, DOI 10.1016/0042-6989(84)90305-5; ATTWOOD PV, 1980, FEBS LETT, V119, P323, DOI 10.1016/0014-5793(80)80281-X; BARRY JA, 1994, BIOCHEMISTRY-US, V33, P8082, DOI 10.1021/bi00192a013; CHIN JJ, 1977, MOL PHARMACOL, V13, P4352; COVARRUBIAS M, 1995, J BIOL CHEM, V270, P19408, DOI 10.1074/jbc.270.33.19408; EMEIS D, 1982, FEBS LETT, V143, P29, DOI 10.1016/0014-5793(82)80266-4; FIRESTONE LL, 1994, MOL PHARMACOL, V46, P508; FRANKS NP, 1994, NATURE, V367, P607, DOI 10.1038/367607a0; FRANKS NP, 1984, NATURE, V310, P599, DOI 10.1038/310599a0; GIBSON NJ, 1993, BIOCHEMISTRY-US, V32, P2438, DOI 10.1021/bi00060a040; JACKSON ML, 1985, BIOCHIM BIOPHYS ACTA, V812, P369, DOI 10.1016/0005-2736(85)90311-6; KIBELBEK J, 1991, BIOCHEMISTRY-US, V30, P6761, DOI 10.1021/bi00241a019; LI CY, 1994, P NATL ACAD SCI USA, V91, P8200, DOI 10.1073/pnas.91.17.8200; LITMAN BJ, 1982, METHOD ENZYMOL, V81, P150; Litman BJ, 1996, LIPIDS, V31, pS193, DOI 10.1007/BF02637075; MATHEWS RG, 1963, J GEN PHYSIOL, V47, P215; MCCREERY MJ, 1978, NEUROPHARMACOLOGY, V17, P451, DOI 10.1016/0028-3908(78)90050-3; MCKENZIE D, 1995, BRIT J PHARMACOL, V115, P275, DOI 10.1111/j.1476-5381.1995.tb15874.x; Meyer H, 1901, ARCH EXP PATHOL PHAR, V46, P338, DOI 10.1007/BF01978064; MILLER KW, 1989, P NATL ACAD SCI USA, V86, P1084, DOI 10.1073/pnas.86.3.1084; MILLER KW, 1985, INT REV NEUROBIOL, V270, P1; MITCHELL DC, 1992, BIOCHEMISTRY-US, V31, P662, DOI 10.1021/bi00118a005; MITCHELL DC, 1994, BIOCHEMISTRY-US, V33, P12752, DOI 10.1021/bi00209a004; MITCHELL DC, 1990, BIOCHEMISTRY-US, V29, P9143, DOI 10.1021/bi00491a007; OBRIEN DF, 1977, BIOCHEMISTRY-US, V16, P1295, DOI 10.1021/bi00626a009; Overton E., 1901, STUDIEN NARKOSE; SLATER SJ, 1993, NATURE, V364, P82, DOI 10.1038/364082a0; SMITH HG, 1982, METHOD ENZYMOL, V81, P57; STONE WL, 1979, EXP EYE RES, V28, P387, DOI 10.1016/0014-4835(79)90114-3; STRAUME M, 1987, BIOCHEMISTRY-US, V26, P5121, DOI 10.1021/bi00390a034; STRAUME M, 1990, BIOCHEMISTRY-US, V29, P9135, DOI 10.1021/bi00491a006; STRAUME M, 1987, BIOCHEMISTRY-US, V26, P5113, DOI 10.1021/bi00390a033; WIEDMANN TS, 1988, BIOCHEMISTRY-US, V27, P6469, DOI 10.1021/bi00417a041	34	66	66	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19033	19036		10.1074/jbc.271.32.19033	http://dx.doi.org/10.1074/jbc.271.32.19033			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702573	hybrid			2022-12-25	WOS:A1996VB68400007
J	Nagaraj, RH; Shipanova, IN; Faust, FM				Nagaraj, RH; Shipanova, IN; Faust, FM			Protein cross-linking by the Maillard reaction - Isolation, characterization, and in vivo detection of a lysine-lysine cross-link derived from methylglyoxal	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCATION END-PRODUCTS; N-ALPHA-HIPPURYLLYSINE; ADVANCED GLYCOSYLATION; ALDOSE REDUCTASE; DIABETES-MELLITUS; DIHYDRODIOL DEHYDROGENASE; GLUTATHIONE METABOLISM; EXTRACELLULAR-MATRIX; ALDEHYDE REDUCTASE; GLYOXALASE SYSTEM	The Maillard reaction, initiated by nonenzymatic glycosylation of amino groups on proteins by reducing sugars, has been studied for its potential role in aging and the complications of diabetes. One of the major consequences of the advanced Maillard reaction in proteins is the formation of covalently cross-linked aggregates, The chemical nature of the cross-linking structures is largely unknown, Recently, methylglyoxal has been shown to be a potential glycating agent in vivo and suggested to be a common intermediate in the Maillard reaction involving glucose. Methylglyoxal can form enzymatically or nonenzymatically from glycolytic intermediates and by retro-aldol cleavage of sugars, Its elevation in tissues in diabetes and its high potency to glycate and cross-link proteins led us to investigate the chemical nature of its advanced Maillard products, Using all approach in which a synthetic model peptide was reacted with methylglyoxal, we isolated and purified a cross-linked peptide dimer, Characterization of this dimer revealed that the peptides are linked through epsilon amino groups of lysine residues, The actual cross-link was shown to be a methylimidazolium, formed horn the reaction of tyro lysines and two methylglyoxal molecules, We have named this cross-link imidazolysine. Imidazolysine was detected in proteins by high performance liquid chromatography using a postcolumn derivatization method, Proteins incubated with methylglyoxal showed a time-dependent formation of imidazolysine. Quantification of imidazolysine in human serum proteins revealed a significant increase (p < 0.05) in diabetic samples (mean +/- S.D., 313.8 +/- 52.7 pmol/mg protein) when compared with normal samples (261.3 +/- 50.4), These values correlated with glycohemoglobin (p < 0.05), These results provide chemical evidence for protein cross-linking by dicarbonyl compounds in vivo.	CASE WESTERN RESERVE UNIV, INST PATHOL, CLEVELAND, OH 44106 USA; CASE WESTERN RESERVE UNIV HOSP, CLEVELAND, OH 44106 USA	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University Hospital	Nagaraj, RH (corresponding author), CASE WESTERN RESERVE UNIV, DEPT OPHTHALMOL, CTR VIS RES, WEARN BLDG, RM 637, CLEVELAND, OH 44106 USA.				NATIONAL EYE INSTITUTE [R01EY009912, R29EY009912] Funding Source: NIH RePORTER; NEI NIH HHS [EY 09912] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BAYNES JW, 1991, DIABETES, V40, P405, DOI 10.2337/diabetes.40.4.405; BRINKMANN E, 1995, J CHEM SOC PERK T 1, P2817, DOI 10.1039/p19950002817; BUCALA R, 1993, P NATL ACAD SCI USA, V90, P6434, DOI 10.1073/pnas.90.14.6434; DAVIDEK T, 1991, J AGR FOOD CHEM, V39, P1376; DELCORSO A, 1989, J BIOL CHEM, V264, P17653; GANDHI CR, 1979, INDIAN J EXP BIOL, V17, P585; GRUNEWALD RW, 1993, BIOCHIM BIOPHYS ACTA, V1225, P39; HAMMES HP, 1991, P NATL ACAD SCI USA, V88, P11555, DOI 10.1073/pnas.88.24.11555; HODGE JE, 1953, J AGR FOOD CHEM, V1, P928, DOI 10.1021/jf60015a004; HORIUCHI S, 1994, GERONTOLOGY, V40, P10; IMANISHI H, 1985, MECH AGEING DEV, V32, P57, DOI 10.1016/0047-6374(85)90035-1; KIRSTEIN M, 1990, P NATL ACAD SCI USA, V87, P9010, DOI 10.1073/pnas.87.22.9010; KONISHI Y, 1994, BIOSCI BIOTECH BIOCH, V58, P1953, DOI 10.1271/bbb.58.1953; LINDSTAD RI, 1993, FEBS LETT, V330, P31, DOI 10.1016/0014-5793(93)80913-F; LO TWC, 1994, J BIOL CHEM, V269, P32299; LOU MF, 1988, EXP EYE RES, V46, P517, DOI 10.1016/S0014-4835(88)80009-5; LYONS TJ, 1991, DIABETES, V40, P1010, DOI 10.2337/diabetes.40.8.1010; MCLELLAN AC, 1994, CLIN SCI, V87, P21, DOI 10.1042/cs0870021; MCLELLAN AC, 1992, ANAL BIOCHEM, V206, P17, DOI 10.1016/S0003-2697(05)80005-3; MONNIER VM, 1990, ADV LIF SCI, P393; MONNIER VM, 1992, DIABETES, V41, P36, DOI 10.2337/diab.41.2.S36; Monnier VM, 1989, MAILLARD REACTION AG, P410; MURAKAMI K, 1989, METABOLISM, V38, P753, DOI 10.1016/0026-0495(89)90061-9; NAGARAJ RH, 1992, BIOCHIM BIOPHYS ACTA, V1116, P34, DOI 10.1016/0304-4165(92)90125-E; NAGARAJ RH, 1991, P NATL ACAD SCI USA, V88, P10257, DOI 10.1073/pnas.88.22.10257; NAKAMURA Y, 1993, AM J PATHOL, V143, P1649; NISHINO T, 1995, HUM PATHOL, V26, P308, DOI 10.1016/0046-8177(95)90063-2; PAPOULIS A, 1995, BIOCHEMISTRY-US, V34, P648, DOI 10.1021/bi00002a032; PHILLIPS SA, 1993, BIOCHEM PHARMACOL, V46, P805, DOI 10.1016/0006-2952(93)90488-I; PHILLIPS SA, 1993, EUR J BIOCHEM, V212, P101, DOI 10.1111/j.1432-1033.1993.tb17638.x; RATHBUN WB, 1991, EXP EYE RES, V53, P205, DOI 10.1016/0014-4835(91)90075-P; RILEY ML, 1995, BBA-MOL BASIS DIS, V1270, P36, DOI 10.1016/0925-4439(94)00069-3; SATO K, 1993, ARCH BIOCHEM BIOPHYS, V307, P286, DOI 10.1006/abbi.1993.1591; SATO K, 1994, J BIOCHEM-TOKYO, V116, P711, DOI 10.1093/oxfordjournals.jbchem.a124585; SELL DR, 1989, J BIOL CHEM, V264, P21597; TAKAHASHI K, 1968, J BIOL CHEM, V243, P6171; TAKAHASHI M, 1995, BIOCHEMISTRY-US, V34, P1433, DOI 10.1021/bi00004a038; THORNALLEY PJ, 1993, MOL ASPECTS MED, V14, P287, DOI 10.1016/0098-2997(93)90002-U; VANDERJAGT DL, 1992, J BIOL CHEM, V267, P4364; VELISEK J, 1989, J FOOD SCI, V54, P1544, DOI 10.1111/j.1365-2621.1989.tb05155.x; VLASSARA H, 1988, SCIENCE, V240, P1546, DOI 10.1126/science.3259727; VLASSARA H, 1994, LAB INVEST, V70, P138; WELLSKNECHT KJ, 1995, BIOCHEMISTRY-US, V34, P3702, DOI 10.1021/bi00011a027; WELLSKNECHT KJ, 1995, J ORG CHEM, V60, P6246, DOI 10.1021/jo00125a001; WESTWOOD ME, 1994, J BIOL CHEM, V269, P32293; YAN SD, 1994, J BIOL CHEM, V269, P9889	46	265	269	0	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19338	19345		10.1074/jbc.271.32.19338	http://dx.doi.org/10.1074/jbc.271.32.19338			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702619	hybrid			2022-12-25	WOS:A1996VB68400053
J	Hemenway, CS; Heitman, J				Hemenway, CS; Heitman, J			Immunosuppressant target protein FKBP12 is required for P-glycoprotein function in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-C-ALPHA; CYCLOPHILIN HOMOLOG NINAA; HAMSTER OVARY CELLS; MULTIDRUG-RESISTANCE; SACCHAROMYCES-CEREVISIAE; CYCLOSPORINE-A; STE6 GENE; SIGNAL-TRANSDUCTION; MAMMALIAN PROTEIN; RECEPTOR COMPLEX	The mammalian P-glycoprotein (Pgp) is a similar to 170-kDa membrane protein that mediates multidrug resistance in many chemotherapy-resistant tumors by effluxing toxic compounds from the cell, Pgp homologs are expressed in many organisms, from bacteria to yeast and mammals, Previous studies established a model system to analyze the function of murine, human, and Plasmodium falciparum Pgp by heterologous expression in the yeast Saccharomyces cerevisiae, However, such studies have been hampered by the inherent resistance of yeast cells to chemotherapeutic agents, We find that an erg6 mutation, which blocks the final synthetic step of the membrane sterol ergosterol, renders yeast sensitive to anthracyclines and dactinomycin, clinically relevant Pgp substrates, We demonstrate that expression of the murine mdr3 gene confers dactinomycin resistance in both the erg6 mutant yeast strain and in an erg6 rad52 DNA repair mutant yeast strain, Similarly, murine mdr3 expression confers resistance to the immunosuppressants cyclosporin A (CsA) and FK506 in a CsA-FR506-sensitive vph6 mutant yeast strain, CsA and FK506 are known to partially overcome Pgp-mediated drug resistance, suggesting the targets of these drugs might regulate Pgp function, We find that both murine mdr3 and the yeast Pgp homolog STE6 function in yeast mutants lacking the CsA target proteins cyclophilin A and calcineurin, In contrast, murine mdr3 function was severely compromised in yeast mutants lacking the FK506/rapamycin target protein FKBP12. Both wild-type FKBP12 and an F43Y FKBP12 mutant with reduced prolyl isomerase activity supported mdr3 function, Our results support the model that immunosuppressants reverse multidrug resistance by competing with other Pgp substrates but reveal that inhibition of FKBP12-dependent Pgp function may also contribute to reversal of multidrug resistance by FK506 and rapamycin.	DUKE UNIV,MED CTR,DEPT GENET,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT PEDIAT,DURHAM,NC 27710; DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT PHARMACOL,DURHAM,NC 27710	Duke University; Duke University; Duke University; Howard Hughes Medical Institute; Duke University			Heitman, Joseph/ABC-6006-2021		NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007031] Funding Source: NIH RePORTER; NIEHS NIH HHS [5 T32 ES07031-15] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AHMAD S, 1993, MOL PHARMACOL, V43, P858; AHMAD S, 1994, BIOCHEMISTRY-US, V33, P10313, DOI 10.1021/bi00200a011; ALANI E, 1987, GENETICS, V116, P541, DOI 10.1534/genetics.112.541.test; ALLIKMETS R, 1993, LEUKEMIA, V7, P513; APERIA A, 1992, P NATL ACAD SCI USA, V89, P7394, DOI 10.1073/pnas.89.16.7394; ARCECI RJ, 1992, BLOOD, V80, P1528; BAKER EK, 1994, EMBO J, V13, P4886, DOI 10.1002/j.1460-2075.1994.tb06816.x; BATES SE, 1993, BIOCHEMISTRY-US, V32, P9156, DOI 10.1021/bi00086a022; BEAUDET L, 1995, J BIOL CHEM, V270, P17159, DOI 10.1074/jbc.270.29.17159; BRAM RJ, 1993, MOL CELL BIOL, V13, P4760, DOI 10.1128/MCB.13.8.4760; BREUDER T, 1994, P NATL ACAD SCI USA, V91, P5372, DOI 10.1073/pnas.91.12.5372; BRILLANTES AMB, 1994, CELL, V77, P513, DOI 10.1016/0092-8674(94)90214-3; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; CAMERON AM, 1995, P NATL ACAD SCI USA, V92, P1784, DOI 10.1073/pnas.92.5.1784; Cardenas Maria E., 1994, Perspectives in Drug Discovery and Design, V2, P103, DOI 10.1007/BF02171739; CARDENAS ME, 1995, EMBO J, V14, P2772, DOI 10.1002/j.1460-2075.1995.tb07277.x; CARDENAS ME, 1995, J BIOL CHEM, V270, P20997, DOI 10.1074/jbc.270.36.20997; CARDENAS ME, 1994, EMBO J, V13, P5944, DOI 10.1002/j.1460-2075.1994.tb06940.x; CARDENAS ME, 1995, EMBO J, V14, P5892, DOI 10.1002/j.1460-2075.1995.tb00277.x; CHAMBERS TC, 1993, J BIOL CHEM, V268, P4592; CHAMBERS TC, 1992, MOL PHARMACOL, V41, P1008; CHIU MI, 1994, P NATL ACAD SCI USA, V91, P12574, DOI 10.1073/pnas.91.26.12574; CYERT MS, 1992, MOL CELL BIOL, V12, P3460, DOI 10.1128/MCB.12.8.3460; DENOBEL JG, 1991, YEAST, V7, P313, DOI 10.1002/yea.320070402; DEVAULT A, 1990, MOL CELL BIOL, V10, P1652, DOI 10.1128/MCB.10.4.1652; ENG WK, 1988, MOL PHARMACOL, V34, P755; EPAND RF, 1991, ANTI-CANCER DRUG DES, V6, P189; FOOR F, 1992, NATURE, V360, P682; FOXWELL BMJ, 1989, MOL PHARMACOL, V36, P543; GABER RF, 1989, MOL CELL BIOL, V9, P3447, DOI 10.1128/MCB.9.8.3447; GAVERIAUX C, 1989, BRIT J CANCER, V60, P867, DOI 10.1038/bjc.1989.381; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; GRAHAM TR, 1993, EMBO J, V12, P869, DOI 10.1002/j.1460-2075.1993.tb05727.x; HAMADA H, 1987, CANCER RES, V47, P2860; HEITMAN J, 1991, P NATL ACAD SCI USA, V88, P1948, DOI 10.1073/pnas.88.5.1948; HEITMAN J, 1992, NEW BIOL, V4, P448; HEMENWAY CS, 1995, GENETICS, V141, P833; JACHEZ B, 1993, ANTI-CANCER DRUG, V4, P223, DOI 10.1097/00001813-199304000-00015; JURANKA PF, 1989, FASEB J, V3, P2583, DOI 10.1096/fasebj.3.14.2574119; KUCHLER K, 1992, P NATL ACAD SCI USA, V89, P2302, DOI 10.1073/pnas.89.6.2302; KUCHLER K, 1989, EMBO J, V8, P3973, DOI 10.1002/j.1460-2075.1989.tb08580.x; LARSSON R, 1992, ANTICANCER RES, V12, P1581; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LOO TW, 1995, J BIOL CHEM, V270, P21839, DOI 10.1074/jbc.270.37.21839; LORENZ MC, 1995, J BIOL CHEM, V270, P27531, DOI 10.1074/jbc.270.46.27531; MCGRATH JP, 1989, NATURE, V340, P400, DOI 10.1038/340400a0; MICHAELIS S, 1988, MOL CELL BIOL, V8, P1309, DOI 10.1128/MCB.8.3.1309; MIZUNO K, 1992, ANTICANCER RES, V12, P21; NAITO M, 1992, CANCER CHEMOTH PHARM, V29, P195, DOI 10.1007/BF00686252; NITISS J, 1988, P NATL ACAD SCI USA, V85, P7501, DOI 10.1073/pnas.85.20.7501; ORR GA, 1993, J BIOL CHEM, V268, P25054; POURTIERMANZANEDO A, 1991, ANTI-CANCER DRUG, V2, P279, DOI 10.1097/00001813-199106000-00010; RAO US, 1994, MOL PHARMACOL, V45, P773; RAYMOND M, 1992, SCIENCE, V256, P232, DOI 10.1126/science.1348873; RAYMOND M, 1994, MOL CELL BIOL, V14, P277, DOI 10.1128/MCB.14.1.277; Rose MD., 1990, METHODS YEAST GENETI; Ruetz S, 1996, J BIOL CHEM, V271, P4154; RUETZ S, 1993, P NATL ACAD SCI USA, V90, P11588, DOI 10.1073/pnas.90.24.11588; RUETZ S, 1994, CELL, V77, P1071, DOI 10.1016/0092-8674(94)90446-4; RUETZ S, 1994, J BIOL CHEM, V269, P12277; SABATINI DM, 1995, J BIOL CHEM, V270, P20875, DOI 10.1074/jbc.270.36.20875; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; SAEKI T, 1991, AGR BIOL CHEM TOKYO, V55, P1859, DOI 10.1080/00021369.1991.10870860; SAEKI T, 1993, J BIOL CHEM, V268, P6077; SCHINKEL AH, 1994, CELL, V77, P491, DOI 10.1016/0092-8674(94)90212-7; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; STAMNES MA, 1991, CELL, V65, P219, DOI 10.1016/0092-8674(91)90156-S; TAMAI I, 1990, J BIOL CHEM, V265, P16509; TIMERMAN AP, 1995, J BIOL CHEM, V270, P2451, DOI 10.1074/jbc.270.6.2451; TWENTYMAN PR, 1988, BRIT J CANCER, V57, P254, DOI 10.1038/bjc.1988.55; TWENTYMAN PR, 1987, BRIT J CANCER, V56, P55, DOI 10.1038/bjc.1987.153; VOLKMAN SK, 1995, P NATL ACAD SCI USA, V92, P8921, DOI 10.1073/pnas.92.19.8921; YU G, 1991, CANCER COMMUN, V3, P181, DOI 10.3727/095535491820873263; ZHU DH, 1995, J BIOL CHEM, V270, P24831, DOI 10.1074/jbc.270.42.24831; [No title captured]	76	49	53	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18527	18534		10.1074/jbc.271.31.18527	http://dx.doi.org/10.1074/jbc.271.31.18527			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702500	hybrid			2022-12-25	WOS:A1996VB68300038
J	Park, MS; Ludwig, DL; Stigger, E; Lee, SH				Park, MS; Ludwig, DL; Stigger, E; Lee, SH			Physical interaction between human RAD52 and RPA is required for homologous recombination in mammalian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPLICATION PROTEIN-A; SIMIAN VIRUS-40 DNA; NUCLEOTIDE EXCISION-REPAIR; BINDING-PROTEIN; SACCHAROMYCES-CEREVISIAE; SV40 ORIGIN; INVITRO; EXPRESSION; INITIATION; POLYMERASE	The yeast RAD52 protein is essential for DNA double-strand break repair, and meiotic and mitotic recombination, RPA is a protein complex of three subunits (70, 34, and II kDa) that has been shown to be involved in DNA replication, nucleotide excision repair, and homologous recombination. Here, we demonstrate a physical interaction between human RAD52 and RPA in vivo and in vitro, In addition, the domain (amino acids 221-280) in RAD52 protein that mediates the interaction with the 34-kDa subunit of RPA was also determined, Overexpression of mutant RAD52 proteins lacking the interaction domain (amino acids 221-240, 241-260, and 261-280) failed to induce homologous recombination in monkey cells, We have previously shown that overexpression of human RAD52 induced homologous recombination in these cells, These results suggest that direct physical interactions between RAD52 and RPA are essential for homologous recombination in mammalian cells.	ST JUDE CHILDRENS RES HOSP, DEPT VIROL & MOL BIOL, MEMPHIS, TN 38101 USA	St Jude Children's Research Hospital	Park, MS (corresponding author), LOS ALAMOS NATL LAB, DIV LIFE SCI, M888, LOS ALAMOS, NM 87545 USA.		Park, Min Sung/HCH-2207-2022		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052358] Funding Source: NIH RePORTER; NIGMS NIH HHS [1RO1 GM52358] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABOUSSEKHRA A, 1995, CELL, V80, P859, DOI 10.1016/0092-8674(95)90289-9; BOROWIEC JA, 1990, CELL, V60, P181, DOI 10.1016/0092-8674(90)90730-3; BRILL SJ, 1989, NATURE, V342, P92, DOI 10.1038/342092a0; COVERLEY D, 1991, NATURE, V349, P538, DOI 10.1038/349538a0; DEAN FB, 1987, P NATL ACAD SCI USA, V84, P16, DOI 10.1073/pnas.84.1.16; FAIRMAN MP, 1988, EMBO J, V7, P1211, DOI 10.1002/j.1460-2075.1988.tb02933.x; FIRMENICH AA, 1995, MOL CELL BIOL, V15, P1620; FRIEDBERG EC, 1991, MOL CELLULAR BIOL YE, V1, P147; HAYS SL, 1995, P NATL ACAD SCI USA, V92, P6925, DOI 10.1073/pnas.92.15.6925; HE ZG, 1995, NATURE, V374, P566, DOI 10.1038/374566a0; HEYER WD, 1990, EMBO J, V9, P2321, DOI 10.1002/j.1460-2075.1990.tb07404.x; JESSBERGER R, 1993, J BIOL CHEM, V268, P15070; JOHNSON RD, 1995, MOL CELL BIOL, V15, P4843; KENNY MK, 1989, P NATL ACAD SCI USA, V86, P9757, DOI 10.1073/pnas.86.24.9757; Kim DK, 1996, J BIOL CHEM, V271, P15124, DOI 10.1074/jbc.271.25.15124; LEE SH, 1995, J BIOL CHEM, V270, P12801, DOI 10.1074/jbc.270.21.12801; LEE SH, 1995, J BIOL CHEM, V270, P21800, DOI 10.1074/jbc.270.37.21800; LI L, 1995, MOL CELL BIOL, V15, P5396; LUDWIG DL, 1994, SOMAT CELL MOLEC GEN, V20, P11, DOI 10.1007/BF02257482; MATSUDA T, 1995, J BIOL CHEM, V270, P4152, DOI 10.1074/jbc.270.8.4152; MATSUMOTO T, 1990, P NATL ACAD SCI USA, V87, P9712, DOI 10.1073/pnas.87.24.9712; MODRICH P, 1994, SCIENCE, V266, P1959, DOI 10.1126/science.7801122; MOORE SP, 1991, P NATL ACAD SCI USA, V88, P9067, DOI 10.1073/pnas.88.20.9067; OGAWA T, 1993, COLD SPRING HARB SYM, V58, P567, DOI 10.1101/SQB.1993.058.01.063; PARK MS, 1995, J BIOL CHEM, V270, P15467, DOI 10.1074/jbc.270.26.15467; Petes T. D., 1991, MOL CELLULAR BIOL YE, P407; RESNICK M A, 1987, P157; SANCAR A, 1994, SCIENCE, V266, P1953; Shen ZY, 1996, J BIOL CHEM, V271, P148, DOI 10.1074/jbc.271.1.148; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; SHINOHARA A, 1995, CELL, V270, P15467; SMITH J, 1995, MOL CELL BIOL, V15, P1632; STIGGER E, 1994, P NATL ACAD SCI USA, V91, P579, DOI 10.1073/pnas.91.2.579; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; WOBBE CR, 1987, P NATL ACAD SCI USA, V84, P1834, DOI 10.1073/pnas.84.7.1834; WOLD MS, 1987, P NATL ACAD SCI USA, V84, P3643, DOI 10.1073/pnas.84.11.3643; WOLD MS, 1988, P NATL ACAD SCI USA, V85, P2523, DOI 10.1073/pnas.85.8.2523	37	178	185	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18996	19000		10.1074/jbc.271.31.18996	http://dx.doi.org/10.1074/jbc.271.31.18996			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702565	hybrid			2022-12-25	WOS:A1996VB68300103
J	Sgroi, D; Nocks, A; Stamenkovic, I				Sgroi, D; Nocks, A; Stamenkovic, I			A single N-linked glycosylation site is implicated in the regulation of ligand recognition by the I-type lectins CD22 and CR33	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION MOLECULE; MYELIN-ASSOCIATED GLYCOPROTEIN; HUMAN TRANSFERRIN RECEPTORS; IMMUNOGLOBULIN SUPERFAMILY; NATURAL LIGANDS; SIALIC ACIDS; B-CELLS; BINDING; OLIGOSACCHARIDE; SIALOADHESIN	CD22 is an immunoglobulin superfamily B lymphocyte-specific adhesion receptor and a member of the recently identified I-type class of lectins, Recent work has shown that CD22 specifically recognizes sialic acid linked alpha 2,6 to terminal N-linked oligosaccharides on selected cell surface glycoproteins, CD22-ligand interaction is regulated by the activity of a beta-galactoside alpha 2,6-sialyltransferase that can inactivate CD22-mediated binding by sialylating the CD22 receptor itself. These observations suggest that N-linked glycosylation sites on the CD22 molecule may play a role in the regulation of CD22-mediated adhesion. In this work we have performed site-specific mutagenesis of potential N-linked glycosylation sites on CD22 in an effort to determine whether they might be involved in ligand recognition. We show that mutation of a single potential N-linked glycosylation site in the first immunoglobulin domain of CD22 completely abrogates ligand recognition, Interestingly, this site is characterized by the sequence NCT, where the cysteine is thought to be involved in an intrachain disulfide bond. Site-directed mutagenesis of similar NC(T/S) motifs in the first or second Ig domains of the I-type lectins myelin-associated glycoprotein, and sialoadhesin did not disrupt their ability to mediate sialic acid binding. In contrast, mutation of a NCS motif in the first Ig domain of the I-type lectin CD33 unmasked its sialic acid binding activity. These observations suggest that a single N-linked glycosylation site located at a similar position in the CD22 and CD33 glycoproteins is critical for regulating ligand recognition by both receptors.	HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,DEPT PATHOL,BOSTON,MA 02129	Harvard University; Harvard Medical School; Massachusetts General Hospital			Sgroi, Dennis/AAV-2487-2021		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI001252] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048614] Funding Source: NIH RePORTER; NIAID NIH HHS [AI/01252] Funding Source: Medline; NIGMS NIH HHS [GM/AI 48614] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; BARTOLAZZI A, 1996, J CELL BIOL, V132, P119; BRAESCHANDERSEN S, 1994, J BIOL CHEM, V269, P11783; CROCKER PR, 1994, EMBO J, V13, P4490, DOI 10.1002/j.1460-2075.1994.tb06771.x; EGGENS I, 1989, J BIOL CHEM, V264, P9476; ELBEIN AD, 1991, FASEB J, V5, P3055, DOI 10.1096/fasebj.5.15.1743438; ENGEL P, 1995, J EXP MED, V181, P1581, DOI 10.1084/jem.181.4.1581; FREEMAN SD, 1995, BLOOD, V85, P2005, DOI 10.1182/blood.V85.8.2005.bloodjournal8582005; HANASAKI K, 1995, J BIOL CHEM, V270, P7533, DOI 10.1074/jbc.270.13.7533; HANASAKI K, 1995, J BIOL CHEM, V270, P7543, DOI 10.1074/jbc.270.13.7543; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOE MH, 1992, J BIOL CHEM, V267, P4916; HUNT RC, 1989, J BIOL CHEM, V264, P9643; KELM S, 1994, CURR BIOL, V4, P965, DOI 10.1016/S0960-9822(00)00220-7; KOJIMA N, 1989, J BIOL CHEM, V264, P20159; LAI C, 1987, P NATL ACAD SCI USA, V84, P4337, DOI 10.1073/pnas.84.12.4337; MOLDENHAUER G, 1986, LEUKOCYTE TYPING 2, V2, P97; PLAAS AHK, 1993, J BIOL CHEM, V268, P26634; POWELL LD, 1993, J BIOL CHEM, V268, P7019; POWELL LD, 1994, J BIOL CHEM, V269, P10628; POWELL LD, 1995, J BIOL CHEM, V270, P14243, DOI 10.1074/jbc.270.24.14243; RECNY MA, 1992, J BIOL CHEM, V267, P22428; SGROI D, 1993, J BIOL CHEM, V268, P7011; SGROI D, 1995, P NATL ACAD SCI USA, V92, P4026, DOI 10.1073/pnas.92.9.4026; SJOBERG ER, 1994, J CELL BIOL, V126, P549, DOI 10.1083/jcb.126.2.549; STAMENKOVIC I, 1990, NATURE, V345, P74, DOI 10.1038/345074a0; STAMENKOVIC I, 1991, CELL, V66, P1133, DOI 10.1016/0092-8674(91)90036-X; WILSON GL, 1991, J EXP MED, V173, P137, DOI 10.1084/jem.173.1.137; WYSS DF, 1995, SCIENCE, V269, P1273, DOI 10.1126/science.7544493; YANG B, 1993, J BIOL CHEM, V268, P7435	30	35	38	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18803	18809		10.1074/jbc.271.31.18803	http://dx.doi.org/10.1074/jbc.271.31.18803			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702538	hybrid			2022-12-25	WOS:A1996VB68300076
J	Shimoni, Y; Galili, G				Shimoni, Y; Galili, G			Intramolecular disulfide bonds between conserved cysteines in wheat gliadins control their deposition into protein bodies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEED STORAGE PROTEINS; ENDOPLASMIC-RETICULUM; TRANSPORT; EXPRESSION; ISOMERASE; BIP	Following synthesis, wheat gliadin storage proteins are deposited into protein bodies inside the endomembrane system in a way that enables not only their efficient accumulation and dehydration during seed maturation, but also their rapid rehydration and degradation during germination. In the present report, we studied the mechanism of gliadin deposition and whether it was controlled by the conformation of these proteins. Although gliadins are generally known to be insoluble in aqueous solutions, sucrose gradient analysis showed that a considerable amount of these proteins appeared as relatively soluble monomers in developing grains, In vitro reduction of the intramolecular disulfide bonds that are present in natural monomeric gliadins caused their precipitation into insoluble aggregates, In addition, pulse-chase experiments in the absence or presence of reducing agents showed that formation of intramolecular disulfide bonds also played a major role in folding and deposition of the gliadins in vivo, Our results imply that following sequestration into the endoplasmic reticulum, the gliadins fold into relatively soluble monomers, which are incompetent for rapid aggregation and gradually assemble into protein bodies, This pattern of deposition apparently depends on the conformation of the gliadins, which is stabilized by in tramolecular disulfide bonds formed between the conserved cysteines, The contribution of this study to the understanding of the evolution and function of gliadins is discussed.			Shimoni, Y (corresponding author), WEIZMANN INST SCI,DEPT PLANT GENET,IL-76100 REHOVOT,ISRAEL.							ALTSCHULER Y, 1994, J BIOL CHEM, V269, P6677; BULLEID NJ, 1988, NATURE, V335, P649, DOI 10.1038/335649a0; CHARBONNIER L, 1980, J SCI FOOD AGR, V31, P54, DOI 10.1002/jsfa.2740310109; CHRISPEELS MJ, 1991, ANNU REV PLANT PHYS, V42, P21, DOI 10.1146/annurev.pp.42.060191.000321; COLE EW, 1984, BIOCHIM BIOPHYS ACTA, V787, P244, DOI 10.1016/0167-4838(84)90315-7; DAMICO L, 1992, PLANT J, V2, P443; GALILI G, 1995, J CELL BIOCH SA, V19, P132; Galili Gad, 1993, Trends in Cell Biology, V3, P437, DOI 10.1016/0962-8924(93)90033-W; GILLIKIN JW, 1995, METHOD CELL BIOL, P309; Kasarda D.D., 1989, WHEAT UNIQUE, V277, P302; Kreis M., 1985, Oxford Surveys of Plant Molecular and Cell Biology, V2, P253; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI XX, 1993, SCIENCE, V262, P1054, DOI 10.1126/science.8235623; PAYNE PI, 1987, ANNU REV PLANT PHYS, V38, P141, DOI 10.1146/annurev.pp.38.060187.001041; PEDRAZZINI E, 1994, PLANT J, V5, P103, DOI 10.1046/j.1365-313X.1994.5010103.x; PENCE JW, 1954, CEREAL CHEM, V31, P29; ROSE MD, 1989, CELL, V57, P1211, DOI 10.1016/0092-8674(89)90058-5; RUBIN R, 1992, PLANT PHYSIOL, V99, P718, DOI 10.1104/pp.99.2.718; SHANI N, 1994, J BIOL CHEM, V269, P8924; SHEWRY PR, 1995, PLANT CELL, V7, P945, DOI 10.1105/tpc.7.7.945; SHEWRY PR, 1995, SEED DEV GERMINATION, P45; SHORROSH BS, 1993, PLANT PHYSIOL, V103, P719, DOI 10.1104/pp.103.3.719; STOTT K, 1995, P NATL ACAD SCI USA, V92, P6509, DOI 10.1073/pnas.92.14.6509; VITALE A, 1993, J EXP BOT, V44, P1417, DOI 10.1093/jxb/44.9.1417; VITALE A, 1995, J CELL BIOCH A S, V19, P132; Vitale A., 1995, SEED DEV GERMINATION, P73	26	33	39	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18869	18874		10.1074/jbc.271.31.18869	http://dx.doi.org/10.1074/jbc.271.31.18869			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702547	hybrid			2022-12-25	WOS:A1996VB68300085
J	Singh, RJ; Hogg, N; Joseph, J; Kalyanaraman, B				Singh, RJ; Hogg, N; Joseph, J; Kalyanaraman, B			Mechanism of nitric oxide release from S-nitrosothiols	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM-ALBUMIN; PLATELET ACTIVATION; L-CYSTEINE; GLUTATHIONE; NITROSOGLUTATHIONE; THIOLS; DECOMPOSITION; NITROSATION; KINETICS; OXYGEN	S-Nitrosothiols have many biological activities and have been suggested to be intermediates in signal transduction. The mechanism and products of S-nitrosothiol decomposition are of great significance to the understanding of nitric oxide ((NO)-N-.) biochemistry. S-Nitrosothiols are stable compounds at 37 degrees C and pH 7.4 in the presence of transition metal ion chelators. The presence of trace transition metal ions (present in all buffers) stimulates the catalytic breakdown of S-nitrosothiols to (NO)-N-. and disulfide. Thiyl radicals are not formed as intermediates in this process; Photolysis of S-nitrosothiols results in the formation of (NO)-N-. and disulfide via the intermediacy of thiyl radicals. Reduced metal ion (e.g, Cu+) decomposes S-nitrosothiols more rapidly than oxidized metal ion (e.g. Cu2+) indicating that reducing agents such as glutathione and ascorbate can stimulate decomposition of S-nitrosothiol by chemical reduction of contaminating transition metal ions. Transnitrosation can also stimulate S-nitrosothiol decomposition if the product S-nitrosothiol is more susceptible to transition metal ion-catalyzed decomposition than the parent S-nitrosothiol. Equilibrium constants for the transnitrosation reactions of reduced glutathione, either with S-nitroso-N-acetyl-DL-penicillamine or with S-nitroso-L-cysteine indicate that S-nitrosoglutathione formation is favored. The biological relevance of S-nitrosothiol decomposition is discussed.	MED COLL WISCONSIN,BIOPHYS RES INST,MILWAUKEE,WI 53226	Medical College of Wisconsin					NATIONAL CANCER INSTITUTE [P01CA049089] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001008] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL045058] Funding Source: NIH RePORTER; NCI NIH HHS [CA49089] Funding Source: Medline; NCRR NIH HHS [RR01008] Funding Source: Medline; NHLBI NIH HHS [HL45058] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARNELLE DR, 1995, ARCH BIOCHEM BIOPHYS, V318, P279, DOI 10.1006/abbi.1995.1231; ASAHI M, 1995, J BIOL CHEM, V270, P21035, DOI 10.1074/jbc.270.36.21035; ASKEW SC, 1995, J CHEM SOC PERK T 2, P741, DOI 10.1039/p29950000741; BARNETT DJ, 1995, J CHEM SOC PERK T 2, P1279, DOI 10.1039/p29950001279; BOESE M, 1995, J BIOL CHEM, V270, P29244, DOI 10.1074/jbc.270.49.29244; BONNER FT, 1986, INORG CHEM, V25, P2676; BUETTNER GR, 1985, FEBS LETT, V177, P295; CLANCY RM, 1994, P NATL ACAD SCI USA, V91, P3680, DOI 10.1073/pnas.91.9.3680; DEBELDER AJ, 1994, CARDIOVASC RES, V28, P691; DEMASTER EG, 1995, BIOCHEMISTRY-US, V34, P11494, DOI 10.1021/bi00036a023; ELLIOTT SJ, 1995, FREE RADICAL BIO MED, V19, P649, DOI 10.1016/0891-5849(95)00080-H; FEELISCH M, 1994, NATURE, V368, P62, DOI 10.1038/368062a0; FEELISCH M, 1991, J CARDIOVASC PHARM, V17, pS25, DOI 10.1097/00005344-199117003-00006; FIELD L, 1978, J CHEM SOC CHEM COMM, P249, DOI 10.1039/c39780000249; GASTON B, 1993, P NATL ACAD SCI USA, V90, P10957, DOI 10.1073/pnas.90.23.10957; GIRARD P, 1993, FEBS LETT, V320, P7, DOI 10.1016/0014-5793(93)81645-G; GOPALAKRISHNA R, 1993, J BIOL CHEM, V268, P27180; GROSS SS, 1995, ANNU REV PHYSIOL, V57, P737, DOI 10.1146/annurev.ph.57.030195.003513; HARMAN LS, 1986, J BIOL CHEM, V261, P1642; HART TW, 1985, TETRAHEDRON LETT, V26, P2013, DOI 10.1016/S0040-4039(00)98368-0; HOGG N, 1995, FREE RADICAL RES, V22, P47, DOI 10.3109/10715769509147527; Hogg N, 1996, FEBS LETT, V382, P223, DOI 10.1016/0014-5793(96)00086-5; IGNARRO LJ, 1981, J PHARMACOL EXP THER, V218, P739; JOSEPHY PD, 1984, TETRAHEDRON LETT, V25, P1685, DOI 10.1016/S0040-4039(01)81144-8; KONOREV EA, 1995, J PHARMACOL EXP THER, V274, P200; KOTAKE Y, 1994, FREE RADICAL BIO MED, V17, P215, DOI 10.1016/0891-5849(94)90077-9; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; MATHEWS WR, 1993, J PHARMACOL EXP THER, V267, P1529; MCANINLY J, 1993, J CHEM SOC CHEM COMM, P1758, DOI 10.1039/c39930001758; MEYER DJ, 1994, FEBS LETT, V345, P177, DOI 10.1016/0014-5793(94)00429-3; MIKUNI T, 1991, BIOCHEM INT, V24, P585; MYERS PR, 1990, NATURE, V345, P161, DOI 10.1038/345161a0; PARK JW, 1993, BIOCHEM MOL BIOL INT, V30, P885; PIETRAFORTE D, 1995, BIOCHEMISTRY-US, V34, P7177, DOI 10.1021/bi00021a032; RADOMSKI MW, 1992, BRIT J PHARMACOL, V107, P745, DOI 10.1111/j.1476-5381.1992.tb14517.x; SCHARFSTEIN JS, 1994, J CLIN INVEST, V94, P1432, DOI 10.1172/JCI117480; SEXTON DJ, 1994, PHOTOCHEM PHOTOBIOL, V59, P463, DOI 10.1111/j.1751-1097.1994.tb05065.x; SINGH RJ, 1995, FEBS LETT, V360, P47, DOI 10.1016/0014-5793(95)00065-H; SMIRNOVA TI, 1995, MAGNET RESON MED, V33, P801, DOI 10.1002/mrm.1910330610; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P444, DOI 10.1073/pnas.89.1.444; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P7674, DOI 10.1073/pnas.89.16.7674; ULLMAN EF, 1972, J AM CHEM SOC, V94, P7049, DOI 10.1021/ja00775a031; WINK DA, 1993, CHEM RES TOXICOL, V6, P23, DOI 10.1021/tx00031a003; WINK DA, 1994, CHEM RES TOXICOL, V7, P519, DOI 10.1021/tx00040a007; [No title captured]	45	483	494	7	64	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18596	18603		10.1074/jbc.271.31.18596	http://dx.doi.org/10.1074/jbc.271.31.18596			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702510	hybrid			2022-12-25	WOS:A1996VB68300048
J	Szallasi, Z; Bogi, K; Gohari, S; Biro, T; Acs, P; Blumberg, PM				Szallasi, Z; Bogi, K; Gohari, S; Biro, T; Acs, P; Blumberg, PM			Non-equivalent roles for the first and second zinc fingers of protein kinase C delta - Effect of their mutation on phorbol ester-induced translocation in NIH 3T3 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTEINE-RICH DOMAIN; DIFFERENTIAL REGULATION; BINDING; PHOSPHOLIPIDS; ACTIVATION; ISOZYMES; REGION; GAMMA	Classical and novel protein kinase C (PKC) isozymes contain two, so-called cysteine-rich zinc finger domains that represent the binding sites for phorbol esters and the diacylglycerols, X-ray crystallographic, mutational, and modeling studies are providing detailed understanding of the interactions between the phorbol esters and individual PKC zinc fingers, In the present study, we explore the roles of the individual zinc fingers in the context of the intact enzyme, Our approach was to mu tate either the first, the second, or both zinc fingers of PKC delta, to express the mutated enzyme in NIH 3T3 cells, and to monitor the effect of the mutations on the dose-response curve for translocation induced by phorbol 12-myristate 13-acetate. The introduced mutations change into glycine the consensus proline in the phorbol ester binding loop of the zinc finger; in the isolated zinc finger, this mutation causes a 125-fold decrease in phorbol ester binding affinity, We observed that mutation in the first zinc finger caused almost no shift in the dose-response curve for translocation; mutation in the second zinc finger caused a al-fold shift, whereas mutation in both zinc fingers caused a 138-fold shift, We conclude that the zinc fingers in the intact PRC are not equivalent and that the second zinc finger plays the predominant role in translocation of protein kinase C gamma in response to phorbol 12-myristate 13-acetate, Our findings have important implications for the understanding and design of PKC inhibitors targeted to the zinc finger domains.	NCI,CELLULAR CARCINOGENESIS & TUMOR PROMOT LAB,MOL MECHANISMS TUMOR PROMOT SECT,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)				Szallasi, Zoltan/0000-0001-5395-7509				BURNS DJ, 1991, J BIOL CHEM, V266, P18330; HOMMEL U, 1994, NAT STRUCT BIOL, V1, P383, DOI 10.1038/nsb0694-383; ICHIKAWA S, 1995, J BIOCHEM-TOKYO, V117, P566, DOI 10.1093/oxfordjournals.jbchem.a124745; KAZANIETZ MG, 1995, J BIOL CHEM, V270, P21852, DOI 10.1074/jbc.270.37.21852; KAZANIETZ MG, 1992, J BIOL CHEM, V267, P20878; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.48.28495; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OLAH Z, 1994, ANAL BIOCHEM, V221, P94, DOI 10.1006/abio.1994.1384; QUEST AFG, 1994, J BIOL CHEM, V269, P2953; QUEST AFG, 1994, J BIOL CHEM, V269, P20000; SHIEH HL, 1995, MOL CARCINOGEN, V12, P166, DOI 10.1002/mc.2940120308; Slater SJ, 1996, J BIOL CHEM, V271, P4627; SZALLASI Z, 1994, J BIOL CHEM, V269, P2118; SZALLASI Z, 1995, BIOCHEM BIOPH RES CO, V214, P888, DOI 10.1006/bbrc.1995.2370; SZALLASI Z, 1995, MOL PHARMACOL, V47, P258; ZHANG GG, 1995, CELL, V81, P917, DOI 10.1016/0092-8674(95)90011-X	16	127	129	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18299	18301		10.1074/jbc.271.31.18299	http://dx.doi.org/10.1074/jbc.271.31.18299			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702464	hybrid			2022-12-25	WOS:A1996VB68300002
J	Toke, DA; Martin, CE				Toke, DA; Martin, CE			Isolation and characterization of a gene affecting fatty acid elongation in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; NEUROSPORA-CRASSA; SYNTHASE; YEAST; PROTEIN; BIOSYNTHESIS; DESATURASE; SEQUENCE; SYSTEM; GOLGI	Fatty acid elongation defective mutants were isolated from Saccharomyces cerevisiae by mutagenizing strains that were defective in fatty acid synthase (FAS) activity, Cells of the fatty acid synthase-defective strains can grow when supplemented with tetradecanoic acid (14:0) due to the presence of membrane bound elongation systems that can extend the 14 carbon fatty acid to longer chain species, After mutagenesis and rescue on medium containing a mixture of 14:0, 16:0 and 18:0, cells were screened for their inability to grow on medium containing only 14:0, From 150,000 colonies, four stable isolates were identified, all of which appear to represent the same complementation group, Gas chromatography of lipid extracts from mutant elo1-1 (designated as elongation defective) cells grown with long or medium chain fatty acids indicates that it fails to efficiently elongate (12, 13, or 14) carbon fatty acids, A gene disrupted fas2 Delta::LEU2;elo1 Delta::HIS3 mutant incorporates 14-18-carbon fatty acids into membrane lipids, indicating that fatty acid transport is not affected by the mutation, Molecular cloning and sequence analysis of the ELO1 gene suggests that the encoded protein is a membrane bound polypeptide that contains at least five potential membrane spanning regions and a presumptive NADPH binding site, Analysis of the ELO1 mRNA levels indicates that the gene is expressed in cells grown on fatty acid deficient medium, It is rapidly induced in wild type cells that are supplemented with 14:0 and is repressed when cells are supplied with 16- and 18-carbon fatty acids.	RUTGERS STATE UNIV,DEPT BIOL SCI,BUR BIOL RES,NELSON BIOL LABS,PISCATAWAY,NJ 08855	Rutgers State University New Brunswick					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045768] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM45768] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AARONSON LR, 1983, BIOCHIM BIOPHYS ACTA, V735, P252, DOI 10.1016/0005-2736(83)90300-0; AARONSON LR, 1982, BIOCHIM BIOPHYS ACTA, V713, P456, DOI 10.1016/0005-2760(82)90265-X; AARONSON LR, 1988, J BIOL CHEM, V263, P14552; AMY CM, 1989, P NATL ACAD SCI USA, V86, P3114, DOI 10.1073/pnas.86.9.3114; Ausubel F.M., 1993, CURRENT PROTOCOLS MO; BESSOULE JJ, 1988, EUR J BIOCHEM, V177, P207, DOI 10.1111/j.1432-1033.1988.tb14363.x; BROWSE J, 1986, PLANT PHYSIOL, V81, P859, DOI 10.1104/pp.81.3.859; CHIRALA SS, 1992, P NATL ACAD SCI USA, V89, P10232, DOI 10.1073/pnas.89.21.10232; Choi JY, 1996, J BIOL CHEM, V271, P3581; CINTI DL, 1992, PROG LIPID RES, V31, P1, DOI 10.1016/0163-7827(92)90014-A; FOX BG, 1994, BIOCHEMISTRY-US, V33, P12776, DOI 10.1021/bi00209a008; GAYNOR EC, 1994, J CELL BIOL, V127, P653, DOI 10.1083/jcb.127.3.653; HERRICK D, 1990, MOL CELL BIOL, V10, P2269, DOI 10.1128/MCB.10.5.2269; HOLZER KP, 1989, P NATL ACAD SCI USA, V86, P4387, DOI 10.1073/pnas.86.12.4387; JAMES DW, 1995, PLANT CELL, V7, P309, DOI 10.2307/3869853; JAYAKUMAR A, 1995, P NATL ACAD SCI USA, V92, P8695, DOI 10.1073/pnas.92.19.8695; KNOLL LJ, 1995, J BIOL CHEM, V270, P10861, DOI 10.1074/jbc.270.18.10861; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; MOHAMED AH, 1988, J BIOL CHEM, V263, P12315; NAGIEC MM, 1993, J BIOL CHEM, V268, P22156; OSEI P, 1989, J BIOL CHEM, V264, P6844; ROGGENKAMP R, 1980, P NATL ACAD SCI-BIOL, V77, P1814, DOI 10.1073/pnas.77.4.1814; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; SCHRODER S, 1995, J CELL BIOL, V131, P895, DOI 10.1083/jcb.131.4.895; SCHWEIZER E, 1978, MOL CELL BIOCHEM, V21, P95; SHANKLIN J, 1994, BIOCHEMISTRY-US, V33, P12787, DOI 10.1021/bi00209a009; Sherman F., 1982, METHODS YEAST GENETI; STRATHERN JN, 1991, METHOD ENZYMOL, V194, P322; STUKEY JE, 1989, J BIOL CHEM, V264, P16537; [No title captured]	32	155	162	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18413	18422		10.1074/jbc.271.31.18413	http://dx.doi.org/10.1074/jbc.271.31.18413			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702485	hybrid			2022-12-25	WOS:A1996VB68300023
J	Wong, EV; Schaefer, AW; Landreth, G; Lemmon, V				Wong, EV; Schaefer, AW; Landreth, G; Lemmon, V			Involvement of p90(rsk) in neurite outgrowth mediated by the cell adhesion molecule L1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PC12 PHEOCHROMOCYTOMA CELLS; 2ND MESSENGER SYSTEMS; RIBOSOMAL S6 KINASE; PROTEIN-KINASE; NERVOUS-SYSTEM; L1-LIKE MOLECULE; IMMUNOGLOBULIN SUPERFAMILY; SIGNAL-TRANSDUCTION; NILE GLYCOPROTEIN; N-CAM	L1 is a neural cell adhesion molecule that has been shown to help guide nascent axons to their targets, This guidance is based on specific interactions of L1 with its binding partners and is likely to involve signaling cascades that alter cytoskeletal elements in response to these binding events. We have examined the phosphorylation of L1 and the role it may have in L1-directed neurite outgrowth. Cytosolic extracts from nerve growth factor-stimulated PC12 cells were fractionated by anion-exchange chromatography, and an activity was found that phosphorylated the cytoplasmic domain of L1. This activity was then assayed using a battery of L1-derived synthetic peptides, Based on these peptide assays and sequencing of radiolabeled L1 proteolytic fragments, the phosphorylation site was determined to be Ser(1152). Western blot analysis demonstrated that the L1 kinase activity from PC12 cells that phosphorylated this site was co-eluted with the S6 kinase, p90(rsk), Moreover, S6 kinase activity and p90(rsk) immunoreactivity co-immunoprecipitate with L1 from brain, and metabolic labeling studies have demonstrated that Ser(1152) is phosphorylated in vivo in the developing rat brain. The phosphorylation site is located in a region of high conservation between mammalian L1 sequences as well as L1-related molecules in vertebrates from fish to birds, We performed studies to investigate the functional significance of this phosphorylation, Neurons were loaded with peptides that encompass the phosphorylation site, as well as the flanking regions, and their effects on neurite outgrowth were observed. The peptides, which include Ser(1152), inhibit neurite outgrowth on L1 but not on a control substrate, laminin. A nonphosphorylatable peptide carrying a Ser to Ala mutation did not affect neurite outgrowth on either substrate, These data demonstrate that the membrane-proximal 15 amino acids of the cytoplasmic domain of L1 are important for neurite outgrowth on L1, and the interactions it mediates may be regulated by phosphorylation of Ser(1152).	CASE WESTERN RESERVE UNIV,DEPT NEUROSCI,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,DEPT NEUROL,CLEVELAND,OH 44106	Case Western Reserve University; Case Western Reserve University			Lemmon, Vance/A-2565-2008; Lemmon, Vance/A-7410-2010	Lemmon, Vance/0000-0003-3550-7576	NEI NIH HHS [R01 EY005285] Funding Source: Medline; PHS HHS [31987, 5285] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY005285] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ALCORTA DA, 1989, MOL CELL BIOL, V9, P3850, DOI 10.1128/MCB.9.9.3850; ATASHI JR, 1992, NEURON, V8, P831, DOI 10.1016/0896-6273(92)90197-L; BIEBER AJ, 1989, CELL, V59, P447, DOI 10.1016/0092-8674(89)90029-9; BJORBAEK C, 1995, J BIOL CHEM, V270, P18848, DOI 10.1074/jbc.270.32.18848; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BRUMMENDORF T, 1993, NEURON, V10, P711; Burden-Gulley Susan M., 1995, Seminars in Developmental Biology, V6, P79, DOI 10.1016/S1044-5781(06)80017-4; BURDENGULLEY SM, 1995, J NEUROSCI, V15, P4370; BURDENGULLEY SM, 1996, IN PRESS CELL MOTIL; CALVO V, 1992, EUR J IMMUNOL, V22, P457, DOI 10.1002/eji.1830220225; CERVELLO M, 1991, P NATL ACAD SCI USA, V88, P10548, DOI 10.1073/pnas.88.23.10548; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; DAVIS JQ, 1993, J CELL BIOL, V121, P121, DOI 10.1083/jcb.121.1.121; DAVIS JQ, 1994, J BIOL CHEM, V269, P27163; DOHERTY P, 1994, J NEUROCHEM, V62, P2124; Doherty Patrick, 1994, Current Opinion in Neurobiology, V4, P49, DOI 10.1016/0959-4388(94)90031-0; ERIKSON RL, 1991, J BIOL CHEM, V266, P6007; FAISSNER A, 1984, DEV BRAIN RES, V15, P69, DOI 10.1016/0165-3806(84)90141-X; FELSENFELD DP, 1994, NEURON, V12, P675, DOI 10.1016/0896-6273(94)90222-4; GLASS DB, 1978, ANAL BIOCHEM, V87, P566, DOI 10.1016/0003-2697(78)90707-8; Goldman SA, 1996, MOL CELL NEUROSCI, V7, P29, DOI 10.1006/mcne.1996.0003; GREENE LA, 1987, METHOD ENZYMOL, V147, P207; GRUMET M, 1991, J CELL BIOL, V113, P1399, DOI 10.1083/jcb.113.6.1399; GRUMET M, 1984, P NATL ACAD SCI-BIOL, V81, P267, DOI 10.1073/pnas.81.1.267; HLAVIN ML, 1991, GENOMICS, V11, P416, DOI 10.1016/0888-7543(91)90150-D; IGNELZI MA, 1994, NEURON, V12, P873, DOI 10.1016/0896-6273(94)90339-5; ITOH K, 1992, BRAIN RES, V580, P233, DOI 10.1016/0006-8993(92)90949-A; JURIVICH DA, 1991, J CELL PHYSIOL, V148, P252, DOI 10.1002/jcp.1041480210; KUHN TB, 1991, J CELL BIOL, V115, P1113, DOI 10.1083/jcb.115.4.1113; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAGENAUR C, 1987, P NATL ACAD SCI USA, V84, P7753, DOI 10.1073/pnas.84.21.7753; LANDMESSER L, 1988, DEV BIOL, V130, P645, DOI 10.1016/0012-1606(88)90358-2; LEMMON V, 1989, NEURON, V2, P1597, DOI 10.1016/0896-6273(89)90048-2; LEMMON V, 1986, J NEUROSCI, V6, P2987; LINDNER J, 1983, NATURE, V305, P427, DOI 10.1038/305427a0; MILEV P, 1994, J CELL BIOL, V127, P1703, DOI 10.1083/jcb.127.6.1703; MIURA M, 1991, FEBS LETT, V289, P91, DOI 10.1016/0014-5793(91)80915-P; MOOS M, 1988, NATURE, V334, P701, DOI 10.1038/334701a0; NOVAKHOFER I, 1984, J BIOL CHEM, V259, P5995; PAPKOFF J, 1994, MOL CELL BIOL, V14, P463, DOI 10.1128/MCB.14.1.463; PAYNE HR, 1992, CELL MOTIL CYTOSKEL, V21, P65, DOI 10.1002/cm.970210108; PRINCE JT, 1989, J NEUROSCI, V9, P1825; RADER C, 1993, EUR J BIOCHEM, V215, P133, DOI 10.1111/j.1432-1033.1993.tb18015.x; RATHJEN FG, 1987, CELL, V51, P841, DOI 10.1016/0092-8674(87)90107-3; RATHJEN FG, 1987, J CELL BIOL, V104, P343, DOI 10.1083/jcb.104.2.343; ROSENTHAL A, 1992, NAT GENET, V2, P107, DOI 10.1038/ng1092-107; SADOUL R, 1989, J NEUROCHEM, V53, P1471, DOI 10.1111/j.1471-4159.1989.tb08540.x; SALTON SRJ, 1983, J NEUROSCI, V3, P2420; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHUCH U, 1989, NEURON, V3, P13, DOI 10.1016/0896-6273(89)90111-6; SCIMECA JC, 1992, J BIOL CHEM, V267, P17369; STALLCUP WB, 1985, P NATL ACAD SCI USA, V82, P1276, DOI 10.1073/pnas.82.4.1276; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; TAYLOR LK, 1994, J BIOL CHEM, V269, P308; TORDAI A, 1994, J BIOL CHEM, V269, P7538; VONBOHLEN F, 1992, EUR J NEUROSCI, V4, P896; WILLIAMS EJ, 1994, NEURON, V13, P583, DOI 10.1016/0896-6273(94)90027-2; WILLIAMS EJ, 1992, J CELL BIOL, V119, P883, DOI 10.1083/jcb.119.4.883; WILLIAMS EJ, 1994, J NEUROCHEM, V62, P1281; Wong EV, 1996, J NEUROCHEM, V66, P779; WONG EV, 1995, TRENDS NEUROSCI, V18, P168, DOI 10.1016/0166-2236(95)93896-6	61	88	91	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					18217	18223		10.1074/jbc.271.30.18217	http://dx.doi.org/10.1074/jbc.271.30.18217			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663493	hybrid			2022-12-25	WOS:A1996UY93500094
J	Pauletti, G; Godolphin, W; Press, MF; Slamon, DJ				Pauletti, G; Godolphin, W; Press, MF; Slamon, DJ			Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization	ONCOGENE			English	Article						HER-2/neu; c-erbB-2; gene amplification; breast cancer; FISH; interphase cytogenetics	INSITU HYBRIDIZATION; C-ERBB-2 AMPLIFICATION; ONCOGENE AMPLIFICATION; PROTO-ONCOGENE; CIRCULAR DNA; CELLS; EXPRESSION; FIXATION; FORMALIN; DISEASE	Amplification and overexpression of the HER-2/neu gene occurs in 25-30% of human breast cancers, This genetic alteration is associated with a poor clinical prognosis in women with either node negative or node positive breast cancers, The initial studies testing this association were somewhat controversial and this controversy was due in large part to significant heterogeneity in both the methods and/or reagents used in testing archival material for the presence of the alteration, These methods included a number of solid matrix blotting techniques for DNA, RNA and protein as well as immunohistochemistry, Fluorescence in situ hybridization (FISH) represents the newest methodologic approach for testing for this genetic alteration, In this study, FISH is compared to Southern, Northern and Western blot analyses as well as immunohistochemistry in a large cohort of archival human breast cancer specimens, FISH was found to be superior to all other methodologies tested in assessing formalin fixed, paraffin embedded material for HER-2/neu amplification, The results from this study also confirm that overexpression of HER-2/neu rarely occurs in the absence of gene amplification in breast cancer (approximately 3% of cases), This method of analysis is rapid, reproducible and extremely reliable in detecting presence of HER-2/neu gene amplification and should have clinical utility.	UNIV CALIF LOS ANGELES,DEPT MED,DIV HEMATOL ONCOL,LOS ANGELES,CA 90095; DEPT CLIN CHEM,VANCOUVER,BC V5Z 1M9,CANADA; UNIV SO CALIF,SCH MED,DEPT PATHOL,LOS ANGELES,CA 90033	University of California System; University of California Los Angeles; University of Southern California			Godolphin, William/AAE-2699-2022		NCI NIH HHS [CA36827, CA48780] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA048780, R01CA036827] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALI IU, 1988, ONCOGENE RES, V3, P139; BATTIFORA H, 1986, J HISTOCHEM CYTOCHEM, V34, P1095, DOI 10.1177/34.8.2426335; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BRISON O, 1993, BIOCHIM BIOPHYS ACTA, V1155, P25, DOI 10.1016/0304-419X(93)90020-D; CARROLL SM, 1987, MOL CELL BIOL, V7, P1740, DOI 10.1128/MCB.7.5.1740; CLARK GM, 1991, CANCER RES, V51, P944; COWELL JK, 1982, ANNU REV GENET, V16, P21, DOI 10.1146/annurev.ge.16.120182.000321; DEVILEE P, 1994, BBA-REV CANCER, V1198, P113, DOI 10.1016/0304-419X(94)90009-4; DHINGRA K, 1992, BREAST CANCER RES TR, V23, P201, DOI 10.1007/BF01833516; GREER CE, 1991, AM J CLIN PATHOL, V95, P117, DOI 10.1093/ajcp/95.2.117; GULLICK WJ, 1991, BRIT J CANCER, V63, P434, DOI 10.1038/bjc.1991.100; GUSTERSON BA, 1988, BRIT J CANCER, V58, P453, DOI 10.1038/bjc.1988.239; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; HYYTINEN E, 1994, CYTOMETRY, V16, P93, DOI 10.1002/cyto.990160202; KALLIONIEMI OP, 1992, P NATL ACAD SCI USA, V89, P5321, DOI 10.1073/pnas.89.12.5321; KURY F, 1990, EUR J CANCER, V26, P946, DOI 10.1016/0277-5379(90)90616-2; LIU E, 1992, ONCOGENE, V7, P1027; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; MATSUMURA K, 1992, CANCER RES, V52, P3474; MAURER BJ, 1987, NATURE, V327, P434, DOI 10.1038/327434a0; MICALE MA, 1994, HUM PATHOL, V25, P29, DOI 10.1016/0046-8177(94)90167-8; MULERIS M, 1995, GENE CHROMOSOME CANC, V14, P155, DOI 10.1002/gcc.2870140302; MURPHY DS, 1995, J NATL CANCER I, V87, P1694, DOI 10.1093/jnci/87.22.1694; MUSS HB, 1994, NEW ENGL J MED, V330, P1260, DOI 10.1056/NEJM199405053301802; NABER SP, 1990, AM J CLIN PATHOL, V94, P125, DOI 10.1093/ajcp/94.2.125; NUOVO GJ, 1989, AM J PATHOL, V134, P837; PAULETTI G, 1990, P NATL ACAD SCI USA, V87, P2955, DOI 10.1073/pnas.87.8.2955; PENAULTLLORCA F, 1994, J PATHOL, V173, P65, DOI 10.1002/path.1711730111; PERSONS DL, 1993, AM J PATHOL, V142, P733; PINKEL D, 1986, P NATL ACAD SCI USA, V83, P2934, DOI 10.1073/pnas.83.9.2934; PODDIGHE PJ, 1992, J PATHOL, V166, P215, DOI 10.1002/path.1711660303; POPESCU NC, 1989, GENOMICS, V4, P362, DOI 10.1016/0888-7543(89)90343-1; PRESS MF, 1993, CANCER RES, V53, P4960; PRESS MF, 1994, CANCER RES, V54, P2771; RENTROP M, 1986, HISTOCHEM J, V18, P271, DOI 10.1007/BF01676237; RICHNER J, 1990, ANN ONCOL, V1, P263, DOI 10.1093/oxfordjournals.annonc.a057745; SAUTER G, 1993, CANCER RES, V53, P2199; SESHADRI R, 1993, J CLIN ONCOL, V11, P1936, DOI 10.1200/JCO.1993.11.10.1936; SHAPIRO DN, 1993, AM J PATHOL, V142, P1339; SILVERSTEIN MJ, 1995, LANCET, V345, P1154; SLAMON DJ, 1989, CANCER CEL, V7, P371; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1988, SCIENCE, V240, P1796, DOI 10.1126/science.240.4860.1796; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; THOMPSON CT, 1994, AM J PATHOL, V144, P237; TRASK BJ, 1991, TRENDS GENET, V7, P149, DOI 10.1016/0168-9525(91)90378-4; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VISSCHER DW, 1995, CYTOMETRY, V21, P95, DOI 10.1002/cyto.990210117; VONHOFF DD, 1988, P NATL ACAD SCI USA, V85, P4804; WAHL GM, 1989, CANCER RES, V49, P1333; WAYE JS, 1986, MOL CELL BIOL, V6, P3156, DOI 10.1128/MCB.6.9.3156; WOLMAN SR, 1983, CANCER METAST REV, V2, P257, DOI 10.1007/BF00048481; ZHOU DJ, 1989, ONCOGENE, V4, P105	54	486	497	0	23	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 4	1996	13	1					63	72						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UX319	8700555				2022-12-25	WOS:A1996UX31900008
J	Gutmann, DH; Giordano, MJ; Mahadeo, DK; Lau, N; Silbergeld, D; Guha, A				Gutmann, DH; Giordano, MJ; Mahadeo, DK; Lau, N; Silbergeld, D; Guha, A			Increased neurofibromatosis 1 gene expression in astrocytic tumors: Positive regulation by p21-ras	ONCOGENE			English	Article						tumor suppressor gene; gliomas; p21-ras; neurofibromin; GAP	TYPE-1 GENE; CELL-LINES; NF1 GENE; PRODUCT; GROWTH; NEUROBLASTOMA; MUTATIONS; ONCOGENES; MELANOMA; NEURONS	The neurofibromatosis 1 (NF1) gene has been implicated in astrocyte growth regulation in several studies, To determine whether loss of NF1 expression is associated with progression towards malignancy in sporadic astrocytomas from individuals without NF1, twenty-eight fresh astrocytoma operative specimens (low and high grade tumors) and seven primary human astrocytoma cell lines were examined for NF1 mRNA and protein expression, In all astrocytomas examined, increased NF1 expression was observed in the tumors relative to normal resting astrocytes, This increased neurofibromin expression correlated with elevated levels of activated p21-ras measured in both the fresh tumor specimens and the primary cell lines, Furthermore, when levels of activated p21 ras were decreased in astrocytoma cells expressing the ras inhibitory Asn-17 dominant-negative mutant, levels of neurofibromin expression decreased, In addition, fibroblasts induced to express oncogenic activated p21-ras(val12) had increased expression of NF1. These results suggested that neurofibromin expression is increased in human astrocytic tumors as a result of positive feedback regulation by increased levels of activated p21-ras.	WASHINGTON UNIV,SCH MED,DEPT GENET,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT NEUROSURG,ST LOUIS,MO 63110; MT SINAI HOSP,SAMUEL LUNENFELD RES INST,TORONTO,ON M5G 1X5,CANADA; TORONTO HOSP,DIV NEUROSURG,TORONTO,ON M5T 2S8,CANADA	Washington University (WUSTL); Washington University (WUSTL); University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Gutmann, DH (corresponding author), WASHINGTON UNIV,SCH MED,DEPT NEUROL,BOX 8111,660 S EUCLID AVE,ST LOUIS,MO 63110, USA.			Gutmann, David/0000-0002-3127-5045	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K08NS001590, R29NS033494] Funding Source: NIH RePORTER; NINDS NIH HHS [NS33494-01, NS01590-04] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDERSEN LB, 1993, MOL CELL BIOL, V13, P487, DOI 10.1128/MCB.13.1.487; ANDERSEN LB, 1993, NAT GENET, V3, P118, DOI 10.1038/ng0293-118; BASU TN, 1992, NATURE, V356, P713, DOI 10.1038/356713a0; BOS JL, 1989, CANCER RES, V49, P4682; DASTON MM, 1992, NEURON, V8, P415, DOI 10.1016/0896-6273(92)90270-N; DECLUE JE, 1992, CELL, V69, P265, DOI 10.1016/0092-8674(92)90407-4; Duffner P K, 1988, Neurofibromatosis, V1, P201; GIORDANO MJ, 1996, J NEUROSCIENCE RS, V46, P246; GREGORY PE, 1993, SOMAT CELL MOLEC GEN, V13, P487; GUHA A, 1995, INT J CANCER, V60, P168, DOI 10.1002/ijc.2910600206; Guha A, 1996, ONCOGENE, V12, P507; GUTMANN DH, 1993, J NEUROSCI RES, V36, P216, DOI 10.1002/jnr.490360212; GUTMANN DH, 1991, P NATL ACAD SCI USA, V88, P9658, DOI 10.1073/pnas.88.21.9658; GUTMANN DH, 1995, CELL GROWTH DIFFER, V6, P315; GUTMANN DH, 1994, J NEUROSCI RES, V37, P398, DOI 10.1002/jnr.490370312; HEWETT SJ, 1993, NEUROSCI LETT, V164, P229, DOI 10.1016/0304-3940(93)90898-U; HEWETT SJ, 1995, NEUROREPORT, V6, P1565, DOI 10.1097/00001756-199507310-00025; JOHNSON MR, 1993, P NATL ACAD SCI USA, V90, P5539, DOI 10.1073/pnas.90.12.5539; KIM HA, 1995, ONCOGENE, V11, P325; LEGIUS E, 1993, NAT GENET, V3, P122, DOI 10.1038/ng0293-122; NISTER M, 1991, J BIOL CHEM, V266, P16755; NORDLUND M, 1993, J NEUROSCI, V13, P1588; NORTON KK, 1996, IN PRESS NEUROREPORT; RICCARDI VM, 1991, NEW ENGL J MED, V324, P1283, DOI 10.1056/NEJM199105023241812; RIDLEY AJ, 1988, EMBO J, V7, P1635, DOI 10.1002/j.1460-2075.1988.tb02990.x; SCHEELE JS, 1995, P NATL ACAD SCI USA, V92, P1097, DOI 10.1073/pnas.92.4.1097; SERVE H, 1995, EMBO J, V14, P473, DOI 10.1002/j.1460-2075.1995.tb07023.x; SHAMAH SM, 1993, MOL CELL BIOL, V13, P7203, DOI 10.1128/MCB.13.12.7203; THE I, 1993, NAT GENET, V3, P62, DOI 10.1038/ng0193-62; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741	30	44	44	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 16	1996	12	10					2121	2127						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UP283	8668337				2022-12-25	WOS:A1996UP28300010
J	Li, SN; Chang, YS; Liu, ST				Li, SN; Chang, YS; Liu, ST			Effect of a 10-amino acid deletion on the oncogenic activity of latent membrane protein 1 of Epstein-Barr virus	ONCOGENE			English	Article						Epstein-Barr virus; BNLF1; latent membrane protein	NASOPHARYNGEAL CARCINOMA; MAMMALIAN-CELLS; BNLF-1 GENE; TRANSFORMATION; LYMPHOCYTES; EXPRESSION; DNA; REPLICATION; INFECTION; PLASMIDS	A previous study has shown that the BNLF1 of Epstein-Barr virus (EBV),isolated from a nasopharyngeal carcinoma biopsy (BNLF1-1510), was able to transform Balb/3T3 cells,On the other hand, BNLF1 of a prototype virus B95-8 (BNLF1-958) was not transforming unless the gene was transcribed from a strong promoter, In this study, we have generated chimeric BNLF1 by exchanging the DNA fragments between BNLF1-1510 and BNLF1-958 and examined their expression and transformation ability in Balb/3T3 cells, Results showed that transformation of Balb/3T3 cells by BNLF1-1510 was not due to the excessive expression of the gene, Transfection of Balb/3T3 cells with chimeric BNLF1 showed that the genes with 3' 453 bp sequence of BNLF1-1510 were oncogenic to the cells, Study also revealed that changing the numbers of the 33 bp repeats in the 3' region of the two BNLF1s did not affect the transformation characteristics. On the other hand, deletion of a 30 bp sequence of BNLF1-958, which is absent in BNLF1-1510, changed the gene oncogenic to oncogenic and insertion of sequence into BNLF1-1510 abolished the transformation ability, BNLF1 without this 30 bp sequence was also found in the tumours of other EBV-related neoplastic disease, suggesting that absence of this 30 bp sequence in BNLF1 may be associated with the oncogenesis of these diseases.	CHANG GUNG COLL MED & TECHNOL,DEPT IMMUNOL & MICROBIOL,GENET MOLEC LAB,TAYUAN 333,TAIWAN; NATL YANG MING UNIV,GRAD INST MICROBIOL & IMMUNOL,TAIPEI 112,TAIWAN	Chang Gung University; National Yang Ming Chiao Tung University								BAICHWAL VR, 1988, ONCOGENE, V2, P461; BAICHWAL VR, 1989, ONCOGENE, V4, P67; BROUSSET P, 1994, BLOOD, V84, P2447; CHANG YS, 1995, INT J CANCER, V62, P673, DOI 10.1002/ijc.2910620605; CHANG YS, 1990, LEUKEMIA RES, V14, P309, DOI 10.1016/0145-2126(90)90157-5; CHEN ML, 1992, ONCOGENE, V7, P2131; CHEN ML, 1995, VIRUS RES, V37, P75; COHEN JI, 1989, P NATL ACAD SCI USA, V86, P9558, DOI 10.1073/pnas.86.23.9558; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; EPSTEIN MA, 1964, LANCET, V1, P702, DOI 10.1016/s0140-6736(64)91524-7; FAHRAEUS R, 1988, INT J CANCER, V42, P329, DOI 10.1002/ijc.2910420305; FENNEWALD S, 1984, J VIROL, V51, P411, DOI 10.1128/JVI.51.2.411-419.1984; FINGEROTH JD, 1984, P NATL ACAD SCI-BIOL, V81, P4510, DOI 10.1073/pnas.81.14.4510; GRAHAM F, 1973, VIROLOGY, V52, P452; HAMMERSCHMIDT W, 1989, J VIROL, V63, P2469, DOI 10.1128/JVI.63.6.2469-2475.1989; HENLE G, 1976, INT J CANCER, V17, P1, DOI 10.1002/ijc.2910170102; HENLE G, 1968, P NATL ACAD SCI USA, V59, P94, DOI 10.1073/pnas.59.1.94; HU LF, 1991, J GEN VIROL, V72, P2399, DOI 10.1099/0022-1317-72-10-2399; HUEN DS, 1995, ONCOGENE, V10, P549; JENG KCG, 1994, J CLIN MICROBIOL, V32, P28, DOI 10.1128/JCM.32.1.28-31.1994; KAYE KM, 1995, J VIROL, V69, P675, DOI 10.1128/JVI.69.2.675-683.1995; KIEFF E, 1990, VIROLOGY, P1889; KNECHT H, 1995, ONCOGENE, V10, P523; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIEBOWITZ D, 1987, MOL CELL BIOL, V7, P2299, DOI 10.1128/MCB.7.7.2299; LINDAHL T, 1976, J MOL BIOL, V102, P511, DOI 10.1016/0022-2836(76)90331-4; LUPTON S, 1985, MOL CELL BIOL, V5, P2533, DOI 10.1128/MCB.5.10.2533; MARTIN J, 1991, J VIROL, V65, P3246, DOI 10.1128/JVI.65.6.3246-3258.1991; MILLER WE, 1994, J GEN VIROL, V75, P2729, DOI 10.1099/0022-1317-75-10-2729; MOORTHY RK, 1993, J VIROL, V67, P1638, DOI 10.1128/JVI.67.3.1638-1646.1993; MOORTHY RK, 1993, J VIROL, V67, P2637, DOI 10.1128/JVI.67.5.2637-2645.1993; MOSIALS G, 1995, CELL, V80, P387; NIEDERMAN JC, 1968, J AMER MED ASSOC, V203, P205; PATHMANATHAN R, 1995, NEW ENGL J MED, V333, P693, DOI 10.1056/NEJM199509143331103; PURTILO DT, 1981, CANCER RES, V41, P4226; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SANDVEJ K, 1994, BLOOD, V84, P4053, DOI 10.1182/blood.V84.12.4053.bloodjournal84124053; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIXBEY JW, 1984, NEW ENGL J MED, V310, P1225, DOI 10.1056/NEJM198405103101905; SU IJ, 1991, BLOOD, V77, P799; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRIVEDI P, 1994, EUR J CANCER, V30A, P84, DOI 10.1016/S0959-8049(05)80024-3; WALLING DM, 1995, J INFECT DIS, V171, P1122, DOI 10.1093/infdis/171.5.1122; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; WANG F, 1990, J VIROL, V64, P3407, DOI 10.1128/JVI.64.7.3407-3416.1990; YATES JL, 1985, NATURE, V313, P812, DOI 10.1038/313812a0; YOUNG LS, 1988, J GEN VIROL, V69, P1051, DOI 10.1099/0022-1317-69-5-1051	47	125	137	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 16	1996	12	10					2129	2135						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UP283	8668338				2022-12-25	WOS:A1996UP28300011
J	Arselin, G; Vaillier, J; Graves, PV; Velours, J				Arselin, G; Vaillier, J; Graves, PV; Velours, J			ATP synthase of yeast mitochondria - Isolation of the subunit h and disruption of the ATP14 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE HEART-MITOCHONDRIA; AMINO-ACID-SEQUENCE; SACCHAROMYCES-CEREVISIAE; STRUCTURAL GENE; ADENOSINE-TRIPHOSPHATASE; MEMBRANE SYSTEM; PURIFICATION; F1-ATPASE; PROTEINS; COMPLEX	A new subunit of the yeast ATP synthase (termed subunit h) has been isolated. Amino acid composition and N-terminal sequencing were determined by chemical methods. These data were in agreement with the sequence of the hypothetical protein L8003.20 whose primary structure was deduced from DNA sequencing of the yeast chromosome XII. The amino acid sequence encoded by ATP14 gene is 32 amino acids longer than the mature protein, which contains 92 amino acids corresponding to a calculated mass of 10,408 Da. The protein is hydrophilic and acidic with a calculated pH(i) of 4.08. It is not apparently related to any subunit described in other ATP synthases. A null mutant was constructed. The mutation was recessive and the mutant strain was unable to grow on glycerol medium. A high percentage of rho(-) cells arose spontaneously. The mutant mitochondria had no detectable oligomycin-sensitive ATPase activity, but still contained ATPase activity with a catalytic sector dissociated from the membranous components. The mutant mitochondria did not contain subunit h, and the mitochondrially encoded hydrophobic subunit 6 was not present.	UNIV BORDEAUX 2,INST BIOCH & GENET CELLULAIRES,CNRS,F-33077 BORDEAUX,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite de Bordeaux								ANSORGE W, 1983, ELECTROPHORESIS 82, P235; ARSELIN G, 1991, J BIOL CHEM, V266, P723; CHOU PY, 1977, J MOL BIOL, V115, P135, DOI 10.1016/0022-2836(77)90094-8; COLLINSON IR, 1994, BIOCHEMISTRY-US, V33, P7971, DOI 10.1021/bi00191a026; DECHATEAUBODEAU GA, 1976, BIOCHIMIE PARIS, V58, P601; DELEAGE G, 1988, COMPUT APPL BIOSCI, V4, P351; EMAUS RK, 1986, BIOCHIM BIOPHYS ACTA, V850, P436, DOI 10.1016/0005-2728(86)90112-X; ENNS RK, 1977, ARCH BIOCHEM BIOPHYS, V182, P587, DOI 10.1016/0003-9861(77)90540-9; FILLINGAME RH, 1990, BACTERIA TREATISE ST, V12, P345; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GIRAUD MF, 1994, EUR J BIOCHEM, V222, P851, DOI 10.1111/j.1432-1033.1994.tb18932.x; GUELIN E, 1993, J BIOL CHEM, V268, P161; Guerin B, 1979, Methods Enzymol, V55, P149; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; HOLLOWAY PW, 1973, ANAL BIOCHEM, V53, P304, DOI 10.1016/0003-2697(73)90436-3; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; LANG B, 1977, ANAL BIOCHEM, V77, P110, DOI 10.1016/0003-2697(77)90295-0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACH H, 1992, ANAL BIOCHEM, V200, P74, DOI 10.1016/0003-2697(92)90279-G; MACINO G, 1980, CELL, V20, P507, DOI 10.1016/0092-8674(80)90637-6; Maniatis T., 1982, MOL CLONING; NAGLEY P, 1988, TRENDS GENET, V4, P46, DOI 10.1016/0168-9525(88)90066-2; NORAIS N, 1991, J BIOL CHEM, V266, P16541; PAUL MF, 1992, EUR J BIOCHEM, V205, P163, DOI 10.1111/j.1432-1033.1992.tb16764.x; PAUL MF, 1989, EUR J BIOCHEM, V185, P163, DOI 10.1111/j.1432-1033.1989.tb15098.x; PAUL MF, 1994, J BIOL CHEM, V269, P26158; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SALTZGABERMULLER J, 1983, J BIOL CHEM, V258, P1465; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SENIOR AE, 1988, PHYSIOL REV, V68, P177, DOI 10.1152/physrev.1988.68.1.177; SIERRA MF, 1973, P NATL ACAD SCI USA, V70, P3155, DOI 10.1073/pnas.70.11.3155; SOMLO M, 1968, EUR J BIOCHEM, V5, P276, DOI 10.1111/j.1432-1033.1968.tb00368.x; TAKEDA M, 1986, J BIOL CHEM, V261, P5126; TZAGOLOFF A, 1990, MICROBIOL REV, V54, P211, DOI 10.1128/MMBR.54.3.211-225.1990; UH M, 1990, J BIOL CHEM, V265, P19047; VELOURS J, 1988, EUR J BIOCHEM, V170, P637, DOI 10.1111/j.1432-1033.1988.tb13745.x; VELOURS J, 1987, EUR J BIOCHEM, V164, P579, DOI 10.1111/j.1432-1033.1987.tb11166.x; VELOURS J, 1984, EMBO J, V3, P207, DOI 10.1002/j.1460-2075.1984.tb01785.x; WALKER JE, 1991, BIOCHEMISTRY-US, V30, P5369, DOI 10.1021/bi00236a007	39	82	86	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20284	20290		10.1074/jbc.271.34.20284	http://dx.doi.org/10.1074/jbc.271.34.20284			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702761	hybrid			2022-12-25	WOS:A1996VD33700013
J	Mould, AP; Akiyama, SK; Humphries, MJ				Mould, AP; Akiyama, SK; Humphries, MJ			The inhibitory anti-beta 1 integrin monoclonal antibody 13 recognizes an epitope that is attenuated by ligand occupancy - Evidence for allosteric inhibition of integrin function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-BINDING DOMAIN; SITE-DIRECTED MUTAGENESIS; HUMAN-PLASMA FIBRONECTIN; LEUKOCYTE INTEGRINS; ADHESION MOLECULE-1; ENDOTHELIAL-CELLS; DIVALENT-CATIONS; ACTIVATION; ALPHA-5-BETA-1; IDENTIFICATION	Integrin-ligand binding causes conformational changes in the integrin, as evidenced by the increased expression of epitopes known as ligand-induced binding sites. Some monoclonal antibodies (mAbs) that recognize ligand-induced binding sites stimulate ligand binding, possibly by stabilizing the ligand-occupied conformation of the integrin. Here we have investigated the effect of ligand recognition by alpha 5 beta 1 on the binding of a mAb that inhibits beta 1 integrin function (mAb 13). Ligand (fibronectin fragment or GRGDS peptide) decreased the binding of mAb 13 to alpha 5 beta 1. Analysis of this inhibition showed that at high ligand concentrations, approximately 50% of the total integrin bound mAb 13 with >50-fold lower affinity than in the absence of ligand. The concentration of ligand required for half-maximal inhibition of antibody binding was independent of antibody concentration, suggesting that ligand acts as an allosteric inhibitor of mAb 13 binding. Hence, ligand and mAb 13 did not appear to compete directly for binding to alpha 5 beta 1. The stimulatory anti-beta 1 mAb 9EG7 was found to increase the maximum level of ligand binding similar to 2-fold, indicating that up to 50% of the total integrin could not bind ligand without 9EG7 stimulation. Analysis of mAb 13 binding in the presence of 9EG7 and ligand (i.e. maximal ligand occupancy) demonstrated that essentially all of the integrin bound mAb 13 with very low or zero affinity. Our results demonstrate that mAb 13 recognizes an epitope that is dramatically attenuated in the ligand-occupied form of alpha 5 beta 1. Hence, since mAb 13 preferentially recognizes the unoccupied conformation of the integrin, the antibody may inhibit ligand binding by stabilizing the unoccupied state of alpha 5 beta 1. In addition, we present evidence that the binding of mAb 13 to ligand-occupied alpha 5 beta 1 may also induce a conformational change in the integrin, resulting in the displacement of ligand.	NIDR,NIH,DEV BIOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Mould, AP (corresponding author), UNIV MANCHESTER,SCH BIOL SCI,WELLCOME TRUST CTR CELL MATRIX RES,2205 STOPFORD BLDG,MANCHESTER M13 9PT,LANCS,ENGLAND.			Mould, Paul/0000-0003-0076-6228; Humphries, Martin/0000-0002-4331-6967	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AKIYAMA SK, 1989, J CELL BIOL, V109, P863, DOI 10.1083/jcb.109.2.863; AOTA S, 1991, J BIOL CHEM, V266, P15938; BAZZONI G, 1995, J BIOL CHEM, V270, P25570, DOI 10.1074/jbc.270.43.25570; BENESCH R, 1969, NATURE, V221, P618, DOI 10.1038/221618a0; CABANAS C, 1993, P NATL ACAD SCI USA, V90, P5838, DOI 10.1073/pnas.90.12.5838; CALVETE JJ, 1994, THROMB HAEMOSTASIS, V72, P1; CHAN BMC, 1993, J CELL BIOL, V120, P537, DOI 10.1083/jcb.120.2.537; CHARO IF, 1990, J CELL BIOL, V111, P2795, DOI 10.1083/jcb.111.6.2795; DANEN EHJ, 1995, J BIOL CHEM, V270, P21612, DOI 10.1074/jbc.270.37.21612; DIAMOND MS, 1993, J CELL BIOL, V120, P545, DOI 10.1083/jcb.120.2.545; DRANSFIELD I, 1992, J CELL BIOL, V116, P1527, DOI 10.1083/jcb.116.6.1527; DRANSFIELD I, 1992, J CELL BIOL, V116, P219, DOI 10.1083/jcb.116.1.219; DU XP, 1991, CELL, V65, P409, DOI 10.1016/0092-8674(91)90458-B; FAULL RJ, 1993, J CELL BIOL, V121, P155, DOI 10.1083/jcb.121.1.155; FAULL RJ, 1994, J EXP MED, V179, P1307, DOI 10.1084/jem.179.4.1307; FRELINGER AL, 1988, J BIOL CHEM, V263, P12397; FRELINGER AL, 1990, J BIOL CHEM, V265, P6346; FRELINGER AL, 1991, J BIOL CHEM, V266, P17106; GARCIAPARDO A, 1989, EXP CELL RES, V181, P420, DOI 10.1016/0014-4827(89)90099-2; HUMPHRIES MJ, 1986, J CELL BIOL, V103, P2637, DOI 10.1083/jcb.103.6.2637; HUMPHRIES MJ, 1987, J BIOL CHEM, V262, P6886; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KAWAGUCHI S, 1993, J BIOL CHEM, V268, P16279; KILMARTIN IV, 1976, BR MED B, V32, P209; KOUNS WC, 1994, BLOOD, V84, P1108; KOVACH NL, 1992, J CELL BIOL, V116, P499, DOI 10.1083/jcb.116.2.499; LENTER M, 1993, P NATL ACAD SCI USA, V90, P9051, DOI 10.1073/pnas.90.19.9051; LOSTER K, 1995, FEBS LETT, V373, P234, DOI 10.1016/0014-5793(95)01053-H; MAHLER HR, 1966, BIOL CHEM, P250; MOULD AP, 1995, BIOCHEM SOC T, V23, pS395, DOI 10.1042/bst023395s; MOULD AP, 1994, J BIOL CHEM, V269, P27224; MOULD AP, 1995, J BIOL CHEM, V270, P26270, DOI 10.1074/jbc.270.44.26270; MOULD AP, 1995, FEBS LETT, V363, P118, DOI 10.1016/0014-5793(95)00301-O; MULLER B, 1993, J BIOL CHEM, V268, P6800; NAGAI T, 1991, J CELL BIOL, V114, P1295, DOI 10.1083/jcb.114.6.1295; OBARA M, 1988, CELL, V53, P649, DOI 10.1016/0092-8674(88)90580-6; PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0; SACHS DH, 1972, P NATL ACAD SCI USA, V69, P3790, DOI 10.1073/pnas.69.12.3790; SIMS PJ, 1991, J BIOL CHEM, V266, P7345; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; STEWART M, 1995, CURR OPIN CELL BIOL, V7, P690, DOI 10.1016/0955-0674(95)80111-1; TAKADA Y, 1993, J BIOL CHEM, V268, P17597; VANDEWIELVANKEMENADE E, 1992, J CELL BIOL, V117, P461, DOI 10.1083/jcb.117.2.461; WEITZMAN JB, 1993, J BIOL CHEM, V268, P8651; YAMADA KM, 1984, J CELL BIOL, V99, P29, DOI 10.1083/jcb.99.1.29; YEDNOCK TA, 1995, J BIOL CHEM, V270, P28740, DOI 10.1074/jbc.270.48.28740	46	89	93	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20365	20374		10.1074/jbc.271.34.20365	http://dx.doi.org/10.1074/jbc.271.34.20365			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702772	hybrid			2022-12-25	WOS:A1996VD33700024
J	Voorhorst, WGB; Eggen, RIL; Geerling, ACM; Platteeuw, C; Siezen, RJ; deVos, WM				Voorhorst, WGB; Eggen, RIL; Geerling, ACM; Platteeuw, C; Siezen, RJ; deVos, WM			Isolation and characterization of the hyperthermostable serine protease, pyrolysin, and its gene from the hyperthermophilic archaeon Pyrococcus furiosus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIPEPTIDYL-PEPTIDASE-II; DODECYL SULFATE-RESISTANT; PROTEOLYTIC ACTIVITY; LACTOCOCCUS-LACTIS; HUMAN-ERYTHROCYTES; BETA-GLUCOSIDASE; SUBTILISIN-LIKE; PURIFICATION; PROTEINASES; MICROORGANISMS	The hyperthermostable serine protease pyrolysin from the hyperthermophilic archaeon Pyrococcus furiosus was purified from membrane fractions. Two proteolytically active fractions were obtained, designated high (HMW) and low (LMW) molecular weight pyrolysin, that showed immunological cross-reaction and identical NH2-terminal sequences in which the third residue could be glycosylated, The HMW pyrolysin showed a subunit mass of 150 kDa after acid denaturation. Incubation of HMW pyrolysin at 95 degrees C resulted in the formation of LMW pyrolysin, probably as a consequence of COOH-terminal autoproteolysis. The 4194-base pair pls gene encoding pyrolysin was isolated and characterized, and its transcription initiation site was identified. The deduced pyrolysin sequence indicated a prepro-enzyme organization, with a 1249-residue mature protein composed of an NH2-terminal catalytic domain with considerable homology to subtilisin-like serine proteases and a COOH-terminal domain that contained most of the 32 possible N-glycosylation sites, The archaeal pyrolysin showed highest homology with eucaryal tripeptidyl peptidases II on the amino acid level but a different cleavage specificity as shown by its endopeptidase activity toward caseins, casein fragments including alpha(S1)-casein and synthetic peptides.	WAGENINGEN UNIV AGR,DEPT MICROBIOL,NL-6703 CT WAGENINGEN,NETHERLANDS; NIZO,DEPT BIOPHYS CHEM,EDE,NETHERLANDS	Wageningen University & Research; NIZO Food Research			Siezen, Roland J/P-5745-2015					ADAMS MWW, 1993, ANNU REV MICROBIOL, V47, P627, DOI 10.1146/annurev.micro.47.1.627; BALOW RM, 1986, J BIOL CHEM, V261, P2409; BLUMENTALS II, 1990, APPL ENVIRON MICROB, V56, P1992, DOI 10.1128/AEM.56.7.1992-1998.1990; CONNARIS H, 1991, J GEN MICROBIOL, V137, P1193, DOI 10.1099/00221287-137-5-1193; COWAN DA, 1987, BIOCHEM J, V247, P121, DOI 10.1042/bj2470121; Dalgaard JZ, 1993, BIOCH ARCHAEA, P535, DOI 10.1016/S0167-7306(08)60266-5; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; EGGEN R, 1990, FEMS MICROBIOL LETT, V71, P17; EGGEN RIL, 1991, J BIOL CHEM, V266, P6883; EXTERKATE FA, 1991, BIOCHEM J, V273, P135, DOI 10.1042/bj2730135; FUSEK M, 1990, J BIOL CHEM, V265, P1496; GERMAIN D, 1992, FEBS LETT, V299, P283, DOI 10.1016/0014-5793(92)80132-Z; Gibson T., 1984, STUDIES EPSTEIN BARR; KELLY RM, 1994, ANTON LEEUW INT J G, V66, P247, DOI 10.1007/BF00871643; KENGEN SWM, 1994, BIOCATALYSIS, V11, P79, DOI 10.3109/10242429409034379; KENGEN SWM, 1994, J BIOL CHEM, V269, P17537; KLINGEBERG M, 1995, APPL ENVIRON MICROB, V61, P3098, DOI 10.1128/AEM.61.8.3098-3104.1995; KUCHINO Y, 1982, NATURE, V298, P684, DOI 10.1038/298684a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEDUC R, 1992, J BIOL CHEM, V267, P14304; LIN XL, 1990, J BIOL CHEM, V265, P1490; MACPHERSON E, 1987, BIOCHEM J, V248, P259, DOI 10.1042/bj2480259; MARSHALL RD, 1972, ANNU REV BIOCHEM, V41, P673, DOI 10.1146/annurev.bi.41.070172.003325; MORIKAWA M, 1994, APPL ENVIRON MICROB, V60, P4559, DOI 10.1128/AEM.60.12.4559-4566.1994; MUKUND S, 1995, J BIOL CHEM, V270, P8389, DOI 10.1074/jbc.270.15.8389; PETERS J, 1995, J MOL BIOL, V245, P385, DOI 10.1006/jmbi.1994.0032; POWER SD, 1986, P NATL ACAD SCI USA, V83, P3096, DOI 10.1073/pnas.83.10.3096; ROWLANDS T, 1994, SCIENCE, V264, P1326, DOI 10.1126/science.8191287; Sambrook J., 2002, MOL CLONING LAB MANU; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SHINDE U, 1993, P NATL ACAD SCI USA, V90, P6924, DOI 10.1073/pnas.90.15.6924; SIEZEN RJ, 1993, PROTEIN ENG, V6, P927, DOI 10.1093/protein/6.8.927; SIEZEN RJ, 1991, PROTEIN ENG, V4, P719, DOI 10.1093/protein/4.7.719; SIEZEN RJ, 1995, INTRAMOLECULAR CHAPE, P238; SNOWDEN LJ, 1992, APPL ENVIRON MICROB, V58, P1134, DOI 10.1128/AEM.58.4.1134-1141.1992; STETTER KO, 1990, FEMS MICROBIOL LETT, V75, P117, DOI 10.1111/j.1574-6968.1990.tb04089.x; TOMKINSON B, 1987, P NATL ACAD SCI USA, V84, P7508, DOI 10.1073/pnas.84.21.7508; TOMKINSON B, 1994, BIOCHEM J, V304, P517, DOI 10.1042/bj3040517; TOMKINSON B, 1994, ARCH BIOCHEM BIOPHYS, V314, P276, DOI 10.1006/abbi.1994.1442; VOLKL P, 1994, PROTEIN SCI, V3, P1329; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; VOORHORST WGB, 1995, J BACTERIOL, V177, P7105, DOI 10.1128/JB.177.24.7105-7111.1995; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P4576, DOI 10.1073/pnas.87.12.4576; ZACHARIUS RM, 1969, ANAL BIOCHEM, V30, P148, DOI 10.1016/0003-2697(69)90383-2	44	51	60	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20426	20431		10.1074/jbc.271.34.20426	http://dx.doi.org/10.1074/jbc.271.34.20426			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702780	hybrid, Green Published			2022-12-25	WOS:A1996VD33700032
J	Digel, JG; Kishinevsky, A; Ong, AM; McCarty, RE				Digel, JG; Kishinevsky, A; Ong, AM; McCarty, RE			Differences between two tight ADP binding sites of the chloroplast coupling factor 1 and their effects on ATPase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL ADENOSINE-TRIPHOSPHATASE; FACTOR-I; CHANGE MECHANISM; CATALYTIC SITE; NUCLEOTIDE; F1-ATPASE; SUBUNIT; ENZYME	Purified chloroplast ATP synthase (CF1) contains 1.2-2 mol of tightly bound ADP/mol of enzyme that resists removal by gel filtration or dialysis. CF1 was depleted of its endogenous nucleotide by treatment with alkaline phosphatase. Tightly bound nucleotide was demonstrated not to have all essential structural role, CF1 depleted of endogenous nucleotide retains its ability to catalyze Ca2+- and Mg2+-dependent ATPase activity and is not more sensitive to cold inactivation than untreated CF1. 2'(3')-O-Trinitrophenyladenosille 5'-diphosphate (TNP-ADP) binds tightly to two sites on nucleotide-depleted CF1, binding to either site at a faster rate than that of exchange of bound nucleotide for medium nucleotide. The nucleotide-depleted enzyme binds about one additional mol of TNP-ADP/mol of CF1, indicating that there is a tight TNP-ADP binding site that does not exchange readily with medium nucleotide, It is MgADP in this nonexchanging site, not the easily exchanging ADP binding site, that is responsible for the MgADP-induced inhibition of the ATPase activity. The rate of exchange of tightly bound ADP from CF1 matches the rate at which the Mg2+-ATPase activity of CF1 is activated but is not itself responsible for the activation.	JOHNS HOPKINS UNIV, DEPT BIOL, BALTIMORE, MD 21218 USA	Johns Hopkins University								BOYER PD, 1989, FASEB J, V3, P2164, DOI 10.1096/fasebj.3.10.2526771; BRUIST MF, 1981, BIOCHEMISTRY-US, V20, P6298, DOI 10.1021/bi00525a003; CARMELI C, 1981, BIOCHEMISTRY-US, V20, P3940, DOI 10.1021/bi00516a042; CERIONE RA, 1982, BIOCHEMISTRY-US, V21, P745, DOI 10.1021/bi00533a026; DIGEL JG, 1995, BIOCHEMISTRY-US, V34, P14482, DOI 10.1021/bi00044a026; DROBINSKAYA IY, 1985, FEBS LETT, V182, P419, DOI 10.1016/0014-5793(85)80346-X; DU ZY, 1990, BIOCHEMISTRY-US, V29, P402, DOI 10.1021/bi00454a014; FELDMAN RI, 1985, J BIOL CHEM, V260, P3088; GARRETT NE, 1975, J BIOL CHEM, V250, P6640; GIRAULT G, 1988, J BIOL CHEM, V263, P14690; Hightower KE, 1996, BIOCHEMISTRY-US, V35, P4852, DOI 10.1021/bi952914h; HOCHMAN Y, 1981, BIOCHEMISTRY-US, V20, P6288; LARSON EM, 1989, BIOCHIM BIOPHYS ACTA, V973, P78, DOI 10.1016/S0005-2728(89)80405-0; LECKBAND D, 1987, BIOCHEMISTRY-US, V26, P2306, DOI 10.1021/bi00382a035; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAYLAN AN, 1994, SOV SCI REV D, V12, P1; MCCARTY RE, 1992, J EXP BIOL, V172, P431; MCCARTY RE, 1966, BROOKHAVEN SYM BIOL, P202; MILGROM YM, 1990, J BIOL CHEM, V265, P18725; MOAL J, 1989, COMP BIOCHEM PHYS B, V93, P307, DOI 10.1016/0305-0491(89)90086-2; PEDERSEN PL, 1995, J BIOL CHEM, V270, P1775, DOI 10.1074/jbc.270.4.1775; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; POSORSKE L, 1976, ARCH BIOCHEM BIOPHYS, V177, P276, DOI 10.1016/0003-9861(76)90437-9; SENIOR AE, 1992, ARCH BIOCHEM BIOPHYS, V297, P340, DOI 10.1016/0003-9861(92)90682-M; SHAPIRO AB, 1990, J BIOL CHEM, V265, P4340; SHAPIRO AB, 1991, J BIOL CHEM, V266, P4194; SOTEROPOULOS P, 1994, J BIOL CHEM, V269, P19810; TAUSSKY HH, 1953, J BIOL CHEM, V202, P675; VANVELDHOVEN PP, 1987, ANAL BIOCHEM, V161, P45, DOI 10.1016/0003-2697(87)90649-X	29	21	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					19976	19982		10.1074/jbc.271.33.19976	http://dx.doi.org/10.1074/jbc.271.33.19976			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702714	hybrid			2022-12-25	WOS:A1996VC66900055
J	Zhou, XB; Ruth, P; Schlossmann, J; Hofmann, F; Korth, M				Zhou, XB; Ruth, P; Schlossmann, J; Hofmann, F; Korth, M			Protein phosphatase 2A is essential for the activation of Ca2+-activated K+ currents by cGMP-dependent protein kinase in tracheal smooth muscle and Chinese hamster ovary cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORTICAL COLLECTING DUCT; POTASSIUM CHANNELS; NITRIC-OXIDE; BASOLATERAL MEMBRANE; LARGE CONDUCTANCE; PATCH-CLAMP; RAT-BRAIN; POTENT; PHOSPHORYLATION; CHARYBDOTOXIN	The regulation of Ca2+ activated K+ channels (K-Ca channels) by cGMP-dependent protein kinase (cGMP kinase) and its molecular mechanism were investigated in Chinese hamster ovary (CHO) and tracheal smooth muscle cells, In CHO wild-type cells (CHO-WT cells) and in CHO cells stably transfected with cGMP kinase I alpha (CHO-cGK cells), K-Ca channels with intermediate conductance (similar to 50 picosiemens) were identified, Due to the basal activity of cGMP kinase, Ca2+-activated K+ currents had a higher sensitivity toward the cytosolic Ca2+ concentration in CHO-cGK cells than in CHO-WT cells. Dialysis of the active fragment of cGMP kinase (300 nM) into CHO-WT cells or of cGMP into CHO-cGK cells increased the Ca2+-activated K+ current, while the catalytic subunit of cAMP-dependent protein kinase (cAMP kinase) was without effect, In cell-attached patches obtained from freshly isolated bovine tracheal smooth muscle cells, the open state probability (NPo) of maxi-K-Ca channels (conductance of similar to 260 picosiemens) was enhanced by 300 mu M 8-(4-chlorophenylthio)-cGMP, a specific and potent activator of cGMP kinase. In contrast, 1 mu M isoprenaline, 20 mu M forskolin, and 3 mM 8-bromo-cAMP failed to enhance K-Ca channel activity. In excised inside-out patches, only the active fragment of cGMP kinase (but not that of cAMP kinase) increased NPo when applied to the cytosolic side of the patch. The enhancement of NPo by cGMP kinase was inhibited in CHO cells as well as in tracheal smooth muscle cells by the cGMP kinase inhibitor MT 5823 (1 mu M) and the protein phosphatase (PP) inhibitors microcystin (5 mu M) and okadaic acid (10 nM). The catalytic subunit of PP2A (but not that of PP1) mimicked the effect of cGMP kinase on NPo in excised, inside-out patches. The results show that cGMP kinase regulates two different K-Ca channels in two unrelated cell types by the same indirect mechanism, which requires the activity of PP2A. The regulation of the K-Ca channel is specific for cGMP kinase and is not mimicked by cAMP kinase.	TECH UNIV MUNICH, INST PHARMAKOL & TOXIKOL, D-80802 MUNICH, GERMANY	Technical University of Munich			Schlossmann, Jens/I-7743-2016	Schlossmann, Jens/0000-0002-2550-6839				ALIOUA A, 1995, AM J PHYSIOL-LUNG C, V268, pL1057, DOI 10.1152/ajplung.1995.268.6.L1057; ARCHER SL, 1994, P NATL ACAD SCI USA, V91, P7583, DOI 10.1073/pnas.91.16.7583; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; BOLLEN M, 1992, CRIT REV BIOCHEM MOL, V27, P227, DOI 10.3109/10409239209082564; BOLOTINA VM, 1994, NATURE, V368, P850, DOI 10.1038/368850a0; CANDIA S, 1992, BIOPHYS J, V63, P583, DOI 10.1016/S0006-3495(92)81630-2; CARL A, 1991, AM J PHYSIOL, V261, pC387, DOI 10.1152/ajpcell.1991.261.2.C387; COHEN P, 1989, FEBS LETT, V250, P596, DOI 10.1016/0014-5793(89)80803-8; EWALD DA, 1985, NATURE, V315, P503, DOI 10.1038/315503a0; FABIATO A, 1988, METHOD ENZYMOL, V157, P378; FARLEY J, 1988, BIOPHYS J, V53, P919, DOI 10.1016/S0006-3495(88)83173-4; FRINDT G, 1989, AM J PHYSIOL, V256, pF143, DOI 10.1152/ajprenal.1989.256.1.F143; Furukawa K, 1996, NATURE, V379, P74, DOI 10.1038/379074a0; GARBERS DL, 1992, CELL, V71, P1; GARDOS G, 1958, BIOCHIM BIOPHYS ACTA, V30, P653, DOI 10.1016/0006-3002(58)90124-0; GREEN KA, 1991, BRIT J PHARMACOL, V102, P871, DOI 10.1111/j.1476-5381.1991.tb12269.x; HAMAGUCHI M, 1992, J PHARMACOL EXP THER, V262, P263; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HEIL WG, 1987, EUR J BIOCHEM, V168, P117, DOI 10.1111/j.1432-1033.1987.tb13395.x; HIDAKA H, 1992, ANNU REV PHARMACOL, V32, P377, DOI 10.1146/annurev.pharmtox.32.1.377; HIRSCH J, 1993, PFLUG ARCH EUR J PHY, V424, P470, DOI 10.1007/BF00374910; HIRSCH J, 1995, PFLUG ARCH EUR J PHY, V429, P338, DOI 10.1007/BF00374148; ISHII K, 1989, AM J PHYSIOL, V256, pC495, DOI 10.1152/ajpcell.1989.256.3.C495; ITO Y, 1978, J PHARMACOL EXP THER, V207, P1022; ITO Y, 1980, BRIT J PHARMACOL, V70, P197, DOI 10.1111/j.1476-5381.1980.tb07925.x; JONES TR, 1990, J PHARMACOL EXP THER, V255, P697; KOLB HA, 1990, REV PHYSIOL BIOCH P, V115, P51; KOTLIKOFF MI, 1993, PHARMACOL THERAPEUT, V58, P1, DOI 10.1016/0163-7258(93)90064-K; KUME H, 1992, P NATL ACAD SCI USA, V89, P11051, DOI 10.1073/pnas.89.22.11051; KUME H, 1994, J CLIN INVEST, V93, P371, DOI 10.1172/JCI116969; KUME H, 1989, NATURE, V341, P152, DOI 10.1038/341152a0; LATORRE R, 1989, ANNU REV PHYSIOL, V51, P385, DOI 10.1146/annurev.ph.51.030189.002125; MACKINTOSH C, 1990, FEBS LETT, V264, P187, DOI 10.1016/0014-5793(90)80245-E; MARTY A, 1989, TRENDS NEUROSCI, V12, P420, DOI 10.1016/0166-2236(89)90090-8; MCCANN JD, 1986, J PHYSIOL-LONDON, V372, P113, DOI 10.1113/jphysiol.1986.sp016000; MEECH RW, 1974, J PHYSIOL-LONDON, V237, P259, DOI 10.1113/jphysiol.1974.sp010481; MERMI J, 1991, BRIT J PHARMACOL, V104, P705, DOI 10.1111/j.1476-5381.1991.tb12492.x; PFEIFER A, 1995, J BIOL CHEM, V270, P9052, DOI 10.1074/jbc.270.16.9052; REINHART PH, 1995, J NEUROSCI, V15, P4572; REINHART PH, 1989, NEURON, V2, P1031, DOI 10.1016/0896-6273(89)90227-4; ROBERTSON BE, 1993, AM J PHYSIOL, V265, pC299; RUTH P, 1993, P NATL ACAD SCI USA, V90, P2623, DOI 10.1073/pnas.90.7.2623; SCHMIDT HHHW, 1994, CELL, V78, P919, DOI 10.1016/0092-8674(94)90267-4; SLAUGHTER RS, 1987, BIOCHIM BIOPHYS ACTA, V904, P92, DOI 10.1016/0005-2736(87)90090-3; STANDEN NB, 1989, SCIENCE, V245, P177, DOI 10.1126/science.2501869; TANIGUCHI J, 1993, PFLUG ARCH EUR J PHY, V423, P167, DOI 10.1007/BF00374390; TARE M, 1990, NATURE, V346, P69, DOI 10.1038/346069a0; WERA S, 1995, BIOCHEM J, V311, P17, DOI 10.1042/bj3110017; WHITE RE, 1993, NATURE, V361, P263, DOI 10.1038/361263a0; WISGIRDA ME, 1994, P NATL ACAD SCI USA, V91, P2858, DOI 10.1073/pnas.91.7.2858	50	103	106	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					19760	19767		10.1074/jbc.271.33.19760	http://dx.doi.org/10.1074/jbc.271.33.19760			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702682	hybrid			2022-12-25	WOS:A1996VC66900023
J	Bantle, S; Keller, S; Haussmann, I; Auerbach, D; Perriard, E; Muhlebach, S; Perriard, JC				Bantle, S; Keller, S; Haussmann, I; Auerbach, D; Perriard, E; Muhlebach, S; Perriard, JC			Tissue-specific isoforms of chicken myomesin are generated by alternative splicing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							M-BAND PROTEINS; MUSCLE A-BAND; SKELETAL-MUSCLE; CREATINE-KINASE; MESSENGER-RNA; M-LINE; DIFFERENTIAL EXPRESSION; 3-DIMENSIONAL STRUCTURE; STRIATED-MUSCLE; PECTORAL MUSCLE	Myomesin is a high molecular weight protein that is present in the M-band of all fiber types of cross-striated skeletal muscle and heart. We have isolated two cDNAs encoding tissue-specific isoforms of chicken myomesin with calculated molecular masses of 174 kDa in skeletal muscle and 152 kDa in heart, Distinct sequences are found at the 3'-end of the two cDNAs, giving rise to different C-terminal domains. Partial analysis of the gene structure has shown that in chicken, both isoforms are generated by alternative splicing of a composite exon. Amino acid sequences show that the main body of myomesin consists of five fibronectin type III (class I motifs) and seven immunoglobulin-like domains (class Il motifs), An identical structure was found in RI-protein and human 190K protein (the human counterpart of chicken myomesin), and a comparable domain arrangement occurs in the M-band associated protein skelemin. We postulate that myomesin, M-protein, and skelemin belong to the same subfamily of high molecular weight RI-band-associated proteins of the immunoglobulin superfamily and that they probably have the same ancestor in evolution.	ETH HONGGERBERG, INST CELL BIOL, CH-8093 ZURICH, SWITZERLAND	ETH Zurich				Haussmann, Irmgard Ursula/0000-0002-7427-8342				CARLSSON E, 1987, CELL TISSUE RES, V248, P169, DOI 10.1007/BF01239978; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAGERLIND A, 1992, HISTOCHEMISTRY, V98, P39, DOI 10.1007/BF00716936; DOETSCHMAN TC, 1984, EUR J CELL BIOL, V33, P265; EDMAN AC, 1988, J ULTRA MOL STRUCT R, V100, P1, DOI 10.1016/0889-1605(88)90054-7; EPPENBERGER HM, 1981, J CELL BIOL, V89, P185, DOI 10.1083/jcb.89.2.185; FURST DO, 1989, J CELL SCI, V94, P119; FURST DO, 1992, J CELL SCI, V102, P769; GROVE BK, 1985, J CELL BIOL, V101, P1413, DOI 10.1083/jcb.101.4.1413; GROVE BK, 1984, J CELL BIOL, V98, P518, DOI 10.1083/jcb.98.2.518; GROVE BK, 1989, CRIT REV NEUROBIOL, V4, P201; GROVE BK, 1989, J HISTOCHEM CYTOCHEM, V37, P447, DOI 10.1177/37.4.2926123; GROVE BK, 1987, DIFFERENTIATION, V34, P106, DOI 10.1111/j.1432-0436.1987.tb00056.x; HOSSLE JP, 1986, NUCLEIC ACIDS RES, V14, P1449, DOI 10.1093/nar/14.3.1449; KNAPPEIS GG, 1968, J CELL BIOL, V38, P202, DOI 10.1083/jcb.38.1.202; KORNBLIHTT AR, 1984, NUCLEIC ACIDS RES, V12, P5853, DOI 10.1093/nar/12.14.5853; LABEIT S, 1990, NATURE, V345, P273, DOI 10.1038/345273a0; LIN ZY, 1989, GENE DEV, V3, P986, DOI 10.1101/gad.3.7.986; LUTHER P, 1978, J MOL BIOL, V125, P313, DOI 10.1016/0022-2836(78)90405-9; LUTHER PK, 1981, J MOL BIOL, V151, P703, DOI 10.1016/0022-2836(81)90430-7; LUTHER PK, 1980, J MOL BIOL, V141, P409, DOI 10.1016/0022-2836(80)90254-5; MANI RS, 1978, BIOCHIM BIOPHYS ACTA, V536, P134, DOI 10.1016/0005-2795(78)90059-4; MASAKI T, 1972, J BIOCHEM, V71, P355, DOI 10.1093/oxfordjournals.jbchem.a129774; MASAKI T, 1974, J BIOCHEM, V75, P367, DOI 10.1093/oxfordjournals.jbchem.a130403; NAVE R, 1989, J CELL BIOL, V109, P2177, DOI 10.1083/jcb.109.5.2177; NOGUCHI J, 1992, J BIOL CHEM, V267, P20302; PASK HT, 1994, J MUSCLE RES CELL M, V15, P633, DOI 10.1007/BF00121071; PETERSEN TE, 1983, P NATL ACAD SCI-BIOL, V80, P137, DOI 10.1073/pnas.80.1.137; PIEROBONBORMIOLI S, 1981, J MUSCLE RES CELL M, V2, P401, DOI 10.1007/BF00711967; PRICE MG, 1987, J CELL BIOL, V104, P1325, DOI 10.1083/jcb.104.5.1325; PRICE MG, 1993, J BIOL CHEM, V268, P21800; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SASSOON DA, 1988, DEVELOPMENT, V104, P155; SCHAFER BW, 1988, J CELL BIOL, V106, P1161, DOI 10.1083/jcb.106.4.1161; SJOSTROM M, 1977, J MOL BIOL, V109, P49, DOI 10.1016/S0022-2836(77)80045-4; STREET SF, 1983, J CELL PHYSIOL, V114, P346, DOI 10.1002/jcp.1041140314; STREHLER EE, 1983, J MOL BIOL, V166, P141, DOI 10.1016/S0022-2836(83)80003-5; STREHLER EE, 1979, EXP CELL RES, V124, P39, DOI 10.1016/0014-4827(79)90255-6; TURNER DC, 1973, P NATL ACAD SCI USA, V70, P702, DOI 10.1073/pnas.70.3.702; VINKEMEIER U, 1993, J CELL SCI, V106, P319; WALLIMANN T, 1983, J MUSCLE RES CELL M, V4, P429, DOI 10.1007/BF00711948; WALLIMANN T, 1983, J CELL BIOL, V96, P1772, DOI 10.1083/jcb.96.6.1772; WANG K, 1983, J CELL BIOL, V96, P562, DOI 10.1083/jcb.96.2.562; WEBER FE, 1993, EUR J BIOCHEM, V216, P661, DOI 10.1111/j.1432-1033.1993.tb18186.x; ZHU H, 1991, MOL CELL BIOL, V11, P2273, DOI 10.1128/MCB.11.4.2273	45	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19042	19052		10.1074/jbc.271.32.19042	http://dx.doi.org/10.1074/jbc.271.32.19042			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702575	hybrid			2022-12-25	WOS:A1996VB68400009
J	Konan, KV; Taylor, MW				Konan, KV; Taylor, MW			Importance of the two interferon-stimulated response-element (ISRE) sequences in the regulation of the human indoleamine 2,3-dioxygenase gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING FACTOR; HUMAN-FIBROBLASTS; DIFFERENTIAL REGULATION; TRANSCRIPTIONAL CONTROL; HOST-CELLS; GAMMA; EXPRESSION; ACTIVATION; ALPHA; INVOLVEMENT	Indoleamine 2,3-dioxygenase (INDO) is the rate-limiting enzyme in the catabolism of the essential amino acid L-tryptophan. It is induced strongly in many cell lines following interferon-gamma treatment. We report the cloning and characterization of the full-length human INDO promoter. This promoter is 1,245 base pairs long and includes two interferon-stimulated response elements (ISRE) separated by an approximately 1-kilobase sequence. The presence of these two ISREs is critical for maximum INDO promoter activity (50-fold induction). When the ISREs are present in two separate fragments cloned upstream of the chloramphenicol acetyltransferase (CAT) reporter vector, the INDO promoter activity drops significantly (7-fold induction). 5' end deletions of the wild type promoter sequence indicate that removal of the ISRE (ISRE1) at position -1126 reduces the induction level to approximately 25-fold. This activity does not change appreciably when the promoter is deleted down to position -241. Furthermore, site-directed mat-agenesis of ISRE1 also decreases the promoter activity in a similar way. When ISRE1 is kept intact, deletion of the second ISRE (ISRE2) at position -111 leads to only 11-fold induction of the promoter. A similar result is obtained when substitution mutations are introduced in ISRE2. Deletion of a 748-base pair sequence between the two ISREs only shows a slight decrease in the INDO promoter activity. These data indicate that the two ISRE sequences are required for the fall transcriptional induction of the interferon-gamma-inducible human INDO gene, INDO activity is not. induced in the hepatic cell line HepG2. An analysis of INDO-CAT activity in this cell line indicated that the lack of INDO activity was at the transcriptional level and could reflect either the presence of a repressor or lack of a transcription factor, This lack of induction could be correlated with a truncated or unstable IRF-1, However, the levels of IRF-2, JAK2, and STAT 91 were similar in both ME180 and HepG2 cells.	INDIANA UNIV,DEPT BIOL,INST MOL & CELLULAR BIOL,BLOOMINGTON,IN 47405	Indiana University System; Indiana University Bloomington								Ausubel FM, 1988, CURRENT PROTOCOLS MO, V1; BENOIST C, 1990, ANNU REV IMMUNOL, V8, P681, DOI 10.1146/annurev.immunol.8.1.681; BRIKEN V, 1995, MOL CELL BIOL, V15, P975; CAPLEN HS, 1988, J BIOL CHEM, V263, P332; CARLIN JM, 1987, J IMMUNOL, V139, P2414; CHON SY, 1995, J INTERF CYTOK RES, V15, P517, DOI 10.1089/jir.1995.15.517; DAI W, 1990, J BIOL CHEM, V265, P19871; DECKER T, 1991, EMBO J, V10, P927, DOI 10.1002/j.1460-2075.1991.tb08026.x; DORN A, 1987, P NATL ACAD SCI USA, V84, P6249, DOI 10.1073/pnas.84.17.6249; FROLOVA LY, 1993, GENE, V128, P237, DOI 10.1016/0378-1119(93)90568-N; GUPTA SL, 1994, INFECT IMMUN, V62, P2277, DOI 10.1128/IAI.62.6.2277-2284.1994; HASSANAIN HH, 1993, J BIOL CHEM, V268, P5077; KADOYA A, 1992, BIOCHEM BIOPH RES CO, V189, P530, DOI 10.1016/0006-291X(92)91590-M; KLEIN SB, 1994, J INTERFERON RES, V14, P333, DOI 10.1089/jir.1994.14.333; KONAN KV, 1995, THESIS INDIANA U BLO; Kunkel T. A., 1989, RECOMBINANT DNA METH, P587; LEVY DE, 1988, GENE DEV, V2, P383, DOI 10.1101/gad.2.4.383; MUSSO T, 1995, BLOOD, V35, P1408; NICOLET CM, 1994, J IMMUNOL, V152, P153; OZES ON, 1994, J INTERFERON RES, V14, P25, DOI 10.1089/jir.1994.14.25; PFEFFERKORN ER, 1984, P NATL ACAD SCI-BIOL, V81, P908, DOI 10.1073/pnas.81.3.908; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TAYLOR MW, 1991, FASEB J, V5, P2516, DOI 10.1096/fasebj.5.11.1907934; THOMAS SM, 1993, J IMMUNOL, V150, P5529	25	84	93	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19140	19145		10.1074/jbc.271.32.19140	http://dx.doi.org/10.1074/jbc.271.32.19140			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702590	hybrid			2022-12-25	WOS:A1996VB68400024
J	Petersen, CE; Ha, CE; Jameson, DM; Bhagavan, NV				Petersen, CE; Ha, CE; Jameson, DM; Bhagavan, NV			Mutations in a specific human serum albumin thyroxine binding site define the structural basis of familial dysalbuminemic hyperthyroxinemia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CIRCULAR-DICHROISM; FLUORESCENCE; HORMONE; AFFINITY; EXCESS; GENE; CONFORMATION; PROTEIN; VARIANT; PLASMA	The familiar dysalbuminemic hyperthyroxinemia (FDR) phenotype results hom a natural human serum albumin (HSA) mutant with histidine instead of arginine at amino acid position 218. This mutation results in an enhanced affinity for thyroxine, Site-directed mutagenesis and a yeast protein expression system were used to synthesize wild type BSA and FDN HSA as well as several other HSA mutants. Studies oil the binding of thyroxine to these HSA species using equilibrium dialysis and quenching of tryptophan 214 fluorescence suggest that the FDH mutation affects a single thyroxine binding site located in the 2A subdomain of HSA. Site-directed mutagenesis of HSA and thyroxine analogs mere used to obtain information about the mechanism of thyroxine binding to both wild type and FDH HSA. These studies suggest that the guanidino group of arginine at,amino acid position 218 in wild type RSA is involved in an unfavorable binding interaction with the amino group of thyroxine, whereas histidine at amino acid position 218 in FDR HSA is involved in a favorable binding interaction with thyroxine. Neither arginine at amino acid position 222 nor tryptophan at amino acid position 214 appears to favorably influence the binding of thyroxine to wild type HSA.	UNIV HAWAII MANOA,DEPT BIOCHEM & BIOPHYS,HONOLULU,HI 96822	University of Hawaii System; University of Hawaii Manoa								BARLOW JW, 1982, J CLIN ENDOCR METAB, V55, P244, DOI 10.1210/jcem-55-2-244; BORST GC, 1982, AM J MED, V73, P283, DOI 10.1016/0002-9343(82)90190-5; CARTER DC, 1994, ADV PROTEIN CHEM, V45, P153; CARTER DC, 1992, NATURE, V358, P208; CHATELAIN P, 1994, J PHARM SCI, V83, P674, DOI 10.1002/jps.2600830516; DOCTER R, 1981, CLIN ENDOCRINOL, V15, P363, DOI 10.1111/j.1365-2265.1981.tb00676.x; DUGHI C, 1993, PHOTOCHEM PHOTOBIOL, V57, P416, DOI 10.1111/j.1751-1097.1993.tb02311.x; FOSTER T, 1948, ANN PHYS, V2, P55; GLATZ JFC, 1983, J BIOCHEM BIOPH METH, V8, P57, DOI 10.1016/0165-022X(83)90021-0; KAMIKUBO K, 1990, J PROTEIN CHEM, V9, P461, DOI 10.1007/BF01024622; LALLOZ MRA, 1983, CLIN ENDOCRINOL, V18, P11, DOI 10.1111/j.1365-2265.1983.tb03181.x; LEE WNP, 1979, J CLIN ENDOCR METAB, V49, P292, DOI 10.1210/jcem-49-2-292; LEVINE RL, 1977, CLIN CHEM, V23, P2292; MINGHETTI PP, 1986, J BIOL CHEM, V261, P6747; OKABE N, 1976, J BIOCHEM-TOKYO, V80, P455, DOI 10.1093/oxfordjournals.jbchem.a131298; OKABE N, 1985, J BIOCHEM-TOKYO, V97, P1317, DOI 10.1093/oxfordjournals.jbchem.a135183; PETERSEN CE, 1995, BIOCHEM BIOPH RES CO, V214, P1121, DOI 10.1006/bbrc.1995.2402; PETERSEN CE, 1994, J MED GENET, V31, P355, DOI 10.1136/jmg.31.5.355; REED RG, 1975, BIOCHEMISTRY-US, V14, P4578, DOI 10.1021/bi00692a004; RUI ZM, 1984, NEW ENGL J MED, V306, P635; SCOTTOLINI AG, 1984, CLIN CHEM, V30, P1179; STEINER RF, 1966, J BIOL CHEM, V241, P560; STERLING K, 1964, J CLIN INVEST, V43, P1721, DOI 10.1172/JCI105047; STERLING K, 1961, J BIOL CHEM, V236, P2241; STERLING K, 1962, J CLIN INVEST, V41, P1021, DOI 10.1172/JCI104552; STOCKIGT JR, 1981, J CLIN ENDOCR METAB, V53, P353, DOI 10.1210/jcem-53-2-353; SUDLOW G, 1976, MOL PHARMACOL, V12, P1052; SUDLOW G, 1975, CLIN EXP PHARMACOL P, V2, P129, DOI 10.1111/j.1440-1681.1975.tb01826.x; SUDLOW G, 1975, MOL PHARMACOL, V11, P824; SUNTHORNTHEPVARAKUL T, 1994, BIOCHEM BIOPH RES CO, V202, P781, DOI 10.1006/bbrc.1994.1998; SUTERCRAZZOLARA C, 1995, BIOTECHNIQUES, V19, P204; TABACHNICK M, 1979, ARCH BIOCHEM BIOPHYS, V198, P403, DOI 10.1016/0003-9861(79)90513-7; TABACHNICK M, 1964, ARCH BIOCHEM BIOPHYS, V105, P563, DOI 10.1016/0003-9861(64)90051-7; TABACHNICK M, 1970, ARCH BIOCHEM BIOPHYS, V136, P467, DOI 10.1016/0003-9861(70)90218-3; TABACHNICK M, 1964, J BIOL CHEM, V239, P1242; TOKUOKA R, 1980, J BIOCHEM-TOKYO, V87, P1729, DOI 10.1093/oxfordjournals.jbchem.a132917; TRAVIS J, 1976, BIOCHEM J, V157, P301, DOI 10.1042/bj1570301; TRITSCH GL, 1961, J BIOL CHEM, V236, P3163; VOELKER JR, 1989, J PHARMACOL EXP THER, V250, P772; WAGNER RL, 1995, NATURE, V378, P690, DOI 10.1038/378690a0; WILTING J, 1980, J BIOL CHEM, V255, P3032	41	51	54	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19110	19117		10.1074/jbc.271.32.19110	http://dx.doi.org/10.1074/jbc.271.32.19110			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702585	hybrid			2022-12-25	WOS:A1996VB68400019
J	Chen, Q; Crosa, JH				Chen, Q; Crosa, JH			Antisense RNA, fur, iron, and the regulation of iron transport genes in Vibrio anguillarum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTER-MEMBRANE PROTEIN; ESCHERICHIA-COLI; MOLECULAR-CLONING; PLASMID PJM1; VIRULENCE PLASMID; MESSENGER-RNA; UPTAKE SYSTEM; SIDEROPHORE; EXPRESSION; TRANSCRIPTION	The negative regulation of the expression of iron transport genes fatA and fatB in Vibrio anguillarum is mediated by a chromosome-encoded Fur protein and a plasmid pJM1-derived antisense RNA (RNA alpha), which is preferentially expressed under iron-rich conditions, In this work, we characterized the RNA alpha promoter region, and by using promoter fusion and rifampicin experiments we were able to demonstrate that iron regulates RNA alpha synthesis posttranscriptionally by stabilizing RNA alpha half-life rather than enhancing transcription initiation, The Fur protein is also essential for RNA alpha synthesis at the transcription initiation level, independently of the iron status of the cell, From experiments assessing the relative contribution of Fur and RNA alpha, we were able to show that RNA alpha may indeed play an important role on the negative regulation of the expression of the iron transport genes under physiological conditions.	OREGON HLTH SCI UNIV,SCH MED,DEPT MOL MICROBIOL & IMMUNOL L220,PORTLAND,OR 97201	Oregon Health & Science University					NIAID NIH HHS [AI19018] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI019018] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ACTIS LA, 1988, J BIOL CHEM, V263, P2853; ACTIS LA, 1985, J BACTERIOL, V161, P736, DOI 10.1128/JB.161.2.736-742.1985; ACTIS LA, 1995, MOL MICROBIOL, V17, P197, DOI 10.1111/j.1365-2958.1995.mmi_17010197.x; ARDITTI R, 1973, J BACTERIOL, V114, P652, DOI 10.1128/JB.114.2.652-655.1973; BAGG A, 1987, MICROBIOL REV, V51, P509, DOI 10.1128/MMBR.51.4.509-518.1987; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BOLIVAR F, 1978, GENE, V4, P121, DOI 10.1016/0378-1119(78)90025-2; BOYER HW, 1969, J MOL BIOL, V41, P459, DOI 10.1016/0022-2836(69)90288-5; BRICKMAN TJ, 1990, J MOL BIOL, V212, P669, DOI 10.1016/0022-2836(90)90229-F; BROSIUS J, 1984, GENE, V27, P151, DOI 10.1016/0378-1119(84)90136-7; Bullen J J, 1978, Curr Top Microbiol Immunol, V80, P1; CHEN Q, 1994, J BACTERIOL, V176, P4226, DOI 10.1128/jb.176.14.4226-4234.1994; COHEN SN, 1972, P NATL ACAD SCI USA, V69, P2110, DOI 10.1073/pnas.69.8.2110; CROSA JH, 1977, INFECT IMMUN, V18, P509, DOI 10.1128/IAI.18.2.509-513.1977; CROSA JH, 1980, NATURE, V284, P566, DOI 10.1038/284566a0; CROSA JH, 1989, MICROBIOL REV, V53, P517, DOI 10.1128/MMBR.53.4.517-530.1989; CROSA JH, 1980, INFECT IMMUN, V27, P897, DOI 10.1128/IAI.27.3.897-902.1980; DELORENZO V, 1987, J BACTERIOL, V169, P2624, DOI 10.1128/jb.169.6.2624-2630.1987; DICKSON RC, 1975, SCIENCE, V187, P27, DOI 10.1126/science.1088926; FASANO A, 1990, INFECT IMMUN, V58, P3737; FOSTER JW, 1992, J BACTERIOL, V174, P4317, DOI 10.1128/JB.174.13.4317-4323.1992; GILBERT W, 1976, RNA POLYMERASE, P192; GRIGGS DW, 1989, J BACTERIOL, V171, P1048, DOI 10.1128/jb.171.2.1048-1054.1989; INOUYE M, 1988, CELL, V53, P5, DOI 10.1016/0092-8674(88)90480-1; KOSTER WL, 1991, J BIOL CHEM, V266, P23829; LITWIN CM, 1993, CLIN MICROBIOL REV, V6, P137, DOI 10.1128/CMR.6.2.137-149.1993; NIEDERHOFFER EC, 1990, J BACTERIOL, V172, P1930, DOI 10.1128/jb.172.4.1930-1938.1990; NORRANDER J, 1983, GENE, V26, P101, DOI 10.1016/0378-1119(83)90040-9; PRINCE RW, 1993, J BACTERIOL, V175, P2589, DOI 10.1128/JB.175.9.2589-2598.1993; REZNIKOFF WS, 1992, J BACTERIOL, V174, P655, DOI 10.1128/jb.174.3.655-658.1992; ROSE MD, 1987, CELL, V48, P1047, DOI 10.1016/0092-8674(87)90712-4; SALINAS PC, 1989, P NATL ACAD SCI USA, V86, P3529, DOI 10.1073/pnas.86.10.3529; SALINAS PC, 1992, GENE AMST, V123, P33; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIMONS RW, 1988, ANNU REV GENET, V22, P567, DOI 10.1146/annurev.ge.22.120188.003031; THEIL EC, 1994, BIOCHEM J, V304, P1; TOLMASKY ME, 1994, J BACTERIOL, V176, P213, DOI 10.1128/JB.176.1.213-220.1994; TOLMASKY ME, 1991, BIOL MET, V4, P33, DOI 10.1007/BF01135554; TOLMASKY ME, 1984, J BACTERIOL, V160, P860, DOI 10.1128/JB.160.3.860-866.1984; TOLMASKY ME, 1988, J BACTERIOL, V170, P1913, DOI 10.1128/jb.170.4.1913-1919.1988; VONGABAIN A, 1983, P NATL ACAD SCI-BIOL, V80, P653; WALDBESER LS, 1995, MOL MICROBIOL, V17, P747, DOI 10.1111/j.1365-2958.1995.mmi_17040747.x; WALDBESER LS, 1993, J BIOL CHEM, V268, P10433; WEINBERG ED, 1989, Q REV BIOL, V64, P261, DOI 10.1086/416359	44	40	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18885	18891		10.1074/jbc.271.31.18885	http://dx.doi.org/10.1074/jbc.271.31.18885			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702549	hybrid			2022-12-25	WOS:A1996VB68300087
J	Li, RG; Hodny, Z; Luciakova, K; Barath, P; Nelson, BD				Li, RG; Hodny, Z; Luciakova, K; Barath, P; Nelson, BD			Sp1 activates and inhibits transcription from separate elements in the proximal promoter of the human adenine nucleotide translocase 2 (ANT2) gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLE-DEPENDENT GENES; SUBUNIT-IV GENE; BOX-BINDING-PROTEINS; RNA POLYMERASE-II; ADP/ATP TRANSLOCASE; DNA-BINDING; MOLECULAR-CLONING; EXPRESSION; DISTINCT; FAMILY	Expression of the adenine nucleotide translocator 2 (ANT2) gene is growth regulated, We report a feature of the ANT2 promoter that involves a novel regulatory function for the Spl transfactor. We show that expression from the ANT2 proximal promoter is modulated through three Spl elements, two of which activate and one of which partially inhibits transcription, The inhibitor site, box C, is juxtaposed to transcription start (nucleotides -7 to -2), Spl bound to box C decreases transcription initiation, This was demonstrated by introducing mutations in box C which (a) increased chloramphenicol acetyltransferase expression in the transient transfection assay and (b) inhibited binding of both purified Spl and Spl in crude nuclear extracts, The activating elements (A and B boxes) are located at adjacent sites in the distal region of the proximal promoter, Mutation of either box inhibits transfection by 90%, indicating that they act in a synergistic manner, Supershift experiments with crude nuclear extracts showed that only Spl was bound to the three GC boxes, The finding that Spl acts as an activator/inhibitor within the same promoter region was verified in NIH3T3, HeLa, JEG3, and COS-1, indicating that this dual effect of Spl is widely preserved, These data suggest a unique role for Spl and raise the possibility that growth activation of the ANT2 gene is regulated by the interaction of Spl on the A, B, and C boxes.	UNIV STOCKHOLM,ARRHENIUS LAB,DEPT BIOCHEM,S-10691 STOCKHOLM,SWEDEN	Stockholm University			Hodny, Zdenek/C-9384-2009; Barath, Peter/T-7563-2019	Barath, Peter/0000-0001-7330-955X				BATTINI R, 1987, J BIOL CHEM, V262, P4355; CARTER RS, 1992, J BIOL CHEM, V267, P23418; CARTER RS, 1994, J BIOL CHEM, V269, P4381; CHEN LI, 1994, MOL CELL BIOL, V14, P4380, DOI 10.1128/MCB.14.7.4380; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; COZENS AL, 1989, J MOL BIOL, V206, P261, DOI 10.1016/0022-2836(89)90477-4; DATTA PK, 1995, NUCLEIC ACIDS RES, V15, P5444; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EMANUEL PA, 1993, P NATL ACAD SCI USA, V90, P8449, DOI 10.1073/pnas.90.18.8449; HAGEN G, 1995, J BIOL CHEM, V270, P24989, DOI 10.1074/jbc.270.42.24989; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; HIRSCHHORN RR, 1984, P NATL ACAD SCI-BIOL, V81, P6004, DOI 10.1073/pnas.81.19.6004; HOULDSWORTH J, 1988, P NATL ACAD SCI USA, V85, P377, DOI 10.1073/pnas.85.2.377; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; KACZMAREK L, 1985, P NATL ACAD SCI USA, V82, P5375, DOI 10.1073/pnas.82.16.5375; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KADONAGA JT, 1988, SCIENCE, V242, P1566, DOI 10.1126/science.3059495; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; KU DH, 1990, J BIOL CHEM, V265, P16060; LEGGETT RW, 1995, J BIOL CHEM, V270, P25879, DOI 10.1074/jbc.270.43.25879; LI K, 1989, J BIOL CHEM, V264, P13998; LIU HT, 1985, MOL CELL BIOL, V5, P2936, DOI 10.1128/MCB.5.11.2936; LUNARDI J, 1991, J BIOL CHEM, V266, P16534; LUNARDI J, 1992, J BIOL CHEM, V267, P15267; MAJELLO B, 1994, NUCLEIC ACIDS RES, V22, P4914, DOI 10.1093/nar/22.23.4914; NECKELMANN N, 1987, P NATL ACAD SCI USA, V84, P7580, DOI 10.1073/pnas.84.21.7580; PASCAL E, 1991, GENE DEV, V5, P1646, DOI 10.1101/gad.5.9.1646; RITTLING SR, 1986, P NATL ACAD SCI USA, V83, P3316, DOI 10.1073/pnas.83.10.3316; STEPIEN G, 1992, J BIOL CHEM, V267, P14592; SU W, 1991, GENE DEV, V5, P820, DOI 10.1101/gad.5.5.820; SUZUKI K, 1995, MOL CELL BIOL, V15, P5243; VIRBASIUS JV, 1991, MOL CELL BIOL, V11, P5631, DOI 10.1128/MCB.11.11.5631; VIRBASIUS JV, 1993, GENE DEV, V7, P380, DOI 10.1101/gad.7.3.380; WILLIAMS T, 1991, GENE DEV, V5, P670, DOI 10.1101/gad.5.4.670	36	70	70	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18925	18930		10.1074/jbc.271.31.18925	http://dx.doi.org/10.1074/jbc.271.31.18925			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702555	hybrid			2022-12-25	WOS:A1996VB68300093
J	Weber, J; Bowman, C; Senior, AE				Weber, J; Bowman, C; Senior, AE			Specific tryptophan substitution in catalytic sites of Escherichia coli F-1-ATPase allows differentiation between bound substrate ATP and product ADP in steady-state catalysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEART MITOCHONDRIAL ATPASE; NUCLEOTIDE-BINDING; BETA-SUBUNIT; ADENOSINE-TRIPHOSPHATASE; MEMBRANE SECTOR; MUTANT STRAINS; F1-ATPASE; MECHANISM; PROTEIN; COMPLEX	Tryptophan was specifically inserted as the residue immediately preceding the P-loop sequence in F-1-ATPase catalytic sites. The mutant enzyme (beta F148W) showed normal enzymatic characteristics. The fluorescence responses of beta-tryptophan 148 enabled us to differentiate between nucleoside di- and triphosphate bound in catalytic sites; MgADP quenched at 350 nm, whereas MgAMPPNP and MgADP . BeFx complex enhanced the fluorescence at 325 nm. With MgATP, both effects were seen simultaneously. This allowed analysis of bound catalytic site nucleotides directly under steady-state MgATP hydrolysis conditions. At mM concentration of MgATP (V-max conditions) one of the three catalytic sites was filled with substrate MgATP and the other two sites were filled with product MgADP. A model for F-1-ATPase steady-state turnover is presented that encompasses these findings. Given the structural similarity of the P-loop in nucleotide-binding proteins, this approach may prove widely useful.			Weber, J (corresponding author), UNIV ROCHESTER, MED CTR, DEPT BIOCHEM, ROCHESTER, NY 14642 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM025349, R01GM025349] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM25349] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; ALSHAWI MK, 1992, BIOCHEMISTRY-US, V31, P886, DOI 10.1021/bi00118a034; ALSHAWI MK, 1992, BIOCHEMISTRY-US, V31, P878, DOI 10.1021/bi00118a033; BIVIN DB, 1993, P NATL ACAD SCI USA, V90, P6791, DOI 10.1073/pnas.90.14.6791; BOYER PD, 1993, BIOCHIM BIOPHYS ACTA, V1140, P215, DOI 10.1016/0005-2728(93)90063-L; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAPALDI RA, 1994, TRENDS BIOCHEM SCI, V19, P284, DOI 10.1016/0968-0004(94)90006-X; DOWNIE JA, 1981, J BACTERIOL, V145, P200, DOI 10.1128/JB.145.1.200-210.1981; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FILLINGAME RH, 1990, BACTERIA TREATISE ST, V12, P345; FISHER AJ, 1995, BIOCHEMISTRY-US, V34, P8960, DOI 10.1021/bi00028a004; GRUBMEYER C, 1982, J BIOL CHEM, V257, P2092; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUNARDI J, 1988, P NATL ACAD SCI USA, V85, P8958, DOI 10.1073/pnas.85.23.8958; MAGGIO MB, 1988, J BIOL CHEM, V263, P4619; PERLIN DS, 1983, J BIOL CHEM, V258, P9793; RAO R, 1988, J BIOL CHEM, V263, P5569; SENIOR AE, 1992, J BIOENERG BIOMEMBR, V24, P479, DOI 10.1007/BF00762365; SENIOR AE, 1979, BIOCHEM J, V180, P111, DOI 10.1042/bj1800111; SENIOR AE, 1992, ARCH BIOCHEM BIOPHYS, V297, P340, DOI 10.1016/0003-9861(92)90682-M; SENIOR AE, 1984, ARCH BIOCHEM BIOPHYS, V228, P49, DOI 10.1016/0003-9861(84)90045-6; SENIOR AE, 1988, PHYSIOL REV, V68, P177, DOI 10.1152/physrev.1988.68.1.177; Senior AE, 1995, FEBS LETT, V377, P285, DOI 10.1016/0014-5793(95)01345-8; Senior AE, 1995, BIOCHEM SOC T, V23, P747, DOI 10.1042/bst0230747; SENIOR AE, 1990, ANNU REV BIOPHYS BIO, V19, P7; SENIOR AE, 1992, J BIOL CHEM, V267, P21471; SHEN HG, 1994, J BIOL CHEM, V269, P9424; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; STORY RM, 1992, NATURE, V355, P374, DOI 10.1038/355374a0; VANDEYAR MA, 1988, GENE, V65, P129, DOI 10.1016/0378-1119(88)90425-8; VANVELDHOVEN PP, 1987, ANAL BIOCHEM, V161, P45, DOI 10.1016/0003-2697(87)90649-X; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WEBB MR, 1980, J BIOL CHEM, V255, P1637; WEBER J, 1994, J BIOL CHEM, V269, P20462; WEBER J, 1992, J BIOL CHEM, V267, P1712; WEBER J, 1992, BIOCHEMISTRY-US, V31, P5112, DOI 10.1021/bi00137a004; WEBER J, 1993, J BIOL CHEM, V268, P20126; WEBER J, 1995, J BIOL CHEM, V270, P12653, DOI 10.1074/jbc.270.21.12653; Weber J, 1996, J BIOL CHEM, V271, P3474; WILKEMOUNTS S, 1994, ARCH BIOCHEM BIOPHYS, V309, P363, DOI 10.1006/abbi.1994.1125; [No title captured]	42	59	60	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18711	18718		10.1074/jbc.271.31.18711	http://dx.doi.org/10.1074/jbc.271.31.18711			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702526	hybrid			2022-12-25	WOS:A1996VB68300064
J	Yasuda, H; Lindorfer, MA; Woodfork, KA; Fletcher, JE; Garrison, JC				Yasuda, H; Lindorfer, MA; Woodfork, KA; Fletcher, JE; Garrison, JC			Role of the prenyl group on the G protein gamma subunit in coupling trimeric G proteins to A1 adenosine receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACULOVIRUS EXPRESSION SYSTEM; HETEROTRIMERIC G-PROTEINS; BETA-GAMMA; SIGNAL-TRANSDUCTION; ALPHA-SUBUNITS; GTP-BINDING; PHOSPHOLIPASE-C; SF9 CELLS; DIMERS; RECONSTITUTION	The coupling of receptors to heterotrimeric G proteins is determined by interactions between the receptor and the G protein alpha subunits and by the composition of the beta gamma dimers, To determine the role of the gamma subunit prenyl modification in this interaction, the CaaX motifs in the gamma(1), and gamma(2) subunits were altered to direct modification with different prenyl groups, recombinant beta gamma dimers expressed in the baculovirus/Sf9 insect cell system, and the dimers purified, The activity of the beta gamma dimers was compared in two assays: formation of the high affinity agonist binding conformation of the Al adenosine receptor and receptor-catalyzed exchange of GDP for GTP on the a subunit, The beta(1) gamma(1) dimer (modified with farnesyl) was significantly less effective than beta(1) gamma(2) (modified with geranylgeranyl) in either assay, The beta(1) gamma(1)-S74L dimer (modified with geranylgeranyl) was nearly as effective as beta(1) gamma(2) in either assay, The beta(1) gamma(2)-L71S dimer (modified with farnesyl) was significantly less active than beta(1) gamma(2). Using I-125-labeled beta gamma subunits, it was determined that native and altered beta gamma dimers reconstituted equally well into Sf9 membranes containing Al adenosine receptors. These data suggest that the prenyl group on the gamma subunit is an important determinant of the interaction between receptors and G protein gamma subunits.			Yasuda, H (corresponding author), UNIV VIRGINIA,HLTH SCI CTR,DEPT PHARMACOL,BOX 448,CHARLOTTESVILLE,VA 22908, USA.				NIDDK NIH HHS [R01-DK-19952] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019952] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAUER PH, 1991, MOL PHARMACOL, V39, P579; BIRNBAUMER L, 1992, CELL, V71, P1069, DOI 10.1016/S0092-8674(05)80056-X; BIRNBAUMER L, 1990, ANNU REV PHARMACOL, V30, P675; BOYER JL, 1994, J BIOL CHEM, V269, P2814; BUTKERAIT P, 1995, J BIOL CHEM, V270, P18691, DOI 10.1074/jbc.270.31.18691; CASEY PJ, 1992, J LIPID RES, V33, P1731; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; CONKLIN BR, 1993, CELL, V73, P631, DOI 10.1016/0092-8674(93)90245-L; DIETRICH A, 1994, EUR J BIOCHEM, V219, P171, DOI 10.1111/j.1432-1033.1994.tb19927.x; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; EXTON JH, 1994, ANNU REV PHYSIOL, V56, P349; FAWZI AB, 1991, J BIOL CHEM, V266, P12194; FLORIO VA, 1985, J BIOL CHEM, V260, P3477; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; FUKADA Y, 1990, NATURE, V346, P658, DOI 10.1038/346658a0; FUNG BKK, 1983, J BIOL CHEM, V258, P495; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GRABER SG, 1992, J BIOL CHEM, V267, P1271; GRABER SG, 1992, J BIOL CHEM, V267, P13123; GRABER SG, 1996, METH NEUROSCI, V29, P207; INIGUEZLLUHI JA, 1992, J BIOL CHEM, V267, P23409; INIGUEZLLUHI JA, 1993, TRENDS CELL BIOL, V3, P2300; KISSELEV O, 1995, P NATL ACAD SCI USA, V92, P9102, DOI 10.1073/pnas.92.20.9102; KISSELEV O, 1995, J BIOL CHEM, V270, P25356, DOI 10.1074/jbc.270.43.25356; KISSELEV O, 1993, J BIOL CHEM, V268, P24519; KISSELEV OG, 1994, J BIOL CHEM, V269, P21399; KLEUSS C, 1992, NATURE, V358, P424, DOI 10.1038/358424a0; KLEUSS C, 1991, NATURE, V353, P43, DOI 10.1038/353043a0; KLEUSS C, 1993, SCIENCE, V259, P832, DOI 10.1126/science.8094261; LAI RK, 1990, P NATL ACAD SCI USA, V87, P7673, DOI 10.1073/pnas.87.19.7673; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; LINDEN J, 1985, CIRC RES, V56, P279, DOI 10.1161/01.RES.56.2.279; Lindorfer MA, 1996, J BIOL CHEM, V271, P18582, DOI 10.1074/jbc.271.31.18582; MARSHALL CJ, 1993, SCIENCE, V259, P1865, DOI 10.1126/science.8456312; MATSUDA T, 1994, J BIOL CHEM, V269, P30358; MORISHITA R, 1995, J BIOL CHEM, V270, P29469, DOI 10.1074/jbc.270.49.29469; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; MULLER S, 1993, P NATL ACAD SCI USA, V90, P10439, DOI 10.1073/pnas.90.22.10439; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P5873, DOI 10.1073/pnas.87.15.5873; MUNTZ KH, 1992, MOL BIOL CELL, V3, P49, DOI 10.1091/mbc.3.1.49; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; OHGURO H, 1991, EMBO J, V10, P3669, DOI 10.1002/j.1460-2075.1991.tb04934.x; ONG OC, 1995, J BIOL CHEM, V270, P8495, DOI 10.1074/jbc.270.15.8495; PFEFFER SR, 1995, J BIOL CHEM, V270, P17057, DOI 10.1074/jbc.270.29.17057; RANDAZZO PA, 1995, J BIOL CHEM, V270, P14809, DOI 10.1074/jbc.270.24.14809; RAY K, 1995, J BIOL CHEM, V270, P21765, DOI 10.1074/jbc.270.37.21765; RYBA NJP, 1995, J BIOL CHEM, V270, P6757, DOI 10.1074/jbc.270.12.6757; SIMONDS WF, 1991, J BIOL CHEM, V266, P5363; SPIEGEL AM, 1992, ENDOCR REV, V13, P536, DOI 10.1210/er.13.3.536; STERNWEIS PC, 1994, CURR OPIN CELL BIOL, V6, P198, DOI 10.1016/0955-0674(94)90136-8; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; SUMMERS MD, 1987, TEXAS AGR EXPT STATI, V1555, P1; TAYLOR CW, 1990, BIOCHEM J, V272, P1; TAYLOR SS, 1993, RECEPTOR, V3, P165; TUCKER AL, 1992, FEBS LETT, V297, P107, DOI 10.1016/0014-5793(92)80338-H; UEDA N, 1994, J BIOL CHEM, V269, P4388; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; WEDEGAERTNER PB, 1995, J BIOL CHEM, V270, P503, DOI 10.1074/jbc.270.2.503; WESS J, 1993, TRENDS PHARMACOL SCI, V14, P308, DOI 10.1016/0165-6147(93)90049-P; WICKMAN KD, 1994, NATURE, V368, P255, DOI 10.1038/368255a0; YAMANE HK, 1990, P NATL ACAD SCI USA, V87, P5868, DOI 10.1073/pnas.87.15.5868	61	89	90	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18588	18595		10.1074/jbc.271.31.18588	http://dx.doi.org/10.1074/jbc.271.31.18588			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702509	hybrid			2022-12-25	WOS:A1996VB68300047
J	Masuda, A; Takenaga, K; Kondoh, F; Fukami, H; Utsumi, K; Okayama, H				Masuda, A; Takenaga, K; Kondoh, F; Fukami, H; Utsumi, K; Okayama, H			Role of a signal transduction pathway which controls disassembly of microfilament bundles and suppression of high-molecular-weight tropomyosin expression in oncogenic transformation of NRK cells	ONCOGENE			English	Article						tropomyosin; microfilament bundles; EGF; NRK cells; anchorage-independent growth	EPIDERMAL GROWTH-FACTOR; RAF-1 PROTEIN-KINASE; STRESS FIBERS; FIBROBLASTS; ISOFORM-2; ABILITY; ABSENCE; LINES; MOUSE; ACTIN	Role of disassembly of microfilament bundles and suppression of high-molecular-weight tropomyosin (TM) expression in growth factor- and various oncogene-induced transformation was studied by using NRK cells and its transformation-deficient mutants. In NRK cells which show a transformed phenotype by treatment with EGF and TGF-beta, cellular stress fibers became dissociated by EGF or EGF and TGF-beta combination, whereas TGF-beta alone caused thicker appearance of stress fibers, Accompanying these changes, the expression of TM isoforms 1 and 2 was suppressed by treatment with EGF or EGF and TGF-beta, but elevated by TGF-beta with similar time courses, On the other hand, the transformation-deficient mutant cell Lines, 39-1 and 39-3, did not show the transformed phenotypes by treatment with EGF and TGF-beta. Neither EGF nor EGF and TGF-beta combination affected cellular stress fibers and expression of TM isoforms 1 and 2 in both mutant lines, The relationship between the formation of stress fibers and the expression of TM isoforms was consistent in NRK cells, the mutant lines and their various oncogene-expressing sublines under various culture conditions, NRK cells overexpressing exogenous mouse TM isoform 2 showed markedly decreased susceptibility to EGF-induced dissociation of stress fibers and decreased anchorage-independent growth potential in the presence of EGF and TGF-beta. These results indicate that the transformation-deficient NRK mutant lines, 39-1 and 39-3 have defects in an EGF signal transduction pathway which induces suppression of high-molecular-weight TM expression and disassembly of microfilament bundles and suggested that the activation of the pathway is important for morphological transformation and oncogenic growth in growth factors- and various oncogene-induced transformation of NRK cells.	CHIBA CANC CTR,RES INST,DIV CHEMOTHERAPY,CHUOH KU,CHIBA 260,JAPAN; UNIV TOKYO,FAC MED,DEPT BIOCHEM,BUNKYO KU,TOKYO 113,JAPAN	Chiba Cancer Center; University of Tokyo	Masuda, A (corresponding author), AICHI CANC CTR,RES INST,LAB ULTRASTRUCT RES,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN.							BAUM G, 1990, DEV BIOL, V142, P115, DOI 10.1016/0012-1606(90)90155-C; BHATTACHARYA B, 1990, CANCER RES, V50, P2105; BISCHEK CB, 1981, CELL, V24, P175; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COOPER HL, 1985, MOL CELL BIOL, V5, P972, DOI 10.1128/MCB.5.5.972; COOPER HL, 1987, CANCER RES, V47, P4493; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; GALLOWAY PG, 1990, LAB INVEST, V62, P163; HENDRICKS M, 1984, MOL CELL BIOL, V4, P1823, DOI 10.1128/MCB.4.9.1823; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; KIZAKAKONDOH S, 1993, FEBS LETT, V336, P255, DOI 10.1016/0014-5793(93)80814-B; KIZAKAKONDOH S, 1992, MOL CELL BIOL, V12, P5078, DOI 10.1128/MCB.12.11.5078; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KUME K, 1992, NEW BIOL, V4, P504; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEESMILLER JP, 1991, BIOESSAYS, V13, P429, DOI 10.1002/bies.950130902; LEONARDI CL, 1982, BIOCHIM BIOPHYS ACTA, V720, P154, DOI 10.1016/0167-4889(82)90007-6; Macpherson I, 1969, FUNDAMENTAL TECHNIQU, P214; MASUDA A, 1992, NEW BIOL, V4, P489; MATSUMURA F, 1983, J BIOL CHEM, V258, P3954; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; POLLACK R, 1975, P NATL ACAD SCI USA, V86, P6940; PRASAD GL, 1993, P NATL ACAD SCI USA, V90, P7039, DOI 10.1073/pnas.90.15.7039; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; ROBERTS AB, 1981, P NATL ACAD SCI-BIOL, V78, P5339, DOI 10.1073/pnas.78.9.5339; TAKENAGA K, 1988, MOL CELL BIOL, V8, P5561, DOI 10.1128/MCB.8.12.5561; TAKENAGA K, 1988, BIOCHEM BIOPH RES CO, V157, P1111, DOI 10.1016/S0006-291X(88)80988-4; TAKENAGA K, 1994, CANCER LETT, V87, P47, DOI 10.1016/0304-3835(94)90408-1; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; WULF E, 1979, P NATL ACAD SCI USA, V76, P4498, DOI 10.1073/pnas.76.9.4498	36	22	22	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 16	1996	12	10					2081	2088						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UP283	8668333				2022-12-25	WOS:A1996UP28300006
J	Arora, PD; McCulloch, CAG				Arora, PD; McCulloch, CAG			Dependence of fibroblast migration on actin severing activity of gelsolin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH MUSCLE ACTIN; F-ACTIN; BINDING PROTEIN; THIN-FILAMENTS; CELLS; EXPRESSION; POLYMERIZATION; LOCALIZATION; MODULATION; MOTILITY	Gelsolin nucleates actin filament assembly, blocks the fast-exchanging ends of actin filaments, and severs filaments, processes that may play an important role in cell mobility. We studied the relationship between cell migration, ion, gelsolin content, and actin severing activity in human gingival fibroblasts. These cells were keratin negative and desmin negative but expressed vimentin and myosin II. Cells were separated by their ability to migrate in response to a chemoattractant stimulus. Northern analysis of mRNA, [S-35]methionine incorporation into immunoprecipitated gelsolin, immunoblots of cell lysates, and quantitative confocal microscopy showed 1.4-2-fold higher levels of gelsolin in nonmigrant compared with migrant cells. Because the concentration of intracellular gelsolin did not appear to be a central determinant of cell migration, we assessed its requirement for motility, Cells that were electroinjected with a gelsolin antibody that inhibits actin severing by gelsolin in vitro showed a 72% reduction of the number of migrant cells compared with controls treated with an irrelevant antibody, Cells that were electroinjected with free gelsolin exhibited a 33% increase in migration compared with cells electroinjected with bovine serum albumin. Compared with nonmigrant cells, migrant cells contained abundant free gelsolin and exhibited gelsolin-dependent F-actin severing activity, which required Ca2+. Serum stimulation of cell migration required increases in [Ca2+](i) because incubation with 3 mu M 1,2-bis-(o-aminophenoxy)-ethane-N,N,N',N'-tetraacetic acid tetra(acetoxymethyl)-ester blocked calcium flux and cell migration, Serum also stimulated the recruitment of gelsolin into the supernatants of lysates from migrant but not from nonmigrant cells, In fibroblasts, gelsolin concentration alone does not apparently determine migratory capacity, Instead, the Ca2+-dependent actin severing activity of free gelsolin appears to be a major determinant of cell migration.	UNIV TORONTO, FAC DENT, MED RES COUNCIL GRP PERIODONTAL PHYSIOL, TORONTO, ON M5S 1A8, CANADA	University of Toronto								ANDRE E, 1989, J CELL BIOL, V108, P985, DOI 10.1083/jcb.108.3.985; ANKENBAUER T, 1988, J CELL BIOL, V107, P1489, DOI 10.1083/jcb.107.4.1489; ARORA PD, 1995, J BIOL CHEM, V270, P6042, DOI 10.1074/jbc.270.11.6042; ARORA PD, 1994, J CELL PHYSIOL, V161, P187, DOI 10.1002/jcp.1041610202; ARORA PD, 1994, J CELL PHYSIOL, V159, P161, DOI 10.1002/jcp.1041590120; BANNO Y, 1992, J BIOL CHEM, V267, P6488; BAYREUTHER K, 1988, J CELL SCI, P115; BELLOWS CG, 1981, J CELL SCI, V50, P299; BORDIN S, 1984, SCIENCE, V223, P171, DOI 10.1126/science.6691142; BRYAN J, 1984, J BIOL CHEM, V259, P7480; BRYAN J, 1985, J CELL BIOL, V101, P1236, DOI 10.1083/jcb.101.4.1236; CARRON CP, 1986, J CELL BIOL, V102, P237, DOI 10.1083/jcb.102.1.237; CHAPONNIER C, 1987, J EXP MED, V165, P97, DOI 10.1084/jem.165.1.97; CHAPONNIER C, 1986, J CELL BIOL, V103, P1473, DOI 10.1083/jcb.103.4.1473; CHAPONNIER C, 1989, AM J PATHOL, V134, P597; CHAPONNIER C, 1990, EUR J BIOCHEM, V190, P559, DOI 10.1111/j.1432-1033.1990.tb15610.x; COOPER JA, 1988, J CELL BIOL, V106, P1229, DOI 10.1083/jcb.106.4.1229; CUNNINGHAM CC, 1991, SCIENCE, V251, P1233, DOI 10.1126/science.1848726; DAVIS TN, 1986, CELL, V47, P423, DOI 10.1016/0092-8674(86)90599-4; DIEFFENBACH CW, 1989, J BIOL CHEM, V264, P13281; EBISAWA K, 1985, BIOMED RES-TOKYO, V6, P161; GLOGAUER M, 1992, EXP CELL RES, V200, P227, DOI 10.1016/0014-4827(92)90168-8; GONSIOR S, 1995, CELL MOTIL CYTOSKEL, V31, P196, DOI 10.1002/cm.970310303; HARRIS HE, 1983, BIOCHEMISTRY-US, V22, P2728, DOI 10.1021/bi00280a022; HARTWIG JH, 1989, J CELL BIOL, V108, P467, DOI 10.1083/jcb.108.2.467; HEACOCK CS, 1983, ANAL BIOCHEM, V135, P22, DOI 10.1016/0003-2697(83)90725-X; HINSSEN H, 1987, J CELL BIOL, V105, P1425, DOI 10.1083/jcb.105.3.1425; HOWARD T, 1990, J CELL BIOL, V110, P1983, DOI 10.1083/jcb.110.6.1983; HOWE JG, 1981, J BIOL CHEM, V256, P2836; HUG C, 1995, CELL, V81, P591, DOI 10.1016/0092-8674(95)90080-2; HUGHES FJ, 1991, J HISTOCHEM CYTOCHEM, V39, P243, DOI 10.1177/39.2.1987269; IRWIN CR, 1994, J CELL SCI, V107, P1333; JANMEY PA, 1986, J MUSCLE RES CELL M, V7, P446, DOI 10.1007/BF01753587; JANMEY PA, 1987, J BIOL CHEM, V262, P12228; JANMEY PA, 1989, J BIOL CHEM, V264, P4825; JANMEY PA, 1987, NATURE, V325, P362, DOI 10.1038/325362a0; KANNO K, 1989, J CELL PHYSIOL, V139, P58, DOI 10.1002/jcp.1041390110; KNOWLES GC, 1992, J HISTOCHEM CYTOCHEM, V40, P1605, DOI 10.1177/40.10.1527379; KOUYAMA T, 1981, EUR J BIOCHEM, V114, P33; KUROKAWA H, 1990, BIOCHEM BIOPH RES CO, V168, P451, DOI 10.1016/0006-291X(90)92342-W; KURTH MC, 1984, J BIOL CHEM, V259, P7473; KWIATKOWSKI DJ, 1988, J CELL BIOL, V106, P375, DOI 10.1083/jcb.106.2.375; KWIATKOWSKI DJ, 1986, NATURE, V323, P455, DOI 10.1038/323455a0; KWIATKOWSKI DJ, 1988, J BIOL CHEM, V263, P13857; Lee Juliet, 1993, Trends in Cell Biology, V3, P366, DOI 10.1016/0962-8924(93)90084-E; LEE WM, 1992, NEW ENGL J MED, V326, P1335; LIND SE, 1987, J CELL BIOL, V105, P833, DOI 10.1083/jcb.105.2.833; MANIATIS T, 1992, MOL CLONING LABORATO, P545; MULLAUER L, 1990, BIOCHEM BIOPH RES CO, V171, P852, DOI 10.1016/0006-291X(90)91224-G; ONJI T, 1988, BIOCHEM BIOPH RES CO, V155, P91, DOI 10.1016/S0006-291X(88)81053-2; PENDER N, 1991, J CELL SCI, V100, P187; POLLARD TD, 1986, ANNU REV BIOCHEM, V55, P987, DOI 10.1146/annurev.bi.55.070186.005011; POSTLETHWAITE AE, 1978, P NATL ACAD SCI USA, V75, P871, DOI 10.1073/pnas.75.2.871; SCHOLZ A, 1995, EXP CELL RES, V219, P384, DOI 10.1006/excr.1995.1243; SCHOR SL, 1987, J CELL SCI, P165; SKALLI O, 1986, J CELL BIOL, V103, P2787, DOI 10.1083/jcb.103.6.2787; STOSSEL TP, 1985, ANNU REV CELL BIOL, V1, P353, DOI 10.1146/annurev.cb.01.110185.002033; WITKE W, 1995, CELL, V81, P41, DOI 10.1016/0092-8674(95)90369-0; YAMAGUCHI O, 1993, UROL RES, V21, P429, DOI 10.1007/BF00300081; YIN HL, 1979, NATURE, V281, P583, DOI 10.1038/281583a0; YIN HL, 1980, J BIOL CHEM, V255, P9494; YIN HL, 1987, BIOESSAYS, V7, P176, DOI 10.1002/bies.950070409	62	71	72	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20516	20523		10.1074/jbc.271.34.20516	http://dx.doi.org/10.1074/jbc.271.34.20516			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702793	hybrid			2022-12-25	WOS:A1996VD33700045
J	King, JS; Fairley, CF; Morgan, WF				King, JS; Fairley, CF; Morgan, WF			DNA end joining by the Klenow fragment of DNA polymerase I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRAND-BREAKS; ESCHERICHIA-COLI; NONHOMOLOGOUS RECOMBINATION; SACCHAROMYCES-CEREVISIAE; CHROMOSOMAL INSTABILITY; MAMMALIAN-CELLS; ILLEGITIMATE RECOMBINATION; TRANSFECTED DNA; KU AUTOANTIGEN; HELICASE-II	DNA end joining is a type of illegitimate recombination characterized by the joining of two DNA ends that lack homology. Using oligonucleotides as substrate, we found that an exonuclease-free derivative of the Klenow fragment of Escherichia coli DNA polymerase I can mediate DNA end joining in vitro. DNA sequence analysis of product DNA indicated that overlap products were formed between direct repeat sequences at the termini of the oligonucleotides. Formation of recombinant products was dependent on the strandedness of the substrate DNA, and the rate of product formation was dependent on the size of the potential overlap. With one to three complementary bases available for pairing at the 3' termini, there was an absolute requirement that one of the oligonucleotides be double-stranded, whereas with four complementary bases, products were also formed in reactions with single-stranded oligonucleotides. When noncomplementary nucleotides were added to the terminus of one of the oligonucleotides, product formation was delayed but not blocked. These data indicate that a DNA polymerase can mediate DNA double strand break rejoining in the absence of other proteins.	UNIV CALIF SAN FRANCISCO,RADIOBIOL & ENVIRONM HLTH LAB,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT RADIAT ONCOL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco					NATIONAL CANCER INSTITUTE [T32CA009215] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007106] Funding Source: NIH RePORTER; NCI NIH HHS [CA 09215-12] Funding Source: Medline; NIEHS NIH HHS [5 T32 ES07106] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ANDERSON CW, 1993, TRENDS BIOCHEM SCI, V18, P433, DOI 10.1016/0968-0004(93)90144-C; BEESE LS, 1993, SCIENCE, V260, P352, DOI 10.1126/science.8469987; BLANCO L, 1991, GENE, V100, P27, DOI 10.1016/0378-1119(91)90346-D; CLARK JM, 1987, J MOL BIOL, V198, P123, DOI 10.1016/0022-2836(87)90462-1; CLARK JM, 1988, NUCLEIC ACIDS RES, V16, P9677, DOI 10.1093/nar/16.20.9677; CLARK JM, 1991, GENE, V104, P75, DOI 10.1016/0378-1119(91)90467-P; DEWEY WC, 1971, P NATL ACAD SCI USA, V68, P667, DOI 10.1073/pnas.68.3.667; FONTANEL ML, 1993, ANAL BIOCHEM, V214, P338, DOI 10.1006/abio.1993.1501; GERONDAKIS S, 1984, CELL, V36, P973, DOI 10.1016/0092-8674(84)90047-3; GETTS RC, 1994, J BIOL CHEM, V269, P15981; GOEDECKE W, 1994, NUCLEIC ACIDS RES, V22, P2094, DOI 10.1093/nar/22.11.2094; JEGGO PA, 1990, MUTAT RES, V239, P1, DOI 10.1016/0165-1110(90)90028-A; KADHIM MA, 1992, NATURE, V355, P738, DOI 10.1038/355738a0; KING JS, 1993, NUCLEIC ACIDS RES, V21, P1055, DOI 10.1093/nar/21.5.1055; KING JS, 1994, J BIOL CHEM, V269, P13061; Kornberg A., 1992, DNA REPLICATION; KRAMER KM, 1994, MOL CELL BIOL, V14, P1293, DOI 10.1128/MCB.14.2.1293; KUNKEL TA, 1988, CELL, V53, P837, DOI 10.1016/S0092-8674(88)90189-4; KUNKEL TA, 1990, BIOCHEMISTRY-US, V29, P8003, DOI 10.1021/bi00487a001; LEHMAN CW, 1994, NUCLEIC ACIDS RES, V22, P434, DOI 10.1093/nar/22.3.434; MARDER BA, 1993, MOL CELL BIOL, V13, P6667, DOI 10.1128/MCB.13.11.6667; MEZARD C, 1994, MOL CELL BIOL, V14, P1278, DOI 10.1128/MCB.14.2.1278; MORGAN WF, 1988, MOL CELL BIOL, V8, P4204, DOI 10.1128/MCB.8.10.4204; MURNANE JP, 1990, NUCLEIC ACIDS RES, V18, P2733, DOI 10.1093/nar/18.9.2733; NAEGELI H, 1993, J BIOL CHEM, V268, P10386; PFEIFFER P, 1988, NUCLEIC ACIDS RES, V16, P907, DOI 10.1093/nar/16.3.907; PFEIFFER P, 1994, MOL CELL BIOL, V14, P888, DOI 10.1128/MCB.14.2.888; PHILLIPS JW, 1994, MOL CELL BIOL, V14, P5794, DOI 10.1128/MCB.14.9.5794; PHILLIPS JW, 1992, RAD RES 20TH CENTURY, V2, P207; RATHMELL WK, 1994, P NATL ACAD SCI USA, V91, P7623, DOI 10.1073/pnas.91.16.7623; RATHMELL WK, 1994, MOL CELL BIOL, V14, P4741, DOI 10.1128/MCB.14.7.4741; Roth D., 1988, GENETIC RECOMBINATIO, P621; ROTH DB, 1985, MOL CELL BIOL, V5, P2599, DOI 10.1128/MCB.5.10.2599; ROTH DB, 1986, MOL CELL BIOL, V6, P4295, DOI 10.1128/MCB.6.12.4295; SABATIER L, 1992, NATURE, V357, P548, DOI 10.1038/357548a0; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; SELBY CP, 1993, SCIENCE, V260, P53, DOI 10.1126/science.8465200; SEN D, 1992, METHOD ENZYMOL, V211, P191; SWEASY JB, 1992, J BIOL CHEM, V267, P1407; SWEASY JB, 1993, P NATL ACAD SCI USA, V90, P4626, DOI 10.1073/pnas.90.10.4626; THODE S, 1990, CELL, V60, P921, DOI 10.1016/0092-8674(90)90340-K; TUTEJA N, 1994, EMBO J, V13, P4991, DOI 10.1002/j.1460-2075.1994.tb06826.x; WAKE CT, 1984, MOL CELL BIOL, V4, P387, DOI 10.1128/MCB.4.3.387; WINDLE B, 1991, GENE DEV, V5, P160, DOI 10.1101/gad.5.2.160; WOLFF S, 1973, ADV RAD RES, P457; ZDZIENICKA MZ, 1995, MUTAT RES-DNA REPAIR, V336, P203, DOI 10.1016/0921-8777(95)00003-3	46	28	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20450	20457		10.1074/jbc.271.34.20450	http://dx.doi.org/10.1074/jbc.271.34.20450			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702784	hybrid			2022-12-25	WOS:A1996VD33700036
J	Ferbeyre, G; Bratty, J; Chen, H; Cedergren, R				Ferbeyre, G; Bratty, J; Chen, H; Cedergren, R			Cell cycle arrest promotes trans-hammerhead ribozyme action in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; SACCHAROMYCES-CEREVISIAE; MESSENGER-RNA; INHIBITION; PROTEIN; PHEROMONE; KINASE; DESTRUCTION; ANTISENSE; CATALYSIS	A hammerhead ribozyme designed to cleave the yeast ADE1 mRNA has been expressed in yeast under the control of a galactose-inducible promoter, RNA prepared from the galactose-induced yeast cultures possesses an activity that cleaves ADE1 mRNA in vitro, However, in spite of high expression levels of the ribozyme, no cleavage activity could be demonstrated in vivo. On the other hand, when the yeast cells expressing hammerhead RNA were treated with the alpha-factor mating pheromone, the level of ADE1 mRNA was reduced by 50%, Similar reductions were observed when this strain was cultured in the presence of lithium acetate or in nitrogen-free medium, Moreover, control experiments ill which disabled hammerhead genes were expressed showed no such reductions, Extension of the length of the flanking recognition arms of the ribozyme from a total of 10 to 16 or 24 nucleotides diminished the inhibitory effect of the ribozyme. These data suggest that ribozymes are able to cleave a trans-RNA target in yeast.	UNIV MONTREAL,DEPT BIOCHIM,MONTREAL,PQ H3C 3J7,CANADA	Universite de Montreal			Ferbeyre, Gerardo/A-1569-2010	Ferbeyre, Gerardo/0000-0002-2146-618X				ATKINS D, 1994, BIOL CHEM H-S, V375, P721; Beck J, 1995, NUCLEIC ACIDS RES, V23, P4954, DOI 10.1093/nar/23.24.4954; BERTRAND E, 1994, NUCLEIC ACIDS RES, V22, P293, DOI 10.1093/nar/22.3.293; BERTRAND EL, 1994, EMBO J, V13, P2904, DOI 10.1002/j.1460-2075.1994.tb06585.x; BRATTY J, 1993, BIOCHIM BIOPHYS ACTA, V1216, P345, DOI 10.1016/0167-4781(93)90001-T; CIEJEK E, 1979, CELL, V18, P623, DOI 10.1016/0092-8674(79)90117-X; COTTEN M, 1989, EMBO J, V8, P3861, DOI 10.1002/j.1460-2075.1989.tb08564.x; CRISELL P, 1993, NUCLEIC ACIDS RES, V21, P3513; CROSS FR, 1991, CELL, V65, P875, DOI 10.1016/0092-8674(91)90394-E; CROSS FR, 1988, MOL CELL BIOL, V8, P4675, DOI 10.1128/MCB.8.11.4675; CZUBAYKO F, 1994, J BIOL CHEM, V269, P21358; EGLI CM, 1994, J BIOL CHEM, V269, P27378; ELLIS J, 1993, NUCLEIC ACIDS RES, V21, P5171, DOI 10.1093/nar/21.22.5171; FERBEYRE G, 1995, GENE, V155, P45, DOI 10.1016/0378-1119(94)00891-U; FINK GR, 1987, CELL, V49, P5, DOI 10.1016/0092-8674(87)90746-X; GUTHRIE C, 1986, TRENDS BIOCHEM SCI, V11, P430, DOI 10.1016/0968-0004(86)90179-9; HASELOFF J, 1988, NATURE, V334, P585, DOI 10.1038/334585a0; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; HERTEL KJ, 1992, NUCLEIC ACIDS RES, V20, P3252, DOI 10.1093/nar/20.12.3252; LAW RHP, 1988, BIOCHEM INT, V17, P673; LHUILLIER PJ, 1992, EMBO J, V11, P4411, DOI 10.1002/j.1460-2075.1992.tb05541.x; LIEBER A, 1995, MOL CELL BIOL, V15, P540, DOI 10.1128/MCB.15.1.540; LO KMS, 1992, VIROLOGY, V190, P176, DOI 10.1016/0042-6822(92)91203-7; MARSCHALL P, 1994, CELL MOL NEUROBIOL, V14, P523, DOI 10.1007/BF02088835; MOORE SA, 1984, J BIOL CHEM, V259, P1004; Nasmyth K, 1993, CURR OPIN CELL BIOL, V5, P166, DOI 10.1016/0955-0674(93)90099-C; OJWANG JO, 1992, P NATL ACAD SCI USA, V89, P10802, DOI 10.1073/pnas.89.22.10802; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PETER M, 1994, SCIENCE, V265, P1228, DOI 10.1126/science.8066461; PONTIUS BW, 1990, P NATL ACAD SCI USA, V87, P8403, DOI 10.1073/pnas.87.21.8403; PRINGLE JR, 1981, MOL BIOL YEAST SACCH, P97; Rose MD., 1990, METHODS YEAST GENETI; ROSSI J J, 1992, Current Opinion in Biotechnology, V3, P3, DOI 10.1016/0958-1669(92)90117-2; RUSO P, 1989, P NATL ACAD SCI USA, V86, P8348; Sambrook J., 2002, MOL CLONING LAB MANU; SARVER N, 1990, SCIENCE, V247, P1222, DOI 10.1126/science.2107573; SMITH BE, 1995, BIOCHEM BIOPH RES CO, V206, P401, DOI 10.1006/bbrc.1995.1055; STEFAN CJ, 1994, MOL CELL BIOL, V14, P3339, DOI 10.1128/MCB.14.5.3339; SULLENGER BA, 1993, SCIENCE, V262, P1566, DOI 10.1126/science.8248806; TSUCHIHASHI Z, 1993, SCIENCE, V262, P99, DOI 10.1126/science.7692597; VANDERKROL AR, 1988, BIOTECHNIQUES, V6, P958; WITTENBERG C, 1990, CELL, V62, P225, DOI 10.1016/0092-8674(90)90361-H	42	14	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19318	19323		10.1074/jbc.271.32.19318	http://dx.doi.org/10.1074/jbc.271.32.19318			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702616	hybrid			2022-12-25	WOS:A1996VB68400050
J	Miller, SP; Karschnia, EJ; Ikeda, TP; LaPorte, DC				Miller, SP; Karschnia, EJ; Ikeda, TP; LaPorte, DC			Isocitrate dehydrogenase kinase/phosphatase - Kinetic characteristics of the wild-type and two mutant proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATP-BINDING-SITE; KINASE PHOSPHATASE; ESCHERICHIA-COLI; PHOSPHORYLATION; ADAPTATION; MECHANISM; CYCLE	Isocitrate dehydrogenase (IDH) of Escherichia coti is regulated by a bifunctional protein, IDH kinase/phosphatase. In addition to the kinase and phosphatase activities, this protein catalyzes an intrinsic ATPase reaction. The initial velocity kinetics of these activities exhibited extensive similarities, IDH kinase and phosphatase both yielded intersecting double-reciprocal plots. In addition, we observed similar values for the kinetic constants describing interactions of the kinase and phosphatase with their protein substrates and the interactions of all three activities with ATP, In contrast, while the maximum velocities of IDH kinase and IDH phosphatase were nearly equal, they were 10-fold less than the maximum velocity of the ATPase. Although the IDH phosphatase reaction required either ATP or ADP, it was not supported by the nonhydrolyzable ATP analogue 5'-adenylyl imidodiphosphate. The kinetic properties of wild-type IDH kinase/phosphatase were compared with those of two mutant derivatives of this protein, The mutations in these proteins selectively inhibit IDH phosphatase activity. Inhibition of IDH phosphatase resulted from three factors: decreases in the maximum velocities, reduced affinities for phospho-IDH, and a loss of coupling between ATP and phospho-IDH, These mutations also affected the properties of IDH kinase, increasing the maximum velocities and decreasing the affinities for ATP and phospho-IDH. The intrinsic ATPase activities also exhibited reduced affinity for ATP, These results are discussed in the context of a model which proposes that all three activities occur at the same active site.	UNIV MINNESOTA,DEPT BIOCHEM,MINNEAPOLIS,MN 55455	University of Minnesota System; University of Minnesota Twin Cities					NIDDK NIH HHS [DK40486.1] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040486] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AXELSON JT, 1981, ANAL BIOCHEM, V116, P357, DOI 10.1016/0003-2697(81)90371-7; BAIS R, 1975, ANAL BIOCHEM, V63, P271, DOI 10.1016/0003-2697(75)90215-8; Cleland W W, 1979, Methods Enzymol, V63, P103; Cleland W.W., 1970, ENZYMES, P1; COLEMAN JE, 1983, ADV ENZYMOL RAMB, V55, P381; GARNAK M, 1979, SCIENCE, V203, P1111, DOI 10.1126/science.34215; GARNAK M, 1979, J BIOL CHEM, V254, P7915; HOLMS WH, 1971, J GEN MICROBIOL, V65, P57, DOI 10.1099/00221287-65-1-57; IKEDA T, 1991, J BACTERIOL, V173, P1801, DOI 10.1128/jb.173.5.1801-1806.1991; IKEDA TP, 1992, J BACTERIOL, V174, P1414, DOI 10.1128/jb.174.4.1414-1416.1992; KLUMPP DJ, 1988, J BACTERIOL, V170, P2763, DOI 10.1128/jb.170.6.2763-2769.1988; LAPORTE DC, 1983, NATURE, V305, P286, DOI 10.1038/305286a0; LAPORTE DC, 1993, J CELL BIOCHEM, V51, P14, DOI 10.1002/jcb.240510104; LAPORTE DC, 1985, J BIOL CHEM, V260, P563; LAPORTE DC, 1985, J BIOL CHEM, V260, P5291; LAPORTE DC, 1982, NATURE, V300, P458, DOI 10.1038/300458a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; STUELAND CS, 1987, J BIOL CHEM, V262, P16095; STUELAND CS, 1989, J BIOL CHEM, V264, P13775; VARELA I, 1988, FEBS LETT, V231, P361, DOI 10.1016/0014-5793(88)80850-0	20	21	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19124	19128		10.1074/jbc.271.32.19124	http://dx.doi.org/10.1074/jbc.271.32.19124			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702587	hybrid			2022-12-25	WOS:A1996VB68400021
J	Nimmesgern, E; Fox, T; Fleming, MA; Thomson, JA				Nimmesgern, E; Fox, T; Fleming, MA; Thomson, JA			Conformational changes and stabilization of inosine 5'-monophosphate dehydrogenase associated with ligand binding and inhibition by mycophenolic acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN IMP DEHYDROGENASE; HUMAN NORMAL LYMPHOCYTES; TRITRICHOMONAS-FETUS; ESCHERICHIA-COLI; CELL LINES; EXPRESSION; PROTEINS; PURIFICATION; MOFETIL; EC-1.1.1.205	The effects of substrate, product, and inhibitor (mycophenolic acid) binding on the conformation and stability of hamster type II inosine 5'-monophosphate dehydrogenase (IMPDH) have been examined. The protein in various states of ligand occupancy was compared by analyzing susceptibility to in vitro proteolysis, the degree of binding of a hydrophobic fluorescent dye, secondary structure content as determined by far-UV circular dichroism spectra, and urea-induced denaturation curves, These analysis methods revealed consistent evidence that IMPDH undergoes a local reorganization when IMP or XMP bind, NAD(+) produced no such effect, In fact, no evidence was found for NAD(+) binding independently of IMP. It is proposed that IMPDH adopts an open conformation around its nucleotide binding sites in the absence of substrates and that binding of IMP stabilizes a closed conformation that has a higher affinity for NAD(+). The data also suggest the enzyme remains in the closed configuration throughout the catalytic steps and then reverts to the open conformation with XMP release, thereby consummating the enzyme cycle. Mycophenolic acid inhibition appeared to impart even greater stability. We propose that localized conformational changes occur during the normal and mycophenolic acid-inhibited reaction sequences of IMPDH.			Nimmesgern, E (corresponding author), VERTEX PHARMACEUT INC, 130 WAVERLY ST, CAMBRIDGE, MA 02139 USA.							ALLISON AC, 1993, IMMUNOL REV, V136, P5, DOI 10.1111/j.1600-065X.1993.tb00652.x; ANTONINO LC, 1994, BIOCHEMISTRY-US, V33, P1760, DOI 10.1021/bi00173a019; BECK JT, 1994, EXP PARASITOL, V78, P101, DOI 10.1006/expr.1994.1010; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROX LW, 1968, BIOCHEMISTRY-US, V7, P2589, DOI 10.1021/bi00847a021; CARDAMONE M, 1992, BIOCHEM J, V282, P589, DOI 10.1042/bj2820589; CARR SF, 1993, J BIOL CHEM, V268, P27286; COLLART FR, 1990, BLOOD, V75, P570; COLLART FR, 1992, CANCER RES, V52, P5826; CRABTREE GW, 1971, CANCER RES, V31, P985; DANOVITCH GM, 1995, KIDNEY INT, V48, pS93; DAYTON JS, 1994, J IMMUNOL, V152, P984; EKLUND H, 1984, BIOCHEMISTRY-US, V23, P5982, DOI 10.1021/bi00320a014; EUGUI EM, 1991, SCAND J IMMUNOL, V33, P161, DOI 10.1111/j.1365-3083.1991.tb03746.x; FERSHT A, 1984, ENZYME STRUCTURE MEC, P390; Fleming MA, 1996, BIOCHEMISTRY-US, V35, P6990, DOI 10.1021/bi9607416; GILBERT HJ, 1979, BIOCHEM J, V183, P481, DOI 10.1042/bj1830481; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Gosio B., 1896, RIV DIGIENE SANITA P, V7, P825; GRIFFITH JP, 1995, CELL, V82, P507, DOI 10.1016/0092-8674(95)90439-5; GRINYO J, 1995, LANCET, V345, P1321; HAGER PW, 1995, BIOCHEM PHARMACOL, V49, P1323, DOI 10.1016/0006-2952(95)00026-V; HEDSTROM L, 1990, BIOCHEMISTRY-US, V29, P849, DOI 10.1021/bi00456a001; HOLMES EW, 1974, BIOCHIM BIOPHYS ACTA, V364, P209, DOI 10.1016/0005-2744(74)90006-0; HUBBARD MJ, 1989, BIOCHEMISTRY-US, V28, P1868, DOI 10.1021/bi00430a066; JACKSON RC, 1975, NATURE, V256, P331, DOI 10.1038/256331a0; KONNO Y, 1991, J BIOL CHEM, V266, P506; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Link JO, 1996, J AM CHEM SOC, V118, P2091, DOI 10.1021/ja9534056; MANAVALAN P, 1987, ANAL BIOCHEM, V167, P76, DOI 10.1016/0003-2697(87)90135-7; Morris RE, 1996, KIDNEY INT, V49, pS26; NAGAI M, 1991, CANCER RES, V51, P3886; NAGAI M, 1992, CANCER RES, V52, P258; NAKAMURA H, 1992, LEUKEMIA RES, V16, P561, DOI 10.1016/0145-2126(92)90002-O; NATSUMEDA Y, 1990, J BIOL CHEM, V265, P5292; NATSUMEDA Y, 1988, CANCER RES, V48, P507; Pace C N, 1986, Methods Enzymol, V131, P266; SANDALOVA T, 1993, FEBS LETT, V327, P361, DOI 10.1016/0014-5793(93)81021-Q; SENDA M, 1994, LIFE SCI, V54, P1917, DOI 10.1016/0024-3205(94)90150-3; SHAW LM, 1995, THER DRUG MONIT, V17, P690, DOI 10.1097/00007691-199512000-00025; Sintchak MD, 1996, CELL, V85, P921, DOI 10.1016/S0092-8674(00)81275-1; SKARZYNSKI T, 1988, J MOL BIOL, V203, P1097, DOI 10.1016/0022-2836(88)90130-1; SNYDER FF, 1972, BIOCHEM PHARMACOL, V21, P2351, DOI 10.1016/0006-2952(72)90386-3; SOLLINGER HW, 1995, TRANSPLANTATION, V60, P225, DOI 10.1097/00007890-199508000-00003; STRYER LUBERT, 1965, J MOL BIOL, V13, P482; TOUMADJE A, 1992, ANAL BIOCHEM, V200, P321, DOI 10.1016/0003-2697(92)90473-K; VERHAM R, 1987, MOL BIOCHEM PARASIT, V24, P1, DOI 10.1016/0166-6851(87)90110-1; WEBER G, 1983, CANCER RES, V43, P3466; WHITE JL, 1976, J MOL BIOL, V102, P759, DOI 10.1016/0022-2836(76)90290-4; WU JC, 1994, PERSPECT DRUG DISCOV, V2, P184; Xiang BS, 1996, J BIOL CHEM, V271, P1435, DOI 10.1074/jbc.271.3.1435; YAMADA Y, 1988, BIOCHEMISTRY-US, V27, P2193, DOI 10.1021/bi00406a057	52	49	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19421	19427		10.1074/jbc.271.32.19421	http://dx.doi.org/10.1074/jbc.271.32.19421			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702630	hybrid			2022-12-25	WOS:A1996VB68400064
J	Kekuda, R; Prasad, PD; Fei, YJ; TorresZamorano, V; Sinha, S; YangFeng, TL; Leibach, FH; Ganapathy, V				Kekuda, R; Prasad, PD; Fei, YJ; TorresZamorano, V; Sinha, S; YangFeng, TL; Leibach, FH; Ganapathy, V			Cloning of the sodium-dependent, broad-scope, neutral amino acid transporter B-O from a human placental choriocarcinoma cell line	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN GLUTAMATE TRANSPORTER; BORDER MEMBRANE-VESICLES; XENOPUS-OOCYTES; NEUROTRANSMITTER TRANSPORTERS; FUNCTIONAL-CHARACTERIZATION; NA+/GLUCOSE COTRANSPORTER; MOLECULAR-CLONING; HUMAN BRAIN; SYSTEM-B; EXPRESSION	We have isolated a cDNA from a human placental choriocarcinoma cell cDNA library which, when expressed in HeLa cells, induces a Na+-dependent amino acid transport system with preference for zwitterionic amino acids, Anionic amino acids, cationic amino acids, imino acids, and N-methylated amino acids are excluded by this system, These characteristics are identical to those described for the amino acid transporter B-o. When expressed in Xenopus laevis oocytes that do not have detectable endogenous activity of the amino acid transporter B-o, the cloned transporter increases alanine transport in the oocytes severalfold and induces alanine-evoked inward currents in the presence of Na+. The cDNA codes for a polypeptide containing 541 amino acids with 10 putative transmembrane domains, Amino acid sequence homology predicts this transporter (hATB(o)) to be a member of a superfamily consisting of the glutamate transporters, the neutral amino acid transport system ASCT, and the insulin-activable neutral/anionic amino acid transporter, Chromosomal assignment studies with somatic cell hybrid analysis and fluorescent in situ hybridization have located the ATB(o) gene to human chromosome 19q13.3.	MED COLL GEORGIA, DEPT BIOCHEM & MOL BIOL, AUGUSTA, GA 30912 USA; YALE UNIV, SCH MED, DEPT GENET, NEW HAVEN, CT 06510 USA	University System of Georgia; Augusta University; Yale University					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD024451] Funding Source: NIH RePORTER; NICHD NIH HHS [HD 24451] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ARRIZA JL, 1993, J BIOL CHEM, V268, P15329; BLAKELY RD, 1991, ANAL BIOCHEM, V194, P302, DOI 10.1016/0003-2697(91)90233-J; CAMPA MJ, 1989, J CELL PHYSIOL, V141, P645, DOI 10.1002/jcp.1041410324; CHRISTENSEN HN, 1989, METHOD ENZYMOL, V173, P576; CHRISTENSEN HN, 1990, PHYSIOL REV, V70, P43, DOI 10.1152/physrev.1990.70.1.43; CLARK JA, 1993, BIOESSAYS, V15, P323, DOI 10.1002/bies.950150506; Ganapathy Vadivel, 1994, P1773; JONES EMC, 1994, GENOMICS, V23, P490, DOI 10.1006/geno.1994.1529; KANAI Y, 1994, J BIOL CHEM, V269, P20599; KAWAKAMI H, 1994, BIOCHEM BIOPH RES CO, V199, P171, DOI 10.1006/bbrc.1994.1210; KILBERG MS, 1993, ANNU REV NUTR, V13, P137, DOI 10.1146/annurev.nu.13.070193.001033; KONG CT, 1993, J BIOL CHEM, V268, P1509; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEVY HL, 1989, METABOLIC BASIS INHE, P2515; LIAO K, 1995, BIOCHEM BIOPH RES CO, V208, P1008, DOI 10.1006/bbrc.1995.1434; LOO DDF, 1993, P NATL ACAD SCI USA, V90, P5767, DOI 10.1073/pnas.90.12.5767; LYNCH AM, 1987, BIOCHIM BIOPHYS ACTA, V899, P176, DOI 10.1016/0005-2736(87)90398-1; MACKENZIE B, 1994, J BIOL CHEM, V269, P22488; MACKENZIE B, 1994, PFLUG ARCH EUR J PHY, V426, P121, DOI 10.1007/BF00374679; MAENZ DD, 1992, J BIOL CHEM, V267, P22079; MCGIVAN JD, 1994, BIOCHEM J, V299, P321, DOI 10.1042/bj2990321; PAN M, 1995, J BIOL CHEM, V270, P3582, DOI 10.1074/jbc.270.8.3582; PARENT L, 1992, J MEMBRANE BIOL, V125, P49; PLAKIDOUDYMOCK S, 1994, BIOCHEM J, V301, P399, DOI 10.1042/bj3010399; RAMAMOORTHY S, 1994, BIOCHEM J, V300, P893, DOI 10.1042/bj3000893; RONG LA, 1995, J BIOL CHEM, V270, P6456, DOI 10.1074/jbc.270.12.6456; SHAFQAT S, 1993, MOL ENDOCRINOL, V7, P1517, DOI 10.1210/me.7.12.1517; SHAFQAT S, 1993, J BIOL CHEM, V268, P15351; SHAPER NL, 1992, GENOMICS, V12, P613, DOI 10.1016/0888-7543(92)90458-5; SHASHIDHARAN P, 1994, BRAIN RES, V662, P245, DOI 10.1016/0006-8993(94)90819-2; SHASHIDHARAN P, 1994, BBA-BIOMEMBRANES, V1191, P393, DOI 10.1016/0005-2736(94)90192-9; STEVENS BR, 1982, J MEMBRANE BIOL, V66, P213, DOI 10.1007/BF01868496; TAYLOR PM, 1989, J MEMBRANE BIOL, V112, P149, DOI 10.1007/BF01871276; VANWINKLE LJ, 1985, J BIOL CHEM, V260, P2118; VANWINKLE LJ, 1993, BIOCHIM BIOPHYS ACTA, V1154, P157, DOI 10.1016/0304-4157(93)90009-D; VOGELI G, 1987, METHOD ENZYMOL, V152, P407; YANGFENG TL, 1995, BIOCHEM BIOPH RES CO, V210, P874, DOI 10.1006/bbrc.1995.1739	37	208	220	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18657	18661		10.1074/jbc.271.31.18657	http://dx.doi.org/10.1074/jbc.271.31.18657			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702519	hybrid			2022-12-25	WOS:A1996VB68300057
J	Huynh, DP; Pulst, SM				Huynh, DP; Pulst, SM			Neurofibromatosis 2 antisense oligodeoxynucleotides induce reversible inhibition of schwannomin synthesis and cell adhesion in STS26T and T98G cells	ONCOGENE			English	Article						schwannomin; merlin; neurofibromatosis 2; antisense oligonucleotides; moesin; Schwann cell	E-CADHERIN; TYROSINE PHOSPHORYLATION; TYPE-2 NEUROFIBROMATOSIS; CYTOPLASMIC DOMAIN; UNITED-KINGDOM; BETA-CATENIN; PROTEIN; EZRIN; GENE; ASSOCIATION	Mutations in the neurofibromatosis 2 (NF2) gene are the predominant cause in the development of sporadic schwannomas and are also involved in the pathogenesis of meningiomas and ependymomas. The product of the NF2 gene, termed merlin or schwannnomin, is thought to act as a tumor suppressor protein. Although its protein sequence shows homology to proteins that are known to link the cytoskeleton to the cell membrane, no direct evidence for this function has been obtained, We used antisense phosphorothioate oligodeoxynucleotides (pODNs) complementary to the human NF2 cDNA sequence and transfected them into Schwann-like STS26T cells permeabilized by streptolysin O. Changes in cell morphology and attachment were observed at 12 to 24 h and continued up to 48 h post transfection. Cells were rounded and easily dislodged from the substratum at 12-24 h. These changes were reversible and cells became bipolar with thin protrusions and began to reattach to the substratum after 48 h. Normal morphology and adhesion were observed at 72 h post transfection. Morphological changes were due to suppression of schwannomin synthesis. Immunoprecipitations with anti-schwannomin antibodies showed schwannomin to be almost absent 3 h after treatment with antisense pODNs and to be significantly suppressed up to 12 h post transfection whereas beta-actin levels remained unchanged. The morphological changes were not the result of cell death, but resulted in increased cell proliferation. These data demonstrate that antisense oligonucleotides can be successfully employed to suppress schwannomin synthesis and indicate that schwannomin may belong to a class of tumor suppressor genes that provide a link between cell adhesion and tumorigenesis.	UNIV CALIF LOS ANGELES, SCH MED, NEUROGENET LAB, LOS ANGELES, CA 90048 USA; UNIV CALIF LOS ANGELES, SCH MED, DIV NEUROL, CSMC BURNS & ALLEN RES INST, LOS ANGELES, CA 90048 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA					NINDS NIH HHS [NS01428-01A1] Funding Source: Medline	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AGOSTI CG, 1995, AM J HUM GENET, V57, P114; ALGRAIN M, 1993, J CELL BIOL, V120, P129, DOI 10.1083/jcb.120.1.129; BARRY ELR, 1993, BIOTECHNIQUES, V15, P1016; BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; BERRYMAN M, 1993, J CELL SCI, V105, P1025; BHAKDI S, 1985, INFECT IMMUN, V47, P52; BIANCHI AB, 1994, NAT GENET, V6, P185, DOI 10.1038/ng0294-185; CONBOY J, 1986, P NATL ACAD SCI USA, V83, P9512, DOI 10.1073/pnas.83.24.9512; DAHLBERG WK, 1993, INT J RADIAT BIOL, V63, P191, DOI 10.1080/09553009314550251; DEPREZ RHL, 1994, AM J HUM GENET, V54, P1022; EVANS DGR, 1992, J MED GENET, V29, P847, DOI 10.1136/jmg.29.12.847; EVANS DGR, 1992, J MED GENET, V29, P841, DOI 10.1136/jmg.29.12.841; FRANCK Z, 1990, J CELL BIOL, V111, P2475, DOI 10.1083/jcb.111.6.2475; FUNAYAMA N, 1991, J CELL BIOL, V115, P1039, DOI 10.1083/jcb.115.4.1039; GOULD KL, 1989, EMBO J, V8, P4133, DOI 10.1002/j.1460-2075.1989.tb08598.x; GU MX, 1991, P NATL ACAD SCI USA, V88, P5867, DOI 10.1073/pnas.88.13.5867; HUYNH DP, 1994, DEV BIOL, V161, P538, DOI 10.1006/dbio.1994.1052; IRVING RM, 1993, ARCH OTOLARYNGOL, V119, P1222; JACOBSON AB, 1984, NUCLEIC ACIDS RES, V12, P45, DOI 10.1093/nar/12.1Part1.45; JACOBY LB, 1994, HUM MOL GENET, V3, P413, DOI 10.1093/hmg/3.3.413; KINTNER C, 1992, CELL, V69, P225, DOI 10.1016/0092-8674(92)90404-Z; KOIKE M, 1995, ONCOGENE, V10, P117; LANKES WT, 1991, P NATL ACAD SCI USA, V88, P8297, DOI 10.1073/pnas.88.19.8297; LUTCHMAN M, 1995, CANCER RES, V55, P2270; MARTUZA RL, 1988, NEW ENGL J MED, V318, P684, DOI 10.1056/NEJM198803173181106; MATSUYOSHI N, 1992, J CELL BIOL, V118, P703, DOI 10.1083/jcb.118.3.703; MAUTNER V, NEUROSURGERY, V38, P880; MURTHY AE, 1995, AM J HUM GENET, V57, P113; NAGAFUCHI A, 1988, EMBO J, V7, P3679, DOI 10.1002/j.1460-2075.1988.tb03249.x; OKA H, 1993, CANCER RES, V53, P1696; REES DJG, 1990, NATURE, V347, P685, DOI 10.1038/347685a0; ROULEAU GA, 1993, NATURE, V363, P515, DOI 10.1038/363515a0; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; RUTTLEDGE MH, 1994, NAT GENET, V6, P180, DOI 10.1038/ng0294-180; SAINZ J, 1994, HUM MOL GENET, V3, P885, DOI 10.1093/hmg/3.6.885; Sainz J, 1996, HUM GENET, V97, P121; SAINZ J, 1995, HUM MOL GENET, V4, P137, DOI 10.1093/hmg/4.1.137; SAMBROOK J, 1989, MOL CLONING LAB MANU, P1830; SATO N, 1992, J CELL SCI, V103, P131; SHIOZAKI H, 1994, AM J PATHOL, V144, P667; SHIOZAKI H, 1991, AM J PATHOL, V139, P17; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; TAKESHIMA H, 1994, ONCOGENE, V9, P2135; TAKEUCHI K, 1994, J CELL BIOL, V125, P1371, DOI 10.1083/jcb.125.6.1371; TROFATTER JA, 1993, CELL, V72, P791, DOI 10.1016/0092-8674(93)90406-G; TSUKITA S, 1989, J CELL BIOL, V108, P2369, DOI 10.1083/jcb.108.6.2369; TSUKITA S, 1994, J CELL BIOL, V126, P391, DOI 10.1083/jcb.126.2.391; Tsukita Shoichiro, 1992, Current Opinion in Cell Biology, V4, P834, DOI 10.1016/0955-0674(92)90108-O; TWIST EC, 1994, HUM MOL GENET, V3, P147, DOI 10.1093/hmg/3.1.147; WAGNER RW, 1994, NATURE, V372, P333, DOI 10.1038/372333a0; WAGNER RW, 1993, SCIENCE, V260, P1510, DOI 10.1126/science.7684856; YANG Q, 1991, P NATL ACAD SCI USA, V88, P5949, DOI 10.1073/pnas.88.14.5949	52	52	53	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 4	1996	13	1					73	84						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UX319	8700556				2022-12-25	WOS:A1996UX31900009
J	Bubb, VJ; Curtis, LJ; Cunningham, C; Dunlop, MG; Carothers, AD; Morris, RG; White, S; Bird, CC; Wyllie, AH				Bubb, VJ; Curtis, LJ; Cunningham, C; Dunlop, MG; Carothers, AD; Morris, RG; White, S; Bird, CC; Wyllie, AH			Microsatellite instability and the role of hMSH2 in sporadic colorectal cancer	ONCOGENE			English	Article						replication errors; sporadic colorectal cancer; hMSH2; prognosis	GENETIC INSTABILITY; GENOMIC INSTABILITY; MUTATIONS; CARCINOMA; HOMOLOG; TUMORS; COLON	Microsatellite instability (MSI) occurs in most tumours from patients with hereditary non-polyposis colorectal cancer (HNPCC) and in around 17% of sporadic colorectal cancers. Germline defects in mismatch repair (MMR) genes are responsible for the majority of large HNPCC families, with hMSH2 accounting for at least 50%. MMR gene defects also occur in a small proportion of sporadic colorectal tumours with MSI. Here we report a systematic analysis of mismatch repair deficiency in 215 Scottish patients with sporadic colorectal tumours. We found that 16.4% of tumours exhibited MSI; survival analysis by Cox proportional hazards method showed a substantial survival advantage for patients with tumours showing MSI, independent of other prognostic factors. Tumours with MSI were screened for hMSH2 mutations and although 61% were found to have alterations, of these only 1/24 was exonic. The majority of these changes were reductions in length at intronic mononucleotide tracts and we postulate that these alterations are the result of a genetic defect elsewhere, although they may compromise hMSH2 function as a second step in tumourigenesis. Our findings indicate that instability confers an improved prognosis in colorectal cancer and, despite the fact that these two groups of tumours share similar biological characteristics, the genetic basis of HNPCC and sporadic colorectal cancer with MSI is different.	UNIV EDINBURGH, ROYAL INFIRM, DEPT SURG, EDINBURGH EH3 9YW, MIDLOTHIAN, SCOTLAND; WESTERN GEN HOSP, MRC, HUMAN GENET UNIT, EDINBURGH EH4 2XU, MIDLOTHIAN, SCOTLAND	Royal Infirmary of Edinburgh; University of Edinburgh; University of Edinburgh	Bubb, VJ (corresponding author), UNIV EDINBURGH, SCH MED, DEPT PATHOL, CRC LABS, TEVIOT PL, EDINBURGH EH8 9AG, MIDLOTHIAN, SCOTLAND.		Dunlop, Malcolm G/F-1973-2011	Dunlop, Malcolm G/0000-0002-3033-5851				AALTONEN LA, 1994, CANCER RES, V54, P1645; AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; BASSAM BJ, 1991, ANAL BIOCHEM, V196, P80, DOI 10.1016/0003-2697(91)90120-I; BORRESEN AL, 1995, HUM MOL GENET, V4, P2065, DOI 10.1093/hmg/4.11.2065; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; *CANC RES CAMP, 1993, 181 CANC RES CAMP; CHEN JS, 1995, CANCER RES, V55, P174; CHONG JM, 1994, CANCER RES, V54, P4595; CHU CS, 1993, NAT GENET, V3, P151, DOI 10.1038/ng0293-151; CURTIS L, 1994, EUR J CANCER, V30A, P984, DOI 10.1016/0959-8049(94)90129-5; DRUMMOND JT, 1995, SCIENCE, V268, P1909, DOI 10.1126/science.7604264; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; FONG KM, 1995, CANCER RES, V55, P28; GAO XA, 1994, ONCOGENE, V9, P2999; GOELZ SE, 1985, BIOCHEM BIOPH RES CO, V130, P118, DOI 10.1016/0006-291X(85)90390-0; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HALL NR, 1994, EUR J CANCER, V30A, P1550, DOI 10.1016/0959-8049(94)00326-Z; HAN HJ, 1993, CANCER RES, V53, P5087; HONCHEL R, 1994, CANCER RES, V54, P1159; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; KIM HG, 1994, AM J PATHOL, V145, P148; KOBAYASHI Y, 1988, FOCUS, V10, P73; KOLODNER RD, 1994, GENOMICS, V24, P516, DOI 10.1006/geno.1994.1661; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LIU B, 1995, NAT GENET, V9, P48, DOI 10.1038/ng0195-48; Liu B, 1996, NAT MED, V2, P169, DOI 10.1038/nm0296-169; LIU B, 1994, CANCER RES, V54, P4590; LOTHE RA, 1993, CANCER RES, V53, P5849; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; MARY JL, 1994, HUM MOL GENET, V3, P2067; MELTZER SJ, 1994, CANCER RES, V54, P3379; MERLO A, 1994, CANCER RES, V54, P2098; MIRONOV NM, 1994, CANCER RES, V54, P41; NAN HJ, 1995, HUM MOL GENET, V4, P237, DOI 10.1093/hmg/4.2.237; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; PALOMBO F, 1995, SCIENCE, V268, P1912, DOI 10.1126/science.7604265; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PAPADOPOULOS N, 1995, SCIENCE, V268, P1915, DOI 10.1126/science.7604266; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; PATEL U, 1994, ONCOGENE, V9, P3695; PELTOMAKI P, 1993, CANCER RES, V53, P5853; PERCESEPPE A, 1994, INT J CANCER, V58, P799, DOI 10.1002/ijc.2910580608; PROLLA TA, 1994, MOL CELL BIOL, V14, P407, DOI 10.1128/MCB.14.1.407; PURDIE CA, 1991, AM J PATHOL, V138, P807; RHYU MG, 1994, ONCOGENE, V9, P29; RISINGER JI, 1993, CANCER RES, V53, P5100; SHRIDHAR V, 1994, CANCER RES, V54, P2084; STORTS DR, 1993, PROMEGA NOTES, V42, P10; SUZUKI H, 1994, CANCER RES, V54, P4841; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; WIERINGA B, 1984, CELL, V37, P915, DOI 10.1016/0092-8674(84)90426-4; WIJNEN J, 1994, HUM MOL GENET, V3, P2268, DOI 10.1093/hmg/3.12.2268-a; WIJNEN J, 1995, AM J HUM GENET, V56, P1060; WU C, 1994, ONCOGENE, V9, P991; YOUNG J, 1993, HUM MUTAT, V2, P351, DOI 10.1002/humu.1380020505	55	231	235	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 20	1996	12	12					2641	2649						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UW487	8700523				2022-12-25	WOS:A1996UW48700018
J	Burns, JL; Guzder, SN; Sung, P; Prakash, S; Prakash, L				Burns, JL; Guzder, SN; Sung, P; Prakash, S; Prakash, L			An affinity of human replication protein A for ultraviolet-damaged DNA - Implications for damage recognition in nucleotide excision repair	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; SACCHAROMYCES-CEREVISIAE; GENE; ENCODES; ENDONUCLEASE; BINDING; HELICASE; RAD1	Replication protein A (RPA), a heterotrimeric protein of 70-, 32-, and 14-kDa subunits, is an essential factor for DNA replication. Biochemical studies with human and yeast RPA have indicated that it is a DNA-binding protein that has higher affinity for single-stranded DNA. Interestingly, in vitro nucleotide excision repair studies with purified protein components have shown an absolute requirement for RPA in the incision of UV-damaged DNA. Here we use a mobility shift assay to demonstrate that human RPA binds a UV damaged duplex DNA fragment preferentially. Complex formation between RPA and the UV-irradiated DNA is not affected by prior enzymatic photo-reactivation of the DNA, suggesting an affinity of RPA for the (6-4) photoproduct. We also show that Mg2+ in the millimolar range is required for preferential binding of RPA to damaged DNA. These findings identify a novel property of RPA and implicate RPA in damage recognition during the incision of UV-damaged DNA.	UNIV TEXAS,MED BRANCH,SEALY CTR MOL SCI,GALVESTON,TX 77555	University of Texas System; University of Texas Medical Branch Galveston			Prakash, Satya/C-6420-2013; Prakash, Louise/C-7891-2012	Prakash, Satya/0000-0001-7228-1444; Prakash, Louise/0000-0001-9143-6261	NCI NIH HHS [CA41261] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA041261, R37CA041261] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOURRE F, 1987, NUCLEIC ACIDS RES, V15, P8861, DOI 10.1093/nar/15.21.8861; BRILL SJ, 1989, NATURE, V342, P92, DOI 10.1038/342092a0; FEAVER WJ, 1993, CELL, V75, P1379, DOI 10.1016/0092-8674(93)90624-Y; GOMES XV, 1995, J BIOL CHEM, V270, P4534, DOI 10.1074/jbc.270.9.4534; GUZDER SN, 1994, NATURE, V369, P578, DOI 10.1038/369578a0; GUZDER SN, 1993, P NATL ACAD SCI USA, V90, P5433, DOI 10.1073/pnas.90.12.5433; GUZDER SN, 1994, NATURE, V367, P91, DOI 10.1038/367091a0; GUZDER SN, 1995, J BIOL CHEM, V270, P12973, DOI 10.1074/jbc.270.22.12973; GUZDER SN, 1995, J BIOL CHEM, V270, P8385, DOI 10.1074/jbc.270.15.8385; HABRAKEN Y, 1994, NUCLEIC ACIDS RES, V22, P3312, DOI 10.1093/nar/22.16.3312; HABRAKEN Y, 1993, NATURE, V366, P365, DOI 10.1038/366365a0; HENRICKSEN LA, 1994, J BIOL CHEM, V269, P11121; JONES CJ, 1993, BIOCHEMISTRY-US, V32, P12096, DOI 10.1021/bi00096a021; KIM CS, 1994, BIOCHEMISTRY-US, V33, P14197, DOI 10.1021/bi00251a031; MA LB, 1994, NUCLEIC ACIDS RES, V22, P4095, DOI 10.1093/nar/22.20.4095; MITSIS PG, 1993, BIOCHEMISTRY-US, V32, P5257, DOI 10.1021/bi00070a038; Mu D, 1996, J BIOL CHEM, V271, P8285, DOI 10.1074/jbc.271.14.8285; PARK CH, 1995, J BIOL CHEM, V270, P22657, DOI 10.1074/jbc.270.39.22657; PRAKASH S, 1993, ANNU REV GENET, V27, P33, DOI 10.1146/annurev.ge.27.120193.000341; QIU HF, 1993, GENE DEV, V7, P2161, DOI 10.1101/gad.7.11.2161; SANCAR GB, 1985, BIOCHEMISTRY-US, V24, P1849, DOI 10.1021/bi00329a007; SPIVAK G, 1988, MUTAT RES, V193, P97, DOI 10.1016/0167-8817(88)90040-5; STILLMAN B, 1994, CELL, V78, P725, DOI 10.1016/S0092-8674(94)90362-X; SUNG P, 1987, P NATL ACAD SCI USA, V84, P6045, DOI 10.1073/pnas.84.17.6045; SUNG P, 1993, J BIOL CHEM, V268, P26391; SUNG P, 1994, SCIENCE, V265, P1241, DOI 10.1126/science.8066464; SUNG P, 1995, CELL, V82, P453, DOI 10.1016/0092-8674(95)90434-4; SUNG P, 1987, P NATL ACAD SCI USA, V84, P8951, DOI 10.1073/pnas.84.24.8951; SUNG P, 1993, NATURE, V365, P852, DOI 10.1038/365852a0; TOMKINSON AE, 1993, NATURE, V362, P860, DOI 10.1038/362860a0	30	109	112	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					11607	11610		10.1074/jbc.271.20.11607	http://dx.doi.org/10.1074/jbc.271.20.11607			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8690733	hybrid			2022-12-25	WOS:A1996UL25000004
J	Takahashi, C; Akiyama, N; Matsuzaki, T; Takai, S; Kitayama, H; Noda, M				Takahashi, C; Akiyama, N; Matsuzaki, T; Takai, S; Kitayama, H; Noda, M			Characterization of a human MSX-2 cDNA and its fragment isolated as a transformation suppressor gene against v-Ki-ras oncogene	ONCOGENE			English	Article						MSX-2 homeobox gene; cellular transformation; revertant; ras oncogene; myogenic differentiation; MyoD gene	RETROVIRAL VECTORS; LEUKEMIA-VIRUS; CELL-LINES; EXPRESSION; MOUSE; DNA; FIBROBLASTS; EFFICIENCY; POLYMERASE; MYOGENESIS	A cDNA (termed CT124) encoding a carboxyl-terminal fragment of the human homeobox protein MSX-2 was found to induce flat reversion when expressed in v-Ki-ras-transformed NIH3T3 cells, Although the expression of endogenous MSX-2 gene is low in most of the normal adult tissues examined, it is frequently carcinoma-derived cell Likewise, inactive in NIH3T3 but is transcriptionally activated after transformation v-Ki-ras oncogene, suggesting that the intact MSX-2. may play a positive, rather than suppressive, role in cell transformation, To test this possibility, we isolated a near full-length human and tested its activities in two cell fibroblast and myoblast, In NIH3T3 fibroblasts, although the gene by itself failed to confer a transformed phenotype, antisense MSX-2 cDNA as well as truncated CT124 cDNA interfered with the transforming activities of v-Ki-ras oncogene, In C2C12 myoblasts, MSX-2 was found to suppress MyoD gene expression, as do activated ras oncogenes, under certain culture conditions, and CT124 was found to inhibit the activities of both MSX-2 and ras in this system as well, Our findings not only suggest that CT124 may act as a dominant suppressor of MSX-2 but also raise the possibility that MSX-2 gene may be an important downstream target for the Ras signaling pathways.	KYOTO UNIV,GRAD SCH MED,DEPT MOLEC ONCOL,SAKYO KU,KYOTO 606,JAPAN; JAPANESE FDN CANC RES,INST CANC,DEPT VIRAL ONCOL,TOSHIMA KU,TOKYO 170,JAPAN; INT MED CTR JAPAN,CLIN RES INST,DEPT GENET,SHINJUKU KU,TOKYO 162,JAPAN	Kyoto University; Japanese Foundation for Cancer Research; National Center for Global Health & Medicine - Japan								ALEMA S, 1994, SEMIN CANCER BIOL, V5, P147; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BASSIN RH, 1970, INT J CANCER, V6, P95, DOI 10.1002/ijc.2910060114; BOS JL, 1989, CANCER RES, V49, P4682; BRAUN T, 1989, EMBO J, V8, P701, DOI 10.1002/j.1460-2075.1989.tb03429.x; CATRON KM, 1995, MOL CELL BIOL, V15, P861; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COELHO CND, 1991, MECH DEVELOP, V34, P143, DOI 10.1016/0925-4773(91)90051-7; CUTLER ML, 1992, MOL CELL BIOL, V12, P3750, DOI 10.1128/MCB.12.9.3750; DAVIDSON D, 1995, TRENDS GENET, V11, P405, DOI 10.1016/S0168-9525(00)89124-6; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; ERCOLANI L, 1988, J BIOL CHEM, V263, P15335; ERLICH HA, 1991, SCIENCE, V252, P1643, DOI 10.1126/science.2047872; GRAHAM A, 1994, NATURE, V372, P684, DOI 10.1038/372684a0; HOLLAND PWH, 1991, GENE, V98, P253, DOI 10.1016/0378-1119(91)90182-B; HSU IC, 1993, CARCINOGENESIS, V14, P987, DOI 10.1093/carcin/14.5.987; JABS EW, 1993, CELL, V75, P443, DOI 10.1016/0092-8674(93)90379-5; JOWETT AK, 1993, DEVELOPMENT, V117, P461; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KOZAK M, 1984, NATURE, V308, P241, DOI 10.1038/308241a0; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MIKI T, 1989, GENE, V83, P137, DOI 10.1016/0378-1119(89)90411-3; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MONAGHAN AP, 1991, DEVELOPMENT, V112, P1053; MONTARRAS D, 1991, NEW BIOL, V3, P592; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; MURRAY MJ, 1983, CELL, V33, P749, DOI 10.1016/0092-8674(83)90017-X; MYERS TW, 1991, BIOCHEMISTRY-US, V30, P7661, DOI 10.1021/bi00245a001; NODA M, 1983, P NATL ACAD SCI-BIOL, V80, P5602, DOI 10.1073/pnas.80.18.5602; NODA M, 1989, P NATL ACAD SCI USA, V86, P162, DOI 10.1073/pnas.86.1.162; NODA M, 1993, BIOCHIM BIOPHYS ACTA, V1155, P97, DOI 10.1016/0304-419X(93)90024-7; NOSA M, 1993, FASEB J, V7, P834; RUDNICKI MA, 1995, BIOESSAYS, V17, P203, DOI 10.1002/bies.950170306; Sambrook J., 2002, MOL CLONING LAB MANU; SANES JR, 1986, EMBO J, V5, P3133, DOI 10.1002/j.1460-2075.1986.tb04620.x; SATOKATA I, 1994, NAT GENET, V6, P348, DOI 10.1038/ng0494-348; SONG KN, 1992, NATURE, V360, P477, DOI 10.1038/360477a0; SUZUKI M, 1993, BIOCHEM BIOPH RES CO, V194, P187, DOI 10.1006/bbrc.1993.1802; TAKAI S, 1994, HUM GENET, V93, P198; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; VAINIO S, 1993, CELL, V75, P45, DOI 10.1016/S0092-8674(05)80083-2; VALENZUELA DM, 1986, NUCLEIC ACIDS RES, V14, P843, DOI 10.1093/nar/14.2.843; WANG YQ, 1995, DEV BIOL, V168, P374, DOI 10.1006/dbio.1995.1087; WOLOSHIN P, 1995, CELL, V82, P611, DOI 10.1016/0092-8674(95)90033-0; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7	45	39	39	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 16	1996	12	10					2137	2146						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UP283	8668339				2022-12-25	WOS:A1996UP28300012
J	VanHouten, JN; Natoli, F; Asch, BB				VanHouten, JN; Natoli, F; Asch, BB			Frequent ectopic expression of a placenta-specific gene at high levels in BALB/c mouse mammary carcinomas	ONCOGENE			English	Article						MIPP; retrotransposon; mammary tumorigenesis; intracisternal A-particle	INTRACISTERNAL-A-PARTICLES; HEMATOPOIETIC-CELLS; DNA REARRANGEMENT; INSERTION; SEQUENCES; RETROTRANSPOSONS; TRANSFORMATION; IDENTIFICATION; TRANSPOSITION; PLASMACYTOMA	A placenta-specific gene, MIPP, is transcriptionally regulated in BALB/c mice by a solo long terminal repeat (LTR) of an intracisternal A-particle (IAP), an endogenous retrotransposon, Expression of IAPs, which is also promoted by LTR sequences, is a frequent aberration in many mouse mammary tumors of BALB/c mice, Given that these retroelements and the placental gene have a common promoter, we hypothesized that the tumors also express the gene, Northern blot analysis and RT-PCR revealed high expression of the placenta-specific gene in BALB/c mouse mammary preneoplasias and carcinomas of diverse etiologies, but not in normal mammary gland from virgin, pregnant and lactating mice, The preneoplasias and tumors expressed two transcripts, one of which is apparently unique to the mammary lesions, The other transcript is the same as one expressed in placenta that is not promoted by the IAP LTR, Despite the parallel expression of the placental gene and IAPs in the mammary tissues, RT-PCR showed that LTR sequences are absent from tumor-associated MIPP transcripts, Southern analysis revealed no gross mutations of the MIPP gene in mammary preneoplasias and tumors, The ectopic expression of the placenta-specific gene in BALB/c mouse mammary preneoplasias and carcinomas raises the possibility that it acts as an oncogene.			VanHouten, JN (corresponding author), ROSWELL PK CANC INST, DEPT EXPTL PATHOL, BUFFALO, NY 14263 USA.				NATIONAL CANCER INSTITUTE [R01CA059906] Funding Source: NIH RePORTER; NCI NIH HHS [CA59906] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALGATE PA, 1993, ONCOGENE, V8, P1221; ASCH BB, 1990, CANCER RES, V50, P2404; ASCH BB, 1993, INT J CANCER, V54, P813, DOI 10.1002/ijc.2910540516; BANVILLE D, 1989, J MOL BIOL, V207, P481, DOI 10.1016/0022-2836(89)90458-0; BLANKENSTEIN T, 1990, J EXP MED, V171, P965, DOI 10.1084/jem.171.3.965; CANAANI E, 1983, P NATL ACAD SCI-BIOL, V80, P7118, DOI 10.1073/pnas.80.23.7118; CARDIFF RD, 1988, ANTICANCER RES, V8, P925; CHANGYEH A, 1993, P NATL ACAD SCI USA, V90, P292, DOI 10.1073/pnas.90.1.292; CHANGYEH A, 1991, NUCLEIC ACIDS RES, V19, P3667, DOI 10.1093/nar/19.13.3667; CHOMCZYNSKI P, 1993, BIOTECHNIQUES, V15, P532; CHRISTY RJ, 1985, NUCLEIC ACIDS RES, V13, P289, DOI 10.1093/nar/13.1.289; DANDEKAR S, 1986, MOL CELL BIOL, V6, P4104, DOI 10.1128/MCB.6.11.4104; HAWLEY RG, 1984, MOL CELL BIOL, V4, P2565, DOI 10.1128/MCB.4.12.2565; JANMEY PA, 1995, CURR OPIN CELL BIOL, V7, P111, DOI 10.1016/0955-0674(95)80052-2; KUFF EL, 1988, ADV CANCER RES, V51, P183, DOI 10.1016/S0065-230X(08)60223-7; KUFF EL, 1990, CANCER CELL-MON REV, V2, P398; LUEDERS KK, 1977, CELL, V12, P963, DOI 10.1016/0092-8674(77)90161-1; MEDINA D, 1987, J NATL CANCER I, V79, P569; MEDINA D, 1970, J NATL CANCER I, V45, P353; MIYAMOTO S, 1990, MOL CELL BIOL, V10, P1593, DOI 10.1128/MCB.10.4.1593; Nusse R, 1991, Curr Top Microbiol Immunol, V171, P43; RECHAVI G, 1982, NATURE, V300, P607, DOI 10.1038/300607a0; SCHMID MF, 1994, J CELL BIOL, V124, P341, DOI 10.1083/jcb.124.3.341; SLAGLE BL, 1987, CELLULAR MOL BIOL MA, P275; STOCKING C, 1988, CELL, V53, P869, DOI 10.1016/S0092-8674(88)90329-7; SUGITA T, 1990, J EXP MED, V171, P2001, DOI 10.1084/jem.171.6.2001; TOHYAMA K, 1990, EMBO J, V9, P1823, DOI 10.1002/j.1460-2075.1990.tb08307.x; VARKEY JP, 1995, GENE DEV, V9, P1074, DOI 10.1101/gad.9.9.1074; VONBULOW M, 1995, EXP CELL RES, V219, P407, DOI 10.1006/excr.1995.1246; WAY M, 1995, J CELL BIOL, V128, P51, DOI 10.1083/jcb.128.1.51; WIVEL NA, 1971, INT J CANCER, V7, P167, DOI 10.1002/ijc.2910070119; WOLF D, 1984, MOL CELL BIOL, V4, P1402, DOI 10.1128/MCB.4.7.1402; WUJCIK KM, 1984, J VIROL, V52, P29, DOI 10.1128/JVI.52.1.29-36.1984; XUE FY, 1993, CELL, V72, P681, DOI 10.1016/0092-8674(93)90397-9; YMER S, 1985, NATURE, V317, P255, DOI 10.1038/317255a0	35	3	3	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 16	1996	12	10					2241	2245						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UP283	8668351				2022-12-25	WOS:A1996UP28300024
J	Belogrudov, GI; Tomich, JM; Hatefi, Y				Belogrudov, GI; Tomich, JM; Hatefi, Y			Membrane topography and near-neighbor relationships of the mitochondrial ATP synthase subunits e, f, and g	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE HEART-MITOCHONDRIA; OXIDATIVE-PHOSPHORYLATION SYSTEM; COMPLEX-V; INHIBITOR PROTEIN; F1-ATPASE; RECONSTITUTION; IDENTIFICATION; PURIFICATION; MECHANISM; STALK	The well characterized subunits of the bovine ATP synthase complex are the alpha, Rho, gamma, delta, and epsilon subunits of the catalytic sector, F-1; the ATPase inhibitor protein; and subunits a, b, c, and d, OSCP (oligomycin Sensitivity-conferring protein), F-6, and A6L, which are present in the membrane sector, F-0, and the 45-Angstrom-long stalk that connects F-1 to F-0. It has been shown recently that bovine ATP synthase preparations also contain three small polypeptides, designated e, f, and g, with respective molecular masses of 8.2, 10.2, and 11.3 kDa. To ascertain their involvement as bonafide subunits of the ATP synthase and to investigate their membrane topography and proximity to the above ATP synthase subunits, polyclonal antipeptide antibodies were raised in the rabbit to the COOH-terminal amino acid residues 57-70 of e, 75-86 off, and 91-102 of g. It was shown that (i) e, f, and g could be immunoprecipitated with anti-OSCP IgG from a fraction of bovine submitochondrial particles enriched in oligomycin-sensitive ATPase; (ii) the NH2 termini of f and g are exposed on the matrix side of the mitochondrial inner membrane and can be curtailed by proteolysis; (iii) the COOH termini of all three polypeptides are exposed on the cytosolic side of the inner membrane; and (iv) f cross links to A6L and to g, and e crosslinks to g and appears to form an e-e dimer. Thus, the bovine ATP synthase complex appears to have 16 unlike subunits, twice as many as its counterpart in Escherichia coli.	SCRIPPS RES INST, DIV BIOCHEM, DEPT MOL & EXPT MED, LA JOLLA, CA 92037 USA; KANSAS STATE UNIV, DEPT BIOCHEM, MANHATTAN, KS 66506 USA	Scripps Research Institute; Kansas State University				TOMICH, JOHN/0000-0001-7848-8307	NIDDK NIH HHS [DK08126] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK008126, R37DK008126] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BELOGRUDOV GI, 1995, J BIOL CHEM, V270, P2053, DOI 10.1074/jbc.270.5.2053; COLLINSON IR, 1994, J MOL BIOL, V242, P408; COLLINSON IR, 1994, BIOCHEM J, V303, P639, DOI 10.1042/bj3030639; COLLINSON IR, 1994, BIOCHEMISTRY-US, V33, P7971, DOI 10.1021/bi00191a026; Errede B, 1978, Methods Enzymol, V53, P40; FILLINGAME RH, 1990, BACTERIA TREATISE ST, V12, P345; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GALANTE YM, 1981, ARCH BIOCHEM BIOPHYS, V211, P643, DOI 10.1016/0003-9861(81)90500-2; GALANTE YM, 1979, J BIOL CHEM, V254, P2372; GALANTE YM, 1981, BIOCHEMISTRY-US, V20, P2671, DOI 10.1021/bi00512a048; GORNALL AG, 1949, J BIOL CHEM, V177, P751; HATEFI Y, 1958, BIOCHIM BIOPHYS ACTA, V27, P83, DOI 10.1016/0006-3002(58)90294-4; Hatefi Y, 1978, Methods Enzymol, V53, P3; HEKMAN C, 1991, J BIOL CHEM, V266, P13564; HIGUTI T, 1992, BIOCHEMISTRY-US, V31, P12451, DOI 10.1021/bi00164a022; KREBS JJR, 1979, J BIOL CHEM, V254, P5308; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATSUNOYAGI A, 1990, J BIOL CHEM, V265, P82; MATSUNOYAGI A, 1984, BIOCHEMISTRY-US, V23, P3508, DOI 10.1021/bi00310a019; RACKER E, 1967, J BIOL CHEM, V242, P2547; ROBBINS BA, 1981, ARCH BIOCHEM BIOPHYS, V210, P489, DOI 10.1016/0003-9861(81)90213-7; SAH JF, 1993, BIOCHEM BIOPH RES CO, V194, P1521, DOI 10.1006/bbrc.1993.1997; STIGGALL DL, 1978, J BIOL CHEM, V253, P956; TOWBIN H, 1982, P NATL ACAD SCI USA, V93, P97; VANHEEKE G, 1993, BIOCHEMISTRY-US, V32, P10140, DOI 10.1021/bi00089a033; WALKER JE, 1994, FEBS LETT, V346, P39, DOI 10.1016/0014-5793(94)00368-8; WALKER JE, 1991, BIOCHEMISTRY-US, V30, P5369, DOI 10.1021/bi00236a007	29	69	70	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20340	20345		10.1074/jbc.271.34.20340	http://dx.doi.org/10.1074/jbc.271.34.20340			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702768	hybrid			2022-12-25	WOS:A1996VD33700020
J	Tian, Y; Wu, LH; Oxender, DL; Chung, FZ				Tian, Y; Wu, LH; Oxender, DL; Chung, FZ			The unpredicted high affinities of a large number of naturally occurring tachykinins for chimeric NK1/NK3 receptors suggest a role for an inhibitory domain in determining receptor specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN SUBSTANCE-P; NEUROKININ-3 RECEPTOR; MOLECULAR-CLONING; NK3 RECEPTORS; K RECEPTORS; BINDING; EXPRESSION; GENE; RAT; IDENTIFICATION	Three chimeric receptors were constructed by exchanging exon sequences between human NK1 and NK3 receptor genes. The resulting chimeric receptors not only retained high affinities for their natural ligands substance P and neurokinin B but also exhibited surprisingly high affinities for other naturally occurring tachykinins including neurokinin A, neuropeptide K, neuropeptide gamma, eledoisin, kassinin, physalaemin, and phyllomedusin. In contrast, these chimeric receptors displayed a wide range of variability in their affinities for non-naturally occurring ligands including selective agonists and antagonists of NK1, NK2, and NK3 receptors. Since the only common feature among these naturally occurring neurokinin peptides is the conserved C-terminal sequences, our data suggest that these conserved sequences must play the major role in conferring high affinity binding to the chimeric receptors. To explain the apparently ''improved'' affinities of these naturally occurring ligands for the chimeric receptors as compared with their affinities for the parent NK1 and NK3 receptors, we are proposing that certain inhibitory domains that are present in the NK1 and/or NK3 receptors are compromised in these chimeric receptors. Upon disruption of these inhibitory domains during the formation of chimeras, the naturally occurring ligands can interact more favorably with chimeric receptors through their conserved C-terminal sequences. Based on this hypothesis, the binding affinities of natural tachykinin ligands may be largely determined by their conserved C-terminal sequences, whereas receptor selectivities of these ligands are influenced more by the presence or absence of inhibitory domains rather than specific binding domains on their target receptors.	WARNER LAMBERT PARKE DAVIS,PARKE DAVIS PHARMACEUT RES DIV,DEPT BIOTECHNOL,ANN ARBOR,MI 48105	Pfizer								BANNON MJ, 1995, BRAIN RES, V695, P19, DOI 10.1016/0006-8993(95)00791-N; BERGSTROM L, 1987, J NEUROCHEM, V48, P125, DOI 10.1111/j.1471-4159.1987.tb13136.x; BUELL G, 1992, FEBS LETT, V299, P90, DOI 10.1016/0014-5793(92)80107-R; CASCIERI MA, 1992, MOL PHARMACOL, V41, P1096; CHUNG FZ, 1994, BIOCHEM BIOPH RES CO, V198, P967, DOI 10.1006/bbrc.1994.1138; CHUNG FZ, 1995, MOL PHARMACOL, V48, P711; FONG TM, 1995, CAN J PHYSIOL PHARM, V73, P860, DOI 10.1139/y95-118; GERARD NP, 1990, J BIOL CHEM, V265, P20455; GETHER U, 1993, J BIOL CHEM, V268, P7893; GRAHAM A, 1991, BIOCHEM BIOPH RES CO, V177, P8, DOI 10.1016/0006-291X(91)91940-E; HEUILLET E, 1993, J NEUROCHEM, V60, P868, DOI 10.1111/j.1471-4159.1993.tb03231.x; HUANG RRC, 1994, BIOCHEMISTRY-US, V33, P3007, DOI 10.1021/bi00176a033; HUANG RRC, 1995, BIOCHEMISTRY-US, V34, P10048, DOI 10.1021/bi00031a029; Krause James E., 1994, P165; MANTYH PW, 1984, NATURE, V309, P795, DOI 10.1038/309795a0; MANTYH PW, 1991, ANN NY ACAD SCI, V632, P263, DOI 10.1111/j.1749-6632.1991.tb33114.x; MAUZY CA, 1992, BIOCHEM BIOPH RES CO, V186, P277, DOI 10.1016/S0006-291X(05)80804-6; MOYLE WR, 1994, NATURE, V368, P251, DOI 10.1038/368251a0; MUSSAP CJ, 1993, J NEUROCHEM, V60, P1987, DOI 10.1111/j.1471-4159.1993.tb03484.x; OURYDONAT F, 1995, J PHARMACOL EXP THER, V274, P148; PATACCHINI R, 1995, ARCH INT PHARMACOD T, V329, P161; PATACCHINI R, 1995, EUR J PHARMACOL, V278, P17, DOI 10.1016/0014-2999(95)00090-8; PRADIER L, 1994, MOL PHARMACOL, V45, P287; REGOLI D, 1994, PHARMACOL REV, V46, P551; SADOWSKI S, 1993, NEUROPEPTIDES, V24, P317, DOI 10.1016/0143-4179(93)90001-Q; SUMANCHAUHAN N, 1994, EUR J PHARM-MOLEC PH, V269, P65, DOI 10.1016/0922-4106(94)90027-2; TAKAHASHI K, 1992, EUR J BIOCHEM, V204, P1025, DOI 10.1111/j.1432-1033.1992.tb16724.x; TAKEDA Y, 1991, BIOCHEM BIOPH RES CO, V179, P1232, DOI 10.1016/0006-291X(91)91704-G; WU LH, 1994, BIOCHEM BIOPH RES CO, V198, P961, DOI 10.1006/bbrc.1994.1137; YOKOTA Y, 1992, EMBO J, V11, P3585, DOI 10.1002/j.1460-2075.1992.tb05442.x	30	28	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20250	20257		10.1074/jbc.271.34.20250	http://dx.doi.org/10.1074/jbc.271.34.20250			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702757	hybrid			2022-12-25	WOS:A1996VD33700009
J	Becker, MA; Taylor, W; Smith, PR; Ahmed, M				Becker, MA; Taylor, W; Smith, PR; Ahmed, M			Overexpression of the normal phosphoribosylpyrophosphate synthetase 1 isoform underlies catalytic superactivity of human phosphoribosylpyrophosphate synthetase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYROPHOSPHATE SYNTHETASE; SUBUNIT-II; PURINE OVERPRODUCTION; HUMAN-FIBROBLASTS; X-CHROMOSOME; CLONING; PRPS1; GENES; LOCALIZATION; METABOLISM	To define the enzymatic and genetic basis of X-linked phosphoribosylpyrophosphate synthetase (PRS) catalytic superactivity, we measured concentrations of X-linked PRS1 and PRS2 isoforms in cultured fibroblasts and lymphoblasts by immunoblotting after separation by polyacrylamide-urea isoelectric focusing. PRS1 comprised >80% of measurable PRS isoforms in all fibroblast strains, but PRS1 concentrations in cells from six affected males exceeded those in normal cells by 2-6-fold, PRS absolute specific activities (activity per mg of PRS isoforms) were comparable in all fibroblast strains and in purified recombinant normal PRS1, confirming selectively increased levels of PRS1 isoform as the enzymatic basis of PRS catalytic superactivity, Cloning, sequencing, and expression of normal subject- and patient-derived PRS cDNAs predicted normal translated region sequences for both PRS isoforms and revealed no differences in catalytic properties of recombinant PRS1. Normal and patient PRPS1 transcribed but untranslated DNA sequences were also identical. Northern blot analysis showed selective increase in relative concentrations of PRS1 transcripts in patient fibroblasts. In PRS catalytic superactivity, overexpression of the normal PRS1 isoform thus appears to result from an altered pretranslational mechanism of PRPS1 expression. In lymphoblasts, however, expression of this alteration is attenuated, explaining the absence of phenotypic expression of PRS catalytic superactivity in these cells.			Becker, MA (corresponding author), UNIV CHICAGO,MED CTR,RHEUMATOL SECT,DEPT MED,5841 S MARYLAND AVE,CHICAGO,IL 60637, USA.				NIDDK NIH HHS [DK 28554] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028554] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKAOKA I, 1981, J RHEUMATOL, V8, P563; AUSUBEL FM, 1987, CURRENT PROTOLS MOL; BECKER MA, 1995, J CLIN INVEST, V96, P2133, DOI 10.1172/JCI118267; BECKER MA, 1980, J CLIN INVEST, V65, P109, DOI 10.1172/JCI109640; BECKER MA, 1987, J BIOL CHEM, V262, P5596; BECKER MA, 1991, ADV EXP MED BIOL, V309, P129; BECKER MA, 1975, J BIOL CHEM, V250, P6822; BECKER MA, 1986, ARTHRITIS RHEUM, V29, P880, DOI 10.1002/art.1780290710; BECKER MA, 1987, J BIOL CHEM, V262, P14531; BECKER MA, 1988, AM J MED, V85, P383, DOI 10.1016/0002-9343(88)90591-8; BECKER MA, 1990, GENOMICS, V8, P555, DOI 10.1016/0888-7543(90)90043-T; BECKER MA, 1973, SCIENCE, V179, P1123, DOI 10.1126/science.179.4078.1123; BECKER MA, 1982, J LAB CLIN MED, V99, P485; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAVIDSON BL, 1991, AM J HUM GENET, V48, P951; IIZASA T, 1989, FEBS LETT, V244, P47, DOI 10.1016/0014-5793(89)81159-7; ISHIZUKA T, 1992, BIOCHIM BIOPHYS ACTA, V1130, P139, DOI 10.1016/0167-4781(92)90521-Z; KITA K, 1994, J BIOL CHEM, V269, P8334; LOSMAN MJ, 1985, J CLIN INVEST, V76, P1657, DOI 10.1172/JCI112151; LOWRY OH, 1951, J BIOL CHEM, V193, P265; NOSAL JM, 1993, J BIOL CHEM, V268, P10168; ROESSLER BJ, 1993, J BIOL CHEM, V268, P26476; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SIMMONDS HA, 1985, NEUROPEDIATRICS, V16, P106, DOI 10.1055/s-2008-1052552; SONODA T, 1991, J BIOCHEM-TOKYO, V109, P361; SPERLING O, 1972, EUR J CLIN BIOL RES, V17, P703; STUDIER RW, 1990, METHOD ENZYMOL, V185, P60; TAIRA M, 1989, BIOCHIM BIOPHYS ACTA, V1007, P203, DOI 10.1016/0167-4781(89)90040-7; TAIRA M, 1989, SOMAT CELL MOLEC GEN, V15, P29, DOI 10.1007/BF01534667; YEN RCK, 1978, P NATL ACAD SCI USA, V75, P482, DOI 10.1073/pnas.75.1.482; ZOREF E, 1975, J CLIN INVEST, V56, P1093, DOI 10.1172/JCI108183	31	32	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					19894	19899		10.1074/jbc.271.33.19894	http://dx.doi.org/10.1074/jbc.271.33.19894			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702702	hybrid			2022-12-25	WOS:A1996VC66900043
J	Nazareth, LV; Weigel, NL				Nazareth, LV; Weigel, NL			Activation of the human androgen receptor through a protein kinase A signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-INDEPENDENT ACTIVATION; STEROID-HORMONE RECEPTORS; HUMAN ESTROGEN-RECEPTOR; EPIDERMAL GROWTH-FACTOR; PROSTATE-CANCER; GENE-EXPRESSION; DNA-BINDING; GLUCOCORTICOID RECEPTOR; PHOSPHORYLATION SITES; BREAST-CANCER	Aberrant activation of the androgen receptor through signaling pathways independent of androgen may be responsible for the progression of prostate tumors to the rapidly proliferating androgen-independent state. In this study, the effects of protein kinase A modulators on human androgen receptor activity were tested. Using an adenoviral DNA delivery system, we demonstrate that the androgen receptor can be activated by a protein kinase A activator, forskolin, in the absence of androgen when androgen receptor is co-transfected into monkey kidney CV1 cells or human prostate PC-3 cells with androgen-responsive reporters. Immunoblotting reveals that there is no significant change in androgen receptor protein level following forskolin treatment, suggesting that the enhanced activity is clue to activation of the. receptor. This activation can be blocked by a protein kinase A inhibitor peptide. Two potent anti-androgens, casodex and flutamide, can significantly reduce this activation, confirming that the ligand-independent pathway is an androgen receptor-mediated phenomenon. An. intact DNA binding domain of the receptor is critical for this alternate signaling pathway since mutants with reduced DNA binding ability are inactive. The phosphorylation status of the androgen receptor or associated. proteins may critically modulate receptor activity and should be considered when designing improved approaches to prostate cancer therapy.	BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030	Baylor College of Medicine					NCI NIH HHS [CA58204] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA058204] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLGOOD VE, 1993, J BIOL CHEM, V268, P20870; ALLGOOD VE, 1994, 76 END SOC M, P631; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BECK CA, 1992, MOL ENDOCRINOL, V6, P607, DOI 10.1210/me.6.4.607; BECK CA, 1993, P NATL ACAD SCI USA, V90, P4441, DOI 10.1073/pnas.90.10.4441; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARTER HB, 1990, PROSTATE, V16, P39; CULIG Z, 1994, CANCER RES, V54, P5474; DENNER LA, 1990, J BIOL CHEM, V265, P16548; DENNER LA, 1990, SCIENCE, V250, P1740, DOI 10.1126/science.2176746; DERUITER PE, 1995, MOL CELL ENDOCRINOL, V110, pR1, DOI 10.1016/0303-7207(95)03534-E; FUJIMOTO N, 1994, MOL ENDOCRINOL, V8, P296, DOI 10.1210/me.8.3.296; HOECK W, 1990, J BIOL CHEM, V265, P5403; HORWITZ KB, 1992, ENDOCR REV, V13, P146, DOI 10.1210/er.13.2.146; IGNARTROWBRIDGE DM, 1992, P NATL ACAD SCI USA, V89, P4658, DOI 10.1073/pnas.89.10.4658; IKONEN T, 1994, ENDOCRINOLOGY, V135, P1359, DOI 10.1210/en.135.4.1359; KALLIO PJ, 1994, ENDOCRINOLOGY, V134, P998, DOI 10.1210/en.134.2.998; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; KEMPPAINEN JA, 1992, J BIOL CHEM, V267, P968; MAUCHER A, 1993, J CANCER RES CLIN, V119, P669, DOI 10.1007/BF01215986; MIGLIACCIO A, 1989, MOL ENDOCRINOL, V3, P1061, DOI 10.1210/mend-3-7-1061; MOYER ML, 1993, J BIOL CHEM, V268, P22933; ORTI E, 1992, ENDOCR REV, V13, P105, DOI 10.1210/er.13.1.105; POWER RF, 1991, SCIENCE, V254, P1636, DOI 10.1126/science.1749936; RENNIE PS, 1993, MOL ENDOCRINOL, V7, P23, DOI 10.1210/me.7.1.23; ROCHETTEEGLY C, 1992, MOL ENDOCRINOL, V6, P2197, DOI 10.1210/me.6.12.2197; SADI MV, 1993, CANCER, V71, P2574, DOI 10.1002/1097-0142(19930415)71:8<2574::AID-CNCR2820710823>3.0.CO;2-1; SMITH CL, 1993, P NATL ACAD SCI USA, V90, P6120, DOI 10.1073/pnas.90.13.6120; TILLEY WD, 1990, CANCER RES, V50, P5382; TSAI SY, 1988, CELL, V55, P361, DOI 10.1016/0092-8674(88)90059-1; VANDERKWAST TH, 1991, INT J CANCER, V48, P189, DOI 10.1002/ijc.2910480206; VANLAAR JH, 1991, J BIOL CHEM, V266, P3734; VELDSCHOLTE J, 1992, BIOCHEMISTRY-US, V31, P2393, DOI 10.1021/bi00123a026; VERHELST J, 1994, CLIN ENDOCRINOL, V41, P525, DOI 10.1111/j.1365-2265.1994.tb02585.x; VOELLER HJ, 1991, MOL ENDOCRINOL, V5, P209, DOI 10.1210/mend-5-2-209; WONG CI, 1993, J BIOL CHEM, V268, P19004; YAN GC, 1992, MOL ENDOCRINOL, V6, P2123, DOI 10.1210/me.6.12.2123; YUAN SX, 1993, CANCER RES, V53, P1304; ZHANG YX, 1994, MOL ENDOCRINOL, V8, P577, DOI 10.1210/me.8.5.577; ZHOU ZX, 1995, MOL ENDOCRINOL, V9, P605, DOI 10.1210/me.9.5.605; ZOPPI S, 1992, MOL ENDOCRINOL, V6, P409, DOI 10.1210/me.6.3.409	41	352	379	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					19900	19907		10.1074/jbc.271.33.19900	http://dx.doi.org/10.1074/jbc.271.33.19900			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702703	hybrid			2022-12-25	WOS:A1996VC66900044
J	Widmann, C; Dolci, W; Thorens, B				Widmann, C; Dolci, W; Thorens, B			Heterologous desensitization of the glucagon-like peptide-1 receptor by phorbol esters requires phosphorylation of the cytoplasmic tail at four different sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; PROTEIN-KINASE-C; BETA-2-ADRENERGIC RECEPTOR; ADENYLYL-CYCLASE; ARRESTIN; IDENTIFICATION; STIMULATION; EXPRESSION; HORMONE; FAMILY	Glucagon-like peptide-1 stimulates glucose-induced insulin secretion by binding to a specific G protein-coupled receptor that activates the adenylyl cyclase pathway, We previously demonstrated that heterologous desensitization of the receptor by protein kinase C correlated with phosphorylation in a 33-amino acid-long segment of the receptor carboxyl-terminal cytoplasmic tail. Here, we determined that the in vivo sites of phosphorylation are four serine doublets present at positions 431/432, 441/442, 444/445, and 451/452. In vitro phosphorylation of fusion proteins containing mutant receptor C-tails, however, indicated that whereas serines at position 431/432 were good substrates for protein kinase C (PKC), serines 444/445 and 451/452 were poor substrates, and serines 441/442 were not substrates. In addition, serine 416 was phosphorylated on fusion protein but not in intact cells. This indicated that in vivo a different PKC isoform or a PKC-activated kinase may phosphorylate the receptor. The role of phosphorylation on receptor desensitization was assessed using receptor mutants expressed in COS cells or Chinese hamster lung fibroblasts. Mutation of any single serine doublet to alanines reduced the extent of phorbol ia-myristate 13-acetate-induced desensitization, whereas substitution of any combination of two serine doublets suppressed it. Our data thus show that the glucagon-like peptide-1 receptor can be phosphorylated in response to phorbol 12-myristate 13-acetate on four different sites within the cytoplasmic tail. Furthermore, phosphorylation of at least three sites was required for desensitization, although maximal desensitization was only achieved when all four sites were phosphorylated.	UNIV LAUSANNE,DEPT PHARMACOL & TOXICOL,CH-1005 LAUSANNE,SWITZERLAND	University of Lausanne			Widmann, Christian/N-9851-2013	Widmann, Christian/0000-0002-6881-0363				ATTRAMADAL H, 1992, J BIOL CHEM, V267, P17882; BEGUIN P, 1994, J BIOL CHEM, V269, P24437; BENOVIC JL, 1986, P NATL ACAD SCI USA, V83, P2797, DOI 10.1073/pnas.83.9.2797; BOUVIER M, 1988, NATURE, V333, P370, DOI 10.1038/333370a0; CHUANG TT, 1995, J BIOL CHEM, V270, P18660, DOI 10.1074/jbc.270.31.18660; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; CREUTZFELDT W, 1992, DIABETES METAB REV, V8, P149, DOI 10.1002/dmr.5610080206; HOLST JJ, 1987, FEBS LETT, V211, P169, DOI 10.1016/0014-5793(87)81430-8; INGLESE J, 1993, J BIOL CHEM, V268, P23735; JOHNSON JA, 1990, MOL PHARMACOL, V38, P289; LOHSE MJ, 1992, J BIOL CHEM, V267, P8558; LOHSE MJ, 1990, J BIOL CHEM, V265, P3202; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; LORENZ W, 1991, P NATL ACAD SCI USA, V88, P8715, DOI 10.1073/pnas.88.19.8715; NELSON RM, 1989, ANAL BIOCHEM, V180, P147, DOI 10.1016/0003-2697(89)90103-6; PIPPIG S, 1993, J BIOL CHEM, V268, P3201; ROACH PJ, 1991, J BIOL CHEM, V266, P14139; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; THORENS B, 1992, P NATL ACAD SCI USA, V89, P8641, DOI 10.1073/pnas.89.18.8641; Thorens Bernard, 1994, P357; WEIR GC, 1989, DIABETES, V38, P338, DOI 10.2337/diabetes.38.3.338; WHALEY BS, 1994, MOL PHARMACOL, V45, P481; WIDMANN C, 1995, BIOCHEM J, V310, P203, DOI 10.1042/bj3100203; WIDMANN C, 1994, MOL PHARMACOL, V45, P1029; Widmann C, 1996, MOL ENDOCRINOL, V10, P62, DOI 10.1210/me.10.1.62; YUAN NY, 1994, J BIOL CHEM, V269, P23032	27	40	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					19957	19963		10.1074/jbc.271.33.19957	http://dx.doi.org/10.1074/jbc.271.33.19957			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702711	hybrid			2022-12-25	WOS:A1996VC66900052
J	Wakarchuk, W; Martin, A; Jennings, MP; Moxon, ER; Richards, JC				Wakarchuk, W; Martin, A; Jennings, MP; Moxon, ER; Richards, JC			Functional relationships of the genetic locus encoding the glycosyltransferase enzymes involved in expression of the Lacto-N-neotetraose terminal lipopolysaccharide structure in Neisseria meningitidis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OLIGOSACCHARIDE COMPONENT; CORE OLIGOSACCHARIDES; MONOCLONAL-ANTIBODIES; COUPLING-CONSTANTS; LIPOOLIGOSACCHARIDES; BIOSYNTHESIS; POLYSACCHARIDE; GONORRHOEAE; SPECIFICITY; HAEMOPHILUS	The biosynthetic function of the lgtABE genetic locus of Neisseria meningitidis was determined by structural analysis of lipopolysaccharide (LPS) derived from mutant strains and enzymic assay for glycosyltransferase activity, LPS was obtained from mutants generated by insertion of antibiotic resistance cassets in each of the three genes IgtA, IgtB, lgtE of the N. meningitidis immunotype L3 strain phi 3 MC58. LPS from the parent strain expresses the terminal lacto-N-neotetraose structure, Gal beta 1 --> 4GlcNAc beta 1 --> 3Gal beta 1 --> 4Glc. Mild hydrazine treatment of the LPS afforded O-deacylated samples that were analyzed directly by electrospray ionization mass spectrometry (ESI-IMS) in the negative ion mode, In conjunction with results from sugar analysis, ESI-RIS revealed successive loss of the sugars Gal, GlcNAc, and Gal in lgt B, lgt A, and lgt E LPS, respectively, The structure of a sample of O- and N-deacylated LPS derived by aqueous KOH treatment of Igt B LPS was determined in detail by two-dimensional home- and heteronuclear NMR methods. Using a synthetic beta-GlcNAc acceptor and a beta-lactose acceptor, the glycosyltransferase activities encoded by the lgtB and IgtA genes were unambiguously established, These data provide the first definitive evidence that the three genes encode the respective glycosyltransferases required for biosynthesis of the terminal trisaccharide moiety of the lacto-N-neotetraose structure in Neisseria LPS, From ESI-MS data, it was also determined that the Gal-deficient LPS expressed by the I,st E mutant is identical to that of the major component expressed by immunotype L3 galE-defieient strains, The galE gene which encodes for UDP-glucose 4-epimerase plays an essential role in the incorporation of Gal into meningococcal LPS.	NATL RES COUNCIL CANADA, INST BIOL SCI, OTTAWA, ON K1A 0R6, CANADA; JOHN RADCLIFFE HOSP, INST MOL MED, MOL INFECT DIS GRP, OXFORD OX3 3DU, ENGLAND; JOHN RADCLIFFE HOSP, INST MOL MED, DEPT PAEDIAT, OXFORD OX3 3DU, ENGLAND	National Research Council Canada; University of Oxford; University of Oxford			Wakarchuk, Warren/Q-9514-2017; Wakarchuk, Warren/AAO-2774-2020; Jennings, Michael P/G-4822-2013	Wakarchuk, Warren/0000-0002-1539-1679; Wakarchuk, Warren/0000-0002-1539-1679; Jennings, Michael P/0000-0002-1027-4684	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALTONA C, 1980, ORG MAGN RESONANCE, V13, P417, DOI 10.1002/mrc.1270130606; AMINOFF D, 1961, BIOCHEM J, V81, P384, DOI 10.1042/bj0810384; Auriola S, 1996, ACS SYM SER, V619, P149; BAX A, 1983, J MAGN RESON, V52, P330, DOI 10.1016/0022-2364(83)90206-8; BAX A, 1981, J MAGN RESON, V42, P164, DOI 10.1016/0022-2364(81)90022-6; BOCK K, 1982, ANNU REP NMR SPECTRO, V13, P1; CARLSON RW, 1988, CARBOHYD RES, V176, P127, DOI 10.1016/0008-6215(88)84064-3; DIFABIO JL, 1990, CAN J CHEM, V68, P1029, DOI 10.1139/v90-160; DOMON B, 1988, GLYCOCONJUGATE J, V5, P397, DOI 10.1007/BF01049915; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; GAMIAN A, 1992, J BIOL CHEM, V267, P922; Gibson BW, 1996, ACS SYM SER, V619, P166; GIBSON BW, 1993, J BACTERIOL, V175, P2702, DOI 10.1128/JB.175.9.2702-2712.1993; GOTSCHLICH EC, 1994, J EXP MED, V180, P2181, DOI 10.1084/jem.180.6.2181; GRIFFISS JM, 1988, REV INFECT DIS S2, V10, P287; HOLST O, 1991, J BACTERIOL, V173, P1862, DOI 10.1128/jb.173.6.1862-1866.1991; HOLST O, 1993, EUR J BIOCHEM, V214, P703, DOI 10.1111/j.1432-1033.1993.tb17971.x; Holst O, 1992, BACTERIAL ENDOTOXIC, VI, P135; JENNINGS HJ, 1983, CARBOHYD RES, V121, P233, DOI 10.1016/0008-6215(83)84020-8; JENNINGS MP, 1993, MOL MICROBIOL, V10, P361, DOI 10.1111/j.1365-2958.1993.tb01962.x; Jennings MP, 1995, MOL MICROBIOL, V18, P729, DOI 10.1111/j.1365-2958.1995.mmi_18040729.x; JONES DM, 1992, MICROB PATHOGENESIS, V13, P219, DOI 10.1016/0882-4010(92)90022-G; Kelly J, 1996, ANAL BIOCHEM, V233, P15, DOI 10.1006/abio.1996.0002; KOMURO T, 1988, J CHROMATOGR, V450, P381, DOI 10.1016/S0021-9673(01)83593-7; KULSHIN VA, 1991, EUR J BIOCHEM, V198, P697, DOI 10.1111/j.1432-1033.1991.tb16069.x; KUMAR A, 1980, BIOCHEM BIOPH RES CO, V95, P1, DOI 10.1016/0006-291X(80)90695-6; LAEMMLI UK, 1973, J MOL BIOL, V80, P575, DOI 10.1016/0022-2836(73)90198-8; LEE FKN, 1995, INFECT IMMUN, V63, P2508, DOI 10.1128/IAI.63.7.2508-2515.1995; MANDRELL RE, 1988, J EXP MED, V168, P107, DOI 10.1084/jem.168.1.107; MASOUD H, 1994, BIOCHEMISTRY-US, V33, P10568, DOI 10.1021/bi00201a002; MICHON F, 1990, J BIOL CHEM, V265, P7243; MORAN AP, 1995, J TOXICOL-TOXIN REV, V14, P47, DOI 10.3109/15569549509089968; PAVLIAK V, 1993, J BIOL CHEM, V268, P14146; PELTOLA H, 1983, REV INFECT DIS, V5, P71; PELTOLA H, 1977, NEW ENGL J MED, V297, P686, DOI 10.1056/NEJM197709292971302; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.bi.59.070190.001021; ROBERTSON BD, 1993, MOL MICROBIOL, V8, P891, DOI 10.1111/j.1365-2958.1993.tb01635.x; SCHNAITMAN CA, 1993, MICROBIOL REV, V57, P655, DOI 10.1128/MMBR.57.3.655-682.1993; SCHOLTEN RJPM, 1994, J MED MICROBIOL, V41, P236, DOI 10.1099/00222615-41-4-236; TSAI CM, 1991, INFECT IMMUN, V59, P3604, DOI 10.1128/IAI.59.10.3604-3609.1991; TSAI CM, 1982, ANAL BIOCHEM, V119, P115, DOI 10.1016/0003-2697(82)90673-X; VERHEUL AFM, 1993, MICROBIOL REV, V57, P34, DOI 10.1128/MMBR.57.1.34-49.1993; Virji M, 1995, MOL MICROBIOL, V18, P741, DOI 10.1111/j.1365-2958.1995.mmi_18040741.x; VIRJI M, 1990, MICROB PATHOGENESIS, V9, P441, DOI 10.1016/0882-4010(90)90062-U; WAKARCHUK WW, 1994, PROTEIN SCI, V3, P467; WEINER SJ, 1984, J AM CHEM SOC, V106, P765, DOI 10.1021/ja00315a051; WESTPHAL O., 1965, METHOD CARBOHYD CHEM, V5, P83; Yang QL, 1996, J EXP MED, V183, P323, DOI 10.1084/jem.183.1.323; YORK WS, 1985, CARBOHYD RES, V138, P109, DOI 10.1016/0008-6215(85)85228-9; ZHOU DG, 1994, J BIOL CHEM, V269, P11162; ZOLLINGER WD, 1980, INFECT IMMUN, V28, P451; ZOLLINGER WD, 1977, INFECT IMMUN, V18, P424, DOI 10.1128/IAI.18.2.424-433.1977	52	103	122	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19166	19173		10.1074/jbc.271.32.19166	http://dx.doi.org/10.1074/jbc.271.32.19166			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702594	Green Published, hybrid			2022-12-25	WOS:A1996VB68400028
J	Park, IS; Michel, LO; Pearson, MA; Jabri, E; Karplus, PA; Wang, SK; Dong, J; Scott, RA; Koehler, BP; Johnson, MK; Hausinger, RP				Park, IS; Michel, LO; Pearson, MA; Jabri, E; Karplus, PA; Wang, SK; Dong, J; Scott, RA; Koehler, BP; Johnson, MK; Hausinger, RP			Characterization of the mononickel metallocenter in H134A mutant urease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KLEBSIELLA-AEROGENES UREASE; MAGNETIC CIRCULAR-DICHROISM; ABSORPTION FINE-STRUCTURE; MICROBIAL UREASES; ACTIVE-SITE; NICKEL; COMPLEXES; BINDING; PROTEIN	A mutant form of Klebsiella aerogenes urease possessing Ala instead of His at position 134 (H134A) is inactive and binds approximately half the normal complement of nickel (Park, I.-S., and Hausinger, R. P. (1993) Protein Sci. 2, 1034-1041). The crystal structure of the H134A protein was obtained at 2.0-Angstrom resolution, and it confirms that only Ni-l of the two nickel ions found in the native enzyme is present. In contrast to the pseudotetrahedral geometry observed for Ni-l in native urease (where it is liganded by His-246, His-272, one oxygen atom of carbamylated Lys-217, and a water molecule at partial occupancy), the mononickel metallocenter in the H134A protein was found to possess octahedral geometry and was coordinated by the above protein ligands plus three water molecules. The nickel site of H134A urease was probed by UV-visible, variable temperature magnetic circular dichroism, and x-ray absorption spectroscopies, The spectroscopic data are consistent with the presence of Ni(II) in octahedral geometry coordinated by two histidylimidazoles and additional oxygen and/or nitrogen donors, These data underscore the requirement of Ni-2 for formation of active urease and demonstrate the important role of Ni-2 in establishing the proper Ni-l coordination geometry.	MICHIGAN STATE UNIV,DEPT MICROBIOL,E LANSING,MI 48824; MICHIGAN STATE UNIV,DEPT BIOCHEM,E LANSING,MI 48824; CORNELL UNIV,BIOCHEM MOL & CELL BIOL SECT,ITHACA,NY 14853; UNIV GEORGIA,DEPT CHEM & BIOCHEM,ATHENS,GA 30602; UNIV GEORGIA,DEPT MOL BIOL,ATHENS,GA 30602; UNIV GEORGIA,CTR METALLOENZYME STUDIES,ATHENS,GA 30602	Michigan State University; Michigan State University; Cornell University; University System of Georgia; University of Georgia; University System of Georgia; University of Georgia; University System of Georgia; University of Georgia				Karplus, Paul/0000-0001-8725-6292; Scott, Robert/0000-0003-2236-1336; Hausinger, Robert/0000-0002-3643-2054; Michel, Linda/0000-0001-7957-7248	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045686] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042025] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK45686, R01 DK045686] Funding Source: Medline; NIGMS NIH HHS [GM42025] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Berg JM., 1994, PRINCIPLES BIOINORGA; BRUNGER AT, 1993, XPLOR VERSION 3 0; COLPAS GJ, 1991, INORG CHEM, V30, P920, DOI 10.1021/ic00005a010; DELEON JM, 1991, PHYS REV B, V44, P4146, DOI 10.1103/PhysRevB.44.4146; FINNEGAN MG, 1991, J AM CHEM SOC, V113, P4030, DOI 10.1021/ja00010a076; Hausinger R.P., 1993, BIOCH NICKEL, V12, P23; JABRI E, 1995, SCIENCE, V268, P998, DOI 10.1126/science.7754395; JABRI E, 1992, J MOL BIOL, V227, P934, DOI 10.1016/0022-2836(92)90232-9; JOHNSON MK, 1988, ACS SYM SER, V372, P326; KIICK KL, 1991, THESIS U GEORGIA ATH; KOWAL AT, 1988, INORG CHEM, V27, P1162, DOI 10.1021/ic00280a015; LEE MH, 1993, PROTEIN SCI, V2, P1042, DOI 10.1002/pro.5560020617; MOBLEY HLT, 1995, MICROBIOL REV, V59, P451, DOI 10.1128/MMBR.59.3.451-480.1995; MOBLEY HLT, 1989, MICROBIOL REV, V53, P85, DOI 10.1128/MMBR.53.1.85-108.1989; MULROONEY SB, 1990, J BACTERIOL, V172, P5837, DOI 10.1128/jb.172.10.5837-5843.1990; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; PARK IS, 1993, PROTEIN SCI, V2, P1034, DOI 10.1002/pro.5560020616; REHR JJ, 1991, J AM CHEM SOC, V113, P5135, DOI 10.1021/ja00014a001; REHR JJ, 1990, PHYS REV B, V41, P8139, DOI 10.1103/PhysRevB.41.8139; ROSENBERG RC, 1975, J AM CHEM SOC, V97, P21, DOI 10.1021/ja00834a006; SACK JS, 1988, J MOL GRAPHICS, V6, P224, DOI 10.1016/S0263-7855(98)80040-4; SCOTT RA, 1985, METHOD ENZYMOL, V117, P414; TODD MJ, 1989, J BIOL CHEM, V264, P15835; WANG S, 1994, INORG CHEM, V33, P1589, DOI 10.1021/ic00086a006; ZONIA LE, 1995, PLANT PHYSIOL, V107, P1097, DOI 10.1104/pp.107.4.1097	25	26	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18632	18637		10.1074/jbc.271.31.18632	http://dx.doi.org/10.1074/jbc.271.31.18632			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702515	hybrid			2022-12-25	WOS:A1996VB68300053
J	Berdiev, BK; Prat, AG; Cantiello, HF; Ausiello, DA; Fuller, CM; Jovov, B; Benos, DJ; Ismailov, II				Berdiev, BK; Prat, AG; Cantiello, HF; Ausiello, DA; Fuller, CM; Jovov, B; Benos, DJ; Ismailov, II			Regulation of epithelial sodium channels by short actin filaments	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA+ CHANNEL; CYTOCHALASIN-D; CELL-VOLUME; APICAL MEMBRANE; ATP HYDROLYSIS; HIGH-AFFINITY; KIDNEY-CELLS; POLYMERIZATION; BINDING; PROTEIN	Cytoskeletal elements play an important role in the regulation of ion transport in epithelia. We have studied the effects of actin filaments of different length on the alpha, beta, gamma-rENaC (rat epithelial Na+ channel) in planar lipid bilayers. We found the following. 1) Short actin filaments caused a a-fold decrease in unitary conductance and a a-fold increase in open probability (P-o) of alpha,beta,gamma-rENaC. 2) alpha,beta,gamma-rENaC could be transiently activated by protein kinase A (PKA) plus ATP in the presence, but not in the absence, of actin. 3) ATP in the presence of actin was also able to induce a transitory activation of alpha,beta,gamma-rENaC, although with a shortened time course and with a lower magnitude of change in P-o. 4) DNase I, an agent known to prohibit elongation of actin filaments, prevented activation of alpha,beta,gamma-rENaC by ATP or PKA plus ATP. 5) Cytochalasin D, added after rundown of alpha,beta,gamma-rENaC activity following ATP or PKA plus ATP treatment, produced a second transient activation of alpha,beta,gamma-rENaC. 6) Gelsolin, a protein that stabilizes polymerization of actin filaments at certain lengths, evoked a sustained activation of alpha,beta,gamma-rENaC at actin/gelsolin ratios of <32:1, with a maximal effect at an actin/gelsolin ratio of 2:1. These results suggest that short actin filaments activate alpha,beta,gamma-rENaC. PKA-mediated phosphorylation augments activation of this channel by decreasing the rate of elongation of actin filaments. These results are consistent with the hypothesis that cloned alpha,beta,gamma-rENaCs form a core conduction unit of epithelial Na+ channels and that interaction of these channels with other associated proteins, such as short actin filaments, confers regulation to channel activity.	UNIV ALABAMA,DEPT PHYSIOL & BIOPHYS,BIRMINGHAM,AL 35294; HARVARD UNIV,MASSACHUSETTS GEN HOSP E,SCH MED,RENAL UNIT,BOSTON,MA 02129	University of Alabama System; University of Alabama Birmingham; Harvard University; Harvard Medical School			Fuller, Cathy/B-4046-2011		NIDDK NIH HHS [DK-37206, DK-19406] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019406, R01DK037206, R56DK037206, R37DK019406] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AWAYDA MS, 1995, AM J PHYSIOL-CELL PH, V268, pC1450, DOI 10.1152/ajpcell.1995.268.6.C1450; BENNETT V, 1991, J CLIN INVEST, V87, P1483, DOI 10.1172/JCI115157; BENOS DJ, 1995, J MEMBRANE BIOL, V143, P1; BRANCO LGS, 1992, J MEMBRANE BIOL, V127, P121; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; CANTIELLO HF, 1995, KIDNEY INT, V48, P970, DOI 10.1038/ki.1995.379; CANTIELLO HF, 1991, AM J PHYSIOL, V261, pC882, DOI 10.1152/ajpcell.1991.261.5.C882; CANTIELLO HF, 1995, AM J PHYSIOL-RENAL, V269, pF637, DOI 10.1152/ajprenal.1995.269.5.F637; CANTIELLO HF, 1993, J BIOL CHEM, V268, P4596; CARLIER MF, 1986, J BIOL CHEM, V261, P785; COOPER JA, 1983, BIOCHEMISTRY-US, V22, P2193, DOI 10.1021/bi00278a021; DRENCKHAHN D, 1985, SCIENCE, V230, P1287, DOI 10.1126/science.2933809; EDELSTEIN NG, 1988, BIOCHEMISTRY-US, V27, P1818, DOI 10.1021/bi00406a003; FRINGS S, 1988, J MEMBRANE BIOL, V106, P157, DOI 10.1007/BF01871398; GODDETTE DW, 1986, J BIOL CHEM, V261, P5974; GODDETTE DW, 1986, J BIOL CHEM, V261, P5970; GUHARAY F, 1984, J PHYSIOL-LONDON, V352, P685, DOI 10.1113/jphysiol.1984.sp015317; Hartwig JH, 1991, CURR OPIN CELL BIOL, V3, P87, DOI 10.1016/0955-0674(91)90170-4; Hille B., 1992, IONIC CHANNELS EXCIT, P607; HITT AL, 1994, CURR OPIN CELL BIOL, V6, P120, DOI 10.1016/0955-0674(94)90125-2; Ismailov II, 1996, J BIOL CHEM, V271, P807, DOI 10.1074/jbc.271.2.807; JANMEY PA, 1990, NATURE, V347, P96; JORGENSEN PL, 1984, BIOCHIM BIOPHYS ACTA, V775, P105; KINOSIAN HJ, 1990, BIOCHIM BIOPHYS ACTA, V1077, P151; KORN ED, 1987, SCIENCE, V238, P638, DOI 10.1126/science.3672117; MAYS RW, 1994, CURR OPIN CELL BIOL, V6, P16, DOI 10.1016/0955-0674(94)90111-2; MORROW JS, 1989, J CELL BIOL, V108, P455, DOI 10.1083/jcb.108.2.455; NELSON WJ, 1989, J CELL BIOL, V108, P893, DOI 10.1083/jcb.108.3.893; NELSON WJ, 1987, NATURE, V328, P533, DOI 10.1038/328533a0; PALMER LG, 1990, J GEN PHYSIOL, V96, P23, DOI 10.1085/jgp.96.1.23; PALMER LG, 1992, ANNU REV PHYSIOL, V54, P51, DOI 10.1146/annurev.ph.54.030192.000411; POLLARD TD, 1986, ANNU REV BIOCHEM, V55, P987, DOI 10.1146/annurev.bi.55.070186.005011; POLLARD TD, 1982, TRENDS BIOCHEM SCI, V7, P55, DOI 10.1016/0968-0004(82)90076-7; PRAT AG, 1995, AM J PHYSIOL-CELL PH, V268, pC1552, DOI 10.1152/ajpcell.1995.268.6.C1552; PRAT AG, 1993, AM J PHYSIOL, V265, pC224, DOI 10.1152/ajpcell.1993.265.1.C224; PRAT AG, 1993, AM J PHYSIOL, V265, pC218, DOI 10.1152/ajpcell.1993.265.1.C218; ROSENMUND C, 1993, NEURON, V10, P805, DOI 10.1016/0896-6273(93)90197-Y; ROTIN D, 1994, EMBO J, V13, P4440, DOI 10.1002/j.1460-2075.1994.tb06766.x; SACKIN H, 1989, P NATL ACAD SCI USA, V86, P1731, DOI 10.1073/pnas.86.5.1731; SARIBANSOHRABY S, 1992, AM J PHYSIOL, V263, pC1111, DOI 10.1152/ajpcell.1992.263.5.C1111; SCHLIWA M, 1982, J CELL BIOL, V92, P79, DOI 10.1083/jcb.92.1.79; SCHWARTZ MA, 1988, J CELL BIOL, V107, P201, DOI 10.1083/jcb.107.1.201; SCHWIEBERT EM, 1994, J BIOL CHEM, V269, P7081; SMITH PR, 1991, P NATL ACAD SCI USA, V88, P6971, DOI 10.1073/pnas.88.16.6971; SMITH PR, 1996, IN PRESS CURR TOP ME; SNYDER PM, 1995, CELL, V83, P969, DOI 10.1016/0092-8674(95)90212-0; SRIMIVASAN Y, 1988, NATURE, V333, P177; STOSSEL TP, 1993, SCIENCE, V260, P1086, DOI 10.1126/science.8493552; STUTTS MJ, 1995, SCIENCE, V269, P847, DOI 10.1126/science.7543698; TOUSSON A, 1996, IN PRESS J CELL SCI; UBL J, 1988, J MEMBRANE BIOL, V104, P223, DOI 10.1007/BF01872324; WANG WH, 1994, AM J PHYSIOL-RENAL, V267, pF592, DOI 10.1152/ajprenal.1994.267.4.F592; WATSON AJM, 1992, J BIOL CHEM, V267, P956; WEIHING RR, 1985, CAN J BIOCHEM CELL B, V63, P397, DOI 10.1139/o85-059; YIN HL, 1980, J BIOL CHEM, V255, P9494	55	141	144	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					17704	17710		10.1074/jbc.271.30.17704	http://dx.doi.org/10.1074/jbc.271.30.17704			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663510	hybrid			2022-12-25	WOS:A1996UY93500020
J	Bock, JB; Lin, RC; Scheller, RH				Bock, JB; Lin, RC; Scheller, RH			A new syntaxin family member implicated in targeting of intracellular transport vesicles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COILED COILS; PROTEINS; RECEPTORS; FUSION; YEAST	Despite the central role vesicular trafficking occupies in protein targeting, the molecular coding of the trafficking signals and the mechanism of vesicle docking and fusion are just beginning to be understood. We report here the cloning and initial characterization of a new member of the syntaxin family of vesicular transport receptors, Syntaxin 6 is a 255-amino acid protein with two domains predicted to form coiled coils, as well as a carboxyl-terminal membrane anchor. Syntaxin 6 is broadly expressed and localizes in the region of the Golgi apparatus, In vitro binding studies established that syntaxin 6 binds to alpha-soluble NSF attachment protein (alpha-SNAP). The sequence homology, topology, localization, and alpha-SNAP binding suggest that syntaxin 6 is involved in intracellular vesicle trafficking.	STANFORD UNIV,MED CTR,HOWARD HUGHES MED INST,DEPT MOLEC & CELLULAR PHYSIOL,STANFORD,CA 94305	Howard Hughes Medical Institute; Stanford University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007365] Funding Source: NIH RePORTER; NIGMS NIH HHS [5T32GM07365] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS MD, 1992, NATURE, V355, P632, DOI 10.1038/355632a0; ADAMS MD, 1991, SCIENCE, V252, P1651, DOI 10.1126/science.2047873; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Becherer KA, 1996, MOL BIOL CELL, V7, P579, DOI 10.1091/mbc.7.4.579; BENNETT MK, 1993, CELL, V74, P863, DOI 10.1016/0092-8674(93)90466-4; BENNETT MK, 1994, ANNU REV BIOCHEM, V63, P63, DOI 10.1146/annurev.bi.63.070194.000431; BENNETT MK, 1993, P NATL ACAD SCI USA, V90, P2559, DOI 10.1073/pnas.90.7.2559; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; CHAPMAN ER, 1994, J BIOL CHEM, V269, P27427; CLARY DO, 1990, CELL, V61, P709, DOI 10.1016/0092-8674(90)90482-T; COHEN C, 1986, TRENDS BIOCHEM SCI, V11, P245, DOI 10.1016/0968-0004(86)90186-6; DASCHER C, 1994, J BIOL CHEM, V269, P29363; Genetic Computer Group, 1994, PROGR MAN WISC PACK; Hay JC, 1996, J BIOL CHEM, V271, P5671, DOI 10.1074/jbc.271.10.5671; HAYASHI T, 1995, EMBO J, V14, P2317, DOI 10.1002/j.1460-2075.1995.tb07226.x; JAHN R, 1994, ANNU REV NEUROSCI, V17, P219, DOI 10.1146/annurev.ne.17.030194.001251; JONES EW, 1977, GENETICS, V85, P23; KEE Y, 1995, NEURON, V14, P991, DOI 10.1016/0896-6273(95)90337-2; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Lupas A, 1996, METHOD ENZYMOL, V266, P513; OAS TG, 1990, BIOCHEMISTRY-US, V29, P2891, DOI 10.1021/bi00464a001; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; PRYER NK, 1992, ANNU REV BIOCHEM, V61, P471; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SCHELLER RH, 1995, NEURON, V14, P893; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SU JY, 1994, BIOCHEMISTRY-US, V33, P15501, DOI 10.1021/bi00255a032; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; VELASCO A, 1993, J CELL BIOL, V122, P39, DOI 10.1083/jcb.122.1.39; WHITEHEART SW, 1993, NATURE, V362, P353, DOI 10.1038/362353a0	31	123	125	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					17961	17965		10.1074/jbc.271.30.17961	http://dx.doi.org/10.1074/jbc.271.30.17961			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663448	hybrid			2022-12-25	WOS:A1996UY93500058
J	Witte, S; Neumann, F; Krawinkel, U; Przybylski, M				Witte, S; Neumann, F; Krawinkel, U; Przybylski, M			Mass spectrometric identification of leucine zipper-like homodimer complexes of the autoantigen L7	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTROSPRAY-IONIZATION; CELL BIOLOGY; AMINO-ACIDS; PROTEINS; SEQUENCE	The eucaryotic protein L7 has been shown to associate in the cytoplasm with the large subunit of ribosomes and to interact specifically with as yet unknown cognate sites of mRNA, thereby inhibiting cell-free translation (Neumann, F,, Hemmerich, P,, von Mikecz, A., Peter, Il, H., and Krawinkel, U, (1995) Nucleic Acids Res, 23, 195-202), The N-terminal region of protein L7 contains a sequence motif similar to the leucine zipper domain of eucaryotic transcription factors, which promotes dimerization through alpha-helical coiled coil formation, Using electrospray-ionization mass spectrometry as a method of molecular specificity, we have directly identified the dimeric complexes comprising the leucine zipper-like region of protein L7 and have determined the dissociation constant of L7 homodimers in an affinity binding assay, We also demonstrate the high content of cu-helicity of the dimer by circular dichroism spectra and computer-based structure simulation and show that the leucine zipper region of protein L7 is fully sufficient to mediate the inhibition of cell-free mRNA translation, A structural basis for the function of L7 to regulate translation is discussed, From the present results we con elude that L7 interacts with double stranded mRNA in a similar fashion as leucine zipper proteins with specific cognate sites on double stranded DNA.	UNIV KONSTANZ, FAK CHEM, D-78434 CONSTANCE, GERMANY	University of Konstanz	Witte, S (corresponding author), UNIV KONSTANZ, FAK BIOL, POSTFACH 5560, D-78434 CONSTANCE, GERMANY.							Alber T, 1992, CURR OPIN GENET DEV, V2, P205, DOI 10.1016/S0959-437X(05)80275-8; ALLEN MH, 1992, J AM SOC MASS SPECTR, V3, P18, DOI 10.1016/1044-0305(92)85014-B; Ausubel FM, 1991, CURRENT PROTOCOLS MO; BUSCH SJ, 1990, TRENDS GENET, V6, P36, DOI 10.1016/0168-9525(90)90071-D; ELLENBERGER TE, 1992, CELL, V71, P1223, DOI 10.1016/S0092-8674(05)80070-4; FORMOSA T, 1991, METHOD ENZYMOL, V208, P24; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GLOCKER MO, 1994, BIOCONJUGATE CHEM, V5, P583, DOI 10.1021/bc00030a014; Hadjiolov A.A., 1985, CELL BIOL MONOGRAPHS, V12; HEMMERICH P, 1993, NUCLEIC ACIDS RES, V21, P223, DOI 10.1093/nar/21.2.223; KALPIN RF, 1994, BIOTECHNIQUES, V17, P730; KARAS M, 1991, MASS SPECTROM REV, V10, P335, DOI 10.1002/mas.1280100503; KONIG P, 1993, J MOL BIOL, V233, P139, DOI 10.1006/jmbi.1993.1490; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LI YT, 1993, J AM CHEM SOC, V115, P8409, DOI 10.1021/ja00071a058; LIN A, 1987, J BIOL CHEM, V262, P12665; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; NEU E, 1995, CLIN EXP IMMUNOL, V100, P198; NEUMANN F, 1995, NUCLEIC ACIDS RES, V23, P195, DOI 10.1093/nar/23.2.195; NIELSEN PF, 1990, MASS SPECTROMETRY LA, P194; ONEIL KT, 1990, SCIENCE, V250, P646, DOI 10.1126/science.2237415; OSHEA EK, 1989, SCIENCE, V243, P538, DOI 10.1126/science.2911757; PARRY DAD, 1982, BIOSCIENCE REP, V2, P1017, DOI 10.1007/BF01122170; PHIZICKY EM, 1995, MICROBIOL REV, V59, P94, DOI 10.1128/MMBR.59.1.94-123.1995; Przybylski M, 1995, TOXICOL LETT, V82-3, P567, DOI 10.1016/0378-4274(95)03502-8; Przybylski M, 1995, ADV MASS SPECTROM, V13, P257; Przybylski M, 1996, ANGEW CHEM INT EDIT, V35, P807; PRZYBYLSKI M, 1994, PEPTIDES CHEM STRUCT, P338; SMITH RD, 1993, BIOL MASS SPECTROM, V22, P493, DOI 10.1002/bms.1200220902; SMITH RD, 1991, MASS SPECTROM REV, V10, P359, DOI 10.1002/mas.1280100504; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TAKACS BJ, 1991, J IMMUNOL METHODS, V143, P231, DOI 10.1016/0022-1759(91)90048-K; Tan E.M., 1989, ADV IMMUNOL, V44, P151, DOI [10.1016/S0065-2776(08)60641-0, DOI 10.1016/S0065-2776(08)60641-0]; TAN EM, 1991, CELL, V67, P841, DOI 10.1016/0092-8674(91)90356-4; TSURUGI K, 1976, J BIOL CHEM, V251, P7940; VONMIKECZ A, 1994, IMMUNOBIOLOGY, V192, P137, DOI 10.1016/S0171-2985(11)80413-4; VONMIKECZ AH, 1995, CLIN EXP IMMUNOL, V100, P205; WENDT H, 1995, PROTEIN SCI, V4, P1563, DOI 10.1002/pro.5560040814; ZHU BY, 1993, PROTEIN SCI, V2, P383	39	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					18171	18175		10.1074/jbc.271.30.18171	http://dx.doi.org/10.1074/jbc.271.30.18171			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663440	hybrid			2022-12-25	WOS:A1996UY93500087
J	Feng, JF; Rhee, SG; Im, MJ				Feng, JF; Rhee, SG; Im, MJ			Evidence that phospholipase delta 1 is the effector in the G(h) (transglutaminase II)-mediated signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-SUBUNITS; C ISOZYMES; G-PROTEIN; ACTIVATION; PURIFICATION; RECONSTITUTION; BINDING; FAMILY; ALPHA(1)-ADRENOCEPTOR; MEDIATOR	A new class of GTP-binding protein transglutaminase II (G(h)) couples to a 69 kDa phospholipase C (PLC). An 8-amino acid region (LeU(665)-Lys(672)) of the alpha-subunit of G(h) (G alpha(h)) is involved in interaction and activation of PLC, an observation that has now been used to characterize the 69-kDa PLC further. A 20-amino acid peptide 673 corresponding to Leu(654)-Leu(673) of G alpha(h) was used to prepare an affinity resin. On incubation with a partially purified PLC preparation from rat liver membranes, the affinity resin-bound similar to 69- and 85-kDa proteins were recognized by an antibody to the 69-kDa PLC. Both purified 69-kDa PLC and PLC-delta 1 bound to the affinity resin; moreover, antibodies to PLC-delta 1 recognized the 69-kDa PLC, and antibodies to the 69 kDa PLC recognized PLC-delta 1. A synthetic peptide corresponding to LeU(661)-Lys(672) of G alpha(h) inhibited the binding of PLC-delta 1 to the affinity resin and also stimulated PLC-delta 1. Reconstitution of PLC-delta 1 with GTP gamma S (guanosine 5'-3-O-(thio)triphosphate)-activated G(h) resulted in activation of PLC-delta 1. Antibodies to G alpha(h) also coimmunoprecipitated PLC-delta 1 upon activation of G(h). These findings indicate that PLC-delta 1 is the effector of G(h)-mediated signaling.	CLEVELAND CLIN FDN,RES INST,DEPT MOLEC CARDIOL FFB37,CLEVELAND,OH 44195; NHLBI,LAB CELL SIGNALING,NIH,BETHESDA,MD 20892	Cleveland Clinic Foundation; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045985] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM45985] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baek KJ, 1996, BIOCHEMISTRY-US, V35, P2651, DOI 10.1021/bi9522965; BAEK KJ, 1993, J BIOL CHEM, V268, P27390; BANNO Y, 1994, J BIOL CHEM, V269, P15846; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Biddlecome GH, 1996, J BIOL CHEM, V271, P7999, DOI 10.1074/jbc.271.14.7999; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHENG HF, 1995, J BIOL CHEM, V270, P5495, DOI 10.1074/jbc.270.10.5495; DAS T, 1993, J BIOL CHEM, V268, P27398; GINGER RS, 1992, EUR J BIOCHEM, V210, P155, DOI 10.1111/j.1432-1033.1992.tb17403.x; GUTOWSKI S, 1991, J BIOL CHEM, V266, P20519; HARRIS BA, 1985, SCIENCE, V229, P1274, DOI 10.1126/science.3839937; HEPLER JR, 1993, J BIOL CHEM, V268, P14367; HWANG KC, 1995, J BIOL CHEM, V270, P27058, DOI 10.1074/jbc.270.45.27058; IM MJ, 1990, J BIOL CHEM, V265, P18952; IM MJ, 1992, J BIOL CHEM, V267, P8887; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; MELDRUM E, 1991, BIOCHIM BIOPHYS ACTA, V1092, P49, DOI 10.1016/0167-4889(91)90177-Y; NAKAOKA H, 1994, SCIENCE, V264, P1593, DOI 10.1126/science.7911253; PARK DG, 1993, J BIOL CHEM, V268, P4573; RHEE SG, 1991, BIOCHEM SOC T, V19, P337, DOI 10.1042/bst0190337; RHEE SG, 1992, J BIOL CHEM, V267, P12393; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; TAYLOR GD, 1992, BIOCHEM BIOPH RES CO, V188, P1176, DOI 10.1016/0006-291X(92)91355-T; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; WU DQ, 1992, J BIOL CHEM, V267, P25798; YAGISAWA H, 1994, J BIOL CHEM, V269, P20179	26	159	161	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16451	16454		10.1074/jbc.271.28.16451	http://dx.doi.org/10.1074/jbc.271.28.16451			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663582	hybrid			2022-12-25	WOS:A1996UX12600006
J	Casciano, I; Marchi, JVM; Muresu, R; Volpi, EV; Rozzo, C; Opdenakker, G; Romani, M				Casciano, I; Marchi, JVM; Muresu, R; Volpi, EV; Rozzo, C; Opdenakker, G; Romani, M			Molecular and genetic studies on the region of translocation and duplication in the neuroblastoma cell line NGP at the 1p36.13-p36.32 chromosomal site	ONCOGENE			English	Article						neuroblastoma; reciprocal translocation; duplication; antioncogenes; chromosome 1	INSITU HYBRIDIZATION; BREAST-CANCER; SHORT ARM; HETEROZYGOSITY; PCR; INTEGRATION; DELETION; 1P	Cytogenic and molecular studies suggest that chromosome 1p might contain oncosuppressor genes involved in the pathogenesis of neuroblastoma and other adult tumors, The isolation of these genes by the 'positional cloning' approach will be facilitated by the characterization of cell lines with well defined chromosomal aberrations, In the present report we provide molecular data on the NGP neuroblastoma cell line which contains a reciprocal t(1;15) translocation, Two regions, possibly hosting oncosuppressor genes, have been identified: one is distal to the ENO1 locus, the other one is comprised between PND and A12M2 and corresponds to that of a constitutional t(1;17) translocation described in a neuroblastoma patient, Genetic data also suggest that the NGP cell line, despite the presence of two chromosomes 1, might be hemizygous for the subtelomeric 1p region.	IST,IST NAZL RIC CANC,LAB POPULAT GENET,ALGHERO,ITALY; CNR,IST GENET MOL,ALGHERO,ITALY; CATHOLIC UNIV LEUVEN,REGA INST,B-3000 LOUVAIN,BELGIUM	University of Genoa; IRCCS AOU San Martino IST; Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica Molecolare (IGM-CNR); KU Leuven			Opdenakker, Ghislain/Q-3130-2017; Rozzo, Carla M/C-4300-2015; Opdenakker, Ghislain/V-8562-2019	Opdenakker, Ghislain/0000-0003-1714-2294; Rozzo, Carla M/0000-0001-6581-2227; Opdenakker, Ghislain/0000-0003-1714-2294; Volpi, Emanuela/0000-0002-2422-9104; casciano, ida/0000-0003-1776-670X				AMLER LC, 1995, ONCOGENE, V10, P1095; BADER SA, 1991, CELL GROWTH DIFFER, V2, P245; BALDINI A, 1992, GENOMICS, V14, P181, DOI 10.1016/S0888-7543(05)80303-9; BALDINI A, 1991, GENOMICS, V9, P770, DOI 10.1016/0888-7543(91)90374-N; BIEGEL JA, 1993, AM J HUM GENET, V52, P176; BRODEUR GM, 1989, CANCER GENET CYTOGEN, V41, P153, DOI 10.1016/0165-4608(89)90243-4; BRODEUR GM, 1977, CANCER-AM CANCER SOC, V40, P2256, DOI 10.1002/1097-0142(197711)40:5<2256::AID-CNCR2820400536>3.0.CO;2-1; CARON H, 1995, HUM MOL GENET, V4, P535, DOI 10.1093/hmg/4.4.535; COLLINS FS, 1995, NAT GENET, V9, P347, DOI 10.1038/ng0495-347; DEAMBROSIS A, 1992, CANCER GENET CYTOGEN, V60, P1, DOI 10.1016/0165-4608(92)90223-U; DRACOPOLI NC, 1989, P NATL ACAD SCI USA, V86, P4614, DOI 10.1073/pnas.86.12.4614; ENGELSTEIN M, 1993, GENOMICS, V15, P251, DOI 10.1006/geno.1993.1054; HAINSWORTH PJ, 1992, BRIT J CANCER, V66, P131, DOI 10.1038/bjc.1992.229; HARNETT PR, 1991, CANCER GENET CYTOGEN, V54, P109, DOI 10.1016/0165-4608(91)90037-U; KNUDSON AG, 1972, AM J HUM GENET, V24, P514; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; LAUREYS G, 1995, ONCOGENE, V10, P1087; LAUREYS G, 1990, GENE CHROMOSOME CANC, V2, P252, DOI 10.1002/gcc.2870020315; LEISTER I, 1990, CANCER RES, V50, P7232; MARS WM, 1991, CANCER DETECT PREV, V15, P145; MURESU R, 1995, GENE CHROMOSOME CANC, V13, P66, DOI 10.1002/gcc.2870130111; NOBILE C, 1994, MAMM GENOME, V5, P566, DOI 10.1007/BF00354931; ROMANI M, 1990, GENE, V95, P231, DOI 10.1016/0378-1119(90)90366-Y; ROMANI M, 1993, GENE, V135, P153, DOI 10.1016/0378-1119(93)90060-G; ROMANI M, 1994, CYTOGENET CELL GENET, V67, P37, DOI 10.1159/000133793; ROMANI M, 1996, IN PRESS J NEURO ONC; SAVALYEVA L, 1994, AM J HUM GENET, V55, P334; SCHLEIERMACHER G, 1994, GENE CHROMOSOME CANC, V10, P275, DOI 10.1002/gcc.2870100409; SIMON D, 1991, ONCOGENE, V6, P765; TAKEDA O, 1994, GENE CHROMOSOME CANC, V10, P30, DOI 10.1002/gcc.2870100106; VANDERDRIFT P, 1994, HUM MOL GENET, V3, P2131, DOI 10.1093/hmg/3.12.2131; VANROY N, 1993, GENOMICS, V18, P71, DOI 10.1006/geno.1993.1427; WEITH A, 1989, GENE CHROMOSOME CANC, V1, P159, DOI 10.1002/gcc.2870010209; WHITE PS, 1993, GENE CHROMOSOME CANC, V7, P102, DOI 10.1002/gcc.2870070207; WHITE PS, 1995, P NATL ACAD SCI USA, V92, P5520, DOI 10.1073/pnas.92.12.5520	35	13	13	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 16	1996	12	10					2101	2108						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UP283	8668335				2022-12-25	WOS:A1996UP28300008
J	Tashiro, S; Kotomura, N; Shinohara, A; Tanaka, K; Ueda, K; Kamada, N				Tashiro, S; Kotomura, N; Shinohara, A; Tanaka, K; Ueda, K; Kamada, N			S phase specific formation of the human Rad51 protein nuclear foci in lymphocytes	ONCOGENE			English	Article						human Rad51 protein; lymphocyte; S phase	RECOMBINATION; GENES; YEAST; RECA	The Rad51 protein, which is a homologue of the bacterial RecA protein, is involved in mitotic and meiotic recombination and in repair of double-strand breaks of DNA in yeast, The Rad51 homologue is conserved from yeast to human, In this study, the Rad51 protein was shown to be induced in peripheral blood lymphocytes (PBLs) 36 h after phytohemagglutinin (PHA) stimulation, Immunofluorescence study revealed that the distribution of the Rad51 protein in the nucleus was not uniform and focus-like staining was observed, Formation of the Rad51 foci was induced at 36 h after treatment of the cells with PHA. Twenty five percent of the cells had the foci at this time and the number of cells with foci declined thereafter, Cell cycle study using laser microscope by double staining method suggested that the appearance of the Rad51 nuclear foci was S phase specific, Furthermore, double staining study for the Rad51 protein and incorporated BrdU confirmed S phase specific appearance of the Rad51 nuclear foci, Formation of the Rad51 nuclear foci in PHA-stimulated lymphocytes might be involved in DNA recombination or DNA repair in S phase, The roles of RAD51 foci in S-phase will be discussed.	HIROSHIMA UNIV,RES INST RADIAT BIOL & MED,DIV MOLEC BIOL,HIROSHIMA 734,JAPAN; HIROSHIMA UNIV,SCH MED,DEPT PEDIAT,HIROSHIMA 734,JAPAN; OSAKA UNIV,FAC SCI,DEPT BIOL,TOYONAKA,OSAKA 560,JAPAN	Hiroshima University; Hiroshima University; Osaka University								BASILE G, 1992, MOL CELL BIOL, V12, P3235, DOI 10.1128/MCB.12.7.3235; FAED MJW, 1978, MUTAT RES, V49, P437, DOI 10.1016/0027-5107(78)90115-X; HAAF T, 1995, P NATL ACAD SCI USA, V92, P2298, DOI 10.1073/pnas.92.6.2298; HAYS SL, 1995, P NATL ACAD SCI USA, V92, P6925, DOI 10.1073/pnas.92.15.6925; HOZAK P, 1994, J CELL SCI, V107, P219; JOHNSON RD, 1995, MOL CELL BIOL, V15, P4843; KOGOMA T, 1994, MOL GEN GENET, V244, P557, DOI 10.1007/BF00583907; MCINTOSH EM, 1993, CURR GENET, V24, P185, DOI 10.1007/BF00351790; Ogawa H, 1990, Adv Biophys, V26, P33, DOI 10.1016/0065-227X(90)90006-F; PANTHIER JJ, 1991, BIOESSAYS, V13, P351, DOI 10.1002/bies.950130709; SHINOHARA A, 1993, NAT GENET, V4, P239, DOI 10.1038/ng0793-239; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; TAUCHI H, 1994, INT J RADIAT BIOL, V65, P449, DOI 10.1080/09553009414550521; TERASAWA M, 1995, GENE DEV, V9, P925, DOI 10.1101/gad.9.8.925; WEST SC, 1992, ANNU REV BIOCHEM, V61, P603, DOI 10.1146/annurev.bi.61.070192.003131; WITKIN EM, 1969, ANNU REV MICROBIOL, V23, P487, DOI 10.1146/annurev.mi.23.100169.002415; WOLFF S, 1974, MUTAT RES, V25, P73, DOI 10.1016/0165-1218(74)90082-2	17	146	146	1	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 16	1996	12	10					2165	2170						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UP283	8668342				2022-12-25	WOS:A1996UP28300015
J	Ekberg, M; Sahlin, M; Eriksson, M; Sjoberg, BM				Ekberg, M; Sahlin, M; Eriksson, M; Sjoberg, BM			Two conserved tyrosine residues in protein R1 participate in an intermolecular electron transfer in ribonucleotide reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; ESCHERICHIA-COLI; DIPHOSPHATE REDUCTASE; PROMOTER SYSTEM; IRON CENTER; SUBUNIT; PROGRAM; PURIFICATION; INACTIVATION; INVOLVEMENT	The enzyme ribonucleotide reductase consists of two nonidentical proteins, R1 and R2, which are each inactive alone, R1 contains the active site and R2 contains a stable tyrosyl radical essential for catalysis, The reduction of ribonucleotides is radical based, and a long range electron transfer chain between the active site in R1 and the radical in R2 has been suggested, To find evidence for such an electron transfer chain in Escherichia coli ribonucleotide reductase, we converted two conserved tyrosines in R1 into phenylalanines by site-directed mutagenesis. The mutant proteins were shown to be enzymatically inactive, In addition, the mechanism-based inhibitor 2'-azido-2'-deoxy-CDP was incapable of scavenging the R2 radical, and no azido-CDP-derived radical intermediate was formed, We also shaw that the loss of enzymatic activity was not due to impaired R1-R2 complex formation or substrate binding, Based on these results, we predict that the two tyrosines, Tyr-730 and Tyr-731, are part of a hydrogenbonded network that constitutes an electron transfer pathway in ribonucleotide reductase, It is demonstrated that there is no electron delocalization over these tyrosines in the resting wild-type complex.	UNIV STOCKHOLM, DEPT MOL BIOL, S-10691 STOCKHOLM, SWEDEN; SWEDISH UNIV AGR SCI, UPPSALA BIOMED CTR, DEPT MOL BIOL, S-75124 UPPSALA, SWEDEN	Stockholm University; Swedish University of Agricultural Sciences				Sjoberg, Britt-Marie/0000-0001-5953-3360				ABERG A, 1989, J BIOL CHEM, V264, P12249; BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BERATAN DN, 1991, SCIENCE, V252, P1285, DOI 10.1126/science.1656523; CLIMENT I, 1992, BIOCHEMISTRY-US, V31, P4801, DOI 10.1021/bi00135a009; DEREGE PJF, 1995, SCIENCE, V269, P1409, DOI 10.1126/science.7660123; ERIKSSON S, 1977, J BIOL CHEM, V252, P6132; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LARSSON A, 1986, EMBO J, V5, P2037, DOI 10.1002/j.1460-2075.1986.tb04461.x; MAO SS, 1992, BIOCHEMISTRY-US, V31, P9752, DOI 10.1021/bi00155a031; MAO SS, 1992, BIOCHEMISTRY-US, V31, P9744, DOI 10.1021/bi00155a030; MARCUS RA, 1985, BIOCHIM BIOPHYS ACTA, V811, P265, DOI 10.1016/0304-4173(85)90014-X; MEAD DA, 1986, PROTEIN ENG, V1, P67, DOI 10.1093/protein/1.1.67; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MINOIR W, 1993, XDISPLAYF PROGRAM; MOSER CC, 1992, NATURE, V355, P796, DOI 10.1038/355796a0; NORDLUND P, 1990, NATURE, V345, P593, DOI 10.1038/345593a0; ORMO M, 1990, ANAL BIOCHEM, V189, P138, DOI 10.1016/0003-2697(90)90059-I; Otwinowski Z., 1993, P CCP4 STUD WEEK DAT, P56; Persson BO, 1996, J BIOL INORG CHEM, V1, P247, DOI 10.1007/s007750050050; ROVA U, 1995, BIOCHEMISTRY-US, V34, P4267, DOI 10.1021/bi00013a016; SAHLIN M, 1987, BIOCHEMISTRY-US, V26, P5541, DOI 10.1021/bi00391a049; Sjoberg B. M., 1995, NUCLEIC ACIDS MOL BI, V9, P192; SJOBERG BM, 1982, BIOCHEMISTRY-US, V21, P96; SJOBERG BM, 1983, J BIOL CHEM, V258, P8060; SJOBERG BM, 1978, J BIOL CHEM, V253, P6863; SJOBERG BM, 1986, J BIOL CHEM, V261, P5658; STUBBE J, 1990, ADV ENZYMOL RAMB, V63, P349; STUBBE JA, 1989, ANNU REV BIOCHEM, V58, P257; SUN L, 1992, MOL BIOL CELL, V3, P1095, DOI 10.1091/mbc.3.10.1095; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; Thelander L, 1978, Methods Enzymol, V51, P227; THELANDER L, 1979, ANNU REV BIOCHEM, V48, P133, DOI 10.1146/annurev.bi.48.070179.001025; THELANDER L, 1973, J BIOL CHEM, V248, P4591; THELANDER L, 1976, J BIOL CHEM, V251, P1398; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; UHLIN U, 1994, NATURE, V370, P533, DOI 10.1038/370533a0; UHLIN U, 1993, FEBS LETT, V336, P148, DOI 10.1016/0014-5793(93)81629-E; VANDERDONK WA, 1995, J AM CHEM SOC, V117, P8908, DOI 10.1021/ja00140a003	41	116	119	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20655	20659		10.1074/jbc.271.34.20655	http://dx.doi.org/10.1074/jbc.271.34.20655			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702814	hybrid			2022-12-25	WOS:A1996VD33700066
J	Frankel, G; Lider, O; Hershkoviz, R; Mould, AP; Kachalsky, SG; Candy, DCA; Cahalon, L; Humphries, MJ; Dougan, G				Frankel, G; Lider, O; Hershkoviz, R; Mould, AP; Kachalsky, SG; Candy, DCA; Cahalon, L; Humphries, MJ; Dougan, G			The cell-binding domain of intimin from enteropathogenic Escherichia coli binds to beta(1) integrins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PSEUDOTUBERCULOSIS INVASIN PROTEIN; HUMAN T-CELLS; EPITHELIAL-CELLS; EXTRACELLULAR-MATRIX; MAMMALIAN-CELLS; TYROSINE PHOSPHORYLATION; YERSINIA-ENTEROCOLITICA; FIBRONECTIN RECEPTOR; SIGNAL TRANSDUCTION; MONOCLONAL-ANTIBODY	Bacteria interact with mammalian cells surface mole cules, such as integrins, to colonize tissues and evade immunological detection. Herein, the ability of intimin, an outer membrane protein from enteropathogenic Escherichia coli, to bind beta(1) integrins was investigated. Solid-phase binding assays revealed binding of the carboxyl-terminal 280 amino acids of intimin (Int280) to alpha(4) beta(1) and alpha(5) beta(1) integrins. The binding required divalent ions (in particular, it was enhanced by Mn2+) and was inhibited by an RGD-containing peptide. Nonderivatized Int280, but not Int280CS (like Int280 but with Cys-937 replaced by Ser) blocked the binding of biotinylated Int280 to integrins. Int280 did not efficiently inhibit beta(1), integrin binding of invasin from Yersinia pseudotuberculosis. Both intimin and invasin, immobilized on plastic surfaces, mediated adherence of resting or phorbol 12-myristate 13-acetate-activated human CD4(+) T cells, whereas fibronectin mediated the adherence of only activated T cells. T cell binding to intimin and invasin was integrin mediated because it was specifically blocked by an RGD containing peptide and by antibodies directed against the integrin subunits beta(1), alpha(4) and alpha(5). These results demonstrate a specific integrin binding activity for intimin that is related to, but distinct from, that of invasin.	WEIZMANN INST SCI, DEPT IMMUNOL, IL-76100 REHOVOT, ISRAEL; UNIV MANCHESTER, SCH BIOL SCI, WELLCOME TRUST CTR CELL MATRIX RES, MANCHESTER M13 9PT, LANCS, ENGLAND	Weizmann Institute of Science; University of Manchester	Frankel, G (corresponding author), UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED, DEPT BIOCHEM, LONDON SW7 2AZ, ENGLAND.			Humphries, Martin/0000-0002-4331-6967; Mould, Paul/0000-0003-0076-6228	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALON R, 1994, J IMMUNOL, V152, P1304; ALON R, 1993, EUR J IMMUNOL, V23, P893, DOI 10.1002/eji.1830230419; BANK I, 1989, CELL IMMUNOL, V122, P416, DOI 10.1016/0008-8749(89)90088-9; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; CANIL C, 1993, INFECT IMMUN, V61, P2755, DOI 10.1128/IAI.61.7.2755-2762.1993; CHARO IF, 1990, J CELL BIOL, V111, P2795, DOI 10.1083/jcb.111.6.2795; DONNENBERG MS, 1993, J BACTERIOL, V175, P4670, DOI 10.1128/JB.175.15.4670-4680.1993; DSOUZA SE, 1988, SCIENCE, V242, P91, DOI 10.1126/science.3262922; ENNIS E, 1993, J EXP MED, V177, P207, DOI 10.1084/jem.177.1.207; FAGUNDESNETO U, 1995, ACTA PAEDIATR, V84, P453, DOI 10.1111/j.1651-2227.1995.tb13670.x; FINLAY BB, 1988, BIOCHIMIE, V70, P1089, DOI 10.1016/0300-9084(88)90271-4; FINLAY BB, 1992, INFECT IMMUN, V60, P2541, DOI 10.1128/IAI.60.6.2541-2543.1992; FOX G, 1989, J GEN VIROL, V70, P625, DOI 10.1099/0022-1317-70-3-625; FRANCIS CL, 1991, J INFECT DIS, V164, P693, DOI 10.1093/infdis/164.4.693; Frankel G, 1995, MICROB PATHOGENESIS, V19, P421, DOI 10.1006/mpat.1995.0076; FRANKEL G, 1995, INFECT IMMUN, V63, P4323, DOI 10.1128/IAI.63.11.4323-4328.1995; FRANKEL G, 1994, INFECT IMMUN, V62, P1835, DOI 10.1128/IAI.62.5.1835-1842.1994; GAILIT J, 1988, J BIOL CHEM, V263, P12927; GILAT D, 1995, J EXP MED, V181, P1929, DOI 10.1084/jem.181.5.1929; HORWITZ A, 1986, NATURE, V320, P531, DOI 10.1038/320531a0; HUMPHRIES MJ, 1993, BIOESSAYS, V15, P391, DOI 10.1002/bies.950150605; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Isberg Ralph R., 1994, Trends in Microbiology, V2, P10, DOI 10.1016/0966-842X(94)90338-7; ISBERG RR, 1987, CELL, V50, P769, DOI 10.1016/0092-8674(87)90335-7; ISBERG RR, 1990, CELL, V60, P861, DOI 10.1016/0092-8674(90)90099-Z; JERSE AE, 1991, INFECT IMMUN, V59, P4302, DOI 10.1128/IAI.59.12.4302-4309.1991; JERSE AE, 1990, P NATL ACAD SCI USA, V87, P7839, DOI 10.1073/pnas.87.20.7839; KENNY B, 1995, P NATL ACAD SCI USA, V92, P7991, DOI 10.1073/pnas.92.17.7991; KERN A, 1994, J BIOL CHEM, V269, P22811; KNUTTON S, 1987, INFECT IMMUN, V55, P69, DOI 10.1128/IAI.55.1.69-77.1987; KOMORIYA A, 1991, J BIOL CHEM, V266, P15075; KORNBERG LJ, 1991, P NATL ACAD SCI USA, V88, P8392, DOI 10.1073/pnas.88.19.8392; LEONG JM, 1993, J BIOL CHEM, V268, P20524; LEONG JM, 1990, EMBO J, V9, P1979, DOI 10.1002/j.1460-2075.1990.tb08326.x; LEONG JM, 1995, EMBO J, V14, P422, DOI 10.1002/j.1460-2075.1995.tb07018.x; LEVINE MM, 1987, J INFECT DIS, V155, P377, DOI 10.1093/infdis/155.3.377; MCDANIEL TK, 1995, P NATL ACAD SCI USA, V92, P1664, DOI 10.1073/pnas.92.5.1664; MIRON S, 1992, CELL IMMUNOL, V144, P182, DOI 10.1016/0008-8749(92)90235-H; MOULD AP, 1994, J BIOL CHEM, V269, P27224; MOULD AP, 1995, FEBS LETT, V363, P118, DOI 10.1016/0014-5793(95)00301-O; NHIEU GTV, 1991, J BIOL CHEM, V266, P24367; NHIEU GTV, 1993, EMBO J, V12, P1887; NOJIMA Y, 1990, J EXP MED, V172, P1185, DOI 10.1084/jem.172.4.1185; OTEY CA, 1990, J CELL BIOL, V111, P721, DOI 10.1083/jcb.111.2.721; PEPE JC, 1995, INFECT IMMUN, V63, P4837, DOI 10.1128/IAI.63.12.4837-4848.1995; ROSENSHINE I, 1992, EMBO J, V11, P3551, DOI 10.1002/j.1460-2075.1992.tb05438.x; ROSENSHINE I, 1992, INFECT IMMUN, V60, P2211, DOI 10.1128/IAI.60.6.2211-2217.1992; SHIMIZU Y, 1990, IMMUNOL REV, V114, P109, DOI 10.1111/j.1600-065X.1990.tb00563.x; SPITZ J, 1995, AM J PHYSIOL-GASTR L, V268, pG374, DOI 10.1152/ajpgi.1995.268.2.G374; ULSHEN MH, 1980, NEW ENGL J MED, V302, P99, DOI 10.1056/NEJM198001103020207; YU J, 1992, MOL MICROBIOL, V6, P411, DOI 10.1111/j.1365-2958.1992.tb01484.x	51	159	162	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20359	20364		10.1074/jbc.271.34.20359	http://dx.doi.org/10.1074/jbc.271.34.20359			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702771	hybrid			2022-12-25	WOS:A1996VD33700023
J	Song, JP; Hirschman, J; Gunn, G; Dohlman, HG				Song, JP; Hirschman, J; Gunn, G; Dohlman, HG			Regulation of membrane and subunit interactions by N-myristoylation of a G protein alpha subunit in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-BINDING PROTEIN; BETA-GAMMA-SUBUNITS; KINASE-C SUBSTRATE; SACCHAROMYCES-CEREVISIAE; LIPID MODIFICATIONS; PHEROMONE RESPONSE; PLASMA-MEMBRANE; MAJOR SUBSTRATE; MYRISTIC ACID; BOVINE BRAIN	Initiation of the mating process in yeast Saccharomyces cerevisiae requires the action of secreted pheromones and G protein-coupled receptors. As in other eu karyotes, the yeast G protein alpha subunit undergoes N-myristoylation (GPA1 gene product, Gpa1p). This modification appears to be essential for function, since a myristoylation site mutation exhibits the null phenotype in vivo (gpa1(G2A)). Here we examine how myristoylation affects Gpa1p activity in vitro. We show that the G2A mutant of Gpa1p, when fused with glutathione S-transferase, can still form a complex with the G protein beta gamma subunits. The complex is stabilized by GDP and is dissociated upon treatment with guanosine 5'-O-(thiotriphosphate). In addition, there is no apparent difference in the relative binding affinity of G(beta gamma) for mutant and wild-type Gpa1p. Using sucrose density gradient fractionation of cell membranes, Gpa1p associates normally with the plasma membrane whereas Gpa1p(G2A) is mislocalized to a microsomal membrane fraction. A portion of G(beta gamma) is also mislocalized in these cells, as it is in a gpa1 Delta strain. In contrast, wild-type Gpa1p reaches the plasma membrane in cells that do not express G(beta gamma) or cell surface receptors. These findings indicate that mislocalization of Gpa1p(G2A) is not caused by a redistribution of G(beta gamma), nor is it the result of any difference in G(beta gamma) binding affinity. These data suggest that myristoylation is required for specific targeting of Gpa1p to the plasma membrane, where it is needed to interact with the receptor and to regulate the release of G(beta gamma).	YALE UNIV, SCH MED, BOYER CTR MOL MED, DEPT PHARMACOL & MOL CARDIOBIOL PROGRAM, NEW HAVEN, CT 06536 USA; UNIV MASSACHUSETTS, MED CTR, WORCESTER, MA 01655 USA	Yale University; University of Massachusetts System; University of Massachusetts Worcester				Dohlman, Henrik/0000-0003-2443-0729	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034719] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM34719] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADEREM AA, 1988, P NATL ACAD SCI USA, V85, P6310, DOI 10.1073/pnas.85.17.6310; ADEREM AA, 1988, NATURE, V332, P362, DOI 10.1038/332362a0; ADEREM AA, 1986, P NATL ACAD SCI USA, V83, P5817, DOI 10.1073/pnas.83.16.5817; ALANI E, 1987, GENETICS, V116, P541, DOI 10.1534/genetics.112.541.test; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BIGAY J, 1994, BIOCHEMISTRY-US, V33, P14081, DOI 10.1021/bi00251a017; BLUMER KJ, 1990, P NATL ACAD SCI USA, V87, P4363, DOI 10.1073/pnas.87.11.4363; BOWSER R, 1991, J CELL BIOL, V112, P1117, DOI 10.1083/jcb.112.6.1117; BUSS JE, 1987, P NATL ACAD SCI USA, V84, P7493, DOI 10.1073/pnas.84.21.7493; CASEY PJ, 1995, SCIENCE, V268, P221, DOI 10.1126/science.7716512; CLARK KL, 1993, MOL CELL BIOL, V13, P1; CONKLIN BR, 1993, CELL, V73, P631, DOI 10.1016/0092-8674(93)90245-L; DASILVA AM, 1990, J CELL BIOL, V111, P401, DOI 10.1083/jcb.111.2.401; DEGTYAREV MY, 1993, BIOCHEMISTRY-US, V32, P8057, DOI 10.1021/bi00083a001; DIETZEL C, 1987, CELL, V50, P1001, DOI 10.1016/0092-8674(87)90166-8; DIZHOOR AM, 1991, SCIENCE, V251, P915, DOI 10.1126/science.1672047; DOHLMAN HG, 1993, P NATL ACAD SCI USA, V90, P9688, DOI 10.1073/pnas.90.20.9688; DURONIO RJ, 1989, SCIENCE, V243, P796, DOI 10.1126/science.2644694; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; GALLEGO C, 1992, P NATL ACAD SCI USA, V89, P9695, DOI 10.1073/pnas.89.20.9695; HAGER KM, 1986, P NATL ACAD SCI USA, V83, P7693, DOI 10.1073/pnas.83.20.7693; Harlow E., 1988, ANTIBODIES LAB MANUA; Hepler JR, 1996, J BIOL CHEM, V271, P496, DOI 10.1074/jbc.271.1.496; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P762; HUXLEY C, 1990, TRENDS GENET, V6, P236, DOI 10.1016/0168-9525(90)90190-H; JOHNSON DR, 1993, J BIOL CHEM, V268, P483; JOHNSON DR, 1994, ANNU REV BIOCHEM, V63, P869, DOI 10.1146/annurev.bi.63.070194.004253; JONES EW, 1991, METHOD ENZYMOL, V194, P428; JONES TLZ, 1990, P NATL ACAD SCI USA, V87, P568, DOI 10.1073/pnas.87.2.568; JULIUS D, 1983, CELL, V32, P839, DOI 10.1016/0092-8674(83)90070-3; JUSTICE JM, 1995, J BIOL CHEM, V270, P17970, DOI 10.1074/jbc.270.30.17970; KOKAME K, 1992, NATURE, V359, P749, DOI 10.1038/359749a0; KUCHLER K, 1993, J CELL BIOL, V120, P1203, DOI 10.1083/jcb.120.5.1203; KURJAN J, 1992, ANNU REV BIOCHEM, V61, P1097; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; LINDER ME, 1993, P NATL ACAD SCI USA, V90, P3675, DOI 10.1073/pnas.90.8.3675; LINDER ME, 1991, J BIOL CHEM, V266, P4654; MANENTI S, 1994, J BIOL CHEM, V269, P8309; MASTERSON WJ, 1992, PROTEIN TARGETING PR; MCILHINNEY RAJ, 1990, BIOCHEM J, V271, P681, DOI 10.1042/bj2710681; MIYAJIMA I, 1987, CELL, V50, P1011, DOI 10.1016/0092-8674(87)90167-X; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P728, DOI 10.1073/pnas.87.2.728; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; NEUBERT TA, 1992, J BIOL CHEM, V267, P18274; PARENTI M, 1993, BIOCHEM J, V291, P349, DOI 10.1042/bj2910349; SCHULTZ AM, 1987, BIOCHEM BIOPH RES CO, V146, P1234, DOI 10.1016/0006-291X(87)90780-7; SCHULTZ J, 1995, CURR OPIN GENET DEV, V5, P31, DOI 10.1016/S0959-437X(95)90050-0; SIKORSKI RS, 1989, GENETICS, V122, P19; SIMONDS WF, 1989, BIOCHEM BIOPH RES CO, V164, P46, DOI 10.1016/0006-291X(89)91680-X; SPIEGEL AM, 1991, TRENDS BIOCHEM SCI, V16, P338, DOI 10.1016/0968-0004(91)90139-M; STERNWEIS PC, 1986, J BIOL CHEM, V261, P631; STONE DE, 1991, GENE DEV, V5, P1969, DOI 10.1101/gad.5.11.1969; TAUSSIG R, 1993, SCIENCE, V261, P218, DOI 10.1126/science.8327893; THELEN M, 1990, P NATL ACAD SCI USA, V87, P5603, DOI 10.1073/pnas.87.15.5603; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; VEIT M, 1994, FEBS LETT, V339, P160, DOI 10.1016/0014-5793(94)80406-0; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; WEDEGAERTNER PB, 1993, J BIOL CHEM, V268, P25001; WEDEGAERTNER PB, 1995, J BIOL CHEM, V270, P503, DOI 10.1074/jbc.270.2.503; WHITEWAY M, 1989, CELL, V56, P467, DOI 10.1016/0092-8674(89)90249-3; WHITEWAY M, 1990, MOL CELL BIOL, V10, P217, DOI 10.1128/MCB.10.1.217; WHITEWAY MS, 1995, SCIENCE, V269, P1572, DOI 10.1126/science.7667635; WILSON PT, 1995, J BIOL CHEM, V270, P9667, DOI 10.1074/jbc.270.16.9667	64	73	75	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20273	20283		10.1074/jbc.271.34.20273	http://dx.doi.org/10.1074/jbc.271.34.20273			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702760	hybrid			2022-12-25	WOS:A1996VD33700012
J	Gardella, TJ; Luck, MD; Jensen, GS; Usdin, TB; Juppner, H				Gardella, TJ; Luck, MD; Jensen, GS; Usdin, TB; Juppner, H			Converting parathyroid hormone-related peptide (PTHrP) into a potent PTH-8 receptor agonist	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NMR SOLUTION STRUCTURE; HUMORAL HYPERCALCEMIA; EXPRESSION CLONING; ADENYLATE-CYCLASE; PLASMA-MEMBRANE; BINDING DOMAINS; COMMON RECEPTOR; FRAGMENT 1-34; ROS 17/2.8; PROTEIN	Most of the bone and kidney-related functions of parathyroid hormone (PTH) and parathyroid hormone-related peptide (PTHrP) are thought to be mediated by the PTH/PTHrP receptor. Recently, a homologous receptor, the PTH-2 receptor, was obtained from rat and human brain cDNA libraries. This receptor displayed the remarkable property of responding potently to PTH, but not to PTHrP. To begin to define residues involved in the ligand specificity of the PTH-2 receptor, we studied the interaction of several PTH/PTHrP hybrid ligands and other related peptide analogs with the human PTH-2 receptor The results showed that two sites in PTH and PTHrP fully account for the different potencies that the tu o ligands exhibited with PTH-2 receptors; residue 5 (His in PTHrP and Ile in PTH) determined signaling capability, while residue 23 (Phe in PTHrP and Trp in PTH) determined binding affinity. By changing these two residues of PTHrP to the corresponding residues of PTH, we were able to convert PTHrP into a ligand that avidly bound to the PTH-2 receptor and fully and potently stimulated cAMP formation, Changing residue 23 alone yielded [Trp(23)]hPTHrP-(1-36), which was an antagonist for the PTH-2 receptor, but a fall agonist for the PTH/PTHrP receptor. Residues 5 and 23 in PTH and PTHrP thus play keg roles in signaling and binding interactions, respectively, with the PTH-2 receptor. Receptor-selective agonists and antagonists derived hom these studies could help to identify the biological role of the PTH-2 receptor and to map specific sites of ligand-receptor interaction.	MASSACHUSETTS GEN HOSP, DEPT MED, BOSTON, MA 02114 USA; MASSACHUSETTS GEN HOSP, CHILDRENS SERV, BOSTON, MA 02114 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02114 USA; NIMH, CELL BIOL LAB, BETHESDA, MD 20892 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)	Gardella, TJ (corresponding author), MASSACHUSETTS GEN HOSP, ENDOCRINE UNIT, BOSTON, MA 02114 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK011794, R01DK050708] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-50708, DK-11794] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABOUSAMRA AB, 1992, P NATL ACAD SCI USA, V89, P2732, DOI 10.1073/pnas.89.7.2732; ABOUSAMRA AB, 1989, ENDOCRINOLOGY, V125, P2215, DOI 10.1210/endo-125-4-2215; BARDEN JA, 1989, EUR J BIOCHEM, V184, P379, DOI 10.1111/j.1432-1033.1989.tb15030.x; BARDEN JA, 1993, BIOCHEMISTRY-US, V32, P7126, DOI 10.1021/bi00079a008; Broadus Arthur E., 1994, P259; BUNDI A, 1978, EUR J BIOCHEM, V91, P201, DOI 10.1111/j.1432-1033.1978.tb20952.x; CAULFIELD MP, 1990, ENDOCRINOLOGY, V127, P83, DOI 10.1210/endo-127-1-83; CAULFIELD MP, 1990, TRENDS ENDOCRINO JAN, P164; GARDELLA TJ, 1995, J BIOL CHEM, V270, P6584, DOI 10.1074/jbc.270.12.6584; GARDELLA TJ, 1992, INT CONGR SER, V1003, P218; ISHIHARA T, 1991, EMBO J, V10, P1635, DOI 10.1002/j.1460-2075.1991.tb07686.x; JELINEK LJ, 1993, SCIENCE, V259, P1614, DOI 10.1126/science.8384375; JUPPNER H, 1991, SCIENCE, V254, P1024, DOI 10.1126/science.1658941; JUPPNER H, 1988, J BIOL CHEM, V263, P8557; KARAPLIS AC, 1994, GENE DEV, V8, P277, DOI 10.1101/gad.8.3.277; KLAUS W, 1991, BIOCHEMISTRY-US, V30, P6936, DOI 10.1021/bi00242a018; KRONENBERG HM, 1993, HDB EXPT PHARM, P185; LEE CW, 1995, MOL ENDOCRINOL, V9, P1269, DOI 10.1210/me.9.10.1269; LIN HY, 1991, SCIENCE, V254, P1022, DOI 10.1126/science.1658940; MARX UC, 1995, J BIOL CHEM, V270, P15194, DOI 10.1074/jbc.270.25.15194; NAKAMOTO C, 1995, BIOCHEMISTRY-US, V34, P10546, DOI 10.1021/bi00033a029; NISSENSON RA, 1988, J BIOL CHEM, V263, P12866; NUSSBAUM SR, 1980, J BIOL CHEM, V255, P183; NUTT RF, 1990, ENDOCRINOLOGY, V127, P491, DOI 10.1210/endo-127-1-491; RAY FR, 1993, EUR J BIOCHEM, V211, P205, DOI 10.1111/j.1432-1033.1993.tb19887.x; ROSENBLATT M, 1977, ENDOCR RES COMMUN, V4, P115, DOI 10.3109/07435807709073917; SCHIPANI E, 1993, ENDOCRINOLOGY, V132, P2157, DOI 10.1210/en.132.5.2157; SHIGENO C, 1988, J BIOL CHEM, V263, P3872; URENA P, 1994, ENDOCRINOLOGY, V134, P451, DOI 10.1210/en.134.1.451; USDIN TB, 1995, J BIOL CHEM, V270, P15455, DOI 10.1074/jbc.270.26.15455	30	76	87	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					19888	19893		10.1074/jbc.271.33.19888	http://dx.doi.org/10.1074/jbc.271.33.19888			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702701	hybrid			2022-12-25	WOS:A1996VC66900042
J	Centrella, M; Ji, CH; Casinghino, S; McCarthy, TL				Centrella, M; Ji, CH; Casinghino, S; McCarthy, TL			Rapid flux in transforming growth factor-beta receptors on bone cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FETAL-RAT BONE; OSTEOBLAST-ENRICHED CULTURES; TGF-BETA; PROTEIN-KINASE; II RECEPTOR; MOLECULAR CHARACTERIZATION; PARIETAL BONE; EXPRESSION; BINDING; COLLAGEN	The proportion of transforming growth factor-beta (TGF-beta) binding among conventional membrane receptors on bone cells can vary with hormone or growth factor treatment or with the state of osteoblast-like activity and appears to determine the nature of its biological effects. Therefore, functional TGF-beta receptor stability could be an important aspect of regulation, Suppression of protein synthesis reduced TGF-beta binding to types I and II receptors with t(1/2) of 2 h and to betaglycan with t(1/2) of 6 h. In contrast, suppression of mRNA transcription reduced TGF-beta binding at least 3-fold more slowly at each receptor site, Preexposure to TGF-beta decreased its binding at all three sites within 4 h in osteoblast-enriched cultures. This effect was transient with lower TGF-beta concentrations, where the receptor profile was nearly fully restored within 24-48 h, In contrast, less differentiated bone cells were less sensitive to ligand-dependent receptor down-regulation. Agents that alter protein kinase and phosphatase activity also modified the TGF-beta binding profile in specific ways, Together, these results indicate that cell surface TGF-beta receptors turn over rapidly by ligand-independent and ligand-dependent mechanisms, demonstrate that the binding capacity of TGF-beta receptors is less stable than their mRNAs, and that functional receptor levels may be determined in part by post-transcriptional events.			Centrella, M (corresponding author), YALE UNIV,SCH MED,DEPT SURG,SECT PLAST SURG,333 CEDAR ST,POB 208041,NEW HAVEN,CT 06520, USA.				NCRR NIH HHS [BRSG/RR-05358] Funding Source: Medline; NIAMS NIH HHS [AR-39201] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR039201, R01AR039201] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Ausubel FM, 1994, CURRENT PROTOCOLS MO; BASSING CH, 1994, SCIENCE, V263, P87, DOI 10.1126/science.8272871; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARCAMO J, 1995, MOL CELL BIOL, V15, P1573; CENTRELLA M, 1994, ENDOCRINOLOGY, V135, P1611, DOI 10.1210/en.135.4.1611; CENTRELLA M, 1988, P NATL ACAD SCI USA, V85, P5889, DOI 10.1073/pnas.85.16.5889; CENTRELLA M, 1987, J BIOL CHEM, V262, P2869; CENTRELLA M, 1992, ENDOCRINOLOGY, V131, P2863, DOI 10.1210/en.131.6.2863; CENTRELLA M, 1995, MOL CELL BIOL, V15, P3273; CENTRELLA M, 1992, J CLIN INVEST, V89, P1076, DOI 10.1172/JCI115687; CENTRELLA M, 1991, MOL CELL BIOL, V11, P4490, DOI 10.1128/MCB.11.9.4490; CENTRELLA M, 1995, HORMONAL REGULATION, P221; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; DERYNCK R, 1994, CYTOKINE HDB, P419; FROLIK CA, 1984, J BIOL CHEM, V259, P995; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; IIMURA T, 1994, BIOCHEM BIOPH RES CO, V204, P918, DOI 10.1006/bbrc.1994.2547; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; LAWSON MA, 1995, NATURE, V377, P75, DOI 10.1038/377075a0; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; LIU F, 1995, MOL CELL BIOL, V15, P3479; LOPEZCASILLAS F, 1991, CELL, V67, P785, DOI 10.1016/0092-8674(91)90073-8; LOWRY OH, 1957, METHOD ENZYMOL, V4, P366, DOI 10.1016/0076-6879(57)04065-3; Massague Joan, 1994, Trends in Cell Biology, V4, P172, DOI 10.1016/0962-8924(94)90202-X; MCCARTHY TL, 1988, J BONE MINER RES, V3, P401; MIYAZONO K, 1994, ADV IMMUNOL, V55, P181; OHTSUKI M, 1992, MOL CELL BIOL, V12, P261, DOI 10.1128/MCB.12.1.261; PETERKOFSKY B, 1971, BIOCHEMISTRY-US, V10, P988, DOI 10.1021/bi00782a009; ROY SK, 1995, ENDOCRINOLOGY, V136, P4610, DOI 10.1210/en.136.10.4610; Sankar S, 1996, J CLIN INVEST, V97, P1436, DOI 10.1172/JCI118565; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; TSUCHIDA K, 1993, BIOCHEM BIOPH RES CO, V191, P790, DOI 10.1006/bbrc.1993.1286; VENTURA F, 1994, EMBO J, V13, P5581, DOI 10.1002/j.1460-2075.1994.tb06895.x; WAKEFIELD LM, 1987, J CELL BIOL, V105, P965, DOI 10.1083/jcb.105.2.965; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0	37	46	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18616	18622		10.1074/jbc.271.31.18616	http://dx.doi.org/10.1074/jbc.271.31.18616			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702513	hybrid			2022-12-25	WOS:A1996VB68300051
J	Mo, JY; Schaaper, RM				Mo, JY; Schaaper, RM			Fidelity and error specificity of the alpha catalytic subunit of Escherichia coli DNA polymerase III	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPONTANEOUS MUTATION; REVERSE-TRANSCRIPTASE; BASE SUBSTITUTION; MISMATCH REPAIR; LACI GENE; PRONE REPLICATION; HOLOENZYME; EXONUCLEASE; MUTAGENESIS; MECHANISMS	Escherichia coli DNA polymerase III holoenzyme is the replicative enzyme primarily responsible for the duplication of the E. coli chromosome. This process occurs with high accuracy, less than 10(-9) to 10(-10) errors being committed per base pair per round of replication. As a first step in understanding the mechanisms responsible for the high fidelity of this process, we have purified the polymerase III alpha catalytic subunit, free of exonuclease activity, and analyzed its fidelity in vitro. We employed a newly developed gap-filling assay using the N-terminal 250 bases of the loci gene as a forward mutational target. When synthesizing across this target, alpha subunit produced mutations at a frequency of 0.6%. DNA sequencing revealed that the mutants created in vitro consisted mostly of frameshift mutations, although some base substitutions were also observed, The frameshifts, occurring at more than 120-fold above the background, consisted largely of -1 deletions. Among them, about 80% were the deletion of a purine template base with a pyrimidine 5'-neighbor, These results suggest that the alpha subunit (i) has a relatively low ability to extend from misincorporated bases, accounting for the low level of observed base substitutions, and (ii) has a relatively high capability of extension after misalignment of a misincorporated base on the next (complementary) template base, accounting for the high level of frameshift mutations. This model is supported by an experiment in which alpha subunit was required to initiate DNA synthesis from a terminal mispair in a sequence context that allowed slippage on the next template base. Among the products of this reaction, frameshifts outnumbered base pair substitutions by greater than 70-fold. A comparison to in vivo mutational spectra suggests that the pol III accessory factors may play a major role in modulating the fidelity of DNA synthesis.	NIEHS, MOL GENET LAB, NIH, RES TRIANGLE PK, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)			Schaaper, Roel M/E-6680-2019	Schaaper, Roel M/0000-0003-1344-3196				BEBENEK K, 1993, J BIOL CHEM, V268, P10324; BEBENEK K, 1992, J BIOL CHEM, V267, P3589; BEBENEK K, 1990, P NATL ACAD SCI USA, V87, P4946, DOI 10.1073/pnas.87.13.4946; BEBENEK K, 1990, J BIOL CHEM, V265, P13878; BEBENEK K, 1989, J BIOL CHEM, V264, P16948; BOOSALIS MS, 1989, J BIOL CHEM, V264, P11360; BOOSALIS MS, 1987, J BIOL CHEM, V262, P14689; CAI H, 1995, J BIOL CHEM, V270, P15327, DOI 10.1074/jbc.270.25.15327; CAPSON TL, 1992, BIOCHEMISTRY-US, V31, P10984, DOI 10.1021/bi00160a007; CARRAWAY M, 1990, MOL MICROBIOL, V4, P1645, DOI 10.1111/j.1365-2958.1990.tb00541.x; DELSAL G, 1989, BIOTECHNIQUES, V7, P514; DONLIN MJ, 1991, BIOCHEMISTRY-US, V30, P538, DOI 10.1021/bi00216a031; DOWER WJ, 1988, NUCLEIC ACIDS RES, V16, P6127, DOI 10.1093/nar/16.13.6127; DRAKE JW, 1991, P NATL ACAD SCI USA, V88, P7160, DOI 10.1073/pnas.88.16.7160; ECHOLS H, 1983, P NATL ACAD SCI-BIOL, V80, P2189, DOI 10.1073/pnas.80.8.2189; FARABAUGH PJ, 1978, NATURE, V274, P765, DOI 10.1038/274765a0; FERSHT AR, 1981, P NATL ACAD SCI-BIOL, V78, P4251, DOI 10.1073/pnas.78.7.4251; Fijalkowska IJ, 1996, P NATL ACAD SCI USA, V93, P2856, DOI 10.1073/pnas.93.7.2856; HUYNH TV, 1985, DNA CLONING, V1, P56; JOYCE CM, 1992, J BIOL CHEM, V267, P24485; KELMAN Z, 1995, ANNU REV BIOCHEM, V64, P171, DOI 10.1146/annurev.bi.64.070195.001131; Kornberg A., 1992, DNA REPLICATION, P165; KUCHTA RD, 1988, BIOCHEMISTRY-US, V27, P6716, DOI 10.1021/bi00418a012; KUNKEL TA, 1989, MOL CELL BIOL, V9, P4447, DOI 10.1128/MCB.9.10.4447; KUNKEL TA, 1985, J BIOL CHEM, V260, P5787; KUNKEL TA, 1985, J BIOL CHEM, V260, P2866; KUNKEL TA, 1988, J BIOL CHEM, V263, P4450; KUNKEL TA, 1986, J BIOL CHEM, V261, P160; KUNKEL TA, 1990, BIOCHEMISTRY-US, V29, P8003, DOI 10.1021/bi00487a001; KUNKEL TA, 1994, P NATL ACAD SCI USA, V91, P6830, DOI 10.1073/pnas.91.15.6830; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAKI H, 1987, P NATL ACAD SCI USA, V84, P4389, DOI 10.1073/pnas.84.13.4389; MAKI H, 1991, J BIOL CHEM, V266, P5055; MAKI H, 1985, J BIOL CHEM, V260, P2987; MAKI H, 1988, J BIOL CHEM, V263, P6570; MCHENRY CS, 1988, ANNU REV BIOCHEM, V57, P519; MENDELMAN LV, 1990, J BIOL CHEM, V265, P2338; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; OLLER AR, 1994, GENETICS, V138, P263; OLLER AR, 1992, P NATL ACAD SCI USA, V89, P11036, DOI 10.1073/pnas.89.22.11036; PERRINO FW, 1989, J BIOL CHEM, V264, P2898; ROBERTS JD, 1989, MOL CELL BIOL, V9, P469, DOI 10.1128/MCB.9.2.469; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAAPER RM, 1991, GENETICS, V129, P317; SCHAAPER RM, 1987, P NATL ACAD SCI USA, V84, P6220, DOI 10.1073/pnas.84.17.6220; SCHAAPER RM, 1985, GENE, V39, P181, DOI 10.1016/0378-1119(85)90312-9; SCHAAPER RM, 1986, J MOL BIOL, V189, P273, DOI 10.1016/0022-2836(86)90509-7; SCHAAPER RM, 1988, P NATL ACAD SCI USA, V85, P8126, DOI 10.1073/pnas.85.21.8126; SCHAAPER RM, 1993, J BIOL CHEM, V268, P23762; SCHAAPER RM, 1993, GENETICS, V134, P1031; SCHEUERMANN RH, 1984, P NATL ACAD SCI-BIOL, V81, P7747, DOI 10.1073/pnas.81.24.7747; SLOANE DL, 1988, NUCLEIC ACIDS RES, V16, P6465, DOI 10.1093/nar/16.14.6465; STREISINGER G, 1985, GENETICS, V109, P633; STREISINGER G, 1966, COLD SPRING HARB SYM, V31, P77, DOI 10.1101/SQB.1966.031.01.014; THOMAS DC, 1991, BIOCHEMISTRY-US, V30, P11751, DOI 10.1021/bi00115a003; TINDALL KR, 1988, BIOCHEMISTRY-US, V27, P6008, DOI 10.1021/bi00416a027; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YU H, 1992, J BIOL CHEM, V267, P10888	58	41	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18947	18953		10.1074/jbc.271.31.18947	http://dx.doi.org/10.1074/jbc.271.31.18947			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702558	hybrid			2022-12-25	WOS:A1996VB68300096
J	Channareddy, S; Jose, SS; Eryomin, VA; Rubin, E; Taraschi, TF; Janes, N				Channareddy, S; Jose, SS; Eryomin, VA; Rubin, E; Taraschi, TF; Janes, N			Saturable ethanol binding in rat liver microsomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONELECTROLYTE PARTITION; MEMBRANES; WATER; COEFFICIENTS; LIPOSOMES	The binding of ethanol to rat liver microsomes is shown to be saturable at clinically relevant ethanol concentrations, whereas this effect is not observed in extracted microsomal phospholipids. Brief exposure of the microsomes to heat abolishes saturable ethanol binding. Equilibrium binding data analysis, although only approximate in this context, suggests the presence of at least two groups of specific sites: high capacity sites with affinities near the pharmacological range and low capacity sites at lesser levels. The results indicate that the specificity of ethanol for tissue is considerably greater than previously recognized.	THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DEPT PATHOL ANAT & CELL BIOL,PHILADELPHIA,PA 19107	Jefferson University					NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [P50AA007186, K21AA000163] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA07215, AA07186, AA00163] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Bennett J., 1985, NEUROTRANSMITTER REC, V2nd, P61; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; DEITRICH RA, 1989, PHARMACOL REV, V41, P489; DEPIERRE JW, 1977, ANNU REV BIOCHEM, V46, P201, DOI 10.1146/annurev.bi.46.070177.001221; Dubey AK, 1996, BIOPHYS J, V70, P2307, DOI 10.1016/S0006-3495(96)79796-5; ELLINGSON JS, 1991, BIOCHIM BIOPHYS ACTA, V1062, P199, DOI 10.1016/0005-2736(91)90393-M; ELMAGHRABI EA, 1992, P NATL ACAD SCI USA, V89, P4329, DOI 10.1073/pnas.89.10.4329; HOEK JB, 1992, FASEB J, V6, P2386, DOI 10.1096/fasebj.6.7.1563591; JANES N, 1992, BIOCHEMISTRY-US, V31, P9467, DOI 10.1021/bi00154a020; JOLY JG, 1973, BIOCHEM PHARMACOL, V22, P1532, DOI 10.1016/0006-2952(73)90334-1; Kates M., 1986, TECHNIQUES LIPIDOLOG; KATZ Y, 1974, J MEMBRANE BIOL, V17, P87, DOI 10.1007/BF01870174; KATZ Y, 1974, J MEMBRANE BIOL, V17, P69, DOI 10.1007/BF01870173; KATZ Y, 1974, J MEMBRANE BIOL, V17, P101, DOI 10.1007/BF01870175; KLOTZ IM, 1982, SCIENCE, V217, P1247, DOI 10.1126/science.6287580; LEO A, 1971, CHEM REV, V71, P525, DOI 10.1021/cr60274a001; Lieber C. S., 1992, MED NUTR COMPLICATIO; NILSSON R, 1973, J CELL BIOL, V56, P762, DOI 10.1083/jcb.56.3.762; OMURA T, 1964, J BIOL CHEM, V239, P2379; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; TARASCHI TF, 1985, BIOCHEMISTRY-US, V24, P7096, DOI 10.1021/bi00346a012; TARASCHI TF, 1985, LAB INVEST, V52, P120	22	10	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					17625	17628		10.1074/jbc.271.30.17625	http://dx.doi.org/10.1074/jbc.271.30.17625			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663606	hybrid			2022-12-25	WOS:A1996UY93500009
J	Weinberg, DH; Sirinathsinghji, DJS; Tan, CP; Shiao, LL; Morin, N; Rigby, MR; Heavens, RH; Rapoport, DR; Bayne, ML; Cascieri, MA; Strader, CD; Linemeyer, DL; MacNeil, DJ				Weinberg, DH; Sirinathsinghji, DJS; Tan, CP; Shiao, LL; Morin, N; Rigby, MR; Heavens, RH; Rapoport, DR; Bayne, ML; Cascieri, MA; Strader, CD; Linemeyer, DL; MacNeil, DJ			Cloning and expression of a novel neuropeptide Y receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; PEPTIDE-YY; BRAIN	The neuropeptide Y family of peptides, which includes neuropeptide Y (NPY), peptide YY (PYY), and pancreatic polypeptide (PP), are found in the central and peripheral nervous system and display a wide array of biological activities. These actions are believed to be mediated through pharmacologically distinct G protein-coupled receptors, and, to date, three members of the NPY receptor family have been cloned. In this study we describe the cloning and expression of a novel NPY receptor from mouse genomic DNA. This receptor, designated NPY Y5, shares 60% amino acid identity to the murine NPY Y1 receptor. The pharmacology of this novel receptor resembles that of the NPY Y1 receptor and is distinct from that described for the NPY Y2, Y3, and Y4 receptors. In situ hybridization of mouse brain sections reveals expression of this receptor within discrete regions of the hypothalamus including the suprachiasmatic nucleus, anterior hypothalamus, bed nucleus stria terminalis, and the ventromedial nucleus with no localization apparent elsewhere in the brain.			Weinberg, DH (corresponding author), MERCK & CO INC,MERCK SHARP & DOHME RES LABS,DEPT MOLEC PHARMACOL & BIOCHEM,POB 2000,R80M-213,RAHWAY,NJ 07065, USA.			MacNeil, Doug/0000-0001-7089-0668				AKABAYASHI A, 1994, MOL BRAIN RES, V21, P55, DOI 10.1016/0169-328X(94)90377-8; ALLEN YS, 1983, SCIENCE, V221, P877, DOI 10.1126/science.6136091; BALLANTYNE GH, 1993, AM J PHYSIOL, V264, pG848, DOI 10.1152/ajpgi.1993.264.5.G848; BARD JA, 1995, J BIOL CHEM, V270, P26762, DOI 10.1074/jbc.270.45.26762; CASCIERI MA, 1992, MOL PHARMACOL, V42, P458; EVA C, 1992, FEBS LETT, V314, P285, DOI 10.1016/0014-5793(92)81490-D; EVA C, 1990, FEBS LETT, V271, P81, DOI 10.1016/0014-5793(90)80377-U; FUHLENDORFF J, 1990, P NATL ACAD SCI USA, V87, P182, DOI 10.1073/pnas.87.1.182; GERALD C, 1995, J BIOL CHEM, V270, P26758, DOI 10.1074/jbc.270.45.26758; GRUNDEMAR L, 1991, J PHARMACOL EXP THER, V258, P633; HERZOG H, 1992, P NATL ACAD SCI USA, V89, P5794, DOI 10.1073/pnas.89.13.5794; LARHAMMAR D, 1992, J BIOL CHEM, V267, P10935; LUNDELL I, 1995, J BIOL CHEM, V270, P29123, DOI 10.1074/jbc.270.49.29123; PROBST WC, 1992, DNA CELL BIOL, V11, P1, DOI 10.1089/dna.1992.11.1; QUIN JA, 1995, J SURG RES, V58, P111, DOI 10.1006/jsre.1995.1018; ROSE PM, 1995, J BIOL CHEM, V270, P22661, DOI 10.1074/jbc.270.39.22661; SIRINATHSINGHJI DJS, 1995, NEUROSCIENCE, V65, P51, DOI 10.1016/0306-4522(94)00485-N; SIRINATHSINGHJI DS, 1993, MOL IMAGING NEUROSCI, P43; Stanley B.G., 1993, BIOL NEUROPEPTIDE RE, P457, DOI [10.1007/978-1-59259-465-8_11, DOI 10.1007/978-1-59259-465-8_11]; STANLEY BG, 1985, P NATL ACAD SCI USA, V82, P3940, DOI 10.1073/pnas.82.11.3940; STANLEY BG, 1993, BRAIN RES, V604, P304; STANLEY BG, 1992, PEPTIDES, V13, P581, DOI 10.1016/0196-9781(92)90093-I; STEPHENS TW, 1995, NATURE, V377, P530, DOI 10.1038/377530a0; TATEMOTO K, 1982, NATURE, V296, P659, DOI 10.1038/296659a0; WAHLESTEDT C, 1986, REGUL PEPTIDES, V13, P307, DOI 10.1016/0167-0115(86)90048-0; WAHLESTEDT C, 1993, ANN REV PHARM TOXICO, V32, P309	26	242	262	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16435	16438		10.1074/jbc.271.28.16435	http://dx.doi.org/10.1074/jbc.271.28.16435			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663568				2022-12-25	WOS:A1996UX12600002
J	Shao, NS; Chai, YL; Shyam, E; Reddy, P; Rao, NV				Shao, NS; Chai, YL; Shyam, E; Reddy, P; Rao, NV			Induction of apoptosis by the tumor suppressor protein BRCA1	ONCOGENE			English	Article						BRCA1 proteins; tumor suppressor; breast and ovarian cancers; apoptosis; therapy		The breast and ovarian cancer susceptibility gene BRCA1, is a nuclear phosphoprotein which functions as a tumor suppressor, To investigate the role of BRCA1 in apoptosis, we have developed mouse fibroblast cell lines and human breast cancer cell lines expressing BRCA1, The expression of BRCA1 protein in the BRCA1 transfectants were analysed by immunofluorescence and immunohistochemistry. The BRCA1 transfectants showed a flattened morphology compared to the parental cells, We show that serum deprivation or calcium ionophore treatment of BRCA1 transfectants resulted in programmed cell death, These results indicate that BRCA1 genes may play a critical role in the regulation of apoptosis, Thus, since a wide variety of human malignancies like breast and ovarian cancers have a decreased ability to undergo apoptosis, this could be due to lack/decreased levels of functional BRCA1 proteins, Treatments that are aimed at increasing the apoptotic threshold by BRCA1 gene therapy may have the potential to prevent the progression of these malignancies.	JEFFERSON MED COLL,DEPT MICROBIOL & IMMUNOL,KIMMEL CANC INST,PHILADELPHIA,PA 19107	Jefferson University					NCI NIH HHS [CA58642, CA57322] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058642, R01CA057322] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BENDALL LJ, 1994, EXP HEMATOL, V22, P1252; CHEN YM, 1995, SCIENCE, V270, P789, DOI 10.1126/science.270.5237.789; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; GUDAS JM, 1995, CANCER RES, V55, P4561; HOFFMAN B, 1994, ONCOGENE, V9, P1807; JIMENEZ B, 1995, ONCOGENE, V10, P811; KONDO S, 1995, ONCOGENE, V10, P2001; LANE TF, 1995, GENE DEV, V9, P2712, DOI 10.1101/gad.9.21.2712; MARQUIS ST, 1995, NAT GENET, V11, P17, DOI 10.1038/ng0995-17; MCCONKEY DJ, 1989, FASEB J, V3, P1843, DOI 10.1096/fasebj.3.7.2497041; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; OBERHAMMER FA, 1994, J CELL BIOL, V126, P827, DOI 10.1083/jcb.126.4.827; Rao VN, 1996, ONCOGENE, V12, P523; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	16	139	145	0	10	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 4	1996	13	1					1	7						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UX319	8700535				2022-12-25	WOS:A1996UX31900001
J	Roy, LM; Haccard, O; Izumi, T; Lattes, BG; Lewellyn, AL; Maller, JL				Roy, LM; Haccard, O; Izumi, T; Lattes, BG; Lewellyn, AL; Maller, JL			Mos proto-oncogene function during oocyte maturation in Xenopus	ONCOGENE			English	Article						Mos; MAP kinase; cell cycle; xenopus oocyte; proto-oncogene	MEIOTIC MATURATION; CYTOSTATIC FACTOR; MAP KINASE; PROTOONCOGENE PRODUCT; PROMOTING FACTOR; CELL-CYCLE; EGGS; REQUIREMENT; METAPHASE; ARREST	The function of the Xenopus c-mos proto-oncogene product (Mos(xe)) has been investigated during oocyte maturation, Experiments with a new antibody able to immunoblot Mos(xe) demonstrated the time course of MAP kinase (MAP K) activation in oocytes paralleled Mos(xe) accumulation, and in activated eggs the deactivation of MAP K paralleled the degradation of Mos(xe), Ablation of Mos synthesis by microinjection of antisense oligodeoxynucleotides abolished activation of MAP K by progesterone, but microinjection of GST-Mos fully restored both MAP K activation and germinal vesicle breakdown (GVBD), The Mos(xe) level at metaphase of Meiosis I(MI) was 2-3-fold less than that at metaphase of Meiosis II (MII), but MAP K activation was maximal at metaphase in both MI and MII, In the transition between MI and MII, both cyclin B and Mos(xe) levels rapidly declined in the presence of cycloheximide and injection of exogenous GST-Mos(xe) did not prevent degradation of either protein, although MAP K was activated, Microinjection of GST-Mos(xe) into oocytes was able to activate MAP K before GVBD and H1 kinase activation, and microinjection of constitutively-activated thiophosphorylated MAP K induced de novo synthesis of Mos(xe) before H1 kinase activation, suggesting the existence of a positive feedback loop between MAP K and Mos(xe) accumulation.	UNIV COLORADO,SCH MED,HOWARD HUGHES MED INST,DENVER,CO 80262; UNIV COLORADO,SCH MED,DEPT PHARMACOL,DENVER,CO 80262	Howard Hughes Medical Institute; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver				Haccard, Olivier/0000-0002-4305-2746	NCI NIH HHS [F32CA0981] Funding Source: Medline; NIDDK NIH HHS [DK28353] Funding Source: Medline; NIGMS NIH HHS [GM26743] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028353] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026743] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARRETT CB, 1990, MOL CELL BIOL, V10, P310, DOI 10.1128/MCB.10.1.310; DAAR I, 1991, J CELL BIOL, V114, P329, DOI 10.1083/jcb.114.2.329; FABIAN JR, 1993, J CELL BIOL, V122, P645, DOI 10.1083/jcb.122.3.645; FREEMAN RS, 1989, P NATL ACAD SCI USA, V86, P5805, DOI 10.1073/pnas.86.15.5805; FREEMAN RS, 1992, J CELL BIOL, V116, P725, DOI 10.1083/jcb.116.3.725; FURUNO N, 1994, EMBO J, V13, P2399, DOI 10.1002/j.1460-2075.1994.tb06524.x; GABRIELLI BG, 1993, SCIENCE, V259, P1766, DOI 10.1126/science.8456304; GABRIELLI BG, 1992, J BIOL CHEM, V267, P18040; GAUTIER J, 1990, CELL, V60, P487, DOI 10.1016/0092-8674(90)90599-A; GERHART J, 1984, J CELL BIOL, V98, P1247, DOI 10.1083/jcb.98.4.1247; HACCARD O, 1995, DEV BIOL, V168, P677, DOI 10.1006/dbio.1995.1112; HACCARD O, 1993, SCIENCE, V262, P1262, DOI 10.1126/science.8235656; HAYLES J, 1994, CELL, V78, P813, DOI 10.1016/S0092-8674(94)90542-8; HUANG WD, 1995, MOL BIOL CELL, V6, P237, DOI 10.1091/mbc.6.3.237; HUCHON D, 1993, BIOL CELL, V77, P133, DOI 10.1016/S0248-4900(05)80181-9; IZUMI T, 1993, MOL BIOL CELL, V4, P1337, DOI 10.1091/mbc.4.12.1337; KANKI JP, 1991, P NATL ACAD SCI USA, V88, P5794, DOI 10.1073/pnas.88.13.5794; KOBAYASHI H, 1991, J CELL BIOL, V114, P755, DOI 10.1083/jcb.114.4.755; KOSAKO H, 1994, J BIOL CHEM, V269, P28354; KOSAKO H, 1994, EMBO J, V13, P2131, DOI 10.1002/j.1460-2075.1994.tb06489.x; LORCA T, 1991, EMBO J, V10, P2087, DOI 10.1002/j.1460-2075.1991.tb07741.x; MASUI Y, 1971, J EXP ZOOL, V177, P129, DOI 10.1002/jez.1401770202; MINSHULL J, 1991, J CELL BIOL, V114, P767, DOI 10.1083/jcb.114.4.767; MUSLIN AJ, 1993, MOL CELL BIOL, V13, P4197, DOI 10.1128/MCB.13.7.4197; NEBREDA AR, 1993, EMBO J, V12, P1979, DOI 10.1002/j.1460-2075.1993.tb05847.x; NISHIZAWA M, 1993, EMBO J, V12, P4021, DOI 10.1002/j.1460-2075.1993.tb06080.x; NISHIZAWA M, 1992, EMBO J, V11, P2433, DOI 10.1002/j.1460-2075.1992.tb05308.x; OCONNELL MJ, 1994, CURR OPIN CELL BIOL, V6, P867, DOI 10.1016/0955-0674(94)90058-2; PIWNICAWORMS H, 1990, CURRENT PROTOCOLS MO; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; REMPEL RE, 1995, J BIOL CHEM, V270, P6843, DOI 10.1074/jbc.270.12.6843; ROY LM, 1990, CELL, V61, P825, DOI 10.1016/0092-8674(90)90192-H; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; SAGATA N, 1989, SCIENCE, V245, P643, DOI 10.1126/science.2474853; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; SHIBUYA EK, 1993, MOL BIOL CELL, V4, P781, DOI 10.1091/mbc.4.8.781; VANRENTERGHEM BB, 1993, J BIOL CHEM, V268, P11935; WASSERMAN WJ, 1982, DEV BIOL, V89, P152, DOI 10.1016/0012-1606(82)90303-7; WATANABE N, 1989, NATURE, V342, P505, DOI 10.1038/342505a0; WATANABE N, 1991, NATURE, V352, P247, DOI 10.1038/352247a0; WEBER M, 1991, DEV BIOL, V148, P393, DOI 10.1016/0012-1606(91)90347-6; YEW N, 1992, NATURE, V355, P649, DOI 10.1038/355649a0; ZHAO X, 1990, ONCOGENE, V5, P1727	43	88	88	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 16	1996	12	10					2203	2211						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UP283	8668347				2022-12-25	WOS:A1996UP28300020
J	Gustafson, KS; Ginder, GD				Gustafson, KS; Ginder, GD			Interferon-gamma induction of the human leukocyte antigen-E gene is mediated through binding of a complex containing STAT1 alpha to a distinct interferon-gamma-responsive element	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLASS-I GENES; PROTEIN-TYROSINE KINASE; EPIDERMAL GROWTH-FACTOR; MUTANT-CELL LINE; IFN-BETA-GENE; TRANSCRIPTION FACTOR; DNA-BINDING; REGULATORY FACTOR; SIGNAL-TRANSDUCTION; HLA-E	Expression of the human major histocompatibility complex (MHC) class I genes has been shown previously to increase at the transcriptional level following exposure to interferon-gamma (IFN-gamma). In this report we have examined the molecular mechanisms involved in the IFN gamma-induced transcription of the human MHC class I gene, HLA-E. Functional analysis of CAT reporter gene constructs under the control of the HLA-E promoter transfected into U937 cells revealed the presence of a distinct IFN-gamma-responsive element, termed the interferon response region (IRR), that was necessary and sufficient to mediate the response to IFN-gamma. This cis-acting regulatory sequence contains an imperfect inverted repeat; the 5'-half of the IRR resembles the IFN-gamma activation site (GAS), and the 3'-half of the IRR resembles the interferon-stimulated response element (ISRE). Gel mobility shift assays demonstrated that the IRR bound a single, specific, IFN-gamma-induced complex (IRR-AC), which was formed rapidly following treatment with IFN-gamma and was independent of protein synthesis. Competition experiments with GAS and ISRE sequences from other IFN-inducible genes showed that GAS sequences competed for the IRR-AC, whereas ISRE sequences did not compete. Mutational analysis demonstrated that point mutations in either the 5'-half or 3'-half of the IRR prevented binding of the complex and abrogated or markedly reduced the IFN-gamma responsiveness of reporter gene constructs. Supershift analysis revealed that the IRR-AC contains a factor that was recognized by antibodies specific for the protein STAT1 alpha (signal transducer and activator of transcription). Taken together, these findings suggest that the mechanism of IFN-gamma-induced transcription of the HLA-E gene is distinct from that of other MHC class I genes.	UNIV MINNESOTA,INST HUMAN GENET,DIV ONCOL,DEPT MED,MINNEAPOLIS,MN 55455; UNIV MINNESOTA,CTR CANC,MINNEAPOLIS,MN 55455	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities					NATIONAL CANCER INSTITUTE [R01CA045634] Funding Source: NIH RePORTER; NCI NIH HHS [CA45634] Funding Source: Medline; NIGMS NIH HHS [GM08244] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABDULKADIR SA, 1995, J EXP MED, V182, P487, DOI 10.1084/jem.182.2.487; AU WC, 1995, P NATL ACAD SCI USA, V92, P11657, DOI 10.1073/pnas.92.25.11657; BLANAR MA, 1989, EMBO J, V8, P1139, DOI 10.1002/j.1460-2075.1989.tb03484.x; BLUYSSEN HAR, 1995, P NATL ACAD SCI USA, V92, P5645, DOI 10.1073/pnas.92.12.5645; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CALDENHOVEN E, 1994, J BIOL CHEM, V269, P21146; CHANG CH, 1992, IMMUNOGENETICS, V35, P378; CHEN E, 1986, MOL CELL BIOL, V6, P1698, DOI 10.1128/MCB.6.5.1698; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DECKER T, 1989, EMBO J, V8, P2009, DOI 10.1002/j.1460-2075.1989.tb03608.x; DECKER T, 1991, EMBO J, V10, P927, DOI 10.1002/j.1460-2075.1991.tb08026.x; Demaeyer E., 1988, INTERFERONS OTHER RE; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DRIGGERS PH, 1990, P NATL ACAD SCI USA, V87, P3743, DOI 10.1073/pnas.87.10.3743; DU W, 1993, CELL, V74, P887, DOI 10.1016/0092-8674(93)90468-6; FU XY, 1990, P NATL ACAD SCI USA, V87, P8555, DOI 10.1073/pnas.87.21.8555; GUYER NB, 1995, J IMMUNOL, V155, P3472; HAKEM R, 1991, J IMMUNOL, V147, P2384; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; HAYES TE, 1987, P NATL ACAD SCI USA, V84, P1272, DOI 10.1073/pnas.84.5.1272; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; IMANI F, 1991, P NATL ACAD SCI USA, V88, P10475, DOI 10.1073/pnas.88.23.10475; ISRAEL A, 1986, NATURE, V322, P743, DOI 10.1038/322743a0; JACKSON PD, 1989, GENE DEV, V3, P1860, DOI 10.1101/gad.3.12a.1860; KANNO Y, 1993, MOL CELL BIOL, V13, P3951, DOI 10.1128/MCB.13.7.3951; KESSLER DS, 1990, GENE DEV, V4, P1753, DOI 10.1101/gad.4.10.1753; KHAN KD, 1993, P NATL ACAD SCI USA, V90, P6806, DOI 10.1073/pnas.90.14.6806; KOLLER BH, 1988, J IMMUNOL, V141, P897; KORBER B, 1988, SCIENCE, V239, P1302, DOI 10.1126/science.3125612; KORBER B, 1987, P NATL ACAD SCI USA, V84, P3380, DOI 10.1073/pnas.84.10.3380; LARNER AC, 1984, P NATL ACAD SCI-BIOL, V81, P6733, DOI 10.1073/pnas.81.21.6733; LEVY DE, 1988, GENE DEV, V2, P383, DOI 10.1101/gad.2.4.383; LEVY DE, 1989, GENE DEV, V3, P1362, DOI 10.1101/gad.3.9.1362; LEW DJ, 1991, MOL CELL BIOL, V11, P182, DOI 10.1128/MCB.11.1.182; LEWIS H, 1994, MOL CELL BIOL, V14, P5701, DOI 10.1128/MCB.14.9.5701; Maxam A M, 1980, Methods Enzymol, V65, P499; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; MULLER M, 1993, EMBO J, V12, P4221, DOI 10.1002/j.1460-2075.1993.tb06106.x; PAMER EG, 1992, CELL, V70, P215, DOI 10.1016/0092-8674(92)90097-V; PEARSE RN, 1993, P NATL ACAD SCI USA, V90, P4314, DOI 10.1073/pnas.90.9.4314; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; PINE R, 1990, MOL CELL BIOL, V10, P2448, DOI 10.1128/MCB.10.6.2448; PLOEGH HL, 1981, CELL, V24, P287, DOI 10.1016/0092-8674(81)90318-4; QUELLE FW, 1995, J BIOL CHEM, V270, P20775, DOI 10.1074/jbc.270.35.20775; QUILLET A, 1988, J IMMUNOL, V141, P17; RAZ R, 1994, J BIOL CHEM, V269, P24391; REID LE, 1989, P NATL ACAD SCI USA, V86, P840, DOI 10.1073/pnas.86.3.840; REVEL M, 1986, TRENDS BIOCHEM SCI, V11, P166, DOI 10.1016/0968-0004(86)90134-9; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SEIDEL HM, 1995, P NATL ACAD SCI USA, V92, P3041, DOI 10.1073/pnas.92.7.3041; SHAWAR SM, 1994, ANNU REV IMMUNOL, V12, P839, DOI 10.1146/annurev.immunol.12.1.839; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; SHUAI K, 1994, CURR OPIN CELL BIOL, V6, P253, DOI 10.1016/0955-0674(94)90144-9; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; SIMS SH, 1993, MOL CELL BIOL, V13, P690, DOI 10.1128/MCB.13.1.690; STORKUS WJ, 1989, J IMMUNOL, V143, P3853; STREHLOW I, 1993, J BIOL CHEM, V268, P16590; STROYNOWSKI I, 1994, CURR OPIN IMMUNOL, V6, P38, DOI 10.1016/0952-7915(94)90031-0; SUGITA K, 1987, MOL CELL BIOL, V7, P2625, DOI 10.1128/MCB.7.7.2625; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125; ULBRECHT M, 1992, J IMMUNOL, V149, P2945; VEALS SA, 1992, MOL CELL BIOL, V12, P3315, DOI 10.1128/MCB.12.8.3315; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; WALLACH D, 1982, NATURE, V299, P833, DOI 10.1038/299833a0; WARING JF, 1995, J BIOL CHEM, V270, P12276, DOI 10.1074/jbc.270.20.12276; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0; WEI XH, 1990, HUM IMMUNOL, V29, P131, DOI 10.1016/0198-8859(90)90076-2; WHITLEY MZ, 1994, MOL CELL BIOL, V14, P6464, DOI 10.1128/MCB.14.10.6464; WONG P, 1994, MOL CELL BIOL, V14, P914, DOI 10.1128/MCB.14.2.914; YUAN JP, 1994, MOL CELL BIOL, V14, P1657, DOI 10.1128/MCB.14.3.1657; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	76	50	50	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					20035	20046		10.1074/jbc.271.33.20035	http://dx.doi.org/10.1074/jbc.271.33.20035			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702722	hybrid			2022-12-25	WOS:A1996VC66900063
J	Shields, JM; Christy, RJ; Yang, VW				Shields, JM; Christy, RJ; Yang, VW			Identification and characterization of a gene encoding a gut-enriched Kruppel-like factor expressed during growth arrest	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZINC FINGER PROTEINS; DNA-BINDING DOMAINS; NUCLEAR PROTEINS; TRANSCRIPTIONAL PROPERTIES; MULTIGENE FAMILY; CACCC ELEMENT; C-FOS; SEQUENCES; CELLS; ACID	A cDNA clone, named gut-enriched Kruppel-like factor (GKLF), was isolated from an NIH 3T3 library using a probe encoding the zinc finger region of the immediate-early transcription factor zif/268. The deduced GKLF amino acid sequence contains three tandem zinc fingers that are related to members of the Kruppel family of transcription factors. By indirect immunofluorescence, GKLF is localized to the cell nucleus. In cultured fibroblasts, GKLF mRNA is found in high levels in growth-arrested cells and is nearly undetectable in cells that are in the exponential phase of proliferation. The growth-arresting nature of GKLF is demonstrated by an inhibition of DNA synthesis in cells transfected with a GKLF-expressing plasmid construct. In the mouse, GKLF mRNA is present in select tissues and is most abundant in the colon, followed by the testis, lung, and small intestine. In situ hybridization experiments indicate that GKLF mRNA is enriched in epithelial cells located in the middle to upper crypt region of the colonic mucosa. Taken together, these results suggest that GKLF is potentially a negative regulator of cell growth in tissues such as the gut mucosa, where cell proliferation is intimately coupled to growth arrest and differentiation.	JOHNS HOPKINS UNIV,SCH MED,DEPT MED,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT BIOL CHEM,BALTIMORE,MD 21205; UNIV TEXAS,HLTH SCI CTR,INST BIOTECHNOL,CTR MOL MED,SAN ANTONIO,TX 78250	Johns Hopkins University; Johns Hopkins University; University of Texas System; University of Texas Health San Antonio					NATIONAL CANCER INSTITUTE [R01CA084197] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052230, P01DK044484] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA084197] Funding Source: Medline; NIDDK NIH HHS [P01 DK044484-100005, R01 DK052230-03, R01 DK052230] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALEXANDROPOULOS K, 1995, P NATL ACAD SCI USA, V92, P3110, DOI 10.1073/pnas.92.8.3110; ANDERSON KP, 1995, MOL CELL BIOL, V15, P5957; Ausubel FM., 2006, ENZYMATIC MANIPULATI; BELLEFROID EJ, 1991, P NATL ACAD SCI USA, V88, P3608, DOI 10.1073/pnas.88.9.3608; BERG JM, 1990, ANNU REV BIOPHYS BIO, V19, P405; BERG JM, 1992, P NATL ACAD SCI USA, V89, P11109, DOI 10.1073/pnas.89.23.11109; Boulikas Teni, 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P193; BRANCOLINI C, 1992, J CELL BIOL, V117, P1251, DOI 10.1083/jcb.117.6.1251; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CAO XM, 1993, J BIOL CHEM, V268, P16949; CHEVAILLIER P, 1993, INT J BIOCHEM, V25, P479, DOI 10.1016/0020-711X(93)90653-V; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOWDHURY K, 1987, CELL, V48, P771, DOI 10.1016/0092-8674(87)90074-2; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; CICCARELLI C, 1990, MOL CELL BIOL, V10, P1525, DOI 10.1128/MCB.10.4.1525; DELSAL G, 1992, CELL, V70, P595, DOI 10.1016/0092-8674(92)90429-G; DUBOIS RN, 1990, J BIOL CHEM, V265, P19185; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; FRASER PD, 1993, BIOCHEM J, V291, P687, DOI 10.1042/bj2910687; GORDON JI, 1992, FASEB J, V6, P3039, DOI 10.1096/fasebj.6.12.1521737; GORSKI DH, 1993, MOL CELL BIOL, V13, P3722, DOI 10.1128/MCB.13.6.3722; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HAMIL KG, 1994, ENDOCRINOLOGY, V134, P1205, DOI 10.1210/en.134.3.1205; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HARTZOG GA, 1993, MOL CELL BIOL, V13, P44, DOI 10.1128/MCB.13.1.44; HOOVERS JMN, 1992, GENOMICS, V12, P254, DOI 10.1016/0888-7543(92)90372-Y; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KINZLER KW, 1988, NATURE, V332, P371, DOI 10.1038/332371a0; KLUG A, 1995, FASEB J, V9, P597, DOI 10.1096/fasebj.9.8.7768350; KNOCHEL W, 1989, P NATL ACAD SCI USA, V86, P6097, DOI 10.1073/pnas.86.16.6097; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANAHAN A, 1992, MOL CELL BIOL, V12, P3919, DOI 10.1128/MCB.12.9.3919; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; MANFIOLETTI G, 1990, MOL CELL BIOL, V10, P2924, DOI 10.1128/MCB.10.6.2924; MILLER IJ, 1993, MOL CELL BIOL, V13, P2776, DOI 10.1128/MCB.13.5.2776; MORRIS JF, 1994, MOL CELL BIOL, V14, P1786, DOI 10.1128/MCB.14.3.1786; NAKAMURA T, 1993, P NATL ACAD SCI USA, V90, P4631, DOI 10.1073/pnas.90.10.4631; NARDELLI J, 1991, NATURE, V349, P175, DOI 10.1038/349175a0; OLIVA MM, 1993, ARCH BIOCHEM BIOPHYS, V302, P183, DOI 10.1006/abbi.1993.1197; PIELER T, 1994, MOL BIOL REP, V20, P1, DOI 10.1007/BF00999848; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; SCHNEIDER C, 1988, CELL, V54, P787, DOI 10.1016/S0092-8674(88)91065-3; SCHUH R, 1986, CELL, V47, P1025, DOI 10.1016/0092-8674(86)90817-2; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SOGAWA K, 1993, NUCLEIC ACIDS RES, V21, P1527, DOI 10.1093/nar/21.7.1527; STANOJEVIC D, 1989, NATURE, V341, P331, DOI 10.1038/341331a0; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUKHATME VP, 1992, KIDNEY INT, V41, P550, DOI 10.1038/ki.1992.79; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; SWICK AG, 1992, P NATL ACAD SCI USA, V89, P1812, DOI 10.1073/pnas.89.5.1812; TIETJEN TG, 1994, HISTOCHEM J, V26, P526, DOI 10.1007/BF00157898; TIETJEN TG, 1994, J HISTOCHEM CYTOCHEM, V42, P745, DOI 10.1177/42.6.8189036; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VARNUM BC, 1995, NATURE, V373, P623, DOI 10.1038/373623a0; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361	63	534	577	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					20009	20017		10.1074/jbc.271.33.20009	http://dx.doi.org/10.1074/jbc.271.33.20009			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702718	hybrid, Green Accepted			2022-12-25	WOS:A1996VC66900059
J	Tsakiridis, T; Taha, C; Grinstein, S; Klip, A				Tsakiridis, T; Taha, C; Grinstein, S; Klip, A			Insulin activates a p21-activated kinase in muscle cells via phosphatidylinositol 3-kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING PROTEIN RAC; PP70 S6 KINASE; PHOSPHOINOSITIDE 3-KINASE; GLUCOSE TRANSPORTERS; SACCHAROMYCES-CEREVISIAE; MOLECULAR-CLONING; ACTIN NETWORK; SH3 DOMAIN; FAMILY; STIMULATION	Insulin activates rapidly a complex cascade of lipid and protein kinases leading to stimulation of mitogenic and metabolic events. Mere we describe a renaturable kinase of 65 kDa (PK65) that becomes rapidly activated by insulin in differentiated L6 muscle cells (myotubes) and can phosphorylate histones immobilized in polyacrylamide gels. Insulin activation of PK65 was abolished by the tyrosine kinase inhibitor erbstatin and by the phosphatidylinositol 3-kinase (PI 3-kinase) inhibitor wortmannin, but was unaffected by inhibitors of protein kinase C or of the activation of p70(S6K). Recently, a number of protein kinases have been described which become activated through interaction with the small GTP-binding proteins Rac and Cdc42 (p21-activated kinases, or PAKs) and lead to activation of the stress-induced mitogen-activated protein kinase (MAPK) p38 MAPK. Two different polyclonal antibodies recognizing the carboxyl-terminal or the Rac-binding domain of a 65-kDa PAK (PAK65) immunoprecipitated the myotube PK65. The insulin-induced activation of PK65 in myotubes was detectable following immunoprecipitation of the kinase, Furthermore, PK65 associated with and became activated by glutathione S-transferase-Cdc42Hs in the presence of GTP gamma S (guanosine 5'-3-O-(thio)triphosphate). In myotubes insulin also induced tyrosine phosphorylation of p38 MAPK. However, this phosphorylation was insensitive to wortmannin, indicating that p38 MAPK is not activated by PK65 in insulin-stimulated cells. The results suggest that insulin activates in muscle cells a renaturable kinase (PK65) closely related to PAK65. Tyrosine kinases and PI 3-kinase act upstream of PK65 in the insulin signaling cascade, Insulin activates p38 MAPK in myotubes, but this occurs by a pathway independent of PI 3-kinase and PK65.	HOSP SICK CHILDREN,DIV CELL BIOL,TORONTO,ON M5G 1X8,CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)								BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; BERGERING BM, 1995, NATURE, V376, P599; BRUMELL JH, 1994, AM J PHYSIOL-CELL PH, V267, pC1574, DOI 10.1152/ajpcell.1994.267.6.C1574; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHEATHAM B, 1995, ENDOCR REV, V16, P117, DOI 10.1210/er.16.2.117; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; DING JB, 1994, FEBS LETT, V348, P149, DOI 10.1016/0014-5793(94)00593-1; DING JB, 1995, J BIOL CHEM, V270, P11684, DOI 10.1074/jbc.270.19.11684; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; FRY MJ, 1994, BBA-MOL BASIS DIS, V1226, P237, DOI 10.1016/0925-4439(94)90036-1; GRINSTEIN S, 1993, J BIOL CHEM, V268, P20223; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P139, DOI 10.1016/0003-2697(89)90181-4; KNAUS UG, 1995, NATURE, V269, P221; KOTANI K, 1995, BIOCHEM BIOPH RES CO, V208, P985, DOI 10.1006/bbrc.1995.1431; KOTANI K, 1994, EMBO J, V13, P2313, DOI 10.1002/j.1460-2075.1994.tb06515.x; KOVACINA KS, 1990, J BIOL CHEM, V265, P12115; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LEBERER E, 1992, EMBO J, V11, P4815, DOI 10.1002/j.1460-2075.1992.tb05587.x; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MANSER E, 1995, J BIOL CHEM, V270, P25070, DOI 10.1074/jbc.270.42.25070; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARTIN GA, 1995, EMBO J, V14, P1970, DOI 10.1002/j.1460-2075.1995.tb07189.x; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; RAMER SW, 1993, P NATL ACAD SCI USA, V90, P452, DOI 10.1073/pnas.90.2.452; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; SHEPHERD PR, 1995, BIOCHEM J, V305, P25, DOI 10.1042/bj3050025; Shepherd PR, 1996, TRENDS CELL BIOL, V6, P92, DOI 10.1016/0962-8924(96)80998-6; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; STAMBOLIC V, 1994, BIOCHEM J, V303, P701, DOI 10.1042/bj3030701; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; TAHA C, 1995, J BIOL CHEM, V270, P24678, DOI 10.1074/jbc.270.42.24678; TEO M, 1995, J BIOL CHEM, V270, P26690, DOI 10.1074/jbc.270.44.26690; TOKER A, 1994, J BIOL CHEM, V269, P32358; TOLIAS KF, 1995, J BIOL CHEM, V270, P17656, DOI 10.1074/jbc.270.30.17656; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; TSAKIRIDIS T, 1995, BIOCHEM J, V309, P1; TSAKIRIDIS T, 1995, ENDOCRINOLOGY, V136, P4315, DOI 10.1210/en.136.10.4315; TSAKIRIDIS T, 1994, J BIOL CHEM, V269, P29934; WENG QP, 1995, P NATL ACAD SCI USA, V92, P5744, DOI 10.1073/pnas.92.12.5744; WHITE MF, 1994, J BIOL CHEM, V269, P1; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934; ZHAO ZS, 1995, MOL CELL BIOL, V15, P5246	46	99	102	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					19664	19667		10.1074/jbc.271.33.19664	http://dx.doi.org/10.1074/jbc.271.33.19664			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702668	hybrid			2022-12-25	WOS:A1996VC66900009
J	Lee, WJ; Hawkins, RA; Peterson, DR; Vina, JR				Lee, WJ; Hawkins, RA; Peterson, DR; Vina, JR			Role of oxoproline in the regulation of neutral amino acid transport across the blood-brain barrier	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-GLUTAMYL-TRANSPEPTIDASE; TRANSFERASE TRANSPEPTIDASE; ENDOTHELIAL-CELLS; MEMBRANE-VESICLES; PLASMA-MEMBRANE; SYSTEM; RAT; GLUTAMYLTRANSFERASE; GLUTATHIONE; LOCALIZATION	Regulation of neutral amino acid transport was studied using isolated plasma membrane vesicles derived from the bovine blood-brain barrier, Neutral amino acids cross the blood-brain barrier by facilitative transport system L1, which may allow both desirable and undesirable amino acids to enter the brain, The sodium-dependent amino acid systems A and B-o,B-+ are located exclusively on abluminal membranes, in a position to pump unwanted amino acids out, gamma-Glutamyl transpeptidase, the first enzyme of the gamma-glutamyl cycle, is an integral protein of the luminal membrane of the blood-brain barrier, We demonstrate that oxoproline, an intracellular product of the gamma-glutamyl cycle, stimulates the sodium-dependent systems A and B-o,B-+ by 70 and 20%, respectively. Study of system A showed that 2 mM oxoproline increased the affinity for its specific substrate N-methylaminoisobutyrate by 50%. This relationship between the activity of the gamma-glutamyl cycle and system A transport may provide a short term regulatory mechanism by which the entry of potentially deleterious amino acids (i.e. neurotransmitters or their precursors) may be retarded and their removal from brain accelerated.	FINCH UNIV HLTH SCI CHICAGO MED SCH, DEPT PHYSIOL & BIOPHYS, N CHICAGO, IL 60064 USA; UNIV VALENCIA, MOL FAC MED & FARM, DEPT BIOQUIM & BIOL, VALENCIA 46010, SPAIN	Chicago Medical School; University of Valencia			Viña, Juan R/ABE-5698-2021	Viña, Juan R/0000-0002-4035-3615	NINDS NIH HHS [NS31017] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS031017] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALLISON RD, 1981, J BIOL CHEM, V256, P2988; BARKER GA, 1990, EXP PHYSIOL, V75, P3, DOI 10.1113/expphysiol.1990.sp003382; BELL JG, 1987, J COMP PHYSIOL B, V157, P161, DOI 10.1007/BF00692360; BETZ AL, 1980, BRAIN RES, V192, P17, DOI 10.1016/0006-8993(80)91004-5; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CANCILLA PA, 1983, J NEUROPATH EXP NEUR, V42, P191, DOI 10.1097/00005072-198303000-00008; CHRISTENSEN HN, 1989, METHOD ENZYMOL, V173, P576; CHRISTENSEN HN, 1965, J BIOL CHEM, V240, P3609; COTGREAVE IA, 1994, BBA-MOL CELL RES, V1222, P375, DOI 10.1016/0167-4889(94)90043-4; CURTO KA, 1988, J HISTOCHEM CYTOCHEM, V36, P159, DOI 10.1177/36.2.2891746; DELPINO MMS, 1992, J BIOL CHEM, V267, P25951; DELPINO MMS, 1995, J BIOL CHEM, V270, P14907, DOI 10.1074/jbc.270.25.14907; DELPINO MMS, 1995, J BIOL CHEM, V270, P14913, DOI 10.1074/jbc.270.25.14913; GARVEY TQ, 1976, GASTROENTEROLOGY, V71, P778; GRAMMAS P, 1992, NEUROPHARMACOLOGY, V31, P409, DOI 10.1016/0028-3908(92)90075-Z; HAWKINS RA, 1986, FASEB J, V45, P2055; HSU BYL, 1984, J MEMBRANE BIOL, V80, P167, DOI 10.1007/BF01868772; KILBERG MS, 1986, TRENDS BIOCHEM SCI, V11, P183, DOI 10.1016/0968-0004(86)90138-6; KILBERG MS, 1993, ANNU REV NUTR, V13, P137, DOI 10.1146/annurev.nu.13.070193.001033; LASH LH, 1984, J BIOL CHEM, V259, P4508; LAUTERBURG BH, 1979, GASTROENTEROLOGY, V77, pA24; MACDONALD RC, 1994, BBA-BIOMEMBRANES, V1191, P362, DOI 10.1016/0005-2736(94)90187-2; MAYER LD, 1986, BIOCHIM BIOPHYS ACTA, V858, P161, DOI 10.1016/0005-2736(86)90302-0; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; MEISTER A, 1973, SCIENCE, V180, P33, DOI 10.1126/science.180.4081.33; MEISTER A, 1983, METABOLIC BASIS INHE, P348; MUNCK LK, 1992, BIOCHIM BIOPHYS ACTA, V1116, P91, DOI 10.1016/0304-4165(92)90104-3; ORLOWSKI M, 1970, P NATL ACAD SCI USA, V67, P1248, DOI 10.1073/pnas.67.3.1248; OXENDER DL, 1963, J BIOL CHEM, V238, P3686; PAYNE GM, 1984, BIOCHEM J, V218, P147, DOI 10.1042/bj2180147; PELLEFIGUE F, 1976, BIOCHEM BIOPH RES CO, V73, P997, DOI 10.1016/0006-291X(76)90221-7; PUENTE IR, 1979, FEBS LETT, V126, P250; SACKS W, 1982, J NEUROSCI RES, V7, P431, DOI 10.1002/jnr.490070409; SCHENERMAN MA, 1986, BIOCHIM BIOPHYS ACTA, V856, P428, DOI 10.1016/0005-2736(86)90133-1; SEPULVEDA FV, 1982, BIOCHEM J, V208, P509, DOI 10.1042/bj2080509; SHOTWELL MA, 1981, J BIOL CHEM, V256, P5422; SMITH QR, 1991, ADV EXP MED BIOL, V291, P55; SMITH QR, 1987, J NEUROCHEM, V49, P1651, DOI 10.1111/j.1471-4159.1987.tb01039.x; STRAUSS G, 1986, BIOCHIM BIOPHYS ACTA, V858, P169, DOI 10.1016/0005-2736(86)90303-2; SWEIRY JH, 1995, J PHYSIOL-LONDON, V485, P167, DOI 10.1113/jphysiol.1995.sp020721; VANDERWE.P, 1974, P NATL ACAD SCI USA, V71, P1026; VANDERWERF P, 1975, ADV ENZYMOL RAMB, V43, P519; VINA J, 1981, BIOCHEM J, V194, P99, DOI 10.1042/bj1940099; VINA JR, 1989, AM J PHYSIOL, V257, pE916, DOI 10.1152/ajpendo.1989.257.6.E916; VINA JR, 1990, FEBS LETT, V269, P86, DOI 10.1016/0014-5793(90)81125-8; VINA JR, 1985, BIOL NEONATE, V48, P250, DOI 10.1159/000242178; VINA JR, 1981, BIOCHEM J, V200, P705, DOI 10.1042/bj2000705	47	41	44	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19129	19133		10.1074/jbc.271.32.19129	http://dx.doi.org/10.1074/jbc.271.32.19129			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702588	hybrid			2022-12-25	WOS:A1996VB68400022
J	Murray, RC; Williams, FMR; Flintoff, WF				Murray, RC; Williams, FMR; Flintoff, WF			Structural organization of the reduced folate carrier gene in Chinese hamster ovary cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN KB CELLS; BINDING-PROTEIN; METHOTREXATE UPTAKE; MOLECULAR-CLONING; LEUKEMIA-CELLS; GENOMIC ORGANIZATION; TRANSPORT-DEFICIENT; MEMBRANE CARRIER; CDNA; DNA	The reduced folate carrier gene (rfc) encodes a putative protein that is involved in the intracellular accumulation of folates. In this report, we describe the organization of the I fe gene from Chinese hamster ovary cells. The hamster rfc gene contains ? exons and 6 introns, which span 15.3 kilobases. It codes for two alternatively spliced messenger RNAs, one that, contains all 7 exons and one that lacks exon 2 but contains the remaining 6 exons. The transcriptional start of the gene has been mapped to six sites approximately 200 base pairs upstream of the putative ATG initiation codon. The promoter region has no TATA box-like sequence but contains a consensus Spl binding site, This is the first report of the genomic structure of the reduced folate carrier gene from any species.	UNIV WESTERN ONTARIO, DEPT MICROBIOL & IMMUNOL, LONDON, ON N6A 5C1, CANADA	Western University (University of Western Ontario)								ANTONY AC, 1985, J BIOL CHEM, V260, P4911; Azizkhan Jane C., 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P229; BRIGLE KE, 1991, J BIOL CHEM, V266, P17243; BRIGLE KE, 1995, J BIOL CHEM, V270, P22974, DOI 10.1074/jbc.270.39.22974; CAMPBELL IG, 1991, CANCER RES, V51, P5329; CHAN FPH, 1995, CYTOGENET CELL GENET, V71, P148, DOI 10.1159/000134095; CONEY LR, 1991, CANCER RES, V51, P6125; DEUTSCH JC, 1989, ARCH BIOCHEM BIOPHYS, V274, P327, DOI 10.1016/0003-9861(89)90446-3; DIXON KH, 1994, J BIOL CHEM, V269, P17; ELWOOD PC, 1986, J BIOL CHEM, V261, P5416; ELWOOD PC, 1989, J BIOL CHEM, V264, P14893; FAN JG, 1991, J BIOL CHEM, V266, P14862; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FLINTOFF WF, 1976, IN VITRO CELL DEV B, V12, P749, DOI 10.1007/BF02835450; FLINTOFF WF, 1976, SOMAT CELL GENET, V2, P245, DOI 10.1007/BF01538963; GROSS-BELLARD MM, 1973, EUR J BIOCHEM, V36, P32, DOI 10.1111/j.1432-1033.1973.tb02881.x; HENDERSON GB, 1988, J MEMBRANE BIOL, V101, P247, DOI 10.1007/BF01872839; JANSEN G, 1989, CANCER RES, V49, P1959; KANE MA, 1989, LAB INVEST, V60, P737; KANE MA, 1986, J BIOL CHEM, V261, P44; KANE MA, 1986, J BIOL CHEM, V261, P5625; LACEY SW, 1989, J CLIN INVEST, V84, P715, DOI 10.1172/JCI114220; LEIBBRANDT MEI, 1994, CELL GROWTH DIFFER, V5, P17; MATHERLY LH, 1994, BIOCHEM PHARMACOL, V47, P1094, DOI 10.1016/0006-2952(94)90423-5; MATHERLY LH, 1992, J BIOL CHEM, V267, P23253; MATHERLY LH, 1991, CANCER RES, V51, P3420; MOSCOW JA, 1995, CANCER RES, V55, P3790; PRASAD PD, 1995, BIOCHEM BIOPH RES CO, V206, P681, DOI 10.1006/bbrc.1995.1096; PRICE EM, 1988, BIOCHEMISTRY-US, V27, P7853, DOI 10.1021/bi00420a040; RAGOUSSIS J, 1992, GENOMICS, V14, P423, DOI 10.1016/S0888-7543(05)80236-8; SADASIVAN E, 1989, J BIOL CHEM, V264, P5806; SADASIVAN E, 1992, BIOCHIM BIOPHYS ACTA, V1131, P91, DOI 10.1016/0167-4781(92)90103-7; SADASIVAN E, 1994, J BIOL CHEM, V269, P4725; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; UNDERHILL TM, 1989, MOL CELL BIOL, V9, P1754, DOI 10.1128/MCB.9.4.1754; UNDERHILL TM, 1989, SOMAT CELL MOLEC GEN, V15, P49, DOI 10.1007/BF01534669; UNDERHILL TM, 1992, SOMAT CELL MOLEC GEN, V18, P337, DOI 10.1007/BF01235757; WILLIAMS FMR, 1994, J BIOL CHEM, V269, P5810; WILLIAMS FMR, 1995, J BIOL CHEM, V270, P2987, DOI 10.1074/jbc.270.7.2987; WONG SC, 1995, J BIOL CHEM, V270, P17468, DOI 10.1074/jbc.270.29.17468	41	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19174	19179		10.1074/jbc.271.32.19174	http://dx.doi.org/10.1074/jbc.271.32.19174			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702595	hybrid			2022-12-25	WOS:A1996VB68400029
J	Prado, GN; Suzuki, H; Wilkinson, N; Cousins, B; Navarro, J				Prado, GN; Suzuki, H; Wilkinson, N; Cousins, B; Navarro, J			Role of the C terminus of the interleukin 8 receptor in signal transduction and internalization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOXYL-TERMINUS; AMINO TERMINUS; DESENSITIZATION; PHOSPHORYLATION; EXPRESSION; PROTEIN; SITES; BETA; IL-8	Interleukin 8 (IL-8) is a potent neutrophil chemoattractant and activator. Two IL-8 receptor subtypes, A and B, are expressed in neutrophils. In this work, we analyzed the role of the C terminus domain of the IL-8 receptor on the signal transduction and receptor internalization mechanisms, The IL-8 receptor A was tagged with an epitope corresponding to the monoclonal antibody 1D4 to monitor the, localization of the IL-8 receptor, We demonstrated IL-S-dependent. receptor internalization by monitoring the density of surface I-125-labeled IL-8 binding sites and by immunofluorescence microscopy, Truncation of the last 27 amino acids of the IL-8 receptor A severely impaired the IL-8-induced internalization of the receptor. Of importance was tire observation that binding of IL-8 to receptors A and B triggered a dramatically faster rate of internalization of receptor B than receptor A, suggesting that the heterologous C termini among receptor subtypes modulate the rate of internalization of IL-8 receptors. However, substitution of the C terminus of the receptor subtype A for the C terminus of receptor B reduced the internalization rate of receptor A. Furthermore, we found that the rate of internalization of IL-8 receptor B triggered by IL-8 was faster than the one induced by the IL-S-related peptide, melanoma growth stimulatory activity, Studies with human neutrophils pretreated with 100 nM IL-8 for 5 min revealed a positive and a negative calcium response mediated by receptors A and B, respectively. In contrast, neutrophils pretreated with melanoma growth stimulatory activity showed positive calcium responses to both receptors A and B. These data suggest that the neutrophil responses mediated by IL-8 are modulated by the rate of internalization of receptors.			Prado, GN (corresponding author), UNIV TEXAS, MED BRANCH, SEALY CTR MOL SCI, DEPT PHYSIOL & BIOPHYS, RT F0641, GALVESTON, TX 77555 USA.			Navarro, Javier/0000-0001-7098-4373	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034031] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI34031] Funding Source: Medline; NIA NIH HHS [AG00115] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BARAK LS, 1994, J BIOL CHEM, V269, P2790; BENBARUCH A, 1995, J BIOL CHEM, V270, P9121, DOI 10.1074/jbc.270.16.9121; BLOUNT P, 1993, J BIOL CHEM, V268, P16388; CHUNTHARAPAI A, 1995, J IMMUNOL, V155, P2587; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; EASON MG, 1995, J BIOL CHEM, V270, P4681, DOI 10.1074/jbc.270.9.4681; GAYLE RB, 1993, J BIOL CHEM, V268, P7283; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701; HUANG ZM, 1995, J BIOL CHEM, V270, P151, DOI 10.1074/jbc.270.1.151; LAROSA GJ, 1992, J BIOL CHEM, V267, P25402; LATTION AL, 1994, J BIOL CHEM, V269, P22887; LEE J, 1992, J BIOL CHEM, V267, P16283; LIGGETT SB, 1993, P NATL ACAD SCI USA, V90, P3665, DOI 10.1073/pnas.90.8.3665; MACKENZIE D, 1984, BIOCHEMISTRY-US, V23, P6544, DOI 10.1021/bi00321a041; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; PALSRYLAARSDAM R, 1995, J BIOL CHEM, V270, P29004, DOI 10.1074/jbc.270.48.29004; PAPKOFF J, 1983, CELL, V33, P161, DOI 10.1016/0092-8674(83)90345-8; PRADO GN, 1994, J BIOL CHEM, V269, P12391; SIBLEY DR, 1987, CELL, V48, P913, DOI 10.1016/0092-8674(87)90700-8; SUZUKI H, 1994, J BIOL CHEM, V269, P18263; THOMAS KM, 1991, J BIOL CHEM, V266, P14839; THOMAS WG, 1995, J BIOL CHEM, V270, P207, DOI 10.1074/jbc.270.1.207	23	65	66	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19186	19190		10.1074/jbc.271.32.19186	http://dx.doi.org/10.1074/jbc.271.32.19186			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702597	hybrid			2022-12-25	WOS:A1996VB68400031
J	Bedoyan, JK; Lejnine, S; Makarov, VL; Langmore, JP				Bedoyan, JK; Lejnine, S; Makarov, VL; Langmore, JP			Condensation of rat telomere-specific nucleosomal arrays containing unusually short DNA repeats and histone H1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGHER-ORDER STRUCTURE; CHROMATIN STRUCTURE; SACCHAROMYCES-CEREVISIAE; LINKER LENGTH; CEREBRAL-CORTEX; UNIT LENGTH; ORGANIZATION; PROTEIN; FORMALDEHYDE; SEQUENCE	Vertebrate telomeres contain arrays of nucleosomes with unusually short and regular repeat lengths (Makarov, V. L., Lejnine, S., Bedoyan, J,, and Langmore, J. P. (1993) Cell 73, 775-787; Lejnine, S., Makarov, V,, and Langmore, J. P, (1995) Proc, Natl. Acad. Sci. U. S. A. 92, 2393-2397), In order to better define the specific structural features of telomere chromatin, we examined the condensation and H1 content of telomere nucleoproteins from rat liver, Velocity sedimentation analysis shows that telomeric nucleosome arrays condense with increasing ionic strength and molecular weight in a manner comparable with that of bulk chromatin despite the very short repeat length. However, these condensed structures do not exhibit the similar to 100-base pair deoxyribonuclease II repeat characteristic of condensed bulk chromatin, Frictional coefficient calculations suggest that telomere-specific higher order structure is more compact than bulk chromatin. Nucleoprotein gel electrophoresis shows that telomeric dinucleosomes from soluble chromatin contain H1, Finally, direct isolation and analysis of telomere nucleoproteins from formaldehyde-cross-linked nuclei indicate the presence of core histone proteins and H1, These results are consistent with the view that a major fraction of the long telomeres of rat are organized as specialized nucleosome arrays with features similar but not identical to those of bulk chromatin.	UNIV MICHIGAN, DIV BIOPHYS RES, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, GRAD PROGRAM CELLULAR & MOL BIOL, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, DEPT BIOL SCI, ANN ARBOR, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007315] Funding Source: NIH RePORTER; NIGMS NIH HHS [5T32GM07315] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLAN J, 1984, J CELL BIOL, V98, P1320, DOI 10.1083/jcb.98.4.1320; ALLSHIRE RC, 1988, NATURE, V332, P656, DOI 10.1038/332656a0; ALTENBURGER W, 1976, NATURE, V264, P517, DOI 10.1038/264517a0; ATHEY BD, 1990, J CELL BIOL, V111, P795, DOI 10.1083/jcb.111.3.795; BAVYKIN SG, 1990, J MOL BIOL, V212, P495, DOI 10.1016/0022-2836(90)90328-J; BIROC SL, 1976, BIOCHEMISTRY-US, V15, P1440, DOI 10.1021/bi00652a014; BLACKBURN EH, 1991, TRENDS BIOCHEM SCI, V16, P378, DOI 10.1016/0968-0004(91)90155-O; BLACKBURN EH, 1981, P NATL ACAD SCI-BIOL, V78, P2263, DOI 10.1073/pnas.78.4.2263; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; BRADBURY EM, 1975, EUR J BIOCHEM, V57, P97, DOI 10.1111/j.1432-1033.1975.tb02280.x; BUTLER PJG, 1980, J MOL BIOL, V140, P505, DOI 10.1016/0022-2836(80)90268-5; BUTLER PJG, 1984, EMBO J, V3, P2599, DOI 10.1002/j.1460-2075.1984.tb02180.x; CANTOR CR, 1980, BIOPHYSICAL CHEM 1, P220; CANTOR CR, 1980, BIOPHYSICAL CHEM 2, P608; CARDENAS ME, 1993, GENE DEV, V7, P883, DOI 10.1101/gad.7.5.883; CARON F, 1981, J MOL BIOL, V146, P513, DOI 10.1016/0022-2836(81)90045-0; CHONG L, 1995, SCIENCE, V270, P1663, DOI 10.1126/science.270.5242.1663; CHUNG HMM, 1990, EMBO J, V9, P2611, DOI 10.1002/j.1460-2075.1990.tb07443.x; CLARK DJ, 1990, J MOL BIOL, V211, P883, DOI 10.1016/0022-2836(90)90081-V; COLES LS, 1987, J BIOL CHEM, V262, P9656; FAJKUS J, 1995, MOL GEN GENET, V247, P633, DOI 10.1007/BF00290355; FOE VE, 1985, J CELL BIOL, V100, P1623, DOI 10.1083/jcb.100.5.1623; GOTTSCHLING DE, 1984, CELL, V38, P501, DOI 10.1016/0092-8674(84)90505-1; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; HORZ W, 1980, J MOL BIOL, V144, P329, DOI 10.1016/0022-2836(80)90094-7; HORZ W, 1980, J MOL BIOL, V144, P305, DOI 10.1016/0022-2836(80)90093-5; HUANG SY, 1989, METHOD ENZYMOL, V170, P116; JACKSON V, 1981, CELL, V23, P121, DOI 10.1016/0092-8674(81)90277-4; JACKSON V, 1978, CELL, V15, P945, DOI 10.1016/0092-8674(78)90278-7; KIPLING D, 1990, NATURE, V347, P400, DOI 10.1038/347400a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEJNINE S, 1995, P NATL ACAD SCI USA, V92, P2393, DOI 10.1073/pnas.92.6.2393; LENNOX RW, 1984, J BIOL CHEM, V259, P669; LOUTERS L, 1985, BIOCHEMISTRY-US, V24, P3080, DOI 10.1021/bi00334a002; LOWARY PT, 1989, P NATL ACAD SCI USA, V86, P8266, DOI 10.1073/pnas.86.21.8266; MAKAROV VL, 1993, CELL, V73, P775, DOI 10.1016/0092-8674(93)90256-P; MCCARTY KS, 1974, ANAL BIOCHEM, V61, P165, DOI 10.1016/0003-2697(74)90343-1; MCCARTY KS, 1968, ANAL BIOCHEM, V24, P314, DOI 10.1016/0003-2697(68)90185-1; MEERSSEMAN G, 1992, EMBO J, V11, P2951, DOI 10.1002/j.1460-2075.1992.tb05365.x; MEERSSEMAN G, 1991, J MOL BIOL, V220, P89, DOI 10.1016/0022-2836(91)90383-H; MEYNE J, 1989, P NATL ACAD SCI USA, V86, P7049, DOI 10.1073/pnas.86.18.7049; MITA K, 1981, BIOPOLYMERS, V20, P1103, DOI 10.1002/bip.1981.360200602; MORRIS NR, 1976, CELL, V8, P357; MOYZIS RK, 1988, P NATL ACAD SCI USA, V85, P6622, DOI 10.1073/pnas.85.18.6622; MUYLDERMANS S, 1994, NUCLEIC ACIDS RES, V22, P5635, DOI 10.1093/nar/22.25.5635; NIMMO ER, 1994, EMBO J, V13, P3801, DOI 10.1002/j.1460-2075.1994.tb06691.x; NOLL H, 1967, NATURE, V215, P360, DOI 10.1038/215360a0; OSIPOVA TN, 1980, EUR J BIOCHEM, V113, P183; PEARSON EC, 1983, EMBO J, V2, P1367, DOI 10.1002/j.1460-2075.1983.tb01593.x; PEARSON EC, 1984, EUR J BIOCHEM, V144, P353, DOI 10.1111/j.1432-1033.1984.tb08471.x; PENNINGS S, 1991, J MOL BIOL, V220, P101, DOI 10.1016/0022-2836(91)90384-I; PENNINGS S, 1992, NUCLEIC ACIDS RES, V20, P6667, DOI 10.1093/nar/20.24.6667; RAWLINS DJ, 1991, CHROMOSOMA, V100, P424, DOI 10.1007/BF00364552; SILVER JC, 1979, BIOCHIM BIOPHYS ACTA, V561, P261, DOI 10.1016/0005-2787(79)90509-4; SOLOMON MJ, 1985, P NATL ACAD SCI USA, V82, P6470, DOI 10.1073/pnas.82.19.6470; SOLOMON MJ, 1988, CELL, V53, P937, DOI 10.1016/S0092-8674(88)90469-2; STARLING JA, 1990, NUCLEIC ACIDS RES, V18, P6881, DOI 10.1093/nar/18.23.6881; THOMAS JO, 1976, FEBS LETT, V66, P274, DOI 10.1016/0014-5793(76)80521-2; THOMAS JO, 1977, CELL, V10, P633, DOI 10.1016/0092-8674(77)90096-4; THOMAS JO, 1980, J MOL BIOL, V144, P89, DOI 10.1016/0022-2836(80)90215-6; TOMMERUP H, 1994, MOL CELL BIOL, V14, P5777, DOI 10.1128/MCB.14.9.5777; VANHOLDE KE, 1989, CHROMATIN, P90; VARSHAVSKY AJ, 1976, NUCLEIC ACIDS RES, V3, P477, DOI 10.1093/nar/3.2.477; VICENZ C, 1992, THESIS U MICHIGAN AN; VINCENZ C, 1991, NUCLEIC ACIDS RES, V19, P1325, DOI 10.1093/nar/19.6.1325; WILLIAMS SP, 1991, BIOPHYS J, V59, P606, DOI 10.1016/S0006-3495(91)82276-7; WILLIAMS SP, 1986, BIOPHYS J, V49, P233, DOI 10.1016/S0006-3495(86)83637-2; WORKMAN JL, 1985, BIOCHEMISTRY-US, V24, P4731, DOI 10.1021/bi00339a004; WRIGHT JH, 1995, NUCLEIC ACIDS RES, V23, P1454, DOI 10.1093/nar/23.9.1454; WRIGHT JH, 1992, GENE DEV, V6, P197, DOI 10.1101/gad.6.2.197; ZAKIAN VA, 1989, ANNU REV GENET, V23, P579, DOI 10.1146/annurev.genet.23.1.579; ZAKIAN VA, 1995, SCIENCE, V270, P1601, DOI 10.1126/science.270.5242.1601	72	24	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18485	18493		10.1074/jbc.271.31.18485	http://dx.doi.org/10.1074/jbc.271.31.18485			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702494	hybrid			2022-12-25	WOS:A1996VB68300032
J	Chon, SY; Hassanain, HH; Gupta, SL				Chon, SY; Hassanain, HH; Gupta, SL			Cooperative role of interferon regulatory factor 1 and p91 (STAT1) response elements in interferon-gamma-inducible expression of human indoleamine 2,3-dioxygenase gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHLAMYDIA-PSITTACI REPLICATION; OXIDE SYNTHASE GENE; HUMAN-FIBROBLASTS; DIFFERENTIAL REGULATION; TRYPTOPHAN CATABOLISM; BINDING PROTEIN; INDUCTION; MECHANISM; ALPHA; LIPOPOLYSACCHARIDE	Interferon (IFN)-gamma induces the expression of the indoleamine 2,3-dioxygenase (INDO) gene in human cells, which plays a role in the inhibitory effect of IFN-gamma on intracellular pathogens and on cell proliferation, Earlier studies established that the IFN-gamma-inducible expression of the INDO gene was dependent on two upstream elements: (i) a 14-base pair sequence homologous to an interferon-stimulated response element (ISRE) sequence found in IFN-alpha-inducible genes and (ii) a 9-base pair palindromic sequence (palindromic element (PE) II) homologous to an interferon-gamma-activated site (GAS) element found in IFN-gamma-inducible genes. A second GAS element (PE I), between ISRE and PE II, was ineffective in supporting a response to IFN-gamma, Studies were carried out to determine the distinction between the two GAS elements and the relative role of the two elements (ISRE and PE II) required for a response to IFN-gamma. The PE I element was able to form a complex with IFN-gamma-activated p91 (STAT1) factor but with lower efficiency than the complex formed with PE II sequence. However, switching the positions of PE I and II sequences in reporter plasmid constructs (containing chloramphenicol acetyltransferase gene) showed that both PE I and PE II were able to support a response to IFN-gamma if located at the position of PE II but not at the position of PE I. Increasing the distance between the ISRE and PE II also affected the level of response, suggesting that the relative position of the two elements is important for optimal stimulus. To explore whether an interaction between the IFN-gamma-regulated factors (IRF-1 and p91) binding to the ISRE and PE II might be important, we tested whether the ISRE sequence could be replaced by another response element, NF-kappa B. The plasmid construct with NF-kappa B element in place of the ISRE was responsive to IFN-gamma, indicating that an interaction between the IRF-1 and p91 factors was not required. The results indicate that the response of INDO gene to IFN-gamma depends on a cooperative role of IFN-gamma-responsive factors binding to the ISRE and GAS elements.	HIPPLE CANC RES CTR,DAYTON,OH 45439						NCI NIH HHS [CA-29991] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA029991] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baron S, 1992, INTERFERON PRINCIPLE; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BYRNE GI, 1986, INFECT IMMUN, V53, P347, DOI 10.1128/IAI.53.2.347-351.1986; CAPLEN HS, 1988, J BIOL CHEM, V263, P332; CARLIN JM, 1989, J INTERFERON RES, V9, P329, DOI 10.1089/jir.1989.9.329; CHON SY, 1995, J INTERF CYTOK RES, V15, P517, DOI 10.1089/jir.1995.15.517; DAI W, 1990, J BIOL CHEM, V265, P19871; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DECKER T, 1989, EMBO J, V8, P2009, DOI 10.1002/j.1460-2075.1989.tb03608.x; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FARRAR MA, 1993, ANNU REV IMMUNOL, V11, P571, DOI 10.1146/annurev.iy.11.040193.003035; FRIDOVICHKEIL JL, 1991, BIOTECHNIQUES, V11, P572; GUPTA SL, 1994, INFECT IMMUN, V62, P2277, DOI 10.1128/IAI.62.6.2277-2284.1994; HABARAOHKUBO A, 1993, INFECT IMMUN, V61, P1810, DOI 10.1128/IAI.61.5.1810-1813.1993; HASSANAIN HH, 1993, J BIOL CHEM, V268, P5077; KAMIJO R, 1994, SCIENCE, V263, P1612, DOI 10.1126/science.7510419; KHAN KD, 1993, P NATL ACAD SCI USA, V90, P6806, DOI 10.1073/pnas.90.14.6806; LORSBACH RB, 1993, J BIOL CHEM, V268, P1908; LOWENSTEIN CJ, 1993, P NATL ACAD SCI USA, V90, P9730, DOI 10.1073/pnas.90.20.9730; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; OZAKI Y, 1988, P NATL ACAD SCI USA, V85, P1242, DOI 10.1073/pnas.85.4.1242; PEARSE RN, 1993, P NATL ACAD SCI USA, V90, P4314, DOI 10.1073/pnas.90.9.4314; PFEFFERKORN ER, 1986, J INTERFERON RES, V6, P267, DOI 10.1089/jir.1986.6.267; PFEFFERKORN ER, 1986, MOL BIOCHEM PARASIT, V20, P215, DOI 10.1016/0166-6851(86)90101-5; PINE R, 1990, MOL CELL BIOL, V10, P2448, DOI 10.1128/MCB.10.6.2448; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEN GC, 1992, J BIOL CHEM, V267, P5017; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; TAKIKAWA O, 1988, J BIOL CHEM, V263, P2041; TAYLOR MW, 1991, FASEB J, V5, P2516, DOI 10.1096/fasebj.5.11.1907934; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; WRIGHT TM, 1991, J EXP MED, V173, P417, DOI 10.1084/jem.173.2.417; XIE QW, 1993, J EXP MED, V177, P1779, DOI 10.1084/jem.177.6.1779	33	128	135	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					17247	17252		10.1074/jbc.271.29.17247	http://dx.doi.org/10.1074/jbc.271.29.17247			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663541	hybrid			2022-12-25	WOS:A1996UX94300043
J	Hsieh, CM; Yoshizumi, M; Endege, WO; Kho, CJ; Jain, MK; Kashiki, S; delosSantos, R; Lee, WS; Perrella, MA; Lee, ME				Hsieh, CM; Yoshizumi, M; Endege, WO; Kho, CJ; Jain, MK; Kashiki, S; delosSantos, R; Lee, WS; Perrella, MA; Lee, ME			APEG-1, a novel gene preferentially expressed in aortic smooth muscle cells, is down-regulated by vascular injury	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIFFERENTIAL DISPLAY; PROTEIN-KINASE; MESSENGER-RNA; MYOD FAMILY; ATHEROSCLEROSIS; GROWTH; ATHEROGENESIS; PATHOGENESIS; ANGIOGENESIS; SYSTEMS	Despite the importance of phenotypic alterations in arterial smooth muscle cells (ASMC) during the pathogenesis of arteriosclerosis, little is known about genes that define differentiated ASMC. Using differential mRNA display, we isolated a novel gene preferentially expressed in the rat aorta and termed this gene APEG-1. The cDNA of rat APEG-1 contained an open reading frame encoding 113 amino acids, which would predict a basic protein of 12.7 kDa. The amino acid sequence of rat APEG-1 was highly conserved among human and mouse homologues (97 and 98% respectively). Using an APEG-1 fusion protein containing an N-terminal c-Myc tag, we identified APEG-1 as a nuclear protein. By in situ hybridization, APEG-1 mRNA was expressed in rat ASMC. Although APEG-1 was expressed highly in differentiated ASMC in vivo, its expression was quickly down-regulated and disappeared in dedifferentiated ASMC in culture. In vivo, APEG-1 mRNA levels decreased by more than 80% in response to vascular injury as ASMC changed from a quiescent to a proliferative phenotype. Taken together, these data indicate that APEG-1 is a novel marker for differentiated ASMC and may have a role in regulating growth and differentiation of this cell type.	HARVARD UNIV,SCH MED,CARDIOVASC BIOL LAB,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DIV PULM,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DIV CARDIOVASC,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital					NHLBI NIH HHS [KO8-HL03194] Funding Source: Medline; NIGMS NIH HHS [R01-GM53249] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL003194] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053249] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Blobel Carl P., 1992, Current Opinion in Cell Biology, V4, P760; BOULIKAS T, 1994, J CELL BIOCHEM, V55, P32, DOI 10.1002/jcb.240550106; CARDOSO MC, 1993, CELL, V74, P979, DOI 10.1016/0092-8674(93)90721-2; CLAYCOMB WC, 1992, TRENDS CARDIOVAS MED, V2, P231, DOI 10.1016/1050-1738(92)90030-V; CLOWES AW, 1983, LAB INVEST, V49, P327; DUBAND JL, 1993, DIFFERENTIATION, V55, P1, DOI 10.1111/j.1432-0436.1993.tb00027.x; FIDLER IJ, 1994, CELL, V79, P185, DOI 10.1016/0092-8674(94)90187-2; FOLKMAN J, 1992, ADV EXP MED BIOL, V313, P355; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; GORSKI DH, 1993, MOL CELL BIOL, V13, P3722, DOI 10.1128/MCB.13.6.3722; GORSKI DH, 1995, CARDIOVASC RES, V30, P585; GUNTHER S, 1982, J CELL BIOL, V92, P289, DOI 10.1083/jcb.92.2.289; HASS TA, 1994, CURR OPIN CELL BIOL, V6, P656; KOZAK M, 1992, ANNU REV CELL BIOL, V8, P197, DOI 10.1146/annurev.cb.08.110192.001213; LEE WS, 1993, ENDOCRINOLOGY, V132, P2136, DOI 10.1210/en.132.5.2136; LI XM, 1994, J BIOL CHEM, V269, P19653; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LIANG P, 1993, NUCLEIC ACIDS RES, V21, P3269, DOI 10.1093/nar/21.14.3269; LIBBY P, 1991, LAB INVEST, V64, P5; MUNRO JM, 1988, LAB INVEST, V58, P249; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; OSBOURN JK, 1995, GENE, V154, P249, DOI 10.1016/0378-1119(94)00847-L; OWENS GK, 1995, PHYSIOL REV, V75, P487; PARKER TG, 1991, ANNU REV PHYSIOL, V53, P179; PAULY RR, 1992, CIRCULATION, V86, P68; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Sambrook J., 2002, MOL CLONING LAB MANU; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHWARTZ SM, 1990, PHYSIOL REV, V70, P1177, DOI 10.1152/physrev.1990.70.4.1177; SOBUE K, 1991, J BIOL CHEM, V266, P12115; SOLWAY J, 1995, J BIOL CHEM, V270, P13460, DOI 10.1074/jbc.270.22.13460; TAN MS, 1994, KIDNEY INT, V46, P690, DOI 10.1038/ki.1994.322; Tsai JC, 1996, J CLIN INVEST, V97, P146, DOI 10.1172/JCI118383; TSAI JC, 1994, P NATL ACAD SCI USA, V91, P6369, DOI 10.1073/pnas.91.14.6369; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3; WINDER SJ, 1991, ADV EXP MED BIOL, V304, P37; YANO H, 1995, J BIOL CHEM, V270, P23661, DOI 10.1074/jbc.270.40.23661; YOSHIZUMI M, 1995, J CLIN INVEST, V95, P2275, DOI 10.1172/JCI117918	39	37	46	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					17354	17359		10.1074/jbc.271.29.17354	http://dx.doi.org/10.1074/jbc.271.29.17354			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663449	hybrid			2022-12-25	WOS:A1996UX94300058
J	Wang, YS; Okan, I; Pokrovskaja, K; Wiman, KG				Wang, YS; Okan, I; Pokrovskaja, K; Wiman, KG			Abrogation of p53-induced G1 arrest by the HPV 16 E7 protein does not inhibit p53-induced apoptosis	ONCOGENE			English	Article						HPV16 E7; p53-induced G1 arrest; apoptosis	WILD-TYPE P53; HUMAN PAPILLOMAVIRUS TYPE-16; ERYTHROLEUKEMIA-CELLS; E6 ONCOPROTEIN; TUMOR-ANTIGEN; LINE; GENE; SUPPRESSION; IRRADIATION; INDUCTION	Wild type (wt) p53 expressed from a temperature-sensitive construct (ts p53) can induce both G1 cell cycle arrest and apoptosis in the p53-negative J3D mouse T lymphoma line (Wang et al., 1995). The human papillomavirus (HPV) 16 E7 protein has been shown to prevent p53-induced G1 cell cycle arrest following DNA damage. We asked whether inhibition of p53-induced G1 arrest by overexpression of the HPV16 E7 protein in the ts p53-transfected J3D cells would interfere with p53-induced apoptosis. Whereas a majority of the ts p53-expressing J3D cells were arrested in the G1 phase 22 h after induction of wt p53 by temperature shift to 32 degrees C, the E7/ts p53-expressing cells showed only a minor increase in the number of cells in G1 at this time point. In addition, the E7/ts p53-expressing cells showed a much less dramatic reduction in number of cells in S phase than the ts p53-expressing cells. This demonstrates that E7 at least partially rescues the cells from p53-induced G1 arrest. In contrast, overexpression of HPV16 E7 did not have any effect on the kinetics nor the frequency of p53-triggered apoptotic death, as shown by PACS analysis, trypan blue exclusion, and DNA fragmentation analysis. These findings support the notion that p53-induced G1 arrest and p53-induced apoptosis are two separate independent pathways.			Wang, YS (corresponding author), KAROLINSKA INST,CTR MICROBIOL & TUMOR BIOL,S-17177 STOCKHOLM,SWEDEN.		Wiman, Klas/AAB-8399-2021	Wiman, Klas/0000-0002-7113-524X; Pokrovskaja Tamm, Katja/0000-0001-6359-1256				CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DEMERS GW, 1994, P NATL ACAD SCI USA, V91, P4382, DOI 10.1073/pnas.91.10.4382; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; EDMONDS C, 1989, J VIROL, V63, P2650, DOI 10.1128/JVI.63.6.2650-2656.1989; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FRITSCHE M, 1993, ONCOGENE, V8, P307; HAASKOGAN DA, 1995, EMBO J, V14, P461, DOI 10.1002/j.1460-2075.1995.tb07022.x; HARPER JW, 1993, CELL, V75, P805; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; HICKMAN ES, 1994, ONCOGENE, V9, P2177; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P775, DOI 10.1128/MCB.13.2.775; JOHNSON P, 1993, MOL CELL BIOL, V13, P1456, DOI 10.1128/MCB.13.3.1456; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1994, P NATL ACAD SCI USA, V91, P2026, DOI 10.1073/pnas.91.6.2026; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; RAMQVIST T, 1993, ONCOGENE, V8, P1495; RYAN JJ, 1993, MOL CELL BIOL, V13, P711, DOI 10.1128/MCB.13.1.711; Sambrook J., 2002, MOL CLONING LAB MANU; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SELIVANOVA G, 1995, ADV CANCER RES, V66, P143, DOI 10.1016/S0065-230X(08)60253-5; SELVAKUMARAN M, 1994, ONCOGENE, V9, P1791; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SLEBOS RJC, 1994, P NATL ACAD SCI USA, V91, P5320, DOI 10.1073/pnas.91.12.5320; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; VOUSDEN K, 1993, FASEB J, V7, P872, DOI 10.1096/fasebj.7.10.8393818; WALDMAN T, 1995, CANCER RES, V55, P5187; WANG YS, 1993, ONCOGENE, V8, P3427; WANG YS, 1993, CELL GROWTH DIFFER, V4, P467; WANG YS, 1995, CELL GROWTH DIFFER, V6, P1071; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	47	15	15	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 20	1996	12	12					2731	2735						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UW487	8700534				2022-12-25	WOS:A1996UW48700029
J	Pratt, MAC; Deonarine, D; Teixeira, C; Novosad, D; Tate, BF; Grippo, JF				Pratt, MAC; Deonarine, D; Teixeira, C; Novosad, D; Tate, BF; Grippo, JF			The AF-2 region of the retinoic acid receptor alpha mediates retinoic acid inhibition of estrogen receptor function in breast cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROID-HORMONE RECEPTORS; GROWTH-FACTOR-ALPHA; RESPONSE ELEMENT; TRANSCRIPTIONAL ACTIVATION; NUCLEAR RECEPTORS; THYROID-HORMONE; CARCINOMA CELLS; PROGESTERONE-RECEPTOR; BINDING DOMAIN; MCF-7 CELLS	The growth of estrogen receptor (ER)-positive breast cancer cells is inhibited by all-trans-retinoic acid (RA). In the present study, estrogen (E2) induction of pS2 mRNA levels was significantly reduced within 6 h following cotreatment with RA. In transient transfection experiments, RA repressed transactivation from a vitellogenin E2-responsive element by approximately 50% and wild-type RA receptor alpha (RAR alpha) or RAR beta enhanced this inhibition. Transfection of truncated RAR alpha mutants terminating before or at amino acid 412 markedly decreased RA inhibition of E2-induced reporter gene activity. Expression of RARs with deletions of amino acids 413 and 414 in the transactivation-2 (AF-2) domain also reduced RA inhibition, while deletions and point mutations beyond amino acid 414 behaved like the wild-type RAR alpha. RA-treated MCF-7 cells transfected with an RAR alpha AF-2 region mutant were twice as sensitive to growth inhibition as untransfected and vector-transfected control cells. Thus, the AF-2 domain in the C terminus of the RAR alpha mediates RA inhibition of ER-induced transcription in breast cancer cells. In addition, transcriptional interference between RARs and ERs may contribute to RA inhibition of ER-positive breast cancer cell growth.	HOFFMANN LA ROCHE INC, DEPT METAB DIS, NUTLEY, NJ 07110 USA	Roche Holding	Pratt, MAC (corresponding author), UNIV OTTAWA, DEPT PHARMACOL, 451 SMYTH RD, OTTAWA, ON K1H 8M5, CANADA.							AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BANIAHMAD C, 1995, MOL ENDOCRINOL, V9, P34, DOI 10.1210/me.9.1.34; BARETTINO D, 1994, EMBO J, V13, P3039, DOI 10.1002/j.1460-2075.1994.tb06603.x; BREITMAN TR, 1981, BLOOD, V57, P1000; BROWN AMC, 1984, P NATL ACAD SCI-BIOL, V81, P6344, DOI 10.1073/pnas.81.20.6344; BUSAM KJ, 1992, J BIOL CHEM, V267, P19971; CAVAILLES V, 1994, P NATL ACAD SCI USA, V91, P10009, DOI 10.1073/pnas.91.21.10009; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHIBA H, 1994, NUCLEIC ACIDS RES, V22, P1815, DOI 10.1093/nar/22.10.1815; CLARKE CL, 1991, J BIOL CHEM, V266, P18969; CLARKE CL, 1990, J BIOL CHEM, V265, P12694; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; DEMIRPENCE E, 1992, BIOCHEM BIOPH RES CO, V183, P100, DOI 10.1016/0006-291X(92)91614-V; DEMIRPENCE E, 1994, CANCER RES, V54, P1458; DURAND B, 1994, EMBO J, V13, P5370, DOI 10.1002/j.1460-2075.1994.tb06872.x; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FONTANA JA, 1990, CANCER RES, V50, P1977; FONTANA JA, 1987, EXP CELL BIOL, V55, P136; FONTANA JA, 1992, CANCER RES, V52, P3938; FREEDMAN LP, 1993, J CELL BIOCHEM, V51, P140, DOI 10.1002/jcb.240510205; GREEN S, 1986, NATURE, V320, P134, DOI 10.1038/320134a0; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; GRONEMEYER H, 1988, AFFINITY LABELLING C, P252; GUDAS LJ, 1992, CELL GROWTH DIFFER, V3, P655; HALACHMI S, 1994, SCIENCE, V264, P1455, DOI 10.1126/science.8197458; HALTER SA, 1993, J CELL PHYSIOL, V156, P80, DOI 10.1002/jcp.1041560112; HOLLENBERG SM, 1988, CELL, V55, P899, DOI 10.1016/0092-8674(88)90145-6; JAKOWLEW SB, 1984, NUCLEIC ACIDS RES, V12, P2861, DOI 10.1093/nar/12.6.2861; KHAVARI PA, 1993, NATURE, V366, P170, DOI 10.1038/366170a0; KLEINHITPASS L, 1986, CELL, V46, P1053, DOI 10.1016/0092-8674(86)90705-1; KOGA M, 1991, J STEROID BIOCHEM, V39, P455, DOI 10.1016/0960-0760(91)90238-Z; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; Lippman M.E., 1985, TXB ENDOCRINOLOGY, P1309; LIPPMAN ME, 1989, RECENT PROG HORM RES, V45, P383; MADER S, 1993, J BIOL CHEM, V268, P591; MANGELSDORF DJ, 1993, RECENT PROG HORM RES, V48, P99; MEYER ME, 1989, CELL, V57, P433, DOI 10.1016/0092-8674(89)90918-5; NAAR AM, 1991, CELL, V65, P1267, DOI 10.1016/0092-8674(91)90021-P; NAGPAL S, 1992, CELL, V70, P1007, DOI 10.1016/0092-8674(92)90250-G; PRATT MAC, 1990, MOL CELL BIOL, V10, P6445, DOI 10.1128/MCB.10.12.6445; SAITOU M, 1994, J BIOL CHEM, V269, P19101; SCHULE R, 1991, P NATL ACAD SCI USA, V88, P6092, DOI 10.1073/pnas.88.14.6092; SEGARS JH, 1993, MOL CELL BIOL, V13, P2258, DOI 10.1128/MCB.13.4.2258; SHEIKH MS, 1994, J BIOL CHEM, V269, P21440; SLEIGH MJ, 1986, ANAL BIOCHEM, V156, P251, DOI 10.1016/0003-2697(86)90180-6; SUCOV HM, 1990, P NATL ACAD SCI USA, V87, P5392, DOI 10.1073/pnas.87.14.5392; TATE BF, 1995, J BIOL CHEM, V270, P20258, DOI 10.1074/jbc.270.35.20258; TATE BF, 1994, MOL CELL BIOL, V14, P2323, DOI 10.1128/MCB.14.4.2323; TITCOMB MW, 1994, MOL ENDOCRINOL, V8, P870, DOI 10.1210/me.8.7.870; UEDA H, 1980, CANCER-AM CANCER SOC, V46, P2203, DOI 10.1002/1097-0142(19801115)46:10<2203::AID-CNCR2820461017>3.0.CO;2-A; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; VANDERBURG B, 1995, MOL CELL ENDOCRINOL, V112, P143, DOI 10.1016/0303-7207(95)03600-C; VANDERBURG B, 1993, MOL CELL ENDOCRINOL, V91, P149, DOI 10.1016/0303-7207(93)90267-N; WEBSTER NJG, 1989, EMBO J, V8, P1441, DOI 10.1002/j.1460-2075.1989.tb03526.x	55	20	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20346	20352		10.1074/jbc.271.34.20346	http://dx.doi.org/10.1074/jbc.271.34.20346			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702769	hybrid			2022-12-25	WOS:A1996VD33700021
J	Beslu, N; LaRose, J; Casteran, N; Birnbaum, D; Lecoq, E; Dubreuil, P; Rottapel, R				Beslu, N; LaRose, J; Casteran, N; Birnbaum, D; Lecoq, E; Dubreuil, P; Rottapel, R			Phosphatidylinositol-3' kinase is not required for mitogenesis or internalization of the Flt3/Flk2 receptor tyrosine kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							GROWTH-FACTOR-RECEPTOR; HEMATOPOIETIC STEM-CELLS; GTPASE-ACTIVATING PROTEIN; FACTOR-BETA-RECEPTOR; C-KIT RECEPTOR; MYELOID-DERIVED CELLS; SIGNAL-TRANSDUCTION; BINDING-SITE; SH2 DOMAIN; 3-KINASE ACTIVITY	Flt3/Flk2 is a receptor tyrosine kinase that is expressed on early hematopoietic progenitor cells. Flt3/Flk2 belongs to a family of receptors, including Kit and colony-stimulating factor-1R, which support growth and differentiation within the hematopoietic system, The Flt3/Flk2 ligand, in combination with other growth factors, tors, stimulates the proliferation of hematopoietic progenitors of both lymphoid and myeloid lineages in vitro. We report that phosphatidylinositol 3'-kinase (PI3K) binds to a unique site in the carboxy tail of murine Flt3/Flk2. In distinction to Kit and colony-stimulating factor-1R, mutant receptors unable to couple to PI3K and expressed in rodent fibroblasts or in the interleukin 3-dependent cell line Ba/F3 provide a mitogenic signal comparable to wild-type receptors, Flt3/Flk2 receptors that do not bind to PI3K also normally down-regulate, a function ascribed to PI3K in the context of other receptor systems, These data point to the existence of other unidentified pathways that, alone or in combination with PI3K, transduce these cellular responses following the activation of Flt3/Flk2.	INSERM, U119, MOL HEMATOL LAB, F-13009 MARSEILLE, FRANCE; INSERM, U119, MOL ONCOL LAB, F-13009 MARSEILLE, FRANCE; UNIV TORONTO, WELLESLEY HOSP, RES INST, TORONTO, ON M4Y 1J3, CANADA; UNIV TORONTO, DEPT MED, TORONTO, ON M56 1A1, CANADA; UNIV TORONTO, DEPT IMMUNOL, TORONTO, ON M56 1A1, CANADA	Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; University of Toronto			dubreuil, patrice/F-5346-2011; Dubreuil, Patrice/V-4816-2019	dubreuil, patrice/0000-0003-1155-1150; Dubreuil, Patrice/0000-0003-1155-1150; Rottapel, Robert/0000-0002-6024-5558				ARVIDSSON AK, 1994, MOL CELL BIOL, V14, P6715, DOI 10.1128/MCB.14.10.6715; BERNSTEIN SE, 1959, P SOC EXP BIOL MED, V101, P769; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; BLUMEJENSEN P, 1995, J BIOL CHEM, V270, P14192, DOI 10.1074/jbc.270.23.14192; BROTT BK, 1991, P NATL ACAD SCI USA, V88, P755, DOI 10.1073/pnas.88.3.755; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; Damen JE, 1996, P NATL ACAD SCI USA, V93, P1689, DOI 10.1073/pnas.93.4.1689; DOSIL M, 1993, MOL CELL BIOL, V13, P6572, DOI 10.1128/MCB.13.10.6572; DUBREUIL P, 1991, P NATL ACAD SCI USA, V88, P2341, DOI 10.1073/pnas.88.6.2341; EERMAN PK, 1991, CELL, V64, P425; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; ESCOBEDO JA, 1991, MOL CELL BIOL, V11, P1125, DOI 10.1128/MCB.11.2.1125; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FIXMAN ED, 1995, ONCOGENE, V10, P237; FLEMING WH, 1993, J CELL BIOL, V122, P897, DOI 10.1083/jcb.122.4.897; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; FUKUI Y, 1989, MOL CELL BIOL, V9, P1651, DOI 10.1128/MCB.9.4.1651; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; GOTOH N, 1994, P NATL ACAD SCI USA, V91, P167, DOI 10.1073/pnas.91.1.167; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; HANNUM C, 1994, NATURE, V368, P643, DOI 10.1038/368643a0; HAWKINS PT, 1995, CURR BIOL, V5, P393, DOI 10.1016/S0960-9822(95)00080-7; HE TC, 1993, BLOOD, V82, P3530; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; IKUTA K, 1992, P NATL ACAD SCI USA, V89, P1502, DOI 10.1073/pnas.89.4.1502; JACOBSEN SEW, 1995, J EXP MED, V181, P1357, DOI 10.1084/jem.181.4.1357; JOLY M, 1995, J BIOL CHEM, V270, P13225, DOI 10.1074/jbc.270.22.13225; JOLY M, 1994, SCIENCE, V263, P684, DOI 10.1126/science.8303278; JORDAN CT, 1990, CELL, V61, P953, DOI 10.1016/0092-8674(90)90061-I; KAPELLER R, 1993, MOL CELL BIOL, V13, P6052, DOI 10.1128/MCB.13.10.6052; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KAVANAUGH WM, 1992, MOL CELL BIOL, V12, P3415, DOI 10.1128/MCB.12.8.3415; KAZLAUSKAS A, 1992, MOL CELL BIOL, V12, P2534, DOI 10.1128/MCB.12.6.2534; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KLIPPEL A, 1992, MOL CELL BIOL, V12, P1451, DOI 10.1128/MCB.12.4.1451; KUNDRA V, 1994, NATURE, V367, P474, DOI 10.1038/367474a0; LEV S, 1992, P NATL ACAD SCI USA, V89, P678, DOI 10.1073/pnas.89.2.678; LI NX, 1994, ONCOGENE, V9, P3457; LIOUBIN MN, 1994, MOL CELL BIOL, V14, P5682, DOI 10.1128/MCB.14.9.5682; Lioubin MN, 1996, GENE DEV, V10, P1084, DOI 10.1101/gad.10.9.1084; LIU L, 1994, MOL CELL BIOL, V14, P6926, DOI 10.1128/MCB.14.10.6926; LIU XQ, 1993, MOL CELL BIOL, V13, P5225, DOI 10.1128/MCB.13.9.5225; LYMAN SD, 1993, CELL, V75, P1157, DOI 10.1016/0092-8674(93)90325-K; MAA MC, 1994, MOL CELL BIOL, V14, P5466, DOI 10.1128/MCB.14.8.5466; MACKAREHTSCHIAN K, 1995, IMMUNITY, V3, P147, DOI 10.1016/1074-7613(95)90167-1; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; MAROC N, 1993, ONCOGENE, V8, P909; MATTHEWS W, 1991, CELL, V65, P1143, DOI 10.1016/0092-8674(91)90010-V; MCCULLOCH EA, 1964, SCIENCE, V144, P844, DOI 10.1126/science.144.3620.844; MCGLADE CJ, 1992, MOL CELL BIOL, V12, P991, DOI 10.1128/MCB.12.3.991; MCKEARN JP, 1985, P NATL ACAD SCI USA, V82, P7414, DOI 10.1073/pnas.82.21.7414; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; MUENCH MO, 1995, BLOOD, V85, P963, DOI 10.1182/blood.V85.4.963.bloodjournal854963; MYLES GM, 1994, MOL CELL BIOL, V14, P4843, DOI 10.1128/MCB.14.7.4843; NISHIMURA R, 1993, MOL CELL BIOL, V13, P6889, DOI 10.1128/MCB.13.11.6889; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OGAWA M, 1991, J EXP MED, V174, P63, DOI 10.1084/jem.174.1.63; OGAWA M, 1993, DEVELOPMENT, V117, P1089; OKADA S, 1991, BLOOD, V78, P1706; OKADA S, 1992, BLOOD, V80, P3044; PAGES F, 1994, NATURE, V369, P327, DOI 10.1038/369327a0; PAPAYANNOPOULOU T, 1991, BLOOD, V78, P1403; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PONZETTO C, 1993, MOL CELL BIOL, V13, P4600, DOI 10.1128/MCB.13.8.4600; PRASAD KVS, 1993, P NATL ACAD SCI USA, V90, P7366, DOI 10.1073/pnas.90.15.7366; Ray RJ, 1996, EUR J IMMUNOL, V26, P1504, DOI 10.1002/eji.1830260715; REEDIJK M, 1992, EMBO J, V11, P1365, DOI 10.1002/j.1460-2075.1992.tb05181.x; RICHARD S, 1995, MOL CELL BIOL, V15, P186, DOI 10.1128/MCB.15.1.186; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; ROTTAPEL R, 1994, ONCOGENE, V9, P1755; ROTTAPEL R, 1991, MOL CELL BIOL, V11, P3043, DOI 10.1128/MCB.11.6.3043; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; Russell E S, 1979, Adv Genet, V20, P357, DOI 10.1016/S0065-2660(08)60549-0; SEGATTO O, 1993, ONCOGENE, V8, P2105; SERUNIAN LA, 1990, J VIROL, V64, P4718, DOI 10.1128/JVI.64.10.4718-4725.1990; SERVE H, 1995, EMBO J, V14, P473, DOI 10.1002/j.1460-2075.1995.tb07023.x; SERVE H, 1994, J BIOL CHEM, V269, P6026; SJOLANDER A, 1991, P NATL ACAD SCI USA, V88, P7908, DOI 10.1073/pnas.88.18.7908; STEPHENS L, 1993, EMBO J, V12, P2265, DOI 10.1002/j.1460-2075.1993.tb05880.x; STEPHENS L, 1994, CELL, V77, P83, DOI 10.1016/0092-8674(94)90237-2; STEPHENS L, 1993, J BIOL CHEM, V268, P17162; STOWERS L, 1995, P NATL ACAD SCI USA, V92, P5027, DOI 10.1073/pnas.92.11.5027; TAICHMAN R, 1993, J BIOL CHEM, V268, P20031; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; TILL JE, 1980, BIOCHIM BIOPHYS ACTA, V605, P431, DOI 10.1016/0304-419X(80)90009-8; TUVESON DA, 1993, SCIENCE, V260, P986, DOI 10.1126/science.7684160; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; VANDERGEER P, 1993, EMBO J, V12, P5161, DOI 10.1002/j.1460-2075.1993.tb06211.x; WANG LL, 1995, J BIOL CHEM, V270, P2010, DOI 10.1074/jbc.270.5.2010; WENG WK, 1994, J BIOL CHEM, V269, P32514; WENG ZG, 1994, MOL CELL BIOL, V14, P4509, DOI 10.1128/MCB.14.7.4509; WHITMAN M, 1987, BIOCHEM J, V247, P165, DOI 10.1042/bj2470165; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; YEE NS, 1994, J BIOL CHEM, V269, P31991; YOKOTE K, 1994, J BIOL CHEM, V269, P15337; YU JC, 1991, MOL CELL BIOL, V11, P3780, DOI 10.1128/MCB.11.7.3780; ZEIGLER FC, 1994, BLOOD, V84, P2422, DOI 10.1182/blood.V84.8.2422.bloodjournal8482422; ZHENG Y, 1994, J BIOL CHEM, V269, P18727; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	106	29	32	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					20075	20081		10.1074/jbc.271.33.20075	http://dx.doi.org/10.1074/jbc.271.33.20075			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702727	hybrid			2022-12-25	WOS:A1996VC66900068
J	Himawan, JS; Richardson, CC				Himawan, JS; Richardson, CC			Amino acid residues critical for the interaction between bacteriophage T7 DNA polymerase and Escherichia coli thioredoxin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEOXYRIBONUCLEIC-ACID; REPLICATION INVITRO; GENE-5 PROTEIN; EXONUCLEASE ACTIVITIES; MUTANT THIOREDOXINS; PURIFICATION; SEQUENCE; PROCESSIVITY; SUBUNITS; CONSTRUCTION	Upon infection of Escherichia coli, bacteriophage T7 annexes a host protein, thioredoxin, to serve as a processivity factor for its DNA polymerase, T7 gene 5 protein, In a previous communication (Himawan, J., and Richardson, C. C. (1992) Proc, Natl. Acad. Sci. U. S. A. 89, 9774-9778), we reported that an E. coli strain encoding a Gly-74 to Asp-74 (G74D) thioredoxin mutation could not support wild type T7 growth and that in vivo, six mutations in T7 gene 5 could individually suppress this G74D thioredoxin defect, In the present study, we report the purification and biochemical characterization of the G74D thioredoxin mutant and two suppressor gene 5 proteins, a Glu-319 to Lys-319 (E319K) mutant of gene 5 protein and an Ala-45 to Thr-45 (A45T) mutant, The suppressor E319K mutation, positioned within the DNA polymerization domain of gene 5 protein, appears to suppress the parental thioredoxin mutation by compensating for the binding defect that was caused by the G74D alteration, We suggest that the Glu-319 residue of T7 gene 5 protein and the Gly-74 residue of E. coli thioredoxin define a contact point or site of interaction between the two proteins. In contrast, the A45T mutation in gene 5 protein, located within the 3' to 5' exonuclease domain, does not suppress the G74D thioredoxin mutation by simple restoration of binding affinity, Based upon our understanding of the mechanisms of suppression, we propose a model for the T7 gene 5 protein-E, coli thioredoxin interaction.	HARVARD UNIV, SCH MED, DEPT BIOL CHEM & MOL PHARMACOL, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School					NIAID NIH HHS [AI-06045] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI006045, R37AI006045] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADLER S, 1983, J BIOL CHEM, V258, P6956; ADLER S, 1979, J BIOL CHEM, V254, P1605; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BECK PJ, 1989, J MOL BIOL, V210, P687, DOI 10.1016/0022-2836(89)90102-2; BEESE LS, 1993, SCIENCE, V260, P352, DOI 10.1126/science.8469987; BERNAD A, 1989, CELL, V59, P219, DOI 10.1016/0092-8674(89)90883-0; BLANCO L, 1991, GENE, V100, P27, DOI 10.1016/0378-1119(91)90346-D; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; CHATTERJEE DK, 1991, GENE, V97, P13, DOI 10.1016/0378-1119(91)90004-U; DAS SK, 1979, J BIOL CHEM, V254, P1227; DELARUE M, 1990, PROTEIN ENG, V3, P461, DOI 10.1093/protein/3.6.461; DUNN JJ, 1983, J MOL BIOL, V166, P477, DOI 10.1016/S0022-2836(83)80282-4; DYSON HJ, 1990, BIOCHEMISTRY-US, V29, P4129, DOI 10.1021/bi00469a016; EKLUND H, 1984, EMBO J, V3, P1443, DOI 10.1002/j.1460-2075.1984.tb01994.x; Ellis EL, 1939, J GEN PHYSIOL, V22, P365, DOI 10.1085/jgp.22.3.365; FUJIMURA RK, 1976, J BIOL CHEM, V251, P2168; GRIPPO P, 1971, J BIOL CHEM, V246, P6867; GRODBERG J, 1988, J BACTERIOL, V170, P1245, DOI 10.1128/jb.170.3.1245-1253.1988; HIMAWAN JS, 1992, P NATL ACAD SCI USA, V89, P9774, DOI 10.1073/pnas.89.20.9774; HIMAWAN JS, 1996, THESIS HARVARD U CAM; HOLMGREN A, 1984, METHOD ENZYMOL, V107, P295; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; HORI K, 1979, J BIOL CHEM, V254, P1598; HORI K, 1979, J BIOL CHEM, V254, P1591; HUBER HE, 1986, J BIOL CHEM, V261, P5006; HUBER HE, 1987, J BIOL CHEM, V262, P16224; Innis MA, 1990, PCR PROTOCOLS GUIDE, P3; JENG MF, 1994, STRUCTURE, V2, P853, DOI 10.1016/S0969-2126(94)00086-7; JENG MF, 1995, BIOCHEMISTRY-US, V34, P611, DOI 10.1021/bi00002a028; KRAUSE G, 1991, J BIOL CHEM, V266, P4056; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; LAURENT TC, 1964, J BIOL CHEM, V239, P3436; LOPEZ P, 1989, J BIOL CHEM, V264, P4255; LUNN CA, 1984, J BIOL CHEM, V259, P469; LUNN CA, 1982, J BIOL CHEM, V257, P1424; MARK DF, 1976, P NATL ACAD SCI USA, V73, P780, DOI 10.1073/pnas.73.3.780; MCALEAR MA, 1994, MOL CELL BIOL, V14, P4390, DOI 10.1128/MCB.14.7.4390; Miller JH, 1972, EXPT MOL GENETICS, P201; MINARIK P, 1993, J BASIC MICROB, V33, P213, DOI 10.1002/jobm.3620330314; MODRICH P, 1975, J BIOL CHEM, V250, P5508; MODRICH P, 1975, J BIOL CHEM, V250, P5515; ODONNELL M, 1993, NUCLEIC ACIDS RES, V21, P1, DOI 10.1093/nar/21.1.1; OEY JL, 1971, EUR J BIOCHEM, V23, P497, DOI 10.1111/j.1432-1033.1971.tb01646.x; OLLIS DL, 1985, NATURE, V313, P762, DOI 10.1038/313762a0; OLLIS DL, 1985, NATURE, V313, P818, DOI 10.1038/313818a0; RUSSEL M, 1983, J BACTERIOL, V154, P1064, DOI 10.1128/JB.154.3.1064-1076.1983; RUSSEL M, 1986, J BIOL CHEM, V261, P4997; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANGER F, 1975, J MOL BIOL, V94, P441, DOI 10.1016/0022-2836(75)90213-2; SCARLATO V, 1992, GENE, V118, P109, DOI 10.1016/0378-1119(92)90256-O; SLABY I, 1989, J BIOL CHEM, V264, P16502; STENT GS, 1963, MOL BIOL BACTERIAL V, P74; STILLMAN B, 1994, CELL, V78, P725, DOI 10.1016/S0092-8674(94)90362-X; STUDIER FW, 1969, VIROLOGY, V39, P562, DOI 10.1016/0042-6822(69)90104-4; TABOR S, 1987, J BIOL CHEM, V262, P16212; TABOR S, 1987, J BIOL CHEM, V262, P15330; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TABOR S, 1995, P NATL ACAD SCI USA, V92, P6339, DOI 10.1073/pnas.92.14.6339; TABOR S, 1989, J BIOL CHEM, V264, P6447; WALKER JR, 1982, P NATL ACAD SCI-BIOL, V79, P3340, DOI 10.1073/pnas.79.10.3340; WYMAN C, 1995, CURR BIOL, V5, P334, DOI 10.1016/S0960-9822(95)00065-0; YAMAMOTO KR, 1970, VIROLOGY, V40, P734, DOI 10.1016/0042-6822(70)90218-7; YEHLE CO, 1973, J BIOL CHEM, V248, P7456	64	25	26	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					19999	20008		10.1074/jbc.271.33.19999	http://dx.doi.org/10.1074/jbc.271.33.19999			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702717	Green Published, hybrid			2022-12-25	WOS:A1996VC66900058
J	Wang, GF; Nikovits, W; Schleinitz, M; Stockdale, FE				Wang, GF; Nikovits, W; Schleinitz, M; Stockdale, FE			Atrial chamber-specific expression of the slow myosin heavy chain 3 gene in the embryonic heart	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-ACTIN PROMOTER; TROPONIN-C GENE; MUSCLE-SPECIFIC EXPRESSION; HOMEOBOX-CONTAINING GENE; CARDIAC-MUSCLE; SKELETAL-MUSCLE; TRANSCRIPTION FACTOR; TRANSGENIC MICE; REGULATORY ELEMENTS; T-GENE	The quail slow myosin heavy chain 3 (slow MyHC 3) gene is expressed in the developing heart and in slow muscles of the developing limb. It is first expressed in the pulsatile cardiac tube in the embryo, and as the heart chamberizes its expression becomes restricted to the atria. To identify regulatory elements responsible for atrial-specific expression, the 5' upstream region of slow MyHC 3 gene was investigated. An atrial regulatory domain (ARD1) between -840 and -680 acts as an atrial cell-specific enhancer in primary cardiocyte cultures. ARD1 also specifies atrial-specific expression in vivo when the ARD1/heterologous promoter was introduced into developing chick embryos by a replication-competent retroviral vector. ARD1 is the first atrial cell-specific enhancer to be identified. Fine deletion and mutation analysis within ARD1 defined a 40)-base pair vitamin D-3 receptor-like element that controls atrial cell-specific expression of the slow MyHC 3 gene by inhibiting its expression in ventricular cardiocytes.	STANFORD UNIV,SCH MED,DEPT MED,STANFORD,CA 94305	Stanford University					NATIONAL INSTITUTE ON AGING [R01AG002822] Funding Source: NIH RePORTER; NIA NIH HHS [AG02822] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AMACHER SL, 1993, MOL CELL BIOL, V13, P2753, DOI 10.1128/MCB.13.5.2753; ARGENTIN S, 1994, MOL CELL BIOL, V14, P777, DOI 10.1128/MCB.14.1.777; BARRY WH, 1986, J GEN PHYSIOL, V88, P393, DOI 10.1085/jgp.88.3.393; BODMER R, 1990, DEVELOPMENT, V110, P661; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CEPKO CL, 1992, CURRENT PROTOCOLS MO, V1; CHRISTENSEN TH, 1993, MOL CELL BIOL, V13, P6752, DOI 10.1128/MCB.13.11.6752; CRIBBS LL, 1989, J BIOL CHEM, V264, P10672; CROW MT, 1986, DEV BIOL, V118, P333, DOI 10.1016/0012-1606(86)90002-3; DEJONG F, 1990, ANAT REC, V226, P213, DOI 10.1002/ar.1092260211; DIMARIO JX, 1993, NATURE, V362, P165, DOI 10.1038/362165a0; EPPENBERGER HM, 1994, TRENDS CARDIOVAS MED, V4, P187, DOI 10.1016/1050-1738(94)90056-6; EVANS D, 1988, DEV BIOL, V127, P376, DOI 10.1016/0012-1606(88)90324-7; GUPTA MP, 1994, J BIOL CHEM, V269, P29677; GUSTAFSON TA, 1987, P NATL ACAD SCI USA, V84, P3122, DOI 10.1073/pnas.84.10.3122; HOH JFY, 1978, J MOL CELL CARDIOL, V10, P1053, DOI 10.1016/0022-2828(78)90401-7; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; Hunter E, 1979, Methods Enzymol, V58, P379; IANNELLO RC, 1991, J BIOL CHEM, V266, P3309; IP HS, 1994, MOL CELL BIOL, V14, P7517, DOI 10.1128/MCB.14.11.7517; JACOBSON AG, 1988, DEVELOPMENT, V104, P341; KELLY R, 1995, J CELL BIOL, V129, P383, DOI 10.1083/jcb.129.2.383; KOMURO I, 1993, P NATL ACAD SCI USA, V90, P8145, DOI 10.1073/pnas.90.17.8145; KUBALAK SW, 1994, J BIOL CHEM, V269, P16961; Kuisk IR, 1996, DEV BIOL, V174, P1, DOI 10.1006/dbio.1996.0046; LAVERRIERE AC, 1994, J BIOL CHEM, V269, P23177; LEE KJ, 1994, MOL CELL BIOL, V14, P1220, DOI 10.1128/MCB.14.2.1220; LI Q, 1994, J BIOL CHEM, V269, P4934; LIBBY P, 1984, J MOL CELL CARDIOL, V16, P803, DOI 10.1016/S0022-2828(84)80004-8; LILLY B, 1995, SCIENCE, V267, P688, DOI 10.1126/science.7839146; LYONS GE, 1990, J CELL BIOL, V111, P2427, DOI 10.1083/jcb.111.6.2427; LYONS I, 1995, GENE DEV, V9, P1654, DOI 10.1101/gad.9.13.1654; MAR JH, 1988, P NATL ACAD SCI USA, V85, P6404, DOI 10.1073/pnas.85.17.6404; MAR JH, 1988, J CELL BIOL, V107, P573, DOI 10.1083/jcb.107.2.573; Miller JH., 1972, EXPT MOL GENETICS; MOLKENTIN JD, 1994, MOL CELL BIOL, V14, P4947, DOI 10.1128/MCB.14.7.4947; MOLKENTIN JD, 1993, J BIOL CHEM, V268, P2602; MORKIN E, 1993, CIRCULATION, V87, P1451, DOI 10.1161/01.CIR.87.5.1451; MOSS JB, 1994, J BIOL CHEM, V269, P12731; NIKOVITS W, 1996, IN PRESS J BIOL CHEM; OBRIEN TX, 1993, P NATL ACAD SCI USA, V90, P5157, DOI 10.1073/pnas.90.11.5157; PAGE S, 1992, DEV BIOL, V154, P118, DOI 10.1016/0012-1606(92)90053-J; PARKER TG, 1992, J BIOL CHEM, V267, P3343; PARMACEK MS, 1994, MOL CELL BIOL, V14, P1870, DOI 10.1128/MCB.14.3.1870; PARMACEK MS, 1992, MOL CELL BIOL, V12, P1967, DOI 10.1128/MCB.12.5.1967; PETROPOULOS CJ, 1992, J VIROL, V66, P3391, DOI 10.1128/JVI.66.6.3391-3397.1992; RINDT H, 1993, J BIOL CHEM, V268, P5332; RINDT H, 1995, P NATL ACAD SCI USA, V92, P1540, DOI 10.1073/pnas.92.5.1540; SALTER DW, 1987, VIROLOGY, V157, P236, DOI 10.1016/0042-6822(87)90334-5; Sambrook J., 2002, MOL CLONING LAB MANU; SARTORELLI V, 1992, P NATL ACAD SCI USA, V89, P4047, DOI 10.1073/pnas.89.9.4047; SEIDMAN CE, 1991, CAN J PHYSIOL PHARM, V69, P1486, DOI 10.1139/y91-223; SRIVASTAVA D, 1995, SCIENCE, V270, P1995, DOI 10.1126/science.270.5244.1995; STEWART AFR, 1994, J BIOL CHEM, V269, P3147; SUBRAMANIAM A, 1993, J BIOL CHEM, V268, P4331; SUBRAMANIAM A, 1991, J BIOL CHEM, V266, P24613; SUCOV HM, 1994, GENE DEV, V8, P1007, DOI 10.1101/gad.8.9.1007; THOMPSON WR, 1991, J BIOL CHEM, V266, P22678; WANG GS, 1994, J BIOL CHEM, V269, P30595; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; YU YT, 1992, GENE DEV, V6, P1783, DOI 10.1101/gad.6.9.1783; YUTZEY KE, 1994, DEVELOPMENT, V120, P871; ZADEH BJ, 1986, DEV BIOL, V115, P204, DOI 10.1016/0012-1606(86)90241-1; ZHOU MD, 1993, MOL CELL BIOL, V13, P1222, DOI 10.1128/MCB.13.2.1222; ZOU YM, 1995, MOL CELL BIOL, V15, P2972	65	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					19836	19845		10.1074/jbc.271.33.19836	http://dx.doi.org/10.1074/jbc.271.33.19836			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702693	hybrid			2022-12-25	WOS:A1996VC66900034
J	Bai, M; Quinn, S; Trivedi, S; Kifor, O; Pearce, SHS; Pollak, MR; Krapcho, K; Hebert, SC; Brown, EM				Bai, M; Quinn, S; Trivedi, S; Kifor, O; Pearce, SHS; Pollak, MR; Krapcho, K; Hebert, SC; Brown, EM			Expression and characterization of inactivating and activating mutations in the human Ca-0(2+)-sensing receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL HYPOCALCIURIC HYPERCALCEMIA; NEONATAL SEVERE HYPERPARATHYROIDISM; EXTRACELLULAR CA2+-SENSING RECEPTOR; GLUTAMATE RECEPTORS; MOLECULAR-CLONING; GENE; CALCIUM; CELLS; CA2+	Nearly 30 mutations have been identified to date in the coding region of the extracellular calcium-sensing receptor (CaR) that are associated with inherited human hypo- and hypercalcemic disorders, To understand the mechanisms by which the mutations alter the function of the receptor may help to discern the structure-function relationships in terms of ligand-binding and G protein coupling. In the present studies, we transiently expressed eight known CaR mutations in HEK293 cells. The effects of the mutations on extracellular calcium- and gadolinium-elicited increases in the cytosolic calcium concentration were then examined. Seven inactivating mutations, which cause familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism, show a reduced functional activity of the receptor because they may 1) reduce its affinity for agonists; 2) prevent conversion of the receptor from a putatively immature, high mannose form into the fully glycosylated and biologically active form of the CaR, in addition to lowering its affinity for agonists; or 3) fail to couple the receptor to and/or activate its respective G protein(s). Conversely, one activating mutation, which causes a form of autosomal dominant hypocalcemia, appears to increase the affinity of the receptor for its agonists.	HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,MOL ENDOCRINOL GRP,LONDON W12 0NN,ENGLAND; HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115; NPS PHARMACEUT INC,SALT LAKE CITY,UT 84108; BRIGHAM & WOMENS HOSP,DIV RENAL,BOSTON,MA 02115	Imperial College London; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	Bai, M (corresponding author), BRIGHAM & WOMENS HOSP,DIV ENDOCRINE HYPERTENS,DEPT MED,221 LONGWOOD AVE,BOSTON,MA 02115, USA.		Pearce, Simon/AAB-3692-2019	Pearce, Simon/0000-0001-8384-8063	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK009436, R01DK041415, R01DK044588] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK44588, DK09436, DK41415] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AIDA K, 1995, J CLIN ENDOCR METAB, V80, P2594, DOI 10.1210/jc.80.9.2594; AIDA K, 1995, BIOCHEM BIOPH RES CO, V214, P524, DOI 10.1006/bbrc.1995.2318; AUSUBEL FM, 1993, ENDOGLYCOSIDASE GLYC; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; BROWN EM, 1991, PHYSIOL REV, V71, P371, DOI 10.1152/physrev.1991.71.2.371; CHOU YHW, 1995, AM J HUM GENET, V56, P1075; Cochran W.G., 1967, STAT METHODS; DUKSIN D, 1982, EUR J BIOCHEM, V129, P77, DOI 10.1111/j.1432-1033.1982.tb07022.x; DUNCAN DB, 1955, BIOMETRICS, V11, P1, DOI 10.2307/3001478; ERICKSON PA, 1993, POSTEMBEDDING IMMUNO, P283; FAJTOVA VT, 1991, AM J PHYSIOL, V261, pE151, DOI 10.1152/ajpendo.1991.261.1.E151; GARRETT JE, 1995, J BIOL CHEM, V270, P12919, DOI 10.1074/jbc.270.21.12919; HAMMERLAND LG, 1995, J BONE MINER RES, V10, pS156; HAWLEY-NELSON P, 1993, FOCUS MADISON, V15, P73; Heath H, 1996, J CLIN ENDOCR METAB, V81, P1312, DOI 10.1210/jcem.81.4.8636323; HO C, 1995, NAT GENET, V11, P389, DOI 10.1038/ng1295-389; JANICIC N, 1995, AM J HUM GENET, V56, P880; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MITHAL A, 1995, ENDOCRINOLOGY, V136, P3087, DOI 10.1210/en.136.7.3087; MORENCY CA, 1987, BIOTECHNIQUES, V5, P444; NAKANISHI S, 1992, SCIENCE, V258, P597, DOI 10.1126/science.1329206; Pearce SHS, 1995, J CLIN INVEST, V96, P2683, DOI 10.1172/JCI118335; POLLAK MR, 1994, NAT GENET, V8, P303, DOI 10.1038/ng1194-303; POLLAK MR, 1993, CELL, V75, P1297, DOI 10.1016/0092-8674(93)90617-Y; SUN GY, 1988, NEUROCHEM INT, V12, P69, DOI 10.1016/0197-0186(88)90150-7; TAKAHASHI K, 1993, J BIOL CHEM, V268, P19341	27	346	361	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19537	19545		10.1074/jbc.271.32.19537	http://dx.doi.org/10.1074/jbc.271.32.19537			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702647	hybrid			2022-12-25	WOS:A1996VB68400081
J	Claessens, F; Alen, P; Devos, A; Peeters, B; Verhoeven, G; Rombauts, W				Claessens, F; Alen, P; Devos, A; Peeters, B; Verhoeven, G; Rombauts, W			The androgen-specific probasin response element 2 interacts differentially with androgen and glucocorticoid receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTATIC BINDING-PROTEIN; ESTROGEN-RECEPTOR; C3(1) GENE; DNA; SEQUENCES; PROMOTER; TRANSCRIPTION; INTRON; DOMAIN; SITE	The nuclear receptors constitute a large family of transcription factors characterized by a well conserved DNA-binding domain. The receptors for glucocorticoids, progestins, mineralocorticoids, and androgens constitute a subgroup because they bind in vitro with high affinity to DNA elements containing a partial palindrome of the core sequence 5'-TGTTCT-3'. In vivo, however, the corresponding steroids differentially regulate the expression of their target genes, even when more than one receptor type is present in a particular cell. The DNA-binding domains of the androgen and of the glucocorticoid receptors bind most androgen response elements with similar relative affinities. In contrast, one element (5'-GGTTCTTGGAGTACT-3') which was recently described in the promoter region of the probasin gene selectively interacts with the DNA-binding domain of the androgen receptor and not with that of the glucocorticoid receptor. From studies with chimeric elements, it can be deduced that it is the left subsequence 5'-GGTTCT-3' which excludes the glucocorticoid receptor domain from binding. In co-transfection experiments where the ARE of the C3(1) gene is responsive to both androgens and glucocorticoids, the probasin element is induced only by androgens and not by glucocorticoids. The existence of response elements which are recognized preferentially by the androgen receptor provides yet another possible mechanism to explain the differences of the in vivo effects between androgens and other steroids of the subgroup.	CATHOLIC UNIV LEUVEN,FAC MED,LAB EXPTL MED & ENDOCRINOL,B-3000 LOUVAIN,BELGIUM	KU Leuven	Claessens, F (corresponding author), CATHOLIC UNIV LEUVEN,FAC MED,DIV BIOCHEM,CAMPUS GASTHUISBERG,B-3000 LOUVAIN,BELGIUM.		Claessens, Frank/M-8565-2016	Claessens, Frank/0000-0002-8676-7709				ADLER AJ, 1993, MOL CELL BIOL, V13, P6326, DOI 10.1128/MCB.13.10.6326; CELIS L, 1993, MOL CELL ENDOCRINOL, V94, P165, DOI 10.1016/0303-7207(93)90165-G; CHALEPAKIS G, 1990, DNA CELL BIOL, V9, P355, DOI 10.1089/dna.1990.9.355; CHANG CS, 1988, P NATL ACAD SCI USA, V85, P7211, DOI 10.1073/pnas.85.19.7211; CHANG CS, 1995, CRIT REV EUKAR GENE, V5, P97, DOI 10.1615/CritRevEukarGeneExpr.v5.i2.10; CLAESSENS F, 1989, BIOCHEM BIOPH RES CO, V164, P833, DOI 10.1016/0006-291X(89)91534-9; CLAESSENS F, 1990, MOL CELL ENDOCRINOL, V74, P203, DOI 10.1016/0303-7207(90)90225-W; CLAESSENS F, 1993, BIOCHEM BIOPH RES CO, V191, P688, DOI 10.1006/bbrc.1993.1272; CROSSLEY M, 1992, SCIENCE, V257, P377, DOI 10.1126/science.1631558; DEVOS A, 1995, THESIS U LEUVEN LEUV; DEVOS P, 1993, MOL CELL ENDOCRINOL, V90, pR11, DOI 10.1016/0303-7207(93)90160-L; DEVOS P, 1991, J BIOL CHEM, V266, P3439; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GORDON DA, 1995, EXP CELL RES, V217, P368, DOI 10.1006/excr.1995.1099; GREENBERG NM, 1994, MOL ENDOCRINOL, V8, P230, DOI 10.1210/me.8.2.230; HAM J, 1988, NUCLEIC ACIDS RES, V16, P5263, DOI 10.1093/nar/16.12.5263; KASPER S, 1994, J BIOL CHEM, V269, P31763; LIEBERMAN BA, 1993, MOL ENDOCRINOL, V7, P515, DOI 10.1210/me.7.4.515; LOMBES M, 1993, BIOCHEM J, V292, P577, DOI 10.1042/bj2920577; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MADER S, 1993, NUCLEIC ACIDS RES, V21, P1125, DOI 10.1093/nar/21.5.1125; MADER S, 1989, NATURE, V338, P271, DOI 10.1038/338271a0; NORDEEN SK, 1990, MOL ENDOCRINOL, V4, P1866, DOI 10.1210/mend-4-12-1866; RENNIE PS, 1993, MOL ENDOCRINOL, V7, P23, DOI 10.1210/me.7.1.23; RIEGMAN PHJ, 1991, MOL ENDOCRINOL, V5, P1921, DOI 10.1210/mend-5-12-1921; ROCHE PJ, 1992, MOL ENDOCRINOL, V6, P2229, DOI 10.1210/me.6.12.2229; ROY AK, 1995, CRIT REV EUKAR GENE, V5, P157, DOI 10.1615/CritRevEukarGeneExpr.v5.i2.30; RUNDLETT SE, 1995, MOL CELL ENDOCRINOL, V109, P1, DOI 10.1016/0303-7207(95)03477-O; RUSHMERE NK, 1987, MOL CELL ENDOCRINOL, V51, P259, DOI 10.1016/0303-7207(87)90036-0; TRUSS M, 1993, ENDOCR REV, V14, P459, DOI 10.1210/er.14.4.459; YAMAMOTO KR, 1985, ANNU REV GENET, V19, P209, DOI 10.1146/annurev.genet.19.1.209; ZILLIACUS J, 1995, MOL ENDOCRINOL, V9, P389, DOI 10.1210/me.9.4.389	32	111	112	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19013	19016		10.1074/jbc.271.32.19013	http://dx.doi.org/10.1074/jbc.271.32.19013			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702568	hybrid			2022-12-25	WOS:A1996VB68400002
J	Gilchrist, RL; Ryu, KS; Ji, IH; Ji, TH				Gilchrist, RL; Ryu, KS; Ji, IH; Ji, TH			The luteinizing hormone chorionic gonadotropin receptor has distinct transmembrane conductors for cAMP and inositol phosphate signals	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MALE PRECOCIOUS PUBERTY; THYROTROPIN RECEPTOR; ACTIVATION; GENE; BINDING; MUTATIONS; PROTEINS; ASP(397); CYCLASE; LOOP	The luteinizing hormone/chorionic gonadotropin receptor is a member of the seven-transmembrane receptor family. It is coupled, presumably via G(s) and G(q), to two signal pathways involving adenylyl cyclase/cAMP and phospholipase C/inositol phosphate (IF). Little is known about the events prior to G-protein coupling: for example, whether these signals are generated from a single or multiple independent origins and mechanisms, when and where they diverge, and how they are transduced, We report novel observations that the cAMP signal and the IP signal originate and diverge upstream of G-protein coupling, The generation of these two signals independently involves Lys(583) in exoloop 3 of the rat receptor. For this study, Lys(583) Of the receptor was substituted with a panel of amino acids, and mutant receptors were assayed for hormone binding and induction of cAMP, inositol monophosphate, inositol bisphosphate, and inositol trisphosphate, No substitutions for Lys(583) were permissible for cAMP induction, despite successful surface expression and hormone binding. In contrast, several substitutions were permissible for IP induction, Our results suggest two distinct transmembrane signal conductors for cAMP and inositol phosphate signals and imply particular models of receptor activation not previously suggested.	UNIV WYOMING,DEPT MOL BIOL,LARAMIE,WY 82071	University of Wyoming					NICHD NIH HHS [HD-18702] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD018702] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALLGEIER A, 1994, J BIOL CHEM, V269, P13733; Fernandez LM, 1996, J BIOL CHEM, V271, P925, DOI 10.1074/jbc.271.2.925; GUDERMANN T, 1992, J BIOL CHEM, V267, P4479; HUANG JN, 1995, J BIOL CHEM, V270, P30023; JI I, 1993, J BIOL CHEM, V268, P20851; JI IH, 1993, J BIOL CHEM, V268, P22971; JI IH, 1991, ENDOCRINOLOGY, V128, P2648, DOI 10.1210/endo-128-5-2648; JI TH, 1995, ENDOCRINE, V3, P187, DOI 10.1007/BF02994442; KOO YB, 1991, ENDOCRINOLOGY, V128, P2297, DOI 10.1210/endo-128-5-2297; KOSUGI S, 1994, MOL ENDOCRINOL, V8, P498, DOI 10.1210/me.8.4.498; KOSUGI S, 1995, HUM MOL GENET, V4, P183, DOI 10.1093/hmg/4.2.183; KOSUGI S, 1994, FEBS LETT, V349, P89, DOI 10.1016/0014-5793(94)00646-6; LAPETINA EG, 1987, METHOD ENZYMOL, V141, P176; LAUE L, 1995, HUM MOL GENET, V4, P1429, DOI 10.1093/hmg/4.8.1429; LAUE L, 1995, P NATL ACAD SCI USA, V92, P1906, DOI 10.1073/pnas.92.6.1906; LEFKOWITZ RJ, 1993, TRENDS PHARMACOL SCI, V14, P303, DOI 10.1016/0165-6147(93)90048-O; MAJERUS PW, 1992, ANNU REV BIOCHEM, V61, P225, DOI 10.1146/annurev.bi.61.070192.001301; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; REMY JJ, 1993, BIOCHEM BIOPH RES CO, V193, P1023, DOI 10.1006/bbrc.1993.1727; Ryu KS, 1996, J BIOL CHEM, V271, P7301, DOI 10.1074/jbc.271.13.7301; SHENKER A, 1993, NATURE, V365, P652, DOI 10.1038/365652a0; TSAIMORRIS CH, 1990, J BIOL CHEM, V265, P19385; TSAIMORRIS CH, 1991, J BIOL CHEM, V266, P11355; XIE YB, 1990, J BIOL CHEM, V265, P21411; YANO K, 1995, J CLIN ENDOCR METAB, V80, P1162, DOI 10.1210/jc.80.4.1162; ZHU X, 1994, MOL PHARMACOL, V46, P460	26	73	76	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19283	19287		10.1074/jbc.271.32.19283	http://dx.doi.org/10.1074/jbc.271.32.19283			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702611	hybrid			2022-12-25	WOS:A1996VB68400045
J	Hu, B; Trinh, K; Figueira, WF; Price, PA				Hu, B; Trinh, K; Figueira, WF; Price, PA			Isolation and sequence of a novel human chondrocyte protein related to mammalian members of the chitinase protein family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACILLUS-CIRCULANS WL-12; ARTICULAR CHONDROCYTES; IDENTIFICATION; CELLS; CHITOTRIOSIDASE; GLYCOPROTEIN; CLONING	We describe the isolation of a novel protein from the conditioned medium of human articular cartilage chondrocytes in primary culture, This 39-kDa protein has the N-terminal sequence YKL, which we have termed YKL-39, The 1434-nucleotide sequence of the YKL-39 cDNA predicts a 385-residue initial translation product and a 364-residue mature YKL-39, The amino acid sequence of YKL-39 is most closely related to YKL-40, followed by macrophage chitotriosidase, oviductal glycoprotein, and macrophage YM-1, All five proteins share significant sequence identity with bacterial chitinases and have the probable structure of an (alpha beta)(8) barrel, YKL-39 lacks the active site glutamate, which is essential for the activity of chitinases, and as expected has no chitinase activity, The highest level of YKL-39 mRNA expression is seen in chondrocytes, followed by synoviocytes, lung, and heart, YKL-39 accounts for 4% of the protein in chondrocyte-conditioned medium, prostromelysin accounts for 17%, and YKL-40 accounts for 33%, In contrast to YKL-40, YRL-39 is not a glycoprotein and does not bind to heparin.	UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093	University of California System; University of California San Diego			Figueira, Will/A-5163-2009	Figueira, Will/0000-0001-9472-8710	NATIONAL INSTITUTE ON AGING [P01AG007996] Funding Source: NIH RePORTER; NIA NIH HHS [AG07996] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ARIAS EB, 1994, BIOL REPROD, V51, P685, DOI 10.1095/biolreprod51.4.685; BOOT RG, 1995, J BIOL CHEM, V270, P26252, DOI 10.1074/jbc.270.44.26252; COULSON AFW, 1994, FEBS LETT, V354, P41, DOI 10.1016/0014-5793(94)01084-6; FARBER GK, 1993, CURR OPIN STRUC BIOL, V3, P409, DOI 10.1016/S0959-440X(05)80114-9; HAKALA BE, 1993, J BIOL CHEM, V268, P25803; HENRISSAT B, 1993, BIOCHEM J, V293, P781, DOI 10.1042/bj2930781; JOHANSEN JS, 1995, EUR J CANCER, V31A, P1437, DOI 10.1016/0959-8049(95)00196-P; JOHANSEN JS, 1993, BRIT J RHEUMATOL, V32, P949; JOHANSEN JS, 1992, J BONE MINER RES, V7, P501; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; MAIER R, 1993, J BIOL CHEM, V268, P21527; MORRISON BW, 1994, ONCOGENE, V9, P3417; MYASHITA K, 1993, BIOSCI BIOTECH BIOCH, V57, P1691; NYIRKOS P, 1990, BIOCHEM J, V268, P265; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; REJMAN JJ, 1988, BIOCHEM BIOPH RES CO, V150, P329, DOI 10.1016/0006-291X(88)90524-4; RENKEMA GH, 1995, J BIOL CHEM, V270, P2198, DOI 10.1074/jbc.270.5.2198; SHACKELTON LM, 1995, J BIOL CHEM, V270, P13076, DOI 10.1074/jbc.270.22.13076; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; WATANABE T, 1993, J BIOL CHEM, V268, P18567; WATANABE T, 1992, J BACTERIOL, V174, P408, DOI 10.1128/jb.174.2.408-414.1992	21	165	178	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19415	19420		10.1074/jbc.271.32.19415	http://dx.doi.org/10.1074/jbc.271.32.19415			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702629	hybrid			2022-12-25	WOS:A1996VB68400063
J	Feng, WJ; Bedows, E; Norton, SE; Ruddon, RW				Feng, WJ; Bedows, E; Norton, SE; Ruddon, RW			Novel covalent chaperone complexes associated with human chorionic gonadotropin beta subunit folding intermediates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER OVARY CELLS; ENDOPLASMIC-RETICULUM; MOLECULAR CHAPERONES; LINKED OLIGOSACCHARIDES; PROTEIN; BIP; CALNEXIN; KINETICS; PATHWAY	Molecular chaperones facilitate the folding of proteins in the endoplasmic reticulum (ER) of mammalian cells, The glycoprotein hormone chorionic gonadotropin beta subunit is a secretory protein whose folding in the ER has been demonstrated (Huth, J, R,, Mountjoy, K,, Perini, F,, and Ruddon, R, W, (1992) J, Biol, Chem, 267, 8870-8879), Because folding of wild type hCG-beta subunit occurs in the ER with a t(1/2) = 4-5 min, stable association of ER chaperones with hCG-beta have been difficult to detect probably because they have a short half-life, However, beta-chaperone complexes containing the ER chaperones BiP, ERp72, and ERp94 have been detected in slow folding mutants of hCG-beta subunit that lack both of the N-linked oligosaccharides (Feng, W,, Matzuk, M, M,, Mountjoy, K., Bedows, E,, Ruddon, R, W,, and Boime, I, (1995) J, Biol, Chem, 270, 11851-11859), The questions addressed here are 1) whether the detection of chaperone-containing complexes is related to the absence of carbohydrate or to the rate of hCG-beta subunit folding, 2) whether such complexes are dead-end or whether they lead to formation of a secreted, mature hCG-beta form, and 3) what the nature of the hCG-beta-chaperone binding is, The data obtained indicate that the amount of detectable hCG-beta-chaperone complexes correlates with the rate or extent of folding, that the complexes of hCG-beta with ER chaperones lead to the formation of secretable beta, and that the complexes of hCG-beta with chaperones involve the formation of intermolecular disulfide bonds.	UNIV NEBRASKA,MED CTR,EPPLEY INST RES CANC & ALLIED DIS,OMAHA,NE 68198; UNIV NEBRASKA,MED CTR,DEPT PHARMACOL,OMAHA,NE 68198; UNIV NEBRASKA,MED CTR,DEPT BIOCHEM & MOL BIOL,OMAHA,NE 68198	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center					NCI NIH HHS [CA32949, P30 CA36727] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA036727, R01CA032949] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEDOWS E, 1992, J BIOL CHEM, V267, P8880; BEDOWS E, 1994, J BIOL CHEM, V269, P10574; BEDOWS E, 1993, J BIOL CHEM, V268, P11655; BRAAKMAN I, 1992, NATURE, V356, P260, DOI 10.1038/356260a0; FENG W, 1995, J BIOL CHEM, V270, P11851, DOI 10.1074/jbc.270.20.11851; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; HAMMOND C, 1994, SCIENCE, V266, P456, DOI 10.1126/science.7939687; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HUTH JR, 1992, J BIOL CHEM, V267, P21396; HUTH JR, 1992, J BIOL CHEM, V267, P8870; KIM PS, 1995, J CELL BIOL, V128, P29, DOI 10.1083/jcb.128.1.29; LANDRY SJ, 1994, ANNU REV BIOPH BIOM, V23, P645, DOI 10.1146/annurev.bb.23.060194.003241; LODISH HF, 1993, J BIOL CHEM, V268, P20598; MATZUK MM, 1988, J BIOL CHEM, V263, P17106; MELNICK J, 1992, J BIOL CHEM, V267, P21303; NAUSEEF WM, 1995, J BIOL CHEM, V270, P4741, DOI 10.1074/jbc.270.9.4741; NIGAM SK, 1994, J BIOL CHEM, V269, P1744; OU WJ, 1993, NATURE, V364, P771, DOI 10.1038/364771a0; PETERS BP, 1984, J BIOL CHEM, V259, P5123; PUIG A, 1994, J BIOL CHEM, V269, P25889; TIAN GL, 1995, J BIOL CHEM, V270, P23910, DOI 10.1074/jbc.270.41.23910; WEISSMAN JS, 1994, CELL, V78, P693, DOI 10.1016/0092-8674(94)90533-9	22	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18543	18548		10.1074/jbc.271.31.18543	http://dx.doi.org/10.1074/jbc.271.31.18543			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702502	hybrid			2022-12-25	WOS:A1996VB68300040
J	Melendez, JA; Davies, KJA				Melendez, JA; Davies, KJA			Manganese superoxide dismutase modulates interleukin-1 alpha levels in HT-1080 fibrosarcoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; NF-KAPPA-B; MESSENGER-RNA; HYDROGEN-PEROXIDE; OXIDATIVE STRESS; TRANSIENT ADAPTATION; TRANSCRIPTION FACTOR; SIGNAL-TRANSDUCTION; INDUCTION; ACTIVATION	Reactive oxygen species of mitochondrial origin have been implicated in regulating the expression of several tumor necrosis factor (TNF)-induced genes. Manganese superoxide dismutase (Mn-SOD) is one of many genes, but only antioxidant enzyme, induced in response to tumor necrosis factor, Mn SOD is a nuclear-encoded mitochondrial matrix protein and serves a protective function by detoxifying superoxide, To address the role of superoxide in regulating gene expression in response to TNF, we have constitutively overexpressed Mn-SOD in a human fibrosarcoma cell line and asked what effect this has on the expression of a number of TNF-responsive genes using reverse transcription-polymerase chain reaction, Of the TNF-induced transcripts analyzed, only interleukin-1 alpha (IL-1 alpha) was modulated in response to Mn-SOD overexpression. In all cases of Mn-SOD overexpression, IL-la protein and mRNA levels were lowered constitutively and in response to TNF when compared to the parental and mock-transfected cell lines. The induction of IL-la by TNF can also be decreased by growth in 3% oxygen as compared to growth in 21% O-2; in addition, growth in low oxygen lowers the basal level of IL-1 alpha protein, The effect of Mn-SOD overexpression on IL-1 alpha expression can be overcome by treatment with the protein kinase C activator, phorbol 12-myristate 13-acetate. Mn-SOD overexpression and low oxygen alter IL-1 alpha mRNA levels by decreasing the stability of the IL-1 alpha mRNA. These findings indicate that both Mn-SOD and O-2 may regulate the levels of a cellular oxidant involved in both basal and TNF induced IL-1 alpha expression, presumably superoxide.	UNIV SO CALIF,ETHEL PERCY ANDRUS GERONTOL CTR,LOS ANGELES,CA 90089; ALBANY MED COLL,DEPT BIOCHEM MOL BIOL,NEW YORK,NY 12208	University of Southern California; Albany Medical College				Davies, Kelvin/0000-0001-7790-3003; Melendez, Juan/0000-0001-8021-3097	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R23ES003598, R56ES003598, R01ES003598] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES03598] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AKASHI M, 1995, J BIOL CHEM, V270, P15864, DOI 10.1074/jbc.270.26.15864; AMES BN, 1983, SCIENCE, V221, P1256, DOI 10.1126/science.6351251; AMES BN, 1989, MUTAT RES, V214, P41, DOI 10.1016/0027-5107(89)90196-6; ASOH K, 1989, BIOCHEM BIOPH RES CO, V162, P794, DOI 10.1016/0006-291X(89)92380-2; BEAUCHAM.C, 1971, ANAL BIOCHEM, V44, P276, DOI 10.1016/0003-2697(71)90370-8; BECK Y, 1987, NUCLEIC ACIDS RES, V15, P9076, DOI 10.1093/nar/15.21.9076; BOVERIS A, 1973, BIOCHEM J, V134, P707, DOI 10.1042/bj1340707; BOVERIS A, 1972, BIOCHEM J, V128, P617, DOI 10.1042/bj1280617; CARTER BZ, 1991, LAB INVEST, V65, P610; DAVIES JMS, 1995, ARCH BIOCHEM BIOPHYS, V317, P1, DOI 10.1006/abbi.1995.1128; FRIDOVICH I, 1986, ADV ENZYMOL RAMB, V58, P61; GOROSPE M, 1993, J BIOL CHEM, V268, P6214; GROUDINE M, 1981, MOL CELL BIOL, V1, P281, DOI 10.1128/MCB.1.3.281; HARRIS CA, 1991, J IMMUNOL, V147, P149; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; KU HH, 1993, FREE RADICAL BIO MED, V15, P621, DOI 10.1016/0891-5849(93)90165-Q; LEE WY, 1994, J BIOL CHEM, V269, P17971; MASUDA A, 1988, FASEB J, V2, P3087, DOI 10.1096/fasebj.2.15.3263930; MCCORD JM, 1982, CAN J PHYSIOL PHARM, V60, P1346, DOI 10.1139/y82-201; MCCORD JM, 1985, NEW ENGL J MED, V312, P159; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; MELENDEZ JA, 1992, FREE RADICAL BIO MED, V12, P151, DOI 10.1016/0891-5849(92)90009-6; MELENDEZ JA, 1993, FREE RADICAL BIO MED, V14, P601, DOI 10.1016/0891-5849(93)90141-G; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; SCHRECK R, 1992, FREE RADICAL RES COM, V17, P221, DOI 10.3109/10715769209079515; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SCHULZEOSTHOFF K, 1992, J BIOL CHEM, V267, P5317; SCHULZEOSTHOFF K, 1993, EMBO J, V12, P3095, DOI 10.1002/j.1460-2075.1993.tb05978.x; SUZUKI YJ, 1992, BIOCHEM BIOPH RES CO, V189, P1709, DOI 10.1016/0006-291X(92)90275-P; SUZUKI YJ, 1994, J IMMUNOL, V153, P5008; VISNER GA, 1990, J BIOL CHEM, V265, P2856; VOLKYL A, 1994, CELL BIOL LAB HDV, P550; WALDMAN AS, 1991, BIOTECHNIQUES, V10, P138; WIESE AG, 1995, ARCH BIOCHEM BIOPHYS, V318, P231, DOI 10.1006/abbi.1995.1225; WONG GHW, 1988, SCIENCE, V242, P941, DOI 10.1126/science.3263703; WONG GHW, 1989, CELL, V58, P923, DOI 10.1016/0092-8674(89)90944-6; WONG GHW, 1992, MOL BIOL FREE RADICA, P69; ZHANG Y, 1990, J BIOL CHEM, V265, P16330	38	28	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18898	18903		10.1074/jbc.271.31.18898	http://dx.doi.org/10.1074/jbc.271.31.18898			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702551	hybrid			2022-12-25	WOS:A1996VB68300089
J	Clementi, E; Riccio, M; Sciorati, C; Nistico, G; Meldolesi, J				Clementi, E; Riccio, M; Sciorati, C; Nistico, G; Meldolesi, J			The type 2 ryanodine receptor of neurosecretory PC12 cells is activated by cyclic ADP-ribose - Role of the nitric oxide cGMP pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+-INDUCED CA2+ RELEASE; DEPENDENT PROTEIN-KINASE; INTRACELLULAR CA2+; INOSITOL 1,4,5-TRISPHOSPHATE; ENDOPLASMIC-RETICULUM; CALCIUM RELEASE; BRAIN; CHANNEL; NEURONS; MUSCLE	Of two neurosecretory PC12 cell clones that respond to NO donors and 8-bromo-cGMP with similar increases in cADP-ribose and that possess molecularly similar Ca2+ stores, only one (clone 16A) expresses the type 2 ryanodine receptor, whereas the other (clone 27) is devoid of ryanodine receptors. In PC12-16A cells, activation of the NO/cGMP pathway induced slow [Ca2+](i) responses, sustained by release from Ca2+ stores. In contrast, PC12 27 cells were insensitive to NO donors. Likewise, in PC12-16A cells preincubated with NO donors, Ca2+ stores were partially depleted, as revealed by a test with thapsigargin, whereas those in clone 27 were unchanged. The NO-induced Ca2+ release was increased synergistically by caffeine, and the corresponding store depletion was magnified by ryanodine. The specificity for the NO/cGMP pathway was confirmed by the effects of two blockers of cGMP-dependent protein kinase I, while the role of cADP-ribose was demonstrated by the effects of its antagonist, 8-amino-cADP-ribose, administered to permeabilized cells. These results demonstrate in neurosecretory cells a ryanodine receptor activation pathway similar to that known in sea urchin oocytes. The signaling events described here could be of great physiological importance, especially in the nervous system.	UNIV REGGIO CALABRIA,FAC PHARM,DEPT PHARMACOL,I-88021 CATANZARO,ITALY; UNIV ROMA TOR VERGATA,MONDINO NEUROBIOL CTR,DEPT BIOL,I-00133 ROME,ITALY; CNR,MOL & CELLULAR PHARMACOL CTR,I-20132 MILAN,ITALY; UNIV MILAN,B CECCARELLI CTR,DEPT PHARMACOL,DIPARTIMENTO BIOTECNOL,SAN RAFFAELE SCI INST,I-20132 MILAN,ITALY	Universita Mediterranea di Reggio Calabria; University of Rome Tor Vergata; Consiglio Nazionale delle Ricerche (CNR); University of Milan; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele			sciorati, clara/K-4823-2016	sciorati, clara/0000-0003-2030-9366				ALDERSON BH, 1989, ARCH BIOCHEM BIOPHYS, V272, P162, DOI 10.1016/0003-9861(89)90207-5; ALLBRITTON NL, 1992, SCIENCE, V258, P1812, DOI 10.1126/science.1465619; BASTIANUTTO C, 1995, J CELL BIOL, V130, P847, DOI 10.1083/jcb.130.4.847; BUTT E, 1990, FEBS LETT, V263, P47, DOI 10.1016/0014-5793(90)80702-K; CLEMENTI E, 1995, MOL PHARMACOL, V47, P517; CLEMENTI E, 1995, EUR J PHARM-MOLEC PH, V289, P113, DOI 10.1016/0922-4106(95)90176-0; CLEMENTI E, 1992, EUR J NEUROSCI, V4, P944, DOI 10.1111/j.1460-9568.1992.tb00121.x; COLYER J, 1989, BIOCHEM J, V262, P439, DOI 10.1042/bj2620439; CURRIE KPM, 1992, MOL BIOL CELL, V3, P1415, DOI 10.1091/mbc.3.12.1415; FASOLATO C, 1991, J BIOL CHEM, V266, P20159; FRUEN BR, 1994, FEBS LETT, V352, P123, DOI 10.1016/0014-5793(94)00931-7; FURUICHI T, 1994, J NEUROSCI, V14, P4794; GALIONE A, 1993, NATURE, V365, P456, DOI 10.1038/365456a0; GALIONE A, 1991, SCIENCE, V253, P1143, DOI 10.1126/science.1909457; GIANNINI G, 1995, J CELL BIOL, V128, P893, DOI 10.1083/jcb.128.5.893; HABY C, 1994, J NEUROCHEM, V62, P496; HORTON JK, 1995, 9 INT C 2 MESS PHOSP, P354; HUA SY, 1994, NEURON, V12, P1073, DOI 10.1016/0896-6273(94)90315-8; INESI G, 1992, ARCH BIOCHEM BIOPHYS, V298, P313, DOI 10.1016/0003-9861(92)90416-T; KASE H, 1987, BIOCHEM BIOPH RES CO, V142, P436, DOI 10.1016/0006-291X(87)90293-2; KOSHIYAMA H, 1991, J BIOL CHEM, V266, P16985; KUEMMERLE JF, 1995, J BIOL CHEM, V270, P25488, DOI 10.1074/jbc.270.43.25488; LEE HC, 1989, J BIOL CHEM, V264, P1608; LEE HC, 1993, J BIOL CHEM, V268, P293; MEISSNER G, 1994, ANNU REV PHYSIOL, V56, P485, DOI 10.1146/annurev.ph.56.030194.002413; MESZAROS LG, 1993, NATURE, V364, P76, DOI 10.1038/364076a0; PEUNOVA N, 1995, NATURE, V375, P68, DOI 10.1038/375068a0; RUTTER GA, 1994, CELL CALCIUM, V16, P71, DOI 10.1016/0143-4160(94)90002-7; SITSAPESAN R, 1995, TRENDS PHARMACOL SCI, V16, P386, DOI 10.1016/S0165-6147(00)89080-X; SITSAPESAN R, 1995, AM J PHYSIOL-CELL PH, V268, pC1235, DOI 10.1152/ajpcell.1995.268.5.C1235; SITSAPESAN R, 1994, CIRC RES, V75, P596, DOI 10.1161/01.RES.75.3.596; THORN P, 1994, EMBO J, V13, P2038, DOI 10.1002/j.1460-2075.1994.tb06478.x; VILLA A, 1992, NEUROSCIENCE, V49, P467, DOI 10.1016/0306-4522(92)90111-E; VILLA A, 1993, J CELL BIOL, V121, P1041, DOI 10.1083/jcb.121.5.1041; WALSETH TF, 1993, BIOCHIM BIOPHYS ACTA, V1178, P235, DOI 10.1016/0167-4889(93)90199-Y; WALSETH TF, 1991, BIOCHIM BIOPHYS ACTA, V1094, P113, DOI 10.1016/0167-4889(91)90032-S; WALTON PD, 1991, J CELL BIOL, V113, P1145, DOI 10.1083/jcb.113.5.1145; WHITE AM, 1993, FEBS LETT, V318, P259, DOI 10.1016/0014-5793(93)80524-X; Willmott N, 1996, J BIOL CHEM, V271, P3699; WILLMOTT NJ, 1995, CELL CALCIUM, V18, P411, DOI 10.1016/0143-4160(95)90056-X; ZACCHETTI D, 1991, J BIOL CHEM, V266, P20152; ZHANG J, 1995, ANNU REV PHARMACOL, V35, P213	42	100	103	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					17739	17745		10.1074/jbc.271.30.17739	http://dx.doi.org/10.1074/jbc.271.30.17739			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663443	hybrid			2022-12-25	WOS:A1996UY93500025
J	Martin, SS; Haruta, T; Morris, AJ; Klippel, A; Williams, LT; Olefsky, JM				Martin, SS; Haruta, T; Morris, AJ; Klippel, A; Williams, LT; Olefsky, JM			Activated phosphatidylinositol 3-kinase is sufficient to mediate actin rearrangement and GLUT4 translocation in 3T3-L1 adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSE TRANSPORTER GLUT4; PLASMA-MEMBRANE; INSULIN-RECEPTOR; DNA-SYNTHESIS; INTACT-CELLS; STIMULATION; TERMINUS; SUBUNIT; SITE; P85	Insulin stimulation of 3T3-L1 adipocytes causes rapid translocation of actin and the GLUT4 glucose transporter to the plasma membrane, Both processes depend on the activity of phosphatidylinositol 3-kinase, Using single cell microinjection, we have transiently expressed a constitutively activated mutant of phosphatidylinositol 3-kinase, p110*, in 3T3-L1 adipocytes, Fluorescent detection of GLUT4 protein and actin within these cells demonstrates that expression of p110* is sufficient to cause translocation of GLUT4 to the plasma membrane and the formation of actin membrane ruffles, These effects are inhibited by wortmannin in the p110*-expressing cells, indicating that the phosphatidylinositol 3-kinase activity of the protein is required, Overexpression of an identical protein containing a point mutation in the kinase domain, p110*Delta kin, was incapable of mediating either action, confirming that neither the microinjection process nor a nonspecific effect of the protein was responsible for the observed effects, These data suggest that although insulin is capable of inducing numerous signaling pathways, the isolated activation of phosphatidylinositol 3-kinase can initiate the signaling cascade leading to both actin rearrangement and GLUT4 translocation in the absence of insulin stimulation.	UNIV CALIF SAN DIEGO,DEPT MED 9111G,VET ADM MED CTR,DIV ENDOCRINOL & METAB,LA JOLLA,CA 92093; CHIRON CORP,EMERYVILLE,CA 94608	University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA); Novartis					NIDDK NIH HHS [DK09415, DK33651] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033651, F32DK009415, R37DK033651] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BACKER JM, 1993, J BIOL CHEM, V268, P8204; BALDINI G, 1991, J BIOL CHEM, V266, P4037; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; HANEY PM, 1991, J CELL BIOL, V114, P689, DOI 10.1083/jcb.114.4.689; HARUTA T, 1995, J BIOL CHEM, V270, P27991; HellerHarrison RA, 1996, J BIOL CHEM, V271, P10200, DOI 10.1074/jbc.271.17.10200; HU P, 1993, MOL CELL BIOL, V13, P7677, DOI 10.1128/MCB.13.12.7677; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; JHUN BH, 1994, MOL CELL BIOL, V14, P7466, DOI 10.1128/MCB.14.11.7466; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; KELADA ASM, 1992, J BIOL CHEM, V267, P7021; KLIPPEL A, 1994, MOL CELL BIOL, V14, P2675, DOI 10.1128/MCB.14.4.2675; KOTANI K, 1995, BIOCHEM BIOPH RES CO, V208, P985, DOI 10.1006/bbrc.1995.1431; KOTANI K, 1994, EMBO J, V13, P2313, DOI 10.1002/j.1460-2075.1994.tb06515.x; LEVYTOLEDANO R, 1994, J BIOL CHEM, V269, P31178; MARCUSOHN J, 1995, CURR BIOL, V5, P1296, DOI 10.1016/S0960-9822(95)00256-9; NISHIYAMA T, 1994, MOL CELL BIOL, V14, P2447, DOI 10.1128/MCB.14.4.2447; OLEFSKY JM, 1994, ELLENBERG RIFKINS DI, P121; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; SMITH RM, 1993, ARCH BIOCHEM BIOPHYS, V300, P238, DOI 10.1006/abbi.1993.1033; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; SUZUKI K, 1980, P NATL ACAD SCI-BIOL, V77, P2542, DOI 10.1073/pnas.77.5.2542; TSAKIRIDIS T, 1994, J BIOL CHEM, V269, P29934	24	186	189	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					17605	17608		10.1074/jbc.271.30.17605	http://dx.doi.org/10.1074/jbc.271.30.17605			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663595	hybrid			2022-12-25	WOS:A1996UY93500004
J	Vertommen, D; Bertrand, L; Sontag, B; DiPietro, A; Louckx, MP; Vidal, H; Hue, L; Rider, MH				Vertommen, D; Bertrand, L; Sontag, B; DiPietro, A; Louckx, MP; Vidal, H; Hue, L; Rider, MH			The ATP-binding site in the 2-kinase domain of liver 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase - Study of the role of Lys-54 and Thr-55 by site-directed mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST MITOCHONDRIAL F1-ATPASE; AMINO-ACID-SEQUENCE; RAT-LIVER; ESCHERICHIA-COLI; 6-PHOSPHOFRUCTO-2-KINASE FRUCTOSE-2,6-BISPHOSPHATASE; NUCLEOTIDE-BINDING; FRUCTOSE 2,6-BISPHOSPHATASE; ADENYLATE KINASE; PROTEIN-KINASE; CATALYTIC SITE	All known 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase isozymes contain a sequence (GX(4)GK(S/T)) in the 6-phosphofructo-2-kinase domain corresponding to the so-called nucleotide binding fold signature or Walker A motif, Mutagenesis and crystal structure data from several nucleotide binding proteins, which also contain this sequence, showed the importance of the lysine and serine/threonine residues in nucleotide binding, We have studied the role of Lys-54 and Thr-55 in MgATP binding in the 6-phosphofructo-2-kinase domain of rat liver 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase by site directed mutagenesis, Lys-54 was mutated to methionine, whereas Thr-55 was mutated to valine, serine, and cysteine, Three mutants, Lys-54 to Met and Thr-55 to Cys or Val, displayed more than a 5000-fold decrease in 6-phosphofructo-2-kinase activity compared with the wild type, The mutations had no effect on fructose-2,6-bisphosphatase activity and did not affect the activation of fructose-2,6-bisphosphatase after phosphorylation by cyclic 3',5'-AMP-dependent protein kinase, Binding experiments with ATP, ADP, and their analogs (3'-N-methylanthraniloyl derivatives) showed that these two residues do not play the same role, Lys-54 is involved in ATP binding, whereas Thr-55 is important for catalysis.	INT INST CELLULAR & MOLEC PATHOL,HORMONE & METAB RES UNIT,B-1200 BRUSSELS,BELGIUM; UNIV CATHOLIQUE LOUVAIN,SCH MED,B-1200 BRUSSELS,BELGIUM; INST BIOL & CHIM PROT,CNRS,F-69367 LYON 07,FRANCE; FAC MED ALEXIS CARREL,INSERM U197,F-69372 LYON 08,FRANCE	Universite Catholique Louvain; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm)			Vidal, Hubert/M-6674-2017	Vidal, Hubert/0000-0002-9467-0317; Vertommen, Didier/0000-0001-7648-8282; Bertrand, Luc/0000-0003-0655-7099				BENSADOUN A, 1976, ANAL BIOCHEM, V70, P241, DOI 10.1016/S0003-2697(76)80064-4; COLOSIA AD, 1987, BIOCHEM BIOPH RES CO, V143, P1092, DOI 10.1016/0006-291X(87)90364-0; CREPIN KM, 1989, BIOCHEM J, V264, P151, DOI 10.1042/bj2640151; CREPIN KM, 1992, J BIOL CHEM, V267, P21698; DARVILLE MI, 1987, FEBS LETT, V224, P317, DOI 10.1016/0014-5793(87)80476-3; DIVITA G, 1993, J BIOL CHEM, V268, P13178; FALSON P, 1993, BIOCHEMISTRY-US, V32, P10387, DOI 10.1021/bi00090a014; HIRATSUKA T, 1983, BIOCHIM BIOPHYS ACTA, V742, P496, DOI 10.1016/0167-4838(83)90267-4; HWANG YW, 1989, ARCH BIOCHEM BIOPHYS, V274, P394, DOI 10.1016/0003-9861(89)90452-9; JAULT JM, 1993, J BIOL CHEM, V268, P20762; KITAJIMA S, 1984, J BIOL CHEM, V259, P6896; KJELDGAARD M, 1992, J MOL BIOL, V223, P721, DOI 10.1016/0022-2836(92)90986-T; KRETSCHMER M, 1984, BIOCHEM BIOPH RES CO, V124, P793, DOI 10.1016/0006-291X(84)91027-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI L, 1992, J BIOL CHEM, V267, P4386; LIVELY MO, 1988, J BIOL CHEM, V263, P839; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MOORE KJM, 1994, BIOCHEMISTRY-US, V33, P14550, DOI 10.1021/bi00252a023; MUELLER DM, 1989, J BIOL CHEM, V264, P16552; MULLER CW, 1992, J MOL BIOL, V224, P159, DOI 10.1016/0022-2836(92)90582-5; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; PILKIS SJ, 1984, J BIOL CHEM, V259, P949; PILKIS SJ, 1995, ANNU REV BIOCHEM, V64, P799, DOI 10.1146/annurev.bi.64.070195.004055; REIMANN EM, 1983, METHOD ENZYMOL, V99, P51; REINSTEIN J, 1990, BIOCHEMISTRY-US, V29, P7451, DOI 10.1021/bi00484a014; RIDER MH, 1995, BIOCHEM J, V309, P341, DOI 10.1042/bj3090341; RIDER MH, 1994, BIOCHEM J, V300, P111, DOI 10.1042/bj3000111; RIDER MH, 1992, BIOCHEM J, V285, P405, DOI 10.1042/bj2850405; ROSKOSKI R, 1983, METHOD ENZYMOL, V99, P3; SAKATA J, 1991, J BIOL CHEM, V266, P15764; SAKATA J, 1990, P NATL ACAD SCI USA, V87, P4951, DOI 10.1073/pnas.87.13.4951; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAYERS JR, 1988, NUCLEIC ACIDS RES, V16, P761; SCHULZ GE, 1974, NATURE, V250, P120, DOI 10.1038/250120a0; STORY RM, 1992, NATURE, V355, P374, DOI 10.1038/355374a0; VANSCHAFTINGEN E, 1982, EUR J BIOCHEM, V124, P143; VIJAYAKUMAR EKS, 1984, BIOPOLYMERS, V23, P877, DOI 10.1002/bip.360230505; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WOODWARD SKA, 1991, BIOCHEMISTRY-US, V30, P422, DOI 10.1021/bi00216a017	39	31	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					17875	17880		10.1074/jbc.271.30.17875	http://dx.doi.org/10.1074/jbc.271.30.17875			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663445	hybrid			2022-12-25	WOS:A1996UY93500045
J	Garippa, RJ; Johnson, A; Park, J; Petrush, RL; McGraw, TE				Garippa, RJ; Johnson, A; Park, J; Petrush, RL; McGraw, TE			The carboxyl terminus of GLUT4 contains a serine-leucine-leucine sequence that functions as a potent internalization motif in Chinese hamster ovary cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATABLE GLUCOSE TRANSPORTER; TRANSFERRIN RECEPTOR; INTRACELLULAR SEQUESTRATION; CYTOPLASMIC DOMAIN; 3T3-L1 ADIPOCYTES; RAT ADIPOCYTES; INSULIN STIMULATION; ENDOCYTIC PATHWAY; PLASMA-MEMBRANE; NH2 TERMINUS	To characterize the trafficking motifs contained in the carboxyl terminus of GLUT4, a chimera (GTCTR) was constructed in which the carboxyl-terminal 30 amino acids of GLUT4 were substituted for the amino-terminal cytoplasmic domain of the transferrin receptor (TR), The endocytic behavior of this chimera was characterized in Chinese hamster ovary cells, The GTCTR chimera had a more predominant intracellular distribution compared to the TR. Only 20% of the GTCTR chimera is on the surface at steady-state compared to 35% of the TR. The GTCTR chimera is internalized 50% more rapidly and recycled 20% more slowly than the TR, Acidification of the cytosol inhibited internalization of the GTCTR chimera, indicating that the chimera is internalized through clathrin-coated pits, Mutations of GTCTR were constructed in which a di-leucine sequence of the carboxyl domain of GLUT4 was mutated to a di-alanine sequence (GTCTR-AA) and serine residue 488, immediately preceding the di-leucine sequence, was mutated to either an alanine or aspartate residue, In each case, albeit to varying degrees, the substitutions shifted the distribution of the mutated GTCTR constructs toward the surface. The shift in the distribution of GTCTR-AA resulted from a 10-fold reduction in internalization, and the shift of serine 488 mutants resulted from a 3-fold reduction in the internalization rate compared to GTCTR, None of these mutations affected the recycling rate, These results demonstrate that the carboxyl terminus of GLUT4 contains a serine-leucine-leucine-based motif that, when expressed in non-insulin responsive cells, functions as a potent internalization motif which promotes more rapid internalization than does the native TR internalization motif.	COLUMBIA UNIV COLL PHYS & SURG, DEPT PATHOL, NEW YORK, NY 10032 USA; COLUMBIA UNIV COLL PHYS & SURG, DEPT PHARMACOL, NEW YORK, NY 10032 USA	Columbia University; Columbia University								ASANO T, 1992, J BIOL CHEM, V267, P19636; COLLAWN JF, 1991, EMBO J, V10, P3247, DOI 10.1002/j.1460-2075.1991.tb04888.x; CORVERA S, 1994, J CELL BIOL, V126, P979, DOI 10.1083/jcb.126.4.979; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; CZECH MP, 1993, J BIOL CHEM, V268, P9187; CZECH MP, 1993, J CELL BIOL, V123, P127, DOI 10.1083/jcb.123.1.127; DAUTRYVARSAT A, 1983, P NATL ACAD SCI-BIOL, V80, P2258, DOI 10.1073/pnas.80.8.2258; GARIPPA RJ, 1994, J CELL BIOL, V124, P705, DOI 10.1083/jcb.124.5.705; HANEY PM, 1995, J CELL BIOL, V129, P641, DOI 10.1083/jcb.129.3.641; HOLMAN GD, 1990, J BIOL CHEM, V265, P18172; James David E., 1994, Trends in Cell Biology, V4, P120, DOI 10.1016/0962-8924(94)90066-3; JAMES DE, 1989, NATURE, V338, P83, DOI 10.1038/338083a0; JHUN BH, 1992, J BIOL CHEM, V267, P17710; JING SQ, 1990, J CELL BIOL, V110, P283, DOI 10.1083/jcb.110.2.283; JOHNSON KF, 1992, J CELL BIOL, V119, P249, DOI 10.1083/jcb.119.2.249; LAWRENCE JC, 1990, J BIOL CHEM, V265, P2324; LAWRENCE JC, 1992, P NATL ACAD SCI USA, V89, P3493, DOI 10.1073/pnas.89.8.3493; LETOURNEUR F, 1992, CELL, V69, P1143, DOI 10.1016/0092-8674(92)90636-Q; MARSH BJ, 1995, J CELL BIOL, V130, P1081, DOI 10.1083/jcb.130.5.1081; MARSHALL BA, 1993, J BIOL CHEM, V268, P26193; MAYOR S, 1993, J CELL BIOL, V121, P1257, DOI 10.1083/jcb.121.6.1257; MCGRAW TE, 1987, J CELL BIOL, V105, P207, DOI 10.1083/jcb.105.1.207; MCGRAW TE, 1990, CELL REGUL, V1, P369, DOI 10.1091/mbc.1.4.369; ODORIZZI CG, 1994, J CELL BIOL, V126, P317, DOI 10.1083/jcb.126.2.317; PIPER RC, 1992, J CELL BIOL, V117, P729, DOI 10.1083/jcb.117.4.729; PIPER RC, 1993, J CELL BIOL, V121, P1221, DOI 10.1083/jcb.121.6.1221; POND L, 1995, J BIOL CHEM, V270, P19989, DOI 10.1074/jbc.270.34.19989; PRESLEY JF, 1993, J CELL BIOL, V122, P1231, DOI 10.1083/jcb.122.6.1231; PYTOWSKI B, 1995, J BIOL CHEM, V270, P9067, DOI 10.1074/jbc.270.16.9067; ROBINSON LJ, 1992, J CELL BIOL, V117, P1181, DOI 10.1083/jcb.117.6.1181; RODNICK KJ, 1992, J BIOL CHEM, V267, P6278; ROTH MG, 1993, ENDOSOMES LYSOSOMES, P19; Sandoval Ignacio V., 1994, Trends in Cell Biology, V4, P292, DOI 10.1016/0962-8924(94)90220-8; SANDVIG K, 1989, METHOD CELL BIOL, V32, P365; SLOT JW, 1991, J CELL BIOL, V113, P123, DOI 10.1083/jcb.113.1.123; SUZUKI K, 1980, P NATL ACAD SCI-BIOL, V77, P2542, DOI 10.1073/pnas.77.5.2542; TANNER LI, 1987, J BIOL CHEM, V262, P8975; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; VERHEY KJ, 1995, J CELL BIOL, V130, P1071, DOI 10.1083/jcb.130.5.1071; VERHEY KJ, 1993, J CELL BIOL, V123, P137, DOI 10.1083/jcb.123.1.137; VERHEY KJ, 1994, J BIOL CHEM, V269, P2353; YANG J, 1993, J BIOL CHEM, V268, P4600	42	55	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20660	20668		10.1074/jbc.271.34.20660	http://dx.doi.org/10.1074/jbc.271.34.20660			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702815	hybrid			2022-12-25	WOS:A1996VD33700067
J	Roher, AE; Chaney, MO; Kuo, YM; Webster, SD; Stine, WB; Haverkamp, LJ; Woods, AS; Cotter, RJ; Tuohy, JM; Krafft, GA; Bonnell, BS; Emmerling, MR				Roher, AE; Chaney, MO; Kuo, YM; Webster, SD; Stine, WB; Haverkamp, LJ; Woods, AS; Cotter, RJ; Tuohy, JM; Krafft, GA; Bonnell, BS; Emmerling, MR			Morphology and toxicity of A beta-(1-42) dimer derived from neuritic and vascular amyloid deposits of Alzheimer's disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-PROTEIN; CEREBROSPINAL-FLUID; MAMMALIAN BRAIN; PEPTIDE; CELLS; MICROGLIA; PHAGOCYTOSIS; AGGREGATION; RELEASE; INJURY	In the course of analyzing the chemical composition of Alzheimer's disease neuritic and vascular amyloid, we have purified stable dimeric and trimeric components of A beta peptides, These peptides (molecular mass 9.0 and 13.5 kDa) were separated by size exclusion chromatography in the presence of 80% formic acid or 5 M. guanidine thiocyanate, pH 7.4, The average ratio of monomers, dimers, and trimers was 55:30:15, respectively, Similar structures were produced over time upon incubation of synthetic A beta-(1-42) at pH 7.4, The stability of these oligomeric forms was also demonstrated by Western blot and mass spectrometry, Atomic force microscopy and electron microscopy rotary shadowing revealed that the monomers polymerized into 8-10-nm filaments, whereas the dimers generated prolate ellipsoids measuring 3-4 nm in diameter, The pathogenic effects of the dimeric A beta-(1-40/42) were tested in cultures of rat hippocampal neuron glia cells. Only in the presence of microglia did the dimer elicit neuronal killing. It is possible that these potentially pathogenic A beta-(1-40/42) dimers and trimers from Alzheimer's disease amyloid represent the soluble oligomers of A beta recently described in Alzheimer's disease brains (Kuo, Y.-M., Emmerling, M. R., Vigo-Pelfrey, C., Kasunic, T. C., Kirkpatrick, J. B., Murdoch, G. H,, Ball, M. J., and Roher, A. E. (1996) J. Biol, Chem., 271, 4077-4081).	ELI LILLY & CO,LILLY RES LABS,BIOTECHNOL CORE,INDIANAPOLIS,IN 46285; ABBOTT LABS,DEPT CELLULAR & MICROSCOP RES,ABBOTT PK,IL 60064; BAYLOR COLL MED,DEPT NEUROL,ALZHEIMERS DIS RES CTR,HOUSTON,TX 77030; JOHNS HOPKINS UNIV,SCH MED,DEPT PHARMACOL & MOL SCI,BALTIMORE,MD 21205; NORTHWESTERN UNIV,SCH MED,DEPT MOL PHARMACOL & BIOL SCI,CHICAGO,IL 60611; ARIZONA STATE UNIV,DEPT ZOOL,TEMPE,AZ 85287; PARKE DAVIS CO,ANN ARBOR,MI 48106	Eli Lilly; Abbott Laboratories; Baylor College of Medicine; Johns Hopkins University; Northwestern University; Arizona State University; Arizona State University-Tempe; Pfizer	Roher, AE (corresponding author), SUN HLTH RES INST,HALDEMAN LAB ALZHEIMERS DIS RES,10515 W SANTA FE DR,SUN CITY,AZ 85372, USA.		Kuo, Yu-Min/A-9050-2013	Kuo, Yu-Min/0000-0003-4867-2482	NATIONAL INSTITUTE ON AGING [R01AG011925, P50AG008664, R01AG012548] Funding Source: NIH RePORTER; NIA NIH HHS [AG-11925, AG-08664, AG-12548] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BANATI RB, 1993, GLIA, V7, P111, DOI 10.1002/glia.440070117; BONNELL B, 1990, J STRUCT BIOL, V105, P123, DOI 10.1016/1047-8477(90)90106-M; COPANI A, 1991, NEUROREPORT, V2, P763, DOI 10.1097/00001756-199112000-00008; DAVIS TL, 1989, BRAIN RES, V504, P216, DOI 10.1016/0006-8993(89)91360-7; DAVISSALINAS J, 1995, J BIOL CHEM, V270, P20887, DOI 10.1074/jbc.270.36.20887; FRAUTSCHY SA, 1992, AM J PATHOL, V140, P1389; GIULIAN D, 1989, J NEUROSCI, V9, P4416; GIULIAN D, 1986, J NEUROSCI, V6, P2163; GIULIAN D, 1995, NEUROCHEM INT, V27, P119, DOI 10.1016/0197-0186(95)00067-I; Giulian D., 1992, CURR TOP NEUROL, V12, P23; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HARIGAYA Y, 1995, BIOCHEM BIOPH RES CO, V211, P1015, DOI 10.1006/bbrc.1995.1912; HSIAO KK, 1995, NEURON, V15, P1203, DOI 10.1016/0896-6273(95)90107-8; Kuo YM, 1996, J BIOL CHEM, V271, P4077; MANN DMA, 1988, NEUROPATH APPL NEURO, V14, P177, DOI 10.1111/j.1365-2990.1988.tb00880.x; MARTIN DL, 1992, GLIA, V5, P81, DOI 10.1002/glia.440050202; MATTSON MP, 1992, J NEUROSCI, V12, P376, DOI 10.1523/jneurosci.12-02-00376.1992; MIRRA SS, 1993, ARCH PATHOL LAB MED, V117, P132; MIYAKAWA T, 1992, ACTA NEUROPATHOL, V83, P340, DOI 10.1007/BF00713523; PODLISNY MB, 1995, J BIOL CHEM, V270, P9564, DOI 10.1074/jbc.270.16.9564; ROGERS J, 1996, IN PRESS NEUROBIOL A, V17; ROHER AE, 1993, P NATL ACAD SCI USA, V90, P10836, DOI 10.1073/pnas.90.22.10836; ROHER AE, 1993, J BIOL CHEM, V268, P3072; ROHER AE, 1993, J NEUROCHEM, V61, P1916, DOI 10.1111/j.1471-4159.1993.tb09834.x; Selkoe DJ, 1996, J BIOL CHEM, V271, P18295, DOI 10.1074/jbc.271.31.18295; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SHINKAI Y, 1995, ANN NEUROL, V38, P421, DOI 10.1002/ana.410380312; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; Stine WB, 1996, J PROTEIN CHEM, V15, P193, DOI 10.1007/BF01887400; TABATON M, 1994, BIOCHEM BIOPH RES CO, V200, P1598, DOI 10.1006/bbrc.1994.1634; TAMAOKA A, 1994, BIOCHEM BIOPH RES CO, V205, P834, DOI 10.1006/bbrc.1994.2740; Teller JK, 1996, NAT MED, V2, P93, DOI 10.1038/nm0196-93; TERRY RD, 1991, ANN NEUROL, V30, P572, DOI 10.1002/ana.410300410; VIGOPELFREY C, 1993, J NEUROCHEM, V61, P1965, DOI 10.1111/j.1471-4159.1993.tb09841.x; VINORES SA, 1993, J NEUROIMMUNOL, V43, P169, DOI 10.1016/0165-5728(93)90088-G; WISNIEWSKI T, 1994, NEUROBIOL AGING, V15, P143, DOI 10.1016/0197-4580(94)90105-8	36	446	478	0	29	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20631	20635		10.1074/jbc.271.34.20631	http://dx.doi.org/10.1074/jbc.271.34.20631			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702810	hybrid			2022-12-25	WOS:A1996VD33700062
J	Amara, FM; Sun, J; Wright, JA				Amara, FM; Sun, J; Wright, JA			Defining a novel cis-element in the 3'-untranslated region of mammalian ribonucleotide reductase component R2 mRNA - cis-trans-interactions and message stability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA STABILITY; 3' UNTRANSLATED REGION; PROTEIN-BINDING; CELLS; EXPRESSION; R1; KINASE; DNA; FIBROBLASTS	Mammalian ribonucleotide reductase is a highly regulated activity essential for DNA synthesis and repair. The 3'-untranslated region (3'-UTR) of mammalian ribonucleotide reductase R2 mRNA has been implicated in the tumor promoter, 12-O-tetradecanoylphorbol-13-acetate-mediated stabilization of mouse BALB/c 3T3 R2 message. We investigated the possibility that the 3'-UTR contains regulatory information for R2 mRNA turnover. Using 3'-end-labeled RNA in gel shift and UV cross-linking analyses, we detected in the 3'-UTR a novel 9-nucleotide cis-element, 5'UCGUGUGCU-3', which interacted with a widely distributed cellular cytosolic protease-sensitive factor(s) in a sequence-specific manner to form a 45-kDa R2 binding protein complex. The binding activity was redox-sensitive and down-regulated by 12-O-tetradecanoylphorbol-13-acetate and okadaic acid in a dose-dependent manner. Insertion of a 154-base pair fragment containing the cis-element led to markedly reduced accumulation of chloramphenicol acetyltransferase hybrid mRNA relative to the same insert carrying a series of G --> A mutations within this element that eliminated binding. We suggest that the 9-nucleotide region functions as a destabilizing element. These results provide a model for ribonucleotide reductase gene expression through a novel and specific mRNA cis-trans-interaction involving a phosphorylation signal pathway that leads to changes in the stability of R2 message.	UNIV MANITOBA,MANITOBA INST CELL BIOL,WINNIPEG,MB R3E 0V9,CANADA; UNIV MANITOBA,DEPT BIOCHEM & MOL BIOL,WINNIPEG,MB R3E 0V9,CANADA	University of Manitoba; University of Manitoba								AMARA FM, 1993, NUCLEIC ACIDS RES, V21, P4803, DOI 10.1093/nar/21.20.4803; AMARA FM, 1994, J BIOL CHEM, V269, P6709; AMARA FM, 1995, CANCER RES, V55, P4503; BLOMANIS R, 1987, CANCER RES, V47, P1273; BOHJANEN PR, 1991, MOL CELL BIOL, V11, P3288, DOI 10.1128/MCB.11.6.3288; BONIN PD, 1990, J BIOL CHEM, V265, P18643; BREWER G, 1991, MOL CELL BIOL, V11, P2460, DOI 10.1128/MCB.11.5.2460; BRUCE AG, 1978, NUCLEIC ACIDS RES, V5, P3665, DOI 10.1093/nar/5.10.3665; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN FY, 1993, EMBO J, V12, P3977, DOI 10.1002/j.1460-2075.1993.tb06075.x; CHEN FY, 1994, BIOCHEM J, V302, P125, DOI 10.1042/bj3020125; CHEN FY, 1994, NUCLEIC ACIDS RES, V22, P4796, DOI 10.1093/nar/22.22.4796; CHOY BK, 1989, BIOCHEM BIOPH RES CO, V162, P1417, DOI 10.1016/0006-291X(89)90832-2; CLERCH LB, 1992, J BIOL CHEM, V267, P2853; COLAMONICI OR, 1986, MOL CELL BIOL, V6, P1847, DOI 10.1128/MCB.6.5.1847; EGAN SE, 1987, MOL CELL BIOL, V7, P830, DOI 10.1128/MCB.7.2.830; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GOUGH NM, 1988, ANAL BIOCHEM, V173, P93, DOI 10.1016/0003-2697(88)90164-9; HURTA RAR, 1992, J BIOL CHEM, V267, P7066; HURTA RAR, 1991, J BIOL CHEM, V266, P24097; IWAI Y, 1991, J BIOL CHEM, V266, P17959; LEE W, 1987, NATURE, V311, P433; LELBOLD EA, 1988, P NATL ACAD SCI USA, V85, P2171; MANZELLA JM, 1992, J BIOL CHEM, V267, P7077; RONDON IJ, 1991, J BIOL CHEM, V266, P16594; SACEDA M, 1991, J BIOL CHEM, V266, P17809; SCHONTHAL A, 1991, ONCOGENE, V6, P423; WEBER G, 1983, CANCER RES, V43, P3466; WRIGHT JA, 1990, BIOCHEM CELL BIOL, V68, P1364, DOI 10.1139/o90-199; WRIGHT JA, 1989, INT ENCY PHARM THERA, V128, P89; ZAIDI SHE, 1994, J BIOL CHEM, V269, P24000	33	24	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					20126	20131		10.1074/jbc.271.33.20126	http://dx.doi.org/10.1074/jbc.271.33.20126			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702735	hybrid			2022-12-25	WOS:A1996VC66900076
J	GuptaRoy, B; Beckingham, K; Griffith, LC				GuptaRoy, B; Beckingham, K; Griffith, LC			Functional diversity of alternatively spliced isoforms of Drosophila Ca2+/calmodulin-dependent protein kinase II - A role for the variable domain in activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDIVIDUAL CA2+-BINDING SITES; LIGHT-CHAIN KINASE; CA2+ BINDING; 2 SERIES; POINT MUTATIONS; CALMODULIN; EXPRESSION; SUBUNIT; CLONING; MUTANTS	Isoforms of calcium/calmodulin-dependent protein kinase II from Drosophila (R1-R6 and R3A) showed differential activation by two series of mutant calmodulins, B1K-B4K and B1Q-B4Q. These mutant calmodulins were generated by changing a glutamic acid in each of the four calcium binding sites to either glutamine or lysine, altering their calcium binding properties. All mutations produced activation defects, with the binding site 4 and B1Q mutants the most severe. Activation differed substantially between isoforms, R4, R5, and R6 were the least sensitive to mutations in calmodulin, while R1, R3, and R3A were the most sensitive, activation of R1 and R2 by B4K and activation of R3 and R3A by B2K and B2Q produced significant (6-fold and almost 3-fold, respectively) differences in K-act between isoforms that differ stracturally by a single amino acid. These differences could not be accounted for by differential binding, as all isoforms showed almost identical binding patterns with the mutants. High binding affinity did not always correlate with ability to increase enzyme activity, implying that activation occurs in at least two steps. The isoform-specific differences seen in this study reflect a role for the COOH-terminal variable region in activation of CaM kinase II.	BRANDEIS UNIV,DEPT BIOL,WALTHAM,MA 02254; BRANDEIS UNIV,CTR COMPLEX SYST,WALTHAM,MA 02254; RICE UNIV,DEPT BIOCHEM & CELL BIOL,HOUSTON,TX 77251	Brandeis University; Brandeis University; Rice University				Griffith, Leslie/0000-0003-3164-9876	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054408, R01GM049155, R55GM049155, P01GM033205] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM49155, R01 GM054408, GM33205] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BABU YS, 1985, NATURE, V315, P37, DOI 10.1038/315037a0; BECKINGHAM K, 1991, J BIOL CHEM, V266, P6027; BENNETT MK, 1987, P NATL ACAD SCI USA, V84, P1794, DOI 10.1073/pnas.84.7.1794; BENSON DL, 1991, J NEUROSCI, V11, P31; CHO KO, 1991, NEURON, V7, P439, DOI 10.1016/0896-6273(91)90296-C; COHEN P, 1988, CALMODULIN, V5, P35; GAO ZH, 1993, J BIOL CHEM, V268, P20096; GRIFFITH LC, 1993, J NEUROCHEM, V61, P1534, DOI 10.1111/j.1471-4159.1993.tb13650.x; GuptaRoy B, 1996, J NEUROCHEM, V66, P1282; HANSON PI, 1992, ANNU REV BIOCHEM, V61, P559, DOI 10.1146/annurev.bi.61.070192.003015; LEVINE H, 1985, P NATL ACAD SCI USA, V82, P287, DOI 10.1073/pnas.82.2.287; MAUNE JF, 1992, BIOCHEMISTRY-US, V31, P7779, DOI 10.1021/bi00149a006; MAUNE JF, 1992, J BIOL CHEM, V267, P5286; MEYER T, 1992, SCIENCE, V256, P1199, DOI 10.1126/science.256.5060.1199; MILLER SG, 1985, J BIOL CHEM, V260, P9039; NGHIEM P, 1993, J BIOL CHEM, V268, P5471; PRATT WB, 1990, PRINCIPLES DRUG ACTI, P56; SCHWORER CM, 1993, J BIOL CHEM, V268, P14443; SRINIVASAN M, 1994, J CELL BIOL, V126, P839, DOI 10.1083/jcb.126.4.839; SU ZH, 1994, J BIOL CHEM, V269, P16761; TAYLOR DA, 1991, J BIOL CHEM, V266, P21375; YAZAWA M, 1987, J BIOL CHEM, V262, P10951; YOSHIDA M, 1983, J BIOCHEM-TOKYO, V94, P1925, DOI 10.1093/oxfordjournals.jbchem.a134546; ZOT HG, 1990, J BIOL CHEM, V265, P14796	24	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					19846	19851		10.1074/jbc.271.33.19846	http://dx.doi.org/10.1074/jbc.271.33.19846			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702694	hybrid			2022-12-25	WOS:A1996VC66900035
J	Kraus, R; Reichl, B; Kimball, SD; Grabner, M; Murphy, BJ; Catterall, WA; Striessnig, J				Kraus, R; Reichl, B; Kimball, SD; Grabner, M; Murphy, BJ; Catterall, WA; Striessnig, J			Identification of benz(othi)azepine-binding regions within L-type calcium channel alpha 1 subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BENZOTHIAZEPINE BINDING DOMAIN; SODIUM DODECYL-SULFATE; SKELETAL-MUSCLE; MOLECULAR DETERMINANTS; GEL-ELECTROPHORESIS; DILTIAZEM-BINDING; CA-2+ CHANNELS; CA2+ CHANNELS; DIHYDROPYRIDINE; RECEPTORS	To identify the binding domain for diltiazem-like Ca2+ antagonists on L-type Ca2+ channel alpha 1 subunits we synthesized the benzazepine [H-3]benziazem as a novel photoaffinity probe. [H-3]Benziazem reversibly labeled the benzothiazepine (BTZ)-binding domain of partially purified skeletal muscle Ca2+ channels with high affinity (K-d = 12 nM) and photoincorporated into its binding domain with high yield (>66%). Antibody mapping of proteolytic labeled fragments revealed specific labeling of regions associated with transmembrane segments S6 in repeats III and IV. More than 50% of the labeling was found in the tryptic fragment alanine 1023-lysine 1077 containing IIIS6 together with extracellular and intracellular amino acid residues. The remaining labeling was identified in a second site comprising segment S6 in repeat IV and adjacent residues. Unlike for dihydropyridines, no labeling was observed in the connecting IIIS5-IIIS6 linker. The [H-3]benziazem photolabeled regions must be in close contact to the drug molecule when bound to the channel. We propose that the determinants for high affinity BTZ binding are located within or in close proximity to segments IIIS6 and/or IVS6. Therefore the binding domain for BTZs, like for the other main classes of Ca2+ antagonists, must be located in close proximity to pore-forming regions of the channel.	UNIV INNSBRUCK, INST BIOCHEM PHARMAKOL, A-6020 INNSBRUCK, AUSTRIA; UNIV WASHINGTON, DEPT PHARMACOL, SEATTLE, WA 98195 USA; BRISTOL MYERS SQUIBB PHARMACEUT RES INST, PRINCETON, NJ 08543 USA	University of Innsbruck; University of Washington; University of Washington Seattle; Bristol-Myers Squibb			Striessnig, Joerg/S-9334-2017	Striessnig, Joerg/0000-0002-9406-7120	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL044948] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL44948] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BRAUNS T, 1995, BIOCHEMISTRY-US, V34, P3461, DOI 10.1021/bi00010a039; Brauns T., 1995, Biophysical Journal, V68, pA258; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; Doring F, 1996, J BIOL CHEM, V271, P11745, DOI 10.1074/jbc.271.20.11745; GARCIA ML, 1986, J BIOL CHEM, V261, P8146; GLOSSMANN H, 1987, TRENDS PHARMACOL SCI, V8, P95, DOI 10.1016/0165-6147(87)90082-4; GLOSSMANN H, 1983, FEBS LETT, V160, P226, DOI 10.1016/0014-5793(83)80972-7; GLOSSMANN H, 1985, METHOD ENZYMOL, V109, P513; GLOSSMANN H, 1990, REV PHYSL BIOCH PHAR, V114, P1; Grabner M, 1996, NEURON, V16, P207, DOI 10.1016/S0896-6273(00)80037-9; HELL JW, 1993, J CELL BIOL, V123, P949, DOI 10.1083/jcb.123.4.949; HERING S, 1993, MOL PHARMACOL, V43, P820; HOCKERMAN GH, 1995, J BIOL CHEM, V270, P22119, DOI 10.1074/jbc.270.38.22119; KIMBALL SD, 1992, J MED CHEM, V35, P780, DOI 10.1021/jm00082a020; MOUREY RJ, 1993, BIOCHEMISTRY-US, V32, P1719, DOI 10.1021/bi00058a004; NAITO K, 1989, J BIOL CHEM, V264, P21211; NAKAYAMA H, 1991, P NATL ACAD SCI USA, V88, P9203, DOI 10.1073/pnas.88.20.9203; OLSZEWSKI JD, 1995, BIOCONJUGATE CHEM, V6, P395, DOI 10.1021/bc00034a009; Peterson BZ, 1996, J BIOL CHEM, V271, P5293, DOI 10.1074/jbc.271.10.5293; RAGSDALE DS, 1994, SCIENCE, V265, P1724, DOI 10.1126/science.8085162; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SEYDL K, 1993, PFLUG ARCH EUR J PHY, V424, P552, DOI 10.1007/BF00374922; STRIESSNIG J, 1991, P NATL ACAD SCI USA, V88, P10769, DOI 10.1073/pnas.88.23.10769; STRIESSNIG J, 1986, FEBS LETT, V197, P204, DOI 10.1016/0014-5793(86)80327-1; STRIESSNIG J, 1990, P NATL ACAD SCI USA, V87, P9108, DOI 10.1073/pnas.87.23.9108; STRIESSNIG J, 1990, J BIOL CHEM, V265, P363; STRIESSNIG J, 1991, METHODS NEUROSCI, V4, P210; TAKAHASHI M, 1987, P NATL ACAD SCI USA, V84, P5478, DOI 10.1073/pnas.84.15.5478; TANABE T, 1987, NATURE, V328, P313, DOI 10.1038/328313a0; WATANABE T, 1993, FEBS LETT, V334, P261, DOI 10.1016/0014-5793(93)80690-V	30	36	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					20113	20118		10.1074/jbc.271.33.20113	http://dx.doi.org/10.1074/jbc.271.33.20113			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702733	hybrid			2022-12-25	WOS:A1996VC66900074
J	Lin, S; Akinbi, HT; Breslin, JS; Weaver, TE				Lin, S; Akinbi, HT; Breslin, JS; Weaver, TE			Structural requirements for targeting of surfactant protein B (SP-B) to secretory granules in vitro and in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANS-GOLGI NETWORK; PULMONARY SURFACTANT; II CELLS; EPITHELIAL-CELLS; LUNG SURFACTANT; SORTING SIGNAL; DISULFIDE BOND; CHROMOGRANIN-B; PATHWAY; PROOPIOMELANOCORTIN	Human surfactant protein B (SP-B) is synthesized by type II cells as a 381-residue preproprotein which is proteolytically processed to a 79-residue mature peptide and targeted to lamellar bodies for secretion. To identify secretory granule targeting determinants, constructs encoding the SP-B preproprotein (SP-B), COOH-terminally deleted SP-B (SP-B-Delta C), the NH2-terminal propeptide (SP-B-N), and a chimeric molecule consisting of albumin and the mature peptide (ALB/SP-B-M) were transfected into AtT-20 and PC12 cells. Pulse-chase studies demonstrated that 10-30% of SP-B and SP-B-Delta C remained in cells in an endoglycosidase H-resistant form. Secretion of stored SP-B was stimulated by forskolin/12-O-tetradecanoylphorbol-13-acetate and intracellular SP-B was localized to secretory granules by immunoelectron microscopy. In contrast, SP-B-N and ALB/SP-B-M were constitutively secreted and not detected in secretory granules. Specific processing of SP-B was not detected in either AtT-20 or PC12 cells. Expression of SP-B-Delta C in transgenic mice resulted in secretion of fully processed mature SP-B, indicating correct processing and targeting of this construct in vivo. We conclude that 1) SP-B processing occurs in a cell-specific manner, 2) the proprotein contains secretory granule targeting determinants that are not cell-specific, 3) the NH2-terminal propeptide and the mature peptide are required for targeting SP-B to lamellar body, and 4) the COOH-terminal propeptide is not required for processing or sorting of SP-B.	CHILDRENS HOSP,MED CTR,DIV PULM BIOL,TCHRF,CINCINNATI,OH 45229	Cincinnati Children's Hospital Medical Center					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056285, R01HL036055, R37HL056285] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL56285, HL36055] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BENDAYAN M, 1983, J HISTOCHEM CYTOCHEM, V31, P101, DOI 10.1177/31.1.6187796; Bonnard C, 1984, IMMUNOLABELING ELECT; BURGESS TL, 1987, ANNU REV CELL BIOL, V3, P243, DOI 10.1146/annurev.cellbio.3.1.243; BURGESS TL, 1987, J CELL BIOL, V105, P659, DOI 10.1083/jcb.105.2.659; CHANAT E, 1994, FEBS LETT, V351, P225, DOI 10.1016/0014-5793(94)00865-5; CHANAT E, 1991, J CELL BIOL, V115, P1505, DOI 10.1083/jcb.115.6.1505; CHANAT E, 1993, EMBO J, V12, P2159, DOI 10.1002/j.1460-2075.1993.tb05864.x; CHANDER A, 1990, AM J PHYSIOL, V258, pL241, DOI 10.1152/ajplung.1990.258.6.L241; CHU WN, 1990, MOL ENDOCRINOL, V4, P1905, DOI 10.1210/mend-4-12-1905; CHUNG KN, 1989, SCIENCE, V243, P192, DOI 10.1126/science.2911732; COOL DR, 1994, BIOCHIMIE, V76, P265, DOI 10.1016/0300-9084(94)90156-2; DICKERSON IM, 1990, J BIOL CHEM, V265, P2462; DOBBS LG, 1986, AM REV RESPIR DIS, V134, P141; GLASSER SW, 1991, AM J PHYSIOL, V261, pL349, DOI 10.1152/ajplung.1991.261.4.L349; GREENE LA, 1977, NATURE, V268, P349, DOI 10.1038/268349a0; GUMBINER B, 1981, P NATL ACAD SCI-BIOL, V78, P318, DOI 10.1073/pnas.78.1.318; HOOK GER, 1982, J BIOL CHEM, V257, P9211; HUTTNER WB, 1991, TRENDS BIOCHEM SCI, V16, P27, DOI 10.1016/0968-0004(91)90012-K; Ikegami M, 1996, AM J PHYSIOL-LUNG C, V270, pL650, DOI 10.1152/ajplung.1996.270.4.L650; JUNG LJ, 1991, SCIENCE, V251, P1330, DOI 10.1126/science.2003219; KELLY RB, 1985, SCIENCE, V230, P25, DOI 10.1126/science.2994224; KIZER JS, 1991, BIOCHEM BIOPH RES CO, V174, P586, DOI 10.1016/0006-291X(91)91457-N; LIN S, 1996, IN PRESS BIOCH BIOPH, V1312; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MILGRAM SL, 1993, J CELL BIOL, V121, P23, DOI 10.1083/jcb.121.1.23; MITRA A, 1994, J BIOL CHEM, V269, P19876; NOGEE LM, 1993, NEW ENGL J MED, V328, P406, DOI 10.1056/NEJM199302113280606; ORCI L, 1987, CELL, V51, P1039, DOI 10.1016/0092-8674(87)90590-3; PLOUG M, 1989, ANAL BIOCHEM, V181, P33, DOI 10.1016/0003-2697(89)90390-4; PRYHUBER GS, 1991, PEDIATR RES, V30, P597, DOI 10.1203/00006450-199112000-00023; REAVES BJ, 1991, MOL CELL ENDOCRINOL, V79, pC141, DOI 10.1016/0303-7207(91)90085-7; ROONEY SA, 1994, FASEB J, V8, P957, DOI 10.1096/fasebj.8.12.8088461; RYAN RM, 1989, J HISTOCHEM CYTOCHEM, V37, P429, DOI 10.1177/37.4.2926121; SAFTIG P, 1995, EMBO J, V14, P3599, DOI 10.1002/j.1460-2075.1995.tb00029.x; Sambrook J., 2002, MOL CLONING LAB MANU; SEVARINO KA, 1989, CELL, V57, P11, DOI 10.1016/0092-8674(89)90167-0; SHANNON JM, 1990, AM J RESP CELL MOL, V2, P183, DOI 10.1165/ajrcmb/2.2.183; SOSSIN WS, 1990, J CELL BIOL, V110, P1, DOI 10.1083/jcb.110.1.1; STOLLER TJ, 1989, J CELL BIOL, V108, P1647, DOI 10.1083/jcb.108.5.1647; SUWABE A, 1991, AM J RESP CELL MOL, V5, P80, DOI 10.1165/ajrcmb/5.1.80; TAM WWH, 1993, EUR J CELL BIOL, V62, P294; TOOZE J, 1987, J CELL BIOL, V105, P1215, DOI 10.1083/jcb.105.3.1215; TOOZE SA, 1990, CELL, V60, P837, DOI 10.1016/0092-8674(90)90097-X; VOORHOUT WF, 1992, AM J PHYSIOL, V263, pL479, DOI 10.1152/ajplung.1992.263.4.L479; WEAVER TE, 1989, AM J PHYSIOL, V257, pL100, DOI 10.1152/ajplung.1989.257.2.L100; WEAVER TE, 1992, AM J PHYSIOL, V263, pL95, DOI 10.1152/ajplung.1992.263.1.L95; WHITSETT JA, 1986, PEDIATR RES, V20, P744, DOI 10.1203/00006450-198608000-00009; WRIGHT JR, 1990, AM J PHYSIOL, V259, pL1, DOI 10.1152/ajplung.1990.259.2.L1; YEI SP, 1994, AM J RESP CELL MOL, V11, P329, DOI 10.1165/ajrcmb.11.3.8086169	49	70	72	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					19689	19695		10.1074/jbc.271.33.19689	http://dx.doi.org/10.1074/jbc.271.33.19689			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702672	hybrid			2022-12-25	WOS:A1996VC66900013
J	Liu, GY; Hinch, B; DavatolHag, H; Lu, Y; Powers, M; Beavis, AD				Liu, GY; Hinch, B; DavatolHag, H; Lu, Y; Powers, M; Beavis, AD			Temperature dependence of the mitochondrial inner membrane anion channel - The relationship between temperature and inhibition by protons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARDIAC SARCOPLASMIC-RETICULUM; HEART-MITOCHONDRIA; TRANSPORT PROTEINS; LIGHT-SCATTERING; KINETICS; CARRIER; MATRIX; CONTRACTION; CONDUCTANCE; MITOPLASTS	In this paper, we investigate the temperature and pH dependence of the mitochondrial inner membrane an ion channel (IMAC) that is believed to be involved in mitochondrial volume homeostasis, At pH 7.4, the flux oil malonate is highly temperature-dependent with rates; increasing from 1 nmol/min . mg at 5 degrees C to 1900 nmol/min . mg at 45 degrees C, The Arrhenius plot is nonlinear with the activation energy increasing from 21 kJ/mol (Q(10) = 1.3) to 193 kJ/mol (Q(10) = 13) as the temperature is decreased. This temperature dependence is unusual and not seen with solutes that are transported through the bilayer such as NH4OAc, malonamide, and KSCN (plus valinomycin) or even for cytochrome c oxidase-depend ent uptake of potassium (plus valinomycin), The temperature dependence of IMAC is closely related to the inhibition of IMAC by protons, Thus, we find that the pIC(50) for protons decreases from 9.3 (Hill coefficient = 1.0) at 5 degrees C to 7.1 (Hill coefficient = 2.5) at 45 degrees C, This behavior is explained on the basis of a new kinetic model for IMAC in which the net open probability is not only modulated by the binding of three protons but also by temperature via effects on the open probability of the unprotonated channel and the pK of one of the inhibitory protonation sites.	MED COLL OHIO,DEPT PHARMACOL,TOLEDO,OH 43699						NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [S15HL047735] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 47735] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANTONENKO YN, 1994, BBA-BIOMEMBRANES, V1194, P247, DOI 10.1016/0005-2736(94)90306-9; AQUILA H, 1987, FEBS LETT, V212, P1, DOI 10.1016/0014-5793(87)81546-6; Beavis A. D., 1995, Biophysical Journal, V68, pA144; BEAVIS AD, 1987, J BIOL CHEM, V262, P15085; BEAVIS AD, 1989, EUR J BIOCHEM, V185, P511, DOI 10.1111/j.1432-1033.1989.tb15143.x; Beavis AD, 1996, J BIOENERG BIOMEMBR, V28, P207, DOI 10.1007/BF02110652; BEAVIS AD, 1989, J BIOL CHEM, V264, P17148; BEAVIS AD, 1985, J BIOL CHEM, V260, P3424; BEAVIS AD, 1992, J BIOL CHEM, V267, P3079; BEAVIS AD, 1992, J BIOENERG BIOMEMBR, V24, P77, DOI 10.1007/BF00769534; BEAVIS AD, 1991, BIOCHIM BIOPHYS ACTA, V1013, P111; BEAVIS AD, 1994, MOL BIOL MITOCHONDRI, P137; CABANTCHIK ZI, 1992, AM J PHYSIOL, V262, pC803, DOI 10.1152/ajpcell.1992.262.4.C803; CORKEY BE, 1986, J BIOL CHEM, V261, P2567; CORREA AM, 1992, BIOPHYS J, V61, P1332, DOI 10.1016/S0006-3495(92)81941-0; DILGER JP, 1991, BIOCHIM BIOPHYS ACTA, V1063, P253, DOI 10.1016/0005-2736(91)90379-M; GARLID KD, 1985, J BIOL CHEM, V260, P3434; GARLID KD, 1986, BIOCHIM BIOPHYS ACTA, V853, P187, DOI 10.1016/0304-4173(87)90001-2; GRYGORCZYK R, 1987, BIOCHIM BIOPHYS ACTA, V902, P159, DOI 10.1016/0005-2736(87)90291-4; HAYMAN KA, 1993, J MEMBRANE BIOL, V136, P181, DOI 10.1007/BF02505762; HILLE B, 1992, IONIC CHANNELS EXCIT, P272; INDIVERI C, 1989, BIOCHIM BIOPHYS ACTA, V977, P187, DOI 10.1016/S0005-2728(89)80070-2; INDIVERI C, 1987, BIOCHIM BIOPHYS ACTA, V890, P310, DOI 10.1016/0005-2728(87)90158-7; JUNG DW, 1990, BIOCHEMISTRY-US, V29, P4121, DOI 10.1021/bi00469a015; KAPLAN RS, 1993, J BIOL CHEM, V268, P13682; KLITSCH T, 1991, J MEMBRANE BIOL, V122, P69, DOI 10.1007/BF01872740; KRAMER R, 1982, BIOCHIM BIOPHYS ACTA, V693, P296, DOI 10.1016/0005-2736(82)90435-7; LATORRE R, 1983, J MEMBRANE BIOL, V71, P11, DOI 10.1007/BF01870671; LEE SC, 1990, BIOPHYS J, V57, P49, DOI 10.1016/S0006-3495(90)82506-6; Liu G., 1995, Biophysical Journal, V68, pA144; MENDE P, 1982, EUR J BIOCHEM, V128, P91; MURRAY AG, 1988, EBEC REP, V5, P206; POWERS MF, 1994, J BIOL CHEM, V269, P10614; RUNSWICK MJ, 1990, BIOCHEMISTRY-US, V29, P11033, DOI 10.1021/bi00502a004; SHEN WK, 1993, BIOPHYS J, V65, P747, DOI 10.1016/S0006-3495(93)81100-7; SITSAPESAN R, 1991, J PHYSIOL-LONDON, V434, P469, DOI 10.1113/jphysiol.1991.sp018481; SORGATO MC, 1993, CRIT REV BIOCHEM MOL, V18, P127; STEIN WD, 1986, TRANSPORT DIFFUSION, P25	38	22	22	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					19717	19723		10.1074/jbc.271.33.19717	http://dx.doi.org/10.1074/jbc.271.33.19717			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702676	hybrid			2022-12-25	WOS:A1996VC66900017
J	Sarkar, S; Schlottmann, K; Cooney, D; Coggeshall, KM				Sarkar, S; Schlottmann, K; Cooney, D; Coggeshall, KM			Negative signaling via Fc gamma RIIB1 in B cells blocks phospholipase C gamma 2 tyrosine phosphorylation but not Syk or Lyn activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CROSS-LINKING; LYMPHOCYTES-B; MEMBRANE IMMUNOGLOBULIN; ANTIGEN RECEPTOR; SURFACE-IMMUNOGLOBULIN; SH2 DOMAIN; KINASES; PHOSPHATASE; CALCIUM; IG	Crosslinking of the B cell antigen receptor surface immunoglobulin induces tyrosine phosphorylation and activation of the Src family and Syk tyrosine protein kinases, tyrosine phosphorylation of phospholipase C gamma 2 (PLC gamma 2) and increases in intracellular second messengers inositol phosphates and Ca2+. These activation events, in conjunction with other pathways, culminate in the induction of B cell proliferation and differentiation. In contrast, co-crosslinking surface Ig with the B cell IgG Fc receptor prevents many of these activation events, including B cell proliferation and differentiation. The precise nature of the negative signal(s) derived from Fc receptors that prevent B cell activation is not known. Here, early activation events were examined in B cells stimulated via the antigen receptor alone or under co-crosslinking conditions. The data indicated a selective block in the tyrosine phosphorylation and activation of PLC gamma 2 hut not in activation of the upstream kinases, Syk and Lyn, under co-crosslinking conditions. We conclude that the negative signal acts directly on PLC gamma 2 and is consistent with recent studies describing an activation-induced association of a phosphotyrosine phosphatase with tyrosine-phosphorylated B cell Fc receptor.	OHIO STATE UNIV,DEPT MICROBIOL,COLUMBUS,OH 43210	University System of Ohio; Ohio State University			Cooney, Damon/J-4762-2014	Cooney, Damon/0000-0002-2786-287X				BIJSTERBOSCH MK, 1985, J EXP MED, V162, P1825, DOI 10.1084/jem.162.6.1825; BURKHARDT AL, 1991, P NATL ACAD SCI USA, V88, P7410, DOI 10.1073/pnas.88.16.7410; CAMBIER JC, 1994, ANNU REV IMMUNOL, V12, P457, DOI 10.1146/annurev.immunol.12.1.457; CAMPBELL MA, 1992, MOL CELL BIOL, V12, P2315, DOI 10.1128/MCB.12.5.2315; CHOQUET D, 1993, J CELL BIOL, V121, P355, DOI 10.1083/jcb.121.2.355; COGGESHALL KM, 1985, J IMMUNOL, V134, P101; COGGESHALL KM, 1992, P NATL ACAD SCI USA, V89, P5660, DOI 10.1073/pnas.89.12.5660; COUTURE C, 1994, P NATL ACAD SCI USA, V91, P5301, DOI 10.1073/pnas.91.12.5301; DAMBROSIO D, 1995, SCIENCE, V268, P293, DOI 10.1126/science.7716523; DIEGEL ML, 1994, J BIOL CHEM, V269, P11409; GOLD MR, 1994, ADV IMMUNOL, V55, P221; GOLD MR, 1992, J IMMUNOL, V148, P2012; HEMPEL WM, 1992, J IMMUNOL, V148, P3021; HUTCHCROFT JE, 1992, J BIOL CHEM, V267, P8613; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; KLAUS GGB, 1984, IMMUNOLOGY, V53, P693; LANE PJL, 1991, J IMMUNOL, V146, P715; MATTHEWS RJ, 1992, MOL CELL BIOL, V12, P2396, DOI 10.1128/MCB.12.5.2396; MUTA T, 1994, NATURE, V369, P340, DOI 10.1038/369340a0; PADEH S, 1991, J CLIN INVEST, V87, P1114, DOI 10.1172/JCI115074; PHILLIPS NE, 1984, J IMMUNOL, V132, P627; PHILLIPS NE, 1983, J IMMUNOL, V130, P602; PLUTZKY J, 1992, P NATL ACAD SCI USA, V89, P1123, DOI 10.1073/pnas.89.3.1123; RANSOM JT, 1986, J IMMUNOL, V136, P66; ROWLEY RB, 1995, J BIOL CHEM, V270, P11590, DOI 10.1074/jbc.270.19.11590; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; SINCLAIR MR, 1987, IMMUNOL TODAY, V6, P76; TAKATA M, 1994, EMBO J, V13, P1341, DOI 10.1002/j.1460-2075.1994.tb06387.x; YI TL, 1993, MOL CELL BIOL, V13, P7577, DOI 10.1128/MCB.13.12.7577; YI TL, 1993, MOL CELL BIOL, V13, P3350, DOI 10.1128/MCB.13.6.3350	30	30	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					20182	20186		10.1074/jbc.271.33.20182	http://dx.doi.org/10.1074/jbc.271.33.20182			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702743	hybrid			2022-12-25	WOS:A1996VC66900085
J	Si, JT; Luo, ZJ; Mei, L				Si, JT; Luo, ZJ; Mei, L			Induction of acetylcholine receptor gene expression by ARIA requires activation of mitogen-activated protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; MAMMARY EPITHELIAL-CELLS; EPSILON-SUBUNIT GENE; NEUROMUSCULAR-JUNCTION; TYROSINE PHOSPHORYLATION; PHOSPHATIDYLINOSITOL 3-KINASE; SKELETAL-MUSCLE; NDF HEREGULIN; MAP KINASE; DIFFERENTIATION	Transcription of genes encoding nicotinic acetylcholine receptor (AChR) subunits (alpha, beta, gamma or epsilon, and delta) is highest in nuclei localized to the synaptic region of the muscle, which contributes to maintain a high density of AChRs at the postjunctional membrane. ARIA (AChR inducing activity) is believed to be the trophic factor utilized by motor neurons to stimulate AChR synthesis in the subsynaptic area. To elucidate the signaling mechanism initiated by ARIA, we established stable C2C12 cell lines carrying the nuclear lacZ gene under the control of the mouse epsilon subunit promoter or chicken ru subunit promoter. ARIA stimulated tyrosine phosphorylation of erbB proteins in these C2C12 cells within 15 s with a peak at 5 min. Immediately following tyrosine phosphorylation of erbB proteins, mitogen-activated protein (MAP) kinase was activated which occurred within 30 s and peaked at 8 min after ARIA stimulation. Concomitantly, expression of AChR genes was induced by ARIA. ARIA-induced AChR subunit transgene expression was observed only in differentiated myotubes and not in myoblasts, suggesting that downstream signaling component(s) are regulated in a manner dependent on the myogenic program. Inhibition of the MAP kinase activity by using a specific MAP kinase kinase inhibitor or by overexpressing dominant negative mutants of Raf or MAP kinase kinase attenuated or abolished the ARIA-induced activation of AChR alpha and epsilon subunit gene expression. These results indicate that regulation of AChR gene expression by ARIA ill C2C12 cells requires activation of the MAP kinase signaling pathway.	UNIV VIRGINIA,SCH MED,DEPT PHARMACOL,CHARLOTTESVILLE,VA 22908; MASSACHUSETTS GEN HOSP,DIABET UNIT,CHARLESTOWN,MA 02129	University of Virginia; Harvard University; Massachusetts General Hospital			Luo, Zhijun/AAE-9302-2019; Mei, Lin/G-8755-2012	Luo, Zhijun/0000-0001-8105-5289; 	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS034062] Funding Source: NIH RePORTER; NINDS NIH HHS [NS34062] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALTIOK N, 1995, EMBO J, V14, P4258, DOI 10.1002/j.1460-2075.1995.tb00100.x; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BLAU HM, 1983, CELL, V32, P1171, DOI 10.1016/0092-8674(83)90300-8; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; CARRAWAY KL, 1995, J BIOL CHEM, V270, P7111, DOI 10.1074/jbc.270.13.7111; CARRAWAY KL, 1994, J BIOL CHEM, V269, P14303; CHU GC, 1995, NEURON, V14, P329, DOI 10.1016/0896-6273(95)90289-9; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; CORFAS G, 1993, P NATL ACAD SCI USA, V90, P1624, DOI 10.1073/pnas.90.4.1624; DSOUZA B, 1994, P NATL ACAD SCI USA, V91, P7202, DOI 10.1073/pnas.91.15.7202; DUCLERT A, 1995, PHYSIOL REV, V75, P339, DOI 10.1152/physrev.1995.75.2.339; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; DUMONT FJ, 1994, J CELL PHYSIOL, V160, P141, DOI 10.1002/jcp.1041600117; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; FROEHNER SC, 1993, ANNU REV NEUROSCI, V16, P347, DOI 10.1146/annurev.ne.16.030193.002023; GOODEARL ADJ, 1995, J CELL BIOL, V130, P1423, DOI 10.1083/jcb.130.6.1423; GUY PM, 1994, P NATL ACAD SCI USA, V91, P8132, DOI 10.1073/pnas.91.17.8132; HALL ZW, 1993, CELL, V72, P99, DOI 10.1016/S0092-8674(05)80031-5; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HUANG CF, 1992, NEURON, V9, P671, DOI 10.1016/0896-6273(92)90030-H; HUANG WD, 1994, P NATL ACAD SCI USA, V91, P8960, DOI 10.1073/pnas.91.19.8960; JESSELL TM, 1979, P NATL ACAD SCI USA, V76, P5397, DOI 10.1073/pnas.76.10.5397; JO SA, 1995, NATURE, V373, P158, DOI 10.1038/373158a0; KING CR, 1985, SCIENCE, V229, P974, DOI 10.1126/science.2992089; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; LAZAR DF, 1995, J BIOL CHEM, V270, P20801, DOI 10.1074/jbc.270.35.20801; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARSHALL MS, 1995, FASEB J, V9, P1311, DOI 10.1096/fasebj.9.13.7557021; MARTE BM, 1995, ONCOGENE, V10, P167; MARTINOU JC, 1991, J NEUROSCI, V11, P1291; MEI L, 1995, LIFE SCI, V57, P1459, DOI 10.1016/0024-3205(95)02118-3; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; PELES E, 1993, EMBO J, V12, P961, DOI 10.1002/j.1460-2075.1993.tb05737.x; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; PLOWMAN GD, 1990, P NATL ACAD SCI USA, V87, P4905, DOI 10.1073/pnas.87.13.4905; QIAN XL, 1994, P NATL ACAD SCI USA, V91, P1500, DOI 10.1073/pnas.91.4.1500; REUTER CWM, 1995, METHOD ENZYMOL, V255, P245; Sambrook J., 2002, MOL CLONING LAB MANU; SANES JR, 1991, DEVELOPMENT, V113, P1181; SEGATTO O, 1993, ONCOGENE, V8, P2105; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; TZAHAR E, 1994, J BIOL CHEM, V269, P25226; UNWIN N, 1995, NATURE, V373, P37, DOI 10.1038/373037a0; WALLASCH C, 1995, EMBO J, V14, P4267, DOI 10.1002/j.1460-2075.1995.tb00101.x; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; WRIGHT JD, 1995, J BIOL CHEM, V270, P12085, DOI 10.1074/jbc.270.20.12085; Xie YM, 1995, J BIOL CHEM, V270, P30717, DOI 10.1074/jbc.270.51.30717; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0; ZHENG CF, 1994, EMBO J, V13, P1123, DOI 10.1002/j.1460-2075.1994.tb06361.x; ZHU XJ, 1995, EMBO J, V14, P5842, DOI 10.1002/j.1460-2075.1995.tb00272.x	55	94	98	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					19752	19759		10.1074/jbc.271.33.19752	http://dx.doi.org/10.1074/jbc.271.33.19752			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702681	hybrid			2022-12-25	WOS:A1996VC66900022
J	Chabardes, D; Firsov, D; Aarab, L; Clabecq, A; Bellanger, AC; SiaumePerez, S; Elalouf, JM				Chabardes, D; Firsov, D; Aarab, L; Clabecq, A; Bellanger, AC; SiaumePerez, S; Elalouf, JM			Localization of mRNAs encoding Ca2+-inhibitable adenylyl cyclases along the renal tubule - Functional consequences for regulation of the cAMP content	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; RAT-KIDNEY; COLLECTING TUBULE; PREDOMINANT EXPRESSION; EXTRACELLULAR CALCIUM; NCB-20 CELLS; GLIOMA-CELLS; INHIBITION; CLONING; ACCUMULATION	Expression of Ca2+-inhibitable types V and VI adenylyl cyclases was studied by reverse transcription-polymerase chain reaction in rat renal glomeruli and nephron segments isolated by microdissection. Quantitation of each mRNA was achieved using a mutant cRNA which differed from the wild type by substituting two bases to create a new restriction site in the corresponding cDNA. Type VI mRNA was present all along the nephron but was more abundant in distal than in proximal segments. The expression of type V mRNA was restricted to the glomerulus and to the initial portions of the collecting duct. Expression of the Ca2+-insensitive type IV mRNA studied on the same samples was evidenced only in the glomerulus, The functional relevance of the expression of Ca2+-inhibitable isoforms was studied by measuring cAMP content in the microdissected enter medullary collecting duct which expressed both type V mRNA (2367 +/- 178 molecules/mm tubular length; n = 8) and type VI mRNA (5658 +/- 543 molecules/mm, n = 8). Agents known to increase intracellular Ca2+ in this segment induced a Ca2+-dependent inhibition on either arginine vasopressin- or glucagon-stimulated cAMP level. The characteristics of these inhibitions suggest a functional and differential expression of types V and VI adenylyl cyclases in two different cell types of the rat outer medullary collecting duct.	COLL FRANCE, LAB PHYSIOL CELLULAIRE, F-75231 PARIS 05, FRANCE	UDICE-French Research Universities; PSL Research University Paris; College de France	Chabardes, D (corresponding author), CEA SACLAY, DEPT BIOL CELLULAIRE & MOL, SBCE, LAB BIOL INTEGREE CELLULES RENALES, BAT 520, F-91191 GIF SUR YVETTE, FRANCE.		Elalouf, Jean-Marc/C-4351-2014	Elalouf, Jean-Marc/0000-0003-0151-6423				AARAB L, 1993, PFLUG ARCH EUR J PHY, V425, P417, DOI 10.1007/BF00374867; AARAB L, 1993, PFLUG ARCH EUR J PHY, V423, P397, DOI 10.1007/BF00374933; BEAVO JA, 1995, PHYSIOL REV, V75, P725, DOI 10.1152/physrev.1995.75.4.725; BOYAJIAN CL, 1991, J BIOL CHEM, V266, P4995; BREYER MD, 1991, AM J PHYSIOL, V260, pF1, DOI 10.1152/ajprenal.1991.260.1.F1; CHABARDES D, 1984, MOL CELL ENDOCRINOL, V37, P263, DOI 10.1016/0303-7207(84)90096-0; CHABARDES D, 1990, MOL CELL ENDOCRINOL, V73, P111, DOI 10.1016/0303-7207(90)90124-Q; CHIONO M, 1995, J BIOL CHEM, V270, P1149, DOI 10.1074/jbc.270.3.1149; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COOPER DMF, 1995, NATURE, V374, P421, DOI 10.1038/374421a0; Costanzo LS, 1992, KIDNEY PHYSL PATHOPH, P2375; DEBERNARDI MA, 1993, BIOCHEM J, V293, P325, DOI 10.1042/bj2930325; DEBERNARDI MA, 1991, P NATL ACAD SCI USA, V88, P9257, DOI 10.1073/pnas.88.20.9257; ELALOUF JM, 1993, J CLIN INVEST, V91, P264, DOI 10.1172/JCI116180; FIRSOV D, 1994, PFLUG ARCH EUR J PHY, V429, P79, DOI 10.1007/BF02584033; GAO BN, 1991, P NATL ACAD SCI USA, V88, P10178, DOI 10.1073/pnas.88.22.10178; GARG LC, 1981, AM J PHYSIOL, V240, pF536, DOI 10.1152/ajprenal.1981.240.6.F536; IYENGAR R, 1993, FASEB J, V7, P768, DOI 10.1096/fasebj.7.9.8330684; JACKSON BA, 1988, MOL CELL ENDOCRINOL, V57, P199, DOI 10.1016/0303-7207(88)90075-5; JACOBOWITZ O, 1993, J BIOL CHEM, V268, P3829; KATSUSHIKA S, 1992, P NATL ACAD SCI USA, V89, P8774, DOI 10.1073/pnas.89.18.8774; Kriz W, 1992, KIDNEY PHYSL PATHOPH, P707; KRUPINSKI J, 1992, J BIOL CHEM, V267, P24858; KUSANO E, 1985, AM J PHYSIOL, V249, pF956, DOI 10.1152/ajprenal.1985.249.6.F956; MADSEN KM, 1986, AM J PHYSIOL, V250, pF1, DOI 10.1152/ajprenal.1986.250.1.F1; MARCHETTI J, 1990, PFLUG ARCH EUR J PHY, V416, P561, DOI 10.1007/BF00382690; MERCIER O, 1989, AM J PHYSIOL, V257, pF1003, DOI 10.1152/ajprenal.1989.257.6.F1003; MOREL F, 1986, PHYSIOL REV, V66, P377, DOI 10.1152/physrev.1986.66.2.377; PREMONT RT, 1992, P NATL ACAD SCI USA, V89, P9809, DOI 10.1073/pnas.89.20.9809; RICCARDI D, 1995, P NATL ACAD SCI USA, V92, P131, DOI 10.1073/pnas.92.1.131; Ross BD, 1982, METABOLIC COMPARTMEN, P363; STEVENS T, 1995, P NATL ACAD SCI USA, V92, P2696, DOI 10.1073/pnas.92.7.2696; TAUSSIG R, 1995, J BIOL CHEM, V270, P1, DOI 10.1074/jbc.270.1.1; WALLACH J, 1994, FEBS LETT, V338, P257, DOI 10.1016/0014-5793(94)80279-3; YOSHIMURA M, 1992, P NATL ACAD SCI USA, V89, P6716, DOI 10.1073/pnas.89.15.6716; YOSHIMURA M, 1993, J BIOL CHEM, V268, P4604; YU HJ, 1993, MOL PHARMACOL, V44, P689; YU HJ, 1995, FEBS LETT, V374, P89	38	92	98	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19264	19271		10.1074/jbc.271.32.19264	http://dx.doi.org/10.1074/jbc.271.32.19264			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702608	hybrid			2022-12-25	WOS:A1996VB68400042
J	Dizhoor, AM; Hurley, JB				Dizhoor, AM; Hurley, JB			Inactivation of EF-hands makes GCAP-2 (p24) a constitutive activator of photoreceptor guanylyl cyclase by preventing a Ca2+-induced ''activator-to-inhibitor'' transition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM; PROTEIN; RECOVERIN; CLONING; BINDING; TRANSDUCTION; EXPRESSION; CALMODULIN; TERMINUS; RETGC	Guanylyl cyclase activator proteins GCAP-1 and GCAP-2 (Dizhoor et al, 1995, Gorczyca et al,, 1995) are members of a recently identified subclass of EF-hand type Ca2+-binding proteins that respond to Ca2+ differently than any other known members of the EF-hand superfamily. GCAPs acquire an activating conformation only in their Ca2+-free form. Free Ca2+ concentrations corresponding to levels in dark-adapted vertebrate photoreceptors inhibit the ability of GCAPs to activate photoreceptor guanylyl cyclases (RetGCs). We studied the effects of mutations that block binding of Ca2+ to the EF-hands of GCAP-2. Unlike other EF-hand proteins, which fail to activate their target when their EF-hands are inactivated by mutations, GCAP-2 with any single EF-hand inactivated remains active and is 3-6 times less sensitive to the inhibitory effect off Ca2+. Inactivation of any two or all three EF-hands produces active forms of GGAP-2 that are insensitive to inhibition by physiological intracellular concentrations of Ca2+. Unexpectedly we also found that activation of RetGCs by a Ca2+-insensitive mutant is inhibited by Ca2+-loaded wild type GCAP-2. We propose the following, 1) GCAP-2 can exist in two extreme functional forms: an apo form that activates RetGCs and a Ca2+-loaded form that blocks activation of RetGCs, 2) All three EF-hands of GCAP-2 contribute to the inhibitory effect of Ca2+. 3) Inactivation of two off three EF-hands is sufficient to shift the ''activator-inhibitor'' transition outside the physiological range of intracellular free Ca2+.	UNIV WASHINGTON, SCH MED, HOWARD HUGHES MED INST, SEATTLE, WA 98195 USA	Howard Hughes Medical Institute; University of Washington; University of Washington Seattle	Dizhoor, AM (corresponding author), UNIV WASHINGTON, SCH MED, DEPT BIOCHEM, POB 357370, SEATTLE, WA 98195 USA.			Dizhoor, Alexander/0000-0001-6770-9186	NATIONAL EYE INSTITUTE [R01EY011522] Funding Source: NIH RePORTER; NEI NIH HHS [EY11522, EY06641] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BABU A, 1992, J BIOL CHEM, V267, P15469; CHASIN WJ, 1995, NATURE SRUCT BIOL, V2, P707; CRIVICI A, 1995, ANNU REV BIOPH BIOM, V24, P85, DOI 10.1146/annurev.bb.24.060195.000505; DIZHOOR AM, 1992, J BIOL CHEM, V267, P16033; DIZHOOR AM, 1993, SCIENCE, V259, P829, DOI 10.1126/science.8430337; DIZHOOR AM, 1995, J BIOL CHEM, V270, P25200, DOI 10.1074/jbc.270.42.25200; DIZHOOR AM, 1991, SCIENCE, V251, P915, DOI 10.1126/science.1672047; DIZHOOR AM, 1994, NEURON, V12, P1345, DOI 10.1016/0896-6273(94)90449-9; FLAHERTY KM, 1993, CELL, V75, P709, DOI 10.1016/0092-8674(93)90491-8; GARBERS DL, 1994, J BIOL CHEM, V269, P30741; GORCZYCA WA, 1995, J BIOL CHEM, V270, P22029, DOI 10.1074/jbc.270.37.22029; GORCZYCA WA, 1994, P NATL ACAD SCI USA, V91, P4014, DOI 10.1073/pnas.91.9.4014; GRAYKELLER MP, 1994, NEURON, V13, P849, DOI 10.1016/0896-6273(94)90251-8; Horton MR, 1991, DIRECTED MUTAGENESIS, P217; KOBAYASHI M, 1993, BIOCHEM BIOPH RES CO, V196, P1017, DOI 10.1006/bbrc.1993.2351; KOCH KW, 1988, NATURE, V334, P64, DOI 10.1038/334064a0; LAGNADO L, 1992, NEURON, V8, P995, DOI 10.1016/0896-6273(92)90122-T; Laura RP, 1996, J BIOL CHEM, V271, P11646, DOI 10.1074/jbc.271.20.11646; LIU YC, 1990, TRENDS PHARMACOL SCI, V11, P107; LOWE DG, 1995, P NATL ACAD SCI USA, V92, P5535, DOI 10.1073/pnas.92.12.5535; MARKS PW, 1991, ANAL BIOCHEM, V193, P61, DOI 10.1016/0003-2697(91)90044-T; McDowell J. H., 1993, PHOTORECEPTOR CELLS, V15, P123; OKAZAKI K, 1992, BIOCHEM BIOPH RES CO, V185, P147, DOI 10.1016/S0006-291X(05)80968-4; PALCZEWSKI K, 1994, NEURON, V13, P395, DOI 10.1016/0896-6273(94)90355-7; STRYNADKA NCJ, 1989, ANNU REV BIOCHEM, V58, P951, DOI 10.1146/annurev.bi.58.070189.004511; TSIEN R, 1989, METHOD ENZYMOL, V172, P230; WALTERSSON Y, 1993, BIOCHEMISTRY-US, V32, P7866, DOI 10.1021/bi00082a005; YARFITZ S, 1994, J BIOL CHEM, V269, P14329	28	97	97	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19346	19350		10.1074/jbc.271.32.19346	http://dx.doi.org/10.1074/jbc.271.32.19346			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702620	hybrid			2022-12-25	WOS:A1996VB68400054
J	Li, B; Ouyang, B; Pan, HQ; Reissmann, PT; Slamon, DJ; Arceci, R; Lu, L; Dai, W				Li, B; Ouyang, B; Pan, HQ; Reissmann, PT; Slamon, DJ; Arceci, R; Lu, L; Dai, W			prk, a cytokine-inducible human protein serine/threonine kinase whose expression appears to be down-regulated in lung carcinomas	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; MEGAKARYOCYTIC DIFFERENTIATION; DROSOPHILA POLO; GENE; IDENTIFICATION; CLONING; LOCALIZATION; INHIBITORS; CANCER; CDC5	We have cloned and characterized a putative protein serine/threonine kinase termed prk through a combination of polymerase chain reaction and conventional cDNA library screening approaches. There are apparently two distinct domains within pll protein deduced from its nucleotide sequences. The amino-terminal portion has the feature of the catalytic domain of a serine/threonine kinase and shows strong homology to mouse fnk and other polo family kinases including mouse snk, human and murine plk, Drosophila polo, and yeast Cdc5, The carboxyl-terminal portion, presumably the regulatory domain, shares extensive homology to mouse fnk, Northern blotting analyses reveal that prk expression is restricted to a very limited number of tissues with placenta, ovaries, and lung containing detectable amounts of prk mRNA. prk mRNA expression is also detected at a low level in the megakaryocytic cell line Dami, MO7e, and three brain glioma cell lines, In addition, refeeding of serum-deprived MO7e, Dami, and K562 cells of hematopoietic origin and GMOO637D of lung fibroblasts rapidly activates prk, mRNA expression with its peak induction around 2 h after serum addition, pl-fi gene activation by the serum requires no new protein synthesis, The recombinant cytokines such as interleukin-3 and thrombopoietin also activate prk mRNA expression in MO7e cells, Furthermore, a survey of RNAs isolated from the tumor and the uninvolved tissues from 18 lung cancer patients reveals that prk mRNA expression is significantly down-regulated in tumor tissues, Southern blotting analysis indicates that the pl h gene is present in a single copy in the genome of tumors and normal cells, Taken together, these results suggest that prk expression may be restricted to proliferating cells and involved in the regulation of cell cycle progression, The molecular cloning- of prk cDNA will facilitate the study of its biological role as well as its potential role in tumorigenesis.	UNIV CINCINNATI,COLL MED,DEPT INTERNAL MED,DIV HEMATOL & ONCOL,CINCINNATI,OH 45267; UNIV CALIF LOS ANGELES,DEPT MED,LOS ANGELES,CA 90095; CHILDRENS HOSP RES FDN,CINCINNATI,OH 45229; WRIGHT STATE UNIV,DEPT PHYSIOL & BIOPHYS,DAYTON,OH 45435	University System of Ohio; University of Cincinnati; University of California System; University of California Los Angeles; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; University System of Ohio; Wright State University Dayton					NATIONAL CANCER INSTITUTE [R01CA059985] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA59985] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CAPLEN HS, 1988, J BIOL CHEM, V263, P332; CHENG T, 1995, LEUKEMIA, V9, P1257; CHENG T, 1994, J BIOL CHEM, V269, P30848; CLAY FJ, 1993, P NATL ACAD SCI USA, V90, P4882, DOI 10.1073/pnas.90.11.4882; CLINE MJ, 1994, NEW ENGL J MED, V330, P328; DAI W, 1994, ONCOGENE, V9, P975; DONOHUE PJ, 1995, J BIOL CHEM, V270, P10351, DOI 10.1074/jbc.270.17.10351; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FENTON B, 1993, NATURE, V363, P637, DOI 10.1038/363637a0; GOLSTEYN RM, 1995, J CELL BIOL, V129, P1617, DOI 10.1083/jcb.129.6.1617; GOLSTEYN RM, 1994, J CELL SCI, V107, P1509; GRANA X, 1994, ONCOGENE, V9, P2097; HAMANAKA R, 1994, CELL GROWTH DIFFER, V5, P249; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARTWELL LH, 1973, J BACTERIOL, V115, P966, DOI 10.1128/JB.115.3.966-974.1973; HIRAMA T, 1995, BLOOD, V86, P841; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; KITADA K, 1993, MOL CELL BIOL, V13, P4445, DOI 10.1128/MCB.13.7.4445; KUROSAWA M, 1994, J PHARMACOL TOXICOL, V31, P135, DOI 10.1016/1056-8719(94)90075-2; LEVIN WJ, 1995, ONCOGENE, V11, P1261; MALTER JS, 1989, SCIENCE, V246, P664, DOI 10.1126/science.2814487; Sambrook J., 2002, MOL CLONING LAB MANU; SCHILD D, 1980, GENETICS, V96, P859; SIMMONS DL, 1992, MOL CELL BIOL, V12, P4164, DOI 10.1128/MCB.12.9.4164; Walworth NC, 1996, SCIENCE, V271, P353, DOI 10.1126/science.271.5247.353; WILHIDE CC, 1995, BLOOD, V86, P294, DOI 10.1182/blood.V86.1.294.bloodjournal861294	26	125	141	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19402	19408		10.1074/jbc.271.32.19402	http://dx.doi.org/10.1074/jbc.271.32.19402			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702627	hybrid			2022-12-25	WOS:A1996VB68400061
J	Cestele, S; Sampieri, F; Rochat, H; Gordon, D				Cestele, S; Sampieri, F; Rochat, H; Gordon, D			Tetrodotoxin reverses brevetoxin allosteric inhibition of scorpion alpha-toxin binding on rat brain sodium channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-SITE; NEUROTOXIN BINDING; SYNAPTOSOMES; VERATRIDINE; MODULATION; MEMBRANES; SAXITOXIN; RESIDUES	Voltage-sensitive sodium channels are responsible for the initiation of action potentials in many excitable cells, Several neurotoxins bind to distinct receptor sites on sodium channels and reveal strong allosteric interactions among them, Scorpion alpha toxins, which inhibit sodium channel inactivation by binding to receptor site 3, have been very important tools to study sodium channel structure and function, Recently, we have shown that brevetoxin induce a strong negative allosteric modulation on scorpion alpha-toxin binding on rat brain sodium channels, in contrast to previously published studies. In this report we have examined the reasons for this discrepancy and found new, unexpected allosteric interactions between the tetrodotoxin and brevetoxin receptor sites, using scorpion alpha-toxin as sensitive probe for subtle conformational changes on sodium channels. Tetrode-toxin reverses the negative modulation induced by brevetoxin on scorpion alpha-toxin binding, revealing new dynamic interactions in sodium channel structure.	FAC MED NORD,JEAN ROCHE INST,BIOCHEM LAB,CNRS URA 1455,F-13916 MARSEILLE 20,FRANCE	UDICE-French Research Universities; Aix-Marseille Universite								BADEN DG, 1989, FASEB J, V3, P1807, DOI 10.1096/fasebj.3.7.2565840; CATTERALL WA, 1980, ANNU REV PHARMACOL, V20, P15, DOI 10.1146/annurev.pa.20.040180.000311; CATTERALL WA, 1986, ANNU REV BIOCHEM, V55, P953, DOI 10.1146/annurev.biochem.55.1.953; CATTERALL WA, 1981, MOL PHARMACOL, V19, P345; CATTERALL WA, 1977, J BIOL CHEM, V252, P8660; CATTERALL WA, 1985, TOXICON, V23, P497, DOI 10.1016/0041-0101(85)90034-0; CATTERALL WA, 1992, PHYSIOL REV, V72, P15; CESTELE S, 1995, J BIOL CHEM, V270, P15153, DOI 10.1074/jbc.270.25.15153; DODD PR, 1981, BRAIN RES, V226, P107, DOI 10.1016/0006-8993(81)91086-6; EDWARDS RA, 1992, MOL BRAIN RES, V14, P64, DOI 10.1016/0169-328X(92)90011-Y; GAWLEY RE, 1992, TOXICON, V30, P780, DOI 10.1016/0041-0101(92)90014-V; HUANG JMC, 1984, J PHARMACOL EXP THER, V229, P615; JOVER E, 1980, BIOCHEMISTRY-US, V19, P463, DOI 10.1021/bi00544a010; KHARRAT R, 1990, TOXICON, V28, P509, DOI 10.1016/0041-0101(90)90295-I; KHARRAT R, 1989, EUR J BIOCHEM, V181, P381, DOI 10.1111/j.1432-1033.1989.tb14735.x; MIRANDA F, 1970, EUR J BIOCHEM, V16, P514, DOI 10.1111/j.1432-1033.1970.tb01111.x; NODA M, 1989, FEBS LETT, V259, P213, DOI 10.1016/0014-5793(89)81531-5; POLI MA, 1986, MOL PHARMACOL, V30, P129; RAY R, 1978, J BIOL CHEM, V253, P7307; Rogers J. C., 1996, Biophysical Journal, V70, pA319; SHARKEY RG, 1987, MOL PHARMACOL, V31, P273; TERLAU H, 1991, FEBS LETT, V293, P93, DOI 10.1016/0014-5793(91)81159-6; THOMSEN WJ, 1989, P NATL ACAD SCI USA, V86, P10161, DOI 10.1073/pnas.86.24.10161; TRAINER VL, 1991, MOL PHARMACOL, V40, P988; TRAINER VL, 1994, J BIOL CHEM, V269, P19904; TRAINER VL, 1993, J BIOL CHEM, V268, P17114; WU CH, 1987, ANN REV PHARM TOXICO, V28, P141	27	14	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18329	18332		10.1074/jbc.271.31.18329	http://dx.doi.org/10.1074/jbc.271.31.18329			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702472	hybrid			2022-12-25	WOS:A1996VB68300010
J	Kainulainen, V; Nelimarkka, L; Jarvelainen, H; Laato, M; Jalkanen, M; Elenius, K				Kainulainen, V; Nelimarkka, L; Jarvelainen, H; Laato, M; Jalkanen, M; Elenius, K			Suppression of syndecan-1 expression tumor necrosis factor-alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCANS; MAMMARY EPITHELIAL-CELLS; FIBROBLAST GROWTH-FACTOR; EMBRYONIC TOOTH MESENCHYME; SURFACE PROTEOGLYCAN; ENDOTHELIAL-CELLS; MALIGNANT TRANSFORMATION; VASCULAR ENDOTHELIUM; KAPPA-B; BINDING	Syndecan-1 is a cell surface proteoglycan that binds extracellular matrix components and modulates the activity of heparin-binding growth factors, The expression of syndecan-1 is modified during development, carcinogenesis, and tissue regeneration, During cutaneous wound healing, syndecan-1 expression is transiently induced in newly-formed capillaries of granulation tissue as well as in proliferating keratinocytes, To study the mechanisms underlying this regulation we investigated the effects of several growth factors/cytokines on syndecan-1 expression in two human cell lines: EA.hy 926 endothelial cells and HaCaT keratinocytes. None of these factors significantly altered syndecan-1 mRNA expression in cultured keratinocytes, but when given to endothelial cells, tumor necrosis factor-alpha (TNF-alpha) specifically and dose-dependently suppressed syndecan-1 expression at both mRNA and protein levels, TNF-alpha reduced the amount of syndecan-1 protein in EA.hy 926 cells in both the presence and absence of serum and, at the same time, induced the expression of intercellular adhesion molecule-1 (ICAM-1). The suppressive effect of TNF-alpha on endothelial syndecan-1 expression was reproducible in in vivo experiments in which TNF-alpha coated beads were administered directly to healing skin wounds of mice. Data supporting these findings were further obtained by injecting TNF-alpha into an experimental rat granulation tissue model, In this tissue TNF a suppressed syndecan-1 mRNA expression by approximately 80%. These results indicate that TNF-alpha is capable of down-regulating syndecan-1 expression in endothelial cells both in vitro and in vivo and suggest that similar mechanisms may be responsible for the changes in syndecan-1 expression observed during various regenerative, developmental, and malignant processes.	UNIV TURKU, DEPT SURG, TURKU 20520, FINLAND; UNIV TURKU, DEPT INTERNAL MED, TURKU 20520, FINLAND; UNIV TURKU, DEPT BIOCHEM MED, TURKU 20520, FINLAND; UNIV TURKU, TURKU CTR BIOTECHNOL, TURKU 20520, FINLAND	University of Turku; University of Turku; University of Turku; University of Turku				Elenius, Klaus/0000-0001-5700-0827				AIRAS L, 1993, J IMMUNOL, V151, P4228; AVIEZER D, 1994, P NATL ACAD SCI USA, V91, P12173, DOI 10.1073/pnas.91.25.12173; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; BEVILACQUA MP, 1986, P NATL ACAD SCI USA, V83, P4533, DOI 10.1073/pnas.83.12.4533; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CIZMECISMITH G, 1993, J BIOL CHEM, V268, P18740; COHEN T, 1995, J BIOL CHEM, V270, P11322, DOI 10.1074/jbc.270.19.11322; DIAMOND MS, 1995, J CELL BIOL, V130, P1473, DOI 10.1083/jcb.130.6.1473; ELENIUS K, 1994, J CELL SCI, V107, P2975; ELENIUS K, 1992, J BIOL CHEM, V267, P6435; ELENIUS K, 1991, J CELL BIOL, V114, P585, DOI 10.1083/jcb.114.3.585; EMEIS JJ, 1988, BLOOD, V71, P1669; FAJARDO LF, 1992, AM J PATHOL, V140, P539; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; FRATERSCHRODER M, 1987, P NATL ACAD SCI USA, V84, P5277, DOI 10.1073/pnas.84.15.5277; GALLATIN WM, 1983, NATURE, V304, P30, DOI 10.1038/304030a0; GALLO RL, 1994, P NATL ACAD SCI USA, V91, P11035, DOI 10.1073/pnas.91.23.11035; GITAYGOREN H, 1992, J BIOL CHEM, V267, P6093; HAVELL EA, 1988, J EXP MED, V167, P1067, DOI 10.1084/jem.167.3.1067; HAYAMIZU TF, 1991, DEV BIOL, V145, P164, DOI 10.1016/0012-1606(91)90222-O; HAYASHI K, 1987, J HISTOCHEM CYTOCHEM, V35, P1079, DOI 10.1177/35.10.2957423; HIGASHIYAMA S, 1993, J CELL BIOL, V122, P933, DOI 10.1083/jcb.122.4.933; HINKES MT, 1993, J BIOL CHEM, V268, P11440; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; INKI P, 1994, BRIT J CANCER, V70, P319, DOI 10.1038/bjc.1994.300; INKI P, 1991, AM J PATHOL, V139, P1333; INKI P, 1994, EUR J CELL BIOL, V63, P43; JAATTELA M, 1991, LAB INVEST, V64, P724; JALKANEN M, 1985, J CELL BIOL, V101, P976, DOI 10.1083/jcb.101.3.976; JALKANEN M, 1993, TRENDS GLYCOSCI GLYC, V5, P107; JOHNSON GR, 1994, J BIOL CHEM, V269, P27149; KATO M, 1995, MOL BIOL CELL, V6, P559, DOI 10.1091/mbc.6.5.559; KIEFER MC, 1990, P NATL ACAD SCI USA, V87, P6985, DOI 10.1073/pnas.87.18.6985; KLAGSBRUN M, 1991, PEPTIDE GROWTH FACTO, P549; KODA JE, 1985, J BIOL CHEM, V260, P8157; KOJIMA T, 1992, J BIOL CHEM, V267, P4859; KRISTENSEN M, 1993, CLIN EXP IMMUNOL, V94, P354; LEIBOVICH SJ, 1987, NATURE, V329, P630, DOI 10.1038/329630a0; LEPPA S, 1992, P NATL ACAD SCI USA, V89, P932, DOI 10.1073/pnas.89.3.932; LINZ DN, 1994, J PEDIATR SURG, V29, P1065, DOI 10.1016/0022-3468(94)90280-1; LOWENTHAL JW, 1989, P NATL ACAD SCI USA, V86, P2331, DOI 10.1073/pnas.86.7.2331; MALI M, 1990, J BIOL CHEM, V265, P6884; MALI M, 1993, J BIOL CHEM, V268, P24215; MALI M, 1994, J BIOL CHEM, V269, P27795; MERTENS G, 1992, J BIOL CHEM, V267, P20435; MOONEY DP, 1990, ANN SURG, V211, P124, DOI 10.1097/00000658-199002000-00002; NIINIKOSKI J, 1971, SURG GYNECOL OBSTETR, V133, P1003; OLWIN BB, 1992, J CELL BIOL, V118, P631, DOI 10.1083/jcb.118.3.631; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; PALLADINO MA, 1987, J IMMUNOL, V138, P4023; POBER JS, 1987, J IMMUNOL, V138, P3319; RAPALA K, 1991, EUR SURG RES, V23, P261, DOI 10.1159/000129163; RAPRAEGER A, 1985, J BIOL CHEM, V260, P1046; RAPRAEGER A, 1985, J BIOL CHEM, V260, P4103; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; REICHSLOTKY R, 1994, J BIOL CHEM, V269, P32279; SALMIVIRTA M, 1991, J BIOL CHEM, V266, P7733; SALOMON GD, 1991, ANN SURG, V214, P175, DOI 10.1097/00000658-199108000-00012; SAUNDERS S, 1989, J CELL BIOL, V108, P1547, DOI 10.1083/jcb.108.4.1547; SUN XJ, 1989, J BIOL CHEM, V264, P11288; TANAKA Y, 1993, NATURE, V361, P79, DOI 10.1038/361079a0; TRACEY KJ, 1993, ANNU REV CELL BIOL, V9, P317, DOI 10.1146/annurev.cb.09.110193.001533; VAINIO S, 1989, J CELL BIOL, V108, P1945, DOI 10.1083/jcb.108.5.1945; VAINIO S, 1992, DEV BIOL, V152, P221, DOI 10.1016/0012-1606(92)90130-9; VIHINEN T, 1993, J BIOL CHEM, V268, P17261; VILJANTO J, 1962, ANN MED EXP BIOL FEN, V40, P118; VOGEL A, 1993, DEVELOPMENT, V119, P199; WRIDE MA, 1993, DEV DYNAM, V198, P225, DOI 10.1002/aja.1001980308; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	70	56	60	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18759	18766		10.1074/jbc.271.31.18759	http://dx.doi.org/10.1074/jbc.271.31.18759			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702532	hybrid			2022-12-25	WOS:A1996VB68300070
J	Tu, LW; Santarelli, V; Sheng, ZF; Skach, W; Pain, D; Deutsch, C				Tu, LW; Santarelli, V; Sheng, ZF; Skach, W; Pain, D; Deutsch, C			Voltage-gated K+ channels contain multiple intersubunit association sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POTASSIUM CHANNELS; PROTEINS; RECOGNITION; EXPRESSION; ACTIVATION; SUBUNITS; PACKING	A domain in the cytoplasmic NH2 terminus of voltage-gated K+ channels supervises the proper assembly of specific tetrameric channels (Li, M., Jan, J. M., and Jan, L. Y. (1992) Science 257, 1225-1230; Shen, N. V., Chen X., Boyer, M. RI., and Pfaffinger, P. (1993) Neuron 11, 67-76). It is referred to as a first tetramerization domain, or TI (Shen, N. V., Chen X., Boyer, RI. M., and Pfaffinger, P. (1993) Neuron 11, 67-76). However, a deletion mutant of Kv1.3 that lacks the first 141 amino acids, Kv1.3 (T1(-)) forms functional channels, suggesting that additional association sites in the central core of Kv1.3 mediate oligomerization. To characterize these sites, we have tested the abilities of cRNA Kv1.3 (T1(-)) fragments coinjected with Kv1.3 (T1(-)) to suppress current in Xenopus oocytes. The fragments include portions of the six putative transmembrane segments, S1 through S6, specifically: S1, S1-S2, S1-S2-S3, S2-S3, S2-S3-S4, S3-S4, S3-S4-S5, S2 through COOH, S3 through COOH, S4 through COOH, and S5-S6-COOH. Electrophysiologic experiments show that the fragments S1-S2-S3, S3-S4-S5, S2 through COOH, and S3 through COOH strongly suppress Kv1.3 (T1(-)) current, while others do not. Suppression of expressed current is due to specific effects of the translated peptide Kv1.3 fragments, as validated by in vivo immunoprecipitation studies of a strong suppressor and a nonsuppressor. Pulse-chase experiments indicate that translation of truncated peptide fragments neither prevents translation of Kv1.3 (T1(-)) nor increases its rate of degradation. Co-immunoprecipitation experiments suggest that suppression involves direct association of a peptide fragment with Kv1.3 (T1(-)). Fragments that strongly suppress Kv1.3 (T1(-)) also suppress an analogous NH2-terminal deletion mutant of Kv2.1 (Kv2.1 (Delta N139)), an isoform belonging to a different subfamily. Our results indicate that sites in the central core of Kv1.3 facilitate intersubunit association and that there are suppression sites in the central core, which are promiscuous across voltage-gated K+ channel subfamilies.	UNIV PENN,SCH MED,DEPT PHYSIOL,PHILADELPHIA,PA 19104; UNIV PENN,DEPT MOL & CELLULAR ENGN,PHILADELPHIA,PA 19104; THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DEPT PHYSIOL,PHILADELPHIA,PA 19107	University of Pennsylvania; University of Pennsylvania; Jefferson University					NATIONAL CANCER INSTITUTE [K11CA001614] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041476, R01GM052302] Funding Source: NIH RePORTER; NCI NIH HHS [CA 01614] Funding Source: Medline; NIGMS NIH HHS [GM 52302, GM 41476] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AIYAR J, 1993, AM J PHYSIOL, V265, pC1571, DOI 10.1152/ajpcell.1993.265.6.C1571; BABILA T, 1994, NEURON, V12, P615, DOI 10.1016/0896-6273(94)90217-8; BEZANILLA F, 1995, BIOPHYS J, V68, P137; BOULAY F, 1988, J CELL BIOL, V106, P629, DOI 10.1083/jcb.106.3.629; CHAHINE M, 1992, J MOL CELL CARDIOL, V24, P1231, DOI 10.1016/0022-2828(92)93090-7; CHOTHIA C, 1981, J MOL BIOL, V145, P215, DOI 10.1016/0022-2836(81)90341-7; GILSON MK, 1988, PROTEINS, V3, P32, DOI 10.1002/prot.340030104; HOPKINS WF, 1994, J NEUROSCI, V14, P1385, DOI 10.1523/JNEUROSCI.14-03-01385.1994; LEE TE, 1994, BIOPHYS J, V66, P667, DOI 10.1016/S0006-3495(94)80840-9; LI M, 1992, SCIENCE, V257, P1225, DOI 10.1126/science.1519059; PAPAZIAN DM, 1995, NEURON, V14, P1293, DOI 10.1016/0896-6273(95)90276-7; PLANELLSCASES R, 1995, P NATL ACAD SCI USA, V92, P9422, DOI 10.1073/pnas.92.20.9422; RICHMOND TJ, 1978, J MOL BIOL, V119, P537, DOI 10.1016/0022-2836(78)90201-2; RUSSELL AJ, 1993, SUBCELL BIOCH, V21, P41; SHEN NV, 1995, NEURON, V14, P625, DOI 10.1016/0896-6273(95)90319-4; SHEN NV, 1993, NEURON, V11, P67; TU L, 1995, BIOPHYS J, V68, P266; TU LW, 1995, BIOPHYS J, V68, P147, DOI 10.1016/S0006-3495(95)80169-4; VANDONGEN AMJ, 1990, NEURON, V5, P433, DOI 10.1016/0896-6273(90)90082-Q; VERRALL S, 1992, CELL, V68, P23, DOI 10.1016/0092-8674(92)90203-O; XU J, 1995, J BIOL CHEM, V270, P24761, DOI 10.1074/jbc.270.42.24761	21	79	79	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18904	18911		10.1074/jbc.271.31.18904	http://dx.doi.org/10.1074/jbc.271.31.18904			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702552	hybrid			2022-12-25	WOS:A1996VB68300090
J	Wastfelt, M; StalhammarCarlemalm, M; Delisse, AM; Cabezon, T; Lindahl, G				Wastfelt, M; StalhammarCarlemalm, M; Delisse, AM; Cabezon, T; Lindahl, G			Identification of a family of streptococcal surface proteins with extremely repetitive structure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROUP-B-STREPTOCOCCI; MOUSE-PROTECTIVE ANTIBODIES; C-PROTEIN; IGA RECEPTOR; SEQUENCE; GENE; ANTIGENS; ALPHA; IMMUNITY	The group B Streptococcus (GBS) causes the majority of life threatening bacterial infections in newborn children. Most GBS strains isolated from such infections express a surface protein, designated Rib, that confers protective immunity and therefore is of interest for analysis of pathogenetic mechanisms. Sequence analysis demonstrated that Rib has an exceptionally long signal peptide (55 amino acid residues) and 12 repeats (79 amino acid residues each) that account for >80% of the sequence of the mature protein. The repeats are identical even at the DNA level, indicating that an efficient mechanism operates to maintain a highly repetitive structure in Rib. The structure of Rib is similar to that of alpha, a previously characterized surface protein that is common among GBS strains lacking Rib, However, highly purified preparations of Rib and alpha did not crossreact immunologically, although the two proteins show extensive amino acid residue identity (47% in the repeat region). When analyzed in Western blots, Rib and alpha give rise to a regularly spaced ladder pattern, apparently due to hydrolysis of acid-labile Asp Pro bonds in the repeats. We conclude that Rib and alpha are members of a novel family of streptococcal surface proteins with unusual repetitive structure.	LUND UNIV, DEPT MED MICROBIOL, S-22362 LUND, SWEDEN; SMITHKLINE BEECHAM BIOL, B-1330 RIXENSART, BELGIUM	Lund University; GlaxoSmithKline								Baker C., 1995, INFECT DIS FETUS NEW, V4th ed., P980; BEVANGER L, 1985, ACTA PATH MICRO IM B, V93, P121; BEVANGER L, 1979, ACTA PATH MICRO IM B, V87, P51; GALLI J, 1993, J BIOL CHEM, V268, P11888; HEDEN LO, 1991, EUR J IMMUNOL, V21, P1481, DOI 10.1002/eji.1830210623; HOLLINGSHEAD SK, 1986, J BIOL CHEM, V261, P1677; JERLSTROM PG, 1991, MOL MICROBIOL, V5, P843, DOI 10.1111/j.1365-2958.1991.tb00757.x; LANCEFIELD RC, 1975, J EXP MED, V142, P165, DOI 10.1084/jem.142.1.165; Landon, 1977, Methods Enzymol, V47, P145; LINDAHL G, 1990, EUR J IMMUNOL, V20, P2241, DOI 10.1002/eji.1830201013; MADOFF LC, 1991, INFECT IMMUN, V59, P2638, DOI 10.1128/IAI.59.8.2638-2644.1991; MCLEAN JW, 1987, NATURE, V330, P132, DOI 10.1038/330132a0; MICHEL JL, 1991, GENETICS AND MOLECULAR BIOLOGY OF STREPTOCOCCI, LACTOCOCCI, AND ENTEROCOCCI, P214; MICHEL JL, 1991, INFECT IMMUN, V59, P2023, DOI 10.1128/IAI.59.6.2023-2028.1991; MICHEL JL, 1992, P NATL ACAD SCI USA, V89, P10060, DOI 10.1073/pnas.89.21.10060; MITA K, 1988, J MOL BIOL, V203, P917, DOI 10.1016/0022-2836(88)90117-9; MUSSER JM, 1989, P NATL ACAD SCI USA, V86, P4731, DOI 10.1073/pnas.86.12.4731; PAAVONEN J, 1983, SCAND J INFECT DIS, P31; RUSSELLJONES GJ, 1984, J EXP MED, V160, P1467, DOI 10.1084/jem.160.5.1467; Sambrook J., 2002, MOL CLONING LAB MANU; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHNEEWIND O, 1993, EMBO J, V12, P4803, DOI 10.1002/j.1460-2075.1993.tb06169.x; STALHAMMARCARLEMALM M, 1993, J EXP MED, V177, P1593, DOI 10.1084/jem.177.6.1593; STROUS GJ, 1992, CRIT REV BIOCHEM MOL, V27, P57, DOI 10.3109/10409239209082559; TIMPTE CS, 1988, J BIOL CHEM, V263, P1081; WESSELS MR, 1990, J CLIN INVEST, V86, P1428, DOI 10.1172/JCI114858; WILKINSON HW, 1971, INFECT IMMUN, V4, P596, DOI 10.1128/IAI.4.5.596-604.1971; ZHENG XT, 1995, INFECT IMMUN, V63, P891, DOI 10.1128/IAI.63.3.891-898.1995; [No title captured]	29	107	119	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18892	18897		10.1074/jbc.271.31.18892	http://dx.doi.org/10.1074/jbc.271.31.18892			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702550	hybrid			2022-12-25	WOS:A1996VB68300088
J	Bisotto, S; Minorgan, S; Rehfuss, RP				Bisotto, S; Minorgan, S; Rehfuss, RP			Identification and characterization of a novel transcriptional activation domain in the CREB-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; CAMP; CBP	The CREB-binding protein (CBP) plays a central role in the regulation of gene expression by several different second messenger pathways including serum growth factors, cAMP and phorbol esters, CBP specifically binds to the phosphorylated forms of CREB and c-Jun and is thought to activate transcription through a C-terminal activation domain, In this report, we demonstrate that the C terminus of CBP is dispensable for its ability to stimulate phospho-CREB activity, and, further, that the deletion of this domain produces highly active, mutant forms of CBP. The novel N-terminal activation identified by this deletional analysis consists of the first 714 amino acids of CBP and is sufficient for high levels of transcriptional activity, This domain is also capable of stimulating the activity of a second cAMP-regulated factor, ATF-1. Surprisingly, ATF-1 activity is not significantly stimulated by full-length CBP suggesting that the C terminal domain of CBP may also serve to regulate ATF-1/CBP activity, Additionally, the demonstration that one of our hyperactive CBP mutants is able to activate a nonphosphorylatable mutant of CREB (M1 CREB) provides the first evidence that CBP may play a role in regulating the basal transcriptional activity of CREB.			Bisotto, S (corresponding author), MCGILL UNIV,ROYAL VICTORIA HOSP,MOLEC ENDOCRINOL LAB,MONTREAL,PQ H3A 1A1,CANADA.							ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; BANNISTER AJ, 1995, EMBO J, V14, P4758, DOI 10.1002/j.1460-2075.1995.tb00157.x; BRINDLE P, 1995, P NATL ACAD SCI USA, V92, P10521, DOI 10.1073/pnas.92.23.10521; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; DEGROOT RP, 1993, MOL ENDOCRINOL, V7, P145, DOI 10.1210/me.7.2.145; ELLIS MJC, 1995, MOL ENDOCRINOL, V9, P255, DOI 10.1210/me.9.2.255; FERRERI K, 1994, P NATL ACAD SCI USA, V91, P1210, DOI 10.1073/pnas.91.4.1210; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GOODMAN RH, 1990, ANNU REV NEUROSCI, V13, P111, DOI 10.1146/annurev.neuro.13.1.111; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LALLI E, 1994, J BIOL CHEM, V269, P17359; LEE JS, 1995, GENE DEV, V9, P1188, DOI 10.1101/gad.9.10.1188; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; MAYER TE, 1993, ENDOCR REV, V14, P269; NORDHEIM A, 1994, NATURE, V370, P177, DOI 10.1038/370177a0; Parker D, 1996, MOL CELL BIOL, V16, P694; REHFUSS RP, 1991, J BIOL CHEM, V266, P18431; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SUN PQ, 1995, J BIOL CHEM, V270, P7041, DOI 10.1074/jbc.270.13.7041; XING LP, 1995, J BIOL CHEM, V270, P17488, DOI 10.1074/jbc.270.29.17488	21	21	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					17746	17750		10.1074/jbc.271.30.17746	http://dx.doi.org/10.1074/jbc.271.30.17746			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663603	hybrid			2022-12-25	WOS:A1996UY93500026
J	Luo, W; Kuwada, TS; Chandrasekaran, L; Zheng, J; Tanzer, ML				Luo, W; Kuwada, TS; Chandrasekaran, L; Zheng, J; Tanzer, ML			Divergent secretory behavior of the opposite ends of aggrecan	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYALURONIC-ACID; CORE PROTEIN; CLONING; PROTEOGLYCANS; CDNA	The proteoglycan, aggrecan has a globular domain, G1, at the N terminus and a different globular domain, G3, at the C terminus, Aggrecan produced by mutant nanomelic chickens is truncated due to a premature stop codon and consequently lacks G3 and a minor portion of its chondroitin sulfate domain (Li, H., Schwartz, N. B., and Vertel, B. M. (1993) J. Biol. Chem. 268, 23504-23511). The mutant protein is retained in the endoplasmic reticulum and fails to enter the Golgi stacks (Vertel, B. M., Walters, L. M., Grier, B., Maine, N., and Goetinck, P. F. (1993) J. Cell Sci. 104, 939-948). The homozygous mutant is lethal because of failure of chondrogenesis and osteogenesis, while the heterozygous mutant is dwarfed, To further elucidate the pathogenetic mechanisms underlying nanomelia and to determine if G1 and G3 are themselves secreted, we expressed them in transfected host cells. Expression was performed in wild type Chinese hamster ovary (CHO) cells and in mutant CHO cells which are unable to link glycosaminoglycan (GAG) chains to core proteins. We compared: (a) secretion of expressed G1 and G3 constructs containing contiguous GAG chain consensus sites and (b) GAG chain modification of the secreted proteins. We find that: 1) G3 is 24-100 times more rapidly secreted than G1; 2) secreted G3 contains contiguous chondroitin sulfate GAG chains, while secreted G1 lacks contiguous GAG chains; 3) G3 secretion is not coupled to xylosylation of contiguous GAG chain consensus sites. These results imply that G1 and G3 intrinsically differ in passage through the cell secretory route.	UNIV CONNECTICUT,CTR HLTH,SCH DENT MED,DEPT BIOSTRUCT & FUNCT,FARMINGTON,CT 06030	University of Connecticut					NIAMS NIH HHS [AR12683] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR012683, R01AR012683] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Amara J F, 1992, Trends Cell Biol, V2, P145, DOI 10.1016/0962-8924(92)90101-R; CHANDRASEKARAN L, 1992, BIOCHEM J, V288, P903, DOI 10.1042/bj2880903; DRICKAMER K, 1993, PROG NUCLEIC ACID RE, V45, P207, DOI 10.1016/S0079-6603(08)60870-3; Dudhia J, 1996, BIOCHEM J, V313, P933, DOI 10.1042/bj3130933; Esko JD, 1991, CURR OPIN CELL BIOL, V3, P805, DOI 10.1016/0955-0674(91)90054-3; HAMMOND C, 1995, CURR OPIN CELL BIOL, V7, P523, DOI 10.1016/0955-0674(95)80009-3; HARDINGHAM TE, 1992, FASEB J, V6, P861, DOI 10.1096/fasebj.6.3.1740236; HARDINGHAM TE, 1973, BIOCHEM J, V135, P905, DOI 10.1042/bj1350905; HASCALL VC, 1974, J BIOL CHEM, V249, P4242; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; JANSSEN JJM, 1995, J BIOL CHEM, V270, P11222, DOI 10.1074/jbc.270.19.11222; LI H, 1993, J BIOL CHEM, V268, P23504; Maniatis T., 1989, MOL CLONING LAB MAN; PRIMORAC D, 1994, MATRIX BIOL, V14, P297, DOI 10.1016/0945-053X(94)90195-3; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SAI S, 1986, P NATL ACAD SCI USA, V83, P5081, DOI 10.1073/pnas.83.14.5081; SCHWARTZ NB, 1995, TRENDS GLYCOSCI GLYC, V7, P429, DOI 10.4052/tigg.7.429; VERTEL BM, 1993, J CELL SCI, V104, P939; VERTEL BM, 1995, TRENDS CELL BIOL, V5, P458, DOI 10.1016/S0962-8924(00)89115-1; YAMADA H, 1994, J BIOL CHEM, V269, P10119; ZHANG L, 1995, J BIOL CHEM, V270, P12557, DOI 10.1074/jbc.270.21.12557; ZHANG LJ, 1994, J BIOL CHEM, V269, P19295	22	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16447	16450		10.1074/jbc.271.28.16447	http://dx.doi.org/10.1074/jbc.271.28.16447			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663569	hybrid			2022-12-25	WOS:A1996UX12600005
J	Matoskova, B; Wong, WT; Nomura, N; Robbins, KC; DiFiore, PP				Matoskova, B; Wong, WT; Nomura, N; Robbins, KC; DiFiore, PP			RN-tre specifically binds to the SH3 domain of eps8 with high affinity and confers growth advantage to NIH3T3 upon carboxy-terminal truncation	ONCOGENE			English	Article						eps8; SH3; tre; signal transduction	GUANINE-NUCLEOTIDE EXCHANGE; ADAPTER PROTEIN; TYROSINE KINASE; EGF RECEPTOR; GRB2; RAS; ONCOGENE; CELLS; SOS; ACTIVATOR	We isolated a cDNA encoding a protein, RN-tre, which shows homology to the N-terminus of the tre oncogene product and has SH3-binding ability as well as an evolutionarily conserved domain, termed TrH, with protein-binding ability in vitro. In the present study, we identify the product of the RN-tre gene as a 97 - 100 kDa protein. We demonstrate stable association in vivo and in vitro between RN-tre and eps8, mediated by the SH3 domain of the latter. In vitro, RN-tre displayed remarkable preference for binding to the eps8-SH3, as compared to eight other SH3s. The Kd for the in vitro interaction between RN-tre and eps8-SH3 was between 10(-8) and 10(-7) M. A role for RN-tre in cell proliferation was suggested by the finding that a C-terminal truncated mutant was able to confer proliferative advantage and reduced serum-requirement to NIH3T3 fibroblasts. Finally, comparison of the structure and biological activities of RN-tre and of the tre oncogene product, provided insight into the mechanism of oncogenic activation of tre.	IST EUROPEO ONCOL, DEPT EXPTL ONCOL, I-20141 MILAN, ITALY; NIDR, CELLULAR DEV & ONCOL LAB, NIH, BETHESDA, MD 20892 USA; NCI, LAB CELLULAR & MOL BIOL, NIH, BETHESDA, MD 20892 USA; KAZASA DNA RES INST, CHIBA 292, JAPAN; FAC MED & CHIRURG, IST MICROBIOL, BARI, ITALY	IRCCS European Institute of Oncology (IEO); National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Di Fiore, Pier Paolo/K-2130-2012	Di Fiore, Pier Paolo/0000-0002-2252-0950				BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CASTAGNINO P, 1995, ONCOGENE, V10, P723; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FAZIOLI F, 1993, EMBO J, V12, P3799, DOI 10.1002/j.1460-2075.1993.tb06058.x; FINAN P, 1994, J BIOL CHEM, V269, P13752; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; HERSKOVITS JS, 1993, P NATL ACAD SCI USA, V90, P11468, DOI 10.1073/pnas.90.24.11468; HUEBNER K, 1988, ONCOGENE, V3, P449; KARLSSON T, 1995, IN PRESS ONCOGENE; KNUDSEN BS, 1994, J BIOL CHEM, V269, P32781; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; Matoskova B, 1996, ONCOGENE, V12, P2563; MATOSKOVA B, 1995, MOL CELL BIOL, V15, P3805; NAKAMURA T, 1992, ONCOGENE, V7, P733; NAKAMURA T, 1988, ONCOGENE RES, V2, P357; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PAPA FR, 1993, NATURE, V366, P313, DOI 10.1038/366313a0; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; RICHARDSON PM, 1995, ONCOGENE, V11, P1139; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SEEDORF K, 1994, J BIOL CHEM, V269, P16009; SUMIMOTO H, 1994, P NATL ACAD SCI USA, V91, P5345, DOI 10.1073/pnas.91.12.5345; WENG ZG, 1994, MOL CELL BIOL, V14, P4509, DOI 10.1128/MCB.14.7.4509; WONG WT, 1994, ONCOGENE, V9, P3057	31	36	37	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 20	1996	12	12					2679	2688						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UW487	8700527				2022-12-25	WOS:A1996UW48700022
J	Bennett, BL; Lacson, RG; Chen, CC; Cruz, R; Wheeler, JS; Kletzien, RF; Tomasselli, AG; Heinrikson, RL; Manning, AM				Bennett, BL; Lacson, RG; Chen, CC; Cruz, R; Wheeler, JS; Kletzien, RF; Tomasselli, AG; Heinrikson, RL; Manning, AM			Identification of signal-induced I kappa B-alpha kinases in human endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-PROTEASOME PATHWAY; DEPENDENT PROTEIN-KINASE; TUMOR-NECROSIS-FACTOR; TRANSCRIPTION FACTOR; INDUCED PHOSPHORYLATION; REGULATORY SYSTEM; TRANSFORMED-CELLS; AP-1 ACTIVITY; E-SELECTIN; ACTIVATION	Activation of the nuclear transcription factor-kappa B is an early event in endothelial activation. NF-kappa B activation is regulated by the inducible phosphorylation and subsequent degradation of the inhibitory subunit I kappa B-alpha. We identified two discrete kinases of approximately 36 and 41 kDa in the cytoplasm of human umbilical vein endothelial cells that specifically bind to and phosphorylate the I kappa B-alpha subunit. I kappa B-alpha kinase activity is transiently elevated following treatment with either tumor necrosis factor alpha, interleukin-1 beta, or bacterial lipopolysaccharides and precedes activation of either mitogen-activated kinase or Jun kinase. Furthermore, activation of the I kappa B-alpha kinases precedes both the appearance of hyperphosphorylated I kappa B-alpha and its subsequent degradation, as well as the translocation of NF-kappa B to the nucleus, Deletion mutagenesis of the I kappa B-alpha polypeptide revealed that these kinases bind in or around the ankyrin repeat domains and phosphorylate residues within the C terminus. These kinases, however, were not identical to casein kinase II and displayed a pharmacologic profile distinct from other known kinases. These kinases may represent components of a signal transduction pathway regulating I kappa B-alpha levels in vascular endothelium.	UPJOHN LABS,CELL BIOL & INFLAMMAT RES,KALAMAZOO,MI 49007; UPJOHN LABS,BIOCHEM,KALAMAZOO,MI 49007; UPJOHN LABS,ENDOCRINE PHARMACOL & METAB,KALAMAZOO,MI 49007									AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BARROGA CF, 1995, P NATL ACAD SCI USA, V92, P7637, DOI 10.1073/pnas.92.17.7637; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; Bell F. P., 1996, FASEB Journal, V10, pA810; BENNETT V, 1992, J BIOL CHEM, V267, P8703; Brand K, 1996, J CLIN INVEST, V97, P1715, DOI 10.1172/JCI118598; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; BRUNS RF, 1991, BIOCHEM BIOPH RES CO, V176, P288, DOI 10.1016/0006-291X(91)90922-T; CHEN CC, 1995, J IMMUNOL, V155, P3538; CHEN CC, 1995, AGENT ACTION SUPPL, V47, P135; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; COLLINS T, 1993, LAB INVEST, V68, P499; COLLINS T, 1993, TRENDS CARDIOVAS MED, V3, P92, DOI 10.1016/1050-1738(93)90030-A; COTRAN RS, 1989, PROG IMMUNOL, V8, P747; DENG TL, 1994, NATURE, V371, P171, DOI 10.1038/371171a0; DIAZMECO MT, 1994, EMBO J, V13, P2842, DOI 10.1002/j.1460-2075.1994.tb06578.x; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; DIDONATO JA, 1995, MOL CELL BIOL, V15, P1302; Essani NA, 1996, J IMMUNOL, V156, P2956; FERRAN C, 1995, BIOCHEM BIOPH RES CO, V214, P212, DOI 10.1006/bbrc.1995.2277; FINCO TS, 1994, P NATL ACAD SCI USA, V91, P11884, DOI 10.1073/pnas.91.25.11884; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GRILLI M, 1993, INT REV CYTOL, V143, P1; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; HERBERT JM, 1990, BIOCHEM BIOPH RES CO, V172, P993, DOI 10.1016/0006-291X(90)91544-3; HIROKAWA K, 1991, J CELL PHYSIOL, V147, P157, DOI 10.1002/jcp.1041470120; KALTSCHMIDT C, 1994, J NEUROIMMUNOL, V55, P99, DOI 10.1016/0165-5728(94)90151-1; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KASE H, 1987, BIOCHEM BIOPH RES CO, V142, P436, DOI 10.1016/0006-291X(87)90293-2; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LI SF, 1993, P NATL ACAD SCI USA, V90, P9247, DOI 10.1073/pnas.90.20.9247; LIN AN, 1992, CELL, V70, P777, DOI 10.1016/0092-8674(92)90311-Y; Lin RT, 1996, MOL CELL BIOL, V16, P1401; LIN YC, 1995, P NATL ACAD SCI USA, V92, P552, DOI 10.1073/pnas.92.2.552; Lindner V, 1996, AM J PATHOL, V148, P427; Manning AM, 1995, J INFLAMM, V45, P283; MANNING AM, 1994, ANNU REP MED CHEM, V29, P235; McElhinny JA, 1996, MOL CELL BIOL, V16, P899; MIYAMOTO S, 1994, P NATL ACAD SCI USA, V91, P12740, DOI 10.1073/pnas.91.26.12740; MUGANDA PM, 1995, BIOCHEM BIOPH RES CO, V207, P740, DOI 10.1006/bbrc.1995.1249; MUNSTERMANN U, 1990, EUR J BIOCHEM, V189, P251, DOI 10.1111/j.1432-1033.1990.tb15484.x; ODELL TJ, 1991, NATURE, V353, P558, DOI 10.1038/353558a0; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PLATT JL, 1990, J EXP MED, V171, P1363, DOI 10.1084/jem.171.4.1363; PROWALD K, 1984, FEBS LETT, V176, P479, DOI 10.1016/0014-5793(84)81222-3; READ MA, 1994, J EXP MED, V179, P503, DOI 10.1084/jem.179.2.503; RICE NR, 1993, EMBO J, V12, P4685, DOI 10.1002/j.1460-2075.1993.tb06157.x; RUBANYI GM, 1993, J CARDIOVASC PHARM, V22, pS1, DOI 10.1097/00005344-199304000-00002; Sambrook J., 2002, MOL CLONING LAB MANU; SHIRAKAWA F, 1989, MOL CELL BIOL, V9, P2424, DOI 10.1128/MCB.9.6.2424; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; Sun SC, 1996, MOL CELL BIOL, V16, P1058; TRAENCKNER EBM, 1994, EMBO J, V13, P5433, DOI 10.1002/j.1460-2075.1994.tb06878.x; WANG HCR, 1992, MOL BIOL CELL, V3, P1329, DOI 10.1091/mbc.3.12.1329; ZABEL U, 1993, EMBO J, V12, P201, DOI 10.1002/j.1460-2075.1993.tb05646.x; ZWAGINGA JJ, 1990, ARTERIOSCLEROSIS, V10, P49, DOI 10.1161/01.ATV.10.1.49	60	22	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					19680	19688		10.1074/jbc.271.33.19680	http://dx.doi.org/10.1074/jbc.271.33.19680			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702671	hybrid			2022-12-25	WOS:A1996VC66900012
J	He, ZH; Fujiki, M; Kohorn, BD				He, ZH; Fujiki, M; Kohorn, BD			A cell wall-associated, receptor-like protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH; EXPRESSION; MEMBRANE; PHOSPHORYLATION; SPECIFICITY; HOMOLOG; PLANTS	Physical connections between higher plant cell walls and the plasma membrane have been identified visually, but the molecules involved in the contact are unknown. We describe here an Arabidopsis thaliana protein kinase, designated Wak1 for wall-associated kinase, whose predicted extracytoplasmic domain contains several epidermal growth factor repeats and identity with a viral movement protein. Wak1 fractionates with insoluble material when plant tissue is ground in a variety of buffers and detergents, suggesting a tight association with the plant extracellular matrix. Immunocytochemistry confirms that Wak1 is associated with the cell wall. Enzymatic digestion of the cell wall allows the release of Wak1 from the insoluble cell wall fraction, and protease experiments indicate that Wak1 likely has a cytoplasmic kinase domain, and the EGF containing domain is extracellular. Wak1 is found in all vegetative tissues of Arabidopsis, and has relatives in other angiosperms, but not Chlamydomonas. We suggest that Wak1 is a good candidate for a physical continuum between the cell wall and the cytoplasm, and since the kinase is cytoplasmic, it also has the potential to mediate signals to the cytoplasm from the cell wall.	DUKE UNIV, DEV CELL & MOLEC BIOL GRP, LEVINE SCI RES CTR, DURHAM, NC 27708 USA	Duke University								CITOVSKY V, 1993, GENE DEV, V7, P904, DOI 10.1101/gad.7.5.904; CULL M, 1990, METHOD ENZYMOL, V182, P147; FEHON RG, 1991, J CELL BIOL, V113, P657, DOI 10.1083/jcb.113.3.657; HAKES DJ, 1992, ANAL BIOCHEM, V202, P293, DOI 10.1016/0003-2697(92)90108-J; HARLOW E, 1988, ANTIBODIES LABORATOR, P490; JENKINS WT, 1991, ANAL BIOCHEM, V194, P136, DOI 10.1016/0003-2697(91)90160-U; KOHORN BD, 1992, P NATL ACAD SCI USA, V89, P10989, DOI 10.1073/pnas.89.22.10989; KOHORN BD, 1995, PROTEIN PHOSPHORYLAT, P297; Kohorn Bruce D., 1993, Methods (Orlando), V5, P156, DOI 10.1006/meth.1993.1020; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARSTON FAO, 1990, METHOD ENZYMOL, V182, P264; MASSON J, 1992, PLANT J, V2, P829, DOI 10.1111/j.1365-313X.1992.tb00153.x; MERRIL CR, 1984, METHOD ENZYMOL, V104, P441; PONTLEZICA RF, 1993, PLANT CELL ENVIRON, V16, P111, DOI 10.1111/j.1365-3040.1993.tb00853.x; RAO Z, 1995, CELL, V82, P131, DOI 10.1016/0092-8674(95)90059-4; Roberts K, 1989, CURR OPIN CELL BIOL, V1, P1020, DOI 10.1016/0955-0674(89)90074-4; Roberts K, 1990, CURR OPIN CELL BIOL, V2, P920, DOI 10.1016/0955-0674(90)90093-T; SANDERS LC, 1991, PLANT CELL, V3, P629, DOI 10.1105/tpc.3.6.629; SCHINDLER M, 1989, J CELL BIOL, V108, P1955, DOI 10.1083/jcb.108.5.1955; SHOWALTER AM, 1993, PLANT CELL, V5, P9, DOI 10.1105/tpc.5.1.9; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITH TA, 1991, P NATL ACAD SCI USA, V88, P5159, DOI 10.1073/pnas.88.12.5159; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; VARNER JE, 1989, CELL, V56, P231, DOI 10.1016/0092-8674(89)90896-9; WHEELER JJ, 1991, BIOCHIM BIOPHYS ACTA, V1086, P310, DOI 10.1016/0005-2760(91)90175-H; Wyatt Sarah E., 1993, Trends in Cell Biology, V3, P413, DOI 10.1016/0962-8924(93)90022-S; ZHU JK, 1994, PLANT CELL, V6, P393, DOI 10.1105/tpc.6.3.393; ZHU JK, 1993, PLANT J, V3, P637, DOI 10.1111/j.1365-313X.1993.00637.x	28	173	190	1	28	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					19789	19793		10.1074/jbc.271.33.19789	http://dx.doi.org/10.1074/jbc.271.33.19789			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702686	hybrid			2022-12-25	WOS:A1996VC66900027
J	Kaliman, P; Vinals, F; Testar, X; Palacin, M; Zorzano, A				Kaliman, P; Vinals, F; Testar, X; Palacin, M; Zorzano, A			Phosphatidylinositol 3-kinase inhibitors block differentiation of skeletal muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOOP-HELIX PROTEINS; INSULIN-RECEPTOR SUBSTRATE-1; FOCAL ADHESION KINASE; GROWTH FACTOR-II; DNA-BINDING; PHOSPHOINOSITIDE 3-KINASE; MYOGENIC LINEAGE; L6E9 CELLS; MYOD; EXPRESSION	Skeletal muscle differentiation involves myoblast alignment, elongation, and fusion into multinucleate myotubes, together with the induction of regulatory and structural muscle-specific genes, were we show that two phosphatidylinositol 3-kinase inhibitors, LY294002 and wortmannin, blocked an essential step in the differentiation of two skeletal muscle cell models, Both inhibitors abolished the capacity of L6E9 myoblasts to form myotubes, without affecting myoblast proliferation, elongation, or alignment, Myogenic events like the induction of myogenin and of glucose carrier GLUT4 were also blocked and myoblasts could not exit the cell cycle, as measured by the lack of mRNA induction of p21 cyclin-dependent kinase inhibitor, Overexpression of MyoD in 10T1/2 cells was not sufficient to bypass the myogenic differentiation blockade by LY294002. Upon serum withdrawal, 10T1/2-MyoD cells formed myotubes and showed increased levels of myogenin and p21, In contrast, LY294002-treated cells exhibited none of these myogenic characteristics and maintained high levels of Id, a negative regulator of myogenesis. These data indicate that whereas phosphatidylinositol 3-kinase is not indispensable for cell proliferation or in the initial events of myoblast differentiation, i.e. elongation and alignment, it appears to be essential for terminal differentiation of muscle cells.	UNIV BARCELONA,FAC BIOL,DEPT BIOQUIM & BIOL MOL,BARCELONA 08028,SPAIN	University of Barcelona			Viñals, Francesc/F-5928-2016; Palacín, Manuel/G-9786-2015; Vinals, Francesc/P-6278-2019; Zorzano, Antonio/R-5479-2018	Viñals, Francesc/0000-0002-9918-6751; Palacin, Manuel/0000-0002-8670-293X				ALEMA S, 1994, SEMIN CANCER BIOL, V5, P147; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRENNAN TJ, 1991, P NATL ACAD SCI USA, V88, P3822, DOI 10.1073/pnas.88.9.3822; BROWN WJ, 1995, J CELL BIOL, V130, P781, DOI 10.1083/jcb.130.4.781; CARUSO M, 1993, ONCOGENE, V8, P267; CASTELLO A, 1994, J BIOL CHEM, V269, P5905; CHAKRABORTY T, 1991, MOL CELL BIOL, V11, P3633, DOI 10.1128/MCB.11.7.3633; CHEN HC, 1994, J BIOL CHEM, V269, P31229; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P136; EDMONDSON DG, 1993, J BIOL CHEM, V268, P755; EWTON DZ, 1987, ENDOCRINOLOGY, V120, P115, DOI 10.1210/endo-120-1-115; FLORINI JR, 1991, ANNU REV PHYSIOL, V53, P201, DOI 10.1146/annurev.ph.53.030191.001221; FLORINI JR, 1991, J BIOL CHEM, V266, P15917; GIORGETTI S, 1993, J BIOL CHEM, V268, P7358; GUINEBAULT C, 1995, J CELL BIOL, V129, P831, DOI 10.1083/jcb.129.3.831; GUO K, 1995, MOL CELL BIOL, V15, P3823; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HASTY P, 1993, NATURE, V364, P501, DOI 10.1038/364501a0; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; KALIMAN P, 1995, BIOCHEM J, V312, P471, DOI 10.1042/bj3120471; KAUSHAL S, 1994, SCIENCE, V266, P1236, DOI 10.1126/science.7973707; KIMURA K, 1994, J BIOL CHEM, V269, P18961; KONG YF, 1995, MOL CELL BIOL, V15, P5205; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAM K, 1994, J BIOL CHEM, V269, P20648; LASSAR AB, 1989, CELL, V58, P659, DOI 10.1016/0092-8674(89)90101-3; LI L, 1992, GENE DEV, V6, P676, DOI 10.1101/gad.6.4.676; LI L, 1992, CELL, V71, P1181, DOI 10.1016/S0092-8674(05)80066-2; MATSUOKA K, 1995, J CELL BIOL, V130, P1307, DOI 10.1083/jcb.130.6.1307; MENKO AS, 1987, CELL, V51, P51, DOI 10.1016/0092-8674(87)90009-2; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MUTHUCHAMY M, 1992, J BIOL CHEM, V267, P18728; MYERS MG, 1994, J BIOL CHEM, V269, P28783; NABESHIMA Y, 1993, NATURE, V364, P532, DOI 10.1038/364532a0; OLSON EN, 1992, DEV BIOL, V154, P261, DOI 10.1016/0012-1606(92)90066-P; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PUJADES C, 1992, J CELL SCI, V102, P815; ROSEN GD, 1992, CELL, V69, P1107, DOI 10.1016/0092-8674(92)90633-N; Rosen K., 1990, FOCUS, V12, P23; ROSENTHAL SM, 1994, ENDOCRINOLOGY, V135, P38, DOI 10.1210/en.135.1.38; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; SHEPHERD PR, 1995, BIOCHEM BIOPH RES CO, V211, P535, DOI 10.1006/bbrc.1995.1846; SILVERMAN LA, 1995, ENDOCRINOLOGY, V136, P720, DOI 10.1210/en.136.2.720; STACK JH, 1994, J BIOL CHEM, V269, P31552; STACK JH, 1995, J CELL BIOL, V129, P321, DOI 10.1083/jcb.129.2.321; STEPHENS L, 1994, CELL, V77, P83, DOI 10.1016/0092-8674(94)90237-2; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; SUN XH, 1991, MOL CELL BIOL, V11, P5603, DOI 10.1128/MCB.11.11.5603; TANTI JF, 1994, BIOCHEM J, V304, P17, DOI 10.1042/bj3040017; THOMASON PA, 1994, J BIOL CHEM, V269, P16525; UI M, 1995, TRENDS BIOCHEM SCI, V20, P303, DOI 10.1016/S0968-0004(00)89056-8; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; VOLINIA S, 1995, EMBO J, V14, P3339, DOI 10.1002/j.1460-2075.1995.tb07340.x; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3	56	183	183	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19146	19151		10.1074/jbc.271.32.19146	http://dx.doi.org/10.1074/jbc.271.32.19146			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702591	hybrid, Green Published			2022-12-25	WOS:A1996VB68400025
J	PinkasKramarski, R; Shelly, M; Glathe, S; Ratzkin, BJ; Yarden, Y				PinkasKramarski, R; Shelly, M; Glathe, S; Ratzkin, BJ; Yarden, Y			Neu differentiation factor neuregulin isoforms activate distinct receptor combinations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; HEREGULIN ISOFORMS; NDF HEREGULIN; GROWTH-FACTOR; COMPLEX; ERBB3; HETERODIMERIZATION; PROTEINS; DOMAIN	The multiple isoforms of Neu differentiation factor (NDF/neuregulin) induce a pleiotropic cellular response that is isoform-specific and cell type-dependent. The molecular basis of this heterogeneity was addressed by comparing the two major groups of isoforms, alpha and beta. Both groups bind to the catalytically impaired receptor tyrosine kinase ErbB-3, whose mitogenic stimulation by NDF requires transactivation by other ErbB proteins, either ErbB-1 or ErbB-2. By expressing each pair of receptors in interleukin S-dependent myeloid cells, we found that both isoforms induced mitogenic signals in cells co-expressing the combination of ErbB-3 with ErbB-2. However, only the beta isoform stimulated cells that expressed both ErbB-3 and ErbB-1, and neither isoform was active on cells expressing ErbB-3 alone. Both isoforms bind to all ErbB-3-expressing cells, albeit with different affinities, but the co-stimulatory mitogenic effect is correlated with the ability of each auxiliary receptor to transphosphorylate ErbB-3. These results imply that NDF isoforms differ in their ability to induce receptor heterodimers; whereas both types of isoforms signal through ErbB-3/ErbB-2 heterodimers, only beta isoforms are able to stabilize ErbB-3/ErbB-1 heterodimers.	WEIZMANN INST SCI,DEPT MOLEC CELL BIOL,IL-76100 REHOVOT,ISRAEL; AMGEN INC,AMGEN CTR,THOUSAND OAKS,CA 91320	Weizmann Institute of Science; Amgen			Mieszkowska, Magdalena/O-6753-2017; YARDEN, YOSEF/K-1467-2012	Pinkas-Kramarski, Ronit/0000-0002-1000-369X; shelly, maya/0000-0002-2211-1751	NCI NIH HHS [CA51712] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA051712] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALIMANDI M, 1995, ONCOGENE, V10, P1813; Beerli RR, 1996, J BIOL CHEM, V271, P6071, DOI 10.1074/jbc.271.11.6071; BLECHMAN JM, 1995, CELL, V80, P103, DOI 10.1016/0092-8674(95)90455-7; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; GRAUSPORTA D, 1995, MOL CELL BIOL, V15, P1182; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; Gullick W J, 1990, Int J Cancer Suppl, V5, P55; GULLICK WJ, 1994, EUR J CANCER, V30A, P2186, DOI 10.1016/0959-8049(94)00365-C; GUY PM, 1994, P NATL ACAD SCI USA, V91, P8132, DOI 10.1073/pnas.91.17.8132; HELDIN CH, 1990, CELL REGUL, V1, P555, DOI 10.1091/mbc.1.8.555; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; MARIKOVSKY M, 1995, ONCOGENE, V10, P1403; MEYER D, 1994, P NATL ACAD SCI USA, V91, P1064, DOI 10.1073/pnas.91.3.1064; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; PELES E, 1993, BIOESSAYS, V15, P815, DOI 10.1002/bies.950151207; PELES E, 1993, EMBO J, V12, P961, DOI 10.1002/j.1460-2075.1993.tb05737.x; PinkasKramarski R, 1996, EMBO J, V15, P2452, DOI 10.1002/j.1460-2075.1996.tb00603.x; RIESE DJ, 1995, MOL CELL BIOL, V15, P5770; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; STERN DF, 1988, EMBO J, V7, P995, DOI 10.1002/j.1460-2075.1988.tb02906.x; TZAHAR E, 1994, J BIOL CHEM, V269, P25226; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; WALLASCH C, 1995, EMBO J, V14, P4267, DOI 10.1002/j.1460-2075.1995.tb00101.x; WEN DZ, 1994, MOL CELL BIOL, V14, P1909, DOI 10.1128/MCB.14.3.1909; Zhang K, 1996, J BIOL CHEM, V271, P3884	30	125	138	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19029	19032		10.1074/jbc.271.32.19029	http://dx.doi.org/10.1074/jbc.271.32.19029			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702572	hybrid			2022-12-25	WOS:A1996VB68400006
J	Ruddock, LW; Coen, JJF; Cheesman, C; Freedman, RB; Hirst, TR				Ruddock, LW; Coen, JJF; Cheesman, C; Freedman, RB; Hirst, TR			Assembly of the B subunit pentamer of Escherichia coli heat-labile enterotoxin - Kinetics and molecular basis of rate-limiting steps in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CIS-TRANS-ISOMERASE; CHOLERA-TOXIN; CRYSTAL-STRUCTURE; VIBRIO-CHOLERAE; CARBOXYL TERMINUS; PROTEINS; STABILITY; SECRETION; OLIGOMER; HOMOLOG	The B subunits of Escherichia coli heat-labile enterotoxin (EtxB) and cholera toxin (CtxB) assemble in vivo into exceptionally stable homopentameric complexes, which maintain their quaternary structure in a range of conditions that would normally be expected to cause protein denaturation, Recently, we showed that the simultaneous protonation of two of the COOH-terminal carboxylates in pentameric EtxB was required to cause its disassembly at pH values below 2.0 (Ruddock, L., Ruston, S. P., Kelly, S. M., Price, N. C., Freedman, R. B., and Hirst., T. R. (1995) J. Biol. Chem. 270, 29953-29958), Here, we investigate the influence of environmental parameters on the kinetics of reassembly of acid-generated EtxB monomers in vitro. Such monomers were found to undergo a further acid-mediated conformational change, with an activation energy of 76 +/- 2 J degrees mol(-1)degrees K-1, consistent with isomerization of the cis-proline residue at position 93, and which prevented subsequent EtxB reassembly. By using rapid neutralization of acid-generated monomers, a high proportion of the B-subunits adopted an assembly-competent conformation, which resulted in up to 75% of the protein reassembling into a stable pentameric complex, indistinguishable from native EtxB pentamers. The rate-limiting step in reassembly, over a concentration range of 50-200 mu g/ml, was shown 60 be due to an intramolecular event, which exhibited a pH dependence with a pK(a) of 7.0, Modification of EtxB with amine-specific probes revealed that the protonation state of the NH2-terminal alanine residue was responsible for the pH dependence of reassembly, The implications of these findings for the biogenesis of Escherichia coli enterotoxin and related enterotoxins in vivo, are considered.	UNIV KENT,RES SCH BIOSCI,CANTERBURY CT2 7NJ,KENT,ENGLAND	University of Kent				Ruddock, Lloyd/0000-0002-6247-686X	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AMIN T, 1994, PROTEIN EXPRES PURIF, V5, P198, DOI 10.1006/prep.1994.1031; BLOND S, 1985, J MOL BIOL, V182, P597, DOI 10.1016/0022-2836(85)90245-1; BRANDTS JF, 1975, BIOCHEMISTRY-US, V14, P4953, DOI 10.1021/bi00693a026; BURNS DL, 1982, J BIOL CHEM, V257, P8648; DOMENIGHINI M, 1995, MOL MICROBIOL, V15, P1165, DOI 10.1111/j.1365-2958.1995.tb02289.x; Freedman Robert B., 1992, P455; HARDY SJS, 1988, P NATL ACAD SCI USA, V85, P7109, DOI 10.1073/pnas.85.19.7109; HAYANO T, 1991, BIOCHEMISTRY-US, V30, P3041, DOI 10.1021/bi00226a009; HIRST TR, 1987, P NATL ACAD SCI USA, V84, P7418, DOI 10.1073/pnas.84.21.7418; HIRST TR, 1995, BACTERIAL TOXINS VIR, P123; HOL WGJ, 1995, BACTERIAL TOXINS VIR, P185; Holmes RK, 1995, BACTERIAL TOXINS VIR, P225; HOLMGREN J, 1985, GASTROENTEROLOGY, V89, P27, DOI 10.1016/0016-5085(85)90741-3; IIDA T, 1989, J BIOL CHEM, V264, P14065; JAENICKE R, 1987, PROG BIOPHYS MOL BIO, V49, P117, DOI 10.1016/0079-6107(87)90011-3; JOBLING MG, 1991, MOL MICROBIOL, V5, P1755, DOI 10.1111/j.1365-2958.1991.tb01925.x; JOBLING MG, 1992, INFECT IMMUN, V60, P4915, DOI 10.1128/IAI.60.11.4915-4924.1992; KAPER JB, 1995, CLIN MICROBIOL REV, V8, P48, DOI 10.1128/CMR.8.1.48; LEVINE MM, 1983, MICROBIOL REV, V47, P510, DOI 10.1128/MMBR.47.4.510-550.1983; LIU J, 1990, P NATL ACAD SCI USA, V87, P4028, DOI 10.1073/pnas.87.11.4028; MCGHEE JR, 1992, VACCINE, V10, P75, DOI 10.1016/0264-410X(92)90021-B; MERRITT EA, 1994, PROTEIN SCI, V3, P166; MOSS J, 1978, J CLIN INVEST, V62, P281, DOI 10.1172/JCI109127; NASHAR TO, 1993, VACCINE, V11, P235, DOI 10.1016/0264-410X(93)90023-Q; Price N. C., 1994, MECH PROTEIN FOLDING, P160; RUDDOCK LW, 1995, J BIOL CHEM, V270, P29953; SANDKVIST M, 1993, MOL MICROBIOL, V10, P635, DOI 10.1111/j.1365-2958.1993.tb00935.x; SANDKVIST M, 1987, J BACTERIOL, V169, P4570, DOI 10.1128/jb.169.10.4570-4576.1987; SANDKVIST M, 1990, J BIOL CHEM, V265, P15239; SCHMID FX, 1978, P NATL ACAD SCI USA, V75, P4764, DOI 10.1073/pnas.75.10.4764; SIXMA TK, 1993, J MOL BIOL, V230, P890, DOI 10.1006/jmbi.1993.1209; SPANGLER BD, 1992, MICROBIOL REV, V56, P622, DOI 10.1128/MMBR.56.4.622-647.1992; STREATFIELD SJ, 1992, P NATL ACAD SCI USA, V89, P12140, DOI 10.1073/pnas.89.24.12140; YU J, 1992, MOL MICROBIOL, V6, P1949, DOI 10.1111/j.1365-2958.1992.tb01368.x; ZHANG RG, 1995, J MOL BIOL, V251, P563, DOI 10.1006/jmbi.1995.0456; ZHANG RG, 1995, J MOL BIOL, V251, P550, DOI 10.1006/jmbi.1995.0455	36	23	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19118	19123		10.1074/jbc.271.32.19118	http://dx.doi.org/10.1074/jbc.271.32.19118			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702586	hybrid			2022-12-25	WOS:A1996VB68400020
J	Matos, M; Fann, MC; Yan, RT; Maloney, PC				Matos, M; Fann, MC; Yan, RT; Maloney, PC			Enzymatic and biochemical probes of residues external to the translocation pathway of UhpT, the sugar phosphate carrier of Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTROPHORETIC TRANSFER; POLYACRYLAMIDE GELS; PROTEIN; MEMBRANE; TOPOLOGY; CHANNEL; IDENTIFICATION; NITROCELLULOSE; RECONSTITUTION; TRANSPORTER	Part of the substrate translocation pathway through UhpT, the Escherichia coli sugar phosphate carrier, has been assigned to a transmembrane helix extending between residues 260 and 282, To set limits on the external portion of the pathway, we identified nearby residues fully exposed to the periplasm, In one case, we used Western blots to evaluate cleavage by extracellular trypsin, The protease cleaved UhpT variants retaining lysine 294, but not those lacking lysine 294, indicating that trypsin acts at a single extracellular site, lysine 294, In other work we labeled single-cysteine variants with 3-(N-maleimidylpropionyl)biocytin and scored accessibility to extracellular streptavidin by shifts of SDS-polyacrylamide gel electrophoresis mobility, Positions 283 and 284 were fully exposed to the periplasm, since the modified residue was bound by streptavidin in the native protein; by contrast, although the biotin-linked probe modified position 276, streptavidin decoration was not achieved without protein denaturation. We conclude that a 12-residue stretch (283-294) of UhpT is sufficiently exposed to be accessible to large probes (trypsin, streptavidin), while position 276 and more proximal residues are more deeply buried or otherwise shielded from the external phase.			Matos, M (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT PHYSIOL,BALTIMORE,MD 21205, USA.				NIGMS NIH HHS [GM24195] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024195, R56GM024195] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKABAS MH, 1994, J BIOL CHEM, V269, P14865; AKABAS MH, 1992, SCIENCE, V258, P307, DOI 10.1126/science.1384130; ALTENBACH C, 1990, SCIENCE, V248, P1088, DOI 10.1126/science.2160734; ARYSTARKHOVA E, 1995, J BIOL CHEM, V270, P8785, DOI 10.1074/jbc.270.15.8785; BrõndÚn CI., 1991, INTRO PROTEIN STRUCT; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CHEN ZG, 1983, J MOL BIOL, V164, P283, DOI 10.1016/0022-2836(83)90078-5; CHIGNELL CF, 1975, J BIOL CHEM, V250, P5622; CRONAN JE, 1990, J BIOL CHEM, V265, P10327; ELMES ML, 1986, J GEN MICROBIOL, V132, P1429; FIERMONTE G, 1993, BIOCHEM J, V294, P293, DOI 10.1042/bj2940293; FRIEDRICH MJ, 1987, J BACTERIOL, V169, P3556, DOI 10.1128/jb.169.8.3556-3563.1987; GOTT P, 1988, MOL MICROBIOL, V2, P655, DOI 10.1111/j.1365-2958.1988.tb00074.x; GREEN NM, 1971, BIOCHEM J, V125, P781, DOI 10.1042/bj1250781; ISLAND MD, 1992, J BACTERIOL, V174, P2754, DOI 10.1128/JB.174.9.2754-2762.1992; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEIVE L, 1968, J BIOL CHEM, V243, P2373; LLOYD AD, 1990, J BACTERIOL, V172, P1688, DOI 10.1128/jb.172.4.1688-1693.1990; LOO TW, 1995, J BIOL CHEM, V270, P843, DOI 10.1074/jbc.270.2.843; LU Q, 1995, SCIENCE, V268, P304, DOI 10.1126/science.7716526; MARGER MD, 1993, TRENDS BIOCHEM SCI, V18, P13, DOI 10.1016/0968-0004(93)90081-W; QIU XQ, 1994, J BIOL CHEM, V269, P7483; RUAN ZS, 1992, J BIOL CHEM, V267, P10537; SAHINTOTH M, 1993, PROTEIN SCI, V2, P1024, DOI 10.1002/pro.5560020615; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; YAN RT, 1993, CELL, V75, P37, DOI 10.1016/S0092-8674(05)80082-0; YAN RT, 1995, P NATL ACAD SCI USA, V92, P5973, DOI 10.1073/pnas.92.13.5973	29	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18571	18575		10.1074/jbc.271.31.18571	http://dx.doi.org/10.1074/jbc.271.31.18571			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702506	hybrid			2022-12-25	WOS:A1996VB68300044
J	Stole, E; Bryant, FR				Stole, E; Bryant, FR			Reengineering the nucleotide cofactor specificity of the RecA protein by mutation of aspartic acid 100	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; RECOMBINATION; EXCHANGE; COMPLEX	We have recently obtained evidence for a direct linkage between the S-0.5 (S-0.5 is the substrate concentration required for half-maximal velocity) value of a nucleoside triphosphate and the conformational state of the RecA-ssDNA complex, with an S-0.5 value of 125 mu M or less required for stabilization of the strand exchange-active conformation, For example, although ATP and ITP are hydrolyzed by the RecA protein with the same turnover number (18 min(-1)), ATP (S-0.5 = 45 mu M) functions as a cofactor for the strand exchange reaction, whereas ITP (S-0.5 = 500 mu M) is inactive as a strand exchange cofactor, The RecA protein crystal structure suggests that cofactor specificity is determined by Asp(100), which likely forms a hydrogen bond with the exocyclic 6-amino group of ATP; the higher S-0.5 value for ITP is presumably due to unfavorable interactions between Asp(100) and the 6-carbonyl group of the inosine ring, To test this hypothesis, we prepared a mutant RecA protein in which Asp(100) was replaced by an asparagine residue. The S-0.5(ITP) for the [D100N]RecA protein is 125 mu M, indicating favorable interactions between the Asn(100) side chain and the 6-carbonyl group of ITP, Correspondingly, ITP functions as a cofactor for the strand exchange activity of the [D100N]RecA protein. This result demonstrates the importance of the residue at position 100 in determining nucleotide cofactor specificity and underscores the importance of the S-0.5 value in the RecA protein-promoted strand exchange reaction.	JOHNS HOPKINS UNIV,SCH PUBL HLTH,DEPT BIOCHEM,BALTIMORE,MD 21205	Johns Hopkins University					NIGMS NIH HHS [F32 GM16284, R01 GM 36516] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM016284, R01GM036516] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRYANT FR, 1988, J BIOL CHEM, V263, P8716; COTTERILL SM, 1982, BIOCHEMISTRY-US, V21, P4332, DOI 10.1021/bi00261a023; COX MM, 1981, P NATL ACAD SCI-BIOL, V78, P3433, DOI 10.1073/pnas.78.6.3433; EGELMAN EH, 1993, CURR OPIN STRUC BIOL, V3, P189, DOI 10.1016/S0959-440X(05)80151-4; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; KOWALCZYKOWSKI SC, 1994, MICROBIOL REV, V58, P401, DOI 10.1128/MMBR.58.3.401-465.1994; MEAH YS, 1993, J BIOL CHEM, V268, P23991; MENGE KL, 1992, BIOCHEMISTRY-US, V31, P5151, DOI 10.1021/bi00137a009; ROCA AI, 1990, CRIT REV BIOCHEM MOL, V25, P415, DOI 10.3109/10409239009090617; STOLE E, 1994, J BIOL CHEM, V269, P7919; STOLE E, 1995, J BIOL CHEM, V270, P20322, DOI 10.1074/jbc.270.35.20322; STORY RM, 1992, NATURE, V355, P318, DOI 10.1038/355318a0; WEINSTOCK GM, 1979, P NATL ACAD SCI USA, V76, P126, DOI 10.1073/pnas.76.1.126	13	15	15	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18326	18328		10.1074/jbc.271.31.18326	http://dx.doi.org/10.1074/jbc.271.31.18326			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702471	hybrid			2022-12-25	WOS:A1996VB68300009
J	Sun, J; Williams, J; Yan, HC; Amin, KM; Albelda, SM; DeLisser, HM				Sun, J; Williams, J; Yan, HC; Amin, KM; Albelda, SM; DeLisser, HM			Platelet endothelial cell adhesion molecule-1 (PECAM-1) hemophilic adhesion is mediated by immunoglobulin-like domains 1 and 2 and depends on the cytoplasmic domain and the level of surface expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCLONAL-ANTIBODY; IN-VIVO; CD31; BINDING; INTEGRIN; REDISTRIBUTION; ACTIVATION; MONOCYTES; ISOFORMS; LIGAND	PECAM-1/CD31 is vascular cell adhesion and signaling molecule of the Ig superfamily that plays a role in neutrophil recruitment at inflammatory sites and may be involved the release of leukocytes from the bone marrow and in cardiovascular development, The interactions of PECAM-1 with its ligands are complex in that it is able to bind both with itself (homophilic adhesion) or with non-PECAM-1 ligands (heterophilic adhesion), Although the factors that regulate ligand binding are not fully understood, these interactions are regulated in part by its large cytoplasmic domain, a region of 118 amino acids encoded by 8 exons of its gene (exons 9-16), The purpose of this work was to better define the mechanisms of PECAM-1-dependent homophilic adhesion by analyzing the binding interactions of L-cells expressing full-length and selectively mutated forms of human, murine, and human/murine chimeric PECAM-1 molecules in an established aggregation assay, These studies demonstrate that 1) the minimal length of the cytoplasmic domain required for cellular aggregation is represented within the sequences encoded by exons 9 and 10, 2) removal or addition of the sequences encoded by exon 14 from the cytoplasmic domain can determine whether the mechanism of aggregation is a heterophilic calcium-dependent process or a hemophilic calcium-independent process, 3) high levels of surface expression of PECAM-1 on the cell surface change the mechanism of aggregation from heterophilic to homophilic, and 4) PECAM-1-dependent homophilic binding appears to involve the direct interaction of only the first two extracellular Ig-like domains, These data suggest that PECAM-1-ligand interactions can be regulated through multiple pathways including alterations of the cytoplasmic domain and the level of surface expression.	UNIV PENN, MED CTR, DEPT MED, DIV PULM & CRIT CARE, PHILADELPHIA, PA 19104 USA	University of Pennsylvania			DeLisser, Horace/AFM-1942-2022		NHLBI NIH HHS [HL-03382, HL-46311] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL046311, K14HL003382, R29HL046311] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBELDA SM, 1991, J CELL BIOL, V114, P1059, DOI 10.1083/jcb.114.5.1059; ALBELDA SM, 1990, J CELL BIOL, V110, P1227, DOI 10.1083/jcb.110.4.1227; BALDWIN HS, 1994, DEVELOPMENT, V120, P2539; BERMAN ME, 1995, J IMMUNOL, V154, P299; BOGEN S, 1994, J EXP MED, V179, P1059, DOI 10.1084/jem.179.3.1059; Buckley CD, 1996, J CELL SCI, V109, P437; DELISSER HM, 1994, IMMUNOL TODAY, V15, P490, DOI 10.1016/0167-5699(94)90195-3; DELISSER HM, 1994, J CELL BIOL, V124, P195, DOI 10.1083/jcb.124.1.195; DELISSER HM, 1993, J BIOL CHEM, V268, P16037; FAWCETT J, 1995, J CELL BIOL, V128, P1229, DOI 10.1083/jcb.128.6.1229; GRUMET M, 1988, J CELL BIOL, V106, P487, DOI 10.1083/jcb.106.2.487; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; KIRSCHBAUM NE, 1994, BLOOD, V84, P4028, DOI 10.1182/blood.V84.12.4028.bloodjournal84124028; LASTRES P, 1994, J IMMUNOL, V153, P4206; LEAVESLEY DI, 1994, J IMMUNOL, V153, P4673; LIAO F, 1995, J EXP MED, V182, P1337, DOI 10.1084/jem.182.5.1337; MAURO VP, 1992, J CELL BIOL, V119, P191, DOI 10.1083/jcb.119.1.191; MILLER J, 1995, J EXP MED, V182, P1231, DOI 10.1084/jem.182.5.1231; MULLER WA, 1989, J EXP MED, V170, P399, DOI 10.1084/jem.170.2.399; MUROHARA T, 1996, J IMMUNOL, V156, P350; NEWMAN PJ, 1992, J CELL BIOL, V119, P239, DOI 10.1083/jcb.119.1.239; NEWMAN PJ, 1994, ANN NY ACAD SCI, V714, P165, DOI 10.1111/j.1749-6632.1994.tb12041.x; OIKAWA S, 1992, BIOCHEM BIOPH RES CO, V186, P881, DOI 10.1016/0006-291X(92)90828-9; Patel KD, 1995, J CELL BIOL, V131, P1893, DOI 10.1083/jcb.131.6.1893; PIALI L, 1993, EUR J IMMUNOL, V23, P2464, DOI 10.1002/eji.1830231013; PIALI L, 1995, J CELL BIOL, V130, P451, DOI 10.1083/jcb.130.2.451; RAO Y, 1992, J CELL BIOL, V118, P937, DOI 10.1083/jcb.118.4.937; ROMER LH, 1995, J IMMUNOL, V154, P6582; SIEBER F, 1981, J CELL BIOL, V90, P55, DOI 10.1083/jcb.90.1.55; SUN QH, 1995, J BIOL CHEM, V270, P23672; TANAKA Y, 1992, J EXP MED, V176, P245, DOI 10.1084/jem.176.1.245; VAPORCIYAN AA, 1993, SCIENCE, V262, P1580, DOI 10.1126/science.8248808; WATT SM, 1993, BLOOD, V82, P2649; WEITZMAN JB, 1995, J CELL SCI, V108, P3635; XIE Y, 1993, P NATL ACAD SCI USA, V90, P5569, DOI 10.1073/pnas.90.12.5569; YAN HC, 1995, CELL ADHES COMMUN, V3, P45, DOI 10.3109/15419069509081277; ZEHNDER JL, 1992, J BIOL CHEM, V267, P5243	37	122	122	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18561	18570		10.1074/jbc.271.31.18561	http://dx.doi.org/10.1074/jbc.271.31.18561			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702505	hybrid			2022-12-25	WOS:A1996VB68300043
J	Regan, LM; StearnsKurosawa, DJ; Kurosawa, S; Mollica, J; Fukudome, K; Esmon, CT				Regan, LM; StearnsKurosawa, DJ; Kurosawa, S; Mollica, J; Fukudome, K; Esmon, CT			The endothelial cell protein C receptor - Inhibition of activated protein C anticoagulant function without modulation of reaction with proteinase inhibitors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-V; BLOOD-COAGULATION; THROMBOMODULIN; THROMBIN; INACTIVATION; CLEAVAGE; BINDING; IDENTIFICATION; SPECIFICITY; RESISTANCE	A soluble form of the endothelial cell protein C receptor (EPCR) was analyzed for the ability to modulate the functional properties of protein C and activated protein C (APC). in a plasma clotting system initiated with factor Xa, EPCR blocked the anticoagulant activity of APC in a dose-dependent fashion. EPCR had no influence on clotting in the absence of APC. Consistent with the plasma results, EPCR slowed the proteolytic inactivation of factor Va by slowing both of the key proteolytic cleavages in the heavy chain of factor Va. EPCR did not prevent protein C activation by the soluble thrombin-thrombomodulin complex, did not alter the inactivation of APC by alpha(1)-antitrypsin or protein C inhibitor, and did not influence the kinetics of peptide paranitroanilide substrate cleavage significantly. We conclude that EPCR binds to an exosite on APC that selectively modulates the enzyme specificity in a manner reminiscent of the influence of thrombomodulin on thrombin.	UNIV OKLAHOMA,HLTH SCI CTR,OKLAHOMA MED RES FDN,CARDIOVASC BIOL RES PROGRAM,DEPT BIOCHEM,OKLAHOMA CITY,OK 73104; UNIV OKLAHOMA,HLTH SCI CTR,OKLAHOMA MED RES FDN,CARDIOVASC BIOL RES PROGRAM,DEPT MOL BIOL,OKLAHOMA CITY,OK 73104; HOWARD HUGHES MED INST,OKLAHOMA CITY,OK 73104	Oklahoma Medical Research Foundation; University of Oklahoma System; University of Oklahoma Health Sciences Center; Oklahoma Medical Research Foundation; University of Oklahoma System; University of Oklahoma Health Sciences Center; Howard Hughes Medical Institute	Regan, LM (corresponding author), UNIV OKLAHOMA,HLTH SCI CTR,OKLAHOMA MED RES FDN,CARDIOVASC BIOL RES PROGRAM,DEPT PATHOL,OKLAHOMA CITY,OK 73104, USA.			Stearns-Kurosawa, Deborah/0000-0003-2486-923X	NHLBI NIH HHS [P01 HL 54804] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL054804] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARENHOLZ Y, 1977, BIOCHEMISTRY-US, V16, P2806, DOI 10.1021/bi00631a035; BERTINA RM, 1994, NATURE, V369, P64, DOI 10.1038/369064a0; DAHLBACK B, 1994, J CLIN INVEST, V94, P923, DOI 10.1172/JCI117458; DITTMAN WA, 1990, BLOOD, V75, P329; ESMON CT, 1995, TRENDS CARDIOVAS MED, V5, P141, DOI 10.1016/1050-1738(95)00054-D; ESMON CT, 1993, METHOD ENZYMOL, V222, P359; ESMON CT, 1979, J BIOL CHEM, V254, P964; ESMON CT, 1982, J BIOL CHEM, V257, P7944; ESMON CT, 1989, J BIOL CHEM, V264, P4743; ESMON NL, 1983, J BIOL CHEM, V258, P2238; ESMON NL, 1983, J BIOL CHEM, V258, P5548; ESPANA F, 1991, BLOOD, V77, P1754; FAY PJ, 1991, J BIOL CHEM, V266, P20139; FUKUDOME K, 1994, J BIOL CHEM, V269, P26486; FUKUDOME K, 1996, J BIOL CHEM, V271, P17499; GALVIN JB, 1986, CIRCULATION, V74, P65; GUINTO ER, 1982, J BIOL CHEM, V257, P38; GUINTO ER, 1983, THESIS U OKLAHOMA HL; JAKUBOWSKI HV, 1986, J BIOL CHEM, V261, P3876; KALAFATIS M, 1994, J BIOL CHEM, V269, P31869; KISIEL W, 1981, METHOD ENZYMOL, V80, P320; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MADISON EL, 1989, NATURE, V339, P721, DOI 10.1038/339721a0; MATHER T, 1995, 21 EMBO S STRUCT FUN, P151; MATHEWS II, 1994, BIOCHEMISTRY-US, V33, P13547, DOI 10.1021/bi00250a006; NICOLAES GAF, 1995, J BIOL CHEM, V270, P21158, DOI 10.1074/jbc.270.36.21158; OWEN WG, 1974, J BIOL CHEM, V249, P594; PHILLIPS JE, 1994, J BIOL CHEM, V269, P16696; POLGAR J, 1986, THROMB RES, V43, P585, DOI 10.1016/0049-3848(86)90079-4; REGAN LM, 1994, J BIOL CHEM, V269, P9445; REZAIE AR, 1995, J BIOL CHEM, V270, P25336, DOI 10.1074/jbc.270.43.25336; TSIANG M, 1990, BIOCHEMISTRY-US, V29, P10602, DOI 10.1021/bi00499a005; WALKER FJ, 1981, J BIOL CHEM, V256, P1128; WALKER FJ, 1980, J BIOL CHEM, V255, P5521; YE J, 1992, J BIOL CHEM, V267, P11023	35	95	99	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					17499	17503		10.1074/jbc.271.29.17499	http://dx.doi.org/10.1074/jbc.271.29.17499			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663474	hybrid			2022-12-25	WOS:A1996UX94300079
J	Kralova, J; Schatzle, JD; Liss, AS; Bargmann, W; Bose, HR				Kralova, J; Schatzle, JD; Liss, AS; Bargmann, W; Bose, HR			Synergistic stimulation of avian I kappa B alpha transcription by rel and fos/jun factors	ONCOGENE			English	Article						I kappa B alpha; Rel/NF-kappa B; AP-1; transcription synergy	DNA-BINDING PROTEIN; FAMILY MEMBERS; V-REL; INHIBITOR; GENE; SUBUNIT; EXPRESSION; ACTIVATION; DORSAL; P50	Rel/NF-kappa B transcription factors and I kappa B alpha function in an autoregulatory network. Avian I kappa B alpha transcription is increased in response to both c-Rel and v-Rel. This study shows that I kappa B alpha transcription is synergistically stimulated by Rel and AP-1 factors (c-Fos and c-Jun). However, the response to v-Rel and the AP-1 factors was not as vigorous as that of c-Rel and AP-1. A 386 bp region of the I kappa B alpha promoter (containing two NF-kappa B and one AP-1 binding sites) was shown to be both necessary and sufficient for response to both Rel factors alone or Rel factors in conjunction with the AP-1 proteins. In addition, an imperfect NF-kappa B binding site was found to overlap the AP-1 binding site. Mutation of either of the NF-kappa B binding sites or the AP-1 binding site dramatically decreased the response of the I kappa B alpha promoter to Rel proteins alone or Rel and AP-1 factors. Overexpression of c-Rel or v-Rel resulted in the formation of DNA binding complexes associated with the imperfect NF-kappa B binding site which overlaps the AP-1 site. v-Rel associated with the imperfect NF-kappa B site stronger than c-Rel, and overexpression of v-Rel also resulted in the formation of a v-Rel containing complex bound to a consensus AP-1 site. These studies address the difference in c-Rel and v-Rel's ability to synergistically stimulate I kappa B alpha expression in conjunction with the AP-1 factors.	UNIV TEXAS,DEPT MICROBIOL,AUSTIN,TX 78712; UNIV TEXAS,CELL RES INST,AUSTIN,TX 78712	University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin			Liss, Andrew/L-9696-2019; Kralova, Jarmila/G-3834-2014	Kralova, Jarmila/0000-0002-4735-8857	NATIONAL CANCER INSTITUTE [F32CA063767, R01CA033192] Funding Source: NIH RePORTER; NCI NIH HHS [CA 33192, CA 63767-02] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BLANK V, 1992, TRENDS BIOCHEM SCI, V17, P135, DOI 10.1016/0968-0004(92)90321-Y; BOSE HR, 1992, BIOCHIM BIOPHYS ACTA, V1114, P1, DOI 10.1016/0304-419X(92)90002-G; BOURS V, 1992, MOL CELL BIOL, V12, P685, DOI 10.1128/MCB.12.2.685; BOURS V, 1990, NATURE, V348, P76, DOI 10.1038/348076a0; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; CHENG Q, 1994, J BIOL CHEM, V269, P13551; CHIAO PJ, 1994, P NATL ACAD SCI USA, V91, P28, DOI 10.1073/pnas.91.1.28; DAVIS N, 1991, SCIENCE, V253, P1268, DOI 10.1126/science.1891714; DEMARTIN R, 1993, EMBO J, V12, P2773, DOI 10.1002/j.1460-2075.1993.tb05938.x; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; DIDONATO JA, 1995, MOL CELL BIOL, V15, P1302; DIEHL JA, 1994, MOL CELL BIOL, V14, P6635, DOI 10.1128/MCB.14.10.6635; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GROVE M, 1993, MOL CELL BIOL, V13, P5276, DOI 10.1128/MCB.13.9.5276; GUILIANI C, 1995, J BIOL CHEM, V270, P11453; HENKEL T, 1992, CELL, V68, P1121, DOI 10.1016/0092-8674(92)90083-O; HRDLICKOVA R, 1995, J VIROL, V69, P3369; IP YT, 1991, CELL, V64, P439; ITO CY, 1994, NUCLEIC ACIDS RES, V22, P3787, DOI 10.1093/nar/22.18.3787; KASZUBSKA W, 1993, MOL CELL BIOL, V13, P7180, DOI 10.1128/MCB.13.11.7180; KERPPOLA TK, 1991, CELL, V66, P317, DOI 10.1016/0092-8674(91)90621-5; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KRALOVA J, 1994, J VIROL, V68, P2073, DOI 10.1128/JVI.68.4.2073-2083.1994; KRISHNAN A, 1995, IN PRESS GENE; LEBAIL O, 1993, EMBO J, V12, P5043, DOI 10.1002/j.1460-2075.1993.tb06197.x; LIOU HC, 1992, EMBO J, V11, P3003, DOI 10.1002/j.1460-2075.1992.tb05370.x; MURR, 1991, LIO, V5, P1464; RADLERPOHL A, 1993, EMBO J, V12, P1005, DOI 10.1002/j.1460-2075.1993.tb05741.x; SCHATZLE JD, 1995, J VIROL, V69, P5383, DOI 10.1128/JVI.69.9.5383-5390.1995; SCHRECK R, 1990, NUCLEIC ACIDS RES, V18, P6497, DOI 10.1093/nar/18.22.6497; SCOTT ML, 1993, GENE DEV, V7, P1266, DOI 10.1101/gad.7.7a.1266; SIF S, 1994, J VIROL, V68, P7131, DOI 10.1128/JVI.68.11.7131-7138.1994; SIF S, 1993, J VIROL, V67, P7612, DOI 10.1128/JVI.67.12.7612-7617.1993; STEIN B, 1989, MOL CELL BIOL, V9, P5169, DOI 10.1128/MCB.9.11.5169; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; TRAENCKNER EBM, 1994, EMBO J, V13, P5433, DOI 10.1002/j.1460-2075.1994.tb06878.x; XU X, 1993, MOL CELL BIOL, V13, P6733, DOI 10.1128/MCB.13.11.6733; ZABEL U, 1993, EMBO J, V12, P201, DOI 10.1002/j.1460-2075.1993.tb05646.x; ZHANG Q, 1994, MOL CELL BIOL, V14, P3915, DOI 10.1128/MCB.14.6.3915	44	11	11	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 20	1996	12	12					2595	2604						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UW487	8700518				2022-12-25	WOS:A1996UW48700013
J	Roemer, K; MuellerLantzsch, N				Roemer, K; MuellerLantzsch, N			p53 transactivation domain mutant Q22, S23 is impaired for repression of promoters and mediation of apoptosis	ONCOGENE			English	Article						programmed cell death; transcription; transfection; MDM-2	WILD-TYPE P53; GENE-EXPRESSION; CELL-GROWTH; PROTEIN; SUPPRESSION; DNA; INHIBITION; CARCINOMA; ONCOGENE; KINASES	p53 is multifunctional, To assess exactly what function is critical for the prevention of neoplastic transformation has proven difficult, Mutants with substitutions at positions 22 and 23 promised to address the relevance of transcription transactivation since they seemed to be defective specifically for this function, We report here that p53 mutant Q22, S23 [p53 (22,23)] is not only impaired for transactivation but for the repression of the fos promoter and SV40 early promoter, Furthermore, whereas p53 (22,23) fails to efficiently transactivate reporter genes in two p53-negative cell lines, it stimulates reporters and suppresses proliferation in two wild-type (wt) p53-positive cell lines strongly above the levels induced by the transfection procedure alone, This transactivation is refractory to inhibition by MDM-2, Finally, p53 (22,23) expressed from large plasmid quantity (1 mu g) is crippled for the mediation of apoptosis in p53-negative Hep3B hepatocarcinoma cells, Nevertheless, at a quantity of only 10 ng, both mutant and wt p53 plasmids but not control plasmid, are able to induce some cell death which is not inhibitable by MDM-2, Thus, a correlation exists between p53's functions to regulate promoters and to efficiently mediate apoptosis in Hep3B cells.			Roemer, K (corresponding author), UNIV SAARLAND,DEPT VIROL,INST MED MICROBIOL,BLDG 47,D-66421 HOMBURG,GERMANY.							ALLDAY MJ, 1995, EMBO J, V14, P4994, DOI 10.1002/j.1460-2075.1995.tb00182.x; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BRESSAC B, 1990, P NATL ACAD SCI USA, V87, P1973, DOI 10.1073/pnas.87.5.1973; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; COX LS, 1995, EMBO J, V14, P2099, DOI 10.1002/j.1460-2075.1995.tb07201.x; COX LS, 1995, BIOESSAYS, V17, P501, DOI 10.1002/bies.950170606; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; DARZYNKIEWICZ Z, 1992, CYTOMETRY, V13, P795, DOI 10.1002/cyto.990130802; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; FRIEDMAN PN, 1993, P NATL ACAD SCI USA, V90, P3319, DOI 10.1073/pnas.90.8.3319; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; HARPER JW, 1993, CELL, V75, P805; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KLEY N, 1992, NUCLEIC ACIDS RES, V20, P4083, DOI 10.1093/nar/20.15.4083; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; LIU X, 1995, MOL CELL BIOL, V15, P6474; MALKIN D, 1993, CANCER GENET CYTOGEN, V66, P83, DOI 10.1016/0165-4608(93)90233-C; MARSTON NJ, 1995, ONCOGENE, V10, P1709; MARSTON NJ, 1994, ONCOGENE, V9, P2707; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MIYASHITA T, 1994, ONCOGENE, V9, P1799; OBEROSLER P, 1993, EMBO J, V12, P2389, DOI 10.1002/j.1460-2075.1993.tb05893.x; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OREN M, 1994, SEMIN CANCER BIOL, V5, P221; PERREM K, 1995, ONCOGENE, V11, P1299; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; PRIVES C, 1994, CELL, V78, P543, DOI 10.1016/0092-8674(94)90519-3; RENZING J, 1995, ONCOGENE, V10, P1865; ROLLEY N, 1995, ONCOGENE, V11, P763; RYAN JJ, 1993, MOL CELL BIOL, V13, P711, DOI 10.1128/MCB.13.1.711; SABBATINI P, 1995, MOL CELL BIOL, V15, P1060; SABBATINI P, 1995, GENE DEV, V9, P2184, DOI 10.1101/gad.9.17.2184; SANG BC, 1994, ONCOGENE, V9, P853; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHAULIAN E, 1995, ONCOGENE, V10, P671; SHEN YQ, 1994, P NATL ACAD SCI USA, V91, P8940, DOI 10.1073/pnas.91.19.8940; SLEIGH MJ, 1986, ANAL BIOCHEM, V156, P251, DOI 10.1016/0003-2697(86)90180-6; SUBLER MA, 1994, ONCOGENE, V9, P1351; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; TURNER DL, 1987, NATURE, V328, P131, DOI 10.1038/328131a0; VAN MEIR EG, 1995, P NATL ACAD SCI USA, V92, P1008, DOI 10.1073/pnas.92.4.1008; VAN MEIR EG, 1994, CANCER RES, V54, P649; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WHITE E, 1989, P NATL ACAD SCI USA, V86, P9886, DOI 10.1073/pnas.86.24.9886; XIAO H, 1994, MOL CELL BIOL, V14, P7013, DOI 10.1128/MCB.14.10.7013; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; XU L, 1989, VIROLOGY, V171, P331, DOI 10.1016/0042-6822(89)90600-4; YEE PR, 1994, GENE DEV, V8, P190; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YONISHROUACH E, 1993, MOL CELL BIOL, V13, P1415, DOI 10.1128/MCB.13.3.1415; YONISHROUACH E, 1996, ONCOGENE, V12, P2197; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZAUBERMAN A, 1995, ONCOGENE, V10, P2361	65	28	29	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 16	1996	12	10					2069	2079						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UP283	8668332				2022-12-25	WOS:A1996UP28300005
J	Creedon, DJ; Johnson, EM; Lawrence, JC				Creedon, DJ; Johnson, EM; Lawrence, JC			Mitogen-activated protein kinase-independent pathways mediate the effects of nerve growth factor and cAMP on neuronal survival	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; TRK PROTOONCOGENE PRODUCT; SERINE THREONINE KINASES; PC12 CELLS; MAP KINASE; SYMPATHETIC NEURONS; CYCLIC-AMP; SIGNAL-TRANSDUCTION; NEURITE OUTGROWTH; B-RAF	Components of the mitogen-activated protein kinase (MAP kinase) signaling pathway, including Pas, Raf, and MAP kinase, are necessary for nerve growth factor (NGF)-induced neurite outgrowth in PC12 cells. We have investigated the role of this pathway in promoting survival of primary sympathetic neurons that die when deprived of NGF. NGF caused rapid and sustained increases (approximately 4-fold) in the activities of the ERK-1 and ERK-2 isoforms of MAP kinase. PD 098059, an inhibitor of MAP kinase kinase activation, blocked the effects of NGF on both kinase isoforms. However, PD 098059 did not attenuate the effects of NGF on neuronal survival, In addition, MAP kinase activity was not increased by chlorophenylthio-cAMP, a cell-permeable analog of cAMP that supports neuronal survival in the absence of NGF. These findings indicate that activation of MAP kinase is not required for the actions of either cAMP or NGF on neuronal survival.	WASHINGTON UNIV, SCH MED, DEPT MOL BIOL & PHARMACOL, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT NEUROL, ST LOUIS, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)					NIA NIH HHS [R37 AG12947] Funding Source: Medline; NIDDK NIH HHS [DK 28312] Funding Source: Medline; NINDS NIH HHS [R01 NS24679] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028312] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024679] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R37AG012947] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AHN NG, 1990, J BIOL CHEM, V265, P11487; BARDE YA, 1989, NEURON, V2, P1525, DOI 10.1016/0896-6273(89)90040-8; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BOCCHINI V, 1969, P NATL ACAD SCI USA, V64, P787, DOI 10.1073/pnas.64.2.787; BORASIO GD, 1989, NEURON, V2, P1087; BORASIO GD, 1990, NEUROSCI LETT, V108, P207, DOI 10.1016/0304-3940(90)90732-O; BORASIO GD, 1993, J CELL BIOL, V121, P665, DOI 10.1083/jcb.121.3.665; BOULTON TG, 1991, CELL REGUL, V2, P357, DOI 10.1091/mbc.2.5.357; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BURSTEIN DE, 1978, P NATL ACAD SCI USA, V75, P6059, DOI 10.1073/pnas.75.12.6059; CHENG HC, 1986, J BIOL CHEM, V261, P989; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CROWLEY C, 1994, CELL, V76, P1001, DOI 10.1016/0092-8674(94)90378-6; DECKWERTH TL, 1993, J CELL BIOL, V123, P1207, DOI 10.1083/jcb.123.5.1207; DOHERTY P, 1989, NEUROSCI LETT, V96, P1, DOI 10.1016/0304-3940(89)90233-4; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; EDWARDS SN, 1994, J CELL BIOL, V124, P537, DOI 10.1083/jcb.124.4.537; EDWARDS SN, 1991, J NEUROCHEM, V57, P2140, DOI 10.1111/j.1471-4159.1991.tb06434.x; ESTUS S, 1994, J CELL BIOL, V127, P1717, DOI 10.1083/jcb.127.6.1717; FERRARI G, 1994, EMBO J, V13, P5922, DOI 10.1002/j.1460-2075.1994.tb06937.x; FRODIN M, 1994, J BIOL CHEM, V269, P6207; GORIN PD, 1980, DEV BIOL, V80, P313, DOI 10.1016/0012-1606(80)90407-8; GRAVES LM, 1993, P NATL ACAD SCI USA, V90, P10300, DOI 10.1073/pnas.90.21.10300; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Greene LA., 1982, ADV CELL NEUROBIOL, V3, P373, DOI [10.1016/B978-0-12-008303-9.50016-5, DOI 10.1016/B978-0-12-008303-9.50016-5]; GUNNING PW, 1981, J CELL BIOL, V89, P240, DOI 10.1083/jcb.89.2.240; HAFNER S, 1994, MOL CELL BIOL, V14, P6696; HAM J, 1995, NEURON, V14, P927, DOI 10.1016/0896-6273(95)90331-3; HEASLEY LE, 1992, MOL BIOL CELL, V3, P545, DOI 10.1091/mbc.3.5.545; HEIDEMANN SR, 1985, J CELL BIOL, V100, P916, DOI 10.1083/jcb.100.3.916; JAISWAL RK, 1994, MOL CELL BIOL, V14, P6944, DOI 10.1128/MCB.14.10.6944; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P139, DOI 10.1016/0003-2697(89)90181-4; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KNUSEL B, 1992, J NEUROCHEM, V59, P1987; LANGECARTER CA, 1994, SCIENCE, V265, P1458, DOI 10.1126/science.8073291; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; LEVIMONTALCINI R, 1960, P NATL ACAD SCI USA, V46, P384, DOI 10.1073/pnas.46.3.384; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; LEVIMONTALCINI R, 1968, PHYSIOL REV, V48, P534, DOI 10.1152/physrev.1968.48.3.534; MARTIN DP, 1988, J CELL BIOL, V106, P829, DOI 10.1083/jcb.106.3.829; MARTIN DP, 1992, J NEUROBIOL, V23, P1205, DOI 10.1002/neu.480230911; NOBES CD, 1995, EUR J NEUROSCI, V7, P344, DOI 10.1111/j.1460-9568.1995.tb01069.x; OHMICHI M, 1994, J BIOL CHEM, V269, P1143; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; PERALDI P, 1995, FEBS LETT, V357, P290, DOI 10.1016/0014-5793(94)01376-C; QIU MS, 1992, NEURON, V9, P705, DOI 10.1016/0896-6273(92)90033-A; ROBBINS DJ, 1992, P NATL ACAD SCI USA, V89, P6924, DOI 10.1073/pnas.89.15.6924; RUIT KG, 1992, NEURON, V8, P573, DOI 10.1016/0896-6273(92)90284-K; RYDEL RE, 1988, P NATL ACAD SCI USA, V85, P1257, DOI 10.1073/pnas.85.4.1257; SCHAAP D, 1993, J BIOL CHEM, V268, P20232; SCHUBERT D, 1978, NATURE, V273, P718, DOI 10.1038/273718a0; SEVETSON BR, 1993, P NATL ACAD SCI USA, V90, P10305, DOI 10.1073/pnas.90.21.10305; SMEYNE RJ, 1994, NATURE, V368, P246, DOI 10.1038/368246a0; STEPHENS RM, 1994, NEURON, V12, P691, DOI 10.1016/0896-6273(94)90223-2; SZEBERENYI J, 1992, ONCOGENE, V7, P2105; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; VAILLANCOURT RR, 1994, MOL CELL BIOL, V14, P6522, DOI 10.1128/MCB.14.10.6522; WOOD KW, 1993, P NATL ACAD SCI USA, V90, P5016, DOI 10.1073/pnas.90.11.5016; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; WRIGHT LL, 1983, J NEUROCYTOL, V12, P727, DOI 10.1007/BF01258147; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YOUNG SW, 1994, FEBS LETT, V338, P212, DOI 10.1016/0014-5793(94)80367-6	68	170	171	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20713	20718		10.1074/jbc.271.34.20713	http://dx.doi.org/10.1074/jbc.271.34.20713			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702822	hybrid			2022-12-25	WOS:A1996VD33700074
J	Gachhui, R; Presta, A; Bentley, DF; AbuSoud, HM; McArthur, R; Brudvig, G; Ghosh, DK; Stuehr, DJ				Gachhui, R; Presta, A; Bentley, DF; AbuSoud, HM; McArthur, R; Brudvig, G; Ghosh, DK; Stuehr, DJ			Characterization of the reductase domain of rat neuronal nitric oxide synthase generated in the methylotrophic yeast Pichia pastoris - Calmodulin response is complete within the reductase domain itself	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME P-450 REDUCTASE; ADENINE-DINUCLEOTIDE PHOSPHATE; DEPENDENT PROTEIN-KINASE; ELECTRON-TRANSFER; SPECTRAL CHARACTERIZATION; SULFITE REDUCTASE; ESCHERICHIA-COLI; HEME-BINDING; L-ARGININE; CALCIUM	Rat neuronal NO synthase (nNOS) is comprised of a flavin-containing reductase domain and a heme-containing oxygenase domain, Calmodulin binding to nNOS increases the rate of electron transfer from NADPH into its flavins, triggers electron transfer from flavins to the heme, activates NO synthesis, and increases reduction of artificial electron accepters such as cytochrome c. To investigate what role the reductase domain plays in calmodulin's activation of these functions, we overexpressed a form of the nNOS reductase domain (amino acids 724-1429) in the yeast Pichia pastoris that for the first time exhibits a complete calmodulin response, The reductase domain was purified by 2',5'-ADP affinity chromatography yielding 25 mg of pure protein per liter of culture. It contained 1 FAD and 0.8 FMN per molecule. Most of the protein as isolated contained an air-stable flavin semiquinone radical that was sensitive to FeCN6 oxidation. Anaerobic titration of the FeCN6-oxidized reductase domain with NADPh indicated the flavin semiquinone re-formed after addition of 1-electron equivalent and the flavins could accept up to 3 electrons from NADPH. Calmodulin binding to the recombinant reductase protein increased its rate of NADPH-dependent flavin reduction and its rate of electron transfer to cytochrome c, FeCN6, or dichlorophenolindophenol to fully match the rate increases achieved when calmodulin bound to native full-length nNOS. Calmodulin's activation of the reductase protein was associated with an increase in domain tryptophan and flavin fluorescence. We conclude that many of calmodulin's actions on native nNOS can be fully accounted for through its interaction with the nNOS reductase domain itself.	YALE UNIV,DEPT CHEM,NEW HAVEN,CT 06511; CASE WESTERN RESERVE UNIV,SCH MED,DEPT PHYSIOL & BIOPHYS,CLEVELAND,OH 44106	Yale University; Case Western Reserve University	Gachhui, R (corresponding author), CLEVELAND CLIN,RES INST,DEPT IMMUNOL,9500 EUCLID AVE,CLEVELAND,OH 44195, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051491] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM51491] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABUSOUD HM, 1994, J BIOL CHEM, V269, P32318; ABUSOUD HM, 1993, P NATL ACAD SCI USA, V90, P10769, DOI 10.1073/pnas.90.22.10769; ABUSOUD HM, 1994, J BIOL CHEM, V269, P32047; BAEK KJ, 1993, J BIOL CHEM, V268, P21120; BAGCHI IC, 1992, MOL ENDOCRINOL, V6, P621, DOI 10.1210/me.6.4.621; BREDT DS, 1992, J BIOL CHEM, V267, P10976; BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; CHEN L, 1991, BIOCHEM BIOPH RES CO, V180, P238, DOI 10.1016/S0006-291X(05)81282-3; CHO HJ, 1992, J EXP MED, V176, P599, DOI 10.1084/jem.176.2.599; CRUZALEGUI FH, 1992, P NATL ACAD SCI USA, V89, P12127, DOI 10.1073/pnas.89.24.12127; Dawson TM, 1995, NEUROSCIENTIST, V1, P7; ESCHENBRENNER M, 1995, J BIOL CHEM, V270, P20550, DOI 10.1074/jbc.270.35.20550; FREY C, 1994, J BIOL CHEM, V269, P26083; FULCO AJ, 1991, ANNU REV PHARMACOL, V31, P177; GARTHWAITE J, 1995, ANNU REV PHYSIOL, V57, P683, DOI 10.1146/annurev.ph.57.030195.003343; Ghosh DK, 1996, BIOCHEMISTRY-US, V35, P1444, DOI 10.1021/bi9521295; GRIFFITH OW, 1995, ANNU REV PHYSIOL, V57, P707, DOI 10.1146/annurev.ph.57.030195.003423; HEINZEL B, 1992, BIOCHEM J, V281, P627, DOI 10.1042/bj2810627; IYANAGI T, 1973, BIOCHEMISTRY-US, V12, P2297, DOI 10.1021/bi00736a018; IYANAGI T, 1974, BIOCHEMISTRY-US, V13, P1701, DOI 10.1021/bi00705a023; KERWIN JF, 1995, J MED CHEM, V38, P4343, DOI 10.1021/jm00022a001; KLATT P, 1994, J BIOL CHEM, V269, P1674; KURZBAN GP, 1986, J BIOL CHEM, V261, P7824; MASTERS BSS, 1975, BIOCHEMISTRY-US, V14, P607, DOI 10.1021/bi00674a022; MATSUOKA A, 1994, J BIOL CHEM, V269, P20335; MCMILLAN K, 1995, BIOCHEMISTRY-US, V34, P3686, DOI 10.1021/bi00011a025; MCMILLAN K, 1992, P NATL ACAD SCI USA, V89, P11141, DOI 10.1073/pnas.89.23.11141; OSTROWSKI J, 1989, J BIOL CHEM, V264, P15796; OTVOS JD, 1986, BIOCHEMISTRY-US, V25, P7220, DOI 10.1021/bi00370a068; PEARSON RB, 1988, SCIENCE, V241, P970, DOI 10.1126/science.3406746; PERRINO BA, 1995, J BIOL CHEM, V270, P340, DOI 10.1074/jbc.270.1.340; PERSECHINI A, 1995, BIOCHEMISTRY-US, V34, P15091, DOI 10.1021/bi00046a015; POU S, 1992, J BIOL CHEM, V267, P24173; SANE PV, 1987, PHYTOCHEMISTRY, V26, P1289, DOI 10.1016/S0031-9422(00)81796-3; SCHMIDT HHHW, 1992, BIOCHEMISTRY-US, V31, P3243, DOI 10.1021/bi00127a028; SHETA EA, 1994, J BIOL CHEM, V269, P15147; STUEHR DJ, 1992, J BIOL CHEM, V267, P20547; SU ZZ, 1995, J BIOL CHEM, V270, P29117, DOI 10.1074/jbc.270.49.29117; VERMILION JL, 1978, J BIOL CHEM, V253, P2694; VERMILION JL, 1981, J BIOL CHEM, V256, P266; VORHERR T, 1993, BIOCHEMISTRY-US, V32, P6081, DOI 10.1021/bi00074a020; WOLFF DJ, 1993, J BIOL CHEM, V268, P9425	43	128	129	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20594	20602		10.1074/jbc.271.34.20594	http://dx.doi.org/10.1074/jbc.271.34.20594			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702805	hybrid			2022-12-25	WOS:A1996VD33700057
J	Kim, DR; McHenry, CS				Kim, DR; McHenry, CS			In vivo assembly of overproduced DNA polymerase III - Overproduction, purification, and characterization of the alpha, alpha-epsilon, and alpha-epsilon-theta subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; GENE-PRODUCT; BETA-SUBUNIT; HOLOENZYME; IDENTIFICATION; REPLICATION; EXONUCLEASE; ORGANIZATION; PROTEIN; COMPLEX	The genes for the polymerase core (alpha epsilon theta) of the DNA polymerase III holoenzyme map to widely separated loci on the Escherichia coli chromosome. To enable efficient overproduction and in vivo assembly of DNA polymerase III core, artificial operons containing the three structural genes, dnaE, dnaQ, and holE, were placed in an expression plasmid. The proteins alpha, alpha epsilon and alpha epsilon theta were overexpressed and assembled in E. coli and purified to homogeneity. The three purified polymerases had a similar specific activity of about 6.0 x 10(6) units/mg in a gap-filling assay. Kinetics studies showed that neither epsilon nor theta influenced the K-m of alpha for deoxynucleotide triphosphate and only slightly decreased the K-m of alpha for DNA, although epsilon was absolutely required for maximal DNA synthesis. The rate of DNA synthesis by alpha-reconstituted holoenzyme using tau complex was about 5-fold less than that of alpha epsilon or alpha epsilon theta-reconstituted holoenzyme as determined by a gel analysis. The processivity of alpha-reconstituted holoenzyme was very similar to that of alpha epsilon theta-reconstituted holoenzyme when tau complex was used as a clamp loader.			Kim, DR (corresponding author), UNIV COLORADO, HLTH SCI CTR, DEPT BIOCHEM BIOPHYS & GENET, DENVER, CO 80262 USA.							BLANCO L, 1991, GENE, V100, P27, DOI 10.1016/0378-1119(91)90346-D; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROSIUS J, 1981, J MOL BIOL, V148, P107, DOI 10.1016/0022-2836(81)90508-8; CARTER JR, 1993, NUCLEIC ACIDS RES, V21, P3281, DOI 10.1093/nar/21.14.3281; Cull MG, 1995, METHOD ENZYMOL, V262, P22; DALLMANN HG, 1995, J BIOL CHEM, V270, P29555, DOI 10.1074/jbc.270.49.29555; DALLMANN HG, 1995, J BIOL CHEM, V270, P29563, DOI 10.1074/jbc.270.49.29563; DIFRANCESCO R, 1984, J BIOL CHEM, V259, P5567; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; FAY PJ, 1981, J BIOL CHEM, V256, P976; GEFTER ML, 1971, P NATL ACAD SCI USA, V68, P3150, DOI 10.1073/pnas.68.12.3150; HAGERMAN PJ, 1985, BIOCHEMISTRY-US, V24, P7033, DOI 10.1021/bi00346a001; HORIUCHI T, 1981, P NATL ACAD SCI-BIOL, V78, P3770, DOI 10.1073/pnas.78.6.3770; JOHANSON KO, 1980, J BIOL CHEM, V255, P984; JOHANSON OK, 1981, STRUCTURE DNA PROTEI, P425; Kim DR, 1996, J BIOL CHEM, V271, P20690, DOI 10.1074/jbc.271.34.20690; Kim S, 1996, J BIOL CHEM, V271, P4315; Kim SS, 1996, CELL, V84, P643, DOI 10.1016/S0092-8674(00)81039-9; LADUCA RJ, 1986, J BIOL CHEM, V261, P7550; LAEMMLI UK, 1972, NATURE, V2270, P70; MAKI H, 1987, P NATL ACAD SCI USA, V84, P4389, DOI 10.1073/pnas.84.13.4389; MAKI H, 1985, J BIOL CHEM, V260, P2987; MCHENRY CS, 1982, J BIOL CHEM, V257, P2657; MCHENRY CS, 1979, J BIOL CHEM, V254, P1748; ONRUST R, 1995, J BIOL CHEM, V270, P13348, DOI 10.1074/jbc.270.22.13348; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SCHEUERMANN R, 1983, P NATL ACAD SCI-BIOL, V80, P7085, DOI 10.1073/pnas.80.23.7085; SCHEUERMANN RH, 1984, P NATL ACAD SCI-BIOL, V81, P7747, DOI 10.1073/pnas.81.24.7747; SLATER SC, 1994, J BACTERIOL, V176, P815, DOI 10.1128/jb.176.3.815-821.1994; STUDWELL PS, 1990, J BIOL CHEM, V265, P1171; STUDWELLVAUGHAN PS, 1991, J BIOL CHEM, V266, P19833; STUDWELLVAUGHAN PS, 1993, J BIOL CHEM, V268, P11785; STUKENBERG PT, 1991, J BIOL CHEM, V266, P11328; TOMASIEWICZ H, 1991, THESIS U COLORADO HL; VANWEZENBEEK PMGF, 1980, GENE, V11, P129, DOI 10.1016/0378-1119(80)90093-1; WELCH MM, 1982, J BACTERIOL, V152, P351; WU CA, 1992, J BIOL CHEM, V267, P4074; WU YH, 1984, J BIOL CHEM, V259, P2117; YOU JC, 1993, J BIOL CHEM, V268, P16519	39	53	56	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20681	20689		10.1074/jbc.271.34.20681	http://dx.doi.org/10.1074/jbc.271.34.20681			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702818	hybrid			2022-12-25	WOS:A1996VD33700070
J	Ryeom, SW; Silverstein, RL; Scotto, A; Sparrow, JR				Ryeom, SW; Silverstein, RL; Scotto, A; Sparrow, JR			Binding of anionic phospholipids to retinal pigment epithelium may be mediated by the scavenger receptor CD36	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAPID EXTRUSION PROCEDURE; ROD OUTER SEGMENTS; VESICLES; RAT; PHAGOCYTOSIS; MACROPHAGES; MEMBRANES; CELLS	The specific recognition of negatively charged phospholipids in cell membranes has been suggested to play an important role in a variety of physiological and pathophysiological processes. Recent work (Rigotti, A., Acton, S. L., and Krieger, M. (1995) J. Biol. Chem. 270, 16221-16224) has described specific and tight binding of anionic phospholipids, such as phosphatidylserine (PS) and phosphatidylinositol (PI), to the class B scavenger receptors, CD36 and SR-B1. We have previously reported that CD36 is present on retinal pigment epithelium (RPE) and plays a role in the phagocytosis of photoreceptor outer segments (ROS), a function critical to the normal visual process (Ryeom, S. W., Sparrow, J. R., and Silverstein, R. L. (1996) J. Cell Sci. 109, 387-395). We now report that phospholipid liposomes PS and PI, but not phosphatidylethanolamine, bind specifically to RPE. Cross competition experiments suggest that PS and PI recognize the same receptor on RPE, while immunoinhibition studies indicate that the receptor is CD36. RPE cells isolated from a mutant rat strain, the RPE of which does not express CD36 (Sparrow, J. R., Ryeom, S. W., Abumrad, N., Ibrahimi, A., and Silverstein, R. L. (1996) Exp. Eye Res., in press), did not bind PS or PI, further confirming the role of CD36. We also showed that purified ROS blocked binding and uptake of anionic phospholipid liposomes by RPE and that PS and PI liposomes blocked ROS uptake by RPE, suggesting that PS and PI on the ROS membrane may be the ligands on ROS recognized by CD36. This is the first demonstration that CD36-phospholipid interactions may play a role in normal physiology.	CORNELL UNIV,COLL MED,DEPT OPHTHALMOL,NEW YORK,NY 10021; CORNELL UNIV,COLL MED,CELL BIOL & GENET PROGRAM,NEW YORK,NY 10021; CORNELL UNIV,COLL MED,DIV HEMATOL & ONCOL,NEW YORK,NY 10021; CORNELL UNIV,COLL MED,DIV DIGEST DIS,NEW YORK,NY 10021	Cornell University; Cornell University; Cornell University; Cornell University					NATIONAL EYE INSTITUTE [R01EY010967] Funding Source: NIH RePORTER; NEI NIH HHS [EY10967] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ANDERSON RE, 1970, BIOCHEMISTRY-US, V9, P3624, DOI 10.1021/bi00820a019; BEVERS EM, 1983, BIOCHIM BIOPHYS ACTA, V736, P57, DOI 10.1016/0005-2736(83)90169-4; BIBB C, 1974, J CELL BIOL, V61, P327, DOI 10.1083/jcb.61.2.327; BOK D, 1971, J CELL BIOL, V49, P664, DOI 10.1083/jcb.49.3.664; BOK D, 1989, RETINA, P69; CHAITIN MH, 1983, INVEST OPHTH VIS SCI, V24, P812; CLARK VM, 1982, EXP EYE RES, V34, P847, DOI 10.1016/0014-4835(82)90065-3; Dittmer J, 1969, METHOD ENZYMOL, V14, P482, DOI [DOI 10.1016/S0076-6879(69)14055-0, 10.1016/S0076-6879(69)14055-0]; EDWARDS RB, 1977, SCIENCE, V197, P1001, DOI 10.1126/science.560718; ENDEMANN G, 1993, J BIOL CHEM, V268, P11811; FADOK VA, 1992, J IMMUNOL, V148, P2207; HOPE MJ, 1985, BIOCHIM BIOPHYS ACTA, V812, P55, DOI 10.1016/0005-2736(85)90521-8; Huh HY, 1996, BLOOD, V87, P2020; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; LUBIN B, 1981, J CLIN INVEST, V67, P1643, DOI 10.1172/JCI110200; MAYER LD, 1986, BIOCHIM BIOPHYS ACTA, V858, P161, DOI 10.1016/0005-2736(86)90302-0; MCLAUGHLIN BJ, 1994, PROG RETIN EYE RES, V13, P147, DOI 10.1016/1350-9462(94)90008-6; NICHOLSON AC, 1995, ARTERIOSCL THROM VAS, V15, P269, DOI 10.1161/01.ATV.15.2.269; NISHIKAWA K, 1990, J BIOL CHEM, V265, P5226; REN Y, 1995, J EXP MED, V181, P1857, DOI 10.1084/jem.181.5.1857; RIGOTTI A, 1995, J BIOL CHEM, V270, P16221, DOI 10.1074/jbc.270.27.16221; Roelofsen Ben, 1994, V40, P7; Ryeom SW, 1996, J CELL SCI, V109, P387; SCHROIT AJ, 1991, BIOCHIM BIOPHYS ACTA, V1071, P313, DOI 10.1016/0304-4157(91)90019-S; SPARROW JR, 1996, IN PRESS EXP EYE RES; [No title captured]	26	122	124	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20536	20539		10.1074/jbc.271.34.20536	http://dx.doi.org/10.1074/jbc.271.34.20536			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702796	hybrid			2022-12-25	WOS:A1996VD33700048
J	Simon, I; Zerial, M; Goody, RS				Simon, I; Zerial, M; Goody, RS			Kinetics of interaction of Rab5 and Rab7 with nucleotides and magnesium ions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							H-RAS P21; GDP-DISSOCIATION INHIBITOR; GTPASE-ACTIVATING PROTEIN; ENDOCYTIC PATHWAY; BINDING-PROTEINS; MECHANISM; MEMBRANE; HYDROLYSIS; EXCHANGE; FAMILY	We describe here the kinetics of the interaction of GTP and GDP with the small GTP-binding proteins Rab5 and Rab7. It was possible to make use of the intrinsic fluorescence of these proteins, since Rab5 contains two and Rab7 three tryptophan residues, respectively, With both enzymes, there is a significant decrease in fluorescence on binding GTP and an increase on binding GDP, As with the small GTP-binding protein Ha-Ras p21 and with EF-Tu, nucleotide binding occurs in at least two steps and is describable in terms of a relatively weak initial interaction followed by a highly irreversible isomerization of the protein-nucleotide complex, which results in a change in the fluorescence properties, Dissociation of GDP and GTP could be followed in a time-dependent manner using fluorescently labeled GDP (methylanthraniloyl GDP) as displacing agent and taking advantage of substantial fluorescent energy transfer from tryptophan to the nucleotide. Fluorescence techniques could also be used to quantitate the interaction of Mg2+ ions with the GTP and GDP forms of Rab7, and it was shown that the metal ion was bound similar to 1000-fold more strongly to the GTP than the GDP form. The rate of GTP cleavage by the two proteins differed by a factor of similar to 20 (2 x 10(-3) s(-1) for Rab5 and 9 x 10(-4) s(-1) for Rab7 at 37 degrees C), Both proteins showed significant discrimination against xanthosine 5'-O-diphosphate (K-d similar to 10(3)-fold higher than that of GDP) and dramatic discrimination against ADP or ATP (K-d similar to 10(6)-fold higher than that of GDP), The results demonstrate a high degree of mechanistic similarity between the Rab proteins and other GTP-binding proteins, which have been examined in detail, including Ha-Ras p21, Ran, and EF-Tu.	MAX PLANCK INST MOL PHYSIOL, PHYS BIOCHEM ABT, D-44139 DORTMUND, GERMANY; EUROPEAN MOL BIOL LAB, D-60912 HEIDELBERG, GERMANY	Max Planck Society; European Molecular Biology Laboratory (EMBL)			Goody, Roger S/J-8845-2014	Goody, Roger S/0000-0002-0772-0444				ANDRES DA, 1993, CELL, V73, P1091, DOI 10.1016/0092-8674(93)90639-8; BURSTEIN ES, 1991, J BIOL CHEM, V266, P2689; BURSTEIN ES, 1992, P NATL ACAD SCI USA, V89, P1154, DOI 10.1073/pnas.89.4.1154; BURTON J, 1993, NATURE, V361, P464, DOI 10.1038/361464a0; CHAVRIER P, 1990, MOL CELL BIOL, V10, P6578, DOI 10.1128/MCB.10.12.6578; EIGEN M, 1960, J AM CHEM SOC, V82, P5951, DOI 10.1021/ja01507a041; FENG Y, 1995, J CELL BIOL, V131, P1; GODA Y, 1988, CELL, V55, P309, DOI 10.1016/0092-8674(88)90054-2; GOODY RS, 1991, TRENDS BIOCHEM SCI, V16, P327, DOI 10.1016/0968-0004(91)90134-H; GOODY RS, 1994, NATURE, V372, P220, DOI 10.1038/372220a0; GOODY RS, 1992, PHILOS T ROY SOC B, V336, P3, DOI 10.1098/rstb.1992.0037; GRIFFITHS G, 1989, J CELL BIOL, V109, P2703, DOI 10.1083/jcb.109.6.2703; GRUENBERG J, 1995, CURR OPIN CELL BIOL, V7, P552, DOI 10.1016/0955-0674(95)80013-1; JOHN J, 1989, NATO ADV SCI I A-LIF, V165, P209; JOHN J, 1990, BIOCHEMISTRY-US, V29, P6058, DOI 10.1021/bi00477a025; JOHN J, 1993, J BIOL CHEM, V268, P923; KABCENELL AK, 1990, J BIOL CHEM, V265, P9366; KLEBE C, 1995, BIOCHEMISTRY-US, V34, P12543, DOI 10.1021/bi00039a008; LEHRER SS, 1971, BIOCHEMISTRY-US, V10, P3254, DOI 10.1021/bi00793a015; LEONARD DA, 1994, BIOCHEMISTRY-US, V33, P12323, DOI 10.1021/bi00206a040; LI C, 1994, NEURON, V13, P885, DOI 10.1016/0896-6273(94)90254-2; MOORE KJM, 1993, BIOCHEMISTRY-US, V32, P7451, DOI 10.1021/bi00080a016; MOYA M, 1993, NATURE, V361, P460, DOI 10.1038/361460a0; NEAL SE, 1990, P NATL ACAD SCI USA, V87, P3652; NOVICK P, 1993, CELL, V75, P597, DOI 10.1016/0092-8674(93)90478-9; NUOFFER C, 1994, ANNU REV BIOCHEM, V63, P949, DOI 10.1146/annurev.bi.63.070194.004505; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; PFEFFER SR, 1995, J BIOL CHEM, V270, P17057, DOI 10.1074/jbc.270.29.17057; PFEFFER SR, 1994, CURR OPIN CELL BIOL, V6, P522, DOI 10.1016/0955-0674(94)90071-X; PRIVE GG, 1992, P NATL ACAD SCI USA, V89, P3649, DOI 10.1073/pnas.89.8.3649; RENSLAND H, 1995, BIOCHEMISTRY-US, V34, P593, DOI 10.1021/bi00002a026; RENSLAND H, 1991, BIOCHEMISTRY-US, V30, P11181, DOI 10.1021/bi00110a023; SCHEIDIG AJ, 1994, ACTA CRYSTALLOGR D, V50, P512, DOI 10.1107/S090744499301443X; SCHWEINS T, 1995, NAT STRUCT BIOL, V2, P36, DOI 10.1038/nsb0195-36; SHIRATAKI H, 1993, MOL CELL BIOL, V13, P2061, DOI 10.1128/MCB.13.4.2061; SOLDATI T, 1994, NATURE, V369, P76, DOI 10.1038/369076a0; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; STEELEMORTIMER O, 1994, EMBO J, V13, P34, DOI 10.1002/j.1460-2075.1994.tb06232.x; STENMARK H, 1995, CELL, V83, P423, DOI 10.1016/0092-8674(95)90120-5; STROM M, 1993, NATURE, V361, P736, DOI 10.1038/361736a0; STUDIER WF, 1990, METHOD ENZYMOL, V185, P60, DOI DOI 10.1016/0076-6879(90)85008-C; TUCKER J, 1986, EMBO J, V5, P1351, DOI 10.1002/j.1460-2075.1986.tb04366.x; ULLRICH O, 1994, NATURE, V368, P157, DOI 10.1038/368157a0; WAGNER A, 1995, BIOCHEMISTRY-US, V34, P12535, DOI 10.1021/bi00039a007; ZAHRAOUI A, 1989, J BIOL CHEM, V264, P12394; Zerial M, 1993, CURR OPIN CELL BIOL, V5, P613, DOI 10.1016/0955-0674(93)90130-I	46	98	99	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20470	20478		10.1074/jbc.271.34.20470	http://dx.doi.org/10.1074/jbc.271.34.20470			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702787	hybrid			2022-12-25	WOS:A1996VD33700039
J	Kojima, N; Tachida, Y; Yoshida, Y; Tsuji, S				Kojima, N; Tachida, Y; Yoshida, Y; Tsuji, S			Characterization of mouse ST8Sia II (STX) as a neural cell adhesion molecule-specific polysialic acid synthase - Requirement of core alpha 1,6-linked fucose and a polypeptide chain for polysialylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEVELOPMENTALLY-REGULATED MEMBER; N-CAM; LINKED OLIGOSACCHARIDES; ALPHA-2,8-SIALYLTRANSFERASE; EXPRESSION; CLONING; FAMILY; BRAIN; MIGRATION; GENE	We previously showed that mouse ST8Sia II (STX) exhibits polysialic acid (PSA) synthase activity in vivo as well as in vitro (Kojima, N., Yoshida, Y., and Tsuji, S. (1995) FEBS Lett. 373, 119-122, 1995). In this paper, we reported that the neural cell adhesion molecule (NCAM) was specifically polysialylated by a single enzyme, ST8Sia II. PSA-expressing Neuro2a cells (N2a-STX) were established by stable transfection of the mouse ST8Sia II gene. Only the 140- and 180-kDa isoforms of NCAM in N2a-STX cells were specifically polysialylated in vivo, although other membrane proteins of N2a-STX were polysialylated in vitro, A recombinant soluble mouse ST8Sia II synthesized PSA on a recombinant soluble NCAM fused with the Fc region of human IgG1 (NCAM-Fc) as well as fetuin, However, NCAM Fe served as a 1500-fold better acceptor for ST8Sia II than fetuin, Treatment of NCAM-Fe with Charonia lampas alpha-fucosidase, which is able to cleave alpha 1,6-linked fucose, clearly reduced the polysialylation of NCAM-Fe by ST8Sia II, PSA was not synthesized on the N-glycanase-treated NCAM-Fc polypeptide or the free N-glycans of NCAM-Fc, When fetuin and its glycopeptide and N-glycans of fetuin were used as substrates for ST8Sia II, PSA was found to be synthesized on native fetuin and its glycopeptide but not on free N-glycans, These results strongly suggested that core alpha 1,6-fucose on N-glycans as well as the antennary structures of N-glycans and the polypeptide regions are required for the polysialylation by ST8Sia II, Furthermore, oligo and single alpha 2,8-sialylated glycoproteins were no longer polysialylated by mouse ST8Sia II. Therefore, the single enzyme, ST8Sia II, directly transferred all alpha 2,8-sialic acid residues on the alpha 2,3-linked sialic acids of N-glycans of specific NCAM isoforms to yield PSA-NCAM. Polysialylation did not require any initiator alpha 2,8-sialyltransferase but did depend on the carbohydrate and protein structures of NCAM.	RIKEN,INST PHYS & CHEM RES,FRONTIER RES PROGRAM,DEPT MOL GLYCOBIOL,WAKO,SAITAMA 35101,JAPAN	RIKEN								Bruses JL, 1995, J NEUROSCI, V15, P8310; ECKHARDT M, 1995, NATURE, V373, P715, DOI 10.1038/373715a0; EDELMAN GM, 1985, ANN REV BIOCH, V54, P15; FROSCH M, 1985, P NATL ACAD SCI USA, V82, P1194, DOI 10.1073/pnas.82.4.1194; GREEN ED, 1988, J BIOL CHEM, V263, P18253; HALLENBECK PC, 1987, J BIOL CHEM, V262, P3553; HOFFMAN S, 1982, J BIOL CHEM, V257, P7720; Johnston D. E., 1976, RNA POLYMERASE, P413; KADMON G, 1990, J CELL BIOL, V110, P209, DOI 10.1083/jcb.110.1.209; KITAJIMA K, 1995, GLYCOCONJUGATE J, V12, P508; KITAZUME S, 1994, J BIOL CHEM, V269, P10330; KOJIMA N, 1994, EXP CELL RES, V214, P537, DOI 10.1006/excr.1994.1291; KOJIMA N, 1995, FEBS LETT, V360, P1, DOI 10.1016/0014-5793(95)00059-I; KOJIMA N, 1995, FEBS LETT, V373, P119, DOI 10.1016/0014-5793(95)01024-9; LIVINGSTON BD, 1993, J BIOL CHEM, V268, P11504; MIZUOCHI T, 1980, BIOCHEM BIOPH RES CO, V97, P772, DOI 10.1016/0006-291X(80)90331-9; Nakayama J, 1996, J BIOL CHEM, V271, P1829, DOI 10.1074/jbc.271.4.1829; OKA S, 1995, J BIOL CHEM, V270, P19357, DOI 10.1074/jbc.270.33.19357; OKA S, 1995, J BIOL CHEM, V270, P17171; ONO K, 1994, NEURON, V13, P595, DOI 10.1016/0896-6273(94)90028-0; RUTISHAUSER U, 1988, SCIENCE, V240, P53, DOI 10.1126/science.3281256; SASAKI K, 1994, J BIOL CHEM, V269, P15950; SCHEIDEGGER EP, 1995, J BIOL CHEM, V270, P22685, DOI 10.1074/jbc.270.39.22685; SIMMONS DL, 1993, CELLULAR INTERACTION, P93; SMALL SJ, 1990, J CELL BIOL, V111, P2089, DOI 10.1083/jcb.111.5.2089; SMALL SJ, 1988, NEURON, V1, P1007, DOI 10.1016/0896-6273(88)90158-4; TNAG J, 1994, NEURON, V13, P405; TROY FA, 1992, GLYCOBIOLOGY, V2, P5, DOI 10.1093/glycob/2.1.5; WALSH FS, 1989, BIOESSAYS, V11, P83, DOI 10.1002/bies.950110402; WANG C, 1994, J NEUROSCI, V14, P4446; YOSHIDA Y, 1995, J BIOCHEM-TOKYO, V118, P658, DOI 10.1093/oxfordjournals.jbchem.a124960; YOSHIDA Y, 1995, J BIOL CHEM, V270, P14628, DOI 10.1074/jbc.270.24.14628; YOSHIMA H, 1981, J BIOL CHEM, V256, P8476	33	109	113	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19457	19463		10.1074/jbc.271.32.19457	http://dx.doi.org/10.1074/jbc.271.32.19457			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702635	hybrid			2022-12-25	WOS:A1996VB68400069
J	MirandaVizuete, A; RodriguezAriza, A; Toribio, F; Holmgren, A; LopezBarea, J; Pueyo, C				MirandaVizuete, A; RodriguezAriza, A; Toribio, F; Holmgren, A; LopezBarea, J; Pueyo, C			The levels of ribonucleotide reductase, thioredoxin, glutaredoxin 1, and GSH are balanced in Escherichia coli K12	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTATHIONE-REDUCTASE; SULFATE REDUCTION; HYDROGEN DONOR; CONSTRUCTION; PURIFICATION; LIVER; K-12; DEOXYRIBONUCLEOTIDE; CHROMATOGRAPHY; SENSITIVITY	The dithiol forms of thioredoxin and glutaredoxin are hydrogen donors for ribonucleotide reductase, We have determined the intracellular levels of ribonucleotide reductase (RRase), thioredoxin (Trx), glutaredoxin 1 (Grx1), and glutathione (GSH) and the glutathione redox status in new Escherichia coli K12 strains lacking thioredoxin (trxA(-)), glutaredoxin 1 (grxA(-)), and/or GSH (gshA(-)) or overproducing Trx or Grx1 from multicopy plasmids, We propose a regulatory network in which RRase levels are balanced with those of Trx, Grx1, and GSH so that deficiency or overproduction of one component would promote the opposite effect on the others to maintain a balanced supply of deoxyribonucleotides. GSH deficiency strongly increased both Grx1 levels and RRase activity, even more than Trx deficiency, Double gshA(-)trxA(-) bacteria were viable, whereas additional deficiency in lipoate synthesis (gshA(-)trxA(-)lipA(-)) caused the inability to grow in minimal medium plates supplemented with acetate plus succinate instead of lipoic acid, Thus, lipoate might be the only substitute of GSH for glutaredoxin reduction in gshA(-)trxA(-) cells, although the extremely high Grx1 content (55-fold) of these bacteria suggests that electron transfer from lipoate might be an inefficient reduction mechanism of glutaredoxins. Moreover, the enhanced Grx1 level of gshA(-)trxA(-) cells could obviate the need for a large increase in RRase activity, in contrast to grxA(-)trxA(-) double mutant cells, Impairment of the sulfate assimilation pathway, leading to very low GSH concentrations, and an oxidized glutathione redox state might explain the inability of grxA(-)trxA(-) cells to grow in minimal medium, Restoration of nearly normal levels of both GSH content and redox status cure the growth defect.	UNIV CORDOBA,DEPT BIOQUIM & BIOL MOL,CORDOBA 14071,SPAIN; UNIV CORDOBA,CTR EXPERIMENTAC BIOL,CORDOBA 14071,SPAIN; KAROLINSKA INST,MED NOBEL INST BIOCHEM,DEPT MED BIOCHEM & BIOPHYS,S-17177 STOCKHOLM,SWEDEN	Universidad de Cordoba; Universidad de Cordoba; Karolinska Institutet			Pueyo, Carmen/B-4509-2016; IBIS, REDOX/J-7473-2017; Rodriguez-Ariza, Antonio/U-4854-2017; Miranda-Vizuete, Antonio/D-6927-2012; Lopez-Barea, Juan/K-7258-2014	Pueyo, Carmen/0000-0002-2624-2011; Rodriguez-Ariza, Antonio/0000-0001-5304-5745; Miranda-Vizuete, Antonio/0000-0002-6856-5396; Lopez-Barea, Juan/0000-0002-2280-3379				ABRIL N, 1992, ENVIRON MOL MUTAGEN, V19, P288, DOI 10.1002/em.2850190405; ALONSOMORAGA A, 1987, MOL CELL BIOCHEM, V73, P61; ASLUND F, 1994, P NATL ACAD SCI USA, V91, P9813, DOI 10.1073/pnas.91.21.9813; Bjornberg O, 1991, Protein Expr Purif, V2, P287, DOI 10.1016/1046-5928(91)90085-W; BOLIVAR F, 1977, GENE, V2, P95, DOI 10.1016/0378-1119(77)90000-2; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DAVIS RW, 1980, MANUAL GENETIC ENG A; DYSON HJ, 1989, BIOCHEMISTRY-US, V28, P7074, DOI 10.1021/bi00443a044; GREENBERG JT, 1986, J BACTERIOL, V168, P1026, DOI 10.1128/jb.168.2.1026-1029.1986; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; HOLMGREN A, 1979, J BIOL CHEM, V254, P3672; HOLMGREN A, 1977, J BIOL CHEM, V252, P4600; HOLMGREN A, 1979, J BIOL CHEM, V254, P9627; HOLMGREN A, 1985, METHOD ENZYMOL, V113, P525; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; HOOG JO, 1986, GENE, V43, P13, DOI 10.1016/0378-1119(86)90003-X; Jordan A, 1996, J BIOL CHEM, V271, P8779, DOI 10.1074/jbc.271.15.8779; KREDICH NM, 1987, ESCHERICHIA COLI SAL, V1, P419; LUTHMAN M, 1982, BIOCHEMISTRY-US, V21, P6628, DOI 10.1021/bi00269a003; Mannervik B., 1983, FUNCTIONS GLUTATHION, P385; MATA AM, 1984, Z NATURFORSCH C, V39, P908; MIRANDAVIZUETE A, 1994, J BIOL CHEM, V269, P16631; REICHARD P, 1988, ANNU REV BIOCHEM, V57, P349, DOI 10.1146/annurev.bi.57.070188.002025; RODRIGUEZARIZA A, 1994, J CHROMATOGR B, V656, P311, DOI 10.1016/0378-4347(94)00111-1; RUSSEL M, 1988, P NATL ACAD SCI USA, V85, P990, DOI 10.1073/pnas.85.4.990; RUSSEL M, 1986, J BIOL CHEM, V261, P4997; RUSSEL M, 1990, J BACTERIOL, V172, P1923, DOI 10.1128/jb.172.4.1923-1929.1990; TSANG MLS, 1981, J BACTERIOL, V146, P1059, DOI 10.1128/JB.146.3.1059-1066.1981; TUGGLE CK, 1985, J BACTERIOL, V162, P448, DOI 10.1128/JB.162.1.448-450.1985; WALLACE BJ, 1984, GENE, V32, P399, DOI 10.1016/0378-1119(84)90015-5	31	56	62	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19099	19103		10.1074/jbc.271.32.19099	http://dx.doi.org/10.1074/jbc.271.32.19099			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702583	hybrid			2022-12-25	WOS:A1996VB68400017
J	Olofsson, B; Pajusola, K; vonEuler, G; Chilov, D; Alitalo, K; Eriksson, U				Olofsson, B; Pajusola, K; vonEuler, G; Chilov, D; Alitalo, K; Eriksson, U			Genomic organization of the mouse and human genes for vascular endothelial growth factor B (VEGF-B) and characterization of a second splice isoform	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE; PDGF RECEPTOR; CDNA CLONING; EXPRESSION; PLACENTA; PROTEIN; ANGIOGENESIS; BINDING; DIFFERENTIATION; VASCULOGENESIS	A second isoform and the genomic structures of mouse and human vascular endothelial growth factor B are described. Both genes consist of seven coding exons and span about 4 kilobases of DNA. The two identified isoforms of vascular endothelial growth factor B are generated by alternative splicing where different, splice acceptor sites in exon 6 introduce a frameshift and a partial use of different but overlapping reading frames, Consequently, the COOK-terminal domains in the two isoforms show no resemblance, Mouse and human cDNA clones for the novel isoform of vascular endothelial growth factor B encoded a secreted protein of 186 amino acid residues. Expression in transfected cells generated a protein of 25 kDa which upon secretion was modified by O-linked glycosylation and displayed a molecular mass of 32 kDa under reducing conditions. The protein was expressed as a disulfide-linked homodimer, and heterodimers were generated when coexpressed with vascular endothelial growth factor. The entirely different COOH-terminal domains in the two isoforms of vascular endothelial growth factor B imply that some functional properties of the two proteins are distinct.	LUDWIG INST CANC RES,STOCKHOLM BRANCH,S-17177 STOCKHOLM,SWEDEN; MOL CANC BIOL LAB,HELSINKI 00014,FINLAND; HAARTMAN INST,HELSINKI 00014,FINLAND	Ludwig Institute for Cancer Research			Alitalo, Kari K/J-5013-2014	Alitalo, Kari K/0000-0002-7331-0902; chilov, dmitri/0000-0002-2279-0854				Ausubel FM, 1992, CURRENT PROTOCOLS MO; BREIER G, 1992, DEVELOPMENT, V114, P521; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLAESSONWELSH L, 1989, P NATL ACAD SCI USA, V86, P4917, DOI 10.1073/pnas.86.13.4917; CLAESSONWELSH L, 1988, MOL CELL BIOL, V8, P3476, DOI 10.1128/MCB.8.8.3476; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; FERRARA N, 1992, ENDOCR REV, V13, P18, DOI 10.1210/er.13.1.18; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; GRONWALD RGK, 1988, P NATL ACAD SCI USA, V85, P3435, DOI 10.1073/pnas.85.10.3435; HAUSER S, 1993, GROWTH FACTORS, V9, P259, DOI 10.3109/08977199308991586; HELDIN CH, 1990, CELL REGUL, V1, P555, DOI 10.1091/mbc.1.8.555; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HOUCK KA, 1991, MOL ENDOCRINOL, V5, P1806, DOI 10.1210/mend-5-12-1806; HUDGINS WR, 1992, J BIOL CHEM, V267, P8153; Joukov V, 1996, EMBO J, V15, P290; Konat Gregory W., 1994, P37; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lee J, 1996, P NATL ACAD SCI USA, V93, P1988, DOI 10.1073/pnas.93.5.1988; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; LU HS, 1995, J BIOL CHEM, V270, P4775, DOI 10.1074/jbc.270.9.4775; MAGLIONE D, 1991, P NATL ACAD SCI USA, V88, P9267, DOI 10.1073/pnas.88.20.9267; MAGLIONE D, 1993, ONCOGENE, V8, P925; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; MUSTONEN T, 1995, J CELL BIOL, V129, P895, DOI 10.1083/jcb.129.4.895; Olofsson B, 1996, P NATL ACAD SCI USA, V93, P2576, DOI 10.1073/pnas.93.6.2576; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; PARK JE, 1994, J BIOL CHEM, V269, P25646; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Shima DT, 1996, J BIOL CHEM, V271, P3877, DOI 10.1074/jbc.271.7.3877; Soker S, 1996, J BIOL CHEM, V271, P5761, DOI 10.1074/jbc.271.10.5761; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; TISCHER E, 1991, J BIOL CHEM, V266, P11947; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0	35	165	176	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19310	19317		10.1074/jbc.271.32.19310	http://dx.doi.org/10.1074/jbc.271.32.19310			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702615	hybrid			2022-12-25	WOS:A1996VB68400049
J	Zheng, Y; Zangrilli, D; Cerione, RA; Eva, A				Zheng, Y; Zangrilli, D; Cerione, RA; Eva, A			The pleckstrin homology domain mediates transformation by oncogenic Dbl through specific intracellular targeting	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; BETA-GAMMA-SUBUNITS; PH DOMAIN; SIGNALING PROTEINS; CRYSTAL-STRUCTURE; BINDING; RAS; IDENTIFICATION; PRODUCT; KINASE	The pleckstrin homology (PH) domain is an similar to 100 amino acid structural motif found in many cellular signaling molecules, including the Dbl oncoprotein and related, putative guanine nucleotide exchange factors (GEFs). Here we have examined the role of the Dbl PH (dPH) domain in the activities of oncogenic Dbl. We report that the dPH domain is not involved in the interaction of Dbl with small GTP-binding proteins and is incapable of transforming NIH 3T3 fibroblasts. On the other hand, co-expression of the dPH domain with on cogenic Dbl inhibits Dbl-induced transformation. A deletion mutant of Dbl that lacks a significant portion of the PH domain retains full GEF activity, but is completely inactive in transformation assays. Replacement of the PH domain by the membrane-targeting sequence of Ras is not sufficient for the recovery of transforming activity. However, subcellular fractionations of Dbl and Dbl mutants revealed that the PH domain is necessary and sufficient for the association of Dbl with the Triton X-100-insoluble cytoskeletal components. Thus, our results suggest that the dPH domain mediates cellular transformation by targeting the Dbl protein to specific cytoskeletal locations to activate Rho-type small GTP-binding proteins.	CORNELL UNIV,DEPT PHARMACOL,ITHACA,NY 14853; NCI,CELLULAR & MOL BIOL LAB,BETHESDA,MD 20892	Cornell University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Eva, Alessandra/J-8268-2016; Zheng, Yi/J-7235-2015	Eva, Alessandra/0000-0003-2949-078X; Zheng, Yi/0000-0001-7089-6074	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047458] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM47458] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; CHUANG TH, 1995, P NATL ACAD SCI USA, V92, P10282, DOI 10.1073/pnas.92.22.10282; DAVIS LH, 1994, J BIOL CHEM, V269, P4409; FERGUSON KM, 1994, CELL, V79, P199, DOI 10.1016/0092-8674(94)90190-2; GIBSON TJ, 1994, TRENDS BIOCHEM SCI, V19, P349, DOI 10.1016/0968-0004(94)90108-2; GRAZIANI G, 1989, ONCOGENE, V4, P823; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HART MJ, 1994, J BIOL CHEM, V269, P62; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; HASLAM RJ, 1993, NATURE, V363, P309, DOI 10.1038/363309b0; HORII Y, 1994, EMBO J, V13, P4776, DOI 10.1002/j.1460-2075.1994.tb06803.x; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; LUTTRELL LM, 1995, J BIOL CHEM, V270, P12984, DOI 10.1074/jbc.270.22.12984; MACIAS MJ, 1994, NATURE, V369, P675, DOI 10.1038/369675a0; MATTINGLY RR, 1994, MOL CELL BIOL, V14, P7943, DOI 10.1128/MCB.14.12.7943; MAYER BJ, 1993, CELL, V73, P629, DOI 10.1016/0092-8674(93)90244-K; MIKI T, 1993, NATURE, V362, P462, DOI 10.1038/362462a0; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; PITCHER JA, 1995, J BIOL CHEM, V270, P11707, DOI 10.1074/jbc.270.20.11707; QUILLIAM LA, 1994, P NATL ACAD SCI USA, V91, P8512, DOI 10.1073/pnas.91.18.8512; RON D, 1991, NEW BIOL, V3, P372; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; SRIVASTAVA SK, 1986, P NATL ACAD SCI USA, V83, P8868, DOI 10.1073/pnas.83.23.8868; TIMM D, 1994, NAT STRUCT BIOL, V1, P782, DOI 10.1038/nsb1194-782; TOKSOZ D, 1994, ONCOGENE, V9, P621; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; TSUKADA S, 1994, P NATL ACAD SCI USA, V91, P11256, DOI 10.1073/pnas.91.23.11256; WHITEHEAD I, 1995, ONCOGENE, V10, P713; WHITEHEAD I, 1995, J BIOL CHEM, V270, P18388, DOI 10.1074/jbc.270.31.18388; YOON HS, 1994, NATURE, V369, P672, DOI 10.1038/369672a0; ZHENG Y, 1995, J BIOL CHEM, V270, P9031, DOI 10.1074/jbc.270.16.9031; ZHENG Y, 1994, J BIOL CHEM, V269, P2369	33	107	110	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19017	19020		10.1074/jbc.271.32.19017	http://dx.doi.org/10.1074/jbc.271.32.19017			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702569	hybrid			2022-12-25	WOS:A1996VB68400003
J	Warriar, N; Page, N; Govindan, MV				Warriar, N; Page, N; Govindan, MV			Expression of human glucocorticoid receptor gene and interaction of nuclear proteins with the transcriptional control element	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMARY-TUMOR VIRUS; POLYMYOSITIS OVERLAP SYNDROME; DNA-BINDING PROTEINS; MAJOR LATE PROMOTER; KU AUTOANTIGEN; EFFICIENT TRANSCRIPTION; CELL-PROLIFERATION; MOLECULAR-CLONING; AUTO-ANTIGEN; SEQUENCE	We have identified sequences responsible for the expression of the human glucocorticoid receptor gene (GR gene) using a set of 5' promoter deletion mutants in HeLa, human placenta, and human breast tumor (MCF-7) cells, The chimeric gene construct -892 5'-GAAGTGACACACTTC3' -878-CAT was sufficient for high level of expression in HeLa and placenta cells in culture, Deletion of palindromic sequences decreased levels of GR expression in these cells, By oligonucleotide-affinity chromatography with the palindromic glucocorticoid receptor enhancing factor-binding element (GREFE), we have isolated from human placenta nu clear extract two novel proteins glucocorticoid receptor enhancing factors 1 and 2 (GREF1 and GREF2), with apparent molecular masses of 80 and 62 kDa, respectively, These proteins, similar to the DNA-binding autoantigen Ku are, like Ku, heterodimers of polypeptide subunits p80 and p62, immunologically related to factors binding to proximal sequence element 1 in the promoter of small nuclear RNA (PSE1) and transferrin receptor enhancing factors, Both Ku80 and Ku70 polypeptides were present in high concentrations in human placenta and HeLa cells, In MCF-7 cells, however, only a high level of p62 was detected. While cotransfection of pcDNA-Ku80 with pHGR(-892 to -878)-CAT potentiated the expression of CAT, introduction of pcDNA-Ku70 did not affect the expression of CAT in transfected MCF-7 cells, UV cross-linking analysis showed that only GREF1 contacted DNA directly. Supershift assays with monoclonal antibodies Ab 111 (Ku80) or Ab N3H10 (Ku70) showed a direct interaction of GREF1 and GREF2 heterodimers with the palindrome, Partial peptide fingerprinting of GREF1 and GREF2 using alpha-chymotrypsin and immunoblotting with Ab 111 and Ab N3H10 confirmed their identities as Ku80 and Ku70, respectively.	UNIV LAVAL,DEPT MOL ENDOCRINOL,HOSP CTR,ST FOY,PQ G1V 4G2,CANADA	Laval University								ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P9; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BANERJI J, 1981, CELL, V27, P299, DOI 10.1016/0092-8674(81)90413-X; BENEDIKTSSON R, 1993, LANCET, V341, P339, DOI 10.1016/0140-6736(93)90138-7; BLASCO MJ, 1986, HORM METAB RES, V18, P638, DOI 10.1055/s-2007-1012393; BLIER PR, 1993, J BIOL CHEM, V268, P7594; BOUBNOV NV, 1995, P NATL ACAD SCI USA, V92, P890, DOI 10.1073/pnas.92.3.890; CASEY JL, 1988, NUCLEIC ACIDS RES, V16, P629, DOI 10.1093/nar/16.2.629; CHALEPAKIS G, 1988, CELL, V53, P371, DOI 10.1016/0092-8674(88)90157-2; CHAN JYC, 1989, J BIOL CHEM, V264, P3651; CHODOSH LA, 1986, MOL CELL BIOL, V6, P4723, DOI 10.1128/MCB.6.12.4723; DEFRANCO DB, 1991, MOL ENDOCRINOL, V5, P1215, DOI 10.1210/mend-5-9-1215; DVIR A, 1992, P NATL ACAD SCI USA, V89, P11920, DOI 10.1073/pnas.89.24.11920; ENCIO IJ, 1991, J BIOL CHEM, V266, P7182; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FRANCOEUR AM, 1986, J IMMUNOL, V136, P1648; GENERSCH E, 1995, EMBO J, V14, P791, DOI 10.1002/j.1460-2075.1995.tb07057.x; GILMAN MZ, 1986, MOL CELL BIOL, V6, P4305, DOI 10.1128/MCB.6.12.4305; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; GOVINDAN MV, 1991, J STEROID BIOCHEM, V40, P317, DOI 10.1016/0960-0760(91)90197-D; GOVINDAN MV, 1982, P NATL ACAD SCI-BIOL, V79, P5157, DOI 10.1073/pnas.79.17.5157; GOVINDAN MV, 1987, SER S, P187; GRIFFITH AJ, 1992, J BIOL CHEM, V267, P331; GUNDERSON SI, 1990, GENE DEV, V4, P2048, DOI 10.1101/gad.4.12a.2048; HEN R, 1982, P NATL ACAD SCI-BIOL, V79, P7132, DOI 10.1073/pnas.79.23.7132; HOLLENBERG SM, 1985, NATURE, V318, P635, DOI 10.1038/318635a0; HURST HC, 1987, GENE DEV, V1, P1132, DOI 10.1101/gad.1.10.1132; JONES NC, 1988, GENE DEV, V2, P267, DOI 10.1101/gad.2.3.267; KADANOGA JT, 1978, CELL, V51, P1079; KNUTH MW, 1990, J BIOL CHEM, V265, P17911; LECLERC S, 1991, J BIOL CHEM, V266, P17333; LECLERC S, 1991, J BIOL CHEM, V266, P8711; LEE KAW, 1987, P NATL ACAD SCI USA, V84, P8355, DOI 10.1073/pnas.84.23.8355; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LEWIN B, 1990, CELL, V61, P743, DOI 10.1016/0092-8674(90)90181-D; MAY G, 1991, J BIOL CHEM, V266, P3052; MIMORI T, 1990, P NATL ACAD SCI USA, V87, P1777, DOI 10.1073/pnas.87.5.1777; MIMORI T, 1986, J BIOL CHEM, V261, P2274; MIMORI T, 1981, J CLIN INVEST, V68, P611, DOI 10.1172/JCI110295; MIMORI T, 1984, J BIOL CHEM, V259, P560; MISKIMINS WK, 1986, J CELL BIOL, V103, P1781, DOI 10.1083/jcb.103.5.1781; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MURPHY BEP, 1981, J STEROID BIOCHEM, V14, P811; MURPHY JT, 1987, J BIOL CHEM, V262, P1795; NOBUKUNI Y, 1995, BIOCHEMISTRY-US, V34, P8207, DOI 10.1021/bi00025a028; OUYANG Q, 1993, MOL CELL BIOL, V13, P1796, DOI 10.1128/MCB.13.3.1796; OWEN D, 1987, EMBO J, V6, P1287, DOI 10.1002/j.1460-2075.1987.tb02366.x; PAYVAR F, 1983, CELL, V35, P381, DOI 10.1016/0092-8674(83)90171-X; PEPIN MC, 1992, MOL PHARMACOL, V41, P1016; PRABHAKAR BS, 1990, J CLIN INVEST, V86, P1301, DOI 10.1172/JCI114838; REEVES WH, 1989, J BIOL CHEM, V264, P5047; REEVES WH, 1985, J EXP MED, V161, P18, DOI 10.1084/jem.161.1.18; ROBERTS MR, 1989, CELL REGUL, V1, P151, DOI 10.1091/mbc.1.1.151; ROBERTS MR, 1994, P NATL ACAD SCI USA, V91, P6354, DOI 10.1073/pnas.91.14.6354; ROMANCER ML, 1994, J BIOL CHEM, V269, P17464; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SCHEIDEREIT C, 1983, NATURE, V304, P749, DOI 10.1038/304749a0; STRAHLE U, 1992, P NATL ACAD SCI USA, V89, P6731, DOI 10.1073/pnas.89.15.6731; STRUHL K, 1989, TRENDS BIOCHEM SCI, V14, P137, DOI 10.1016/0968-0004(89)90145-X; STUIVER MH, 1990, J EXP MED, V172, P1049, DOI 10.1084/jem.172.4.1049; TUTEJA N, 1994, EMBO J, V13, P4991, DOI 10.1002/j.1460-2075.1994.tb06826.x; WU L, 1986, P NATL ACAD SCI USA, V83, P629; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0; YAMAMOTO KR, 1985, ANNU REV GENET, V19, P209, DOI 10.1146/annurev.genet.19.1.209; YANEVA M, 1985, BIOCHIM BIOPHYS ACTA, V841, P22, DOI 10.1016/0304-4165(85)90270-3; YANEVA M, 1991, BIOCHIM BIOPHYS ACTA, V1090, P181, DOI 10.1016/0167-4781(91)90099-8; YANEVA M, 1986, BIOCHEMISTRY-US, V25, P5057, DOI 10.1021/bi00366a013; YANEVA M, 1989, J BIOL CHEM, V264, P13407; ZONG J, 1990, MOL CELL BIOL, V10, P5580, DOI 10.1128/MCB.10.10.5580	70	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18662	18671		10.1074/jbc.271.31.18662	http://dx.doi.org/10.1074/jbc.271.31.18662			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702520	hybrid			2022-12-25	WOS:A1996VB68300058
J	Zhang, WL; Lane, RD; Mellgren, RL				Zhang, WL; Lane, RD; Mellgren, RL			The major calpain isozymes are long-lived proteins - Design of an antisense strategy for calpain depletion in cultured cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-DEPENDENT PROTEASES; MU-CALPAIN; NEUTRAL PROTEASE; HUMAN PLATELETS; MUSCLE-CELLS; INVOLVEMENT; CALPASTATIN; ANTIBODIES; DIFFERENTIATION; PROLIFERATION	Calpains are intracellular Ca2+-dependent proteases that are thought to participate in Ca2+-associated signal transduction pathways, It has been proposed that calpains are activated by an autoproteolytic mechanism, If this is true one would expect a relatively short half-life for calpain protein in cells, To test this hypothesis, WI-38 human diploid fibroblasts were pulse-labeled with [S-35]methionine, and calpain was immunoprecipitated at various times after chasing with nonradioactive methionine to determine residual radioactivity, The results demonstrated that the two major calpain isozymes, m-calpain and mu-calpain, had metabolic half-lives of approximately 5 days, Calpains were long-lived proteins in several human cell lines, A-431, HeLa, VA-13, C-33A, and TE2 cells, In addition, calpastatin, the calpain-specific inhibitor protein, also had a long metabolic half-life, These observations suggest that the model for calpain activation by autoproteolysis requires re-investigation. Based on a knowledge of calpain metabolic stability, a protocol was devised for chronic exposure of WI-38 cells and HeLa cells to a calpain small subunit antisense oligodeoxyribonucleotide. Depletion of calpain small subunit after 5 or more days of treatment led to inhibition of cell proliferation that could be reversed by removal of antisense oligodeoxyribonucleotide from the culture medium, Together with previous studies, these results indicate a requirement for calpains in mammalian cell proliferation.	MED COLL OHIO, DEPT PHARMACOL, TOLEDO, OH 43690 USA; MED COLL OHIO, DEPT THERAPEUT, TOLEDO, OH 43690 USA; MED COLL OHIO, DEPT ANAT, TOLEDO, OH 43690 USA						NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036573] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 36573] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANAGLI J, 1993, BIOCHEM J, V289, P93, DOI 10.1042/bj2890093; ANAGLI J, 1991, BIOCHEM J, V274, P497, DOI 10.1042/bj2740497; BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; CONG JY, 1989, J BIOL CHEM, V264, P10096; COTTIN P, 1994, BBA-MOL CELL RES, V1223, P170, DOI 10.1016/0167-4889(94)90223-2; Crawford C., 1990, INTRACELLULAR CALCIU, P75; DESHAIES RJ, 1995, TRENDS CELL BIOL, V5, P428, DOI 10.1016/S0962-8924(00)89102-3; EMORI Y, 1994, J BIOL CHEM, V269, P25137; JOHNSON P, 1990, INT J BIOCHEM, V22, P811, DOI 10.1016/0020-711X(90)90284-A; KWAK KB, 1993, BIOCHIM BIOPHYS ACTA, V1175, P243, DOI 10.1016/0167-4889(93)90212-8; LANE RD, 1992, EXP CELL RES, V203, P5, DOI 10.1016/0014-4827(92)90033-5; Maki M., 1990, INTRACELLULAR CALCIU, P37; MARCH KL, 1993, CIRC RES, V72, P413, DOI 10.1161/01.RES.72.2.413; MELLGREN RL, 1988, BIOCHIM BIOPHYS ACTA, V954, P154, DOI 10.1016/0167-4838(88)90066-0; MELLGREN RL, 1994, EXP CELL RES, V215, P164, DOI 10.1006/excr.1994.1328; MELLGREN RL, 1980, FEBS LETT, V109, P129, DOI 10.1016/0014-5793(80)81326-3; MELLGREN RL, 1987, FASEB J, V1, P110, DOI 10.1096/fasebj.1.2.2886390; MOLINARI M, 1994, J BIOL CHEM, V269, P27992; MOLINARI M, 1995, J BIOL CHEM, V270, P14576, DOI 10.1074/jbc.270.24.14576; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; MURACHI T, 1981, BIOCHEM INT, V2, P651; NAGAO S, 1994, J BIOCHEM, V115, P1178, DOI 10.1093/oxfordjournals.jbchem.a124476; RESING KA, 1993, J BIOL CHEM, V268, P25139; SAIDO TC, 1992, J BIOCHEM, V111, P81, DOI 10.1093/oxfordjournals.jbchem.a123723; SAIDO TC, 1994, FASEB J, V8, P814, DOI 10.1096/fasebj.8.11.8070630; SAMIS JA, 1987, BIOCHEM J, V246, P481, DOI 10.1042/bj2460481; SCHOLLMEYER JE, 1988, SCIENCE, V240, P911, DOI 10.1126/science.2834825; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SORIMACHI H, 1994, FEBS LETT, V343, P1, DOI 10.1016/0014-5793(94)80595-4; SUZUKI K, 1987, TRENDS BIOCHEM SCI, V12, P103, DOI 10.1016/0968-0004(87)90048-X; SUZUKI K, 1988, ADV ENZYME REGUL, V27, P153; WANG KKW, 1989, BIOCHEM J, V262, P693, DOI 10.1042/bj2620693; WANG KKW, 1994, TRENDS PHARMACOL SCI, V15, P412, DOI 10.1016/0165-6147(94)90090-6	33	73	77	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18825	18830		10.1074/jbc.271.31.18825	http://dx.doi.org/10.1074/jbc.271.31.18825			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702541	Green Submitted, hybrid			2022-12-25	WOS:A1996VB68300079
J	Wang, XN; Coons, LB; Taylor, DB; Stevens, ES; Gartner, TK				Wang, XN; Coons, LB; Taylor, DB; Stevens, ES; Gartner, TK			Variabilin, a novel RGD-containing antagonist of glycoprotein IIb-IIIa and platelet aggregation inhibitor from the hard tick Dermacentor variabilis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; VONWILLEBRAND-FACTOR; ORNITHODOROS-MOUBATA; MONOCLONAL-ANTIBODY; FIBRINOGEN BINDING; ALPHA-SUBUNIT; VIPER VENOMS; GPIIB-IIIA; RECEPTOR; COMPLEX	A novel inhibitor of human platelet aggregation, named variabilin, was isolated from salivary glands of the hard tick Dermacentor variabilis using a combination of gel filtration and high pressure liquid chromatography, Variabilin was a potent antagonist of the fibrinogen receptor glycoprotein IIb-IIIa (GPIIb-IIIa; alpha(IIb)beta(3)) and the vitronectin receptor alpha(v) beta(3). Amino acid sequence analysis by Edman degradation revealed that it has 47 residues, with a molecular weight of 4968.5. Like many other naturally occurring antagonists of GPIIb-IIIa, variabilin contains the RGD (Arg-Gly-Asp) motif. However, unlike the RGD-containing antagonists of GPIIb-IIIa, the RGD sequence of variabilin is not positioned in a loop bracketed by cysteine residues, It has little sequence homology to the other known naturally occurring antagonists of GPIIb-IIIa, including the disintegrins from snakes, decorsin and ornatin from leeches, and disagregin from soft ticks. Variabilin is the first RGD containing antagonist isolated from ticks.	MEMPHIS UNIV,DEPT BIOL,DIV MOL SCI & MICROBIOL,MEMPHIS,TN 38152; ILLINOIS BENEDICTINE COLL,DEPT BIOL,LISLE,IL 60532	University of Memphis					NHLBI NIH HHS [HL 46152] Funding Source: Medline; NIAID NIH HHS [AI 33665] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL046152] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033665] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALDER M, 1991, Science (Washington D C), V253, P445; BEACHAM DA, 1992, J BIOL CHEM, V267, P3409; BENNETT JS, 1983, P NATL ACAD SCI-BIOL, V80, P2417, DOI 10.1073/pnas.80.9.2417; BENNETT JS, 1988, J BIOL CHEM, V263, P12948; BENNETT JS, 1979, J CLIN INVEST, V64, P1393, DOI 10.1172/JCI109597; BERLINER S, 1988, J BIOL CHEM, V263, P7500; Blobel Carl P., 1992, Current Opinion in Cell Biology, V4, P760; CHERESH DA, 1989, CELL, V58, P845; CHERNY RC, 1993, J BIOL CHEM, V268, P9725; COOKE RM, 1991, EUR J BIOCHEM, V202, P323, DOI 10.1111/j.1432-1033.1991.tb16379.x; DSOUZA SE, 1990, J BIOL CHEM, V265, P3440; FARRELL DH, 1992, P NATL ACAD SCI USA, V89, P10729, DOI 10.1073/pnas.89.22.10729; GARTNER TK, 1985, J BIOL CHEM, V260, P1891; GARTNER TK, 1993, THROMB RES, V71, P47; GOULD RJ, 1990, P SOC EXP BIOL MED, V195, P168, DOI 10.3181/00379727-195-43129B; HAAS TA, 1994, CURR OPIN CELL BIOL, V6, P656, DOI 10.1016/0955-0674(94)90091-4; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; IKEDA Y, 1991, J CLIN INVEST, V87, P1234, DOI 10.1172/JCI115124; KARCZEWSKI J, 1994, J BIOL CHEM, V269, P6702; KREZEL AM, 1994, SCIENCE, V264, P1944, DOI 10.1126/science.8009227; MARGUERIE GA, 1979, J BIOL CHEM, V254, P5357; MAZUR P, 1991, EUR J BIOCHEM, V202, P1073, DOI 10.1111/j.1432-1033.1991.tb16472.x; MCDOWELL RS, 1992, BIOCHEMISTRY-US, V31, P4766, DOI 10.1021/bi00135a004; NEWMAN PJ, 1985, BLOOD, V65, P227; PETERSON DM, 1987, BLOOD, V69, P625; PHILLIPS DR, 1992, METHOD ENZYMOL, V215, P244; PHILLIPS DR, 1988, BLOOD, V71, P831; PONCZ M, 1987, J BIOL CHEM, V262, P8476; SANTORO SA, 1987, CELL, V48, P867, DOI 10.1016/0092-8674(87)90083-3; SCARBOROUGH RM, 1991, J BIOL CHEM, V266, P9359; SCARBOROUGH RM, 1993, J BIOL CHEM, V268, P1058; SEYMOUR JL, 1990, J BIOL CHEM, V265, P10143; Sonenshine DE, 1991, BIOL TICKS, V1; SUZUKI S, 1987, J BIOL CHEM, V262, P14080; WAXMAN L, 1993, J BIOL CHEM, V268, P5445; WAXMAN L, 1990, SCIENCE, V248, P593, DOI 10.1126/science.2333510; YAMADA KM, 1991, J BIOL CHEM, V266, P12809; 1994, NEW ENGL J MED, V330, P956	38	74	84	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					17785	17790		10.1074/jbc.271.30.17785	http://dx.doi.org/10.1074/jbc.271.30.17785			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663513	hybrid			2022-12-25	WOS:A1996UY93500032
J	Capaccioli, S; Quattrone, A; Schiavone, N; Calastretti, A; Copreni, E; Bevilacqua, A; Canti, G; Gong, L; Morelli, S; Nicolin, A				Capaccioli, S; Quattrone, A; Schiavone, N; Calastretti, A; Copreni, E; Bevilacqua, A; Canti, G; Gong, L; Morelli, S; Nicolin, A			A bcl-2/IgH antisense transcript deregulates bcl-2 gene expression in human follicular lymphoma t(14;18) cell lines	ONCOGENE			English	Article						antisense RNA; hybrid RNA; synthetic oligonucleotides; apoptosis; bcl-2 regulation	MESSENGER-RNA DEGRADATION; FIBROBLAST GROWTH-FACTOR; 3' UNTRANSLATED REGION; AU-RICH SEQUENCES; C-MYC GENE; BURKITTS-LYMPHOMA; CHROMOSOMAL TRANSLOCATION; IN-VITRO; B-CELLS; GM-CSF	The 14;18 chromosome translocation, characteristic of most human follicular B-cell lymphomas, juxtaposes the bcl-2 gene with the IgH locus, creating a bcl-2/IgH hybrid gene, By mechanisms that are still under investigation, this event increases the cellular levels of the bcl-2 mRNA and thereby induces an overproduction of the antiapoptotic BCL-2 protein which is likely responsible for neoplastic transformation, In an effort to identify potential upregulators of bcl-2 activity in t(14;18) cells, we found, by strand-specific RT-PCR, a bcl-2 antisense transcript that is present in the t(14;18) DOHHZ and SU-DHL-4 but not in the t(14;18)-negative Raji and Jurkat lymphoid cell lines, and thus appears to be dependent on the bcl-2/IgH fusion, This antisense transcript is a hybrid bcl-2/IgH RNA, that originates in the IgH locus, encompasses the t(14;18) fusion site and spans at least the complete 3' UTR region of the bcl-2 mRNA, To achieve some insight into its biological function, we treated the t(14;18) DOHH2 cell line with oligonucleotides (ODNs) by specifically targeting the bcl-2/IgH antisense strand, These ODNs lowered bcl-2 gene expression, inhibited neoplastic cell growth by inducing apoptosis, We would like to propose the hypothesis that the bcl-2/IgH antisense transcript may contribute, by an unknown mechanism, to upregulation of bcl-2 gene expression in t(14;18) cells. The possibility has been considered that the hybrid antisense transcript mask AU-rich motifs present in the 3' UTR of the bcl-2 mRNA characterized in other genes as mRNA destabilizing elements.	SCH MED, DEPT PHARMACOL, I-20129 MILAN, ITALY; UNIV FLORENCE, INST GEN PATHOL, I-50134 FLORENCE, ITALY	University of Florence			Bevilacqua, Annamaria/C-6357-2008	Bevilacqua, Annamaria/0000-0002-3136-3424; Quattrone, Alessandro/0000-0003-3333-7630; Schiavone, Nicola/0000-0002-1592-4244				ADAMS JM, 1991, SCIENCE, V254, P1161, DOI 10.1126/science.1957168; AIELLO A, 1992, CYTOMETRY, V13, P502, DOI 10.1002/cyto.990130509; AIELLO A, 1990, HEMATOL ONCOL, V8, P229, DOI 10.1002/hon.2900080407; APEL TW, 1992, ONCOGENE, V7, P1267; ASSONBATRES MA, 1994, ANN NY ACAD SCI, V712, P34, DOI 10.1111/j.1749-6632.1994.tb33560.x; BICKEL M, 1992, P NATL ACAD SCI USA, V89, P10001, DOI 10.1073/pnas.89.21.10001; BREWER G, 1988, MOL CELL BIOL, V8, P1697, DOI 10.1128/MCB.8.4.1697; CAPACCIOLI S, 1993, BIOCHEM BIOPH RES CO, V197, P818, DOI 10.1006/bbrc.1993.2552; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; CARBONARI M, 1994, BLOOD, V83, P1268; CELANO P, 1992, J BIOL CHEM, V267, P15092; CHENLEVY Z, 1989, MOL CELL BIOL, V9, P701, DOI 10.1128/MCB.9.2.701; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; CORNELISSEN M, 1989, NUCLEIC ACIDS RES, V17, P7203, DOI 10.1093/nar/17.18.7203; CORY S, 1986, ADV CANCER RES, V47, P189, DOI 10.1016/S0065-230X(08)60200-6; COTTER FE, 1994, ONCOGENE, V9, P3049; DALLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P7824, DOI 10.1073/pnas.79.24.7824; DELIA D, 1993, CANCER RES, V53, P6036; DENIZOT F, 1986, J IMMUNOL METHODS, V89, P271, DOI 10.1016/0022-1759(86)90368-6; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; GESSANI S, 1993, VIROLOGY, V193, P507, DOI 10.1006/viro.1993.1154; GRANINGER WB, 1987, J CLIN INVEST, V80, P1512, DOI 10.1172/JCI113235; GREENBERG ME, 1990, ENZYME, V44, P181, DOI 10.1159/000468756; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; HALDAR S, 1994, CANCER RES, V54, P2095; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; JACOB CO, 1993, NUCLEIC ACIDS RES, V21, P2761, DOI 10.1093/nar/21.11.2761; JACOBSON MD, 1993, NATURE, V361, P365, DOI 10.1038/361365a0; JOCHUM C, 1990, J VIROL, V64, P1956, DOI 10.1128/JVI.64.5.1956-1963.1990; KHOCHBIN S, 1992, ANN NY ACAD SCI, V660, P77, DOI 10.1111/j.1749-6632.1992.tb21060.x; KIMELMAN D, 1989, CELL, V59, P687, DOI 10.1016/0092-8674(89)90015-9; KITADA S, 1994, ANTISENSE RES DEV, V4, P71, DOI 10.1089/ard.1994.4.71; Kitada S, 1993, Antisense Res Dev, V3, P157; KLUINNELEMANS HC, 1991, LEUKEMIA, V5, P221; KNEBA M, 1991, CANCER RES, V51, P3243; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; KORSMEYER SJ, 1990, CURR TOP MICROBIOL, V166, P203; KRYSTAL GW, 1990, MOL CELL BIOL, V10, P4180, DOI 10.1128/MCB.10.8.4180; LENOIR GM, 1982, NATURE, V298, P474, DOI 10.1038/298474a0; LERNER A, 1993, J IMMUNOL, V151, P3152; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MIYASHITA T, 1994, CANCER RES, V54, P3131; MUNIR MI, 1992, ANTISENSE RNA PRODUC; MURPHY PR, 1994, MOL ENDOCRINOL, V8, P852, DOI 10.1210/me.8.7.852; NELLEN W, 1993, TRENDS BIOCHEM SCI, V18, P419, DOI 10.1016/0968-0004(93)90137-C; NG SY, 1985, MOL CELL BIOL, V5, P2720, DOI 10.1128/MCB.5.10.2720; NOGUCHI M, 1994, J BIOL CHEM, V269, P29161; NOWELL PC, 1987, DEV RECOGNITION TRAN; NUNEZ G, 1990, J IMMUNOL, V144, P3602; PEPPEL K, 1991, J EXP MED, V173, P349, DOI 10.1084/jem.173.2.349; PETERSON JA, 1993, NUCLEIC ACIDS RES, V21, P5500, DOI 10.1093/nar/21.23.5500; PEZZELLA F, 1990, AM J PATHOL, V137, P225; POLACK A, 1993, EMBO J, V12, P3913, DOI 10.1002/j.1460-2075.1993.tb06069.x; QUATTRONE A, 1995, CANCER RES, V55, P90; RAVETCH JV, 1981, CELL, V27, P583, DOI 10.1016/0092-8674(81)90400-1; RAYMOND V, 1989, ONCOGENE RES, V5, P1; REED JC, 1989, ONCOGENE RES, V4, P271; REED JC, 1990, CANCER RES, V50, P6565; RIVKIN M, 1993, MOL REPROD DEV, V35, P394, DOI 10.1002/mrd.1080350413; ROWLEY JD, 1990, CANCER RES, V50, P3816; ROY N, 1992, NUCLEIC ACIDS RES, V20, P5753, DOI 10.1093/nar/20.21.5753; SCHULER GD, 1988, CELL, V55, P1115, DOI 10.1016/0092-8674(88)90256-5; SELVAKUMARAN M, 1994, ONCOGENE, V9, P1791; SETO M, 1988, EMBO J, V7, P123, DOI 10.1002/j.1460-2075.1988.tb02791.x; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHIANG R, 1993, AM J HUM GENET, V53, P836; SILVERMAN TA, 1992, J BIOL CHEM, V267, P9738; SPICER DB, 1992, MOL CELL BIOL, V12, P1324, DOI 10.1128/MCB.12.3.1324; STANBRIDGE EJ, 1990, CELL, V63, P867, DOI 10.1016/0092-8674(90)90490-6; TAYLOR ER, 1991, J MOL ENDOCRINOL, V7, P145, DOI 10.1677/jme.0.0070145; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VOLK R, 1989, EMBO J, V8, P2983, DOI 10.1002/j.1460-2075.1989.tb08448.x; WAGNER RW, 1994, NATURE, V372, P333, DOI 10.1038/372333a0; WEISS A, 1984, J EXP MED, V160, P1284, DOI 10.1084/jem.160.5.1284; WHITTEMORE LA, 1990, P NATL ACAD SCI USA, V87, P7799, DOI 10.1073/pnas.87.20.7799; WILSON T, 1988, NATURE, V336, P396, DOI 10.1038/336396a0; ZHOU BS, 1992, CANCER RES, V52, P4280; ZUNIGA A, 1993, DEV BIOL, V157, P110, DOI 10.1006/dbio.1993.1116	80	59	64	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 4	1996	13	1					105	115						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UX319	8700536				2022-12-25	WOS:A1996UX31900012
J	Banerjee, A; Barry, VA; DasGupta, BR; Martin, TFJ				Banerjee, A; Barry, VA; DasGupta, BR; Martin, TFJ			N-ethylmaleimide-sensitive factor acts at a profusion ATP-dependent step in Ca2+-activated exocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-PROTEIN INTERACTIONS; ADRENAL CHROMAFFIN CELLS; NSF ATTACHMENT PROTEINS; MEMBRANE-FUSION COMPLEX; IN-VITRO; SECRETION; TRANSPORT; SYNTAXIN; DOCKING	An ATP-dependent activity of NSF (N-ethylmaleimide-sensitive factor) that rearranges soluble NSF attachment protein (SNAP) receptor (SNARE) protein complexes was proposed to be the driving force for membrane fusion. The Ca2+-activated fusion of secretory vesicles with the plasma membrane in permeable PC12 cells requires ATP; however, the ATP requirement is for a priming step that precedes the Ca2+-triggered fusion reaction. While phosphoinositide phosphorylation is a key reaction required for priming, additional ATP-dependent reactions are also necessary. Here we report that the NSF-catalyzed rearrangement of SNARE protein complexes occurs during ATP-dependent priming, NSF with alpha-SNAP (soluble NSF attachment protein) were required for ATP-dependent priming but not Ca2+-triggered fusion, indicating that NSF acts at an ATP-dependent prefusion step rather than at fusion itself. NSF-catalyzed activation of SNARE proteins may reorganize membranes to generate a vesicle-plasma membrane prefusion intermediate that is poised for conversion to full fusion by Ca2+-dependent mechanisms.	UNIV WISCONSIN,DEPT BIOCHEM,MADISON,WI 53706; UNIV WISCONSIN,DEPT FOOD MICROBIOL & TOXICOL,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK025861, R37DK025861, R01DK040428] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS017742] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK40428, DK25861] Funding Source: Medline; NINDS NIH HHS [NS17742] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BAJJALIEH SM, 1995, J BIOL CHEM, V270, P1971, DOI 10.1074/jbc.270.5.1971; BLOCK MR, 1988, P NATL ACAD SCI USA, V85, P7852, DOI 10.1073/pnas.85.21.7852; DEBELLO WM, 1995, NATURE, V373, P626, DOI 10.1038/373626a0; HANSON PI, 1995, J BIOL CHEM, V270, P16955, DOI 10.1074/jbc.270.28.16955; HAY JC, 1993, NATURE, V366, P572, DOI 10.1038/366572a0; HAY JC, 1992, J CELL BIOL, V119, P139, DOI 10.1083/jcb.119.1.139; HAY JC, 1995, NATURE, V374, P173, DOI 10.1038/374173a0; HAYASHI T, 1995, EMBO J, V14, P2317, DOI 10.1002/j.1460-2075.1995.tb07226.x; HAYASHI T, 1994, EMBO J, V13, P5051, DOI 10.1002/j.1460-2075.1994.tb06834.x; HOLZ RW, 1989, J BIOL CHEM, V264, P5412; JAHN R, 1994, ANNU REV NEUROSCI, V17, P219, DOI 10.1146/annurev.ne.17.030194.001251; KEE Y, 1995, NEURON, V14, P991, DOI 10.1016/0896-6273(95)90337-2; KEMBLE GW, 1994, CELL, V76, P383, DOI 10.1016/0092-8674(94)90344-1; Martin Thomas F. J., 1994, Current Opinion in Neurobiology, V4, P626, DOI 10.1016/0959-4388(94)90002-7; MORGAN A, 1994, J BIOL CHEM, V269, P29347; MORGAN A, 1995, TRENDS CELL BIOL, V5, P335, DOI 10.1016/S0962-8924(00)89059-5; MORGAN A, 1995, EMBO J, V14, P232, DOI 10.1002/j.1460-2075.1995.tb06996.x; OCONNOR V, 1994, CELL, V76, P785, DOI 10.1016/0092-8674(94)90352-2; PALLANCK L, 1995, NATURE, V376, P25, DOI 10.1038/376025a0; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SCHAFER T, 1987, BIOSCIENCE REP, V7, P269, DOI 10.1007/BF01121448; SCHIAVO G, 1995, NATURE, V378, P733, DOI 10.1038/378733a0; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; WALENT JH, 1992, CELL, V70, P765, DOI 10.1016/0092-8674(92)90310-9	26	187	189	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20223	20226		10.1074/jbc.271.34.20223	http://dx.doi.org/10.1074/jbc.271.34.20223			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702750	hybrid			2022-12-25	WOS:A1996VD33700002
J	Buczylko, J; Saari, JC; Crouch, RK; Palczewski, K				Buczylko, J; Saari, JC; Crouch, RK; Palczewski, K			Mechanisms of opsin activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFORM INFRARED-SPECTROSCOPY; SCHIFF-BASE COUNTERION; CONSTITUTIVELY ACTIVE MUTANTS; VISUAL PIGMENT ANALOGS; ROD OUTER SEGMENT; METARHODOPSIN-II; BOVINE RHODOPSIN; TRANSDUCIN ACTIVATION; G-PROTEIN; SUBSTRATE-SPECIFICITY	Rhodopsin is constrained in an inactive conformation by interactions with 11-cis-retinal including formation of a protonated Schiff base with Lys(296). Upon photoisomerization, major structural rearrangements that involve protonation of the active site Glu(113) and cytoplasmic acidic residues, including Glu(134), lead to the formation of the active form of the receptor, metarhodopsin II b, which decays to opsin. However, an activated receptor may be generated without illumination by addition of all-trans-retinal or its analogues to opsin, as measured in this study by the increased phosphorylation of opsin by rhodopsin kinase, The potency of stimulation depended on the chemical and isomeric nature of the analogues and the length of the polyene chain with all-trans-C17 aldehyde and all-trans-retinal being the most active and trans-C12 aldehyde being the least active. Certain cis-isomers, 11-cis-13-demethyl-retinal and 9-cis-C17 aldehyde, were also active. Most of the retinal analogues tested did not regenerate a spectrally identifiable pigment, and many were incapable of Schiff base formation (ketone, stable oximes, and Schiff base-derivatives of retinal), Thus, receptor activation resulted from formation of non-covalent complexes with opsin. pH titrations suggested that an equilibrium exists between partially active (protonated) and inactive (deprotonated) forms of opsin, These findings are consistent with a model in which protonation of one or more cytoplasmic carboxyl groups of opsin is essential for activity. Upon addition of retinoids, the partially active conformation of opsin is converted to a more active intermediate similar to metarhodopsin II b. The model provides an understanding of the structural requirements for opsin activation and an interpretation of the observed activities of natural and experimental opsin mutants.	UNIV WASHINGTON, SCH MED, DEPT BIOCHEM, SEATTLE, WA 98195 USA; UNIV WASHINGTON, SCH MED, DEPT PHARMACOL, SEATTLE, WA 98195 USA; MED UNIV S CAROLINA, DEPT OPHTHALMOL, CHARLESTON, SC 29425 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Medical University of South Carolina	Buczylko, J (corresponding author), UNIV WASHINGTON, SCH MED, DEPT OPHTHALMOL, BOX 356485, SEATTLE, WA 98195 USA.				NEI NIH HHS [EY08161, EY04939, EY02317] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY004939, R43EY008161] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ARNIS S, 1995, BIOCHEMISTRY-US, V34, P9333, DOI 10.1021/bi00029a008; ARNIS S, 1993, P NATL ACAD SCI USA, V90, P7849, DOI 10.1073/pnas.90.16.7849; ARNIS S, 1994, J BIOL CHEM, V269, P23879; BENNETT N, 1980, EUR J BIOCHEM, V111, P99; BOWNDS D, 1967, NATURE, V216, P1178, DOI 10.1038/2161178a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COHEN GB, 1992, BIOCHEMISTRY-US, V31, P12592, DOI 10.1021/bi00165a008; COHEN GB, 1993, BIOCHEMISTRY-US, V32, P6111, DOI 10.1021/bi00074a024; COOPER A, 1981, FEBS LETT, V123, P324, DOI 10.1016/0014-5793(81)80319-5; CORNWALL MC, 1995, J GEN PHYSIOL, V106, P543, DOI 10.1085/jgp.106.3.543; CORNWALL MC, 1990, J GEN PHYSIOL, V96, P345, DOI 10.1085/jgp.96.2.345; CORSON DW, 1994, P NATL ACAD SCI USA, V91, P6958, DOI 10.1073/pnas.91.15.6958; CORSON DW, 1990, P NATL ACAD SCI USA, V87, P6823, DOI 10.1073/pnas.87.17.6823; Corson DW, 1996, PHOTOCHEM PHOTOBIOL, V63, P595, DOI 10.1111/j.1751-1097.1996.tb05661.x; DOUKAS AG, 1978, BIOCHEMISTRY-US, V17, P2430, DOI 10.1021/bi00605a028; EBREY T, 1980, FEBS LETT, V116, P217, DOI 10.1016/0014-5793(80)80647-8; FAHMY K, 1995, BIOPHYS CHEM, V56, P171, DOI 10.1016/0301-4622(95)00030-2; FAHMY K, 1993, P NATL ACAD SCI USA, V90, P10206, DOI 10.1073/pnas.90.21.10206; FAHMY K, 1993, BIOCHEMISTRY-US, V32, P9165, DOI 10.1021/bi00086a023; FAHMY K, 1994, BIOCHEMISTRY-US, V33, P13700, DOI 10.1021/bi00250a021; FLOCCO MW, 1995, J MOL BIOL, V254, P96, DOI 10.1006/jmbi.1995.0602; FUKADA Y, 1981, BIOCHIM BIOPHYS ACTA, V675, P195, DOI 10.1016/0304-4165(81)90226-9; GANTER UM, 1989, BIOCHEMISTRY-US, V28, P5954, DOI 10.1021/bi00440a036; GANTER UM, 1991, BIOPHYS J, V59, P640, DOI 10.1016/S0006-3495(91)82279-2; GOVARDHAN CP, 1994, J BIOL CHEM, V269, P6524; Granit R, 1939, J PHYSIOL-LONDON, V96, P31, DOI 10.1113/jphysiol.1939.sp003755; HAN M, 1995, BIOPHYS CHEM, V56, P23, DOI 10.1016/0301-4622(95)00011-L; HARGRAVE PA, 1993, BIOESSAYS, V15, P43, DOI 10.1002/bies.950150107; HARGRAVE PA, 1983, BIOPHYS STRUCT MECH, V9, P235, DOI 10.1007/BF00535659; HOFMANN KP, 1992, J BIOL CHEM, V267, P15701; HONIG B, 1979, P NATL ACAD SCI USA, V76, P2503, DOI 10.1073/pnas.76.6.2503; HUBBARD R, 1971, METHOD ENZYMOL, V33, P615; JAGER F, 1994, BIOCHEMISTRY-US, V33, P7389; JAGER F, 1994, BIOCHEMISTRY-US, V33, P10878; Jager S, 1996, BIOCHEMISTRY-US, V35, P2901, DOI 10.1021/bi9524068; JENTOFT N, 1983, METHOD ENZYMOL, V91, P570; JIN J, 1993, NEURON, V11, P513, DOI 10.1016/0896-6273(93)90155-K; JONES GJ, 1989, P NATL ACAD SCI USA, V86, P9606, DOI 10.1073/pnas.86.23.9606; JONES GJ, 1993, J GEN PHYSIOL, V102, P483, DOI 10.1085/jgp.102.3.483; KIBELBEK J, 1991, BIOCHEMISTRY-US, V30, P6761, DOI 10.1021/bi00241a019; KROPF A, 1973, EXP EYE RES, V17, P591, DOI 10.1016/0014-4835(73)90088-2; LACY M, 1992, VISION RES, V22, P1451; LAMOLA AA, 1974, BIOCHEMISTRY-US, V13, P738, DOI 10.1021/bi00701a016; LEWIS JW, 1992, J BIOENERG BIOMEMBR, V24, P201, DOI 10.1007/BF00762678; LIN SW, 1992, BIOCHEMISTRY-US, V31, P5105, DOI 10.1021/bi00137a003; LITMAN BJ, 1982, METHOD ENZYMOL, V81, P150; LONGSTAFF C, 1985, BIOCHEMISTRY-US, V24, P8137, DOI 10.1021/bi00348a045; LONGSTAFF C, 1986, P NATL ACAD SCI USA, V83, P4209, DOI 10.1073/pnas.83.12.4209; MORRISON DF, 1995, J BIOL CHEM, V270, P6718, DOI 10.1074/jbc.270.12.6718; NELSON R, 1970, P NATL ACAD SCI USA, V66, P531, DOI 10.1073/pnas.66.2.531; OHGURO H, 1994, PROTEIN SCI, V3, P2428, DOI 10.1002/pro.5560031226; Ohguro H, 1996, J BIOL CHEM, V271, P5215; PALCZEWSKI K, 1994, BIOCHEMISTRY-US, V33, P13741, DOI 10.1021/bi00250a027; PALCZEWSKI K, 1988, BIOCHEMISTRY-US, V27, P2306, DOI 10.1021/bi00407a010; PALCZEWSKI K, 1994, PROTEIN SCI, V3, P1355, DOI 10.1002/pro.5560030901; PALCZEWSKI K, 1993, METH NEUROSCI, V15, P217; QUINTANA DG, 1995, BIOPHYS J, V69, P1077, DOI 10.1016/S0006-3495(95)79981-7; RAO MJ, 1994, METHOD ENZYMOL, V231, P246; RESEK JF, 1993, BIOCHEMISTRY-US, V32, P12025, DOI 10.1021/bi00096a012; RIM J, 1995, BIOCHEMISTRY-US, V34, P11938, DOI 10.1021/bi00037a035; ROBINSON PR, 1994, P NATL ACAD SCI USA, V91, P5411, DOI 10.1073/pnas.91.12.5411; ROBINSON PR, 1992, NEURON, V9, P719, DOI 10.1016/0896-6273(92)90034-B; SAARI JC, 1993, ANAL BIOCHEM, V213, P128, DOI 10.1006/abio.1993.1395; SAKMAR TP, 1991, P NATL ACAD SCI USA, V88, P3079, DOI 10.1073/pnas.88.8.3079; SAKMAR TP, 1989, P NATL ACAD SCI USA, V86, P8309, DOI 10.1073/pnas.86.21.8309; SHICHIDA Y, 1981, BIOCHEMISTRY-US, V20, P1962, DOI 10.1021/bi00510a035; STEINBERG G, 1993, BIOPHYS J, V64, P1499, DOI 10.1016/S0006-3495(93)81518-2; SURYA A, 1995, J BIOL CHEM, V270, P5024, DOI 10.1074/jbc.270.10.5024; TOKUNAGA F, 1977, BIOPHYS J, V19, P191, DOI 10.1016/S0006-3495(77)85580-X; TOWNER P, 1981, EUR J BIOCHEM, V117, P353, DOI 10.1111/j.1432-1033.1981.tb06345.x; VANDENTEMPEL PJ, 1966, TETRAHEDRON, V46, P233; VANKUIJK FJGM, 1985, J CHROMATOGR, V348, P241, DOI 10.1016/S0021-9673(01)92458-6; VONISLER O, 1956, HELV CHIM ACTA, V39, P259; WALLIN E, 1995, PROTEIN ENG, V8, P693, DOI 10.1093/protein/8.7.693; WEITZ CJ, 1993, BIOCHEMISTRY-US, V32, P14176, DOI 10.1021/bi00214a016; WEITZ CJ, 1992, NEURON, V8, P465, DOI 10.1016/0896-6273(92)90274-H; ZHUKOVSKY EA, 1991, SCIENCE, V251, P558, DOI 10.1126/science.1990431; ZHUKOVSKY EA, 1989, SCIENCE, V246, P928, DOI 10.1126/science.2573154; ZHUKOVSKY EA, 1992, BIOCHEMISTRY-US, V31, P10400, DOI 10.1021/bi00157a030; ZVYAGA TA, 1994, BIOCHEMISTRY-US, V33, P9753, DOI 10.1021/bi00198a046	80	92	99	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20621	20630		10.1074/jbc.271.34.20621	http://dx.doi.org/10.1074/jbc.271.34.20621			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702809	hybrid			2022-12-25	WOS:A1996VD33700061
J	Arion, D; Borkow, G; Gu, ZG; Wainberg, MA; Parniak, MA				Arion, D; Borkow, G; Gu, ZG; Wainberg, MA; Parniak, MA			The K65R mutation confers increased DNA polymerase processivity to HIV-1 reverse transcriptase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; TEMPLATE; BINDING; INHIBITION; RESISTANCE; 3'-AZIDO-3'-DEOXYTHYMIDINE; 5'-TRIPHOSPHATE; TERMINATION; MECHANISM; SUBSTRATE	The K65R mutation in HIV-1 reverse transcriptase (RT) is associated with viral cross-resistance to 2',3'-dideoxyinosine, 2',3'-dideoxycytidine, and 2',3'-dideoxy-3'-thiacytidine. We have found that in vitro DNA synthesis by K65R RT is significantly more processive than that of wild type (wt) RT. Depending on the template/ primer (T/P) used, the total incorporation of nucleotides under single processive cycle conditions was 20-50% higher with K65R RT than with wt RT. With heteropolymeric T/P, the total incorporation of dNMP by K65R and wt RT was similar under continuous DNA synthesis reaction conditions. However, under single processive cycle conditions, the rate of full-length polymerization product synthesis by K65R RT was about S-fold higher than that by wt RT. We also found a decreased rate of T/P dissociation during K65R RT DNA synthesis, which is consistent with the increased processivity of the enzyme. We postulate that the increased processivity of the R65R RT may be a compensatory response to the decreased affinity of this mutant for certain dNTP substrates, allowing normal viral replication kinetics.	SMBD JGH,LADY DAVIS INST MED RES,MONTREAL,PQ H3T 1E2,CANADA; MCGILL UNIV,AIDS CTR,SIR MORTIMER B DAVIS JEWISH GEN HOSP,MONTREAL,PQ H3T 1E2,CANADA	Lady Davis Institute; McGill University; McGill University			Borkow, Gadi/W-4294-2019					ABBOTTS J, 1993, J BIOL CHEM, V268, P10312; ARTS EJ, 1994, J BIOL CHEM, V269, P14672; BOYER PL, 1994, P NATL ACAD SCI USA, V91, P4882, DOI 10.1073/pnas.91.11.4882; BOYER PL, 1995, ANTIMICROB AGENTS CH, V39, P1624, DOI 10.1128/AAC.39.7.1624; Caliendo AM, 1996, J VIROL, V70, P2146, DOI 10.1128/JVI.70.4.2146-2153.1996; CHENG N, 1993, BIOCHEMISTRY-US, V32, P7630, DOI 10.1021/bi00081a005; DECLERCQ E, 1994, BIOCHEM PHARMACOL, V47, P155, DOI 10.1016/0006-2952(94)90001-9; DESTEFANO JJ, 1992, BIOCHIM BIOPHYS ACTA, V1131, P270, DOI 10.1016/0167-4781(92)90025-U; DUBE DK, 1976, BIOCHEMISTRY-US, V15, P3605, DOI 10.1021/bi00661a031; Fletcher RS, 1996, PROTEIN EXPRES PURIF, V7, P27, DOI 10.1006/prep.1996.0004; FURMAN PA, 1986, P NATL ACAD SCI USA, V83, P8333, DOI 10.1073/pnas.83.21.8333; GOODY RS, 1991, FEBS LETT, V291, P1, DOI 10.1016/0014-5793(91)81089-Q; GU ZX, 1995, P NATL ACAD SCI USA, V92, P2760, DOI 10.1073/pnas.92.7.2760; GU ZX, 1994, J BIOL CHEM, V269, P28118; GU ZX, 1994, ANTIMICROB AGENTS CH, V38, P275, DOI 10.1128/AAC.38.2.275; HUBER HE, 1989, J BIOL CHEM, V264, P4669; KLARMANN GJ, 1993, J BIOL CHEM, V268, P9793; MAJUMDAR C, 1988, J BIOL CHEM, V263, P15657; REARDON JE, 1990, J BIOL CHEM, V265, P20302; RICHMAN DD, 1993, ANNU REV PHARMACOL, V33, P149, DOI 10.1146/annurev.pa.33.040193.001053; SARAFIANOS SG, 1995, BIOCHEMISTRY-US, V34, P7207, DOI 10.1021/bi00021a036; TANTILLO C, 1994, J MOL BIOL, V243, P369, DOI 10.1006/jmbi.1994.1665; TRAUT TW, 1994, MOL CELL BIOCHEM, V140, P1, DOI 10.1007/BF00928361; WILLIAMS KJ, 1990, J BIOL CHEM, V265, P18682; WU J, 1993, J BIOL CHEM, V268, P9980	25	47	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					19860	19864		10.1074/jbc.271.33.19860	http://dx.doi.org/10.1074/jbc.271.33.19860			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702696	hybrid			2022-12-25	WOS:A1996VC66900037
J	Ekena, K; Weis, KE; Katzenellenbogen, JA; Katzenellenbogen, BS				Ekena, K; Weis, KE; Katzenellenbogen, JA; Katzenellenbogen, BS			Identification of amino acids in the hormone binding domain of the human estrogen receptor important in estrogen binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER CELLS; TRANSCRIPTIONAL ACTIVATION; LIGAND-BINDING; CRYSTAL-STRUCTURE; PROMOTER-CONTEXT; MUTAGENESIS; ANTIESTROGENS; CYSTEINES; RESIDUES; MUTANTS	The initial step in the regulation of the transcriptional activity of the estrogen receptor (ER) is the binding of hormone, Previous studies have suggested that the region between amino acids 515 and 535 near the C terminus of the human ER is likely to be important in ligand binding. In order to explicitly define which amino acids in this region are critical for ligand recognition and binding, we have utilized alanine-scanning mutagenesis over the complete 515-535 region, The ability of these 21 mutants to activate transcription in response to the natural estrogen, 17 beta-estradiol (E(2)), was evaluated in cell co-transfection assays with estrogen-responsive reporter genes, In addition, their ability to bind E(2) was also tested. Mutations at four sites in the 521-528 region had the greatest effects on E(2)-induced transcription, with L525A reducing responsiveness 250-fold, G521A and H524A 35-fold, and M528A 11-fold. Mutations at other sites had either no effect or a 4-fold or lesser reduction in sensitivity to E(2) (M517A, Y526A, N532A, and P535A). Three of the mutants most affected in their transcriptional response, G521A, H524A, and M528A, showed a coordinate reduction in E(2) binding affinity, E(2) binding by the most affected mutant, L525A, could not be detected, Thus, the altered transcriptional response of these ER mutants appears to derive solely from an alteration in their affinity for the ligand E(2). The four sites most affected by alanine substitution, 521, 524, 525, and 528, follow an alpha-helical periodicity, such that they would be positioned on one face of an alpha-helix, Furthermore, they correspond precisely to residues in an alpha-helix shown to be in contact with ligand in the recently described x-ray crystal structures of two other members of the nuclear hormone receptor superfamily, namely the retinoic acid receptor- and thyroid hormone receptor-ligand complexes. Our findings, which broaden observations to the steroid receptor family within the superfamily of nuclear receptors, suggest that this region of the estrogen receptor is in contact with its cognate ligand in a similar fashion.	UNIV ILLINOIS, DEPT MOL & INTEGRAT PHYSIOL, URBANA, IL 61801 USA; UNIV ILLINOIS, DEPT CHEM, URBANA, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign					NATIONAL CANCER INSTITUTE [F32CA068653, R37CA018119] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK015556] Funding Source: NIH RePORTER; NCI NIH HHS [1 F32 CA68653, 2R37CA18119] Funding Source: Medline; NIDDK NIH HHS [2R37DK15556] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BERRY M, 1990, EMBO J, V9, P2811, DOI 10.1002/j.1460-2075.1990.tb07469.x; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; DANIELIAN PS, 1993, MOL ENDOCRINOL, V7, P232, DOI 10.1210/me.7.2.232; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FAWELL SE, 1990, CELL, V60, P953, DOI 10.1016/0092-8674(90)90343-D; FUJIMOTO N, 1994, MOL ENDOCRINOL, V8, P296, DOI 10.1210/me.8.3.296; GRONEMEYER H, 1991, ANNU REV GENET, V25, P89, DOI 10.1146/annurev.ge.25.120191.000513; HARLOW KW, 1989, J BIOL CHEM, V264, P17476; Katzenellenbogen BS, 1996, BIOL REPROD, V54, P287, DOI 10.1095/biolreprod54.2.287; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEES JA, 1990, MOL CELL BIOL, V10, P5529, DOI 10.1128/MCB.10.10.5529; MEAD DA, 1986, PROTEIN ENG, V1, P67, DOI 10.1093/protein/1.1.67; Montano MM, 1996, MOL ENDOCRINOL, V10, P230, DOI 10.1210/me.10.3.230; MONTANO MM, 1995, MOL ENDOCRINOL, V9, P814, DOI 10.1210/me.9.7.814; PAKDEL F, 1993, MOL ENDOCRINOL, V7, P1408, DOI 10.1210/me.7.11.1408; PAKDEL F, 1992, J BIOL CHEM, V267, P3429; READ LD, 1991, ADV CELLULAR MOL BIO, P277; REESE JC, 1992, MOL ENDOCRINOL, V6, P2160, DOI 10.1210/me.6.12.2160; REESE JC, 1991, J BIOL CHEM, V266, P10880; RENAUD JP, 1995, NATURE, V378, P681, DOI 10.1038/378681a0; Sarrel P.M., 1994, SCI MED, V1, P44; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; TRUSS M, 1993, ENDOCR REV, V14, P459, DOI 10.1210/er.14.4.459; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; TZUKERMAN MT, 1994, MOL ENDOCRINOL, V8, P21, DOI 10.1210/me.8.1.21; WAGNER RL, 1995, NATURE, V378, P690, DOI 10.1038/378690a0; WELLS JA, 1991, METHOD ENZYMOL, V202, P390; WRENN CK, 1990, MOL ENDOCRINOL, V4, P1647, DOI 10.1210/mend-4-11-1647; WRENN CK, 1993, J BIOL CHEM, V268, P24089; Wurtz JM, 1996, NAT STRUCT BIOL, V3, P87, DOI 10.1038/nsb0196-87	33	99	103	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					20053	20059		10.1074/jbc.271.33.20053	http://dx.doi.org/10.1074/jbc.271.33.20053			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702724	hybrid			2022-12-25	WOS:A1996VC66900065
J	Keith, DE; Murray, SR; Zaki, PA; Chu, PC; Lissin, DV; Kang, L; Evans, CJ; vonZastrow, M				Keith, DE; Murray, SR; Zaki, PA; Chu, PC; Lissin, DV; Kang, L; Evans, CJ; vonZastrow, M			Morphine activates opioid receptors without causing their rapid internalization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; NG108-15 HYBRID-CELLS; MU-OPIATE RECEPTOR; PHARMACOLOGICAL CHARACTERIZATION; INTRACELLULAR TRAFFICKING; ADRENERGIC-RECEPTOR; PHOSPHORYLATION; ENKEPHALIN; MEMBRANE; CLONING	We have examined the endocytic trafficking of epitope-tagged delta and mu opioid receptors expressed in human embryonic kidney (HEK) 293 cells, These receptors are activated by peptide agonists (enkephalins) as well as by the alkaloid agonist drugs etorphine and morphine. Enkephalins and etorphine cause opioid receptors to internalize rapidly (t(1/2) similar to 6 min) by a mechanism similar to that utilized by a number of other classes of receptor, as indicated by localization of internalized opioid receptors in transferrin-containing endosomes and inhibition of opioid receptor internalization by hypertonic media, Remarkably, morphine does not stimulate the rapid internalization of either delta or mu opioid receptors, even at high concentrations that strongly inhibit adenylyl cyclase, These data indicate that agonist ligands, which have similar effects on receptor-mediated signaling, can have dramatically different effects on the intracellular trafficking of a G protein-coupled receptor.	UNIV CALIF SAN FRANCISCO,DEPT PSYCHIAT,NINA IRELAND LAB,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT CELLULAR & MOLEC PHARMACOL,SAN FRANCISCO,CA 94143; UNIV CALIF LOS ANGELES,DEPT PSYCHIAT & BIOBEHAV SCI,LOS ANGELES,CA 90024	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California Los Angeles					NCI NIH HHS [CA-16042] Funding Source: Medline; NIDA NIH HHS [DA-00218, DA-05010, P50 DA005010] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016042] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [P50DA005010] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		ARDEN JR, 1995, J NEUROCHEM, V65, P1636; EVANS CJ, 1992, SCIENCE, V258, P1952, DOI 10.1126/science.1335167; FUKUDA K, 1995, FEBS LETT, V373, P177, DOI 10.1016/0014-5793(95)01034-C; GARLAND AM, 1994, BIOCHEM J, V303, P177, DOI 10.1042/bj3030177; GUAN XM, 1992, J BIOL CHEM, V267, P21995; HEUSER JE, 1989, J CELL BIOL, V108, P389, DOI 10.1083/jcb.108.2.389; HOXIE JA, 1993, J BIOL CHEM, V268, P13756; HUGHES J, 1977, BRIT MED BULL, V33, P157, DOI 10.1093/oxfordjournals.bmb.a071416; JASPER JR, 1992, BIOCHEM PHARMACOL, V43, P119, DOI 10.1016/0006-2952(92)90268-N; KAUFMAN DL, 1995, J BIOL CHEM, V270, P15877, DOI 10.1074/jbc.270.26.15877; KONG HY, 1993, J BIOL CHEM, V268, P23055; Kosterlitz H W, 1978, Adv Biochem Psychopharmacol, V18, P31; LAW PY, 1984, J BIOL CHEM, V259, P4096; LAW SK, 1982, P NATL ACAD SCI USA, V72, P1; LOUIE AK, 1988, BIOCHEM BIOPH RES CO, V152, P1369, DOI 10.1016/S0006-291X(88)80436-4; MESTEK A, 1995, J NEUROSCI, V15, P2396, DOI 10.1523/JNEUROSCI.15-03-02396.1995; METZGER TG, 1995, FEBS LETT, V375, P1, DOI 10.1016/0014-5793(95)01185-H; NESTLER EJ, 1993, CRIT REV NEUROBIOL, V7, P23; Okayama H, 1992, Biotechnology, V24, P270; PEI G, 1995, MOL PHARMACOL, V48, P173; RAYNOR K, 1994, MOL PHARMACOL, V45, P330; REINSCHEID RK, 1995, SCIENCE, V270, P792, DOI 10.1126/science.270.5237.792; SCHMID I, 1988, CYTOMETRY, V9, P533, DOI 10.1002/cyto.990090605; SMITH CFC, 1983, LIFE SCI, V33, P327, DOI 10.1016/0024-3205(83)90509-X; SURRATT CK, 1994, J BIOL CHEM, V269, P20548; TRAYNOR JR, 1995, MOL PHARMACOL, V47, P848; VONZASTROW M, 1994, J BIOL CHEM, V269, P18448; VONZASTROW M, 1992, J BIOL CHEM, V267, P3530; VONZASTROW M, 1994, REGUL PEPTIDES, V54, P315, DOI 10.1016/0167-0115(94)90516-9; VONZASTROW M, 1993, MOL PHARMACOL, V44, P166; WANG JB, 1994, FEBS LETT, V338, P217, DOI 10.1016/0014-5793(94)80368-4; YASUDA K, 1993, P NATL ACAD SCI USA, V90, P6736, DOI 10.1073/pnas.90.14.6736	32	462	471	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19021	19024		10.1074/jbc.271.32.19021	http://dx.doi.org/10.1074/jbc.271.32.19021			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702570	hybrid			2022-12-25	WOS:A1996VB68400004
J	Lavie, Y; Cao, HT; Bursten, SL; Giuliano, AE; Cabot, MC				Lavie, Y; Cao, HT; Bursten, SL; Giuliano, AE; Cabot, MC			Accumulation of glucosylceramides in multidrug-resistant cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPHINGOLIPID SYNTHESIS; P-GLYCOPROTEIN; TUMOR PROGRESSION; LEUKEMIA-CELLS; BIOSYNTHESIS; INHIBITION; SYNTHASE; MELANOMA; CERAMIDE; GENE	Multidrug-resistant (MDR) tumors and cancer cell lines demonstrate a wide variety of biochemical changes. In this study we used drug-sensitive wild-type (wt) cancer cell lines and respective MDR subclones, and we demonstrate the accumulation of distinct lipids in MDR cells. These lipids were either absent or present at very low levels in drug-sensitive cells. The compounds, termed lipid-1 and lipid-2, migrated on thin-layer chromatography as a doublet. They could be radiolabeled by incubating MCF-7-AdrR (Adriamycin-resistant) breast cancer cells with [H-3]serine, [H-3]palmitic acid, or [H-3]galactose. Utilization of these precursors by MCF-7-wt cells for synthesis of lipid-1 and -2 was minimal. Two inhibitors of sphingolipid biosynthesis, L-cycloserine and fumonisin B-1, prevented the observed accumulation of the lipid compounds. An inhibitor of glucosylceramide synthesis, 1-phenyl-2-palmitoylamino-3-morpholino-1-propanol, completely abolished the formation of lipid-1 and -2 in MCF-7-AdrR cells and, to a lesser extent, inhibited the formation of lactosylceramides and gangliosides. Utilizing mass spectrometry, the multidrug resistance-associated lipids were further characterized as monoglycosylceramides of two major species that contained either 16-carbon (palmitic) or 24-carbon (lignoceric and nervonic) fatty acids. The carbohydrate head group of glycosylceramides was identified as glucose, not galactose, thus designating the accumulated lipids as glucosylceramides. Incorporation of [H-3]palmitic acid into glucosylceramide was strikingly higher (8-10 times) in MCF-7-AdrR cells compared with MCF-7-wt cells. Since the rate of glucosylceramide degradation in MCF-7-AdrR cells was not attenuated, accelerated glycosphingolipid synthesis in MDR cells is suggested. Glucosylceramide also accumulated in KBV-1, a vinblastine-resistant epidermoid carcinoma but not in KB-3-1, drug-sensitive wt cells. MDR ovarian adenocarcinoma cells (NIH:OVCAR-3) also contained elevated levels of glucosylceramide. Our results demonstrate a correlation between cellular drug resistance and alterations in glucosylceramide metabolism.	ST JOHNS HOSP,JOHN WAYNE CANC INST,SANTA MONICA,CA 90404; CTR HLTH,SANTA MONICA,CA 90404	John Wayne Cancer Institute								ABE A, 1992, J BIOCHEM-TOKYO, V111, P191, DOI 10.1093/oxfordjournals.jbchem.a123736; ALAWQATI Q, 1995, SCIENCE, V269, P805, DOI 10.1126/science.7543697; BIEDLER JL, 1983, CANCER TREAT REP, V67, P859; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; BRADLEY G, 1994, CANCER METAST REV, V13, P223, DOI 10.1007/BF00689638; BRADLEY G, 1988, BIOCHIM BIOPHYS ACTA, V948, P87, DOI 10.1016/0304-419X(88)90006-6; CHERESH DA, 1984, P NATL ACAD SCI-BIOL, V81, P5767, DOI 10.1073/pnas.81.18.5767; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; DRESSLER KA, 1992, SCIENCE, V255, P1715, DOI 10.1126/science.1313189; FUKUDA MN, 1986, J BIOL CHEM, V261, P2376; FURUYA S, 1995, J NEUROCHEM, V65, P1551; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; GRABOWSKI GA, 1990, CRC CRIT REV BIOCH M, V25, P384; HAKOMORI SI, 1981, ANNU REV BIOCHEM, V50, P733, DOI 10.1146/annurev.bi.50.070181.003505; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; HAREL R, 1993, J BIOL CHEM, V268, P14476; HOLLERAN WM, 1986, CANCER CHEMOTH PHARM, V17, P11, DOI 10.1007/BF00299859; LEE KJ, 1985, CARBOHYD RES, V144, P148, DOI 10.1016/0008-6215(85)85015-1; MAHDIYOUN S, 1992, ARCH BIOCHEM BIOPHYS, V292, P506, DOI 10.1016/0003-9861(92)90023-P; MERRILL AH, 1986, J BIOL CHEM, V261, P3764; MORTON DL, 1994, PROG BRAIN RES, V101, P251; Nakamura S, 1996, J BIOL CHEM, V271, P1255, DOI 10.1074/jbc.271.3.1255; NILSSON O, 1982, J NEUROCHEM, V39, P709, DOI 10.1111/j.1471-4159.1982.tb07950.x; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; OLIVERA A, 1992, J BIOL CHEM, V267, P26121; RAMU A, 1984, CANCER TREAT REP, V68, P637; RANI CSS, 1995, J BIOL CHEM, V270, P2859, DOI 10.1074/jbc.270.6.2859; ROGAN AM, 1984, SCIENCE, V224, P994, DOI 10.1126/science.6372095; RUETZ S, 1994, CELL, V77, P1071, DOI 10.1016/0092-8674(94)90446-4; SABBATINI ARM, 1994, INT J CANCER, V59, P208, DOI 10.1002/ijc.2910590212; SCHWARZ A, 1995, J BIOL CHEM, V270, P10990, DOI 10.1074/jbc.270.18.10990; SHIMABUKU AM, 1992, J BIOL CHEM, V267, P4308; SUNDARAM KS, 1984, J NEUROCHEM, V42, P577, DOI 10.1111/j.1471-4159.1984.tb02716.x; TAKI T, 1986, J BIOL CHEM, V261, P3075; THURIN J, 1986, FEBS LETT, V208, P17, DOI 10.1016/0014-5793(86)81522-8; Vance DE., 1985, BIOCH LIPIDS MEMBRAN; VOLM M, 1993, CANCER, V71, P3981, DOI 10.1002/1097-0142(19930615)71:12<3981::AID-CNCR2820711231>3.0.CO;2-A; WANG E, 1991, J BIOL CHEM, V266, P14486; WELSH CJ, 1994, BIOCHEM BIOPH RES CO, V202, P211, DOI 10.1006/bbrc.1994.1914; WELSH CJ, 1994, ARCH BIOCHEM BIOPHYS, V315, P41, DOI 10.1006/abbi.1994.1468; WU WI, 1995, J BIOL CHEM, V270, P13171, DOI 10.1074/jbc.270.22.13171; YAN JP, 1995, J BIOL CHEM, V270, P22836, DOI 10.1074/jbc.270.39.22836	44	299	321	2	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19530	19536		10.1074/jbc.271.32.19530	http://dx.doi.org/10.1074/jbc.271.32.19530			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702646	hybrid			2022-12-25	WOS:A1996VB68400080
J	Minami, Y; Hohfeld, J; Ohtsuka, K; Hartl, FU				Minami, Y; Hohfeld, J; Ohtsuka, K; Hartl, FU			Regulation of the heat-shock protein 70 reaction cycle by the mammalian DnaJ homolog, Hsp40	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI DNAJ; NASCENT POLYPEPTIDE-CHAINS; SUBSTRATE-BINDING; ATPASE ACTIVITY; MOLECULAR CHAPERONE; PEPTIDE-BINDING; ENDOPLASMIC-RETICULUM; SECONDARY STRUCTURE; HSP70; TRANSLOCATION	The effects of the human DnaJ homolog, Hsp40, on the ATPase and chaperone functions of the constitutively expressed Hsp70 homolog, Hsc70, were analyzed. Hsp40 stimulates the hydrolysis of ATP by Hsc70, causing a similar to 7-fold increase in its steady-state ATPase activity, In contrast to the prokaryotic Hsp70 system, ATP-hydrolysis and not the release of bound ADP is the rate-limiting step in the overall ATPase cycle of mammalian Hsc70. The ability to activate the Hsc70 ATPase is partially preserved in a deletion mutant containing the J-domain and the G/F region of Hsp40 but not in a deletion mutant that contains the J-domain alone, As a result of its ATPase stimulating activity, addition of Hsp40 allows Hsc70 to bind peptide in the presence of ATP, whereas in the absence of Hsp40, peptide is efficiently released upon ATP binding to Hsc70. The functional cooperation of Hsp40 with Hsc70 is essential to ensure the ATP hydrolysis-dependent binding of aggregation-sensitive denatured polypeptides, such as thermally denatured firefly luciferase and chemically denatured rhodanese, Binding of these proteins results in the formation of ternary complexes of Hsc70, Hsp40, and substrates. Hsc70 and Hsp40 cooperate with further factors in protein renaturation, as demonstrated by the finding that luciferase, thermally denatured in the presence of Hsc70, Hsp40, and ATP, refolds upon addition of rabbit reticulocyte cytosol, Our results indicate that Hsp40 has a critical regulatory function in the Hsc70 ATPase cycle that is required for the efficient loading of peptide substrate onto Hsc70.	MEM SLOAN KETTERING CANC CTR,HOWARD HUGHES MED INST,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,CELLULAR BIOCHEM & BIOPHYS PROGRAM,NEW YORK,NY 10021; AICHI CANC CTR,RES INST,EXPTL RADIOL LAB,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN	Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Aichi Cancer Center			Hartl, F. Ulrich/Y-8206-2019		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048742] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 48742] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS MD, 1995, NATURE S, V77, P3; BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; BLONDELGUINDI S, 1993, CELL, V75, P717, DOI 10.1016/0092-8674(93)90492-9; BRIGHTMAN SE, 1995, GENE, V153, P249, DOI 10.1016/0378-1119(94)00741-A; BUCHBERGER A, 1995, J BIOL CHEM, V270, P16903, DOI 10.1074/jbc.270.28.16903; BUCHBERGER A, 1994, EMBO J, V13, P1687, DOI 10.1002/j.1460-2075.1994.tb06433.x; CHAPPELL TG, 1987, J BIOL CHEM, V262, P746; CHEETHAM ME, 1994, EUR J BIOCHEM, V226, P99, DOI 10.1111/j.1432-1033.1994.tb20030.x; CYR DM, 1995, FEBS LETT, V359, P129, DOI 10.1016/0014-5793(95)00024-4; CYR DM, 1994, TRENDS BIOCHEM SCI, V19, P176, DOI 10.1016/0968-0004(94)90281-X; CYR DM, 1994, J BIOL CHEM, V269, P9798; FLAHERTY KM, 1990, NATURE, V346, P623, DOI 10.1038/346623a0; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; FREEMAN BC, 1995, EMBO J, V14, P2281, DOI 10.1002/j.1460-2075.1995.tb07222.x; FRYDMAN J, 1994, NATURE, V370, P111, DOI 10.1038/370111a0; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GRAGEROV A, 1994, J MOL BIOL, V235, P848, DOI 10.1006/jmbi.1994.1043; GREENE LE, 1995, J BIOL CHEM, V270, P2967, DOI 10.1074/jbc.270.7.2967; HANSEN WJ, 1994, J BIOL CHEM, V269, P26610; Hendrick JP, 1995, FASEB J, V9, P1559, DOI 10.1096/fasebj.9.15.8529835; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HENDRICK JP, 1993, P NATL ACAD SCI USA, V90, P10216, DOI 10.1073/pnas.90.21.10216; HILL RB, 1995, BIOCHEMISTRY-US, V34, P5587, DOI 10.1021/bi00016a033; HOHFELD J, 1995, CELL, V83, P589; LANDRY SJ, 1992, NATURE, V355, P455, DOI 10.1038/355455a0; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LEVY EJ, 1995, FEBS LETT, V368, P435, DOI 10.1016/0014-5793(95)00704-D; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; LIBEREK K, 1991, J BIOL CHEM, V266, P14491; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MCCARTY JS, 1995, J MOL BIOL, V249, P126, DOI 10.1006/jmbi.1995.0284; MORGHAUSER RC, 1995, BIOCHEMISTRY-US, V24, P6261; OHTSUKA K, 1993, BIOCHEM BIOPH RES CO, V197, P235, DOI 10.1006/bbrc.1993.2466; PALLEROS DR, 1993, NATURE, V365, P664, DOI 10.1038/365664a0; QUIAN YQ, 1996, IN PRESS J MOL BIOL; SAMBROOK J, 1989, MOL CLONING LAB MOL; SANDERS SL, 1992, J BIOL CHEM, V267, P13791; SCHLENSTEDT G, 1995, J CELL BIOL, V129, P979, DOI 10.1083/jcb.129.4.979; SCHLOSSMAN DM, 1984, J CELL BIOL, V99, P723, DOI 10.1083/jcb.99.2.723; SCHMID D, 1994, SCIENCE, V263, P971, DOI 10.1126/science.8310296; SCHRODER H, 1993, EMBO J, V12, P4137, DOI 10.1002/j.1460-2075.1993.tb06097.x; STUART RA, 1994, TRENDS BIOCHEM SCI, V19, P87, DOI 10.1016/0968-0004(94)90041-8; Szabo A, 1996, EMBO J, V15, P408, DOI 10.1002/j.1460-2075.1996.tb00371.x; SZABO A, 1994, P NATL ACAD SCI USA, V91, P10345, DOI 10.1073/pnas.91.22.10345; SZYPERSKI T, 1994, P NATL ACAD SCI USA, V91, P11343, DOI 10.1073/pnas.91.24.11343; TANDON S, 1986, J BIOL CHEM, V261, P5615; UNGEWICKELL E, 1995, NATURE, V378, P632, DOI 10.1038/378632a0; WALL D, 1994, J BIOL CHEM, V269, P5446; WALL D, 1995, J BIOL CHEM, V270, P2139, DOI 10.1074/jbc.270.5.2139; WANG TF, 1993, J BIOL CHEM, V268, P26049; ZIEGELHOFFER T, 1995, J BIOL CHEM, V270, P10412, DOI 10.1074/jbc.270.18.10412	52	277	298	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19617	19624		10.1074/jbc.271.32.19617	http://dx.doi.org/10.1074/jbc.271.32.19617			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702658	hybrid			2022-12-25	WOS:A1996VB68400092
J	Nikitovic, D; Holmgren, A				Nikitovic, D; Holmgren, A			S-nitrosoglutathione is cleaved by the thioredoxin system with liberation of glutathione and redox regulating nitric oxide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN NEUTROPHILS; OXIDATION; REDUCTASE; CYSTEINE; NITROSO; SELENODIGLUTATHIONE; NITROSYLATION; ACTIVATION; MECHANISM; RESIDUES	In activated human neutrophils a burst of nitric oxide (NO) converts intracellular GSH to S-nitrosoglutathione (GSNO) which is subsequently cleaved to restore GSH by an unknown mechanism, We discovered that GSNO is an NADPH oxidizing substrate for human or calf thymus thioredoxin reductase (TR) with an apparent K-m value of 60 mu M and a K-cat of 0.6 x s(-1). Addition of human thioredoxin (Trx) stimulated the initial NADPH oxidation rate severalfold but was accompanied by progressive inactivation of TR. Escherichia coli TR lacked activity with GSNO, but with E. coli Trx present, GSNO was reduced without inhibition of the enzyme, Chemically reduced E. coli Trx (SH)(2) was oxidized to Trx-S-2 by GSNO with a rate constant of 760 M(-1) s(-1) (7-fold faster than by GSSG) as measured by tryptophan fluorescence. Analysis of this reaction in the presence of oxymyoglobin revealed quantitative formation of metmyoglobin indicative of NO. release, Analysis of GSNO reduction demonstrated that oxidation of NADPH produced a stoichiometric amount of free GSH. These results demonstrate a homolytic cleavage mechanism of GSNO, giving rise to GSH and NO.. GSNO efficiently inhibited the protein disulfide reductase activity of the complete human or calf thymus thioredoxin systems, Our results demonstrate enzymatic cleavage of GSNO by TR or Trx and suggest novel mechanisms for redox signaling.	KAROLINSKA INST,DEPT MED BIOCHEM & BIOPHYS,MED NOBEL INST BIOCHEM,S-17177 STOCKHOLM,SWEDEN	Karolinska Institutet			Nikitovic, Dragana/AAS-6215-2020	Nikitovic, Dragana/0000-0003-3882-7399				ANNELLE JS, 1995, ARCH BIOCHEM BIOPHYS, V318, P279; BAZYLINSKI DA, 1985, J AM CHEM SOC, V107, P79828; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BJORNSTEDT M, 1992, J BIOL CHEM, V267, P8030; CLANCY RM, 1992, ANAL BIOCHEM, V204, P365, DOI 10.1016/0003-2697(92)90253-4; CLANCY RM, 1994, P NATL ACAD SCI USA, V91, P3680, DOI 10.1073/pnas.91.9.3680; DUHE RJ, 1994, J BIOL CHEM, V269, P7290; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; GASTON B, 1993, P NATL ACAD SCI USA, V90, P10957, DOI 10.1073/pnas.90.23.10957; GOLDMAN R, 1995, BIOCHEMISTRY-US, V34, P4765, DOI 10.1021/bi00014a034; HART TW, 1985, TETRAHEDRON LETT, V26, P2013, DOI 10.1016/S0040-4039(00)98368-0; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; HOLMGREN A, 1972, J BIOL CHEM, V247, P1992; HOLMGREN A, 1995, STRUCTURE, V3, P239, DOI 10.1016/S0969-2126(01)00153-8; HOLMGREN A, 1995, METHOD ENZYMOL, V252, P199; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; JENG MF, 1994, STRUCTURE, V2, P853, DOI 10.1016/S0969-2126(94)00086-7; KHARITONOV VG, 1994, J BIOL CHEM, V269, P5881; LANDER HM, 1995, J BIOL CHEM, V270, P7017, DOI 10.1074/jbc.270.13.7017; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; RADOMSKI MW, 1992, BRIT J PHARMACOL, V107, P745, DOI 10.1111/j.1476-5381.1992.tb14517.x; REN XL, 1993, BIOCHEMISTRY-US, V32, P9701, DOI 10.1021/bi00088a023; ROZELL B, 1985, EUR J CELL BIOL, V38, P79; SCHMIDT HHHW, 1994, CELL, V78, P919, DOI 10.1016/0092-8674(94)90267-4; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P444, DOI 10.1073/pnas.89.1.444; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; STONE JR, 1994, BIOCHEMISTRY-US, V33, P5636, DOI 10.1021/bi00184a036; STUEHR DJ, 1985, P NATL ACAD SCI USA, V82, P7738, DOI 10.1073/pnas.82.22.7738; WINK DA, 1994, CHEM RES TOXICOL, V7, P519, DOI 10.1021/tx00040a007	31	287	295	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19180	19185		10.1074/jbc.271.32.19180	http://dx.doi.org/10.1074/jbc.271.32.19180			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702596	hybrid			2022-12-25	WOS:A1996VB68400030
J	Bangs, JD; Brouch, EM; Ransom, DM; Roggy, JL				Bangs, JD; Brouch, EM; Ransom, DM; Roggy, JL			A soluble secretory reporter system in Trypanosoma brucei - Studies on endoplasmic reticulum targeting	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VARIANT SURFACE GLYCOPROTEIN; AFRICAN TRYPANOSOMES; BLOOD-STREAM; NUCLEOTIDE-SEQUENCE; FLAGELLAR POCKET; ACID-PHOSPHATASE; RETENTION SIGNAL; GIARDIA-LAMBLIA; MEMBRANE ANCHOR; PROTEIN	A homolog of the endoplasmic reticulum (ER) hsp70 protein, binding protein (BiP), from the parasitic protozoan Trypanosoma brucei (Bangs, J. D., Uyetake, L., Brickman, M. J., Balber, A. E., and Boothroyd, J. C. (1993) J. Cell Sci, 105, 1101-1113) is further characterized, In co-precipitation experiments, BiP transiently associates with newly synthesized secretory proteins, including variant surface glycoprotein (VSG), confirming its role as a molecular chaperone, To study the molecular signals targeting BiP to the ER, we have developed soluble secretory reporters for expression in transformed procyclic trypanosomes. Deletion of the BiP C-terminal tetrapeptide (MDDL) and the glycosylphosphatidylinositol-anchor addition sequence of VSG converts these proteins to secreted forms, Attachment of MDDL to VSG results in intracellular retention confirming that MDDL is a trypanosomal ER localization signal, Secretion of both reporters is inefficient, but further truncation of the BiP C-terminal peptide binding domain allows quantitative export (t1/2 similar to 1 h) of the N-terminal ATPase domain (BiPN), consistent with the conserved domain structure of hsp70 proteins, This is the first demonstration of soluble protein secretion in African trypanosomes. Using the BiPN reporter, the sequence specificity of C-terminal tetrapeptide retention signals in trypanosomes is analyzed and found to be similar to higher eukaryotes. These results indicate that the basic signals mediating protein targeting to the ER lumen are conserved throughout the wide range of eukaryotic evolution.			Bangs, JD (corresponding author), UNIV WISCONSIN, SCH MED, DEPT MED MICROBIOL & IMMUNOL, 1300 UNIV AVE, MADISON, WI 53706 USA.				NIAID NIH HHS [AI35739-02, AI07414-04, R01 AI035739, R29 AI035739] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI035739, R01AI035739, T32AI007414] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDRES DA, 1991, J BIOL CHEM, V266, P14277; ANDREWS NW, 1989, MOL BIOCHEM PARASIT, V33, P249, DOI 10.1016/0166-6851(89)90086-8; BALBER AE, 1990, CRIT REV IMMUNOL, V10, P177; BANGS JD, 1993, J CELL SCI, V105, P1101; BANGS JD, 1988, J BIOL CHEM, V263, P17697; BANGS JD, 1986, J CELL BIOL, V103, P255, DOI 10.1083/jcb.103.1.255; BATES PA, 1987, MOL BIOCHEM PARASIT, V26, P289, DOI 10.1016/0166-6851(87)90081-8; BOLE DG, 1986, J CELL BIOL, V102, P1558, DOI 10.1083/jcb.102.5.1558; CHAPPELL TG, 1987, J BIOL CHEM, V262, P746; CLAYTON C, 1995, MICROBIOL REV, V59, P325, DOI 10.1128/MMBR.59.3.325-344.1995; CROSS GAM, 1975, PARASITOLOGY, V71, P393, DOI 10.1017/S003118200004717X; DELAHUNTY MD, 1993, J BIOL CHEM, V268, P12017; Doering TL, 1996, EMBO J, V15, P182, DOI 10.1002/j.1460-2075.1996.tb00346.x; ENGLUND PT, 1993, ANNU REV BIOCHEM, V62, P121, DOI 10.1146/annurev.bi.62.070193.001005; FERGUSON MAJ, 1986, J BIOL CHEM, V261, P356; FIELD MC, 1994, J BIOL CHEM, V269, P10830; FLAHERTY KM, 1990, NATURE, V346, P623, DOI 10.1038/346623a0; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GUPTA RS, 1994, P NATL ACAD SCI USA, V91, P2895, DOI 10.1073/pnas.91.8.2895; HAMMOND C, 1994, SCIENCE, V266, P456, DOI 10.1126/science.7939687; HENDERSHOT LM, 1995, MOL BIOL CELL, V6, P283, DOI 10.1091/mbc.6.3.283; HIRUMI H, 1994, PARASITOL TODAY, V10, P81; HSU MP, 1989, BIOCHEMISTRY-US, V28, P6440, DOI 10.1021/bi00441a042; HUG M, 1993, MOL BIOCHEM PARASIT, V61, P8; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; ILG T, 1991, J CELL SCI, V99, P175; KEKU TO, 1993, EXP PARASITOL, V77, P306, DOI 10.1006/expr.1993.1088; KIMMEL BE, 1985, GENE, V35, P237, DOI 10.1016/0378-1119(85)90002-2; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; KUMAR N, 1992, MOL BIOCHEM PARASIT, V56, P353, DOI 10.1016/0166-6851(92)90187-O; LANGRETH SG, 1975, J PROTOZOOL, V22, P40, DOI 10.1111/j.1550-7408.1975.tb00943.x; LEE MGS, 1990, SCIENCE, V250, P1583, DOI 10.1126/science.2177225; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; NWAGWU M, 1988, T ROY SOC TROP MED H, V82, P577, DOI 10.1016/0035-9203(88)90515-9; OLSSON T, 1991, EUR J IMMUNOL, V21, P2447, DOI 10.1002/eji.1830211022; OVERATH P, 1986, EUR J BIOCHEM, V160, P175, DOI 10.1111/j.1432-1033.1986.tb09955.x; OVERATH P, 1994, PARASITOL TODAY, V10, P53, DOI 10.1016/0169-4758(94)90393-X; PELHAM H R B, 1991, Current Opinion in Cell Biology, V3, P585, DOI 10.1016/0955-0674(91)90027-V; PELHAM HRB, 1990, TRENDS BIOCHEM SCI, V15, P483, DOI 10.1016/0968-0004(90)90303-S; PIDOUX AL, 1992, EMBO J, V11, P1583, DOI 10.1002/j.1460-2075.1992.tb05203.x; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SHERMAN DR, 1991, EMBO J, V10, P3379, DOI 10.1002/j.1460-2075.1991.tb04902.x; SOGIN ML, 1989, SCIENCE, V243, P75, DOI 10.1126/science.2911720; STEBECK CR, 1994, EXP PARASITOL, V78, P432, DOI 10.1006/expr.1994.1050; TENASBROEK ALMA, 1990, NATURE, V348, P174, DOI 10.1038/348174a0; VICKERMAN K, 1969, J PROTOZOOL, V16, P54, DOI 10.1111/j.1550-7408.1969.tb02233.x; WEBSTER P, 1993, PARASITOL TODAY, V9, P201, DOI 10.1016/0169-4758(93)90008-4	47	121	124	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18387	18393		10.1074/jbc.271.31.18387	http://dx.doi.org/10.1074/jbc.271.31.18387			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702482	hybrid			2022-12-25	WOS:A1996VB68300020
J	Jensen, J; Serup, P; Karlsen, C; Nielsen, TF; Madsen, OD				Jensen, J; Serup, P; Karlsen, C; Nielsen, TF; Madsen, OD			mRNA profiling of rat islet tumors reveals Nkx 6.1 as a beta-cell-specific homeodomain transcription factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC ALPHA-CELLS; GENE-RELATED PEPTIDE; INSULIN GENE; SOMATOSTATIN EXPRESSION; BINDING PROTEINS; TRANSGENIC MICE; HOMEOBOX FACTOR; NEUROPEPTIDE-Y; LINES; POLYPEPTIDE	Development of a high capacity multiplex reverse transcriptase-polymerase chain reaction protocol has allowed us to screen lineage related rat islet tumors classified as alpha-, beta-, and delta-like as judged by their hormone profile for differential expression of more than 50 selected genes, We find that in addition to insulin the insulinoma express the normal beta-cell markers Pdx-1, IAPP, and Glut-2, and that these markers are absent from the glucagonoma: a reflection of the normal alpha-cell, Furthermore, this study suggests that the GLP-1, glucagon, GIP, IGF-1, and insulin receptors as well as E-cadherin, R-cadherin, Id-1, and Id-2 are differentially expressed within the islet of Langerhans, Importantly, insulinoma-specific expression of the recently cloned homeodomain protein Nkx 6.1 predicted beta-cell-specific expression in the normal islet, Immunohistochemistry using antibodies raised against recombinant Nkx 6.1 did indeed localize Nkx 6.1 expression exclusively to the nuclei of normal islet beta-cells, Apart from pancreatic islets only the antral part of the stomach contained Nkx 6.1 mRNA, We conclude that multiplex reverse transcriptase-polymerase chain reaction-based mRNA profiling is a powerful tool to identify differentially expressed genes within phenotypically related cells and propose that Nkx 6.1 is involved in specifying the unique characteristics of the beta-cell.	HAGEDORN RES INST, DK-2820 GENTOFTE, DENMARK	Novo Nordisk; Hagedorn Research Institute			Madsen, Ole D./A-7415-2011; Serup, Palle/A-7407-2011	Madsen, Ole D./0000-0002-2753-5203; Serup, Palle/0000-0002-0858-590X; Jensen, Jan/0000-0003-0657-4032				ALPERT S, 1988, CELL, V53, P295, DOI 10.1016/0092-8674(88)90391-1; ATAR D, 1989, J IMMUNOL, V143, P533; BORDI C, 1974, VIRCHOWS ARCH B, V17, P13; BRETHERTONWATT D, 1992, ANN NY ACAD SCI, V657, P299, DOI 10.1111/j.1749-6632.1992.tb22777.x; CHICK WL, 1977, P NATL ACAD SCI USA, V74, P628, DOI 10.1073/pnas.74.2.628; CORDLE SR, 1991, MOL CELL BIOL, V11, P1734, DOI 10.1128/MCB.11.3.1734; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; EBIOU JC, 1992, ENDOCRINOLOGY, V130, P1371, DOI 10.1210/en.130.3.1371; EFRAT S, 1988, NEURON, V1, P605, DOI 10.1016/0896-6273(88)90110-9; EFRAT S, 1988, P NATL ACAD SCI USA, V85, P9037, DOI 10.1073/pnas.85.23.9037; GERMAN MS, 1992, GENE DEV, V6, P2165, DOI 10.1101/gad.6.11.2165; GRUPE A, 1995, CELL, V83, P69, DOI 10.1016/0092-8674(95)90235-X; GUZ Y, 1995, DEVELOPMENT, V121, P11; HAMAGUCHI K, 1990, DIABETES, V39, P415, DOI 10.2337/diabetes.39.4.415; JAMAL H, 1991, ENDOCRINOLOGY, V129, P3372, DOI 10.1210/endo-129-6-3372; JETTON TL, 1994, J BIOL CHEM, V269, P3641; JONSSON J, 1994, NATURE, V371, P606, DOI 10.1038/371606a0; KARLSSON O, 1990, NATURE, V344, P879, DOI 10.1038/344879a0; LARSSON LI, 1994, ENDOCRINE, V2, P759; LARSSON LI, 1975, AM J PATHOL, V79, P271; LEONARD J, 1992, P NATL ACAD SCI USA, V89, P6247, DOI 10.1073/pnas.89.14.6247; LEONARD J, 1993, MOL ENDOCRINOL, V7, P1275, DOI 10.1210/me.7.10.1275; LI S, 1990, NATURE, V347, P528, DOI 10.1038/347528a0; MADSEN OD, 1993, ENDOCRINOLOGY, V133, P2022, DOI 10.1210/en.133.5.2022; MADSEN OD, 1986, J CELL BIOL, V103, P2025, DOI 10.1083/jcb.103.5.2025; MADSEN OD, 1988, P NATL ACAD SCI USA, V85, P6652, DOI 10.1073/pnas.85.18.6652; MADSEN OD, 1991, MOL ENDOCRINOL, V5, P143, DOI 10.1210/mend-5-1-143; MOLLER CJ, 1992, MOL ENDOCRINOL, V6, P1332, DOI 10.1210/me.6.8.1332; NAYA FJ, 1995, GENE DEV, V9, P1009, DOI 10.1101/gad.9.8.1009; NIELSEN JH, 1989, MOL ENDOCRINOL, V3, P165, DOI 10.1210/mend-3-1-165; NIELSEN JH, 1989, EXP CLIN ENDOCRINOL, V93, P277; OHLSSON H, 1993, EMBO J, V12, P4251, DOI 10.1002/j.1460-2075.1993.tb06109.x; OHLSSON H, 1991, MOL ENDOCRINOL, V5, P897, DOI 10.1210/mend-5-7-897; PANG K, 1994, P NATL ACAD SCI USA, V91, P9559, DOI 10.1073/pnas.91.20.9559; PEERS B, 1994, MOL ENDOCRINOL, V8, P1798, DOI 10.1210/me.8.12.1798; RUDNICK A, 1994, P NATL ACAD SCI USA, V91, P12203, DOI 10.1073/pnas.91.25.12203; SERUP P, 1995, BIOCHEM J, V310, P997, DOI 10.1042/bj3100997; SERUP P, 1992, DIABETOLOGIA, V35, pA118; TEITELMAN G, 1993, DEVELOPMENT, V118, P1031; THORENS B, 1988, CELL, V55, P281, DOI 10.1016/0092-8674(88)90051-7; UPCHURCH BH, 1994, DEVELOPMENT, V120, P245	41	191	196	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18749	18758		10.1074/jbc.271.31.18749	http://dx.doi.org/10.1074/jbc.271.31.18749			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702531	hybrid			2022-12-25	WOS:A1996VB68300069
J	Vecchi, M; Baulida, J; Carpenter, G				Vecchi, M; Baulida, J; Carpenter, G			Selective cleavage of the heregulin receptor ErbB-4 by protein kinase C activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; NEU DIFFERENTIATION FACTOR; SMOOTH-MUSCLE CELLS; HUMAN-BREAST; TYROSINE KINASE; PHORBOL ESTER; DOWN-REGULATION; EGF RECEPTORS; MESSENGER-RNA; GENE-PRODUCT	The 180-kDa transmembrane tyrosine kinase ErbB-4 is a receptor for the growth factor heregulin, I-125-Heregulin binding to NIH 3T3 cells overexpressing the ErbB-4 receptor is rapidly decreased by 12-O-tetradecanoylphorbol-13-acetate (TPA) pretreatment. Immunologic analysis demonstrates that TPA treatment of cells induces the proteolytic cleavage of ErbB-4, producing an 80-kDa cytoplasmic domain fragment, which contains a low level of phosphotyrosine, and a 120-kDa ectodomain fragment, which is released into the extracellular medium, Cleavage of ErbB-4 was also enhanced by other protein kinase C activators, i,e, platelet-derived growth factor, ionomycin, and synthetic diacylglycerol, while protein kinase C inhibition or down-regulation suppressed the TPA stimulation of ErbB-4 degradation, TPA did not induce the degradation of related receptors (ErbB-1, ErbB-2, and ErbB-3) in the EGF receptor family, The phorbol ester-induced cleavage of ErbB-4 occurs within or close to the ectodomain, as the 80-kDa cytoplasmic domain fragment is recognized by antibody to the ErbB-4 carboxyl terminus and is membrane-associated, Coprecipitation experiments show that, while the 80-kDa ErbB-4 fragment is associated with the SH2-containing molecules PLC-gamma 1 and She, TPA did not induce the phosphorylation of these substrates in intact cells, In addition, kinase assays in vitro indicate that the 80-kDa fragment is not an active tyrosine kinase, These results show that protein kinase C negatively regulates heregulin signaling through the ErbB-4 receptor by the activation of a selective proteolytic mechanism.	VANDERBILT UNIV,SCH MED,DEPT BIOCHEM,NASHVILLE,TN 37232; VANDERBILT UNIV,SCH MED,DEPT MED,NASHVILLE,TN 37232	Vanderbilt University; Vanderbilt University			Vecchi, Manuela/L-3502-2017	Vecchi, Manuela/0000-0002-2750-9160	NCI NIH HHS [CA24071] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA024071] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARTEAGA CL, 1991, P NATL ACAD SCI USA, V88, P10435, DOI 10.1073/pnas.88.23.10435; BALLESTER R, 1985, J BIOL CHEM, V260, P5194; Baulida J, 1996, J BIOL CHEM, V271, P5251; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN KD, 1979, BIOCHEM BIOPH RES CO, V86, P1037, DOI 10.1016/0006-291X(79)90221-3; BURGESS TL, 1995, J BIOL CHEM, V270, P19188, DOI 10.1074/jbc.270.32.19188; CAO HN, 1991, ONCOGENE, V6, P705; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; CARRAWAY KL, 1994, J BIOL CHEM, V269, P14303; CHIDA K, 1986, J BIOL CHEM, V261, P3013; DLUZ SM, 1993, J BIOL CHEM, V268, P18330; DONG Z, 1995, CELL, V15, P585; DOWNING JR, 1989, MOL CELL BIOL, V9, P2890, DOI 10.1128/MCB.9.7.2890; EARP HS, 1995, BREAST CANCER RES TR, V35, P115, DOI 10.1007/BF00694752; FRIEDMAN BA, 1987, J CELL BIOCHEM, V34, P1, DOI 10.1002/jcb.240340102; GOLDMAN R, 1990, BIOCHEMISTRY-US, V29, P11024, DOI 10.1021/bi00502a002; Gullick W J, 1990, Int J Cancer Suppl, V5, P55; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; KARUNAGARAN D, 1995, J BIOL CHEM, V270, P9982, DOI 10.1074/jbc.270.17.9982; KRAUS MH, 1993, P NATL ACAD SCI USA, V90, P2900, DOI 10.1073/pnas.90.7.2900; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEMOINE NR, 1992, BRIT J CANCER, V66, P1116, DOI 10.1038/bjc.1992.420; MAGUN BE, 1980, J BIOL CHEM, V255, P6373; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MUDGE AW, 1993, CURR BIOL, V3, P361, DOI 10.1016/0960-9822(93)90201-X; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; OBRYAN JP, 1995, J BIOL CHEM, V270, P551, DOI 10.1074/jbc.270.2.551; OLASHAW NE, 1987, J CELL BIOCHEM, V34, P143, DOI 10.1002/jcb.240340208; OLASHAW NE, 1986, P NATL ACAD SCI USA, V83, P3834, DOI 10.1073/pnas.83.11.3834; PANDIELLA A, 1992, J BIOL CHEM, V267, P24028; PANDIELLA A, 1991, J BIOL CHEM, V266, P5769; PANDIELLA A, 1991, P NATL ACAD SCI USA, V88, P1726, DOI 10.1073/pnas.88.5.1726; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; RAAB G, 1994, BIOCHEM BIOPH RES CO, V204, P592, DOI 10.1006/bbrc.1994.2500; RIESE DJ, 1995, MOL CELL BIOL, V15, P5770; SHOYAB M, 1988, P NATL ACAD SCI USA, V85, P6528, DOI 10.1073/pnas.85.17.6528; SHOYAB M, 1979, NATURE, V279, P387, DOI 10.1038/279387a0; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; SOLER C, 1995, GUIDEBOOK CYTOKINES, P194; SORKIN A, 1992, J BIOL CHEM, V267, P8672; SORKIN A, 1993, ONCOGENE, V8, P3021; SORKIN A, 1993, SCIENCE, V261, P612, DOI 10.1126/science.8342026; SORKIN A, 1993, BIOESSAYS, V15, P375, DOI 10.1002/bies.950150603; TEMIZER DH, 1992, J BIOL CHEM, V267, P24892; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; TZAHAR E, 1994, J BIOL CHEM, V269, P25226; WADA T, 1990, CELL, V61, P1339, DOI 10.1016/0092-8674(90)90697-D; YEE NS, 1993, J BIOL CHEM, V268, P14189; YEE NS, 1994, J BIOL CHEM, V269, P31991	53	111	116	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18989	18995		10.1074/jbc.271.31.18989	http://dx.doi.org/10.1074/jbc.271.31.18989			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702564	hybrid			2022-12-25	WOS:A1996VB68300102
J	Zeng, WZ; Xu, X; Muallem, S				Zeng, WZ; Xu, X; Muallem, S			G beta gamma transduces [Ca2+](i) oscillations and G alpha(q) a sustained response during stimulation of pancreatic acinar cells with [Ca2+](i)-mobilizing agonists	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE HYDROLYSIS; PHOSPHOLIPASE-C ISOZYMES; EVOKED CALCIUM RELEASE; PROTEIN ALPHA-SUBUNIT; CA2+ RELEASE; MUSCARINIC RECEPTOR; INOSITOL 1,4,5-TRISPHOSPHATE; INTRACELLULAR STORES; ACTIVATION; KINASE	A central unresolved question in agonist-evoked [Ca2+](i) signaling is the pathway by which [Ca2+](i) oscillations and a sustained response are transduced. We show here that activation of G beta gamma signal [Ca2+](i) oscillations and activation of G alpha(q) signal a sustained response during stimulation by a number of Ca2+-modilizing agonists. Thus, infusion of purified G beta gamma into pancreatic acinar cells through a patch pipette evokes [Ca2+](i) oscillations by Ca2+ release from internal stores, which were inhibited by two independent scavengers of G beta gamma, the beta-adrenergic receptor kinase fragment, and a mutated G alpha(i1G203A). These proteins, as well as an inhibitory antibody against G alpha(q/11), prevent [Ca2+](i) oscillations and the sustained response when applied before cell stimulation, possibly by preventing the dissociation of G(q) into its subunits. After cell stimulation and dissociation of G(q) into G beta gamma and G alpha(q), scavenging G beta gamma stabilized the sustained response and inhibited reassociation of the subunits on termination of cell stimulation with antagonist, whereas scavenging G alpha(q) inhibited the sustained response and uncovered the G beta gamma-dependent oscillations. These findings provide a general mechanism by which Ca2+-mobilizing agonists can control the type of [Ca2+](i) signal to be transduced to the cell interior.	UNIV TEXAS,SW MED CTR,DEPT PHYSIOL,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NIDDK NIH HHS [DK46591, DK38938] Funding Source: Medline; NIGMS NIH HHS [GM31954] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046591, R01DK038938] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031954] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASHKENAZI A, 1989, CELL, V56, P487, DOI 10.1016/0092-8674(89)90251-1; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BERSTEIN G, 1992, J BIOL CHEM, V267, P8081; BLANK JL, 1992, J BIOL CHEM, V267, P23069; BOYER JL, 1992, J BIOL CHEM, V267, P25451; CAMERON AM, 1995, CELL, V83, P463, DOI 10.1016/0092-8674(95)90124-8; CAMPS M, 1992, NATURE, V360, P684, DOI 10.1038/360684a0; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; CONKLIN BR, 1993, NATURE, V363, P274, DOI 10.1038/363274a0; GHOSH TK, 1988, J BIOL CHEM, V263, P11075; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GUALLEM S, 1988, AM J PHYSIOL, V255, pG229; GUTOWSKI S, 1991, J BIOL CHEM, V266, P20519; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HEPLER JR, 1993, J BIOL CHEM, V268, P14367; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; KASE H, 1991, PFLUG ARCH EUR J PHY, V419, P668, DOI 10.1007/BF00370314; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; KOCH WJ, 1994, J BIOL CHEM, V269, P6193; LEE E, 1992, J BIOL CHEM, V267, P1212; LIU J, 1995, P NATL ACAD SCI USA, V92, P11642, DOI 10.1073/pnas.92.25.11642; LOESSBERG PA, 1991, J BIOL CHEM, V266, P1363; MATOZAKI T, 1990, J BIOL CHEM, V265, P6247; MUALLEM S, 1988, BIOCHEM J, V255, P301; MUALLEM S, 1989, J BIOL CHEM, V264, P205; MUALLEM S, 1988, AM J PHYSIOL, V255, pG221, DOI 10.1152/ajpgi.1988.255.2.G221; MUALLEM S, 1992, ADV SEC MESS PHOSPH, P351; PARK DG, 1993, J BIOL CHEM, V268, P4573; PERALTA EG, 1988, NATURE, V334, P434, DOI 10.1038/334434a0; PETERSEN OH, 1992, J PHYSIOL-LONDON, V448, P1; PUSCH M, 1988, PFLUG ARCH EUR J PHY, V411, P204, DOI 10.1007/BF00582316; SLEPAK VZ, 1993, J BIOL CHEM, V268, P1414; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; SMRCKA AV, 1993, J BIOL CHEM, V268, P9667; STEHNOBITTEL L, 1995, J BIOL CHEM, V270, P30068; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; THORN P, 1993, CELL, V74, P661, DOI 10.1016/0092-8674(93)90513-P; TORTORICI G, 1994, J BIOL CHEM, V269, P29621; Williams John A., 1993, P167; WU DQ, 1993, SCIENCE, V261, P101, DOI 10.1126/science.8316840; WU DQ, 1992, J BIOL CHEM, V267, P1811; Xu X, 1996, J PHYSIOL-LONDON, V491, P647, DOI 10.1113/jphysiol.1996.sp021246; Xu X, 1996, J BIOL CHEM, V271, P11737, DOI 10.1074/jbc.271.20.11737; ZHANG BX, 1992, J BIOL CHEM, V267, P24387; ZHANG BX, 1993, J BIOL CHEM, V268, P10997; ZHAO H, 1994, J GEN PHYSIOL, V104, P57, DOI 10.1085/jgp.104.1.57; ZHAO H, 1990, J BIOL CHEM, V265, P14822	49	49	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18520	18526		10.1074/jbc.271.31.18520	http://dx.doi.org/10.1074/jbc.271.31.18520			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702499	hybrid			2022-12-25	WOS:A1996VB68300037
J	Zhu, GH; Spreitzer, RJ				Zhu, GH; Spreitzer, RJ			Directed mutagenesis of chloroplast ribulose-1,5-bisphosphate carboxylase/oxygenase - Loop 6 substitutions complement for structural stability but decrease catalytic efficiency	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBULOSE-BISPHOSPHATE CARBOXYLASE; LARGE-SUBUNIT; ACTIVE-SITE; CO2/O-2 SPECIFICITY; CHLAMYDOMONAS-REINHARDII; 1,5-BISPHOSPHATE CARBOXYLASE; RHODOSPIRILLUM-RUBRUM; SUBSTRATE-SPECIFICITY; ANACYSTIS-NIDULANS; RBCL GENE	The structure of active site loop 6 plays a role in determining the CO2/O-2 specificity of chloroplast ribulose-1,5-bisphosphate carboxylase/oxygenase (Rubisco, EC 4.1.1.39), Rubisco from the green alga Chlamydomonas reinhardtii differs from higher plant Rubisco within the loop 6 region, and the C, reinhardtii enzyme has a CO2/O-2 specificity 25% lower than that of higher plant enzymes, To examine whether differences in sequence may account for differences in catalytic efficiency, we focused on a conserved pair of residues that are in van der Waals contact at the base of loop 6, C, reinhardtii Rubisco contains Leu-326 and Met-349, whereas higher plant enzymes contain Ile-326 and Leu-349, By employing in vitro mutagenesis and chloroplast transformation, L326I and M349L substitutions were created within the Rubisco large subunit of C, reinhardtii. M349L had little effect, but L326I destabilized the holoenzyme in vivo and in vitro, When present together, the M349L substitution partially alleviated the instability resulting from the L326I substitution, but caused a 21% decrease in CO2/O-2 specificity and a 74% decrease in the V-max of carboxylation, Interactions between loop 6 and other structural regions are likely to be responsible for both holoenzyme stability and catalytic efficiency in higher plant Rubisco enzymes.	UNIV NEBRASKA,DEPT BIOCHEM,LINCOLN,NE 68588	University of Nebraska System; University of Nebraska Lincoln								ALDRICH J, 1986, NUCLEIC ACIDS RES, V14, P9535, DOI 10.1093/nar/14.23.9535; ALDRICH J, 1986, NUCLEIC ACIDS RES, V14, P9534, DOI 10.1093/nar/14.23.9534; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN Z, 1988, P NATL ACAD SCI USA, V85, P4696, DOI 10.1073/pnas.85.13.4696; CHEN ZX, 1992, PHOTOSYNTH RES, V31, P157, DOI 10.1007/BF00028792; CHEN ZX, 1991, PLANTA, V183, P597, DOI 10.1007/BF00194282; CHEN ZX, 1991, BIOCHEMISTRY-US, V30, P8846, DOI 10.1021/bi00100a017; CHEN ZX, 1989, J BIOL CHEM, V264, P3051; DAY AG, 1993, BIOCHEMISTRY-US, V32, P1940, DOI 10.1021/bi00059a009; DRON M, 1982, J MOL BIOL, V162, P775, DOI 10.1016/0022-2836(82)90547-2; FINER JJ, 1992, PLANT CELL REP, V11, P323, DOI 10.1007/BF00233358; GUTTERIDGE S, 1993, J BIOL CHEM, V268, P7818; HARPEL MR, 1992, J BIOL CHEM, V267, P6475; HARTMAN FC, 1994, ANNU REV BIOCHEM, V63, P197, DOI 10.1146/annurev.biochem.63.1.197; HWANG SR, 1991, J BIOL CHEM, V266, P6271; JORDAN DB, 1981, NATURE, V291, P513, DOI 10.1038/291513a0; JORDAN DB, 1981, PLANT PHYSIOL, V67, P237, DOI 10.1104/pp.67.2.237; KNIGHT S, 1990, J MOL BIOL, V215, P113, DOI 10.1016/S0022-2836(05)80100-7; KUEHN GD, 1978, BIOCHEM J, V175, P909, DOI 10.1042/bj1750909; LAING WA, 1974, PLANT PHYSIOL, V54, P678, DOI 10.1104/pp.54.5.678; LARIMER FW, 1987, J BIOL CHEM, V262, P15327; LARSON EM, 1995, BIOCHEMISTRY-US, V34, P4531, DOI 10.1021/bi00014a005; LEE GJ, 1993, PROTEIN SCI, V2, P1147, DOI 10.1002/pro.5560020709; LEE GJ, 1992, BIOCHEMISTRY-US, V31, P2304, DOI 10.1021/bi00123a014; LORIMER GH, 1993, BIOCHEMISTRY-US, V32, P9018, DOI 10.1021/bi00086a006; MCINTOSH L, 1980, NATURE, V288, P556, DOI 10.1038/288556a0; MOON E, 1987, NUCLEIC ACIDS RES, V15, P611, DOI 10.1093/nar/15.2.611; NEWMAN SM, 1991, MOL GEN GENET, V230, P65, DOI 10.1007/BF00290652; PARRY MAJ, 1992, PLANTA, V187, P109, DOI 10.1007/BF00201631; PIERCE J, 1980, BIOCHEMISTRY-US, V19, P934, DOI 10.1021/bi00546a018; PIERCE J, 1986, J BIOL CHEM, V261, P248; POULSEN C, 1981, CARLSBERG RES COMMUN, V46, P259, DOI 10.1007/BF02906502; READ BA, 1994, ARCH BIOCHEM BIOPHYS, V312, P210, DOI 10.1006/abbi.1994.1301; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SCHREUDER HA, 1993, P NATL ACAD SCI USA, V90, P9968, DOI 10.1073/pnas.90.21.9968; SHINOZAKI K, 1983, P NATL ACAD SCI-BIOL, V80, P4050, DOI 10.1073/pnas.80.13.4050; SOPER TS, 1988, PROTEIN ENG, V2, P39, DOI 10.1093/protein/2.1.39; SPREITZER RJ, 1981, PLANT PHYSIOL, V67, P565, DOI 10.1104/pp.67.3.565; SPREITZER RJ, 1982, FEBS LETT, V148, P117, DOI 10.1016/0014-5793(82)81255-6; SPREITZER RJ, 1985, P NATL ACAD SCI USA, V82, P5460, DOI 10.1073/pnas.82.16.5460; SPREITZER RJ, 1987, CURR GENET, V11, P611, DOI 10.1007/BF00393924; SPREITZER RJ, 1993, ANNU REV PLANT PHYS, V44, P411, DOI 10.1146/annurev.pp.44.060193.002211; SPREITZER RJ, 1995, PLANT PHYSIOL, V109, P681, DOI 10.1104/pp.109.2.681; THOW G, 1994, BIOCHEMISTRY-US, V33, P5109, DOI 10.1021/bi00183a014; VANDEYAR MA, 1988, GENE, V65, P129, DOI 10.1016/0378-1119(88)90425-8; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZHU GH, 1990, PLANT PHYSIOL, V93, P244, DOI 10.1104/pp.93.1.244; ZHU GH, 1994, J BIOL CHEM, V269, P3952; ZURAWSKI G, 1981, NUCLEIC ACIDS RES, V9, P3251, DOI 10.1093/nar/9.14.3251	49	40	42	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18494	18498		10.1074/jbc.271.31.18494	http://dx.doi.org/10.1074/jbc.271.31.18494			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702495	hybrid			2022-12-25	WOS:A1996VB68300033
J	Duplay, P; Alcover, A; Fargeas, C; Sekaly, RP; Branton, PE				Duplay, P; Alcover, A; Fargeas, C; Sekaly, RP; Branton, PE			An activated epidermal growth factor receptor/Lck chimera restores early T cell receptor-mediated calcium response in a CD45-deficient T cell line	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE-PROTEIN-KINASE; CD45 PHOSPHOTYROSINE PHOSPHATASE; HUMAN LYMPHOCYTES-T; ANTIGEN RECEPTOR; SIGNAL-TRANSDUCTION; SH2 DOMAIN; INTERLEUKIN-2 PRODUCTION; FUNCTIONAL COMPLEX; ZAP-70 KINASE; CROSS-LINKING	In T cells, cell surface expression of CD45, a transmembrane tyrosine phosphatase, is required for T cell receptor (TCR) signal transduction, Indirect evidence suggests that CD45 function in TCR signaling involves the dephosphorylation of the C-terminal negative regulatory site of p56(lck), Tyr-505, To evaluate the importance of CD45-mediated dephosphorylation of p56(lck) Tyr-505 in TCR signaling, we established CD45(-) Jurkat cell lines expressing various forms of a chimera containing the extracellular and transmembrane domains of the epidermal growth factor receptor (EGFR) fused to p56(lck) We report that an activated EGFR/Lck chimera is able to reconstitute a Ca2+ response after CD3 stimulation in the absence of CD45 expression, In addition, the wild-type and kinase inactive versions of the EGFR/Lck chimera fail to restore early signaling, Restoration of the response by EGFR/LckF505 required EGF binding to the chimeric kinase, Altogether, these results provide the first direct evidence that the lack of efficient dephosphorylation of p56(lck) Tyr-505 ist in part, responsible for the unresponsiveness of CD45(-) cells, They also indicate that a second event is required for p56(lck) function in TCR signaling in addition to its dephosphorylation at Tyr-505.	INST PASTEUR,UNITE BIOL INTERACT CELLULAIRES,CNRS URA 1960,F-75724 PARIS 15,FRANCE; INST RECH CLIN MONTREAL,IMMUNOL LAB,MONTREAL,PQ H2W 1R7,CANADA	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal	Duplay, P (corresponding author), MCGILL UNIV,DEPT BIOCHEM,MCINTYRE MED SCI BLDG,MONTREAL,PQ H3G 1Y6,CANADA.			Alcover, Andres/0000-0002-9507-3450				ABRAHAM N, 1991, NATURE, V350, P62, DOI 10.1038/350062a0; ADAM D, 1993, J BIOL CHEM, V268, P19882; ALCOVER A, 1988, EMBO J, V7, P1973, DOI 10.1002/j.1460-2075.1988.tb03035.x; APPLEBY MW, 1992, CELL, V70, P751, DOI 10.1016/0092-8674(92)90309-Z; ARPAIA E, 1994, CELL, V76, P947, DOI 10.1016/0092-8674(94)90368-9; BALDARI CT, 1995, EUR J IMMUNOL, V25, P919, DOI 10.1002/eji.1830250409; BIFFEN M, 1994, EMBO J, V13, P1920, DOI 10.1002/j.1460-2075.1994.tb06461.x; BURNS CM, 1994, J BIOL CHEM, V269, P13594; CHAN AC, 1994, SCIENCE, V264, P1599, DOI 10.1126/science.8202713; CHAN AC, 1994, ANNU REV IMMUNOL, V12, P555, DOI 10.1146/annurev.iy.12.040194.003011; CHAN AC, 1991, P NATL ACAD SCI USA, V88, P9166, DOI 10.1073/pnas.88.20.9166; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; CHAN AC, 1994, J IMMUNOL, V152, P4758; COOKE MP, 1991, CELL, V65, P281, DOI 10.1016/0092-8674(91)90162-R; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; COUTURE C, 1994, MOL CELL BIOL, V14, P5249, DOI 10.1128/MCB.14.8.5249; DANIELIAN S, 1992, EUR J IMMUNOL, V22, P2915, DOI 10.1002/eji.1830221124; DANOVAN JA, 1994, J BIOL CHEM, V269, P22921; DEANS JP, 1992, EUR J IMMUNOL, V22, P661, DOI 10.1002/eji.1830220308; DESAI DM, 1993, CELL, V73, P541, DOI 10.1016/0092-8674(93)90141-C; DESAI DM, 1994, J BIOL CHEM, V269, P22830; DUPLAY P, 1994, J EXP MED, V179, P1163, DOI 10.1084/jem.179.4.1163; FISHER EH, 1991, SCIENCE, V253, P401; GERVAIS FG, 1993, MOL CELL BIOL, V13, P7112, DOI 10.1128/MCB.13.11.7112; GERVAIS FG, 1995, MOL CELL BIOL, V15, P2393; GUTTINGER M, 1992, INT IMMUNOL, V4, P1325, DOI 10.1093/intimm/4.11.1325; HARDWICK JS, 1995, P NATL ACAD SCI USA, V92, P4527, DOI 10.1073/pnas.92.10.4527; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HOVIS RR, 1993, SCIENCE, V260, P544, DOI 10.1126/science.8475387; HURLEY TR, 1993, MOL CELL BIOL, V13, P1651, DOI 10.1128/MCB.13.3.1651; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; JUNE CH, 1990, J IMMUNOL, V144, P1591; KARNITZ L, 1992, MOL CELL BIOL, V12, P4521, DOI 10.1128/MCB.12.10.4521; KOLANUS W, 1993, CELL, V74, P171, DOI 10.1016/0092-8674(93)90304-9; KORETZKY GA, 1993, J BIOL CHEM, V268, P8958; KORETZKY GA, 1992, J IMMUNOL, V149, P1138; KORETZKY GA, 1990, NATURE, V346, P66, DOI 10.1038/346066a0; KORETZKY GA, 1991, P NATL ACAD SCI USA, V88, P2037, DOI 10.1073/pnas.88.6.2037; Lee JM, 1996, ONCOGENE, V12, P253; LUO KX, 1990, MOL CELL BIOL, V10, P5305, DOI 10.1128/MCB.10.10.5305; LUO KX, 1992, MOL CELL BIOL, V12, P4724, DOI 10.1128/MCB.12.10.4724; MCFARLAND EDC, 1993, P NATL ACAD SCI USA, V90, P1402, DOI 10.1073/pnas.90.4.1402; MUSTELIN T, 1989, P NATL ACAD SCI USA, V86, P6302, DOI 10.1073/pnas.86.16.6302; MUSTELIN T, 1992, EUR J IMMUNOL, V22, P1173, DOI 10.1002/eji.1830220510; NEGISHI I, 1995, NATURE, V376, P435, DOI 10.1038/376435a0; NIKLINSKA BB, 1994, MOL CELL BIOL, V14, P8078, DOI 10.1128/MCB.14.12.8078; OSTERGAARD HL, 1990, J EXP MED, V172, P347, DOI 10.1084/jem.172.1.347; PERI KG, 1993, ONCOGENE, V8, P2765; PEYRON JF, 1991, INT IMMUNOL, V3, P1357, DOI 10.1093/intimm/3.12.1357; SCHRAVEN B, 1991, EUR J IMMUNOL, V21, P2469, DOI 10.1002/eji.1830211025; SCHRAVEN B, 1992, EUR J IMMUNOL, V22, P1857, DOI 10.1002/eji.1830220727; SHIROO M, 1992, EMBO J, V11, P4887, DOI 10.1002/j.1460-2075.1992.tb05595.x; SIEH M, 1993, EMBO J, V12, P315, DOI 10.1002/j.1460-2075.1993.tb05659.x; SOULA M, 1993, J BIOL CHEM, V268, P27420; STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; THOME M, 1995, J EXP MED, V181, P1997, DOI 10.1084/jem.181.6.1997; TROWBRIDGE IS, 1994, ANNU REV IMMUNOL, V12, P85, DOI 10.1146/annurev.iy.12.040194.000505; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; VANDENBERGHE PA, 1990, J IMMUNOL METHODS, V127, P197, DOI 10.1016/0022-1759(90)90069-8; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0; VEILLETTE A, 1989, MOL CELL BIOL, V9, P4441, DOI 10.1128/MCB.9.10.4441; VOLAREVIC S, 1993, SCIENCE, V260, P541, DOI 10.1126/science.8475386; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; XU H, 1993, CELL, V74, P633, DOI 10.1016/0092-8674(93)90511-N	66	15	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					17896	17902		10.1074/jbc.271.30.17896	http://dx.doi.org/10.1074/jbc.271.30.17896			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663450	hybrid			2022-12-25	WOS:A1996UY93500048
J	GharaeeKermani, M; Denholm, EM; Phan, SH				GharaeeKermani, M; Denholm, EM; Phan, SH			Costimulation of fibroblast collagen and transforming growth factor beta(1) gene expression by monocyte chemoattractant protein-1 via specific receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED PULMONARY FIBROSIS; TUMOR-NECROSIS-FACTOR; IN-SITU HYBRIDIZATION; MESSENGER-RNA; ALVEOLAR MACROPHAGES; INSITU HYBRIDIZATION; HUMAN BASOPHILS; FACTOR-ALPHA; BLEOMYCIN; RAT	Recent studies indicate potential roles of monocyte chemotactic protein-1 (MCP-1) in recruitment of monocytes to sites of inflammation, However, their increased expression does not always correlate with monocyte influx, suggesting other possible biological activities for this member of the C-C chemokine family. In view of its potential role in regulating extracellular matrix expression in fibrotic disorders, the effects of MCP-1 on lung fibroblast collagen expression were evaluated. Isolated rat lung fibroblasts were treated with increasing doses of MCP-1 for variable periods of time and examined for effects on collagen synthesis and expression of procollagen alpha(1)(I) mRNA expression, The results show that MCP-1 was able to stimulate collagen expression in these cells in a dose-dependent manner but required over 24 h for significant elevation to occur, In view of this delayed time course, the possibility of mediation via endogenous transforming growth factor beta (TGF beta) was tested by the ability of anti-TGF beta antibody to inhibit this MCP-1 stimulation of collagen expression. Significant but incomplete inhibition by this antibody was observed. Pretreatment of the cells with antisense but not by sense or missense TGF beta(1) oligodeoxyribonucleotides caused essentially complete inhibition of this MCP-1 stimulatory effect. Furthermore, MCP-1 treatment was found to also stimulate TGF beta secretion and mRNA expression, which was also abolished by pretreatment with antisense TGF beta(1) oligodeoxyribonucleotides. The kinetics of TGF beta expression indicates that significant increase preceded that for collagen expression. Binding studies using I-125-labeled MCP-1 indicated the presence of specific and saturable binding sites with a dissociation constant consistent with the dose response curves for stimulation of fibroblast collagen synthesis and TGF beta activity by MCP-1. These results taken together suggest that MCP-1 stimulates fibroblast collagen expression via specific receptors and endogenous up-regulation of TGF beta expression. The latter then results in autocrine and/or juxtacrine stimulation of collagen gene expression.	UNIV MICHIGAN, SCH MED, DEPT PATHOL M0602, ANN ARBOR, MI 48109 USA; ICOS CORP, BOTHELL, WA 98021 USA	University of Michigan System; University of Michigan; Icos Corporation			Phan, Sem H/A-7033-2009	Phan, Sem H/0000-0002-3711-2159	NHLBI NIH HHS [HL31963, HL28737, HL46487] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL031963, P50HL046487, R37HL028737, R01HL028737] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMSON IYR, 1974, AM J PATHOL, V77, P185; ANTONIADES HN, 1992, P NATL ACAD SCI USA, V89, P5371, DOI 10.1073/pnas.89.12.5371; BISCHOFF SC, 1992, J EXP MED, V175, P1271, DOI 10.1084/jem.175.5.1271; BREEN E, 1992, AM J RESP CELL MOL, V6, P146, DOI 10.1165/ajrcmb/6.2.146; BRIELAND JK, 1993, AM J RESP CELL MOL, V9, P300, DOI 10.1165/ajrcmb/9.3.300; BURDICK MD, 1994, AM J PATHOL, V146, P130; CARR MW, 1994, P NATL ACAD SCI USA, V91, P3652, DOI 10.1073/pnas.91.9.3652; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CONTI P, 1995, IMMUNOLOGY, V86, P434; DANIELPOUR D, 1989, J CELL PHYSIOL, V138, P79, DOI 10.1002/jcp.1041380112; DESMOULIERE A, 1992, LAB INVEST, V67, P716; ELIAS JA, 1990, CHEST, V97, P1439, DOI 10.1378/chest.97.6.1439; FLORY CM, 1993, LAB INVEST, V69, P396; HOYT DG, 1988, J PHARMACOL EXP THER, V246, P765; IGNOTZ RA, 1986, J BIOL CHEM, V261, P4337; JAATTELA M, 1991, LAB INVEST, V64, P724; JIANG YL, 1992, J IMMUNOL, V148, P2423; JONES ML, 1992, LAB INVEST, V66, P498; KUNA P, 1992, J IMMUNOL, V149, P636; LARJAVA H, 1990, LAB INVEST, V62, P96; LEONARD EJ, 1991, ADV EXP MED BIOL, V305, P57; LEONARD EJ, 1990, IMMUNOL TODAY, V11, P97, DOI 10.1016/0167-5699(90)90035-8; LLOYD RV, 1988, AM J PATHOL, V133, P397; LUKACS NW, 1993, J EXP MED, V177, P1551, DOI 10.1084/jem.177.6.1551; MAUVIEL A, 1988, BIOCHEM J, V252, P247, DOI 10.1042/bj2520247; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; PELTONEN J, 1991, J INVEST DERMATOL, V97, P240, DOI 10.1111/1523-1747.ep12480289; PETERKOFSKY B, 1971, BIOCHEMISTRY-US, V10, P988, DOI 10.1021/bi00782a009; PHAN SH, 1985, J CLIN INVEST, V76, P241, DOI 10.1172/JCI111953; PHAN SH, 1992, EXP LUNG RES, V18, P29, DOI 10.3109/01902149209020649; PHAN SH, 1992, J IMMUNOL, V149, P103; PHAN SH, 1991, J CLIN INVEST, V87, P148, DOI 10.1172/JCI114964; PHAN SH, 1989, LUNG CELL BIOL, P907; PIGUET PF, 1989, J EXP MED, V170, P655, DOI 10.1084/jem.170.3.655; PIGUET PF, 1990, NATURE, V344, P245, DOI 10.1038/344245a0; RAGHOW R, 1989, J CLIN INVEST, V84, P1836, DOI 10.1172/JCI114369; REKHTER MD, 1993, AM J PATHOL, V143, P1634; ROBERTS AB, 1986, P NATL ACAD SCI USA, V83, P4167, DOI 10.1073/pnas.83.12.4167; ROLFE MW, 1992, AM J PHYSIOL, V263, pL536, DOI 10.1152/ajplung.1992.263.5.L536; ROLLINS BJ, 1992, AM J RESP CELL MOL, V7, P126, DOI 10.1165/ajrcmb/7.2.126; ROLLINS BJ, 1991, BLOOD, V78, P1112; SCHARFFETTER K, 1989, J INVEST DERMATOL, V93, P405, DOI 10.1111/1523-1747.ep12280295; SCHRIER DJ, 1983, AM REV RESPIR DIS, V127, P614, DOI 10.1164/arrd.1983.127.5.614; SMITH RE, 1995, J LEUKOCYTE BIOL, V57, P782, DOI 10.1002/jlb.57.5.782; SPORN MB, 1986, SCIENCE, V233, P532, DOI 10.1126/science.3487831; STANDIFORD TJ, 1991, J BIOL CHEM, V266, P9912; STRIETER RM, 1993, ADV EXP MED BIOL, V351, P19; STRIETER RM, 1989, BIOCHEM BIOPH RES CO, V162, P694, DOI 10.1016/0006-291X(89)92366-8; STRIETER RM, 1989, J BIOL CHEM, V264, P10621; SUWABE A, 1988, AM J PATHOL, V132, P512; THRALL RS, 1981, AM J PATHOL, V105, P76; VALENTE AJ, 1988, BIOCHEMISTRY-US, V27, P4162, DOI 10.1021/bi00411a039; YOSHIMURA T, 1990, J IMMUNOL, V144, P2377; YOSHIMURA T, 1991, BIOCHEM BIOPH RES CO, V174, P504, DOI 10.1016/0006-291X(91)91445-I; YOSHIMURA T, 1989, J IMMUNOL, V142, P1956; ZHANG K, 1994, LAB INVEST, V70, P192; ZHANG K, 1994, J IMMUNOL, V153, P4733; ZHANG K, 1994, AM J PATHOL, V145, P114	58	372	385	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					17779	17784		10.1074/jbc.271.30.17779	http://dx.doi.org/10.1074/jbc.271.30.17779			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663511	hybrid			2022-12-25	WOS:A1996UY93500031
J	Ninomiya, Y; Kishimoto, T; Miyashita, Y; Kasai, H				Ninomiya, Y; Kishimoto, T; Miyashita, Y; Kasai, H			Ca2+-dependent exocytotic pathways in Chinese hamster ovary fibroblasts revealed by a caged-Ca2+ compound	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE CHROMAFFIN CELLS; CAPACITANCE MEASUREMENTS; EXOCRINE PANCREAS; SECRETION; CA2+; ENDOCYTOSIS; MEMBRANE; RELEASE	Ca2+-dependent exocytosis and endocytosis of Chinese hamster ovary (CHO) fibroblasts were investigated using capacitance measurement and rapid photolysis of a caged-Ca2+ compound, dimethoxynitrophenamine tetrasodium salt. CHO cells exhibited large and fast in creases in membrane capacitance (1.9 +/- 1 picofarads, or 13 +/- 7% of total membrane area, mean +/- S.D., n = 37) upon Ca2+ jumps to [Ca2+](i) larger than 20 mu M. The fast exocytosis occurred with a delay (20-80 ms), and exhibited a rate constant that was strongly dependent on [Ca2+](i). The maximal rate constant of exocytosis was 2.8/s, and a half-maximal rate was achieved at 30 mu M. The fast exocytosis was followed by rapid endocytosis in 28% of the cells. The endocytosis often began after a delay of 0.5-2 s. Ca2+ jumps also induced stepwise increases in membrane capacitance of 10-134 femtofarads in 40% of the cells, indicating fusion of large vesicles with diameters of 0.4-1.5 mu m. The exocytosis of the large vesicles could selectively be induced with smaller Ca2+ jumps (6-20 mu M), and occurred slowly with a rate constant of 0.3/s. These data indicate that CHO fibroblasts possess Ca2+-dependent exocytotic mechanisms, Moreover, two parallel exocytotic pathways may exist reminiscent of those of neurons and endocrine cells. A kinetic model was constructed to account for the fast exocytosis of CHO cells.	UNIV TOKYO,FAC MED,DEPT PHYSIOL,BUNKYO KU,TOKYO 113,JAPAN	University of Tokyo			Miyashita, Yasushi/B-7171-2019	Miyashita, Yasushi/0000-0003-3496-8637; Kasai, Haruo/0000-0003-2327-9027				ALMERS W, 1985, FEBS LETT, V192, P13, DOI 10.1016/0014-5793(85)80033-8; BAUDET S, 1994, PRACTICAL GUIDE STUD, P94; DAN Y, 1992, NATURE, V359, P733, DOI 10.1038/359733a0; DECAMILLI P, 1990, ANNU REV PHYSIOL, V52, P625, DOI 10.1146/annurev.ph.52.030190.003205; FIDLER N, 1989, BIOPHYS J, V56, P1153, DOI 10.1016/S0006-3495(89)82762-6; HEIDELBERGER R, 1994, NATURE, V371, P513, DOI 10.1038/371513a0; HEINEMANN C, 1994, BIOPHYS J, V67, P2546, DOI 10.1016/S0006-3495(94)80744-1; IATRIDOU H, 1994, CELL CALCIUM, V15, P190, DOI 10.1016/0143-4160(94)90058-2; JOHNSTON PA, 1989, EMBO J, V8, P2836; JOSHI C, 1988, BIOPHYS J, V53, P885, DOI 10.1016/S0006-3495(88)83169-2; KASAI H, 1993, CELL, V74, P669, DOI 10.1016/0092-8674(93)90514-Q; KASAI H, 1996, IN PRESS J PHYSL; KELLY RB, 1993, CELL, V72, P43, DOI 10.1016/S0092-8674(05)80027-3; KISS JZ, 1994, EMBO J, V13, P5284, DOI 10.1002/j.1460-2075.1994.tb06862.x; LI C, 1995, NATURE, V375, P594, DOI 10.1038/375594a0; LINSTEDT AD, 1991, NEURON, V7, P309, DOI 10.1016/0896-6273(91)90269-6; MARUYAMA Y, 1993, EMBO J, V12, P3017, DOI 10.1002/j.1460-2075.1993.tb05970.x; MORIMOTO T, 1995, NEURON, V15, P689, DOI 10.1016/0896-6273(95)90156-6; NEHER E, 1993, NEURON, V10, P21, DOI 10.1016/0896-6273(93)90238-M; ROSENBOOM H, 1994, P NATL ACAD SCI USA, V91, P5267, DOI 10.1073/pnas.91.12.5267; SUDHOF TC, 1995, NATURE, V756, P6357; THOMAS P, 1994, J CELL BIOL, V124, P667, DOI 10.1083/jcb.124.5.667; THOMAS P, 1993, NEURON, V11, P93, DOI 10.1016/0896-6273(93)90274-U; THOMASREETZ AC, 1994, FASEB J, V8, P209, DOI 10.1096/fasebj.8.2.7907072; ZUCKER RS, 1992, CELL CALCIUM, V13, P29, DOI 10.1016/0143-4160(92)90027-P	25	67	67	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					17751	17754		10.1074/jbc.271.30.17751	http://dx.doi.org/10.1074/jbc.271.30.17751			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663485	hybrid			2022-12-25	WOS:A1996UY93500027
J	Scheid, MP; Duronio, V				Scheid, MP; Duronio, V			Phosphatidylinositol 3-OH kinase activity is not required for activation of mitogen-activated protein kinase by cytokines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE KINASE-3; WORTMANNIN; 3-KINASE; INSULIN; INHIBITOR; CELLS; RAS; PHOSPHORYLATION; NEUTROPHILS; PATHWAY	Hemopoietic cells respond to cytokines by initiating tyrosine phosphorylation of receptors and receptor-associated proteins, leading to the activation of numerous cytosolic and membrane associated enzymes, including phosphatidylinositol 3-OH kinase (PI 3-kinase). Recent reports have suggested that PIS-kinase may serve as an upstream activator of mitogen-activated protein (MAP) kinase. After stimulation with interleukin-3 and granulocyte-macrophage colony stimulating factor, we show here that inhibition of MAP kinase activity by two inhibitors of PI 3-kinase, wortmannin and LY-294002, does not correlate with their ability to inhibit PI 3-kinase or p70 S6 kinase phosphorylation. Complete inhibition of phosphatidylinositol 3,4,5-trisphosphate production occurred at approximately 100 nM WM or 25 mu M LY-294002, but at these concentrations, WM significantly inhibited MAP kinase activation, while LY-294002 had virtually no effect on MAP kinase activity. Furthermore, WM does not inhibit phorbol ester-mediated MAP kinase activation, but LY-294002 does. Together these results suggest WM and LY-294002 are differentially inhibiting enzymes other than PI 3-kinase that function upstream of MAP kinase.	UNIV BRITISH COLUMBIA,DEPT MED,JACK BELL RES CTR,VANCOUVER,BC V6H 3Z6,CANADA	University of British Columbia								ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; CROSS DAE, 1994, BIOCHEM J, V303, P21, DOI 10.1042/bj3030021; CROSS MJ, 1995, J BIOL CHEM, V270, P25352, DOI 10.1074/jbc.270.43.25352; DING JB, 1995, J BIOL CHEM, V270, P11684, DOI 10.1074/jbc.270.19.11684; DURONIO V, 1992, P NATL ACAD SCI USA, V89, P1587, DOI 10.1073/pnas.89.5.1587; FERBY IM, 1994, J BIOL CHEM, V269, P30485; FERRARI S, 1992, P NATL ACAD SCI USA, V89, P7282, DOI 10.1073/pnas.89.15.7282; FINGAR DC, 1993, J BIOL CHEM, V268, P3005; GOLD MR, 1994, J BIOL CHEM, V269, P5403; HAN JW, 1995, J BIOL CHEM, V270, P21396, DOI 10.1074/jbc.270.36.21396; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; KARNITZ LM, 1995, MOL CELL BIOL, V15, P3249; MONFAR M, 1995, MOL CELL BIOL, V15, P326, DOI 10.1128/MCB.15.1.326; Nishioka N, 1995, FEBS LETT, V377, P393, DOI 10.1016/0014-5793(95)01382-2; PETRITSCH C, 1995, EUR J BIOCHEM, V230, P431, DOI 10.1111/j.1432-1033.1995.0431h.x; POWIS G, 1994, CANCER RES, V54, P2419; SAKANAKA C, 1994, BIOCHEM BIOPH RES CO, V205, P18, DOI 10.1006/bbrc.1994.2623; SATOH T, 1991, P NATL ACAD SCI USA, V88, P3314, DOI 10.1073/pnas.88.8.3314; SCHEID MP, 1995, BIOCHEM J, V312, P159, DOI 10.1042/bj3120159; SHEPHERD PR, 1995, BIOCHEM J, V305, P25, DOI 10.1042/bj3050025; TOUHARA K, 1995, P NATL ACAD SCI USA, V92, P9284, DOI 10.1073/pnas.92.20.9284; TRAYNORKAPLAN AE, 1989, J BIOL CHEM, V264, P15668; UEHARA T, 1995, BIOCHEM BIOPH RES CO, V210, P574, DOI 10.1006/bbrc.1995.1698; URICH M, 1995, J BIOL CHEM, V270, P29286, DOI 10.1074/jbc.270.49.29286; VLAHOS CJ, 1995, J IMMUNOL, V154, P2413; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; vonWillebrand M, 1996, EUR J BIOCHEM, V235, P828; WANG LM, 1992, EMBO J, V11, P4899, DOI 10.1002/j.1460-2075.1992.tb05596.x; WELHAM MJ, 1994, J BIOL CHEM, V269, P5865; WELHAM MJ, 1992, J IMMUNOL, V149, P1683; WELSH GI, 1994, BIOCHEM J, V303, P15, DOI 10.1042/bj3030015; WENG QP, 1995, P NATL ACAD SCI USA, V92, P5744, DOI 10.1073/pnas.92.12.5744; WENG QP, 1995, MOL CELL BIOL, V15, P2333; YAMAUCHI K, 1993, J BIOL CHEM, V268, P14597; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324	36	54	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					18134	18139		10.1074/jbc.271.30.18134	http://dx.doi.org/10.1074/jbc.271.30.18134			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663437	hybrid			2022-12-25	WOS:A1996UY93500082
J	Fukudome, K; Kurosawa, S; StearnsKurosawa, DJ; He, XH; Rezaie, AR; Esmon, CT				Fukudome, K; Kurosawa, S; StearnsKurosawa, DJ; He, XH; Rezaie, AR; Esmon, CT			The endothelial cell protein C receptor - Cell surface expression and direct ligand binding by the soluble receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOD-COAGULATION; TISSUE FACTOR; ACTIVE-SITE; ACTIVATION; THROMBIN; THROMBOMODULIN; DISTINCT; CALCIUM; VECTOR	Expression of the endothelial cell protein C receptor (EPCR) gene in mammalian cells imparts the capacity to bind activated protein C (APC) or protein C. Immunochemical analysis of CCD41, apparently the murine homologue of EPCR, suggested centrosomal localization, raising questions about the location of the EPCR gene product and its role in protein C binding, In this study, we express a soluble form of EPCR, demonstrate EPCR expression on the cell surface, and direct binding between soluble EPCR and protein C/APC. Affinity purified polyclonal and a monoclonal antibody against EPCR bound to the cell surface of EPCR-transfected cells but not to control cells. A 49-kDa protein, a mass similar to soluble EPCR, was immunoprecipitated from the cell surface of endothelium and cells transfected with human EPCR but not from control cells, The FLAG(TM) antibody and APC bound to cells expressing an EPCR construct containing the FLAG(TM) epitope located in a putative extracellular domain, whereas an EPCR construct truncated just before the putative transmembrane domain produced only soluble EPCR antigen, Soluble EPCR inhibited APC binding to EPCR expressing cells in a concentration-dependent fashion, K-d (app) = 29 nM and bound to immobilized protein C in a Ca2+-dependent fashion. Thus, EPCR is a type 1 transmembrane protein that binds directly to APC.	UNIV OKLAHOMA,CARDIOVASC BIOL RES PROGRAM,OKLAHOMA MED RES FDN,HLTH SCI CTR,DEPT BIOCHEM,OKLAHOMA CITY,OK 73104; UNIV OKLAHOMA,CARDIOVASC BIOL RES PROGRAM,OKLAHOMA MED RES FDN,HLTH SCI CTR,DEPT MOL BIOL,OKLAHOMA CITY,OK 73104; HOWARD HUGHES MED INST,OKLAHOMA CITY,OK 73104	Oklahoma Medical Research Foundation; University of Oklahoma System; University of Oklahoma Health Sciences Center; Oklahoma Medical Research Foundation; University of Oklahoma System; University of Oklahoma Health Sciences Center; Howard Hughes Medical Institute	Fukudome, K (corresponding author), UNIV OKLAHOMA,CARDIOVASC BIOL RES PROGRAM,OKLAHOMA MED RES FDN,HLTH SCI CTR,DEPT PATHOL,OKLAHOMA CITY,OK 73104, USA.			Stearns-Kurosawa, Deborah/0000-0003-2486-923X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL054804] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL54804] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BANGALORE N, 1994, THROMB HAEMOSTASIS, V72, P465; BERG DT, 1992, NUCLEIC ACIDS RES, V20, P5485, DOI 10.1093/nar/20.20.5485; BERTINA RM, 1994, NATURE, V369, P64, DOI 10.1038/369064a0; BOCK PE, 1988, BIOCHEMISTRY-US, V27, P6633, DOI 10.1021/bi00417a063; COUGHLIN SR, 1994, TRENDS CARDIOVAS MED, V4, P77, DOI 10.1016/1050-1738(94)90013-2; DAHLBACK B, 1995, BLOOD, V85, P607, DOI 10.1182/blood.V85.3.607.bloodjournal853607; EDGINGTON TS, 1991, THROMB HAEMOSTASIS, V66, P67; ESMON CT, 1995, TRENDS CARDIOVAS MED, V5, P141, DOI 10.1016/1050-1738(95)00054-D; ESMON CT, 1993, METHOD ENZYMOL, V222, P359; ESMON CT, 1995, FASEB J, V9, P946, DOI 10.1096/fasebj.9.10.7615164; ESMON CT, 1989, J BIOL CHEM, V264, P4743; FUKUDOME K, 1995, J BIOL CHEM, V270, P5571, DOI 10.1074/jbc.270.10.5571; FUKUDOME K, 1994, J BIOL CHEM, V269, P26486; GERMAIN RN, 1994, CELL, V76, P287, DOI 10.1016/0092-8674(94)90336-0; GREY ST, 1994, J IMMUNOL, V153, P3664; GRINNELL BW, 1994, GLYCOBIOLOGY, V4, P221, DOI 10.1093/glycob/4.2.221; KISIEL W, 1981, METHOD ENZYMOL, V80, P320; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MIYAKE K, 1991, J EXP MED, V173, P599, DOI 10.1084/jem.173.3.599; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; REGAN L, 1995, BLOOD, V86, P197; REGAN LM, 1996, J BIOL CHEM, V271, P17504; REZAIE AR, 1992, PROTEIN EXPRES PURIF, V3, P453, DOI 10.1016/1046-5928(92)90062-2; REZAIE AR, 1992, J BIOL CHEM, V267, P26104; RIVARD GE, 1995, J PEDIATR-US, V126, P646, DOI 10.1016/S0022-3476(95)70369-1; ROTHBARTH K, 1993, J CELL SCI, V104, P19; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEKIYA F, 1995, J BIOL CHEM, V270, P14325, DOI 10.1074/jbc.270.24.14325; STERNS DJ, 1988, J BIOL CHEM, V263, P826; TAYLOR FB, 1987, J CLIN INVEST, V79, P918, DOI 10.1172/JCI112902; YE J, 1991, J BIOL CHEM, V266, P23016	31	126	130	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					17491	17498		10.1074/jbc.271.29.17491	http://dx.doi.org/10.1074/jbc.271.29.17491			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663475	hybrid			2022-12-25	WOS:A1996UX94300078
J	MacColl, R; Eisele, LE; Williams, EC; Bowser, SS				MacColl, R; Eisele, LE; Williams, EC; Bowser, SS			The discovery of a novel R-phycoerythrin from an Antarctic Red Alga	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BILIN ATTACHMENT SITES; ENERGY-TRANSFER; GAMMA-SUBUNITS; CYANOBACTERIUM; SYNECHOCOCCUS	A novel biliprotein, named R-phycoerythrin IV, has been discovered, It absorbs blue light better than any other known red algal biliprotein. The protein was found in Phyllophora antarctica, a benthic macroalga, which grows beneath the coastal waters of McMurdo Sound, Antarctica. Fluorescence emission and fluorescence excitation polarization spectroscopy demonstrated that R-phycoerythrin IV behaved as a typical R-phycoerythrin in the functioning of energy migration and has an emission maximum at 577 nn. The circular dichroism (CD) spectrum of the chromophores was compared with visible absorption spectrum, and both were deconvoluted. This process showed the energy states of various individual chromophores. The molecular weight of the protein suggested a alpha(6) beta(6) gamma polypeptide structure, and far UV CD studies revealed polypeptides with highly alpha-helical secondary structures, Dynamic light scattering indicated that the protein had a 5.54 nm radius, and its shape was nonspherical, R-phycoerythrin was also purified from a second benthic Antarctic red alga, Iridaea cordata. Its spectroscopic properties were similar to those of some R-phycoerythrins from nonpolar regions. The unique spectroscopic properties of R-phycocerythrin IV may help enable the alga to occupy its niche deeper in the water column than the red alga that has the typical R-phycoerythrin.	SUNY ALBANY,DEPT BIOMED SCI,ALBANY,NY 12201	State University of New York (SUNY) System; State University of New York (SUNY) Albany	MacColl, R (corresponding author), NYSDOH,WADSWORTH CTR,POB 509,ALBANY,NY 12201, USA.							ALBERTE RS, 1984, PLANT PHYSIOL, V75, P732, DOI 10.1104/pp.75.3.732; DAGNOLO E, 1994, PHYTOCHEMISTRY, V35, P693, DOI 10.1016/S0031-9422(00)90589-2; GANTT E, 1981, ANNU REV PLANT PHYS, V32, P327, DOI 10.1146/annurev.pp.32.060181.001551; HOLZWARTH AR, 1991, PHYSIOL PLANTARUM, V83, P518, DOI 10.1111/j.1399-3054.1991.tb00129.x; KLOTZ AV, 1985, J BIOL CHEM, V260, P4856; KURSAR TA, 1981, P NATL ACAD SCI USA, V78, P1; MacColl R., 1987, P1; Maccoll R, 1991, J Fluoresc, V1, P135, DOI 10.1007/BF00865209; MACCOLL R, 1995, J BIOL CHEM, V270, P27555, DOI 10.1074/jbc.270.46.27555; MILLER KA, 1991, AM ZOOL, V31, P35; NAGY JO, 1985, J BIOL CHEM, V260, P4864; ONG LJ, 1991, J BIOL CHEM, V266, P9515; ONG LJ, 1984, SCIENCE, V224, P80, DOI 10.1126/science.224.4644.80; RENNIS DS, 1992, PHYCOLOGIA, V31, P192, DOI 10.2216/i0031-8884-31-2-192.1; SCHEER H, 1981, ANGEW CHEM INT EDIT, V20, P241, DOI 10.1002/anie.198102411; Sidler W., 1988, PHOTOSYNTHETIC LIGHT, P49; STADNICHUK I N, 1984, Molekulyarnaya Biologiya (Moscow), V18, P343; STADNICHUK IN, 1993, J PHOTOCH PHOTOBIO B, V18, P169, DOI 10.1016/1011-1344(93)80059-I; STADNICHUK IN, 1993, PHOTOSYNTHETICA, V29, P55; WOOD AM, 1985, NATURE, V316, P353; YANG JT, 1986, METHOD ENZYMOL, V130, P208; YU MH, 1981, PLANT PHYSIOL, V68, P482, DOI 10.1104/pp.68.2.482; ZILINSKAS BA, 1986, PHOTOSYNTH RES, V10, P7, DOI 10.1007/BF00024183	23	38	42	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					17157	17160		10.1074/jbc.271.29.17157	http://dx.doi.org/10.1074/jbc.271.29.17157			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663533	hybrid			2022-12-25	WOS:A1996UX94300029
J	White, MA; Vale, T; Camonis, JH; Schaefer, E; Wigler, MH				White, MA; Vale, T; Camonis, JH; Schaefer, E; Wigler, MH			A role for the Ral guanine nucleotide dissociation stimulator in mediating Ras-induced transformation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-KINASE; ACTIVATION; PATHWAY; CELLS	Oncogenic Ras transforms cells through the activation of multiple downstream pathways mediated by separate effector molecules, one of which is Raf. Here we report the identification of a second ras-binding protein that can induce cellular transformation in parallel with activation of the Raf/mitogen-activated protein kinase cascade. The Ral guanine nucleotide dissociation stimulator (RalGDS) was isolated from a screen for Ras-binding proteins that specifically interact with a Ras effector-loop mutant, ras(12V,37G), that uncouples Ras from activation of Raf1. RalGDS, like ras(12V,37G), cooperates synergistically with mutationally activated Raf to induce foci of growth and morphologically transformed NIH 3T3 cells. RalGDS does not significantly enhance MAP kinase activation by activated Raf, suggesting that the cooperativity in focus formation is due to a distinct pathway acting downstream of Ras and parallel to Raf.	INST CURIE,INSERM U248,SECT RECH,F-75231 PARIS,FRANCE; PROMEGA CORP,MADISON,WI 53711; COLD SPRING HARBOR LABS,COLD SPRING HARBOR,NY 10021	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Promega Corporation; Cold Spring Harbor Laboratory	White, MA (corresponding author), UNIV TEXAS,SW MED CTR,DEPT CELL BIOL & NEUROSCI,5323 HARRY HINES BLVD,DALLAS,TX 75235, USA.			Wigler, Michael/0000-0003-4396-1971				ALBRIGHT CF, 1993, EMBO J, V12, P339, DOI 10.1002/j.1460-2075.1993.tb05662.x; ALESSI DR, 1995, METHOD ENZYMOL, V255, P279; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; CHARDIN P, 1986, EMBO J, V5, P2203, DOI 10.1002/j.1460-2075.1986.tb04485.x; CHEN SY, 1994, ONCOGENE, V9, P2691; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DIAZMECO MT, 1994, J BIOL CHEM, V269, P31706; FIELDS S, 1994, TRENDS GENET, V10, P286, DOI 10.1016/0168-9525(90)90012-U; FRECH M, 1990, J BIOL CHEM, V265, P6353; HAN LM, 1995, MOL CELL BIOL, V15, P1318; HOFER F, 1994, P NATL ACAD SCI USA, V91, P11089, DOI 10.1073/pnas.91.23.11089; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; JULLIENFLORES V, 1995, J BIOL CHEM, V270, P22473, DOI 10.1074/jbc.270.38.22473; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; Kikuchi A, 1996, J BIOL CHEM, V271, P588, DOI 10.1074/jbc.271.1.588; KIKUCHI A, 1994, MOL CELL BIOL, V14, P7483, DOI 10.1128/MCB.14.11.7483; Kuriyama M, 1996, J BIOL CHEM, V271, P607, DOI 10.1074/jbc.271.2.607; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; MACDONALD SG, 1993, MOL CELL BIOL, V13, P6615, DOI 10.1128/MCB.13.11.6615; POWERS S, 1989, MOL CELL BIOL, V9, P390, DOI 10.1128/MCB.9.2.390; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RUSSELL M, 1995, J BIOL CHEM, V270, P11757, DOI 10.1074/jbc.270.20.11757; SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P12609, DOI 10.1073/pnas.91.26.12609; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373	31	223	224	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16439	16442		10.1074/jbc.271.28.16439	http://dx.doi.org/10.1074/jbc.271.28.16439			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663585	hybrid, Green Accepted			2022-12-25	WOS:A1996UX12600003
J	Gately, DP; Howell, SB				Gately, DP; Howell, SB			Paclitaxel activation of the GADD153 promoter through a cellular injury response element containing an essential Sp1 binding site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; SP1-MEDIATED TRANSCRIPTION; TYROSINE PHOSPHORYLATION; GENOTOXIC STRESS; DNA DAMAGE; GENE; INDUCTION; CELLS; PROTEINS; FAMILY	The GADD153 promoter is transcriptionally activated by paclitaxel-induced injury. Promoter deletion from -786 to -85 base pairs relative to the start of transcription had no significant effect on activation, but deletion to the TATA box abolished it. Placement of the 39 bases from -74 to the TATA box (cellular injury response element, CIRE) upstream of the adenovirus E4 TATA box conferred paclitaxel inducibility. The only consensus sequence present in the CIRE is an Sp1 site; mutation of this site inhibited paclitaxel activation. Paclitaxel failed to activate a SV40-driven luciferase construct containing five Sp1 sequences, and Sp1 sites further upstream in the GADD153 promoter were not essential for activation. Pure Sp1 and nuclear extracts from uninjured and paclitaxel-injured cells protected the same region from -62 to -48 bases on the noncoding strand and -74 to -53 on the coding strand. Nuclear extracts shifted the CIRE to the same extent as purified Sp1 but had no effect on a CIRE with a mutated Sp1 site in gel shift assays. Immunodepletion of Sp1 abolished the shift; antibody to Sp1 produced a supershift. These data indicate that paclitaxel activates the GADD153 promoter through a constitutively occupied Sp1 site at -61 bases.	UNIV CALIF SAN DIEGO, DEPT MED, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego	Gately, DP (corresponding author), UNIV CALIF SAN DIEGO, DEPT BIOMED SCI, 9500 GILMAN DR 0812, LA JOLLA, CA 92093 USA.							BARONE MV, 1994, GENE DEV, V8, P453, DOI 10.1101/gad.8.4.453; BORELLINI F, 1993, J BIOL CHEM, V268, P7923; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; CHEN HM, 1993, J BIOL CHEM, V268, P8230; CHEN LI, 1994, MOL CELL BIOL, V14, P4380, DOI 10.1128/MCB.14.7.4380; DAVIS LG, 1986, BASIC METHODS MOL BI, P129; DING AH, 1990, SCIENCE, V248, P370, DOI 10.1126/science.1970196; DISAIA PJ, 1972, AM J OBSTET GYNECOL, V114, P979, DOI 10.1016/0002-9378(72)90109-3; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FORNACE AJ, 1988, P NATL ACAD SCI USA, V85, P8800, DOI 10.1073/pnas.85.23.8800; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; Gately DP, 1996, BRIT J CANCER, V73, P18, DOI 10.1038/bjc.1996.4; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; HALDAR S, 1995, P NATL ACAD SCI USA, V92, P4507, DOI 10.1073/pnas.92.10.4507; HOLBROOK NJ, 1991, NEW BIOL, V3, P825; JACKMAN J, 1994, CANCER RES, V54, P5656; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KIM SJ, 1992, MOL CELL BIOL, V12, P2455, DOI 10.1128/MCB.12.6.2455; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; LIU YO, 1994, BIOCHEM PHARMACOL, V48, P1265; LUETHY JD, 1992, CANCER RES, V52, P5; MAJELLO B, 1994, NUCLEIC ACIDS RES, V22, P4914, DOI 10.1093/nar/22.23.4914; MANTHEY CL, 1992, J IMMUNOL, V149, P2459; PARK JS, 1992, GENE, V116, P259, DOI 10.1016/0378-1119(92)90523-R; POSTLIND H, 1993, TOXICOL APPL PHARM, V118, P255, DOI 10.1006/taap.1993.1031; ROSE JK, 1991, BIOTECHNIQUES, V10, P520; SYLVESTER SL, 1994, J BIOL CHEM, V269, P20119; VLACH J, 1995, VIROLOGY, V208, P753, DOI 10.1006/viro.1995.1207; YIEH L, 1995, P NATL ACAD SCI USA, V92, P6102, DOI 10.1073/pnas.92.13.6102; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361; ZHANG DE, 1994, J BIOL CHEM, V269, P11425	34	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20588	20593		10.1074/jbc.271.34.20588	http://dx.doi.org/10.1074/jbc.271.34.20588			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702804	hybrid			2022-12-25	WOS:A1996VD33700056
J	Ueda, A; Yoshimura, T				Ueda, A; Yoshimura, T			Characterization of cis-acting elements of the gene for macrophage-stimulating protein from the human - The involvement of positive and negative regulatory elements	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATOCYTE-GROWTH-FACTOR; CCAAT-BINDING PROTEIN; TRANSCRIPTION FACTOR; TYROSINE KINASE; DNA-BINDING; MOLECULAR-CLONING; EUKARYOTIC TRANSCRIPTION; HETEROLOGOUS SUBUNITS; SEQUENCE IDENTITY; NUCLEAR FACTOR	To analyze the promotor region of the human macrophage-stimulating protein (MSP) gene, the 5'-flanking region of this gene was cloned. The major initiation site was determined at T located 49 base pairs upstream of the translation initiation site by primer extention with mRNA from HepG2 and Hep3B cells. There was no TATA sequence in this region. Transient transfection assay with 5'-deletion constructs showed that the transcription of this gene was regulated by positive and negative regulatory elements (PRE and NRE). The PRE (-34 to +2) was essential for the maximal transcription of this gene, and the NRE (-141 to -34) appeared to be responsible for the tissue-specific expression of the gene. The PRE contained the CCAAT sequence and a mutation from CCAAT to CTGAT resulted in a significant loss of the transcriptional activity. Electrophoretic mobility shift assay suggested that two different proteins bound to the PRE (MSP-PRE-binding protein-1 (MSP-PREB1) and 2). MSP-PREB1 and 2 were detected in various cell types, and the CCAAT sequence was involved in these bindings. These findings indicate that MSP-PREB1 and 2 are positive regulators. Further characterization also revealed that MSP-PREB2 was identical to CCAAT binding transcription factor, also known as NF-Y.			Ueda, A (corresponding author), NCI,FREDERICK CANC RES & DEV CTR,IMMUNOBIOL LAB,IMMUNOPATHOL SECT,FREDERICK,MD 21702, USA.			Yoshimura, Teizo/0000-0002-3853-2075				AUSUBEL FM, 1990, CURRENT PROTOCOLS MO; BEZERRA JA, 1994, BIOCHEM BIOPH RES CO, V203, P666, DOI 10.1006/bbrc.1994.2234; CHODOSH LA, 1988, CELL, V53, P25, DOI 10.1016/0092-8674(88)90484-9; CHODOSH LA, 1988, CELL, V53, P11, DOI 10.1016/0092-8674(88)90483-7; COSTA RH, 1988, P NATL ACAD SCI USA, V85, P3840, DOI 10.1073/pnas.85.11.3840; COURTOIS G, 1987, SCIENCE, V238, P688, DOI 10.1126/science.3499668; DEGEN SJF, 1991, BIOCHEMISTRY-US, V30, P9781, DOI 10.1021/bi00104a030; DORN A, 1987, CELL, V50, P863, DOI 10.1016/0092-8674(87)90513-7; FIGUEIREDO MS, 1995, J BIOL CHEM, V270, P11828, DOI 10.1074/jbc.270.20.11828; GAUDINO G, 1994, EMBO J, V13, P3524, DOI 10.1002/j.1460-2075.1994.tb06659.x; HAN S, 1991, BIOCHEMISTRY-US, V30, P9768, DOI 10.1021/bi00104a029; HARRISON P, 1994, LANCET, V344, P27, DOI 10.1016/S0140-6736(94)91050-2; HATAMOCHI A, 1988, J BIOL CHEM, V263, P5940; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; HUIJSDUIJNEN RH, 1990, EMBO J, V9, P3119; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; IWAMA A, 1994, BLOOD, V83, P3160, DOI 10.1182/blood.V83.11.3160.bloodjournal83113160; JONES KA, 1987, CELL, V48, P79, DOI 10.1016/0092-8674(87)90358-8; LAI E, 1991, TRENDS BIOCHEM SCI, V16, P427, DOI 10.1016/0968-0004(91)90169-V; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; LEASK A, 1991, P NATL ACAD SCI USA, V88, P7948, DOI 10.1073/pnas.88.18.7948; LUM LSY, 1990, MOL CELL BIOL, V10, P6709, DOI 10.1128/MCB.10.12.6709; MAIRE P, 1989, SCIENCE, V244, P343, DOI 10.1126/science.2711183; MAITY SN, 1990, P NATL ACAD SCI USA, V87, P5378, DOI 10.1073/pnas.87.14.5378; MAITY SN, 1988, SCIENCE, V241, P582, DOI 10.1126/science.3399893; MANTOVANI R, 1992, EMBO J, V11, P3315, DOI 10.1002/j.1460-2075.1992.tb05410.x; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; PANG JH, 1993, J BIOL CHEM, V268, P2909; RONSIN C, 1993, ONCOGENE, V8, P1195; ROY B, 1995, MOL CELL BIOL, V15, P2263; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0; SINHA S, 1995, P NATL ACAD SCI USA, V92, P1624, DOI 10.1073/pnas.92.5.1624; SKEEL A, 1991, J EXP MED, V173, P1227, DOI 10.1084/jem.173.5.1227; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SWICK AG, 1989, NUCLEIC ACIDS RES, V17, P9291, DOI 10.1093/nar/17.22.9291; THERY C, 1995, DEV GENET, V17, P90, DOI 10.1002/dvg.1020170110; UEDA A, 1994, J IMMUNOL, V153, P2052; VUORIO T, 1990, J BIOL CHEM, V265, P22480; WANG MH, 1995, P NATL ACAD SCI USA, V92, P3933, DOI 10.1073/pnas.92.9.3933; WANG MH, 1994, SCIENCE, V266, P117, DOI 10.1126/science.7939629; WANG MH, 1993, J LEUKOCYTE BIOL, V54, P289, DOI 10.1002/jlb.54.4.289; WANG MH, 1994, J BIOL CHEM, V269, P13806; WANG MH, 1994, J BIOL CHEM, V269, P3436; WEINTRAUB H, 1989, P NATL ACAD SCI USA, V86, P5434, DOI 10.1073/pnas.86.14.5434; WEIS L, 1992, FASEB J, V6, P3300, DOI 10.1096/fasebj.6.14.1426767; WELCH HM, 1989, GENOMICS, V5, P423, DOI 10.1016/0888-7543(89)90005-0; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; YOSHIMURA T, 1993, J BIOL CHEM, V268, P15461; ZANNIS VI, 1994, LIVER GENE EXPRESSIO, P63; ZORBAS H, 1992, J BIOL CHEM, V267, P8478	51	12	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20265	20272		10.1074/jbc.271.34.20265	http://dx.doi.org/10.1074/jbc.271.34.20265			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702759	hybrid			2022-12-25	WOS:A1996VD33700011
J	Farfel, Z; Iiri, T; Shapira, H; Roitman, A; Mouallem, M; Bourne, HR				Farfel, Z; Iiri, T; Shapira, H; Roitman, A; Mouallem, M; Bourne, HR			Pseudohypoparathyroidism, a novel mutation in the beta gamma-contact region of G(s)alpha impairs receptor stimulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; ADENYLYL-CYCLASE; GTP HYDROLYSIS; ALPHA-SUBUNIT; G-PROTEIN; G(I-ALPHA-1); ACTIVATION; MECHANISM	Pseudohypoparathyroidism, type Ia (PHP-Ia), is a dominantly inherited endocrine disorder characterized by resistance to hormones that act by stimulating adenylyl cyclase. It is caused by inheritance of an autosomal mutation that inactivates the alpha subunit (alpha(s)) of G(s), the stimulatory regulator of adenylyl cyclase. In three members of a family, the PHP-Ia phenotype is associated with a mutation (R231H) that substitutes histidine for an arginine at position 231 in alpha(s). We assessed signaling function of alpha(s)-WT versus alpha(s)-R231H transiently transfected in HEK293 cells. Hormone receptor-dependent stimulation of cAMP accumulation in cells expressing alpha(s)-R231H is reduced by similar to 75% in comparison to cAMP accumulation in cells expressing alpha(s)-WT. A second mutation, alpha(s)-R201C, inhibits the GTPase turnoff reaction of alpha(s), thus producing receptor-independent stimulation of cAMP accumulation. The double mutant, alpha(s)-R231H/R201C, stimulates cAMP accumulation almost as well (similar to 80%) as does alpha(s)-R201C itself, indicating that the R231H mutation selectively impairs receptor-dependent signaling. In three-dimensional structures of G protein heterotrimers, Arg-231 is located in a region, switch 2, that is thought to interact with the beta gamma subunit rather than with the hormone receptor. Thus, the R231H phenotype suggests that switch 2 (perhaps in concert with beta gamma) mediates G protein activation by receptors at a site distant from the receptor-G protein contact surface.	TEL AVIV UNIV,CHAIM SHEBA MED CTR,BIOCHEM PHARMACOL LAB,IL-52621 TEL HASHOMER,ISRAEL; MACCABI SICK FUND,TEL AVIV,ISRAEL; UNIV CALIF SAN FRANCISCO,DEPT PHARMACOL,SAN FRANCISCO,CA 94143	Chaim Sheba Medical Center; Tel Aviv University; University of California System; University of California San Francisco	Farfel, Z (corresponding author), TEL AVIV UNIV,CHAIM SHEBA MED CTR,DEPT MED E,IL-52621 TEL HASHOMER,ISRAEL.							Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; FARFEL Z, 1980, NEW ENGL J MED, V303, P237, DOI 10.1056/NEJM198007313030501; IIRI T, 1994, NATURE, V371, P164, DOI 10.1038/371164a0; KOZASA T, 1988, P NATL ACAD SCI USA, V85, P2081, DOI 10.1073/pnas.85.7.2081; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LEVINE MA, 1980, BIOCHEM BIOPH RES CO, V94, P1319, DOI 10.1016/0006-291X(80)90563-X; LEVINE MA, 1995, ENDOCRINOLOGY, P1136; LEVIS MJ, 1992, J CELL BIOL, V119, P1297, DOI 10.1083/jcb.119.5.1297; MIXON MB, 1995, SCIENCE, V270, P954, DOI 10.1126/science.270.5238.954; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; SCHWINDINGER WF, 1994, J BIOL CHEM, V269, P25387; Shapira H, 1996, HUM GENET, V97, P73; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; WEDEGAERTNER PB, 1993, J BIOL CHEM, V268, P25001; WONG YH, 1991, NATURE, V351, P63, DOI 10.1038/351063a0	19	63	64	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					19653	19655		10.1074/jbc.271.33.19653	http://dx.doi.org/10.1074/jbc.271.33.19653			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702665	hybrid			2022-12-25	WOS:A1996VC66900006
J	Bass, J; Kurose, T; Pashmforoush, M; Steiner, DF				Bass, J; Kurose, T; Pashmforoush, M; Steiner, DF			Fusion of insulin receptor ectodomains to immunoglobulin constant domains reproduces high-affinity insulin binding in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE-ACTIVITY; FACTOR-I RECEPTOR; STRUCTURAL BASIS; ALPHA-SUBUNIT; MONOCLONAL-ANTIBODIES; LIGAND-BINDING; EFFICIENT NEUTRALIZATION; NEGATIVE COOPERATIVITY; ENDOPLASMIC-RETICULUM; EXTRACELLULAR DOMAIN	A unique feature of the insulin receptor is that it is dimeric in the absence of ligand, Dimerization of two adjacent transmembrane domain (TMD) alpha helices has been shown to be critical in receptor kinase activation, Moreover, previous work has suggested that the TMD is involved in stabilizing the high-affinity binding site; soluble receptors expressed after simple truncation at the ectodomain-TMD junction have reduced affinity for insulin. To further examine this issue, we have replaced the TMD and intracellular domain of the soluble human insulin receptor (HIRs) with constant domains from immunoglobulin Fc and lambda subunits (HIRs-Fc and HIRs-lambda), Studies of receptor biosynthesis and binding characteristics were performed following transient transfection of receptor cDNAs into human embryonal kidney 293 cells. Each hybrid receptor was initially synthesized as a single chain proreceptor, followed by cleavage into alpha- and beta-Fc or beta-lambda subunits. The majority of secreted protein appeared in the cell medium as fully processed heterotetramer, Fe fragments released from HIRs-Fc by papain digestion and analyzed by nonreducing SDS-polyacrylamide gel electrophoresis were dimeric, Furthermore, dissociation constants for both chimeras were similar to those for the full-length holoreceptor (wild-type receptor, K-d1 = 200 pM and K-d2 = 2 nM; HIRs-Fc, K-d1 = 200 pM and K-d2 = 40 nM; and HIRs-lambda, K-d1 = 200 pw and K-d2 = 5 nM). These results extend previous observations that dimerization of the membrane-proximal ectodomain is necessary to maintain an intact high-affinity insulin-binding site.	UNIV CHICAGO,DEPT BIOCHEM & MOL BIOL,CHICAGO,IL 60637; UNIV CHICAGO,HOWARD HUGHES MED INST,CHICAGO,IL 60637	University of Chicago; Howard Hughes Medical Institute; University of Chicago	Bass, J (corresponding author), UNIV CHICAGO,DEPT MED,ENDOCRINOL SECT,5841 S MARYLAND AVE,MC 1028,CHICAGO,IL 60637, USA.				NIDDK NIH HHS [DK 13914, T32 DK07011, DK 20595] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007011, R37DK013914, P60DK020595, P30DK020595, R01DK013914] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ACCILI D, 1992, J BIOL CHEM, V267, P586; ARAKAKI RF, 1987, J BIOL CHEM, V262, P11886; ASHKENAZI A, 1991, P NATL ACAD SCI USA, V88, P10535, DOI 10.1073/pnas.88.23.10535; BENNETT MJ, 1994, P NATL ACAD SCI USA, V91, P3127, DOI 10.1073/pnas.91.8.3127; BHARUCHA DB, 1990, J BIOL CHEM, V265, P3070; BONISCHNETZLER M, 1987, J BIOL CHEM, V262, P8395; BRAVO DA, 1994, J BIOL CHEM, V269, P25830; CAPON DJ, 1989, NATURE, V337, P525, DOI 10.1038/337525a0; CHEATHAM B, 1993, P NATL ACAD SCI USA, V90, P7336, DOI 10.1073/pnas.90.15.7336; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CUATRECASAS P, 1972, J BIOL CHEM, V247, P1980; DAVID V, 1993, J BIOL CHEM, V268, P9585; DEMEYTS P, 1994, DIABETOLOGIA, V37, pS135, DOI 10.1007/BF00400837; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; FABRY M, 1992, J BIOL CHEM, V267, P8950; FRATTALI AL, 1993, J BIOL CHEM, V268, P7393; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GUSTAFSON TA, 1990, J BIOL CHEM, V265, P18663; HAAKFRENDSCHO M, 1993, J IMMUNOL, V151, P351; Harlow E., 1988, ANTIBODIES LAB MANUA; HELENIUS A, 1994, MOL BIOL CELL, V5, P253, DOI 10.1091/mbc.5.3.253; HSU TA, 1994, PROTEIN EXPRES PURIF, V5, P595, DOI 10.1006/prep.1994.1082; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; KASUGA M, 1982, J BIOL CHEM, V257, P392; KJELDSEN T, 1994, J BIOL CHEM, V269, P32942; KLEIN M, 1977, BIOCHEMISTRY-US, V16, P552, DOI 10.1021/bi00622a032; KUROSE T, 1994, J BIOL CHEM, V269, P29190; LAURELL CB, 1975, J EXP MED, V141, P453, DOI 10.1084/jem.141.2.453; LEE JS, 1993, J BIOL CHEM, V268, P4092; Maniatis T, 1989, DECONTAMINATION DILU; MARKUSSEN J, 1991, J BIOL CHEM, V266, P18814; MARTIN S, 1993, J VIROL, V67, P3561, DOI 10.1128/JVI.67.6.3561-3568.1993; MEINICK J, 1994, NATURE, V370, P373; Mynarcik DC, 1996, J BIOL CHEM, V271, P2439, DOI 10.1074/jbc.271.5.2439; OLSON TS, 1988, J BIOL CHEM, V263, P7342; PASHMFOROUSH M, 1994, J BIOL CHEM, V269, P32639; PAUL JI, 1990, J BIOL CHEM, V265, P13074; PILCH PF, 1980, J BIOL CHEM, V255, P1722; PRIGENT SA, 1990, J BIOL CHEM, V265, P9970; ROBINSON AS, 1994, BIO-TECHNOL, V12, P381, DOI 10.1038/nbt0494-381; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHAEFER EM, 1990, J BIOL CHEM, V265, P13248; SCHIFFER M, 1973, BIOCHEMISTRY-US, V12, P4620, DOI 10.1021/bi00747a013; SCHUMACHER R, 1993, J BIOL CHEM, V268, P1087; SISSOM J, 1989, BIOCHEM J, V261, P119, DOI 10.1042/bj2610119; SWEET LJ, 1987, J BIOL CHEM, V262, P6939; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; TAOUIS M, 1994, J BIOL CHEM, V269, P14912; TAYLOR R, 1987, BIOCHEM J, V242, P123, DOI 10.1042/bj2420123; Taylor Simeon I., 1994, P1; TRAUNECKER A, 1989, NATURE, V339, P68, DOI 10.1038/339068a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; WAUGH SM, 1989, BIOCHEMISTRY-US, V28, P3448, DOI 10.1021/bi00434a045; WEBER S, 1992, NATURE, V356, P793, DOI 10.1038/356793a0; WHITE MF, 1994, J BIOL CHEM, V269, P1; WHITTAKER J, 1994, MOL ENDOCRINOL, V8, P1521, DOI 10.1210/me.8.11.1521; WHITTAKER J, 1987, P NATL ACAD SCI USA, V84, P5237, DOI 10.1073/pnas.84.15.5237; WILLIAMS PF, 1995, J BIOL CHEM, V270, P3012, DOI 10.1074/jbc.270.7.3012; YAMADA K, 1995, BIOCHEMISTRY-US, V34, P946, DOI 10.1021/bi00003a029; YAMADA K, 1992, J BIOL CHEM, V267, P12452; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YILLA M, 1992, J CELL BIOL, V118, P245, DOI 10.1083/jcb.118.2.245; YIP CC, 1988, BIOCHEM BIOPH RES CO, V157, P321, DOI 10.1016/S0006-291X(88)80050-0; YOSHIMASA Y, 1988, SCIENCE, V240, P784, DOI 10.1126/science.3283938; YOSHIMASA Y, 1990, J BIOL CHEM, V265, P17230; ZHANG B, 1991, P NATL ACAD SCI USA, V88, P9858, DOI 10.1073/pnas.88.21.9858; ZHANG B, 1991, BIOCHEMISTRY-US, V30, P5113, DOI 10.1021/bi00235a001	68	35	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19367	19375		10.1074/jbc.271.32.19367	http://dx.doi.org/10.1074/jbc.271.32.19367			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702623	hybrid			2022-12-25	WOS:A1996VB68400057
J	Guo, QP; Wang, LH; Ruan, KH; Kulmacz, RJ				Guo, QP; Wang, LH; Ruan, KH; Kulmacz, RJ			Role of Val(509) in time-dependent inhibition of human prostaglandin H synthase-2 cyclooxygenase activity by isoform-selective agents	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; ANTI-INFLAMMATORY DRUGS; G/H SYNTHASE-1; ASPIRIN; SITE; REQUIREMENTS; PURIFICATION; SYNTHETASE; TEMPLATES; PROTEIN	Prostaglandin H synthase (PGHS), a hey enzyme in prostanoid biosynthesis, exists as two isoforms. PGHS-1 is considered a basal enzyme; PGHS-2 is associated with inflammation and cell proliferation A number of highly selective inhibitors for PGHS-2 cyclooxygenase activity are known. Inhibition by these agents involves an initial reversible binding, followed by a time-dependent transition to a much higher affinity enzyme-inhibitor complex, making these agents potent and poorly reversible PGHS-2 inhibitors, To investigate the PGHS-2 structural features that influence the time-dependent action of the selective inhibitors, we have constructed a three-dimensional model of human PGHS-2 by homologous modeling, Examination of the PGHS-2 model identified Val(509) as a cyclooxygenase active site residue, that was not conserved in PGHS-1. Recombinant human PGHS-2 with Val(509) mutated to either Ile (the corresponding residue in PGHS-1), Ala, Glu, or Lys was expressed by transient transfection of COS-l cells to evaluate the effects of the mutations on cyclooxygenase activity and on inhibition by four agents reported to be selective for PGHS-2 (NS398, nimesulide, DuP697, and SC58125), All the recombinant proteins were of the expected mass, The mutants exhibited 45-210% of wild-type cyclooxygenase activity, with K-m values for arachidonate of 2.1-7.6 mu M (wild-type PGHS-2, 3.8 mu M), indicating that changes in position 509 had modest effects on cyclooxygenase catalysis, Each of the agents inhibited wild-type PGHS-2 in a Dime-dependent fashion, and all but nimesulide did the same for the V509A mutant, In contrast, the V509E and V509I PGHS-2 mutants, like recombinant human PGHS-1, did not show time-dependent inhibition with any of the agents, and the V509K mutant responded in a time-dependent manlier only to DuP697, Reversible inhibition was still observed with Val(509) mutants that did not show time-dependent inhibition, Thus, the side chain structure at position 509 markedly influenced the ability of PGHS-2 to undergo the time-dependent transition without removing inhibitor or substrate binding, These results indicate that Val(509) in PGHS-2 has a major role in the structural transition that underlies time-dependent inhibition by the isoform-selective agents.	UNIV TEXAS,HLTH SCI CTR,DEPT INTERNAL MED,DIV HEMATOL,HOUSTON,TX 77030; UNIV HOUSTON,DEPT BIOL,HOUSTON,TX 77204	University of Texas System; University of Texas Health Science Center Houston; University of Houston System; University of Houston					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052170] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 52170] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARNES WM, 1994, P NATL ACAD SCI USA, V91, P2216, DOI 10.1073/pnas.91.6.2216; BARNETT J, 1994, BBA-PROTEIN STRUCT M, V1209, P130, DOI 10.1016/0167-4838(94)90148-1; Bhattacharyya DK, 1996, J BIOL CHEM, V271, P2179, DOI 10.1074/jbc.271.4.2179; Callan OH, 1996, J BIOL CHEM, V271, P3548; CHOTHIA C, 1986, EMBO J, V5, P823, DOI 10.1002/j.1460-2075.1986.tb04288.x; COPELAND RA, 1994, P NATL ACAD SCI USA, V91, P11202, DOI 10.1073/pnas.91.23.11202; FUTAKI N, 1994, PROSTAGLANDINS, V47, P55, DOI 10.1016/0090-6980(94)90074-4; HEMSLEY A, 1989, NUCLEIC ACIDS RES, V17, P6545, DOI 10.1093/nar/17.16.6545; Herschman HR, 1996, BBA-LIPID LIPID MET, V1299, P125, DOI 10.1016/0005-2760(95)00194-8; HLA T, 1992, P NATL ACAD SCI USA, V89, P7384, DOI 10.1073/pnas.89.16.7384; Johnson JL, 1995, ARCH BIOCHEM BIOPHYS, V324, P26, DOI 10.1006/abbi.1995.9934; KULMACZ RJ, 1989, J BIOL CHEM, V264, P14136; KULMACZ RJ, 1985, J BIOL CHEM, V260, P2572; KULMACZ RJ, 1995, J BIOL CHEM, V270, P24019, DOI 10.1074/jbc.270.41.24019; Kulmacz RJ, 1987, PROSTAGLANDINS RELAT, P209; LANEUVILLE O, 1994, J PHARMACOL EXP THER, V271, P927; LECOMTE M, 1994, J BIOL CHEM, V269, P13207; MANCINI JA, 1995, J BIOL CHEM, V270, P29372, DOI 10.1074/jbc.270.49.29372; MIZUNO K, 1982, PROSTAGLANDINS, V23, P743; OUELLET M, 1995, BIOCHEM J, V306, P247, DOI 10.1042/bj3060247; PERCIVAL MD, 1994, ARCH BIOCHEM BIOPHYS, V315, P111, DOI 10.1006/abbi.1994.1478; PETERSON GL, 1983, METHOD ENZYMOL, V91, P95; PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0; REN Y, 1995, ARCH BIOCHEM BIOPHYS, V316, P751, DOI 10.1006/abbi.1995.1100; ROME LH, 1975, P NATL ACAD SCI USA, V72, P4863, DOI 10.1073/pnas.72.12.4863; ROTH GJ, 1983, BIOCHEMISTRY-US, V22, P4672, DOI 10.1021/bi00289a010; RUAN KH, 1994, PROTEIN ENG, V7, P1345, DOI 10.1093/protein/7.11.1345; SAMUELSSON B, 1978, ANNU REV BIOCHEM, V47, P997, DOI 10.1146/annurev.bi.47.070178.005025; SEIBERT K, 1994, P NATL ACAD SCI USA, V91, P12013, DOI 10.1073/pnas.91.25.12013; SMITH WL, 1994, MET IONS BIOL SYST, V30, P163; STANFORD N, 1977, PROSTAGLANDINS, V13, P669, DOI 10.1016/0090-6980(77)90237-4; WENNOGLE LP, 1995, FEBS LETT, V371, P315, DOI 10.1016/0014-5793(95)00930-8	32	112	113	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19134	19139		10.1074/jbc.271.32.19134	http://dx.doi.org/10.1074/jbc.271.32.19134			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702589	hybrid			2022-12-25	WOS:A1996VB68400023
J	Kusakabe, T; Richardson, CC				Kusakabe, T; Richardson, CC			The role of the zinc motif in sequence recognition by DNA primases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI PRIMASE; RNA PRIMER SYNTHESIS; T7 DEOXYRIBONUCLEIC-ACID; LAGGING-STRAND SYNTHESIS; COORDINATED LEADING-STRAND; 63-KDA GENE-4 PROTEIN; REPLICATION FORK; BACTERIOPHAGE-T7 DNA; TRANSCRIPTION FACTORS; TEMPLATE RECOGNITION	The DNA primase of bacteriophage T7 has a zinc-binding motif that is essential for the recognition of the sequence 3'-CTG-5'. The T7 primase also catalyzes helicase activity, a reaction coupled to nucleotide hydrolysis. We have replaced the zinc motif of the T7 primase with those found in the gene 61 primase of phage T4 and the DnaG primase of Escherichia coli. The T4 and E. coli primases recognize the sequences 3'-T(C/T)G-5' and 3'-GTC-5', respectively. Both chimeric proteins can partially replace T7 primase in vivo. The two chimeric primases catalyze the synthesis of oligoribonucleotides albeit at a reduced rate and DNA dependent dTTPase activity is reduced by 3-10-fold. Both chimeric proteins recognize 3'-(A/G)CG-5' sites on single-stranded DNA, sites that differ from those recognized by the T7, T4, or E. coli primases, indicating that the zinc motif is only one determinant in site-specific recognition.	HARVARD UNIV, SCH MED, DEPT BIOL CHEM, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT MOL PHARMACOL, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI006045, R37AI006045] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-06045] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARAI K, 1981, J BIOL CHEM, V256, P5260; ARAI K, 1981, J BIOL CHEM, V256, P5267; ARGARWAL K, 1991, BIOCHEMISTRY-US, V30, P7842; BECK PJ, 1989, J MOL BIOL, V210, P687, DOI 10.1016/0022-2836(89)90102-2; BERNSTEIN JA, 1988, P NATL ACAD SCI USA, V85, P396, DOI 10.1073/pnas.85.2.396; CHA TA, 1986, J BIOL CHEM, V261, P7001; CHA TA, 1990, BIOCHEMISTRY-US, V29, P1791, DOI 10.1021/bi00459a018; COLEMAN JE, 1992, ANNU REV BIOCHEM, V61, P897, DOI 10.1146/annurev.bi.61.070192.004341; DEBYSER Z, 1994, CELL, V77, P157, DOI 10.1016/0092-8674(94)90243-7; DUNN JJ, 1983, J MOL BIOL, V166, P477, DOI 10.1016/S0022-2836(83)80282-4; EGELMAN EH, 1995, P NATL ACAD SCI USA, V92, P3869, DOI 10.1073/pnas.92.9.3869; HIASA H, 1989, GENE, V84, P9, DOI 10.1016/0378-1119(89)90133-9; HINE AV, 1994, P NATL ACAD SCI USA, V91, P12327, DOI 10.1073/pnas.91.25.12327; HINTON DM, 1987, J BIOL CHEM, V262, P10873; ILYINA TV, 1992, J MOL EVOL, V34, P351, DOI 10.1007/BF00160243; KITANI T, 1985, J MOL BIOL, V184, P45, DOI 10.1016/0022-2836(85)90042-7; KOLODNER R, 1977, P NATL ACAD SCI USA, V74, P1525, DOI 10.1073/pnas.74.4.1525; KORNBERG A, 1992, DNA REPLICATION, P275; KRUGER DH, 1981, MICROBIOL REV, V45, P9; LIU CC, 1981, J BIOL CHEM, V256, P2813; LIU CC, 1980, P NATL ACAD SCI-BIOL, V77, P5698, DOI 10.1073/pnas.77.10.5698; LIU CC, 1981, J BIOL CHEM, V256, P2821; MACDONALD PM, 1984, EMBO J, V3, P2863, DOI 10.1002/j.1460-2075.1984.tb02221.x; MATSON SW, 1985, J BIOL CHEM, V260, P2281; MENDELMAN LV, 1994, EMBO J, V13, P3909, DOI 10.1002/j.1460-2075.1994.tb06702.x; MENDELMAN LV, 1993, J BIOL CHEM, V268, P27208; MENDELMAN LV, 1991, J BIOL CHEM, V266, P23240; MENDELMAN LV, 1992, P NATL ACAD SCI USA, V89, P10628; MUSTAEV AA, 1995, J BIOL CHEM, V270, P15711, DOI 10.1074/jbc.270.26.15711; NAKAI H, 1986, J BIOL CHEM, V261, P5217; NAKAI H, 1986, J BIOL CHEM, V261, P5208; NAKAI H, 1988, J BIOL CHEM, V263, P9818; NARDELLI J, 1991, NATURE, V349, P175, DOI 10.1038/349175a0; NOSSAL NG, 1987, J BIOL CHEM, V262, P10879; NOSSAL NG, 1980, J BIOL CHEM, V255, P2176; NOTARNICOLA SM, 1995, J BIOL CHEM, V270, P20215, DOI 10.1074/jbc.270.34.20215; NOTARNICOLA SM, 1993, J BIOL CHEM, V268, P27196; PATEL SS, 1993, J BIOL CHEM, V268, P10668; PATEL SS, 1994, BIOCHEMISTRY-US, V33, P7857, DOI 10.1021/bi00191a013; PAVLETICH NP, 1993, SCIENCE, V261, P1701, DOI 10.1126/science.8378770; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; POMERANTZ JL, 1995, SCIENCE, V267, P93, DOI 10.1126/science.7809612; QIAN XQ, 1993, BIOCHEMISTRY-US, V32, P9944, DOI 10.1021/bi00089a010; ROMANO LJ, 1979, J BIOL CHEM, V254, P483; ROSENBERG AH, 1992, J BIOL CHEM, V267, P15005; Sambrook J., 2002, MOL CLONING LAB MANU; SCHERZINGER E, 1977, NUCLEIC ACIDS RES, V4, P4151, DOI 10.1093/nar/4.12.4151; SEKI T, 1979, NUCLEIC ACIDS RES, V7, P1603, DOI 10.1093/nar/7.6.1603; SMILEY BL, 1982, P NATL ACAD SCI-BIOL, V79, P4550, DOI 10.1073/pnas.79.15.4550; STAMFORD NPJ, 1992, BIOCHIM BIOPHYS ACTA, V1132, P17, DOI 10.1016/0167-4781(92)90047-4; SWART JR, 1993, J BIOL CHEM, V268, P12970; TABOR S, 1981, P NATL ACAD SCI-BIOL, V78, P205, DOI 10.1073/pnas.78.1.205; TENNEY DJ, 1995, J BIOL CHEM, V270, P9129, DOI 10.1074/jbc.270.16.9129; TOUGU K, 1994, J BIOL CHEM, V269, P4675; YODA K, 1991, MOL GEN GENET, V227, P1, DOI 10.1007/BF00260698; ZECHNER EL, 1992, J BIOL CHEM, V267, P4054; ZECHNER EL, 1992, J BIOL CHEM, V267, P4045	57	59	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19563	19570		10.1074/jbc.271.32.19563	http://dx.doi.org/10.1074/jbc.271.32.19563			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702650	Green Published, hybrid			2022-12-25	WOS:A1996VB68400084
J	Pang, L; Sivaram, P; Goldberg, IJ				Pang, L; Sivaram, P; Goldberg, IJ			Cell-surface expression of an amino-terminal fragment of apolipoprotein B increases lipoprotein lipase binding to cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-RELATED PROTEIN; HEPARAN-SULFATE PROTEOGLYCANS; FIBROBLAST GROWTH-FACTOR; ENDOTHELIAL-CELLS; ALPHA(2)-MACROGLOBULIN RECEPTOR; IDENTIFICATION; DEGRADATION; SECRETION; TRANSLOCATION; MUTAGENESIS	Previous studies (Sivaram, P., Choi, S. Y., Curtiss, L. K., and Goldberg, I. J. (1994) J. Biol. Chem. 269, 9409-9412) from this laboratory showed that the NH2-terminal region of apoB (NTAB) has binding domains for lipoprotein lipase (LPL), LPL binding to endothelial cells, we hypothesize, involves interaction both with heparan sulfate proteoglycans and with a protein that has homology to NTAB. To test whether cell-surface NTAB would increase the amount and affinity of LPL binding to cells, we produced stable Chinese hamster ovary cell Lilies that have NTAB anchored to the cell surface, A cDNA encoding the amino-terminal 17% of apoB (apoB17) was fused to a cDNA coding for the last 37 amino acids of decay-accelerating factor (DAF), which contains the signal for glycosylphosphatidylinositol anchor attachment, The fused construct was sequence-verified and cloned into expression vector pCMV5, The pCMV5-apoB17-DAF plasmid was cotransfected with a neomycin resistance gene into wild-type (WT) cells and mutant heparan sulfate proteoglycan-deficient Chinese hamster ovary cells (745 cells), and stable cell lines mere established, Expression of apoB17 on the cell surface was confirmed by the release of apoB17 by phosphatidylinositol-specific phospholipase C. LPL binding to WT and apoB17-DAF-transfected cells was determined, Using 0.8-6 mu g of LPL, 1.3-2.2-foId more LPL associated with apoB17-DAF WT cells compared with WT cells; apoB17-DAF also increased LPL binding to 745 cells, After heparinase treatment, LPL binding to apoB17-DAF cells was still greater than to treated WT cells, This increased binding to apoB17-DAF cells was almost abolished by treatment of cells with phosphatidylinositol-specific phospholipase C or anti-apoB monoclonal antibody, LPL dissociated from WT cells with k(-1) = 2.55 x 10(-2) min(-1), whereas LPL dissociated more slowly from apoB17-DAF-containing cells with k(-1) = 1.08 x 10(-2) min(-1), Furthermore, almost 95% of the LPL on WT cells was dissociated by 1 nr NaCl, while only 65% of the LPL dissociated from apoB17-DAF cells at the same high salt concentration. Similarly, in high salt, more LPL remained associated with apoB17-DAF cells than with nontransfected 745 cells, These data show that NTAB on cell surfaces can function as a LPL binding protein, Moreover, they demonstrate that LPL association with cells can be increased by simultaneously binding to both proteoglycan and non-proteoglycan binding sites.	COLUMBIA UNIV,COLL PHYS & SURG,DEPT MED,DIV PREVENT MED,NEW YORK,NY 10032	Columbia University					NHLBI NIH HHS [HL21006, HL45095] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL045095, P50HL021006, R01HL045095] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BEISIEGEL U, 1989, NATURE, V341, P162, DOI 10.1038/341162a0; BEISIEGEL U, 1991, P NATL ACAD SCI USA, V88, P8342, DOI 10.1073/pnas.88.19.8342; BERRYMAN DE, 1993, J BIOL CHEM, V268, P3272; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARAS IW, 1987, SCIENCE, V238, P1280, DOI 10.1126/science.2446389; CHAJEKSHAUL T, 1988, BIOCHIM BIOPHYS ACTA, V963, P183, DOI 10.1016/0005-2760(88)90279-2; CHAPPELL DA, 1992, J BIOL CHEM, V267, P25764; CHENG CF, 1981, J BIOL CHEM, V256, P2893; CISAR LA, 1989, J BIOL CHEM, V264, P1767; CUPP M, 1987, J BIOL CHEM, V262, P6383; DENNINGTON PM, 1994, CLIN EXP PHARMACOL P, V21, P349, DOI 10.1111/j.1440-1681.1994.tb02527.x; DU EZ, 1994, J BIOL CHEM, V269, P24169; ECKEL RH, 1989, NEW ENGL J MED, V320, P1060; ESKO JD, 1985, P NATL ACAD SCI USA, V82, P3197, DOI 10.1073/pnas.82.10.3197; FRIEDMAN G, 1982, BIOCHIM BIOPHYS ACTA, V711, P114, DOI 10.1016/0005-2760(82)90016-9; FRIEDMAN G, 1983, BIOCHIM BIOPHYS ACTA, V752, P106, DOI 10.1016/0005-2760(83)90238-2; HATA A, 1993, J BIOL CHEM, V268, P8447; HERSCOVITZ H, 1991, P NATL ACAD SCI USA, V88, P7313, DOI 10.1073/pnas.88.16.7313; JI ZS, 1993, J BIOL CHEM, V268, P10160; LUPU F, 1994, ARTERIOSCLER THROMB, V14, P1438, DOI 10.1161/01.ATV.14.9.1438; MA YH, 1994, J LIPID RES, V35, P2049; MIKHAILENKO I, 1995, J BIOL CHEM, V270, P9543, DOI 10.1074/jbc.270.16.9543; MOSCATELLI D, 1992, J BIOL CHEM, V267, P25803; MURRAY EJ, 1991, GENE TRANSFER EXPRES, V7, P245; NILSSONEHLE P, 1976, J LIPID RES, V17, P536; NYKJAER A, 1993, J BIOL CHEM, V268, P15048; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; SAXENA U, 1991, J BIOL CHEM, V266, P17516; SAXENA U, 1989, J BIOL CHEM, V264, P12880; SHIMADA K, 1981, J CLIN INVEST, V68, P995, DOI 10.1172/JCI110354; Sivaram P, 1996, J BIOL CHEM, V271, P15261, DOI 10.1074/jbc.271.25.15261; SIVARAM P, 1994, J BIOL CHEM, V269, P9409; SIVARAM P, 1992, J BIOL CHEM, V267, P16517; SOCORRO L, 1985, PREP BIOCHEM, V15, P133, DOI 10.1080/10826068508062267; STINS MF, 1992, ARTERIOSCLER THROMB, V12, P1437, DOI 10.1161/01.ATV.12.12.1437; STINS MF, 1993, J LIPID RES, V34, P1853; STRICKLAND DK, 1995, FASEB J, V9, P890, DOI 10.1096/fasebj.9.10.7615159; THRIFT RN, 1992, P NATL ACAD SCI USA, V89, P9161, DOI 10.1073/pnas.89.19.9161; VILARO S, 1988, AM J PHYSIOL, V254, pG711, DOI 10.1152/ajpgi.1988.254.5.G711; WALLINDER L, 1979, BIOCHIM BIOPHYS ACTA, V575, P166, DOI 10.1016/0005-2760(79)90142-5; WANGIVERSON P, 1980, ATHEROSCLEROSIS, V5, P375; WARSHAWSKY I, 1994, P NATL ACAD SCI USA, V91, P6664, DOI 10.1073/pnas.91.14.6664; WEBB LMC, 1993, P NATL ACAD SCI USA, V90, P7158, DOI 10.1073/pnas.90.15.7158; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; YOUNG SG, 1990, CIRCULATION, V82, P1574, DOI 10.1161/01.CIR.82.5.1574	45	18	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19518	19523		10.1074/jbc.271.32.19518	http://dx.doi.org/10.1074/jbc.271.32.19518			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702644	hybrid			2022-12-25	WOS:A1996VB68400078
J	Caldeira, J; Feicht, R; White, H; Teixeira, M; Moura, JJG; Simon, H; Moura, I				Caldeira, J; Feicht, R; White, H; Teixeira, M; Moura, JJG; Simon, H; Moura, I			EPR and Mossbauer spectroscopic studies on enoate reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-SULFUR CLUSTERS; DESULFOVIBRIO-GIGAS; 4FE-4S CLUSTER; ACTIVATED ACONITASE; PROTEIN; HYDROGENASE; BINDING; CENTERS; INTERCONVERSIONS; DEHYDRATASE	Enoate reductase (EC 1.3.1.31) is a protein isolated from Clostridium tyrobutyricum that contains iron, labile sulfide, FAD, and FMN. The enzyme reduces the alpha,beta carbon-carbon double bond of nonactivated 2-enoates and in a reversible way that of 2-enals at the expense of NADH or reduced methyl viologen, UV-visible and EPR potentiometric titrations detect a semiquinone species in redox intermediate states characterized by an isotropic EPR signal at g = 2.0 without contribution at 580 nm, EPR redox titration shows two widely spread mid-point redox potentials (-190 and -350 mV at pH 7.0), and a nearly stoichiometric amount of this species is detected, The data suggest the semiquinone radical has an anionic nature. In the reduced form, the [Fe-S] moiety is characterized by a single rhombic EPR spectrum, observed in a wide range of temperatures (4.2-60 K) with g values at 2.013, 1.943, and 1.860 (-180 mV at pH 7.0). The g(max) value is low when compared with what has been reported for other iron-sulfur clusters, Mossbauer studies reveal the presence of a [4Fe-4S](+2/+1) center, One of the subcomponents of the spectrum shows an unusually large value of quadrupole splitting (ferrous character) in both the oxidized and reduced states, Substrate binding to the reduced enzyme induces subtle changes in the spectroscopic Mossbauer parameters, The Mossbauer data together with known kinetic information suggest the involvement of this iron-sulfur center in the enzyme mechanism.	UNIV NOVA LISBOA,FAC CIENCIAS & TECNOL,DEPT QUIM,P-2825 MONTE DE CAPARICA,PORTUGAL; UNIV NOVA LISBOA,FAC CIENCIAS & TECNOL,CTR QUIM FINA & BIOTECNOL,P-2825 MONTE DE CAPARICA,PORTUGAL; INST SUPER CIENCIAS SAUDE SUL,P-2825 MONTE DE CAPARICA,PORTUGAL; TECH UNIV MUNICH,LEHRSTUHL ORGAN CHEM & BIOCHEM,D-85747 GARCHING,GERMANY; UNIV NOVA LISBOA,INST TECNOL QUIM & BIOL,P-2780 OEIRAS,PORTUGAL	Universidade Nova de Lisboa; Universidade Nova de Lisboa; Technical University of Munich; Universidade Nova de Lisboa			Teixeira, Miguel/M-1509-2019; Moura, José J G/D-6426-2013; Teixeira, Miguel/A-9098-2011; Moura, Isabel/D-6339-2013; Caldeira, Jorge/A-5702-2016	Teixeira, Miguel/0000-0003-4124-6237; Moura, José J G/0000-0002-4726-2388; Teixeira, Miguel/0000-0003-4124-6237; Moura, Isabel/0000-0003-0971-4977; Caldeira, Jorge/0000-0002-0976-2111				BADER J, 1983, FEMS MICROBIOL LETT, V20, P171; BARBER MJ, 1992, J BIOL CHEM, V267, P6611; BEINERT H, 1989, EUR J BIOCHEM, V186, P5, DOI 10.1111/j.1432-1033.1989.tb15170.x; BUHLER M, 1982, H-S Z PHYSIOL CHEM, V363, P609, DOI 10.1515/bchm2.1982.363.1.609; BUHLER M, 1981, THESIS TU MUNICH GER; CALDEIRA J, 1994, EUR J BIOCHEM, V220, P987, DOI 10.1111/j.1432-1033.1994.tb18703.x; CAMMACK R, 1992, ADV INORG CHEM, V38, P281, DOI 10.1016/S0898-8838(08)60066-5; CHRISTNER JA, 1983, J BIOL CHEM, V258, P1157; COX TC, 1991, EMBO J, V10, P1891, DOI 10.1002/j.1460-2075.1991.tb07715.x; CUNNINGHAM RP, 1989, BIOCHEMISTRY-US, V28, P4450, DOI 10.1021/bi00436a049; DUTTON PL, 1971, BIOCHIM BIOPHYS ACTA, V226, P63, DOI 10.1016/0005-2728(71)90178-2; EMPTAGE MH, 1983, P NATL ACAD SCI-BIOL, V80, P4674, DOI 10.1073/pnas.80.15.4674; EMPTAGE MH, 1988, METAL CLUSTERS PROTE, P343; FLINT DH, 1993, J BIOL CHEM, V268, P14732; FRANKLUND CV, 1993, J BACTERIOL, V175, P3002, DOI 10.1128/JB.175.10.3002-3012.1993; GEARY PJ, 1981, BIOCHEM J, V195, P199, DOI 10.1042/bj1950199; GERLT JA, 1992, J AM CHEM SOC, V114, P5929; GIESEL H, 1983, ARCH MICROBIOL, V135, P51, DOI 10.1007/BF00419482; KENT TA, 1985, J BIOL CHEM, V260, P6871; KENT TA, 1982, P NATL ACAD SCI-BIOL, V79, P1096, DOI 10.1073/pnas.79.4.1096; KUNO S, 1985, BIOL CHEM H-S, V366, P463, DOI 10.1515/bchm3.1985.366.1.463; LAMPREIA J, 1990, EUR J BIOCHEM, V188, P653, DOI 10.1111/j.1432-1033.1990.tb15447.x; MIDDLETON P, 1980, EUR J BIOCHEM, V104, P289, DOI 10.1111/j.1432-1033.1980.tb04427.x; MIDDLETON P, 1978, EUR J BIOCHEM, V88, P135, DOI 10.1111/j.1432-1033.1978.tb12430.x; MOURA JJG, 1994, METHOD ENZYMOL, V243, P165; MOURA JJG, 1982, J BIOL CHEM, V257, P6259; MOURA L, 1990, J AM CHEM SOC, V110, P1075; PALMER G, 1971, FLAVINS FLAVOPROTEIN; ROBBINS AH, 1989, P NATL ACAD SCI USA, V86, P3639, DOI 10.1073/pnas.86.10.3639; ROUAULT TA, 1991, CELL, V64, P881, DOI 10.1016/0092-8674(91)90312-M; SCHERF U, 1993, EUR J BIOCHEM, V215, P421, DOI 10.1111/j.1432-1033.1993.tb18049.x; SEDLMAIER H, 1979, FEBS LETT, V100, P129, DOI 10.1016/0014-5793(79)81147-3; SIMON H, 1985, ANGEW CHEM INT EDIT, V24, P539, DOI 10.1002/anie.198505391; SIMON H, 1991, CHEM BIOCH FLAVOENZY, V2, P317; SWITZER R L, 1989, Biofactors, V2, P77; TEIXEIRA M, 1990, EUR J BIOCHEM, V189, P381, DOI 10.1111/j.1432-1033.1990.tb15499.x; TEIXEIRA M, 1989, J BIOL CHEM, V264, P16435; THANOS I, 1988, BIOL CHEM H-S, V369, P451, DOI 10.1515/bchm3.1988.369.1.451; TISCHER W, 1979, EUR J BIOCHEM, V97, P103, DOI 10.1111/j.1432-1033.1979.tb13090.x; VOLBEDA A, 1995, NATURE, V373, P580, DOI 10.1038/373580a0	40	11	11	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18743	18748		10.1074/jbc.271.31.18743	http://dx.doi.org/10.1074/jbc.271.31.18743			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702530	hybrid			2022-12-25	WOS:A1996VB68300068
J	Wilkins, PP; McEver, RP; Cummings, RD				Wilkins, PP; McEver, RP; Cummings, RD			Structures of the O-glycans on P-selectin glycoprotein ligand-1 from HL-60 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIALYL-LEWIS-X; LINKED OLIGOSACCHARIDES; MYELOID CELLS; ALPHA(1,3)-FUCOSYL-TRANSFERASE GENE; EXPRESSION CLONING; TYROSINE SULFATION; HUMAN-GRANULOCYTES; MOLECULAR-CLONING; HUMAN NEUTROPHILS; CYSTIC-FIBROSIS	P-selectin glycoprotein ligand-1 (PSGL-1) is a disulfide-bonded homodimeric mucin-like glycoprotein on leukocytes that interacts with both P- and E-selectin. In this report we describe the structures of the Ser/Thr-linked O-glycans of PSGL-1 synthesized by HL-60 cells metabolically radiolabeled with H-3-sugar precursors. In control studies, the O-glycans on CD43 (leukosialin), a mucin-like glycoprotein also expressed by HL 60 cells, were analyzed and compared to those of PSGL-1, O-Glycans were released from Ser/Thr residues by mild base/borohydride treatment of purified glycoproteins, and glycan structures were determined by a combination of techniques, In contrast to expectations, PSGL-1 is not heavily fucosylated; a majority of the O-glycans are disialylated or neutral forms of the core-2 tetrasaccharide GaI beta 1-4GlcNAc beta 1-6(Gal beta 1-->3)GaINAcOH, A minority of the O-glycans are alpha-1,3-fucosylated that occur as two major species containing the sialyl Lewis x antigen; one species is a disialylated, monofucosylated glycan, [GRAPHICS] and the other is a monosialylated, trifucosylated glycan having a polylactosamine backbone. [GRAPHICS] CD43 lacks the fucosylated glycans found on PSGL-1 and is enriched for the nonfucosylated, disialylated core-2 hexasaccharide. These results demonstrate that PSGL-1 contains unique fucosylated O-glycans that are predicted to be critical for high affinity interactions between PSGL-1 and selectins.	UNIV OKLAHOMA,HLTH SCI CTR,DEPT BIOCHEM & MOL BIOL,OKLAHOMA CITY,OK 73190; UNIV OKLAHOMA,HLTH SCI CTR,W K WARREN MED RES INST,OKLAHOMA CITY,OK 73190; UNIV OKLAHOMA,HLTH SCI CTR,DEPT MED,OKLAHOMA CITY,OK 73190; OKLAHOMA MED RES FDN,CARDIOVASC BIOL RES PROGRAM,OKLAHOMA CITY,OK 73190	University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; Oklahoma Medical Research Foundation					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL054804] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL54804] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARUFFO A, 1991, CELL, V67, P35, DOI 10.1016/0092-8674(91)90570-O; ASA D, 1995, J BIOL CHEM, V270, P11662, DOI 10.1074/jbc.270.19.11662; BIERHUIZEN MFA, 1994, J BIOL CHEM, V269, P4473; BREG J, 1987, EUR J BIOCHEM, V168, P57, DOI 10.1111/j.1432-1033.1987.tb13387.x; CARLSSON SR, 1986, J BIOL CHEM, V261, P2787; CECCONI O, 1994, J BIOL CHEM, V269, P15060; CUMMINGS RD, 1982, J BIOL CHEM, V257, P1235; CUMMINGS RD, 1983, J BIOL CHEM, V258, P5261; CUMMINGS RD, 1993, GLYCOBIOLOGY PRACTIC, P243; CUMMINGS RD, 1989, METHOD CELL BIOL, V32, P142; DeBoseBoyd R, 1996, EXP PARASITOL, V82, P1, DOI 10.1006/expr.1996.0001; FUKUDA M, 1991, Glycobiology, V1, P347, DOI 10.1093/glycob/1.4.347; FUKUDA M, 1984, J BIOL CHEM, V259, P925; GOELZ S, 1994, J BIOL CHEM, V269, P1033; GOELZ SE, 1990, CELL, V63, P1349, DOI 10.1016/0092-8674(90)90430-M; HEMMERICH S, 1994, J EXP MED, V180, P2219, DOI 10.1084/jem.180.6.2219; HEMMERICH S, 1994, BIOCHEMISTRY-US, V33, P4830, DOI 10.1021/bi00182a011; HEMMERICH S, 1994, BIOCHEMISTRY-US, V33, P11104; IMAI Y, 1993, NATURE, V361, P555; IYER RN, 1971, ARCH BIOCHEM BIOPHYS, V142, P101, DOI 10.1016/0003-9861(71)90263-3; KOBATA A, 1993, GLYCOBIOLOGY PRACTIC, P165; KUMAR R, 1991, J BIOL CHEM, V266, P21777; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKY LA, 1995, ANNU REV BIOCHEM, V64, P113, DOI 10.1146/annurev.bi.64.070195.000553; LENTER M, 1994, J CELL BIOL, V125, P471, DOI 10.1083/jcb.125.2.471; LI E, 1978, J BIOL CHEM, V253, P7762; Li FG, 1996, J BIOL CHEM, V271, P6342, DOI 10.1074/jbc.271.11.6342; Li FG, 1996, J BIOL CHEM, V271, P3255, DOI 10.1074/jbc.271.6.3255; LI SC, 1975, J BIOL CHEM, V250, P6786; LOGUIDICE JM, 1994, J BIOL CHEM, V269, P18794; LOWE JB, 1991, J BIOL CHEM, V266, P17467; MAEMURA K, 1992, J BIOL CHEM, V267, P24379; MCEVER RP, 1995, J BIOL CHEM, V270, P11025, DOI 10.1074/jbc.270.19.11025; MOORE KL, 1992, J CELL BIOL, V118, P445, DOI 10.1083/jcb.118.2.445; MOORE KL, 1994, J BIOL CHEM, V269, P23318; MOORE KL, 1995, J CELL BIOL, V128, P661, DOI 10.1083/jcb.128.4.661; NATSUKA S, 1994, J BIOL CHEM, V269, P16789; NELSON RM, 1993, BLOOD, V82, P3253; Nelson RM, 1995, ANNU REV CELL DEV BI, V11, P601, DOI 10.1146/annurev.cellbio.11.1.601; NORGARD KE, 1993, J BIOL CHEM, V268, P12764; NORMAN KE, 1995, BLOOD, V86, P4417, DOI 10.1182/blood.V86.12.4417.bloodjournal86124417; PATEL KD, 1995, J CLIN INVEST, V96, P1887, DOI 10.1172/JCI118234; PATEL TP, 1994, BIOCHEMISTRY-US, V33, P14815, DOI 10.1021/bi00253a021; PAULSON JC, 1982, J BIOL CHEM, V257, P2734; POUYANI T, 1995, CELL, V83, P333, DOI 10.1016/0092-8674(95)90174-4; SAKO D, 1995, CELL, V83, P323, DOI 10.1016/0092-8674(95)90173-6; SAKO D, 1993, CELL, V75, P1179, DOI 10.1016/0092-8674(93)90327-M; SANO M, 1992, J BIOL CHEM, V267, P1522; SASAKI K, 1994, J BIOL CHEM, V269, P14730; SKINNER MP, 1989, BIOCHEM BIOPH RES CO, V164, P1373, DOI 10.1016/0006-291X(89)91821-4; SPOONCER E, 1984, J BIOL CHEM, V259, P4792; SRIVATSAN J, 1992, J BIOL CHEM, V267, P20196; STEEGMAIER M, 1995, NATURE, V373, P615, DOI 10.1038/373615a0; SUEYOSHI S, 1994, J BIOL CHEM, V269, P32342; USHIYAMA S, 1993, J BIOL CHEM, V268, P15229; VANDENEIJNDEN DH, 1995, BIOCHEM SOC T, V23, P175, DOI 10.1042/bst0230175; VARKI A, 1994, METHOD ENZYMOL, V230, P16; VARKI A, 1983, J BIOL CHEM, V258, P2808; WILKINS PP, 1995, J BIOL CHEM, V270, P22677, DOI 10.1074/jbc.270.39.22677; YUREWICZ EC, 1987, J BIOL CHEM, V262, P4733; ZHOU Q, 1991, J CELL BIOL, V115, P557, DOI 10.1083/jcb.115.2.557	61	234	244	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18732	18742		10.1074/jbc.271.31.18732	http://dx.doi.org/10.1074/jbc.271.31.18732			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702529	hybrid			2022-12-25	WOS:A1996VB68300067
J	Zhang, J; Ferguson, SG; Barak, LS; Menard, L; Caron, MG				Zhang, J; Ferguson, SG; Barak, LS; Menard, L; Caron, MG			Dynamin and beta-arrestin reveal distinct mechanisms for G protein-coupled receptor internalization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COATED VESICLE FORMATION; ANGIOTENSIN-II RECEPTOR; ADRENERGIC-RECEPTOR; BETA-2-ADRENERGIC RECEPTOR; SIGNAL-TRANSDUCTION; SEQUESTRATION; MUTANT; ENDOCYTOSIS; PHOSPHORYLATION; EXPRESSION	The process of agonist-promoted internalization (sequestration) of G protein-coupled receptors (GPCRs) is intimately linked to the regulation of GPCR responsiveness, Following agonist-mediated desensitization, sequestration of GPCR is presumably associated with the dephosphorylation and recycling of functional receptors, However, the exact mechanisms responsible for GPCR sequestration, even for the prototypic beta(2)-adrenergic receptor (beta(2)AR), have remained controversial, We demonstrate here that dynamin, a GTPase that regulates the formation and internalization of clathrin-coated vesicles, is essential for the agonist-promoted sequestration of the beta(2)AR, suggesting that the beta(2)AR internalizes via the clathrin-coated vesicle-mediated endocytic pathway, In contrast, internalization of the angiotensin II type 1A receptor (AT(1A)R), another typical GPCR, does not require dynamin, In addition, the AT(1A)R internalizes independent of the function of beta-arrestin, a critical component for beta(2)AR cellular trafficking, but additional AT(1A)Rs are mobilized to the dynamin-dependent pathway upon overexpression of beta- arrestin. These findings demonstrate that GPCRs can utilize distinct endocytic pathways, distinguishable by dynamin and beta-arrestin, and that beta-arrestins function as adaptor proteins specifically targeting GPCRs for dynamin-dependent endocytosis via clathrin-coated vesicles.	DUKE UNIV,MED CTR,HOWARD HUGHES MED INST LABS,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT CELL BIOL,DURHAM,NC 27710	Duke University; Duke University					NINDS NIH HHS [NS 19576] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS019576] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ASHWORTH R, 1995, P NATL ACAD SCI USA, V92, P512, DOI 10.1073/pnas.92.2.512; BARAK LS, 1994, J BIOL CHEM, V269, P2790; CHEUNG AH, 1989, MOL PHARMACOL, V35, P132; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; FERGUSON SSG, 1995, J BIOL CHEM, V270, P24782, DOI 10.1074/jbc.270.42.24782; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; GUERVICH VV, 1995, J BIOL CHEM, V270, P720; HAUSDORFF WP, 1989, J BIOL CHEM, V264, P12657; HERSKOVITS JS, 1993, J CELL BIOL, V122, P565, DOI 10.1083/jcb.122.3.565; HINSHAW JE, 1995, NATURE, V374, P190, DOI 10.1038/374190a0; HUNYADY L, 1995, J BIOL CHEM, V270, P16602, DOI 10.1074/jbc.270.28.16602; HUNYADY L, 1994, J BIOL CHEM, V269, P24798; INAGAMI T, 1994, J HYPERTENS, V12, pS83; KOSAKA T, 1983, J CELL BIOL, V97, P499, DOI 10.1083/jcb.97.2.499; MOORE RH, 1995, J CELL SCI, V108, P2983; Oppermann M, 1996, J BIOL CHEM, V271, P13266, DOI 10.1074/jbc.271.22.13266; PIPPIG S, 1995, MOL PHARMACOL, V47, P666; RAPOSO G, 1989, EUR J CELL BIOL, V50, P340; Robinson MS, 1996, CELL, V84, P13, DOI 10.1016/S0092-8674(00)80988-5; ROETTGER BF, 1995, J CELL BIOL, V128, P1029, DOI 10.1083/jcb.128.6.1029; SCHWINN DA, 1992, HEART CARDIOVASCULAR; SHPETNER HS, 1992, NATURE, V355, P733, DOI 10.1038/355733a0; SHPETNER HS, 1989, CELL, V59, P421, DOI 10.1016/0092-8674(89)90027-5; Shpetner HS, 1996, J BIOL CHEM, V271, P13, DOI 10.1074/jbc.271.1.13; SIBLEY DR, 1986, P NATL ACAD SCI USA, V83, P9408, DOI 10.1073/pnas.83.24.9408; SONTAG JM, 1994, J BIOL CHEM, V269, P4547; TAKEI K, 1995, NATURE, V374, P186, DOI 10.1038/374186a0; TAN PK, 1993, J CELL BIOL, V123, P1707, DOI 10.1083/jcb.123.6.1707; THOMAS WG, 1995, J BIOL CHEM, V270, P207, DOI 10.1074/jbc.270.1.207; TSUGA H, 1994, J BIOL CHEM, V269, P32522; VANDERBLIEK AM, 1991, NATURE, V351, P411, DOI 10.1038/351411a0; VANDERBLIEK AM, 1993, J CELL BIOL, V122, P553, DOI 10.1083/jcb.122.3.553; VONZASTROW M, 1994, J BIOL CHEM, V269, P18448; VONZASTROW M, 1992, J BIOL CHEM, V267, P3530; YU SS, 1993, J BIOL CHEM, V268, P337	36	397	406	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18302	18305		10.1074/jbc.271.31.18302	http://dx.doi.org/10.1074/jbc.271.31.18302			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702465	hybrid			2022-12-25	WOS:A1996VB68300003
J	Hsu, JL; Hsieh, YS; Tu, CK; OConnor, D; Nick, HS; Silverman, DN				Hsu, JL; Hsieh, YS; Tu, CK; OConnor, D; Nick, HS; Silverman, DN			Catalytic properties of human manganese superoxide dismutase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACILLUS-STEAROTHERMOPHILUS; THERMUS-THERMOPHILUS; ESCHERICHIA-COLI; PULSE-RADIOLYSIS; ENZYME; IRON; RESOLUTION; PROTEIN; MODEL	The depletion of superoxide catalyzed by human manganese superoxide dismutase (MnSOD) was observed spectrophotometrically by measuring the absorbance of superoxide at 250-280 nm following pulse radiolysis and by stopped-flow spectrophotometry. Catalysis showed an initial burst of activity lasting approximately 1 ms followed by the rapid emergence of a greatly inhibited catalysis of zero-order rate. These catalytic properties of human MnSOD are qualitatively similar to those reported for MnSOD from Thermus thermophilus (Bull, C,, Niederhoffer, E, C,, Yoshida, T,, and Fee, J, A. (1991) J, Am, Chem, Sec. 113, 4069-4076), However, there are significant quantitative differences; the emergence of the inhibited form is approximately 30-fold more rapid for human MnSOD. The turnover number for human MnSOD at pH 9.4 and 20 degrees C was k(cat) = 4 x 10(4) s(-1) and k(cat)/K-m 8 x 10(8) M(-1) s(-1), determined by a simulated fit of the model of Bull ct al, (1991) to the pulse radiolysis data, We also report that the maximum of the visible absorption spectrum of human MnSOD (epsilon(480) = 525 M(-1) cm(-1)) showed a strong dependence on pH that could be described by an ionization of pK(a) 9.4 +/- 0.1 with a maximum at low pH.	UNIV FLORIDA, CTR HLTH, COLL MED, DEPT THERAPEUT & PHARMACOL, GAINESVILLE, FL 32610 USA; UNIV FLORIDA, COLL MED, DEPT BIOCHEM & MOLEC BIOL, GAINESVILLE, FL 32610 USA; UNIV TEXAS, CTR FAST KINET RES, AUSTIN, TX 78712 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida; University of Texas System; University of Texas Austin								BARSHOP BA, 1983, ANAL BIOCHEM, V130, P134, DOI 10.1016/0003-2697(83)90660-7; BECK Y, 1987, NUCLEIC ACIDS RES, V15, P9076, DOI 10.1093/nar/15.21.9076; BECK Y, 1988, BIO-TECHNOL, V6, P930, DOI 10.1038/nbt0888-930; BEYER W, 1991, PROG NUCLEIC ACID RE, V40, P221; BORGSTAHL GEO, 1992, CELL, V71, P107, DOI 10.1016/0092-8674(92)90270-M; BULL C, 1991, J AM CHEM SOC, V113, P4069, DOI 10.1021/ja00011a003; BULL C, 1985, J AM CHEM SOC, V107, P3295, DOI 10.1021/ja00297a040; LAH MS, 1995, BIOCHEMISTRY-US, V34, P1646, DOI 10.1021/bi00005a021; Leatherbarrow R.J, 1987, ENZFITTER NONLINEAR; LUDWIG ML, 1991, J MOL BIOL, V219, P335, DOI 10.1016/0022-2836(91)90569-R; MCADAM ME, 1977, BIOCHEM J, V165, P71, DOI 10.1042/bj1650071; MCADAM ME, 1977, BIOCHEM J, V165, P81, DOI 10.1042/bj1650081; McCord JM, 1977, SUPEROXIDE SUPEROXID, P129; PARKER MW, 1988, J MOL BIOL, V199, P649, DOI 10.1016/0022-2836(88)90308-7; RABANI J, 1969, J PHYS CHEM-US, V73, P3736, DOI 10.1021/j100845a030; SCHWARZ HA, 1981, J CHEM EDUC, V58, P101, DOI 10.1021/ed058p101; STODDARD BL, 1990, PROTEIN ENG, V4, P113, DOI 10.1093/protein/4.2.113; TAINER JA, 1991, STUDY ENZYMES, V2, P499; TANHAUSER SM, 1992, GENE, V117, P113, DOI 10.1016/0378-1119(92)90498-E; VALENTINE JS, 1975, J AM CHEM SOC, V97, P224, DOI 10.1021/ja00834a058; ZIMMERLE CT, 1989, BIOCHEM J, V258, P381, DOI 10.1042/bj2580381	21	127	135	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					17687	17691		10.1074/jbc.271.30.17687	http://dx.doi.org/10.1074/jbc.271.30.17687			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663465	hybrid			2022-12-25	WOS:A1996UY93500017
J	Bacus, SS; Yarden, Y; Oren, M; Chin, DM; Lyass, L; Zelnick, CR; Kazarov, A; Toyofuku, W; GrayBablin, J; Beerli, RR; Hynes, NE; Nikiforov, M; Haffner, R; Gudkov, A; Keyomarsi, K				Bacus, SS; Yarden, Y; Oren, M; Chin, DM; Lyass, L; Zelnick, CR; Kazarov, A; Toyofuku, W; GrayBablin, J; Beerli, RR; Hynes, NE; Nikiforov, M; Haffner, R; Gudkov, A; Keyomarsi, K			Neu differentiation factor (Heregulin) activates a p53-dependent pathway in cancer cells	ONCOGENE			English	Article						heregulin; Neu; p53; p21(WAF1/CIP1); cell cycle; erbB-2	EPIDERMAL GROWTH-FACTOR; HUMAN-BREAST-CANCER; MONOCLONAL-ANTIBODIES; MAMMARY-TUMORS; P53; PROTEIN; GENE; PHOSPHORYLATION; IDENTIFICATION; AMPLIFICATION	Previously we reported that neu differentiation factor (NDF)/heregulin (HRG) elevates tyrosine phosphorylation of its receptors erbB-3, erbB-4, and erbB-2 (through heterodimer formation). We also showed that both NDF/HRG and antibodies to erbB-2 can arrest growth and induce differentiation in breast cancer cells. In this study, we report on the mechanism of NDF/HRG-induced cellular effects. We show that NDF/HRG and antibodies to erbB-2 receptors up-regulate expression of p53 by stabilizing the protein. This is accompanied by upregulation of the p53 inducible gene, p21(CIP1/WAF1), in a variety of cell lines: MCF7 and their derivatives (MCF7/HER2, MN1 and MCF-7-puro), ZR75T and LnCap cells, The induction of p21 is further enhanced when cells are treated with both NDF/HRG and DNA-damaging chemotherapeutic agents (i.e. doxorubicin). The NDF/HRG mediated induction of p21 is dependent on wildtype p53, as it fails to occur in cells expressing dominant negative p53 (MDD2). Furthermore, p21 induction is capable of inactivating cdk2 complexes as measured by Histone H1 phosphorylation assays. Finally, we show that in primary cultures of breast and other cancers, p21 is significantly induced in response to NDF/HRG treatment. Collectively, these observations suggest that the mechanism of breast cancer cell growth inhibition and differentiation via erbB receptors activation is through a p53-mediated pathway.	NEW YORK STATE DEPT HLTH, WADSWORTH CTR, ALBANY, NY 12201 USA; ADV CELLULAR DIAGNOST INC, ELMHURST, IL 60126 USA; UNIV ILLINOIS, CHICAGO, IL 60612 USA; WEIZMANN INST SCI, DEPT CHEM IMMUNOL, IL-76100 REHOVOT, ISRAEL; FRIEDRICH MIESCHER INST, CH-4002 BASEL, SWITZERLAND	State University of New York (SUNY) System; Wadsworth Center; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Weizmann Institute of Science; Friedrich Miescher Institute for Biomedical Research			Keyomarsi, Khandan/H-2716-2016; YARDEN, YOSEF/K-1467-2012	Keyomarsi, Khandan/0000-0002-5440-0849; Gudkov, Andrei/0000-0003-2548-0154	NATIONAL CANCER INSTITUTE [R21CA062045, R01CA060730] Funding Source: NIH RePORTER; NCI NIH HHS [CA62045, CA60730] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMAGASE H, 1990, J PHARMACOBIO-DYNAM, V13, P263, DOI 10.1248/bpb1978.13.263; ARTEAGA CL, 1994, CANCER RES, V54, P3758; BACUS SS, 1990, MOL CARCINOGEN, V3, P350, DOI 10.1002/mc.2940030607; BACUS SS, 1993, CANCER RES, V53, P5251; BACUS SS, 1992, CANCER RES, V52, P2580; BEERLI RR, 1994, J BIOL CHEM, V269, P23931; CARPENTER G, 1979, ANNU REV BIOCHEM, V48, P193, DOI 10.1146/annurev.bi.48.070179.001205; CARRAWAY KL, 1994, J BIOL CHEM, V269, P14303; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DIKIC I, 1994, CURR BIOL, V4, P702, DOI 10.1016/S0960-9822(00)00155-X; DOLBEARE F, 1983, P NATL ACAD SCI-BIOL, V80, P5573, DOI 10.1073/pnas.80.18.5573; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; GRAUSPORTA D, 1995, MOL CELL BIOL, V15, P1182; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; GUDAS J, 1995, ONCOGENE, V11, P253; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HANCOCK MC, 1991, CANCER RES, V51, P4575; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HARPER JW, 1993, CELL, V75, P805; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HUDZIAK RM, 1989, MOL CELL BIOL, V9, P1165, DOI 10.1128/MCB.9.3.1165; HUI Z, 1993, MOL BIOL CELL, V4, P897, DOI 10.1091/mbc.4.9.897; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; KASTAN MB, 1991, CANCER RES, V51, P6304; KEYOMARSI K, 1994, CANCER RES, V54, P380; KEYOMARSI K, 1995, ONCOGENE, V11, P941; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; KWOK TT, 1991, INT J CANCER, V49, P73, DOI 10.1002/ijc.2910490114; KWOK TT, 1989, J NATL CANCER I, V81, P1020, DOI 10.1093/jnci/81.13.1020; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Liu Y, 1996, CANCER RES, V56, P31; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MUSS HB, 1994, NEW ENGL J MED, V330, P1260, DOI 10.1056/NEJM199405053301802; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; OREN M, 1992, FASEB J, V6, P3169, DOI 10.1096/fasebj.6.13.1397838; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; PELES E, 1991, EMBO J, V10, P2077, DOI 10.1002/j.1460-2075.1991.tb07739.x; PELES E, 1993, EMBO J, V12, P961, DOI 10.1002/j.1460-2075.1993.tb05737.x; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; PIETRAS RJ, 1994, ONCOGENE, V9, P1829; PINKASKRAMARSKI R, 1994, P NATL ACAD SCI USA, V91, P9387, DOI 10.1073/pnas.91.20.9387; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Ronen D, 1996, CELL GROWTH DIFFER, V7, P21; SACHS L, 1987, CANCER RES, V47, P1981; SEMBA K, 1985, P NATL ACAD SCI USA, V82, P6497, DOI 10.1073/pnas.82.19.6497; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; SHEIKH MS, 1994, ONCOGENE, V9, P3407; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SIEGALL CB, 1995, J BIOL CHEM, V270, P7625, DOI 10.1074/jbc.270.13.7625; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; TAGLIABUE E, 1991, INT J CANCER, V47, P933, DOI 10.1002/ijc.2910470625; TRAVERSE S, 1994, CURR BIOL, V4, P694, DOI 10.1016/S0960-9822(00)00154-8; TZAHAR E, 1994, J BIOL CHEM, V269, P25226; WEN DZ, 1994, MOL CELL BIOL, V14, P1909, DOI 10.1128/MCB.14.3.1909; WU XP, 1995, J CLIN INVEST, V95, P1897, DOI 10.1172/JCI117871; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750; ZHANG W, 1995, CANCER RES, V55, P668; ZIANG H, 1993, MOL BIOL CELL DIFF, V1, P285	67	72	75	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 20	1996	12	12					2535	2547						13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UW487	8700512				2022-12-25	WOS:A1996UW48700007
J	Khwaja, A; Hallberg, B; Warne, PH; Downward, J				Khwaja, A; Hallberg, B; Warne, PH; Downward, J			Networks of interaction of p120(cbl) and p130(cas) with Crk and Grb2 adaptor proteins	ONCOGENE			English	Article						Cb1; Grb2; Crk; oncogene; tyrosine phosphorylation	RECEPTOR TYROSINE KINASES; V-CBL ONCOGENE; SH3 DOMAINS; IDENTIFICATION; TRANSFORMATION; ASSOCIATION; TRUNCATION; BINDS; CELLS	P120(cbl), the product of the c-cbl proto-oncogene, has previously been shown to become tyrosine phosphorylated following EGF stimulation of cells, and to bind constitutively to the SH3 domain of the adaptor protein Grb2. Here we show that another adaptor protein, Crk, binds through its SH2 domain to tyrosine phosphorylated p120(cbl). In addition, Crk becomes phosphorylated on tyrosine and serine following EGF treatment of PC12 and other cell lines. In unstimulated cells, while Grb2 is not bound to any tyrosine phosphoprotein, Crk is bound via its SH2 domain to tyrosine phosphorylated p130(cas), the Crk-associated v-Src substrate. Following EGF treatment, Crk dissociates from p130(cas), possibly due to a higher affinity of Crk SH2 for p120(cbl) compared with p130(cas). Interaction between Grb2 and p120(cbl) increases threefold following EGF treatment of cells; in vitro, this induction of Grb2 association with unphosphorylated p120(cbl) can be mimicked by the addition of tyrosine phosphorylated She, suggesting a transfer of information between the SH2 and SH3 domains of Grb2. These data indicate that adaptor proteins can exchange binding partners in response to stimuli, and that different adaptor proteins can bind to the same partners by different mechanisms.	IMPERIAL CANC RES FUND, LONDON WC2A 3PX, ENGLAND	Cancer Research UK			Khwaja, Asim/C-1509-2008	Downward, Julian/0000-0002-2331-4729				ADCOCK MR, 1993, NATURE, V363, P83; ADCOCK MR, 1992, NATURE, V360, P689; BEITNERJOHNSON D, 1995, J BIOL CHEM, V270, P5187, DOI 10.1074/jbc.270.10.5187; BIRGE RB, 1993, MOL CELL BIOL, V13, P4648, DOI 10.1128/MCB.13.8.4648; BLAKE TJ, 1991, ONCOGENE, V6, P653; BLAKE TJ, 1993, EMBO J, V12, P2017, DOI 10.1002/j.1460-2075.1993.tb05851.x; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; DOWNWARD J, 1994, FEBS LETT, V338, P113, DOI 10.1016/0014-5793(94)80346-3; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FELLER SM, 1994, TRENDS BIOCHEM SCI, V19, P453, DOI 10.1016/0968-0004(94)90129-5; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; FUKAZAWA T, 1995, J BIOL CHEM, V270, P19141, DOI 10.1074/jbc.270.32.19141; GALISTEO ML, 1995, J BIOL CHEM, V270, P20242, DOI 10.1074/jbc.270.35.20242; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; HEMPSTEAD BL, 1994, MOL CELL BIOL, V14, P1964, DOI 10.1128/MCB.14.3.1964; JACKMAN JK, 1995, J BIOL CHEM, V270, P7029, DOI 10.1074/jbc.270.13.7029; KANNER SB, 1991, EMBO J, V10, P1689, DOI 10.1002/j.1460-2075.1991.tb07693.x; KNUDSEN BS, 1994, J BIOL CHEM, V269, P32781; KOCH CA, 1992, MOL CELL BIOL, V12, P1366, DOI 10.1128/MCB.12.3.1366; LEZCANO OMR, 1994, J BIOL CHEM, V269, P17363; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MAIGNAN S, 1995, SCIENCE, V268, P291, DOI 10.1126/science.7716522; MARCILLA A, 1995, J BIOL CHEM, V270, P9115, DOI 10.1074/jbc.270.16.9115; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MEISNER H, 1995, MOL CELL BIOL, V15, P3571; ODAI H, 1995, J BIOL CHEM, V270, P10800, DOI 10.1074/jbc.270.18.10800; PATCH LA, 1995, J CELL SCI, V108, P1371; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; RANKIN S, 1994, J BIOL CHEM, V269, P704; RAVICHANDRAN KS, 1995, MOL CELL BIOL, V15, P593; REGNIER DC, 1989, J VIROL, V63, P3678, DOI 10.1128/JVI.63.9.3678-3682.1989; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; SCHLAEPFER DD, 1994, NATURE, V372, P786; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SEUFFERLEIN T, 1994, J BIOL CHEM, V269, P9345; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; TANAKA S, 1995, J BIOL CHEM, V270, P14347, DOI 10.1074/jbc.270.24.14347; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; TAUCHI T, 1994, J BIOL CHEM, V269, P25206; YOON CH, 1995, SCIENCE, V269, P1102, DOI 10.1126/science.7652556; ZACHARY I, 1992, J BIOL CHEM, V267, P19031; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	46	48	48	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 20	1996	12	12					2491	2498						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UW487	8700507				2022-12-25	WOS:A1996UW48700002
J	Chou, MY; Li, SC; Li, YT				Chou, MY; Li, SC; Li, YT			Cloning and expression of sialidase L, a NeuAc alpha 2->3Gal-specific sialidase from the leech, Macrobdella decora	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURAMINIDASE GENE; ESCHERICHIA-COLI; CLOSTRIDIUM-PERFRINGENS; CONSERVED SEQUENCES; BACTERIAL; PROTEINS; NANH; AMPLIFICATION; ACID	Sialidase L is a NeuAc alpha 2-->3Gal linkage-specific sialidase that releases 2,7-anhydro-NeuAc instead of NeuAc from sialoglycoconjugates (Chou, M.-Y., Li, S.-C., Kiso, M,, Hasegawa, A., and Li, Y.-T, (1994) J. Biol, Chem. 269, 18821-18826), A 2.5-kilobase cDNA of sialidase L was cloned by a combination of methods based on polymerase chain reactions, The composite cDNA sequence reveals an open reading frame coding for 762 amino acids, including a putative 28-residue signal peptide at the N terminus that is similar to the signal sequence of the Clostridium septicum sialidase, The result suggests that sialidase L is a secretory enzyme, The coding sequence excluding the putative signal peptide of sialidase L was overexpressed in Escherichia coli. The purified recombinant enzyme was characterized to be as active as the enzyme isolated from the leech, It also possessed the strict NeuAc alpha 2-->3Gal linkage specificity and released the unique cleavage product, 2,7-anhydro-NeuAc from sialoglycoconjugates. The deduced amino acid sequence of sialidase L exhibits little similarity with other reported sialidases, However, sialidase L contains a conserved ''FRIP region'' and four repeating ''Asp box'' motifs that align well with the corresponding positions of bacterial sialidases. The predicted beta-strand structures near the conserved motifs of sialidase L are similar to those of Salmonella typhimurium sialidase. Several conserved single amino acid residues of bacterial sialidases, including those known to be involved in the active site of Salmonella enzyme, are conserved in the deduced amino acid sequence of sialidase L, This observation suggests that part of the catalytic mechanism of sialidase L may be similar to the ordinary sialidase.	TULANE UNIV,SCH MED,DEPT BIOCHEM,NEW ORLEANS,LA 70112	Tulane University					NINDS NIH HHS [NS 09626] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS009626] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AKIMOTO S, 1994, BIOCHEM BIOPH RES CO, V203, P914, DOI 10.1006/bbrc.1994.2269; CAMARA M, 1994, INFECT IMMUN, V62, P3688; CHOU MY, 1994, J BIOL CHEM, V269, P18821; CRENNELL SJ, 1993, P NATL ACAD SCI USA, V90, P9852, DOI 10.1073/pnas.90.21.9852; FERRARI J, 1994, GLYCOBIOLOGY, V4, P367, DOI 10.1093/glycob/4.3.367; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; HAN JH, 1987, BIOCHEMISTRY-US, V26, P1617, DOI 10.1021/bi00380a020; HARRIS G, 1954, CHEM IND-LONDON, P249; HENNINGSEN M, 1991, BIOL CHEM H-S, V372, P1065, DOI 10.1515/bchm3.1991.372.2.1065; HOYER LL, 1992, MOL MICROBIOL, V6, P873, DOI 10.1111/j.1365-2958.1992.tb01538.x; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI YT, 1990, J BIOL CHEM, V265, P21629; LIU XW, 1993, NUCLEIC ACIDS RES, V21, P4954, DOI 10.1093/nar/21.21.4954; MIYAGI T, 1993, J BIOL CHEM, V268, P26435; ROGGENTIN P, 1989, GLYCOCONJUGATE J, V6, P349, DOI 10.1007/BF01047853; ROGGENTIN P, 1993, MOL MICROBIOL, V9, P915, DOI 10.1111/j.1365-2958.1993.tb01221.x; ROGGENTIN P, 1988, FEBS LETT, V238, P31, DOI 10.1016/0014-5793(88)80219-9; ROGGENTIN T, 1992, GLYCOCONJUGATE J, V9, P235, DOI 10.1007/BF00731135; ROTHE B, 1989, J GEN MICROBIOL, V135, P3087; ROTHE B, 1991, MOL GEN GENET, V226, P190, DOI 10.1007/BF00273603; RUSSO TA, 1990, J BACTERIOL, V172, P2594, DOI 10.1128/jb.172.5.2594-2600.1990; Saito M, 1995, BIOL SIALIC ACIDS, P261, DOI [10.1007/978-1-4757-9504-2_8, DOI 10.1007/978-1-4757-9504-2_8]; SAKURADA K, 1992, J BACTERIOL, V174, P6896, DOI 10.1128/JB.174.21.6896-6903.1992; Sambrook J., 2002, MOL CLONING LAB MANU; SCHAUER R, 1982, SIALIC ACIDS CHEM ME, P1; SCHAUER R, 1983, STRUCTURAL CARBOHYDR, P83; SINNOTT ML, 1993, J AM CHEM SOC, V115, P3334, DOI 10.1021/ja00061a044; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; VIMR ER, 1988, J BACTERIOL, V170, P1495, DOI 10.1128/jb.170.4.1495-1504.1988	31	23	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19219	19224		10.1074/jbc.271.32.19219	http://dx.doi.org/10.1074/jbc.271.32.19219			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702601	hybrid			2022-12-25	WOS:A1996VB68400035
J	Vostal, JG; Shafer, B				Vostal, JG; Shafer, B			Thapsigargin-induced calcium influx in the absence of detectable tyrosine phosphorylation in human platelets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR CA2+ STORES; PROTEIN-KINASE-C; PLASMA-MEMBRANE; CA-2+ ENTRY; GENISTEIN; ACTIVATION; INHIBITORS; RECEPTOR; MOBILIZATION; MECHANISMS	Tyrosine phosphorylation is a potential mechanism for mediating store-operated calcium (SOC) influx in platelets and other nonexcitable cells. Thapsigargin induces calcium-dependent tyrosine phosphorylation and SOC influx in platelets. We prevented thapsigargin-induced tyrosine phosphorylation by buffering cytosolic calcium rise with the calcium chelator 1,2-bis-(o-aminophenoxy) ethane-N,N,N',N'-tetraacetic acid-acetomethoxyester (BAPTA-AM). Calcium influx, induced by thapsigargin and measured by Ca-45(2+) accumulation, persisted in BAPTA-loaded platelets in the absence of tyrosine phosphorylation. This calcium influx was blocked by the SOC influx inhibitor SKF-96365. Tyrosine kinase inhibitors have been used to demonstrate a role for tyrosine phosphorylation in SOC influx. We compared the effects of four tyrosine kinase inhibitors genistein, methyl-2,5-dihydroxycinnamate (erbstatin analog), tyrphostin A47, and lavendustin A, on thapsigargin-induced tyrosine phosphorylation in control platelets and on thapsigargin-induced SOC influx into BAPTA-loaded platelets in absence of tyrosine phosphorylation, Tyrphostin A47 prevented all measurable tyrosine phosphorylation in control platelets, but did not decrease calcium influx into BAPTA-loaded platelets. Genistein and the erbstatin analog were poor inhibitors of tyrosine phosphorylation but decreased SOC influx into BAPTA-loaded platelets to 55.8 +/- 3% and 51.9 +/- 7.5% of control, respectively. Lavendustin A did not decrease tyrosine phosphorylation or calcium influx. Thus, thapsigargin-induced SOC influx can occur without detectable tyrosine phosphorylation and the inhibition of SOC influx by tyrosine kinase inhibitors does not correlate with their ability to prevent tyrosine phosphorylation.			Vostal, JG (corresponding author), US FDA,CBER,DIV HEMATOL,LAB CELLULAR HEMATOL,BLDG 29,RM 323,HFM 335,BETHESDA,MD 20892, USA.							ALVAREZ J, 1992, FASEB J, V6, P786, DOI 10.1096/fasebj.6.2.1537469; BISCHOF G, 1995, AM J PHYSIOL-CELL PH, V268, pC154, DOI 10.1152/ajpcell.1995.268.1.C154; BOURGUIGNON LYW, 1995, J BIOL CHEM, V270, P7257, DOI 10.1074/jbc.270.13.7257; CARAFOLI E, 1992, J BIOL CHEM, V267, P2115; CLAPHAM DE, 1995, NATURE, V375, P634, DOI 10.1038/375634a0; FALET H, 1994, FEBS LETT, V345, P87, DOI 10.1016/0014-5793(94)00414-5; FERRELL JE, 1989, P NATL ACAD SCI USA, V86, P2234, DOI 10.1073/pnas.86.7.2234; GARCIASANCHO J, 1992, TRENDS PHARMACOL SCI, V13, P12, DOI 10.1016/0165-6147(92)90007-S; GOIDEN A, 1986, P NATL ACAD SCI USA, V83, P852; HAJNOCZKY G, 1994, J BIOL CHEM, V269, P10280; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; JONAS JC, 1995, BRIT J PHARMACOL, V114, P872, DOI 10.1111/j.1476-5381.1995.tb13285.x; LEE KM, 1993, J BIOL CHEM, V268, P9945; LEVY LA, 1987, AM J PHYSIOL, V252, pC441, DOI 10.1152/ajpcell.1987.252.4.C441; MARTELL AE, 1974, CRITICAL STABILITY C, V1, P269; MCNICOL A, 1993, PROSTAG LEUKOTR ESS, V48, P379, DOI 10.1016/0952-3278(93)90118-G; MERRITT JE, 1990, BIOCHEM J, V271, P515, DOI 10.1042/bj2710515; NAKAMURA K, 1995, AM J PHYSIOL, V267, pC958; OZAKI Y, 1993, BIOCHEM PHARMACOL, V46, P395; PANDOL SJ, 1990, J BIOL CHEM, V265, P12846; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; SARGEANT P, 1993, FEBS LETT, V315, P242, DOI 10.1016/0014-5793(93)81172-V; SARGEANT P, 1993, J BIOL CHEM, V268, P18151; SIESS W, 1989, PHYSIOL REV, V69, P58, DOI 10.1152/physrev.1989.69.1.58; TAKAYAMA H, 1991, BIOCHEM BIOPH RES CO, V174, P922, DOI 10.1016/0006-291X(91)91506-8; THASTRUP O, 1990, AGENTS ACTIONS, V29, P8, DOI 10.1007/BF01964706; TSIEN RY, 1980, BIOCHEMISTRY-US, V19, P2396, DOI 10.1021/bi00552a018; Turner CE, 1991, CURR OPIN CELL BIOL, V3, P849, DOI 10.1016/0955-0674(91)90059-8; VONTSCHARNER V, 1986, NATURE, V324, P369, DOI 10.1038/324369a0; VOSTAL JG, 1993, BIOCHEM J, V294, P675, DOI 10.1042/bj2940675; VOSTAL JG, 1991, J BIOL CHEM, V266, P16911; VOSTAL JG, 1993, BIOCHEM J, V295, P525, DOI 10.1042/bj2950525; WIJETUNGE S, 1992, BIOCHEM BIOPH RES CO, V189, P1620, DOI 10.1016/0006-291X(92)90262-J; YUIE DI, 1994, BIOCHEM BIOPH RES CO, V202, P1697	36	26	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19524	19529		10.1074/jbc.271.32.19524	http://dx.doi.org/10.1074/jbc.271.32.19524			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702645	hybrid			2022-12-25	WOS:A1996VB68400079
J	Wieland, SJ; Gong, QH; Poblete, H; Fletcher, JE; Chen, LQ; Kallen, RG				Wieland, SJ; Gong, QH; Poblete, H; Fletcher, JE; Chen, LQ; Kallen, RG			Modulation of human muscle sodium channels by intracellular fatty acids is dependent on the channel isoform	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; SKELETAL-MUSCLE; FUNCTIONAL EXPRESSION; CELLS; NA+; CONDUCTANCE	Free fatty acids (FFAs), including arachidonic acid (AA), are implicated in the direct and indirect modulation of a spectrum of voltage-gated ion channels, Skeletal muscle sodium channels can be either activated or inhibited by FFA exposure; the response is dependent on both FFA structure and site of exposure. Recombi nant human skeletal muscle sodium channels (hSkM1) were transfected into heterologous human renal epithelium HEK293t cells, Cytoplasmic delivery of 5 mu M AA augmented the voltage-activated sodium current of hSkM1 channels by 190% (+/- 54 S.E., n = 7) over a 20-min period, Similar results were seen with 5 mu M oleic acid, Sodium currents in HEK293t cells transfected with human cardiac muscle sodium channels (hH1) were insensitive to AA treatment, and exposure to oleic acid inhibited the hH1 currents over a 20-min period by 29% (+/- 13 S.E., n = 5), The increase in hSkM1 current was not accompanied by shifts in voltage dependence of activation, steady-state inactivation, or markedly altered kinetics of inactivation of the macroscopic current, The FFA-induced increase in sodium currents was not dependent on protein kinase C activity, In contrast, both isoforms were reversibly inhibited by external application of unsaturated FFA, Thus, the differential effects of FFA on skeletal muscle sodium channels first noted in cultured muscle cells can be reproduced by expressing recombinant sodium channels in epithelial cells, Although the responses to applied FFAs could be direct or indirect, we suggest that: 1) SkM1 has two classes of response to FFA, one which produces augmentation of macroscopic currents with intracellular FFA, and a second which produces inhibition with extracellular FFA; 2) H1 has only one class of response, which produces inhibition with extracellular FFA, A testable hypothesis is that the presence or absence of each response is due to a specific structure in SkM1 or H1. These specific structures may directly interact with FFA or may interact with intermediate components.	MED COLL PENN & HAHNEMANN UNIV,DEPT ANESTHESIOL,PHILADELPHIA,PA 19102; UNIV PENN,SCH MED,DEPT BIOCHEM & BIOPHYS,PHILADELPHIA,PA 19102	Drexel University; University of Pennsylvania	Wieland, SJ (corresponding author), MED COLL PENN & HAHNEMANN UNIV,DEPT NEUROBIOL & ANAT,MAIL STOP 408,BROAD & VINE,PHILADELPHIA,PA 19102, USA.							Ausubel F.M., 1992, SHORT PROTOCOLS MOL; BELL RM, 1991, J BIOL CHEM, V266, P4661; CANNON SC, 1993, NEURON, V10, P317, DOI 10.1016/0896-6273(93)90321-H; GELLENS ME, 1992, P NATL ACAD SCI USA, V89, P554, DOI 10.1073/pnas.89.2.554; GEORGE AL, 1992, ANN NEUROL, V31, P131, DOI 10.1002/ana.410310203; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HILLE B, 1992, IONIC CHANNELS EXCIT, P250; HUANG JMC, 1992, P NATL ACAD SCI USA, V89, P6452, DOI 10.1073/pnas.89.14.6452; HWANG TC, 1990, P NATL ACAD SCI USA, V87, P5706, DOI 10.1073/pnas.87.15.5706; KALLEN RG, 1990, NEURON, V4, P233, DOI 10.1016/0896-6273(90)90098-Z; KUBO Y, 1993, NATURE, V362, P127, DOI 10.1038/362127a0; LINDEN DJ, 1989, J PHYSIOL-LONDON, V419, P95, DOI 10.1113/jphysiol.1989.sp017863; NUMANN R, 1991, SCIENCE, V254, P115, DOI 10.1126/science.1656525; ORDWAY RW, 1989, SCIENCE, V244, P1176, DOI 10.1126/science.2471269; ORDWAY RW, 1991, TRENDS NEUROSCI, V14, P96, DOI 10.1016/0166-2236(91)90069-7; ROGART RB, 1989, P NATL ACAD SCI USA, V86, P8170, DOI 10.1073/pnas.86.20.8170; UKOMADU C, 1992, NEURON, V8, P663, DOI 10.1016/0896-6273(92)90088-U; Wieland S. J., 1995, Society for Neuroscience Abstracts, V21, P1820; WIELAND SJ, 1990, J CELL PHYSIOL, V142, P643, DOI 10.1002/jcp.1041420326; WIELAND SJ, 1992, AM J PHYSIOL, V263, pC308, DOI 10.1152/ajpcell.1992.263.2.C308; WU JT, 1991, J BIOL CHEM, V266, P14893; YANG JSJ, 1991, NEURON, V7, P421, DOI 10.1016/0896-6273(91)90294-A	22	26	26	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19037	19041		10.1074/jbc.271.32.19037	http://dx.doi.org/10.1074/jbc.271.32.19037			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702574	hybrid			2022-12-25	WOS:A1996VB68400008
J	DeLuca, A; Santra, M; Baldi, A; Giordano, A; Iozzo, RV				DeLuca, A; Santra, M; Baldi, A; Giordano, A; Iozzo, RV			Decorin-induced growth suppression is associated with up-regulation of p21, an inhibitor of cyclin-dependent kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLON-CARCINOMA-CELLS; HEPARAN-SULFATE PROTEOGLYCAN; P53-MEDIATED G(1) ARREST; GENE-EXPRESSION; EXTRACELLULAR-MATRIX; CANCER-CELLS; FACTOR-BETA; INDUCTION; HYPOMETHYLATION; DIFFERENTIATION	The secreted proteoglycan decorin has been impli cated in the negative control of cell proliferation primarily by virtue of its ability to block transforming growth factor-beta, Moreover, decorin expression is markedly up-regulated during quiescence but suppressed upon viral transformation, whereas de novo decorin expression in colon carcinoma cells abrogates the malignant phenotype by arresting the cells in the G(1) phase of the cell cycle, Here we show that this decorin-induced growth arrest is associated with up-regulation of p21 mRNA and protein in a transforming growth factor-beta- and p53-independent pathway, The augmented p21 protein is present as a multimeric complex with various cyclins and cyclin-dependent kinases in the nuclei of decorin-expressing cells, thereby leading to suppression of cyclin-dependent kinase activity and block of cell division, Through the usage of decorin-specific antisense oligodeoxynucleotide treatment, we demonstrate that the expression of decorin is closely linked to that of p21 and that abrogation of decorin leads to suppression of p21 and restoration of cell division, Collectively, our results provide a plausible mechanism by which decorin may contribute to retard and suppress the growth of tumor cells in vivo.	THOMAS JEFFERSON UNIV,DEPT PATHOL ANAT & CELL BIOL,PHILADELPHIA,PA 19107; THOMAS JEFFERSON UNIV,KIMMEL CANC CTR,PHILADELPHIA,PA 19107; THOMAS JEFFERSON UNIV,DEPT MICROBIOL & IMMUNOL,PHILADELPHIA,PA 19107	Jefferson University; Jefferson University; Jefferson University			De Luca, Antonio/AAD-9562-2020; Giordano, Antonio/F-1927-2010; Iozzo, Renato/AAS-1980-2020; Baldi, Alfonso/ABG-2397-2021	De Luca, Antonio/0000-0002-3905-6154; Giordano, Antonio/0000-0002-5959-016X; Baldi, Alfonso/0000-0002-8693-3842; Iozzo, Renato/0000-0002-5908-5112	NCI NIH HHS [R01 CA60999, R01 CA47282, R01 CA39481] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA060999, R01CA047282, R01CA039481] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADANY R, 1991, BIOCHEM J, V276, P301, DOI 10.1042/bj2760301; ADANY R, 1990, J BIOL CHEM, V265, P11389; ASUNDI VK, 1992, EUR J CELL BIOL, V59, P314; BIDANSET DJ, 1992, J BIOL CHEM, V267, P5250; BUTTKE TM, 1993, J IMMUNOL METHODS, V157, P233, DOI 10.1016/0022-1759(93)90092-L; CLARKE AS, 1995, J BIOL CHEM, V270, P22673, DOI 10.1074/jbc.270.39.22673; COPPOCK DL, 1993, CELL GROWTH DIFFER, V4, P483; DANIELSON KG, 1993, GENOMICS, V15, P146, DOI 10.1006/geno.1993.1022; DODGE GR, 1990, J BIOL CHEM, V265, P18023; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fang F, 1996, SCIENCE, V271, P499, DOI 10.1126/science.271.5248.499; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HARPER JW, 1993, CELL, V75, P805; IOZZO RV, 1993, EXPERIENTIA, V49, P447, DOI 10.1007/BF01923588; IOZZO RV, 1985, J BIOL CHEM, V260, P7464; Iozzo RV, 1996, FASEB J, V10, P598, DOI 10.1096/fasebj.10.5.8621059; IOZZO RV, 1984, J CELL BIOL, V99, P403, DOI 10.1083/jcb.99.2.403; JIANG HP, 1994, ONCOGENE, V9, P3397; KRUSIUS T, 1986, P NATL ACAD SCI USA, V83, P7683, DOI 10.1073/pnas.83.20.7683; LI CY, 1995, J BIOL CHEM, V270, P4971, DOI 10.1074/jbc.270.10.4971; MACLACHLAN TK, 1995, CRIT REV EUKAR GENE, V5, P127, DOI 10.1615/CritRevEukarGeneExpr.v5.i2.20; MAUVIEL A, 1995, J BIOL CHEM, V270, P11692, DOI 10.1074/jbc.270.19.11692; MICHIELI P, 1994, CANCER RES, V54, P3391; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; PINES J, 1995, SEMIN CANCER BIOL, V6, P63, DOI 10.1006/scbi.1995.0009; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; SANTRA M, 1995, P NATL ACAD SCI USA, V92, P7016, DOI 10.1073/pnas.92.15.7016; SCHOLZEN T, 1994, J BIOL CHEM, V269, P28270; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; STEINMAN RA, 1994, ONCOGENE, V9, P3389; VOGEL KG, 1984, BIOCHEM J, V223, P587, DOI 10.1042/bj2230587; WALDMAN T, 1995, CANCER RES, V55, P5187; YAMAGUCHI Y, 1988, NATURE, V336, P244, DOI 10.1038/336244a0; YAMAGUCHI Y, 1990, NATURE, V346, P281, DOI 10.1038/346281a0	37	211	214	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18961	18965		10.1074/jbc.271.31.18961	http://dx.doi.org/10.1074/jbc.271.31.18961			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702560	hybrid			2022-12-25	WOS:A1996VB68300098
J	GagnouxPalacios, L; Vailly, J; DurandClement, M; Wagner, E; Ortonne, JP; Meneguzzi, G				GagnouxPalacios, L; Vailly, J; DurandClement, M; Wagner, E; Ortonne, JP; Meneguzzi, G			Functional re-expression of laminin-5 in laminin-gamma 2-deficient human keratinocytes modifies cell morphology, motility, and adhesion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							JUNCTIONAL EPIDERMOLYSIS-BULLOSA; MONOCLONAL-ANTIBODY GB3; BASEMENT-MEMBRANES; INITIAL BINDING; ALPHA-3 CHAIN; DNA COMPLEXES; HEMIDESMOSOMES; NICEIN/KALININ; INTEGRIN; KALININ	Herlitz junctional epidermolysis bullosa (H-JEB) is characterized by a reduced adherence of keratinocytes consequent to deficient expression of the extracellular adhesive ligand laminin-5, To complement the genetic defect causing H-JEB, we transferred an eukaryotic cassette expressing the cDNA for the gamma 2 chain of laminin-5 into H-JEB keratinocytes in which the expression of the polypeptide is hampered by a homozygous mutation generating a premature termination codon. Transfection using adenovirus-polylysin-transferrin DNA complexes resulted in a transient synthesis of the recombinant laminin gamma 2 chain that associated with the endogenous alpha 3 and beta 3 chains to form laminin-5 molecules readily deposited on the tissue culture substrate, Furthermore, retroviral mediated transduction of the gamma 2 cDNA yielded persistent expression and polarized secretion of laminin-5, The protein incorporated into the basement membrane produced by the revertant cells inoculated subcutaneously in nude mice. In these transfectants, re-expression of laminin-5 induced changes in cell morphology and reorganization of focal adhesions that assumed the shape and distribution of the counterparts detected in normal keratinocytes. These observations correlated with an enhanced cell-substrate adhesion and a reduced motility of the transfected cells, Our results demonstrate that a restored expression of laminin-5 induces a phenotypic reversion of genetically altered H-JEB keratinocytes and open new perspectives to the analysis of the mechanisms regulating adhesion of epithelial cells.	FAC MED NICE, UFR MED, INSERM U385, F-06107 NICE 2, FRANCE; HOP LOUIS PASTEUR, SERV DERMATOL, F-06002 NICE 1, FRANCE; BENDER AG, A-1121 VIENNA, AUSTRIA	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; CHU Nice			Gagnoux, Laurent/O-9954-2016; Gagnoux, Laurent/O-9990-2016; Wagner, Ernst/ABB-5976-2020; Wagner, Ernst/A-7435-2012	Wagner, Ernst/0000-0001-8413-0934; Wagner, Ernst/0000-0001-8413-0934; Meneguzzi, Guerrino/0000-0002-1609-6540				ABERDAM D, 1994, NAT GENET, V6, P299, DOI 10.1038/ng0394-299; ABERDAM D, 1994, CELL ADHES COMMUN, V2, P115, DOI 10.3109/15419069409004431; ALBRECHTBUEHLER G, 1977, CELL, V11, P395, DOI 10.1016/0092-8674(77)90057-5; BAUDOIN C, 1994, J CLIN INVEST, V93, P862, DOI 10.1172/JCI117041; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; CARTER WG, 1991, CELL, V65, P599, DOI 10.1016/0092-8674(91)90092-D; CEPKO C, 1989, NEUROMETHODS, V16, P177; CHEN JD, IN PRESS LAB INVEST; COTTEN M, 1992, P NATL ACAD SCI USA, V89, P6094, DOI 10.1073/pnas.89.13.6094; DANOS O, 1988, P NATL ACAD SCI USA, V85, P6460, DOI 10.1073/pnas.85.17.6460; DIMILLA PA, 1993, J CELL BIOL, V122, P729, DOI 10.1083/jcb.122.3.729; ENGEL J, 1992, BIOCHEMISTRY-US, V31, P10643, DOI 10.1021/bi00159a001; ENGVALL E, 1993, KIDNEY INT, V43, P2, DOI 10.1038/ki.1993.2; FERNANDEZ JLR, 1993, J CELL BIOL, V122, P1285, DOI 10.1083/jcb.122.6.1285; FINE JD, 1991, J AM ACAD DERMATOL, V24, P119, DOI 10.1016/0190-9622(91)70021-S; GALLIANO MF, 1995, J BIOL CHEM, V270, P21820, DOI 10.1074/jbc.270.37.21820; GERECKE DR, 1994, J BIOL CHEM, V269, P11073; GIL SG, 1994, J INVEST DERMATOL, V103, pS31, DOI 10.1111/1523-1747.ep12398953; GREEN TL, 1992, J BIOL CHEM, V267, P2014; HORMIA M, 1995, J INVEST DERMATOL, V105, P557, DOI 10.1111/1523-1747.ep12323451; IZZARD CS, 1976, J CELL SCI, V21, P129; JIANG CK, 1991, J INVEST DERMATOL, V97, P969, DOI 10.1111/1523-1747.ep12491889; KRUEGER JG, 1991, J INVEST DERMATOL, V97, P849, DOI 10.1111/1523-1747.ep12491525; KUBLER MD, 1993, J INVEST DERMATOL, V100, P785, DOI 10.1111/1523-1747.ep12476492; LANGHOFER M, 1993, J CELL SCI, V105, P753; LOTZ MM, 1989, J CELL BIOL, V109, P1795, DOI 10.1083/jcb.109.4.1795; MARINKOVICH MP, 1992, J BIOL CHEM, V267, P17900; MATSUI C, 1995, J BIOL CHEM, V270, P23496, DOI 10.1074/jbc.270.40.23496; MATSUI C, 1995, J INVEST DERMATOL, V105, P648, DOI 10.1111/1523-1747.ep12324108; MCCLAY DR, 1981, P NATL ACAD SCI-BIOL, V78, P4975, DOI 10.1073/pnas.78.8.4975; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; Miquel C, 1996, EXP CELL RES, V224, P279, DOI 10.1006/excr.1996.0138; OrianRousseau V, 1996, DEV DYNAM, V206, P12, DOI 10.1002/(SICI)1097-0177(199605)206:1<12::AID-AJA2>3.0.CO;2-3; ROSDY M, 1993, BRIT J DERMATOL, V129, P227, DOI 10.1111/j.1365-2133.1993.tb11839.x; ROUSSELLE P, 1991, J CELL BIOL, V114, P567, DOI 10.1083/jcb.114.3.567; RYAN MC, 1994, J BIOL CHEM, V269, P22779; SONNENBERG A, 1993, J CELL SCI, V106, P1083; SPINARDI L, 1995, J CELL BIOL, V129, P473, DOI 10.1083/jcb.129.2.473; STAEDEL C, 1994, J INVEST DERMATOL, V102, P768, DOI 10.1111/1523-1747.ep12377673; TIMPL R, 1989, EUR J BIOCHEM, V180, P487, DOI 10.1111/j.1432-1033.1989.tb14673.x; VAILLY J, 1994, EUR J BIOCHEM, V219, P209, DOI 10.1111/j.1432-1033.1994.tb19932.x; VERRANDO P, 1987, EXP CELL RES, V170, P116, DOI 10.1016/0014-4827(87)90121-2; VERRANDO P, 1993, J INVEST DERMATOL, V101, P738, DOI 10.1111/1523-1747.ep12371685; VERRANDO P, 1994, LAB INVEST, V71, P567; VIDAL F, 1995, GENOMICS, V30, P273, DOI 10.1006/geno.1995.9877; WAGNER E, 1992, P NATL ACAD SCI USA, V89, P6099, DOI 10.1073/pnas.89.13.6099; WOODLEY DT, 1991, WOUND HEALING, P91; YURCHENCO PD, 1990, FASEB J, V4, P1577, DOI 10.1096/fasebj.4.6.2180767	48	72	74	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18437	18444		10.1074/jbc.271.31.18437	http://dx.doi.org/10.1074/jbc.271.31.18437			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702488	hybrid			2022-12-25	WOS:A1996VB68300026
J	Hwang, SC; Jhon, DY; Bae, YS; Kim, JH; Rhee, SG				Hwang, SC; Jhon, DY; Bae, YS; Kim, JH; Rhee, SG			Activation of phospholipase C-gamma by the concerted action of tau proteins and arachidonic acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATES PHOSPHOINOSITIDE HYDROLYSIS; PLACENTAL-LACTOGEN RELEASE; UNSATURATED FATTY-ACIDS; CYTOSOLIC PHOSPHOLIPASE-A2; INTERFACIAL CATALYSIS; SIGNAL-TRANSDUCTION; PHOSPHATIDIC-ACID; KINASE-C; DOMAIN; CELLS	Phospholipase C-gamma (PLC-gamma) isozymes are thought to be activated by receptor-induced tyrosine phosphorylation. Proteins that activate PLC-gamma 1 have now been purified from bovine brain and identified as members of the tan family of microtubule-associated proteins. Activation of PLC-gamma by tau was enhanced in the presence of unsaturated fatty acids such as arachidonic acid, saturated fatty acids being ineffective. Maximal (15-20-fold) activation was apparent in the presence of 0.15 mu M tau and 25 mu M arachidonic acid (AA). The effect of tau and AA was specific to PLC-gamma isozymes in the presence of submicromolar concentrations of Ca2+ and was markedly inhibited by phosphatidylcholine. These results suggest that in cells that express tau, receptor to cytosolic phospholipase A, may activate PLC-gamma isozymes indirectly in the absence of tyrosine phosphorylation through the hydrolysis of phosphatidylcholine to generate AA.	NHLBI, LAB CELL SIGNALING, NIH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)				Hwang, Sung Chul/0000-0003-2401-619X				BAUDIER J, 1987, J BIOL CHEM, V262, P17584; BOGUSLAVSKY V, 1994, BIOCHEMISTRY-US, V33, P3032, DOI 10.1021/bi00176a036; CHOW SC, 1990, J BIOL CHEM, V265, P902; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; CURRIE S, 1992, J BIOL CHEM, V267, P6056; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; GERZER R, 1986, BIOCHIM BIOPHYS ACTA, V886, P383, DOI 10.1016/0167-4889(86)90173-4; Glick J, 1996, J BIOL CHEM, V271, P2949, DOI 10.1074/jbc.271.6.2949; GLICK R, 1996, BIOCHIM BIOPHYS ACTA, V271, P2949; HANEL AM, 1993, BIOCHEMISTRY-US, V32, P5949, DOI 10.1021/bi00074a005; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HAZEN SL, 1990, J BIOL CHEM, V265, P10622; HIMMLER A, 1989, MOL CELL BIOL, V9, P1389, DOI 10.1128/MCB.9.4.1389; HOFMANN SL, 1982, J BIOL CHEM, V257, P4359; HYVONEN M, 1995, EMBO J, V14, P4676, DOI 10.1002/j.1460-2075.1995.tb00149.x; IRVINE RF, 1979, BIOCHEM J, V178, P497, DOI 10.1042/bj1780497; JAMES SR, 1995, J BIOL CHEM, V270, P11872, DOI 10.1074/jbc.270.20.11872; JONES GA, 1993, J BIOL CHEM, V268, P20845; KAST R, 1993, J BIOL CHEM, V268, P16795; KRAMER RM, 1994, SIGNAL ACTIVATED PHO, P13; LEE G, 1990, CELL MOTIL CYTOSKEL, V15, P199, DOI 10.1002/cm.970150402; LYNCH MA, 1990, J NEUROCHEM, V55, P215, DOI 10.1111/j.1471-4159.1990.tb08841.x; MANDELKOW EM, 1993, TRENDS BIOCHEM SCI, V18, P480, DOI 10.1016/0968-0004(93)90011-B; MCPHAIL LC, 1984, SCIENCE, V224, P622, DOI 10.1126/science.6231726; NEGISHI M, 1990, BIOCHEM BIOPH RES CO, V169, P773, DOI 10.1016/0006-291X(90)90398-7; NISHIKAWA M, 1988, BIOCHEM PHARMACOL, V37, P3079, DOI 10.1016/0006-2952(88)90304-8; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NOH DY, 1995, BBA-REV CANCER, V1242, P99, DOI 10.1016/0304-419X(95)00006-0; PARK D, 1992, J BIOL CHEM, V267, P16048; PIOMELLI D, 1989, P NATL ACAD SCI USA, V86, P8550, DOI 10.1073/pnas.86.21.8550; SHARP JD, 1991, J BIOL CHEM, V266, P14850; SIESS W, 1983, J BIOL CHEM, V258, P1236; SUMIDA C, 1993, PROSTAG LEUKOTR ESS, V48, P117, DOI 10.1016/0952-3278(93)90019-S; TAKENAWA T, 1981, J BIOL CHEM, V256, P6769; TAYLOR GD, 1992, BIOCHEM BIOPH RES CO, V188, P1176, DOI 10.1016/0006-291X(92)91355-T; TOUNY SE, 1990, J BIOL CHEM, V265, P16437; WOLF BA, 1986, J BIOL CHEM, V261, P3501; YOON HS, 1994, NATURE, V369, P672, DOI 10.1038/369672a0; ZEITLER P, 1985, MOL PHARMACOL, V28, P549; ZEITLER P, 1991, LIFE SCI, V48, P2089, DOI 10.1016/0024-3205(91)90166-9	41	162	168	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18342	18349		10.1074/jbc.271.31.18342	http://dx.doi.org/10.1074/jbc.271.31.18342			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702475	hybrid			2022-12-25	WOS:A1996VB68300013
J	Krebs, A; Kuchumov, AR; Sharma, PK; Braswell, EH; Zipper, P; Weber, RE; Chottard, G; Vinogradov, SN				Krebs, A; Kuchumov, AR; Sharma, PK; Braswell, EH; Zipper, P; Weber, RE; Chottard, G; Vinogradov, SN			Molecular shape, dissociation, and oxygen binding of the dodecamer subunit of Lumbricus terrestris hemoglobin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCES; EXTRACELLULAR HEMOGLOBIN; EARTHWORM HEMOGLOBIN; QUATERNARY STRUCTURE; PROTEIN; ERYTHROCRUORIN; TRIMER; CHAINS; MODELS; PH	Small angle x-ray scattering of the 213-kDa dodecamer of Lumbricus terrestris Hb yielded radius of gyration = 3.74 +/- 0.01 nm, maximum diameter = 10.59 +/- 0.01 nm, and volume = 255 +/- 10 nm(3), with no difference between the oxy and deoxy states. Sedimentation velocity studies indicate the dodecamer to have a spherical shape and concentration- and Ca2+-dependent equilibria with its constituent subunits, the disulfide-bonded trimer of chains a-e and chain d. Equilibrium sedimentation data were fitted best with a trimer-dodecamer model, In K-4 = 7 (association K in liters(3)/g(3)) at 1 degrees C and 4 at 25 degrees C, providing Delta H = -20 kcal/mol and Delta S = 4.4 eu/mol. Oxydodecamer dissociation at pH 8.0, in urea, GdmCl, heteropolytungstate K-8[SiW11O39] and of metdodecamer at pH 7, was followed by gel filtration. Elution profiles were fitted with exponentially modified gaussians to represent the three peaks. Two exponentials were necessary to fit all the dissociations except in [SiW11O39](-8). Equilibrium oxygen binding measurements at pH 6.5-8.5, provided P-50 = 8.5, 11.5-11.9 and 11.9-13.5 torr, and n(50) = 5.2-9.5, 3.2-4.9, and 1.8-2.7 for blood, Hb, and dodecamer, respectively, at pH 7.5, 25 degrees C, P-50 was decreased 3- and 2-fold in similar to 100 nM Ca2+ and Mg2+, respectively, with concomitant but smaller increases in cooperativity.	WAYNE STATE UNIV,SCH MED,DEPT BIOCHEM,DETROIT,MI 48201; GRAZ UNIV,INST PHYS CHEM,A-8010 GRAZ,AUSTRIA; UNIV CONNECTICUT,DEPT MOL & CELL BIOL,STORRS,CT 06260; AARHUS UNIV,INST BIOL SCI,AARHUS 8000 C,DENMARK; UNIV PARIS 06,URA 419,CHIM MET TRANSIT LAB,F-75252 PARIS,FRANCE	Wayne State University; University of Graz; University of Connecticut; Aarhus University; UDICE-French Research Universities; Sorbonne Universite					NIDDK NIH HHS [DK38674] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038674] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANSEVIN AT, 1970, ANAL BIOCHEM, V34, P237, DOI 10.1016/0003-2697(70)90103-X; BLOOMFIE.V, 1967, BIOPOLYMERS, V5, P135, DOI 10.1002/bip.1967.360050202; CHOTTARD G, 1992, BIOCHIM BIOPHYS ACTA, V1122, P113, DOI 10.1016/0167-4838(92)90312-2; Cohn E. J., 1943, PROTEINS AMINO ACIDS, P370; deHaas F, 1996, J MOL BIOL, V255, P140, DOI 10.1006/jmbi.1996.0012; deHaas F, 1996, BIOPHYS J, V70, P1973, DOI 10.1016/S0006-3495(96)79762-X; FUSHITANI K, 1986, J BIOL CHEM, V261, P8414; FUSHITANI K, 1988, J BIOL CHEM, V263, P6502; GLATTER O, 1980, ACTA PHYS AUSTRIACA, V52, P243; JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4; KLEMPERER WG, 1990, INORG SYN, V27, P71, DOI 10.1002/9780470132586.ch14; Kratky O, 1982, SMALL ANGLE XRAY SCA, DOI [10.1002/actp.1985.010360520, DOI 10.1002/ACTP.1985.010360520]; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Martin PD, 1996, J MOL BIOL, V255, P170, DOI 10.1006/jmbi.1996.0014; Martin PD, 1996, J MOL BIOL, V255, P154, DOI 10.1006/jmbi.1996.0013; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; Novak J., 1987, CHROMATOGRAPHIC THEO, P103; OCHIAI T, 1993, BIOCHIM BIOPHYS ACTA, V1203, P310, DOI 10.1016/0167-4838(93)90100-6; Pilz I, 1979, Methods Enzymol, V61, P148; REH E, 1995, TRAC-TREND ANAL CHEM, V14, P1, DOI 10.1016/0165-9936(95)91139-J; SANTUCCI R, 1984, J MOL BIOL, V179, P713, DOI 10.1016/0022-2836(84)90163-3; Sharma PK, 1996, J BIOL CHEM, V271, P8754, DOI 10.1074/jbc.271.15.8754; SHISHIKURA F, 1986, BIOCHIM BIOPHYS ACTA, V869, P314, DOI 10.1016/0167-4838(86)90071-3; SHISHIKURA F, 1987, J BIOL CHEM, V262, P3123; STAFFORD WF, 1992, ANAL BIOCHEM, V203, P295, DOI 10.1016/0003-2697(92)90316-Y; SUZUKI T, 1993, J BIOL CHEM, V268, P13548; Szabo Z. G., 1969, COMPREHENSIVE CHEM K, V2, P1; VIDUGIRIS GJA, 1993, J BIOL CHEM, V268, P26190; Vinogradov S.N., 1985, P9; Vinogradov S. N., 1982, ELECTRON MICROS, P135; VINOGRADOV SN, 1994, METHOD ENZYMOL, V231, P112; VINOGRADOV SN, 1977, BIOCHIM BIOPHYS ACTA, V492, P136, DOI 10.1016/0005-2795(77)90221-5; VINOGRADOV SN, 1986, P NATL ACAD SCI USA, V83, P8034, DOI 10.1073/pnas.83.21.8034; VINOGRADOV SN, 1991, J BIOL CHEM, V266, P13091; VINOGRADOV SN, 1993, COMP BIOCHEM PHYS B, V106, P1, DOI 10.1016/0305-0491(93)90002-M; WEBER RE, 1987, J COMP PHYSIOL B, V157, P145, DOI 10.1007/BF00692358; WEBER RE, 1995, J MOL BIOL, V251, P703, DOI 10.1006/jmbi.1995.0466; WEBER RE, 1981, NATURE, V292, P386, DOI 10.1038/292386a0; WEBER RE, 1992, J APPL PHYSIOL, V72, P1611, DOI 10.1152/jappl.1992.72.4.1611; YPHANTIS DA, 1960, ANN NY ACAD SCI, V88, P586, DOI 10.1111/j.1749-6632.1960.tb20055.x	40	35	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18695	18704		10.1074/jbc.271.31.18695	http://dx.doi.org/10.1074/jbc.271.31.18695			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702524	hybrid			2022-12-25	WOS:A1996VB68300062
J	MacLeod, JN; BurtonWurster, N; Gu, DN; Lust, G				MacLeod, JN; BurtonWurster, N; Gu, DN; Lust, G			Fibronectin mRNA splice variant in articular cartilage lacks bases encoding the V, III-15, and I-10 protein segments	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; ED-A; GENE; CHONDROCYTES; EXPRESSION; EXTRACTION; CULTURE; PLASMA; DOMAIN; FORM	Fibronectin is an extracellular matrix glycoprotein encoded by a single gene. Alternative RNA splicing has been reported at three sites, ED (extra type III domain)-A, ED-B, and the variable or V region. Articular cartilage fibronectin monomers are rarely (ED-A)(+), but approximately 25% are (ED-B)(+). RNA gel electrophoresis and Northern blot analysis identified two (ED-B)(+) and two (ED-B)(-) fibronectin transcripts in cartilage, each pair differing by similar to 750 bases, This difference results from a previously unreported RNA splicing pattern that eliminates not only the V region but also nucleotides encoding protein segments III-15 and I-10, This new splice variant, which we designate (V+C)(-), represents the majority of fibronectin transcripts in equine, canine, and rabbit articular cartilage but is absent in the liver, Reverse transcriptase-polymerase chain reaction analyses of II additional equine tissues failed to detect the (V+C)(-) splice variant, except for very low levels in lymph node, bone, aorta, and skin, Furthermore, chondrocytes grown in monolayer culture main tain high levels of fibronectin expression but stop expressing (V+C)(-) transcripts over time. The tissue-specific expression pattern of this novel fibronectin isoform suggests that it may have an important function in the matrix organization of cartilage.	CORNELL UNIV,COLL VET MED,JAMES A BAKER INST ANIM HLTH,DEPT MICROBIOL & IMMUNOL,ITHACA,NY 14853	Cornell University	MacLeod, JN (corresponding author), CORNELL UNIV,COLL VET MED,JAMES A BAKER INST ANIM HLTH,DEPT PHYSIOL,HUNGERFORD HILL RD,ITHACA,NY 14853, USA.							ADAMS ME, 1992, ANAL BIOCHEM, V202, P89, DOI 10.1016/0003-2697(92)90211-O; BENNETT VD, 1991, J BIOL CHEM, V266, P5918; BURTONWURSTER N, 1989, ARCH BIOCHEM BIOPHYS, V269, P32, DOI 10.1016/0003-9861(89)90084-2; BURTONWURSTER N, 1988, BIOCHEM BIOPH RES CO, V154, P1088, DOI 10.1016/0006-291X(88)90252-5; BURTONWURSTER N, 1993, ARCH BIOCHEM BIOPHYS, V306, P309, DOI 10.1006/abbi.1993.1517; BURTONWURSTER N, 1986, J RHEUMATOL, V13, P175; BURTONWURSTER N, 1989, BIOCHEM BIOPH RES CO, V165, P782, DOI 10.1016/S0006-291X(89)80034-8; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; HOMANDBERG GA, 1992, J BIOL CHEM, V267, P3597; Hynes RO, 1990, FIBRONECTINS; ICHIHARATANAKA K, 1995, J CELL SCI, V108, P907; KORNBLIHTT AR, 1985, EMBO J, V4, P1755, DOI 10.1002/j.1460-2075.1985.tb03847.x; LEIPOLD HR, 1992, J ORTHOP RES, V10, P33, DOI 10.1002/jor.1100100105; LEVINE RA, 1993, NUCLEIC ACIDS RES, V21, P4426, DOI 10.1093/nar/21.18.4426; MORLA A, 1994, NATURE, V367, P193, DOI 10.1038/367193a0; NIXON AJ, 1992, AM J VET RES, V53, P2364; NORTON PA, 1987, MOL CELL BIOL, V7, P4297, DOI 10.1128/MCB.7.12.4297; ODERMATT E, 1985, P NATL ACAD SCI USA, V82, P6571, DOI 10.1073/pnas.82.19.6571; PANDE H, 1987, EUR J BIOCHEM, V162, P403, DOI 10.1111/j.1432-1033.1987.tb10616.x; RENCIC A, 1995, OSTEOARTHR CARTILAGE, V3, P187, DOI 10.1016/S1063-4584(05)80053-6; Sambrook J., 2002, MOL CLONING LAB MANU; SCHWARZBAUER JE, 1991, BIOESSAYS, V13, P527, DOI 10.1002/bies.950131006; SCHWARZBAUER JE, 1987, EMBO J, V6, P2573, DOI 10.1002/j.1460-2075.1987.tb02547.x; SCHWARZBAUER JE, 1985, P NATL ACAD SCI USA, V82, P1424, DOI 10.1073/pnas.82.5.1424; TAMKUN JW, 1984, P NATL ACAD SCI-BIOL, V81, P5140, DOI 10.1073/pnas.81.16.5140; VIBEPEDERSEN K, 1984, EMBO J, V3, P2511, DOI 10.1002/j.1460-2075.1984.tb02165.x; VIBEPEDERSEN K, 1986, FEBS LETT, V207, P287, DOI 10.1016/0014-5793(86)81506-X; WURSTER NB, 1982, BIOCHEM BIOPH RES CO, V109, P1094, DOI 10.1016/0006-291X(82)91889-7; ZHANG D, 1995, MATRIX BIOL, V14, P623; ZHANG DW, 1995, J BIOL CHEM, V270, P1817, DOI 10.1074/jbc.270.4.1817	30	75	88	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18954	18960		10.1074/jbc.271.31.18954	http://dx.doi.org/10.1074/jbc.271.31.18954			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702559	hybrid			2022-12-25	WOS:A1996VB68300097
J	Maisner, A; Liszewski, MK; Atkinson, JP; SchwartzAlbiez, R; Herrler, G				Maisner, A; Liszewski, MK; Atkinson, JP; SchwartzAlbiez, R; Herrler, G			Two different cytoplasmic tails direct isoforms of the membrane cofactor protein (CD46) to the basolateral surface of Madin-Darby canine kidney cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLARIZED EPITHELIAL-CELLS; POLYMERIC IMMUNOGLOBULIN RECEPTOR; MDCK CELLS; MEASLES-VIRUS; ANCHORED PROTEINS; MULTIPLE ISOFORMS; TARGETING SIGNAL; LDL RECEPTOR; N-GLYCANS; DOMAIN	Membrane cofactor protein (MCP; CD46), a widely distributed regulatory protein of the complement system, was analyzed for expression in polarized epithelial cells, Both a human and a simian (Vero C1008) cell line were found to contain endogenous MCP mainly on the basolateral surface, Transfected Madin-Darby canine kidney cells stably expressing human MCP delivered this protein also predominantly to the basolateral surface, A deletion mutant lacking the cytoplasmic tail was transported in a nonpolarized fashion, indicating that the targeting signal for the basolateral transport is located in the cytoplasmic domain, A characteristic feature of MCP is the presence of various isoforms that contain either of two different cytoplasmic tails as a consequence of alternative splicing, Two isoforms differing only in the cytoplasmic tail (tail 1 or 2) were analyzed for polarized expression in Madin-Darby canine kidney cells, Surface biotinylation, as well as confocal immuno fluorescence microscopy, indicated that both proteins were transported to the basolateral surface, Because no sequence similarity has been observed, the two tails contain different basolateral targeting signals, A deletion mutant lacking the only tyrosine residue in tail 1 retained the polarized expression indicating that, in contrast to most basolateral sorting signals, the transport signal of the tail 1 isoform is not dependent on tyrosine, The maintenance of a targeting motif in two distinct cytoplasmic tails suggests that the basolateral expression of MCP in polarized epithelial cells is of physiological importance.	UNIV MARBURG,INST VIROL,D-35037 MARBURG,GERMANY; UNIV WASHINGTON,SCH MED,DEPT INTERNAL MED,DIV RHEUMATOL,ST LOUIS,MO 63110; DEUTSCH KREBSFORSCHUNGSZENTRUM,D-69120 HEIDELBERG,GERMANY	Philipps University Marburg; Washington University (WUSTL); Helmholtz Association; German Cancer Research Center (DKFZ)				Atkinson, John/0000-0002-2514-3441				AROETI B, 1993, J CELL BIOL, V123, P1149, DOI 10.1083/jcb.123.5.1149; BARTLES JR, 1987, J CELL BIOL, V105, P1241, DOI 10.1083/jcb.105.3.1241; BLAU DM, 1995, VIROLOGY, V210, P91, DOI 10.1006/viro.1995.1320; BREWER CB, 1991, J CELL BIOL, V114, P413, DOI 10.1083/jcb.114.3.413; CAPLAN M, 1989, FUNCTIONAL EPITHELIA, P71; CASANOVA JE, 1991, CELL, V66, P65, DOI 10.1016/0092-8674(91)90139-P; DORIG RE, 1993, CELL, V75, P295, DOI 10.1016/0092-8674(93)80071-L; FIEDLER K, 1995, CELL, V81, P309, DOI 10.1016/0092-8674(95)90380-1; FUHRER C, 1991, J CELL BIOL, V114, P423, DOI 10.1083/jcb.114.3.423; FULLER SD, 1985, EMBO J, V4, P297, DOI 10.1002/j.1460-2075.1985.tb03629.x; GEFFEN I, 1993, J BIOL CHEM, V268, P20772; GRIFFITHS G, 1986, SCIENCE, V234, P438, DOI 10.1126/science.2945253; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; HUNZIKER W, 1991, CELL, V66, P907, DOI 10.1016/0092-8674(91)90437-4; INOUE H, 1994, ACTA MED OKAYAMA, V48, P271; LEBIVIC A, 1991, J CELL BIOL, V115, P607, DOI 10.1083/jcb.115.3.607; LEBIVIC A, 1990, J CELL BIOL, V111, P1351, DOI 10.1083/jcb.111.4.1351; LILJESTROM P, 1991, BIO-TECHNOL, V9, P1356, DOI 10.1038/nbt1291-1356; LISANTI MP, 1989, J CELL BIOL, V109, P2145, DOI 10.1083/jcb.109.5.2145; LISANTI MP, 1988, P NATL ACAD SCI USA, V85, P9557, DOI 10.1073/pnas.85.24.9557; LISZEWSKI MK, 1994, J BIOL CHEM, V269, P10776; LISZEWSKI MK, 1992, CURR TOP MICROBIOL, V178, P45; MAISNER A, 1994, J VIROL, V68, P6299, DOI 10.1128/JVI.68.10.6299-6304.1994; MANCHESTER M, 1994, P NATL ACAD SCI USA, V91, P2161, DOI 10.1073/pnas.91.6.2161; MATTER K, 1994, CURR OPIN CELL BIOL, V6, P545, DOI 10.1016/0955-0674(94)90075-2; MATTER K, 1990, CELL, V60, P429, DOI 10.1016/0092-8674(90)90594-5; MATTER K, 1994, J CELL BIOL, V126, P991, DOI 10.1083/jcb.126.4.991; MATTER K, 1992, CELL, V71, P741, DOI 10.1016/0092-8674(92)90551-M; MOSTOV K, 1992, J CELL BIOL, V116, P577, DOI 10.1083/jcb.116.3.577; NANICHE D, 1993, J VIROL, V67, P6025, DOI 10.1128/JVI.67.10.6025-6032.1993; POST TW, 1991, J EXP MED, V174, P93, DOI 10.1084/jem.174.1.93; PRILL V, 1993, EMBO J, V12, P2181, DOI 10.1002/j.1460-2075.1993.tb05866.x; RINDLER MJ, 1984, J CELL BIOL, V98, P1304, DOI 10.1083/jcb.98.4.1304; SCHULTZE B, 1991, J VIROL, V65, P6232, DOI 10.1128/JVI.65.11.6232-6237.1991; SIMONS K, 1990, CELL, V62, P207, DOI 10.1016/0092-8674(90)90357-K; SRINIVAS RV, 1986, J VIROL, V58, P689, DOI 10.1128/JVI.58.2.689-693.1986; THOMAS DC, 1994, J BIOL CHEM, V269, P15732; WANDINGERNESS A, 1990, J CELL BIOL, V111, P987, DOI 10.1083/jcb.111.3.987; YOKODE M, 1992, J CELL BIOL, V117, P39, DOI 10.1083/jcb.117.1.39; ZURZOLO C, 1993, J CELL BIOL, V121, P1031, DOI 10.1083/jcb.121.5.1031	40	34	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18853	18858		10.1074/jbc.271.31.18853	http://dx.doi.org/10.1074/jbc.271.31.18853			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702545	hybrid			2022-12-25	WOS:A1996VB68300083
J	McLeod, RS; Wang, YW; Wang, S; Rusinol, A; Links, P; Yao, ZM				McLeod, RS; Wang, YW; Wang, S; Rusinol, A; Links, P; Yao, ZM			Apolipoprotein B sequence requirements for hepatic very low density lipoprotein assembly - Evidence that hydrophobic sequences within apolipoprotein B48 mediate lipid recruitment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOXYL-TERMINAL TRUNCATION; HEP G2 CELLS; ENDOPLASMIC-RETICULUM; RAT-LIVER; APO-B; MESSENGER-RNA; INTRACELLULAR-DISTRIBUTION; MONOCLONAL-ANTIBODIES; MCA-RH7777 CELLS; PAUSE TRANSFER	We studied the structural requirements of apolipoprotein (apo) B for assembly of very low density lipoproteins (VLDL) using rat hepatoma McA-RH7777 cells expressing human apoB (h-apoB), Recombinant h-apoB48, like endogenous rat apoB48 (r-apoB48), was secreted as VLDL in addition to high density lipoproteins (HDL) by transfected cells, indicating that the N-terminal 48% of apoB contains sequences sufficient for VLDL assembly, Truncation of the C terminus of h-apo-B48 to -B42 or -B37 had little effect on the ability of apoB to assemble VLDL, whereas truncation to -B34 or -B29 markedly diminished or abolished VLDL formation, None of the truncations affected the integration of apoB into HDL, To determine whether the ability to assemble VLDL is governed by apoB length or by sequences beyond apoB29, we created chimeric proteins that contained human apoA-I and a segment derived from between the C-terminal 29 and 34%, 34 and 37%, or 37 and 42% of apoB100, The resulting chimeras, namely AI/B29-34, AI/B34-37, and AI/B37-42, were secreted by the transfected cells as lipoproteins with buoyant density (d < 1.006 g/ml), electrophoretic mobility (pre-beta), and size characteristics of human plasma VLDL, The chimeras could assemble discrete VLDL particles devoid of endogenous of apoB100, and could actively recruit triglycerides and phospholipids into the lipoproteins. However, these chimeras were secreted inefficiently, Pulse-chase analysis showed that less than 5% of the newly synthesized AI/B proteins were secreted, and more than 70% was degraded intracellularly, Degradation of the chimeras could be blocked by the cysteine protease inhibitor N-acetyl-leucyl-leucyl-norleucinal, but the treatment did not enhance their secretion, Protease protection analysis of microsomes isolated from transfected cells indicated that > 65% of AI/B chimeras (compared with < 25% of r-apoB100) were inaccessible to exogenous trypsin, These data suggest that the recruitment of large quantitles of triglycerides during VLDL formation is not governed simply by apoB length, but is mediated by short hydrophobic sequences ranging from 152 to 237 amino acids (3-5%) of apoB, The existence of multiple such hydrophobic sequences within apoB48 may facilitate efficient assembly of hepatic VLDL particles.	UNIV OTTAWA,INST HEART,DEPT PATHOL & LAB MED,LIPOPROT & ATHEROSCLEROSIS GRP,OTTAWA,ON K1Y 4E9,CANADA; UNIV OTTAWA,INST HEART,DEPT BIOCHEM,OTTAWA,ON K1Y 4E9,CANADA; UNIV ALBERTA,LIPID & LIPOPROT RES GRP,EDMONTON,AB T6G 2M8,CANADA	University of Ottawa; University of Ottawa Heart Institute; University of Ottawa; University of Ottawa Heart Institute; University of Alberta			McLeod, Roger/F-8014-2015	McLeod, Roger/0000-0002-6740-5569				ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BLACKHART BD, 1990, J BIOL CHEM, V265, P8358; BOREN J, 1992, J BIOL CHEM, V267, P9858; BOREN J, 1994, J BIOL CHEM, V269, P25879; CARTWRIGHT IJ, 1993, J BIOL CHEM, V268, P20937; CHAN L, 1992, J BIOL CHEM, V267, P25621; CHEN SH, 1986, J BIOL CHEM, V261, P2918; CHRISTENSEN NJ, 1983, J LIPID RES, V24, P1229; CHUCK SL, 1993, J BIOL CHEM, V268, P22794; CHUCK SL, 1992, CELL, V68, P9, DOI 10.1016/0092-8674(92)90202-N; DAVIS RA, 1989, J LIPID RES, V30, P1185; DAVIS RA, 1990, J BIOL CHEM, V265, P10005; DU EZ, 1994, J BIOL CHEM, V269, P24169; ELOVSON J, 1992, CIRCULATION S1, V86, P693; FAZIO S, 1995, ARTERIOSCL THROM VAS, V15, P593, DOI 10.1161/01.ATV.15.5.593; FURUKAWA S, 1992, J BIOL CHEM, V267, P22630; GORDON DA, 1995, TRENDS CELL BIOL, V5, P317, DOI 10.1016/S0962-8924(00)89054-6; GRAHAM DL, 1991, BIOCHEMISTRY-US, V30, P5616, DOI 10.1021/bi00236a040; GREEVE J, 1993, J LIPID RES, V34, P1367; GRETCH DG, 1996, J BIOL CHEM, V270, P8682; HUSSAIN MM, 1995, ARTERIOSCL THROM VAS, V15, P485, DOI 10.1161/01.ATV.15.4.485; KNOTT TJ, 1986, NATURE, V323, P734, DOI 10.1038/323734a0; LINTON MF, 1993, J LIPID RES, V34, P521; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARCEL YL, 1984, J BIOL CHEM, V259, P6952; MARSH JB, 1982, P SOC EXP BIOL MED, V170, P178, DOI 10.3181/00379727-170-41415; MCLEOD RS, 1994, BIOCHEM J, V302, P641, DOI 10.1042/bj3020641; MCLEOD RS, 1994, J BIOL CHEM, V269, P2852; MILNE RW, 1983, ARTERIOSCLEROSIS, V3, P23, DOI 10.1161/01.ATV.3.1.23; NAKAHARA DH, 1994, J BIOL CHEM, V269, P7617; PEASE RJ, 1991, NATURE, V353, P448, DOI 10.1038/353448a0; RUSINOL AE, 1993, J BIOL CHEM, V268, P25168; RUSINOL AE, 1995, J BIOL CHEM, V270, P13318, DOI 10.1074/jbc.270.22.13318; RUSTAEUS S, 1995, J BIOL CHEM, V270, P28879, DOI 10.1074/jbc.270.48.28879; SEGREST JP, 1992, J LIPID RES, V33, P141; SEGREST JP, 1994, ARTERIOSCLER THROMB, V14, P1674, DOI 10.1161/01.ATV.14.10.1674; SELBY SL, 1995, ARTERIOSCL THROM VAS, V15, P1900, DOI 10.1161/01.ATV.15.11.1900; SHELNESS GS, 1995, CIRCULATION S1, V92, P362; SPRING DJ, 1992, J BIOL CHEM, V267, P14839; SWIFT LL, 1995, J LIPID RES, V36, P395; TENG BB, 1993, SCIENCE, V260, P1816, DOI 10.1126/science.8511591; WHITE AL, 1992, J BIOL CHEM, V267, P15657; WONG L, 1987, EUR J BIOCHEM, V164, P357, DOI 10.1111/j.1432-1033.1987.tb11066.x; WONG L, 1987, BIOCHIM BIOPHYS ACTA, V918, P16, DOI 10.1016/0005-2760(87)90004-X; YAO ZM, 1993, ARTERIOSCLER THROMB, V13, P1476, DOI 10.1161/01.ATV.13.10.1476; YAO ZM, 1991, J BIOL CHEM, V266, P3300; YAO ZM, 1992, J BIOL CHEM, V267, P1175	47	63	64	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18445	18455		10.1074/jbc.271.31.18445	http://dx.doi.org/10.1074/jbc.271.31.18445			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702489	hybrid			2022-12-25	WOS:A1996VB68300027
J	McCudden, CR; PowersLee, SG				McCudden, CR; PowersLee, SG			Required allosteric effector site for N-acetylglutamate on carbamoyl-phosphate synthetase I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIFUNCTIONAL PROTEIN CAD; COOH-TERMINAL DOMAIN; ACETYL-L-GLUTAMATE; ESCHERICHIA-COLI; BINDING-SITES; CROSS-LINKS; AMIDOTRANSFERASE DOMAIN; CATALYTIC SUBUNIT; LIVER; RAT	Carbamoyl-phosphate synthetase I (CPSase I) catalyzes the entry and rate-limiting step in the urea cycle, the pathway by which mammals detoxify ammonia, One facet of CPSase I regulation is a requirement for N-acetylglutamate (AGA), which induces an active enzyme conformation and does not participate directly in the chemical reaction, We have utilized labeling with carbodiimide-activated [C-14]AGA to identify peptides 120-127, 234-237, 625-630, and 1351-1356 as potentially being near the binding site for AGA, Identification of peptide 1351-1356 confirms the previous demonstration (Rodriquez-Aparicio, L, B,, Guadalajara, A. M., and Rubio, V, (1989) Biochemistry 28, 3070-3074) that the C-terminal region is involved in binding AGA, Identification of peptides 120-127 and 234-237 constitutes the first evidence that the N-terminal region of the synthetase is involved in ligand binding, Since peptides 631-638 and 1327-1348 have been identified near the ATP site of CPSase I (Potter, M, D,, and Powers-Lee, S, G, (1992) J, Biol, Chem, 267, 2023-2031), the present finding of involvement of peptides 625-630 and 1351-1356 at an ''allosteric'' activator site was unexpected, The idea that portions of the AGA effector site might be derived from an ancestral glutamine substrate site via a gene duplication and diversification event was considered.	NORTHEASTERN UNIV, DEPT BIOL, BOSTON, MA 02115 USA	Northeastern University					NIDDK NIH HHS [DK-33460, DK-1319] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033460, K04DK001319] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLEN G, 1989, SEQUENCING PROTEINS, P233; ANDERSON PM, 1965, BIOCHEMISTRY-US, V4, P2803, DOI 10.1021/bi00888a034; ANDERSON PM, 1995, NITROGEN METABOLISM, P33; BECK JT, 1989, BIOCHEMISTRY-US, V28, P6931, DOI 10.1021/bi00443a023; BEIN K, 1991, J BIOL CHEM, V266, P3791; BOSCH J, 1985, TETRAHEDRON, V41, P2557, DOI 10.1016/S0040-4020(01)96651-7; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRENNER SE, 1995, NATURE, V378, P140, DOI 10.1038/378140a0; BRITTON HG, 1990, EUR J BIOCHEM, V188, P47, DOI 10.1111/j.1432-1033.1990.tb15369.x; BRITTON HG, 1979, EUR J BIOCHEM, V102, P521, DOI 10.1111/j.1432-1033.1979.tb04268.x; BUECHLER JA, 1989, BIOCHEMISTRY-US, V28, P2065, DOI 10.1021/bi00431a015; BUECHLER JA, 1988, BIOCHEMISTRY-US, V27, P7356, DOI 10.1021/bi00419a027; BUESO J, 1994, BIOCHEM BIOPH RES CO, V203, P1083, DOI 10.1006/bbrc.1994.2293; Carraway K L, 1972, Methods Enzymol, V25, P616, DOI 10.1016/S0076-6879(72)25060-1; CERVERA J, 1993, J BIOL CHEM, V268, P12504; COHEN NS, 1985, BIOCHEM J, V229, P205, DOI 10.1042/bj2290205; EVANS DR, 1988, BIOCHIM BIOPHYS ACTA, V953, P185, DOI 10.1016/0167-4838(88)90023-4; FENG DF, 1985, J MOL EVOL, V21, P112, DOI 10.1007/BF02100085; GUILLOU F, 1989, P NATL ACAD SCI USA, V86, P8304, DOI 10.1073/pnas.86.21.8304; GUY HI, 1995, J BIOL CHEM, V270, P2190, DOI 10.1074/jbc.270.5.2190; GUY HI, 1994, J BIOL CHEM, V269, P7702; HELBING CC, 1994, J BIOL CHEM, V269, P11743; HENDERSON GB, 1980, J BIOL CHEM, V255, P4829; HONG J, 1994, J MOL BIOL, V243, P131, DOI 10.1006/jmbi.1994.1638; HORSPOOL W, 1992, ORG PHOTOCHEM, P444; ITALIEN JJ, 1986, METHODS PROTEIN MICR, P279; KIM HS, 1992, J BIOL CHEM, V267, P7177; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU X, 1994, J BIOL CHEM, V269, P27747; LUSTY CJ, 1983, J BIOL CHEM, V258, P4466; MARAS B, 1994, J BIOL CHEM, V269, P18429; MARSHALL M, 1988, ARCH BIOCHEM BIOPHYS, V262, P455, DOI 10.1016/0003-9861(88)90397-9; MEIJER AJ, 1979, TRENDS BIOCHEM SCI, V4, P83, DOI 10.1016/0968-0004(79)90188-9; MEISTER A, 1989, ADV ENZYMOL RAMB, V62, P315; NYUNOYA H, 1983, P NATL ACAD SCI-BIOL, V80, P4629, DOI 10.1073/pnas.80.15.4629; NYUNOYA H, 1985, J BIOL CHEM, V260, P9346; NYUNOYA H, 1984, J BIOL CHEM, V259, P9790; PAULUS H, 1983, CURR TOP CELL REGUL, V22, P177; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; PIERARD A, 1978, J BACTERIOL, V134, P167; PIETTE J, 1984, P NATL ACAD SCI-BIOL, V81, P4134, DOI 10.1073/pnas.81.13.4134; POST LE, 1990, J BIOL CHEM, V265, P7742; POTTER MD, 1992, J BIOL CHEM, V267, P2023; POTTER MD, 1993, ARCH BIOCHEM BIOPHYS, V306, P377, DOI 10.1006/abbi.1993.1526; POWERS SG, 1983, J BIOL CHEM, V258, P7545; POWERS SG, 1981, J BIOL CHEM, V256, P1160; POWERS SG, 1977, J BIOL CHEM, V252, P3558; POWERS SG, 1978, J BIOL CHEM, V253, P800; POWERSLEE SG, 1986, J BIOL CHEM, V261, P5349; POWERSLEE SG, 1987, J BIOL CHEM, V262, P9052; PRICE CW, 1978, J GEN MICROBIOL, V106, P145, DOI 10.1099/00221287-106-1-145; RODRIGUEZAPARICIO LB, 1989, BIOCHEMISTRY-US, V28, P3070, DOI 10.1021/bi00433a050; RUBINO SD, 1986, J BIOL CHEM, V261, P1320; RUBIO V, 1983, EUR J BIOCHEM, V134, P337, DOI 10.1111/j.1432-1033.1983.tb07572.x; RUBIO V, 1991, BIOCHEMISTRY-US, V30, P1068, DOI 10.1021/bi00218a027; RUBIO V, 1979, EUR J BIOCHEM, V93, P245, DOI 10.1111/j.1432-1033.1979.tb12817.x; Rubio V, 1995, BIOCHEM SOC T, V23, P879, DOI 10.1042/bst0230879; SIMMER JP, 1990, J BIOL CHEM, V265, P10395; Smith JL, 1995, BIOCHEM SOC T, V23, P894, DOI 10.1042/bst0230894; SOTTRUPJENSEN L, 1990, J BIOL CHEM, V265, P17727; SOUCIET JL, 1987, MOL GEN GENET, V207, P314, DOI 10.1007/BF00331595; STRITTMATTER P, 1990, J BIOL CHEM, V265, P21709; TROTTA PP, 1971, P NATL ACAD SCI USA, V68, P2599, DOI 10.1073/pnas.68.10.2599; vandenHoff MJB, 1995, J MOL EVOL, V41, P813, DOI 10.1007/BF00173161; WAGNER C, 1984, ARCH BIOCHEM BIOPHYS, V233, P457, DOI 10.1016/0003-9861(84)90467-3; Zalkin H, 1993, Adv Enzymol Relat Areas Mol Biol, V66, P203	66	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					18285	18294		10.1074/jbc.271.30.18285	http://dx.doi.org/10.1074/jbc.271.30.18285			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663466	hybrid			2022-12-25	WOS:A1996UY93500103
J	Nelson, KL; Becker, NA; Pahwa, GS; Hollingsworth, MA; Maher, LJ				Nelson, KL; Becker, NA; Pahwa, GS; Hollingsworth, MA; Maher, LJ			Potential for H-DNA in the human MUC1 mucin gene promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KI-RAS PROMOTER; SUPERCOILED DNA; BINDING-PROTEIN; MIRROR REPEATS; TRIPLEXES; SEQUENCE; HOMOPURINE; PLASMIDS; EXPRESSION; ELEMENTS	Similar imperfect purine/pyrimidine mirror repeat (PMR) elements have previously been identified up stream of the human MUC1 mucin and CFTR genes. These elements confer S1 nuclease sensitivity on isolated plasmid DNA at low pH. We now present a detailed characterization of the non-B DNA structure responsible for S1 nuclease sensitivity upstream of the MUC1 gene. A similar to 90-base pair (bp) DNA fragment containing a 32-bp PMR element termed M-PMR3 was subcloned into a recombinant vector. This fragment conferred S1 nuclease sensitivity on the resulting supercoiled plasmid. High resolution mapping of sites reactive to S1 and P1 nucleases demonstrates that cleavage occurs within the M-PMR3 element. High resolution mapping with chemical agents selective for non-B DNA provides evidence that M-PMR3 adopts an H-DNA structure (intramolecular triple helix) in the less common H-y5 isomer at low pH. This result is observed in the presence or absence of Mg2+. Mutation of the native M-PMR3 element to create perfect homopurine/homopyrimidine mirror symmetry alters the preferred folding to the more common H-y3 tripler DNA isomer. These results demonstrate that imperfections in mirror symmetry can alter the relative stabilities of different H-DNA isomers.	MAYO CLIN & MAYO FDN,DEPT BIOCHEM & MOLEC BIOL,ROCHESTER,MN 55905; UNIV NEBRASKA,MED CTR,EPPLEY INST RES CANC & ALLIED DIS,OMAHA,NE 68198	Mayo Clinic; University of Nebraska System; University of Nebraska Medical Center					NATIONAL CANCER INSTITUTE [R01CA057362] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044762] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM047814] Funding Source: NIH RePORTER; NCI NIH HHS [CA57362] Funding Source: Medline; NIDDK NIH HHS [DK44762] Funding Source: Medline; NIGMS NIH HHS [GM47814] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABE M, 1993, P NATL ACAD SCI USA, V90, P282, DOI 10.1073/pnas.90.1.282; BARAN N, 1991, P NATL ACAD SCI USA, V88, P507, DOI 10.1073/pnas.88.2.507; BERNUES J, 1990, NUCLEIC ACIDS RES, V18, P4067, DOI 10.1093/nar/18.14.4067; BRUNEL F, 1991, NUCLEIC ACIDS RES, V19, P5237, DOI 10.1093/nar/19.19.5237; CADDLE MS, 1990, J MOL BIOL, V211, P19, DOI 10.1016/0022-2836(90)90008-A; CHAMBERS JA, 1994, J CELL SCI, V107, P415; COLLIER DA, 1990, J BIOL CHEM, V265, P10652; DAYN A, 1992, P NATL ACAD SCI USA, V89, P11406, DOI 10.1073/pnas.89.23.11406; ENGELHARDT JF, 1992, NAT GENET, V2, P240, DOI 10.1038/ng1192-240; FRANKKAMENETSKII MD, 1995, ANNU REV BIOCHEM, V64, P65, DOI 10.1146/annurev.bi.64.070195.000433; GILMOUR DS, 1989, SCIENCE, V245, P1487, DOI 10.1126/science.2781290; GLASER RL, 1990, J MOL BIOL, V211, P751, DOI 10.1016/0022-2836(90)90075-W; HANVEY JC, 1988, J BIOL CHEM, V263, P7386; HANVEY JC, 1988, P NATL ACAD SCI USA, V85, P6292, DOI 10.1073/pnas.85.17.6292; HOLLINGSWORTH MA, 1994, INT J CANCER, V57, P198, DOI 10.1002/ijc.2910570212; HOLLINGSWORTH MA, 1994, NUCLEIC ACIDS RES, V22, P1138, DOI 10.1093/nar/22.7.1138; HOOPES BC, 1981, NUCLEIC ACIDS RES, V9, P5493, DOI 10.1093/nar/9.20.5493; HTUN H, 1988, SCIENCE, V241, P1791, DOI 10.1126/science.3175620; HTUN H, 1989, SCIENCE, V243, P1571, DOI 10.1126/science.2648571; JOHNSTON BH, 1988, SCIENCE, V241, P1800, DOI 10.1126/science.2845572; KANG S, 1992, J BIOL CHEM, V267, P1259; KANG S, 1992, J BIOL CHEM, V267, P20889; KOHWI Y, 1993, GENE DEV, V7, P1766, DOI 10.1101/gad.7.9.1766; KOHWI Y, 1988, P NATL ACAD SCI USA, V85, P3781, DOI 10.1073/pnas.85.11.3781; KOHWI Y, 1992, J MOL BIOL, V223, P817, DOI 10.1016/0022-2836(92)90242-C; KOHWISHIGEMATSU T, 1985, CELL, V43, P199, DOI 10.1016/0092-8674(85)90024-8; KOLLURI R, 1992, NUCLEIC ACIDS RES, V20, P111, DOI 10.1093/nar/20.1.111; KOVARIK A, 1993, J BIOL CHEM, V268, P9917; LAPIDOT A, 1989, NUCLEIC ACIDS RES, V17, P883, DOI 10.1093/nar/17.3.883; LEE JS, 1987, NUCLEIC ACIDS RES, V15, P1047, DOI 10.1093/nar/15.3.1047; LILLEY DMJ, 1980, P NATL ACAD SCI-BIOL, V77, P6468, DOI 10.1073/pnas.77.11.6468; LYAMICHEV VI, 1986, J BIOMOL STRUCT DYN, V3, P667, DOI 10.1080/07391102.1986.10508454; MCDONALD CD, 1994, GENE, V150, P267, DOI 10.1016/0378-1119(94)90436-7; MURAISO T, 1992, NUCLEIC ACIDS RES, V20, P6631, DOI 10.1093/nar/20.24.6631; PELEG M, 1995, NUCLEIC ACIDS RES, V23, P1292, DOI 10.1093/nar/23.8.1292; PESTOV DG, 1991, NUCLEIC ACIDS RES, V19, P6527, DOI 10.1093/nar/19.23.6527; RADHAKRISHNAN I, 1994, BIOCHEMISTRY-US, V33, P11405, DOI 10.1021/bi00204a001; RAGHU G, 1994, NUCLEIC ACIDS RES, V22, P3271, DOI 10.1093/nar/22.16.3271; ROONEY SM, 1995, P NATL ACAD SCI USA, V92, P2141, DOI 10.1073/pnas.92.6.2141; Sambrook J., 2002, MOL CLONING LAB MANU; SCHROTH GP, 1995, NUCLEIC ACIDS RES, V23, P1977, DOI 10.1093/nar/23.11.1977; SHIMIZU M, 1994, J MOL BIOL, V235, P185, DOI 10.1016/S0022-2836(05)80025-7; SHIROTANI K, 1994, J BIOL CHEM, V269, P15030; TOMIZAWA J, 1984, CELL, V38, P861, DOI 10.1016/0092-8674(84)90281-2; TREZISE AEO, 1993, HUM MOL GENET, V2, P213, DOI 10.1093/hmg/2.3.213; VOJTISKOVA M, 1988, FEBS LETT, V234, P295, DOI 10.1016/0014-5793(88)80102-9; VOLOSHIN ON, 1988, NATURE, V333, P475, DOI 10.1038/333475a0; WELLS RD, 1988, FASEB J, V2, P2939, DOI 10.1096/fasebj.2.14.3053307; YEE HA, 1991, NUCLEIC ACIDS RES, V19, P949, DOI 10.1093/nar/19.4.949; ZOTTER S, 1988, Cancer Reviews, V11-12, P55	50	19	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					18061	18067		10.1074/jbc.271.30.18061	http://dx.doi.org/10.1074/jbc.271.30.18061			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663482	hybrid			2022-12-25	WOS:A1996UY93500071
J	Giardina, B; Ascenzi, P; Clementi, ME; DeSanctis, G; Rizzi, M; Coletta, M				Giardina, B; Ascenzi, P; Clementi, ME; DeSanctis, G; Rizzi, M; Coletta, M			Functional modulation by lactate of myoglobin - A monomeric allosteric hemoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEMOGLOBIN; BINDING; OXYGEN	The effect of lactate on O-2 binding properties of sperm whale and horse heart myoglobins (Mb) has been investigated at moderately acid pH (i.e. pH 6.5, a condition which may be achieved in vivo under a physical effort). Addition of lactate brings about a decrease of O-2 affinity (i.e. an increase of P-50) in sperm whale and horse heart myoglobins. Accordingly, lactate shows a different affinity for the deoxygenated and oxygenated form, behaving as a heterotropic modulator. The lactate effect on O-2 affinity appears to differ for sperm whale and horse heart Mb, delta logP(50) being approximate to 1.0 and approximate to 0.4, respectively. From the kinetic viewpoint, the variation of O-2 affinity for both myoglobins can be attributed mainly to a decrease of the kinetic association rate constant for ligand binding.	UNIV CAMERINO, DEPT MOLEC CELLULAR & ANIM BIOL, I-62032 CAMERINO, MC, ITALY; UNIV CATTOLICA SACRO CUORE, CNR, CTR RECEPTOR CHEM, I-00168 ROME, ITALY; UNIV CATTOLICA SACRO CUORE, INST CHEM & CLIN CHEM, I-00168 ROME, ITALY; UNIV ROME 3, DEPT BIOL, I-00154 ROME, ITALY; UNIV ROMA TOR VERGATA, DEPT EXPTL MED & BIOCHEM SCI, I-00133 ROME, ITALY; UNIV PAVIA, DEPT GENET & MICROBIOL, I-27100 PAVIA, ITALY	University of Camerino; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Consiglio Nazionale delle Ricerche (CNR); Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Roma Tre University; University of Rome Tor Vergata; University of Pavia			Clementi, Maria Elisabetta/E-5936-2017; Clementi, Maria Elisabetta/AAA-1450-2022; Coletta, Massimo/N-9049-2015; Coletta, Massimiliano/GSN-5927-2022	Clementi, Maria Elisabetta/0000-0002-4615-7826; Clementi, Maria Elisabetta/0000-0002-4615-7826; COLETTA, Massimiliano/0000-0002-5489-9467				ANSARI A, 1994, BIOCHEMISTRY-US, V33, P5128, DOI 10.1021/bi00183a017; Antonini E., 1971, HEMOGLOBIN MYOGLOBIN; BASHFORD D, 1987, J MOL BIOL, V196, P199, DOI 10.1016/0022-2836(87)90521-3; BROOKS GA, 1986, MED SCI SPORT EXER, V18, P360, DOI 10.1249/00005768-198606000-00019; DAVIS JA, 1985, MED SCI SPORT EXER, V17, P6; Giardina B, 1981, Methods Enzymol, V76, P417; GIBSON QH, 1973, P NATL ACAD SCI USA, V70, P1, DOI 10.1073/pnas.70.1.1; HOCHACHKA PW, 1984, BIOCH ADAPTATION, P183; KOMIYAMA NH, 1995, NATURE, V373, P244, DOI 10.1038/373244a0; PERUTZ MF, 1990, ANNU REV PHYSIOL, V52, P1; PHILLIPS SEV, 1980, J MOL BIOL, V142, P531, DOI 10.1016/0022-2836(80)90262-4; SENO Y, 1990, J MOL BIOL, V216, P111, DOI 10.1016/S0022-2836(05)80064-6; WITTENBE.JB, 1966, J BIOL CHEM, V241, P104; WYMAN J, 1966, J BIOL CHEM, V241, P115; WYMAN J, 1964, ADV PROTEIN CHEM, V19, P223, DOI 10.1016/S0065-3233(08)60190-4	15	51	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					16999	17001		10.1074/jbc.271.29.16999	http://dx.doi.org/10.1074/jbc.271.29.16999			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663546	hybrid			2022-12-25	WOS:A1996UX94300005
J	Katagiri, H; Asano, T; Ishihara, H; Inukai, K; Shibasaki, Y; Kikuchi, M; Yazaki, Y; Oka, Y				Katagiri, H; Asano, T; Ishihara, H; Inukai, K; Shibasaki, Y; Kikuchi, M; Yazaki, Y; Oka, Y			Overexpression of catalytic subunit p110 alpha of phosphatidylinositol 3-kinase increases glucose transport activity with translocation of glucose transporters in 3T3-L1 adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASES; INSULIN; EXPRESSION; CLONING; LOCALIZATION; PI3-KINASE; COMPLEXES; PROTEINS; BINDING; DOMAINS	To elucidate the mechanisms of phosphatidylinositol (PI) 3-kinase involvement in insulin-stimulated glucose transport activity, the epitope-tagged p110 alpha subunit of PI 3-kinase was overexpressed in 3T3-L1 adipocytes using an adenovirus-mediated gene transduction system, Overexpression of p110 alpha was confirmed by immunoblot using anti-tagged epitope antibody, p110 alpha overexpression induced a 2.5-fold increase in PI 3-kinase activity associated with its regulatory subunits in the basal state, an increase exceeding that of the maximally insulin-stimulated control cells, while PI 3-kinase activity associated with phosphotyrosyl protein was only modestly elevated, Overexpression of p110 alpha induced an approximately 14-fold increase in the basal glucose transport rate, which was also greater than that observed in the stimulated control. No apparent difference was observed in the cellular expression level of either GLUT1 or GLUT4 proteins between control and p110 alpha-overexpressing 3T3-L1 adipocytes, Subcellular fractionation revealed translocation of glucose transporters from intracellular to plasma membranes in basal p110 alpha-overexpressing cells, The translocation of GLUT4 protein to the plasma membrane was further confirmed using a membrane sheet assay, These findings indicate that an increment in PI 3-kinase activity induced by overexpression of p110 alpha of PI 3-kinase stimulates glucose transport activity with translocation of glucose transporters, i,e,, mimics the effect of insulin.	ASAHI LIFE FDN,INST ADULT DIS,SHINJUKU KU,TOKYO 160,JAPAN; YAMAGUCHI UNIV,SCH MED,DEPT INTERNAL MED 3,UBE,YAMAGUCHI 755,JAPAN	Asahi Life Foundation; Yamaguchi University	Katagiri, H (corresponding author), UNIV TOKYO,FAC MED,DEPT INTERNAL MED 3,BUNKYO KU,TOKYO 113,JAPAN.							ASANO T, 1992, J BIOL CHEM, V267, P19636; BIRNBAUM MJ, 1992, INT REV CYTOL, V137A, P239; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4903; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FINGAR DC, 1994, J BIOL CHEM, V269, P10127; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; HARUTA T, 1995, J BIOL CHEM, V270, P27991; HERBST JJ, 1995, J BIOL CHEM, V270, P26000, DOI 10.1074/jbc.270.43.26000; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; HU P, 1993, MOL CELL BIOL, V13, P7677, DOI 10.1128/MCB.13.12.7677; Inukai K, 1996, J BIOL CHEM, V271, P5317, DOI 10.1074/jbc.271.10.5317; ISAKOFF SJ, 1995, P NATL ACAD SCI USA, V92, P10247, DOI 10.1073/pnas.92.22.10247; JAMES DE, 1993, J CELL SCI, V104, P607; KAMOHARA S, 1995, P NATL ACAD SCI USA, V92, P1077, DOI 10.1073/pnas.92.4.1077; KANEGAE Y, 1995, NUCLEIC ACIDS RES, V23, P3816, DOI 10.1093/nar/23.19.3816; KAPELLER R, 1993, MOL CELL BIOL, V13, P6052, DOI 10.1128/MCB.13.10.6052; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; KATAGIRI H, 1992, J BIOL CHEM, V267, P22550; Keller Susanne R., 1994, Trends in Cell Biology, V4, P115, DOI 10.1016/0962-8924(94)90065-5; KELLY KL, 1993, J BIOL CHEM, V268, P4391; KOTANI K, 1995, BIOCHEM BIOPH RES CO, V209, P343, DOI 10.1006/bbrc.1995.1509; KOZMA L, 1993, P NATL ACAD SCI USA, V90, P4460, DOI 10.1073/pnas.90.10.4460; MARCUSOHN J, 1995, CURR BIOL, V5, P1296, DOI 10.1016/S0960-9822(95)00256-9; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; OKA Y, 1988, J BIOL CHEM, V263, P13432; OKADA T, 1994, J BIOL CHEM, V269, P3568; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PANAYOTOU G, 1993, BIOESSAYS, V15, P171, DOI 10.1002/bies.950150305; PIPER RC, 1991, AM J PHYSIOL, V260, pC571; PONS S, 1995, MOL CELL BIOL, V15, P4453; ROBINSON LJ, 1992, J CELL BIOL, V117, P1181, DOI 10.1083/jcb.117.6.1181; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; WENNSTROM S, 1994, CURR BIOL, V4, P385, DOI 10.1016/S0960-9822(00)00087-7; WHITE MF, 1994, J BIOL CHEM, V269, P1; WIESE RJ, 1995, J BIOL CHEM, V270, P3442, DOI 10.1074/jbc.270.7.3442	36	156	159	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					16987	16990		10.1074/jbc.271.29.16987	http://dx.doi.org/10.1074/jbc.271.29.16987			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663584	hybrid			2022-12-25	WOS:A1996UX94300002
J	Armstrong, RC; Aja, T; Xiang, JL; Gaur, S; Krebs, JF; Hoang, K; Bai, X; Korsmeyer, J; Karanewsky, DS; Fritz, LC; Tomaselli, KJ				Armstrong, RC; Aja, T; Xiang, JL; Gaur, S; Krebs, JF; Hoang, K; Bai, X; Korsmeyer, J; Karanewsky, DS; Fritz, LC; Tomaselli, KJ			Fas-induced activation of the cell death-related protease CPP32 is inhibited by Bcl-2 and by ICE family protease inhibitors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE; SURVIVAL; ENZYME	The human proto oncogene bcl-2 and its Caenorhabditis elegans homologue ced-9 inhibit programmed cell death, In contrast, members of the human interleukin-lp converting enzyme (ICE) family of cysteine proteases and their C, elegans homologue CED-3 promote the death program, Genetic experiments in C, elegans have shown that ced-9 is formally a negative regulator of ced-3 function, but neither those studies nor others have determined whether CED-9 or Bcl-2 proteins act biochemically upstream or downstream of CED-3/ICE proteases, CPP32, like all known members of the CED-3/ICE family, is synthesized as a proenzyme that is subsequently processed into an active protease with specificity for cleavage at Asp-X peptide bonds, In this report, we demonstrate that the CPP32 proenzyme is proteolytically processed and activated in Jurkat cells induced to die by Fas ligation, CPP32 activation is blocked by cell-permeable inhibitors of aspartate-directed, cysteine proteases, suggesting that pro-CPP32 is cleaved by active CPP32 or by other ICE family members, Heterologous expression of Bcl-2 in Jurkat cells prevents Fas-induced cell death as well as proteolytic processing and activation of CPP32, Thus, Bcl-2 acts at or upstream of the CPP32 activation step to inhibit apoptosis induced by Fas stimulation.	IDUN PHARMACEUT INC,LA JOLLA,CA 92037; WASHINGTON UNIV,SCH MED,HOWARD HUGHES MED INST,ST LOUIS,MO 63110	Howard Hughes Medical Institute; Washington University (WUSTL)								BEIDLER DR, 1995, J BIOL CHEM, V270, P16526, DOI 10.1074/jbc.270.28.16526; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; Boulakia CA, 1996, ONCOGENE, V12, P529; BUMP NJ, 1995, SCIENCE, V269, P1885, DOI 10.1126/science.7569933; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; CLEM RJ, 1991, SCIENCE, V254, P1388, DOI 10.1126/science.1962198; DARMON AJ, 1995, NATURE, V377, P446, DOI 10.1038/377446a0; Demuth H U, 1990, J Enzyme Inhib, V3, P249, DOI 10.3109/14756369009030375; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; ENARI M, 1995, EMBO J, V14, P5201, DOI 10.1002/j.1460-2075.1995.tb00204.x; ESSER RE, 1994, ARTHRITIS RHEUM, V37, P236, DOI 10.1002/art.1780370213; FAUCHEU C, 1995, EMBO J, V14, P1914, DOI 10.1002/j.1460-2075.1995.tb07183.x; FERNANDESALNEMR.T, 1995, CANCER RES, V55, P3737; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P6045; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; GAGLIARDINI V, 1994, SCIENCE, V263, P826, DOI 10.1126/science.8303301; GRAYBILL TL, 1994, INT J PEPT PROT RES, V44, P173; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HENGARTNER MO, 1992, NATURE, V356, P494, DOI 10.1038/356494a0; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HORVITZ HR, 1994, COLD SPRING HARB SYM, V59, P377, DOI 10.1101/SQB.1994.059.01.042; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; LAZEBNIK YA, 1995, P NATL ACAD SCI USA, V92, P9042, DOI 10.1073/pnas.92.20.9042; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; MARTIN SJ, 1995, EMBO J, V14, P5191, DOI 10.1002/j.1460-2075.1995.tb00203.x; MILLIGAN CE, 1995, NEURON, V15, P385, DOI 10.1016/0896-6273(95)90042-X; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; MUNDAY NA, 1995, J BIOL CHEM, V270, P15870, DOI 10.1074/jbc.270.26.15870; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Pronk GJ, 1996, SCIENCE, V271, P808, DOI 10.1126/science.271.5250.808; RABIZADEH S, 1993, J NEUROCHEM, V61, P2318, DOI 10.1111/j.1471-4159.1993.tb07477.x; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; RAMAGE P, 1995, J BIOL CHEM, V270, P9378, DOI 10.1074/jbc.270.16.9378; RANJIT GB, 1995, CLIN CANCER RES, V1, P223; RASNICK D, 1985, ANAL BIOCHEM, V149, P461, DOI 10.1016/0003-2697(85)90598-6; REVESZ L, 1994, TETRAHEDRON LETT, V35, P9693, DOI 10.1016/0040-4039(94)88361-0; Slee EA, 1996, BIOCHEM J, V315, P21, DOI 10.1042/bj3150021; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; TEWARI M, 1995, J BIOL CHEM, V270, P18738, DOI 10.1074/jbc.270.32.18738; TEWARI M, 1995, J BIOL CHEM, V270, P22705, DOI 10.1074/jbc.270.39.22705; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; THORNBERRY NA, 1994, BIOCHEMISTRY-US, V33, P3934, DOI 10.1021/bi00179a020; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VAUX DL, 1994, CELL, V76, P777, DOI 10.1016/0092-8674(94)90350-6; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; XUE D, 1995, NATURE, V377, P248, DOI 10.1038/377248a0; YANG T, 1995, J CELL BIOL, V128, P1173, DOI 10.1083/jcb.128.6.1173; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	51	314	324	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16850	16855		10.1074/jbc.271.28.16850	http://dx.doi.org/10.1074/jbc.271.28.16850			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663439	hybrid			2022-12-25	WOS:A1996UX12600066
J	Krishnan, K; Yan, H; Lim, JTE; Krolewski, JJ				Krishnan, K; Yan, H; Lim, JTE; Krolewski, JJ			Dimerization of a chimeric CD4-interferon-alpha receptor reconstitutes the signaling events preceding STAT phosphorylation	ONCOGENE			English	Article						interferon; signaling; receptor; tyrosine phosphorylation; STAT	INTERFERON-ALPHA RECEPTOR; PROTEIN-TYROSINE KINASE; GROWTH-FACTOR RECEPTOR; TRANSCRIPTION FACTOR; TRANSDUCTION; CLONING; FAMILY; MEMBER; MPL	Interferon-alpha induces the rapid tyrosine phosphorylation of a number of molecules, including the cognate receptors, JAK-family kinases (Jak1 and tyk2), and latent transcription factors (STATs 1 and 2), Here, we describe the use of chimeric molecules composed of the extracellular domain of CD4 fused to the intracellular domain of the interferon-alpha receptor subunit 1 (IFNaR1), Antibody mediated crosslinking dimerizes the transfected chimeras, activates tyk2 and induces a tyk2-dependent tyrosine phosphorylation of the intracellular domain of the chimera, We further define the major site of IFNaR1 phosphorylation, and show that phosphorylation of this site is required for association with STAT2, Finally, we show that homodimerization of IFNaR1 is not sufficient to activate the STATs, suggesting a role for the IFNaR2 subunit and Jak1 in the transduction of the interferon-alpha signal.	COLUMBIA UNIV COLL PHYS & SURG,DEPT PATHOL,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,CTR CANC,NEW YORK,NY 10032	Columbia University; Columbia University					NATIONAL CANCER INSTITUTE [R01CA056862] Funding Source: NIH RePORTER; NCI NIH HHS [CA56862] Funding Source: Medline; NIGMS NIH HHS [GM07367] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAMOVICH C, 1994, EMBO J, V13, P5871, DOI 10.1002/j.1460-2075.1994.tb06932.x; BARBIERI G, 1994, EUR J BIOCHEM, V223, P427, DOI 10.1111/j.1432-1033.1994.tb19010.x; COLAMONICI O, 1994, MOL CELL BIOL, V14, P8133, DOI 10.1128/MCB.14.12.8133; COLAMONICI OR, 1994, J BIOL CHEM, V269, P3518; COLAMONICI OR, 1991, PHARMACOL THERAPEUT, V52, P227, DOI 10.1016/0163-7258(91)90010-J; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Davis E, 1996, LEUKEMIA, V10, P543; DOMANSKI P, 1995, J BIOL CHEM, V270, P21606, DOI 10.1074/jbc.270.37.21606; FU XY, 1992, P NATL ACAD SCI USA, V89, P7840, DOI 10.1073/pnas.89.16.7840; FU XY, 1992, CELL, V70, P323, DOI 10.1016/0092-8674(92)90106-M; GUPTA S, 1996, EMBO J, V15; HANRATTY WP, 1993, MOL GEN GENET, V238, P33, DOI 10.1007/BF00279527; HEIM MH, 1995, SCIENCE, V267, P1347, DOI 10.1126/science.7871432; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; LEE AW, 1990, P NATL ACAD SCI USA, V87, P7270, DOI 10.1073/pnas.87.18.7270; LEUNG S, 1995, MOL CELL BIOL, V15, P1312; LUO H, 1995, EMBO J, V14, P1412, DOI 10.1002/j.1460-2075.1995.tb07127.x; LUO KX, 1990, MOL CELL BIOL, V10, P5305, DOI 10.1128/MCB.10.10.5305; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; NOVICK D, 1994, CELL, V77, P391, DOI 10.1016/0092-8674(94)90154-6; PLATANIAS LC, 1994, J BIOL CHEM, V269, P17761; Sambrook J., 2002, MOL CLONING LAB MANU; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCHLESSINGER J, 1988, BIOCHEMISTRY-US, V27, P3119, DOI 10.1021/bi00409a002; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; SKODA RC, 1993, EMBO J, V12, P2645, DOI 10.1002/j.1460-2075.1993.tb05925.x; SOH JM, 1994, J BIOL CHEM, V269, P18102; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; SUDOL M, 1993, NONRECEPTOR TYROSINE, P203; TANNER JW, 1995, J BIOL CHEM, V270, P6523, DOI 10.1074/jbc.270.12.6523; UZE G, 1990, CELL, V60, P225, DOI 10.1016/0092-8674(90)90738-Z; UZE G, 1995, J INTERF CYTOK RES, V15, P3, DOI 10.1089/jir.1995.15.3; VANDERKUUR JA, 1994, J BIOL CHEM, V269, P21709; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; VELAZQUEZ L, 1995, J BIOL CHEM, V270, P3327, DOI 10.1074/jbc.270.7.3327; VIGON I, 1993, ONCOGENE, V8, P2607; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; Yan H, 1996, EMBO J, V15, P1064, DOI 10.1002/j.1460-2075.1996.tb00444.x; YAN H, 1995, ANAL BIOCHEM, V231, P455, DOI 10.1006/abio.1995.0080; Yan H, 1996, MOL CELL BIOL, V16, P2074	43	24	26	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 4	1996	13	1					125	133						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UX319	8700538				2022-12-25	WOS:A1996UX31900014
J	Mehle, C; Piatyszek, MA; Ljungberg, B; Shay, JW; Roos, G				Mehle, C; Piatyszek, MA; Ljungberg, B; Shay, JW; Roos, G			Telomerase activity in human renal cell carcinoma	ONCOGENE			English	Article						renal cell carcinoma; telomerase; clinical course	TUMOR HETEROGENEITY	Telomeres have a vital role in maintaining chromosome stability and are essential for long term viability, Since the very ends of linear chromosomes cannot replicate, telomeres shorten in normal somatic cells eventually resulting in growth inhibition, However, most immortal cell lines maintain stable telomeres indicating that mechanisms exist to compensate for the end replication problem, Telomerase activity, leading to synthesis of telomeric DNA repeats, has been proposed to be an important step in the immortalization process of tumor cells, In the present study, 56 renal cell carcinomas were tested for telomerase activity using the sensitive TRAP (telomeric repeat amplification protocol), Forty of the analysed tumors (71%) were positive for telomerase activity, whereas none of the 56 corresponding normal kidney samples showed telomerase activity, All telomerase negative tumors had a reduction in mean telomere restriction fragment (TRF) length and a decrease in total telomere repeat hybridization signal, though cases were observed with an increase in peak TRF lengths, No obvious association between the presence of telomerase activity and clinicopathological parameters (histopathologic grade, DNA-ploidy, stage and clinical outcome) was found, The high frequency of detection of telomerase activity in the renal cell carcinomas indicates that this enzyme is likely to be an important factor involved in the evolution of this tumor type.	UMEA UNIV,DEPT UROL & ANDROL,S-90187 UMEA,SWEDEN; UNIV TEXAS,SW MED CTR,DEPT CELL BIOL & NEUROSCI,DALLAS,TX 75235	Umea University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Mehle, C (corresponding author), UMEA UNIV,DEPT PATHOL,S-90187 UMEA,SWEDEN.				NATIONAL INSTITUTE ON AGING [R01AG007992] Funding Source: NIH RePORTER; NIA NIH HHS [AG07992] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; ALLSOPP RC, 1995, EXP CELL RES, V219, P130, DOI 10.1006/excr.1995.1213; BROCCOLI D, 1995, P NATL ACAD SCI USA, V92, P9082, DOI 10.1073/pnas.92.20.9082; BRYAN MT, 1995, EMBO J, V14, P4240; CHADENEAU C, 1995, CANCER RES, V55, P2533; COUNTER CM, 1995, BLOOD, V85, P2315, DOI 10.1182/blood.V85.9.2315.bloodjournal8592315; COUNTER CM, 1994, P NATL ACAD SCI USA, V91, P2900, DOI 10.1073/pnas.91.8.2900; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; COUNTER CM, 1994, J VIROL, V68, P3410, DOI 10.1128/JVI.68.5.3410-3414.1994; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; Hiyama E, 1996, J NATL CANCER I, V88, P116, DOI 10.1093/jnci/88.2.116; HIYAMA E, 1995, CANCER RES, V55, P3258; HIYAMA E, 1995, NAT MED, V1, P249, DOI 10.1038/nm0395-249; HIYAMA K, 1995, J NATL CANCER I, V87, P895, DOI 10.1093/jnci/87.12.895; HOLT SE, 1996, IN PRESS MOL CELL BI; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; KIPLING D, 1995, TELOMERE, P1; KLINGELHUTZ AJ, 1994, MOL CELL BIOL, V14, P961, DOI 10.1128/MCB.14.2.961; LANGFORD LA, 1995, LANCET, V346, P1267, DOI 10.1016/S0140-6736(95)91865-5; LARSSON P, 1993, INT J CANCER, V55, P566, DOI 10.1002/ijc.2910550408; LJUNGBERG B, 1985, CANCER, V56, P503, DOI 10.1002/1097-0142(19850801)56:3<503::AID-CNCR2820560316>3.0.CO;2-N; LJUNGBERG B, 1996, IN PRESS BR J CANC; MEHLE C, 1994, CANCER RES, V54, P236; MEHLE C, 1993, GENE CHROMOSOME CANC, V6, P86, DOI 10.1002/gcc.2870060204; MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4; MURNANE JP, 1994, EMBO J, V13, P4953, DOI 10.1002/j.1460-2075.1994.tb06822.x; NILSSON P, 1994, ONCOGENE, V9, P3043; NORDENSON I, 1988, CANCER GENET CYTOGEN, V32, P35, DOI 10.1016/0165-4608(88)90309-3; Piatyszek Mieczyslaw A., 1995, Methods in Cell Science, V17, P1, DOI 10.1007/BF00981880; ROBSON CJ, 1969, J UROLOGY, V101, P239; ROGAN EM, 1995, MOL CELL BIOL, V15, P4745; SHAY JW, 1991, BIOCHIM BIOPHYS ACTA, V1072, P1, DOI 10.1016/0304-419X(91)90003-4; SHAY JW, 1995, MOL MED TODAY, V1, P378, DOI 10.1016/S1357-4310(95)93872-9; SKINNER DG, 1971, CANCER-AM CANCER SOC, V28, P1165, DOI 10.1002/1097-0142(1971)28:5<1165::AID-CNCR2820280513>3.0.CO;2-G; Sommerfeld HJ, 1996, CANCER RES, V56, P218; Strahl C, 1996, MOL CELL BIOL, V16, P53; TAHARA H, 1995, CANCER RES, V55, P2734; WHITAKER NJ, 1995, ONCOGENE, V11, P971; WRIGHT WE, 1995, NUCLEIC ACIDS RES, V23, P3794, DOI 10.1093/nar/23.18.3794	40	98	105	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 4	1996	13	1					161	166						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UX319	8700542				2022-12-25	WOS:A1996UX31900018
J	Cleary, SF; Du, ZM; Cao, GH; Liu, LM; McCrady, C				Cleary, SF; Du, ZM; Cao, GH; Liu, LM; McCrady, C			Effect of isothermal radiofrequency radiation on cytolytic T lymphocytes	FASEB JOURNAL			English	Article						[H-3]TdR; log phase; CTLL-2; IL-2 receptor; specific absorption rates; T cell proliferation	PHASE-TRANSITION; INTERLEUKIN-2; INVITRO; PERMEABILITY; TEMPERATURE; ERYTHROCYTE; VIABILITY; MICROWAVE	Previous in vitro studies provide evidence that RF electromagnetic radiation modulates proliferation of human glioma, lymphocytes, and other cell types, The mechanism of RF radiation cell proliferation modulation, as well as mechanisms for effects on other cell physiologic endpoints, are not well understood, To obtain insight regarding interaction mechanisms, we investigated effects of RF radiation exposure on interleukin 2 (IL-2)-dependent proliferation of cytolytic T lymphocytes (CTLL-2). After exposure to RF radiation in the presence or absence of IL-2 cells were cultured at various physiological concentrations of IL-2, Treatment effects on CTLL-2 proliferation were determined by tritiated thymidine incorporation immediately or 24 h after exposure, Exposure to 2450 MHz RF radiation at specific absorption rates (SARs) of greater than 25 W/kg (induced E-field strength 98.4 V/m) induced a consistent, statistically significant reduction in CTLL-2 proliferation, especially at low IL-2 concentrations, At lower SARs, 2450 MHz exposure increased CTLL-2 proliferation immediately after exposure but reduced 24 h postexposure proliferation, RF radiation effects depended on the mitotic state of the cells at the time of exposure, Comparison of the effects of temperature elevation and RF radiation indicated significant qualitative and quantitative differences.			Cleary, SF (corresponding author), VIRGINIA COMMONWEALTH UNIV, MED COLL VIRGINIA, DEPT PHYSIOL & BIOPHYS, BIOELECTROMAGNET LAB, RICHMOND, VA 23298 USA.				NIEHS NIH HHS [ES5417] Funding Source: Medline	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BUDD RA, 1985, J MICROWAVE POWER EE, V20, P217; CAO GH, 1995, BIOELECTROCH BIOENER, V37, P131, DOI 10.1016/0302-4598(95)05022-Z; CLEARY SF, 1992, ANN NY ACAD SCI, V649, P166, DOI 10.1111/j.1749-6632.1992.tb49606.x; CLEARY SF, 1985, BIOELECTROMAGNETICS, V6, P53, DOI 10.1002/bem.2250060106; CLEARY SF, 1985, BIOELECTROMAGNETICS, V6, P313, DOI 10.1002/bem.2250060311; CLEARY SF, 1990, BIOELECTROMAGNETICS, V11, P47, DOI 10.1002/bem.2250110107; CLEARY SF, 1990, RADIAT RES, V121, P38, DOI 10.2307/3577561; CLEARY SF, IN PRESS BIOELECTROC; CLEARY SF, 1991, 13 ANN M BIOEL SOC S; CLEARY SF, 1988, ENCY MED DEVICES INS, P274; DINZEO G, 1988, BIOELECTROMAGNETICS, V9, P363, DOI 10.1002/bem.2250090406; FREY AH, 1993, FASEB J, V7, P272, DOI 10.1096/fasebj.7.2.8440406; GREEN LM, 1984, J IMMUNOL METHODS, V70, P257, DOI 10.1016/0022-1759(84)90190-X; KOLOMITKIN OV, 1994, CHARGE FIELD EFFECTS, V4; KONDO M, 1993, SCIENCE, V262, P1874, DOI 10.1126/science.8266076; LIBURDY RP, 1984, BIOELECTROMAGNETICS, V5, P283, DOI 10.1002/bem.2250050215; LIBURDY RP, 1988, RADIAT RES, V114, P500, DOI 10.2307/3577121; LIU LM, 1988, BIOELECTROMAGNETICS, V9, P249, DOI 10.1002/bem.2250090306; LIU LM, 1995, BIOELECTROMAGNETICS, V16, P160, DOI 10.1002/bem.2250160304; LIU LM, 1994, CHARGE FIELD EFFECTS, V4; OGARRA A, 1988, IMMUNOL TODAY, V9, P45, DOI 10.1016/0167-5699(88)91259-5; PHILIPPOVA TM, 1988, BIOELECTROMAGNETICS, V9, P347, DOI 10.1002/bem.2250090404; PHILIPPOVA TM, 1994, BIOELECTROMAGNETICS, V15, P183, DOI 10.1002/bem.2250150303; RIEGEL JS, 1992, CHEM IMMUNOL, V51, P266; SISKEN JE, 1965, EXP CELL RES, V39, P103, DOI 10.1016/0014-4827(65)90012-1; SMITH KA, 1983, J IMMUNOL, V131, P1808; SMITH KA, 1988, SCIENCE, V240, P1169, DOI 10.1126/science.3131876	27	39	43	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	1996	10	8					913	919						7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	UQ456	8666169				2022-12-25	WOS:A1996UQ45600014
J	Cao, X; Teitelbaum, SL; Zhu, HJ; Zhang, LM; Feng, X; Ross, FP				Cao, X; Teitelbaum, SL; Zhu, HJ; Zhang, LM; Feng, X; Ross, FP			Competition for a unique response element mediates retinoic acid inhibition of vitamin D-3-stimulated transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN OSTEOCALCIN GENE; HORMONE RECEPTOR-BETA; THYROID-HORMONE; BONE-RESORPTION; DNA-BINDING; DIRECT REPEATS; LIGAND SENSITIVITY; NUCLEAR RECEPTORS; CELL-ADHESION; SUBUNIT GENE	We have identified a novel steroid hormone response element in the avian beta(3) integrin promoter. This sequence, comprising three hexameric direct repeat half-sites separated by nine and three nucleotides binds vitamin D receptor (VDR)-retinoid X receptor (RXR) and retinoic acid receptor (RAR)-RXR heterodimers. VDR-RXR binds direct repeats separated by three basepairs, and RAR-RXR recognizes half-sites separated by nine bases, whereas the central half-site interacts with both heterodimers. Retinoic acid and 1,25-dihydroxyvitamin D-3 activate both a genomic fragment including the transcriptional start site and an oligonucleotide containing the three repeats, linked to a heterologous promoter. Co-addition of the steroids produces neither synergy nor an additive effect; rather the result equals that for retinoic acid alone. Scatchard analysis demonstrates that RAR-RXR has greater affinity than VDR-RXR for the composite element. Based on these findings we propose a model in which there is specific, polarity-defined binding of VDR-RXR and RAR-RXR to three half-sites, which form two overlapping steroid response elements, with the central half-site common to both, Our results identify a novel mechanism by which one steroid hormone can modulate the activity of a second, by competing for a shared half-site in a composite response element.	UNIV WASHINGTON,SCH MED,DEPT PATHOL,ST LOUIS,MO 63110	Washington University (WUSTL)				Teitelbaum, Steven/0000-0002-4054-6679	NIAMS NIH HHS [AR32788, AR42404] Funding Source: Medline; NIDCR NIH HHS [DE05413] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR032788, R01AR042404] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALBELDA SM, 1990, FASEB J, V4, P2868, DOI 10.1096/fasebj.4.11.2199285; BALDWIN AS, 1994, CURRENT PROTOCOLS MO; BANIAHMAD A, 1993, P NATL ACAD SCI USA, V90, P8832, DOI 10.1073/pnas.90.19.8832; BERKENSTAM A, 1992, CELL, V69, P401, DOI 10.1016/0092-8674(92)90443-G; BLANCO JCG, 1995, P NATL ACAD SCI USA, V92, P1535, DOI 10.1073/pnas.92.5.1535; CAO X, 1993, J BIOL CHEM, V268, P27371; DRESNERPOLLAK R, 1994, J CELL BIOCHEM, V56, P323, DOI 10.1002/jcb.240560308; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FAWELL SE, 1990, P NATL ACAD SCI USA, V87, P6883, DOI 10.1073/pnas.87.17.6883; FISHER JE, 1993, ENDOCRINOLOGY, V132, P1411, DOI 10.1210/en.132.3.1411; GIGUERE V, 1994, ENDOCR REV, V15, P61, DOI 10.1210/er.15.1.61; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; GRONOWICZ GA, 1994, J BONE MINER RES, V9, P193, DOI 10.1002/jbmr.5650090208; HORTON MA, 1991, EXP CELL RES, V195, P368, DOI 10.1016/0014-4827(91)90386-9; HORTON MA, 1995, ANN NY ACAD SCI, V760, P190, DOI 10.1111/j.1749-6632.1995.tb44630.x; HOUGH S, 1988, ENDOCRINOLOGY, V122, P2933, DOI 10.1210/endo-122-6-2933; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; KAJI H, 1995, LIFE SCI, V56, P1903, DOI 10.1016/0024-3205(95)00165-3; KERNER SA, 1989, P NATL ACAD SCI USA, V86, P4455, DOI 10.1073/pnas.86.12.4455; KING KL, 1994, J BONE MINER RES, V9, P381; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KUROKAWA R, 1993, GENE DEV, V7, P1423, DOI 10.1101/gad.7.7b.1423; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LIUSI BF, 1991, NATURE, V352, P497; MACDONALD PN, 1995, J BIOL CHEM, V270, P4748, DOI 10.1074/jbc.270.9.4748; MACDONALD PN, 1991, J BIOL CHEM, V266, P18808; MACDONALD PN, 1993, MOL CELL BIOL, V13, P5907, DOI 10.1128/MCB.13.9.5907; MIMURA H, 1994, ENDOCRINOLOGY, V134, P1061, DOI 10.1210/en.134.3.1061; NAAR AM, 1991, CELL, V65, P1267, DOI 10.1016/0092-8674(91)90021-P; NICHOLSON RC, 1990, EMBO J, V9, P4443, DOI 10.1002/j.1460-2075.1990.tb07895.x; PERLMANN T, 1993, GENE DEV, V7, P1411, DOI 10.1101/gad.7.7b.1411; QUELO I, 1994, DNA CELL BIOL, V13, P1181, DOI 10.1089/dna.1994.13.1181; RASTINEJAD F, 1995, NATURE, V375, P203, DOI 10.1038/375203a0; ROSS FP, 1993, J BIOL CHEM, V268, P9901; Sastry SK, 1993, CURR OPIN CELL BIOL, V5, P819, DOI 10.1016/0955-0674(93)90031-K; SATO M, 1990, J CELL BIOL, V111, P1713, DOI 10.1083/jcb.111.4.1713; SCHRADER M, 1995, MOL CELL BIOL, V15, P1154; SCHRADER M, 1994, NATURE, V370, P382, DOI 10.1038/370382a0; SCHRADER M, 1994, J BIOL CHEM, V269, P5501; SCHRADER M, 1994, J MOL ENDOCRINOL, V12, P327, DOI 10.1677/jme.0.0120327; SCHULE R, 1990, CELL, V61, P497, DOI 10.1016/0092-8674(90)90531-I; SEGARS JH, 1993, MOL CELL BIOL, V13, P2258, DOI 10.1128/MCB.13.4.2258; SLATER EP, 1985, MOL CELL BIOL, V5, P2984, DOI 10.1128/MCB.5.11.2984; SUDA T, 1992, ENDOCR REV, V13, P66, DOI 10.1210/er.13.1.66; TONG GX, 1995, J BIOL CHEM, V270, P10601, DOI 10.1074/jbc.270.18.10601; TSAI SY, 1988, CELL, V55, P361, DOI 10.1016/0092-8674(88)90059-1; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; YAMADA KM, 1995, CURR OPIN CELL BIOL, V7, P681, DOI 10.1016/0955-0674(95)80110-3; ZECHEL C, 1994, EMBO J, V13, P1425, DOI 10.1002/j.1460-2075.1994.tb06396.x	51	24	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20650	20654		10.1074/jbc.271.34.20650	http://dx.doi.org/10.1074/jbc.271.34.20650			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702813	hybrid			2022-12-25	WOS:A1996VD33700065
J	Cooper, CE; Lynagh, GR; Hoyes, KP; Hider, RC; Cammack, R; Porter, JB				Cooper, CE; Lynagh, GR; Hoyes, KP; Hider, RC; Cammack, R; Porter, JB			The relationship of intracellular iron chelation to the inhibition and regeneration of human ribonucleotide reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; SMALL SUBUNIT; CELL-GROWTH; PROTEIN; ENZYME; DESFERRIOXAMINE; MOSSBAUER; MECHANISM; RESONANCE; OXYGEN	The depletion of cellular iron can lead to the inhibition of ribonucleotide reductase, preventing new DNA synthesis and hence inhibiting cell proliferation. Electron paramagnetic resonance (EPR) spectroscopy has been used to examine simultaneously for the first time the relationship between chelation of intracellular iron and the rate of removal and regeneration of the tyrosyl radical of ribonucleotide reductase within intact human leukemia K562 cells. The different physiochemical characteristics of relatively hydrophobic low molecular weight bidentate hydroxypyridinone chelators and the higher molecular weight hexadentate ferrioxamine have been exploited to elucidate these interactions further. The base-line concentration of EPR detectable mononuclear nonheme iron complexes was 3.15 +/- 1.05 mu M, rising on incubation with chelators more rapidly with hydroxypyridinones than with desferrioxamine. Hydroxypyridinones also removed the tyrosyl radical more rapidly, apparently as a consequence of depletion of the intracellular iron pools necessary to regenerate the active enzyme and compatible with their reportedly greater cell toxicity. The radical decay rate is consistent with previous models, suggesting that iron is spontaneously removed from mammalian ribonucleotide reductase. Upon removal of extracellular chelator the regeneration of the tyrosyl radical was significantly faster for hydroxypyridinones than for desferrioxamine, consistent with their differential effects on cell cycle synchronization.	UCL, SCH MED, DEPT HAEMATOL, LONDON WC1E 6HX, ENGLAND; UNIV LONDON KINGS COLL, DIV LIFE SCI, MET BIOL & MED CTR, LONDON W8 7AH, ENGLAND	University of London; University College London; UCL Medical School; University of London; King's College London	Cooper, CE (corresponding author), UNIV ESSEX, DEPT BIOL & CHEM SCI, CENT CAMPUS, WIVENHOE PK, COLCHESTER CO4 3SQ, ESSEX, ENGLAND.		Cammack, Richard/B-7841-2008; Cooper, Chris/AAK-9729-2020	Cooper, Chris/0000-0003-0381-3990; Porter, John/0000-0003-3000-9359	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ATKIN CL, 1973, J BIOL CHEM, V248, P7464; BARANKIEWICZ J, 1987, BIOCHEM PHARMACOL, V36, P2343, DOI 10.1016/0006-2952(87)90601-0; BROWN NC, 1969, EUR J BIOCHEM, V9, P512, DOI 10.1111/j.1432-1033.1969.tb00639.x; CAMMACK R, 1988, METHOD ENZYMOL, V167, P427; CAMMACK R, 1993, METHOD ENZYMOL, V227, P353, DOI 10.1016/0076-6879(93)27014-8; CHITAMBAR CR, 1988, BLOOD, V72, P1930; COOPER CE, 1994, FREE RADICAL DAMAGE, P65; DOBBIN PS, 1993, J MED CHEM, V36, P2448, DOI 10.1021/jm00069a002; ENGSTROM Y, 1985, J BIOL CHEM, V260, P9114; ERIKSSON S, 1984, J BIOL CHEM, V259, P1695; FONTECAVE M, 1989, J BIOL CHEM, V264, P9164; GEREZ C, 1992, BIOCHEMISTRY-US, V31, P780, DOI 10.1021/bi00118a020; GRASLUND A, 1982, J BIOL CHEM, V257, P5711; GRASLUND A, 1985, ENVIRON HEALTH PERSP, V64, P139, DOI 10.2307/3430005; HIDER RC, 1994, DEVELOPMENT OF IRON CHELATORS FOR CLINICAL USE, P353; HOYES KP, 1993, BRIT J HAEMATOL, V85, P393, DOI 10.1111/j.1365-2141.1993.tb03184.x; HOYES KP, 1992, CANCER RES, V52, P4591; KONTOGHIORGHES GJ, 1990, CLIN PHARMACOL THER, V48, P255, DOI 10.1038/clpt.1990.147; LAMMERS M, 1983, STRUCT BOND, V54, P27; LEE P, 1993, DRUG METAB DISPOS, V21, P640; LYNCH JB, 1989, J BIOL CHEM, V264, P8091; NOCENTINI G, 1993, CANCER RES, V53, P19; NORDLUND P, 1990, NATURE, V345, P593, DOI 10.1038/345593a0; NYHOLM S, 1993, J BIOL CHEM, V268, P26200; PETERSSON L, 1980, J BIOL CHEM, V255, P6706; Porter J. B., 1994, British Journal of Haematology, V87, P114; PORTER JB, 1994, ADV EXP MED BIOL, V356, P361; PORTER JB, 1989, CLIN HAEMATOL, V2, P257; PORTER JB, 1994, BR J HAEMATOL S1, V84, P64; REICHARD P, 1983, SCIENCE, V221, P514, DOI 10.1126/science.6306767; REICHARD P, 1988, ANNU REV BIOCHEM, V57, P349, DOI 10.1146/annurev.bi.57.070188.002025; ROBERTS PJ, 1990, BLOOD, V75, P976; SIMPSON RJ, 1992, BIOCHIM BIOPHYS ACTA, V1156, P19, DOI 10.1016/0304-4165(92)90090-H; SJOBERG BM, 1982, BIOCHEMISTRY-US, V21, P96; SJOBERG BM, 1978, J BIOL CHEM, V253, P6863; STUBBE JA, 1990, J BIOL CHEM, V265, P5329; THELANDER L, 1983, J BIOL CHEM, V258, P4063; THELANDER L, 1983, BIOCHEM BIOPH RES CO, V110, P859, DOI 10.1016/0006-291X(83)91040-9; THELANDER M, 1985, J BIOL CHEM, V260, P2737; WEIR MP, 1985, BIOCHIM BIOPHYS ACTA, V828, P298, DOI 10.1016/0167-4838(85)90311-5	40	169	172	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20291	20299		10.1074/jbc.271.34.20291	http://dx.doi.org/10.1074/jbc.271.34.20291			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702762	hybrid			2022-12-25	WOS:A1996VD33700014
J	Detimary, P; VandenBerghe, G; Henquin, JC				Detimary, P; VandenBerghe, G; Henquin, JC			Concentration dependence and time course of the effects of glucose on adenine and guanine nucleotides in mouse pancreatic islets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE POTASSIUM CHANNELS; INSULIN-SECRETING CELLS; INTACT RAT ISLETS; BETA-CELLS; K+-CHANNELS; B-CELLS; ENERGY-STATE; HIT CELLS; G-PROTEIN; 2 SITES	Changes in the ATP:ADP ratio in pancreatic B cells may participate in the regulation of insulin secretion by glucose. Here, we have investigated the possible role of guanine nucleotides. Mouse islets were incubated in a control medium (when K+-ATP channels are the major site of regulation) or in a high K+ medium (when glucose modulates the effectiveness of cytosolic Ca2+ on exocytosis). Glucose induced a concentration-dependent (0-20 mM) increase in GTP and a decrease in GDP in both types of medium, thus causing a progressive rise of the GTP:GDP ratio, ATP and ADP levels were 4-5-fold higher but varied in a similar way as those of guanine nucleotides. Insulin secretion was inversely correlated with ADP and GDP levels and positively correlated with the ATP:ADP and GTP:GDP ratios between 6 and 20 mM glucose in control medium and between 0 and 20 mM glucose in high K+ medium, The increases in the GTP:GDP and ATP:ADP ratios induced by a rise of glucose were faster than the decreases induced by a fall in glucose, but the changes of both ratios were again parallel. In conclusion, glucose causes large, concentration-dependent changes in guanine as well as in adenine nucleotides in islet cells. This raises the possibility that both participate in the regulation of nutrient-induced insulin secretion.	UNIV CATHOLIQUE LOUVAIN,FAC MED,UNITE ENDOCRINOL & METAB,B-1200 BRUSSELS,BELGIUM; UNIV CATHOLIQUE LOUVAIN,FAC MED,CHIM PHYSIOL LAB,B-1200 BRUSSELS,BELGIUM	Universite Catholique Louvain; Universite Catholique Louvain								ALEYASSINE H, 1970, ENDOCRINOLOGY, V87, P84, DOI 10.1210/endo-87-1-84; ASHCROFT FM, 1989, PROG BIOPHYS MOL BIO, V54, P87, DOI 10.1016/0079-6107(89)90013-8; ASHCROFT FM, 1992, INSULIN MOL BIOL PAT, P97; ASHCROFT SJ, 1973, BIOCHEM J, V132, P223, DOI 10.1042/bj1320223; BOKVIST K, 1991, P ROY SOC B-BIOL SCI, V243, P139, DOI 10.1098/rspb.1991.0022; COOK DL, 1984, NATURE, V311, P271, DOI 10.1038/311271a0; DETIMARY P, 1994, BIOCHEM J, V297, P455, DOI 10.1042/bj2970455; DETIMARY P, 1995, J CLIN INVEST, V96, P1738, DOI 10.1172/JCI118219; DUNNE MJ, 1989, EMBO J, V8, P413, DOI 10.1002/j.1460-2075.1989.tb03392.x; DUNNE MJ, 1991, BIOCHIM BIOPHYS ACTA, V1071, P67, DOI 10.1016/0304-4157(91)90012-L; DUNNE MJ, 1986, PFLUG ARCH EUR J PHY, V407, P564, DOI 10.1007/BF00657518; ERECINSKA M, 1992, BIOCHIM BIOPHYS ACTA, V1101, P273, DOI 10.1016/0167-4838(92)90555-R; FINDLAY I, 1987, J PHYSIOL-LONDON, V391, P611, DOI 10.1113/jphysiol.1987.sp016759; FRANKLIN TJ, 1969, BIOCHEM J, V113, P515, DOI 10.1042/bj1130515; GEMBAL M, 1993, J CLIN INVEST, V91, P871, DOI 10.1172/JCI116308; GEMBAL M, 1992, J CLIN INVEST, V89, P1288, DOI 10.1172/JCI115714; GHOSH A, 1991, J BIOL CHEM, V266, P22887; HAMMPP R, 1986, METHOD ENZYMAT AN, P870; HELLMAN B, 1969, DIABETES, V18, P509, DOI 10.2337/diab.18.8.509; HENQUIN JC, 1994, JOSLINS DIABETES MEL, P56; HIGASHIJIMA T, 1990, J BIOL CHEM, V265, P14176; HOENIG M, 1987, METABOLISM, V36, P295, DOI 10.1016/0026-0495(87)90192-2; HOPKINS WF, 1992, J MEMBRANE BIOL, V129, P287; JONAS JC, 1994, BIOCHEM J, V301, P523, DOI 10.1042/bj3010523; JONES PM, 1993, MOL CELL ENDOCRINOL, V94, P97, DOI 10.1016/0303-7207(93)90056-P; KARL DM, 1978, METHOD ENZYMOL, V57, P85; KOCH G, 1992, BIOCHEM BIOPH RES CO, V186, P448, DOI 10.1016/S0006-291X(05)80828-9; KOMATSU M, 1993, J BIOL CHEM, V268, P23297; KONRAD RJ, 1995, J BIOL CHEM, V270, P12869, DOI 10.1074/jbc.270.21.12869; KOWLURU A, 1994, BIOCHEMISTRY-US, V33, P12495, DOI 10.1021/bi00207a017; MACDONALD MJ, 1990, DIABETES, V39, P1461, DOI 10.2337/diabetes.39.12.1461; MALAISSE WJ, 1979, DIABETOLOGIA, V16, P331, DOI 10.1007/BF01223623; MEGLASSON M D, 1986, Diabetes Metabolism Reviews, V2, P163; MEGLASSON MD, 1989, METABOLISM, V38, P1188, DOI 10.1016/0026-0495(89)90158-3; MEREDITH M, 1995, J CLIN INVEST, V96, P811, DOI 10.1172/JCI118127; METZ SA, 1992, J BIOL CHEM, V267, P12517; MISLER S, 1992, DIABETES, V41, P1221, DOI 10.2337/diabetes.41.10.1221; NEWGARD CB, 1995, ANNU REV BIOCHEM, V64, P689, DOI 10.1146/annurev.biochem.64.1.689; NICHOLS CG, 1990, J PHYSIOL-LONDON, V423, P91, DOI 10.1113/jphysiol.1990.sp018013; OHTA M, 1990, J BIOL CHEM, V265, P17525; RAMANADHAM S, 1993, BIOCHEMISTRY-US, V32, P337, DOI 10.1021/bi00052a042; RAMANADHAM S, 1994, BIOCHEMISTRY-US, V33, P7442, DOI 10.1021/bi00189a052; SATO Y, 1992, DIABETES, V41, P438, DOI 10.2337/diabetes.41.4.438; SCHWANSTECHER C, 1994, BRIT J PHARMACOL, V111, P302, DOI 10.1111/j.1476-5381.1994.tb14060.x; SCHWANSTECHER C, 1992, BRIT J PHARMACOL, V107, P87, DOI 10.1111/j.1476-5381.1992.tb14467.x; Sokal R. R., 1969, BIOMETRY PRINCIPLES, P1; VALLAR L, 1987, J BIOL CHEM, V262, P5049; VINCENT MF, 1991, DIABETES, V40, P1259, DOI 10.2337/diabetes.40.10.1259; ZAWALICH WS, 1990, MOL CELL ENDOCRINOL, V70, P119, DOI 10.1016/0303-7207(90)90152-X; ZUNKLER BJ, 1986, IRCS MED SCI-BIOCHEM, V14, P354	50	112	113	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20559	20565		10.1074/jbc.271.34.20559	http://dx.doi.org/10.1074/jbc.271.34.20559			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702800	hybrid			2022-12-25	WOS:A1996VD33700052
J	Limbourg, FP; Stadtler, H; Chinnadurai, G; Baeuerle, PA; Schmitz, ML				Limbourg, FP; Stadtler, H; Chinnadurai, G; Baeuerle, PA; Schmitz, ML			A hydrophobic region within the adenovirus E1B 19 kDa protein is necessary for the transient inhibition of NF-kappa B activated by different stimuli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; P53-MEDIATED TRANSCRIPTIONAL REPRESSION; 19-KILODALTON PROTEIN; CELL-TRANSFORMATION; TARGETED DISRUPTION; BCL-2 PROTEINS; MICE LACKING; FACTOR-ALPHA; LP+ LOCUS; DNA	The early transcribed adenovirus proteins E1A and E1B display a variety of functions in the transformation of primary rodent cells and the regulation of apoptosis and transcription. We have recently shown recently that the E1B 19 kDa protein from Adenovirus 5 (Ad 5) can functionally antagonize the stimulatory effect of E1A 13S on the human transcription factor NF-kappa B. Here we show that expression of E1B 19 kDa negatively interfered with the activation of NF-kappa B by different stimuli, such as the E1A 13S protein, and treatment with phorbol ester and tumor necrosis factor alpha. This suggests that E1B 19 kDa acts on a common upstream signaling event. Band shift experiments showed that expression of E1B 19 kDa impaired the generation of the nuclear, DNA-binding form of NF-kappa B. Domain mapping experiments employing various E1B 19 kDa mutants revealed the necessity of a hydrophobic Bcl-2 homology region between amino acids 90 and 96 for NF-kappa B inhibition. Cotransfection experiments showed that the inhibitory effect of E1B 19 kDa on E1A 13S-activated NF-kappa B transcription was gradually lost in the course of time. Thus the continuous stimulatory action of E1A 13S can finally override the antagonistic effects of E1B 19 kDa on NF-kappa B activity. In contrast to E1B 19 kDa, expression of the E1B 55 kDa protein did not result in a de novo activation of NF-kappa B, but co-stimulated the transcriptional potential of activated NF-kappa B.	UNIV FREIBURG, INST BIOCHEM & MOL BIOL, D-79104 FREIBURG, GERMANY; ST LOUIS UNIV, HLTH SCI CTR, INST MOL VIROL, ST LOUIS, MO 63110 USA; TULARIK INC, San Francisco, CA 94080 USA	University of Freiburg; Saint Louis University			Limbourg, Florian/AAF-5010-2019; Schmitz, M. Lienhard/D-9328-2017	Limbourg, Florian/0000-0002-8313-7226; Schmitz, M. Lienhard/0000-0002-6984-7192	NCI NIH HHS [R01 CA033616] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA033616] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akusjarvi G, 1993, Trends Microbiol, V1, P163, DOI 10.1016/0966-842X(93)90085-6; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BEG AA, 1995, GENE DEV, V9, P2736, DOI 10.1101/gad.9.22.2736; BERGMAN Y, 1988, J IMMUNOL, V140, P2073; BOYD JM, 1994, CELL, V79, P341, DOI 10.1016/0092-8674(94)90202-X; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHINNADURAI G, 1983, CELL, V33, P759, DOI 10.1016/0092-8674(83)90018-1; CHIOU SK, 1994, J VIROL, V68, P6553, DOI 10.1128/JVI.68.10.6553-6566.1994; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DERYCKERE F, 1995, IMMUNOBIOLOGY, V193, P186, DOI 10.1016/S0171-2985(11)80542-5; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; Eick D, 1996, TRENDS GENET, V12, P4, DOI 10.1016/0168-9525(96)81374-6; EVANS AS, 1958, AM J HYG, V67, P256, DOI 10.1093/oxfordjournals.aje.a119932; EZOE H, 1981, J VIROL, V40, P20, DOI 10.1128/JVI.40.1.20-27.1981; FOX JP, 1977, AM J EPIDEMIOL, V105, P362, DOI 10.1093/oxfordjournals.aje.a112394; GOODING LR, 1991, J VIROL, V65, P3083, DOI 10.1128/JVI.65.6.3083-3094.1991; GREEN M, 1983, J VIROL, V48, P604, DOI 10.1128/JVI.48.3.604-615.1983; GRILLI M, 1993, INT REV CYTOL, V143, P1; GRIMM S, 1996, IN PRESS J CELL BIOL; HASHIMOTO S, 1991, INT IMMUNOL, V3, P343, DOI 10.1093/intimm/3.4.343; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; ISRAEL A, 1995, TRENDS GENET, V11, P203, DOI 10.1016/S0168-9525(00)89045-9; ISRAEL N, 1992, J IMMUNOL, V149, P3386; KONTGEN F, 1995, GENE DEV, V9, P1965, DOI 10.1101/gad.9.16.1965; LIN KI, 1995, J CELL BIOL, V131, P1149, DOI 10.1083/jcb.131.5.1149; LIU F, 1994, NATURE, V368, P520, DOI 10.1038/368520a0; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; NGUYEN M, 1994, J BIOL CHEM, V269, P16521; PELLEGRINI S, 1993, TRENDS BIOCHEM SCI, V18, P338, DOI 10.1016/0968-0004(93)90070-4; PIERCE JW, 1988, P NATL ACAD SCI USA, V85, P1482, DOI 10.1073/pnas.85.5.1482; PILDER S, 1984, J VIROL, V52, P664, DOI 10.1128/JVI.52.2.664-671.1984; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; SABBATINI P, 1995, MOL CELL BIOL, V15, P1060; SCHMIDT KN, 1995, CHEM BIOL, V2, P13, DOI 10.1016/1074-5521(95)90076-4; Schmitz ML, 1995, TOXICOL LETT, V82-3, P407, DOI 10.1016/0378-4274(95)03491-9; SCHMITZ ML, 1995, NATO ASI SER H, V92, P279; SCHMITZ ML, 1996, IN PRESS MOL CELL BI; SCHOLER HR, 1991, CELL, V66, P291, DOI 10.1016/0092-8674(91)90619-A; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SHA WC, 1995, CELL, V80, P321, DOI 10.1016/0092-8674(95)90415-8; SHEN YQ, 1994, P NATL ACAD SCI USA, V91, P8940, DOI 10.1073/pnas.91.19.8940; Subramanian T, 1995, ONCOGENE, V11, P2403; SUBRAMANIAN T, 1984, J BIOL CHEM, V259, P1777; SUBRAMANIAN T, 1993, GENE, V124, P173, DOI 10.1016/0378-1119(93)90391-F; SUBRAMANIAN T, 1984, J VIROL, V52, P336, DOI 10.1128/JVI.52.2.336-343.1984; TARODI B, 1993, INT J ONCOL, V3, P467; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; WEIGEL RJ, 1990, P NATL ACAD SCI USA, V87, P9878, DOI 10.1073/pnas.87.24.9878; WEIH F, 1995, CELL, V80, P331, DOI 10.1016/0092-8674(95)90416-6; WESTENDORP MO, 1995, EMBO J, V14, P546, DOI 10.1002/j.1460-2075.1995.tb07030.x; WHITE E, 1994, NATURE, V371, P21, DOI 10.1038/371021a0; WHITE E, 1990, MOL CELL BIOL, V10, P120, DOI 10.1128/MCB.10.1.120; WHITE E, 1992, MOL CELL BIOL, V12, P2570, DOI 10.1128/MCB.12.6.2570; WHITE E, 1984, J VIROL, V52, P410, DOI 10.1128/JVI.52.2.410-419.1984; WHITE E, 1993, P SOC EXP BIOL MED, V204, P30; WHITE E, 1984, MOL CELL BIOL, V4, P2865, DOI 10.1128/MCB.4.12.2865; WOLD WSM, 1991, VIROLOGY, V184, P1, DOI 10.1016/0042-6822(91)90815-S; WONG GHW, 1986, NATURE, V323, P819, DOI 10.1038/323819a0; YEW PR, 1994, GENE DEV, V8, P190, DOI 10.1101/gad.8.2.190; ZABEL U, 1993, EMBO J, V12, P201, DOI 10.1002/j.1460-2075.1993.tb05646.x	65	11	11	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20392	20398		10.1074/jbc.271.34.20392	http://dx.doi.org/10.1074/jbc.271.34.20392			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702775	hybrid			2022-12-25	WOS:A1996VD33700027
J	Orlowski, J; Kandasamy, RA				Orlowski, J; Kandasamy, RA			Delineation of transmembrane domains of the Na+/H+ exchanger that confer sensitivity to pharmacological antagonists	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT NA/H EXCHANGER; MOLECULAR-CLONING; H+ EXCHANGER; FUNCTIONAL EXPRESSION; AMILORIDE INHIBITION; CARDIAC ISCHEMIA; ISOFORM NHE-2; ANTIPORTER; MEMBRANE; CELLS	Plasma membrane Na+/H+ exchanger (NHE) isoforms NNE1 and NHE3 exhibit very different sensitivities to amiloride and its 5-amino-substituted analogues, benzoyl guanidinium derivatives (e.g. (3-methylsulfonyl-4-piperidinobenzoyl)guanidine methanesulfonate (HOE-694)), and cimetidine. To define structural domains that confer differential sensitivity to these antagonists, unique restriction endonuclease sites were engineered into cDNAs for each isoform near the regions that encode the putative membrane-spanning domains. These new sites did not modify their pharmacological properties and allowed several chimeric Na+/H+ exchangers to be constructed by exchanging homologous segments. The modified parental (E1(+) and E3(+)) and chimeric molecules were stably expressed in exchanger-deficient. Chinese hamster ovary AP-1 cells and assayed for their sensitivities to amiloride, ethylisopropylamiloride, HOE694, and cimetidine. Most chimeras showed drug sensitivities corresponding to the dominant parental segment. However, interchanging a 66-amino acid segment containing the putative ninth transmembrane (M9) domain and its adjacent loops caused reciprocal alterations in the sensitivities of E1' and E3' to all antagonists, In addition, substituting the first five putative membrane-spanning domains of E3' with the corresponding region of E1' modestly reduced the transporter's sensitivity to cimetidine but not the other compounds, These data indicate that the protein segment between M8 and M10 mag be a major site of interaction with these antagonists, although other regions modestly influence sensitivity to certain drugs.			Orlowski, J (corresponding author), MCGILL UNIV,DEPT PHYSIOL,MCINTYRE MED SCI BLDG,3655 DRUMMOND ST,MONTREAL,PQ H3G 1Y6,CANADA.			Orlowski, John/0000-0001-7371-175X				BORON WF, 1976, J GEN PHYSIOL, V67, P91, DOI 10.1085/jgp.67.1.91; Cabado AG, 1996, J BIOL CHEM, V271, P3590; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COUNILLON L, 1993, MOL PHARMACOL, V44, P1041; COUNILLON L, 1993, P NATL ACAD SCI USA, V90, P4508, DOI 10.1073/pnas.90.10.4508; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; FAFOURNOUX P, 1994, J BIOL CHEM, V269, P2589; FRANCHI A, 1986, P NATL ACAD SCI USA, V83, P9388, DOI 10.1073/pnas.83.24.9388; FRANCHI A, 1986, J BIOL CHEM, V261, P4614; GANAPATHY V, 1986, J PHARMACOL EXP THER, V239, P192; GRINSTEIN S, 1989, BIOCHIM BIOPHYS ACTA, V988, P73, DOI 10.1016/0304-4157(89)90004-X; HARPER IS, 1993, BASIC RES CARDIOL, V88, P430, DOI 10.1007/BF00795410; IVES HE, 1983, J BIOL CHEM, V258, P9710; KINSELLA JL, 1981, AM J PHYSIOL, V241, pF374, DOI 10.1152/ajprenal.1981.241.4.F374; KLANKE CA, 1995, GENOMICS, V25, P615, DOI 10.1016/0888-7543(95)80002-4; KLEYMAN TR, 1988, J MEMBRANE BIOL, V105, P1, DOI 10.1007/BF01871102; LALLEMAIN G, 1984, J BIOL CHEM, V259, P4313; MAHNENSMITH RL, 1985, J BIOL CHEM, V260, P2586; MAHNENSMITH RL, 1985, CIRC RES, V56, P773, DOI 10.1161/01.RES.56.6.773; MORDUCHOWICZ GA, 1989, KIDNEY INT, V36, P576, DOI 10.1038/ki.1989.233; NOEL J, 1995, AM J PHYSIOL-CELL PH, V268, pC283, DOI 10.1152/ajpcell.1995.268.2.C283; ORLOWSKI J, 1992, J BIOL CHEM, V267, P9331; ORLOWSKI J, 1993, J BIOL CHEM, V268, P16369; PARIS S, 1983, J BIOL CHEM, V258, P3503; ROTIN D, 1989, AM J PHYSIOL, V257, pC1158, DOI 10.1152/ajpcell.1989.257.6.C1158; SARDET C, 1989, CELL, V56, P271, DOI 10.1016/0092-8674(89)90901-X; SCHOLZ W, 1995, CARDIOVASC RES, V29, P260, DOI 10.1016/S0008-6363(96)88579-8; SCHOLZ W, 1993, BRIT J PHARMACOL, V109, P562, DOI 10.1111/j.1476-5381.1993.tb13607.x; TSE CM, 1991, EMBO J, V10, P1957, DOI 10.1002/j.1460-2075.1991.tb07725.x; TSE CM, 1992, J BIOL CHEM, V267, P9340; TSE CM, 1993, J BIOL CHEM, V268, P11917; WANG DH, 1995, AM J PHYSIOL-CELL PH, V269, pC392, DOI 10.1152/ajpcell.1995.269.2.C392; WANG Z, 1993, J BIOL CHEM, V268, P11925; WARNOCK DG, 1988, J BIOL CHEM, V263, P7216; YU FH, 1993, J BIOL CHEM, V268, P25536; YUN CHC, 1993, BIOCHEM BIOPH RES CO, V193, P532, DOI 10.1006/bbrc.1993.1656; YUN CHC, 1995, AM J PHYSIOL-GASTR L, V269, pG1, DOI 10.1152/ajpgi.1995.269.1.G1	37	92	94	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					19922	19927		10.1074/jbc.271.33.19922	http://dx.doi.org/10.1074/jbc.271.33.19922			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702706	hybrid			2022-12-25	WOS:A1996VC66900047
J	Pohlschroder, M; Murphy, C; Beckwith, J				Pohlschroder, M; Murphy, C; Beckwith, J			In vivo analyses of interactions between SecE and SecY, core components of the Escherichia coli protein translocation machinery	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-PROTEINS; SIGNAL-SEQUENCE; PREPROTEIN TRANSLOCASE; EXPORT; RECONSTITUTION; MUTATIONS; GENE; DETERMINANTS; TEMPERATURE; SUFFICIENT	We have carried out structure-function studies on the cytoplasmic membrane protein, SecE, a component of the Escherichia coli secretion machinery. SecE, along with SecY, form a complex in the cytoplasmic membrane essential for protein translocation. By directed mutagenesis, we altered highly conserved residues of the second cytoplasmic domain (CD2) and of the COOH-terminaI periplasmic region (PD2) of SecE. These mutants, as well as previously constructed mutations in the third membrane-spanning segment of SecE (MSS3), were tested for their ability to complement a secE null mutation, for their effects on protein export in vivo, and for their ability to form a stable complex with SecY. Most single mutations at the conserved positions in CD2 caused secretion defects, but had Little effect on growth at 37 degrees C. Double mutations in CD2, or the introduction Or removal of proline residues, affected growth and protein translocation more severely. Co-immunoprecipitations of SecE and SecY revealed that all mutant proteins, except those altered in PD2, destabilized the SecE-SecY complex. These results suggest that several regions contribute to the formation of a stable SecE-SecY complex but the elimination of a single contact point does not necessarily affect the functionality of the complex.	HARVARD UNIV,SCH MED,DEPT MICROBIOL & MOL GENET,BOSTON,MA 02115; MYCO PHARMACEUT,CAMBRIDGE,MA 02139	Harvard University; Harvard Medical School			Pohlschroder, Mechy/P-3206-2019					AKIMARU J, 1991, P NATL ACAD SCI USA, V88, P6545, DOI 10.1073/pnas.88.15.6545; AKIYAMA Y, 1987, EMBO J, V6, P3465, DOI 10.1002/j.1460-2075.1987.tb02670.x; BABA T, 1994, P NATL ACAD SCI USA, V91, P4539, DOI 10.1073/pnas.91.10.4539; BEDOUELLE H, 1980, NATURE, V285, P78, DOI 10.1038/285078a0; BLOBEL G, 1975, J CELL BIOL, V67, P835, DOI 10.1083/jcb.67.3.835; BOST S, 1995, EMBO J, V14, P4412, DOI 10.1002/j.1460-2075.1995.tb00120.x; BOYD D, 1990, CELL, V62, P1031, DOI 10.1016/0092-8674(90)90378-R; BOYD D, 1987, P NATL ACAD SCI USA, V84, P8525, DOI 10.1073/pnas.84.23.8525; BRUNDAGE L, 1990, CELL, V62, P649, DOI 10.1016/0092-8674(90)90111-Q; BRUNDAGE L, 1992, J BIOL CHEM, V267, P4166; CASADABAN MJ, 1976, J MOL BIOL, V104, P541, DOI 10.1016/0022-2836(76)90119-4; EMR SD, 1981, CELL, V23, P79, DOI 10.1016/0092-8674(81)90272-5; ESNAULT Y, 1994, J BIOL CHEM, V269, P27478; FLOWER AM, 1995, EMBO J, V14, P884, DOI 10.1002/j.1460-2075.1995.tb07070.x; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; GUZMAN LM, 1992, J BACTERIOL, V174, P7717; HANADA M, 1994, J BIOL CHEM, V269, P23625; HARTMANN E, 1993, EUR J BIOCHEM, V214, P375, DOI 10.1111/j.1432-1033.1993.tb17933.x; HARTMANN E, 1994, NATURE, V367, P954; INOUYE H, 1977, P NATL ACAD SCI USA, V74, P1440, DOI 10.1073/pnas.74.4.1440; INOUYE S, 1977, P NATL ACAD SCI USA, V74, P1004, DOI 10.1073/pnas.74.3.1004; ITO K, 1983, CELL, V32, P789, DOI 10.1016/0092-8674(83)90065-X; JOLY JC, 1994, P NATL ACAD SCI USA, V91, P4703, DOI 10.1073/pnas.91.11.4703; MATSUYAMA S, 1990, FEBS LETT, V269, P96, DOI 10.1016/0014-5793(90)81128-B; MEACOCK PA, 1980, CELL, V20, P529, DOI 10.1016/0092-8674(80)90639-X; Miller J.H., 1972, EXPT MOL GENETICS; MILLER JD, 1994, NATURE, V367, P657, DOI 10.1038/367657a0; MURPHY C, 1996, COLD SPRING HARB SYM, V60, P277; MURPHY CK, 1994, P NATL ACAD SCI USA, V91, P2557, DOI 10.1073/pnas.91.7.2557; MURPHY CK, 1995, GENE, V155, P1, DOI 10.1016/0378-1119(94)00920-N; NISHIYAMA K, 1992, J BIOL CHEM, V267, P7170; NISHIYAMA K, 1994, EMBO J, V13, P3272, DOI 10.1002/j.1460-2075.1994.tb06628.x; PANZNER S, 1995, CELL, V81, P561, DOI 10.1016/0092-8674(95)90077-2; POGLIANO JA, 1994, EMBO J, V13, P554, DOI 10.1002/j.1460-2075.1994.tb06293.x; POGLIANO KJ, 1993, GENETICS, V133, P763; Sambrook J., 2002, MOL CLONING LAB MANU; SCHATZ PJ, 1991, EMBO J, V10, P1749, DOI 10.1002/j.1460-2075.1991.tb07699.x; SCHATZ PJ, 1989, GENE DEV, V3, P1035, DOI 10.1101/gad.3.7.1035; SIMON SM, 1992, CELL, V69, P677, DOI 10.1016/0092-8674(92)90231-Z; STADER J, 1989, GENE DEV, V3, P1045, DOI 10.1101/gad.3.7.1045; TAURA T, 1993, J BACTERIOL, V175, P7771, DOI 10.1128/JB.175.24.7771-7775.1993; Traxler B, 1996, J BIOL CHEM, V271, P12394, DOI 10.1074/jbc.271.21.12394; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; WOLIN SL, 1994, CELL, V77, P787, DOI 10.1016/0092-8674(94)90124-4	44	40	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					19908	19914		10.1074/jbc.271.33.19908	http://dx.doi.org/10.1074/jbc.271.33.19908			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702704	hybrid			2022-12-25	WOS:A1996VC66900045
J	Dong, F; vonHippel, PH				Dong, F; vonHippel, PH			The ATP-activated hexameric helicase of bacteriophage T4 (gp41) forms a stable primosome with a single subunit of T4-coded primase (gp61)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA PRIMER SYNTHESIS; DNA-REPLICATION SYSTEM; LEADING-STRAND; NUCLEOTIDE-BINDING; EXPRESSED PROTEIN; ASSEMBLY PROTEIN; GENE-41 PROTEIN; PURIFICATION; T4-61-PROTEIN; T4-41-PROTEIN	We have examined the formation of the primosome subassembly of the bacteriophage T4-coded DNA replication (elongation) complex from its helicase, primase, and DNA components, Previously, we had shown that the T4 helicase (gp41) exists in solution in a stable monomer <--> dimer equilibrium at physiological protein (and salt) concentrations and forms a hexamer upon activation by ATP (or GTP) binding (Dong, F., Gogol, E. P., and von Hippel, P. H. (1995) J. Biol. Chem. 270, 7462-7473), Here we report that the T4 primase (gp61) is a monomer in solution under the same conditions, and that the ATP-activated helicase binds to a single gp61 primase molecule on appropriate DNA templates to reconstitute a stable primosome. We show that: (i) the gp41 helicase alone does not form a stable complex with DNA templates, although this helicase by itself can carry out moderately processive ATP-driven translocation along single-stranded DNA (Young, M. C., Schultz, D. E., Ring, D., and von Hippel, P. H. (1994) J. Mel. Biol. 235, 1447-1458); (ii) the primase alone does form a stable complex with DNA; (iii) the helicase can bind to the primase-DNA complex in the presence of ATP or GTP to form a stable ternary complex; (iv) this complex consists of six helicase subunits and one primase subunit; and (v) the reconstituted primosome is stable for at least 10 to 20 min after NTP cleavage and dissociation of the hydrolysis products, These results strongly suggest that the functional T4 DNA replication primosome consists of an integrated 6:1 helicase-primase complex bound to DNA, and that the ATP-activated helicase hexamer remains intact throughout the processive DNA replication process.	UNIV OREGON,INST MOL BIOL,EUGENE,OR 97403; UNIV OREGON,DEPT CHEM,EUGENE,OR 97403	University of Oregon; University of Oregon				von Hippel, Peter H./0000-0003-2512-8097	NIGMS NIH HHS [GM-29158, GM-15792] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM015792, R01GM029158, R01GM015792] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; ALBERTS BM, 1987, PHILOS T ROY SOC B, V317, P395, DOI 10.1098/rstb.1987.0068; BARRY J, 1994, J BIOL CHEM, V269, P33049; CHA TA, 1986, J BIOL CHEM, V261, P7001; CHA TA, 1990, BIOCHEMISTRY-US, V29, P1791, DOI 10.1021/bi00459a018; CHA TA, 1988, CANCER CELL, V6, P1; DONG F, 1995, J BIOL CHEM, V270, P7462, DOI 10.1074/jbc.270.13.7462; HINTON DM, 1985, J BIOL CHEM, V260, P2851; HINTON DM, 1987, J BIOL CHEM, V262, P10873; HINTON DM, 1985, J BIOL CHEM, V260, P2858; Kornberg A., 1992, DNA REPLICATION; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LECHNER RL, 1983, J BIOL CHEM, V258, P1185; LIU CC, 1980, P NATL ACAD SCI-BIOL, V77, P5698, DOI 10.1073/pnas.77.10.5698; LIU CC, 1981, J BIOL CHEM, V256, P2821; MENDELMAN LV, 1993, J BIOL CHEM, V268, P27208; MORRICAL SW, 1994, J BIOL CHEM, V269, P33069; Nossal Nancy G., 1994, P43; NOSSAL NG, 1987, J BIOL CHEM, V262, P10879; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; PATEL SS, 1995, BIOPHYS J, V68, pS186; RICHARDSON RW, 1989, J BIOL CHEM, V264, P4725; RICHARDSON RW, 1989, J BIOL CHEM, V264, P4732; SPACCIAPOLI P, 1994, J BIOL CHEM, V269, P447; Weber K., 1975, PROTEINS, VI, P179; YOUNG MC, 1994, J MOL BIOL, V235, P1447, DOI 10.1006/jmbi.1994.1100	26	45	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19625	19631		10.1074/jbc.271.32.19625	http://dx.doi.org/10.1074/jbc.271.32.19625			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702659	hybrid			2022-12-25	WOS:A1996VB68400093
J	Tyedmers, J; Brunke, M; Lechte, M; Sandholzer, U; Dierks, T; Schlotterhose, P; Schmidt, B; Zimmermann, R				Tyedmers, J; Brunke, M; Lechte, M; Sandholzer, U; Dierks, T; Schlotterhose, P; Schmidt, B; Zimmermann, R			Efficient folding of firefly luciferase after transport into mammalian microsomes in the absence of luminal chaperones and folding catalysts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; MOLECULAR CHAPERONES; PRESECRETORY PROTEINS; TRANSLOCATION; IMMUNOPHILINS; MEMBRANE; CELL; ATP	Folding of polypeptides emerging from the protein translocase in the membrane of mammalian microsomes was analyzed after synthesis of corresponding precursor proteins in a mammalian translation system. Firefly luciferase was used as a model protein; the corresponding hybrid precursor contained the preprolactin signal peptide. The rates and efficiencies of folding of luciferase in microsomes were compared with those of folding of luciferase in the cytosol. Furthermore, folding of luciferase in microsomes was compared with that in proteoliposomes, i.e. in the absence of luminal molecular chaperones and folding catalysts. Folding in microsomes was less efficient compared with folding in the cytosol. Folding in the absence of luminal proteins was more efficient compared with folding in their presence and identical to folding in the cytosol. Thus, firefly luciferase emerging from translocase can efficiently fold to its native conformation without chaperoning by any luminal proteins. There may be molecular chaperones present in the microsomal membrane that can efficiently substitute for the cytosolic chaperone machinery comprising Hsp40, Hsp60, and Hsp70 with respect to folding of firefly luciferase.	UNIV SAARLAND,D-66421 HOMBURG,GERMANY; UNIV GOTTINGEN,INST BIOCHEM & MOL ZELLBIOL,D-37073 GOTTINGEN,GERMANY	Saarland University; University of Gottingen			Dierks, Thomas/A-3596-2012	Dierks, Thomas/0000-0001-6426-1339				BERGERON JJM, 1994, TRENDS BIOCHEM SCI, V19, P124, DOI 10.1016/0968-0004(94)90205-4; CLAIRMONT CA, 1992, J BIOL CHEM, V267, P3983; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; FRYDMAN J, 1994, NATURE, V370, P111, DOI 10.1038/370111a0; GEORGOPOULOS C, 1993, ANNU REV CELL BIOL, V9, P601, DOI 10.1146/annurev.cb.09.110193.003125; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GORLICH D, 1993, CELL, V75, P615, DOI 10.1016/0092-8674(93)90483-7; HARTL FU, 1994, TRENDS BIOCHEM SCI, V19, P20, DOI 10.1016/0968-0004(94)90169-4; HELENIUS A, 1994, TRENDS BIOCHEM SCI, V19, P227; KENDALL RL, 1990, METHOD ENZYMOL, V185, P398; KLAPPA P, 1991, EMBO J, V10, P2795, DOI 10.1002/j.1460-2075.1991.tb07828.x; KOLB VA, 1994, EMBO J, V13, P3631, DOI 10.1002/j.1460-2075.1994.tb06670.x; KRUSE M, 1995, J BIOL CHEM, V270, P2588, DOI 10.1074/jbc.270.6.2588; KUNZ J, 1993, TRENDS BIOCHEM SCI, V18, P334, DOI 10.1016/0968-0004(93)90069-Y; MARQUARDT T, 1993, J BIOL CHEM, V268, P19618; SCHLENSTEDT G, 1990, J BIOL CHEM, V265, P13960; SCHLENSTEDT G, 1992, J BIOL CHEM, V267, P24328; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904	18	12	12	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19509	19513		10.1074/jbc.271.32.19509	http://dx.doi.org/10.1074/jbc.271.32.19509			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702642	hybrid			2022-12-25	WOS:A1996VB68400076
J	Biesiada, E; Razandi, M; Levin, ER				Biesiada, E; Razandi, M; Levin, ER			Egr-1 activates basic fibroblast growth factor transcription - Mechanistic implications for astrocyte proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM RESPONSE ELEMENTS; COLONY-STIMULATING FACTOR; TERNARY COMPLEX FACTORS; DNA-BINDING DOMAINS; RAT MESANGIAL CELLS; TUMOR GENE-PRODUCT; RNA POLYMERASE-II; PROTEIN-KINASE-C; EXPRESSION; PROMOTER	The mechanisms controlling the proliferation of astrocytes are of great interest but are not well defined, We have previously shown that the endogenous neuropeptides, endothelin-3 (ET-3), and atrial natriuretic peptide (ANP), modulate the proliferation of astrocytes through positively and negatively regulating the transcription of the immediate-early gene egr-1 which transactivates basic fibroblast growth factor (bFGF) by unknown mechanisms, In these studies, we determined the involvement of MAP kinase (Erk) activation by ET-3 in the transcription of egr-1, and the molecular determinants by which Egr-1 transactivates bFGF. Transfection of astrocytes with a mitogen-activated protein (MAP) kinase (MAPK) expression vector increased the transcription of a cotransfected egr-chloramphenicol acetyltransferase (CAT) construct 3-fold, This induction was totally abolished by a dominant negative MAPK mutant, A 3-fold induction of egr-CAT expression by ET-3 was significantly reduced by treatment with ANP, or a cotransfected dominant negative MAPK plasmid, Using mobility shift assays, we showed that ET-3 induced the expression of Egr-1 protein which bound specifically to several early growth-related protein (Egr-1) binding sites on the bFGF promoter, and that this effect was significantly reversed by treatment with ANP, We also found that the Spl transcriptional factor was bound at these same sites, but was not stimulated by ET-3, Deletion experiments indicated that only the site at -160 bp of the bFGF promoter was significant for bFGF transactivation by Egr-1, We conclude that the astrocyte mitogen, ET-3, stimulates egr-1 transcription through a MAP kinase (Erk) related mechanism, and that Egr-1 transactivates bFGF through a specific noncanonical, Egr-1 site on the promoter. ANP inhibits each of these steps, providing a pathway for its anti-proliferative action.	VET AFFAIRS MED CTR, MED SERV 111I, LONG BEACH, CA 90822 USA; UNIV CALIF IRVINE, DEPT MED, IRVINE, CA 92716 USA; UNIV CALIF IRVINE, DEPT PHARMACOL, IRVINE, CA 92716 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Long Beach Healthcare System; University of California System; University of California Irvine; University of California System; University of California Irvine			Levin, Ellis/J-5402-2013		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050161] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030521] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-50161] Funding Source: Medline; NINDS NIH HHS [NS-30521] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ACKERMAN SL, 1991, P NATL ACAD SCI USA, V88, P7523, DOI 10.1073/pnas.88.17.7523; ALEXANDROPOULOS K, 1992, NUCLEIC ACIDS RES, V20, P2355, DOI 10.1093/nar/20.9.2355; ARENANDER AT, 1989, J NEUROSCI RES, V24, P107, DOI 10.1002/jnr.490240115; BENO DWA, 1995, J BIOL CHEM, V270, P3642, DOI 10.1074/jbc.270.8.3642; CAO XM, 1990, MOL CELL BIOL, V10, P1931, DOI 10.1128/MCB.10.5.1931; CAO XM, 1993, J BIOL CHEM, V268, P16949; CAZAUBON S, 1993, BIOCHEM J, V293, P381, DOI 10.1042/bj2930381; CHRISTY B, 1989, P NATL ACAD SCI USA, V86, P8737, DOI 10.1073/pnas.86.22.8737; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; Cui MZ, 1996, J BIOL CHEM, V271, P2731, DOI 10.1074/jbc.271.5.2731; DEFRANCO C, 1993, MOL ENDOCRINOL, V7, P365, DOI 10.1210/me.7.3.365; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; Emoto N, 1989, GROWTH FACTORS, V2, P21, DOI 10.3109/08977198909069078; GASSER UE, 1990, J NEUROSCI, V10, P1276; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GILMAN MZ, 1986, MOL CELL BIOL, V6, P4305, DOI 10.1128/MCB.6.12.4305; HAMILTON TB, 1995, NUCLEIC ACIDS RES, V23, P277, DOI 10.1093/nar/23.2.277; HARRINGTON MA, 1993, J BIOL CHEM, V268, P21271; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; HIPSKIND RA, 1994, GENE DEV, V8, P1803, DOI 10.1101/gad.8.15.1803; HU RM, 1994, J CLIN INVEST, V93, P1820, DOI 10.1172/JCI117167; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KHARBANDA S, 1994, CELL GROWTH DIFFER, V5, P259; LEMAIRE P, 1988, P NATL ACAD SCI USA, V85, P4691, DOI 10.1073/pnas.85.13.4691; LEMAIRE P, 1990, MOL CELL BIOL, V10, P3456, DOI 10.1128/MCB.10.7.3456; LIM RW, 1987, ONCOGENE, V1, P263; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MCMAHON SB, 1995, MOL CELL BIOL, V15, P1086; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; MORRIS CHT, 1988, NUCLEIC ACIDS RES, V16, P8835, DOI 10.1093/nar/16.18.8835; MORRIS JF, 1991, ONCOGENE, V6, P2339; MURPHY PR, 1988, MOL ENDOCRINOL, V2, P1196, DOI 10.1210/mend-2-12-1196; NAKAGAMA H, 1995, MOL CELL BIOL, V15, P1489; NARDELLI J, 1991, NATURE, V349, P175, DOI 10.1038/349175a0; Prins BA, 1996, J BIOL CHEM, V271, P14156, DOI 10.1074/jbc.271.24.14156; PRINS BA, 1994, J BIOL CHEM, V269, P11938; QURESHI SA, 1991, J BIOL CHEM, V266, P10802; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; RUPPRECHT HD, 1993, AM J PHYSIOL, V265, pF351, DOI 10.1152/ajprenal.1993.265.3.F351; SAKAMOTO KM, 1994, MOL CELL BIOL, V14, P5975, DOI 10.1128/MCB.14.9.5975; Shibata F, 1991, GROWTH FACTORS, V4, P277, DOI 10.3109/08977199109043913; SHINGU T, 1994, J BIOL CHEM, V269, P32551; SHINODA H, 1989, SCIENCE, V245, P415, DOI 10.1126/science.2569236; SHUBEITA HE, 1990, J BIOL CHEM, V265, P20555; Simonson MS, 1996, J BIOL CHEM, V271, P77, DOI 10.1074/jbc.271.1.77; SKERKA C, 1995, J BIOL CHEM, V270, P22500, DOI 10.1074/jbc.270.38.22500; STACHOWIAK MK, 1994, J CELL BIOL, V127, P203, DOI 10.1083/jcb.127.1.203; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; TAKAHASHI JA, 1990, P NATL ACAD SCI USA, V87, P5710, DOI 10.1073/pnas.87.15.5710; THIEL G, 1994, J BIOL CHEM, V269, P15294; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; UEBA T, 1994, P NATL ACAD SCI USA, V91, P9009, DOI 10.1073/pnas.91.19.9009; WANG YZ, 1992, BIOCHEM J, V287, P589, DOI 10.1042/bj2870589; WANG ZY, 1992, J BIOL CHEM, V267, P21999; WOODWARD WR, 1992, J NEUROSCI, V12, P142	57	188	190	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18576	18581		10.1074/jbc.271.31.18576	http://dx.doi.org/10.1074/jbc.271.31.18576			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702507	hybrid			2022-12-25	WOS:A1996VB68300045
J	Hinz, M; Moore, MJ; Bindereif, A				Hinz, M; Moore, MJ; Bindereif, A			Domain analysis of human U5 RNA - Cap trimethylation, protein binding, and spliceosome assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; SMALL NUCLEAR RIBONUCLEOPROTEIN; YEAST PRP8 PROTEIN; SNRNP PROTEIN; SPLICING FACTOR; U2 SNRNP; SITE; SM; CONSERVATION; PURIFICATION	We have analyzed the sequence requirements of the human U5 RNA during small nuclear ribonucleoprotein (snRNP) and spliceosome assembly. A collection of mutant derivatives of the human U5 RNA gene was constructed in a U1 expression vector and transiently transfected in mammalian cells. Using immunoprecipitation and affinity selection assays, the cap trimethylation, the binding of Sm proteins and of the U5 snRNP-specific protein p220, as well as the assembly of the U4/U5/U6 triple snRNP and of spliceosomes were determined. By mutational analysis we were able to assign distinct functions to several structural elements of the human U5 RNA. Efficient binding of the Sm proteins requires the 3' stem-loop. Both the Sm protein-binding site and the 3' stem-loop are necessary for the formation of the trimethyl guanosine cap, consistent with Sm protein binding being a prerequisite for cap trimethylation. Specific elements of the U5 RNA 5' stem-loop contribute to efficient p220 association, in particular stem Ib. Interestingly, the highly conserved loop I appears to be a multifunctional element; in addition to its function in splice-site selection the 5' loop is involved in binding of p220 and in the assembly of the U4/U5/U6 triple snRNP. In sum, this mutational analysis has identified four functional domains of the human U5 RNA.	HUMBOLDT UNIV BERLIN, FAK MED, INST BIOCHEM, D-10117 BERLIN, GERMANY; BRANDEIS UNIV, DEPT BIOCHEM, WALTHAM, MA 02254 USA	Humboldt University of Berlin; Brandeis University			Hinz, Michael/HCI-0550-2022	Hinz, Michael/0000-0003-2611-4121				ACH RA, 1987, MOL CELL BIOL, V7, P2070, DOI 10.1128/MCB.7.6.2070; ANDERSON GJ, 1989, NATURE, V342, P819, DOI 10.1038/342819a0; BACH M, 1989, P NATL ACAD SCI USA, V86, P6038, DOI 10.1073/pnas.86.16.6038; BACH M, 1991, BIOCHIM BIOPHYS ACTA, V1088, P139, DOI 10.1016/0167-4781(91)90164-H; BARABINO SML, 1989, EMBO J, V8, P4171, DOI 10.1002/j.1460-2075.1989.tb08602.x; Baserga S., 1993, RNA WORLD, P359; BEHRENS SE, 1991, GENE DEV, V5, P1439, DOI 10.1101/gad.5.8.1439; BLACK DL, 1989, MOL CELL BIOL, V9, P3350, DOI 10.1128/MCB.9.8.3350; BRINGMANN P, 1983, EMBO J, V2, P1129, DOI 10.1002/j.1460-2075.1983.tb01557.x; CHENG SC, 1987, GENE DEV, V1, P1014, DOI 10.1101/gad.1.9.1014; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CORTES JJ, 1993, EMBO J, V12, P5181, DOI 10.1002/j.1460-2075.1993.tb06213.x; CROSS M, 1991, MOL CELL BIOL, V11, P5516, DOI 10.1128/MCB.11.11.5516; FRANK DN, 1994, MOL CELL BIOL, V14, P2180, DOI 10.1128/MCB.14.3.2180; GARCIABLANCO MA, 1990, P NATL ACAD SCI USA, V87, P3082, DOI 10.1073/pnas.87.8.3082; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; GUTHRIE C, 1988, ANNU REV GENET, V22, P387, DOI 10.1146/annurev.ge.22.120188.002131; HODGES PE, 1995, YEAST, V11, P337; JACKSON SP, 1988, MOL CELL BIOL, V8, P1067, DOI 10.1128/MCB.8.3.1067; JARMOLOWSKI A, 1993, EMBO J, V12, P223, DOI 10.1002/j.1460-2075.1993.tb05648.x; Kramer A., 1995, PREMRNA PROCESSING, P35; LEE KAW, 1988, GENE ANAL TECH, V5, P22, DOI 10.1016/0735-0651(88)90023-4; LOSSKY M, 1987, CELL, V51, P1019, DOI 10.1016/0092-8674(87)90588-5; LUHRMANN R, 1990, BIOCHIM BIOPHYS ACTA, V1087, P265, DOI 10.1016/0167-4781(90)90001-I; MACMILLAN AM, 1994, GENE DEV, V8, P3008, DOI 10.1101/gad.8.24.3008; MATTAJ IW, 1986, CELL, V46, P905, DOI 10.1016/0092-8674(86)90072-3; Moore M., 1993, RNA WORLD, P303; NEWMAN A, 1991, CELL, V65, P115, DOI 10.1016/0092-8674(91)90413-S; NEWMAN AJ, 1992, CELL, V68, P743, DOI 10.1016/0092-8674(92)90149-7; NILSEN TW, 1994, CELL, V78, P1, DOI 10.1016/0092-8674(94)90563-0; SEGAULT V, 1995, EMBO J, V14, P4010, DOI 10.1002/j.1460-2075.1995.tb00072.x; SHARP PA, 1994, CELL, V77, P805, DOI 10.1016/0092-8674(94)90130-9; SONTHEIMER EJ, 1993, SCIENCE, V262, P1989, DOI 10.1126/science.8266094; SPROAT BS, 1989, NUCLEIC ACIDS RES, V17, P3373, DOI 10.1093/nar/17.9.3373; TEIGELKAMP S, 1995, NUCLEIC ACIDS RES, V23, P320, DOI 10.1093/nar/23.3.320; TEIGELKAMP S, 1995, EMBO J, V14, P2602, DOI 10.1002/j.1460-2075.1995.tb07258.x; UMEN JG, 1995, GENE DEV, V9, P855, DOI 10.1101/gad.9.7.855; WEINER AM, 1993, CELL, V72, P161, DOI 10.1016/0092-8674(93)90654-9; WHITTAKER E, 1991, NUCLEIC ACIDS RES, V19, P5483, DOI 10.1093/nar/19.20.5483; WOLFF T, 1992, EMBO J, V11, P345, DOI 10.1002/j.1460-2075.1992.tb05057.x; WOLFF T, 1993, GENE DEV, V7, P1377, DOI 10.1101/gad.7.7b.1377; WU J, 1989, GENE DEV, V3, P1553, DOI 10.1101/gad.3.10.1553; WYATT JR, 1992, GENE DEV, V6, P2542, DOI 10.1101/gad.6.12b.2542; ZILLMANN M, 1988, MOL CELL BIOL, V8, P814, DOI 10.1128/MCB.8.2.814	44	16	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					19001	19007		10.1074/jbc.271.31.19001	http://dx.doi.org/10.1074/jbc.271.31.19001			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702566	hybrid			2022-12-25	WOS:A1996VB68300104
J	Kamata, T; Irie, A; Tokuhira, M; Takada, Y				Kamata, T; Irie, A; Tokuhira, M; Takada, Y			Critical residues of integrin alpha IIb subunit for binding of alpha IIb beta 3 (glycoprotein IIb-IIIa) to fibrinogen and ligand-mimetic antibodies (PAC-1, OP-G2, and LJ-CP3)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERCELLULAR-ADHESION MOLECULE-1; PLATELET INTEGRIN; GPIIB-IIIA; CELL-ADHESION; GAMMA-CHAIN; I-DOMAIN; ALPHA-2-BETA-1 VLA-2; RECOGNITION SITE; IIB/IIIA COMPLEX; BETA(3) INTEGRIN	Integrin alpha IIb beta 3 plays a critical role in platelet aggregation through its interaction with fibrinogen, Elucidation of the mechanisms of alpha IIb beta 3-fibrinogen interaction is critical to understanding hemostasis and thrombosis. Here we report that mutations of Gly-184, Tyr-189, Tyr-190, Phe-191, and Gly-193 within the predicted turn structure of the third amino-terminal repeat of alpha IIb significantly block binding of alpha IIb beta 3 to soluble fibrinogen. These mutations also block binding of alpha IIb beta 3 to ligand-mimetic monoclonal antibodies PAC-1, OP-G2, LJ-CP3, which have an RGD-related RYD sequence in their antigen-binding sites, These mutations do not significantly affect the expression of alpha IIb beta 3, in contrast to most of the natural alpha IIb mutations occurring in Glanzmann's thrombasthenic patients, The data suggest that these residues are critically involved in alpha IIb beta 3-ligand interactions.	Scripps Res Inst, DEPT VASC BIOL, LA JOLLA, CA 92037 USA; KEIO UNIV, SCH MED, DEPT INTERNAL MED, SHINJUKU KU, TOKYO 160, JAPAN	Scripps Research Institute; Keio University				takada, yoshikazu/0000-0001-5481-9589	NIGMS NIH HHS [GM49899, GM47157] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047157, R01GM049899] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAJT ML, 1992, J BIOL CHEM, V267, P3789; BAJT ML, 1994, J BIOL CHEM, V269, P20913; BRAY PF, 1994, THROMB HAEMOSTASIS, V72, P492; CALVETE JJ, 1992, EUR J BIOCHEM, V206, P759, DOI 10.1111/j.1432-1033.1992.tb16982.x; CALVETE JJ, 1993, FEBS LETT, V335, P132, DOI 10.1016/0014-5793(93)80454-3; CHARO IF, 1991, J BIOL CHEM, V266, P1415; CHERESH DA, 1989, CELL, V58, P945, DOI 10.1016/0092-8674(89)90946-X; COOK JJ, 1992, BIOCHIM BIOPHYS ACTA, V1119, P312, DOI 10.1016/0167-4838(92)90219-4; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DSOUZA SE, 1991, NATURE, V350, P66, DOI 10.1038/350066a0; DSOUZA SE, 1988, SCIENCE, V242, P91, DOI 10.1126/science.3262922; DSOUZA SE, 1994, CELL, V79, P659, DOI 10.1016/0092-8674(94)90551-7; DSOUZA SE, 1990, J BIOL CHEM, V265, P3440; FARRELL DH, 1992, P NATL ACAD SCI USA, V89, P10729, DOI 10.1073/pnas.89.22.10729; FARRELL DH, 1994, J BIOL CHEM, V269, P226; FITZGERALD LA, 1987, BIOCHEMISTRY-US, V26, P8158, DOI 10.1021/bi00399a021; FRELINGER AL, 1990, J BIOL CHEM, V265, P6346; GOTO S, 1995, J BIOL CHEM, V270, P23352, DOI 10.1074/jbc.270.40.23352; GULINO D, 1992, J BIOL CHEM, V267, P1001; HAWIGER J, 1982, P NATL ACAD SCI-BIOL, V79, P2068, DOI 10.1073/pnas.79.6.2068; IRIE A, 1995, EMBO J, V14, P5550, DOI 10.1002/j.1460-2075.1995.tb00242.x; KAMATA T, 1995, BIOCHEM J, V305, P945, DOI 10.1042/bj3050945; KAMATA T, 1994, J BIOL CHEM, V269, P26006; KAMATA T, 1994, J BIOL CHEM, V269, P9659; KAMATA T, 1995, J BIOL CHEM, V270, P12531, DOI 10.1074/jbc.270.21.12531; KLOCZEWIAK M, 1982, BIOCHEM BIOPH RES CO, V107, P181, DOI 10.1016/0006-291X(82)91686-2; KODANDAPANI R, 1995, J BIOL CHEM, V270, P2268, DOI 10.1074/jbc.270.5.2268; LAM SCT, 1992, J BIOL CHEM, V267, P5649; LANZA F, 1992, J CLIN INVEST, V89, P1995, DOI 10.1172/JCI115808; LASZ EC, 1993, BIOCHEM BIOPH RES CO, V190, P118, DOI 10.1006/bbrc.1993.1019; LIN AY, 1990, SCIENCE, V249, P677, DOI 10.1126/science.1696397; LOFTUS J, 1994, INTEGRINS  BIOL PROB, P55; LOFTUS JC, 1994, J BIOL CHEM, V269, P25235; Loftus JC, 1996, J BIOL CHEM, V271, P2033, DOI 10.1074/jbc.271.4.2033; LOFTUS JC, 1990, SCIENCE, V249, P915, DOI 10.1126/science.2392682; MASUMOTO A, 1993, J CELL BIOL, V123, P245, DOI 10.1083/jcb.123.1.245; NIIYA K, 1987, BLOOD, V70, P475; OTOOLE TE, 1990, CELL REGUL, V1, P883, DOI 10.1091/mbc.1.12.883; PHILLIPS DR, 1988, BLOOD, V71, P831; PONCZ M, 1987, J BIOL CHEM, V262, P8476; PYTELA R, 1986, SCIENCE, V231, P1559, DOI 10.1126/science.2420006; RANDI AM, 1994, J BIOL CHEM, V269, P12395; RINDERKNECHT H, 1962, NATURE, V193, P167, DOI 10.1038/193167b0; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SANTORO SA, 1988, BIOCHEM BIOPH RES CO, V153, P217, DOI 10.1016/S0006-291X(88)81211-7; SMITH JW, 1990, J BIOL CHEM, V265, P12267; STEINER B, 1993, J BIOL CHEM, V268, P6870; TAKADA Y, 1993, J BIOL CHEM, V268, P17597; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TAUB R, 1989, J BIOL CHEM, V264, P259; TOMIYAMA Y, 1992, J BIOL CHEM, V267, P18085; TOMIYAMA Y, 1992, BLOOD, V79, P2303; TUCKWELL DS, 1994, CELL ADHES COMMUN, V2, P385, DOI 10.3109/15419069409004450; UEDA T, 1994, P NATL ACAD SCI USA, V91, P10680, DOI 10.1073/pnas.91.22.10680; WOODS VL, 1984, BLOOD, V63, P368; YLANNE J, 1993, J CELL BIOL, V122, P223, DOI 10.1083/jcb.122.1.223; YLANNE J, 1988, BLOOD, V72, P1478; ZHOU LB, 1994, J BIOL CHEM, V269, P17075	58	82	82	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18610	18615		10.1074/jbc.271.31.18610	http://dx.doi.org/10.1074/jbc.271.31.18610			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702512	hybrid			2022-12-25	WOS:A1996VB68300050
J	Rivard, N; LAllemain, G; Bartek, J; Pouyssegur, J				Rivard, N; LAllemain, G; Bartek, J; Pouyssegur, J			Abrogation of p27(Kip1) by cDNA antisense suppresses quiescence (G(0) state) in fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT KINASE INHIBITOR; CELL-CYCLE CONTROL; GROWTH-FACTOR-BETA; HAMSTER FIBROBLASTS; POTENTIAL MEDIATOR; DNA-REPLICATION; CDK6 INHIBITOR; PROTEIN; EXPRESSION; GENE	Progression of eukaryotic cells through the cell cycle is governed by the sequential formation, activation, and subsequent inactivation of a series of cyclin-dependent kinase (Cdk) complexes, p27(Kip1) (p27) is a Cdk inhibitor that blocks, in vitro, the activity of cyclin D-Cdk4, cyclin D-Cdk6, cyclin E-Cdk2 as well as cyclin A-Cdk2, a complex active during S phase, The level of p27 protein expression, usually high in G(0)/G(1) resting cells, declines as cells progress toward S phase and enforced expression of p27 in fibroblasts causes G(1) arrest. This situation prevails in CCL39, a Chinese hamster lung fibroblast cell line (this report), However, in addition to p27, several other Cdk inhibitors known to alter G(1) progression coexist in most mammalian cells, To investigate the specific contribution of p27 in the control of the mitogen-sensitive G(0)/G(1) arrest, we specifically reduced its synthesis by expressing a full-length p27 antisense cDNA in CCL39 cells. Interestingly, reduction of up to 90% of p27 protein expression increased both basal and serum-stimulated gene transcription of cyclin D1, cyclin A, dihydrofolate reductase, and DNA synthesis reinitiation. Moreover, overexpression of this antisense allows cells to grow for several generations in a serum-free medium supplemented with insulin and transferrin only, thus suggesting that p27-depleted cells cannot exit the cell cycle. These effects were fully reversed by coexpression of a plasmid encoding p27 sense. We conclude that p27, by setting the level of growth factor requirement, plays a pivotal role in controlling cell cycle exit, a fundamental step in growth control.	DANISH CANC SOC,DEPT CELL CYCLE & CANC,DIV CANC BIOL,DK-2100 COPENHAGEN,DENMARK	Danish Cancer Society	Rivard, N (corresponding author), UNIV NICE,CTR BIOCHIM,CNRS,PARC VALROSE,F-06108 NICE,FRANCE.		Bartek, Jiri/G-5870-2014					BARLAT I, 1993, CELL GROWTH DIFFER, V4, P105; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; CHAN FKM, 1995, MOL CELL BIOL, V15, P2682; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FIRPO EJ, 1994, MOL CELL BIOL, V14, P4889, DOI 10.1128/MCB.14.7.4889; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARPER JW, 1993, CELL, V75, P805; HERBER B, 1994, ONCOGENE, V9, P1295; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; LI Y, 1994, ONCOGENE, V9, P2261; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; MCKENZIE FR, 1996, J BIOL CHEM, V271, P15762; MORI T, 1994, CANCER RES, V54, P3396; NAKANISHI M, 1995, P NATL ACAD SCI USA, V92, P4352, DOI 10.1073/pnas.92.10.4352; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; Noel J, 1996, J CELL SCI, V109, P929; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; POUYSSEGUR J, 1984, P NATL ACAD SCI-BIOL, V81, P4833, DOI 10.1073/pnas.81.15.4833; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; SARDET C, 1989, CELL, V56, P271, DOI 10.1016/0092-8674(89)90901-X; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHEIKH MS, 1994, ONCOGENE, V9, P3407; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; SLINGERLAND JM, 1994, MOL CELL BIOL, V14, P3683, DOI 10.1128/MCB.14.6.3683; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; VANOBBERGHENSCHILLING E, 1983, EXP CELL RES, V147, P369, DOI 10.1016/0014-4827(83)90219-7; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WEINBERG R, 1994, CELL, V81, P323; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	47	200	217	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18337	18341		10.1074/jbc.271.31.18337	http://dx.doi.org/10.1074/jbc.271.31.18337			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702474	hybrid			2022-12-25	WOS:A1996VB68300012
J	Prat, AG; Holtzman, EJ; Brown, D; Cunningham, CC; Reisin, IL; Kleyman, TR; McLaughlin, M; Jackson, GR; Lydon, J; Cantiello, HF				Prat, AG; Holtzman, EJ; Brown, D; Cunningham, CC; Reisin, IL; Kleyman, TR; McLaughlin, M; Jackson, GR; Lydon, J; Cantiello, HF			Renal epithelial protein (Apx) is an actin cytoskeleton-regulated Na+ channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE SODIUM-CHANNEL; CORTICAL COLLECTING TUBULE; PLANAR LIPID BILAYERS; APICAL MEMBRANE; AMILORIDE; ACTIVATION; SUBUNIT; CELLS; VASOPRESSIN; RECORDINGS	Apr, the amphibian protein associated with renal amiloride-sensitive Na+ channel activity and with properties consistent with the pore-forming 150-kDa subunit of an epithelial Na+ channel complex initially purified by Benos et al. (Benos, D. J., Saccomani, G., and Sariban-Sohraby, S. (1987) J. Biol. Chem. 262, 10613-10618), has previously failed to generate amiloride-sensitive Na+ currents (Staub, O., Verrey, F., Kleyman, T. R., Benos, D. J., Rossier, B. C., and Kraehenbuhl, J.-P. (1992) J. Cell Biol. 119, 1497-1506). Renal epithelial Na+ channel activity is tonically inhibited by endogenous actin filaments (Cantiello, H. F., Stow, J., Prat, A. G;., and Ausiello, D. A. (1991) Am. J. Physiol. 261, C882-C888). Thus, Apr was expressed and its function examined in human melanoma cells with a defective actin-based cytoskeleton. Apx-transfection was associated with a 60-900% increase in amiloride-sensitive (K-i = 3 mu M) Na+ currents. Single channel Na+ currents had a similar functional fingerprint to the vasopressin sensitive, and actin-regulated epithelial Na+ channel of A6 cells, including a 6-7 pS single channel conductance and a perm-selectivity of Na+:K+ of 4:1. Na+ channel activity was either spontaneous, or induced by addition of actin or protein kinase A plus ATP to the bathing solution of excised inside-out patches. Therefore, Apr may be responsible for the ionic conductance involved in the vasopressin-activated Na+ reabsorption in the amphibian kidney.	MASSACHUSETTS GEN HOSP E,RENAL UNIT,CHARLESTOWN,MA 02129; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,BOSTON,MA 02115; FAC FARM & BIOQUIM,CATEDRA QUIM GEN & INORGAN,BUENOS AIRES,DF,ARGENTINA; UNIV PENN,DEPT PHYSIOL,PHILADELPHIA,PA 19104; UNIV PENN,DEPT MED,PHILADELPHIA,PA 19104; VET ADM MED CTR,PHILADELPHIA,PA 19104	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; University of Buenos Aires; University of Pennsylvania; University of Pennsylvania; US Department of Veterans Affairs; Veterans Health Administration (VHA)								AHN AH, 1993, NAT GENET, V3, P283, DOI 10.1038/ng0493-283; Alvarez O., 1986, ION CHANNEL RECONSTI, P115; ARPIN M, 1988, J CELL BIOL, V107, P1759, DOI 10.1083/jcb.107.5.1759; BENOS DJ, 1987, J BIOL CHEM, V262, P10613; BENOS DJ, 1995, J MEMBRANE BIOL, V143, P1; BENOS DJ, 1986, P NATL ACAD SCI USA, V83, P8525, DOI 10.1073/pnas.83.22.8525; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; CANTIELLO HF, 1990, J BIOL CHEM, V265, P21624; CANTIELLO HF, 1989, J BIOL CHEM, V264, P20867; CANTIELLO HF, 1991, AM J PHYSIOL, V261, pC882, DOI 10.1152/ajpcell.1991.261.5.C882; CANTIELLO HF, 1993, J BIOL CHEM, V268, P4596; CUNNINGHAM CC, 1992, SCIENCE, V255, P325, DOI 10.1126/science.1549777; GARTY H, 1994, FASEB J, V8, P522, DOI 10.1096/fasebj.8.8.8181670; HAMILTON KL, 1985, AM J PHYSIOL, V249, pC200, DOI 10.1152/ajpcell.1985.249.3.C200; HAMILTON KL, 1986, MEMBRANE BIOCHEM, V6, P149, DOI 10.3109/09687688609065447; HEMMINGS L, 1992, J CELL BIOL, V116, P1369, DOI 10.1083/jcb.116.6.1369; KATSURA T, 1995, P NATL ACAD SCI USA, V92, P7212, DOI 10.1073/pnas.92.16.7212; LIGHT DB, 1988, AM J PHYSIOL, V255, pF278, DOI 10.1152/ajprenal.1988.255.2.F278; MARUNAKA Y, 1991, AM J PHYSIOL, V260, pC1071, DOI 10.1152/ajpcell.1991.260.5.C1071; MARUNAKA Y, 1992, AM J PHYSIOL, V263, pF392, DOI 10.1152/ajprenal.1992.263.3.F392; MATSUDAIRA P, 1991, TRENDS BIOCHEM SCI, V16, P87, DOI 10.1016/0968-0004(91)90039-X; OH Y, 1993, AM J PHYSIOL, V264, pC1489, DOI 10.1152/ajpcell.1993.264.6.C1489; OH YS, 1993, AM J PHYSIOL, V265, pC85, DOI 10.1152/ajpcell.1993.265.1.C85; PALMER LG, 1986, P NATL ACAD SCI USA, V83, P2767, DOI 10.1073/pnas.83.8.2767; PALMER LG, 1988, J GEN PHYSIOL, V92, P121, DOI 10.1085/jgp.92.1.121; PRAT AG, 1995, AM J PHYSIOL-CELL PH, V268, pC1552, DOI 10.1152/ajpcell.1995.268.6.C1552; PRAT AG, 1993, AM J PHYSIOL, V265, pC224, DOI 10.1152/ajpcell.1993.265.1.C224; PRAT AG, 1993, AM J PHYSIOL, V265, pC218, DOI 10.1152/ajpcell.1993.265.1.C218; ROTIN D, 1994, EMBO J, V13, P440; SARIBANSOHRABY S, 1992, AM J PHYSIOL, V263, pC1111, DOI 10.1152/ajpcell.1992.263.5.C1111; SMITH PR, 1991, P NATL ACAD SCI USA, V88, P6971, DOI 10.1073/pnas.88.16.6971; STAUB O, 1992, J CELL BIOL, V119, P1497, DOI 10.1083/jcb.119.6.1497	32	31	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					18045	18053		10.1074/jbc.271.30.18045	http://dx.doi.org/10.1074/jbc.271.30.18045			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663566	hybrid			2022-12-25	WOS:A1996UY93500069
J	Nascimento, AAC; Cheney, RE; Tauhata, SBF; Larson, RE; Mooseker, MS				Nascimento, AAC; Cheney, RE; Tauhata, SBF; Larson, RE; Mooseker, MS			Enzymatic characterization and functional domain mapping of brain myosin-V	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALMODULIN-BINDING PROTEINS; RABBIT SKELETAL-MUSCLE; UNCONVENTIONAL MYOSIN; LIGHT-CHAINS; ACANTHAMOEBA-CASTELLANII; PROTEOLYTIC FRAGMENTS; CALCIUM-CALMODULIN; VERTEBRATE BRAIN; INVITRO MOTILITY; ATPASE ACTIVITY	The actin binding and ATPase properties, as well as the functional domain structure of chick brain myosin-V, a two-headed, unconventional myosin, is reported here, Compared to conventional myosin from skeletal muscle, brain myosin-V exhibits low K-EDTA- and Ca-ATPase activities (1.8 and 0.8 ATP/s per head), The physiologically relevant Mg-ATPase is also low (similar to 0.3 ATP/s), unless activated by the presence of both F-actin and Ca2+ (V-max of 27 ATP/s), Ca2+ stimulates the actin-activated Mg-ATPase over a narrow concentration range between 1 and 3 mu M. In the presence of saturating Ca2+ and 75 mM KCl, surprisingly low concentrations of F-actin activate the Mg-ATPase in a hyperbolic manner (K-ATPase of 1.3 mu M). Brain myosin-V also binds with relatively high affinity (compared to other known myosins) to F-actin in the presence of ATP, as assayed by cosedimentation, Digestion of brain myosin-V with calpain yielded a 65-kDa head domain fragment that cosediments with actin in an ATP-sensitive manner and a 80-kDa tail fragment that does not interact with F-actin, The 80-kDa fragment results from cleavage one residue beyond the proline-, glutamate-, serine-, threonine-rich region, Our data indicate that the Mg-ATPase cycle of brain myosin-V is tightly regulated by Ca2+, probably via direct binding to the calmodulin light chains in the neck domain, which like brush border myosin-I, results in partial (similar to 30%) dissociation of the calmodulin associated with brain myosin-V, The effect of Ca2+ binding, which appears to relieve suppression by the neck domain, can be mimicked by calpain cleavage near the head/neck junction.	YALE UNIV, DEPT BIOL, NEW HAVEN, CT 06520 USA; YALE UNIV, DEPT CELL BIOL, NEW HAVEN, CT 06520 USA; YALE UNIV, DEPT PATHOL, NEW HAVEN, CT 06520 USA; UNIV SAO PAULO, SCH MED, DEPT BIOCHEM, BR-14049900 RIBEIRAO PRETO, SP, BRAZIL	Yale University; Yale University; Yale University; Universidade de Sao Paulo				Tauhata, Sinji/0000-0002-6617-4244; Cheney, Richard/0000-0001-6565-7888	NIDDK NIH HHS [DK25387, DK38979] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK025387, R37DK025387, R56DK025387, P01DK038979] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADELSTEIN RS, 1980, ANNU REV BIOCHEM, V49, P921, DOI 10.1146/annurev.bi.49.070180.004421; ALBANESI JP, 1983, J BIOL CHEM, V258, P176; BARYLKO B, 1992, P NATL ACAD SCI USA, V89, P490, DOI 10.1073/pnas.89.2.490; Bidlingmeyer BA, 1986, METHODS PROTEIN SEQU, P229; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARBONI JM, 1988, J CELL BIOL, V4107, P1749; CHALOVICH JM, 1984, J BIOL CHEM, V259, P2617; CHENEY RE, 1993, CELL, V75, P13, DOI 10.1016/0092-8674(93)90675-G; COELHO MV, 1993, BRAZ J MED BIOL RES, V26, P465; CONZELMAN KA, 1987, J CELL BIOL, V105, P313, DOI 10.1083/jcb.105.1.313; COOKE R, 1989, CELL MOTIL CYTOSKEL, V14, P183, DOI 10.1002/cm.970140204; COOPER DMF, 1988, J CELL BIOCHEM, V36, P417, DOI 10.1002/jcb.240360410; ESPINDOLA FS, 1992, J CELL BIOL, V118, P359, DOI 10.1083/jcb.118.2.359; ESPREAFICO EM, 1992, J CELL BIOL, V119, P1541, DOI 10.1083/jcb.119.6.1541; FABIATO A, 1988, METHOD ENZYMOL, V157, P378; KLEE CB, 1982, ADV PROTEIN CHEM, V35, P213, DOI 10.1016/S0065-3233(08)60470-2; LARSON RE, 1990, J NEUROCHEM, V54, P1288, DOI 10.1111/j.1471-4159.1990.tb01961.x; LARSON RE, 1988, BRAZ J MED BIOL RES, V21, P213; Larson RE, 1996, BRAZ J MED BIOL RES, V29, P309; LOWEY S, 1993, NATURE, V365, P454, DOI 10.1038/365454a0; LYNCH TJ, 1989, J BIOL CHEM, V264, P19333; MARGOSSIAN SS, 1982, METHOD ENZYMOL, V85, P55; Mooseker MS, 1995, ANNU REV CELL DEV BI, V11, P633, DOI 10.1146/annurev.cellbio.11.1.633; MORNET D, 1989, J MUSCLE RES CELL M, V10, P10, DOI 10.1007/BF01739853; POINTING CP, 1995, TRENDS BIOCHEM SCI, V20, P265; POLLARD TD, 1991, ANNU REV PHYSIOL, V53, P653, DOI 10.1146/annurev.ph.53.030191.003253; PORTER JA, 1993, SCIENCE, V262, P1038, DOI 10.1126/science.8235618; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; Rechsteiner M, 1990, Semin Cell Biol, V1, P433; SANDERS G, 1992, FEBS LETT, V311, P295, DOI 10.1016/0014-5793(92)81123-4; SPUDICH JA, 1994, NATURE, V372, P515, DOI 10.1038/372515a0; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; SWANLJUNGCOLLINS H, 1991, J BIOL CHEM, V266, P1312; SZENTGYORGYI AG, 1994, MYOLOGY, P506; TAKIGUCHI K, 1990, J BIOCHEM-TOKYO, V107, P671, DOI 10.1093/oxfordjournals.jbchem.a123106; TAUSSKY HH, 1953, J BIOL CHEM, V202, P675; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRYBUS KM, 1994, J CELL BIOL, V124, P963, DOI 10.1083/jcb.124.6.963; UMEMOTO S, 1990, J BIOL CHEM, V265, P14864; VIBERT P, 1988, J MUSCLE RES CELL M, V9, P296, DOI 10.1007/BF01773873; WANG KKW, 1989, BIOCHEM J, V262, P693, DOI 10.1042/bj2620693; WARRICK HM, 1987, ANNU REV CELL BIOL, V3, P379, DOI 10.1146/annurev.cb.03.110187.002115; WELLS C, 1994, NATURE, V313, P306; WOLENSKI JS, 1993, J CELL BIOL, V122, P613, DOI 10.1083/jcb.122.3.613; WOLENSKI JS, 1995, TRENDS CELL BIOL, V5, P310, DOI 10.1016/S0962-8924(00)89053-4; XIE X, 1994, NATURE, V368, P306, DOI 10.1038/368306a0	46	103	105	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					17561	17569		10.1074/jbc.271.29.17561	http://dx.doi.org/10.1074/jbc.271.29.17561			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663447	hybrid			2022-12-25	WOS:A1996UX94300087
J	Bhatia, K; Raj, A; Gutierrez, MI; Judde, JG; Spangler, G; Venkatesh, H; Magrath, IT				Bhatia, K; Raj, A; Gutierrez, MI; Judde, JG; Spangler, G; Venkatesh, H; Magrath, IT			Variation in the sequence of Epstein Barr virus nuclear antigen 1 in normal peripheral blood lymphocytes and in Burkitt's lymphomas	ONCOGENE			English	Article						EBV; EBNA-1; Burkitt's lymphoma; mutations; lymphomagenesis	CELLS; ASSOCIATION; EXPRESSION; TUMORS; EBV	We have examined sequence variations in the EBNA-1 protein of EBV in normal peripheral blood lymphocytes (PBL) and Burkitt's lymphomas (BL), We find two EBNA-1 strains P (prototype) and V (variant) which differ by 15 amino acids, Each strain has two subtypes defined by the amino acid at position 487 (P-ala, P-thr, V-pro and V-leu), In PBLs from 32 normal individuals, up to three of these subtypes were found in each sample, but the V strain did not occur in the absence of P strain viruses, nor was the V-leu subtype ever observed in normal PBL, In BLs only a single subtype was observed in each tumor, The P-thr and V-leu subtypes were more frequently seen than the P-ala and V-pro subtypes, which occurred in only two and one of the 36 tumor samples respectively, The P-thr was the most commonly observed peripheral blood of both American and as well as in African tumors, However, in 11 of 12 American tumors, the EBNA-1 subtype was V-leu, These data indicate that some EBNA-1 subtypes are more likely to lead to oncogenesis, and one subtype, V-leu, appears only to occur in tumors.			Bhatia, K (corresponding author), NATL CANC INST,LYMPHOMA BIOL SECT,PEDIAT BRANCH,NIH,BLDG 10,ROOM 13N240,10 CTR DR MSC 1928,BETHESDA,MD 20892, USA.							BHATIA KG, 1992, CANCER RES, V52, P4273; CHANG YS, 1990, J CLIN MICROBIOL, V28, P2398, DOI 10.1128/JCM.28.11.2398-2402.1990; COLES RE, 1994, ANN SURG ONCOL, V1, P405, DOI 10.1007/BF02303813; FRANK D, 1995, BLOOD, V85, P1396, DOI 10.1182/blood.V85.5.1396.bloodjournal8551396; GUTIERREZ MI, 1992, BLOOD, V79, P3261; HENLE W, 1967, J NATL CANCER I, V43, P1147; HENNESSY K, 1983, P NATL ACAD SCI-BIOL, V80, P5665, DOI 10.1073/pnas.80.18.5665; LABRECQUE LG, 1995, CANCER RES, V55, P39; Magrath I, 1992, Semin Cancer Biol, V3, P285; MURRAY RJ, 1992, J EXP MED, V176, P157, DOI 10.1084/jem.176.1.157; PALLESEN G, 1991, LANCET, V337, P320, DOI 10.1016/0140-6736(91)90943-J; PIZZO PA, 1978, NATURE, V272, P629, DOI 10.1038/272629a0; ROGERS RP, 1992, ADV CANCER RES, V58, P1, DOI 10.1016/S0065-230X(08)60288-2; SAMPLE J, 1990, J VIROL, V64, P4084, DOI 10.1128/JVI.64.9.4084-4092.1990; SHIRAMIZU B, 1991, BLOOD, V77, P1516; SNUDDEN DK, 1995, ONCOGENE, V10, P1545; STRAUS SE, 1993, ANN INTERN MED, V118, P45, DOI 10.7326/0003-4819-118-1-199301010-00009; SUZUSHIMA H, 1995, BLOOD, V85, P480, DOI 10.1182/blood.V85.2.480.bloodjournal852480; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; WRIGHTHAM MN, 1995, VIROLOGY, V208, P521, DOI 10.1006/viro.1995.1183	20	109	115	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 4	1996	13	1					177	181						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UX319	8700544				2022-12-25	WOS:A1996UX31900020
J	Brown, MA; Xu, CF; Nicolai, H; Griffiths, B; Chambers, JA; Black, D; Solomon, E				Brown, MA; Xu, CF; Nicolai, H; Griffiths, B; Chambers, JA; Black, D; Solomon, E			The 5' end of the BRCA1 gene lies within a duplicated region of human chromosome 17q21	ONCOGENE			English	Article						BRCA1; tumour-suppressor gene; breast/ovarian tumorigenesis; gene duplication; pseudogene	FAMILIAL BREAST; WILD-TYPE; HETEROZYGOSITY; EVOLUTION; CANCER	To begin to address the hypothesis that abnormal regulation of the breast/ovarian cancer susceptibility gene BRCA1 is a critical step in sporadic breast/ovarian tumorigenesis, we have determined the detailed structure of the BRCA1 genomic region, We show that this region of the genome contains a tandem duplication of approximately 30 kilobases, which results in two copies of BRCA1 exons 1 and 2, of exons 1 and 3 of the adjacent 1A1-3B gene and of the previously reported 295 base pair intergenic region. Sequence analysis of the duplicated exons of BRCA1 and 1A1-3B and flanking genomic DNA reveals maintenance of the intron-exon structure and a high degree of nucleotide sequence identity, suggesting that these are non-processed pseudogenes and that the duplication is a recent event in evolutionary terms, We also show that a processed pseudogene of the acidic ribosomal phosphoprotein P1 (ARPP1) is inserted directly upstream of pseudo-BRCA1 exon 1A, We believe that these findings could not only confound BRCA1 mutation analysis, but could have implications for the normal and abnormal regulation of BRCA1 transcription, translation and function.	BEATSON INST CANC RES, GLASGOW G61 1BD, LANARK, SCOTLAND	Beatson Institute	Brown, MA (corresponding author), IMPERIAL CANC RES FUND, SOMAT CELL GENET LAB, LONDON WC2A 3PX, ENGLAND.		Brown, Melissa A/F-1451-2010	Xu, Chun-Fang/0000-0002-8747-0683; Brown, Melissa/0000-0002-2830-9259				AHUJA SK, 1992, NAT GENET, V2, P31, DOI 10.1038/ng0992-31; BENARIE N, 1994, HUM MOL GENET, V3, P229, DOI 10.1093/hmg/3.2.229; BROWN MA, 1994, NATURE, V372, P733, DOI 10.1038/372733a0; BROWN MA, 1995, P NATL ACAD SCI USA, V92, P4362, DOI 10.1073/pnas.92.10.4362; CAMPBELL IG, 1994, HUM MOL GENET, V3, P589, DOI 10.1093/hmg/3.4.589; CORTESE JF, 1994, J BIOL CHEM, V269, P21898; CROPP CS, 1994, CANCER RES, V54, P2548; ERICKSON LM, 1992, GENOMICS, V14, P948, DOI 10.1016/S0888-7543(05)80116-8; FOULKES WD, 1993, INT J CANCER, V54, P220, DOI 10.1002/ijc.2910540210; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; HARVEY M, 1995, NAT GENET, V9, P305, DOI 10.1038/ng0395-305; HOSKING L, 1995, NAT GENET, V9, P343, DOI 10.1038/ng0495-343; JEFFREYS AJ, 1982, NATURE, V296, P9, DOI 10.1038/296009a0; KNUDSON AG, 1993, P NATL ACAD SCI USA, V90, P10914, DOI 10.1073/pnas.90.23.10914; LINDBLOM A, 1993, HUM GENET, V91, P6; MARCHESE A, 1995, GENE, V154, P153, DOI 10.1016/0378-1119(94)00879-W; MATSUSHIMA M, 1995, HUM MOL GENET, V4, P1953, DOI 10.1093/hmg/4.10.1953; MERAJVER SD, 1995, NAT GENET, V9, P439, DOI 10.1038/ng0495-439; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; RICH BE, 1987, MOL CELL BIOL, V7, P4065, DOI 10.1128/MCB.7.11.4065; SAPI E, 1994, GENOMICS, V22, P641, DOI 10.1006/geno.1994.1440; SMITH SA, 1992, NAT GENET, V2, P128, DOI 10.1038/ng1092-128; STRUEWING JP, 1995, NAT GENET, V11, P198, DOI 10.1038/ng1095-198; SU LK, 1993, CANCER RES, V53, P2728; SUZUKI H, 1994, GENE, V147, P277, DOI 10.1016/0378-1119(94)90081-7; VANIN EF, 1985, ANNU REV GENET, V19, P253, DOI 10.1146/annurev.genet.19.1.253; XU CF, 1995, HUM MOL GENET, V4, P2259, DOI 10.1093/hmg/4.12.2259; XU CF, 1996, SEMINARS CANC BIOL	28	67	71	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 20	1996	12	12					2507	2513						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UW487	8700509				2022-12-25	WOS:A1996UW48700004
J	Feinmesser, RL; Gray, K; Means, AR; Chantry, A				Feinmesser, RL; Gray, K; Means, AR; Chantry, A			HER-2/c-erbB2 is phosphorylated by calmodulin-dependent protein kinase II on a single site in the cytoplasmic tail at threonine-1172	ONCOGENE			English	Article						tyrosine kinases; HER-2/c-erbB2; calmodulin-dependent protein kinase; desensitisation	GROWTH-FACTOR RECEPTOR; TYROSINE KINASE; NEU ONCOGENE; CELLS; RESIDUES	Calmodulin-dependent protein kinase II (Cam kinase II) is known to desensitise epidermal growth factor receptor (HER-1) tyrosine kinase activity by a process involving phosphorylation at serines 1046/47 in the cytoplasmic tail, We have developed an experimental system to investigate phosphorylation of the related HER-2/cerbB2 proto-oncogene utilising purified Cam kinase II and recombinant glutathione-S-transferase (GST) fusion proteins, The cDNA for rat Cam kinase II-alpha was transfected into human embryonic kidney (HEK) 293 fibroblasts and the expressed protein purified to homogeneity by calmodulin-agarose affinity chromatography, A GST fusion protein comprising residues 1126-1255 of HER-2 was phosphorylated by purified Cam kinase II, in contrast to a GST protein comprising residues 1005-1125, Phosphoamino-acid analysis and site-directed mutagenesis indicated that HER-2 was phosphorylated on a single site at threonine-1172 which resides within a consensus Cam kinase II phosphorylation site (RAKT), HER-2 (threonine-1172-alanine), in the form of a ligand-inducible chimaera HER-1/2, was co-transfected into HEK-293 fibroblasts with a constitutively active form of Cam kinase II, followed by in vivo labelling of these cells with P-32-orthophosphate, Immunoprecipitation of ligand-activated receptors followed by two-dimensional phosphopeptide mapping indicated that threonine-1172 in HER-2 is a newly identified in vivo site which can be hyper-phosphorylated by constitutively active Cam kinase II, In addition, when over-expressed in HEK 293 fibroblasts, HER-1/2 (threonine-1172-alanine) showed a defect in desensitisation and underwent a more sustained EGF-induced receptor autophosphorylation compared to wild-type HER-1/2.	CHARING CROSS & WESTMINSTER MED SCH, DEPT BIOCHEM, LONDON W6 8RP, ENGLAND; CHARING CROSS & WESTMINSTER MED SCH, DEPT MED ONCOL, LONDON W6 8RP, ENGLAND; DUKE UNIV, MED CTR, DEPT PHARMACOL, DURHAM, NC 27710 USA	Imperial College London; Imperial College London; Duke University					Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AKIYAMA T, 1988, MOL CELL BIOL, V8, P1019, DOI 10.1128/MCB.8.3.1019; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CHANTRY A, 1995, J BIOL CHEM, V270, P3068; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COUNTAWAY JL, 1992, J BIOL CHEM, V267, P1129; COUNTAWAY JL, 1990, J BIOL CHEM, V265, P3407; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; CRUZALEGUI FH, 1992, P NATL ACAD SCI USA, V89, P12127, DOI 10.1073/pnas.89.24.12127; DAVIS RJ, 1988, J BIOL CHEM, V263, P9462; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DIFIORE PP, 1992, EMBO J, V11, P3927, DOI 10.1002/j.1460-2075.1992.tb05486.x; DOBASHI K, 1989, DNA-J MOLEC CELL BIO, V8, P723, DOI 10.1089/dna.1989.8.723; GORMAN CM, 1989, VIROLOGY, V171, P377, DOI 10.1016/0042-6822(89)90605-3; HEISERMANN GJ, 1988, J BIOL CHEM, V263, P13152; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; KUPPUSWAMY D, 1993, J BIOL CHEM, V268, P19134; LEE J, 1989, EMBO J, V8, P167, DOI 10.1002/j.1460-2075.1989.tb03361.x; LEMMON MA, 1994, TRENDS BIOCHEM SCI, V19, P459, DOI 10.1016/0968-0004(94)90130-9; MORRISON P, 1993, J BIOL CHEM, V268, P15536; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; THEROUX SJ, 1992, J BIOL CHEM, V267, P7967; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K	24	14	14	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 20	1996	12	12					2725	2730						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UW487	8700533				2022-12-25	WOS:A1996UW48700028
J	Guan, RJ; Moss, SF; Arber, N; Krajewski, S; Reed, JC; Holt, PR				Guan, RJ; Moss, SF; Arber, N; Krajewski, S; Reed, JC; Holt, PR			30 KDa phosphorylated form of Bcl-2 protein in human colon	ONCOGENE			English	Article						Bcl-2; protein phosphorylation; colon cancer; apoptosis; programmed cell death	CELL-DEATH; GENE	Bcl-2 expression was studied in a human colon cell line (HT-29) and in human colonic biopsies by Western and Northern blotting, Polyclonal antibodies raised against the Bcl-2 protein detected the expected 26 KDa protein in human colon, However, although Bcl-2 mRNA was present, the 26 KDa Bcl-2 protein was absent in HT-29 cells, Instead, a 30 KDa protein band strongly reacting with anti-Bcl-2 antibodies was found in HT-29 cells, and also in human colon, tonsil, and some other tissues, Alkaline phosphatase shifted the 30 KDa protein to the 26 KDa position in a time-dependent manner. P-32-labeling of HT-29 cells showed that the 30 KDa protein was phosphorylated, A 27 KDa phosphorylated protein was also immunoprecipitated by anti-Bcl-2 antibody, Phosphopeptide mapping showed that the 27 KDa protein contained a minimum of 3 and the 30 KDa protein at least an additional four phosphorylation sites, Phosphoamino acid analysis revealed that both the 30 KDa and 27 KDa proteins were phosphorylated on serine residues, These findings strongly suggest that the 30 KDa protein is a phosphorylated form of Bcl-2, which is widely distributed in human tissues.	UNIV COLOGNE, ST LUKES ROOSEVELT HOSP CTR, DEPT MED, DIV GASTROENTEROL, NEW YORK, NY 10025 USA; LA JOLLA CANC RES FDN, LA JOLLA, CA 92037 USA	Mount Sinai St. Luke's; Mount Sinai West; Sanford Burnham Prebys Medical Discovery Institute				holt, peter/0000-0002-8469-2766; Arber, Nadir/0000-0001-5283-6991				ALNEMRI ES, 1992, P NATL ACAD SCI USA, V89, P7295, DOI 10.1073/pnas.89.16.7295; BAXTER GD, 1992, J IMMUNOL, V148, P1949; BEDI A, 1995, CANCER RES, V55, P1811; BODRUG SE, 1995, CELL DEATH DIFFER, V2, P173; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BOYD JM, 1994, CELL, V79, P341, DOI 10.1016/0092-8674(94)90202-X; GEIER A, 1995, J CELL PHYSIOL, V163, P570, DOI 10.1002/jcp.1041630318; GUAN RJ, 1992, J NEUROCHEM, V58, P1365, DOI 10.1111/j.1471-4159.1992.tb11351.x; GUAN RJ, 1991, J BIOL CHEM, V266, P8262; HALDAR S, 1995, P NATL ACAD SCI USA, V92, P4507, DOI 10.1073/pnas.92.10.4507; HANADA M, 1995, J BIOL CHEM, V270, P11962, DOI 10.1074/jbc.270.20.11962; KEMP BE, 1991, METHOD ENZYMOL, V200, P121; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; KRAJEWSKI S, 1994, AM J PATHOL, V145, P515; MAY WS, 1994, J BIOL CHEM, V269, P26865; MOSS SF, 1995, GASTROENTEROLOGY, V108, pA511, DOI 10.1016/0016-5085(95)26359-4; NUNEZ G, 1994, IMMUNOL TODAY, V15, P582, DOI 10.1016/0167-5699(94)90221-6; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; ROBAYE B, 1994, ELECTROPHORESIS, V15, P503, DOI 10.1002/elps.1150150168; SATO T, 1994, P NATL ACAD SCI USA, V91, P9238, DOI 10.1073/pnas.91.20.9238; SATO T, 1995, SCIENCE, V268, P411, DOI 10.1126/science.7536343; TAKAYAMA S, 1995, CELL, V80, P279, DOI 10.1016/0092-8674(95)90410-7; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; WANG HG, 1994, ONCOGENE, V9, P2751; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0	29	28	28	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 20	1996	12	12					2605	2609						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UW487	8700519				2022-12-25	WOS:A1996UW48700014
J	Wang, HY; Lian, ZR; Lerch, MM; Chen, ZJ; Xie, WF; Ullrich, A				Wang, HY; Lian, ZR; Lerch, MM; Chen, ZJ; Xie, WF; Ullrich, A			Characterization of PCP-2, a novel receptor protein tyrosine phosphatase of the MAM domain family	ONCOGENE			English	Article						protein tyrosine phosphatase; cell contact; signal transduction; cell adhesion signals	CELL-ADHESION MOLECULE; NERVOUS-SYSTEM; IMMUNOGLOBULIN SUPERFAMILY; CHROMOSOMAL LOCALIZATION; EXTRACELLULAR REGION; HUMAN-PLACENTA; PURIFICATION; EXPRESSION; DROSOPHILA; CLEAVAGE	DNA sequences encoding a novel member of the receptor protein tyrosine phosphatase (R-PTP) family, termed PCP-2, were identified in a human pancreatic adenocarcinoma cDNA library, Human PCP-2 cDNA predicts a protein of 1430 amino acids with a calculated M(r) of 160 kDa, The predicted PCP-2 enzyme consists of a 740 amino acid extracellular region, a single transmembrane domain, and a 666 amino acid intracellular portion, The extracellular sequence contains a MAM (meprin/A5/PTP mu) domain, an immunoglobulin-like domain and four fibronectin type m-like repeats, suggesting that it is a member of the PTP kappa and PTP mu subfamily, The intracellular region contains two tandemly-repeated protein tyrosine phosphatase domains, Northern blot analyses revealed a single transcript of 5.5 kilobases, which is expressed at different levels in many human tissues except spleen and placenta, Upon transfection of PCP-2 cDNA into human embryonic kidney fibroblast 293 cells, a protein with an apparent M(r) of 180 000 was detected by immunoblot analysis, This size was reduced to the predicted M(r) upon treatment with endoglycosidase F, indicating that PCP-2 is glycosylated and, hence, expressed at the cell surface, A potential role of PCP-2 in cell-cell recognition and adhesion is supported by its co-localization with cell adhesion molecules, such as beta-catenin and E-cadherin, at sites of cell-cell contact.	MAX PLANCK INST BIOCHEM,DEPT MOLEC BIOL,D-82152 MARTINSRIED,GERMANY	Max Planck Society			Lerch, Markus M./E-2206-2016; Wang, Hongyang/B-1340-2010; Lian, Zhaorui/AAW-2379-2020	Lerch, Markus M./0000-0002-9643-8263; 				ALEXANDER D R, 1990, New Biologist, V2, P1049; BECKMANN G, 1993, TRENDS BIOCHEM SCI, V18, P40, DOI 10.1016/0968-0004(93)90049-S; BEYNON RJ, 1981, BIOCHEM J, V199, P591, DOI 10.1042/bj1990591; BLASCHUK OW, 1990, J MOL BIOL, V211, P679, DOI 10.1016/0022-2836(90)90065-T; Brady-Kalnay S, 1994, ADV PROTEIN PHOSPHAT, V8, P241; CHARBONNEAU H, 1989, P NATL ACAD SCI USA, V86, P5252, DOI 10.1073/pnas.86.14.5252; CHARBONNEAU H, 1992, ANNU REV CELL BIOL, V8, P463, DOI 10.1146/annurev.cellbio.8.1.463; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CUNNINGHAM BA, 1987, SCIENCE, V236, P799, DOI 10.1126/science.3576199; EATON DL, 1986, BIOCHEMISTRY-US, V25, P8345; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; GEBBINK MFBG, 1995, J CELL BIOL, V131, P251, DOI 10.1083/jcb.131.1.251; GEBBINK MFBG, 1993, J BIOL CHEM, V268, P16101; GEBBINK MFBG, 1991, FEBS LETT, V290, P123, DOI 10.1016/0014-5793(91)81241-Y; GORBEA CM, 1993, J BIOL CHEM, V268, P21035; Grumet M, 1991, Curr Opin Neurobiol, V1, P370, DOI 10.1016/0959-4388(91)90055-C; HOSAKA M, 1991, J BIOL CHEM, V266, P12127; JIANG WP, 1992, J BIOL CHEM, V267, P9185; JIANG YP, 1993, MOL CELL BIOL, V13, P2942, DOI 10.1128/MCB.13.5.2942; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x; LAMMERS R, 1993, J BIOL CHEM, V268, P22456; LAU KHW, 1993, CRIT REV ONCOGENESIS, V4, P451; MAURO VP, 1992, J CELL BIOL, V119, P191, DOI 10.1083/jcb.119.1.191; MIZUNO K, 1994, FEBS LETT, V355, P223, DOI 10.1016/0014-5793(94)01188-5; MOOS M, 1988, NATURE, V334, P701, DOI 10.1038/334701a0; PALLEN CJ, 1991, BIOCHEM J, V276, P315, DOI 10.1042/bj2760315; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAP J, 1994, MOL CELL BIOL, V14, P1; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SONDEREGGER P, 1992, J CELL BIOL, V119, P1387, DOI 10.1083/jcb.119.6.1387; STREULI M, 1992, EMBO J, V11, P897, DOI 10.1002/j.1460-2075.1992.tb05128.x; STREULI M, 1989, P NATL ACAD SCI USA, V86, P8698, DOI 10.1073/pnas.86.22.8698; TAKAGI S, 1991, NEURON, V7, P295, DOI 10.1016/0896-6273(91)90268-5; TIAN SS, 1991, CELL, V67, P675, DOI 10.1016/0092-8674(91)90063-5; TONKS NK, 1988, J BIOL CHEM, V263, P6722; ULLRICH A, 1977, SCIENCE, V196, P1313, DOI 10.1126/science.325648; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WALTON KM, 1993, ANNU REV BIOCHEM, V62, P101; YANG XH, 1991, CELL, V67, P661, DOI 10.1016/0092-8674(91)90062-4	42	40	51	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 20	1996	12	12					2555	2562						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UW487	8700514				2022-12-25	WOS:A1996UW48700009
J	Binder, BM; OConnor, TM; Bownds, MD; Arshavsky, VY				Binder, BM; OConnor, TM; Bownds, MD; Arshavsky, VY			Phosphorylation of non-bleached rhodopsin in intact retinas and living frogs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROD OUTER SEGMENTS; PROTEIN-KINASE-C; PHOTORECEPTOR-MEMBRANES; CYCLIC-GMP; PHOSPHODIESTERASE ACTIVATION; VERTEBRATE PHOTORECEPTORS; VISUAL TRANSDUCTION; LIGHT; PHOTOTRANSDUCTION; DEPHOSPHORYLATION	The photoresponse in retinal photoreceptors begins when a molecule of rhodopsin is excited by a photon of light. Photoexcited rhodopsin activates an enzymatic cascade including the G-protein transducin and cyclic GMP phosphodiesterase. As a result, cytoplasmic cyclic GMP concentration is decreased and the photoresponse is initiated. This process is terminated when rhodopsin is phosphorylated by rhodopsin kinase and subsequently blocked by a protein called arrestin. It has been noted by several investigators that light can cause phosphorylation of not only photoexcited but also non-excited rhodopsin in rod photoreceptors. A goal of this study was to determine how much non-bleached rhodopsin is phosphorylated. To determine how the structural integrity of the photoreceptor influences the extent of non-breached rhodopsin phosphorylation, we studied the reaction in electropermeabilized rod outer segments, in rod outer segments still attached to isolated retinas and in living frogs. In the first two preparations, we found that the maximum extent of non-bleached rhodopsin phosphorylation was approximately 1% of the total rhodopsin pool. In living frogs, the maximal amount of non-bleached rhodopsin phosphorylation was similar to 2% of the total rhodopsin pool and occurred after prolonged illumination by the relatively dim light intensity of 20 lux. These data appear to exclude models for light adaptation that postulate high levels of phosphorylation of non-bleached rhodopsin in rod photoreceptors.	HARVARD UNIV, SCH MED, MASSACHUSETTS EYE & EAR INFIRM, HOWE LAB OPHTHALMOL, BOSTON, MA 02114 USA; UNIV WISCONSIN, MOL BIOL LAB, MADISON, WI 53706 USA; UNIV WISCONSIN, DEPT ZOOL, MADISON, WI 53706 USA	Harvard University; Harvard Medical School; Massachusetts Eye & Ear Infirmary; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison				Binder, Brad/0000-0002-8172-2034	NATIONAL EYE INSTITUTE [R01EY010336] Funding Source: NIH RePORTER; NEI NIH HHS [EY-10336, EY-00463] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ARSHAVSKY VY, 1986, BIOL MEMBRANY, V3, P1197; ATON BR, 1986, BIOCHEMISTRY-US, V25, P677, DOI 10.1021/bi00351a025; ATON BR, 1984, J GEN PHYSIOL, V85, P83; BARBEHENN EK, 1986, EXP EYE RES, V43, P729, DOI 10.1016/S0014-4835(86)80004-5; BAUMANN C, 1970, VISION RES, V10, P627, DOI 10.1016/0042-6989(70)90011-8; BIERNBAUM MS, 1985, J GEN PHYSIOL, V85, P83, DOI 10.1085/jgp.85.1.83; BIERNBAUM MS, 1991, VISUAL NEUROSCI, V7, P499, DOI 10.1017/S0952523800009780; BINDER BM, 1990, J BIOL CHEM, V265, P15333; BOWNDS D, 1974, EXP EYE RES, V18, P253, DOI 10.1016/0014-4835(74)90153-5; BOWNDS D, 1972, NATURE-NEW BIOL, V237, P125, DOI 10.1038/newbio237125a0; BOWNDS D, 1971, J GEN PHYSIOL, V58, P225, DOI 10.1085/jgp.58.3.225; BOWNDS MD, 1995, BEHAV BRAIN SCI, V18, P415, DOI 10.1017/S0140525X00039170; CHABRE M, 1989, EUR J BIOCHEM, V179, P255, DOI 10.1111/j.1432-1033.1989.tb14549.x; CHEN CK, 1995, J BIOL CHEM, V270, P18060, DOI 10.1074/jbc.270.30.18060; COCOZZA JD, 1987, VISION RES, V27, P1085, DOI 10.1016/0042-6989(87)90023-X; DEAN KR, 1993, EUR J BIOCHEM, V213, P881, DOI 10.1111/j.1432-1033.1993.tb17832.x; DEAZEREDO FAM, 1981, J BIOL CHEM, V256, P2731; DIZHOOR AM, 1985, BIOL MEMBRANY, V2, P272; FONG SL, 1985, VISION RES, V25, P1387, DOI 10.1016/0042-6989(85)90216-0; FOWLES C, 1988, FEBS LETT, V238, P56, DOI 10.1016/0014-5793(88)80224-2; FUNG BKK, 1983, J BIOL CHEM, V258, P503; GREENE NM, 1995, J BIOL CHEM, V270, P6710, DOI 10.1074/jbc.270.12.6710; HARGRAVE PA, 1993, BIOESSAYS, V15, P43, DOI 10.1002/bies.950150107; HURLEY JB, 1992, J BIOENERG BIOMEMBR, V24, P219, DOI 10.1007/BF00762680; KLENCHIN VA, 1995, J BIOL CHEM, V270, P16147, DOI 10.1074/jbc.270.27.16147; Koutalos Y, 1993, Curr Opin Neurobiol, V3, P513, DOI 10.1016/0959-4388(93)90049-5; KUHN H, 1977, BIOPHYS STRUCT MECH, V3, P199, DOI 10.1007/BF00535820; KUHN H, 1974, NATURE, V250, P588, DOI 10.1038/250588a0; KUHN H, 1976, BIOCHIM BIOPHYS ACTA, V428, P13, DOI 10.1016/0304-4165(76)90103-3; LAGNADO L, 1992, NEURON, V8, P995, DOI 10.1016/0896-6273(92)90122-T; MAKINO CL, 1990, J GEN PHYSIOL, V96, P1199, DOI 10.1085/jgp.96.6.1199; MALINSKI JA, 1992, BIOCHEMISTRY-US, V31, P9502, DOI 10.1021/bi00154a024; MILLER JA, 1975, J BIOL CHEM, V250, P4427; MILLER JA, 1977, BIOCHEMISTRY-US, V16, P2633, DOI 10.1021/bi00631a009; NEWTON AC, 1991, J BIOL CHEM, V266, P17725; NEWTON AC, 1993, J BIOL CHEM, V268, P18181; OHGURO H, 1995, J BIOL CHEM, V270, P14259, DOI 10.1074/jbc.270.24.14259; PALCZEWSKI K, 1991, J BIOL CHEM, V266, P12949; PEPPERBERG DR, 1992, EXP EYE RES, V54, P369, DOI 10.1016/0014-4835(92)90049-X; PERLMAN JI, 1982, J GEN PHYSIOL, V80, P885, DOI 10.1085/jgp.80.6.885; PUGH EN, 1990, VISION RES, V30, P1923, DOI 10.1016/0042-6989(90)90013-B; SITARAMAYYA A, 1983, J BIOL CHEM, V258, P2106; STRYER L, 1986, ANNU REV NEUROSCI, V9, P87, DOI 10.1146/annurev.ne.09.030186.000511; TYMINSKI PN, 1984, BIOCHEMISTRY-US, V23, P3986, DOI 10.1021/bi00312a028	44	31	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					19826	19830		10.1074/jbc.271.33.19826	http://dx.doi.org/10.1074/jbc.271.33.19826			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702691	hybrid			2022-12-25	WOS:A1996VC66900032
J	Cobuzzi, RJ; Burhans, WC; Beerman, TA				Cobuzzi, RJ; Burhans, WC; Beerman, TA			Inhibition of initiation of simian virus 40 DNA replication in infected BSC-1 cells by the DNA alkylating drug adozelesin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONCOVALENT BINDING SELECTIVITY; ANTITUMOR ANTIBIOTIC CC-1065; SEQUENCE SPECIFICITY; (+)-CC-1065; POLYMERASE; MECHANISM; INVITRO; DAMAGE; AGENT; SITE	Adozelesin is a member of a family of extraordinarily cytotoxic DNA damaging agents that bind to the DNA minor groove in a sequence-specific manner and form covalent adducts with adenines. Previous studies employing purified enzymes and adozelesin-modified template DNAs suggested that adozelesin-DNA adducts inhibit DNA replication at the level of nascent DNA chain elongation. In this study, neutral/neutral two-dimensional agarose gel electrophoresis was employed to analyze simian virus 40 (SV40) DNA replication intermediates recovered from adozelesin-treated SV40 virus-infected cells. SV40 replication intermediates rapidly disappeared from infected cells when they were treated with adozelesin, but not when the cells were also treated with aphidicolin to block maturation of replicating SV40 DNA. We conclude that the disappearance of SV40 replication intermediates induced by adozelesin treatment was a consequence of maturation of these intermediates in the absence of new initiation events. Adozelesin inhibition of nascent chain elongation is first observed at concentrations above those needed to block initiation. Adozelesin treatment inhibits SV40 DNA replication at concentrations that produce adducts on just a small fraction of the intracellular population of SV40 DNA molecules.	ROSWELL PK CANC INST,DEPT EXPT THERAPEUT,BUFFALO,NY 14263; ROSWELL PK CANC INST,DEPT MOL & CELLULAR BIOL,BUFFALO,NY 14263	Roswell Park Cancer Institute; Roswell Park Cancer Institute					NCI NIH HHS [CA16056] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016056] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BHUYAN BK, 1992, CANCER CHEMOTH PHARM, V30, P348, DOI 10.1007/BF00689961; BHUYAN BK, 1992, CANCER RES, V52, P5687; BOGER DL, 1991, P NATL ACAD SCI USA, V88, P1431, DOI 10.1073/pnas.88.4.1431; BOGER DL, 1991, J AM CHEM SOC, V113, P3980, DOI 10.1021/ja00010a046; BOGER DL, 1991, TETRAHEDRON, V47, P2661, DOI 10.1016/S0040-4020(01)81798-1; BREWER BJ, 1987, CELL, V51, P463, DOI 10.1016/0092-8674(87)90642-8; CHIDESTER CG, 1981, J AM CHEM SOC, V103, P7629, DOI 10.1021/ja00415a035; CLEAVER JE, 1990, RADIAT RES, V124, P294, DOI 10.2307/3577842; CLEAVER JE, 1992, RADIAT RES, V131, P338, DOI 10.2307/3578425; COLVIN M, 1990, CANCER CHEMOTHERAPY, P276; COTE S, 1993, ANTI-CANCER DRUG, V4, P327, DOI 10.1097/00001813-199306000-00006; FLEMING GF, 1994, J NATL CANCER I, V86, P368, DOI 10.1093/jnci/86.5.368; GILBERT DM, 1995, MOL CELL BIOL, V15, P2942; GILBERT DM, 1995, J BIOL CHEM, V270, P9597, DOI 10.1074/jbc.270.16.9597; GOSCIN LP, 1982, BIOCHEMISTRY-US, V21, P2513, DOI 10.1021/bi00539a034; HIGHTOWER RD, 1992, GYNECOL ONCOL, V47, P186, DOI 10.1016/0090-8258(92)90104-Q; HURLEY LH, 1988, BIOCHEMISTRY-US, V27, P3886, DOI 10.1021/bi00410a054; HURLEY LH, 1984, SCIENCE, V226, P843, DOI 10.1126/science.6494915; LAMB JR, 1989, INT J RADIAT BIOL, V56, P125, DOI 10.1080/09553008914551271; LEE CS, 1994, BIOCHEMISTRY-US, V33, P6024, DOI 10.1021/bi00185a043; Lee M Y, 1981, Prog Nucleic Acid Res Mol Biol, V26, P83; LI LH, 1991, INVEST NEW DRUG, V9, P137; LI LH, 1982, CANCER RES, V42, P990; LINSKENS MHK, 1990, CELL, V62, P845, DOI 10.1016/0092-8674(90)90258-G; MCHUGH MM, 1994, BIOCHEMISTRY-US, V33, P9158, DOI 10.1021/bi00197a019; MURNANE JP, 1995, CANCER METAST REV, V14, P17, DOI 10.1007/BF00690208; NGUYEN HN, 1992, CANCER CHEMOTH PHARM, V30, P37, DOI 10.1007/BF00686483; PAULOVICH AG, 1995, CELL, V82, P841, DOI 10.1016/0092-8674(95)90481-6; REYNOLDS VL, 1985, BIOCHEMISTRY-US, V24, P6228, DOI 10.1021/bi00343a029; SNAPKA RM, 1991, NUCLEIC ACIDS RES, V19, P5065, DOI 10.1093/nar/19.18.5065; SPADARI S, 1984, ADV EXP MED BIOL, V179, P169; SUN D, 1992, BIOCHEMISTRY-US, V31, P2822, DOI 10.1021/bi00125a025; SUN DK, 1992, ANTI-CANCER DRUG DES, V7, P15; SUN DY, 1992, J MED CHEM, V35, P1773, DOI 10.1021/jm00088a012; SWENSON DH, 1982, CANCER RES, V42, P2821; TEGTMEYER P, 1972, J VIROL, V10, P591, DOI 10.1128/JVI.10.4.591-598.1972; WARPEHOSKI MA, 1988, CHEM RES TOXICOL, V1, P315, DOI 10.1021/tx00006a001; WARPEHOSKI MA, 1988, J MED CHEM, V31, P590, DOI 10.1021/jm00398a017; WEILAND KL, 1991, BIOCHEMISTRY-US, V30, P7559, DOI 10.1021/bi00244a027; ZHUKOVSKAYA N, 1994, CARCINOGENESIS, V15, P2189, DOI 10.1093/carcin/15.10.2189; ZSIDO TJ, 1992, BIOCHEM PHARMACOL, V43, P1817, DOI 10.1016/0006-2952(92)90715-U	41	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					19852	19859		10.1074/jbc.271.33.19852	http://dx.doi.org/10.1074/jbc.271.33.19852			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702695	hybrid			2022-12-25	WOS:A1996VC66900036
J	Gu, XY; Bennett, RAO; Povirk, LF				Gu, XY; Bennett, RAO; Povirk, LF			End-joining of free radical-mediated DNA double-strand breaks in vitro is blocked by the kinase inhibitor wortmannin at a step preceding removal of damaged 3' termini	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							V(D)J RECOMBINATION; PROTEIN-KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; NONHOMOLOGOUS RECOMBINATION; MAMMALIAN-CELLS; SHUTTLE VECTOR; REPAIR; GENE; ACTIVATION; EXPRESSION	Both mammalian cells and Xenopus eggs possess activities for the joining of nonhomologous DNA ends, and such activities may play a major role in double-strand break repair. In order to dissect the biochemical processing of breaks with oxidatively modified ends, vectors containing various site-specific double-strand breaks with 3'-phosphoglycolate termini were constructed and treated with Xenopus egg extracts. These vectors were rejoined by the extracts at rates 30-100 times slower than comparable 3'-hydroxyl vectors. Vectors with blunt or cohesive 3'-phosphoglycolate ends yielded single repair products corresponding to simple phosphoglycolate removal followed by ligation, while a vector with mismatched ends was also rejoined but yielded a mixture of products, Addition of the kinase inhibitors wortmannin and dimethylaminopurine not only blocked rejoining, but also suppressed phosphoglycolate removal, implying an early, essential, kinase-dependent restriction point in the pathway. The results suggest that double-strand breaks with oxidatively modified ends are repaired in Xenopus eggs by a highly conservative and stringently regulated end-joining pathway, in which all biochemical processing of the breaks is contingent on both end alignment and a specific phosphorylation event. Several lines of indirect evidence suggest DNA-dependent protein kinase as a likely candidate for effecting this phosphorylation.	VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT PHARMACOL & TOXICOL,RICHMOND,VA 23298	Virginia Commonwealth University					NATIONAL CANCER INSTITUTE [R01CA040615] Funding Source: NIH RePORTER; NCI NIH HHS [CA40615] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BENNETT RAO, 1996, IN PRESS INT J RAD B; BLUNT T, 1995, CELL, V80, P813, DOI 10.1016/0092-8674(95)90360-7; Casnellie J E, 1991, Adv Pharmacol, V22, P167, DOI 10.1016/S1054-3589(08)60035-6; CHOUDHURY GG, 1994, KIDNEY INT, V46, P37, DOI 10.1038/ki.1994.242; DEMPLE B, 1991, P NATL ACAD SCI USA, V88, P11450, DOI 10.1073/pnas.88.24.11450; DERBYSHIRE MK, 1994, MOL CELL BIOL, V14, P156, DOI 10.1128/MCB.14.1.156; ENGLUND PT, 1972, J MOL BIOL, V66, P209, DOI 10.1016/0022-2836(72)90474-3; GETTS RC, 1994, J BIOL CHEM, V269, P15981; GOEDECKE W, 1992, MOL CELL BIOL, V12, P811, DOI 10.1128/MCB.12.2.811; GOEDECKE W, 1994, NUCLEIC ACIDS RES, V22, P2094, DOI 10.1093/nar/22.11.2094; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; JEGGO PA, 1990, MUTAT RES, V239, P1, DOI 10.1016/0165-1110(90)90028-A; KEITH CT, 1995, SCIENCE, V270, P50, DOI 10.1126/science.270.5233.50; KING JS, 1993, NUCLEIC ACIDS RES, V21, P1055, DOI 10.1093/nar/21.5.1055; KIRCHGESSNER CU, 1995, SCIENCE, V267, P1178, DOI 10.1126/science.7855601; KRASIN F, 1977, J MOL BIOL, V116, P81, DOI 10.1016/0022-2836(77)90120-6; LABHART P, 1995, P NATL ACAD SCI USA, V92, P2934, DOI 10.1073/pnas.92.7.2934; LEESMILLER SP, 1995, SCIENCE, V267, P1183, DOI 10.1126/science.7855602; LEHMAN CW, 1993, MOL CELL BIOL, V13, P6897, DOI 10.1128/MCB.13.11.6897; LOPEZ B, 1987, NUCLEIC ACIDS RES, V17, P6813; NORTH P, 1990, NUCLEIC ACIDS RES, V18, P6205, DOI 10.1093/nar/18.21.6205; PERGOLA F, 1993, MOL CELL BIOL, V13, P3464, DOI 10.1128/MCB.13.6.3464; PFEIFFER P, 1994, MOL CELL BIOL, V14, P888, DOI 10.1128/MCB.14.2.888; RESNICK MA, 1979, NUCLEIC ACIDS RES, V6, P3145, DOI 10.1093/nar/6.9.3145; RESNICK MA, 1976, MOL GEN GENET, V143, P119, DOI 10.1007/BF00266917; ROTH DB, 1986, MOL CELL BIOL, V6, P4295, DOI 10.1128/MCB.6.12.4295; SANDER M, 1995, BIOCHEMISTRY-US, V34, P1267, DOI 10.1021/bi00004a021; SCHAAL H, 1993, GENE, V124, P275, DOI 10.1016/0378-1119(93)90405-R; SEIDMAN MM, 1985, GENE, V38, P233, DOI 10.1016/0378-1119(85)90222-7; SMIDER V, 1994, SCIENCE, V266, P288, DOI 10.1126/science.7939667; TACCIOLI GE, 1994, SCIENCE, V265, P1442, DOI 10.1126/science.8073286; WALKER AI, 1985, EMBO J, V4, P139, DOI 10.1002/j.1460-2075.1985.tb02328.x; WANG P, 1990, CANCER RES, V50, P7527; WINTERS TA, 1992, NUCLEIC ACIDS RES, V20, P2573, DOI 10.1093/nar/20.10.2573; YANO H, 1993, J BIOL CHEM, V268, P25846	35	54	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					19660	19663		10.1074/jbc.271.33.19660	http://dx.doi.org/10.1074/jbc.271.33.19660			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702667	hybrid			2022-12-25	WOS:A1996VC66900008
J	Kon, N; Suhadolnik, RJ				Kon, N; Suhadolnik, RJ			Identification of the ATP binding domain of recombinant human 40-kDa 2',5'-oligoadenylate synthetase by photoaffinity labeling with 8-azido-[alpha-P-32]ATP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; ESCHERICHIA-COLI; 2-5A SYNTHETASE; HUMAN-CELLS; INTERFERON; 2-AZIDOADENOSINE; TRIPHOSPHATE; PURIFICATION; EXPRESSION; PEPTIDES	Three isoforms of the interferon-inducible 2',5'-oligoadenylate (2-5A) synthetase that require double-stranded RNA have been isolated and cloned. However, identification of the amino acid(s) of 2-5A synthetase directly interacting with ATP is crucial to the elucidation of the mechanism of the enzymatic conversion of ATP to 2',5'-oligoadenylates by 2-5A synthetase. Recombinant human 40-kDa 2-5A synthetase has been expressed as a glutathione S-transferase fusion protein in E. coli and purified to near homogeneity in milligram quantities. The azido photoprobe, 8-azido-[alpha-P-32]ATP, has been used to identify the ATP binding domain of the recombinant human 40-kDa 2-5A synthetase. Specific covalent photoincorporation of 8-azido-[alpha-P-32]ATP into the 2-5A synthetase, tryptic digestion of the covalently P-32-labeled enzyme, isolation of the photolabeled phosphopeptide by metal (Al3+) chelate chromatography, and high pressure liquid chromatography identified a P-32-pentapeptide, which has been assigned to the ATP binding domain of 2-5A synthetase. The radioactive pentapeptide has the sequence D(196)FLKQ(200) in which the photoprobe, 8-azido-[alpha-P-32]ATP, chemically modified the amino acid lysine 199. The catalytic importance of Lys(199) was further established by mutation of lysine 199 to arginine 199 and histidine 199 using site directed mutagenesis, The K199R and K199H recombinant human 40-kDa 2-5A synthetase mutants bind 8-azido-ATP and the allosteric activator, poly(I). poly(C) but are enzymatically inactive. These photoaffinity labeling and mutation data strongly suggest that lysine 199 is essential for the formation of a productive 2-5A synthetase-ATP double-stranded RNA complex for the enzymatic conversion of ATP to 2-5A.	TEMPLE UNIV, SCH MED, DEPT BIOCHEM, PHILADELPHIA, PA 19140 USA; TEMPLE UNIV, SCH MED, FELS INST CANC RES & MOL BIOL, PHILADELPHIA, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University					NATIONAL CANCER INSTITUTE [P30CA012227] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034765] Funding Source: NIH RePORTER; NCI NIH HHS [P30-CA12227] Funding Source: Medline; NIAID NIH HHS [R01-AI-34765] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARBER GN, 1995, MOL CELL BIOL, V15, P3138; Chebath J, 1985, Prog Clin Biol Res, V202, P149; CHEBATH J, 1987, J BIOL CHEM, V262, P3852; DOMBROWSKI KE, 1992, BIOCHEMISTRY-US, V31, P3785, DOI 10.1021/bi00130a008; FERBUS D, 1981, BIOCHEM BIOPH RES CO, V100, P847, DOI 10.1016/S0006-291X(81)80251-3; GHOSH SK, 1991, J BIOL CHEM, V266, P15293; GRAMMER JC, 1993, BIOCHEMISTRY-US, V32, P5725, DOI 10.1021/bi00073a001; HASSEL BA, 1993, EMBO J, V12, P3297, DOI 10.1002/j.1460-2075.1993.tb05999.x; IEHII Y, 1986, NUCLEIC ACIDS RES, V14, P10117; JULIN DA, 1987, J BIOL CHEM, V262, P9044; JUSTESEN J, 1980, P NATL ACAD SCI-BIOL, V77, P4618, DOI 10.1073/pnas.77.8.4618; KUNKEL TA, 1991, CURRENT PROTOCOLS MO, V1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEUNG S, 1995, MOL CELL BIOL, V15, P1312; LI SW, 1990, J BIOL CHEM, V265, P5470; MARIE I, 1992, J BIOL CHEM, V267, P9933; MULLER M, 1993, EMBO J, V12, P4221, DOI 10.1002/j.1460-2075.1993.tb06106.x; O IS, 1994, J BIOL CHEM, V269, P5009; OLCOTT MC, 1994, BIOCHEMISTRY-US, V33, P11935, DOI 10.1021/bi00205a032; PATTERSON JB, 1995, MOL CELL BIOL, V15, P5376, DOI 10.1128/mcb.15.10.5376; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; RINGHEIM GE, 1990, J BIOL CHEM, V265, P19472; SALVUCCI ME, 1992, BIOCHEMISTRY-US, V31, P4479, DOI 10.1021/bi00133a014; SAMUEL CE, 1991, VIROLOGY, V183, P1, DOI 10.1016/0042-6822(91)90112-O; SEN GC, 1992, J BIOL CHEM, V267, P5017; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITH DB, 1991, CURRENT PROTOCOLS MO, V2; SUHADOLNIK RJ, 1988, BIOCHEMISTRY-US, V27, P8846, DOI 10.1021/bi00424a024; SZUMILO T, 1993, J BIOL CHEM, V268, P17943; TRUVE E, 1993, PROG MOL SUBCELL BIO, V14, P139	30	33	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					19983	19990		10.1074/jbc.271.33.19983	http://dx.doi.org/10.1074/jbc.271.33.19983			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702715	hybrid			2022-12-25	WOS:A1996VC66900056
J	Morrical, SW; Beernink, HTH; Dash, A; Hempstead, K				Morrical, SW; Beernink, HTH; Dash, A; Hempstead, K			The gene 59 protein of bacteriophage T4 - Characterization of protein-protein interactions with gene 32 protein, the T4 single-stranded DNA binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HELICASE ASSEMBLY PROTEIN; NUCLEIC-ACIDS; REPLICATION; RECOMBINATION; PURIFICATION; MUTATIONS; REQUIRES; PHAGE	The gene 59 protein (gp59) of bacteriophage T4 stimulates the activities of gene 41 protein (gp41), the T4 replicative DNA helicase, by promoting the assembly of gp41 onto single-stranded (ss)-DNA molecules that are covered with cooperatively bound gene 32 protein (gp32). This helicase-ssDNA assembly process, which is important for the reconstitution of the primosome component of the T4 DNA replication fork, appears to require both gp59-gp41 and gp59-gp32 protein-protein interactions. In this study we characterize the physical and functional interactions of gp59 with gp32, the T4 ssDNA-binding protein. Experimental results presented herein indicate: 1) that gp59 binds specifically to both free and ssDNA-bound gp32 molecules; and 2) that in both cases binding involves contacts of gp32 (the so-called ''A-domain''). We further show that single-stranded DNA molecules coated with (gp32-A), a truncated form of gp32 lacking A-domain, are refractory to gp59-dependent helicase assembly. The data indicate that specific contacts between gp59 molecules and the A-domains of gp32 molecules are essential for gp59-dependent assembly of gp41 onto gp32-ssDNA complexes. Our results are consistent with a model in which gp59 binds to gp32 molecules within the gp32-ssDNA complex and therein forms a target site for helicase-ssDNA assembly.	UNIV VERMONT, VERMONT CANC CTR, COLL MED, BURLINGTON, VT 05405 USA; UNIV VERMONT, DEPT BIOCHEM, COLL MED, BURLINGTON, VT 05405 USA	University of Vermont; University of Vermont	Morrical, SW (corresponding author), UNIV VERMONT, DEPT MICROBIOL & MOL GENET, COLL MED, BURLINGTON, VT 05405 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048847, R56GM048847] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM48847] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alberts B.M., 1971, METHODS ENZYMOL, V21, P198; ALBERTS BM, 1987, PHILOS T ROY SOC B, V317, P395, DOI 10.1098/rstb.1987.0068; BARRY J, 1994, J BIOL CHEM, V269, P33063; BARRY J, 1994, J BIOL CHEM, V269, P33049; CHASE JW, 1986, ANNU REV BIOCHEM, V55, P103, DOI 10.1146/annurev.biochem.55.1.103; CUNNINGHAM RP, 1977, VIROLOGY, V80, P67, DOI 10.1016/0042-6822(77)90381-6; CUNNINGHAM RP, 1978, VIROLOGY, V88, P62, DOI 10.1016/0042-6822(78)90110-1; DOHERTY DH, 1982, MOL GEN GENET, V188, P77, DOI 10.1007/BF00332998; FORMOSA T, 1983, P NATL ACAD SCI-BIOL, V80, P2442, DOI 10.1073/pnas.80.9.2442; GAUSS P, 1983, P NATL ACAD SCI-BIOL, V80, P1669, DOI 10.1073/pnas.80.6.1669; GAUSS P, 1994, J BACTERIOL, V176, P1667, DOI 10.1128/jb.176.6.1667-1672.1994; HURLEY JM, 1993, J MOL BIOL, V229, P398, DOI 10.1006/jmbi.1993.1042; JIANG H, 1993, J BIOL CHEM, V268, P7904; KOWALCZYKOWSKI SC, 1981, J MOL BIOL, V145, P75, DOI 10.1016/0022-2836(81)90335-1; Kreuzer K. N., 1994, MOL BIOL BACTERIOP T, P28; Kreuzer Kenneth N., 1994, P89; LONBERG N, 1981, J MOL BIOL, V145, P123, DOI 10.1016/0022-2836(81)90337-5; MILLER H, 1987, METHOD ENZYMOL, V152, P145; MOISE H, 1976, NATURE, V259, P455, DOI 10.1038/259455a0; MORRICAL SW, 1994, J BIOL CHEM, V269, P33069; Mosig Gisela, 1994, P54; NEWPORT JW, 1981, J MOL BIOL, V145, P105, DOI 10.1016/0022-2836(81)90336-3; Nossal N.G., 1994, MOL BIOL BACTERIOP T, P43; SALINAS F, 1995, CELL, V82, P111, DOI 10.1016/0092-8674(95)90057-8; SPACCIAPOLI P, 1994, J BIOL CHEM, V269, P447; TARUMI K, 1995, J BIOL CHEM, V270, P2614, DOI 10.1074/jbc.270.6.2614; Williams Kenneth R., 1994, P301; WILLIAMS KR, 1978, J BIOL CHEM, V253, P2463; YAMAMOTO KR, 1970, VIROLOGY, V40, P734, DOI 10.1016/0042-6822(70)90218-7; YONESAKI T, 1994, J BIOL CHEM, V269, P1284	30	42	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					20198	20207		10.1074/jbc.271.33.20198	http://dx.doi.org/10.1074/jbc.271.33.20198			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702746	hybrid			2022-12-25	WOS:A1996VC66900088
J	Raufman, JP; Lin, JY; Raffaniello, RD				Raufman, JP; Lin, JY; Raffaniello, RD			Calcineurin mediates calcium-induced potentiation of adenylyl cyclase activity in dispersed chief cells from guinea pig stomach - Further evidence for cross-talk between signal transduction pathways that regulate pepsinogen secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASES; CYCLOSPORINE-A; PHOSPHATASES; PHOSPHORYLATION; INHIBITORS; CALMODULIN; CAMP; YANG; CA2+; YIN	In cholera toxin treated gastric chief cells, incubation with a cholinergic agonist (carbamylcholine), a regulatory peptide (cholecystokinin), or a calcium ionophore (A23187) causes a dose- and time-dependent potentiation of cAMP levels. Because this augmented response is calcium/calmodulin dependent, we hypothesized that it was mediated by calcineurin (protein phosphatase 2B). To test this hypothesis, we examined the actions of calcineurin inhibitors on secretagogue-induced potentiation of cAMP levels in guinea pig chief cells. Preincubation of cells with 0.1 CCM FK-506 completely prevented carbachol-induced augmentation of cAMP levels and pepsinogen secretion from cholera toxin-treated cells. Cyclosporin-A, another calcineurin inhibitor, also prevented the augmented cAMP response, FK-506 and cyclosporin inhibited augmentation of cAMP levels following treatment with cholecystokinin(26-33) and A23187, but not the smaller increase in cAMP following treatment with a phorbol ester that activates protein kinase C. Hence, the actions of calcineurin inhibitors were limited to secretagogues that increase cellular calcium, Rapamycin, an agent that competes with FK-506 for the immunophilin, FK binding protein 12, does not inhibit calcineurin. In the present study, preincubation with rapamycin did not prevent carbachol-induced augmentation of cAMP levels in cholera toxin-treated chief cells, However, a molar excess of rapamycin reversed the inhibitory actions of FK-506. These experiments provide further evidence that the actions of FK-506 on cholera toxin-treated gastric chief cells are caused by its inhibitory actions on calcineurin. FK-506 also inhibited potentiation of cAMP levels when carbachol was added to cells that were preincubated with forskolin, an agent that directly activates adenylyl cyclase. We conclude that, in gastric chief cells, calcineurin mediates crosstalk between the calcium/calmodulin and adenylyl cyclase signaling pathways.	SUNY HLTH SCI CTR,DEPT MED,GASTROINTESTINAL CELL BIOL LAB,BROOKLYN,NY 11203	State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center	Raufman, JP (corresponding author), UNIV ARKANSAS MED SCI HOSP,DIV GASTROENTEROL,SLOT 567,4301 W MARKHAM ST,LITTLE ROCK,AR 72205, USA.							BAUKAL AJ, 1994, J BIOL CHEM, V269, P24546; CALI JJ, 1994, J BIOL CHEM, V269, P12190; CHANG HY, 1995, NATURE, V376, P686, DOI 10.1038/376686a0; CHOI EJ, 1992, BIOCHEMISTRY-US, V31, P6492, DOI 10.1021/bi00143a019; COOPER DMF, 1995, NATURE, V374, P421, DOI 10.1038/374421a0; COOPERSTEIN SJ, 1995, BIOCHEM BIOPH RES CO, V2156, P75; GARDNER JD, 1979, BIOCHIM BIOPHYS ACTA, V585, P250, DOI 10.1016/0304-4165(79)90025-4; GROBLEWSKI GE, 1994, J BIOL CHEM, V269, P15111; HENDEY B, 1992, SCIENCE, V258, P296, DOI 10.1126/science.1384129; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; KISSINGER CR, 1995, NATURE, V378, P641, DOI 10.1038/378641a0; KUNZ J, 1993, TRENDS BIOCHEM SCI, V18, P334, DOI 10.1016/0968-0004(93)90069-Y; LAWSON MA, 1995, NATURE, V377, P75, DOI 10.1038/377075a0; Lu YF, 1996, NEUROSCI LETT, V205, P103, DOI 10.1016/0304-3940(96)12384-3; MACKINTOSH C, 1994, TRENDS BIOCHEM SCI, V19, P444, DOI 10.1016/0968-0004(94)90127-9; MALHOTRA R, 1993, GASTROENTEROLOGY, V104, pA139; MALHOTRA R, 1994, GASTROENTEROLOGY, V106, pA824; MONS N, 1995, TRENDS NEUROSCI, V18, P536, DOI 10.1016/0166-2236(95)98375-9; PAN GZ, 1992, BICOH BIOPHYS ACTA, V720, P338; PATERSON JM, 1995, BIOCHEM BIOPH RES CO, V214, P1000, DOI 10.1006/bbrc.1995.2385; RAUFMAN JP, 1984, AM J PHYSIOL, V247, pG95, DOI 10.1152/ajpgi.1984.247.1.G95; RAUFMAN JP, 1992, GASTROENTEROLOGY, V102, P699, DOI 10.1016/0016-5085(92)90124-H; RAUFMAN JP, 1987, J BIOL CHEM, V262, P5957; RAUFMAN JP, 1986, BIOCHEM BIOPH RES CO, V137, P281, DOI 10.1016/0006-291X(86)91207-6; RAUFMAN JP, 1992, BIOCHIM BIOPHYS ACTA, V1135, P61, DOI 10.1016/0167-4889(92)90166-9; SHENOLIKAR S, 1994, ANNU REV CELL BIOL, V10, P55, DOI 10.1146/annurev.cellbio.10.1.55; SNYDER SH, 1995, NAT MED, V1, P32, DOI 10.1038/nm0195-32; SUTLIFF VE, 1986, AM J PHYSIOL, V251, pG96, DOI 10.1152/ajpgi.1986.251.1.G96; TAN YH, 1993, SCIENCE, V262, P376, DOI 10.1126/science.7692598; TANG WJ, 1991, J BIOL CHEM, V266, P8595; WAYMAN GA, 1995, J BIOL CHEM, V270, P21480, DOI 10.1074/jbc.270.37.21480; WERA S, 1995, BIOCHEM J, V311, P17, DOI 10.1042/bj3110017	32	19	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					19877	19882		10.1074/jbc.271.33.19877	http://dx.doi.org/10.1074/jbc.271.33.19877			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702699	hybrid			2022-12-25	WOS:A1996VC66900040
J	Smith, BF; Stedman, H; Rajpurohit, Y; Henthorn, PS; Wolfe, JH; Patterson, DF; Giger, U				Smith, BF; Stedman, H; Rajpurohit, Y; Henthorn, PS; Wolfe, JH; Patterson, DF; Giger, U			Molecular basis of canine muscle type phosphofructokinase deficiency	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI PHOSPHOFRUCTOKINASE; SKELETAL-MUSCLE; GENE; EXPRESSION; ISOZYMES; CDNA; METABOLISM; HEMOLYSIS; MYOBLASTS; SUBUNITS	Muscle type phosphofructokinase (M-PFK) deficiency is a rare inherited glycogen storage disease in humans that causes exertional myopathy and hemolysis. The molecular basis of canine M-PFK deficiency, the only naturally occurring animal homologue, was investigated. Lack of M-PFK enzyme activity was caused by a nonsense mutation in the penultimate exon of the M-PFK gene, leading to rapid degradation of a truncated (40 amino acids) and therefore unstable M-PFK protein, A polymerase chain reaction-based test was devised to identify M-PFK-deficient and carrier animals, This represents one of only a fe rv inborn errors of metabolism where the molecular defect has been identified in a large animal model which can now be used to develop and assess novel therapeutic strategies.	UNIV PENN,SCH VET MED,MED GENET SECT,PHILADELPHIA,PA 19104; UNIV PENN,SCH VET MED,PATHOL LAB,PHILADELPHIA,PA 19104	University of Pennsylvania; University of Pennsylvania					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R55DK037602, R23DK037602, R01DK037602] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007170] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK37602] Funding Source: Medline; NIGMS NIH HHS [5-T32-GM07170] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANNEREN G, 1988, UPSALA J MED SCI, V93, P33, DOI 10.1517/03009734000000034; BUSCHMEIER B, 1987, J BIOL CHEM, V262, P9454; CREPIN KM, 1989, EUR J BIOCHEM, V183, P433, DOI 10.1111/j.1432-1033.1989.tb14946.x; DUNAWAY GA, 1988, BIOCHEM J, V251, P677, DOI 10.1042/bj2510677; GEKAKIS N, 1989, J BIOL CHEM, V264, P3658; GIGER U, 1987, J AM VET MED ASSOC, V191, P453; GIGER U, 1985, BLOOD, V65, P345; GIGER U, 1986, ANIM GENET, V17, P15, DOI 10.1111/j.1365-2052.1986.tb03184.x; GIGER U, 1988, ENZYME, V40, P25, DOI 10.1159/000469137; GUIXE V, 1988, ARCH BIOCHEM BIOPHYS, V264, P519, DOI 10.1016/0003-9861(88)90317-7; LAU FTK, 1987, BIOCHEMISTRY-US, V26, P4143, DOI 10.1021/bi00387a060; LEBRAS G, 1986, BIOCHEMISTRY-US, V25, P2490, DOI 10.1021/bi00357a031; LEE CP, 1987, J BIOL CHEM, V262, P4195; LEVANON D, 1987, BIOCHEM BIOPH RES CO, V147, P1182, DOI 10.1016/S0006-291X(87)80194-8; MANDARINO LJ, 1987, J CLIN INVEST, V80, P655, DOI 10.1172/JCI113118; MEHTA J, 1987, ANN NUTR METAB, V31, P35, DOI 10.1159/000177246; MNASKAR Y, 1991, ENZYME, V45, P137; MORRISON N, 1992, HUM GENET, V89, P105, DOI 10.1007/BF00207053; NAKAJIMA H, 1987, FEBS LETT, V223, P113, DOI 10.1016/0014-5793(87)80519-7; NAKAJIMA H, 1990, J BIOL CHEM, V265, P9392; NEWTON PA, 1989, BIOCHEM SOC T, V17, P1106, DOI 10.1042/bst0171106; NOBLE NA, 1989, BLOOD, V74, P475; POLYMEROPOULOS MH, 1991, NUCLEIC ACIDS RES, V19, P2517, DOI 10.1093/nar/19.9.2517; RABEN N, 1995, AM J HUM GENET, V56, P131; ROBERTS SJ, 1987, BIOCHEMISTRY-US, V26, P3437, DOI 10.1021/bi00386a028; ROWLAND LP, 1986, MYOLOGY, P1603; RYPNIEWSKI WR, 1989, J MOL BIOL, V207, P805, DOI 10.1016/0022-2836(89)90246-5; SHARMA PM, 1989, GENE, V77, P177, DOI 10.1016/0378-1119(89)90372-7; SHERMAN JB, 1994, AM J HUM GENET, V55, P305; SMITH BF, 1990, MOL CELL BIOL, V10, P3268, DOI 10.1128/MCB.10.6.3268; SMITH BF, 1995, GENE AMST, V168, P275; TRIGUN SK, 1987, CELL MOL BIOL, V33, P767; TRIGUN SK, 1988, ARCH GERONTOL GERIAT, V7, P239, DOI 10.1016/0167-4943(88)90007-6; VORA S, 1985, P NATL ACAD SCI USA, V82, P8109, DOI 10.1073/pnas.82.23.8109; WILLS KN, 1990, ARCH BIOCHEM BIOPHYS, V278, P81, DOI 10.1016/0003-9861(90)90234-P	35	36	36	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					20070	20074		10.1074/jbc.271.33.20070	http://dx.doi.org/10.1074/jbc.271.33.20070			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702726	hybrid			2022-12-25	WOS:A1996VC66900067
J	Turcatti, G; Nemeth, K; Edgerton, MD; Meseth, U; Talabot, F; Peitsch, M; Knowles, J; Vogel, H; Chollet, A				Turcatti, G; Nemeth, K; Edgerton, MD; Meseth, U; Talabot, F; Peitsch, M; Knowles, J; Vogel, H; Chollet, A			Probing the structure and function of the tachykinin neurokinin-2 receptor through biosynthetic incorporation of fluorescent amino acids at specific sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST TRANSFER RNAPHE; CONNECTING HELIX-C; TRANSFER-RNAS; NK2 RECEPTOR; XENOPUS OOCYTES; ENERGY-TRANSFER; BINDING; PROTEINS; ANTAGONISTS; NUCLEOTIDES	A general method for understanding the mechanisms of ligand recognition and activation of G protein coupled receptors has been developed, A study of ligand-receptor interactions in the prototypic seven-transmembrane neurokinin-a receptor (NK2) using this fluorescence-based approach is presented, A fluorescent unnatural amino acid was introduced at known sites into NK2 by suppression of UAG nonsense codons with the aid of a chemically misacylated synthetic tRNA specifically designed for the incorporation of unnatural amino acids during heterologous expression in Xenopus oocytes, Fluorescence-labeled NK2 mutants containing an unique 3-N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)-2,3-diaminopropionic acid (NBD-Dap) residue at either site 103, in the first extracellular loop, or 248, in the third cytoplasmic loop, were functionally active, The fluorescent NK2 mutants were investigated by microspectrofluorimetry in a native membrane environment, Intermolecular distances were determined by measuring the fluorescence resonance energy transfer (FRET) between the fluorescent unnatural amino acid and a fluorescently labeled NK2 heptapeptide antagonist, These distances, calculated by the theory of Forster, permit to fix the ligand in space and define the structure of the receptor in a molecular model for NK2 ligand-receptor interactions, Our data are the first report of the incorporation of a fluorescent unnatural amino acid into a membrane protein in intact cells by the method of nonsense codon suppression, as well as the first measurement of experimental distances between a G protein-coupled receptor and its ligand by FRET, The method presented here can be generally applied to the analysis of spatial relationships in integral membrane proteins such as receptors or channels.	GLAXO WELLCOME, GENEVA BIOMED RES INST, CH-1228 GENEVA, SWITZERLAND; ECOLE POLYTECH FED LAUSANNE, INST CHIM PHYS, CH-1015 LAUSANNE, SWITZERLAND	GlaxoSmithKline; Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne			Vogel, Horst/AAJ-5490-2021; Peitsch, Manuel/J-7416-2017	Peitsch, Manuel/0000-0001-5324-359X				AKINSTALL S, 1994, FEBS LETT, V338, P75; BAIN JD, 1991, BIOCHEMISTRY-US, V30, P5411, DOI 10.1021/bi00236a013; BALDWIN JM, 1993, EMBO J, V12, P1693, DOI 10.1002/j.1460-2075.1993.tb05814.x; BRADSHAW CG, 1994, J MED CHEM, V37, P1991, DOI 10.1021/jm00039a012; BRUCE AG, 1982, P NATL ACAD SCI-BIOL, V79, P7127, DOI 10.1073/pnas.79.23.7127; BURSTEIN ES, 1995, J BIOL CHEM, V270, P3141, DOI 10.1074/jbc.270.7.3141; CHERRY JM, 1991, METHOD CELL BIOL, V36, P675; Chollet Andre, 1996, P177; CORNISH VW, 1995, ANGEW CHEM INT EDIT, V34, P621, DOI 10.1002/anie.199506211; FARAHBAKHSH ZT, 1995, BIOCHEMISTRY-US, V34, P8812, DOI 10.1021/bi00027a033; FAY SP, 1993, BIOCHEMISTRY-US, V32, P1627, DOI 10.1021/bi00057a029; FORSTER T, 1948, ANN PHYS-BERLIN, V2, P55, DOI 10.1002/andp.19484370105; GETHER U, 1995, J BIOL CHEM, V270, P28268; HARADA Y, 1987, J NEUROSCI, V7, P3265; Herzyk P, 1995, BIOPHYS J, V69, P2419, DOI 10.1016/S0006-3495(95)80112-8; HUBBELL WL, 1994, CURR OPIN STRUC BIOL, V4, P566, DOI 10.1016/S0959-440X(94)90219-4; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; LAKOWICZ J, 1983, PRINCIPLES FLUORESCE, P131; LAKOWICZ JR, 1990, BIOPHYS CHEM, V36, P99, DOI 10.1016/0301-4622(90)85014-W; LEFKOWITZ RJ, 1993, TRENDS PHARMACOL SCI, V14, P303, DOI 10.1016/0165-6147(93)90048-O; LIU J, 1995, P NATL ACAD SCI USA, V92, P11642, DOI 10.1073/pnas.92.25.11642; NAKANISHI S, 1991, ANNU REV NEUROSCI, V14, P123, DOI 10.1146/annurev.ne.14.030191.001011; NEMETH K, 1995, J BIOL CHEM, V270, P27601, DOI 10.1074/jbc.270.46.27601; NOREN CJ, 1990, NUCLEIC ACIDS RES, V18, P83, DOI 10.1093/nar/18.1.83; NOREN CJ, 1989, SCIENCE, V244, P182, DOI 10.1126/science.2649980; NOWAK MW, 1995, SCIENCE, V268, P439, DOI 10.1126/science.7716551; RIDGE KD, 1995, BIOCHEMISTRY-US, V34, P8804, DOI 10.1021/bi00027a032; ROBERTSON SA, 1991, J AM CHEM SOC, V113, P2722, DOI 10.1021/ja00007a055; ROSENKILDE MM, 1994, J BIOL CHEM, V269, P28160; SAMPSON JR, 1989, SCIENCE, V243, P1363; SCHERTLER GFX, 1993, NATURE, V362, P770, DOI 10.1038/362770a0; SMITH PW, 1993, BIOORG MED CHEM LETT, V3, P931, DOI 10.1016/S0960-894X(00)80695-2; SOLARI G, 1977, NUCLEIC ACIDS RES, V4, P1873; STRYER L, 1978, ANNU REV BIOCHEM, V47, P819, DOI 10.1146/annurev.bi.47.070178.004131; TURCATTI G, 1995, BIOCHEMISTRY-US, V34, P3972, DOI 10.1021/bi00012a015; VOGEL H, 1993, EUR J BIOCHEM, V212, P305, DOI 10.1111/j.1432-1033.1993.tb17663.x; WALKER P, 1994, J BIOL CHEM, V269, P2863; WEBER G, 1957, T FARADAY SOC, V53, P646, DOI 10.1039/tf9575300646; WHITE SH, 1994, CURR OPIN STRUC BIOL, V4, P79, DOI 10.1016/S0959-440X(94)90063-9; ZOZYULA SA, 1990, PROTEIN ENG, V3, P453	41	110	167	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					19991	19998		10.1074/jbc.271.33.19991	http://dx.doi.org/10.1074/jbc.271.33.19991			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702716	hybrid			2022-12-25	WOS:A1996VC66900057
J	Chamberlain, LH; Henry, J; Burgoyne, RD				Chamberlain, LH; Henry, J; Burgoyne, RD			Cysteine string proteins are associated with chromaffin granules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRESYNAPTIC CALCIUM-CHANNEL; SYNAPTIC VESICLES; SUPPRESSION CLONING; ENDOCRINE-CELLS; DROSOPHILA; MUTANTS; NEURONS; CDNA; RAT	In this work, we have examined the subcellular distribution of cysteine string proteins (Csps) in bovine adrenal medullary chromaffin cells. Csps did not, leak from digitonin-permeabilized chromaffin cells, suggesting that there is no cytosolic pool of the protein in these cells. Subcellular fractionation studies confirmed that there was essentially no Csp immunoreactivity in the cytosolic fraction. However, immunoreactivity was detected in the membrane fractions of these cells. Csp immunoreactivity codistributed with dopamine beta-hydroxylase, a granule marker protein, in sucrose gradient-separated granule fractions. Immunofluorescence studies showed that all chromaffin cells in culture were stained with a punctate appearance consistent with a granular localization. These results mere confirmed by immunogold labeling which demonstrated specific labeling of chromaffin granule membranes. In addition to its presence on synaptic vesicles, cysteine. string protein is therefore a bona fide chromaffin granule membrane protein.	UNIV LIVERPOOL, PHYSIOL LAB, LIVERPOOL L69 3BX, MERSEYSIDE, ENGLAND; UNIV LIVERPOOL, DEPT VET PRECLIN SCI, LIVERPOOL L69 3BX, MERSEYSIDE, ENGLAND	University of Liverpool; University of Liverpool			Burgoyne, Robert/C-6706-2008; Burgoyne, Robert D/P-6641-2019	Burgoyne, Robert/0000-0002-9219-0387; Burgoyne, Robert D/0000-0002-9219-0387	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BAUMERT M, 1990, J CELL BIOL, V110, P1285, DOI 10.1083/jcb.110.4.1285; BRAUN JEA, 1995, NEUROPHARMACOLOGY, V34, P1361, DOI 10.1016/0028-3908(95)00114-L; BURGOYNE RD, 1992, NEUROMETHODS, V20, P433; Chamberlain LH, 1996, J BIOL CHEM, V271, P7320, DOI 10.1074/jbc.271.13.7320; DECAMILLI P, 1983, J CELL BIOL, V96, P1355, DOI 10.1083/jcb.96.5.1355; GUNDERSEN CB, 1992, NEURON, V9, P527, DOI 10.1016/0896-6273(92)90190-O; GUNDERSEN CB, 1994, J BIOL CHEM, V269, P19197; KOHAN SA, 1995, J NEUROSCI, V15, P6230; MASTROGIACOMO A, 1994, SCIENCE, V263, P981, DOI 10.1126/science.7906056; MASTROGIACOMO A, 1994, J NEUROCHEM, V62, P873; MASTROGIACOMO A, 1995, MOL BRAIN RES, V28, P12, DOI 10.1016/0169-328X(94)00172-B; NAVONE F, 1986, J CELL BIOL, V103, P2511, DOI 10.1083/jcb.103.6.2511; SARAFIAN T, 1987, J BIOL CHEM, V262, P16671; UMBACH JA, 1991, ANN NY ACAD SCI, V635, P443, DOI 10.1111/j.1749-6632.1991.tb36522.x; UMBACH JA, 1994, NEURON, V13, P899, DOI 10.1016/0896-6273(94)90255-0; VANDEGOOR J, 1995, P NATL ACAD SCI USA, V92, P5739, DOI 10.1073/pnas.92.12.5739; ZINSMAIER KE, 1994, SCIENCE, V263, P977, DOI 10.1126/science.8310297; ZINSMAIER KE, 1990, J NEUROGENET, V7, P15, DOI 10.3109/01677069009084150	18	65	67	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19514	19517		10.1074/jbc.271.32.19514	http://dx.doi.org/10.1074/jbc.271.32.19514			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702643	hybrid			2022-12-25	WOS:A1996VB68400077
J	Wang, ZD; Gurel, O; Baatz, JE; Notter, RH				Wang, ZD; Gurel, O; Baatz, JE; Notter, RH			Acylation of pulmonary surfactant protein-C is required for its optimal surface active interactions with phospholipids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYPEPTIDE SP-C; NATURAL LUNG SURFACTANT; AIR-WATER-INTERFACE; SP-B; BIOPHYSICAL ACTIVITY; SECONDARY STRUCTURE; DIPALMITOYL PHOSPHATIDYLCHOLINE; MIXTURES; LIPIDS; SEPARATION	This study investigates the importance of thioester-linked acyl groups in lung surfactant protein C (SP-C) in facilitating interactions with phospholipids that yield functionally important surface active behaviors, Native SP-C, palmitoylated at cysteine residues at positions 5 and 6, was isolated from bovine lung surfactant by liquid chromatography, Deacylated SP C (dSP-C), unchanged in composition and sequence from SP-C but having a decreased alpha-helical content in films with dipalmitoyl phosphatidylcholine (DPPC) of 52 versus 70%, was obtained by treatment with 0.1 M sodium carbonate buffer at pH 10, Surface activity was studied for SP-C and dSP-C combined with column-purified phospholipids (PPL) from calf lung surfactant or with synthetic phospholipids (DPPC or a synthetic phospholipid mixture (SPL) containing 50:35:15, DPPC:egg phosphatidylcholine:egg phosphatidylglycerol). Interfacial measurements included surface pressure time adsorption isotherms for dispersed surfactants with diffusion minimized, dynamic surface pressure area isotherms and respreading for films in the Wilhelmy balance, and overall surface tension lowering at physiologic cycling rate in oscillating bubble experiments, Dispersions of PPL:SP-C and SPL:SP-C rapidly adsorbed to high equilibrium surface pressures of 47-48 mN/m, significantly better than corresponding dispersions containing dSP-C. The adsorption of PPL:dSP-C was essentially unchanged from that of PPL alone, and the adsorption of SPL:dSP-C was improved only slightly over SPL alone, In Wilhelmy balance studies, dynamic respreading was significantly improved over phospholipids alone in films of SP-C plus PPL, SPL, or DPPC. Respreading was improved less markedly by dSP-C in corresponding films with SPL or DPPC and not at all in films with PPL. Maximum surface pressures were also higher in cycled films of SP-C vel sus dSP-C combined with PPL or SPL, In bubble experiments (37 degrees C, 20 cycles/min), dispersions of PPL:SP-C and SPL:SP-C reached low minimum surface tensions of <1 and 5 mN/m, respectively, whereas PPL:dSP-C and SPL:dSP-C only reached minima of similar to 20 mN/m as did PPL and SPL alone, Acylation in SP-C is crucial for its interactions with phospholipids over the full spectrum of adsorption and dynamic surface behaviors important for lung surfactant.	UNIV ROCHESTER,DEPT PEDIAT,ROCHESTER,NY 14642; UNIV ROCHESTER,DEPT ENVIRONM MED,ROCHESTER,NY 14642; UNIV ROCHESTER,DEPT CHEM ENGN,ROCHESTER,NY 14642; MED UNIV S CAROLINA,DEPT PEDIAT,CHARLESTON,SC 29425	University of Rochester; University of Rochester; University of Rochester; Medical University of South Carolina				Baatz, John/0000-0001-5870-1000	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL036543] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-36543] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAATZ JE, 1992, CHEM PHYS LIPIDS, V63, P91, DOI 10.1016/0009-3084(92)90026-L; CLEMENTS JA, 1957, P SOC EXP BIOL MED, V95, P170; CREUWELS LAJM, 1993, J BIOL CHEM, V268, P26752; CREUWELS LAJM, 1995, BBA-LIPID LIPID MET, V1254, P326, DOI 10.1016/0005-2760(94)00195-5; CREUWELS LAJM, 1995, J BIOL CHEM, V270, P16225, DOI 10.1074/jbc.270.27.16225; CURSTEDT T, 1987, EUR J BIOCHEM, V168, P255, DOI 10.1111/j.1432-1033.1987.tb13414.x; CURSTEDT T, 1990, P NATL ACAD SCI USA, V87, P2985, DOI 10.1073/pnas.87.8.2985; ELLEDGE B W, 1989, American Review of Respiratory Disease, V139, pA285; ENHORNING G, 1977, J APPL PHYSIOL, V43, P198, DOI 10.1152/jappl.1977.43.2.198; GLASSER SW, 1988, J BIOL CHEM, V263, P9; GUNTHER A, 1993, AM J PHYSIOL, V265, pL186, DOI 10.1152/ajplung.1993.265.2.L186; HALL SB, 1993, J APPL PHYSIOL, V75, P468, DOI 10.1152/jappl.1993.75.1.468; HALL SB, 1994, J LIPID RES, V35, P1386; HAWCO MW, 1981, J APPL PHYSIOL, V51, P509, DOI 10.1152/jappl.1981.51.2.509; HOROWITZ AD, 1993, BIOCHEMISTRY-US, V32, P9513, DOI 10.1021/bi00088a001; HOROWITZ AD, 1995, CHEM PHYS LIPIDS, V76, P27, DOI 10.1016/0009-3084(94)02426-6; HOROWITZ AD, 1992, BIOCHIM BIOPHYS ACTA, V1107, P44, DOI 10.1016/0005-2736(92)90327-I; JAMES G, 1989, J BIOL CHEM, V264, P20998; JOHANSSON J, 1995, FEBS LETT, V362, P261, DOI 10.1016/0014-5793(95)00216-V; JOHANSSON J, 1994, EUR RESPIR J, V7, P372, DOI 10.1183/09031936.94.07020372; JOHANSSON J, 1995, BIOCHEM J, V307, P535, DOI 10.1042/bj3070535; JOHANSSON J, 1988, FEBS LETT, V232, P61, DOI 10.1016/0014-5793(88)80386-7; JOHANSSON J, 1994, BIOCHEMISTRY-US, V33, P6015, DOI 10.1021/bi00185a042; JOHANSSON J, 1991, FEBS LETT, V281, P119, DOI 10.1016/0014-5793(91)80373-B; KAPLAN RS, 1985, ANAL BIOCHEM, V150, P97, DOI 10.1016/0003-2697(85)90445-2; KELLER A, 1992, AM J RESP CELL MOL, V6, P601, DOI 10.1165/ajrcmb/6.6.601; KUROKI Y, 1994, J BIOL CHEM, V269, P25943; NOTTER R H, 1989, P19; NOTTER RH, 1980, J LIPID RES, V21, P10; NOTTER RH, 1982, PEDIATR RES, V16, P515, DOI 10.1203/00006450-198207000-00003; NOTTER RH, 1983, CHEM PHYS LIPIDS, V33, P67, DOI 10.1016/0009-3084(83)90009-9; NOTTER RH, 1986, PEDIATR RES, V20, P97, DOI 10.1203/00006450-198601000-00026; PASTRANA B, 1991, BIOCHEMISTRY-US, V30, P10058, DOI 10.1021/bi00105a033; PATTLE RE, 1955, NATURE, V175, P1125, DOI 10.1038/1751125b0; PEREZGIL J, 1993, BIOCHIM BIOPHYS ACTA, V1168, P261, DOI 10.1016/0005-2760(93)90181-8; PEREZGIL J, 1992, BIOPHYS J, V63, P197, DOI 10.1016/S0006-3495(92)81582-5; PEREZGIL J, 1994, BIOCHEM SOC T, V22, pS372, DOI 10.1042/bst022372s; QANBAR R, 1995, BBA-LIPID LIPID MET, V1255, P251, DOI 10.1016/0005-2760(94)00224-M; ROSS GF, 1986, J BIOL CHEM, V261, P14283; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHMIDT MFG, 1989, BIOCHIM BIOPHYS ACTA, V988, P411, DOI 10.1016/0304-4157(89)90013-0; SEEGER W, 1991, BIOCHIM BIOPHYS ACTA, V1081, P45, DOI 10.1016/0005-2760(91)90248-G; SHIFFER K, 1993, BIOCHEMISTRY-US, V32, P590, DOI 10.1021/bi00053a026; SHIN YS, 1962, ANAL CHEM, V34, P1164, DOI 10.1021/ac60189a043; SIMATOS GA, 1990, BIOCHEMISTRY-US, V29, P5807, DOI 10.1021/bi00476a023; SMALL DM, 1986, HDB LIPID RES PHYSIC, V4; STULTS JT, 1991, AM J PHYSIOL, V261, pL118, DOI 10.1152/ajplung.1991.261.2.L118; SUDO Y, 1992, EMBO J, V11, P2095, DOI 10.1002/j.1460-2075.1992.tb05268.x; TABAK SA, 1977, REV SCI INSTRUM, V48, P1196, DOI 10.1063/1.1135220; TOUCHSTONE JC, 1980, LIPIDS, V15, P61, DOI 10.1007/BF02534120; TURCOTTE JG, 1977, BIOCHIM BIOPHYS ACTA, V488, P235, DOI 10.1016/0005-2760(77)90181-3; VANDENBUSSCHE G, 1992, EUR J BIOCHEM, V203, P201, DOI 10.1111/j.1432-1033.1992.tb19848.x; VANGOLDE LMG, 1988, PHYSIOL REV, V68, P374, DOI 10.1152/physrev.1988.68.2.374; VORBROKER DK, 1992, BIOCHIM BIOPHYS ACTA, V1105, P161, DOI 10.1016/0005-2736(92)90175-L; VOSS T, 1992, BIOCHIM BIOPHYS ACTA, V1138, P261, DOI 10.1016/0925-4439(92)90002-5; WANG ZD, 1995, J LIPID RES, V36, P1283; WHITSETT JA, 1992, PULMONARY SURFACTANT, P55; ZHANG YP, 1992, BIOCHEMISTRY-US, V31, P11579, DOI 10.1021/bi00161a042	58	57	64	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19104	19109		10.1074/jbc.271.32.19104	http://dx.doi.org/10.1074/jbc.271.32.19104			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702584	hybrid			2022-12-25	WOS:A1996VB68400018
J	Colombo, MI; Taddese, M; Whiteheart, SW; Stahl, PD				Colombo, MI; Taddese, M; Whiteheart, SW; Stahl, PD			A possible predocking attachment site for N-ethylmaleimide-sensitive fusion protein - Insights from in vitro endosome fusion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VESICULAR TRANSPORT; ALPHA-SNAP; REGULATED EXOCYTOSIS; MEMBRANE-FUSION; VESICLES; NSF; HYDROLYSIS; REQUIRES; RECEPTOR; PARTICLE	N-Ethylmaleimide-sensitive fusion protein (NSF) is an ubiquitous protein required for multiple vesicular transport events, We have investigated the role of the two nucleotide-binding regions of NSF in endosomal fusion by analyzing NSF mutants in a cell-free system, Our results indicate that mutations on the first ATP-binding domain, that render a protein defective in either ATP binding or ATP hydrolysis, results in almost complete inhibition of endosomal fusion, A mutation in the second ATP-binding site of NSF was only slightly inhibitory. The inhibitory effect was observed only when the mutant proteins were added at early times during the fusion reaction indicating that NSF may be required for an early step during the docking/fusion process, Binding studies using Western blotting reveal that the binding of NSF mutants to endosomal membranes is differentially affected by Ca2+, Our results indicate that NSF, depending on its nucleotide state, may interact with membranes via an alternate mechanism, Our findings suggest the existence of a predocking binding site either independent of the docking complex or a site that leads to the formation of the SNAP-SNARE complex (e,g, 20 S particle).	UNIV KENTUCKY,COLL MED,DEPT BIOCHEM,ALBERT B CHANDLER MED CTR,LEXINGTON,KY 40536	University of Kentucky	Colombo, MI (corresponding author), WASHINGTON UNIV,SCH MED,DEPT CELL BIOL & PHYSIOL,660 S EUCLID AVE,ST LOUIS,MO 63110, USA.		Stahl, Philip/D-6315-2012	Whiteheart, Sidney/0000-0001-5577-0473				BARBIERI MA, 1994, J BIOL CHEM, V269, P18720; BECKERS CJM, 1989, NATURE, V339, P397, DOI 10.1038/339397a0; BENNETT MK, 1995, CURR OPIN CELL BIOL, V7, P581, DOI 10.1016/0955-0674(95)80016-6; BLOCK MR, 1988, P NATL ACAD SCI USA, V85, P7852, DOI 10.1073/pnas.85.21.7852; CHAMBERLAIN LH, 1995, J CELL BIOL, V130, P1063, DOI 10.1083/jcb.130.5.1063; COLOMBO MI, 1992, METHOD ENZYMOL, V219, P32; DIAZ R, 1988, J BIOL CHEM, V263, P6093; DIAZ R, 1989, NATURE, V339, P398, DOI 10.1038/339398a0; ERDMANN R, 1991, CELL, V64, P499, DOI 10.1016/0092-8674(91)90234-P; GEPPERT M, 1994, CELL, V79, P717, DOI 10.1016/0092-8674(94)90556-8; HANSON PI, 1995, J BIOL CHEM, V270, P16955, DOI 10.1074/jbc.270.28.16955; HONG RM, 1994, FEBS LETT, V350, P253, DOI 10.1016/0014-5793(94)00778-0; LIAN JP, 1994, NATURE, V372, P698, DOI 10.1038/372698a0; MORGAN A, 1995, EMBO J, V14, P232, DOI 10.1002/j.1460-2075.1995.tb06996.x; NAGIEC EE, 1995, J BIOL CHEM, V270, P29182, DOI 10.1074/jbc.270.49.29182; RODRIGUEZ L, 1994, MOL BIOL CELL, V5, P773, DOI 10.1091/mbc.5.7.773; ROTHMAN JE, 1994, CURR BIOL, V4, P220, DOI 10.1016/S0960-9822(00)00051-8; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SCHIAVO G, 1995, NATURE, V378, P733, DOI 10.1038/378733a0; SOGAARD M, 1994, CELL, V78, P937, DOI 10.1016/0092-8674(94)90270-4; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; Steel GJ, 1996, EMBO J, V15, P745, DOI 10.1002/j.1460-2075.1996.tb00410.x; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; SUMIDA M, 1994, J BIOL CHEM, V269, P20636; SZTUL E, 1993, J BIOL CHEM, V268, P1876; TAGAYA M, 1993, J BIOL CHEM, V268, P2662; WALCHSOLIMENA C, 1995, J CELL BIOL, V128, P637, DOI 10.1083/jcb.128.4.637; WATTENBERG BW, 1992, J CELL BIOL, V118, P1321, DOI 10.1083/jcb.118.6.1321; WEIDMAN PJ, 1989, J CELL BIOL, V108, P1589, DOI 10.1083/jcb.108.5.1589; WHITEHEART SW, 1994, J CELL BIOL, V126, P945, DOI 10.1083/jcb.126.4.945; WHITEHEART SW, 1995, TRENDS CELL BIOL, V5, P64, DOI 10.1016/S0962-8924(00)88948-5; WILSON DW, 1992, J CELL BIOL, V117, P531, DOI 10.1083/jcb.117.3.531; WILSON DW, 1989, NATURE, V339, P355, DOI 10.1038/339355a0; Zerial M, 1993, CURR OPIN CELL BIOL, V5, P613, DOI 10.1016/0955-0674(93)90130-I	34	51	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18810	18816		10.1074/jbc.271.31.18810	http://dx.doi.org/10.1074/jbc.271.31.18810			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702539	hybrid			2022-12-25	WOS:A1996VB68300077
J	Hoffman, JF; Linderman, JJ; Omann, GM				Hoffman, JF; Linderman, JJ; Omann, GM			Receptor up-regulation, internalization, and interconverting receptor states - Critical components of a quantitative description of N-formyl peptide-receptor dynamics in the neutrophil	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-BINDING-PROTEINS; METHIONYL-LEUCYL-PHENYLALANINE; REAL-TIME ANALYSIS; SIGNAL TRANSDUCTION; CHEMOTACTIC PEPTIDE; HUMAN-GRANULOCYTES; POLYMORPHONUCLEAR LEUKOCYTES; CHEMOATTRACTANT RECEPTORS; CYTOSKELETAL ACTIVATION; OXIDANT PRODUCTION	High resolution kinetic data of the binding of fluorescent peptide to the N-formyl peptide receptor of neutrophils at 37 degrees C has allowed for the development of a ligand binding model that predicts statistically larger binding rate constants than those previously reported for intact neutrophils. The new model accounts for ligand association and dissociation, receptor up-regulation, ligand-receptor complex internalization, a change in receptor affinity, and the quenching of internalized fluorescent ligand. We determined that receptor up-regulation is both agonist- and temperature-induced and is inhibited by both phenylarsine oxide and pertussis toxin treatment. Model fits of ligand association to pertussis toxin-treated cells show that while receptor upregulation was inhibited, rate constants for ligand binding, receptor affinity conversion, and internalization of ligand-receptor complexes were unaffected. Results suggest G(1)-protein mediated receptor up-regulation and G(1)-protein-independent receptor affinity conversion, Simulation of ligand infusion using our model gives insight into the quantitative and dynamic relationship between the low affinity ligand-receptor complex and the actin polymerization response.	VET ADM MED CTR, RES SERV 151, ANN ARBOR, MI 48105 USA; UNIV MICHIGAN, DEPT CHEM ENGN, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, SCH MED, DEPT BIOL CHEM, ANN ARBOR, MI 48105 USA; UNIV MICHIGAN, SCH MED, DEPT SURG, ANN ARBOR, MI 48105 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008353] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM08353] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS JA, 1995, THESIS U MICHIGAN AN; ANDERSON BO, 1990, J TRAUMA, V30, pS44; DECKERT M, 1994, BIOCHEM J, V297, P567, DOI 10.1042/bj2970567; FAY SP, 1991, BIOCHEMISTRY-US, V30, P5066, DOI 10.1021/bi00234a033; FINNEY DA, 1983, CYTOMETRY, V4, P54, DOI 10.1002/cyto.990040108; FLETCHER MP, 1983, BLOOD, V62, P792; FOREHAND JR, 1989, J CLIN INVEST, V83, P74, DOI 10.1172/JCI113887; GIERSCHIK P, 1992, CURR TOP MICROBIOL, V175, P69; GOLDMAN DW, 1986, J IMMUNOL, V137, P1971; GUTHRIE LA, 1984, J EXP MED, V160, P1656, DOI 10.1084/jem.160.6.1656; HOFFMAN JF, 1995, THESIS U MICHIGAN AN, P153; HYSLOP PA, 1984, ANAL BIOCHEM, V141, P280, DOI 10.1016/0003-2697(84)90457-3; JESAITIS A J, 1988, P325; JESAITIS AJ, 1988, J CELL BIOL, V107, P921, DOI 10.1083/jcb.107.3.921; JESAITIS AJ, 1993, EUR J HAEMATOL, V51, P288; JESAITIS AJ, 1983, J BIOL CHEM, V258, P1968; JESAITIS AJ, 1984, J CELL BIOL, V98, P1378, DOI 10.1083/jcb.98.4.1378; JESAITIS AJ, 1989, J CELL BIOL, V109, P2783, DOI 10.1083/jcb.109.6.2783; JOHANSSON B, 1993, J CELL BIOL, V121, P1281, DOI 10.1083/jcb.121.6.1281; KLOTZ KN, 1994, BIOESSAYS, V16, P193, DOI 10.1002/bies.950160310; KLOTZ KN, 1994, J IMMUNOL, V152, P801; KOO C, 1982, BIOCHEM BIOPH RES CO, V106, P442, DOI 10.1016/0006-291X(82)91130-5; KOREN R, 1976, BIOCHEMISTRY-US, V15, P1165, DOI 10.1021/bi00650a032; KUBES P, 1993, CAN J PHYSIOL PHARM, V71, P88, DOI 10.1139/y93-013; Lauffenburger D. A., 1993, RECEPTORS MODELS BIN; LOW DA, 1981, P NATL ACAD SCI-BIOL, V78, P2340, DOI 10.1073/pnas.78.4.2340; LU DJ, 1990, J BIOL CHEM, V265, P13721; MIKLAVC A, 1990, BIOCHEM PHARMACOL, V40, P663, DOI 10.1016/0006-2952(90)90299-Z; MOOD AM, 1974, INTRO THEORY STATIST; NEUBIG RR, 1993, MOL PHARMACOL, V43, P734; NIEDEL J, 1979, J BIOL CHEM, V254, P700; NORGAUER J, 1991, J IMMUNOL, V146, P975; NORGAUER J, 1989, J CELL BIOL, V109, P1133, DOI 10.1083/jcb.109.3.1133; OLSSON I, 1980, ALLERGY, V35, P1, DOI 10.1111/j.1398-9995.1980.tb01711.x; OMANN GM, 1988, J CELL BIOL, V107, P951, DOI 10.1083/jcb.107.3.951; OMANN GM, 1987, PHYSIOL REV, V67, P285, DOI 10.1152/physrev.1987.67.1.285; OMANN GM, 1992, J IMMUNOL, V149, P2172; ONARAN HO, 1993, MOL PHARMACOL, V43, P245; PAINTER RG, 1987, J CELL BIOL, V105, P2959, DOI 10.1083/jcb.105.6.2959; POSNER RG, 1994, MOL PHARMACOL, V45, P65; SCHONBRUNN A, 1978, J BIOL CHEM, V253, P6473; Seber G., 1989, NONLINEAR REGRESSION; SENGELOV H, 1994, BIOCHEM J, V299, P473, DOI 10.1042/bj2990473; SENGELOV H, 1993, J IMMUNOL, V150, P1535; Sklar L A, 1984, Contemp Top Immunobiol, V14, P29; SKLAR LA, 1984, J BIOL CHEM, V259, P5661; SKLAR LA, 1989, J BIOL CHEM, V264, P8483; SKLAR LA, 1986, ADV IMMUNOL, V39, P95; SKLAR LA, 1987, J BIOL CHEM, V262, P135; SKLAR LA, 1985, J BIOL CHEM, V260, P1461; SKLAR LA, 1982, CYTOMETRY, V3, P161, DOI 10.1002/cyto.990030304; SKLAR LA, 1987, ANNU REV BIOPHYS BIO, V16, P479, DOI 10.1146/annurev.biophys.16.1.479; SKLAR LA, 1985, MOL PHARMACOL, V28, P323; SKLAR LA, 1985, J CELL BIOL, V101, P1161, DOI 10.1083/jcb.101.3.1161; SKLAR LA, 1985, BIOPHYS J, V47, pA165; TENNENBERG SD, 1988, J IMMUNOL, V141, P3937; TOLLEY JO, 1987, J LEUKOCYTE BIOL, V42, P43, DOI 10.1002/jlb.42.1.43; WILEY HS, 1982, J BIOL CHEM, V257, P4222; YEE J, 1993, J IMMUNOL, V150, P1988; ZIGMOND SH, 1982, J CELL BIOL, V92, P34, DOI 10.1083/jcb.92.1.34	60	47	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18394	18404		10.1074/jbc.271.31.18394	http://dx.doi.org/10.1074/jbc.271.31.18394			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702483	hybrid			2022-12-25	WOS:A1996VB68300021
J	Lu, L; Berkey, KA; Casero, RA				Lu, L; Berkey, KA; Casero, RA			RGFGIGS is an amino acid sequence required for acetyl coenzyme A binding and activity of human spermidine/spermine N(1)acetyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEROTONIN N-ACETYLTRANSFERASE; SPERMINE N1-ACETYLTRANSFERASE; CHOLINE-ACETYLTRANSFERASE; MELANOMA XENOGRAFTS; ANTITUMOR-ACTIVITY; POLYAMINE; INDUCTION; CELLS; N-1-ACETYLTRANSFERASE; ANALOGS	Polyamine catabolism is rate limited by spermidine/spermine N-1-acetyltransferase (SSAT), Although the amino acid sequence of SSAT is known, the substrate binding and catalytic sites are not, The goal of this study was to define the region responsible for acetyl coenzyme A binding, Human SSAT contains a region of 20 amino acids homologous to several microbial antibiotic N-acetyltransferases. The highest;homology is represented in the Campylobacter coli streptothricin acetyltransferase sat4 gene, where 16 identical or highly conserved amino acids exist in a 20-residue stretch, The most conserved residues within this region are RGF-GIGS beginning at Arg-101 in the human SSAT, Site-directed mutations to Arg-101, Gly-104, and Gly-106 resulted in proteins with no measurable activity, The G102D mutation produced a partially active protein with a decreased affinity for acetyl coenzyme A and with a K-m >10-fold that of the wild-type protein, Analysis using the PredictProtein program suggests a common structure among the microbial and eukaryotic N-acetyltransferases in the region corresponding to the RGF-GIGS of human SSAT consisting of an cu-helix usually preceded by a glycine loop, Our data are consistent with the hypothesis that Arg-101 and the proximal glycine loop are necessary for the activity of human SSAT.	JOHNS HOPKINS ONCOL CTR LABS, BALTIMORE, MD 21231 USA	Johns Hopkins University; Johns Hopkins Medicine				Casero, Robert/0000-0001-5653-3306	NATIONAL CANCER INSTITUTE [R01CA051085, P50CA058184] Funding Source: NIH RePORTER; NCI NIH HHS [CA51085, CA58184] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BERNACKI RJ, 1992, CANCER RES, V52, P2424; BORJIGIN J, 1995, NATURE, V378, P783, DOI 10.1038/378783a0; CARBINI L, 1990, BRAIN RES BULL, V24, P119, DOI 10.1016/0361-9230(90)90295-B; CASERO RA, 1990, BIOCHEM J, V270, P615, DOI 10.1042/bj2700615; CASERO RA, 1989, CANCER RES, V49, P3829; CASERO RA, 1991, J BIOL CHEM, V266, P810; CASERO RA, 1993, FASEB J, V7, P653, DOI 10.1096/fasebj.7.8.8500690; CHANG BK, 1992, CANCER CHEMOTH PHARM, V30, P179, DOI 10.1007/BF00686308; COLEMAN CS, 1995, BIOCHEMISTRY-US, V34, P13423, DOI 10.1021/bi00041a020; COON SL, 1995, SCIENCE, V270, P1681, DOI 10.1126/science.270.5242.1681; CURRIER SF, 1974, P NATL ACAD SCI USA, V71, P3355, DOI 10.1073/pnas.71.9.3355; DELLARAGIONE F, 1983, BIOCHEM J, V213, P707, DOI 10.1042/bj2130707; DELLARAGIONE F, 1983, BIOCHEM J, V213, P701, DOI 10.1042/bj2130701; FOGELPETROVIC M, 1993, BIOCHIM BIOPHYS ACTA, V1216, P255, DOI 10.1016/0167-4781(93)90152-4; FOGELPETROVIC M, 1993, J BIOL CHEM, V268, P19118; FUKUCHI J, 1994, J BIOL CHEM, V269, P22581; FULLER DJM, 1990, BIOCHEM J, V267, P601, DOI 10.1042/bj2670601; GERNER EW, 1993, BIOCHEM J, V294, P491, DOI 10.1042/bj2940491; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEI X, 1992, BIOCHEM BIOPH RES CO, V187, P1493, DOI 10.1016/0006-291X(92)90471-V; LIBBY PR, 1991, ARCH BIOCHEM BIOPHYS, V284, P238, DOI 10.1016/0003-9861(91)90291-P; PEGG AE, 1992, BIOCHIM BIOPHYS ACTA, V1171, P106, DOI 10.1016/0167-4781(92)90148-S; PERSSON L, 1984, J BIOL CHEM, V259, P2364; PORTER CW, 1991, CANCER RES, V51, P3715; PORTER CW, 1993, CANCER RES, V53, P581; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHULZ GE, 1992, CURR OPIN STRUC BIOL, V2, P61; SEILER N, 1987, CAN J PHYSIOL PHARM, V65, P2024, DOI 10.1139/y87-317; Seiler N, 1988, Adv Exp Med Biol, V250, P127; SHAPPELL NW, 1993, FEBS LETT, V321, P179, DOI 10.1016/0014-5793(93)80103-2; SUMBILLA C, 1993, J BIOL CHEM, V268, P21185; TERCERO JC, 1992, J BIOL CHEM, V267, P20270; WU DH, 1995, J BIOL CHEM, V270, P29111, DOI 10.1074/jbc.270.49.29111; Xiao L, 1996, BIOCHEM J, V313, P691, DOI 10.1042/bj3130691	35	75	76	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18920	18924		10.1074/jbc.271.31.18920	http://dx.doi.org/10.1074/jbc.271.31.18920			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702554	hybrid			2022-12-25	WOS:A1996VB68300092
J	Lechleider, RJ; deCaestecker, MP; Dehejia, A; Polymeropoulos, MH; Roberts, AB				Lechleider, RJ; deCaestecker, MP; Dehejia, A; Polymeropoulos, MH; Roberts, AB			Serine phosphorylation, chromosomal localization, and transforming growth factor-beta signal transduction by human bsp-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TGF-BETA; EPITHELIAL-CELLS; RECEPTOR; GENE; ACTIVATION; DROSOPHILA; PATHWAYS; HOMOLOG; PATTERN	The transforming growth factor-beta (TGF-beta) superfamily regulates a multitude of cellular and developmental events. TGF-beta family ligands signal through transmembrane serine/threonine kinase receptors whose downstream effecters are largely unknown, Using genetic data from the fruit fly, we have identified a downstream effector of TGF-beta-induced signaling. TGF-beta signaling protein-1 (BSP-1) is rapidly phosphorylated in response to TGF-beta. Localization of bsp-l to chromosome 4q28 suggests a role in carcinogenesis. These data suggest that BSP-1 is the prototype of a new class of signaling molecules.	NATL CTR HUMAN GENOME RES,LAB GENET DIS RES,GENE MAPPING UNIT,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)	Lechleider, RJ (corresponding author), NCI,CHEMOPREVENT LAB,NIH,41 LIB DR,BETHESDA,MD 20892, USA.							ALEXANDROW MG, 1995, CANCER RES, V55, P1452; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ATFI A, 1994, J BIOL CHEM, V269, P30688; ATTISANO L, 1994, BBA-MOL CELL RES, V1222, P71, DOI 10.1016/0167-4889(94)90026-4; AUFFRAY C, 1995, CR ACAD SCI III-VIE, V318, P263; Boige V., 1996, Proceedings of the American Association for Cancer Research Annual Meeting, V37, P551; CHEN RH, 1995, NATURE, V377, P548, DOI 10.1038/377548a0; DERYNCK R, 1994, TRENDS BIOCHEM SCI, V19, P548, DOI 10.1016/0968-0004(94)90059-0; FERGUSON EL, 1992, CELL, V71, P451, DOI 10.1016/0092-8674(92)90514-D; GELBART WM, 1989, DEVELOPMENT, V107, P65; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; HUDSON TJ, 1995, SCIENCE, V270, P1945, DOI 10.1126/science.270.5244.1945; KAWABATA M, 1995, J BIOL CHEM, V270, P29628; KIM SJ, 1992, J BIOL CHEM, V267, P13702; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P13434; LETSOU A, 1995, CELL, V80, P899, DOI 10.1016/0092-8674(95)90293-7; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; MASSAGUE J, 1995, CURR OPIN GENET DEV, V5, P91, DOI 10.1016/S0959-437X(95)90059-4; MULDER KM, 1992, J BIOL CHEM, V267, P5029; PARK KC, 1994, P NATL ACAD SCI USA, V91, P8772, DOI 10.1073/pnas.91.19.8772; PARSONS R, 1995, CANCER RES, V55, P5548; RAFTERY LA, 1995, GENETICS, V139, P241; ROBERTS AB, 1993, GROWTH FACTORS, V8, P1; Sambrook J., 2002, MOL CLONING LAB MANU; Savage C, 1996, P NATL ACAD SCI USA, V93, P790, DOI 10.1073/pnas.93.2.790; SEKELSKY JJ, 1995, GENETICS, V139, P1347; SPORN MB, 1992, J CELL BIOL, V119, P1017, DOI 10.1083/jcb.119.5.1017; VENTURA F, 1994, EMBO J, V13, P5581, DOI 10.1002/j.1460-2075.1994.tb06895.x; WALTER MA, 1994, NAT GENET, V7, P22, DOI 10.1038/ng0594-22; Wang TW, 1996, SCIENCE, V271, P1120, DOI 10.1126/science.271.5252.1120; WANG TW, 1994, SCIENCE, V265, P674, DOI 10.1126/science.7518616; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; YAN ZF, 1994, J BIOL CHEM, V269, P13231; YINGLING JM, 1995, BBA-REV CANCER, V1242, P115, DOI 10.1016/0304-419X(95)00007-2	36	74	81	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					17617	17620		10.1074/jbc.271.30.17617	http://dx.doi.org/10.1074/jbc.271.30.17617			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663601	hybrid			2022-12-25	WOS:A1996UY93500007
J	Piersen, CE; Prasad, R; Wilson, SH; Lloyd, RS				Piersen, CE; Prasad, R; Wilson, SH; Lloyd, RS			Evidence for an imino intermediate in the DNA polymerase beta deoxyribose phosphate excision reaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYTIC MECHANISM; AMINO-TERMINUS; SITE; BINDING; REPAIR; IDENTIFICATION; RESIDUES; DOMAIN; T4-ENDONUCLEASE-V; ENDONUCLEASE	A recent study demonstrated that rat DNA polymerase beta (beta-pol) releases 5'-deoxyribose phosphate (dRP) termini from preincised apurinic/apyrimidinic DNA, a substrate generated during certain types of base excision repair, This catalytic activity resides within the amino-terminal, 8-kDa domain of beta-pol and occurs via beta-elimination as opposed to hydrolysis (Matsumoto, Y., and Rim, K. (1995) Science 269, 699-702), The latter finding suggested that the dRP excision reaction might proceed via an imine intermediate. In order to test this hypothesis, we attempted to trap beta-pol on preincised apurinic/apyrimidinic DNA using NaBH4 as the reducing agent, Both 8-kDa domain-DNA and intact beta-pol-DNA complexes were detected and identified by autoradiography coupled to immunoblotting, Our results indicate that the chemical mechanism of the beta-pol dRpase reaction does proceed through an imine enzyme-DNA intermediate and that the active site residue responsible for dRP release must therefore contain a primary amine.	UNIV TEXAS,MED BRANCH,SEALY CTR MOL SCI,GALVESTON,TX 77555	University of Texas System; University of Texas Medical Branch Galveston			Wilson, Samuel H/E-6644-2019	Wilson, Samuel H/0000-0002-1702-5293; Lloyd, R. Stephen/0000-0001-7273-372X; Piersen, Colleen/0000-0002-2913-4956	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006676, R01ES004091, R01ES006492] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES04091, ES06676, ES06492] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BAILLY V, 1989, BIOCHEM J, V259, P751, DOI 10.1042/bj2590751; BASU A, 1989, BIOCHEMISTRY-US, V28, P6305, DOI 10.1021/bi00441a023; CASASFINET JR, 1991, J BIOL CHEM, V266, P19618; DIANOV G, 1992, MOL CELL BIOL, V12, P1605, DOI 10.1128/MCB.12.4.1605; DODSON ML, 1993, BIOCHEMISTRY-US, V32, P8284, DOI 10.1021/bi00083a032; FISCHER EH, 1958, J AM CHEM SOC, V80, P2906, DOI 10.1021/ja01544a082; FRIDOVICH I, 1962, J AM CHEM SOC, V84, P3208, DOI 10.1021/ja00875a050; HARLOW E, 1988, ANTIBODIES LABORATOR; KUMAR A, 1990, J BIOL CHEM, V265, P2124; LIU DJ, 1994, BIOCHEMISTRY-US, V33, P9537, DOI 10.1021/bi00198a020; MATSUMOTO Y, 1995, SCIENCE, V269, P699, DOI 10.1126/science.7624801; MATSUMOTO Y, 1994, MOL CELL BIOL, V14, P6187, DOI 10.1128/MCB.14.9.6187; PELLETIER H, 1994, SCIENCE, V264, P1891, DOI 10.1126/science.7516580; PELLETIER H, 1996, IN PRESS BIOCHEMISTR; PIERSEN CE, 1995, J BIOL CHEM, V270, P23475, DOI 10.1074/jbc.270.40.23475; PRASAD R, 1993, J BIOL CHEM, V268, P22746; PRASAD R, 1994, J BIOL CHEM, V269, P18096; SAWAYA MR, 1994, SCIENCE, V264, P1930, DOI 10.1126/science.7516581; SCHROCK RD, 1991, J BIOL CHEM, V266, P17631; SCHROCK RD, 1993, J BIOL CHEM, V268, P880; SINGHAL RK, 1995, J BIOL CHEM, V270, P949, DOI 10.1074/jbc.270.2.949; Sobol RW, 1996, NATURE, V379, P183, DOI 10.1038/379183a0; SPECK JC, 1963, J AM CHEM SOC, V85, P1012, DOI 10.1021/ja00890a048; SUN B, 1995, J BIOL CHEM, V270, P19501, DOI 10.1074/jbc.270.33.19501; TCHOU J, 1995, J BIOL CHEM, V270, P11671, DOI 10.1074/jbc.270.19.11671; WARREN S, 1966, BIOCHEMISTRY-US, V5, P817, DOI 10.1021/bi00867a002; WIEBAUER K, 1990, P NATL ACAD SCI USA, V87, P5842, DOI 10.1073/pnas.87.15.5842	27	149	150	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					17811	17815		10.1074/jbc.271.30.17811	http://dx.doi.org/10.1074/jbc.271.30.17811			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663612	hybrid			2022-12-25	WOS:A1996UY93500036
J	Rutberg, SE; Saez, E; Glick, A; Dlugosz, AA; Spiegelman, BM; Yuspa, SH				Rutberg, SE; Saez, E; Glick, A; Dlugosz, AA; Spiegelman, BM; Yuspa, SH			Differentiation of mouse keratinocytes is accompanied by PKC-dependent changes in AP-1 proteins	ONCOGENE			English	Article						AP-1; keratinocytes; protein kinase C; mouse skin; differentiation; c-fos	TISSUE-SPECIFIC EXPRESSION; KINASE-C-DELTA; EPIDERMAL DIFFERENTIATION; SELECTIVE INHIBITOR; SKIN CARCINOGENESIS; BINDING-PROTEINS; GENE-EXPRESSION; PHORBOL ESTER; CYCLIC-AMP; FOS	The conversion of cultured basal keratinocytes to the spinous and granular cell phenotypes seen in the skin can be stimulated by raising the levels of extracellular calcium, Here me show that AP-1 DNA binding activity is very low in primary cultures of basal keratinocytes, but that this activity is induced 24-48 h after increasing the concentration of extracellular calcium from 0.05 to 0.12 mM. As such, the induction of AP-1 DNA binding activity correlates with events occurring during the terminal stages of keratinocyte differentiation, Calcium-induced AP-1 DNA binding complexes consist of Pra-1, Fra-2, c-Jun, JunB and JunD and are independent of c-Fos, since the induction of DNA binding activity and the composition of the AP-1 binding complexes are identical in differentiating keratinocytes derived from c-fos null and wild type mice, The formation of calcium-induced AP-1 binding complexes is regulated by protein kinase C (PKC) and requires a functional PKC alpha isozyme, as determined through pharmacological down-modulation of specific PKC isozymes in differentiating keratinocytes, Moreover, PKC activation is required for the increased expression of Fra-2, JunB and JunD in the nucleus of differentiating cells in vitro. This observation provides a link between the obligate activation of PKC during keratinocyte differentiation and the nuclear response required to alter gene expression, In vivo expression patterns suggest that the predominant AP-1 heterodimer in the granular layer consists of Fra-2 and JunB while a JunD and Fra-1 complex predominates the spinous layer of mouse epidermis, These findings suggest distinct functions for different AP-1 proteins in the regulation of events related to keratinocyte maturation.	NCI, CELLULAR CARCINOGENESIS & TUMOR PROMOT LAB, BETHESDA, MD 20892 USA; NCI, TUMOR VIRUS BIOL LAB, BETHESDA, MD 20892 USA; HARVARD UNIV, SCH MED, DANA FARBER CANC INST, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT CELL BIOL, BOSTON, MA 02115 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School								AN G, 1993, J BIOL CHEM, V268, P10977; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; AU YPT, 1994, CIRC RES, V75, P15, DOI 10.1161/01.RES.75.1.15; BASSETSEGUIN N, 1994, ONCOGENE, V9, P765; BASSETSEGUIN N, 1991, J INVEST DERMATOL, V97, P672, DOI 10.1111/1523-1747.ep12483807; Bernerd Francoise, 1993, Gene Expression, V3, P187; CARRASCO D, 1995, ONCOGENE, V10, P1069; CASATORRES J, 1994, J BIOL CHEM, V269, P20489; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; CHODOSH LA, 1988, CELL, V53, P11, DOI 10.1016/0092-8674(88)90483-7; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DENNING MF, 1993, J BIOL CHEM, V268, P26079; DENNING MF, 1995, CELL GROWTH DIFFER, V6, P149; DISEPIO D, 1995, J BIOL CHEM, V270, P10792, DOI 10.1074/jbc.270.18.10792; DLUGOSZ AA, 1992, MOL CARCINOGEN, V5, P286, DOI 10.1002/mc.2940050409; DLUGOSZ AA, 1994, J INVEST DERMATOL, V102, P409, DOI 10.1111/1523-1747.ep12372171; DLUGOSZ AA, 1993, J CELL BIOL, V120, P217, DOI 10.1083/jcb.120.1.217; DLUGOSZ AA, 1994, CANCER RES, V54, P6413; FISHER C, 1991, DEVELOPMENT, V111, P253; FRANZA BR, 1987, ONCOGENE, V1, P213; FUCHS E, 1990, J CELL BIOL, V111, P2807, DOI 10.1083/jcb.111.6.2807; GANDARILLAS A, 1995, ONCOGENE, V11, P1403; GILLARDON F, 1994, ONCOGENE, V9, P3219; GRUDA MC, 1994, ONCOGENE, V9, P2537; HENNINGS H, 1980, CELL, V19, P245, DOI 10.1016/0092-8674(80)90406-7; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HUFF CA, 1991, J INVEST DERMATOL, V96; JOHNSON RS, 1992, CELL, V71, P577, DOI 10.1016/0092-8674(92)90592-Z; KOVARY K, 1992, MOL CELL BIOL, V12, P5015, DOI 10.1128/MCB.12.11.5015; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; KULESH DA, 1988, MOL CELL BIOL, V8, P1540, DOI 10.1128/MCB.8.4.1540; LU B, 1994, J BIOL CHEM, V269, P7443; MALMQVIST KG, 1984, NUCL INSTRUM METH B, V3, P611, DOI 10.1016/0168-583X(84)90447-6; MENON GK, 1985, J INVEST DERMATOL, V84, P508, DOI 10.1111/1523-1747.ep12273485; ONEILL EA, 1988, SCIENCE, V241, P1210, DOI 10.1126/science.3413485; OSHIMA R G, 1992, Current Opinion in Cell Biology, V4, P110, DOI 10.1016/0955-0674(92)90067-M; PETTIT GR, 1991, CAN J CHEM, V69, P856, DOI 10.1139/v91-126; PRESLAND RB, 1992, J BIOL CHEM, V267, P23772; RANSONE LJ, 1990, ANNU REV CELL BIOL, V6, P539, DOI 10.1146/annurev.cellbio.6.1.539; REDEMANNFIBI B, 1991, DIFFERENTIATION, V46, P43, DOI 10.1111/j.1432-0436.1991.tb00864.x; RICE RH, 1979, CELL, V18, P681, DOI 10.1016/0092-8674(79)90123-5; RODDEY PK, 1994, J INVEST DERMATOL, V102, P296, DOI 10.1111/1523-1747.ep12371785; ROOP DR, 1988, CANCER RES, V48, P3245; ROTHNAGEL JA, 1994, GENOMICS, V23, P450, DOI 10.1006/geno.1994.1522; ROTHNAGEL JA, 1993, J INVEST DERMATOL, V101, P506, DOI 10.1111/1523-1747.ep12365886; ROTHNAGEL JA, 1987, J BIOL CHEM, V262, P15643; SAEZ E, 1995, CELL, V82, P721, DOI 10.1016/0092-8674(95)90469-7; SAKO T, 1987, CANCER RES, V47, P5445; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SMEYNE RJ, 1992, NEURON, V8, P13, DOI 10.1016/0896-6273(92)90105-M; SONOBE MH, 1995, ONCOGENE, V10, P689; Stanwell C, 1996, J INVEST DERMATOL, V106, P482, DOI 10.1111/1523-1747.ep12343690; STOLER A, 1988, J CELL BIOL, V107, P427, DOI 10.1083/jcb.107.2.427; SUZUKI T, 1991, NUCLEIC ACIDS RES, V19, P5537, DOI 10.1093/nar/19.20.5537; SZALLASI Z, 1994, MOL PHARMACOL, V46, P840; Takahashi S., 1994, Journal of Dermatological Science, V7, P54, DOI 10.1016/0923-1811(94)90022-1; TANGUAY DA, 1994, CELL IMMUNOL, V158, P281, DOI 10.1006/cimm.1994.1276; TENNENBAUM T, 1993, CANCER RES, V53, P4803; TOKUMITSU H, 1990, J BIOL CHEM, V265, P4315; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; WELTER JF, 1995, J BIOL CHEM, V270, P12614, DOI 10.1074/jbc.270.21.12614; WILKINSON DG, 1989, DEVELOPMENT, V106, P465; WOODGETT JR, 1993, ADV SEC MESS PHOSPH, V28, P261; YAMANISHI K, 1992, J BIOL CHEM, V267, P17858; YOON JK, 1994, MOL CELL BIOL, V14, P7731, DOI 10.1128/MCB.14.12.7731; YUSPA SH, 1994, CANCER RES, V54, P1178; YUSPA SH, 1989, J CELL BIOL, V109, P1207, DOI 10.1083/jcb.109.3.1207	67	114	115	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 4	1996	13	1					167	176						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UX319	8700543				2022-12-25	WOS:A1996UX31900019
J	Butcher, BA; Turco, SJ; Hilty, BA; Pimenta, PF; Panunzio, M; Sacks, DL				Butcher, BA; Turco, SJ; Hilty, BA; Pimenta, PF; Panunzio, M; Sacks, DL			Deficiency in beta 1,3-galactosyltransferase of a Leishmania major lipophosphoglycan mutant adversely influences the Leishmania sand fly interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROMASTIGOTES; DONOVANI; IDENTIFICATION; EXPRESSION; VIRULENCE	To study the function of side chain oligosaccharides of the cell-surface lipophosphoglycan (LPG), mutagenized Leishmania major defective in side chain biosynthesis were negatively selected by agglutination with the monoclonal antibody WIC79,3, which recognizes the galactose-containing side chains of L, major LPG, One such mutant, called Spock, lacked the ability to bind significantly to midguts of the natural L. major vector, Phlebotomus papatasi, and to maintain infection in the sand fly after excretion of the digested bloodmeal, Biochemical characterization of Spock LPG revealed its structural similarity to the LPG of Leishmania donovani, a species whose inability to bind to and maintain infections in P, papatasi midguts has been strongly correlated with the expression of a surface LPG lacking galactose-terminated oligosaccharide side chains, An in vitro galactosyltransferase assay using wild-type or Spock membranes was used to determine that the defect in Spock LPG biosynthesis is a result of defective beta 1,3-galactosyltransferase activity as opposed to a modification of LPG, which would prevent it from serving as a competent substrate for galactose addition, The results of these experiments show that Speck lacks the beta 1,3-galactosyltransferase for side chain addition and that the LPG side chains are required for L, major to bind to and to produce transmissible infection in P, papatasi.	UNIV KENTUCKY,MED CTR,DEPT BIOCHEM,LEXINGTON,KY 40536; NIH,PARASIT DIS LAB,INTRACELLULAR PARASITE BIOL SECT,BETHESDA,MD 20892; UNIV ESTADUAL NORTE FLUMINENSE,PARASITOL LAB,CTR BIOCIENCIAS & BITECNOL,RIO JANEIRO,BRAZIL; UNIV BARI,INST MED MICROBIOL,BARI,ITALY	University of Kentucky; National Institutes of Health (NIH) - USA; Universidade Estadual do Norte Fluminense; Universita degli Studi di Bari Aldo Moro			Pimenta, Paulo/AAH-1502-2020		NIAID NIH HHS [R37 AI20491] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANET EFLJ, 1954, NATURE, V174, P930, DOI 10.1038/174930a0; BERGER EG, 1994, TRENDS CELL BIOL, V2, P103; CAPPAI R, 1994, PARASITOLOGY, V108, P397, DOI 10.1017/S0031182000075946; ELHAY M, 1990, MOL BIOCHEM PARASIT, V40, P255, DOI 10.1016/0166-6851(90)90047-P; HANDMAN E, 1984, EMBO J, V3, P2301, DOI 10.1002/j.1460-2075.1984.tb02130.x; IOVANNISCI DM, 1984, J BIOL CHEM, V259, P4617; KELLEHER M, 1992, P NATL ACAD SCI USA, V89, P6, DOI 10.1073/pnas.89.1.6; KELLEHER M, 1992, P NATL ACAD SCI USA, V66, P187; LOW MG, 1983, BIOCHEM J, V215, P325, DOI 10.1042/bj2150325; MCCONVILLE MJ, 1990, J BIOL CHEM, V265, P19611; MCCONVILLE MJ, 1990, MOL BIOCHEM PARASIT, V38, P57, DOI 10.1016/0166-6851(90)90205-Z; MCCONVILLE MJ, 1995, BIOCHEM J, V307, P807; MCNEELY T B, 1990, Glycobiology, V1, P63, DOI 10.1093/glycob/1.1.63; NG K, 1994, GLYCOBIOLOGY, V4, P845, DOI 10.1093/glycob/4.6.845; ORLANDI PA, 1987, J BIOL CHEM, V262, P10384; PIMENTA PFP, 1992, SCIENCE, V256, P1812, DOI 10.1126/science.1615326; PIMENTA PFP, 1994, P NATL ACAD SCI USA, V91, P9155, DOI 10.1073/pnas.91.19.9155; RYAN KA, 1993, P NATL ACAD SCI USA, V90, P8609, DOI 10.1073/pnas.90.18.8609; SACKS DL, 1985, J IMMUNOL, V135, P564; TESH RB, 1987, AM J TROP MED HYG, V33, P41; THOMAS JR, 1992, J BIOL CHEM, V267, P6829; THURNHER M, 1993, J CLIN INVEST, V91, P2103, DOI 10.1172/JCI116434; TOLSON DL, 1994, PARASITOL RES, V80, P537, DOI 10.1007/BF00932704; TURCO SJ, 1990, EXP PARASITOL, V70, P241, DOI 10.1016/0014-4894(90)90105-L; TURCO SJ, 1992, ANNU REV MICROBIOL, V46, P65, DOI 10.1146/annurev.mi.46.100192.000433	25	69	72	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20573	20579		10.1074/jbc.271.34.20573	http://dx.doi.org/10.1074/jbc.271.34.20573			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702802	hybrid			2022-12-25	WOS:A1996VD33700054
J	Roberts, LJ; Moore, KP; Zackert, WE; Oates, JA; Morrow, JD				Roberts, LJ; Moore, KP; Zackert, WE; Oates, JA; Morrow, JD			Identification of the major urinary metabolite of the F-2-isoprostane 8-iso-prostaglandin F-2 alpha in humans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPID-PEROXIDATION; PROSTANOIDS F2-ISOPROSTANES; FREE-RADICALS; HUMAN-DISEASE; RAT; PROSTAGLANDIN; NONCYCLOOXYGENASE; THROMBOXANE-B2; MECHANISM; RECEPTORS	F-2-isoprostanes are prostaglandin-like products of nonenzymatic lipid peroxidation, Measurement of levels of endogenous unmetabolized F-2-isoprostanes has proven to be a valuable approach to assess oxidative stress in vivo. However, measurement of levels of urinary metabolites of F-2-isoprostanes in timed urine collections offers an advantage over measuring unmetabolized F-2-isoprostanes, e,g, in a plasma sample, in that it can provide an integrated index of isoprostane production over time. Therefore, we sought to identify the major urinary metabolite in humans of one of the more abundant F-2-isoprostanes produced, 8-iso-prostaglandin F-2 alpha (8-iso-PGF(2 alpha)). 20 mu Ci of tritiated 8-iso PGF(2 alpha) was infused over 1 h into a male volunteer, 75% of the infused radioactivity was excreted into the urine during the following 4.5 h and was combined with urine collected for 4 h from a rhesus monkey following infusion of 500 mu g of unlabeled 8 iso PGF(2 alpha). Urinary metabolites were isolated and purified by adsorption chromatography and high pressure liquid chromatography. The major urinary metabolite, representing 29% of the total extractable recovered radioactivity in the urine, was structurally identified by gas chromatography and mass spectrometry as 2,3-dinor-5,6-dihydro-8-iso-prostaglandin F-2 alpha. The identification of 2,3 dinor-5,6-dihydro-prostaglandin F-2 alpha as the major urinary metabolite of 8-iso-prostaglandin F-2 alpha provides the basis for the development of methods of assay for its quantification as a means to obtain an integrated assessment of oxidative stress status in humans.	VANDERBILT UNIV,DEPT PHARMACOL,NASHVILLE,TN 37232; ROYAL FREE HOSP,SCH MED,DEPT MED,LONDON NW3 2PF,ENGLAND; VANDERBILT UNIV,DEPT MED,NASHVILLE,TN 37232	Vanderbilt University; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; Vanderbilt University								AMES BN, 1983, SCIENCE, V221, P1256, DOI 10.1126/science.6351251; AWAD JA, 1993, J BIOL CHEM, V268, P4161; BANERJEE M, 1992, AM J PHYSIOL, V263, pH660, DOI 10.1152/ajpheart.1992.263.3.H660; FUKUNAGA M, 1993, AM J PHYSIOL, V264, pC1619, DOI 10.1152/ajpcell.1993.264.6.C1619; GRANSTROM E, 1968, J BIOL CHEM, V243, P4104; GREEN K, 1971, BIOCHIM BIOPHYS ACTA, V231, P419, DOI 10.1016/0005-2760(71)90111-1; GUTTERIDGE JMC, 1990, TRENDS BIOCHEM SCI, V15, P129, DOI 10.1016/0968-0004(90)90206-Q; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1; HARMAN D, 1981, P NATL ACAD SCI-BIOL, V78, P7124, DOI 10.1073/pnas.78.11.7124; MORROW JD, 1995, NEW ENGL J MED, V332, P1198, DOI 10.1056/NEJM199505043321804; MORROW JD, 1994, BBA-LIPID LIPID MET, V1210, P244, DOI 10.1016/0005-2760(94)90128-7; MORROW JD, 1992, P NATL ACAD SCI USA, V89, P10721, DOI 10.1073/pnas.89.22.10721; MORROW JD, 1990, P NATL ACAD SCI USA, V87, P9383, DOI 10.1073/pnas.87.23.9383; MORROW JD, 1994, J BIOL CHEM, V269, P4317; MORROW JD, 1991, ANAL BIOCHEM, V193, P142, DOI 10.1016/0003-2697(91)90054-W; MORROW JD, 1992, J CLIN INVEST, V90, P2502, DOI 10.1172/JCI116143; MORROW JD, 1990, ANAL BIOCHEM, V184, P1, DOI 10.1016/0003-2697(90)90002-Q; PACEASCIAK CR, 1989, ADV PROSTAGLANDIN TH, V18, P322; ROBERTS LJ, 1977, J BIOL CHEM, V252, P7415; ROBERTS LJ, 1981, J BIOL CHEM, V256, P8384; ROBERTS LJ, 1987, CRC HDB EICOSANOIDS, P233; SOUTHORN PA, 1988, MAYO CLIN PROC, V63, P390, DOI 10.1016/S0025-6196(12)64862-9; TAKAHASHI K, 1992, J CLIN INVEST, V90, P136, DOI 10.1172/JCI115826; TAYLOR BM, 1980, J PHARMACOL EXP THER, V214, P24	24	137	139	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20617	20620		10.1074/jbc.271.34.20617	http://dx.doi.org/10.1074/jbc.271.34.20617			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702808	hybrid			2022-12-25	WOS:A1996VD33700060
J	Titorenko, VI; Eitzen, GA; Rachubinski, RA				Titorenko, VI; Eitzen, GA; Rachubinski, RA			Mutations in the PAY5 gene of the yeast Yarrowia lipolytica cause the accumulation of multiple subpopulations of peroxisomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER; SACCHAROMYCES-CEREVISIAE; PHOSPHOLIPID-SYNTHESIS; BIOGENESIS; PROTEIN; GOLGI; MEMBRANES; MITOCHONDRIA; POPULATIONS; TRANSPORT	We previously reported the cloning of the PAYS gene of the yeast Yarrowia lipolytica by complementation of the peroxisome assembly mutant pay5-1 (Eitzen, G. A., Titorenko, V. I., Smith, J. J., Veenhuis, M., Szilard, R. K., and Rachubinski, R. A. (1996) J Biol. Chem. 271, 20300-20306). The peroxisomal integral membrane protein Pay5p is a homologue of mammalian PAF-1 proteins, which are essential for peroxisome assembly and whose mutation in humans results in peroxisome biogenesis disorders, Mutations in the PAYS gene result in the accumulation of three distinct peroxisomal subpopulations. These subpopulations are characterized by differences in 1) buoyant density, 2) the relative distribution of peroxisomal matrix and membrane proteins, 3) the efficiency of import of several peroxisomal matrix proteins, and 4) the phospholipid levels of peroxisomal membranes. These data, together with the analysis of temporal changes in the relative abundance of individual peroxisomal subpopulations in pay5 mutants, suggest that these subpopulations represent intermediates in a multistep peroxisome assembly pathway normally operating in yeast cells.	UNIV ALBERTA, DEPT ANAT & CELL BIOL, EDMONTON, AB T6G 2H7, CANADA	University of Alberta			Eitzen, Gary/D-3682-2009					ABEIJON C, 1989, P NATL ACAD SCI USA, V86, P6935, DOI 10.1073/pnas.86.18.6935; AIKAWA J, 1991, P NATL ACAD SCI USA, V88, P10084, DOI 10.1073/pnas.88.22.10084; AITCHISON JD, 1991, J BIOL CHEM, V266, P23197; ARDAIL D, 1993, J BIOL CHEM, V268, P25985; DONALDSO.RP, 1972, ARCH BIOCHEM BIOPHYS, V152, P199, DOI 10.1016/0003-9861(72)90208-1; Eitzen GA, 1996, J BIOL CHEM, V271, P20300, DOI 10.1074/jbc.271.34.20300; FAHIMI HD, 1993, BIOCHIMIE, V75, P201, DOI 10.1016/0300-9084(93)90078-7; GAIGG B, 1995, BBA-BIOMEMBRANES, V1234, P214, DOI 10.1016/0005-2736(94)00287-Y; GRAHAM TR, 1991, J CELL BIOL, V114, P207, DOI 10.1083/jcb.114.2.207; HEINEMANN P, 1992, FEBS LETT, V300, P179, DOI 10.1016/0014-5793(92)80191-I; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; LAZAROW PB, 1985, ANNU REV CELL BIOL, V1, P489, DOI 10.1146/annurev.cb.01.110185.002421; LAZAROW PB, 1994, METABOLIC BASIS INHE, P2287; LUERS G, 1993, J CELL BIOL, V121, P1271, DOI 10.1083/jcb.121.6.1271; MCGEE TP, 1994, J CELL BIOL, V124, P273, DOI 10.1083/jcb.124.3.273; NORDLIE RC, 1966, METHOD ENZYMOL, V9, P619; NUTTLEY WM, 1993, YEAST, V9, P507, DOI 10.1002/yea.320090506; RACHUBINSKI RA, 1995, CELL, V83, P525, DOI 10.1016/0092-8674(95)90091-8; ROBERTS CJ, 1991, METHOD ENZYMOL, V194, P644; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SZILARD RK, 1995, J CELL BIOL, V131, P1453, DOI 10.1083/jcb.131.6.1453; THIERINGER R, 1991, MOL CELL BIOL, V11, P510, DOI 10.1128/MCB.11.1.510; VANCE JE, 1988, J BIOL CHEM, V263, P5898; VANCE JE, 1990, J BIOL CHEM, V265, P7248; VANDENBOSCH H, 1992, ANNU REV BIOCHEM, V61, P157, DOI 10.1146/annurev.bi.61.070192.001105; VOELKER DR, 1991, MICROBIOL REV, V55, P543, DOI 10.1128/MMBR.55.4.543-560.1991; WATERHAM HR, 1992, J BACTERIOL, V174, P4057, DOI 10.1128/jb.174.12.4057-4063.1992; WILCKE M, 1995, J BIOL CHEM, V270, P6949, DOI 10.1074/jbc.270.12.6949; ZAAR K, 1987, BIOCHIM BIOPHYS ACTA, V897, P135, DOI 10.1016/0005-2736(87)90321-X; ZINSER E, 1991, J BACTERIOL, V173, P2026, DOI 10.1128/jb.173.6.2026-2034.1991	33	33	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20307	20314		10.1074/jbc.271.34.20307	http://dx.doi.org/10.1074/jbc.271.34.20307			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702764	hybrid			2022-12-25	WOS:A1996VD33700016
J	Cancedda, FD; Malpeli, M; Gentili, C; DiMarzo, V; Bet, P; Carlevaro, M; Cermelli, S; Cancedda, R				Cancedda, FD; Malpeli, M; Gentili, C; DiMarzo, V; Bet, P; Carlevaro, M; Cermelli, S; Cancedda, R			The developmentally regulated avian Ch21 lipocalin is an extracellular fatty acid-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPERTROPHIC CHONDROCYTES UNDERGO; ENDOCHONDRAL BONE-FORMATION; IN-VITRO DIFFERENTIATION; DEVELOPING CHICK-EMBRYO; OSTEOBLAST-LIKE CELLS; HYDROPHOBIC MOLECULES; EPIPHYSEAL CARTILAGE; EXPRESSION; COLLAGEN; IDENTIFICATION	Ch21, a developmentally regulated extracellular protein expressed in chick embryos and in cultured chondrocytes, was expressed in the baculovirus system, and the recombinant protein was purified to homogeneity by gel-filtration chromatography. Separation of two isoforms was achieved on an ion-exchange column. Previous work had shown that Ch21 belongs to the superfamily of lipocalins, which are transport proteins for small hydrophobic molecules. Studies were performed to identify the Ch21 ligand. By analysis of recombinant Ch21 on native polyacrylamide gel electrophoresis and by Lipidex assay, the binding of fatty acid to the protein was shown and a preferential binding of long-chain unsaturated fatty acids was observed. Both isoforms had the same behavior. The binding was saturable. Stoichiometry was about 0.7 mol of ligand/mol of protein. The protein binds the ligand in its monomeric form. Calculated dissociation constants were 2 x 10(-7) M for unsaturated fatty acids and 5 x 10(-7) M for stearic acid. The binding was specific; other hydrophobic molecules, as retinoic acid, progesterone, prostaglandins, and long-chain alcohols and aldehydes did not bind to the protein. Short-chain fatty acids did not bind to the protein. Ch21, also present in chicken serum, represents the first extracellular protein able to selectively bind and transport fatty acid in extracellular fluids and serum. We propose to rename the Ch21 protein as (e) under bar xtracellular (f) under bar atty (a) under bar cid-(b) under bar inding (p) under bar rotein (Ex-FABP).	IST NAZL RIC CANC,CTR BIOTECNOL AVANZATE,I-16132 GENOA,ITALY; UNIV GENOA,IST ONCOL CLIN & SPERIMENTALE,I-16132 GENOA,ITALY; CNR,IST INT GENET & BIOFIS,I-80100 NAPLES,ITALY; CNR,IST CHIM MOL INTERESSE BIOL,I-80100 NAPLES,ITALY	University of Genoa; IRCCS AOU San Martino IST; University of Genoa; Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica e Biofisica "Adriano Buzzati-Traverso" (IGB-CNR); Consiglio Nazionale delle Ricerche (CNR)			Di Marzo, Vincenzo/AAD-7742-2019; Gentili, Chiara/AAE-8046-2021	Di Marzo, Vincenzo/0000-0002-1490-3070; GENTILI, CHIARA/0000-0001-6745-3782	Telethon [E.0166] Funding Source: Medline	Telethon(Fondazione Telethon)		ASHBROOK JD, 1975, J BIOL CHEM, V250, P2333; BERMAN P, 1987, CELL, V51, P135, DOI 10.1016/0092-8674(87)90018-3; BOESKEI Z, 1992, NATURE, V360, P186; BOHMER FD, 1987, J BIOL CHEM, V262, P15137; BONUCCI E, 1994, BONE, V15, P153, DOI 10.1016/8756-3282(94)90702-1; CANCEDDA FD, 1988, J CELL BIOL, V107, P2455, DOI 10.1083/jcb.107.6.2455; CANCEDDA FD, 1990, BIOCHEM BIOPH RES CO, V168, P933, DOI 10.1016/0006-291X(90)91118-C; CANCEDDA FD, 1990, J BIOL CHEM, V265, P19060; CANCEDDA FD, 1995, EUR J CELL BIOL, V66, P60; CANCEDDA FD, 1992, J CELL BIOL, V117, P427, DOI 10.1083/jcb.117.2.427; CAPASSO O, 1984, MOL CELL BIOL, V4, P1163, DOI 10.1128/MCB.4.6.1163; CAPASSO O, 1982, EXP CELL RES, V142, P197, DOI 10.1016/0014-4827(82)90423-2; CASTAGNOLA P, 1988, J CELL BIOL, V106, P461, DOI 10.1083/jcb.106.2.461; CAVAGGIONI A, 1987, FEBS LETT, V212, P225, DOI 10.1016/0014-5793(87)81349-2; CORSETTI MT, 1992, NUCLEIC ACIDS RES, V20, P4465, DOI 10.1093/nar/20.17.4465; DIMARZO V, 1994, NATURE, V372, P686, DOI 10.1038/372686a0; DOZIN B, 1992, J BIOL CHEM, V267, P2979; FLORES LD, 1994, ANAT REC, V238, P68; GALOTTO M, 1994, J BONE MINER RES, V9, P1239; GALOTTO M, 1985, EUR J CELL BIOL, V67, P99; GENTILI C, 1994, J CELL BIOL, V124, P579, DOI 10.1083/jcb.124.4.579; GENTILI C, 1993, J CELL BIOL, V122, P703, DOI 10.1083/jcb.122.3.703; GODOVAC-ZIMMERMANN J, 1988, TRENDS BIOCHEM SCI, V13, P64, DOI 10.1016/0968-0004(88)90031-X; HARADA S, 1994, J CLIN INVEST, V93, P2490, DOI 10.1172/JCI117258; HAYASHI M, 1986, J CELL BIOL, V102, P2302, DOI 10.1083/jcb.102.6.2302; HOLDEN HM, 1987, EMBO J, V6, P1565, DOI 10.1002/j.1460-2075.1987.tb02401.x; HUBBELL T, 1994, BIOCHEMISTRY-US, V33, P3327, DOI 10.1021/bi00177a025; HUBER R, 1987, J MOL BIOL, V195, P423, DOI 10.1016/0022-2836(87)90661-9; KOSHER RA, 1983, CARTILAGE, V1, P59; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Levi G, 1996, DEVELOPMENT, V122, P113; MANDUCA P, 1989, EUR J CELL BIOL, V50, P154; MATARESE V, 1988, J BIOL CHEM, V263, P14544; NEWCOMER ME, 1984, EMBO J, V3, P1451, DOI 10.1002/j.1460-2075.1984.tb01995.x; NEWCOMER ME, 1993, STRUCTURE, V1, P7, DOI 10.1016/0969-2126(93)90004-Z; OCKNER RK, 1982, J BIOL CHEM, V257, P7872; OCKNER RK, 1974, J CLIN INVEST, V54, P326, DOI 10.1172/JCI107768; OKIJI T, 1993, ARCH ORAL BIOL, V38, P31, DOI 10.1016/0003-9969(93)90151-B; Owen M., 1985, BONE MINERAL RES ANN, V1, P1; PEARLMAN WH, 1973, J BIOL CHEM, V248, P5736; ROACH HI, 1989, BONE MINER, V6, P289, DOI 10.1016/0169-6009(89)90035-4; RODBARD D, 1971, ANAL BIOCHEM, V40, P95, DOI 10.1016/0003-2697(71)90086-8; SACCHETTINI JC, 1986, J BIOL CHEM, V261, P8218; SCHMID TM, 1985, DEV BIOL, V107, P373, DOI 10.1016/0012-1606(85)90319-7; SCHMID TM, 1983, J BIOL CHEM, V258, P9504; STRAUSS PG, 1990, J CELL BIOL, V110, P1369, DOI 10.1083/jcb.110.4.1369; SUMMERS MD, 1987, TEX AGR EXP STN B, V1555; SUZUKI M, 1982, J NEUROCHEM, V39, P1756; SWAIN LD, 1992, BONE MINER, V17, P192, DOI 10.1016/0169-6009(92)90735-V; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; YANG CY, 1992, EICOSANOIDS, V5, P109; YOSHIOKA C, 1988, J CRAN GENET DEV BIO, V8, P253	52	39	43	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					20163	20169		10.1074/jbc.271.33.20163	http://dx.doi.org/10.1074/jbc.271.33.20163			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702740	hybrid			2022-12-25	WOS:A1996VC66900082
J	Kawabe, J; Toya, Y; Schwencke, C; Oka, N; Ebina, T; Ishikawa, Y				Kawabe, J; Toya, Y; Schwencke, C; Oka, N; Ebina, T; Ishikawa, Y			Soluble adenylyl cyclase from Spodoptera frugiperda (Sf9) cells - Purification and biochemical characterization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT TESTIS; ACTIVATION; CALMODULIN; PROTEIN; STIMULATION; BINDING; BRAIN; SITE	An insect ovarian cell, Spodoptera frugiperda (Sf9), has been widely used to express recombinant proteins, including adenylyl cyclase, as a host cell in the baculovirus expression system. We report the presence and characterization of a soluble adenylyl cyclase (sAC) distinct from a membrane-bound form of adenylyl cyclase (mAC) that is also present in Sf9 cells. sAC was purified 3,500-fold to near homogeneity; a single band at 25 kDa on SDS-polyacrylamide gel electrophoresis correlated well with adenylyl cyclase catalytic activity. The purified enzyme had a catalytic activity of 0.1 mu mol/min . mg and the K-m of 0.55 mM for the substrate ATP. In contrast to mAC, sAC was heat-stable. Enzymatic activity of sAC was not stimulated by forskolin and was inhibited by salts at high concentrations. sAC utilized both manganese- and magnesium-ATP as substrate. Di- or triphosphate-containing nucleotides, such as GTP and GDP, as well as pyrophosphate, noncompetitively inhibited sAC. Our data suggest that the physical and biochemical characteristics of sAC are different from those of mAC in Sf9 cells as well as from those of other known forms of adenylyl cyclase in animal cells; sAC in Sf9 cells may constitute a new member of adenylyl cyclase found in animals.	HARVARD UNIV, BRIGHAM & WOMENS HOSP, SCH MED, DEPT MED, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL038070] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL38070] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON WB, 1978, J BIOL CHEM, V253, P2921; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAUN T, 1975, P NATL ACAD SCI USA, V72, P1097, DOI 10.1073/pnas.72.3.1097; BRAUN T, 1977, BIOCHIM BIOPHYS ACTA, V481, P227, DOI 10.1016/0005-2744(77)90155-3; BRAUN T, 1991, METHOD ENZYMOL, V195, P130; DANCHIN A, 1993, ADV SEC MESS PHOSPH, V27, P109; DUHE RJ, 1994, J BIOL CHEM, V269, P7290; FEINSTEIN PG, 1991, P NATL ACAD SCI USA, V88, P10173, DOI 10.1073/pnas.88.22.10173; GILMAN AG, 1990, ADV SEC MESS PHOSPH, V24, P51; GREENBERGER LM, 1994, TRENDS CARDIOVAS MED, V4, P193, DOI 10.1016/1050-1738(94)90057-4; HEIDEMAN W, 1987, J BIOL CHEM, V262, P7087; ISHIKAWA Y, 1992, J BIOL CHEM, V267, P13553; JACOBOWITZ O, 1994, P NATL ACAD SCI USA, V91, P10630, DOI 10.1073/pnas.91.22.10630; KAWABE J, 1994, J BIOL CHEM, V269, P24906; KAWABE J, 1994, J BIOL CHEM, V269, P16554; KORNBLIHTT AR, 1981, BIOCHEMISTRY-US, V20, P1262, DOI 10.1021/bi00508a033; LATHIGRA R, 1986, GENE, V44, P89, DOI 10.1016/0378-1119(86)90046-6; LEPPLA SH, 1982, P NATL ACAD SCI-BIOL, V79, P3162, DOI 10.1073/pnas.79.10.3162; LEVIN LR, 1992, CELL, V68, P479, DOI 10.1016/0092-8674(92)90185-F; MARSHAK DR, 1980, J BIOL CHEM, V255, P4781; Neer E J, 1978, Adv Cyclic Nucleotide Res, V9, P69; NEER EJ, 1978, J BIOL CHEM, V253, P5808; ONODA JM, 1987, BIOCHEM PHARMACOL, V36, P1907, DOI 10.1016/0006-2952(87)90487-4; PETERKOFSKY A, 1993, PROG NUCLEIC ACID RE, V44, P31, DOI 10.1016/S0079-6603(08)60216-0; PIERONI JP, 1995, J BIOL CHEM, V270, P21368, DOI 10.1074/jbc.270.36.21368; SANO M, 1983, ARCH BIOCHEM BIOPHYS, V220, P333, DOI 10.1016/0003-9861(83)90421-6; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; STENGEL D, 1982, J BIOL CHEM, V257, P818; TANG WJ, 1991, J BIOL CHEM, V266, P8595; YANG JK, 1983, J BIOL CHEM, V258, P3750	30	6	6	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					20132	20137		10.1074/jbc.271.33.20132	http://dx.doi.org/10.1074/jbc.271.33.20132			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702736	hybrid			2022-12-25	WOS:A1996VC66900077
J	Kenner, KA; Anyanwu, E; Olefsky, JM; Kusari, J				Kenner, KA; Anyanwu, E; Olefsky, JM; Kusari, J			Protein-tyrosine phosphatase 1B is a negative regulator of insulin- and insulin-like growth factor-I-stimulated signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SRC HOMOLOGY-2 DOMAINS; RECEPTOR SUBSTRATE-1; XENOPUS OOCYTES; KINASE-ACTIVITY; DEPHOSPHORYLATION; PHOSPHORYLATION; RESISTANCE; ACTIVATION; SUBUNIT; CLONING	To understand the physiological role of protein-tyrosine phosphatase 1B (PTPase 1B) in insulin and insulinlike growth factor-I (IGF-I) signaling we established clonal cell lines overexpressing wild type or inactive mutant (C215S) PTPase 1B in cells overexpressing insulin (Hirc) or IGF-I (CIGFR) receptors. PTPase 1B overexpression in transfected cells was verified by immunoblot analysis with a molloclonal PTPase 1B antibody. Subfractionation of parental cells demonstrated that greater than 90% of PTPase activity was localized in the Triton X-100-soluble particulate (P1) cell fraction. PTPase activity in the P1 fraction of cells overexpressing wild type PTPase 1B was 3-6-fold higher than parental cells but was unaltered in all fractions from C215S PTPase 1B-containing cells. The overexpression of wild type and C215S PTPase 1B had no effects on intrinsic receptor kinase activity growth rate, or general. cell morphology. The effects of PTPase IB overexpression on cellular protein tyrosine phosphorylation were examined by anti-phosphotyrosine immunoblot analysis. No differences were apparent under basal conditions, but hormone-stimulated receptor autophosphorylation and/or insulin receptor substrate tyrosine phosphorylation were inhibited in cells overexpressing wild type PTPase 1B and increased in cells expressing mutant PTPase 1B, in comparison with parental cells. Metalbolic signaling, assessed by ligand-stimulated [C-14]glucose incorporation into glycogen, was also inhibited in cells overexpressing active PTPase 1B and enhanced in cells containing C215S PTPase 1B. These data strongly suggest that PTPase 1B acts as a negative regulator of insulin and IGF-I signaling.	TULANE UNIV,MED CTR,DEPT PHYSIOL,NEW ORLEANS,LA 70112; UNIV CALIF SAN DIEGO,DEPT MED,DIV ENDOCRINOL METAB,LA JOLLA,CA 92093; VET ADM MED CTR,SAN DIEGO,CA 92161	Tulane University; University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA)					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK033651, R29DK046490, R01DK033651] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 46490-02, DK 33651] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHMAD F, 1995, BBA-PROTEIN STRUCT M, V1248, P57, DOI 10.1016/0167-4838(95)00003-D; AHMAD S, 1993, P NATL ACAD SCI USA, V90, P2197, DOI 10.1073/pnas.90.6.2197; ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brautigan David L., 1993, Molecular and Cellular Biochemistry, V127-128, P121, DOI 10.1007/BF01076763; BURGESS JW, 1992, J BIOL CHEM, V267, P10077; CHERNOFF J, 1990, P NATL ACAD SCI USA, V87, P2735, DOI 10.1073/pnas.87.7.2735; CICIRELLI MF, 1990, P NATL ACAD SCI USA, V87, P5514, DOI 10.1073/pnas.87.14.5514; DING W, 1994, BIOCHEM BIOPH RES CO, V202, P902, DOI 10.1006/bbrc.1994.2015; FAURE R, 1992, J BIOL CHEM, V267, P11215; FRANGIONI JV, 1992, CELL, V68, P545, DOI 10.1016/0092-8674(92)90190-N; FREIDENBERG GR, 1987, J CLIN INVEST, V79, P240, DOI 10.1172/JCI112789; GOLDSTEIN BJ, 1993, RECEPTOR, V3, P1; GUAN K, 1991, J BIOL CHEM, V266, P12964; HASHIMOTO N, 1992, BIOCHEM BIOPH RES CO, V188, P1305, DOI 10.1016/0006-291X(92)91373-X; HASHIMOTO N, 1992, BIOCHEM J, V284, P569, DOI 10.1042/bj2840569; HSU D, 1994, ENDOCRINOLOGY, V134, P744, DOI 10.1210/en.134.2.744; IDE R, 1994, BIOCHEM BIOPH RES CO, V201, P71, DOI 10.1006/bbrc.1994.1670; JIA ZC, 1995, SCIENCE, V268, P1754, DOI 10.1126/science.7540771; KASUGA M, 1982, SCIENCE, V215, P185, DOI 10.1126/science.7031900; KENNER KA, 1993, J BIOL CHEM, V268, P25455; KUHNE MR, 1995, BIOCHEM BIOPH RES CO, V211, P190, DOI 10.1006/bbrc.1995.1795; KUHNE MR, 1994, J BIOL CHEM, V269, P15833; KULAS DT, 1995, J BIOL CHEM, V270, P2435, DOI 10.1074/jbc.270.6.2435; KUSARI J, 1994, J CLIN INVEST, V93, P1156, DOI 10.1172/JCI117068; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAEGAWA H, 1995, J BIOL CHEM, V270, P7724, DOI 10.1074/jbc.270.13.7724; MCCLAIN DA, 1987, J BIOL CHEM, V262, P14663; MEYEROVITCH J, 1991, J CLIN INVEST, V87, P1286, DOI 10.1172/JCI115131; MILARSKI KL, 1993, J BIOL CHEM, V268, P23634; MILARSKI KL, 1994, J BIOL CHEM, V269, P21239; NOGUCHI T, 1994, MOL CELL BIOL, V14, P6674, DOI 10.1128/MCB.14.10.6674; OBBERGHEN EV, 1983, P NATL ACAD SCI USA, V80, P945; OLEFSKY JM, 1990, DIABETES, V39, P1009, DOI 10.2337/diabetes.39.9.1009; RAMACHANDRAN C, 1992, BIOCHEMISTRY-US, V31, P4232, DOI 10.1021/bi00132a012; ROSEN OM, 1987, SCIENCE, V237, P1452, DOI 10.1126/science.2442814; SHACTER E, 1984, ANAL BIOCHEM, V138, P416, DOI 10.1016/0003-2697(84)90831-5; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SPARKS JW, 1985, J BIOL CHEM, V260, P2042; SU J, 1994, J BIOL CHEM, V269, P18731; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TAKATA Y, 1991, J BIOL CHEM, V266, P9135; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; TONKS NK, 1990, MOL CELL BIOL, V10, P458, DOI 10.1128/MCB.10.2.458; UCHIDA T, 1994, J BIOL CHEM, V269, P12220; UGI S, 1994, FEBS LETT, V340, P516; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; XIAO S, 1994, J BIOL CHEM, V269, P2124; YAMAUCHI K, 1995, P NATL ACAD SCI USA, V92, P664, DOI 10.1073/pnas.92.3.664; YU KT, 1984, J BIOL CHEM, V259, P5277; ZHANG WR, 1991, BIOCHEM BIOPH RES CO, V178, P1291, DOI 10.1016/0006-291X(91)91034-A; ZHU GC, 1993, J BIOL CHEM, V268, P1775	52	366	379	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					19810	19816		10.1074/jbc.271.33.19810	http://dx.doi.org/10.1074/jbc.271.33.19810			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702689	hybrid			2022-12-25	WOS:A1996VC66900030
J	Riese, DJ; Kim, ED; Elenius, K; Buckley, S; Klagsbrun, M; Plowman, GD; Stern, DF				Riese, DJ; Kim, ED; Elenius, K; Buckley, S; Klagsbrun, M; Plowman, GD; Stern, DF			The epidermal growth factor receptor couples transforming growth factor-alpha, heparin-binding epidermal growth factor-like factor, and amphiregulin to Neu, ErbB-3, and ErbB-4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PHOSPHORYLATION; PHOSPHATIDYLINOSITOL 3-KINASE; EGF RECEPTOR; NEUREGULIN RECEPTOR; CARDIAC DEVELOPMENT; KINASE-ACTIVITY; FAMILY MEMBERS; GENE-PRODUCT; HEREGULIN; PROTEIN	The epidermal growth factor (EGF) family hormones amphiregulin (AR), transforming growth factor-alpha (TGF-alpha), and heparin-binding EGF-like growth factor (HB-EGF) are thought to play significant roles in the genesis or progression of a number of human malignancies. However, the ability of these ligands to activate all four erbB family receptors has not been evaluated. Therefore, we have assessed the stimulation of erbB family receptor tyrosine phosphorylation by these hormones in a panel of mouse Ba/F3 cell lines expressing the four erbB family receptors, singly and in pairwise combinations. We also measured the stimulation of interleukin-3-independent survival or proliferation in this panel of Ba/F3 cell lines to compare the patterns of erbB family receptor coupling to physiologic responses induced by these peptides. EGF, TGF-alpha, AR, and HB-EGF all stimulated qualitatively similar patterns of erbB family receptor tyrosine phosphorylation and coupling to physiologic responses. Therefore, EGF, TGF-alpha, AR, and HB-EGF are functionally identical in this model system and behave differently from the EGF family hormones beta-cellulin and neuregulins.	YALE UNIV,SCH MED,DEPT PATHOL,NEW HAVEN,CT 06520; CHILDRENS HOSP,DEPT SURG RES,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115; BRISTOL MYERS SQUIBB PHARMACEUT RES INST,SEATTLE,WA 98121; SUGEN INC,REDWOOD CITY,CA 94063	Yale University; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Bristol-Myers Squibb			PLOWMAN, Greg D/E-2012-2011; Riese, David/AAF-3581-2020	Elenius, Klaus/0000-0001-5700-0827; Riese, David/0000-0002-8823-5802	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [T32HD007149] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA045708] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047397] Funding Source: NIH RePORTER; NCI NIH HHS [CA-45708] Funding Source: Medline; NICHD NIH HHS [HD-07149] Funding Source: Medline; NIGMS NIH HHS [GM-47397] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKIYAMA T, 1988, MOL CELL BIOL, V8, P1019, DOI 10.1128/MCB.8.3.1019; ALIMANDI M, 1995, ONCOGENE, V10, P1813; BARBACCI EG, 1995, J BIOL CHEM, V270, P9585, DOI 10.1074/jbc.270.16.9585; BEERLI RR, 1995, MOL CELL BIOL, V15, P6496; CARRAWAY KL, 1995, J BIOL CHEM, V270, P7111, DOI 10.1074/jbc.270.13.7111; CARRAWAY KL, 1994, J BIOL CHEM, V269, P14303; CONNELLY PA, 1990, P NATL ACAD SCI USA, V87, P6054, DOI 10.1073/pnas.87.16.6054; DIFIORE PP, 1990, MOL CELL BIOL, V10, P2749, DOI 10.1128/MCB.10.6.2749; DIFIORE PP, 1990, SCIENCE, V248, P79, DOI 10.1126/science.2181668; EARP HS, 1995, BREAST CANCER RES TR, V35, P115, DOI 10.1007/BF00694752; FAZIOLI F, 1992, J BIOL CHEM, V267, P5155; FEDI P, 1994, MOL CELL BIOL, V14, P492, DOI 10.1128/MCB.14.1.492; GASSMANN M, 1995, NATURE, V378, P390, DOI 10.1038/378390a0; GILL GN, 1984, J BIOL CHEM, V259, P7755; GROENEN LC, 1994, GROWTH FACTORS, V11, P235, DOI 10.3109/08977199409010997; GUY PM, 1994, P NATL ACAD SCI USA, V91, P8132, DOI 10.1073/pnas.91.17.8132; HARWERTH IM, 1992, J BIOL CHEM, V267, P15160; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; HIGASHIYAMA S, 1992, J BIOL CHEM, V267, P6205; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; JOHNSON GR, 1993, J BIOL CHEM, V268, P2924; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; KARUNAGARAN D, 1995, J BIOL CHEM, V270, P9982, DOI 10.1074/jbc.270.17.9982; KIM HH, 1994, J BIOL CHEM, V269, P24747; KING CR, 1988, EMBO J, V7, P1647, DOI 10.1002/j.1460-2075.1988.tb02991.x; KITA YA, 1994, FEBS LETT, V349, P139, DOI 10.1016/0014-5793(94)00644-X; LEE DC, 1995, PHARMACOL REV, V47, P51; LEE KF, 1995, NATURE, V378, P394, DOI 10.1038/378394a0; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MEYER D, 1995, NATURE, V378, P386, DOI 10.1038/378386a0; MUTHUSWAMY SK, 1995, ONCOGENE, V11, P271; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; PRIGENT SA, 1994, EMBO J, V13, P2831, DOI 10.1002/j.1460-2075.1994.tb06577.x; RIESE DJ, 1995, MOL CELL BIOL, V15, P5770; Riese DJ, 1996, ONCOGENE, V12, P345; SALOMON DS, 1995, CRIT REV ONCOL HEMAT, V19, P183, DOI 10.1016/1040-8428(94)00144-I; SEGATTO O, 1991, MOL CELL BIOL, V11, P3191, DOI 10.1128/MCB.11.6.3191; SHOYAB M, 1989, SCIENCE, V243, P1074, DOI 10.1126/science.2466334; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; STERN DF, 1988, EMBO J, V7, P995, DOI 10.1002/j.1460-2075.1988.tb02906.x; THOMPSON SA, 1994, J BIOL CHEM, V269, P2541; THORNE BA, 1994, MOL CELL BIOL, V14, P1635, DOI 10.1128/MCB.14.3.1635; WONG ST, 1989, CELL, V56, P495, DOI 10.1016/0092-8674(89)90252-3; ZAR JH, 1984, BIOSTAT ANAL, P79; Zhang K, 1996, J BIOL CHEM, V271, P3884	46	153	154	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					20047	20052		10.1074/jbc.271.33.20047	http://dx.doi.org/10.1074/jbc.271.33.20047			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702723	hybrid			2022-12-25	WOS:A1996VC66900064
J	Segal, RA; Bhattacharyya, A; Rua, LA; Alberta, JA; Stephens, RM; Kaplan, DR; Stiles, CD				Segal, RA; Bhattacharyya, A; Rua, LA; Alberta, JA; Stephens, RM; Kaplan, DR; Stiles, CD			Differential utilization of Trk autophosphorylation sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; RECEPTOR TYROSINE KINASE; NEURONAL DIFFERENTIATION; SIGNAL-TRANSDUCTION; NEUROTROPHIC FACTOR; PC12 CELLS; MAP KINASE; INSULIN-RECEPTOR; BINDING-SITES; ACTIVATION	Tyrosine autophosphorylation controls the catalytic and signaling activities of the neurotrophin receptors, the Trks. To analyze the regulation of distinct tyrosine sites, we generated a panel of antibodies that report the phosphorylation state of individual tyrosines within the Trk cytoplasmic domain. Using pheochromocytoma-derived cell lines, we show that individual tyrosines within the nerve growth factor receptor TrkA are phosphorylated in a non-coordinate fashion following receptor activation. The non-coordinate response of these tyrosines reflects their separate functions in regulating the catalytic and signaling activities of Trk receptors. The differential utilization of distinct sites on Trk receptor tyrosine kinases suggests that the receptor can specify both the timing and the nature of neurotrophin-stimulated signal transduction pathways. Moreover, we show that these Trk autophosphorylation sites, which have hitherto been mapped and characterized only in non-neuronal cell lines, are activated in normal neurons in response to ligand stimulation.	DANA FARBER CANC INST, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT NEUROL, BOSTON, MA 02115 USA; BETH ISRAEL HOSP, BOSTON, MA 02215 USA; HARVARD UNIV, SCH MED, DEPT MICROBIOL & MOL GENET, BOSTON, MA 02115 USA; NCI, FREDERICK CANC RES & DEV CTR, ABL BASIC RES PROGRAM, FREDERICK, MD 21702 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick				Bhattacharyya, Anita/0000-0002-0360-7145	NCI NIH HHS [N01-CO-74101] Funding Source: Medline; OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BANGALORE L, 1992, P NATL ACAD SCI USA, V89, P11637, DOI 10.1073/pnas.89.23.11637; BARBACID M, 1994, J NEUROBIOL, V25, P1386, DOI 10.1002/neu.480251107; BARBACID M, 1995, CURR OPIN CELL BIOL, V7, P148, DOI 10.1016/0955-0674(95)80022-0; BARKER PA, 1994, NEURON, V13, P203, DOI 10.1016/0896-6273(94)90470-7; BOTHWELL M, 1995, ANNU REV NEUROSCI, V18, P223, DOI 10.1146/annurev.neuro.18.1.223; EPSTEIN RJ, 1992, P NATL ACAD SCI USA, V89, P10435, DOI 10.1073/pnas.89.21.10435; FLIER JS, 1989, NEW ENGL J MED, V321, P1383, DOI 10.1056/NEJM198911163212007; GAO WQ, 1995, J NEUROSCI, V15, P2656; Greene LA., 1982, ADV CELL NEUROBIOL, V3, P373, DOI [10.1016/B978-0-12-008303-9.50016-5, DOI 10.1016/B978-0-12-008303-9.50016-5]; GUITON M, 1994, J BIOL CHEM, V269, P30370; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANTZOPOULOS PA, 1994, NEURON, V13, P187, DOI 10.1016/0896-6273(94)90469-3; HEMPSTEAD BL, 1992, NEURON, V9, P883, DOI 10.1016/0896-6273(92)90241-5; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; JING SQ, 1992, NEURON, V9, P1067, DOI 10.1016/0896-6273(92)90066-M; KAPLAN DR, 1994, J NEUROBIOL, V25, P1404, DOI 10.1002/neu.480251108; KORSCHING S, 1993, J NEUROSCI, V13, P2739; LAMBALLE F, 1991, CELL, V66, P967, DOI 10.1016/0092-8674(91)90442-2; LEVINE BA, 1991, J BIOL CHEM, V266, P3565; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MIDDLEMAS DS, 1994, J BIOL CHEM, V269, P5458; MITRA G, 1991, ONCOGENE, V6, P2237; NEBREDA AR, 1991, SCIENCE, V252, P558, DOI 10.1126/science.1850550; OBERMEIER A, 1993, EMBO J, V12, P933, DOI 10.1002/j.1460-2075.1993.tb05734.x; OBERMEIER A, 1993, J BIOL CHEM, V268, P22963; OBERMEIER A, 1994, EMBO J, V13, P1585, DOI 10.1002/j.1460-2075.1994.tb06421.x; QIU MS, 1992, NEURON, V9, P705, DOI 10.1016/0896-6273(92)90033-A; RAFFIONI S, 1993, ANNU REV BIOCHEM, V62, P823; ROSEN LB, 1994, NEURON, V12, P1207, DOI 10.1016/0896-6273(94)90438-3; SEGAL RA, 1995, J NEUROSCI, V15, P4970; SNIDER WD, 1994, CELL, V77, P627, DOI 10.1016/0092-8674(94)90048-5; SOLTOFF SP, 1992, J BIOL CHEM, V267, P17472; SOPPET D, 1991, CELL, V65, P895, DOI 10.1016/0092-8674(91)90396-G; STEPHENS RM, 1994, NEURON, V12, P691, DOI 10.1016/0896-6273(94)90223-2; TRAVERSE S, 1994, CURR BIOL, V4, P694, DOI 10.1016/S0960-9822(00)00154-8; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; VANDERGEER P, 1995, CURR BIOL, V5, P404, DOI 10.1016/S0960-9822(95)00081-9; VERDI JM, 1994, NEURON, V12, P733, DOI 10.1016/0896-6273(94)90327-1; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0	41	117	121	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					20175	20181		10.1074/jbc.271.33.20175	http://dx.doi.org/10.1074/jbc.271.33.20175			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702742	hybrid			2022-12-25	WOS:A1996VC66900084
J	Kamiya, K; Huang, P; Plunkett, W				Kamiya, K; Huang, P; Plunkett, W			Inhibition of the 3'->5' exonuclease of human DNA polymerase epsilon by fludarabine-terminated DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSINE-ARABINOSIDE MONOPHOSPHATE; CHRONIC LYMPHOCYTIC-LEUKEMIA; LOW-GRADE LYMPHOMA; RIBONUCLEOTIDE REDUCTASE; 9-BETA-D-ARABINOFURANOSYL-2-FLUOROADENINE; DELTA; TRIPHOSPHATE; MECHANISM; PRIMASE; CELLS	Incorporation of the anticancer drug fludarabine (9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate; F-ara-AMP) into the 3'-end of DNA during replication causes termination of DNA strand elongation and is strongly correlated with loss of clonogenicity. Because the proofreading mechanisms that remove 3'-Fara-AMP from DNA represent a possible means of resistance to the drug, the present study investigated the excision of incorporated F-ara-AMP from DNA by the 3' -->5'-exonuclease activity of DNA polymerase epsilon from human leukemia CEM cells. Using the drug-containing and normal deoxynucleotide oligomers (21-base) annealed to M13mp18(+) DNA as the excision substrates, we demonstrated eel that DNA polymerase a was unable to effectively remove F-ara-AMP from the 3'-end of the oligomer, However, 3'-terminal dAMP and subsequently other deoxynucleotides were readily excised from DNA in a distributive fashion, Kinetic evaluation demonstrated that although DNA polymerase epsilon has a higher affinity for F-ara-AMP-terminated DNA (K-m=7.1 pM) than for dAMP-terminated DNA of otherwise identical sequence (K-m=265 pM), excision of F-ara-AMP proceeded at a substantially slower rate (V-max=0.053 pmol/min/mg) than for 3'-terminal dAMP (V-max=1.96 pmol/min/mg). When the 3'-5' phosphodiester bond between F-ara-AMP at the 3'-terminus and the adjacent normal deoxynucleotide was cleaved by DNA polymerase epsilon, the reaction products appeared to remain associated with the enzyme but without the formation of a covalent bond. No further excision of the remaining oligomers was observed after the addition of fresh DNA polymerase epsilon to the reaction. Furthermore, the addition of DNA polymerase alpha and deoxynucleoside triphosphates to the excision reaction failed to extend the oligomers. After DNA polymerase epsilon had been incubated with 3'-F-ara-AMP-21-mer for 10 min, the enzyme was no longer able to excise 3'-terminal dAMP from a freshly added normal 21-mer annealed to M13mp18(+) template. We conclude that the 3'-->5' exonuclease of human DNA polymerase epsilon can remove 3'-termimal F-ara-AMP hom DNA with difficulty and that this excision results in a mechanism-mediated formation of ''dead end complex.''	UNIV TEXAS,MD ANDERSON CANCER CTR,SECT CELLULAR & MOL PHARMACOL,DEPT CLIN INVEST,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center					NATIONAL CANCER INSTITUTE [R01CA028596] Funding Source: NIH RePORTER; NCI NIH HHS [CA28596] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAMBARA RA, 1991, BIOCHIM BIOPHYS ACTA, V1088, P11, DOI 10.1016/0167-4781(91)90147-E; BIALEK G, 1993, J BIOL CHEM, V268, P6024; BROCKMAN RW, 1977, BIOCHEM PHARMACOL, V26, P2193, DOI 10.1016/0006-2952(77)90275-1; BURGERS PMJ, 1990, EUR J BIOCHEM, V191, P617, DOI 10.1111/j.1432-1033.1990.tb19165.x; CATAPANO CV, 1993, J BIOL CHEM, V268, P7179; CHENG CH, 1993, BIOCHEMISTRY-US, V32, P8568, DOI 10.1021/bi00084a025; CHOU J, 1985, DOSE EFFECT ANAL MIC, P5; COTTERILL SM, 1987, P NATL ACAD SCI USA, V84, P5635, DOI 10.1073/pnas.84.16.5635; DONLIN MJ, 1991, BIOCHEMISTRY-US, V30, P538, DOI 10.1021/bi00216a031; GANDHI V, 1988, CANCER RES, V48, P329; GAO YG, 1991, BIOCHEMISTRY-US, V30, P9922, DOI 10.1021/bi00105a016; GOSCIN LP, 1982, BIOCHEMISTRY-US, V21, P2513, DOI 10.1021/bi00539a034; HOCHSTER HS, 1992, J CLIN ONCOL, V10, P28, DOI 10.1200/JCO.1992.10.1.28; HOLLIS GF, 1981, J BIOL CHEM, V256, P8074; HUANG P, 1992, J BIOL CHEM, V267, P2817; HUANG P, 1991, CANCER RES, V51, P6110; HUANG P, 1995, CANCER CHEMOTH PHARM, V36, P181, DOI 10.1007/BF00685844; Huang P, 1995, CLIN CANCER RES, V1, P1005; HUANG P, 1989, MUTAT RES, V210, P291, DOI 10.1016/0027-5107(89)90090-0; HUANG P, 1990, J BIOL CHEM, V265, P16617; KEATING MJ, 1993, BLOOD, V81, P2878; KUNKEL TA, 1987, P NATL ACAD SCI USA, V84, P4865, DOI 10.1073/pnas.84.14.4865; KUNKEL TA, 1988, J BIOL CHEM, V263, P4450; KUNKEL TA, 1989, BIOCHEMISTRY-US, V28, P988, DOI 10.1021/bi00429a011; LEE MYWT, 1980, BIOCHEMISTRY-US, V19, P215, DOI 10.1021/bi00542a032; LINDAHL T, 1969, J BIOL CHEM, V244, P5014; LU CD, 1992, BIOCHEMISTRY-US, V31, P12403, DOI 10.1021/bi00164a015; MIKITA T, 1988, BIOCHEMISTRY-US, V27, P4698, DOI 10.1021/bi00413a018; MORRISON A, 1991, P NATL ACAD SCI USA, V88, P9473, DOI 10.1073/pnas.88.21.9473; MOSBAUGH DW, 1980, J BIOL CHEM, V255, P239; NAVAS TA, 1995, CELL, V80, P29, DOI 10.1016/0092-8674(95)90448-4; NICKEL W, 1992, J BIOL CHEM, V267, P848; NISHIDA C, 1988, J BIOL CHEM, V263, P501; NOVOTNY L, 1990, NUCL ACID CHEM 4, P337; PARKER WB, 1987, MOL PHARMACOL, V31, P146; PARKER WB, 1988, MOL PHARMACOL, V34, P485; PERRINO FW, 1990, BIOCHEMISTRY-US, V29, P5226, DOI 10.1021/bi00474a002; PERRINO FW, 1994, J BIOL CHEM, V269, P16357; PERRINO FW, 1992, J BIOL CHEM, V267, P23043; PLUNKETT W, 1990, SEMIN ONCOL, V17, P3; PLUNKETT W, 1980, CANCER RES, V40, P2349; Reardon J E, 1991, Adv Pharmacol, V22, P1, DOI 10.1016/S1054-3589(08)60031-9; REARDON JE, 1989, J BIOL CHEM, V264, P7405; REDMAN JR, 1992, J CLIN ONCOL, V10, P790, DOI 10.1200/JCO.1992.10.5.790; ROBERTSON LE, 1993, BLOOD, V81, P143; SABATINO RD, 1990, CANCER RES, V50, P5340; SCHAAPER RM, 1988, P NATL ACAD SCI USA, V85, P8126, DOI 10.1073/pnas.85.21.8126; SIMON M, 1991, EMBO J, V10, P2166; SKALSKI V, 1995, BIOCHEM PHARMACOL, V50, P815, DOI 10.1016/0006-2952(95)00205-E; SKARNES W, 1986, J BIOL CHEM, V261, P6629; SKERRA A, 1992, NUCLEIC ACIDS RES, V20, P3551, DOI 10.1093/nar/20.14.3551; SPRIGGS D, 1986, BIOCHEM PHARMACOL, V35, P247, DOI 10.1016/0006-2952(86)90521-6; THOMAS DC, 1991, BIOCHEMISTRY-US, V30, P11751, DOI 10.1021/bi00115a003; TSENG WC, 1982, MOL PHARMACOL, V21, P474; VASQUEZPADUA MA, 1990, CANCER COMMUN, V2, P55; WHITE EL, 1982, CANCER RES, V42, P2260; WONG I, 1991, BIOCHEMISTRY-US, V30, P526, DOI 10.1021/bi00216a030; YANG CL, 1991, BIOCHEMISTRY-US, V30, P7534, DOI 10.1021/bi00244a024; YANG SW, 1992, J BIOL CHEM, V267, P2345	59	29	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19428	19435		10.1074/jbc.271.32.19428	http://dx.doi.org/10.1074/jbc.271.32.19428			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702631	hybrid			2022-12-25	WOS:A1996VB68400065
J	Yu, PY; Eisner, GM; Yamaguchi, I; Mouradian, MM; Felder, RA; Jose, PA				Yu, PY; Eisner, GM; Yamaguchi, I; Mouradian, MM; Felder, RA; Jose, PA			Dopamine D-1A receptor regulation of phospholipase C isoform	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; PROTEIN-KINASE-C; SPONTANEOUSLY HYPERTENSIVE RATS; ALPHA-SUBUNIT; PHOSPHOINOSITIDE HYDROLYSIS; TYROSINE PHOSPHORYLATION; ADENYLATE-CYCLASE; MUSCLE CELLS; TUBULE CELLS; K+-ATPASE	In LTK(-) cells stably transfected with rat D-1A receptor cDNA, fenoldopam, a D-1 agonist, increased phosphatidylinositol 4,5-bisphosphate hydrolysis in a time-dependent manner. In the cytosol, phospholipase C (PLC) activity increased (50 +/- 7%) in 30 s, returned to basal level at 4 h, and decreased below basal values by 24 h; in the membrane, PLC activity also increased (36 +/- 13%) in 30 s, returned to basal level at 10 min, and decreased below basal value at 4 and 24 h. Fenoldopam also increased PLC-gamma protein in a time-dependent manner. The latter was blocked by the D-1 antagonist SKF83742 and by a D-1A antisense oligodeoxynucleotide, indicating involvement of the D-1A receptor. The fenoldopam-induced increase in PLC-gamma and activity was mediated by protein kinase A (PKA) since it was blocked by the PKA antagonist R(p)-8-CTP-adenosine cyclic 3':5'-monophosphorothioate (R(p)-8-CTP-cAMP-S) and mimicked by direct stimulation of adenylyl cyclase with forskolin or by a PKA agonist, S-p-cAMP-S. Protein kinase C (PKC) was also involved, since the fenoldopam-induced increase in PLC-gamma protein was blocked by two different PKC inhibitors, calphostin C and chelerythrine; calphostin C also blocked the fenoldopam-induced increase in PLC activity. In addition, forskolin and a PKA agonist, S-p-8-CTP-cAMP-S, increased PKC activity, and direct stimulation of PKC with phorbol 12-myristate 13-acetate increased PLC-gamma protein and activity, effects that were blocked by calphostin C. We suggest that the D-1A-mediated stimulation of PLC occurs as a result of PKA activation. PKA then stimulates PLC-gamma in cytosol and membrane via activation of PKC.	GEORGETOWN UNIV, MED CTR, DEPT PEDIAT, WASHINGTON, DC 20007 USA; GEORGETOWN UNIV, SCH MED, DEPT PHYSIOL & BIOPHYS, WASHINGTON, DC 20007 USA; UNIV VIRGINIA, SCH MED, DEPT PATHOL, CHARLOTTESVILLE, VA 22908 USA; NINCDS, GENET PHARMACOL UNIT, NIH, BETHESDA, MD 20892 USA	Georgetown University; Georgetown University; University of Virginia; National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)				Mouradian, M. Maral/0000-0002-9937-412X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK044756, R29DK042185, R01DK039308] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK39308, DK42185, DK44756] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BERTORELLO A, 1989, AM J PHYSIOL, V256, pF370, DOI 10.1152/ajprenal.1989.256.2.F370; BLACKMORE PF, 1986, J BIOL CHEM, V261, P1056; BLANK JL, 1992, J BIOL CHEM, V267, P23069; BOYER JL, 1994, J BIOL CHEM, V269, P2814; CHEN CJ, 1993, HYPERTENSION, V21, P364, DOI 10.1161/01.HYP.21.3.364; CHEN CJ, 1992, HYPERTENSION, V19, P102, DOI 10.1161/01.HYP.19.1.102; CIVELLI O, 1993, ANNU REV PHARMACOL, V33, P281, DOI 10.1146/annurev.pa.33.040193.001433; CONKLIN BR, 1992, J BIOL CHEM, V267, P31; DELAPENA P, 1995, J BIOL CHEM, V270, P3554, DOI 10.1074/jbc.270.8.3554; DEMCHYSHYN LL, 1995, J BIOL CHEM, V270, P4005, DOI 10.1074/jbc.270.8.4005; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; FELDER CC, 1989, J BIOL CHEM, V264, P8739; FELDER CC, 1989, J PHARMACOL EXP THER, V248, P171; FELDER CC, 1993, AM J PHYSIOL, V264, pF1032, DOI 10.1152/ajprenal.1993.264.6.F1032; FELDER CC, 1990, AM J PHYSIOL, V259, pF297, DOI 10.1152/ajprenal.1990.259.2.F297; FISHER SK, 1992, MOL PHARMACOL, V42, P340; FRAIL DE, 1993, MOL PHARMACOL, V44, P1113; GESEK FA, 1990, AM J PHYSIOL, V258, pF514, DOI 10.1152/ajprenal.1990.258.3.F514; GINGRICH JA, 1993, ANNU REV NEUROSCI, V16, P299, DOI 10.1146/annurev.ne.16.030193.001503; Goo Rhee Sue, 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P35; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; HORIUCHI A, 1993, MOL PHARMACOL, V43, P281; JOSE PA, 1993, ADV BIOSCI, V88, P51; KANSRA V, 1995, CLIN EXP HYPERTENS, V17, P837, DOI 10.3109/10641969509033638; LAITINEN JT, 1993, J NEUROCHEM, V61, P1461, DOI 10.1111/j.1471-4159.1993.tb13641.x; LAUFER R, 1989, J BIOL CHEM, V264, P2683; LEE CW, 1994, J BIOL CHEM, V269, P25335; LIU YF, 1992, MOL ENDOCRINOL, V6, P1815, DOI 10.1210/me.6.11.1815; MAHAN LC, 1990, P NATL ACAD SCI USA, V87, P2196, DOI 10.1073/pnas.87.6.2196; MARRERO MB, 1994, J BIOL CHEM, V269, P10935; MCMILLIAN MK, 1992, J NEUROCHEM, V58, P1308, DOI 10.1111/j.1471-4159.1992.tb11343.x; MEISTER B, 1989, P NATL ACAD SCI USA, V86, P8068, DOI 10.1073/pnas.86.20.8068; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; OCONNELL DP, 1995, AM J PHYSIOL-RENAL, V268, pF1185, DOI 10.1152/ajprenal.1995.268.6.F1185; PIZZI M, 1988, BRAIN RES, V456, P235, DOI 10.1016/0006-8993(88)90222-3; RODRIGUES PD, 1990, P NATL ACAD SCI USA, V87, P9693, DOI 10.1073/pnas.87.24.9693; RUBINSTEIN JE, 1990, BIOCHEM PHARMACOL, V39, P1965, DOI 10.1016/0006-2952(90)90616-S; SATOH T, 1993, J CLIN INVEST, V91, P409, DOI 10.1172/JCI116215; SEEMAN P, 1994, TRENDS PHARMACOL SCI, V15, P264, DOI 10.1016/0165-6147(94)90323-9; SIBLEY DR, 1992, TRENDS PHARMACOL SCI, V13, P61, DOI 10.1016/0165-6147(92)90025-2; SMRCKA AV, 1993, J BIOL CHEM, V268, P9667; SUGAMORI KS, 1994, P NATL ACAD SCI USA, V91, P10536, DOI 10.1073/pnas.91.22.10536; SUH PG, 1988, J BIOL CHEM, V263, P14497; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; TIBERI M, 1994, J BIOL CHEM, V269, P27925; UNDIE AS, 1994, J NEUROCHEM, V62, P2045; VALLAR L, 1990, J BIOL CHEM, V265, P10320; VYAS SJ, 1992, J PHARMACOL EXP THER, V260, P134; WU DQ, 1992, J BIOL CHEM, V267, P25798; Yamaguchi I, 1995, Hypertens Res, V18 Suppl 1, pS19, DOI 10.1291/hypres.18.SupplementI_S19; YU PY, 1995, J CLIN INVEST, V95, P304, DOI 10.1172/JCI117656	52	58	60	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19503	19508		10.1074/jbc.271.32.19503	http://dx.doi.org/10.1074/jbc.271.32.19503			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702641	hybrid			2022-12-25	WOS:A1996VB68400075
J	FerrerMontiel, AV; Canaves, JM; DasGupta, BR; Wilson, MC; Montal, M				FerrerMontiel, AV; Canaves, JM; DasGupta, BR; Wilson, MC; Montal, M			Tyrosine phosphorylation modulates the activity of clostridial neurotoxins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; BOTULINUM NEUROTOXINS; SIGNAL-TRANSDUCTION; SEROTYPE-A; PC12 CELLS; PROTEIN; SNAP-25; RELEASE; IDENTIFICATION; INHIBITION	Clostridial neurotoxins' metalloprotease domain selectively cleaves proteins implicated in the process of synaptic vesicle fusion with the plasma membrane and, accordingly, blocks neurotransmitter release into the synaptic cleft, Here we investigate the potential modulation of these neurotoxins by intracellular cascades triggered by environmental signals, which in turn may alter its activity on target substrates. We report that the nonreceptor tyrosine kinase Src phosphorylates botulinum neurotoxins A, B, and E and tetanus neurotoxin. Protein tyrosine phosphorylation of serotypes A and E dramatically increases both their catalytic activity and thermal stability, while dephosphorylation reverses the effect. This suggests that the biologically significant form of the neurotoxins inside neurons is phosphorylated. Indeed, in PC12 cells in which tyrosine kinases such as Src and PYK2 are highly abundant, stimulation by membrane depolarization in presence of extracellular calcium induces rapid and selective tyrosine phosphorylation of internalized light chain, the metalloprotease domain, of botulinum toxin A. These findings provide a conceptual framework to connect intracellular signaling pathways involving tyrosine kinases, G-proteins, phosphoinositides, and calcium with the action of botulinum neurotoxins in abrogating vesicle fusion and neurosecretion.	UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093; UNIV WISCONSIN,MADISON,WI 53706; SCRIPPS CLIN & RES FDN,DEPT NEUROPHARMACOL,LA JOLLA,CA 92037	University of California System; University of California San Diego; University of Wisconsin System; University of Wisconsin Madison; Scripps Research Institute			Ferrer-Montiel, Antonio/C-3072-2015	Ferrer-Montiel, Antonio/0000-0002-2973-6607	NIMH NIH HHS [MH48989] Funding Source: Medline; NINDS NIH HHS [NS17742] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH048989] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS017742] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BANERJEE A, 1993, NEUROSCI LETT, V164, P93, DOI 10.1016/0304-3940(93)90865-I; BINZ T, 1994, J BIOL CHEM, V269, P1617; BLASI J, 1993, NATURE, V365, P160, DOI 10.1038/365160a0; BOROFF DA, 1971, MICROBIAL TOXINS   A, V2, P1; BRUGGE JS, 1985, NATURE, V316, P554, DOI 10.1038/316554a0; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; EVELETH DD, 1989, J NEUROSCI RES, V24, P67, DOI 10.1002/jnr.490240110; FERRERMONTIEL AV, 1995, P NATL ACAD SCI USA, V92, P8021, DOI 10.1073/pnas.92.17.8021; FERRERMONTIEL AV, 1991, P NATL ACAD SCI USA, V88, P6418; GREENE LA, 1987, METHOD ENZYMOL, V147, P207; HAYASHI T, 1994, EMBO J, V13, P5051, DOI 10.1002/j.1460-2075.1994.tb06834.x; HEIDELBERGER R, 1994, NATURE, V371, P513, DOI 10.1038/371513a0; JANKOVIC J, 1994, CURR OPIN NEUROL, V7, P358, DOI 10.1097/00019052-199408000-00014; KREMER NE, 1991, J CELL BIOL, V115, P809, DOI 10.1083/jcb.115.3.809; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; LISCOVITCH M, 1995, CELL, V81, P659, DOI 10.1016/0092-8674(95)90525-1; MAHER PA, 1988, P NATL ACAD SCI USA, V85, P6788, DOI 10.1073/pnas.85.18.6788; McPherson PS, 1996, NATURE, V379, P353, DOI 10.1038/379353a0; OYLER GA, 1989, J CELL BIOL, V109, P3039, DOI 10.1083/jcb.109.6.3039; Rusanescu G, 1995, NEURON, V15, P1415, DOI 10.1016/0896-6273(95)90019-5; SATHYAMOORTHY V, 1985, J BIOL CHEM, V260, P461; SCHELLER RH, 1995, NEURON, V14, P893; SCHIAVO G, 1992, NATURE, V359, P832, DOI 10.1038/359832a0; SCHIAVO G, 1992, J BIOL CHEM, V267, P23479; SCHIAVO G, 1993, J BIOL CHEM, V268, P23784; SCHIAVO G, 1993, FEBS LETT, V335, P99, DOI 10.1016/0014-5793(93)80448-4; SELLIN LC, 1983, ACTA PHYSIOL SCAND, V119, P127, DOI 10.1111/j.1748-1716.1983.tb07317.x; SHONE CC, 1992, EUR J BIOCHEM, V207, P1009, DOI 10.1111/j.1432-1033.1992.tb17137.x; SIMPSON LL, 1981, PHARMACOL REV, V33, P155; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0	31	46	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18322	18325		10.1074/jbc.271.31.18322	http://dx.doi.org/10.1074/jbc.271.31.18322			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702470	hybrid			2022-12-25	WOS:A1996VB68300008
J	Kai, M; Wada, I; Imai, S; Sakane, F; Kanoh, H				Kai, M; Wada, I; Imai, S; Sakane, F; Kanoh, H			Identification and cDNA cloning of 35-kDa phosphatidic acid phosphatase (Type 2) bound to plasma membranes - Polymerase chain reaction amplification of mouse H2O2-inducible hic53 clone yielded the cDNA encoding phosphatidic acid phosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER; SIGNAL-TRANSDUCTION; PHOSPHOHYDROLASE; PROTEIN; KINASE; PURIFICATION; LIPIDS; CELLS	We previously described the purification of an 83-kDa phosphatidic acid phosphatase (PAP) from the porcine thymus membranes (Kanoh, H., Imai, S.-i., Yamada, K. and Sakane, F. (1992) J. Biol. Chem. 267, 25309-25314). However, we found that a minor 35-kDa protein could account for the PAP activity when the purified enzyme preparation was further analyzed. We thus determined the N-terminal sequence of the 35-kDa candidate protein and prepared antipeptide antibody against the determined sequence, MFDKTRLPYVALDVL. The antibody almost completely precipitated the purified enzyme activity. Furthermore, the antibody precipitated from the radioiodinated enzyme preparation a single 35-kDa protein, which was converted to a 29-kDa form when treated with N-glycanase. We also found that the immunoprecipitable PAP activity was exclusively associated with the plasma membranes of porcine thymocytes. These results indicated that the 35-kDa glycosylated protein represents the plasma membrane-bound (type 2) PAP. We surprisingly noted that the N-terminal sequence of the porcine PAP was almost completely conserved in the internal sequence encoded by a mouse partial cDNA clone, hic53, reported as a H2O2-inducible gene (Egawa, K., Yoshiwara, M., Shibanuma, M., and Nose, K. (1995) FEES Lett. 372, 74-77). We thus amplified from the mouse kidney RNA the hic53 clone by polymerase chain reaction, and obtained a cDNA encoding a novel protein of 283 amino acid residues with a calculated M(r) of 31,894. Methionine reported as an internal residue was found to serve as an initiator, and the C-terminal 64 residues were lacking in hic53. The protein contains several putative membrane-spanning domains and two N-glycosylation sites. When transfected into 293 cells, the cDNA gave more than 10-fold increase of the membrane-bound PAP activity, which could be precipitated by the antipeptide antibody. In [S-35]methionine-labeled cells, the translational product was confirmed to be a 35-kDa protein, which became 30 kDa in cells treated with tunicamycin, an inhibitor of N-glycosylation. We thus succeeded first in identifying the porcine type 2 PAP and subsequently in determining the primary structure of a mouse homolog of the PAP.	SAPPORO MED UNIV,SCH MED,DEPT BIOCHEM,CHUO KU,SAPPORO,HOKKAIDO 060,JAPAN	Sapporo Medical University			Sakane, Fumio/H-2693-2017	Sakane, Fumio/0000-0003-0857-0377; Wada, Ikuo/0000-0001-5668-6994				ARIDORPITERMAN O, 1992, EUR J BIOCHEM, V204, P561, DOI 10.1111/j.1432-1033.1992.tb16668.x; BARRNETT RJ, 1983, METHOD ENZYMOL, V96, P627; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; DAY CP, 1993, CLIN SCI, V85, P281, DOI 10.1042/cs0850281; EGAWA K, 1995, FEBS LETT, V372, P74, DOI 10.1016/0014-5793(95)00957-B; EXTON JH, 1990, J BIOL CHEM, V265, P1; Fleischer S, 1974, Methods Enzymol, V31, P6; FLEMING IN, 1995, BIOCHEM J, V308, P983, DOI 10.1042/bj3080983; GOMEZMUNOZ A, 1992, FEBS LETT, V301, P103, DOI 10.1016/0014-5793(92)80219-7; HELLMAN U, 1995, ANAL BIOCHEM, V224, P451, DOI 10.1006/abio.1995.1070; JAMAL Z, 1991, J BIOL CHEM, V266, P2988; KAI M, 1994, J BIOL CHEM, V269, P18492; KANOH H, 1992, J BIOL CHEM, V267, P25309; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARTIN A, 1987, BIOCHEM J, V245, P347, DOI 10.1042/bj2450347; MARTIN A, 1993, J BIOL CHEM, V268, P23924; MOOLENAAR WH, 1992, REV PHYSIOL BIOCH P, V119, P47; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; OWENS RJ, 1984, EMBO J, V3, P945, DOI 10.1002/j.1460-2075.1984.tb01912.x; Sakane F, 1996, J BIOL CHEM, V271, P8394, DOI 10.1074/jbc.271.14.8394; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIESS EA, 1996, FEBS LETT, V381, P1699; WAGGONER DW, 1995, J BIOL CHEM, V270, P19422, DOI 10.1074/jbc.270.33.19422; WALSH JP, 1986, J BIOL CHEM, V261, P6239; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6	29	96	102	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18931	18938		10.1074/jbc.271.31.18931	http://dx.doi.org/10.1074/jbc.271.31.18931			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702556	hybrid			2022-12-25	WOS:A1996VB68300094
J	Lee, JS; Zhang, XL; Shi, Y				Lee, JS; Zhang, XL; Shi, Y			Differential interactions of the CREB/ATF family of transcription factors with p300 and adenovirus E1A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING PROPERTIES; REGION 1A PROTEINS; MESSENGER-RNAS; ACTIVATES TRANSCRIPTION; TRANSFORMING GENES; FUNCTIONAL DOMAINS; CELLULAR PROTEINS; PRODUCTS; REPRESSION; PROMOTER	The adenovirus E1A-associated protein p300 is a transcriptional cofactor that interacts with YY1 and mediates the relief of YY1 transcriptional repression by E1A. These observations raise the possibility that p300 may function as a bridging factor between E1A and cellular transcription factors. Here we show that p300, but not a mutant defective for binding to E1A, activated cAMP-responsive element-binding protein/activating transcription factor (CREB/ATF) binding site-mediated transcription in the presence of E1A. Among proteins that can recognize the CREB/ATF site, CREB appeared to be modulated by E1A in a p300 binding-dependent manner. This effect of E1A was cor related with a specific physical interaction between CREB and p300. These results suggest that p300 plays a crucial role in mediating the functional interplay between E1A and certain members of the CREB/ATF family. Two separate domains within p300 were identified that are capable of activating transcription. One of the domains interacted with the basal factor TFIIB, suggesting that p300 may function as a coactivator by making contacts with both sequence-specific transcription factors and the basal transcriptional machinery. This pivotal role of p300 may make it a prime target for viral proteins such as E1A in programming the cellular transcription machinery.	HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,COMM VIROL,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053874] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM53874, GM 18221] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAM SE, 1993, ONCOGENE, V8, P1639; ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; ARANY Z, 1994, CELL, V77, P799, DOI 10.1016/0092-8674(94)90127-9; BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; BERK AJ, 1978, CELL, V14, P695, DOI 10.1016/0092-8674(78)90252-0; BORRELLI E, 1984, NATURE, V312, P608, DOI 10.1038/312608a0; CHATTERJEE PK, 1988, EMBO J, V7, P835, DOI 10.1002/j.1460-2075.1988.tb02882.x; CHATTON B, 1993, MOL CELL BIOL, V13, P561, DOI 10.1128/MCB.13.1.561; CHOW LT, 1979, J MOL BIOL, V134, P265, DOI 10.1016/0022-2836(79)90036-6; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; DEAN DC, 1987, P NATL ACAD SCI USA, V84, P1876, DOI 10.1073/pnas.84.7.1876; DEAN DC, 1989, MOL CELL BIOL, V9, P1498, DOI 10.1128/MCB.9.4.1498; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DWARKI VJ, 1990, EMBO J, V9, P225, DOI 10.1002/j.1460-2075.1990.tb08099.x; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; FERGUSON B, 1985, MOL CELL BIOL, V5, P2653, DOI 10.1128/MCB.5.10.2653; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FLINT J, 1989, ANNU REV GENET, V23, P141, DOI 10.1146/annurev.genet.23.1.141; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HAI T, 1988, GENE DEV, V2, P1216, DOI 10.1101/gad.2.10.1216; HARLOW E, 1985, J VIROL, V55, P533, DOI 10.1128/JVI.55.3.533-546.1985; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; HEN R, 1985, SCIENCE, V230, P1391, DOI 10.1126/science.2999984; HORIKOSHI N, 1991, P NATL ACAD SCI USA, V88, P5124, DOI 10.1073/pnas.88.12.5124; HOUWELING A, 1980, VIROLOGY, V105, P537, DOI 10.1016/0042-6822(80)90054-9; JELSMA TN, 1989, VIROLOGY, V171, P120, DOI 10.1016/0042-6822(89)90518-7; KACZMAREK L, 1986, VIROLOGY, V152, P1, DOI 10.1016/0042-6822(86)90366-1; KRAUS VB, 1992, MOL CELL BIOL, V12, P4391, DOI 10.1128/MCB.12.10.4391; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LEE JS, 1995, NUCLEIC ACIDS RES, V23, P925, DOI 10.1093/nar/23.6.925; LEE JS, 1995, GENE DEV, V9, P1188, DOI 10.1101/gad.9.10.1188; LEE JS, 1996, IN PRESS MOL CELL BI; LEE KAW, 1987, P NATL ACAD SCI USA, V84, P8355, DOI 10.1073/pnas.84.23.8355; LEE WS, 1991, CELL, V67, P365, DOI 10.1016/0092-8674(91)90188-5; LEFF T, 1984, P NATL ACAD SCI-BIOL, V81, P4381, DOI 10.1073/pnas.81.14.4381; LEWIS JB, 1980, CELL, V21, P303, DOI 10.1016/0092-8674(80)90138-5; LILLIE JW, 1986, CELL, V46, P1043, DOI 10.1016/0092-8674(86)90704-X; LILLIE JW, 1987, CELL, V50, P1091, DOI 10.1016/0092-8674(87)90175-9; LIN YS, 1988, P NATL ACAD SCI USA, V85, P3396, DOI 10.1073/pnas.85.10.3396; LIU F, 1994, NATURE, V368, P520, DOI 10.1038/368520a0; LIU F, 1993, J BIOL CHEM, V268, P6714; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; LORIAUX MM, 1993, P NATL ACAD SCI USA, V90, P9046, DOI 10.1073/pnas.90.19.9046; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; MARUYAMA K, 1987, ONCOGENE, V1, P361; NEVINS JR, 1981, CELL, V26, P213, DOI 10.1016/0092-8674(81)90304-4; NEVINS JR, 1992, SCIENCE, V258, P424; OFFRINGA R, 1990, CELL, V62, P527, DOI 10.1016/0092-8674(90)90017-9; PERRICAUDET M, 1979, NATURE, V281, P694, DOI 10.1038/281694a0; REHFUSS RP, 1991, J BIOL CHEM, V266, P18431; RIKITAKE Y, 1992, MOL CELL BIOL, V12, P2826, DOI 10.1128/MCB.12.6.2826; ROCHETTEEGLY C, 1990, GENE DEV, V4, P137, DOI 10.1101/gad.4.1.137; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; SIMON MC, 1988, CELL, V52, P723, DOI 10.1016/0092-8674(88)90410-2; SIMON MC, 1987, MOL CELL BIOL, V7, P2884, DOI 10.1128/MCB.7.8.2884; STABEL S, 1985, EMBO J, V4, P2329, DOI 10.1002/j.1460-2075.1985.tb03934.x; STEIN RW, 1990, J VIROL, V64, P4421, DOI 10.1128/JVI.64.9.4421-4427.1990; STEIN RW, 1987, MOL CELL BIOL, V7, P1164, DOI 10.1128/MCB.7.3.1164; TAYLOR DA, 1993, MOL CELL BIOL, V13, P4714, DOI 10.1128/MCB.13.8.4714; VANDENELSEN P, 1983, VIROLOGY, V131, P242, DOI 10.1016/0042-6822(83)90549-4; VANDENELSEN P, 1982, GENE, V18, P175, DOI 10.1016/0378-1119(82)90115-9; VANDEREB AJ, 1979, COLD SPRING HARB SYM, V44, P383, DOI 10.1101/SQB.1980.044.01.043; VELCICH A, 1985, CELL, V40, P705, DOI 10.1016/0092-8674(85)90219-3; WANG HGH, 1993, J VIROL, V67, P476, DOI 10.1128/JVI.67.1.476-488.1993; WEBSTER KA, 1988, NATURE, V344, P260; WEINTRAUB SJ, 1992, MOL CELL BIOL, V12, P512, DOI 10.1128/MCB.12.2.512; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WINBERG G, 1984, EMBO J, V3, P1907, DOI 10.1002/j.1460-2075.1984.tb02066.x; YEE SP, 1983, J VIROL, V46, P1003, DOI 10.1128/JVI.46.3.1003-1013.1983; YEE SP, 1985, VIROLOGY, V147, P142, DOI 10.1016/0042-6822(85)90234-X; ZERLER B, 1987, MOL CELL BIOL, V7, P821, DOI 10.1128/MCB.7.2.821	75	41	42	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					17666	17674		10.1074/jbc.271.30.17666	http://dx.doi.org/10.1074/jbc.271.30.17666			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663457	hybrid			2022-12-25	WOS:A1996UY93500015
J	Series, F; Cote, C; Simoneau, JA; StPierre, S; Marc, I				Series, F; Cote, C; Simoneau, JA; StPierre, S; Marc, I			Upper airway collapsibility, and contractile and metabolic characteristics of musculus uvulae	FASEB JOURNAL			English	Article						upper airway dilator muscle; muscle fatigue; muscle fiber area; metabolic profile; human skeletal muscle	OBSTRUCTIVE SLEEP-APNEA; GENIOGLOSSAL EMG ACTIVITY; MUSCLE-FIBER-TYPE; PHARYNGEAL RESISTANCE; CLOSING PRESSURES; ENZYME-ACTIVITIES; FLOW; UVULOPALATOPHARYNGOPLASTY; STIMULATION; ACTIVATION	Physiologic, metabolic, and histochemical characteristics of one upper airway (UA) dilator muscle (musculus uvulae; MU) differ between sleep apnea hypopnea syndrome (SAPS) and nonapneic snorers, We hypothesized that these differences in MU characteristics could result from the cumulative effects of the diurnal and nocturnal intermittent contractions of UA muscles in order to compensate for a permanent increase in UA collapsibility, The aim of this study was to determine the influence of UA collapsibility on MU characteristics. Seventeen SAHS and three nonapneic snorers, who underwent an uvulo-palato-pharyngoplasty as a treatment for snoring or SAHS, participated in the study, Awake and sleeping UA critical pressure (Pcrit) was measured during continuous positive or negative airway pressure trials by analysis of the relationship between maximal inspiratory flow and the upstream pressure of flow-limited breathing cycles, Maximum isometric twitch (P-t) and tetanic tension (P-o), fatigability measurements, activities of marker enzymes for anaerobic and aerobic-oxidative profile, and fiber type proportions and areas of MU were determined, There was a significant positive relationship between Pt, Po,, and Pcrit measured during wakefulness and sleep, The fatigability index was negatively correlated with awake Pcrit values (r = -0.19), Activity level of the anaerobic enzymes as well as the percentage of surface occupied by type I and type TIA muscle fibers as correlated with awake Pcrit, We conclude that the differences in awake UA collapsibility help to determine the contractile properties and metabolic and histochemical characteristics of MU.	CHU LAVAL,HORMONALE BIOREGULAT LAB,LAVAL,PQ,CANADA; HOP LAVAL,DEPT ORL,LAVAL,PQ G1V 4G5,CANADA; UNIV LAVAL,LAB SCI ACTIV PHYS,LAVAL,PQ,CANADA	Laval University; Laval University; Laval University	Series, F (corresponding author), HOP LAVAL,CTR PNEUMOL,UNITE RECH,2725 CHEMIN STE FOY,ST FOY,PQ G1V 4G5,CANADA.			Marc, Isabelle/0000-0001-6060-8550				ANCH AM, 1982, J APPL PHYSIOL, V53, P1158, DOI 10.1152/jappl.1982.53.5.1158; ANDERSEN P, 1977, ACTA PHYSIOL SCAND, V99, P123, DOI 10.1111/j.1748-1716.1977.tb10361.x; [Anonymous], 1992, SLEEP, V15, P174; BAYDUR A, 1982, AM REV RESPIR DIS, V126, P788; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROUILLETTE RT, 1980, J APPL PHYSIOL, V49, P801, DOI 10.1152/jappl.1980.49.5.801; CHADHA TS, 1982, AM REV RESPIR DIS, V125, P644; COSTILL DL, 1979, J APPL PHYSIOL, V46, P96, DOI 10.1152/jappl.1979.46.1.96; FREMONT P, 1991, AM J PHYSIOL, V260, pR615, DOI 10.1152/ajpregu.1991.260.3.R615; FUJITA S, 1981, OTOLARYNG HEAD NECK, V89, P923, DOI 10.1177/019459988108900609; GAUTHIER JM, 1992, MED SCI SPORT EXER, V24, P1252; GLEADHILL IC, 1991, AM REV RESPIR DIS, V143, P1300, DOI 10.1164/ajrccm/143.6.1300; GONYEA WJ, 1986, EUR J APPL PHYSIOL O, V55, P137, DOI 10.1007/BF00714995; GOULD GA, 1988, AM REV RESPIR DIS, V137, P895, DOI 10.1164/ajrccm/137.4.895; HOWALD H, 1990, INT J SPORTS MED, V11, pS10, DOI 10.1055/s-2007-1024847; ISSA FG, 1984, J APPL PHYSIOL, V57, P520, DOI 10.1152/jappl.1984.57.2.520; LEITER JC, 1992, J APPL PHYSIOL, V73, P584, DOI 10.1152/jappl.1992.73.2.584; LEITER JC, 1992, J APPL PHYSIOL, V73, P576, DOI 10.1152/jappl.1992.73.2.576; MABUCHI K, 1980, MUSCLE NERVE, V3, P227, DOI 10.1002/mus.880030307; MATHEW OP, 1982, J APPL PHYSIOL, V52, P438, DOI 10.1152/jappl.1982.52.2.438; MEZZANOTTE WS, 1992, J CLIN INVEST, V89, P1571, DOI 10.1172/JCI115751; MORRISON DL, 1993, AM REV RESPIR DIS, V148, P606, DOI 10.1164/ajrccm/148.3.606; OLIVEN A, 1989, RESP PHYSIOL, V75, P29, DOI 10.1016/0034-5687(89)90084-4; PEPIN JL, 1992, THORAX, V47, P150, DOI 10.1136/thx.47.3.150; PETROF BJ, 1994, J APPL PHYSIOL, V76, P1746, DOI 10.1152/jappl.1994.76.4.1746; PRINCE FP, 1976, PFLUG ARCH EUR J PHY, V363, P19, DOI 10.1007/BF00587397; Rechtschaffen A., 1968, MANUAL STANDARDIZED; REMMERS JE, 1978, J APPL PHYSIOL, V44, P931, DOI 10.1152/jappl.1978.44.6.931; ROBERTS JL, 1985, J APPL PHYSIOL, V58, P290, DOI 10.1152/jappl.1985.58.1.290; SCHWARTZ AR, 1992, AM REV RESPIR DIS, V145, P527, DOI 10.1164/ajrccm/145.3.527; SCHWARTZ AR, 1989, J APPL PHYSIOL, V66, P1626, DOI 10.1152/jappl.1989.66.4.1626; SCHWARTZ AR, 1991, AM REV RESPIR DIS, V144, P494, DOI 10.1164/ajrccm/144.3_Pt_1.494; SERIES F, 1995, J CLIN INVEST, V95, P20, DOI 10.1172/JCI117640; SERIES F, 1993, CHEST, V104, P14, DOI 10.1378/chest.104.1.14; SERIES F, 1993, J APPL PHYSIOL, V75, P1222, DOI 10.1152/jappl.1993.75.3.1222; SIMONEAU J A, 1991, Medicine and Science in Sports and Exercise, V23, pS149; SIMONEAU JA, 1988, PFLUG ARCH EUR J PHY, V412, P86, DOI 10.1007/BF00583735; SIMONEAU JA, 1989, AM J PHYSIOL, V257, pE567, DOI 10.1152/ajpendo.1989.257.4.E567; SMIRNE S, 1991, LANCET, V337, P597; STROHL KP, 1980, J APPL PHYSIOL, V49, P638, DOI 10.1152/jappl.1980.49.4.638; SURATT PM, 1988, AM REV RESPIR DIS, V137, P889, DOI 10.1164/ajrccm/137.4.889; SURATT PM, 1984, J APPL PHYSIOL, V57, P140, DOI 10.1152/jappl.1984.57.1.140; THERIAULT R, 1994, J APPL PHYSIOL, V77, P1885, DOI 10.1152/jappl.1994.77.4.1885; VANDERTOUW T, 1994, J APPL PHYSIOL, V76, P424, DOI 10.1152/jappl.1994.76.1.424; WASICKO MJ, 1990, AM REV RESPIR DIS, V141, P1569, DOI 10.1164/ajrccm/141.6.1569; YOUNG T, 1993, NEW ENGL J MED, V328, P1230, DOI 10.1056/NEJM199304293281704	46	31	31	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUN	1996	10	8					897	904		10.1096/fasebj.10.8.8666167	http://dx.doi.org/10.1096/fasebj.10.8.8666167			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	UQ456	8666167				2022-12-25	WOS:A1996UQ45600012
J	Kunicki, TJ; Annis, DS; Deng, YJ; Loftus, JC; Shattil, SJ				Kunicki, TJ; Annis, DS; Deng, YJ; Loftus, JC; Shattil, SJ			A molecular basis for affinity modulation of Fab ligand binding to integrin alpha(IIb)beta(3)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN-IIB-IIIA; GLY-ASP RGD; PLATELET FIBRINOGEN RECEPTORS; THROMBIN-STIMULATED PLATELETS; OUT SIGNAL-TRANSDUCTION; GPIIB-IIIA; NONACTIVATED PLATELETS; CYTOPLASMIC DOMAINS; ADHESION RECEPTOR; RECOGNITION SITE	The Arg-Gly-Asp (RGD) sequence within the third complementarity-determining region (CDR3) of the heavy chain (H3) is responsible for the binding of the recombinant murine Fab molecules, AP7 and PAC1.1, to the platelet integrin alpha(IIb)beta(3). AP7 binding is minimally influenced by the conformational state of this receptor, whereas PAC1.1 binds preferentially to the activated state of the receptor induced by platelet agonists. To study the molecular basis for this functional difference, we replaced the AP7 H3 loop (HPFYRGDGGN) with all or segments of the analogous sequence from PAC1.1 (RSPSYYRGDGAGP). AP7 Fd (V-H domain + C(gamma)1 domain) segments containing these H3 loop sequences were expressed as active Fab molecules by coinfection of Spo-doptera frugiperda cell lines with recombinant baculoviruses containing Fd and AP7 kappa chain cDNA. Replacement of the entire AP7 H3 loop with that from PAC1.1 generated the mutant AP7.3 Fab molecule, which bound selectively to either activated, gel-filtered platelets or to purified alpha(IIb)beta(3) in a manner identical to that of PAC1.1. Identical results were obtained when solely the sequences flanking the amino side of RGD within the respective H3 loops were exchanged. AP7.3 and PAC1.1 exhibited saturable but submaximal binding to activated gel-filtered platelets. Relative to AP7, the number of AP7.3 or PAC 1.1 Fab molecules bound per platelet was 17% in the presence of 1 mM Ca2+ + 1 mM Mg2+ or 40% in the presence of 10 mu M Mn2+. The ratio of Fab molecules bound after versus before activation (mean +/- S.D,; n = 3) was: for AP7.3, 9.8 +/- 0.6; for PAC1.1, 8.8 +/- 0.3; and for AP7, 1.4 +/- 0.2. In addition, AP7 bound to the stably expressed integrin mutant alpha(IIb)beta(3)(S123A), whereas AP7.3 and PAC1 did not. Because AP7.3 behaves in every respect like PAC1.1, we conclude that the ability of RGD-based ligands to distinguish activated from resting conformations of the integrin alpha(IIb)beta(3) can be regulated by limited amino acid sequences immediately adjacent to the RGD tripeptide. Furthermore, those Fab molecules that exhibit increased selectivity for the activated conformation of alpha(IIb)beta(3) bind to a subpopulation of this integrin on platelets that is modulated by divalent cations.	Scripps Res Inst, DEPT VASC BIOL, ROON RES CTR ARTERIOSCLEROSIS & THROMBOSIS, LA JOLLA, CA 92037 USA; UNIV PENN, SCH MED, DEPT MED, DIV HEMATOL ONCOL, PHILADELPHIA, PA 19104 USA	Scripps Research Institute; University of Pennsylvania	Kunicki, TJ (corresponding author), Scripps Res Inst, DEPT MOL & EXPT MED, ROON RES CTR ARTERIOSCLEROSIS & THROMBOSIS, LA JOLLA, CA 92037 USA.				NHLBI NIH HHS [HL-40387, HL-54023, R01 HL-46979] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL040387, R01HL046979] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABRAMS C, 1994, J BIOL CHEM, V269, P18781; BAJT ML, 1994, J BIOL CHEM, V269, P20913; BEER JH, 1992, BLOOD, V79, P117; BENNETT JS, 1979, J CLIN INVEST, V64, P1393, DOI 10.1172/JCI109597; BOWDITCH RD, 1991, J BIOL CHEM, V266, P23323; BOWDITCH RD, 1994, J BIOL CHEM, V269, P10856; CHAN BMC, 1993, J CELL BIOL, V120, P537, DOI 10.1083/jcb.120.2.537; CHARO IF, 1991, J BIOL CHEM, V266, P1415; CHEN YP, 1994, J BIOL CHEM, V269, P18307; DeNichilo MO, 1996, J IMMUNOL, V156, P284; DSOUZA SE, 1991, NATURE, V350, P66, DOI 10.1038/350066a0; DSOUZA SE, 1988, SCIENCE, V242, P91, DOI 10.1126/science.3262922; DSOUZA SE, 1990, J BIOL CHEM, V265, P3440; DU XP, 1993, J BIOL CHEM, V268, P23087; FURIHATA K, 1987, J CLIN INVEST, V80, P1624, DOI 10.1172/JCI113250; Ginsberg Mark H., 1992, Current Opinion in Cell Biology, V4, P766, DOI 10.1016/0955-0674(92)90099-X; GINSBERG MH, 1992, COLD SPRING HARB SYM, V57, P221, DOI 10.1101/SQB.1992.057.01.027; HAUNG M, 1993, J CELL BIOL, V12, P473; HAVERSTICK DM, 1985, BLOOD, V66, P946; KIRCHHOFER D, 1990, J BIOL CHEM, V265, P18525; KLOCZEWIAK M, 1989, BIOCHEMISTRY-US, V28, P2915, DOI 10.1021/bi00433a025; KODANDAPANI R, 1995, J BIOL CHEM, V270, P2268, DOI 10.1074/jbc.270.5.2268; KUNICKI TJ, 1995, J BIOL CHEM, V270, P16660, DOI 10.1074/jbc.270.28.16660; LOFTUS JC, 1990, SCIENCE, V249, P915, DOI 10.1126/science.2392682; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; NIEWIAROWSKI S, 1994, SEMIN HEMATOL, V31, P289; OTOOLE TE, 1994, J CELL BIOL, V124, P1047, DOI 10.1083/jcb.124.6.1047; PLOW EF, 1992, SEMIN THROMB HEMOST, V18, P324, DOI 10.1055/s-2007-1002571; SAVAGE B, 1991, J BIOL CHEM, V266, P11227; SAVAGE B, 1992, J BIOL CHEM, V267, P11300; SMITH JW, 1990, J BIOL CHEM, V265, P11008; STENBERG PE, 1984, J CELL BIOL, V98, P748, DOI 10.1083/jcb.98.2.748; TOMIYAMA Y, 1992, BLOOD, V79, P2303; WENCELDRAKE JD, 1984, AM J PATHOL, V115, P156	34	24	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20315	20321		10.1074/jbc.271.34.20315	http://dx.doi.org/10.1074/jbc.271.34.20315			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702765	hybrid			2022-12-25	WOS:A1996VD33700017
J	Lou, KL; Saint, N; Prilipov, A; Rummel, G; Benson, SA; Rosenbusch, JP; Schirmer, T				Lou, KL; Saint, N; Prilipov, A; Rummel, G; Benson, SA; Rosenbusch, JP; Schirmer, T			Structural and functional characterization of OmpF porin mutants selected for larger pore size .1. Crystallographic analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; OUTER-MEMBRANE; ANGSTROM RESOLUTION; BACTERIAL PORIN; CHANNELS; PH	OmpF porin is a nonspecific pore protein from the outer membrane of Escherichia coli. Previously, a set of mutants was selected that allow the passage of long maltodextrins that do not translocate through the wild-type pore. Here, we describe the crystal structures of four point mutants and one deletion mutant from this set; their functional characterization is reported in the accompanying paper (Saint, N,, Leu, K.-L., Widmer, C,, Luckey, M., Schirmer, T,, Rosenbusch, J, P, (1996) J, Biol. Chem. 271, 20676-20680), All mutations have a local effect on the structure of the pore constriction and result in a larger pore cross-section, Substitution of each of the three closely packed arginine residues at the pore constriction (Arg-42, Arg-82, and Arg-132) by shorter uncharged residues causes rearrangement of the adjacent basic residues, This demonstrates mutual stabilization of these residues in the wild-type porin, Deletion of six residues from the internal loop (Delta 109-114) results in disorder of seven adjacent residues but does not alter the structure of the beta-barrel framework, Thus, the large hollow beta-barrel motif can be regarded as an autonomous structure.	UNIV BASEL,DEPT BIOL STRUCT,BIOZENTRUM,CH-4056 BASEL,SWITZERLAND; UNIV BASEL,BIOZENTRUM,DEPT MICROBIOL,CH-4056 BASEL,SWITZERLAND; UNIV MARYLAND,DEPT MICROBIOL,COLLEGE PK,MD 20740	University of Basel; University of Basel; University System of Maryland; University of Maryland College Park			Saint, Nathalie/S-5286-2016	Saint, Nathalie/0000-0001-5219-9486				[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; BENSON SA, 1988, J MOL BIOL, V203, P961, DOI 10.1016/0022-2836(88)90121-0; BENZ R, 1988, EUR J BIOCHEM, V176, P1, DOI 10.1111/j.1432-1033.1988.tb14245.x; BRUNGER AT, 1992, XPLOR MANUAL VERSION; BUEHLER LK, 1991, J BIOL CHEM, V266, P24446; COWAN SW, 1992, NATURE, V358, P727, DOI 10.1038/358727a0; FOUREL D, 1993, J BACTERIOL, V175, P2754, DOI 10.1128/JB.175.9.2754-2757.1993; GARAVITO RM, 1986, METHOD ENZYMOL, V125, P309; JEANTEUR D, 1994, P NATL ACAD SCI USA, V91, P10675, DOI 10.1073/pnas.91.22.10675; JONES TA, 1990, MANUAL O VERSION 5 6; KARSHIKOFF A, 1994, J MOL BIOL, V240, P372, DOI 10.1006/jmbi.1994.1451; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KREUSCH A, 1994, PROTEIN SCI, V3, P58; LESLIE AGW, 1992, JOINT CCP4 ESF EACBM; LOBELLO M, 1995, J BIOL CHEM, V270, P1249; LOU KL, 1996, THESIS U BASEL BASEL; MACKINNON R, 1995, NEURON, V14, P889, DOI 10.1016/0896-6273(95)90327-5; MESSERSCHMIDT A, 1987, J APPL CRYSTALLOGR, V20, P306, DOI 10.1107/S002188988708662X; NIKAIDO H, 1994, J BIOL CHEM, V269, P3905; NIKAIDO H, 1985, MICROBIOL REV, V49, P1; NIKAIDO H, 1989, ANTIMICROB AGENTS CH, V33, P1831, DOI 10.1128/AAC.33.11.1831; PAUPTIT RA, 1991, J MOL BIOL, V218, P505, DOI 10.1016/0022-2836(91)90696-4; Saint N, 1996, J BIOL CHEM, V271, P20676, DOI 10.1074/jbc.271.34.20676; Sambrook J., 2002, MOL CLONING LAB MANU; SCHIRMER T, 1995, SCIENCE, V267, P512, DOI 10.1126/science.7824948; TODT JC, 1992, BIOCHEMISTRY-US, V31, P10471, DOI 10.1021/bi00158a009; TODT JC, 1992, BIOCHEMISTRY-US, V31, P10479, DOI 10.1021/bi00158a010; WEISS MS, 1992, J MOL BIOL, V227, P493, DOI 10.1016/0022-2836(92)90903-W	28	68	70	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20669	20675		10.1074/jbc.271.34.20669	http://dx.doi.org/10.1074/jbc.271.34.20669			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702816	hybrid			2022-12-25	WOS:A1996VD33700068
J	Mahapatra, S; Adhya, S				Mahapatra, S; Adhya, S			Import of RNA into Leishmania mitochondria occurs through direct interaction with membrane-bound receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRYPANOSOMA-BRUCEI; VARIABLE REGION; ORGANIZATION; PROTEINS; DONOVANI; INVIVO; DNA	Cytoplasmic tRNAs are imported into the kinetoplast mitochondrion of Leishmania, but the mechanism of import is unknown, particularly whether RNA is transferred as a ribonucleoprotein complex through the protein import pathway or by a distinct receptor-mediated mechanism. Using isolated mitochondria, it was shown that a small, importable RNA, which is structurally homologous to tRNA, binds rapidly, specifically, and with high affinity to the mitochondrial surface in the absence of soluble protein factors to form an import intermediate, Two classes of binding site of apparent K-d 0.3 and 10 an, respectively, were distinguished. tRNA from Leishmania, but not yeast, competitively inhibited the binding. Northwestern blot analysis revealed the presence of a 15-kDa RNA binding protein on the mitochondrial surface, whereas receptor binding was resistant to heparin and KCl, internalization was sensitive to both reagents, These results are consistent with the presence of a direct mechanism of receptor-mediated RNA import on Leishmania mitochondria.	INDIAN INST CHEM BIOL,GENET ENGN LAB,CALCUTTA 700032,W BENGAL,INDIA	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Indian Institute of Chemical Biology (IICB)								DAS S, 1990, J BIOSCIENCES, V15, P239, DOI 10.1007/BF02702665; GHOSH A, 1994, NUCLEIC ACIDS RES, V22, P1663, DOI 10.1093/nar/22.9.1663; HANCOCK K, 1990, J BIOL CHEM, V265, P19208; HARRIS ME, 1990, J BIOL CHEM, V265, P11368; Hatefi Y, 1978, Methods Enzymol, V53, P27; HAUCKE V, 1995, J BIOL CHEM, V270, P5565, DOI 10.1074/jbc.270.10.5565; HAUSER R, 1995, EMBO J, V14, P4212, DOI 10.1002/j.1460-2075.1995.tb00095.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LYE LF, 1993, MOL BIOCHEM PARASIT, V58, P233, DOI 10.1016/0166-6851(93)90045-Y; MAHAPATRA S, 1994, NUCLEIC ACIDS RES, V22, P3381, DOI 10.1093/nar/22.16.3381; MAYER A, 1995, EMBO J, V14, P4204, DOI 10.1002/j.1460-2075.1995.tb00094.x; MOTTRAM JC, 1991, J BIOL CHEM, V266, P18313; MYLER PJ, 1993, NUCLEIC ACIDS RES, V21, P687, DOI 10.1093/nar/21.3.687; NAGLEY P, 1989, TRENDS GENET, V5, P67, DOI 10.1016/0168-9525(89)90028-0; SCHNEIDER A, 1994, MOL CELL BIOL, V14, P2317, DOI 10.1128/MCB.14.4.2317; SIMPSON AM, 1989, NUCLEIC ACIDS RES, V17, P5427, DOI 10.1093/nar/17.14.5427; SLOOF P, 1992, MOL BIOCHEM PARASIT, V56, P289, DOI 10.1016/0166-6851(92)90178-M; SMALL I, 1992, EMBO J, V11, P1291, DOI 10.1002/j.1460-2075.1992.tb05172.x; SUYAMA Y, 1967, GENETICS BIOGENESIS, P763; TARASSOV I, 1995, J MOL BIOL, V245, P315, DOI 10.1006/jmbi.1994.0026; TARASSOV IA, 1992, NUCLEIC ACIDS RES, V20, P1277, DOI 10.1093/nar/20.6.1277; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350	22	41	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20432	20437		10.1074/jbc.271.34.20432	http://dx.doi.org/10.1074/jbc.271.34.20432			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702781	hybrid			2022-12-25	WOS:A1996VD33700033
J	Drummond, JT; Anthoney, A; Brown, R; Modrich, P				Drummond, JT; Anthoney, A; Brown, R; Modrich, P			Cisplatin and adriamycin resistance are associated with MutL alpha and mismatch repair deficiency in an ovarian tumor cell line	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONPOLYPOSIS COLON-CANCER; ANTICANCER DRUG CISPLATIN; MUTATOR PHENOTYPE; MICROSATELLITE INSTABILITY; COLORECTAL-CANCER; NUCLEAR EXTRACTS; DNA DAMAGE; HOMOLOG; MUTATIONS; TOLERANT	In contrast to parental A2780 ovarian tumor cells, extracts of one doxorubicin-resistant and two independent cis-diamminedichloroplatinum(II)-resistant derivatives are defective in strand-specific mismatch repair. The repair defect of the three hypermutable, drug-resistant cell lines is only evident when the strand break that directs the reaction is located 3' to the mismatch, and in each case repair is restored to extracts by addition of purified MutL alpha heterodimer. As judged by immunological assay, drug resistance is associated with the virtual absence of the MutL alpha MLH1 subunit and greatly reduced levels of the PMS2 subunit. These findings implicate a functional mismatch repair system in the cytotoxic effects of these antitumor drugs and may have ramifications for their clinical application.	DUKE UNIV, MED CTR, HOWARD HUGHES MED INST, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT BIOCHEM, DURHAM, NC 27710 USA; CRC, BEATSON LABS, DEPT MED ONCOL, GLASGOW G61 1BD, LANARK, SCOTLAND	Duke University; Howard Hughes Medical Institute; Duke University; Beatson Institute				Modrich, Paul/0000-0001-8708-9885	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045190] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM45190] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; Anthoney DA, 1996, CANCER RES, V56, P1374; AQUILINA G, 1995, CANCER RES, V55, P2569; BECK WT, 1987, BIOCHEM PHARMACOL, V36, P2879, DOI 10.1016/0006-2952(87)90198-5; BEHRENS BC, 1987, CANCER RES, V47, P414; BRANCH P, 1993, NATURE, V362, P652, DOI 10.1038/362652a0; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; BROWN R, 1993, INT J CANCER, V55, P678, DOI 10.1002/ijc.2910550428; CUMMINGS J, 1991, EUR J CANCER, V27, P532, DOI 10.1016/0277-5379(91)90209-V; DRUMMOND JT, 1995, SCIENCE, V268, P1909, DOI 10.1126/science.7604264; Duckett DR, 1996, P NATL ACAD SCI USA, V93, P6443, DOI 10.1073/pnas.93.13.6443; EASTMAN A, 1986, BIOCHEMISTRY-US, V25, P3912, DOI 10.1021/bi00361a026; FANG WH, 1993, J BIOL CHEM, V268, P11838; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; FRAM RJ, 1985, MOL PHARMACOL, V28, P51; GOLDMACHER VS, 1986, J BIOL CHEM, V261, P2462; HAWN MT, 1995, CANCER RES, V55, P3721; HOLMES J, 1990, P NATL ACAD SCI USA, V87, P5837, DOI 10.1073/pnas.87.15.5837; HUANG JC, 1994, P NATL ACAD SCI USA, V91, P10394, DOI 10.1073/pnas.91.22.10394; HUGHES EN, 1992, J BIOL CHEM, V267, P13520; KARRAN P, 1992, NUCLEIC ACIDS RES, V20, P2933, DOI 10.1093/nar/20.12.2933; KAT A, 1993, P NATL ACAD SCI USA, V90, P6424, DOI 10.1073/pnas.90.14.6424; KOI M, 1994, CANCER RES, V54, P4308; Kolodner Richard D., 1994, Current Opinion in Biotechnology, V5, P585, DOI 10.1016/0958-1669(94)90079-5; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LI GM, 1995, P NATL ACAD SCI USA, V92, P1950, DOI 10.1073/pnas.92.6.1950; LIPPARD SJ, 1993, R A WELCH FDN 37 C C, P49; LOEB LA, 1994, CANCER RES, V54, P5059; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; PALOMBO F, 1995, SCIENCE, V268, P1912, DOI 10.1126/science.7604265; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PAPADOPOULOS N, 1995, SCIENCE, V268, P1915, DOI 10.1126/science.7604266; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; PIL PM, 1992, SCIENCE, V256, P234, DOI 10.1126/science.1566071; RISINGER JI, 1995, J BIOL CHEM, V270, P18183, DOI 10.1074/jbc.270.31.18183; ROGAN AM, 1984, SCIENCE, V224, P994, DOI 10.1126/science.6372095; SCANLON KJ, 1991, PHARMACOL THERAPEUT, V52, P385, DOI 10.1016/0163-7258(91)90033-I; SHERMAN SE, 1987, CHEM REV, V87, P1153, DOI 10.1021/cr00081a013; SKLADANOWSKI A, 1994, BIOCHEM PHARMACOL, V47, P2279, DOI 10.1016/0006-2952(94)90266-6	40	271	290	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					19645	19648		10.1074/jbc.271.33.19645	http://dx.doi.org/10.1074/jbc.271.33.19645			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702663	hybrid			2022-12-25	WOS:A1996VC66900004
J	RehaKrantz, LJ; Nonay, RL; Day, RS; Wilson, SH				RehaKrantz, LJ; Nonay, RL; Day, RS; Wilson, SH			Replication of O-6-methylguanine-containing DNA by repair and replicative DNA polymerases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI DNA; MAMMALIAN-CELLS; HUMAN-TUMOR; BACTERIOPHAGE-T4; BETA; STRAINS; THYMINE; N-METHYL-N'-NITRO-N-NITROSOGUANIDINE; OLIGONUCLEOTIDE; PURIFICATION	The biological consequences of O-6-methylguanine (m6G) in DNA are well recognized, When template m6G is encountered by DNA polymerases, replication is hindered and trans-lesion replication results in the preferential incorporation of dTMP opposite template m6G. Thus, unrepaired m6G in DNA is both cytotoxic and mutagenic, Yet, cell limes tolerant to m6G in DNA have been isolated, which indicates that some cellular DNA polymerases may replicate m6G-containing DNA with reasonable efficiency, Previous reports suggested that mammalian pol beta could not replicate m6G-containing DNA, but we find that pol beta can catalyze trams-lesion replication; however, the lesion must reside in the optimal context for pol beta activity, single- or short nucleotide gapped substrates. Primed single-stranded DNA templates, with or without template m6G, were poor substrates for pol beta as reported in earlier studies. In contrast, trans-lesion replication by bacteriophage T4 DNA polymerase Nas observed for primed single-stranded DNA templates, Replication of m6G-containing DNA by T4 DNA polymerase required the gp45 accessory protein that clamps the polymerase to the DNA template. The rate-limiting step in replicating m6G-containing DNAs by both DNA polymerases tested was incorporation of dTMP across horn the lesion.	CROSS CANC INST, EDMONTON, AB T6G 1Z2, CANADA; UNIV TEXAS, MED BRANCH, SEALY CTR MOL SCI, GALVESTON, TX 77555 USA	University of Alberta; University of Texas System; University of Texas Medical Branch Galveston	RehaKrantz, LJ (corresponding author), UNIV ALBERTA, DEPT BIOL SCI, EDMONTON, AB T6G 2E9, CANADA.		Wilson, Samuel H/E-6644-2019; Reha-Krantz, Linda/A-3748-2014	Wilson, Samuel H/0000-0002-1702-5293; Reha-Krantz, Linda/0000-0003-4497-423X				ABBOTTS J, 1988, BIOCHEMISTRY-US, V27, P901, DOI 10.1021/bi00403a010; BOWLING JM, 1991, NUCLEIC ACIDS RES, V19, P3089, DOI 10.1093/nar/19.11.3089; BRANCH P, 1993, NATURE, V362, P652, DOI 10.1038/362652a0; CAPSON TL, 1992, BIOCHEMISTRY-US, V31, P10984, DOI 10.1021/bi00160a007; COULONDRE C, 1977, J MOL BIOL, V117, P577, DOI 10.1016/0022-2836(77)90059-6; DAY RS, 1980, NATURE, V288, P724, DOI 10.1038/288724a0; DOSANJH MK, 1991, BIOCHEMISTRY-US, V30, P11595, DOI 10.1021/bi00113a015; ELLISON KS, 1989, P NATL ACAD SCI USA, V86, P8620, DOI 10.1073/pnas.86.22.8620; GOLDMACHER VS, 1986, J BIOL CHEM, V261, P2462; KARRAN P, 1992, NUCLEIC ACIDS RES, V20, P2933, DOI 10.1093/nar/20.12.2933; KARRAN P, 1982, NATURE, V296, P868, DOI 10.1038/296868a0; KAT A, 1993, P NATL ACAD SCI USA, V90, P6424, DOI 10.1073/pnas.90.14.6424; KUMAR A, 1990, J BIOL CHEM, V265, P2124; LIN TC, 1987, P NATL ACAD SCI USA, V84, P7000, DOI 10.1073/pnas.84.20.7000; LOECHLER EL, 1984, P NATL ACAD SCI-BIOL, V81, P6271, DOI 10.1073/pnas.81.20.6271; Maniatis T., 1982, MOL CLONING; MANLEY JL, 1980, P NATL ACAD SCI-BIOL, V77, P3855, DOI 10.1073/pnas.77.7.3855; MATSUMOTO Y, 1995, SCIENCE, V269, P699, DOI 10.1126/science.7624801; MORRIS CF, 1979, J BIOL CHEM, V254, P6787; NEDDERMANN P, 1993, J BIOL CHEM, V268, P21218; REDDY MK, 1992, J BIOL CHEM, V267, P14157; REHAKRANTZ LJ, 1993, J BIOL CHEM, V268, P27100; REHAKRANTZ LJ, 1993, J VIROL, V67, P60, DOI 10.1128/JVI.67.1.60-66.1993; REHAKRANTZ LJ, 1994, J BIOL CHEM, V269, P5635; SCUDIERO DA, 1984, CANCER RES, V44, P961; SIBGHATULLAH, 1989, NUCLEIC ACIDS RES, V17, P4471, DOI 10.1093/nar/17.12.4471; SIBGHATULLAH, 1992, BIOCHEMISTRY-US, V31, P7998, DOI 10.1021/bi00149a034; SINGER B, 1989, P NATL ACAD SCI USA, V86, P8271, DOI 10.1073/pnas.86.21.8271; SINGHAL RK, 1993, J BIOL CHEM, V268, P15906; SNOW ET, 1984, J BIOL CHEM, V259, P8095; Sobol RW, 1996, NATURE, V379, P183, DOI 10.1038/379183a0; TSURIMOTO T, 1990, P NATL ACAD SCI USA, V87, P1023, DOI 10.1073/pnas.87.3.1023; WIEBAUER K, 1990, P NATL ACAD SCI USA, V87, P5842, DOI 10.1073/pnas.87.15.5842; YAROSH DB, 1983, CARCINOGENESIS, V4, P199, DOI 10.1093/carcin/4.2.199	34	31	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					20088	20095		10.1074/jbc.271.33.20088	http://dx.doi.org/10.1074/jbc.271.33.20088			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702729	hybrid			2022-12-25	WOS:A1996VC66900070
J	Parra, KJ; Kane, PM				Parra, KJ; Kane, PM			Wild-type and mutant vacuolar membranes support pH-dependent reassembly of the yeast vacuolar H+-ATPase in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSLOCATING ADENOSINE-TRIPHOSPHATASE; VESICLE PROTON PUMP; SACCHAROMYCES-CEREVISIAE; GENE ENCODES; NEUROSPORA-CRASSA; ENZYME COMPLEX; SUBUNIT-A; ACIDIFICATION; INACTIVATION; INHIBITION	Treatment of the yeast vacuolar proton-translocating ATPase (H+-ATPase) with 300 mM RI in tile presence of 5 mM Mg-ATP results ill a 90% inhibition of ATPase activity accompanied by removal of at least five of the peripheral subunits of the enzyme from the membrane. Functional reassembly of the enzyme, as indicated by reattachment of the peripheral subunits and a partial (30-70%) recovery of ATPase activity, could be achieved by dialysis of the stripped wild-type membranes to remove the KI and MgATP, but proved to be strongly pH-dependent, with optimal reassembly and recovery of activity occurring after dialysis at pH 5.5. Vacuolar membranes isolated from vma2 Delta mutants, which lack one of the peripheral subunits of the enzyme, do not contain any of the peripheral subunits but are shown to contain assembled membrane (V-o) complexes. The vma2 Delta mutant vacuoles are demonstrated to be competent for attachment of KI-stripped peripheral subunits and reactivation of ATPase activity, The results indicate that previously assembled V-o complexes are capable of inducing assembly of the peripheral subunits. both with each other and with the membrane subunits, and of activating the ATPase activity that resides in the peripheral subunits in a pH-dependent manner.	SUNY HLTH SCI CTR, DEPT BIOCHEM & MOL BIOL, SYRACUSE, NY 13210 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050322] Funding Source: NIH RePORTER; NIGMS NIH HHS [1R01-GM50322, R01 GM050322] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANRAKU Y, 1992, J BIOENERG BIOMEMBR, V24, P395, DOI 10.1007/BF00762532; ARAI H, 1989, BIOCHEMISTRY-US, V28, P3075, DOI 10.1021/bi00433a051; BAUERLE C, 1993, J BIOL CHEM, V268, P12749; BOWMAN BJ, 1989, J BIOL CHEM, V264, P15606; BOWMAN EJ, 1986, P NATL ACAD SCI USA, V83, P48, DOI 10.1073/pnas.83.1.48; CASPANI G, 1985, FEBS LETT, V186, P75, DOI 10.1016/0014-5793(85)81342-9; CHATTERJEE D, 1993, BIOCHEMISTRY-US, V32, P2808, DOI 10.1021/bi00062a011; DOHERTY RD, 1993, J BIOL CHEM, V268, P16845; DROSE S, 1993, BIOCHEMISTRY-US, V32, P3902, DOI 10.1021/bi00066a008; DSCHIDA WJA, 1995, J BIOL CHEM, V270, P1557, DOI 10.1074/jbc.270.4.1557; FENG Y, 1994, J BIOL CHEM, V269, P13224; FORGAC M, 1989, PHYSIOL REV, V69, P765, DOI 10.1152/physrev.1989.69.3.765; GRAHAM LA, 1995, J BIOL CHEM, V270, P15037, DOI 10.1074/jbc.270.25.15037; HO MN, 1993, J BIOL CHEM, V268, P18286; HO MN, 1993, J BIOL CHEM, V268, P221; KANE PM, 1989, J BIOL CHEM, V264, P19236; KANE PM, 1995, J BIOL CHEM, V270, P17025; KANE PM, 1992, J BIOL CHEM, V267, P447; KANE PM, 1992, J BIOENERG BIOMEMBR, V24, P383, DOI 10.1007/BF00762531; KIBAK H, 1993, J BIOL CHEM, V268, P23325; KLIONSKY DJ, 1990, MICROBIOL REV, V54, P266, DOI 10.1128/MMBR.54.3.266-292.1990; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI SP, 1988, J BIOL CHEM, V263, P16731; LOTSCHER HR, 1984, BIOCHEMISTRY-US, V23, P4128, DOI 10.1021/bi00313a018; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANOLSON MF, 1992, J BIOL CHEM, V267, P14294; MORIYAMA Y, 1989, J BIOL CHEM, V264, P3577; MYERS M, 1993, J CELL PHYSIOL, V156, P35, DOI 10.1002/jcp.1041560106; NELSON H, 1989, FEBS LETT, V247, P147, DOI 10.1016/0014-5793(89)81259-1; NELSON H, 1994, J BIOL CHEM, V269, P24150; NELSON H, 1990, P NATL ACAD SCI USA, V87, P3503, DOI 10.1073/pnas.87.9.3503; NOUMI T, 1991, P NATL ACAD SCI USA, V88, P1938, DOI 10.1073/pnas.88.5.1938; PUOPOLO K, 1990, J BIOL CHEM, V265, P14836; PURWIN C, 1986, J BIOL CHEM, V261, P8744; REA PA, 1987, BIOCHIM BIOPHYS ACTA, V904, P1, DOI 10.1016/0005-2736(87)90080-0; ROBERTS CJ, 1991, METHOD ENZYMOL, V194, P644; SHERMAN F, 1982, METHODS YEAST GENETI, P177; SUMMER JP, 1995, J BIOL CHEM, V270, P5649; SUPEKOVA L, 1995, J BIOL CHEM, V270, P13726; UCHIDA E, 1988, J BIOL CHEM, V263, P45; UCHIDA E, 1985, J BIOL CHEM, V260, P1090; UMEMOTO N, 1991, J BIOL CHEM, V266, P24526; WANG ZQ, 1990, J BIOL CHEM, V265, P21957; WARD JM, 1992, PLANT PHYSIOL, V99, P161, DOI 10.1104/pp.99.1.161; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; YAMASHIRO CT, 1990, MOL CELL BIOL, V10, P3737, DOI 10.1128/MCB.10.7.3737; ZHANG JM, 1992, J BIOL CHEM, V267, P9773	47	35	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19592	19598		10.1074/jbc.271.32.19592	http://dx.doi.org/10.1074/jbc.271.32.19592			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702654	hybrid			2022-12-25	WOS:A1996VB68400088
J	Reardon, JT; Mu, D; Sancar, A				Reardon, JT; Mu, D; Sancar, A			Overproduction, purification, and characterization of the XPC subunit of the human DNA repair excision nuclease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLEMENTATION GROUP-C; PIGMENTOSUM GROUP-C; TRANSCRIPTION FACTOR TFIIH; SACCHAROMYCES-CEREVISIAE; PYRIMIDINE DIMERS; PROTEIN; RAD23; GENE; COMPLEX; RECONSTITUTION	Xeroderma pigmentosum complementation group C gene (XPC) encodes a protein of 125 kDa which is present in a tight complex with a 58-kDa protein encoded by the human homolog of the yeast RAD23 gene, HHR23B (Masutani, C., Sugasawa, K., Yanagisawa, J., Sonoyama, T., Ui, M., Enomoto, T., Takio, K., Tanaka, K., van der Spek, P. J., Bootsma, D., Hoeijmakers, J. H. J., and Hanaoka, F. (1994) EMBO J. 13, 1831-1843). The XPC-HHR23B complex is required for excision of thymine dimers from DNA in a human excision nuclease system reconstituted from purified proteins. In order to understand the role of the XPC-HHR23B complex in excision repair, we have overexpressed each subunit alone and the heterodimer in heterologous systems, purified them, and characterized their biochemical properties. We find that both XPC and the heterodimer bind DNA with high affinity and UV-damaged DNA with slightly higher preference. Surprisingly, we find that the XPC subunit alone is sufficient for reconstitution of the human excision nuclease and that the HHR23B subunit has no detectable effect on the excision activity of the reconstituted system.	UNIV N CAROLINA,SCH MED,DEPT BIOCHEM & BIOPHYS,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine			Mu, David/E-8933-2011	Mu, David/0000-0002-7762-0182	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032833] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM32833] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABOUSSEKHRA A, 1995, CELL, V80, P859, DOI 10.1016/0092-8674(95)90289-9; ASO T, 1995, SCIENCE, V269, P1439, DOI 10.1126/science.7660129; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cleaver J. E., 1989, METABOLIC BASIS INHE, V2, P2949; EVANS MK, 1993, J BIOL CHEM, V268, P4839; FINLEY D, 1989, NATURE, V338, P394, DOI 10.1038/338394a0; FRIEDBERG EC, 1995, DNA REPAIR; GARRETT KP, 1995, P NATL ACAD SCI USA, V92, P7172, DOI 10.1073/pnas.92.16.7172; GUZDER SN, 1995, J BIOL CHEM, V270, P12973, DOI 10.1074/jbc.270.22.12973; GUZDER SN, 1995, J BIOL CHEM, V270, P8385, DOI 10.1074/jbc.270.15.8385; HUANG JC, 1992, P NATL ACAD SCI USA, V89, P3664, DOI 10.1073/pnas.89.8.3664; KANTOR GJ, 1990, MUTAT RES, V235, P171, DOI 10.1016/0921-8777(90)90071-C; LEGERSKI R, 1992, NATURE, V359, P70, DOI 10.1038/359070a0; LI L, 1993, NAT GENET, V5, P413, DOI 10.1038/ng1293-413; MANLEY JL, 1980, P NATL ACAD SCI-BIOL, V77, P3855, DOI 10.1073/pnas.77.7.3855; MASUTANI C, 1994, EMBO J, V13, P1831, DOI 10.1002/j.1460-2075.1994.tb06452.x; MATSUNAGA T, 1995, J BIOL CHEM, V270, P20862, DOI 10.1074/jbc.270.35.20862; MCCREADY S, 1994, MUTAT RES-DNA REPAIR, V315, P261, DOI 10.1016/0921-8777(94)90037-X; MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6; MILLER RD, 1982, MOL GEN GENET, V188, P235, DOI 10.1007/BF00332681; Mu D, 1996, J BIOL CHEM, V271, P8285, DOI 10.1074/jbc.271.14.8285; MU D, 1995, J BIOL CHEM, V270, P2415, DOI 10.1074/jbc.270.6.2415; O'Reilly D.R., 1994, BACULOVIRUS EXPRESSI; PARK CH, 1995, J BIOL CHEM, V270, P4896, DOI 10.1074/jbc.270.9.4896; PEROZZI G, 1986, MOL CELL BIOL, V6, P1497, DOI 10.1128/MCB.6.5.1497; PRAKASH S, 1993, ANNU REV GENET, V27, P33, DOI 10.1146/annurev.ge.27.120193.000341; REARDON JT, 1993, COLD SPRING HARB SYM, V58, P605, DOI 10.1101/SQB.1993.058.01.067; Sancar A, 1996, ANNU REV BIOCHEM, V65, P43, DOI 10.1146/annurev.bi.65.070196.000355; VENEMA J, 1990, NUCLEIC ACIDS RES, V18, P443, DOI 10.1093/nar/18.3.443; VENEMA J, 1991, MOL CELL BIOL, V11, P4128, DOI 10.1128/MCB.11.8.4128; Verhage RA, 1996, MUTAT RES-DNA REPAIR, V362, P155, DOI 10.1016/0921-8777(95)00045-3; Verhage RA, 1996, NUCLEIC ACIDS RES, V24, P1020, DOI 10.1093/nar/24.6.1020; WATKINS JF, 1993, MOL CELL BIOL, V13, P7757, DOI 10.1128/MCB.13.12.7757	33	104	105	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19451	19456		10.1074/jbc.271.32.19451	http://dx.doi.org/10.1074/jbc.271.32.19451			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702634	Green Published, hybrid			2022-12-25	WOS:A1996VB68400068
J	Baillet, B; Kohorn, BD				Baillet, B; Kohorn, BD			Hydrophobic core but not amino-terminal charged residues are required for translocation of an integral thylakoid membrane protein in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; CHLOROPLAST TRANSFORMATION; SECY HOMOLOG; TRANSPORT; CHLAMYDOMONAS; GENES; PATHWAYS; SEQUENCE; RNA	The integral membrane protein cytochrome f contains an amino-terminal signal sequence that is required for translocation into the thylakoid membrane, The signal sequence contains a hydrophobic core neighbored by an amino-terminal charged residue. Mutations that introduce charged amino acids into the hydrophobic core are inhibitory to cytochrome f translocation, and thus render cells non-photosynthetic. We have isolated both nuclear and chloroplast suppressors of these mutations by selecting for restoration of photosynthetic growth of Chlamydomonas. Here we describe the characterization of two chloroplast, second site suppressor mutations, Both suppressors remove the positively charged amino acid that borders the amino terminus of the hydrophobic core, and replace this arginine with either a cysteine or a leucine, The existence of these suppressors suggests that the hydrophobic core can be shifted in position within the signal sequence, and analysis of triple mutants in the signal confirms this hypothesis, Thus this signal that mediates translocation into the thylakoid membrane is characterized by a hydrophobic region whose exact amino acid content is not critical, and that need not be flanked on its amino terminus by a charged residue.	DUKE UNIV,LEVINE SCI RES CTR,DURHAM,NC 27708	Duke University								AUCHINCLOSS AH, 1992, J BIOL CHEM, V267, P10439; BIEKER KL, 1990, J BIOENERG BIOMEMBR, V22, P291, DOI 10.1007/BF00763169; BIEKER KL, 1990, CELL, V61, P833, DOI 10.1016/0092-8674(90)90193-I; BOYNTON JE, 1993, METHOD ENZYMOL, V217, P510; BOYNTON JE, 1988, SCIENCE, V240, P1534, DOI 10.1126/science.2897716; BUSCHLEN S, 1991, FEBS LETT, V284, P257, DOI 10.1016/0014-5793(91)80698-3; CLINE K, 1992, J BIOL CHEM, V267, P2688; CLINE K, 1993, EMBO J, V12, P4105, DOI 10.1002/j.1460-2075.1993.tb06094.x; DOUGLAS SE, 1992, FEBS LETT, V298, P93, DOI 10.1016/0014-5793(92)80029-G; Harris E. H., 1989, CHLAMYDOMONAS SOURCE; HARTMANN E, 1994, NATURE, V367, P654, DOI 10.1038/367654a0; HENRY R, 1994, J BIOL CHEM, V269, P10189; HOWE G, 1993, P NATL ACAD SCI USA, V90, P1862, DOI 10.1073/pnas.90.5.1862; LAIDLER V, 1995, J BIOL CHEM, V270, P17664, DOI 10.1074/jbc.270.30.17664; LI XX, 1995, P NATL ACAD SCI USA, V92, P3789, DOI 10.1073/pnas.92.9.3789; NEWMAN SM, 1990, GENETICS, V126, P875; ROBINSON C, 1994, PLANT MOL BIOL, V26, P15, DOI 10.1007/BF00039516; Sambrook J., 2002, MOL CLONING LAB MANU; SMEEKENS S, 1986, CELL, V46, P365, DOI 10.1016/0092-8674(86)90657-4; SMITH TA, 1994, J CELL BIOL, V126, P365, DOI 10.1083/jcb.126.2.365; VONHEIJNE G, 1990, J MEMBRANE BIOL, V115, P195, DOI 10.1007/BF01868635; WICKNER W, 1991, ANNU REV BIOCHEM, V60, P101, DOI 10.1146/annurev.bi.60.070191.000533; WILLEY DL, 1984, CELL, V36, P555, DOI 10.1016/0092-8674(84)90248-4; YUAN JG, 1994, SCIENCE, V266, P796, DOI 10.1126/science.7973633; ZARLENGA DS, 1987, ANAL BIOCHEM, V162, P569, DOI 10.1016/0003-2697(87)90435-0	25	5	5	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18375	18378		10.1074/jbc.271.31.18375	http://dx.doi.org/10.1074/jbc.271.31.18375			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702480	hybrid			2022-12-25	WOS:A1996VB68300018
J	Ferraris, JD; Williams, CK; Jung, KY; Bedford, JJ; Burg, MB; GarciaPerez, A				Ferraris, JD; Williams, CK; Jung, KY; Bedford, JJ; Burg, MB; GarciaPerez, A			ORE, a eukaryotic minimal essential osmotic response element - The aldose reductase gene in hyperosmotic stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RENAL MEDULLARY CELLS; EXTRACELLULAR NACL; TRANSPORTER GENE; TRANSCRIPTION; INDUCTION; CLONING; RNA; PROMOTER	Organisms, almost universally, adapt to hyperosmotic stress through increased accumulation of organic osmolytes but the molecular mechanisms have only begun to be addressed, Among mammalian tissues, renal medullary cells are uniquely exposed to extreme hyperosmotic stress. Sorbitol, synthesized through aldose reductase, is a predominant osmolyte induced under hyperosmotic conditions in renal cells, Using a rabbit renal cell line, we originally demonstrated that hyperosmotic stress induces transcription of the aldose reductase gene, Recently, we cloned the rabbit aldose reductase gene, characterized its structure, and found the first evidence of an osmotic response region in a eukaryotic gene, Now, we have progressively subdivided this 3221-base pair (bp) region into discrete fragments in reporter gene constructs. Thereby, we have functionally defined the smallest sequence able to confer hyperosmotic response on a downstream gene independent of other putative cis-elements, that is, a minimal essential osmotic response element (ORE). The sequence of the ORE is CGGAAAATCAC(C) (bp -1105/-1094). A 17-bp fragment (-1108/-1092) containing the ORE used as a probe in electrophoretic mobility shift assays suggests hyperosmotic induction of a slowly migrating band. Isolation of trans-acting factor(s) and characterization of their interaction with the ORE should elucidate the basic mechanisms for regulation of gene expression by hyperosmotic stress.			Ferraris, JD (corresponding author), NHLBI,KIDNEY & ELECTROLYTE METAB LAB,NIH,BLDG 10,RM 6N307,10 CTR DR MSC 1598,BETHESDA,MD 20892, USA.							ALBERTYN J, 1994, MOL CELL BIOL, V14, P4135, DOI 10.1128/MCB.14.6.4135; BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BAGNASCO SM, 1987, P NATL ACAD SCI USA, V84, P1718, DOI 10.1073/pnas.84.6.1718; CHAUHAN SS, 1992, GENE, V120, P281, DOI 10.1016/0378-1119(92)90106-Y; COWLEY BD, 1990, AM J PHYSIOL, V258, pF154, DOI 10.1152/ajprenal.1990.258.1.F154; FERRARIS JD, 1994, P NATL ACAD SCI USA, V91, P10742, DOI 10.1073/pnas.91.22.10742; FRAIN M, 1989, CELL, V59, P145, DOI 10.1016/0092-8674(89)90877-5; GARCIAPEREZ A, 1989, J BIOL CHEM, V264, P16815; GARCIAPEREZ A, 1991, PHYSIOL REV, V71, P1081, DOI 10.1152/physrev.1991.71.4.1081; HAGENBUCHLE O, 1992, NUCLEIC ACIDS RES, V20, P3555, DOI 10.1093/nar/20.14.3555; LEVIN DE, 1995, CURR OPIN CELL BIOL, V7, P197, DOI 10.1016/0955-0674(95)80028-X; LIU JM, 1991, VIROLOGY, V182, P361, DOI 10.1016/0042-6822(91)90682-2; LUCHT JM, 1994, FEMS MICROBIOL REV, V14, P3, DOI 10.1016/0168-6445(94)90008-6; MORIYAMA T, 1989, J BIOL CHEM, V264, P16810; MORIYAMA T, 1990, AM J PHYSIOL, V259, pF847, DOI 10.1152/ajprenal.1990.259.5.F847; ROBEY RB, 1991, J BIOL CHEM, V266, P10400; SMARDO FL, 1992, AM J PHYSIOL, V262, pC776, DOI 10.1152/ajpcell.1992.262.3.C776; TAKENAKA M, 1995, P NATL ACAD SCI USA, V92, P1072, DOI 10.1073/pnas.92.4.1072; TAKENAKA M, 1994, J BIOL CHEM, V269, P29379; UCHIDA S, 1989, AM J PHYSIOL, V256, pC614, DOI 10.1152/ajpcell.1989.256.3.C614; UCHIDA S, 1987, AM J PHYSIOL, V253, pC230, DOI 10.1152/ajpcell.1987.253.2.C230; WANG K, 1993, J BIOL CHEM, V268, P16052; YAMAUCHI A, 1992, J BIOL CHEM, V267, P649; YANCEY PH, 1982, SCIENCE, V217, P1214, DOI 10.1126/science.7112124	24	150	152	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18318	18321		10.1074/jbc.271.31.18318	http://dx.doi.org/10.1074/jbc.271.31.18318			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702469	hybrid			2022-12-25	WOS:A1996VB68300007
J	Spady, DK; Cuthbert, JA; Willard, MN; Meidell, RS				Spady, DK; Cuthbert, JA; Willard, MN; Meidell, RS			Feedback regulation of hepatic 7 alpha-hydroxylase expression by bile salts in the hamster	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENCODING CHOLESTEROL 7-ALPHA-HYDROXYLASE; ADENOVIRUS-MEDIATED TRANSFER; RAT HEPATOCYTE CULTURES; COENZYME-A REDUCTASE; MESSENGER-RNA LEVELS; ACID SYNTHESIS; TRANSCRIPTIONAL REGULATION; DUCT LIGATION; LIPOPROTEIN-X; FATTY-ACIDS	Hepatic 7 alpha-hydroxylase activity appears to be regulated at the transcriptional level by the quantity of bile salts fluxing through the enterohepatic circulation. Whether bile salts directly suppress 7 alpha-hydroxylase expression at the level of the hepatocyte or do so indirectly by promoting the release or absorption of an intestinal factor has not been resolved. We have investigated the ability of primary bile salts to suppress hepatic 7 alpha-hydroxylase expression in bile-diverted hamsters, Biliary diversion was accompanied by derepression of both hepatic 7 alpha-hydroxylase activity (4-5-fold) and bile salt secretion (similar to 3-fold). Derepression of hepatic 7 alpha-hydroxylase expression could be prevented by several interventions that increase the availability of bile salts within the hepatocyte including 1) overexpression of an exogenous 7 alpha-hydroxylase gene by adenovirus-mediated gene transfer, 2) obstruction of the common bile duct, and 3) intravenous infusions of taurocholate. In contrast, none of these interventions prevented derepression of hepatic cholesterol synthesis or significantly down-regulated hepatic low density lipoprotein receptor expression over the relatively short time course (24 h) of these studies. Together, these data indicate that primary bile salts contribute to the regulation of bile salt synthesis through feedback repression of 7 alpha-hydroxylase expression at the level of the hepatocyte.			Spady, DK (corresponding author), UNIV TEXAS, SW MED CTR, DEPT INTERNAL MED, 5323 HARRY HINES BLVD, DALLAS, TX 75235 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047551, R01HL038049, P50HL017669] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-47551, HL-38049, HL-17669] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKERLUND JE, 1990, J LIPID RES, V31, P2159; BJORKHEM I, 1978, J LIPID RES, V19, P359; BOTHAM KM, 1981, BIOCHIM BIOPHYS ACTA, V666, P238, DOI 10.1016/0005-2760(81)90113-2; CAREY MC, 1988, ENTEROHEPATIC CIRCUL, P573; CASTEELS M, 1988, J BIOL CHEM, V263, P4654; CHIANG JYL, 1994, J BIOL CHEM, V269, P17502; CHIANG JYL, 1991, METHOD ENZYMOL, V206, P483; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CRONHOLM T, 1967, EUR J BIOCHEM, V2, P375, DOI 10.1111/j.1432-1033.1967.tb00148.x; DAVIS RA, 1988, J LIPID RES, V29, P202; DIETSCHY JM, 1993, J LIPID RES, V34, P1637; DOERNER KC, 1995, J LIPID RES, V36, P1168; DUANE WC, 1988, J LIPID RES, V29, P212; DUELAND S, 1993, J LIPID RES, V34, P923; DUELAND S, 1991, BIOCHEM J, V280, P373, DOI 10.1042/bj2800373; EDWARDS CM, 1993, METABOLISM, V42, P807, DOI 10.1016/0026-0495(93)90051-O; EKLUND A, 1980, EUR J CLIN INVEST, V10, P349, DOI 10.1111/j.1365-2362.1980.tb00044.x; FUKUSHIMA K, 1995, J LIPID RES, V36, P315; GALEAZZI R, 1977, J CLIN INVEST, V60, P693, DOI 10.1172/JCI108821; GIELEN JE, 1976, ARCH TOXICOL, V36, P255, DOI 10.1007/BF00340533; GLASS CK, 1983, J BIOL CHEM, V258, P7161; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; GREIM H, 1972, GASTROENTEROLOGY, V63, P837; GURANTZ D, 1984, AM J PHYSIOL, V247, pG736, DOI 10.1152/ajpgi.1984.247.6.G736; HERZ J, 1993, P NATL ACAD SCI USA, V90, P2812, DOI 10.1073/pnas.90.7.2812; HEUMAN DM, 1988, HEPATOLOGY, V8, P358, DOI 10.1002/hep.1840080228; HEUMAN DM, 1989, J LIPID RES, V30, P1161; HOEKMAN MFM, 1993, GENE, V130, P217, DOI 10.1016/0378-1119(93)90422-Y; HOFFMAN NE, 1977, P SOC EXP BIOL MED, V154, P49; HORTON JD, 1993, J CLIN INVEST, V92, P743, DOI 10.1172/JCI116645; HORTON JD, 1995, J BIOL CHEM, V270, P5381, DOI 10.1074/jbc.270.10.5381; HULCHER FH, 1978, BIOCHIM BIOPHYS ACTA, V529, P409, DOI 10.1016/0005-2760(78)90085-1; HYLEMON PB, 1992, J BIOL CHEM, V267, P16866; ICHIMIYA H, 1987, J LIPID RES, V28, P1028; KINUGASA T, 1981, J LIPID RES, V22, P201; KUBASKA WM, 1985, J BIOL CHEM, V260, P3459; KWEKKEBOOM J, 1989, BIOCHEM BIOPH RES CO, V162, P619, DOI 10.1016/0006-291X(89)92355-3; MAHLEY RW, 1980, P NATL ACAD SCI-BIOL, V77, P225, DOI 10.1073/pnas.77.1.225; MEREDITH JT, 1986, ARCH PATHOL LAB MED, V110, P1123; MOLOWA DT, 1992, BIOCHEMISTRY-US, V31, P2539, DOI 10.1021/bi00124a014; MYANT NB, 1977, J LIPID RES, V18, P135; NERVI FO, 1978, J CLIN INVEST, V61, P895, DOI 10.1172/JCI109015; OKAMOTO S, 1994, HEPATOLOGY, V20, P95, DOI 10.1016/0270-9139(94)90139-2; PANDAK WM, 1995, GASTROENTEROLOGY, V108, P533, DOI 10.1016/0016-5085(95)90083-7; PANDAK WM, 1991, J BIOL CHEM, V266, P3416; RAMIREZ MI, 1994, MOL CELL BIOL, V14, P2809, DOI 10.1128/MCB.14.4.2809; REDINGER RN, 1974, AM J PHYSIOL, V226, P776, DOI 10.1152/ajplegacy.1974.226.4.776; RUSSELL DW, 1992, BIOCHEMISTRY-US, V31, P4737, DOI 10.1021/bi00135a001; SCHOENFIELD LJ, 1973, J LAB CLIN MED, V82, P858; SHEFER S, 1990, J CLIN INVEST, V85, P1191, DOI 10.1172/JCI114552; SHEFFER S, 1970, J LIPID RES, V11, P404; SINGHAL AK, 1983, BIOCHIM BIOPHYS ACTA, V752, P214, DOI 10.1016/0005-2760(83)90115-7; SPADY DK, 1983, J LIPID RES, V24, P303; SPADY DK, 1993, ANNU REV NUTR, V13, P355, DOI [10.1146/annurev.nutr.13.1.355, 10.1146/annurev.nu.13.070193.002035]; SPADY DK, 1995, J CLIN INVEST, V96, P700, DOI 10.1172/JCI118113; STANGE EF, 1988, HEPATOLOGY, V8, P879, DOI 10.1002/hep.1840080429; STRAKA MS, 1990, J BIOL CHEM, V265, P7145; STRAVITZ RT, 1993, J BIOL CHEM, V268, P13987; TAKITA M, 1988, J BIOCHEM-TOKYO, V103, P778, DOI 10.1093/oxfordjournals.jbchem.a122346; WALLI AK, 1984, J CLIN INVEST, V74, P867, DOI 10.1172/JCI111504; WEIS HJ, 1969, J CLIN INVEST, V48, P2398, DOI 10.1172/JCI106206; WHITING MJ, 1989, BIOCHIM BIOPHYS ACTA, V1001, P176, DOI 10.1016/0005-2760(89)90145-8; WILLARD JE, 1994, CIRCULATION, V89, P2190, DOI 10.1161/01.CIR.89.5.2190	63	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18623	18631		10.1074/jbc.271.31.18623	http://dx.doi.org/10.1074/jbc.271.31.18623			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702514	hybrid			2022-12-25	WOS:A1996VB68300052
J	Yoza, BK; Hu, JYQ; McCall, CE				Yoza, BK; Hu, JYQ; McCall, CE			Protein-tyrosine kinase activation is required for lipopolysaccharide induction of interleukin 1 beta and NF kappa B activation, but not NF kappa B nuclear translocation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN PROINTERLEUKIN-1-BETA GENE; TUMOR-NECROSIS-FACTOR; TRANSCRIPTIONAL REGULATION; PHOSPHORYLATION; MACROPHAGES; MECHANISMS; ENDOTOXIN; CELLS; SITE; CYTOKINES	In human monocytes, interleukin 1 beta protein production and steady state mRNA levels are increased in response to lipopolysaccharide, predominantly as a result of increased transcription of the interleukin 1 beta gene, Expression of interleukin 1 beta and other cytokines, such as interleukin 6 and tumor necrosis factor alpha, has been shown to be dependent on the activation of the transcription factor, NF kappa B. Since recent studies have shown that lipopolysaccharide-induced tyrosine kinase activation is not required for NF kappa B nuclear translocation, we sought to determine whether NF kappa B translocated in the absence of tyrosine kinase activity was active in stimulating transcription. We have found that, in the human pro-monocytic cell line, THP-1, the lipopolysaccharide-induced expression of interleukin 1 beta is dependent on tyrosine kinase activation. Tyrosine kinases are not required for lipopolysaccharide-mediated nuclear translocation of NF kappa B, However, in the absence of tyrosine kinase activity, the ability of NF kappa B to stimulate transcription is impaired. This inhibition of transcription is specific for NF kappa B; in the absence of tyrosine kinase activity, AP-1-dependent transcription is enhanced. These results suggest that, while lipopolysaccharide-induced expression of inflammatory mediators requires tyrosine kinase activity, tyrosine kinase activity is not obligatory for lipopolysaccharide signal transduction.			Yoza, BK (corresponding author), WAKE FOREST UNIV,BOWMAN GRAY SCH MED,DEPT MED,INFECT DIS SECT,300 S HAWTHORNE RD,WINSTON SALEM,NC 27157, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL029293] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI009169, R01AI009169] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL29293] Funding Source: Medline; NIAID NIH HHS [AI09169] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; CHEDID M, 1991, J IMMUNOL, V147, P867; COGSWELL JP, 1994, J IMMUNOL, V153, P712; DELUDE RL, 1994, J BIOL CHEM, V269, P22253; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; FENTON MJ, 1987, J IMMUNOL, V138, P3972; GENG Y, 1993, J IMMUNOL, V151, P6692; HAN JH, 1993, J BIOL CHEM, V268, P25009; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HISCOTT J, 1993, MOL CELL BIOL, V13, P6231, DOI 10.1128/MCB.13.10.6231; LARUE KEA, 1994, J EXP MED, V180, P2269, DOI 10.1084/jem.180.6.2269; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; NOVOGRODSKY A, 1994, SCIENCE, V264, P1319, DOI 10.1126/science.8191285; PARRILLO JE, 1993, NEW ENGL J MED, V328, P1471, DOI 10.1056/nejm199305203282008; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; SCHMITZ ML, 1995, J BIOL CHEM, V270, P7219, DOI 10.1074/jbc.270.13.7219; SHAKHOV AN, 1990, J EXP MED, V171, P35, DOI 10.1084/jem.171.1.35; SHIRAKAWA F, 1993, MOL CELL BIOL, V13, P1332, DOI 10.1128/MCB.13.3.1332; SLEIGH MJ, 1986, ANAL BIOCHEM, V156, P251, DOI 10.1016/0003-2697(86)90180-6; STEFANOVA I, 1993, J BIOL CHEM, V268, P20725; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; VILCEK J, 1991, J BIOL CHEM, V266, P7313; WATSON RWG, 1994, J LEUKOCYTE BIOL, V56, P95, DOI 10.1002/jlb.56.1.95; WEINSTEIN SL, 1992, J BIOL CHEM, V267, P14955; WEINSTEIN SL, 1991, P NATL ACAD SCI USA, V88, P4148, DOI 10.1073/pnas.88.10.4148; WEINSTEIN SL, 1993, J IMMUNOL, V151, P3829	27	67	74	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18306	18309		10.1074/jbc.271.31.18306	http://dx.doi.org/10.1074/jbc.271.31.18306			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702466	hybrid			2022-12-25	WOS:A1996VB68300004
J	Fannon, M; Nugent, MA				Fannon, M; Nugent, MA			Basic fibroblast growth factor binds its receptors, is internalized, and stimulates DNA synthesis in Balb/c3T3 cells in the absence of heparan sulfate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPILLARY ENDOTHELIAL-CELLS; SMOOTH-MUSCLE CELLS; SIGNAL TRANSDUCTION; POINT MUTATION; FGF; AFFINITY; BFGF; DIFFERENTIATION; MITOGENESIS; TRANSCRIPTION	We have investigated the interaction of basic fibroblast growth factor (bFCTF) with its receptors and heparan sulfate proteoglycans (HSPG), It has been suggested that in the absence of HSPG, cells are not able to bind bFGF or respond to treatment with bFGF, In our stud ies, Balb/c3T3 fibroblasts were treated with 50 mM sodium chlorate to completely inhibit (99%) sulfation of proteoglycans, We found that bFGF was able to bind, be internalized, and stimulate DNA synthesis in the absence of HSPG in a dose-dependent manner, bFGF bound to its receptors on chlorate-treated cells with a lower apparent affinity and no change in receptor number, To determine if this decreased affinity bFGF-receptor interaction is functional, we quantitatively analyzed bFGF internalization and stimulation of DNA synthesis in control and chlorate-treated cells, Endocytotic rate constants (k(e)) for chlorate-treated and control cells were k(e) = 0.078 +/- 0.022 min(-1) and k(e) = 0.043 +/- 0.012 min(-1), respectively, suggesting that the process of bFGF internalization is not dramatically altered by HSPG, bFGF stimulated DNA synthesis to the same maximal level under both conditions, but chlorate-treated cells were significantly less responsive at low bFGF doses (similar to 10-fold increase in ED(50)). The differences observed for control and chlorate-treated cells in the dose-response curves for stimulation of DNA synthesis and receptor binding correlated directly, suggesting that receptors are equally capable of eliciting a mitogenic signal under both conditions, It is unlikely that these results are due to residual HSPG since heparinase (I and III) digestion of chlorate-treated cells had little effect, Although the presence of HSPG on the cell surface increases the affinity of bFGF for its receptors, our observations suggest that HSPG are not ''absolutely'' required for binding, internalization, or stimulation of mitogenic activity.	BOSTON UNIV, SCH MED, DEPT BIOCHEM, BOSTON, MA 02118 USA	Boston University				Nugent, Matthew/0000-0002-8630-4712				AVIEZER D, 1994, CELL, V79, P1005, DOI 10.1016/0092-8674(94)90031-0; BALDIN V, 1990, EMBO J, V9, P1511, DOI 10.1002/j.1460-2075.1990.tb08269.x; BOUCHE G, 1987, P NATL ACAD SCI USA, V84, P6770, DOI 10.1073/pnas.84.19.6770; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; COOK PW, 1995, J CELL PHYSIOL, V163, P418, DOI 10.1002/jcp.1041630222; EDELMAN ER, 1992, J CLIN INVEST, V89, P465, DOI 10.1172/JCI115607; GIVOL D, 1992, FASEB J, V6, P3362, DOI 10.1096/fasebj.6.15.1464370; HAWKER JR, 1992, AM J PHYSIOL, V262, pH1525, DOI 10.1152/ajpheart.1992.262.5.H1525; HOPKINS CR, 1994, BIOCHEM PHARMACOL, V47, P151, DOI 10.1016/0006-2952(94)90449-9; ISHIHARA M, 1993, J BIOL CHEM, V268, P4675; JAYE M, 1992, BIOCHIM BIOPHYS ACTA, V1135, P185, DOI 10.1016/0167-4889(92)90136-Y; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; KAN MK, 1993, SCIENCE, V259, P1918, DOI 10.1126/science.8456318; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; Klagsbrun M, 1989, Prog Growth Factor Res, V1, P207, DOI 10.1016/0955-2235(89)90012-4; Lauffenburger D. A., 1993, RECEPTORS MODELS BIN; MASON IJ, 1994, CELL, V78, P547, DOI 10.1016/0092-8674(94)90520-7; MOSCATELLI D, 1988, J CELL BIOL, V107, P753, DOI 10.1083/jcb.107.2.753; MOSCATELLI D, 1992, J BIOL CHEM, V267, P25803; MOSCATELLI D, 1987, J CELL PHYSIOL, V131, P123, DOI 10.1002/jcp.1041310118; NATHAN A, 1995, P NATL ACAD SCI USA, V92, P8130, DOI 10.1073/pnas.92.18.8130; NUGENT MA, 1992, J BIOL CHEM, V267, P21256; NUGENT MA, 1993, CIRC RES, V73, P1051, DOI 10.1161/01.RES.73.6.1051; NUGENT MA, 1992, BIOCHEMISTRY-US, V31, P8876, DOI 10.1021/bi00152a026; OLWIN BB, 1992, J CELL BIOL, V118, P631, DOI 10.1083/jcb.118.3.631; ORNITZ DM, 1992, J BIOL CHEM, V267, P16305; ORNITZ DM, 1992, MOL CELL BIOL, V12, P240, DOI 10.1128/MCB.12.1.240; ORNITZ DM, 1995, SCIENCE, V268, P432, DOI 10.1126/science.7536345; PANTOLIANO MW, 1994, BIOCHEMISTRY-US, V33, P10229, DOI 10.1021/bi00200a003; PETERS KG, 1992, NATURE, V358, P678, DOI 10.1038/358678a0; QUARTO N, 1994, J CELL SCI, V107, P3201; RAKE JB, 1991, J BIOL CHEM, V266, P5348; RAPRAEGER A, 1989, ANAL BIOCHEM, V179, P361, DOI 10.1016/0003-2697(89)90145-0; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; REILAND J, 1993, J CELL SCI, V105, P1085; ROGHANI M, 1994, J BIOL CHEM, V269, P3976; SASISEKHARAN R, 1994, P NATL ACAD SCI USA, V91, P1524, DOI 10.1073/pnas.91.4.1524; SPEIR E, 1991, J CELL PHYSIOL, V147, P362, DOI 10.1002/jcp.1041470223; SPIVAKKROIZMAN T, 1994, J BIOL CHEM, V269, P14419; SPIVAKKROIZMAN T, 1994, CELL, V79, P1015, DOI 10.1016/0092-8674(94)90032-9; THOMPSON LD, 1994, BIOCHEMISTRY-US, V33, P3831, DOI 10.1021/bi00179a006; TRIPATHI RC, 1992, EXP EYE RES, V54, P447, DOI 10.1016/0014-4835(92)90056-X; TURNBULL JE, 1993, BIOCHEM SOC T, V21, P477, DOI 10.1042/bst0210477; WALKER A, 1994, J BIOL CHEM, V269, P931; WEDER HG, 1974, EUR J BIOCHEM, V42, P475, DOI 10.1111/j.1432-1033.1974.tb03361.x; WILEY HS, 1982, J BIOL CHEM, V257, P4222; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	47	86	88	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					17949	17956		10.1074/jbc.271.30.17949	http://dx.doi.org/10.1074/jbc.271.30.17949			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663512	hybrid			2022-12-25	WOS:A1996UY93500056
J	Jiang, Y; Chen, CH; Li, ZJ; Guo, W; Gegner, JA; Lin, SC; Han, JH				Jiang, Y; Chen, CH; Li, ZJ; Guo, W; Gegner, JA; Lin, SC; Han, JH			Characterization of the structure and function of a new mitogen-activated protein kinase (p38 beta)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-JUN; TRANSCRIPTION FACTORS; GENE-PRODUCT; PHOSPHORYLATION; TYROSINE; BINDING; STRESS; FAMILY; CELLS; CAMP	Mitogen-activated protein (MAP) kinase cascades represent one of the major signal systems used by eukaryotic cells to transduce extracellular signals into cellular responses, Four MAP kinase subgroups have been identified in humans: ERK, JNK (SAPK), ERK5 (BMK), and p38, Here we characterize a new MAP kinase, p38 beta. p38 beta is a 372-amino acid protein most closely related to p38. It contains a TGY dual phosphorylation site, which is required for its kinase activity. Like p38, p38 beta is activated by proinflammatory cytokines and environmental stress. A comparison of events associated with the activation of p38 beta and p38 revealed differences, most notably in the preferred activation of p38 beta by MAP kinase kinase 6 (MKK6), whereas p38 was activated nearly equally by MKK3, MKK4, and MKK6. Moreover, in. vitro and in vivo experiments showed a strong substrate preference by p38 beta for activating transcription factor 2 (ATF2), Enhancement of ATF2-dependent gene expression by p38 beta was similar to 2O-fold greater than that of p38 and other MAP kinases tested, The data reported here suggest that while closely related, p38 beta and p38 may be regulated by differing mechanisms and may exert their actions on separate downstream targets.	Scripps Res Inst, DEPT IMMUNOL, LA JOLLA, CA 92037 USA; NATL UNIV SINGAPORE, INST MOLEC & CELL BIOL, SINGAPORE 117548, SINGAPORE	Scripps Research Institute; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore			Lin, SC/G-4666-2010; Han, J/G-4671-2010		NIGMS NIH HHS [GM51417] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADLER V, 1995, J BIOL CHEM, V270, P26071, DOI 10.1074/jbc.270.44.26071; AMARAL MC, 1993, J CLIN INVEST, V92, P848, DOI 10.1172/JCI116659; BENBROOK DM, 1990, ONCOGENE, V5, P295; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BLUMER KJ, 1994, TRENDS BIOCHEM SCI, V19, P236, DOI 10.1016/0968-0004(94)90147-3; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BRENNER DA, 1989, NATURE, V337, P661, DOI 10.1038/337661a0; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DELUCA LG, 1994, J BIOL CHEM, V269, P19193; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; HAN JH, 1993, J BIOL CHEM, V268, P25009; HAN JH, 1991, BIOCHIM BIOPHYS ACTA, V1090, P22, DOI 10.1016/0167-4781(91)90032-H; INNIS MA, 1990, PCR PROTOCOLS GUIDE, P177; IVASHKIV LB, 1990, MOL CELL BIOL, V10, P1609, DOI 10.1128/MCB.10.4.1609; IWASAKI T, 1992, FEBS LETT, V298, P240, DOI 10.1016/0014-5793(92)80067-Q; Johnson NL, 1996, J BIOL CHEM, V271, P3229, DOI 10.1074/jbc.271.6.3229; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; KARLSSON R, 1993, ACTA CRYSTALLOGR D, V49, P381, DOI 10.1107/S0907444993002306; KIM SJ, 1992, NATURE, V358, P331, DOI 10.1038/358331a0; KRAVCHENKO VV, 1995, J BIOL CHEM, V270, P14928, DOI 10.1074/jbc.270.25.14928; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LEE JD, 1995, BIOCHEM BIOPH RES CO, V213, P715, DOI 10.1006/bbrc.1995.2189; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; Liou HC, 1993, CURR OPIN CELL BIOL, V5, P477, DOI 10.1016/0955-0674(93)90014-H; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Sambrook J., 2002, MOL CLONING LAB MANU; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SEGER R, 1991, P NATL ACAD SCI USA, V88, P6142, DOI 10.1073/pnas.88.14.6142; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; Wu XY, 1996, J BIOL CHEM, V271, P3265, DOI 10.1074/jbc.271.6.3265; ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934; ZHOU G, 1995, J BIOL CHEM, V270, P12664; ZIFF EB, 1990, TRENDS GENET, V6, P69, DOI 10.1016/0168-9525(90)90081-G; ZU YL, 1994, BIOCHEM BIOPH RES CO, V200, P1118, DOI 10.1006/bbrc.1994.1566	49	640	720	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					17920	17926		10.1074/jbc.271.30.17920	http://dx.doi.org/10.1074/jbc.271.30.17920			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663524	hybrid			2022-12-25	WOS:A1996UY93500051
J	Yoshikawa, F; Morita, M; Monkawa, T; Michikawa, T; Furuichi, T; Mikoshiba, K				Yoshikawa, F; Morita, M; Monkawa, T; Michikawa, T; Furuichi, T; Mikoshiba, K			Mutational analysis of the ligand binding site of the inositol 1,4,5-trisphosphate receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE SARCOPLASMIC-RETICULUM; CHANNEL RYANODINE RECEPTOR; CALCIUM RELEASE CHANNEL; TRISPHOSPHATE RECEPTOR; METABOLIC ENZYMES; MOLECULAR-CLONING; FUNCTIONAL-CHARACTERIZATION; MOUSE CEREBELLUM; INSP3 RECEPTOR; P400 PROTEIN	To define the structural determinants for inositol 1,4,5-trisphosphate (IP3) binding of the type 1 inositol 1,4,5-trisphosphate receptor (IP(3)R1), we developed a means of expressing the N-terminal 734 amino acids of IP(3)R1 (T734), which contain the IP3 binding region, in Escherichia coli. The T734 protein expressed in E. coli exhibited a similar binding specificity and affinity for IP3 as the native IP(3)R from mouse cerebellum. Deletion mutagenesis, in which T734 was serially deleted from the N terminus up to residue 215, markedly reduced IP3 binding activity. However, when deleted a little more toward the C terminus (to residues 220, 223, and 225), the binding activity was retrieved, Further N-terminal deletions over the first 228 amino acids completely abolished it again. C-terminal deletions up to residue 579 did not affect the binding activity, whereas those up to residue 568 completely abolished it. In addition, the expressed 356-amino acid polypeptide (residues 224-579) exhibited specific binding activity. Taken together, residues 226-578 were sufficient and close enough to the minimum region for the specific IP3 binding, and thus formed an IP3 binding ''core.'' Site-directed mutagenesis was performed on 41 basic Arg and Lys residues within the N-terminal 650 amino acids of T734. We showed that single amino acid substitutions for 10 residues, which were widely distributed within the binding core and conserved among all members of the IP(3)R family, significantly reduced the binding activity. Among them, three (Arg-265, Lys-508, and Arg-511) were critical for the specific binding, and Arg-568 was implicated in the binding specificity for various inositol phosphates. We suggest that some of these 10 residues form a basic pocket that interacts with the negatively charged phosphate groups of IP3.	UNIV TOKYO,INST MED SCI,DEPT MOLEC NEUROBIOL,MINATO KU,TOKYO 108,JAPAN; JAPAN TOBACCO INC,PHARMACEUT BASIC RES LABS,YOKOHAMA,KANAGAWA 236,JAPAN; KEIO UNIV,SCH MED,DEPT INTERNAL MED,TOKYO 160,JAPAN; RIKEN,TSUKUBA LIFE SCI CTR,INST PHYS & CHEM RES,MOLEC NEUROBIOL LAB,TSUKUBA,IBARAKI 305,JAPAN	University of Tokyo; Japan Tobacco Inc.; Keio University; RIKEN			Monkawa, Toshiaki/F-2361-2010; Mikoshiba, Katsuhiko/N-7943-2015; Furuichi, Teiichi/B-5086-2014	Monkawa, Toshiaki/0000-0002-7876-7661; Furuichi, Teiichi/0000-0002-9676-1888; Morita, Mitsuhiro/0000-0002-9891-0242				Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BLONDEL O, 1993, J BIOL CHEM, V268, P11356; DAYHOFF MO, 1983, METHOD ENZYMOL, V91, P524; FERGUSON KM, 1995, CELL, V83, P1037, DOI 10.1016/0092-8674(95)90219-8; FERRIS CD, 1989, NATURE, V342, P87, DOI 10.1038/342087a0; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; FURUICHI T, 1995, J NEUROCHEM, V64, P953, DOI 10.1046/j.1471-4159.1995.64030953.x; Furuichi Teiichi, 1994, Current Opinion in Neurobiology, V4, P294, DOI 10.1016/0959-4388(94)90089-2; HAKAMATA Y, 1992, FEBS LETT, V312, P229, DOI 10.1016/0014-5793(92)80941-9; HIRATA M, 1993, J BIOL CHEM, V268, P19260; HIRATA M, 1990, J BIOL CHEM, V265, P8404; HYVONEN M, 1995, EMBO J, V14, P4676, DOI 10.1002/j.1460-2075.1995.tb00149.x; IKEMURA T, 1985, MOL BIOL EVOL, V2, P13; KUME S, 1993, CELL, V73, P555, DOI 10.1016/0092-8674(93)90142-D; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MACLENNAN DH, 1992, SCIENCE, V256, P789, DOI 10.1126/science.1589759; MAEDA N, 1990, EMBO J, V9, P61, DOI 10.1002/j.1460-2075.1990.tb08080.x; MAEDA N, 1991, J BIOL CHEM, V266, P1109; MAEDA N, 1989, DEV BIOL, V133, P67, DOI 10.1016/0012-1606(89)90297-2; MARANTO AR, 1994, J BIOL CHEM, V269, P1222; MICHIKAWA T, 1994, J BIOL CHEM, V269, P9184; MIGNERY GA, 1990, EMBO J, V9, P3893, DOI 10.1002/j.1460-2075.1990.tb07609.x; MIGNERY GA, 1990, J BIOL CHEM, V265, P12679; MIYAWAKI A, 1991, P NATL ACAD SCI USA, V88, P4911, DOI 10.1073/pnas.88.11.4911; MIYAWAKI A, 1990, NEURON, V5, P11, DOI 10.1016/0896-6273(90)90029-F; MOUREY RJ, 1993, BIOCHEMISTRY-US, V32, P1719, DOI 10.1021/bi00058a004; NAHORSKI SR, 1989, TRENDS PHARMACOL SCI, V10, P139, DOI 10.1016/0165-6147(89)90165-X; NAKAI J, 1990, FEBS LETT, V271, P169, DOI 10.1016/0014-5793(90)80399-4; NEWTON CL, 1994, J BIOL CHEM, V269, P28613; OROURKE F, 1990, BIOCHEM J, V267, P297, DOI 10.1042/bj2670297; OTSU K, 1990, J BIOL CHEM, V265, P13472; SAFRANY ST, 1991, FEBS LETT, V278, P252, DOI 10.1016/0014-5793(91)80128-P; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMIDT TGM, 1993, PROTEIN ENG, V6, P109, DOI 10.1093/protein/6.1.109; SMITH JW, 1987, J BIOL CHEM, V262, P11964; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUDHOF TC, 1991, EMBO J, V10, P3199, DOI 10.1002/j.1460-2075.1991.tb04882.x; SUPATTAPONE S, 1988, J BIOL CHEM, V263, P1530; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; WHITE AM, 1991, BIOCHEM J, V278, P759, DOI 10.1042/bj2780759; WORLEY PF, 1987, J BIOL CHEM, V262, P12132; YAMADA N, 1994, BIOCHEM J, V302, P781, DOI 10.1042/bj3020781; YAMAMOTOHINO M, 1994, RECEPTOR CHANNEL, V2, P9; YOSHIKAWA S, 1992, J BIOL CHEM, V267, P16613; ZORZATO F, 1990, J BIOL CHEM, V265, P2244	47	187	193	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					18277	18284		10.1074/jbc.271.30.18277	http://dx.doi.org/10.1074/jbc.271.30.18277			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663526	hybrid			2022-12-25	WOS:A1996UY93500102
J	Milev, P; Maurel, P; Haring, M; Margolis, RK; Margolis, RU				Milev, P; Maurel, P; Haring, M; Margolis, RK; Margolis, RU			TAG-1/axonin-1 is a high-affinity ligand of neurocan, phosphacan/protein-tyrosine phosphatase-zeta/beta, and N-CAM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION MOLECULE; CHONDROITIN SULFATE; HOMOPHILIC BINDING; NEURITE OUTGROWTH; AXONIN-1; BRAIN; CLONING; PROTEIN; CD2; PROTEOGLYCANS	Proteoglycans appear to play an important role in modulating cell-cell and cell-matrix interactions during nervous tissue histogenesis, The nervous tissue-specific chondroitin sulfate proteoglycans neurocan and phosphacan/protein-tyrosine phosphatase-zeta/beta were found to be high-affinity ligands of the neural cell adhesion molecule TAG-1/axonin-1, with dissociation constants of 0.3 nM and 0.04 nM, respectively, Phosphacan binding was decreased by similar to 70% following chondroitinase treatment, whereas binding of neurocan was not affected. The contribution of chondroitin sulfate chains to the binding of neurocan and phosphacan to TAG-1/axonin-1 is therefore the opposite of that previously observed for their binding to two other Ig-superfamily neural cell adhesion molecules, Ng-CAM/L1 and N-CAM. Moreover, whereas phosphacan interactions with certain proteins are mediated at least in part by N-linked oligosaccharides on the proteoglycan, N-deglycosylation of phosphacan had no effect on its binding to TAG-1/axonin-1. In addition to the chondroitin sulfate proteoglycans described above, we have demonstrated that N-CAM is a high-affinity ligand of TAG-1/axonin-1 (K-d similar to 1 nM), and specific binding of TAG-1/axonin-1 to tenascin-C was also observed (K-d similar to 9 nM). Immunocytochemical studies of embryonic and early postnatal nervous tissue showed an overlapping localization of TAG-1/axonin-1 with all four of these ligands, further supporting the biological significance of their ability to interact in vitro.	NYU,MED CTR,DEPT PHARMACOL,NEW YORK,NY 10016; SUNY HLTH SCI CTR,DEPT PHARMACOL,BROOKLYN,NY 11203	New York University; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center			Maurel, Patrice/E-9559-2017		NIMH NIH HHS [MH-00129] Funding Source: Medline; NINDS NIH HHS [NS-13876] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [K05MH000129] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS013876] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BRUMMENDORF T, 1995, PROTEIN PROFILE, V2, P963; CHAN PY, 1991, J CELL BIOL, V115, P245, DOI 10.1083/jcb.115.1.245; CUATRECASAS P, 1976, ADV PROTEIN CHEM, V30, P252; CUNNINGHAM BA, 1995, CURR OPIN CELL BIOL, V7, P628, DOI 10.1016/0955-0674(95)80103-0; DENBURG JL, 1995, J COMP NEUROL, V354, P533, DOI 10.1002/cne.903540405; DODD J, 1988, NEURON, V1, P105, DOI 10.1016/0896-6273(88)90194-8; DUSTIN ML, 1989, J EXP MED, V169, P503, DOI 10.1084/jem.169.2.503; Engel M, 1996, J COMP NEUROL, V366, P34; FELSENFELD DP, 1994, NEURON, V12, P675, DOI 10.1016/0896-6273(94)90222-4; FRIEDLANDER DR, 1994, J CELL BIOL, V125, P669, DOI 10.1083/jcb.125.3.669; FURLEY AJ, 1990, CELL, V61, P157, DOI 10.1016/0092-8674(90)90223-2; GRUMET M, 1993, J CELL BIOL, V120, P815, DOI 10.1083/jcb.120.3.815; GRUMET M, 1994, J BIOL CHEM, V269, P12142; HASLER TH, 1993, EUR J BIOCHEM, V211, P329, DOI 10.1111/j.1432-1033.1993.tb19902.x; HOFFMAN S, 1983, P NATL ACAD SCI-BIOL, V80, P5762, DOI 10.1073/pnas.80.18.5762; KRUEGER NX, 1992, P NATL ACAD SCI USA, V89, P7417, DOI 10.1073/pnas.89.16.7417; KUHN TB, 1991, J CELL BIOL, V115, P1113, DOI 10.1083/jcb.115.4.1113; LEVY JB, 1993, J BIOL CHEM, V268, P10573; MAEDA N, 1994, FEBS LETT, V354, P67, DOI 10.1016/0014-5793(94)01093-5; MARGOLIS RK, 1996, IN PRESS PERSPECT DE; MAUREL P, 1995, DNA SEQUENCE, V5, P323, DOI 10.3109/10425179509030989; MAUREL P, 1994, P NATL ACAD SCI USA, V91, P2512, DOI 10.1073/pnas.91.7.2512; MEYERPUTTLITZ B, 1995, J NEUROCHEM, V65, P2327; MeyerPuttlitz B, 1996, J COMP NEUROL, V366, P44, DOI 10.1002/(SICI)1096-9861(19960226)366:1<44::AID-CNE4>3.0.CO;2-K; MILEV P, 1994, J CELL BIOL, V127, P1703, DOI 10.1083/jcb.127.6.1703; MILOEV P, 1995, J BIOL CHEM, V270, P24650; MORAN N, 1988, FEBS LETT, V242, P121, DOI 10.1016/0014-5793(88)80998-0; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; PELES E, 1995, CELL, V82, P251, DOI 10.1016/0092-8674(95)90312-7; RADER C, 1993, EUR J BIOCHEM, V215, P133, DOI 10.1111/j.1432-1033.1993.tb18015.x; RAUCH U, 1992, J BIOL CHEM, V267, P19536; RAUCH U, 1991, J BIOL CHEM, V266, P14785; RUEGG MA, 1989, J CELL BIOL, V109, P2363, DOI 10.1083/jcb.109.5.2363; SAKURAI T, 1994, DEV BRAIN RES, V83, P99, DOI 10.1016/0165-3806(94)90183-X; Sakurai T, 1996, J NEUROSCI RES, V43, P694, DOI 10.1002/(SICI)1097-4547(19960315)43:6<694::AID-JNR6>3.3.CO;2-9; SHITARA K, 1994, J BIOL CHEM, V269, P20189; STOECKLI ET, 1995, NEURON, V14, P1165, DOI 10.1016/0896-6273(95)90264-3; STOECKLI ET, 1991, J CELL BIOL, V112, P1449; STRUYK AF, 1995, J NEUROSCI, V15, P2141, DOI 10.1523/JNEUROSCI.15-03-02141.1995; SUTER DM, 1995, J CELL BIOL, V131, P1067, DOI 10.1083/jcb.131.4.1067; TSIOTRA PC, 1993, GENOMICS, V18, P562, DOI 10.1016/S0888-7543(05)80357-X; VANDERMERWE PA, 1993, EMBO J, V12, P4945, DOI 10.1002/j.1460-2075.1993.tb06188.x; VANDERMERWE PA, 1994, TRENDS BIOCHEM SCI, V19, P354; YOSHIHARA Y, 1995, J NEUROBIOL, V28, P51, DOI 10.1002/neu.480280106; ZUELLIG RA, 1992, EUR J BIOCHEM, V204, P453, DOI 10.1111/j.1432-1033.1992.tb16655.x	45	167	169	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15716	15723		10.1074/jbc.271.26.15716	http://dx.doi.org/10.1074/jbc.271.26.15716			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8663515	hybrid			2022-12-25	WOS:A1996UV29900063
J	Gauzzi, MC; Velazquez, L; McKendry, R; Mogensen, KE; Fellous, M; Pellegrini, S				Gauzzi, MC; Velazquez, L; McKendry, R; Mogensen, KE; Fellous, M; Pellegrini, S			Interferon-alpha-dependent activation of Tyk2 requires phosphorylation of positive regulatory tyrosines by another kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							JAK-3 JANUS KINASE; SIGNAL-TRANSDUCTION; CATALYTIC DOMAIN; PROTEIN-KINASE; BETA RECEPTOR; SUBUNIT; FAMILY; AUTOPHOSPHORYLATION; EXPRESSION; PATHWAY	Tyk2 and JAK1, members of the Janus kinase (JAK) family of protein tyrosine kinases, are required for interferon-alpha/beta binding and signaling, Both enzymes are associated with the interferon-alpha/beta receptor, and upon ligand binding, they undergo tyrosine phosphorylation and catalytic activation in an interdependent manner. To identify residues involved in Tyk2 regulation and to understand the basis of the interdependence of Tyk2 and JAK1, six mutated versions of Tyk2 bearing single or multiple point mutations in the tyrosine kinase domain were studied in a cell line lacking endogenous Tyk2. The Y1054F/Y1055F substitutions in the putative activation loop prevented ligand-dependent activation of Tyk2, without abolishing its catalytic potential. The K930R mutation in the ATP binding site generated a kinase-negative protein, which however, still became phosphorylated upon interferon-cu treatment, The Y1054F/Y1055F substitutions in this kinase-negative Tyk2 abolished the induced phosphorylation. These results indicate that Tyk2 is activated by phosphorylation on Tyr-1054 and/or Tyr-1055 and that this phosphorylation requires another kinase, most likely JAK1. While the Tyk2 forms mutated on Tyr-1054 and Tyr-1055 or on Lys-930 allowed some inducible gene expression, the combination of the three point mutations totally abolished signaling.	INST PASTEUR, INSERM, U276, F-75724 PARIS 15, FRANCE; INST GENET MOL, CNRS, UMR 9942, MONTPELLIER, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier			Pellegrini, Sandra -/G-5546-2015; Gauzzi, Maria Cristina/N-7038-2017; Pellegrini, Sandra/Y-6351-2019	Pellegrini, Sandra -/0000-0001-5837-7589; Gauzzi, Maria Cristina/0000-0002-2996-5231; Pellegrini, Sandra/0000-0001-5837-7589				ABRAMOVICH C, 1994, EMBO J, V13, P5871, DOI 10.1002/j.1460-2075.1994.tb06932.x; ALLEN G, 1982, J GEN VIROL, V63, P207, DOI 10.1099/0022-1317-63-1-207; BARBIERI G, 1994, EUR J BIOCHEM, V223, P427, DOI 10.1111/j.1432-1033.1994.tb19010.x; BINARI R, 1994, GENE DEV, V8, P300, DOI 10.1101/gad.8.3.300; Briscoe J, 1996, EMBO J, V15, P799, DOI 10.1002/j.1460-2075.1996.tb00415.x; CALALB MB, 1995, MOL CELL BIOL, V15, P954; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; CHAN AC, 1995, EMBO J, V14, P2499, DOI 10.1002/j.1460-2075.1995.tb07247.x; COLAMONICI O, 1994, MOL CELL BIOL, V14, P8133, DOI 10.1128/MCB.14.12.8133; COLAMONICI OR, 1994, J BIOL CHEM, V269, P3518; CONSTANTINESCU SN, 1994, P NATL ACAD SCI USA, V91, P9602, DOI 10.1073/pnas.91.20.9602; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; DAVID M, 1995, MOL CELL BIOL, V15, P7050; DOMANSKI P, 1995, J BIOL CHEM, V270, P21606, DOI 10.1074/jbc.270.37.21606; DUHE RJ, 1995, J BIOL CHEM, V270, P23084, DOI 10.1074/jbc.270.39.23084; EID P, 1988, EUR J BIOCHEM, V171, P675, DOI 10.1111/j.1432-1033.1988.tb13839.x; FIRMBACHKRAFT I, 1990, ONCOGENE, V5, P1329; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HARPUR AG, 1992, ONCOGENE, V7, P1347; HER JH, 1993, BIOCHEM J, V296, P25, DOI 10.1042/bj2960025; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; JOHNSTON JA, 1994, NATURE, V370, P151, DOI 10.1038/370151a0; KMIECIK TE, 1988, MOL CELL BIOL, V8, P4541, DOI 10.1128/MCB.8.10.4541; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LONGATI P, 1994, ONCOGENE, V9, P49; LUTFALLA G, 1995, EMBO J, V14, P5100, DOI 10.1002/j.1460-2075.1995.tb00192.x; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; NOVICK D, 1994, CELL, V77, P391, DOI 10.1016/0092-8674(94)90154-6; PELLEGRINI S, 1989, MOL CELL BIOL, V9, P4605, DOI 10.1128/MCB.9.11.4605; PLATANIAS LC, 1994, J BIOL CHEM, V269, P17761; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; TAYLOR SS, 1995, FASEB J, V9, P1255, DOI 10.1096/fasebj.9.13.7557015; UZE G, 1990, CELL, V60, P225, DOI 10.1016/0092-8674(90)90738-Z; UZE G, 1995, J INTERF CYTOK RES, V15, P3, DOI 10.1089/jir.1995.15.3; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; VELAZQUEZ L, 1995, J BIOL CHEM, V270, P3327, DOI 10.1074/jbc.270.7.3327; WANGE RL, 1995, J BIOL CHEM, V270, P18730, DOI 10.1074/jbc.270.32.18730; WILDEN PA, 1992, J BIOL CHEM, V267, P16660; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	45	136	141	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20494	20500		10.1074/jbc.271.34.20494	http://dx.doi.org/10.1074/jbc.271.34.20494			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702790	Green Published, hybrid			2022-12-25	WOS:A1996VD33700042
J	MarieCardine, A; Fischer, S; Gorvel, JP; MaridonneauParini, I				MarieCardine, A; Fischer, S; Gorvel, JP; MaridonneauParini, I			Recruitment of activated p56(lck) on endosomes of CD2-triggered T cells, colocalization with ZAP-70	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; THROMBIN-STIMULATED PLATELETS; EPIDERMAL GROWTH-FACTOR; HUMAN LYMPHOCYTES-T; HUMAN NEUTROPHILS; INTRACELLULAR-LOCALIZATION; PLASMA-MEMBRANE; FUSION INVITRO; EGF RECEPTOR; JURKAT CELLS	We have previously established that upon CD2 activation of T cells, p56(lck) showed a transient increase in its kinase activity and was partially internalized. Here we studied the possibility that p56(lck) could retain its kinase activity in the endosomes of CD2-triggered cells. T cells were fractionated on a sucrose gradient, and the endosomal fraction was isolated. In CD2-triggered cells, part of Lck was internalized and presented a maximal kinase activity in the endosome-enriched fraction after 5 min, decreasing thereafter. In the endosomal fraction of activated cells, four tyrosine-phosphorylated proteins of apparent molecular masses of 30, 40, 56, and 70 kDa were detected. We demonstrated that the protein tyrosine kinase ZAP-70 was recruited to the endosomal fraction upon CD2 stimulation with kinetics similar to that of p56(lck), suggesting that recruitment of protein tyrosine kinases to endosomal vesicles could promote specific transduction signals at the intracellular level.	INST COCHIN GENET MOL, INSERM, U332, F-75014 PARIS, FRANCE; CNRS, INSERM, CTR IMMUNOL, F-13288 MARSEILLE, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm)			Maridonneau-Parini, Isabelle/F-1985-2011; Gorvel, Jean-Pierre/O-1332-2018	Gorvel, Jean-Pierre/0000-0002-2829-9804; Maridonneau-Parini, Isabelle/0000-0003-0189-0976				ANAND R, 1993, ONCOGENE, V8, P3013; BEAUFAY H, 1974, J CELL BIOL, V61, P188, DOI 10.1083/jcb.61.1.188; BELL GM, 1992, MOL CELL BIOL, V12, P5548, DOI 10.1128/MCB.12.12.5548; CARMO AM, 1993, EUR J IMMUNOL, V23, P2196, DOI 10.1002/eji.1830230922; CARPENTER G, 1976, J CELL BIOL, V71, P159, DOI 10.1083/jcb.71.1.159; CLARK EA, 1993, MOL CELL BIOL, V13, P1863, DOI 10.1128/MCB.13.3.1863; COOPER JA, 1986, MOL CELL BIOL, V6, P4467, DOI 10.1128/MCB.6.12.4467; DANIELIAN S, 1992, EUR J IMMUNOL, V22, P2915, DOI 10.1002/eji.1830221124; DANIELIAN S, 1991, EUR J IMMUNOL, V21, P1967, DOI 10.1002/eji.1830210828; DANIELIAN S, 1989, EUR J IMMUNOL, V19, P2183, DOI 10.1002/eji.1830191202; DHAR A, 1991, J BIOL CHEM, V266, P18797; DUPLAY P, 1994, J EXP MED, V179, P1163, DOI 10.1084/jem.179.4.1163; ESCOLA JM, 1995, J CELL SCI, V108, P2337; FELDER S, 1990, CELL, V61, P623, DOI 10.1016/0092-8674(90)90474-S; FERRELL JE, 1990, ONCOGENE, V5, P1033; FISCHER S, 1987, BIOCHEM BIOPH RES CO, V143, P819, DOI 10.1016/0006-291X(87)90322-6; GLENNEY JR, 1988, CELL, V52, P675, DOI 10.1016/0092-8674(88)90405-9; GORVEL JP, 1995, J BIOL CHEM, V270, P2741, DOI 10.1074/jbc.270.6.2741; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; GRONDIN P, 1991, J BIOL CHEM, V266, P15705; GRUENBERG J, 1989, J CELL BIOL, V108, P1301, DOI 10.1083/jcb.108.4.1301; GUTKIND JS, 1989, P NATL ACAD SCI USA, V86, P8783, DOI 10.1073/pnas.86.22.8783; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; HORVATH AR, 1992, EMBO J, V11, P855, DOI 10.1002/j.1460-2075.1992.tb05123.x; KAPLAN KB, 1992, J CELL BIOL, V118, P321, DOI 10.1083/jcb.118.2.321; LECABEC V, 1995, J BIOL CHEM, V270, P2067; LEY SC, 1994, J CELL BIOL, V125, P639, DOI 10.1083/jcb.125.3.639; MARIDONNEAUPARINI I, 1991, J CLIN INVEST, V87, P901, DOI 10.1172/JCI115096; MARIDONNEAUPARINI I, 1992, J BIOL CHEM, V267, P6396; MARIECARDINE A, 1992, J IMMUNOL, V148, P3879; MARIECARDINE A, 1994, EUR J IMMUNOL, V24, P1255, DOI 10.1002/eji.1830240603; MARTH JD, 1989, J IMMUNOL, V142, P2430; MOHN H, 1995, BIOCHEM J, V309, P657; PUMIGLIA KM, 1993, BIOCHEM J, V294, P253, DOI 10.1042/bj2940253; RENDU F, 1989, BLOOD, V73, P1545; ROSENFELD M, 1984, CELL PHYSL, V121, P236; ROSS SE, 1994, BIOCHEM BIOPH RES CO, V198, P88, DOI 10.1006/bbrc.1994.1013; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SCHRAVEN B, 1991, EUR J IMMUNOL, V21, P2469, DOI 10.1002/eji.1830211025; SCHRAVEN B, 1992, EUR J IMMUNOL, V22, P1857, DOI 10.1002/eji.1830220727; SOULA M, 1993, J BIOL CHEM, V268, P27420; VEILLETTE A, 1988, MOL CELL BIOL, V8, P4353, DOI 10.1128/MCB.8.10.4353; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; WALKER F, 1993, J BIOL CHEM, V268, P19552	44	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20734	20739		10.1074/jbc.271.34.20734	http://dx.doi.org/10.1074/jbc.271.34.20734			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702825	hybrid			2022-12-25	WOS:A1996VD33700077
J	Parekh, BS; Sheridan, SD; Hatfield, GW				Parekh, BS; Sheridan, SD; Hatfield, GW			Effects of integration host factor and DNA supercoiling on transcription from the ilvP(G) promoter of Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-SPECIFIC RECOMBINATION; ILVGMEDA OPERON; RNA-POLYMERASE; FACTOR IHF; PROTEIN; MUTATIONS; BINDING; LAMBDA; GROWTH; GENE	Integration host factor (IHF) activates transcription from the ilvP(G) promoter by severely distorting the DNA helix in an upstream region of a supercoiled DNA template in a way that alters the structure of the DNA in the downstream promoter region and facilitates open complex formation. In this report, the in vivo and in vitro influence of DNA supercoiling on transcription from this promoter is examined. In the absence of IHF, promoter activity increases with increased DNA supercoiling. In the presence of IHF, the same increases in superhelical DNA densities result in larger increases in promoter activity until a maximal activation of 5-fold is obtained. However, the relative transcriptional activities of the promoter in the presence and absence of IHF at any given DNA superhelical density remains the same. Thus, IHF and increased DNA supercoiling activate transcription by different mechanisms. Also, IHF binds with equal affinities to its target site on linear and supercoiled DNA templates. Therefore, IHF binding does not activate transcription simply by increasing the local negative supercoiling of the DNA helix in the downstream promoter region or by differential binding to relaxed and supercoiled DNA templates.	UNIV CALIF IRVINE,DEPT MICROBIOL & MOL GENET,COLL MED,IRVINE,CA 92697	University of California System; University of California Irvine					NIGMS NIH HHS [GM49388, GM07311] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049388] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel F.M., 1993, CURRENT PROTOCOLS MO; BAUER WR, 1995, J MOL BIOL, V253, P438, DOI 10.1006/jmbi.1995.0565; BAUER WR, 1993, J MOL BIOL, V284, P1184; BIEK DP, 1989, J BACTERIOL, V171, P2066, DOI 10.1128/jb.171.4.2066-2074.1989; BRENOWITZ M, 1986, METHOD ENZYMOL, V130, P132; COLE JR, 1986, P NATL ACAD SCI USA, V83, P4129, DOI 10.1073/pnas.83.12.4129; DITTO MD, 1994, J BACTERIOL, V176, P3738, DOI 10.1128/JB.176.12.3738-3748.1994; DRLICA K, 1992, MOL MICROBIOL, V6, P425, DOI 10.1111/j.1365-2958.1992.tb01486.x; FREUNDLICH M, 1992, MOL MICROBIOL, V6, P2557, DOI 10.1111/j.1365-2958.1992.tb01432.x; FRIEDMAN DI, 1984, J BACTERIOL, V157, P490, DOI 10.1128/JB.157.2.490-497.1984; FRIEDMAN DI, 1984, J BACTERIOL, V157, P484, DOI 10.1128/JB.157.2.484-489.1984; FRIEDMAN DI, 1988, CELL, V55, P545, DOI 10.1016/0092-8674(88)90213-9; GELLERT M, 1983, COLD SPRING HARB SYM, V2, P763; GOODMAN SD, 1992, P NATL ACAD SCI USA, V89, P11910, DOI 10.1073/pnas.89.24.11910; HAUSER CA, 1985, J BIOL CHEM, V260, P1765; HECK JD, 1988, J BIOL CHEM, V263, P857; HIGGINS NP, 1989, J BIOL CHEM, V264, P3035; Hildebrand F. B., 1974, INTRO NUMERICAL ANAL; HWANG DS, 1992, J BIOL CHEM, V267, P23083; JOHNSON ML, 1985, METHOD ENZYMOL, V117, P301; KELLER W, 1975, P NATL ACAD SCI USA, V72, P4876, DOI 10.1073/pnas.72.12.4876; KOWALSKI D, 1988, P NATL ACAD SCI USA, V85, P9464, DOI 10.1073/pnas.85.24.9464; Kusano S, 1996, J BIOL CHEM, V271, P1998, DOI 10.1074/jbc.271.4.1998; LAWTHER RP, 1987, NUCLEIC ACIDS RES, V15, P2137, DOI 10.1093/nar/15.5.2137; LILLEY DMJ, 1986, BIOCHEM SOC T, V14, P489, DOI 10.1042/bst0140489; LUTTINGER A, 1995, MOL MICROBIOL, V15, P601, DOI 10.1111/j.1365-2958.1995.tb02369.x; MALOY SR, 1981, J BACTERIOL, V145, P1110, DOI 10.1128/JB.145.2.1110-1111.1981; MENDELSON I, 1991, J BACTERIOL, V173, P1670, DOI 10.1128/jb.173.5.1670-1676.1991; Miller J.H., 1972, EXPT MOL GENETICS; NASH HA, 1987, J BACTERIOL, V169, P4124, DOI 10.1128/jb.169.9.4124-4127.1987; PAGEL JM, 1992, J MOL BIOL, V224, P919, DOI 10.1016/0022-2836(92)90460-2; Parekh BS, 1996, P NATL ACAD SCI USA, V93, P1173, DOI 10.1073/pnas.93.3.1173; PEREIRA RF, 1988, NUCLEIC ACIDS RES, V16, P5973, DOI 10.1093/nar/16.13.5973; ROSS W, 1993, SCIENCE, V262, P1407, DOI 10.1126/science.8248780; Sambrook J., 2002, MOL CLONING LAB MANU; SIMONS RW, 1987, GENE, V53, P85, DOI 10.1016/0378-1119(87)90095-3; SINGLETON CK, 1982, ANAL BIOCHEM, V122, P253, DOI 10.1016/0003-2697(82)90277-9; TSUI P, 1988, J MOL BIOL, V203, P817, DOI 10.1016/0022-2836(88)90212-4; UMBARGER HE, 1987, ESCHERICHIA COLI SAL, V1, P302; VANRIJN PA, 1988, NUCLEIC ACIDS RES, V16, P4595, DOI 10.1093/nar/16.10.4595; WANG JC, 1982, PROMOTERS STRUCTURE; WINKELMAN JW, 1990, J BIOL CHEM, V265, P10055; Yang SW, 1995, EMBO J, V14, P6292, DOI 10.1002/j.1460-2075.1995.tb00319.x	43	23	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	1996	271	34					20258	20264		10.1074/jbc.271.34.20258	http://dx.doi.org/10.1074/jbc.271.34.20258			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VD337	8702758	hybrid			2022-12-25	WOS:A1996VD33700010
J	Brown, CY; Lagnado, CA; Vadas, MA; Goodall, GJ				Brown, CY; Lagnado, CA; Vadas, MA; Goodall, GJ			Differential regulation of the stability of cytokine mRNAs in lipopolysaccharide-activated blood monocytes in response to interleukin-10	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; HUMAN POLYMORPHONUCLEAR LEUKOCYTES; MESSENGER-RNA DEGRADATION; IL-10; EXPRESSION; CELLS; COLONY; SEQUENCE; RELEASE	Adenosine-uridine (AU) instability elements, found in the 3'-untranslated regions of numerous mRNAs, target these mRNAs for rapid degradation. In addition, the degradation rate of some mRNAs that contain AU instability elements can change. This modulation of mRNA stability is an important component in the regulation of expression of many of the cytokines that control the production and function of blood cells. However, it has not been clear whether the instabilities of individual cytokine mRNAs that contain AU instability elements are coordinately regulated or whether different mRNAs can be independently regulated. We have investigated the influence of the cytokine synthesis inhibitory factor interleukin (IL)-10 on the turnover of granulocyte-colony stimulating factor (G-CSF), and IL-10 mRNAs in human blood monocytes stimulated with lipopolysaccharide. We find that all three mRNAs are destabilized in response to IL-10 but at different times. The G-CSF and GM-CSF mRNAs respond similarly, being rapidly destabilized, consistent with a direct influence of IL-10 receptor-mediated signals on the stability of these mRNAs. In contrast the IL-10 mRNA became unstable only after several hours of treatment with IL-10, suggesting that the IL-10 mRNA, although it also contains AU instability elements, is not co-regulated with the G-CSF and GM-CSF mRNAs but is regulated by a secondary factor produced in response to IL-10.	INST MED & VET SCI,HANSON CTR CANC RES,ADELAIDE,SA 5000,AUSTRALIA	Institute Medical & Veterinary Science Australia			Vadas, Mathew/R-1378-2019	Goodall, Gregory/0000-0003-1294-0692				AKASHI M, 1990, J CLIN INVEST, V85, P121, DOI 10.1172/JCI114401; BOGDAN C, 1992, J BIOL CHEM, V267, P23301; BOGDAN C, 1991, J EXP MED, V174, P1549, DOI 10.1084/jem.174.6.1549; CASSATELLA MA, 1993, J EXP MED, V178, P2207, DOI 10.1084/jem.178.6.2207; CASSATELLA MA, 1994, J EXP MED, V179, P1695, DOI 10.1084/jem.179.5.1695; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; ELIAS JA, 1990, J IMMUNOL, V145, P161; ERNST TJ, 1989, J BIOL CHEM, V264, P5700; FIORENTINO DF, 1989, J EXP MED, V170, P2081, DOI 10.1084/jem.170.6.2081; FIORENTINO DF, 1991, J IMMUNOL, V147, P3815; GOODALL GJ, 1990, METHOD ENZYMOL, V181, P148; GUBA SC, 1989, J CLIN INVEST, V84, P1701, DOI 10.1172/JCI114352; IWAI Y, 1991, J BIOL CHEM, V266, P17959; KASAMA T, 1994, J IMMUNOL, V152, P3559; KOEFFLER HP, 1988, MOL CELL BIOL, V8, P3432, DOI 10.1128/MCB.8.8.3432; LAGNADO CA, 1994, MOL CELL BIOL, V14, P7984, DOI 10.1128/MCB.14.12.7984; LINDSTEN T, 1989, SCIENCE, V244, P339, DOI 10.1126/science.2540528; MALEFYT RD, 1991, J EXP MED, V174, P1209; MOORE KW, 1993, ANNU REV IMMUNOL, V11, P165, DOI 10.1146/annurev.immunol.11.1.165; MOSMANN TR, 1994, ADV IMMUNOL, V56, P1, DOI 10.1016/S0065-2776(08)60449-6; TAKANASKI S, 1994, J EXP MED, V180, P711, DOI 10.1084/jem.180.2.711; WANG P, 1994, J IMMUNOL, V153, P811; WANG P, 1994, BLOOD, V83, P2678, DOI 10.1182/blood.V83.9.2678.bloodjournal8392678; YANG L, 1994, J BIOL CHEM, V269, P32732; ZUBIAGA AM, 1995, MOL CELL BIOL, V15, P2219	25	85	85	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					20108	20112		10.1074/jbc.271.33.20108	http://dx.doi.org/10.1074/jbc.271.33.20108			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702732	hybrid			2022-12-25	WOS:A1996VC66900073
J	DAngelo, DD; Oliver, BG; Davis, MG; McCluskey, TS; Dorn, GW				DAngelo, DD; Oliver, BG; Davis, MG; McCluskey, TS; Dorn, GW			Novel role for Sp1 in phorbol ester enhancement of human platelet thromboxane receptor gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE MYOCARDIAL-INFARCTION; RNA POLYMERASE-II; PROTEIN-KINASE-C; TRANSCRIPTION FACTORS; ACTIVATION; PROMOTER; THROMBIN; CELLS; GENERATION; INDUCTION	Expression of platelet thromboxane receptors is transcriptionally increased during megakaryocytic differentiation stimulated by phorbol 12-myristate 13-acetate (PMA). We previously cloned and characterized the promoter region of the human thromboxane receptor gene and localized PMA-responsive elements to a region between 1.84 and 1.95 kilobase pairs (kb) 5' of the transcription initiation site (D'Angelo, D. D., Davis, M. G., Houser, W. A., Eubank, J. J., Ritchie, M. E., and Dorn, G. W., II (1995) Circ. Res. 77, 466-474). Herein we report the localization of the PMA response element to a 14-nucleotide C-rich sequence, flanked by an octanucleotide inverted repeat, located -1.938 to -1.925 kb 5' of the transcription start site of this gene. We further identify the PMA-responsive enhancer factor that binds to this C-rich sequence as Sp1. Heterologous thromboxane receptor gene promoter/thymidilate kinase reporter constructs transfected into K562 cells exhibited PMA responsiveness when the C-rich element was included with additional 3' sequence from -1.924 to -1.84 kb. However, mutations of the C-rich element that disrupted a GC box located on the inverse strand eliminated PMA responsiveness and, in gel mobility shift assays, eliminated binding of Sp1. PMA treatment of K562 cells significantly increased, by 5-fold, Sp1 binding to the C-rich element and increased both phosphorylated and nonphosphorylated Sp1 protein levels by 2-fold. Furthermore, PMA treatment transiently increased Sp1 mRNA levels prior to increasing thromboxane receptor mRNA, suggesting that up-regulation of Sp1 contributes to up-regulation of thromboxane receptors. Finally, we have detected an unidentified K562 nuclear protein that binds specifically to the sense strand of the C-rich sequence overlapping the Sp1 binding site and that, by stabilizing a double stem-loop conformation of this DNA segment, may also play a role in Sp1 regulation of this gene. These studies are the first to describe regulatory and regulated roles for Sp1 in PMA-responsive gene expression and suggest that modulation of Sp1 levels controls thromboxane receptor expression during megakaryocytic differentiation.	UNIV CINCINNATI,CINCINNATI,OH 45267; VET ADM MED CTR,CINCINNATI,OH 45267	University System of Ohio; University of Cincinnati; US Department of Veterans Affairs; Veterans Health Administration (VHA); Cincinnati VA Medical Center					NHLBI NIH HHS [HL49267] Funding Source: Medline; PHS HHS [P50 52318-01] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049267] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BOSHART M, 1992, GENE, V110, P129, DOI 10.1016/0378-1119(92)90456-Y; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COUREY AJ, 1989, CELL, V59, P827, DOI 10.1016/0092-8674(89)90606-5; DANGELO DD, 1995, CIRC RES, V77, P466, DOI 10.1161/01.RES.77.3.466; Daniel S, 1996, J BIOL CHEM, V271, P1385, DOI 10.1074/jbc.271.3.1385; DORN GW, 1990, CIRCULATION, V81, P212, DOI 10.1161/01.CIR.81.1.212; DORN GW, 1994, AM J PHYSIOL, V266, pC1231, DOI 10.1152/ajpcell.1994.266.5.C1231; DORN GW, 1992, AM J PHYSIOL, V262, pC991, DOI 10.1152/ajpcell.1992.262.4.C991; DORN GW, 1992, AM J PHYSIOL, V263, pC864, DOI 10.1152/ajpcell.1992.263.4.C864; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; DYNAN WS, 1983, CELL, V32, P669, DOI 10.1016/0092-8674(83)90053-3; FITZGERALD DJ, 1986, NEW ENGL J MED, V315, P983, DOI 10.1056/NEJM198610163151602; GIDONI D, 1985, SCIENCE, V230, P511, DOI 10.1126/science.2996137; GRANGER CB, 1995, CIRCULATION, V91, P1929, DOI 10.1161/01.CIR.91.7.1929; HAMBERG M, 1975, P NATL ACAD SCI USA, V72, P2994, DOI 10.1073/pnas.72.8.2994; HIRSH P D, 1981, New England Journal of Medicine, V304, P685, DOI 10.1056/NEJM198103193041201; *HIT SOFTW ENG, 1993, HIBIO MACDNASIS PRO; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KARNS LR, 1995, J BIOL CHEM, V270, P410, DOI 10.1074/jbc.270.1.410; KINSELLA BT, 1994, J BIOL CHEM, V269, P29914; LEE JS, 1993, P NATL ACAD SCI USA, V90, P6145, DOI 10.1073/pnas.90.13.6145; MERCHANT JL, 1995, J BIOL CHEM, V270, P6314, DOI 10.1074/jbc.270.11.6314; MERIKA M, 1995, MOL CELL BIOL, V15, P2437; MODESTI PA, 1995, AM HEART J, V129, P873, DOI 10.1016/0002-8703(95)90106-X; NAKAJIMA M, 1989, BIOCHEM BIOPH RES CO, V158, P958, DOI 10.1016/0006-291X(89)92815-5; PERKINS ND, 1994, MOL CELL BIOL, V14, P6570, DOI 10.1128/MCB.14.10.6570; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; QUINN JP, 1995, BBA-GENE STRUCT EXPR, V1263, P25, DOI 10.1016/0167-4781(95)00071-N; SUN SQ, 1995, MOL CELL BIOL, V15, P2429; SZCZEKLIK A, 1992, ARTERIOSCLER THROMB, V12, P548, DOI 10.1161/01.ATV.12.5.548; VENEPALLY P, 1995, J BIOL CHEM, V270, P25402, DOI 10.1074/jbc.270.43.25402	32	70	70	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	1996	271	33					19696	19704		10.1074/jbc.271.33.19696	http://dx.doi.org/10.1074/jbc.271.33.19696			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VC669	8702673	hybrid			2022-12-25	WOS:A1996VC66900014
J	Chen, L; Zhang, H; Powers, RW; Russell, PT; Larsen, WJ				Chen, L; Zhang, H; Powers, RW; Russell, PT; Larsen, WJ			Covalent linkage between proteins of the inter-alpha-inhibitor family and hyaluronic acid is mediated by a factor produced by granulosa cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CUMULUS EXTRACELLULAR-MATRIX; TRYPSIN INHIBITOR; HEAVY-CHAINS; CROSS-LINKS; BINDING; IDENTIFICATION; EXPANSION; MOUSE; SERUM; MASS	The direct interaction of hyaluronic acid (HA) and proteins of the inter-alpha-inhibitor family plays a critical role in organization and stabilization of the expanding cumulus extracellular matrix (cECM) following an ovulatory stimulus, Despite similarities in the morphology of cumulus oocyte complexes (COCs) expanding in vivo and in vitro, we find that the cECM of COCs which expand within intact follicles are more elastic and resistant to shear stress than the cECM of those stabilized in vitro, Western blot analysis shows that only the heavy chains of inter-alpha-inhibitor are incorporated into the cECM and appears to be covalently linked to HA after stabilization in vivo while intact inter-alpha-inhibitor is bound to the HA-enriched cECM by a non-covalent mechanism in in vitro stabilized COCs, However, purified pre-alpha-inhibitor and HA can form covalent linkage in the presence of granulosa cells or with granulosa cell-conditioned medium, In addition, COCs resistance to shear stress is also enhanced by coincubation with granulosa cells, Upon formation of the apparent covalent linkage between heavy chains and HA in culture medium, the light chain (bikunin) is concomitantly released into the medium as a complex with chondroitin sulfate moieties of inter-alpha-inhibitor supporting the possibility that HA may replace the chondroitin sulfate linkage to the heavy chains, We speculate that a factor(s) secreted by granulosa cells within the follicle may catalyze a transesterification reaction resulting in an exchange of chondroitin sulfate with HA at the heavy chain/chondroitin sulfate junction followed by release of chondroitin sulfate-bikunin into the follicular fluid. It is also possible that the consequent further stabilization of the cECM through the covalent interaction of HA and heavy chains of inter-alpha-inhibitor may play an important role in the process of ovulation.	UNIV CINCINNATI,COLL MED,DEPT ANAT CELL BIOL & NEUROBIOL,CINCINNATI,OH 45267; CHRIST HOSP,FERTIL LAB,CINCINNATI,OH 45267	University System of Ohio; University of Cincinnati; Christ Hospital - Ohio					NICHD NIH HHS [HD29894] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD029894] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BJERSING L, 1974, CELL TISSUE RES, V149, P287, DOI 10.1007/BF00226764; Blandau R. J., 1969, MAMMALIAN OVIDUCT, P129; CASTILLO GM, 1993, FEBS LETT, V318, P292, DOI 10.1016/0014-5793(93)80531-X; CHEN L, 1993, MOL REPROD DEV, V34, P87, DOI 10.1002/mrd.1080340114; CHEN L, 1992, J BIOL CHEM, V267, P12380; CHEN L, 1994, J BIOL CHEM, V269, P28282; CHEN L, 1990, MOL REPROD DEV, V26, P236, DOI 10.1002/mrd.1080260307; CHEN L, 1995, BIOL REPROD, V52, P195; ENGHILD JJ, 1991, J BIOL CHEM, V266, P747; ENGHILD JJ, 1993, J BIOL CHEM, V268, P8711; GEBHARD W, 1990, BIOL CHEM H-S, V371, P13; HENDRIX EM, 1992, TISSUE CELL, V24, P61, DOI 10.1016/0040-8166(92)90081-H; HUANG L, 1993, J BIOL CHEM, V268, P26725; HUTADILOK N, 1988, ANN RHEUM DIS, V47, P377, DOI 10.1136/ard.47.5.377; JESSEN TE, 1994, BIOL CHEM H-S, V375, P521, DOI 10.1515/bchm3.1994.375.8.521; JESSEN TE, 1988, FEBS LETT, V230, P195, DOI 10.1016/0014-5793(88)80670-7; MALKI N, 1992, BIOL CHEM H-S, V373, P1009, DOI 10.1515/bchm3.1992.373.2.1009; MORELLE W, 1994, EUR J BIOCHEM, V221, P881, DOI 10.1111/j.1432-1033.1994.tb18803.x; OHYA T, 1970, BIOCHIM BIOPHYS ACTA, V198, P607, DOI 10.1016/0005-2744(70)90139-7; POWERS RW, 1995, AM J PHYSIOL-ENDOC M, V269, pE290, DOI 10.1152/ajpendo.1995.269.2.E290; SALIER JP, 1987, P NATL ACAD SCI USA, V84, P8272, DOI 10.1073/pnas.84.23.8272; SALUSTRI A, 1989, J BIOL CHEM, V264, P13840; SALUSTRI A, 1990, DEV BIOL, V138, P26, DOI 10.1016/0012-1606(90)90173-G; ZHAO M, 1995, J BIOL CHEM, V270, P26657, DOI 10.1074/jbc.270.44.26657	24	95	96	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19409	19414		10.1074/jbc.271.32.19409	http://dx.doi.org/10.1074/jbc.271.32.19409			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702628	hybrid			2022-12-25	WOS:A1996VB68400062
J	Holvoet, P; Zhao, Z; Deridder, E; Dhoest, A; Collen, D				Holvoet, P; Zhao, Z; Deridder, E; Dhoest, A; Collen, D			Effects of deletion of the carboxyl terminal domain of ApoA-I or of its substitution with helices of ApoA-II on in vitro and in vivo lipoprotein association	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; APOLIPOPROTEIN-A-I; LECITHIN-CHOLESTEROL ACYLTRANSFERASE; BINDING; PROTEINS; FIBROBLASTS; ACTIVATION; RECEPTORS; MEMBRANES; LIPIDS	In the present study, the lipoprotein association of apoA-I, an apoA-I (Delta Ala(190)-Gln(243)) deletion mutant and an apoA-I (Asp(1)-Leu(189))/apoA-II (Ser(12)-Gln(77)) chimera were compared. At equilibrium, 80% of the I-125-labeled apolipoproteins associated with lipoproteins in rabbit or human plasma but with very different distribution profiles. High density lipoprotein (HDL),(2,3)-associated fractions were 0.60 for apoA-I, 0.30 for the chimera, and 0.15 for the deletion mutant, and corresponding very high density lipoprotein-associated fractions were 0.20, 0.50, and 0.65. Clearance curves after intravenous bolus injection of I-125-labeled apolipoproteins (3 mu g/kg) in normolipemic rabbits could be adequately fitted with a sum of three exponential terms, yielding overall plasma clearance rates of 0.028 +/- 0.0012 ml . min(-1) for apoA-I (mean +/- S.E.; n = 6), 0.10 +/- 0.008 ml . min(-1) for the chimera (p < 0.001 versus apoA-I) and 0.38 +/- 0.022 ml . min(-1) for the deletion mutant (p < 0.001 versus apoA-I and versus the chimera). Fractions that were initially cleared with a t1/2 of 3 min, most probably representing free apolipoproteins, were 0.30 +/- 0.04, 0.50 +/- 0.06 (p = 0.02 versus apoA-I), and 0.64 +/- 0.07 (p = 0.002 versus apoA-I), respectively. At 20 min after the bolus, the fractions of injected material associated with HDL(2,3) were 0.55 +/- 0.06, 0.25 +/- 0.03 (p = 0.001 versus apoA-I), and 0.09 +/- 0.01 (p < 0.001 versus apoA-I and versus the chimera), respectively, whereas the fractions associated with very high density lipoprotein were 0.15 +/- 0.006, 0.25 +/- 0.03 (p = 0.008 versus apoA-I), and 0.27 +/- 0.03 (p = 0.003 versus apoA-I), respectively. The ability of the different apolipoproteins to bind to HDL, particles and displace apoA-I in vitro were compared, The molar ratios at which 50% of I-125-labeled apoA-I was displaced from the surface of HDL, particles were 1:1 for apoA-I, 3:1 for the chimera and 12:1 for the deletion mutant, indicating 3- and 12-fold reductions of the affinities for HDL, of the chimera and the deletion mutant, respectively. These data suggest that the carboxyl-terminal pair of helices of apoA-I are involved in the initial rapid binding of apoA-I to the lipid surface of HDL. Although the lipid affinity of apoA-II is higher than that of apoA-I, substitution of the carboxyl-terminal helices of apoA-I with those of apoA-II only partially restores its lipoprotein association. Thus, this substitution may affect cooperative interactions with the middle amphipathic helices of apoA-I that are critical for its specific distribution over the different HDL species.			Holvoet, P (corresponding author), UNIV LOUVAIN,CTR MOL & VASC BIOL,CAMPUS GASTHUISBERG,O&N HEREST 49,B-3000 LOUVAIN,BELGIUM.		HOLVOET, PAUL/T-8434-2017	HOLVOET, PAUL/0000-0001-9201-0772				ALLAN CM, 1992, J BIOL CHEM, V267, P13257; ASSMANN G, 1974, P NATL ACAD SCI USA, V71, P989, DOI 10.1073/pnas.71.3.989; BOLTON AE, 1973, BIOCHIM BIOPHYS ACTA, V329, P318, DOI 10.1016/0304-4165(73)90296-1; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRASSEUR R, 1990, BIOCHIM BIOPHYS ACTA, V1043, P245, DOI 10.1016/0005-2760(90)90023-Q; BRASSEUR R, 1991, J BIOL CHEM, V266, P16120; BREWER HB, 1978, BIOCHEM BIOPH RES CO, V80, P623, DOI 10.1016/0006-291X(78)91614-5; BRINTON EA, 1991, J CLIN INVEST, V87, P536, DOI 10.1172/JCI115028; CHEN TC, 1979, BIOCHEMISTRY-US, V18, P1617, DOI 10.1021/bi00575a037; CHEUNG MC, 1987, J LIPID RES, V28, P913; CHRISTIAN JC, 1990, ARTERIOSCLEROSIS, V10, P1020, DOI 10.1161/01.ATV.10.6.1020; DALTON MB, 1993, J BIOL CHEM, V268, P19273; DANIELS RJ, 1981, J BIOL CHEM, V256, P4978; DEBACKER G, 1986, AM HEART J, V112, P478, DOI 10.1016/0002-8703(86)90510-7; DEEB SS, 1991, J BIOL CHEM, V266, P13654; FIELDING C J, 1981, Proceedings of the National Academy of Sciences of the United States of America, V78, P3911, DOI 10.1073/pnas.78.6.3911; FIELDING CJ, 1972, BIOCHEM BIOPH RES CO, V46, P1493, DOI 10.1016/0006-291X(72)90776-0; GIBALDI M, 1983, PHARMACOKINETICS, P45; GLOMSET JA, 1968, J LIPID RES, V9, P155; GORDON DJ, 1989, NEW ENGL J MED, V321, P1311; HARA H, 1991, J BIOL CHEM, V266, P3080; HOLVOET P, 1995, BIOCHEMISTRY-US, V34, P13334, DOI 10.1021/bi00041a009; HUNT SC, 1989, AM J EPIDEMIOL, V129, P625, DOI 10.1093/oxfordjournals.aje.a115175; IKEWAKI K, 1993, J LIPID RES, V34, P2207; JI Y, 1995, J BIOL CHEM, V270, P11290, DOI 10.1074/jbc.270.19.11290; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LE NA, 1988, METABOLISM, V37, P614, DOI 10.1016/0026-0495(88)90077-7; LOEB J, 1983, MOL CELL BIOCHEM, V52, P161; MAO SJT, 1977, BIOCHEMISTRY-US, V16, P4150, DOI 10.1021/bi00638a003; MILLER NE, 1985, NATURE, V314, P109, DOI 10.1038/314109a0; MINNICH A, 1992, J BIOL CHEM, V267, P16553; MORRISON J, 1991, J BIOL CHEM, V266, P18780; MORRISON JR, 1992, J BIOL CHEM, V267, P13205; ORAM JF, 1981, J BIOL CHEM, V256, P8348; ORAM JF, 1990, ATHEROSCLER REV, V20, P103; Palgunachari MN, 1996, ARTERIOSCL THROM VAS, V16, P328, DOI 10.1161/01.ATV.16.2.328; POMETTA D, 1979, ATHEROSCLEROSIS, V34, P419, DOI 10.1016/0021-9150(79)90066-2; POWNALL HJ, 1981, J BIOL CHEM, V256, P9849; RADER DJ, 1992, J LIPID RES, V33, P755; RYE KA, 1990, BIOCHIM BIOPHYS ACTA, V1042, P227, DOI 10.1016/0005-2760(90)90013-N; SCHMIDT HHJ, 1995, J BIOL CHEM, V270, P5469, DOI 10.1074/jbc.270.10.5469; SEGREST JP, 1974, FEBS LETT, V38, P247, DOI 10.1016/0014-5793(74)80064-5; SEGREST JP, 1991, PROTEINS, V9, P79; SEGREST JP, 1992, J LIPID RES, V33, P141; SLOTTE JP, 1987, J BIOL CHEM, V262, P12904; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VITELLO LB, 1976, J BIOL CHEM, V251, P1131	47	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19395	19401		10.1074/jbc.271.32.19395	http://dx.doi.org/10.1074/jbc.271.32.19395			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702626	hybrid			2022-12-25	WOS:A1996VB68400060
J	Karnieli, E; Werner, H; Rauscher, FJ; Benjamin, LE; LeRoith, D				Karnieli, E; Werner, H; Rauscher, FJ; Benjamin, LE; LeRoith, D			The IGF-I receptor gene promoter is a molecular target for the Ewing's sarcoma Wilms' tumor 1 fusion protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROUND-CELL TUMOR; GROWTH-FACTOR RECEPTOR; ZINC FINGER PROTEIN; CHROMOSOME-TRANSLOCATION; TRANSCRIPTION FACTOR; PERIPHERAL NEUROEPITHELIOMA; CHIMERIC TRANSCRIPTS; SUPPRESSOR WT1; BINDING; PRODUCT	Desmoplastic small round cell tumor (DSRCT) is an abdominal malignancy in children which is characterized by a recurrent chromosomal translocation, t(11; 22)(p13;q12). This rearrangement results in the fusion of the ubiquitously expressed EWS1 gene to the Wilms' tumor suppressor (WT1) gene. The chimeric protein contains the N-terminal domain of EWS1 fused to the DNA-binding domain of WT1, including zinc fingers 2-4, Because WT1 has been shown previously to bind and repress the insulin-like growth factor I (IGF-I-R) promoter, we investigated whether this promoter is, in addition, a target for the aberrant EWS/WT1 transcription factor. EWS/WT1 activated the ICF-I-R. promoter similar to 340%, whereas a fusion protein containing a three-amino acid insert (KTS) between zinc fingers 3 and 4 had no effect. On the other hand, expression vectors encoding either WT1 or EWS1 reduced the activity of the promoter to 46 and 58% of control values, respectively. Results of gel shift assays indicate that the binding affinity of EWS/WT1 to a fragment of the 5'-flanking region of the receptor promoter was higher than the affinity of WT1 itself. Consistent with the results of functional assays, the binding of EWS/WT1(+KTS) was significantly reduced. Due to the central role of the IGF-I-R in tumorigenesis, activation of the receptor promoter by EWS/WT1 may constitute a potential mechanism for the etiology and/or progression of DSRCT.	NIDDK, DIABET BRANCH, SECT MOL & CELLULAR PHYSIOL, NIH, BETHESDA, MD 20892 USA; TECHNION ISRAEL INST TECHNOL, BRUCE RAPPAPORT FAC MED, IL-31096 HAIFA, ISRAEL; TECHNION ISRAEL INST TECHNOL, RAMBAM MED CTR, INST ENDOCRINOL & METAB, IL-31096 HAIFA, ISRAEL; WISTAR INST ANAT & BIOL, PHILADELPHIA, PA 19104 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Rambam Health Care Campus; Technion Israel Institute of Technology; The Wistar Institute					NCI NIH HHS [CA52009, CA10815] Funding Source: Medline; NIDDK NIH HHS [DK49210] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA010815, P01CA052009] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK049210] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAKER J, 1993, CELL, V75, P73, DOI 10.1016/0092-8674(93)90680-O; BASERGA R, 1992, RECEPTOR, V2, P261; BECKWITH J B, 1990, Pediatric Pathology, V10, P1; BIEGEL JA, 1993, GENE CHROMOSOME CANC, V7, P119, DOI 10.1002/gcc.2870070210; BRAUN BS, 1995, MOL CELL BIOL, V15, P4623; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; COPPOLA D, 1994, MOL CELL BIOL, V14, P4588, DOI 10.1128/MCB.14.7.4588; DEKLEIN A, 1982, NATURE, V300, P765, DOI 10.1038/300765a0; DELATTRE O, 1994, NEW ENGL J MED, V331, P294, DOI 10.1056/NEJM199408043310503; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DRUMMOND IA, 1994, MOL CELL BIOL, V14, P3800, DOI 10.1128/MCB.14.6.3800; GARVIN AJ, 1993, AM J PATHOL, V142, P375; GERALD WL, 1995, P NATL ACAD SCI USA, V92, P1028, DOI 10.1073/pnas.92.4.1028; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; LADANYI M, 1994, CANCER RES, V54, P2837; LEROITH D, 1991, TRENDS ENDOCRIN MET, V2, P134, DOI 10.1016/1043-2760(91)90003-6; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/S0092-8674(05)80084-4; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MAHESWARAN S, 1993, P NATL ACAD SCI USA, V90, P5100, DOI 10.1073/pnas.90.11.5100; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; MAY WA, 1993, P NATL ACAD SCI USA, V90, P5752, DOI 10.1073/pnas.90.12.5752; MORRIS JF, 1991, ONCOGENE, V6, P2339; ORDONEZ NG, 1993, HUM PATHOL, V24, P850, DOI 10.1016/0046-8177(93)90135-4; RABBITTS TH, 1991, ADV IMMUNOL, V50, P119; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; RAUSCHER FJ, 1994, COLD SPRING HARB SYM, V59, P137, DOI 10.1101/SQB.1994.059.01.017; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; RAUSCHER FJ, 1993, FASEB J, V7, P896, DOI 10.1096/fasebj.7.10.8393820; ROSE EA, 1990, CELL, V60, P495, DOI 10.1016/0092-8674(90)90600-J; SAWYER JR, 1992, AM J SURG PATHOL, V16, P411, DOI 10.1097/00000478-199204000-00010; SELL C, 1994, MOL CELL BIOL, V14, P3604, DOI 10.1128/MCB.14.6.3604; SELL C, 1993, P NATL ACAD SCI USA, V90, P11217, DOI 10.1073/pnas.90.23.11217; SHEN WPV, 1992, CANCER GENET CYTOGEN, V64, P189; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; WERNER H, 1994, J BIOL CHEM, V269, P12577; WERNER H, 1995, MOL CELL BIOL, V15, P3516; WERNER H, 1992, MOL ENDOCRINOL, V6, P1545, DOI 10.1210/me.6.10.1545; WERNER H, 1993, P NATL ACAD SCI USA, V90, P5828, DOI 10.1073/pnas.90.12.5828; Werner H, 1996, ADV CANCER RES, V68, P183, DOI 10.1016/S0065-230X(08)60354-1; WERNER H, 1989, P NATL ACAD SCI USA, V86, P7451, DOI 10.1073/pnas.86.19.7451; Werner H, 1991, INSULIN LIKE GROWTH, P17; WERNER H, 1996, IN PRESS P NATL ACAD; WHANGPENG J, 1984, NEW ENGL J MED, V311, P584, DOI 10.1056/NEJM198408303110907; ZUCMAN J, 1993, NAT GENET, V4, P341, DOI 10.1038/ng0893-341; ZUCMAN J, 1992, GENE CHROMOSOME CANC, V5, P271, DOI 10.1002/gcc.2870050402	45	72	76	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19304	19309		10.1074/jbc.271.32.19304	http://dx.doi.org/10.1074/jbc.271.32.19304			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702614	hybrid			2022-12-25	WOS:A1996VB68400048
J	Nelson, CC; Hendy, SC; Faris, JS; Romaniuk, PJ				Nelson, CC; Hendy, SC; Faris, JS; Romaniuk, PJ			Retinoid X receptor alters the determination of DNA binding specificity by the P-box amino acids of the thyroid hormone receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPONSE ELEMENTS; DIRECT REPEATS; NUCLEAR RECEPTORS; ESTROGEN-RECEPTOR; GLUCOCORTICOID RECEPTOR; HALF-SITES; RXR-BETA; GENE; HETERODIMERS; PROMOTER	Nuclear hormone receptors bind to hormone response elements in DNA consisting of two half-sites of 6 base pairs. The P-box amino acids of each receptor determine the identities of the central nucleotides of the half-site, 57 P-box variants of the human thyroid hormone receptor (hT3R beta) were used to demonstrate the relationship between P-box sequence and DNA binding specificity by homodimers and heterodimers formed with the retinoid X receptor (RXR). In general, the formation of heterodimers relieved many of the constraints on the compatibility of hT3R beta P-box sequences with DNA binding. Effects were most dramatic for heterodimers bound to a direct repeat spaced by four base pairs. RXR also overrides the P-box-derived DNA binding specificity of hT3R beta when heterodimers are bound to inverted or everted repeat elements, These effects of RXR are most pronounced on AGGTCA half-sites but are squelched when the RXR partner of the heterodimer is bound to an AGGACA half-site. The influence of RXR on hT3R beta DNA binding specificity varies with the orientation of half-sites in the element, the identity of the fourth base pair of the half-site, and the spacing between the half-sites of direct repeats. These differences suggest that the DNA binding domains of RXR-hT3R beta heterodimers are not positioned equivalently on the various elements, affecting the manner in which the P-box amino acids of hT3R beta interact with base pairs within the half-site.	UNIV VICTORIA,DEPT BIOCHEM & MICROBIOL,VICTORIA,BC V8W 3P6,CANADA	University of Victoria				Romaniuk, Paul/0000-0002-5931-8879				AHLQUIST JAO, 1989, BIOCHIM BIOPHYS ACTA, V1008, P251, DOI 10.1016/0167-4781(80)90017-2; BANIAHMAD A, 1990, CELL, V61, P505, DOI 10.1016/0092-8674(90)90532-J; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BONDE BG, 1991, J VIROL, V65, P2037, DOI 10.1128/JVI.65.4.2037-2046.1991; BRENT GA, 1989, J BIOL CHEM, V264, P178; BUGGE TH, 1992, EMBO J, V11, P1409, DOI 10.1002/j.1460-2075.1992.tb05186.x; CHATTERJEE VKK, 1989, P NATL ACAD SCI USA, V86, P9114, DOI 10.1073/pnas.86.23.9114; DANIELSEN M, 1989, CELL, V57, P1131, DOI 10.1016/0092-8674(89)90050-0; DARLING DS, 1989, MOL ENDOCRINOL, V3, P1359, DOI 10.1210/mend-3-9-1359; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FLINK IL, 1990, J BIOL CHEM, V265, P11233; FORMAN BM, 1992, MOL ENDOCRINOL, V6, P429, DOI 10.1210/me.6.3.429; GEWIRTH DT, 1995, NAT STRUCT BIOL, V2, P386, DOI 10.1038/nsb0595-386; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; HAM J, 1988, NUCLEIC ACIDS RES, V16, P5263, DOI 10.1093/nar/16.12.5263; Judelson C, 1996, J BIOL CHEM, V271, P10800, DOI 10.1074/jbc.271.18.10800; KATZ RW, 1993, J BIOL CHEM, V268, P19392; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KOENIG RJ, 1987, P NATL ACAD SCI USA, V84, P5670, DOI 10.1073/pnas.84.16.5670; KUROKAWA R, 1993, GENE DEV, V7, P1423, DOI 10.1101/gad.7.7b.1423; LAUDET V, 1992, EMBO J, V11, P1003, DOI 10.1002/j.1460-2075.1992.tb05139.x; LAVIN TN, 1988, J BIOL CHEM, V263, P9418; LIPKIN SM, 1992, P NATL ACAD SCI USA, V89, P1209, DOI 10.1073/pnas.89.4.1209; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MADER S, 1993, EMBO J, V12, P5029, DOI 10.1002/j.1460-2075.1993.tb06196.x; MADER S, 1989, NATURE, V338, P271, DOI 10.1038/338271a0; MARKS MS, 1992, EMBO J, V11, P1419, DOI 10.1002/j.1460-2075.1992.tb05187.x; NAAR AM, 1991, CELL, V65, P1267, DOI 10.1016/0092-8674(91)90021-P; NELSON CC, 1995, J BIOL CHEM, V270, P16981, DOI 10.1074/jbc.270.28.16981; NELSON CC, 1995, J BIOL CHEM, V270, P16988, DOI 10.1074/jbc.270.28.16988; NELSON CC, 1994, MOL ENDOCRINOL, V8, P829, DOI 10.1210/me.8.7.829; NELSON CC, 1993, MOL ENDOCRINOL, V7, P1185, DOI 10.1210/me.7.9.1185; NORMAN MF, 1989, J BIOL CHEM, V264, P12063; PERLMANN T, 1993, GENE DEV, V7, P1411, DOI 10.1101/gad.7.7b.1411; PETTY KJ, 1990, J BIOL CHEM, V265, P7395; PREDKI PF, 1995, BIOCHEM J, V305, P805, DOI 10.1042/bj3050805; RASTINEJAD F, 1995, NATURE, V375, P203, DOI 10.1038/375203a0; SAP J, 1990, EMBO J, V9, P887, DOI 10.1002/j.1460-2075.1990.tb08186.x; SCHRADER M, 1994, J BIOL CHEM, V269, P6444; SCHWABE JWR, 1993, CELL, V75, P567, DOI 10.1016/0092-8674(93)90390-C; SMITMCBRIDE Z, 1994, MOL ENDOCRINOL, V8, P819, DOI 10.1210/me.8.7.819; UMESONO K, 1989, CELL, V57, P1139, DOI 10.1016/0092-8674(89)90051-2; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; VOZ ML, 1991, J BIOL CHEM, V266, P13397; WAHLI W, 1991, FASEB J, V5, P2243, DOI 10.1096/fasebj.5.9.1860615; WAHLSTROM GM, 1992, MOL ENDOCRINOL, V6, P1013, DOI 10.1210/me.6.7.1013; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZECHEL C, 1994, EMBO J, V13, P1425, DOI 10.1002/j.1460-2075.1994.tb06396.x; ZECHEL C, 1994, EMBO J, V13, P1414, DOI 10.1002/j.1460-2075.1994.tb06395.x; ZHANG XK, 1993, TRENDS ENDOCRIN MET, V4, P156, DOI 10.1016/1043-2760(93)90105-N; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0; ZILLIACUS J, 1994, P NATL ACAD SCI USA, V91, P4175, DOI 10.1073/pnas.91.10.4175	52	17	18	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19464	19474		10.1074/jbc.271.32.19464	http://dx.doi.org/10.1074/jbc.271.32.19464			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702636	hybrid			2022-12-25	WOS:A1996VB68400070
J	Ballestar, E; Abad, C; Franco, L				Ballestar, E; Abad, C; Franco, L			Core histones are glutaminyl substrates for tissue transglutaminase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYZED CROSS-LINKING; FACTOR-XIIIA; NUCLEOSOMES; PROTEIN; IDENTIFICATION; POLYAMINES; CHROMATIN; APOPTOSIS; OCTAMER; DNA	Chicken erythrocyte core histones are glutaminyl substrates in the transglutaminase (TGase) reaction with monodansylcadaverine (DNC) as donor amine, The modification is very fast when compared with that of many native substrates of TGase, Out of the 18 glutamines of the four histones, nine (namely glutamine 95 of H2B; glutamines 5, 19, and 125 of H3; glutamines 27 and 93 of H4; and glutamines 24, 104, and 112 of H2A) are the amine accepters in free histones, The use of Gln(112) of H2A requires a temperature-dependent partial unfolding of the histone, showing that structural determinants are decisive for the glutamine specificity, The structures of H2A and H2B do not appreciably change upon modification with DNC as determined by circular dichroism, and core particles reconstituted from these DNC-modified histones are indistinguishable from native nucleosome cores, When the reaction is carried out with native nucleosomes, only glutamines 5 and 19 of H3, which are located in the N-terminal tail, and glutamine 22 of H2B, which is not labeled in free histone, are modified, Methylamine and putrescine also are incorporated into nucleosomes by the TGase reaction, Our results reveal several possibilities for the application of the TGase reaction in the chromatin field, and taking into account that histones are easily cross-linked or modified by polyamines in vitro, the possibility that they may be TGase substrates in vivo is discussed.	UNIV VALENCIA, DEPT BIOCHEM & MOL BIOL, E-46100 BURJASSOT, VALENCIA, SPAIN	University of Valencia			Ballestar, Esteban/ABG-8561-2020	Ballestar, Esteban/0000-0002-1400-2440; Franco, Luis/0000-0001-9610-6448				AESCHLIMANN D, 1992, J BIOL CHEM, V267, P11316; AESCHLIMANN D, 1994, THROMB HAEMOSTASIS, V71, P402; ALLEN G, 1989, SEQUENCING PROTEINS; ARENTS G, 1993, P NATL ACAD SCI USA, V90, P10489, DOI 10.1073/pnas.90.22.10489; ARENTS G, 1995, P NATL ACAD SCI USA, V92, P11170, DOI 10.1073/pnas.92.24.11170; ARENTS G, 1991, P NATL ACAD SCI USA, V88, P10148, DOI 10.1073/pnas.88.22.10148; CHODOSH LA, 1995, CURRENT PROTOCOLS MO, V2; COUSSONS PJ, 1992, BIOCHEM J, V282, P929, DOI 10.1042/bj2820929; COUSSONS PJ, 1991, BIOCHEM J, V273, P73, DOI 10.1042/bj2730073; DABAN JR, 1989, METHOD ENZYMOL, V170, P192; DELDUCA S, 1995, BIOCHEM J, V305, P233, DOI 10.1042/bj3050233; FERRANDIZ C, 1994, BIOCHEM BIOPH RES CO, V203, P359, DOI 10.1006/bbrc.1994.2190; FESUS L, 1991, EUR J CELL BIOL, V56, P170; FOLK JE, 1980, ANNU REV BIOCHEM, V49, P517, DOI 10.1146/annurev.bi.49.070180.002505; FOLK JE, 1980, J BIOL CHEM, V255, P3695; GROOTJANS JJ, 1995, J BIOL CHEM, V270, P22855, DOI 10.1074/jbc.270.39.22855; GURLEY LR, 1983, ANAL BIOCHEM, V129, P132, DOI 10.1016/0003-2697(83)90061-1; HAND D, 1993, INT J DEV NEUROSCI, V11, P709, DOI 10.1016/0736-5748(93)90060-Q; ISENBERG I, 1979, ANNU REV BIOCHEM, V48, P159, DOI 10.1146/annurev.bi.48.070179.001111; JENSEN PH, 1993, EUR J BIOCHEM, V214, P141, DOI 10.1111/j.1432-1033.1993.tb17906.x; Johns E W, 1977, Methods Cell Biol, V16, P183; KORNBERG RD, 1989, METHOD ENZYMOL, V170, P3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDSEY GG, 1990, BIOCHIM BIOPHYS ACTA, V1049, P9, DOI 10.1016/0167-4781(90)90077-F; LOIDL P, 1994, CHROMOSOMA, V103, P441; LUCIANO L, 1995, CELL DEATH DIFFER, V2, P259; LUTTER LC, 1989, METHOD ENZYMOL, V170, P264; MARVIN KW, 1990, J BIOL CHEM, V265, P19839; MATTHEWS HR, 1993, BIOESSAYS, V15, P561, DOI 10.1002/bies.950150811; MCCONKEY DJ, 1994, IMMUNOL REV, V142, P343, DOI 10.1111/j.1600-065X.1994.tb00896.x; MICHALSKISCRIVE C, 1982, BIOCHIMIE, V64, P347, DOI 10.1016/S0300-9084(82)80439-2; MURTHY SNP, 1994, J BIOL CHEM, V269, P22907; PASCAUD LT, 1987, ANAL BIOCHEM, V167, P47; RICHMOND TJ, 1988, J MOL BIOL, V199, P161, DOI 10.1016/0022-2836(88)90386-5; RICHMOND TJ, 1984, NATURE, V311, P532, DOI 10.1038/311532a0; RUSSELL DH, 1981, BIOCHEM BIOPH RES CO, V157, P115; Shimizu T, 1996, NATURE, V380, P32, DOI 10.1038/380032a0; TAKAGI J, 1995, EUR J BIOCHEM, V232, P773, DOI 10.1111/j.1432-1033.1995.773zz.x; USUI T, 1993, J BIOL CHEM, V268, P12311; van Holde K.E., 1988, CHROMATIN; WEINTRAUB H, 1975, CELL, V6, P85, DOI 10.1016/0092-8674(75)90077-X; Zweidler A, 1978, Methods Cell Biol, V17, P223, DOI 10.1016/S0091-679X(08)61145-0	42	99	100	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18817	18824		10.1074/jbc.271.31.18817	http://dx.doi.org/10.1074/jbc.271.31.18817			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702540	hybrid			2022-12-25	WOS:A1996VB68300078
J	Church, C; Chapon, C; Poyton, RO				Church, C; Chapon, C; Poyton, RO			Cloning and characterization of PET100, a gene required for the assembly of yeast cytochrome c oxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; NUCLEAR GENE; CYOE GENE; PARACOCCUS-DENITRIFICANS; SUBUNIT COMPOSITION; SCO1 PROTEIN; BO OPERON; HEME; EXPRESSION	The biogenesis of cytochrome c oxidase in Saccharomyces cerevisiae requires a protein encoded by the nuclear gene, PET100. Cells carrying a recessive mutation (pet100-1) in PET100 are respiratory deficient and have reduced levels of cytochrome c oxidase activity. The PET100 gene has been cloned by complementation of pet100-1, sequenced and disrupted. PET100 is located adjacent to the PDC2 gene on chromosome IV and contains an open reading frame of 333 base pairs. The PET100 protein contains a possible membrane-spanning segment and a putative mitochondrial import sequence at its NH2 terminus. A strain carrying a null mutation in PET100 lacks cytochrome c oxidase activity and assembled cytochromes a and a(3), but the other respiratory chain carriers are present, The respiratory-deficient phenotype of this strain is not rescued by added hemin or heme A. These findings indicate that the mutation is specific for cytochrome c oxidase and does not affect the biosynthesis of heme A. In addition, mitochondria from the strain carrying a null mutation in PET100 contain each of the subunit polypeptides of cytochrome c oxidase. Together, these findings suggest that PET100p is not required for the synthesis or localization of cytochrome c oxidase subunits to mitochondria, but is required at a later step in their assembly into an active holoenzyme.	UNIV COLORADO, DEPT MOL CELLULAR & DEV BIOL, BOULDER, CO 80309 USA	University of Colorado System; University of Colorado Boulder					NIGMS NIH HHS [GM30228] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030228] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN LA, 1995, J BIOL CHEM, V270, P110, DOI 10.1074/jbc.270.1.110; BENNETZEN JL, 1982, J BIOL CHEM, V257, P3026; BONNEAUD N, 1991, YEAST, V7, P609, DOI 10.1002/yea.320070609; BONNEFOY N, 1994, J MOL BIOL, V239, P201, DOI 10.1006/jmbi.1994.1363; BROACH JR, 1979, GENE, V8, P121, DOI 10.1016/0378-1119(79)90012-X; BUCHWALD P, 1991, MOL GEN GENET, V229, P413, DOI 10.1007/BF00267464; CHOU PY, 1978, ADV ENZYMOL RELAT AR; COSTANZO MC, 1990, ANNU REV GENET, V24, P91; COSTER F, 1995, YEAST, V11, P85, DOI 10.1002/yea.320110111; DEWINDE JH, 1993, PROG NUCLEIC ACID RE, V46, P51, DOI 10.1016/S0079-6603(08)61018-1; DIECKMANN CL, 1994, INT REV CYTOL, V152, P145, DOI 10.1016/S0074-7696(08)62556-5; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FERGUSONMILLER S, 1978, J BIOL CHEM, V253, P149; GAVEL Y, 1990, PROTEIN ENG, V4, P33, DOI 10.1093/protein/4.1.33; Gibson T.J., 1984, THESIS CAMBRIDGE U U; GLERUM DM, 1994, P NATL ACAD SCI USA, V91, P8452, DOI 10.1073/pnas.91.18.8452; GLERUM DM, 1995, J BIOL CHEM, V270, P15585, DOI 10.1074/jbc.270.26.15585; HENDRICK JP, 1989, P NATL ACAD SCI USA, V86, P4056, DOI 10.1073/pnas.86.11.4056; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; HOHMANN S, 1993, MOL GEN GENET, V241, P657, DOI 10.1007/BF00279908; IWATA S, 1995, NATURE, V376, P660, DOI 10.1038/376660a0; KOTYLAK Z, 1977, MITOCHONDRIA 1977, P83; KRUMMECK G, 1990, CURR GENET, V18, P13, DOI 10.1007/BF00321109; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAMARCHE AEP, 1992, J BIOL CHEM, V267, P22473; LEMIRE BD, 1989, J BIOL CHEM, V264, P20206; MCEWEN JE, 1986, J BIOL CHEM, V261, P1872; MCEWEN JE, 1985, J BACTERIOL, V161, P831, DOI 10.1128/JB.161.3.831-835.1985; MCEWEN JE, 1993, CURR GENET, V23, P9, DOI 10.1007/BF00336742; MERLE P, 1980, EUR J BIOCHEM, V105, P499, DOI 10.1111/j.1432-1033.1980.tb04525.x; MYERS AM, 1987, J BIOL CHEM, V262, P16822; NOBREGA MP, 1990, J BIOL CHEM, V265, P14220; PATTERSON TE, 1986, J BIOL CHEM, V261, P7192; PON L, 1991, MOL CELLULAR BIOL YE, P333; POWER SD, 1984, J BIOL CHEM, V259, P6564; POWER SD, 1984, J BIOL CHEM, V47, P45; Poyton RO, 1995, METHOD ENZYMOL, V260, P97, DOI 10.1016/0076-6879(95)60133-3; Poyton RO, 1996, ANNU REV BIOCHEM, V65, P563, DOI 10.1146/annurev.bi.65.070196.003023; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SAIKI K, 1993, J BIOL CHEM, V268, P26041; SAIKI K, 1993, J BIOL CHEM, V268, P26927; SAIKI K, 1992, BIOCHEM BIOPH RES CO, V189, P1491, DOI 10.1016/0006-291X(92)90243-E; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; SPENCER F, 1990, GENETICS, V124, P237; SVENSSON B, 1993, MOL MICROBIOL, V10, P193, DOI 10.1111/j.1365-2958.1993.tb00915.x; TAANMAN JW, 1992, J BIOL CHEM, V267, P22481; TAANMAN JW, 1993, J BIOL CHEM, V268, P18754; TRUEBLOOD CE, 1987, MOL CELL BIOL, V7, P3520, DOI 10.1128/MCB.7.10.3520; TRUMPOWER BL, 1994, ANNU REV BIOCHEM, V63, P675, DOI 10.1146/annurev.bi.63.070194.003331; TSUKIHARA T, 1995, SCIENCE, V269, P1069, DOI 10.1126/science.7652554; TZAGOLOFF A, 1993, BIOCHEM MOL BIOL INT, V31, P593; TZAGOLOFF A, 1990, EMBO J, V9, P2759, DOI 10.1002/j.1460-2075.1990.tb07463.x; TZAGOLOFF A, 1990, MICROBIOL REV, V54, P211, DOI 10.1128/MMBR.54.3.211-225.1990; WATERLAND RA, 1991, J BIOL CHEM, V266, P4180; WRIGHT RM, 1986, J BIOL CHEM, V261, P7183; WRIGHT RM, 1987, CYTOCHROME SYSTEMS M, P253	61	37	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18499	18507		10.1074/jbc.271.31.18499	http://dx.doi.org/10.1074/jbc.271.31.18499			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702496	hybrid			2022-12-25	WOS:A1996VB68300034
J	Maekawa, H; Tollefsen, DM				Maekawa, H; Tollefsen, DM			Role of the proposed serpin-enzyme complex receptor recognition site in binding and internalization of thrombin-heparin cofactor II complexes by hepatocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-1-PROTEINASE INHIBITOR; ANTITHROMBIN-III; SEC RECEPTOR; INVIVO CATABOLISM; NEUTROPHIL CHEMOATTRACTANT; PROTEINASE-INHIBITORS; PLASMA ELIMINATION; CDNA SEQUENCE; ELASTASE; ALPHA-1-ANTITRYPSIN	Several serpin-enzyme complexes bind to a receptor on hepatocytes that mediates their endocytosis and lysosomal degradation, Joslin et al, (Joslin, G,, Fallen, R, J,, Bullock, J,, Adams, S, P,, and Perlmutter, D, H, (1991) J, Biol, Chem, 266, 11282-11288) proposed that a sequence near the C-terminal end of the serpin (e,g, FVFLM in alpha 1-antitrypsin) binds to the serpin-enzyme complex receptor (SEC receptor), In experiments with synthetic peptides, they found that substitution of alanine at the fourth or fifth position in this sequence reduced the affinity of peptide binding to Hep G2 cells, To test the hypothesis that the corresponding sequence in heparin cofactor II (HCII), FLFLI (residues 456-460), mediates binding and uptake of the thrombin-HCII complex by Hep G2 cells, we constructed five recombinant HCII variants, F456A, L457A, F458A, L459A, and I460A, At 4 degrees C, the I-125-thrombin-HCII (native) complex bound reversibly to 0.6-2.6 x 10(5) sites per Hep G2 cell with a K-d of 19-32 nM. Binding was inhibited by excess unlabeled thrombin-HCII(native), thrombin-antithrombin, or elastase-alpha 1-antitrypsin, but not by free HCII or thrombin, which is consistent with the reported specificity of the SEC receptor, However, complexes of thrombin with each of the HCII variants inhibited binding as effectively as the complex with native HCII. Competitive binding experiments with various concentrations of unlabeled thrombin-HCII (native) or thrombin-HCII (I460A) indicated that these complexes bind to Hep G2 cells with equal affinity, At 37 degrees C, complexes of I-125-thrombin with each of the five HCII variants were internalized and degraded at the same rate as the complex with native HCII. Our data suggest that the pentapeptide FLFLI in HCII is not involved in binding, internalization, and degradation of thrombin-HCII complexes by Hep G2 cells.	WASHINGTON UNIV,SCH MED,DEPT INTERNAL MED,DIV HEMATOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT BIOCHEM & MOL BIOPHYS,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL)					NHLBI NIH HHS [HL-14147] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL014147] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BANDA MJ, 1988, J EXP MED, V167, P1608, DOI 10.1084/jem.167.5.1608; BANDA MJ, 1988, J BIOL CHEM, V263, P4481; BLINDER MA, 1988, BIOCHEMISTRY-US, V27, P752, DOI 10.1021/bi00402a039; CARRELL RW, 1985, NATURE, V317, P730, DOI 10.1038/317730a0; FUCHS HE, 1982, BIOCHIM BIOPHYS ACTA, V716, P151, DOI 10.1016/0304-4165(82)90263-X; FUCHS HE, 1984, J CELL BIOCHEM, V24, P197, DOI 10.1002/jcb.240240302; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GONIAS SL, 1982, THROMB HAEMOSTASIS, V48, P208; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; JOHNSON D, 1977, BIOCHEM J, V163, P639, DOI 10.1042/bj1630639; JOSLIN G, 1991, J BIOL CHEM, V266, P11282; JOSLIN G, 1993, J BIOL CHEM, V268, P1886; JOSLIN G, 1992, J CLIN INVEST, V90, P1150, DOI 10.1172/JCI115934; KETTNER C, 1979, THROMB RES, V14, P969, DOI 10.1016/0049-3848(79)90014-8; Kounnas MZ, 1996, J BIOL CHEM, V271, P6523, DOI 10.1074/jbc.271.11.6523; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAST AE, 1992, BIOCHEMISTRY-US, V31, P2720, DOI 10.1021/bi00125a012; MAST AE, 1991, BIOCHEMISTRY-US, V30, P1723, DOI 10.1021/bi00220a039; NORDENMAN B, 1977, EUR J BIOCHEM, V78, P195, DOI 10.1111/j.1432-1033.1977.tb11730.x; PERLMUTTER DH, 1988, J CLIN INVEST, V81, P1774, DOI 10.1172/JCI113519; PERLMUTTER DH, 1988, J BIOL CHEM, V263, P16499; PERLMUTTER DH, 1990, J BIOL CHEM, V265, P16713; PERLMUTTER DH, 1990, P NATL ACAD SCI USA, V87, P3753, DOI 10.1073/pnas.87.10.3753; PERLMUTTER DH, 1994, PEDIATR RES, V36, P271, DOI 10.1203/00006450-199409000-00001; PIZZO SV, 1988, BIOCHIM BIOPHYS ACTA, V967, P158, DOI 10.1016/0304-4165(88)90005-0; POTEMPA J, 1994, J BIOL CHEM, V269, P15957; PRATT CW, 1988, ARCH BIOCHEM BIOPHYS, V262, P111, DOI 10.1016/0003-9861(88)90173-7; PRATT CW, 1990, J BIOL CHEM, V265, P6092; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHULZE AJ, 1994, FEBS LETT, V344, P117, DOI 10.1016/0014-5793(94)00369-6; SHEEHAN JP, 1994, J BIOL CHEM, V269, P32747; SHIFMAN MA, 1982, J BIOL CHEM, V257, P3243; TOLLEFSEN DM, 1982, J BIOL CHEM, V257, P2162; TOLLEFSEN DM, 1995, THROMB HAEMOSTASIS, V74, P1209; TOLLEFSEN DM, 1983, J BIOL CHEM, V258, P6713; ZHANG GS, 1994, BIOCHEMISTRY-US, V33, P3632, DOI 10.1021/bi00178a021	36	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18604	18609		10.1074/jbc.271.31.18604	http://dx.doi.org/10.1074/jbc.271.31.18604			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702511	hybrid			2022-12-25	WOS:A1996VB68300049
J	Dlakic, M; Park, K; Griffith, JD; Harvey, SC; Harrington, RE				Dlakic, M; Park, K; Griffith, JD; Harvey, SC; Harrington, RE			The organic crystallizing agent 2-methyl-2,4-pentanediol reduces DNA curvature by means of structural changes in A-tracts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRINSICALLY BENT DNA; T-G-G; CURVED DNA; KINETOPLAST DNA; B-DNA; MINOR-GROOVE; ADENINE TRACT; DIRECTED CURVATURE; SEQUENCE ELEMENTS; HYDRATION	Contemporary predictive models for sequence-dependent DNA structure provide a good estimation of overall DNA curvature in most cases, However, the two current models differ fundamentally in their view of the origin of DNA curvature, An earlier model that associates DNA bending primarily, although not exclusively, with stretches of adenines (A-tracts) is based on results of comparative gel retardation, cyclization kinetics, hydroxyl radical cutting, and other solution measurements. It represents an intersection of wedge and junction models, More recently, a non-A-tract bending model has been proposed, built on structural results from x-ray crystallography and molecular modeling, In this view, A-tracts are proposed to be straight and rigid, whereas mixed sequence DNA is bent. Because a key premise of the non-A-tract bending model is the crystallographic observation that A-tracts are straight, we have examined the effect in solution of 2-methyl-2,4-pentanediol (MPD), an organic solvent used in crystal preparation for crystallographic DNA structure determinations, Using cyclization analysis, DNase I cutting, chemical probing, and electron microscopy on DNA oligomers with and without A-tracts, we show that the presence of MPD in solution dramatically affects A-tracts and that the effect is specific to these sequence elements. Combined with the previous observation that MPD affects gel mobility of curved sequences with A-tracts, our findings support the bent A-tract model and call for caution in the interpretation of crystallographic results on DNA structure as these are presently obtained.	UNIV NEVADA,DEPT BIOCHEM 330,RENO,NV 89557; UNIV N CAROLINA,SCH MED,LINEBERGER CANC RES CTR,CHAPEL HILL,NC 27599; UNIV ALABAMA,DEPT BIOCHEM & MOLEC GENET,BIRMINGHAM,AL 35294	Nevada System of Higher Education (NSHE); University of Nevada Reno; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of Alabama System; University of Alabama Birmingham			Dlakic, Mensur/S-2702-2019	Dlakic, Mensur/0000-0003-4315-1514	NATIONAL CANCER INSTITUTE [R01CA070274] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R55HG000656] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031819] Funding Source: NIH RePORTER; NCI NIH HHS [CA70274] Funding Source: Medline; NHGRI NIH HHS [HG00656] Funding Source: Medline; NIGMS NIH HHS [GM31819] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOLSHOY A, 1991, P NATL ACAD SCI USA, V88, P2312, DOI 10.1073/pnas.88.6.2312; BOROWIEC JA, 1987, J MOL BIOL, V196, P101, DOI 10.1016/0022-2836(87)90513-4; BRUKNER I, 1995, EMBO J, V14, P1812, DOI 10.1002/j.1460-2075.1995.tb07169.x; BRUKNER I, 1994, J MOL BIOL, V236, P26, DOI 10.1006/jmbi.1994.1115; BRUKNER I, 1990, NUCLEIC ACIDS RES, V18, P891, DOI 10.1093/nar/18.4.891; BRUKNER I, 1993, NUCLEIC ACIDS RES, V21, P1025, DOI 10.1093/nar/21.4.1025; BUCKIN VA, 1989, NUCLEIC ACIDS RES, V17, P4189, DOI 10.1093/nar/17.11.4189; BUCKIN VA, 1989, NATURE, V340, P321, DOI 10.1038/340321a0; BUCKIN VA, 1994, J AM CHEM SOC, V116, P9423, DOI 10.1021/ja00100a003; BURKHOFF AM, 1987, CELL, V48, P935, DOI 10.1016/0092-8674(87)90702-1; BURKHOFF AM, 1988, NATURE, V331, P455, DOI 10.1038/331455a0; CALLADINE CR, 1988, J MOL BIOL, V201, P127, DOI 10.1016/0022-2836(88)90444-5; CHAN SS, 1993, BIOCHEMISTRY-US, V32, P11776, DOI 10.1021/bi00095a005; CHAN SS, 1990, BIOCHEMISTRY-US, V29, P6161, DOI 10.1021/bi00478a008; CHUPRINA VP, 1985, FEBS LETT, V186, P98, DOI 10.1016/0014-5793(85)81347-8; CHUPRINA VP, 1987, NUCLEIC ACIDS RES, V15, P293, DOI 10.1093/nar/15.1.293; COLL M, 1987, P NATL ACAD SCI USA, V84, P8385, DOI 10.1073/pnas.84.23.8385; CROTHERS DM, 1992, METHOD ENZYMOL, V212, P3; CROTHERS DM, 1990, J BIOL CHEM, V265, P7093; DESANTIS P, 1990, BIOCHEMISTRY-US, V29, P9269, DOI 10.1021/bi00491a023; Dickerson RE, 1996, J MOL BIOL, V256, P108, DOI 10.1006/jmbi.1996.0071; DIEKMANN S, 1987, NUCLEIC ACIDS RES, V15, P247, DOI 10.1093/nar/15.1.247; DIGABRIELE AD, 1989, P NATL ACAD SCI USA, V86, P1816, DOI 10.1073/pnas.86.6.1816; Dlakic M, 1996, P NATL ACAD SCI USA, V93, P3847, DOI 10.1073/pnas.93.9.3847; DLAKIC M, 1995, J BIOL CHEM, V270, P29945; DREW HR, 1984, J MOL BIOL, V176, P535, DOI 10.1016/0022-2836(84)90176-1; DREW HR, 1987, J MOL BIOL, V195, P143, DOI 10.1016/0022-2836(87)90333-0; DREW HR, 1985, J MOL BIOL, V186, P773, DOI 10.1016/0022-2836(85)90396-1; DREW HR, 1984, CELL, V37, P491, DOI 10.1016/0092-8674(84)90379-9; EDWARDS KJ, 1992, J MOL BIOL, V226, P1161, DOI 10.1016/0022-2836(92)91059-X; GOODSELL DS, 1994, NUCLEIC ACIDS RES, V22, P5497, DOI 10.1093/nar/22.24.5497; GOODSELL DS, 1994, J MOL BIOL, V239, P79, DOI 10.1006/jmbi.1994.1352; GOODSELL DS, 1993, P NATL ACAD SCI USA, V90, P2930, DOI 10.1073/pnas.90.7.2930; GRIFFITH J, 1986, CELL, V46, P717, DOI 10.1016/0092-8674(86)90347-8; GRIFFITH JD, 1978, ANNU REV BIOPHYS BIO, V7, P19, DOI 10.1146/annurev.bb.07.060178.000315; GRZESKOWIAK K, 1993, BIOCHEMISTRY-US, V32, P8923, DOI 10.1021/bi00085a025; HAGERMAN PJ, 1986, NATURE, V321, P449, DOI 10.1038/321449a0; HAGERMAN PJ, 1990, J MOL BIOL, V212, P351, DOI 10.1016/0022-2836(90)90130-E; HAGERMAN PJ, 1985, BIOCHEMISTRY-US, V24, P7033, DOI 10.1021/bi00346a001; HAGERMAN PJ, 1990, ANNU REV BIOCHEM, V59, P755, DOI 10.1146/annurev.biochem.59.1.755; HARAN TE, 1994, J MOL BIOL, V244, P135, DOI 10.1006/jmbi.1994.1713; HARRINGTON RE, 1993, ELECTROPHORESIS, V14, P732, DOI 10.1002/elps.11501401116; HARVEY SC, 1995, J BIOMOL STRUCT DYN, V13, P301, DOI 10.1080/07391102.1995.10508841; HERRERA JE, 1989, BIOCHEMISTRY-US, V28, P1993, DOI 10.1021/bi00431a006; HOGAN ME, 1989, P NATL ACAD SCI USA, V86, P9273, DOI 10.1073/pnas.86.23.9273; KAHN JD, 1994, NATURE, V368, P163, DOI 10.1038/368163a0; KITCHIN PA, 1986, J BIOL CHEM, V261, P1302; KOO HS, 1986, NATURE, V320, P501, DOI 10.1038/320501a0; KOO HS, 1990, BIOCHEMISTRY-US, V29, P4227, DOI 10.1021/bi00469a027; KOO HS, 1988, P NATL ACAD SCI USA, V85, P1763, DOI 10.1073/pnas.85.6.1763; KUBINEC MG, 1992, J AM CHEM SOC, V114, P8739, DOI 10.1021/ja00048a079; LEVENE SD, 1983, J BIOMOL STRUCT DYN, V1, P429, DOI 10.1080/07391102.1983.10507452; LIEPINSH E, 1992, NUCLEIC ACIDS RES, V20, P6549, DOI 10.1093/nar/20.24.6549; LILLEY DMJ, 1992, METHOD ENZYMOL, V212, P133; LIVSHITS MA, 1994, MOL BIOL+, V28, P687; MARINI JC, 1984, J BIOL CHEM, V259, P8974; MARINI JC, 1982, P NATL ACAD SCI-BIOL, V79, P7664, DOI 10.1073/pnas.79.24.7664; MARKY LA, 1989, BIOCHEMISTRY-US, V28, P9982, DOI 10.1021/bi00452a016; MAROUN RC, 1988, BIOPOLYMERS, V27, P585, DOI 10.1002/bip.360270404; MCCARTHY JG, 1990, BIOCHEMISTRY-US, V29, P6071, DOI 10.1021/bi00477a027; MCNAMARA PT, 1991, J BIOL CHEM, V266, P12548; MILTON DL, 1990, NUCLEIC ACIDS RES, V18, P817, DOI 10.1093/nar/18.4.817; NELSON HCM, 1987, NATURE, V330, P221, DOI 10.1038/330221a0; OLSON WK, 1993, J MOL BIOL, V232, P530, DOI 10.1006/jmbi.1993.1409; PARK YW, 1991, P NATL ACAD SCI USA, V88, P1551, DOI 10.1073/pnas.88.4.1551; PRICE MA, 1993, BIOCHEMISTRY-US, V32, P127, DOI 10.1021/bi00052a018; PRICE MA, 1992, METHOD ENZYMOL, V212, P194; QUINTANA JR, 1992, J MOL BIOL, V225, P379, DOI 10.1016/0022-2836(92)90928-D; SASSEDWIGHT S, 1989, J BIOL CHEM, V264, P8074; SATCHWELL SC, 1986, J MOL BIOL, V191, P659, DOI 10.1016/0022-2836(86)90452-3; SCHELLMAN JA, 1995, BIOPHYS CHEM, V55, P95, DOI 10.1016/0301-4622(94)00144-9; SHORE D, 1983, J MOL BIOL, V170, P957, DOI 10.1016/S0022-2836(83)80198-3; SHORE D, 1981, P NATL ACAD SCI-BIOL, V78, P4833, DOI 10.1073/pnas.78.8.4833; SHRADER TE, 1989, P NATL ACAD SCI USA, V86, P7418, DOI 10.1073/pnas.86.19.7418; SPROUS D, 1995, NUCLEIC ACIDS RES, V23, P1816, DOI 10.1093/nar/23.10.1816; SUCK D, 1988, NATURE, V332, P464, DOI 10.1038/332464a0; TRAVERS AA, 1987, TRENDS BIOCHEM SCI, V12, P108, DOI 10.1016/0968-0004(87)90050-8; TRIFONOV EN, 1991, TRENDS BIOCHEM SCI, V16, P467; TRIFONOV EN, 1980, P NATL ACAD SCI-BIOL, V77, P3816, DOI 10.1073/pnas.77.7.3816; TRIFONOV EN, 1985, CRC CR REV BIOCH MOL, V19, P89, DOI 10.3109/10409238509082540; TULLIUS TD, 1985, SCIENCE, V230, P679, DOI 10.1126/science.2996145; TULLIUS TD, 1986, P NATL ACAD SCI USA, V83, P5469, DOI 10.1073/pnas.83.15.5469; ULANOVSKY L, 1986, P NATL ACAD SCI USA, V83, P862, DOI 10.1073/pnas.83.4.862; ULANOVSKY LE, 1987, NATURE, V326, P720, DOI 10.1038/326720a0; WANG YH, 1991, BIOCHEMISTRY-US, V30, P5443, DOI 10.1021/bi00236a017; WESTON SA, 1992, J MOL BIOL, V226, P1237, DOI 10.1016/0022-2836(92)91064-V; WU HM, 1984, NATURE, V308, P509, DOI 10.1038/308509a0; ZAHN K, 1987, SCIENCE, V236, P416, DOI 10.1126/science.2951850; ZHURKIN VB, 1991, P NATL ACAD SCI USA, V88, P7046, DOI 10.1073/pnas.88.16.7046	89	50	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					17911	17919		10.1074/jbc.271.30.17911	http://dx.doi.org/10.1074/jbc.271.30.17911			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663567	hybrid, Green Published			2022-12-25	WOS:A1996UY93500050
J	Franks, RR; Rencic, A; Gordon, J; Zoltick, PW; Curtis, M; Knobler, RL; Khalili, K				Franks, RR; Rencic, A; Gordon, J; Zoltick, PW; Curtis, M; Knobler, RL; Khalili, K			Formation of undifferentiated mesenteric tumors in transgenic mice expressing human neurotropic polyomavirus early protein	ONCOGENE			English	Article						T-antigen; JCV; animal model for CNS tumors	PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; HUMAN PAPOVAVIRUS JC; DNA-BINDING PROTEIN; HUMAN-BRAIN; STIMULATES TRANSCRIPTION; EARLY REGION; VIRUS; PROMOTER; DYSMYELINATION; INDUCTION	The human polyomavirus, JCV, is the established etiologic agent of the human demyelinating disease, progressive multifocal leukoencephalopathy (PML) seen in immunosuppressed individuals. In PML patients, the viral early protein, which is produced exclusively in glial cells is responsible for initiation of the viral lytic cycle. The JCV early protein, T-antigen, has greater than 70% homology to the web characterized SV40 early protein which has established oncogenic properties. To investigate the role of JCV T-antigen in tumorigenesis, transgenic mice containing the viral early genome were produced. Of the four positive transgenic animals, one developed severe neurological abnormalities and succumbed to death at 3 weeks of age. Another animal died with no visible gross pathology and the cause of death was not determined. The remaining two founders developed massive, undifferentiated, solid mesenteric tumors with no obvious neurological symptoms. Results from histologic analysis demonstrated the presence of highly cellular, poorly differentiated neoplastic cells in the tumor tissue. Electron microscopic evaluation of the tumor revealed the presence of a small blue cell-like tumor of epithelial/neuroectodermal origin. Results from RNA analysis by non-quantitative and highly sensitive RT-PCR indicated the presence of the JCV early transcript in various tissues, including kidney, liver, spleen, heart, lung, and brain, as well as in the tumors. However, analysis of the viral early protein by Western blot and immunohistochemistry indicated high level production of JCV early protein in the tumor tissue, but not in any other tissues. These observations present the first evidence for the development of inheritable neuroectodermal tumors induced by the human polyomavirus, JCV, early protein in a whole animal system.	THOMAS JEFFERSON UNIV,DEPT BIOCHEM & MOLEC BIOL,JEFFERSON INST MOLEC MED,MOLEC NEUROVIROL SECT,PHILADELPHIA,PA 19107; UNIV ILLINOIS,COLL MED,DEPT GENET,CHICAGO,IL 60612; THOMAS JEFFERSON UNIV,DEPT PATHOL,PHILADELPHIA,PA 19107; THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DEPT NEUROL,PHILADELPHIA,PA 19107	Jefferson University; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Jefferson University; Jefferson University								AHMED S, 1990, J BIOL CHEM, V265, P13899; AMEMIYA K, 1989, J BIOL CHEM, V264, P7025; Ausubel F. M., 1988, CURRENT PROTOCOLS MO; BERGER JR, 1995, J NEUROVIROL, V1, P5, DOI 10.3109/13550289509111006; CASTAIGNE P, 1974, REV NEUROL-FRANCE, V130, P379; CHEN NN, 1995, P NATL ACAD SCI USA, V92, P1087, DOI 10.1073/pnas.92.4.1087; FEIGENBAUM L, 1987, P NATL ACAD SCI USA, V84, P3695, DOI 10.1073/pnas.84.11.3695; FEIGENBAUM L, 1992, J VIROL, V66, P1176, DOI 10.1128/JVI.66.2.1176-1182.1992; Flint S. J, 1981, DNA TUMOR VIRUSES; Frisque RJ, 1992, MOL NEUROVIROLOGY PA, P25; GIARUSSO MH, 1978, J NEUROL SCI, V35, P391, DOI 10.1016/0022-510X(78)90019-9; GORDON JW, 1983, METHOD ENZYMOL, V101, P411; HAAS S, 1994, VIROLOGY, V202, P89, DOI 10.1006/viro.1994.1325; HOUFF SA, 1983, POLYOMAVIRUSES NEURO, P223; KENNEY S, 1984, SCIENCE, V226, P1337, DOI 10.1126/science.6095453; KERR D, 1991, J BIOL CHEM, V266, P15876; KHALILI K, 1988, EMBO J, V7, P1205, DOI 10.1002/j.1460-2075.1988.tb02932.x; LONDON WT, 1978, SCIENCE, V201, P1246, DOI 10.1126/science.211583; MAJOR EO, 1992, CLIN MICROBIOL REV, V5, P49, DOI 10.1128/CMR.5.1.49-73.1992; OHSUMI S, 1986, ACTA PATHOL JAPON, V36, P815; PADGETT BL, 1977, CANCER RES, V37, P718; PIPAS JM, 1992, J VIROL, V66, P3979, DOI 10.1128/JVI.66.7.3979-3985.1992; RAJ GV, 1994, MOL CELL BIOL, V14, P7770, DOI 10.1128/MCB.14.12.7770; RAJ GV, 1995, VIROLOGY, V213, P283, DOI 10.1006/viro.1995.0001; SIMA AAF, 1983, ANN NEUROL, V14, P183, DOI 10.1002/ana.410140205; SMALL JA, 1986, CELL, V46, P13, DOI 10.1016/0092-8674(86)90855-X; SMALL JA, 1986, P NATL ACAD SCI USA, V83, P8288, DOI 10.1073/pnas.83.21.8288; SOBRINHOSIMOES M, 1990, ARCH PATHOL LAB MED, V114, P369; TADA H, 1989, J VIROL, V63, P463, DOI 10.1128/JVI.63.1.463-466.1989; TADA H, 1991, VIROLOGY, V180, P327, DOI 10.1016/0042-6822(91)90037-C; TADA H, 1992, J VIROL, V66, P6885, DOI 10.1128/JVI.66.12.6885-6892.1992; TRAPP BD, 1988, ANN NEUROL, V23, P38, DOI 10.1002/ana.410230108; VARAKIS J, 1978, CANCER RES, V38, P1718; WALKER DL, 1973, SCIENCE, V181, P674, DOI 10.1126/science.181.4100.674; ZURHEIN GM, 1983, POLYOMAVIRUSES HUMAN, P205	35	43	44	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 20	1996	12	12					2573	2578						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UW487	8700516				2022-12-25	WOS:A1996UW48700011
J	Sato, M; Rippy, MK; Bryant, HU				Sato, M; Rippy, MK; Bryant, HU			Raloxifene, tamoxifen, nafoxidine, or estrogen effects on reproductive and nonreproductive tissues in ovariectomized rats	FASEB JOURNAL			English	Article						osteoporosis; uterus; bone; cholesterol; osteoclast	LONG-TERM ESTROGEN; BONE-MINERAL DENSITY; REPLACEMENT THERAPY; BREAST-CANCER; POSTMENOPAUSAL WOMEN; ENDOMETRIAL CARCINOMA; ELDERLY WOMEN; BODY-WEIGHT; FOOD-INTAKE; OSTEOPOROSIS	For the first time, four wen-characterized compounds from four distinct chemical classes were directly compared for efficacy and potency in bone, uteri, lipids, and adipose tissues in an ovariectomized model with 6 month old rats. Five weeks of oral dosing confirmed that ethynyl estradiol, tamoxifen, and raloxifene are potent inhibitors of the loss in volumetric bone mineral density (BMD, mg/cc) induced by ovariectomy, as measured by computed tomography. In the metaphysis of distal femora from ovariectomized rats, analysis showed a significant 12-20% decrease (P < 0.01) in the BMD. Linear regression analysis was used to calculate half-maximal efficacious doses for ethynyl estradiol ED(50) = 0.04 mg/kg, which was threefold more potent than tamoxifen, which in turn was threefold more potent than raloxifene, which was more efficacious than nafoxidine. In the uterus, raloxifene had minimal effects on the endometrium and smaller effects on uterine eosinophil peroxidase activity than nafoxidine, tamoxifen, or estrogen, respectively, Estrogen was the most potent in reducing cholesterol levels in ovariectomized rats, whereas tamoxifen and nafoxidine were more effective than raloxifene in blocking gain in body weight. Distinct compounds had advantages in the management of bone, uterine, serum cholesterol, and adipose tissues after ovariectomy. Tire distinct pattern of pharmacological effects may be best understood in terms of their respective chemical structure, specifically estrogens, benzothiophenes (raloxifene), dihydronapthylenes (nafoxidine), and triphenylethylenes (tamoxifen). These data point to advantages of separate compounds in the management of bone, uterine, serum cholesterol, and adipose tissues after estrogen deficiency, and show that the benzothiophene raloxifene has potentially important advantages over estrogen, tamoxifen, or nafoxidine in the uterus.			Sato, M (corresponding author), ELI LILLY & CO,LILLY CORP CTR,DEPT ENDOCRINE RES,INDIANAPOLIS,IN 46285, USA.							BLACK LJ, 1994, J CLIN INVEST, V93, P63, DOI 10.1172/JCI116985; BLACK LJ, 1983, LIFE SCI, V32, P1031, DOI 10.1016/0024-3205(83)90935-9; BURCH JC, 1974, AM J OBSTET GYNECOL, V118, P778, DOI 10.1016/0002-9378(74)90487-6; CHRISTIANSEN C, 1992, BONE, V13, pS35, DOI 10.1016/S8756-3282(09)80008-2; DEMPSTER DW, 1993, LANCET, V341, P797, DOI 10.1016/0140-6736(93)90570-7; DEVOR M, 1992, AM J MED, V92, P275, DOI 10.1016/0002-9343(92)90077-O; DRAPER MW, 1993, 4TH P INT S OST, P119; DUKES M, 1994, J ENDOCRINOL, V141, P335, DOI 10.1677/joe.0.1410335; DUPONT WD, 1991, ARCH INTERN MED, V151, P67, DOI 10.1001/archinte.151.1.67; FELSON DT, 1993, NEW ENGL J MED, V329, P1141, DOI 10.1056/NEJM199310143291601; FROST HM, 1992, BONE MINER, V18, P227, DOI 10.1016/0169-6009(92)90809-R; FUCHSYOUNG Y, 1995, 77 ANN M END SOC WAS, P57; GALAND P, 1984, J STEROID BIOCHEM, V21, P43, DOI 10.1016/0022-4731(84)90058-X; GRAY JM, 1981, AM J PHYSIOL, V240, pE474, DOI 10.1152/ajpendo.1981.240.5.E474; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAMMOND CB, 1979, AM J OBSTET GYNECOL, V133, P525, DOI 10.1016/0002-9378(79)90288-6; JORDAN VC, 1980, CANCER TREAT REP, V64, P745; KALU DN, 1991, BONE MINER, V15, P175, DOI 10.1016/0169-6009(91)90124-I; KALU DN, 1991, BONE MINER, V14, P175, DOI 10.1016/0169-6009(91)90021-Q; KALU DN, 1991, BONE MINER, V15, P109, DOI 10.1016/0169-6009(91)90002-H; Katzenellenbogen B S, 1979, Recent Prog Horm Res, V35, P259; KEDAR RP, 1994, LANCET, V343, P1318, DOI 10.1016/S0140-6736(94)92466-X; LINDSAY R, 1980, LANCET, V2, P1151; LINDSAY R, 1993, LANCET, V341, P801, DOI 10.1016/0140-6736(93)90571-W; LOVE RR, 1992, NEW ENGL J MED, V326, P852, DOI 10.1056/NEJM199203263261302; LOVE RR, 1991, ANN INTERN MED, V115, P860, DOI 10.7326/0003-4819-115-11-860; LYTTLE CR, 1977, P NATL ACAD SCI USA, V74, P3162, DOI 10.1073/pnas.74.8.3162; MCDONNELL DP, 1995, MOL ENDOCRINOL, V9, P659, DOI 10.1210/me.9.6.659; MOON LY, 1991, ENDOCRINOLOGY, V129, P1568, DOI 10.1210/endo-129-3-1568; MOORE M, 1990, J BONE MINER RES, V5, P659; QUIGLEY MET, 1987, AM J OBSTET GYNECOL, V156, P1516; SATO M, 1995, J PHARMACOL EXP THER, V272, P1252; SATO M, 1994, J BONE MINER RES, V9, P715; SATO M, 1995, BONE, V17, pS157, DOI 10.1016/8756-3282(95)00288-O; SMITH DC, 1975, NEW ENGL J MED, V293, P1164, DOI 10.1056/NEJM197512042932302; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P756, DOI 10.1056/NEJM199109123251102; STEINBERG KK, 1991, JAMA-J AM MED ASSOC, V265, P1985, DOI 10.1001/jama.265.15.1985; SUNDERLAND MC, 1991, J CLIN ONCOL, V9, P1283, DOI 10.1200/JCO.1991.9.7.1283; TURNER RT, 1988, ENDOCRINOLOGY, V122, P1146, DOI 10.1210/endo-122-3-1146; VESEY MP, 1984, J ROY SOC MED, V77, P542; WADE GN, 1993, AM J PHYSIOL, V264, pR1219, DOI 10.1152/ajpregu.1993.264.6.R1219; WEISS NS, 1980, NEW ENGL J MED, V303, P1195, DOI 10.1056/NEJM198011203032102; WHITE SR, 1991, J IMMUNOL METHODS, V44, P257; Wronski TJ., 1992, CELLS MAT, V1, P69; ZIEL HK, 1975, NEW ENGL J MED, V293, P1167, DOI 10.1056/NEJM197512042932303	45	236	243	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUN	1996	10	8					905	912		10.1096/fasebj.10.8.8666168	http://dx.doi.org/10.1096/fasebj.10.8.8666168			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	UQ456	8666168				2022-12-25	WOS:A1996UQ45600013
J	Fotedar, R; Fitzgerald, P; Rousselle, T; Cannella, D; Doree, M; Messier, H; Fotedar, A				Fotedar, R; Fitzgerald, P; Rousselle, T; Cannella, D; Doree, M; Messier, H; Fotedar, A			p21 contains independent binding sites for cyclin and cdk2: Both sites are required to inhibit cdk2 kinase activity	ONCOGENE			English	Article						cell cycle; cyclin-dependent kinase; cyclin-dependent kinase inhibitor; domains of p21	DEPENDENT KINASES; PHOSPHORYLATION; PROTEIN; ACTIVATION; P34CDC2; SUBUNIT; CDC2; GENE; DNA	Cyclin dependent kinases regulate the progression of eukaryotic cells through the cell cycle, p21(Cip1/Waf1/Sdi1) is an inhibitor of cdk-cyclin kinase activity, and has been shown to form complexes with cdk-cyclins and with PCNA, an accessory protein of DNA polymerase delta, The kinase inhibitory domain maps to the N-terminus (1-82) and contains the cdk2 binding site (28-82), We have generated a panel of deletion mutants of p21, A functional characterization of p21 mutants in the N-terminal domain reveals that cyclins bind to this domain independently of cdk2, Correlating with these results we find that p21 can associate with cyclin-cdk kinases in two functionally distinct forms, one in which the kinase activity is inhibited and the other in which the kinase is still active, The cdk2 and cyclin binding sites on p21 are both required to inhibit kinase activity, The second type of interaction, in which an active cyclin-cdk complex only interacts with p21 either via the cyclin or the cdk2 binding site but not through both, does not lead to inhibition of cyclin kinase activity, These results thus provide a basis for understanding the mechanism by which p21, and perhaps other cdk-cyclin kinase inhibitory proteins, suppress kinase activity.	LA JOLLA INST ALLERGY & IMMUNOL,DIV MOLEC BIOL,LA JOLLA,CA 92037; CTR RECH BIOCHIM MACROMOL,CNRS UPR 9008,F-34033 MONTPELLIER,FRANCE	La Jolla Institute for Immunology; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Fotedar, R (corresponding author), INST BIOL STRUCT JP EBEL,41 AVE MARTYRS,F-38027 GRENOBLE 1,FRANCE.		Cannella, Dominique/F-4879-2019	Cannella, Dominique/0000-0002-1665-9833	NIAID NIH HHS [R01AI31453] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI031453] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		APRELIKOVA O, 1995, J BIOL CHEM, V270, P18195, DOI 10.1074/jbc.270.31.18195; BRENOTBOSC F, 1995, CHROMOSOMA, V103, P517, DOI 10.1007/BF00355316; CHAN FKM, 1995, MOL CELL BIOL, V15, P2682; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DESAI D, 1992, MOL BIOL CELL, V3, P571, DOI 10.1091/mbc.3.5.571; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDIERY WS, 1993, CELL, V75, P817; ELLEDGE SJ, 1994, CURR OPIN CELL BIOL, V6, P847, DOI 10.1016/0955-0674(94)90055-8; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; FOTEDAR R, 1991, COLD SH Q B, V56, P325; FOTEDAR R, 1995, MOL CELL BIOL, V15, P932; FOTEDAR R, 1992, EMBO J, V11, P2177, DOI 10.1002/j.1460-2075.1992.tb05277.x; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GOUBIN F, 1995, ONCOGENE, V10, P2281; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HALL M, 1995, ONCOGENE, V11, P1581; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HARPER JW, 1993, CELL, V75, P805; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; HU L, 1995, GENE DEV, V9, P1740; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; LABBE JC, 1989, EMBO J, V8, P3053, DOI 10.1002/j.1460-2075.1989.tb08456.x; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; LI Y, 1994, ONCOGENE, V9, P2261; LORCA T, 1992, J CELL SCI, V102, P55; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; MESSIER H, 1993, P NATL ACAD SCI USA, V90, P2685, DOI 10.1073/pnas.90.7.2685; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; NAKANISHI M, 1995, EMBO J, V14, P555, DOI 10.1002/j.1460-2075.1995.tb07031.x; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; PONDAVEN P, 1990, GENE DEV, V4, P9, DOI 10.1101/gad.4.1.9; POON RYC, 1995, MOL BIOL CELL, V6, P1197, DOI 10.1091/mbc.6.9.1197; PRELICH G, 1987, NATURE, V326, P517, DOI 10.1038/326517a0; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WARBRICK E, 1995, CURR BIOL, V5, P275, DOI 10.1016/S0960-9822(95)00058-3; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750	50	93	94	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 16	1996	12	10					2155	2164						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UP283	8668341				2022-12-25	WOS:A1996UP28300014
